

09.09.2022

10:15 - 11:45	Type: Industry Satellite Symposium Title: Mirati Therapeutics, Inc. - Advancing Tailored Therapies in NSCLC and KRASG12C-Driven Tumors Chair(s): Fabrice Barlesi, FR	7.2.E - Évry Auditorium
10:15 - 10:20	Welcome and Introduction <u>F. Barlesi</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
10:20 - 10:40	Unmet Needs and Recent Advances for NSCLC <u>J. Naidoo</u> , Beaumont Hospital, Dublin, IE	
10:40 - 11:00	Emerging Therapies to Overcome CPI Resistance in NSCLC <u>F. Barlesi</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
11:00 - 11:30	New Perspectives with Targeted Options for KRAS -Driven Tumors <u>S. Gadgeel</u> , Henry Ford Cancer Institute-Henry Ford Health, Detroit, US	
11:30 - 11:40	Q&A <u>F. Barlesi</u> ¹ , <u>J. Naidoo</u> ² , <u>S. Gadgeel</u> ³ , ¹ Gustave Roussy - Cancer Campus, Villejuif, FR, ² Beaumont Hospital, Dublin, IE, ³ Henry Ford Cancer Institute-Henry Ford Health, Detroit, US	
11:40 - 11:45	Summary & Close <u>F. Barlesi</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	

10:15 - 11:45	Type: Industry Satellite Symposium Title: Deciphera Pharmaceuticals - From clinical trial to clinical practice: novel strategies for treating patients with advanced GIST Chair(s): Peter Reichardt, DE	7.1.D - Dijon Auditorium
10:15 - 10:20	Welcome and introduction <u>P. Reichardt</u> , Helios Klinikum Berlin-Buch, Berlin, DE	
10:20 - 10:40	Clinical update in advanced GIST <u>A. Le Cesne</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
10:40 - 11:00	Scope of treatment through progressive lines in metastatic GIST: stable disease and QoL <u>A. Italiano</u> , Institute Bergonié, Bordeaux, FR	
11:00 - 11:20	Management of treatment to progression: radiologic progression vs clinical benefit <u>P. Reichardt</u> , Helios Klinikum Berlin-Buch, Berlin, DE	
11:20 - 11:45	Discussion and conclusions <u>P. Reichardt</u> , Helios Klinikum Berlin-Buch, Berlin, DE	

10:15 - 11:45	Type: Industry Satellite Symposium Title: Novartis - Guiding Through Oesophageal Cancer: Expert Insights on the Patient Journey From Diagnosis to Treatment Chair(s): Sylvie Lorenzen, DE	7.3.G - Grenoble Auditorium
10:15 - 10:20	Welcome and Programme Overview <u>S. Lorenzen</u> , Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE	
10:20 - 10:30	Diagnosis and Staging of a Patient With Oesophageal Cancer <u>H. Van Laarhoven</u> , Academic Medical Center, University of Amsterdam, Amsterdam, NL	
10:30 - 10:35	Panel Case Discussion <u>S. Lorenzen</u> ¹ , <u>A. Adenis</u> ² , <u>H. Van Laarhoven</u> ³ , ¹ Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE, ² ICM - Institut du Cancer de Montpellier, Montpellier, Cedex 5, FR, ³ Academic Medical Center, University of Amsterdam, Amsterdam, NL	
10:35 - 10:50	Biomarker Testing in Oesophageal Cancer <u>S. Lorenzen</u> , Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE	
10:50 - 11:00	Panel Discussion <u>S. Lorenzen</u> ¹ , <u>A. Adenis</u> ² , <u>H. Van Laarhoven</u> ³ , ¹ Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE, ² ICM - Institut du Cancer de Montpellier, Montpellier, Cedex 5, FR, ³ Academic Medical Center, University of Amsterdam, Amsterdam, NL	
11:00 - 11:15	First-line Treatment Option in Oesophageal Cancer <u>A. Adenis</u> , ICM - Institut du Cancer de Montpellier, Montpellier, Cedex 5, FR	
11:15 - 11:30	Panel Discussion <u>S. Lorenzen</u> ¹ , <u>A. Adenis</u> ² , <u>H. Van Laarhoven</u> ³ , ¹ Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE, ² ICM - Institut du Cancer de Montpellier, Montpellier, Cedex 5, FR, ³ Academic Medical Center, University of Amsterdam, Amsterdam, NL	
11:30 - 11:45	Q&A Session <u>S. Lorenzen</u> ¹ , <u>A. Adenis</u> ² , <u>H. Van Laarhoven</u> ³ , ¹ Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE, ² ICM - Institut du Cancer de Montpellier, Montpellier, Cedex 5, FR, ³ Academic Medical Center, University of Amsterdam, Amsterdam, NL	

10:15 - 11:45	Type: Industry Satellite Symposium Title: PeerView Oncology - Targeting HER2-Low Expression in Breast Cancer: Evaluating the Evidence, Challenges, and Opportunities for Expanding Treatment Benefit to More Patients Chair(s): Aleix Prat, ES	7.3.H - Honfleur Auditorium
10:15 - 10:20	Welcome and Introduction <u>A. Prat</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, ES	
10:20 - 10:40	Understanding the Foundational Concepts of HER2-Low Breast Cancer: Challenges and Opportunities of an Evolving Definition <u>P. Tarantino</u> , Dana Farber Cancer Institute, Boston, US	
10:40 - 11:00	Extending Anti-HER2 Therapy Benefits to a Larger Population of Patients: Emerging Evidence, Implementation in Clinical Practice, and Future Directions <u>S. Modi</u> , MSKCC - Memorial Sloan Kettering Cancer Center, New York, US	
11:00 - 11:20	Unveiling the Biology of HER2-Low Breast Cancer: Insights From Genomics, Transcriptomics, and Opportunities With Evolving Testing Approaches <u>A. Prat</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, ES	
11:20 - 11:40	Exploring the Nuances of HER2-Targeted Treatment Selection for Patients With HER2-Low Breast Cancer: Expert Insights Into Implications for Practice and Team-Based Approaches to Individualizing Patient Care <u>A. Prat</u> ¹ , <u>P. Tarantino</u> ² , <u>S. Modi</u> ³ , ¹ Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ² Dana Farber Cancer Institute, Boston, US, ³ MSKCC - Memorial Sloan Kettering Cancer Center, New York, US	
11:40 - 11:45	Summary, Reflections, and Key Takeaways <u>A. Prat</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, ES	

10:15 - 11:45	Type: Industry Satellite Symposium Title: Bristol Myers Squibb - GI Cancer and Immuno-Oncology Today: Best Practice and Clinical Challenges Chair(s): Myriam Chalabi, NL; Ian Chau, GB	7.3.O - Orléans Auditorium
10:15 - 10:20	Welcome and Introduction <u>M. Chalabi</u> , Netherlands Cancer Institute, Amsterdam, NL	
10:20 - 10:40	Current Status of I-O for Treating CRC <u>M. Chalabi</u> , Netherlands Cancer Institute, Amsterdam, NL	
10:40 - 11:00	Treating Gastric Cancer Today: I-O-focused Update <u>K. Muro</u> , Aichi Cancer Center Hospital, Nagoya, JP	
11:00 - 11:20	Emerging Treatments for Esophageal Cancer: First-Line Metastatic Disease and Earlier Stages <u>E. Samalin-Scalzi</u> , ICM - Institut du Cancer de Montpellier, Montpellier, Cedex 5, FR	
11:20 - 11:40	Roundtable Case Discussion, Q&A, and Summary <u>I. Chau</u> , The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB	
11:40 - 11:45	Close <u>I. Chau</u> , The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB	

10:15 - 11:45	Type: Industry Satellite Symposium Title: ACE Oncology - Navigating Treatment Decisions in Advanced NSCLC: Update on Molecular Testing and New Targeted Treatment Options Chair(s): Julien Mazieres, FR	7.3.Q - Quimper Auditorium
10:15 - 10:22	Welcome, introduction, and warm-up quiz <u>J. Mazieres</u> , Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR	
10:22 - 10:38	Fine-tuning molecular profiling in advanced NSCLC <u>F. Länger</u> , Hannover Medical School, Hannover, DE	
10:38 - 10:54	Update on new targeted treatment options for patients with specific NSCLC subtypes <u>N. Leighl</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
10:54 - 11:10	Tackling resistance to targeted therapy <u>J. Vansteenkiste</u> , University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE	
11:10 - 11:25	Treatment decision-making: An interactive case discussion <u>J. Mazieres</u> , Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR	
11:25 - 11:33	Quiz questions revisited <u>J. Mazieres</u> , Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR	
11:33 - 11:43	Q&A <u>J. Mazieres</u> ¹ , <u>N. Leighl</u> ² , <u>J. Vansteenkiste</u> ³ , <u>F. Länger</u> ⁴ , ¹ Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR, ² UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ³ University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁴ Hannover Medical School, Hannover, DE	
11:43 - 11:45	Pearls for practice <u>J. Mazieres</u> , Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR	

12:00 - 13:45	Type: Opening session Title: Opening session	6.P - Paris Auditorium
12:00 - 12:18	Welcome and Presidential address <u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
12:18 - 12:22	Scientific Co-Chair addresses <u>F. André</u> ¹ , <u>C. Swanton</u> ² , ¹ Gustave Roussy - Cancer Campus, Villejuif, FR, ² Francis Crick Institute, London, GB	
12:22 - 12:35	Presentation of ESMO awards 2020 and 2021 <u>A. Psyrri</u> , Attikon University Hospital, Haidari, GR	
12:35 - 12:52	ESMO Award 2022 - Is oncology complex or simple? <u>K. Fizazi</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
12:52 - 13:09	ESMO Award for Translational Research 2022 - Making sense of cancer evolution for patient benefit <u>S. Turajlic</u> , The Royal Marsden Hospital - Chelsea, London, GB	
13:09 - 13:26	ESMO Women for Oncology Award 2022 - Gender gap and women's rights: One step forward, two steps back?! <u>F. Cardoso</u> , Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT	
13:26 - 13:43	ESMO Lifetime Achievement Award 2022 - Renal cancer: A model for oncology training <u>B. Escudier</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
13:43 - 13:45	Closure of the Opening Ceremony <u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	

14:00 - 15:30	Type: Special symposium Title: Are novel immunotherapeutics and targeted treatments going to transform the management of CRC? Chair(s): Clara Montagut Viladot, ES; Andrea Sartore Bianchi, IT	4.A - Antibes Auditorium
14:00 - 14:05	Introduction and scientific background <u>C. Montagut Viladot</u> , Hospital del Mar - Parc de Salut Mar, Barcelona, ES	
14:05 - 14:20	Targeting the uncommon molecular alterations <u>A. Sartore Bianchi</u> , Università degli Studi di Milano, Milan, IT	
14:20 - 14:35	Drugging KRAS in CRC: where do we stand? <u>R. Dienstmann</u> , Grupo Oncoclinicas, Sao Paulo, BR	
14:35 - 14:50	Immunomodulatory strategies for non-MSI-H metastatic colorectal cancer <u>G. Argiles Martinez</u> , Memorial Sloan Kettering Cancer Center, New York, US	
14:50 - 15:05	Neoadjuvant immunotherapy in CRC: where do we go from here? <u>M. Chalabi</u> , Netherlands Cancer Institute, Amsterdam, NL	
15:05 - 15:10	Conclusions and perspectives <u>A. Sartore Bianchi</u> , Università degli Studi di Milano, Milan, IT	
15:10 - 15:30	Discussion	
14:00 - 15:30	Type: Educational session Title: Updates in the standard of care of metastatic breast cancer Chair(s): Lisa Carey, US; Shaheenah Dawood, AE	4.B - Brest Auditorium
14:00 - 14:25	ER+ HER2 - advanced breast cancer <u>S. Johnston</u> , London, GB	
14:25 - 14:50	HER2+ advanced breast cancer <u>S. Modi</u> , MSKCC - Memorial Sloan Kettering Cancer Center, New York, US	
14:50 - 15:15	Triple negative advanced breast cancer <u>L. Carey</u> , Chapel Hill, NC, US	
15:15 - 15:30	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

14:00 - 15:30	Type: Educational session Title: Using molecular data that impacts clinical practice Chair(s): Elena Castro Marcos, ES; Gerhardt Attard, GB	7.1.C - Cannes Auditorium
14:00 - 14:25	Matching a molecular readout to a novel therapeutic M. Lolkema, Erasmus MC - University Medical Center, Rotterdam, NL	
14:25 - 14:50	Neuroendocrine disease: Molecular data and new models H. Beltran, Boston, MA, US	
14:50 - 15:15	Is germline testing needed and does it impact treatment decisions? E. Castro Marcos, Hospital Universitario 12 de Octubre, Madrid, ES	
15:15 - 15:30	Discussion A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH	
14:00 - 15:30	Type: Proffered Paper session Title: Proffered Paper session: Gynaecological cancers Chair(s): Jonathan Ledermann, GB; Alexandra Leary, FR	7.2.F - Fécamp Auditorium
14:00 - 14:10	LBA29 - Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) I. Ray-Coquard ¹ , A. Leary ² , S. Pignata ³ , C. Cropet ¹ , A.J. Gonzalez Martin ⁴ , G. Bogner ⁵ , H. Yoshida ⁶ , I. Vergote ⁷ , N. Colombo ⁸ , J. Maenpaa ⁹ , F. Selle ¹⁰ , B. Schmalfeldt ¹¹ , G. Scambia ¹² , E.M. Guerra Alia ¹³ , C. Lefeuvre-Plesse ¹⁴ , A. Belau ¹⁵ , A. Lortholary ¹⁶ , M. Gropp-Meier ¹⁷ , E. Pujade-Lauraine ¹⁸ , P. Harter ¹⁹ , ¹ Centre Léon Bérard, and GINECO, Lyon, FR, ² Institut Gustave Roussy, and GINECO, Villejuif, FR, ³ Istituto Nazionale Tumori 'Fondazione G Pascale', IRCCS, and MITO, Napoli, IT, ⁴ Clínica Universidad de Navarra, and GEICO, Madrid, ES, ⁵ Paracelsus Medical University Salzburg, and AGO Au, Salzburg, AT, ⁶ Saitama Medical University International Medical Center, and GOTIC, Saitama, JP, ⁷ University Hospital Leuven, Leuven Cancer Institute, and BGOG, Leuven, BE, ⁸ University of Milan-Bicocca and Istituto Europeo di Oncologia IRCCS Milan, and MANGO, Milan, IT, ⁹ Tampere University and University Hospital, and NSGO, Tampere, FI, ¹⁰ Groupe Hospitalier Diaconesses Croix Saint-Simon, and GINECO, Paris, FR, ¹¹ Universitätsklinikum Hamburg-Eppendorf, and AGO, Hamburg, DE, ¹² U.O. di Ginecologia Oncologica - Fondazione Policlinico Universitario Gemelli Università Cattolica del Sacro Cuore di Roma, and MITO, Rome, IT, ¹³ Hospital Universitario Ramón y Cajal, and GEICO, Madrid, ES, ¹⁴ Centre Eugène Marquis, and GINECO, Rennes, FR, ¹⁵ Universitätsmedizin Greifswald, Frauenklinik and Frauenarztpraxis Dr. Belau, and AGO, Greifswald, DE, ¹⁶ Centre Catherine de Sienne, Hopital privé du Confluent, and GINECO, Nantes, FR, ¹⁷ Onkologie Ravensburg, and AGO, Ravensburg, DE, ¹⁸ ARCAGY Research, Paris, FR, ¹⁹ Kliniken Essen-Mitte, and AGO, Essen, DE	
14:10 - 14:20	5170 - Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm)	

who received maintenance olaparib in the SOLO1/GOG-3004 trial

P. Disilvestro¹, S. Banerjee², N. Colombo³, G. Scambia⁴, B.-G. Kim⁵, A. Oaknin⁶, M. Friedlander⁷, A. Lisyanskaya⁸, A. Floquet⁹, A. Leary¹⁰, G. Sonke¹¹, C. Gourley¹², A. Oza¹³, A.J. Gonzalez Martin¹⁴, C. Aghajanian¹⁵, W. Bradley¹⁶, C. Mathews¹, J. Mcnamara¹⁷, E. Lowe¹⁸, K. Moore¹⁹, ¹Women & Infants Hospital, Providence, US, ²The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, GB, ³University of Milan-Bicocca and Istituto Europeo di Oncologia, Milan, IT, ⁴Università Cattolica del Sacro Cuore-Fondazione Policlinico A. Gemelli, IRCCS, Rome, IT, ⁵Sungkyunkwan University School of Medicine, Seoul, KR, ⁶Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁷University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, AU, ⁸St Petersburg City Oncological Dispensary, Saint-Petersburg, RU, ⁹Institut Bergonié, Comprehensive Cancer Centre and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Bordeaux, FR, ¹⁰Institut Gustave-Roussy and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Villejuif, FR, ¹¹The Netherlands Cancer Institute, Amsterdam, NL, ¹²Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, GB, ¹³Princess Margaret Cancer Centre, Toronto, CA, ¹⁴Clinica Universidad de Navarra, Madrid, ES, ¹⁵Memorial Sloan Kettering Cancer Center, New York, US, ¹⁶Froedtert and the Medical College of Wisconsin, Milwaukee, US, ¹⁷AstraZeneca, Cambridge, GB, ¹⁸AstraZeneca, Gaithersburg, US, ¹⁹Stephenson Oklahoma Cancer Center, Oklahoma City, US

14:20 - 14:30

5180 - Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation

A. Oza¹, A. Lisyanskaya², A. Fedenko³, A. De Melo⁴, Y. Shparik⁵, I. Bondarenko⁶, N. Colombo⁷, D. Lorusso⁸, D. Cibula⁹, R.L. Póka¹⁰, A. Oaknin¹¹, T. Safra¹², B. Maćkowiak-Matejczyk¹³, L. Ma¹⁴, D. Thomas¹⁵, K. Lin¹⁵, K. Mclachlan¹⁵, S. Goble¹⁵, R. Kristeleit¹⁶, ¹Princess Margaret Cancer Centre, University Health Network, Toronto, CA, ²Saint Petersburg City Oncological Dispensary, Saint Petersburg, RU, ³N.N. Blokhin Russian Cancer Research Center, Moscow, RU, ⁴Instituto Nacional de Câncer - Hospital do Câncer II, Rio de Janeiro, BR, ⁵Lviv Regional Oncology Dispensary, Lviv, UA, ⁶Dnipropetrovsk Medical Academy, Dnipro, UA, ⁷University of Milan-Bicocca and European Institute of Oncology (IEO) IRCCS, Milan, IT, ⁸Fondazione Policlinico Universitario Gemelli IRCCS and Catholic University of Sacred Heart, Rome, IT, ⁹First Faculty of Medicine, Charles University and General University Hospital, Prague, CZ, ¹⁰Clinical Center, University of Debrecen, Debrecen, HU, ¹¹Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, ¹²Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IL, ¹³Białostockie Centrum Onkologii im. Marii Skłodowskiej-Curie, Białostockie, PL, ¹⁴Rocky Mountain Cancer Centers, Lakewood, US, ¹⁵Clovis Oncology, Inc., Boulder, US, ¹⁶Guy's and St Thomas' NHS Foundation Trust, London, GB

14:30 - 14:40

Invited Discussant LBA29, 5170 and 5180

J. Ledermann, UCL Cancer Institute - UCL - London's Global University, London, GB

14:40 - 14:50

Q&A

- 14:50 - 15:00 **LBA30 - Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)**
J.E. Kurtz¹, E. Pujade-Lauraine², A. Oaknin³, L. Belin⁴, I. Tsibulak⁵, D. Cibula⁶, I. Vergote⁷, O. Rosengarten⁸, M. Rodrigues⁹, N. De Gregorio¹⁰, J. Martinez-Garcia¹¹, P. Pautier¹², M.A. Mouret Reynier¹³, F. Selle¹⁴, V. D'Hondt¹⁵, F. Joly Lobbedez¹⁶, E. Bultot Boissier¹⁷, A. Floquet¹⁸, P.-E. Heudel¹⁹, F. Heitz²⁰, ¹Service d'Oncologie médicale, Strasbourg, FR, ²RESEARCH, Paris, FR, ³Medical Oncology, Barcelona, ES, ⁴Hôpital Pitié Salpêtrière, Département de Santé Publique, Unité de Recherche Clinique PSL-CFX, CIC-1901, Paris, FR, ⁵Gynecology & Obstetrics Department, Innsbruck, AT, ⁶Department of Obstetrics and Gynecology, Prague, CZ, ⁷Department of Gynecology, Leuven, BE, ⁸Oncology department, Jerusalem, IL, ⁹Medical Oncology, Paris, FR, ¹⁰Oncology department, Heilbronn, DE, ¹¹Medical Oncology department, El Palmar, ES, ¹²Medicine Dept., Villejuif, Cedex, FR, ¹³Oncology department, Clermont-Ferrand, FR, ¹⁴Oncology department, Paris, FR, ¹⁵Medical Oncology, Montpellier, Cedex, FR, ¹⁶Medical oncology department, Caen, Cedex, FR, ¹⁷Oncology department, PARIS, FR, ¹⁸Medical Oncology Dept, Bordeaux, FR, ¹⁹Oncology department, Lyon, FR, ²⁰Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, BERLIN, DE
- 15:00 - 15:10 **LBA31 - Randomized phase III trial of maintenance chemotherapy with tegafur-uracil versus observation following concurrent chemoradiotherapy for locally advanced cervical cancer, GOTIC-002 LUFT trial**
K. Fujiwara¹, S. Nishio², K. Yamamoto³, H. Fujiwara⁴, H. Itagaki⁵, T. Nagai⁶, H. Takano⁷, S. Yamaguchi⁸, A. Kudoh⁹, Y. Suzuki¹⁰, T. Nakamoto¹¹, M. Kamio¹², K. Kato¹³, K. Nakamura¹⁴, K. Takehara¹⁵, H. Yahata¹⁶, H. Kobayashi¹⁷, M. Saito¹⁸, K. Ushijima², K. Hasegawa¹, ¹Saitama Medical University International Medical Center, Saitama, JP, ²Kurume University School of Medicine, Kurume, JP, ³Yokohama City University, School of Medicine, Yokohama, JP, ⁴Jichi Medical University Hospital, Shimotsuke, JP, ⁵University of Tsukuba, Tsukuba, JP, ⁶Saitama Medical Center, Saitama Medical University, Saitama, JP, ⁷Jikei University Kashiwa Hospital, Kashiwa, JP, ⁸Hyogo Cancer Center, Akashi, JP, ⁹Tottori University Hospital, Yonago, JP, ¹⁰Saitama Cancer Center, Kita-Adachi-gun, JP, ¹¹Ryukoku University, Otsu, JP, ¹²Kagoshima Medical Center, Kagoshima, JP, ¹³Kitasato University, Sagamihara City, JP, ¹⁴Gunma Prefectural Cancer Center, Ota, JP, ¹⁵Shikoku Cancer Center, Matsuyama, JP, ¹⁶Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, ¹⁷Kagoshima University, Kagoshima, JP, ¹⁸Jikei University School of Medicine, Tokyo, JP
- 15:10 - 15:20 **Invited Discussant LBA30 and LBA31**
M.R. Mirza, Rigshospitalet, Copenhagen, DK
- 15:20 - 15:30 **Q&A**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

14:00 - 15:30	Type: Special symposium Title: Exploiting synthetic lethality: The next generation Chair(s): Timothy Yap, US; Violeta Serra, ES	7.1.D - Dijon Auditorium
14:00 - 14:05	Introduction and scientific background <u>T. Yap</u> , The University of Texas M. D. Anderson Cancer Center, Houston, US	
14:05 - 14:20	Next generation synthetic lethal target discovery using high-throughput CRISPR technology <u>M. Garnett</u> , Wellcome Trust Sanger Institute, Cambridge, GB	
14:20 - 14:35	Modern translational correlatives for synthetic lethality trials <u>V. Serra</u> , Barcelona, ES	
14:35 - 14:50	Clinical development of next generation DDR agents for molecularly-selected tumours <u>T. Yap</u> , The University of Texas M. D. Anderson Cancer Center, Houston, US	
14:50 - 15:05	Exploiting synthetic lethality for non-DDR approaches in the clinic <u>S. Martin</u> , London,	
15:05 - 15:10	Conclusions and perspectives <u>V. Serra</u> , Barcelona, ES	
15:10 - 15:30	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

14:00 - 15:30 **Type: Educational session** **7.3.G - Grenoble Auditorium**
Title: Ultra-rare sarcoma: Navigating an endless sea
 Chair(s): Silvia Stacchiotti, IT; Herbert Ho Fung Loong, HK

14:00 - 14:25 **The role of molecular biology in defining new entities**
I.-M. Schaefer, Brigham and Women's Hospital, Boston, US

14:25 - 14:50 **New drugs for ultrarare sarcoma**
S. Stacchiotti, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

14:50 - 15:15 **Advocating for patients with ultra-rare cancer**
H. Leonard, EHE Rare Cancer Charity, Kingston-Upon-Thames, GB

15:15 - 15:30 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

14:00 - 15:30 **Type: Special symposium** **7.3.H - Honfleur Auditorium**
Title: How the tumour microenvironment affects outcome and therapy response?
 Chair(s): Adil Daud, US; Alessandra Curioni, CH

14:00 - 14:10 **Introduction and scientific background**
A. Curioni, USZ - University Hospital Zürich, Zurich, CH

14:10 - 14:25 **Organ-specific tumour microenvironment**
A. Daud, San Francisco, CA, US

14:25 - 14:40 **The role of B cell/TLS**
C. Sautes-Fridman, Centre de Recherche des Cordeliers, Paris, FR

14:40 - 14:55 **Immune signatures in the tumour microenvironment**
K. Litchfield, UCL Cancer Institute - UCL - London's Global University, London, GB

14:55 - 15:00 **Conclusions and perspectives**
A. Daud, San Francisco, CA, US

15:00 - 15:20 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

14:00 - 15:30 **Type: Educational session** **7.3.O - Orléans Auditorium**
Title: Advances in non-cutaneous melanoma
 Chair(s): Sapna Patel, US; Teresa Troiani, IT

14:00 - 14:25 **Uveal melanoma**

S. Patel, MD Anderson Cancer Center, Houston, US

14:25 - 14:50 **Mucosal melanoma**

J. Hassel, NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE

14:50 - 15:15 **Acral melanoma**

M. Carlino, Westmead, AU

15:15 - 15:30 **Discussion**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

14:00 - 15:30 **Type: Proffered Paper session** **7.3.Q - Quimper Auditorium**
Title: Proffered Paper session: CNS tumours
 Chair(s): Giuseppe Minniti, IT; Dieta Brandsma, NL

14:00 - 14:10 **2770 - The ReSPECT-GBM#x2122; phase I/IIa trial of rhenium-186 nanoliposome (186RNL) in recurrent glioma via convection enhanced delivery (CED) and planned phase IIb trial**

A. Brenner¹, W. Phillips², A. Bao³, M.H. Hedrick⁴, J. Michalek², N. Lafrance⁴, T. Patel⁵, J. Weinberg⁶, J. Floyd⁷, ¹Institute for Drug Development Cancer Therapy Research Center, San Antonio, US, ²UTHSCSA - University of Texas Health Science Center at San Antonio, San Antonio, US, ³The University Hospital Cleveland Medical Center, Cleveland, US, ⁴Plus Therapeutics, Austin, US, ⁵UT Southwestern Medical Center, Dallas, US, ⁶The University of Texas MD Anderson Cancer Center, Houston, US, ⁷UT Health San Antonio, San Antonio, US

14:10 - 14:20 **2780 - Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295**

J. Campian¹, O. Butt², J. Huang³, J. Luo³, Y. Tao³, R. Strowd⁴, D. Hissim⁴, S. Kizilbash¹, C. Abraham³, G. Ansstas², T. Johanns², A. Kim², M. Ciorba², M. Chheda², ¹Mayo Clinic, Rochester, US, ²Washington University School of Medicine in St. Louis - Siteman Cancer Center, St. Louis, US, ³Washington University School of Medicine in St. Louis, St. Louis, US, ⁴Wake Forest University Comprehensive Cancer Center, Winston-Salem, US

14:20 - 14:30 **Invited Discussant 2770 and 2780**

G. Minniti, University of Siena, Siena, IT

14:30 - 14:40 **Q&A**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

- 14:40 - 14:50 **2790 - ctDNA detection in cerebrospinal fluid and concordance with the primary tumor in a multicenter prospective study of patients with glioma**
S. Cabezas-Camarero¹, R. Pérez-Alfayate¹, V. García-Barberán¹, M. Gandía², P. García-Feijóo², I. López-Cade¹, I. Casado-Fariñas¹, N. Cerón¹, M. Sotelo Lezama³, P. Pérez Segura¹, ¹Hospital Clinico Universitario San Carlos, Madrid, ES, ²Hospital Universitario La Paz, Madrid, ES, ³Hospital Maria Auxiliadora, Lima, PE
- 14:50 - 15:00 **2800 - Pharmacokinetics and pharmacodynamics of paxalisib in newly diagnosed glioblastoma patients with unmethylated MGMT promoter status: Final phase II study results**
P. Wen¹, J. De Groot², J. Battiste³, S. Goldlust⁴, D. Damek⁵, B. Ellingson⁶, J. Garner⁷, J. Friend⁷, J. Simpson⁷, A. Olivero⁸, T. Cloughesy⁹, ¹Dana Farber Cancer Institute, Boston, US, ²The University of Texas M. D. Anderson Cancer Center, Houston, US, ³Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, ⁴John Theurer Cancer Center - Hackensack University Medical Center, Hackensack, US, ⁵UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, ⁶UCLA Brain Tumor Imaging Laboratory, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, US, ⁷Kazia Therapeutics Limited, Sydney, AU, ⁸Olivero Consulting, Half Moon Bay, US, ⁹Ronald Reagan UCLA Medical Center University of California, Los Angeles, US
- 15:00 - 15:10 **Invited Discussant 2790 and 2800**
F. De Vos, UMC - University Medical Center Utrecht, Utrecht, NL
- 15:10 - 15:20 **Q&A**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

14:00 - 15:30	Type: Special symposium Title: How diagnostic tools impact therapy of haematological malignancies Chair(s): Lars Bullinger, DE	7.3.T - Toulouse Auditorium
14:00 - 14:15	Acute myeloid leukaemia <u>L. Bullinger</u> , Universitätsklinik Charité - Campus Virchow Klinikum, Berlin, DE	
14:15 - 14:30	PET: New applications <u>M. Mayerhoefer</u> , New York, NY, US	
14:30 - 14:45	Molecular classification of aggressive lymphoma <u>F. Jardin</u> , Rouen, FR	
14:45 - 15:00	Will circulating tumour DNA have a role in treatment decisions? <u>F. Scherer</u> , University Medical Center Freiburg, Freiburg im Breisgau, DE	
15:00 - 15:05	Conclusions and perspectives <u>L. Bullinger</u> , Universitätsklinik Charité - Campus Virchow Klinikum, Berlin, DE	
15:05 - 15:30	Discussion	

14:00 - 15:30	Type: Patient Advocacy session Title: The impact of COVID-19 on patients with cancer: Lessons learnt and pathway for the future Chair(s): Christopher Curtis, GB; Tanja Spanic, SI	7.3.M - Marseille Auditorium
14:00 - 14:15	The impact of COVID-19 pandemic on cancer patients and early diagnosis - Time to act! <u>M. Lawler</u> , Queen's University Belfast, Belfast, GB	
14:15 - 14:30	The impact of COVID-19 on patient-physician communication and the role of telemedicine <u>I. Ratos</u> , Institute of Oncology Ljubljana, Ljubljana, SI	
14:30 - 14:45	The impact of COVID-19 on surgery <u>F. Rimareix</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
14:45 - 15:00	The impact of COVID-19 on advocacy networks <u>L. Makaroff</u> , Fight Bladder Cancer, Chinnor, GB	
15:00 - 15:15	COVID-19 and the pathway for the future to support patients with cancer <u>C. Curtis</u> , Chris Curtis Consultant Ltd, Blackpool, GB	
15:15 - 15:25	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
15:25 - 15:30	Conclusion	

14:00 - 15:30	Type: Special session Title: 5-year impact of new registered indications on the ESMO-MCBS Chair(s): E.G. Elisabeth de Vries, NL; Nathan Cherny, IL	7.3.U - Urval Auditorium
14:00 - 14:05	Introduction <u>E.G.E. De Vries</u> , Groningen, NL	
14:05 - 14:30	Five years of FDA approvals (2017-2022): A report from the ESMO-MCBS <u>N. Cherny</u> , Shaare Zedek Medical Center, Jerusalem, IL	
14:30 - 14:55	Long term follow-up on single arm registration studies: what have we learned? <u>B. Gyawali</u> , KAHS - Karnali Academy of Health Sciences, Chandannath, NP	
14:55 - 15:20	ICI landscape in solid tumours: what are the scores, are there differences and why? <u>L. Castelo-Branco</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
15:20 - 15:30	Conclusions and Q&A <u>E.G.E. De Vries</u> , Groningen, NL	

14:00 - 15:30 Type: Young Oncologist session 7.3.L - Lyon
Title: ON-SITE ONLY: Young Oncologist Mentorship sessions

14:00 - 14:00	<p>Table 1: Clinical oncology</p> <p><u>M. Lambertini</u>¹, <u>A. Prat</u>², ¹IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ²Hospital Clinic y Provincial de Barcelona, Barcelona, ES</p>
14:00 - 14:00	<p>Table 2: Clinical oncology</p> <p><u>S. Braga</u>¹, <u>E. Connolly</u>², ¹José de Mello Saúde, Lisbon, PT, ²Chris O'Brien Lifehouse, Camperdown, AU</p>
14:00 - 14:00	<p>Table 3: Translational research</p> <p><u>S. Turajlic</u>¹, <u>A. Matikas</u>², ¹The Royal Marsden Hospital - Chelsea, London, GB, ²Karolinska Institutet, Huddinge, SE</p>
14:00 - 14:00	<p>Table 4: Translational research</p> <p><u>C.B. Westphalen</u>¹, <u>M. Kfoury</u>², ¹LMU Klinikum der Universität München, Munich, DE, ²Institut Gustave Roussy, Villejuif, Cedex, FR</p>
14:00 - 14:00	<p>Table 5: Becoming an early phase trial oncologist</p> <p><u>N. Cook</u>, <u>R. Pihlak</u>, The Christie NHS Foundation Trust, Manchester, GB</p>
14:00 - 14:00	<p>Table 6: The role of clinician scientist</p> <p><u>M.E. Elez Fernandez</u>¹, <u>R. Sanchez Bayona</u>², ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Hospital Universitario 12 de Octubre, Madrid, ES</p>
14:00 - 14:00	<p>Table 7: The role of clinician-scientist</p> <p><u>C. Serrano</u>¹, <u>K.H.J. Lim</u>², ¹Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ²The Francis Crick Institute, London, GB</p>
14:00 - 14:00	<p>Table 8: Policy making and public health</p> <p><u>A. Ilbawi</u>¹, <u>E. Mariamidze</u>², ¹WHO - World Health Organization, Geneva, CH, ²Todua Clinic, Tbilisi, GE</p>

15:45 - 17:30	Type: Special session Title: 7th ESMO Designated Centres of Integrated Oncology and Palliative Care and Awards Session: Where are we going and what's next Chair(s): Stein Kaasa, NO; Gudrun Kreye, AT	7.3.U - Urval Auditorium
15:45 - 15:50	Introduction <u>S. Kaasa</u> , Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO	
15:50 - 16:05	Designated Centres Survey: Education, research, programme development - Final results <u>G. Kreye</u> , Universitätsklinikum Krems, Krems an der Donau, AT	
16:05 - 16:20	My Path: improving the content, quality and cost-effectiveness of cancer treatment <u>S. Kaasa</u> , Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO	
16:20 - 16:35	Financial toxicity and out of pocket cost for supportive care medications among cancer patients <u>R. Giusti</u> , AOU Sant'Andrea, Rome, IT	
16:35 - 17:00	Panel Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
17:00 - 17:10	Conclusion and next steps <u>S. Kaasa</u> , Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO	
17:10 - 17:30	Designated Centre and Palliative Care Fellowship Awards <u>G. Kreye</u> , Universitätsklinikum Krems, Krems an der Donau, AT	
16:00 - 17:30	Type: Proffered Paper session Title: Proffered Paper session: Breast cancer, metastatic Chair(s): Peter Schmid, GB; Sibylle Loibl, DE	4.B - Brest Auditorium
16:00 - 16:10	LBA15 - MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR⁺, HER2-advanced breast cancer (ABC) <u>M. Goetz</u> ¹ , M. Toi ² , J. Huober ³ , J. Sohn ⁴ , O. Tredan ⁵ , I.H. Park ⁶ , M. Campone ⁷ , S.C. Chen ⁸ , L. Manso Sanchez ⁹ , S. Paluch-Shimon ¹⁰ , G. Van Hal ¹¹ , A. Shahir ¹¹ , H. Iwata ¹² , S. Johnston ¹³ , ¹ Mayo Clinic, Rochester, US, ² Kyoto University Hospital, Kyoto, JP, ³ Kantonsspital St. Gallen, St. Gallen, CH, ⁴ Yonsei University, Seoul, KR, ⁵ Centre Léon Bérard, Lyon, FR, ⁶ Korea University College of Medicine, Seoul, KR, ⁷ ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁸ Chang Gung Medical Foundation- Taipei Chang Gung Memorial Hospital, Taipei City, TW, ⁹ Hospital Universitario 12 de Octubre, Madrid, ES, ¹⁰ Hadassah University Hospital - Ein Kerem, Jerusalem, IL, ¹¹ Eli Lilly and Company, Indianapolis, US, ¹² Aichi Cancer Center Hospital,	

Nagoya, JP, ¹³Royal Marsden Hospital, London, GB

- 16:10 - 16:20 **LBA16 - Dapiciclib plus letrozole or anastrozole as first-line treatment for HR⁺/HER2- advanced breast cancer (DAWNA-2): A phase III trial**
B. Xu¹, Q.Y. Zhang², P. Zhang¹, Z. Tong³, T. Sun⁴, W. Li⁵, Q. Ouyang⁶, X. Hu⁷, Y. Cheng⁸, M. Yan⁹, Y. Teng¹⁰, Y. Pan¹¹, X. Yan¹², Y. Wang¹³, W. Xie¹⁴, X. Zeng¹⁵, S. Jiang¹⁶, N. Bayaxi¹⁶, X. Zhu¹⁶, ¹National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ²Harbin Medical University Cancer Hospital, Harbin, CN, ³Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ⁴Cancer Hospital of China Medical University/Liaoning Cancer Hospital, Shenyang, CN, ⁵The First Hospital of Jilin University, Changchun, CN, ⁶Hunan Cancer Hospital, Changsha, CN, ⁷Fudan University Shanghai Cancer Center, Shanghai, CN, ⁸Jilin Cancer Hospital, Changchun, CN, ⁹Henan Breast Cancer Center/the affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN, ¹⁰The First Affiliated Hospital of China Medical University, Shenyang, CN, ¹¹Anhui Provincial Hospital, Hefei, CN, ¹²West China Hospital, Sichuan University, Chengdu, CN, ¹³Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, CN, ¹⁴Guangxi Medical University Cancer Hospital, Nanning, CN, ¹⁵Chongqing University Cancer Hospital/Chongqing Cancer Hospital, Chongqing, CN, ¹⁶Jiangsu Hengrui Pharmaceutical Co., Ltd., Shanghai, CN
- 16:20 - 16:30 **LBA76 - Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR⁺/HER2- metastatic breast cancer (mBC)**
H. Rugo¹, A. Bardia², F. Marmé³, J. Cortés⁴, P. Schmid⁵, D. Loirat⁶, O. Tredan⁷, E. Ciruelos⁸, F. Dalenc⁹, P. Gomez Pardo¹⁰, K. Jhaveri¹¹, R. Delaney¹², T. Valdez¹², H. Wang¹², W. Verret¹², S. Tolaney¹³, ¹University of California-San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ²Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US, ³Medical Faculty Mannheim, Heidelberg University, Department of Obstetrics and Gynaecology, Mannheim, DE, ⁴International Breast Cancer Center (IBCC), Pangaea Oncology, Quirosalud Group, Madrid & Barcelona, Spain, Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, ES, ⁵Barts Cancer Institute, Queen Mary University of London, London, GB, ⁶Institut Curie, Paris, FR, ⁷Centre Léon Bérard, Lyon, FR, ⁸Hospital Universitario 12 de Octubre, Madrid, ES, ⁹Institut Claudius Régaud, Toulouse, FR, ¹⁰Hospital Universitari Vall D'Hebron, Barcelona, ES, ¹¹Memorial Sloan-Kettering Cancer Center (MSKCC), New York, US, ¹²Gilead Sciences, Inc., Foster City, US, ¹³Dana-Farber Cancer Institute, Harvard Medical School, Boston, US
- 16:30 - 16:40 **Invited Discussant LBA15, LBA16 and LBA76**
M. Bellet Ezquerro, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES
- 16:40 - 16:50 **Q&A**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH
- 16:50 - 17:00 **2100 - Mutational signature analysis reveals patterns of genomic instability**

linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)

A. Marra¹, A. Gazzo¹, A. Gupta¹, P. Selenica¹, E. Da Silva¹, F. Pareja¹, X. Pei¹, Y. Zhu¹, P. Razavi¹, A. Safonov¹, E. Ferraro¹, R. Harris², N. Riaz¹, J. Reis-Filho¹, S. Chandarlapaty¹,
¹Memorial Sloan Kettering Cancer Center, New York, US, ²University of Minnesota, Minneapolis, US

17:00 - 17:10

LBA17 - Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)

L. Buisseret¹, D. Loirat², P. Aftimos³, K. Punie⁴, C. Maurer⁵, V. Debien¹, A. Goncalves⁶, F. Ghiringhelli⁷, D. Taylor⁸, F. Clatot⁹, T. Van Den Mooter¹⁰, J.-M. Ferrero¹¹, H. Bonnefoi¹², J.-L. Canon¹³, F. Duhoux¹⁴, F. Bazan¹⁵, P. Kristanto¹⁶, E. De Azambuja¹⁷, M. Ignatiadis¹⁶, M. Piccart¹⁶,
¹Institute Jules Bordet, Brussels, BE, ²Institut Curie, Paris, FR, ³Institute Jules Bordet, Bruxelles, BE, ⁴Leuven Cancer Institute, University Hospitals Leuven, Leuven, BE, ⁵Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; University of Cologne, Cologne, DE, ⁶Institut Paoli-Calmettes, Marseille, FR, ⁷Centre Georges-François Leclerc (Dijon), Dijon, FR, ⁸CHU-UCL-Namur - Site Sainte-Elisabeth, Namur, BE, ⁹Centre Henri Becquerel, Rouen, FR, ¹⁰GZA Ziekenhuizen Campus Sint-Augustinus, Antwerp, BE, ¹¹Centre Antoine Lacassagne, Nice, FR, ¹²Institut Bergonié, Bordeaux, FR, ¹³Grand Hôpital de Charleroi - Site Notre Dame, Charleroi, BE, ¹⁴Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Brussels, BE, ¹⁵CHRU Besançon - Hôpital Jean Minjoz, Besançon, FR, ¹⁶Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, BE, ¹⁷Institute Jules Bordet, Université Libre de Bruxelles (ULB), Bruxelles, BE

17:10 - 17:20

Invited Discussant 2100 and LBA17

P. Schmid, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB

17:20 - 17:30

Q&A

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

16:00 - 17:30	Type: Educational session Title: Adjuvant and perioperative therapy for non-colorectal GI cancers: Latest status Chair(s): Elizabeth Smyth, GB; Lam Chan, HK	7.1.C - Cannes Auditorium
16:00 - 16:25	Gastroesophageal cancer <u>E. Smyth</u> , Addenbrooke's Hospital, Cambridge, GB	
16:25 - 16:50	Hepatobiliary cancer <u>J. Knox</u> , Toronto, ON, CA	
16:50 - 17:15	Pancreatic cancer <u>T. Conroy</u> , Vandoeuvre-lès-Nancy, FR	
17:15 - 17:30	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
16:00 - 17:30	Type: Educational session Title: Perioperative strategies in high-risk and oligometastatic renal cell (RCC) and urothelial cancers (UC) Chair(s): Elizabeth Plimack, US; Enrique Grande, ES	7.2.E - Évry Auditorium
16:00 - 16:25	Management of high-risk UC: Latest data <u>J. Bellmunt</u> , Boston, US	
16:25 - 16:50	Management of high-risk RCC: Latest data <u>J. Larkin</u> , The Royal Marsden Hospital - NHS Foundation Trust, London, GB	
16:50 - 17:15	Management of oligometastatic renal and urothelial cancers: Incorporating best practices <u>E. Plimack</u> , Fox Chase Cancer Center - Main Campus, Philadelphia, US	
17:15 - 17:30	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
16:00 - 17:15	Type: Proffered Paper session Title: Proffered Paper session: Investigational immunotherapy Chair(s): John Haanen, NL; Evan Lipson, US	7.2.F - Fécamp Auditorium
16:00 - 16:10	LBA37 - A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung) <u>M. Schuler</u> ¹ , K. Cuppens ² , T. Ploenes ³ , M. Vanboeckrijck ² , M. Wiesweg ¹ , K. Darwiche ³ , A. Schramm ¹ , B. Maes ² , B. Hegedus ⁴ , H.-U. Schildhaus ¹ , H. Hautzel ¹ , D. Theegarten ¹ , P. Baas ⁵ , K. Hartemink ⁵ , B. Du Pont ² , C. Aigner ³ , ¹ University Hospital Essen, Essen, DE,	

²Jessa Hospital, Hasselt, BE, ³University Medicine Essen - Ruhrlandklinik, Essen, DE, ⁴University Medicine Essen - Ruhrlandklinik, Essen, DE, ⁵Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

16:10 - 16:20 **Invited Discussant LBA37**

E. Lipson, Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US

16:20 - 16:30 **Q&A**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

16:30 - 16:40 **LBA38 - BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours**

A. Mackensen¹, J. Haanen², C. Koenecke³, W. Alsdorf⁴, E. Wagner-Drouet⁵, D. Heudobler⁶, P. Borchmann⁷, C. Bokemeyer⁴, S. Klobuch², E. Smit², F. Müller¹, A. Desuki⁵, F. Lüke⁶, E. Wiegert⁸, C. Flemmig⁹, C. Schulz-Eying⁹, B. Rengstl⁹, L. Preussner⁹, Ö. Türeci⁹, U. Sahin⁹, ¹University Hospital Erlangen, Erlangen, DE, ²Netherlands Cancer Institute, Amsterdam, NL, ³Hannover Medical School, Hannover, DE, ⁴University Medical Center Hamburg-Eppendorf, Hamburg, DE, ⁵University Medical Center Mainz, Mainz, DE, ⁶University Hospital Regensburg, Regensburg, DE, ⁷University Hospital of Cologne, Cologne, DE, ⁸Bexon Clinical Consulting, Montclair, US, ⁹BioNTech SE, Mainz, DE

16:40 - 16:50 **7280 - Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors**

O. Hamid¹, T. Sato², D. Davar³, M. Callahan⁴, F. Thistlethwaite⁵, R. Aljumaily⁶, M. Johnson⁷, H.-T. Arkenau⁸, E. Ileana Dumbrava⁹, B. Izar¹⁰, H.A. Chen¹¹, S. Marshall¹², Y. Yuan¹², M. Deo¹³, S. Stanhope¹⁴, L. Collins¹⁵, R. Mundy¹³, S. Abdullah¹³, J. Lopez¹⁶, ^{1A}Cedars Sinai Affiliate, Los Angeles, US, ²Thomas Jefferson Univ Hospital, Philadelphia, US, ³University of Pittsburgh Cancer Institute, Pittsburgh, US, ⁴Memorial Sloan Kettering Cancer Center, New York, US, ⁵The Christie NHS Foundation Trust, Manchester, GB, ⁶University of Oklahoma, Oklahoma City, US, ⁷Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ⁸Sarah Cannon Research Institute SCRI UK, London, GB, ⁹The University of Texas M. D. Anderson Cancer Center, Houston, US, ¹⁰Columbia University Medical Center, New York, US, ¹¹University of California Davis Comprehensive Cancer Center, Sacramento, US, ¹²Immunocore LLC, Rockville, US, ¹³Immunocore LLC, Conshohocken, US, ¹⁴Immunocore Ltd, Abingdon-on-Thames, GB, ¹⁵Immunocore Limited, Abingdon-on-Thames, GB, ¹⁶The Royal Marsden Hospital NHS Foundation Trust, Sutton, GB

16:50 - 17:00 **Invited Discussant LBA38 TBC and 7280**

D. Braun, Yale University School of Medicine - Yale Cancer Center, New Haven, US

17:00 - 17:15 **Q&A**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

16:00 - 17:30	Type: Educational session Title: Emerging treatment strategies for non-metastatic NSCLC Chair(s): Mariano Provencio Pulla, ES; Kersti Oselin, EE	7.1.D - Dijon Auditorium
----------------------	--	---------------------------------

16:00 - 16:25 **Perioperative targeted therapy for early-stage NSCLC**

H. Wakelee, Stanford University, Stanford, US

16:25 - 16:50 **Perioperative immunotherapy for early-stage NSCLC**

M. Provencio Pulla, University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES

16:50 - 17:15 **Pathologic assessment post neo-adjuvant treatment**

S. Dacic, Pennsylvania, PA, US

17:15 - 17:30 **Discussion**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

16:00 - 17:30	Type: Educational session Title: New discoveries in cancer using single cell and spatial technologies Chair(s): Göran Jönsson, SE; Sherene Loi, AU	7.3.G - Grenoble Auditorium
----------------------	--	------------------------------------

16:00 - 16:25 **Single cell genomics to understand cancer evolution**

C. Curtis, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford, US

16:25 - 16:50 **Single cell pathology using spatial proteomics**

R. Casanova, UZH - Universität Zürich, Zurich, CH

16:50 - 17:15 **Spatial gene expression and mapping tumor morphology**

G. Jönsson, Lund University, Lund, SE

17:15 - 17:30 **Discussion**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

16:00 - 17:30	Type: Special session Title: ESMO in collaboration with MASCC- Emerging toxicities to targeted therapies: Management strategies and future directions Chair(s): Maryam Lustberg, US; Ines Vaz Luis, FR	7.3.O - Orléans Auditorium
16:00 - 16:05	Introduction <u>I. Vaz Luis</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
16:05 - 16:20	Safety management of Antibody-Drug-Conjugates <u>M. Lustberg</u> , Yale University School of Medicine, New Heaven, US	
16:20 - 16:35	Immune-check point inhibitors: From acute to long term toxicities <u>O. Lambotte</u> , CHU de Bicêtre, Le Kremlin Bicetre, FR	
16:35 - 16:50	New oral targeted therapies: Main toxicities, improve management to increase adherence <u>I. Vaz Luis</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
16:50 - 17:05	How to step up systems to better learn and manage new toxicities? <u>A. Charalambous</u> , Cyprus University of Technology - Nursing Science, Limassol, CY	
17:05 - 17:25	Panel discussion on safety management of new anticancer drugs with case discussion and Q&A <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
17:25 - 17:30	Conclusions <u>M. Lustberg</u> , Yale University School of Medicine, New Heaven, US	

16:00 - 17:30	Type: Special symposium Title: Challenging the use of small cell lung cancer as a paradigm for extrapulmonary neuroendocrine carcinoma Chair(s): Emily Bergsland, US; Halfdan Sorbye, NO	7.3.T - Toulouse Auditorium
16:00 - 16:05	Introduction and scientific background <u>H. Sorbye</u> , Haukeland Universitetssykehus, Bergen, NO	
16:05 - 16:20	Clinical and molecular features distinguish small cell lung carcinoma from extrapulmonary NEC <u>E. Bergsland</u> , UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US	
16:20 - 16:35	Treatment of gastroenteropancreatic NEC <u>H. Sorbye</u> , Haukeland Universitetssykehus, Bergen, NO	
16:35 - 16:50	Neuroendocrine prostate cancer (NEPC): A model for phenotypic plasticity <u>F. Demichelis</u> , University of Trento, Trento, IT	
16:50 - 17:05	Gynaecological NEC <u>M. Frumovitz</u> , Houston, TX, US	
17:05 - 17:10	Conclusions and perspectives <u>E. Bergsland</u> , UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US	
17:10 - 17:30	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

16:00 - 17:30	Type: Patient Advocacy session Title: Patient Advocates and their expertise: How to get involved Chair(s): Natacha Bolanos Fernandez, ES; Ananda Plate, DE	7.3.M - Marseille Auditorium
16:00 - 16:15	The importance of patients' involvement in the decision-making process <u>B. Ryll</u> , Melanoma Patient Network Europe MPNE, Uppsala, SE	
16:15 - 16:30	How to interact with policymakers <u>A. Cardone</u> , Pancreatic Cancer Europe (PCE), Brussels, BE	
16:30 - 16:45	How to grow your network <u>A. Plate</u> , Patvocates, Munich, DE	
16:45 - 17:00	How to get funding <u>J. Fratzak Kazana</u> , Alivia - Fundacja Onkologiczna Osób Młodych (Alivia - Young People Cancer Foundation), Warsaw, PL	
17:00 - 17:10	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
17:10 - 17:15	Conclusion	

16:15 - 17:15 **Type: Multidisciplinary session** **7.3.H - Honfleur Auditorium**
Title: Plenty of choices in rectal cancer
 Chair(s): Gerard Beets, NL

16:15 - 16:20 **Presentation of case/condition**
G. Folprecht, Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE

16:20 - 16:35 **Are we in the era of total neoadjuvant treatment?**
G. Folprecht, Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE

16:35 - 16:50 **Role, timing and duration of neo-adjuvant (chemo)radiotherapy**
K. Haustermans, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

16:50 - 17:05 **The surgeon's perspective: TME, local excision or watch and wait?**
G. Beets, The Netherlands Cancer Institute, Amsterdam, NL

17:05 - 17:15 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

16:15 - 17:15 **Type: Special session** **7.3.Q - Quimper Auditorium**
Title: Special session: Ovarian cancer Consensus
 Chair(s): Anna Fagotti, IT; Jonathan Ledermann, GB

16:15 - 16:20 **Clinical case 1**
M. Kfoury, Institut Gustave Roussy, Villejuif, Cedex, FR

16:20 - 16:35 **Case 1 Discussant**
A. Fagotti, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT

16:35 - 16:45 **Case 1 Discussion / Q&A**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

16:45 - 16:50 **Clinical case 2**
M. Kfoury, Institut Gustave Roussy, Villejuif, Cedex, FR

16:50 - 17:05 **Case 2 Discussant**
J. Ledermann, UCL Cancer Institute - UCL - London's Global University, London, GB

17:05 - 17:15 **Case 2 Discussion / Q&A**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

17:30 - 18:30	Type: Young Oncologist session Title: ON-SITE ONLY: Young Oncologists Vesalius Talk Chair(s): Maria Kfoury, FR; Teresa Amaral, DE; Elene Mariamidze, GE	Networking Hub
17:30 - 17:40	Introduction by the Chairs	
17:40 - 18:30	Panel discussion <u>T.S.K. Mok</u> ¹ , <u>P. Vuylsteke</u> ² , <u>M. Garassino</u> ³ , <u>A. Leary</u> ⁴ , ¹ Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK, ² University of Botswana, Gaborone, BW, ³ University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, ⁴ Institut Gustave Roussy, Villejuif, FR	
18:00 - 19:30	Type: Industry Satellite Symposium Title: Gilead and Kite Oncology - CAR T-cell therapy: The next frontier in immuno-oncology Chair(s): Mohamad Mohty, FR; Jean-Philippe Spano, FR	7.2.E - Évry Auditorium
18:00 - 18:08	Building the foundations of CAR T-cell therapy <u>M. Mohty</u> ¹ , <u>J.-P. Spano</u> ² , ¹ Hopital Saint-Antoine, Paris, FR, ² Hopital Pitié Salpêtrière AP-HP, Paris, FR	
18:08 - 18:28	CAR T-cell therapy: Pioneering the way in haematological malignancies <u>A. Sureda</u> , ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Barcelona, ES	
18:28 - 18:43	Expanding the reach of CAR T <u>M. Mohty</u> , Hopital Saint-Antoine, Paris, FR	
18:43 - 19:07	New avenues for CAR technology <u>F. Thistlethwaite</u> , The Christie NHS Foundation Trust, Manchester, GB	
19:07 - 19:15	Exploring CARs in solid tumours and closing remarks <u>J.-P. Spano</u> , Hopital Pitié Salpêtrière AP-HP, Paris, FR	
19:15 - 19:30	Q&A <u>J.-P. Spano</u> ¹ , <u>M. Mohty</u> ² , <u>A. Sureda</u> ³ , <u>F. Thistlethwaite</u> ⁴ , ¹ Hopital Pitié Salpêtrière AP-HP, Paris, FR, ² Hopital Saint-Antoine, Paris, FR, ³ ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Barcelona, ES, ⁴ The Christie NHS Foundation Trust, Manchester, GB	

18:00 - 19:30	Type: Industry Satellite Symposium Title: Servier - Interpreting real-world data to better manage patients with metastatic colorectal cancer Chair(s): Julien Taieb, FR	7.1.D - Dijon Auditorium
----------------------	---	---------------------------------

18:00 - 18:10	Introduction <u>J. Taieb</u> , Hopital European George Pompidou, Paris, FR	
18:10 - 18:25	Is there a need for real-world data? <u>C. Cremolini</u> , AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT	
18:25 - 18:40	Real-world data in mCRC <u>M. Koopman</u> , UMC - University Medical Center Utrecht, Utrecht, NL	
18:40 - 18:55	Patient insights and perspectives on real-world data <u>F. Marti</u> , The Christie NHS Foundation Trust, Manchester, GB	
18:55 - 19:10	Optimization and management of treatment in mCRC <u>D. Modest</u> , Charité - Universitaetsmedizin Berlin, Berlin, DE	
19:10 - 19:30	Conclusion and Q&A <u>J. Taieb</u> , Hopital European George Pompidou, Paris, FR	

18:00 - 19:30	Type: Industry Satellite Symposium Title: PeerView Oncology - SERDs at the Inflection Point in Pretreated ER+/HER2- Breast Cancer: Addressing Unmet Needs, Establishing New Standards of Care, and Improving Patient Outcomes With Novel ER-Targeting Therapies Chair(s): Javier Cortés, ES	7.3.G - Grenoble Auditorium
18:00 - 18:05	Welcome and Introduction <u>J. Cortés</u> , Hospital Ruber Internacional, Madrid, ES	
18:05 - 18:25	Modern Approaches in the Treatment of ER+/HER2- Breast Cancer: Understanding the Biology and Foundational Concepts <u>F.C. Bidard</u> , Institut Curie, Paris, FR	
18:25 - 18:45	ER+/HER2- Breast Cancer Pre-Treated With Endocrine Therapy as an Inflection Point: Unmet Needs and Novel Rational Treatment Strategies <u>J. Cortés</u> , Hospital Ruber Internacional, Madrid, ES	
18:45 - 19:05	Emerging Options in the Treatment of ER+/HER2- Breast Cancer: The Expanding Evidence Base on Oral SERDs and Other ER-Targeting Agents <u>A. Bardia</u> , Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US	
19:05 - 19:30	Accelerating Progress in the Treatment of Previously Treated ER+HER2- Breast Cancer With Novel Therapies: Translating Research Advances to Improvements in Practice <u>J. Cortés</u> ¹ , <u>A. Bardia</u> ² , <u>F.C. Bidard</u> ³ , ¹ Hospital Ruber Internacional, Madrid, ES, ² Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US, ³ Institut Curie, Paris, FR	

18:00 - 19:30	Type: Industry Satellite Symposium Title: F. Hoffman-La Roche LTD - Navigating the possibilities of personalised healthcare in oncology Chair(s): Allan Hackshaw, GB	7.3.H - Honfleur Auditorium
18:00 - 18:10	A guide to the expanding possibilities in personalised healthcare <u>A. Hackshaw</u> , Cancer Research UK & University College London Cancer Trials Centre, London, GB	
18:10 - 18:25	Cancer of unknown primary: Making the unknown known <u>A. Krämer</u> , DKFZ - German Cancer Research Center, Heidelberg, DE	
18:25 - 18:35	Panel discussion: Progress in personalised healthcare <u>A. Hackshaw</u> ¹ , <u>A. Krämer</u> ² , <u>J.-Y. Blay</u> ³ , <u>C. Alessi</u> ⁴ , <u>W. Minnaard</u> ⁵ , ¹ Cancer Research UK & University College London Cancer Trials Centre, London, GB, ² DKFZ - German Cancer Research Center, Heidelberg, DE, ³ Centre Léon Bérard, Lyon, FR, ⁴ HIMSS - Healthcare Information and Management Systems Society, London, GB, ⁵ Missie Tumor Onbekend, NL	
18:35 - 18:50	Staying at the frontier of comprehensive genomic profiling and liquid biopsy <u>J.-Y. Blay</u> , Centre Léon Bérard, Lyon, FR	
18:50 - 19:05	The value of real-world data for augmenting personalised healthcare at several levels <u>A. Hackshaw</u> , Cancer Research UK & University College London Cancer Trials Centre, London, GB	
19:05 - 19:25	Panel discussion: Putting the possibilities into practice <u>A. Hackshaw</u> ¹ , <u>J.-Y. Blay</u> ² , <u>A. Krämer</u> ³ , <u>C. Alessi</u> ⁴ , <u>W. Minnaard</u> ⁵ , ¹ Cancer Research UK & University College London Cancer Trials Centre, London, GB, ² Centre Léon Bérard, Lyon, FR, ³ DKFZ - German Cancer Research Center, Heidelberg, DE, ⁴ HIMSS - Healthcare Information and Management Systems Society, London, GB, ⁵ Missie Tumor Onbekend, NL	
19:25 - 19:30	Conclusion <u>A. Hackshaw</u> , Cancer Research UK & University College London Cancer Trials Centre, London, GB	

18:00 - 19:30	Type: Industry Satellite Symposium Title: Janssen-Cilag International NV - Catching it early, getting it right: optimal disease and patient management from biomarkers to treatment selection for bladder cancer Chair(s): Maria De Santis, DE; Thomas Powles, GB	7.3.O - Orléans Auditorium
18:00 - 18:05	Welcome and introduction <u>M. De Santis</u> , Charité - Universitätsmedizin Berlin, Berlin, DE	
18:05 - 18:25	Patient case presentation and discussion: From the pathologist's and urologists' perspectives <u>M. De Santis</u> ¹ , <u>T. Powles</u> ² , <u>E. Comperat</u> ³ , <u>S.F. Shariat</u> ³ , ¹ Charité - Universitätsmedizin Berlin, Berlin, DE, ² St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, ³ MedUni Wien - Medical University of Vienna, Vienna, AT	
18:25 - 18:45	Patient case analysis: how do we select the best treatment in challenging cases? <u>M. De Santis</u> ¹ , <u>T. Powles</u> ² , <u>E. Comperat</u> ³ , <u>S.F. Shariat</u> ³ , ¹ Charité - Universitätsmedizin Berlin, Berlin, DE, ² St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, ³ MedUni Wien - Medical University of Vienna, Vienna, AT	
18:45 - 19:10	Treatment selection and managing patients safety: a discussion on the treatment landscape <u>M. De Santis</u> ¹ , <u>T. Powles</u> ² , <u>E. Comperat</u> ³ , <u>S.F. Shariat</u> ³ , ¹ Charité - Universitätsmedizin Berlin, Berlin, DE, ² St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, ³ MedUni Wien - Medical University of Vienna, Vienna, AT	
19:10 - 19:25	Audience Q&A <u>M. De Santis</u> ¹ , <u>T. Powles</u> ² , <u>E. Comperat</u> ³ , <u>S.F. Shariat</u> ³ , ¹ Charité - Universitätsmedizin Berlin, Berlin, DE, ² St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, ³ MedUni Wien - Medical University of Vienna, Vienna, AT	
19:25 - 19:30	Summary and close <u>T. Powles</u> , St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB	

18:00 - 19:30	Type: Industry Satellite Symposium Title: Merck - From complex to simple: The journey to strategic sequencing in the management of mCRC Chair(s): Marc Van Den Eynde, BE	7.3.Q - Quimper Auditorium
18:00 - 18:05	Welcome and introduction <u>M. Van Den Eynde</u> , Institut Roi Albert II - Cliniques universitaires St-Luc, Brussels, BE	
18:05 - 18:25	One step closer: Treatment sequencing in RAS wt mCRC <u>M. Van Den Eynde</u> , Institut Roi Albert II - Cliniques universitaires St-Luc, Brussels, BE	
18:25 - 18:45	Going the extra mile: Building in an additional line of treatment with $\geq 3L$ rechallenge <u>C. Parseghian</u> , MD Anderson Cancer Center, Houston, US	
18:45 - 18:55	Panel discussion <u>M. Van Den Eynde</u> ¹ , <u>C. Parseghian</u> ² , <u>T. Price</u> ³ , ¹ Institut Roi Albert II - Cliniques universitaires St-Luc, Brussels, BE, ² MD Anderson Cancer Center, Houston, US, ³ The Queen Elizabeth Hospital - Emergency Department, Woodville, AU	
18:55 - 19:15	The next steps forward: Co-targeting KRAS G12C mt mCRC <u>T. Price</u> , The Queen Elizabeth Hospital - Emergency Department, Woodville, AU	
19:15 - 19:25	Panel discussion <u>M. Van Den Eynde</u> ¹ , <u>C. Parseghian</u> ² , <u>T. Price</u> ³ , ¹ Institut Roi Albert II - Cliniques universitaires St-Luc, Brussels, BE, ² MD Anderson Cancer Center, Houston, US, ³ The Queen Elizabeth Hospital - Emergency Department, Woodville, AU	
19:25 - 19:30	Meeting close <u>M. Van Den Eynde</u> , Institut Roi Albert II - Cliniques universitaires St-Luc, Brussels, BE	

10.09.2022

08:30 - 10:00 **Type: Special symposium** **4.A - Antibes Auditorium**
Title: Antibody-drug conjugates to transform outcome of patients with metastatic breast cancer
 Chair(s): Eva Ciruelos, ES; Aditya Bardia, US

08:30 - 08:35 **Introduction and scientific background**

E. Ciruelos, Hospital Universitario 12 de Octubre, Madrid, ES

08:35 - 08:50 **Antibody-drug conjugates: Constructs and targets**

B. Pistilli, Institut Gustave Roussy, Villejuif, Cedex, FR

08:50 - 09:05 **ADCs for patients with triple negative breast cancer: Moving towards combinations with I-O and agents targeting DDR**

A. Bardia, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US

09:05 - 09:20 **Which impact of Her2-directed ADCs?**

I. Krop, Yale University School of Medicine - Yale Cancer Center, New Haven, US

09:20 - 09:35 **Finding the right population and combination to develop ADCs in patients with HR+/Her2- mBC**

K. Jhaveri, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

09:35 - 09:40 **Conclusions and perspectives**

E. Ciruelos, Hospital Universitario 12 de Octubre, Madrid, ES

09:40 - 10:00 **Discussion**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

08:30 - 10:00	Type: Special symposium Title: Progress in the identification of new immune targets Chair(s): Sergio Quezada, GB; John Haanen, NL	4.B - Brest Auditorium
----------------------	---	-------------------------------

08:30 - 08:40	Introduction and scientific background <u>S. Quezada</u> , London, GB	
08:40 - 08:55	Novel immune checkpoints <u>P. Sharma</u> , Houston, TX, US	
08:55 - 09:10	Cytokines <u>S. Kobold</u> , LMU Klinikum der Universität München, Munich, DE	
09:10 - 09:25	Targeting regulatory T cells <u>S. Quezada</u> , London, GB	
09:25 - 09:40	Vaccines <u>P. Ott</u> , Dana Farber Cancer Institute, Boston, US	
09:40 - 09:45	Conclusions and perspectives <u>S. Quezada</u> , London, GB	
09:45 - 10:00	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

08:30 - 09:50	Type: Proffered Paper session Title: Proffered Paper session 1: GI, upper digestive Chair(s): Angela Lamarca, ES; Lam Chan, HK	7.1.C - Cannes Auditorium
----------------------	--	----------------------------------

08:30 - 08:40	LBA34 - Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC) <u>R. Finn</u> ¹ , M. Kudo ² , P. Merle ³ , T. Meyer ⁴ , S. Qin ⁵ , M. Ikeda ⁶ , R. Xu ⁷ , J. Edeline ⁸ , B.-Y. Ryoo ⁹ , Z. Ren ¹⁰ , A.-L. Cheng ¹¹ , P. Galle ¹² , S. Kaneko ¹³ , H. Kumada ¹⁴ , A. Wang ¹⁵ , K. Mody ¹⁶ , L. Dubrovsky ¹⁵ , A. Siegel ¹⁷ , J. Llovet ¹⁸ , ¹ University of California, Los Angeles, Los Angeles, US, ² Kindai University - Faculty of Medicine, Osaka, JP, ³ Hôpital de la Croix-Rousse, Lyon, FR, ⁴ Royal Free Hospital-Royal Free London NHS Foundation Trust, London, GB, ⁵ Cancer Center of Nanjing, Jinling Hospital Nanjing University of Chinese Medicine, Nanjing, CN, ⁶ National Cancer Center Hospital East, Kashiwa, JP, ⁷ Hunan Cancer Hospital, Changsha, CN, ⁸ Centre Eugene - Marquis, Rennes, FR, ⁹ Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ¹⁰ Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, ¹¹ NTUH - National Taiwan University Hospital, Taipei City, TW, ¹² Universitätsmedizin der Johannes Gutenberg-Universität	
---------------	--	--

Mainz, Mainz, DE, ¹³Kanazawa University, Kanazawa, JP, ¹⁴Toranomon Hospital, Minato-ku, JP, ¹⁵Merck & Co., Inc., Rahway, US, ¹⁶Eisai Inc., Nutley, US, ¹⁷Merck & Co. Inc., Rahway, US, ¹⁸Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA & August Pi i Sunyer Biomedical Research Institute-Hospital Clinic, University of Barcelona, Catalonia, Spain, Barcelona, ES

08:40 - 08:50 **LBA35 - Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial**

S. Qin¹, L. Chan², S. Gu³, Y. Bai⁴, Z. Ren⁵, X. Lin⁶, Z. Chen⁷, W. Jia⁸, Y. Jin⁹, Y. Guo¹⁰, A. Sultanbaev¹¹, M. Pazgan-Simon¹², M. Pisetska¹³, X. Liang¹⁴, C. Chen¹⁴, Z. Nie¹⁴, L. Wang¹⁴, A.-L. Cheng¹⁵, A. Kaseb¹⁶, A. Vogel¹⁷, ¹Nanjing University of Chinese Medicine, Nanjing, CN, ²The Chinese University of Hong Kong Medical Center, Sha Tin, HK, ³Hunan Cancer Hospital, Changsha, CN, ⁴The Affiliated Tumor Hospital of Harbin Medical University, Harbin, CN, ⁵Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, ⁶Fujian Medical University Union Hospital, Fuzhou, CN, ⁷The Second Affiliated Hospital of Anhui Medical University, Hefei, CN, ⁸The First Affiliated Hospital of USTC/ Anhui Provincial Hospital, Hefei, CN, ⁹Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, CN, ¹⁰Nanfang Hospital, Southern Medical University, Guangzhou, CN, ¹¹Republican Clinical Oncological Dispensary of the Ministry of Health of the Republic of Bashkortostan, Ufa, RU, ¹²Wroclaw Medical University, and Centrum Badań Klinicznych P.Napora, Wroclaw, PL, ¹³Communal Non-profit Enterprise Regional Center of Oncology, Kharkiv, UA, ¹⁴Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, CN, ¹⁵National Taiwan University Hospital, Taipei City, TW, ¹⁶The University of Texas M. D. Anderson Cancer Center, Houston, US, ¹⁷Hannover Medical School, Hannover, DE

08:50 - 09:00 **Invited Discussant LBA34 and LBA35**

R.K. Kelley, UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US

09:00 - 09:15 **Q&A**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

09:15 - 09:25 **LBA36 - Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma**

S. Qin¹, M. Kudo², T. Meyer³, R. Finn⁴, A. Vogel⁵, Y. Bai⁶, Y. Guo⁷, Z. Meng⁸, T. Zhang⁹, T. Satoh¹⁰, A. Hiraoka¹¹, D. Marino¹², E. Assenat¹³, L. Wyrwicz¹⁴, M. Calvo Campos¹⁵, K. Hsing-Tao¹⁶, F. Boissarie¹⁷, S. Li¹⁷, Y. Chen¹⁸, A. Zhu¹⁹, ¹Nanjing University of Chinese Medicine, Nanjing, CN, ²Kindai University Faculty of Medicine, Osaka, JP, ³Royal Free Hospital NHS Trust and UCL Cancer Institute, London, GB, ⁴University of California Los Angeles, Los Angeles, US, ⁵Hepatology and Endocrinology, Hannover Medical School, Hannover, DE, ⁶Harbin Medical University Cancer Hospital, Harbin, CN, ⁷Nanfang Hospital, Southern Medical University, Guangzhou, CN, ⁸Fudan University Shanghai Cancer Hospital, Shanghai, CN, ⁹Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ¹⁰Osaka University, Osaka, JP, ¹¹Ehime Prefectural Central Hospital, Matsuyama, JP, ¹²Ordine Mauriziano Hospital,

Turin, IT, ¹³Montpellier University Hospital, Montpellier, FR, ¹⁴Maria Sklodowska-Curie National Cancer Research Institute, Warsaw, PL, ¹⁵Institut Català d'Oncologia, Barcelona, ES, ¹⁶Chi Mei Medical Center, Tainan, TW, ¹⁷BeiGene, Ltd., Ridgefield Park, US, ¹⁸BeiGene (Beijing) Co., Ltd., Beijing, CN, ¹⁹Massachusetts General Hospital Cancer Center, Boston, MA, United States; Jiahui International Cancer Center, Jiahui Health, Shanghai, CN

09:25 - 09:35 **Invited Discussant LBA36**

L. Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK

09:35 - 09:50 **Q&A**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

08:30 - 10:00 Type: Mini Oral session 7.2.E - Évry Auditorium
Title: Mini Oral session 1: Gynaecological cancers
 Chair(s): Susana Banerjee, GB; Iain McNeish, GB; Robert Coleman, US

08:30 - 08:35 **519MO - Phase III EMPower-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis**

A. Oaknin¹, B. Monk², L. Polastro³, A. Cristina De Melo⁴, H.S. Kim⁵, Y.M. Kim⁶, A. Lisyanskaya⁷, V. Samouëlian⁸, D. Lorusso⁹, F. Damian¹⁰, C.-L. Chang¹¹, S. Takahashi¹², D. Ramone¹³, B. Maćkowiak-Matejczyk¹⁴, J. Li¹⁵, S. Jamil¹⁵, M. Mathias¹⁵, M. Fury¹⁵, K. Tewari¹⁶, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²University of Arizona and Creighton University, Phoenix, US, ³Institut Jules Bordet, Anderlecht, BE, ⁴Brazilian National Cancer Institute, Rio de Janeiro, BR, ⁵Seoul National University College of Medicine, Seoul, KR, ⁶Asan Medical Center, University of Ulsan, Seoul, KR, ⁷St. Petersburg State Budgetary Healthcare Institution "City Oncological Dispensary", St. Petersburg, RU, ⁸Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, CA, ⁹Division of Gynecologic Oncology, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, IT, ¹⁰Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, BR, ¹¹Mackay Memorial Hospital, Taipei, TW, ¹²Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JP, ¹³Barretos Cancer Hospital (Pio XII Foundation), Sao Paulo, BR, ¹⁴Białostockie Centrum Onkologii, Białostockie, PL, ¹⁵Regeneron Pharmaceuticals, Inc., Tarrytown, US, ¹⁶University of California, Irvine, US

08:35 - 08:40 **LBA32 - Efficacy and safety of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab in HPV 16- and/or 18- positive advanced cervical cancer (phase II): Safe and effective in both PD-L1 positive and negative**

S. Lee¹, M.-C. Lim², Y.M. Kim³, J.H. No⁴, B.-G. Kim⁵, C.H. Cho⁶, S.H. Kim⁷, D.H. Jeong⁸, J.-K. Lee⁹, J.S. Park¹⁰, Y.-J. Choi¹⁰, K.O. Jeon¹⁰, J.W. Woo¹⁰, Y.C. Sung¹⁰, S. Hur¹, ¹The Catholic University of Korea - College of Medicine, Seoul, KR, ²National Cancer Center, Goyang-si, Gyeonggi-do, KR, ³Asan Medical Center, Seoul, KR, ⁴Seoul National University Bundang Hospital, Seongnam, KR, ⁵Samsung Medical Center, Seoul, KR, ⁶Dongsan Medical Center, Daegu, KR, ⁷Severance Hospital - Yonsei University College of Medicine, Seoul, KR, ⁸Inje University Busan Paik Hospital, Busan, KR, ⁹Korea University Guro Hospital, Seoul, KR, ¹⁰Genexine, Inc., Seoul, KR

- 08:40 - 08:45 **520MO - Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358**
- A. Oaknin¹, K. Moore², T. Meyer³, J.L. González⁴, L. Devriese⁵, A. Amin⁶, C. Lao⁷, V. Boni⁸, W. Sharfman⁹, J.C. Park¹⁰, M. Tahara¹¹, S. Topalian⁹, M. Magallanes Maciel¹², A. Molina Alavez¹³, A. Khan¹⁴, C. Copigneaux¹⁴, M. Lee¹⁴, C. Garnett-Benson¹⁴, X. Wang¹⁴, R. Naumann⁶, ¹Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, ²Stephenson Cancer Center, Oklahoma City, US, ³University College London, London, GB, ⁴Clinica Universidad de Navarra, Madrid, ES, ⁵Universitair Medisch Centrum Utrecht, Utrecht, NL, ⁶Levine Cancer Institute, Atrium Health, Charlotte, US, ⁷Rogel Cancer Center at the University of Michigan, Ann Arbor, US, ⁸START Madrid, Centro Integral Oncológico Clara Campal, Hospital Madrid Norte Sanchinarro, Madrid, ES, ⁹Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, US, ¹⁰Massachusetts General Hospital, Boston, US, ¹¹National Cancer Center Hospital East, Kashiwa, JP, ¹²Centro Oncológico Internacional, Ciudad de Mexico, MX, ¹³Centro de Atención e Investigación Clínica en Oncología, Merida, MX, ¹⁴Bristol Myers Squibb, Princeton, US
- 08:45 - 09:00 **Invited Discussant 519MO, LBA32 and 520MO**
- R. Coleman, US Oncology Research, The Woodlands, US
- 09:00 - 09:05 **521MO - Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): Phase II PEACOC trial**
- R. Kristeleit¹, A. Clamp², C. Gourley³, R. Roux⁴, M. Hall⁵, M.-J. Devlin⁶, R. Nirsimloo⁷, V. Kounnis⁸, L. Hughes⁹, N. Counsell¹⁰, L. Farrelly¹⁰, R. Miller¹¹, ¹Guy's and St Thomas' NHS Foundation Trust, London, GB, ²The Christie NHS Foundation Trust, Manchester, GB, ³Cancer Research UK Edinburgh Centre, Edinburgh, GB, ⁴Churchill Hospital, Oxford, GB, ⁵Mount Vernon Cancer Centre, Northwood, GB, ⁶QMUL - Queen Mary University of London - Charterhouse Square, London, GB, ⁷ECC - Edinburgh Cancer Centre - SCAN, Edinburgh, GB, ⁸Churchill Hospital - Oxford University Hospitals NHS Foundation Trust, Oxford, GB, ⁹UCL - University College London, London, GB, ¹⁰Cancer Research UK & University College London Cancer Trials Centre, London, GB, ¹¹UCLH - University College London Hospitals NHS Foundation Trust, London, GB
- 09:05 - 09:10 **522MO - Preliminary results of sintilimab (Sin)+bevacizumab (Bev) in recurrent/persistent ovarian clear cell carcinoma (INOVA): A multicenter, single-arm, phase II trial**
- X. Liu¹, B. Xia², W. Zhang¹, L. Sun³, C. Feng¹, Y. Huang⁴, Y. Gao⁵, J. Jiang⁶, G. Li⁷, Q. Gao¹, ¹Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ²The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, CN, ³Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ⁴Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ⁵Peking University Cancer Hospital and Institute, Beijing, CN, ⁶Qilu Hospital of Shandong University, Jinan, CN, ⁷Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN
- 09:10 - 09:25 **Invited Discussant 521MO and 522MO**

S. Banerjee, The Royal Marsden Hospital - Chelsea, London, GB

09:25 - 09:30

523MO - Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis

E. Van Nieuwenhuysen¹, D. O'Malley², R. O'Cearbhaill³, K. Moore⁴, E. Hamilton⁵, O. Yeku⁶, S. Boubberhan⁶, J.Y. Hou⁷, S.-Y. Yoo⁸, J. Brouwer-Visser⁸, H.K. Cheung⁸, M. Peterman⁸, P. Goncalves⁸, T. Schmidt⁸, M. Zhu⁸, I. Lowy⁸, T. Rowlands⁸, T. Uldrick⁸, E. Miller⁸, J. Liu⁹, ¹University Hospitals Leuven, Leuven, BE, ²The Ohio State University, The James Cancer Center, Columbus, US, ³Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US, ⁴Stephenson Cancer Center, University of Oklahoma Health Sciences Center/Sarah Cannon Research Institute, Oklahoma City, US, ⁵Sarah Cannon Research Institute Tennessee Oncology, Nashville, US, ⁶Massachusetts General Hospital, Boston, US, ⁷Columbia University Medical Center, New York, US, ⁸Regeneron Pharmaceuticals, Inc., Tarrytown, US, ⁹Dana Farber Cancer Institute, Boston, US

09:30 - 09:35

524MO - Glucocorticoid receptor expression and activity in a phase II ovarian cancer trial of the glucocorticoid receptor modulator relacorilant in combination with nab-paclitaxel

D. Lorusso¹, A. Greenstein², S. Wadekar², I.C. Tudor², H. Hunt², B. Guyer², ¹Fondazione Policlinico Universitario Gemelli IRCCS and Catholic University of Sacred Heart, Rome, IT, ²Corcept Therapeutics, Menlo Park, US

09:35 - 09:50

Invited Discussant 523MO and 524MO

I. Mcneish, London, GB

08:30 - 10:00	Type: Educational session Title: The Universal Health Coverage (UHC) dilemma: Can we afford to pay for what we want? Chair(s): E.G. Elisabeth de Vries, NL; Dario Trapani, US	7.3.M - Marseille Auditorium
08:30 - 08:35	Introduction and scientific background <u>E.G.E. De Vries</u> , Groningen, NL	
08:35 - 08:50	ESMO ANMS 2.0 survey about access to cancer medicines <u>D. Trapani</u> , Dana Farber Cancer Institute, Boston, US	
08:50 - 09:05	ESMO's economic model <u>P. Kanavos</u> , The London School of Economics and Political Science, London, GB	
09:05 - 09:20	WHO pricing guidelines to improve access to medicines <u>K. Tay-Teo</u> , WHO - World Health Organization, Geneva, CH	
09:20 - 09:35	The patient perspective <u>B. Ryll</u> , Melanoma Patient Network Europe MPNE, Uppsala, SE	
09:35 - 09:40	Conclusions and perspectives <u>E.G.E. De Vries</u> , Groningen, NL	
09:40 - 10:00	Discussion	

08:30 - 10:00 **Type: Special symposium** **7.3.U - Urval Auditorium**
Title: Current and future perspectives in SCLC
Chair(s): Fiona Blackhall, GB; Lauren Byers, US

- 08:30 - 08:35 **Introduction and scientific background**
F. Blackhall, Manchester, GB
- 08:35 - 08:50 **Transcriptomic and immune landscape in SCLC**
L. Byers, Houston, TX, US
- 08:50 - 09:05 **Immunotherapy in the current management of SCLC**
F. Blackhall, Manchester, GB
- 09:05 - 09:20 **Controversies in SCLC radiotherapy treatment**
B.H. Gronberg, Trondheim, NO
- 09:20 - 09:35 **Future perspectives**
T. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, US
- 09:35 - 09:40 **Conclusions and perspectives**
L. Byers, Houston, TX, US
- 09:40 - 10:00 **Discussion**

08:30 - 09:30	Type: Young Oncologist session Title: Young Oncologist Boxing session Chair(s): Kok Haw Jonathan Lim, GB; Pawel Sobczuk, PL	7.3.R - Rennes Auditorium
08:30 - 08:40	Pro: Tumor mutational burden as a tumor agnostic biomarker? <u>A. Marabelle</u> , Institut Gustave Roussy, Villejuif, FR	
08:40 - 08:50	Contra: Tumor mutational burden as a tumor agnostic biomarker? <u>A. Addeo</u> , HUG - Hopitaux Universitaires de Geneve, Geneva, CH	
08:50 - 09:00	Discussion led by chairs	
09:00 - 09:10	Pro: Medical oncology in 21st century - general or cancer type specialist? <u>A. Awada</u> , Institute Jules Bordet, Brussels, BE	
09:10 - 09:20	Contra: Medical oncology in 21st century: General or cancer type specialist? <u>J. Barriuso</u> , The Christie NHS Foundation Trust, Manchester, GB	
09:20 - 09:30	Discussion led by chairs	

08:30 - 10:00	Type: EONS session Title: Welcome to the EONS15 conference Chair(s): Johan De Munter, BE	7.3.S - Strasbourg Auditorium
----------------------	--	--------------------------------------

08:30 - 08:35	Welcome to EONS15 the conference <u>J. De Munter</u> , UZ Gent - Universitair Ziekenhuis Gent, Gent, BE	
08:35 - 08:40	Welcome from Association Française des Infirmier(e)s de Cancérologie - French Oncology Nurses Society <u>P. Dielenseger</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
08:40 - 09:00	World Code against Cancer Framework: Evidence-based recommendations for cancer prevention <u>C. Espina</u> , IARC - International Agency for Research on Cancer, Lyon, FR	
09:00 - 09:20	Psycho-oncology in cancer care: Current state and future directions <u>L. Fallowfield</u> , Brighton and Sussex Medical School - University of Sussex, Brighton, GB	
09:20 - 09:40	My Survival Story: What we can learn from each other to get through cancer <u>M. Inderbitzin</u> , My Survival Story Foundation, Zurich, CH	
09:40 - 09:50	EONS Awards: Lifetime Achievement Award and RECaN Award <u>J. De Munter</u> , UZ Gent - Universitair Ziekenhuis Gent, Gent, BE	
09:50 - 10:00	Q&A and discussion	

09:00 - 10:00	Type: Poster session Title: Poster session 19	Poster Area, Hall 4
----------------------	--	----------------------------

09:00 - 09:01	CN3 - An integrated care model for the management of patients receiving oral anti-cancer agents (OAM) by an advanced nurse practitioner (ANP): Planning and development process <u>J. Richmond</u> ¹ , M.G. Kelly ¹ , A. Johnston ² , P. Murphy ³ , P. Gillespie ³ , K. Roche ³ , A. Murphy ³ , ¹ Letterkenny General Hospital, Letterkenny, IE, ² Letterkenny University Hospital, Letterkenny, IE, ³ NUI - National University of Ireland Galway, Galway, IE	
09:01 - 09:02	CN4 - iGestSa#&#xfad;de: Portuguese mobile application for the self-management of symptoms associated with chemotherapy treatment <u>B. Magalhaes</u> ¹ , C. Fernandes ² , C. Santos ² , ¹ Portuguese Oncology Institute of Porto (IPO Porto), Porto, PT, ² Escola Superior de Enfermagem do Porto, Porto, PT	
09:02 - 09:03	CN5 - Barriers to digital health in patients with head and neck cancer <u>A. Cotton</u> ¹ , V. Lavender ² , M. Lei ¹ , ¹ Guy's & St Thomas' NHS Foundation Trust, London,	

GB, ²Guy's Hospital, London, GB

- 09:03 - 09:04 **CN6 - E-health applied to oncology treatment, education and knowledge for cancer care: A systematic review**
M.J. Dias¹, P. Fernández Ortega², E. Fernandez³, D.H. Rodrigues⁴, ¹Barcelona University, L'Hospitalet de Llobregat, PT, ²ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ³Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat, Barcelona, ES, ⁴FMUP - Faculdade de Medicina da Universidade do Porto, Porto, PT
- 09:04 - 09:05 **CN7 - Women with breast cancer stories about divergent approaches of obtaining information of health, diagnosis, and treatment: A deductive approach based on dimensions of health literacy**
A. Grynne, M. Brovall, Jonkoping University, Jonkoping, SE
- 09:05 - 09:06 **CN8 - Implementation of reporting symptoms from chemotherapy treatment via an app: Patients' perception of reporting digitally**
S. Wallberg, Karolinska University Hospital-Solna, Solna, SE
- 09:06 - 09:07 **CN9 - Mapping the Functional Assessment of Cancer Therapy (FACT-G) in Greek patients with neoplasm: An interplay of statistical and bioinformatics approach**
E. Stalika¹, K. Gavrilaki¹, I. Koziokos², I. Chouvarda¹, M. Lavdaniti², ¹Aristotelio Thassaloniki, Thessaloniki, GR, ²Hellenic Cancer Society, Athens, GR
- 09:07 - 09:08 **CN10 - Digital in-home training before breath-adapted radiotherapy**
F. Smith¹, M. Brovall², A. Karlsson³, ¹Chalmers University of Technology, Gothenburg, SE, ²Jonkoping University, Jonkoping, SE, ³University of Gothenburg - The Sahlgrenska Academy, Göteborg, SE
- 09:08 - 09:09 **CN11 - Patient involvement in development of digital pathway eHealth service**
M. Rekunen¹, H. Salmenoja¹, M. Siekkinen¹, P. Vihinen², ¹Turku University Hospital (Tyks), Turku, FI, ²University of Turku, Turku, FI
- 09:09 - 09:10 **CN16 - Lung cancer risk prediction nomogram in Chinese female non-smokers**
L. Guo, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN
- 09:10 - 09:11 **CN18 - Challenges in genetic counseling in hereditary cancer syndromes in Mexican population and prevention clinic experience**
C. Burciaga-Flores, M.L. Garza-Rodriguez, M. Noriega Iriondo, O. Zayas, F. Alcorta-Nuñez, J. Gonzalez Guerrero, A. Alcorta-Garza, D. Hernandez Barajas, O. Vidal-Gutiérrez, D. Pérez-Ibave, Hospital Universitario Dr José Eleuterio Gonzalez, Monterrey, MX
- 09:11 - 09:12 **CN19 - Comparison of Charlson and Elixhauser method for predicting nursing indicator in gastrectomy with gastric cancer patients**

C.-G. Kim¹, K.-S. Bae², ¹College of Medicine, Chungbuk National University, Cheongju, KR, ²Asan Medical Center - University of Ulsan, Seoul, KR

- 09:12 - 09:13 **CN20 - Nutriscore as a tool for selecting patients with low risk of nutritional complication safely**
L. Raventos, R. Legido-Diaz, L. Arribas, M. Bellver, A.R. Gonzalez, I. Peiró Martínez, Institut Català d'Oncologia (ICO-L'Hospitalet), Hospitalet de Llobregat, ES
- 09:13 - 09:14 **CN21 - Early identification of cancer-related malnutrition in patients with colorectal cancer: Experts' interviews**
E. Wimmer¹, A. Glaus², ¹Kalaidos University of Applied Sciences - Department of Health Science, Zürich, CH, ²Tumorzentrum ZeTuP St.Gallen, St. Gallen, CH
- 09:14 - 09:15 **CN22 - Patient reported experiences (PREM): Cancer care pathway in the Stockholm-Gotland region**
Å. Wilson¹, B. Sunde², ¹Visby Lasarett, Visby, SE, ²Karolinska Institutet - Cancer Center Karolinska (CCK), Stockholm, SE
- 09:15 - 09:16 **CN28 - Impact of serious illness care program to patients with hematopoietic stem cell transplantation on goals of care documentation and acute healthcare utilization**
K.W. Tsang, Grantham Hospital, Hong Kong, HK
- 09:16 - 09:17 **CN29 - Integration and development of palliative care in a comprehensive cancer centre: A quality improvement project**
H. Ullgren¹, Y. Wengström², ¹Karolinska Comprehensive Cancer Center, Solna, SE, ²Karolinska Institutet, Huddinge, SE
- 09:17 - 09:18 **CN34 - Importance of work environment for oncology nurses**
E. Gunes, Manchester Metropolitan University - Cheshire Campus, Manchester, GB
- 09:18 - 09:19 **CN35 - Workplace violence against cancer nurses during the COVID-19 pandemic: A correlational-predictive study**
G. Catania¹, N. Pagnucci¹, R. Alvaro², G. Cicolini³, A. Dal Molin⁴, L. Lancia⁵, M. Lusignani⁶, D. Mecugni⁷, P.C. Motta⁸, R. Watson⁹, M. Hayter¹⁰, F. Napolitano¹, M. Zanini¹, L. Sasso¹, A. Bagnasco¹, ¹Università degli Studi di Genova, Genova, IT, ²Università degli Studi di Roma Tor Vergata, Roma, IT, ³Università degli Studi di Bari Aldo Moro, Bari, IT, ⁴Università del Piemonte Orientale, Novara, IT, ⁵Università degli Studi dell'Aquila, L'Aquila, IT, ⁶Università degli Studi di Milano, Milano, IT, ⁷Università degli Studi di Modena e Reggio Emilia, Reggio Emilia, IT, ⁸Università degli Studi di Brescia, Brescia, IT, ⁹Southwest Medical University, Luzhou, CN, ¹⁰Manchester Metropolitan University, Manchester, GB
- 09:19 - 09:20 **CN44 - Development of a research agenda for oncological nursing in Germany: GRAN-ONCO - German Research Agenda for Nursing & Oncology**
M. Zilezinski, M. Ritter-Herschbach, P. Jahn, Universitätsmedizin Halle (Saale), Halle, DE

- 09:20 - 09:21 **CN45 - The Gastrointestinal and Lymphoma Unit Advanced Nurse Practitioner role in clinical research at The Royal Marsden Hospital**
L. Hobbis¹, J. Duncan², F. Kinnaird¹, C. Fong¹, S. Li¹, A. Gordon¹, I. Chau³, N. Starling⁴, S. Rao⁵, D. Watkins⁶, C. Fribbens⁴, D. Cunningham⁷, ¹The Royal Marsden Hospital (Sutton), Sutton, GB, ²Royal Marsden Hospital NHS Foundation Trust, London, GB, ³The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, ⁴The Royal Marsden Hospital - Chelsea, London, GB, ⁵The Royal Marsden Hospital - Chelsea, Sutton, GB, ⁶The Royal Marsden Hospital (Sutton) - NHS Foundation Trust, Sutton, GB, ⁷The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB
- 09:21 - 09:22 **CN46 - Catheter-related venous thrombosis: Experience with blue advance peripherally inserted central catheter (PICC) in a day hospital during the pandemic**
F. Losa, M. Mancha, N. Moragriega, A. Perez, A. Manzana, A. Rios, A. Aranda, E. Cabezudo, Hospital de Sant Joan Despi Moisès Broggi, Sant Joan Despi, ES
- 09:22 - 09:23 **CN47 - Future-proofing the Irish Association for Nurses in Oncology: Identifying the professional and educational needs of members**
Y. Gahan¹, P. Hunt², C. Duggan³, K. Geraghty⁴, R. Murphy⁵, ¹The Mater Misericordiae University Hospital, Dublin, IE, ²South East Technological University, Waterford, IE, ³Portiuncula Hospital, Ballinasloe, IE, ⁴Galway Clinic, Galway, IE, ⁵University Hospital Limerick, Limerick, IE
- 09:23 - 09:24 **CN48 - Achieving global standards in pediatric oncology nursing: Pediatric oncology clinical profile of Turkey**
P. Yilmaz¹, R. Semerci², ¹Hacettepe University Oncology Hospital, Ankara, TR, ²Koç University, Istanbul, TR
- 09:24 - 09:25 **CN49 - Do we need psychooncological nursing care? Perspective of Croatian oncology nurses**
T. Gašpert¹, K. Kuljanić¹, S. Bošković², V. Predovan¹, L. Luksetić¹, M. Jurišić¹, ¹University Hospital KBC Rijeka, Rijeka, HR, ²Faculty of Health Studies, Rijeka, HR
- 09:25 - 09:26 **CN50 - Facing negative emotions: Evaluating the effects of training in affirmative communication for contact nurses in cancer care**
S. Edlund¹, J. Carstens-Söderstrand², B. Åkerman¹, E. Hed¹, M. Larsson³, M. Tillfors³, C. Olsson³, ¹Örebro University, Örebro, SE, ²Mälardalen University, Västerås, SE, ³Karlstad University, Karlstad, SE
- 09:26 - 09:27 **CN51 - Oncology nursing as core competences in a late effect clinic after cancer**
K. Dieperink¹, T. Mattson¹, S.H. Knudsen¹, L. Fechner¹, L. Tolstrup², ¹Odense University Hospital, Odense, DK, ²OUH - Odense University Hospital, Odense, DK
- 09:27 - 09:28 **CN53 - Enhancing healthcare professional-led sexual support in cancer care: Acceptability and usability of an eLearning resource and its impact on attitudes towards providing sexual support**

S. Bingham¹, C. Semple², C. Flannagan¹, L. Dunwoody³, ¹Ulster University, Jordanstown, GB, ²Ulster Hospital - South Eastern Health and Social Care Trust, Dundonald, GB, ³Ulster University, Coleraine, GB

- 09:28 - 09:29 **CN54 - The implementation of NEWS2 Score in oncology patients and nursing handover with SBAR method: A pilot study**
M.R. Esposito, Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli, Naples, IT
- 09:29 - 09:30 **CN55 - The testing times project: Collaboration in action**
M. Foulkes¹, P. Hunt², S. Orton³, N. Sharma⁴, L. Cox⁵, ¹Royal Berkshire Hospital - NHS Foundation Trust, Reading, GB, ²West Berkshire CCG, Reading, GB, ³Macmillan Cancer Support, Glasgow, GB, ⁴Macmillan Cancer Support, Edinburgh, GB, ⁵Thames Valley Cancer Alliance, Oxford, GB
- 09:30 - 09:31 **CN56 - Patients' and contact nurses' (CN) views on opportunities for patient participation in cancer care: An on-going study**
B. Westman¹, M. Bergenmar¹, K. Bergkvist¹, L. Sharp², ¹Sophiahemmet Universty, Stockholm, SE, ²RCC Stockholm-Gotland, HSF, Stockholm, SE
- 09:31 - 09:32 **CN57 - Cancer survivors' perceptions of priorities for geriatric oncology research: A qualitative study**
A. Drury¹, A. O'Brien¹, L. O'Connell², M. Harkin³, L. Rogers¹, ¹University College Dublin, Dublin, IE, ²Tallaght University Hospital, Dublin, IE, ³Age and Opportunity, Dublin, IE
- 09:32 - 09:33 **CN64 - Occurrence of adverse events in cancer patients undergoing immune checkpoint inhibitors**
C. Vasques¹, J. Barbosa Lacerda¹, M. Ciol², ¹University of Brasilia - Health Sciences College, Brasilia, BR, ²University of Washington, Seattle, US
- 09:33 - 09:34 **CN65 - Feasibility, acceptability and utility of a pilot nurse-led survivorship program for people with metastatic melanoma**
J. Lai-Kwon¹, B. Kelly², S. Lane¹, R. Biviano¹, I. Bartula¹, F. Brennan¹, I. Kivikoski², H. Dhillon³, J. Thompson¹, A. Menzies¹, G. Long¹, ¹Melanoma Institute Australia, Wollstonecraft, AU, ²Melanoma Patients Australia, Varsity Lakes, AU, ³School of Psychology, Faculty of Science, University of Sydney, Sydney, AU
- 09:34 - 09:35 **CN66 - Evolution of quality of life and symptoms in patients with lung cancer or melanoma during the first months of immune checkpoint blockade treatment**
S. Colomer-Lahiguera¹, A.C. Guerra Da Souza², C. Darnac³, K. Soukup¹, R. Marcone², M. Eicher³, ¹Institute of Higher Education and Research in Healthcare - IUFRS, CHUV, Lausanne, CH, ²SIB - Swiss Institute of Bioinformatics, Lausanne, CH, ³CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH
- 09:35 - 09:36 **CN67 - Scattered ward care: The importance of appropriate nursing skill mix in managing oncology inpatients**
M. Clarke, M. O'Connor, C. Cluxton, E. Farrell, O. Fitzpatrick, L. Keogh, W. Grogan, D.

Mcmahon, A. Murphy, L. Judge, M. Conroy, J. Naidoo, C. Matassa, R. Mclaughlin, P. Morris, B. Hennessy, K. Egan, C. O'Shea, D. O'Doherty, O. Breathnach, Beaumont RCSI Cancer Centre, Dublin, IE

- 09:36 - 09:37 **CN68 - A systematic approach to identify patients' individual rehabilitation needs**
J. Rundgren¹, S. Kordnejad², ¹Tema Cancer, Karolinska University Hospital, Solna, SE, ²Karolinska Institutet - Cancer Center Karolinska (CCK), Solna, SE
- 09:37 - 09:38 **CN69 - Reducing fear and stress through educational interventions during therapeutic procedures in children and adolescents with cancer: A systematic review**
K. Michail¹, T. Theologia¹, J. De Munter², A. Charalambous¹, ¹Cyprus University of Technology - Nursing Science, Limassol, CY, ²UZ Gent - Universitair Ziekenhuis Gent, Gent, BE
- 09:38 - 09:39 **CN70 - Patients with glioblastoma and seizures: Insights into care**
D. O'Doherty, O. Fitzpatrick, T. Doyle, D. McMahon, L. Judge, R. Mclaughlin, C. Matassa, M. Conroy, N. Cooley, F. Barrett, O. Breathnach, S. Hamilton, Beaumont RCSI Cancer Centre, Dublin, IE
- 09:39 - 09:40 **CN71 - Evaluating real-world caregiver involvement from a survey of patients (pts) with metastatic urothelial cancer (mUC) receiving systemic anticancer treatment in France, Germany, Italy, Spain, and the UK (Eu5)**
M. La Puente¹, M. Berry², N. Milloy², R. Montgomery², C. Bleasdale², C. Kluth², M. Kirker³, M. Kearney⁴, N. Costa⁵, J. Chang³, ¹St. Bartholomew's Hospital, London, GB, ²Adelphi Real World, Bollington, GB, ³Pfizer, New York, US, ⁴Merck Healthcare KGaA, Darmstadt, DE, ⁵Pfizer, Porto Salvo, PT
- 09:40 - 09:41 **CN72 - What Greek patients with advanced cancer believe about the medical use of cannabis? A pilot study**
M. Tzeveleku¹, E. Patiraki¹, K. Mystakidou², S. Katsaragakis¹, ¹National and Kapodistrian University of Athens, Athens, GR, ²National & Kapodistrian University of Athens, Athens, GR
- 09:41 - 09:42 **CN73 - Circadian rhythms of cortisol, α-amylase and pro- / anti-inflammatory cytokines of osteosarcoma pediatric patients under chemotherapy**
L.C. Lopes-Júnior¹, D.S.C. Silveira², L.C. Veronez², J. Santos³, G.S. Bisson⁴, R.A.G.D. Lima⁴, ¹Universidade Federal do Espírito Santo, Campus de Maruípe, Vitoria, BR, ²University of Sao Paulo - Faculty of Medicine, Sao Paulo, BR, ³Cedars-Sinai Medical Center, Los Angeles, US, ⁴University of Sao Paulo, Ribeirao Preto, BR
- 09:42 - 09:43 **CN74 - Addressing unmet patient needs through an immunotherapy late effects clinic**
J. Bird, S. Danson, D. Greenfield, Weston Park Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB

- 09:43 - 09:44 **CN75 - The impact of cancer on financial and work-related needs: Lymphoma-specific concerns**
V. Boland¹, A. Drury², A.-M. Brady¹, ¹Trinity College Dublin, Dublin, IE, ²University College Dublin, Dublin, IE
- 09:44 - 09:45 **CN76 - Cost effectiveness of high versus low-to-moderate intensity exercise during oncological treatment: The Phys-Can RCT**
A.-K. Ax¹, M. Husberg², B. Johansson³, I. Demmelmaier⁴, S. Berntsen⁵, K. Sjövall⁶, S. Börjeson², K. Nordin⁴, T. Davidson², ¹LiU - Linköping University, Linköping, SE, ²Linköping University, Linköping, SE, ³Uppsala University - Rudbecklaboratoriet, Uppsala, SE, ⁴Uppsala University, Uppsala, SE, ⁵University of Agder, Kristiansand, NO, ⁶Kristianstad University, Kristianstad, SE
- 09:45 - 09:46 **CN77 - Effect of chewing gum on the management of chemotherapy-induced oral mucositis in children: Systematic review of experimental studies**
R. Semerci¹, E.N. Kocaaslan², ¹Koç University, Istanbul, TR, ²Trakya University, Edirne, TR
- 09:46 - 09:47 **CN78 - Initiating a personalised follow-up (PFU) programme for patients with head and neck cancer (HNC)**
L. Dean¹, C. Oakley², T. Guerrerourbano³, M. Lei², ¹Guy's & St Thomas NHS Foundation Trust, London, GB, ²Guy's Hospital, London, GB, ³Guys and St Thomas NHS Trust, London, GB
- 09:47 - 09:48 **CN79 - Patients' experience of hope during cancer treatment: The different dimensions of hope**
A. Shahriari, E. Selenius, Tema Cancer, Karolinska University Hospital, Solna, SE
- 09:48 - 09:49 **CN80 - Do we educate cancer patient about sexual dysfunction?**
M. Kozuh, Institute of Oncology Ljubljana, Ljubljana, SI
- 09:49 - 09:50 **CN81 - What are the barriers and enablers to the psychological process of empowerment in patients with lung cancer? A literature review**
L.M. Evetts, t Peter's Hospital - Ashford and St. Peter's Hospitals NHS Foundation Trust, Chertsey, GB
- 09:50 - 09:51 **CN82 - The impact of a discharge coordinator on patients' experiences of transition from hospital to home: A qualitative study**
A. Hessellund, M. Stie, Sygehus Lillebaelt - Vejle Sygehus, Vejle, DK
- 09:51 - 09:52 **CN83 - Interventions to alleviate depression and anxiety in women with ovarian cancer to improve mental health and health-related quality of life**
K. Mackenzie, G. Kotronoulas, University of Glasgow, Glasgow, GB
- 09:52 - 09:53 **CN84 - Anaemia & iron deficiency in oncology & haemato-oncology patients undergoing systemic anti-cancer therapy**
E. Flanagan, Churchill Hospital, Oxford, GB

09:53 - 09:54	<p>CN85 - Use of chamomile liposomal gel to prevent moist desquamation in breast cancer patients</p> <p><u>A. Meneses</u>¹, E. Ferreira¹, L. Vieira¹, P. Bontempo¹, E. Guerra¹, M. Ciol², P. Reis¹, ¹University of Brasilia - Health Sciences College, Brasilia, BR, ²University of Washington, Seattle, US</p>
09:54 - 09:55	<p>CN86 - Experiences of everyday life and self during outpatient cancer treatment and care: A qualitative study</p> <p><u>T. Siersbaek</u>, Sygehus Lillebaelt - Vejle Sygehus, Vejle, DK</p>
09:55 - 09:56	<p>CN87 - Pre-surgery demographic, clinical, and symptom characteristics associated with different self-reported cognitive processes in patients with breast cancer</p> <p><u>Y.-Y. Allemann-Su</u>¹, M. Vetter², H. Koechlin³, S.M. Paul⁴, B.A. Cooper⁴, K. Oppegaard⁴, M. Melisko⁵, J.D. Levine⁵, Y. Conley⁶, C. Miaskowski⁴, M. Katapodi¹, ¹University of Basel - Clinical Research, Basel, CH, ²KSBL - Kantonsspital Baselland Liestal, Liestal, CH, ³University of Zurich, Zurich, CH, ⁴UCSF - University of California San Francisco, San Francisco, US, ⁵University of California San Francisco, San Francisco, US, ⁶University of Pittsburgh - School of Nursing, Pittsburgh, US</p>
09:00 - 11:00	<p>Type: Poster session</p> <p>Title: Poster session 07</p> <p>Poster Area, Hall 4</p>
09:00 - 09:01	<p>3P - Beyond first-line therapy in metastatic adrenal cortical cancer (ACC): Is it time to move on from chemotherapy?</p> <p><u>A. Mittal</u>¹, L. Amer², O. Ayodele³, S. Radi², X. Li¹, O. Mete¹, J. Pasternak¹, D.M. Jiang¹, V. Kumar¹, A. Hansen¹, ¹UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ²UHN - University Health Network - Toronto General Hospital, Toronto, CA, ³Princess Margaret Cancer Center, Toronto, ON, Toronto, CA</p>
09:01 - 09:02	<p>4P - Immune checkpoint inhibitors in adrenocortical carcinoma: A meta-analysis</p> <p><u>O. Ababneh</u>, S. Al-Horani, A. Ghazou, M. Alawajneh, B. Shehadeh, O. Kadoumi, S. Alhaj Mohammad, A. Bani-Hani, N. Alrabadi, Jordan University of Science and Technology, Irbid, JO</p>
09:02 - 09:03	<p>5P - Application of a novel machine learning model in predicting survival in adrenocortical cancer (ACC)</p> <p><u>D. Varghese</u>¹, K. Saleh-Anaraki², O. Lokre³, A. Sedlack², B. Kikani², R. Munian-Govindan³, T. Perk³, J. Del Rivero², ¹NIH-National Institutes of Health, Bethesda, US, ²NIH - National Institutes of Health, Bethesda, US, ³AIQ Solutions, Madison, US</p>
09:03 - 09:04	<p>6P - Sensitization of pancreatic and colorectal cancer to radiotherapy, chemotherapy and inhibition of PD-1 expression by newly developed proprotein convertase inhibitors</p> <p><u>S. Pernot</u>¹, A. François², F. Soulet², G. Desolneux³, S. Evrard¹, G. Siegfried², M. Khatib², ¹Institut Bergonié, Bordeaux Cedex, FR, ²RYTME, Bordeaux institute of oncology (BRIC), Pessac, FR, ³Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC),</p>

Bordeaux, FR

- 09:04 - 09:05 **7P - HIFA1 inhibition as a therapeutic strategy for overcoming castration resistance in PTEN-deficient prostate cancer**
J. Terzic¹, M. Abu El Maaty¹, C. Keime², M. Jung², R. Lutting¹, D. Metzger¹, ¹Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch-Graffenstaden, FR, ²Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch-Graffenstaden, FR
- 09:05 - 09:06 **8P - The TTYH3/MK5 positive feedback loop via GSK3- β -catenin signaling regulates hepatocellular carcinoma progression**
C. Zhu¹, Y. Wang², Y. Xie¹, B. Dong¹, W. Xue¹, S. Chen³, M. Shimada³, Q. Dong¹, J. Cao¹, ¹The Affiliated Hospital of Qingdao University, Qingdao, CN, ²Fudan University Shanghai Cancer Center, Shanghai, CN, ³Tokushima University Graduate School, Tokushima, JP
- 09:06 - 09:07 **9P - The role of ICAM1 in glioblastoma tumor associated macrophages under hypoxia**
K. Devaraja, University Health Network, Toronto, CA
- 09:07 - 09:08 **10P - Sodium selenite presents a great antitumor activity against pancreatic cancer by AIF activation and potentiates gemcitabine by p38 pathway: In vitro and in vivo study**
K. Doello¹, C. Mestas², G. Perazzoli², L. Cabeza², F. Quiñonero², R. Ortiz², ¹Virgen de las Nieves Hospital, Granada, ES, ²University of Granada, Granada, ES
- 09:08 - 09:09 **11P - WU-NK-101: An enhanced NK cell therapy optimized for function in the tumor microenvironment (TME)**
S. Rutella¹, J. Muth², J. Vadakekulathu¹, M. Mathyer², B. Tumala², M. Foster², J. Baughman³, P. Comune Pennacchi⁴, V. Tolstikov⁵, A. Carter², D. Primo⁴, J. Gorrochategui⁴, K. Magee², P. Shah⁵, M. Kiebish⁵, J. Ballesteros⁴, M.L. Cooper², M. Berrien-Elliott⁶, T.A. Fehniger⁷, J. Davidson-Moncada², ¹Nottingham Trent University-Clifton Campus, Nottingham, GB, ²Wugen, Inc., SAINT LOUIS, US, ³Alviso Clinical Research, San Francisco, US, ⁴ViviaBiotech S.L., Tres Cantos, ES, ⁵BERG, LLC, Framingham, US, ⁶Washington University School of Medicine in St. Louis, St. Louis, US, ⁷Washington University School of Medicine in St. Louis - Siteman Cancer Center, St. Louis, US
- 09:09 - 09:10 **12P - In vitro and in vivo investigations of anlotinib in bladder cancer treatment**
Z. Meng¹, K. Wu¹, X. Pei², Y. Gu¹, L. Li¹, D. He¹, ¹The First Affiliated Hospital of Xi'an Jiaotong University, Xi' An, CN, ²Shaanxi Provincial People's Hospital, Xian, CN
- 09:10 - 09:11 **13P - Berberine associated to SGLT2i dapagliflozin synergistically reduces cardiac cell apoptosis during exposure to trastuzumab through induction of pAMPK and reduction of NLRP3 inflammasome, IL-6, methylglyoxal and leukotrienes-B4 levels**
A. Bonelli¹, V. Quagliariello², S. Buccolo¹, F. Maurea¹, A. Paccone¹, N. Maurea², ¹Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ²Istituto Nazionale Tumori -

IRCCS - Fondazione Pascale, Napoli, IT

- 09:11 - 09:12 **14P - Sacubitril-valsartan increases pAMPK and reduces NLRP3, MyD88, interleukin-6 and galectin-3 in short-term doxorubicin-treated mice improving longitudinal strain and ejection fraction**
A. Caronna¹, V. Quagliariello², S. Buccolo¹, F. Maurea¹, A. Luciano¹, A. Barbieri¹, G. Palma¹, A. Paccone¹, N. Maurea², ¹Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ²Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT
- 09:12 - 09:13 **15P - The analgesic compound palmitoylethanolamide reduces inflammation in human cardiomyocytes and vascular endothelial cells exposed to doxorubicin and anti-HER2 monoclonal antibody through PPAR- α ; and NLRP3-related pathways**
S. Buccolo¹, V. Quagliariello², C. Maurea³, M. Berretta⁴, A. Paccone¹, M. De Laurentiis², N. Maurea², ¹Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ²Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ³University of Salerno, Fisciano, IT, ⁴University of Messina, Messina, IT
- 09:13 - 09:14 **16P - Development of a 3D lung cancer model and evaluation of the efficiency of a human antibody directed against a novel target**
E. Hatzidaki¹, P. Apostolou¹, I. Papasotiriou², ¹RGCC - Research Genetic Cancer Centre S.A., Florina, GR, ²RGCC - Research Genetic Cancer Centre GmbH, Zug, CH
- 09:14 - 09:15 **17P - Preclinical mouse model of palbociclib/fulvestrant resistance in hormone-receptor-positive breast cancer**
Y.W. Moon¹, K. Pandey², ¹CHA Bundang Medical Center, Seongnam, KR, ²UT Southwestern Medical Center, Dallas, US
- 09:15 - 09:16 **18P - Adoptive cell therapy (ACT) with bispecific gamma delta TCR α β ; invariant TCR α β ; NKT-like cells for multiple myeloma (MM): Comparison of preconditioning (PC) on outcome**
T. Deisher, P. Jarzyna, S. Sawas, M. Pathak, S. Limasi, AVM Biotechnology, Seattle, US
- 09:16 - 09:17 **19P - Gene expression profile (GEP) of extensive small-cell lung cancer (eSCLC) patients (pts) receiving first-line platinum-etoposide plus atezolizumab (PEA)**
M. Lorenzi¹, A. Tosi¹, G. Crivellaro², S. Frega², A. Ferro², A. Dal Maso², L. Bonanno², A. Rosato¹, V. Guarneri¹, G. Pasello¹, ¹University of Padua, Padova, IT, ²Veneto Institute of Oncology - IRCCS, Padova, IT
- 09:17 - 09:18 **20P - Liquid biopsy of early-stage lung cancer using extracellular vesicles**
R. Kurzrock¹, J. Hineostroza², J. Lewis², H. Balcer², G. Schroeder², P. Billings³, ¹Medical College of Wisconsin, Milwaukee, US, ²Biological Dynamics, Inc., San Diego, US, ³Biological Dynamics, San Diego, US
- 09:18 - 09:19 **21P - Circulating free and extracellular vesicles-derived microRNA as prognostic biomarkers in resected early-stage non-small cell lung cancer**
P. Ulivi¹, L. Pasini¹, E. Petracci¹, M. Urbini¹, E. Felip², F. Stella³, F. Davoli³, M. Salvi³, M.

Beau-Faller⁴, M. Tebaldi¹, I. Azzali¹, P. Solli⁵, G. Lai⁵, R. Amat⁶, C. Carbonell⁶, A. Martinez-Marti², E. Pencreach⁴, A. Delmonte⁷, L. Crinò⁷, ¹Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) IRCCS, Meldola, IT, ²Vall d'Hebron University Hospital, Barcelona, ES, ³AUSL Romagna, Italy, Forlì, IT, ⁴CHU Hautepierre, Strasbourg, FR, ⁵IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, IT, ⁶Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁷IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS S.r.l., Meldola, IT

09:19 - 09:20

23P - MRE-seq based cancer screening for lung and colorectal cancer by deep learning analysis of cfDNA methylation pattern cancer screening

S.H. Shin¹, H.-J. Kwon², H.H. Kim³, N.Y. Min², Y. Lim², T. Joo², K.J. Lee², M.-S. Jeong², H. Kim², S.-W. Um¹, C. An⁴, S. Lee², ¹Samsung Medical Center (SMC), Seoul, KR, ²Eone Diagnostics Genome Center, Incheon, KR, ³The Catholic University of Korea - Bucheon St. Mary's Hospital, Bucheon, KR, ⁴The Catholic University of Korea Bucheon?St. Mary's Hospital, Bucheon, KR

09:20 - 09:21

24P - Preliminary data on INHERITY LC: Germline mutations of a cohort of selected non-small cell lung cancer (NSCLC) patients

M. Zurera¹, R. Lastra¹, L. Mezquita², O. Higuera Gomez³, J. De Castro Carpeno³, J. Corral Jaime⁴, P. Garrido Lopez⁵, E. Felipe⁶, M. Majem Tarruella⁷, D. Marquez Medina⁸, S. Menao¹, A.L. Ortega Granados⁹, J. Remon Masip¹⁰, N. Vinolas Segarra², M. Arruebo¹, D. Isla¹, ¹Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, ²Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ³Hospital Universitario La Paz, Madrid, ES, ⁴Clinica Universidad de Navarra, Pamplona, ES, ⁵Hospital Universitario Ramon y Cajal, Madrid, ES, ⁶Vall d'Hebron University Hospital, Barcelona, ES, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁸Hospital Universitario Miguel Servet, Zaragoza, ES, ⁹Hospital Universitario de Jaén, Jaén, ES, ¹⁰HM CIOCC - Centro Integral Oncológico Clara Campal, Barcelona, ES

09:21 - 09:22

25P - Identification of novel kinase-activating fusions in non-small cell lung carcinomas (NSCLCs)

E. Imyanitov, F. Zagrebina, R. Mulkidzhan, E. Krivosheeva, E. Saitova, A. Iyevleva, I. Bizin, E. Preobrazhenskaya, N.N. Petrov Institute of Oncology, Saint-Petersburg, RU

09:22 - 09:23

26P - NOTCH1 driven metastasis in BRAF mutated colorectal cancer

M. White¹, P. Tsantoulis², T. Lannagan¹, A. Najumudeen¹, R. Ridgeway¹, A. Campbell¹, R. Jackstadt³, R. Wilson⁴, O. Sansom¹, ¹CRUK - Cancer Research UK Beatson Institute, Glasgow, GB, ²UNIGE - University of Geneva - Faculty of Medicine, Geneva, CH, ³German Cancer Research Center (DKFZ), Heidelberg, DE, ⁴Wolfson Wohl Cancer Research Centre - Institute of Cancer Science, Glasgow, GB

09:23 - 09:24

27P - Influence of single nucleotide polymorphisms (SNPs) in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer

M. Veerman¹, R. Boosman², M. Jebbink², E. Oomen-De Hoop³, A.J. Van Der Wekken⁴, I. Bahce⁵, L. Hendriks⁶, C. Steendam⁷, E. De Jonge⁸, S. Koolen¹, R. Van Schaik¹, E. Smit², A.-M. Dingemans¹, A. Huitema⁹, R. Mathijssen¹⁰, ¹Erasmus MC - University Medical Center, Rotterdam, NL, ²NKI-AVL - Netherlands Cancer Institute/Antoni van

Leeuwenhoek Hospital, Amsterdam, NL, ³Erasmus MC Cancer Institute, Rotterdam, NL, ⁴UMCG - University Medical Center Groningen, Groningen, NL, ⁵Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, ⁶Maastricht UMC, Maastricht, NL, ⁷Amphia Ziekenhuis-location Molengracht, Breda, NL, ⁸Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, NL, ⁹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ¹⁰Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL

- 09:24 - 09:25 **28P - Identification of convergent gene repression mechanisms through integrative genomic and DNA methylation analysis in NSCLC**
C. Castignani¹, F. Gimeno-Valiente², E. Larose Cadieux¹, K. Chen², N. Mensah¹, O. Chervova², T. Watkins¹, P. Dhami², H. Vaikkinen², S. Saghafeinia², T. Karasaki¹, C. Hiley², A. Feber², C. Tracerx³, J. Demeulemeester¹, M. Tanic², S. Beck², P. Van Loo¹, C. Swanton¹, N. Kanu², ¹The Francis Crick Institute, London, GB, ²University College London Cancer Institute, London, GB, ³TRACERx Consortium, London, GB
- 09:25 - 09:26 **29P - Dynamic NK cell activity as a prognostic biomarker in non-small cell lung cancer treated with curative surgery**
S. Wen¹, L. Nederby¹, T. Hansen², A. Jakobsen², O. Hilberg¹, ¹Vejle Hospital, part of University Hospital of Southern Denmark, Vejle, DK, ²Vejle Hospital, part of University Hospital of Southern Denmark, Middelfart, DK
- 09:26 - 09:27 **30P - Hes1 protein expression and its significance in resected small cell lung cancers**
X. Sun¹, L. Liu², J. Dong¹, L. Yang¹, P. Xing³, ¹National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ²National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ³Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN
- 09:27 - 09:28 **31P - Detection of breast cancer cells with potency to organ-specific metastasis using 10X genomics visium platform**
E. Grigoryeva, L. Tashireva, M. Zavyalova, V. Perelmuter, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RU
- 09:28 - 09:29 **32P - Untargeted metabolomics and lipidomics identified four subtypes of small cell lung cancer**
C. Zhang¹, X. Shang², H. Wang², ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN
- 09:29 - 09:30 **33P - Immune checkpoint inhibitor-induced cardiotoxicity is driven through inflammation, autophagy and stress**
P. Efentakis¹, M. Gavriatopoulou¹, E. Choustoulaki¹, A. Georgoulis¹, G. Tsekenis², Z. Chakim², I. Ntanasis-Stathopoulos¹, M. Dimopoulos¹, E. Terpos¹, I. Andreadou¹, ¹National and Kapodistrian University of Athens, Athens, GR, ²Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, GR

- 09:30 - 09:31 **34P - Addition of oncolytic virus is as effective as addition of cytoreductive nephrectomy to the first-line treatment of anti-PD-1/anti-CTLA-4 antibodies in the murine metastatic renal cell carcinoma model**
J.S. Park¹, W.S. Ham², M.E. Lee², W.S. Jang², K. Oh³, N. Lee³, ¹Sorokdo National Hospital, Jeonnam, KR, ²Yonsei University College of Medicine, Seoul, KR, ³SillaJen, Inc., Seoul, KR
- 09:31 - 09:32 **35P - Targeting the secreted gelsolin-DNGR-1 dendritic cell axis to enhance anti-cancer therapies**
K.H.J. Lim¹, E. Giampazolias², O. Schulz², N.C. Rogers², A. Wilkins², E. Sahai², J. Strid³, C. Reis E Sousa², ¹The Francis Crick Institute & Imperial College London, London, GB, ²The Francis Crick Institute, London, GB, ³Imperial College London - Hammersmith Campus, London, GB
- 09:32 - 09:33 **36P - Short-term immune check-point inhibitor treatment reduces cardiac pAMPK and IL-10, increases vascular NF-kB expression and serum IL-1, IL-2 and IL-6 levels**
A. Paccone¹, V. Quagliariello², M. Passariello³, S. Buccolo¹, A. Barbieri¹, G. Palma¹, A. Luciano¹, A. Di Mauro¹, C. Cipullo¹, C. De Lorenzo³, N. Maurea², ¹Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ²Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ³Università degli Studi di Napoli Federico II, Napoli, IT
- 09:33 - 09:34 **37P - Breast cancer immunopeptidomes reveal a large number of targetable tumor antigens**
E. Kina, J.-P. Laverdure, C. Durette, J. Lanoix, Q. Zhao, A. Apavaloaei, L. Hesnard, M.-V. Ruiz Cuevas, J.-D. Larouche, M.-P. Hardy, K. Vincent, M. Courcelles, P. Thibault, C. Perreault, IRIC - Institute for Research in Immunology and Cancer - Université de Montréal, Montreal, CA
- 09:34 - 09:35 **38P - Development of therapeutic biomarkers for oncolytic vaccinia virus using cell-line derived xenograft mouse model**
W.S. Ham¹, J.S. Park², M.E. Lee¹, W.S. Jang¹, K. Oh³, N. Lee³, ¹Yonsei University College of Medicine, Seoul, KR, ²Sorokdo National Hospital, Jeonnam, KR, ³SillaJen, Inc., Seoul, KR
- 09:35 - 09:36 **39P - ANV419 is a novel CD122-biased IL-2/anti-IL-2 fusion protein with potent CD8 T cell and NK cell stimulating capacity that shows additive efficacy in combination with checkpoint inhibitors and treatments acting through antibody dependent cellular cytotoxicity**
K. Richter, N. Egli, L. Petersen, P. Murer, A. Katopodis, C. Huber, Anaveon AG, Basel, CH
- 09:36 - 09:37 **40P - Identification of a PD-1/LAG-3 co-expression profile in human tumor-infiltrating T cells uncovers a T cell dysfunctionality genetic regulated programme**
L. Chocarro¹, E. Blanco¹, H. Arasan², L. Fernández-Rubio¹, A.I. Bocanegra Gondan¹, M. Echaide¹, M. Garnica¹, P. Ramos¹, S. Pineiro-Hermida¹, M.J. García-Granda¹, R. Vera², E. Santamaría¹, J. Fernández-Irigoyen¹, G. Kochan¹, D. Escors¹, ¹Navarrabiomed-Fundación Miguel Servet, Universidad Pública de Navarra (UPNA), Hospital Universitario de

Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, ES,
²Hospital Universitario de Navarra (HUN), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, ES

- 09:37 - 09:38 **41P - Clinical characteristics and outcomes of COVID-19 in 1295 new cancer patients: Single-center, prospective cohort study from Iran**
S.A. Javadinia, Vasei Hospital, Sabzevar, IR
- 09:38 - 09:39 **42P - Antitumor activity of zolbetuximab combined with chemotherapy and anti-mouse PD-1 antibody (anti-mPD-1) in a syngeneic mouse model and a virtual preclinical trial using a quantitative systems pharmacology (QSP) model**
T. Nakayama, M. Oishi, J. Weng, K. Omori, C. Kwon, T. Nakazawa, T. Nishibata, F. Kinugasa, T. Yoshida, Y. Nagasaka, Astellas Pharma Inc., Tsukuba, JP
- 09:39 - 09:40 **43P - Influence of chromosomal instability on cGAS/STING activation and metastatic behavior of lung and colorectal cancer cells**
G. Mühlmeier, B. Kraft, T. Wohlfrohm, A. Krämer, DKFZ - German Cancer Research Center, Heidelberg, DE
- 09:40 - 09:41 **44P - Dendritic cells direct circadian anti-tumor immune responses**
C. Wang, C. Barnoud, B. Kizil, C. Scheiermann, UNIGE - University of Geneva - Faculty of Medicine, Geneva, CH
- 09:41 - 09:42 **45P - Monocyte subpopulations and myeloid-derived suppressor cells in peripheral blood of cancer patients receiving immune checkpoint inhibition-based treatment**
C. Peischl, M. Preusser, A.S. Berghoff, B. Fendl, Medical University of Vienna, Vienna, AT
- 09:42 - 09:43 **46P - Inhibition of cell invasion and migration by targeting matrix metalloproteinase-9 expression via sirtuin 6 silencing in human breast cancer cells**
H.J. Youn, Chonbuk National University Hospital, Jeonju, KR
- 09:43 - 09:44 **47P - Inhibition of PD-1 expression by sulconazole through NF- κ B repression**
M. Khatib¹, T. Mercedes¹, S. Evrard², B. Villoutreix³, S. Pernot², ¹RYTME, Bordeaux institute of oncology (BRIC), Pessac, FR, ²Institut Bergonié, Bordeaux Cedex, FR, ³Université de Paris, Paris, FR
- 09:44 - 09:45 **48P - Tertiary lymphoid structure predicts major pathological response in resectable non-small cell lung cancer patients with neoadjuvant chemotherapy**
W. Cai¹, J. Miao¹, J. Wen¹, Y. Gu², X. Zhao³, Z. Xue⁴, ¹The First Medical Center of Chinese PLA General Hospital, Beijing, CN, ²3D Medicines, Inc., shanghai, CN, ³3D Medicines Inc, Shanghai, CN, ⁴Chinese PLA General Hospital (301 Military Hospital), Beijing, CN
- 09:45 - 09:46 **49P - Identifying peripheral immune predictors of durable clinical response to PD-L1 blockade in small cell lung cancer**

M. Galindo Campos¹, M. Hardy-Werbin¹, A. Rios Hoyo², J. Gibert¹, A. Rossell¹, S. Gonzalez¹, P. Simoes Da Rocha², R. Del Rey-Vergara¹, L. Masfarré², N. Navarro Gorro², A. Taus Garcia², A. Rovira¹, E. Arriola², ¹IMIM - Institut Hospital del Mar d'Investigacions Mediques, Barcelona, ES, ²Hospital del Mar - Parc de Salut Mar, Barcelona, ES

09:46 - 09:47 **50P - T regulatory type 1 (Tr1) cells, a potential target in EGFR TKI-resistant NSCLC**

H. Guo, R. Han, F. Zhou, C. Zhou, Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, CN

09:47 - 09:48 **51P - miR-4487 enhances gefitinib-mediated ubiquitination and autophagic degradation of EGFR in non-small cell lung cancer cells by targeting USP37**

S.-H. Yang, M.S. Kim, M.S. Kim, Wonkwang University, Iksan, KR

09:48 - 09:49 **321P - A comprehensive predicting model of recurrence in stage III colon cancer from PETACC-8 trial**

C. Gallois¹, M. Sroussi², S. Mouillet-Richard³, C. Mulot³, L.M. Dourthe⁴, T. Mazard⁵, M. Jary⁶, C. De La Fouchardiere⁷, C. Lecaille⁸, W. Lahlou⁹, J. Tabernero¹⁰, J.-L. Van Laethem¹¹, C. Lepage¹², J.F. Emile¹³, J. Taieb¹⁴, A. De Reynies¹, P. Laurent-Puig¹, ¹Centre de Recherche des Cordeliers - Université Paris Cité, Paris, FR, ²PSL Research University, Paris, FR, ³Centre de Recherche des Cordeliers, Paris, FR, ⁴Clinique Saint Anne, Strasbourg, FR, ⁵ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ⁶CHU de Clermont-Ferrand - Site Estaing, Clermont-Ferrand, Cedex, FR, ⁷Centre Léon Bérard, Lyon, FR, ⁸Polyclinique Bordeaux Nord Aquitaine, Bordeaux, FR, ⁹HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, ¹⁰Vall d'Hebron University Hospital, Barcelona, ES, ¹¹Erasmus University Hospital-(Universite Libre de Bruxelles), Brussels, BE, ¹²CHU Dijon, Dijon, FR, ¹³Hopital Ambroise Pare, Boulogne-Billancourt, FR, ¹⁴Hopital European George Pompidou, Paris, FR

09:49 - 09:50 **322P - Genomic landscape of early-onset sporadic colorectal cancer**

A. Holowatyj¹, S. Hardikar², D. Nix², B. Haaland², M. Larson², E. Siegel³, J. Carpten⁴, H. Hampel⁵, T. Kennedy⁶, C. Lieu⁷, M. Reilley⁸, R. Pearlman⁹, M. Lewis¹⁰, M. Churchman¹¹, H. Colman¹², C. Ulrich¹³, ¹Vanderbilt University, Nashville, US, ²University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US, ³H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ⁴Keck School of Medicine - University of Southern California USC, Los Angeles, US, ⁵City of Hope Comprehensive Cancer Center, Duarte, US, ⁶Rutgers Cancer Institute of New Jersey, New Brunswick, US, ⁷University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora, US, ⁸University of Virginia Comprehensive Cancer Center, Charlottesville, US, ⁹OSUCCC - The Ohio State University Comprehensive Cancer Center - James, Columbus, US, ¹⁰Intermountain Medical Center - Intermountain Healthcare, Murray, US, ¹¹M2GEN, Tampa, US, ¹²University of Utah Health - Cancer Hospital, Salt Lake City, US, ¹³Huntsman Cancer Institute, Salt Lake City, USA, US

09:50 - 09:51 **323P - Five-year efficacy and safety in a randomized phase III trial investigating duration of adjuvant oxaliplatin-based therapy (3- vs. 6-months) for patients with high-risk stage II colon cancer: ACHIEVE-2 trial**

A. Makiyama¹, K. Yamazaki², M. Shiozawa³, D. Manaka⁴, M. Kotaka⁵, Y. Sakamoto⁶, A. Shiomi², Y. Munemoto⁷, T. Rikiyama⁸, M. Fukunaga⁹, U. Takashi¹⁰, K. Shitara¹¹, H. Shinkai¹², N. Tanida¹³, E. Oki¹⁴, T. Misumi¹⁵, E. Sunami¹⁶, A. Ohtsu¹¹, Y. Maehara¹⁷, T. Yoshino¹¹, ¹Gifu University Hospital, Gifu, JP, ²Shizuoka Cancer Center, Shizuoka, JP, ³Kanagawa Cancer Center, Yokohama, JP, ⁴Kyoto-Katsura Hospital, Kyoto, JP, ⁵Sano Hospital-Gastrointestinal Cancer Centre, Kobe, JP, ⁶Osaki Citizen Hospital, Osaki, JP, ⁷Fukui Saiseikai Hospital, Fukui, JP, ⁸Jichi Medical University Saitama Medical Center, Saitama, JP, ⁹Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, JP, ¹⁰Hamanomachi Hospital, Fukuoka, JP, ¹¹National Cancer Center Hospital East, Kashiwa, JP, ¹²Chigasaki Municipal Hospital, Chigasaki, JP, ¹³Japanese red cross kochi hospital, Kochi, JP, ¹⁴Kyushu University - Graduate School of Medical Sciences - Faculty of Medical Sciences, Fukuoka, JP, ¹⁵National Cancer Center Hospital East, Kashiwa, Japan, Kashiwa, JP, ¹⁶Kyorin University Faculty of Medicine, Mitaka, JP, ¹⁷Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, JP

09:51 - 09:52 **324P - Effects of screening and treatment improvement on colon cancer survival over 20 years in Korea**

H.S. Kim¹, H. Kim¹, J. Jeon¹, S.Y. Choi², J.Y. Ahn², S.-H. Beom¹, S.J. Shin¹, S.H. Park³, J.B. Ahn¹, ¹Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ²Severance hospital, Seoul, KR, ³Yonsei University College of Medicine, Seoul, KR

09:52 - 09:53 **325P - Early-onset colorectal cancer in the United States: Trends in prevalence, stage, and survival**

M. Gouda¹, A. Allam¹, M. Elsayed¹, M. Khalafallah², O. Aboshady¹, ¹Faculty of Medicine, Menoufia University, Shebeen El-Kom, EG, ²Faculty of Medicine, Menoufia University, Birmingham, US

09:53 - 09:54 **326P - The predictive value of vitamin D follow-up and replacement on recurrence in patients with colorectal cancer**

T. Kus¹, E. Isbilen², G. Aktas³, H. Arak¹, ¹Gaziantep University Onkoloji Hastanesi, Gaziantep, TR, ²Gaziantep University School of Medicine, Gaziantep, TR, ³Gaziantep Medical park hospital, Gaziantep, TR

09:54 - 09:55 **327P - Traditional Chinese medicine jianpi-bushen sequential formula modulating gut microbiota for stage II&III colon cancer patients during adjuvant chemotherapy: Results from a multi-center randomized double-blind placebo-controlled clinical trial in China**

Y. Yan¹, L. Sun², Y. Yang³, ¹Beijing University of Chinese Medicine, Beijing, CN, ²Xiyuan Hospital CACMS, Beijing, CN, ³Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, CN

09:55 - 09:56 **328P - Association of skeletal muscle loss with patient-reported treatment toxicity among colon cancer patients receiving adjuvant chemotherapy**

K. Smit¹, J. Derksen¹, W. Veldhuis¹, P. Moeskops², D. Sommeijer³, L. Van Leeuwen-Snoeks⁴, M. Koopman¹, A. May¹, ¹UMC - University Medical Center Utrecht, Utrecht, NL, ²Quantib, Rotterdam, NL, ³Flevo Hospital, Almere, NL, ⁴Diakonessenhuis, Utrecht, NL

- 09:56 - 09:57 **329P - Duration of adjuvant therapy in stage III colon cancer: A real world multi-institutional US-based experience**
D. Walden¹, F.-S. Ou², J. Larson³, S. Kang⁴, A. Liu¹, D. Huff¹, C. Griswold¹, B. Ueberroth¹, P. Bhamini⁴, A. Draper⁴, B. Grieb⁵, K. Ciombor⁵, P. Raman¹, M. Sonbol¹, M. Borad¹, T. Bekaii-Saab¹, C. Wu¹, D. Ahn¹, ¹Mayo Clinic Cancer Center, Phoenix, US, ²Mayo Clinic, Jacksonville, US, ³Mayo Clinic Cancer Center, Rochester, US, ⁴Winship Cancer Institute of Emory University, Atlanta, US, ⁵Vanderbilt Ingram Cancer Center, Nashville, US
- 09:57 - 09:58 **330P - Does hepatitis C independently increase the risk of colorectal adenoma?**
M. Gogtay¹, Y. Singh¹, A. Bullappa², A. Yekula¹, G. Abraham¹, ¹Saint Vincent Hospital, Worcester, US, ²S.S.Institute of medical sciences, Davangere, IN
- 09:58 - 09:59 **331P - Predicting outcomes following colorectal cancer resection: Using real-world data to empower adjuvant treatment decision making**
A. Pennycuick¹, H. Selway¹, J. Lam², K. Khan³, ¹UCL - University College London, London, GB, ²UCLH - University College London Hospitals NHS Foundation Trust, London, GB, ³The Royal Marsden Hospital - NHS Foundation Trust, London, GB
- 09:59 - 10:00 **332P - Impact of the COVID-19 pandemic in the early-onset colorectal cancer (EOCRC)**
I. Baraibar Argota¹, A. Garcia Rodriguez¹, F. Salvà Ballabrera¹, F.J. Ros Montana¹, N. Saoudi Gonzalez¹, R. Comas¹, G. Castillo¹, M. Sanchis¹, J. Hernando Cubero¹, A. García-Alvarez¹, J. Capdevila Castillon¹, M. Martí¹, S. Landolfi¹, E. Espin¹, P. Nuciforo², A. Vivancos¹, J. Tabernero¹, M.E. Elez Fernandez¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES
- 10:00 - 10:01 **333P - Pharmaceutical agents as potential drivers in development of early-onset colorectal cancer (EOCRC)**
I. Ben-Aharon¹, R. Rotem², A. Cercek³, E. Half¹, T. Goshen - Lago¹, G. Chodick², D. Kelsen³, ¹Rambam Health Care Campus, Haifa, IL, ²Maccabi Healthcare Services, Tel Aviv, IL, ³Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US
- 10:01 - 10:02 **334P - Adjuvant radiotherapy improves overall survival in patients with stage T4N0-2M0 sigmoid colon cancer**
Y. Lin¹, L. Shao², L. Hong², S. Liu³, W. Junxin¹, ¹Fujian Medical University, Fuzhou, CN, ²Fujian Cancer Hospital, Fuzhou, CN, ³Fujian Children's Hospital, Fuzhou, CN
- 10:02 - 10:03 **335P - Early-onset colorectal cancer: A single centre experience**
A. Angelakas, N. Peters, M. Braun, N. Cook, The Christie NHS Foundation Trust, Manchester, GB
- 10:03 - 10:04 **336P - Prognostic and predictive value of Immunoscore in stage III colorectal cancer in the combined SCOT and IDEA-HORG studies**
D. Church¹, J. Hay², O. Sansom³, N. Maka⁴, K. Oien⁴, T. Iveson⁵, M. Saunders⁶, J. Edwards², A. Harkin⁷, I. Boukovinas⁸, E. Moustou⁹, I. Messaritakis¹⁰, M. Chondrozoumaki¹¹, V. Georgoulis¹¹, I. Boquet¹², F. Pages¹³, A. Catteau¹², J. Galon¹⁴, C.

Kelly², I. Souglakos¹¹, ¹Wellcome Trust Centre for Human Genetics, Oxford, GB, ²University of Glasgow, Glasgow, GB, ³CRUK - Cancer Research UK Beatson Institute, Glasgow, GB, ⁴NHS Greater Glasgow and Clyde, Glasgow, GB, ⁵Southampton General Hospital, Southampton, GB, ⁶The Christie NHS Foundation Trust, Manchester, GB, ⁷BWSSCC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, ⁸Bioclinic Oncology Unit of Thessaloniki, Thessaloniki, GR, ⁹University Hospital of Heraklion,, Crete, GR, ¹⁰University of Crete - School of Medicine, Heraklion, GR, ¹¹University of Crete - School of Medicine, Heraklion, GR, ¹²VERACYTE, Marseille, FR, ¹³VERACYTE, Marseille, Cedex, FR, ¹⁴Institut national de la santé et de la recherche médicale, Paris, FR

- 10:04 - 10:05 **337P - Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials**
S. Hassanieh¹, E. Domingo¹, A. Blake¹, D. Fisher², K.L. Redmond³, S. Richman⁴, S. Walker⁵, P. Quirke⁴, R. Wilson⁶, R. Kennedy³, I. Tomlinson⁷, R. Kaplan², L. Brown², P. Dunne³, M. Seymour⁴, D. Morton⁸, R. Adams⁹, N. West⁴, T. Maughan¹, ¹University of Oxford, Oxford, GB, ²University College London, London, GB, ³Queen's University Belfast, Belfast, GB, ⁴St. James's University Hospital, Leeds, GB, ⁵Almac Diagnostics, Craigavon, GB, ⁶University of Glasgow, Glasgow, GB, ⁷University of Edinburgh, Edinburgh, GB, ⁸University of Birmingham, Birmingham, GB, ⁹Cardiff University, Cardiff, GB
- 10:05 - 10:06 **338P - A new clinically applicable immune-metabolic signature (IMMETCOLS) reveals metabolic singularities in consensus molecular subtypes (CMS) in colorectal cancer**
S. Madurga¹, C. Foguet², H. Oliveres³, F. Mas¹, J. Maurel³, M. Cascante⁴, ¹Universitat de Barcelona, Barcelona, ES, ²Department of Biochemistry and Molecular Biomedicine & Institute of Biomedicine of Universitat de Barcelona, Barcelona, ES, ³Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁴Barcelona University, Barcelona, ES
- 10:06 - 10:07 **339P - Molecular subtyping for chemotherapy response prediction in early stage colon cancer**
S. Van De Weerd¹, A. Torang¹, M. Smit², I. Van Den Berg³, J. Roelands², W. Mesker², D. Bedognetti⁴, P. Kuppen², H. Putter², R. Tollenaar², W. Hendrickx⁴, C. Jimenez⁵, G. Vink⁶, M. Koopman⁶, J. Roodhart⁶, J. Ijzermans³, H. Van Krieken⁷, J.-P. Medema¹, ¹Amsterdam University Medical Center (UMC) - locatie Academic Medical Center (AMC), Amsterdam, NL, ²LUMC-Leiden University Medical Center, Leiden, NL, ³Erasmus MC - Erasmus University Rotterdam, Rotterdam, NL, ⁴Sidra Medical and Research Center, Al-Rayyan, QA, ⁵Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, ⁶UMC - University Medical Center Utrecht, Utrecht, NL, ⁷Radboud University Medical Center, Nijmegen, NL
- 10:07 - 10:08 **340P - Prediction of relapse in colon cancer patients by machine learning models combining radiomics and deep features extracted from baseline computed tomography**
A. Bueno Gómez¹, N. Tarazona Llaveró¹, A. Alcolado Jaramillo², F. Gimeno-Valiente³, J. Carbonell-Asins⁴, M. Huerta¹, T. Fleitas¹, S. Roselló Keränen¹, L. Candia², D. Roda Perez¹, P. Moreno Ruiz⁵, A. Jiménez Pastor⁵, A. Alberich-Bayarri⁵, A. Cervantes¹, ¹INCLIVA Biomedical Research Institute, Valencia, ES, ²Hospital Clinico Universitario de

Valencia, Valencia, ES, ³University College London Cancer Institute, London, GB,
⁴Microbiology Service, Fundación INCLIVA, Hospital Clínico Universitario, Valencia, ES,
⁵Quibim, Quantitative Imaging Biomarkers in Medicine, Valencia, ES

10:08 - 10:09

341P - Trop2 and Nectin4 immunohistochemical expression in metastatic colorectal cancer: An exploratory analysis of the TRIBE2 study

V. Conca¹, M. Germani¹, R. Moretto², M. Giordano¹, F. Bergamo³, M. Prisciandaro⁴, C. Antoniotti¹, C. Ugolini¹, D. Santini⁵, S. Cupini⁶, A. Boccaccino¹, G. Barsotti⁷, F. Pagani⁴, C. Niccoli⁸, A. Zaniboni⁹, A. Passardi¹⁰, E. Tamburini¹¹, T.P. Latiano¹², G. Fontanini¹, C. Cremolini¹, ¹University of Pisa, Pisa, IT, ²Azienda Ospedaliera Universitaria Pisana, Pisa, IT, ³Veneto Institute of Oncology IOV - IRCCS, Padova, IT, ⁴Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁵University Campus Biomedico, Rome, IT, ⁶Livorno - Azienda Toscana Nord-Ovest, Livorno, IT, ⁷Veneto Institute of Oncology IOV - IRCCS; University of Padua, Padua, IT, ⁸Azienda Ospedaliero-Universitaria Pisana, Pisa, IT, ⁹Fondazione Poliambulanza, Brescia, IT, ¹⁰IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS S.r.l., Meldola, IT, ¹¹Cardinale Panico Tricase City Hospital, Tricase, IT, ¹²Fondazione IRCCS Casa Solievo della Sofferenza, San Giovanni Rotondo, IT

10:09 - 10:10

342P - A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

A. Rodriguez-Ariza¹, M.A. Gomez España², M.E. Elez Fernandez³, M.C. Gravalos Castro⁴, P. García-Alfonso⁵, F. Losa⁶, I.C. Ales Diaz⁷, B. Grana Suarez⁸, I. Gallego⁹, M.V. García-Ortiz¹⁰, E. Polo Marques¹¹, M. Salgado Fernandez¹², F. Rivera Herrero¹³, M.J. Safont Aguilera¹⁴, M.A. Salud Salvia¹⁵, A. Ruiz-Casado¹⁶, J. Tabernero¹⁷, M.C. Riesco Martinez¹⁸, M. Toledano-Fonseca¹⁹, E. Aranda Aguilar²⁰, ¹Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) Hospital Universitario Reina Sofía. CIBERONC, Córdoba, ES, ²Maimónides Biomedical Research Institute of Córdoba (IMIBIC), University Hospital Reina Sofia, Córdoba, ES, ³Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, ES, ⁴Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12), UCM, Madrid, ES, ⁵Hospital General Universitario Gregorio Marañón, Madrid, ES, ⁶ICO-CSI. H. Sant Joan Despí - Moisés Broggi, Sant Joan Despí, ES, ⁷Unidad de Gestión Clínica Intercentros de Oncología Médica. Hospitales Universitarios Regional y Virgen de la Victoria. IBIMA, Malaga, ES, ⁸CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, ⁹Hospital Virgen del Rocío, IBIS, Seville, ES, ¹⁰Maimónides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba; Cancer Network Biomedical Research Center (CIBERONC), Instituto de Salud Carlos III, Madrid, Córdoba, ES, ¹¹Hospital Universitario Miguel Servet, Zaragoza, ES, ¹²Complejo Hospitalario Universitario de Ourense, Ourense, ES, ¹³HUMV - Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, ES, ¹⁴General Universitario, CIBERONC, Universidad de Valencia, Valencia, ES, ¹⁵Hospital Universitario Arnau de Vilanova, Lleida, ES, ¹⁶University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES, ¹⁷Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, ES, ¹⁸Hospital Universitario 12 de Octubre, Imas12, UCM, Madrid, ES, ¹⁹Maimónides Biomedical Research Institute of Córdoba (IMIBIC), University Hospital Reina Sofía. CIBERONC, Córdoba, ES, ²⁰IMIBIC, Reina Sofía Hospital, University of Cordoba, CIBERONC, Cordoba, ES

- 10:10 - 10:11 **343P - DPYD gene sequencing and in silico functionality prediction of polymorphisms in 3,471 colorectal cancer patients treated with fluoropyrimidine (FP)**
- M.-C. Etienne-Grimaldi¹, J.-C. Boyer², E. Menoret³, J.-P. Desvignes³, V. Boige⁴, J. Taieb⁵, P. Laurent-Puig⁶, Y. Wettergren⁷, M. Schwab⁸, S. Ackland⁹, B. Jennings¹⁰, E. Seutin¹, J. Rousset¹, G. Le Teuff¹¹, N. Cozic¹¹, Y. Koudou¹¹, C. Bérout³, ¹Centre Antoine Lacassagne, Nice, FR, ²CHU Nîmes - Hôpital Universitaire Carémieu, Nîmes, Cedex, FR, ³Aix-Marseille University - Faculté de Médecine - Timone, Marseille, FR, ⁴Institut Gustave Roussy, Villejuif, Cedex, FR, ⁵Hôpital Européen George Pompidou, Paris, FR, ⁶Paris Descartes University, Paris, FR, ⁷University of Gothenburg - The Sahlgrenska Academy, Göteborg, SE, ⁸Universitätsklinikum Tübingen Medizinische Universitätsklinik, Tübingen, DE, ⁹The University of Newcastle, Callaghan, AU, ¹⁰University of East Anglia, Norwich, GB, ¹¹Gustave Roussy - Cancer Campus, Villejuif, FR
- 10:11 - 10:12 **344P - Tumor organoids from multifocal metastatic colorectal cancers for personalized oncology**
- K. Kryeziu¹, K. C. G. Berg², M. Totland¹, S.H. Moosavi¹, B. Niederdorfer¹, S. Klokke¹, C. Bergsland², T.K. Guren¹, K. Lassen³, A. Nesbakken², S. Yaqub³, A. Sveen², R. Lothe¹, ¹Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, ²Oslo University Hospital - Radiumhospitalet, Oslo, NO, ³Oslo University Hospital - Rikshospitalet, Oslo, NO
- 10:12 - 10:13 **345P - The prognostic value of pre-treatment circulating biomarkers of systemic inflammation (CRP, neutrophil-to-lymphocyte ratio, IL-6, and YKL-40) in vulnerable older patients with metastatic colorectal cancer: The randomized NORDIC9-study**
- G. Liposits¹, H. Skuladottir², J. Ryg¹, S. Winther¹, S. Möller³, E. Hofsløi⁴, C.-H. Shah⁵, L. Poulsen Oestergaard⁶, A. Berglund⁷, C. Qvortrup⁸, P. Osterlund⁹, J. Johansen¹⁰, B. Glimelius⁷, H. Sorbye¹¹, P. Pfeiffer¹, ¹OUH - Odense University Hospital, Odense, DK, ²Regional Hospital Gødstrup, Herning, DK, ³University of Southern Denmark, Odense, DK, ⁴St. Olavs Hospital HF, Trondheim, NO, ⁵Karolinska University Hospital and Karolinska Institute, Stockholm, SE, ⁶Aalborg University Hospital, Aalborg, DK, ⁷University Hospital Uppsala/Akademiska Sjukhuset, Uppsala, SE, ⁸Copenhagen University Hospital, Copenhagen, DK, ⁹Tampere University Hospital (Tays), Tampere, FI, ¹⁰Herlev and Gentofte Hospital, Herlev, DK, ¹¹Haukeland University Hospital, Bergen, NO
- 10:13 - 10:14 **346P - Influence of single nucleotide polymorphisms in genes involved in capecitabine activation pathway on treatment toxicity in patients with colorectal cancer**
- Y. Cura¹, C. Pérez-Ramírez², A. Sánchez-Martín¹, E. González-Flores³, A. Jiménez-Morales¹, ¹Hospital Universitario Virgen de las Nieves, Granada, ES, ²Institute of nutrition and food technology "José Mataix". Centre of biomedical research, Churriana de la Vega, ES, ³Hospital Universitario Virgen de las Nieves. Institute of Biosanitary Research, ibs.Granada, Granada, ES
- 10:14 - 10:15 **347P - Prognostic impact of signet ring cell proportion in colorectal cancer patients with peritoneal metastases**

V. Kepenekian¹, A. Kefleyesus², G. Petrides³, S. Barat³, I. Bonnefoy², S. Valle³, J. Peron⁴, N. Alzahrani³, O. Glehen⁵, D. Morris³, ¹Hospices Civils de Lyon - HCL - Lyon University Hospital Center, Pierre-Bénite, FR, ²Lyon Sud Hospital Center - HCL, Pierre-Bénite, FR, ³St George Hospital and UNSW, Kogarah, AU, ⁴Ch Lyon Sud, Pierre Benite, FR, ⁵Hospices Civils de Lyon, Bron, FR

10:15 - 10:16 **348P - Prediction of sensitivity to anti-EGFR inhibitors in salvage-line treatment for metastatic colorectal cancer using a modified MethyLight assay**

K. Ouchi¹, S. Takahashi¹, H. Osumi², Y. Otsuki¹, K. Sasaki¹, E. Shinozaki², C. Ishioka¹, ¹Tohoku University Hospital, Sendai, JP, ²The Cancer Institute Hospital of JFCR, Koto-ku, JP

10:16 - 10:17 **349P - Analysis of plasma angiogenesis factors on the efficacy of 2nd-line (2L) chemotherapy (chemo) combined with angiogenesis inhibitors (AIs) in metastatic colorectal cancer (mCRC): Results from GI-SCREEN CRC Ukit study**

S. Yuki¹, K. Yamazaki², Y. Sunakawa³, H. Taniguchi⁴, T. Masuishi⁴, M. Shiozawa⁵, H. Bando⁶, T. Nishina⁷, H. Yasui⁸, T. Ohta⁹, N. Takahashi¹⁰, T. Denda¹¹, K. Yoshida¹², T. Kato¹³, E. Oki¹⁴, Y. Okugawa¹⁵, H. Ebi¹⁶, Y. Abe¹⁷, S. Nomura⁶, T. Yoshino⁶, ¹Hokkaido University Hospital, Sapporo, JP, ²Shizuoka Cancer Center, Shizuoka, JP, ³St. Marianna University School of Medicine, Kawasaki, JP, ⁴Aichi Cancer Center Hospital, Nagoya, JP, ⁵Kanagawa Cancer Center, Yokohama, JP, ⁶National Cancer Center Hospital East, Kashiwa, JP, ⁷Shikoku Cancer Center, Matsuyama, JP, ⁸Kobe City Medical Center General Hospital, Kobe, JP, ⁹Kansai Rosai Hospital, Amagasaki, JP, ¹⁰Saitama Cancer Center, Ina, JP, ¹¹Chiba Cancer Center, Chiba, JP, ¹²Gifu University Hospital, Gifu, JP, ¹³National Hospital Organization Osaka National Hospital, Osaka, JP, ¹⁴Kyushu University, Graduate School of Medical Sciences - Faculty of Medical Science, Fukuoka, JP, ¹⁵Mie University Hospital, Tsu, JP, ¹⁶Aichi Cancer Center Research Institute, Nagoya, JP, ¹⁷G&G Science Co., Ltd., Fukushima, JP

10:17 - 10:18 **350P - Postoperative histopathological, clinical and molecular risk score for patients with colorectal liver metastases**

B. Martin Cullell¹, A.C. Virgili Manrique¹, P. Riera¹, C. Fumagalli¹, A. Sebio Garcia¹, O. Mirallas², F. Pelegrin¹, S. Sánchez-Cabús¹, V. Molina¹, A. Gonzalez¹, J. Szafranska¹, D. Paez¹, ¹Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ²Vall d'Hebron University Hospital, Barcelona, ES

10:18 - 10:19 **351P - Prevalence of ERBB alterations in colorectal cancer patients using genomic profiling**

M. Kundranda¹, M. Wang², D. Hall², J. Hoag², F. Alyaqoub², P. Noel², S. Szelinger², S. Udhane², A. Ozols², J. Lobello², F.L. Baehner², S. Thakkar², ¹Banner MD Anderson Cancer Center, Phoenix, US, ²Exact Sciences Corporation, Madison, US

10:19 - 10:20 **352P - Mutations of SMAD4 and FBXW7 predict poor outcome in TP53-driven metastatic colorectal cancer**

S. Lahoz¹, A. Rodriguez Hernandez², L. Fernández Mañas², T. Gorria², R. Zambrano¹, F. Esposito², T. Sauri Nadal², D. Pesantez Coronel², G. Riu², M. Cuatrecasas², P. Jares¹, L. Pedrosa², E. Pineda², A. Postigo³, A. Castells¹, A. Prat⁴, J. Maurel², J. Camps¹, ¹Hospital Clinic of Barcelona, Barcelona, ES, ²Hospital Clinic y Provincial de Barcelona, Barcelona,

ES, ³IDIBAPS - August Pi i Sunyer Biomedical Research Institute, Barcelona, ES, ⁴SOLTI / IDIBAPS/ Hospital Clinic of Barcelona, Barcelona, ES

- 10:20 - 10:21 **353P - Loss of CDX2 and high COX2 (PTGS2) expression in stage IV colorectal cancer**
A. Caldas¹, W. Nunes¹, R. Taboada², M. Cesca³, J. Germano⁴, R. Riechelmann¹, ¹A.C. Camargo Cancer Center - Unidade Antonio Prudente, Sao Paulo, BR, ²AC Camargo Cancer Center, Sao Paulo, BR, ³A.C. Camargo Cancer Center - Fundacao Antonio Prudente, Sao Paulo, BR, ⁴A.C. Camargo Cancer Center - Centro Internacional de Pesquisa (CIPE), Sao Paulo, BR
- 10:21 - 10:22 **354P - NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin (NUFOX) or irinotecan (NUFIRI) in patients with advanced colorectal cancer (CRC) (NuTide:302)**
A. Coveler¹, A. Skolariki², K. Ciombor³, H. Marijon Jourdier⁴, J. Graham⁵, M.L. Peters⁶, S. Cohen⁷, M. Myers⁸, E. Oelmann⁸, J. Bloss⁸, S. Blagden², A. De Gramont⁴, J. Berlin⁹, T.R.J. Evans¹⁰, ¹Fred Hutchinson Cancer Center/University of Washington, Seattle, US, ²Churchill Hospital - Oxford University Hospitals NHS Foundation Trust, Oxford, GB, ³Vanderbilt University Medical Center - Preston Cancer Research Building, Nashville, US, ⁴Franco-britannique hospital, paris, FR, ⁵BWSCC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, ⁶Beth Israel Deaconess Medical Center, Boston, US, ⁷University of Washington, Seattle, US, ⁸NuCan, Edinburgh, GB, ⁹Vanderbilt University Medical Center, Nashville, US, ¹⁰University of Glasgow and Beatson West of Scotland Cancer Centre, Glasgow, GB
- 10:22 - 10:23 **355P - The prognostic role of HIF-1 α and NF- κ B expression in RAS wild-type metastatic colorectal cancer (mCRC) patients: A Turkish oncology group (TOG) study**
A. Demirkiran, F. Kılınç, M.Z. Koçak, M. Korkmaz, D. Demirkiran, M. Karakurt Eryılmaz, M. Araz, M. Karaağaç, M. Artac, Necmettin Erbakan University - Meram Medical Faculty, Konya, TR
- 10:23 - 10:24 **356P - Biallelic MUTYH germline inactivation in patients with colon polyposis and subjects with sporadic colorectal cancer**
E. Imyanitov, A. Martianov, S. Chuinyshena, Y. Gorgul, E. Kuligina, T. Laidus, E. Suspitsin, A. Togo, G. Yanus, N.N. Petrov Institute of Oncology, Saint-Petersburg, RU
- 10:24 - 10:25 **357P - Novel potential predictive biomarker to immunotherapy (Io) treatment in metastatic colorectal cancer (mCRC) patients: The role of the VHIO immune gene-expression signature (VIGex)**
N. Saoudi Gonzalez¹, M. Vila Casadesus², F.J. Ros Montana¹, I. Baraibar Argota¹, F. Salvà Ballabrera¹, A. Garcia Rodriguez¹, D. López Valbuena¹, D. Gómez-Puerto¹, A. Hernando-Calvo³, J. Tabernero⁴, A. Vivancos¹, M.E. Elez Fernandez¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ³Early Drug Development Unit, "La Caixa Research" UITM - Vall d'Hebron Institute of Oncology (VHIO). Vall D'Hebron, Barcelona, ES, ⁴Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, ES

- 10:25 - 10:26 **358P - Analysis of microbiome signatures in plasma for early CRC detection**
J. Kinross¹, A. Bertossi², F. Mancuso³, P. Canal-Noguer³, P. Knap², K. Kruusmaa², ¹St. Mary's Hospital - Imperial College Healthcare NHS Trust, London, GB, ²Universal Diagnostics d.o.o., Ljubljana, SI, ³Universal Diagnostics S.L., Seville, ES
- 10:26 - 10:27 **359P - Analysis of TMB and tumor microenvironment in Polymerase epsilon (POLE) deficient colorectal cancer**
W. Lu¹, Z. Huang¹, J. Wang¹, Y. Chen², M. Huang³, ¹Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, CN, ²3D Medicines Inc, Shanghai, CN, ³3D Medicines Inc. - Headquarter, Shanghai, CN
- 10:27 - 10:28 **360P - Epigenetic engineering on CDX2 allows to determine the interplaying consequences with other genetic and transcriptomic events in colorectal cancer**
F. Gimeno-Valiente¹, E. Duréndez², J. Badía³, C. Martínez-Ciarpaglini⁴, M. Iglesias³, J. Linares³, M. Huerta², D. Moro⁴, V. Gambardella⁵, J. Martín-Arana², T. Fleitas⁵, S. Roselló Keränen⁵, M. Cabeza Segura², B. García-Mico², P. Rentero-Garrido², D. Roda⁵, J. Castillo⁶, A. Cervantes⁵, A. Calon³, N. Tarazona Llaveró⁵, ¹University College London Cancer Institute, London, GB, ²INCLIVA Biomedical Research Institute, Valencia, ES, ³IMIM - Institut Hospital del Mar d'Investigacions Mediques, Barcelona, ES, ⁴INCLIVA Instituto de Investigación Sanitaria, Valencia, ES, ⁵Hospital Clinico Universitario de Valencia -- Health Institute Carlos III CIBERONC, Valencia, ES, ⁶University of Valencia, Valencia, ES
- 10:28 - 10:29 **361P - Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER**
C. Wu¹, J. Strickler², A. Cercek³, S. Siena⁴, T. André⁵, K. Ng⁶, E. Van Cutsem⁷, A. Paulson⁸, J. Hubbard⁹, A. Coveler¹⁰, C. Fountzilas¹¹, A. Kardosh¹², P. Kasi¹³, H.J. Lenz¹⁴, K. Ciombor¹⁵, M.E. Elez Fernandez¹⁶, L.-I. Hsu¹⁷, M. Stecher¹⁷, K. Zhao¹⁸, T. Bekaii-Saab¹, ¹Mayo Clinic Cancer Center, Phoenix, US, ²Duke University Medical Center, Durham, US, ³Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ⁴Università degli Studi di Milano, and Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, IT, ⁵Hopital Saint-Antoine, Paris, FR, ⁶Dana Farber Cancer Institute, Boston, US, ⁷University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, BE, ⁸Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, US, ⁹Mayo Clinic, Rochester, US, ¹⁰Fred Hutchinson Cancer Center/University of Washington, Seattle, US, ¹¹Roswell Park Comprehensive Cancer Center, Buffalo, US, ¹²OHSU - Oregon Health Science University, Portland, US, ¹³Weill Cornell Medicine, New York, US, ¹⁴USC Norris Comprehensive Cancer Center, Los Angeles, US, ¹⁵Vanderbilt University Medical Center - Preston Cancer Research Building, Nashville, US, ¹⁶Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, ES, ¹⁷Seagen Inc., Seattle, US, ¹⁸Seagen Inc., Bothell, US
- 10:29 - 10:30 **362P - Phase Ia study to evaluate GDC-6036 monotherapy in patients with colorectal cancer (CRC) with KRAS G12C mutation**
J. Desai¹, S.-W. Han², M. Forster³, T.W. Kim⁴, G. Alonso Casal⁵, E. Shacham Shmueli⁶, S.

Bowyer⁷, M.J. De Miguel⁸, A. Falcon Gonzalez⁹, R. Jones¹⁰, M. Krebs¹¹, W. Miller¹², L. Paz-Ares¹³, P. Lorusso¹⁴, A. Sacher¹⁵, N. Dharia¹⁶, M. Lin¹⁶, J. Schutzman¹⁶, Z. Shi¹⁶, M. Patel¹⁷, ¹Peter MacCallum Cancer Centre, Melbourne, AU, ²Seoul National University Hospital, Seoul, KR, ³UCL Cancer Institute/University College London Hospitals, London, GB, ⁴Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ⁵Vall d'Hebron University Hospital, Barcelona, ES, ⁶Chaim Sheba Medical Center, Ramat Gan, IL, ⁷Sir Charles Gairdner Hospital & Linear Clinical Research, Nedlands, AU, ⁸START MADRID, Hospital Universitario HM Sanchinarro - CIOCC, Madrid, ES, ⁹Hospital Universitario Virgen del Rocío, Seville, ES, ¹⁰Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff, GB, ¹¹The Christie NHS Foundation Trust and The University of Manchester, Manchester, GB, ¹²Lady Davis Institute and Segal Cancer Center, Jewish General Hospital, Montreal, CA, ¹³Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Ciberonc and Universidad Complutense, Madrid, ES, ¹⁴Yale Smilow Cancer Center, New Haven, US, ¹⁵Princess Margaret Cancer Centre, University Health Network, Toronto, CA, ¹⁶Genentech, Inc., South San Francisco, US, ¹⁷Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, US

- 10:30 - 10:31 **363P - Prevalence of acquired (acq) genomic alterations (GAs) after progression on anti-EGFR mAb (EGFRi) based therapy in metastatic colorectal cancer (mCRC): A systematic review and meta-analysis**
K. Raghav¹, R. Sun², J. Willis¹, V. Morris³, M. Eluri¹, N.A. Dasari², Y. Yuan³, S. Kopetz³, C. Parseghian¹, ¹The M.D. Anderson Cancer Center, Houston, US, ²MD Anderson Cancer Center, Houston, US, ³The University of Texas M. D. Anderson Cancer Center, Houston, US
- 10:31 - 10:32 **364P - Prevalence, treatment and survival of NTRK gene fusions in microsatellite instable metastatic colorectal cancer patients**
S. Schraa, M. Laclé, K. Zwart, E. Gort, M. Koopman, W. De Leng, G. Vink, G. Bol, UMC - University Medical Center Utrecht, Utrecht, NL
- 10:32 - 10:33 **365P - Prognostic value of Lynch syndrome, BRAFV600E and RAS mutation status in dMMR/MSI-H metastatic colorectal cancer in a pooled analysis of the national Dutch and French cohorts**
K. Zwart¹, F. Van Der Baan¹, M. Koopman¹, G. Vink¹, E. Wensink¹, C. Punt², R. Verheijden¹, R. Cohen³, A. Zaanen⁴, C. De La Fouchardiere⁵, D. Sefrioui⁶, T. Lecomte⁷, T. Aparicio⁸, D. Tougeron⁹, J. Roodhart¹, ¹UMC - University Medical Center Utrecht, Utrecht, NL, ²University Medical Center Utrecht, Utrecht, NL, ³Hopital Saint-Antoine, Paris, FR, ⁴Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, ⁵Centre Léon Bérard, Lyon, FR, ⁶Hopital Charles-Nicolle - CHU de Rouen, Rouen, FR, ⁷CHU de Tours, Hôpital Trousseau, Chambray-lès-Tours, FR, ⁸Hopital Saint Louis AP-HP, Paris, FR, ⁹CHU Poitiers - Jean Bernard Hôpital, Poitiers, FR
- 10:33 - 10:34 **366P - The PLK1 inhibitor onvansertib overcomes irinotecan resistance in RAS-mutated (mRAS) metastatic colorectal cancer (mCRC) in vivo and in patients (pts)**
S. Kopetz¹, M. Ridinger², A. Sorokin¹, P. Kanikarla¹, F. Gao¹, Z. Liu¹, E. Samuels³, T. Smeal³, J. Starr⁴, M. Sharma⁵, ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²Cardiff Oncology Inc., San Diego, US, ³Cardiff Oncology, San Diego, US, ⁴Mayo Clinic, Jacksonville, US, ⁵START Midwest, Grand Rapids, US

- 10:34 - 10:35 **367P - Prospective evaluation of emergent RAS and BRAF mutations in pre-treated metastatic colorectal cancer patients candidate to anti-EGFR re-treatment: Preliminary findings from the PARERE study**
- M. Germani¹, D. Rossini¹, G. Vetere¹, M. Giordano², I. Capone³, P. Manca⁴, F. Bergamo⁵, V. Conca¹, B. Borelli¹, A. Boccaccino¹, M. Angelini⁴, F. Simionato⁶, N. Pella⁷, C. Morelli⁸, G. Zucchelli⁹, C. Cremolini¹, ¹University of Pisa and Azienda Ospedaliero-Universitaria Pisana, Pisa, IT, ²Universita' Degli Studi Di Pisa - Facoltà di Medicina e Chirurgia, Pisa, IT, ³Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, IT, ⁴Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁵IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁶AOU Integrata di Verona - Ospedale Borgo Roma, Verona, IT, ⁷ASU Friuli Centrale - Ospedale S. Maria della Misericordia, Udine, IT, ⁸Policlinico Tor Vergata, Rome, IT, ⁹Azienda Usl Toscana Sud Est, Grosseto, Italy, Pisa, IT
- 10:35 - 10:36 **368P - Characteristics and survival of metastatic colorectal cancer patients receiving local treatment with deficient mismatch repair versus proficient mismatch repair**
- J. Roodhart¹, K. Zwart¹, C. Punt², E. Wensink¹, K. Bolhuis³, M. Laclé¹, W. Van Grevenstein¹, J. Hagendoorn¹, I. De Hingh⁴, M. Koopman¹, G. Vink¹, F. Van Der Baan¹, ¹UMC - University Medical Center Utrecht, Utrecht, NL, ²University Medical Center Utrecht, Utrecht, NL, ³Academic Medical Center, University of Amsterdam, Amsterdam, NL, ⁴Catharina Hospital Eindhoven, Eindhoven, NL
- 10:36 - 10:37 **369P - Irinotecan is superior to oxaliplatin in KRAS-G12C-mutated (K-G12C-m) colorectal cancer (CRC) and should be preferred in combination strategies with K-G12C inhibitors. A multicenter propensity score-matched (PSM) retrospective analysis**
- C. Morelli¹, J. Lucchetti², M.A. Calegari³, M. Rofei¹, S. Guerriero¹, S. Riondino¹, V. Flaminio¹, G. Parisi¹, F. Lo Prinzi², G. Trovato³, B. Vincenzi², L. Salvatore³, M. Roselli¹, V. Formica¹, ¹Policlinico Tor Vergata, Rome, IT, ²Division of Medical Oncology, Policlinico Universitario Campus Bio-Medico, Rome, IT, ³Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT
- 10:37 - 10:38 **370P - Trastuzumab-emtansine (T-DM1) in HER2-amplified metastatic colorectal cancer patients progressing to trastuzumab-lapatinib: The HERACLES RESCUE phase II trial**
- A. Sartore Bianchi¹, S. Lonardi², A. Amatu³, F. Bergamo², G. Mauri¹, C. Martino⁴, K. Bencardino³, M.D. Rizzato², F. Tosi³, S. Ghezzi³, A. Sapino⁵, A. Bardelli⁵, L. Trusolino⁵, S. Marsoni⁶, S. Siena¹, ¹Università degli Studi di Milano and Grande Ospedale Metropolitano Niguarda, Milan, IT, ²IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ³Grande Ospedale Metropolitano Niguarda, Milan, IT, ⁴Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Turin), IT, ⁵Università degli Studi di Torino and Candiolo Cancer Institute, FPO -IRCCS, Torino, IT, ⁶IFOM, FIRC Institute of Molecular Oncology, Milan, Italy, Candiolo, IT
- 10:38 - 10:39 **371P - A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers**
- J. Harding¹, R.D. Hofheinz², M.E. Elez Fernandez³, Y. Kuboki⁴, D. Rasco⁵, M. Cecchini⁶,

L. Shen⁷, S. Archuadze⁸, J. Geng⁹, F. Haderk¹⁰, S. Pant¹¹, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²Universitätsklinikum Mannheim, Mannheim, Baden Württemberg, DE, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴National Cancer Center Hospital East, Kashiwa, JP, ⁵Center for Cancer Care, San Antonio, US, ⁶Yale University, New Haven, US, ⁷Peking University Cancer Hospital & Institute, Beijing, CN, ⁸Boehringer Ingelheim, Ingelheim am Rhein, DE, ⁹Boehringer Ingelheim, Ridgefield, US, ¹⁰Boehringer Ingelheim, Biberach an der Riss, DE, ¹¹University of Texas MD Anderson Cancer Center, Houston, US

09:00 - 14:00 Type: Poster session Title: Poster session 16 Poster Area, Hall 4

- 09:00 - 09:01 **1150P - Progression of advanced non-small cell lung cancer after durable clinical benefit on anti-PD-1/PD-L1 monotherapy: Prolonged post-progression survival and interest of tumor growth rate**
I. Pourmir¹, R.-T. Elaidi², Z. Maaradji³, B. Gazeau⁴, L. Gibault⁴, M. Ung⁵, E. Fabre-Guillevin⁴, ¹Université de Paris, Paris, FR, ²ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Paris, cedex, FR, ³Hopital European George Pompidou, Paris, FR, ⁴HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, ⁵Hôtel-Dieu - AP-HP, Paris, FR
- 09:01 - 09:02 **1151P - Evolution of biomarker testing among non-squamous/non-small cell lung cancer (NSCLC) patients (Pts) and impact on turnaround times (TAT)**
Z.(. Fan¹, R. Tudor¹, L. Le¹, J. Law¹, S. Kuang², N. Meti³, A. Fung⁴, K. Perdrizet⁵, K. Chen¹, J. Li¹, N. Ghumman¹, L. Ranich⁶, C. Wei⁶, P. Sabatani⁶, M.-S. Tsao¹, N. Leighl¹, M. Cabanero¹, ¹UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ²BC Cancer Agency - Vancouver, Vancouver, CA, ³St Mary's Hospital, Montreal, CA, ⁴Kingston Health Sciences Centre, Kingston, CA, ⁵William Osler Health System - Brampton Civic Hospital, Brampton, CA, ⁶Toronto General Hospital, Toronto, CA
- 09:02 - 09:03 **1152P - Lung cancer metastasis patterns and racial disparities: A SEER database population study 2010–2018**
A.R. Armashi¹, F. Hammad¹, A. Al Zubaidi², D. Elantably³, K. Patell¹, F. Somoza-Cano¹, M. Homeida¹, M. Cruz Peralta¹, K. Ravakhah¹, A. Alkrekhshi³, ¹St. Vincent Charity Medical Center, Cleveland, US, ²Baptist Health - University of Arkansas for Medical Sciences, North Little Rock, US, ³Case Western Reserve University / University Hospitals, Cleveland, US
- 09:03 - 09:04 **1153P - A first in class DNA repair inhibitor for the treatment of NSCLC**
D. Boucher¹, L. Croft¹, S. Beard¹, I. Mohd Najib¹, A. Rajapakse¹, P. Duijf¹, D. Richard¹, K. O'Byrne², ¹Queensland University of Technology, Brisbane, AU, ²Princess Alexandra Hospital - Metro South Health, Woolloongabba, AU
- 09:04 - 09:05 **1154P - Geriatrics predictors of 3-months overall survival and chemotherapy toxicities in older patients with metastatic non-small cell lung cancer**
S. Gendarme¹, S. Zebachi², R. Corre³, L. Greillier⁴, G. Justeau⁵, O. Bylicki⁶, C. Decroisette⁷, J.B. Auliac⁸, F. Guisier⁹, M. Geier¹⁰, C. Ricordel¹¹, M. Frelaut¹², E. Paillaud¹³, C. Chouaid¹⁴, F. Canouï-Poitaine¹⁵, ¹Université Paris Est Créteil, INSERM,

IMRB, Créteil, FR, ²Université Paris Est Créteil, IMRB, Créteil, FR, ³Centre Hospitalier de Cornouaille - Site de Laennec, Quimper, Cedex, FR, ⁴Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ⁵CHU Angers, Angers, FR, ⁶Hopital d'instruction des armées Sainte-Anne, Toulon, FR, ⁷CH Annecy-Genevois, Metz-Tessy, FR, ⁸CHI - Centre Hospitalier Intercommunal de Créteil, Créteil, Cedex, FR, ⁹CHU Rouen, Rouen, FR, ¹⁰CHU Brest, Brest, FR, ¹¹CHU Rennes, Rennes, FR, ¹²Gustave Roussy - Cancer Campus, Villejuif, FR, ¹³Assistance Publique - Hopitaux De Paris, Paris, FR, ¹⁴CH Intercommunal de Créteil, Créteil, FR, ¹⁵Assistance Publique - Hopitaux De Paris, Créteil, FR

- 09:05 - 09:06 **1155P - Adherence to treatment recommendations from multidisciplinary tumor boards: Initial data from 644 lung cancer cases**
J. Roeper¹, A. Blanksma¹, L. Kathmann¹, L. Ansmann², F. Griesinger¹, ¹Pius Hospital, Oldenburg, DE, ²Carl von Ossietzky University Oldenburg, Oldenburg, DE
- 09:06 - 09:07 **1156P - Quality-adjusted survival with brigatinib (BRG) versus crizotinib (CRZ) in ALK-positive (ALK⁺) non-small cell lung cancer (NSCLC): Results from the ALTA-1L trial**
M.R. Garcia Campelo¹, Y. Wan², M. Lin², T. Chen², J. Shen², P. Zhang², M. Humphries², D.R. Camidge³, ¹Complejo Hospitalario Universitario A Coruña, A Coruña, ES, ²Takeda Development Center Americas, Inc., Lexington, US, ³University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora, US
- 09:07 - 09:08 **1158P - Study of patients' characteristics associated with osimertinib outcomes upfront or in following lines in EGFR-positive NSCLC**
E. Auclin¹, P. Du Rusquec², V. Albarran³, F. Aboubakar⁴, H. Gerber⁵, N. Epailard⁶, G. Recondo⁷, H. Berthou¹, E. Fabre-Guillevin¹, J.C. Laguna Montes³, J.B. Blaquier⁸, B. Jimenez Munarriz⁹, M. Tagliamento¹⁰, G. Sacco¹¹, J.N. Minatta¹², N. Girard², M.T. Moran Bueno¹³, R. López Castro¹⁴, B. Besse¹⁵, L. Mezquita¹⁶, ¹HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, ²Institut Curie, Paris, FR, ³Hospital Clinic of Barcelona, Barcelona, ES, ⁴UCLouvain Brussels Woluwe, Brussels, BE, ⁵Institut Gustave Roussy, Villejuif, Cedex, FR, ⁶CH Pacifique, Pirae, PF, ⁷University of Buenos Aires CEMIC, Buenos Aires, AR, ⁸CEMIC - Centro de Educacion Medica e Investigacones Clinicas Dr Norberto Quirno, Buenos Aires, AR, ⁹Centro Integral Oncologico Clara Campal, Madrid, ES, ¹⁰Gustave Roussy, Villejuif, Cedex, FR, ¹¹Università degli Studi di Genova e Ospedale Policlinico San Martino IRCCS - DiMI, Genova, IT, ¹²Hospital Italiano de Buenos Aires, Buenos Aires, AR, ¹³ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ¹⁴Hospital Clinico Universitario De Valladolid, Valladolid, ES, ¹⁵Institut Gustave Roussy, Villejuif, FR, ¹⁶Hospital Clinic y Provincial de Barcelona, Barcelona, ES
- 09:08 - 09:09 **1159P - The immune checkpoint inhibitors induced endocrinopathies and their effect on prognosis in advanced non-small cell lung cancer patients**
M. Jo, Y. Yang, H.K. Kim, D.-H. Lee, J.H. Kwon, H.S. Han, K. Lee, Chungbuk National University Hospital, Cheongju, KR
- 09:09 - 09:10 **1160P - Survival impact of second-line immune checkpoint inhibitors in the elderly patients with advanced squamous non-small cell lung cancer: Post-hoc**

analysis from a CAPITAL study

Y. Kogure¹, A. Kada¹, H. Hashimoto², S. Atagi³, Y. Takiguchi⁴, H. Saka¹, N. Ebi⁵, A. Inoue⁶, T. Kurata⁷, Y. Fujita⁸, Y. Nishii⁹, T. Shibayama¹⁰, H. Itani¹¹, T. Endo¹², N. Yamamoto¹³, A. Gemma¹⁴, ¹National Hospital Organization, Nagoya Medical Center, Nagoya, JP, ²Nagoya City University Graduate School of Medical Sciences, Nagoya, JP, ³JCHO Yamatokoriyama Hospital, Koriyama, JP, ⁴Chiba University, School of Medicine, Chiba, JP, ⁵Fukuoka University Hospital, Fukuoka Johanan, JP, ⁶Tohoku University Hospital, Sendai, JP, ⁷Kansai Medical University, Hirakata, JP, ⁸Asahikawa Medical Center, Asahikawa, JP, ⁹Matsusaka Municipal Hospital, Matsusaka, JP, ¹⁰NHO Okayama Medical Center, Okayama, JP, ¹¹Ise Red Cross Hospital, Ise, JP, ¹²NHO Mito Medical Center, Ibaraki, JP, ¹³Wakayama Medical University, Wakayama, JP, ¹⁴Nippon Medical School Main Hospital, Tokyo, JP

09:10 - 09:11 **1161P - Clinical outcomes of bronchoscopic cryotherapy for malignant central airway obstruction in patients with non-small cell lung cancer**

J. Kim¹, J.H. Jeong², C.-M. Choi³, W. Ji¹, ¹Asan Medical Center - University of Ulsan, Seoul, KR, ²Gyeongsang National University Hospital and Gyeongsang National University School of Medicine, Jinju, KR, ³Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR

09:11 - 09:12 **1162P - Tissue and liquid biopsy utilization in advanced NSCLC in a large community US practice**

L. Gordan¹, M. Diaz², A. Patel³, M. Fink⁴, D. Wenk⁵, A. Roos⁶, J. Jiang⁶, J. Tam⁶, P. Sathyan⁶, P. Febbo⁷, ¹Florida Cancer Specialists & Research Institute (FCS), Fort Myers, US, ²Florida Cancer Specialists & Research Institute (FCS), St. Petersburg, US, ³Florida Cancer Specialists & Research Institute (FCS), Sarasota, US, ⁴Florida Cancer Specialists & Research Institute (FCS), Tampa, US, ⁵Florida Cancer Specialists & Research Institute (FCS), Trinity, US, ⁶Illumina, Inc., San Diego, US, ⁷Illumina, San Diego, US

09:12 - 09:13 **1163P - Impact of brain metastases in synchronous single organ oligometastatic lung cancer (OMD)**

H. Al Sheik¹, J. Roeper², K. Wedeken², L. Heukamp³, F. Griesinger², ¹Carl von Ossietzky University Oldenburg, Oldenburg, DE, ²Pius Hospital, Oldenburg, DE, ³Hematopathology Hamburg, Hamburg, DE

09:13 - 09:14 **1164P - Patient-reported outcomes in patients with advanced NSCLC before and during the COVID-19 pandemic in the German prospective CRISP Registry real-world cohort (AIO-TRK-0315)**

M. Sebastian¹, F. Griesinger², E. Von Der Heyde³, S. Dörfel⁴, J. Wiegand⁵, C. Schiefer⁶, C. Losem⁷, M. Jänicke⁸, A. Fleitz⁸, S. Zacharias⁸, A. Hipper⁹, C. Dietel⁹, A. Bleckmann¹⁰, R. Benkelmann¹¹, M. Boesche¹², C. Grah¹³, A. Müller¹⁴, W. Eberhardt¹⁵, M. Thomas¹⁶, ¹University Hospital Frankfurt, Frankfurt, DE, ²Pius Hospital, Oldenburg, DE, ³Onkologische Schwerpunktpraxis, Hannover, DE, ⁴Onkozentrum Dresden/Freiburg, Dresden, DE, ⁵Gemeinschaftspraxis für Hämatologie und Onkologie, Moers, DE, ⁶Pneumologische Praxis Markkleeberg, Markkleeberg, DE, ⁷TZN - Tumorzentrum Niederrhein GmbH, Neuss, DE, ⁸iOMEDICO AG, Freiburg im Breisgau, DE, ⁹AIO-Studien-gGmbH, Berlin, DE, ¹⁰UKM - University Hospital Muenster, Muenster, DE, ¹¹Zentrum für Innere Medizin Klinikum Konstanz, Konstanz, DE, ¹²Universitätsmedizin Greifswald Klinik und Poliklinik für Innere Medizin B, Greifswald, DE,

¹³Gemeinschaftskrankenhaus Havelhöhe, Berlin, DE, ¹⁴Katholisches Klinikum Koblenz, Koblenz, DE, ¹⁵University Hospital Essen, West German Cancer Center and Ruhrlandklinik, University Duisburg-Essen, Essen, DE, ¹⁶Thoraxklinik Heidelberg gGmbH, Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, DE

- 09:14 - 09:15 **1165P - Incidence of clinically relevant hyperglycaemia in patients with non-small cell lung cancer treated with immunotherapy**
S. Farag¹, B. Moore¹, K. Mulla², N. Yousaf¹, S. Popat³, D. Morganstein², ¹The Royal Marsden Hospital - Chelsea, London, GB, ²Chelsea and Westminster Hospital - NHS Trust, London, GB, ³The Royal Marsden Hospital - NHS Foundation Trust, London, GB
- 09:15 - 09:16 **1166P - Social determinants of lung cancer in East London**
C. Alves Soares, F. Chamberlain, U. Mukherjee, W. Ricketts, J. Conibear, J. Steele, P. Szlosarek, F.L. Lim, A. Januszewski, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB
- 09:16 - 09:17 **1167P - Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis**
S. Kang¹, H. Jeong², J.E. Park³, H.S. Kim³, Y.-H. Kim³, K. Sang-We², J.C. Lee², C.-M. Choi², S. Yoon², D.H. Lee², ¹Chungnam National University Hospital, Daejeon, KR, ²Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ³Asan Medical Center - University of Ulsan, Seoul, KR
- 09:17 - 09:18 **1168P - Effect of antibiotic treatment on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer**
G. Alkan¹, N. Senturk Oztas¹, Z.H. Turna¹, M. Ozguroglu², ¹Istanbul University - Cerrahpasa Faculty of Medicine, Istanbul, TR, ²Istanbul University Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, TR
- 09:18 - 09:19 **1169P - Aggregated cancer registry data from Norway to create an external cohort for patients with metastatic NSCLC squamous cell carcinoma**
S. Børø, University of Oslo, Institute of Clinical medicine, Oslo, NO
- 09:19 - 09:20 **1170P - Updated efficacy and safety data from the phase I/II ARROW study of pralsetinib in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC)**
B. Besse¹, F. Griesinger², G. Curigliano³, M. Thomas⁴, V. Subbiah⁵, C. Baik⁶, D.S.W. Tan⁷, D.H. Lee⁸, E. Garralda⁹, D.-W. Kim¹⁰, A.J. Van Der Wekken¹¹, J. Gainor¹², L. Paz-Ares¹³, S. Liu¹⁴, D. Bowles¹⁵, A. Zalutskaya¹⁶, T. Ruf¹⁷, A. Rahman¹⁸, G. Chen¹⁹, J. Mazieres²⁰, ¹Gustave Roussy Cancer Centre, Villejuif, FR, ²Pius-Hospital, University of Oldenburg, Oldenburg, DE, ³and Department of Oncology and Hemato-Oncology, University of Milano, Milan, IT, ⁴Thoraxklinik, University Heidelberg and Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, DE, ⁵University of Texas MD Anderson Cancer Center, Houston, US, ⁶University of Washington School of Medicine, Seattle, US, ⁷National Cancer Centre Singapore, Singapore, SG, ⁸Asan Medical Center, University of Ulsan College of

Medicine, Seoul, KR, ⁹Vall d'Hebron University Hospital, Barcelona, ES, ¹⁰Seoul National University College of Medicine and Seoul National University Hospital, Seoul, KR, ¹¹University of Groningen and University Medical Center Groningen, Groningen, NL, ¹²Massachusetts General Hospital, Boston, US, ¹³Hospital Universitario 12 de Octubre, Madrid, ES, ¹⁴Georgetown University, Washington, US, ¹⁵University of Colorado School of Medicine, Aurora, US, ¹⁶Blueprint Medicines Corporation, Cambridge, US, ¹⁷F. Hoffmann-La Roche Ltd, Basel, CH, ¹⁸F. Hoffmann-La Roche Ltd, Welwyn, GB, ¹⁹Genentech, Inc., South San Francisco, US, ²⁰Institut Universitaire du Cancer, Toulouse, FR

09:20 - 09:21

1171P - A phase II theranostic study with osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC) progressing on EGFR tyrosine kinase inhibitors (TKI) and undetectable EGFR T790M (THEROS)

M. Wiesweg¹, J. Hense¹, K. Darwiche², S. Michels³, H. Hautzel¹, C. Kobe³, M. Metzenmacher¹, T. Herold¹, G. Zaun¹, K. Laue¹, A. Drzezga³, H.-U. Schildhaus¹, J. Wolf³, K. Herrmann¹, M. Schuler¹, ¹University Hospital Essen, Essen, DE, ²University Medicine Essen - Ruhrlandklinik, Essen, DE, ³University Hospital Cologne, Köln, DE

09:21 - 09:22

1172P - High activity of poziotinib in G778_P780dup HER2 exon 20 insertion mutations in non-small cell lung cancer (NSCLC)

X. Le¹, S. Sun², E. Haura³, E. Bertino⁴, C. Baik⁵, H. Mamdani⁶, S. Leu⁷, A. Thiagalingam⁸, J. Kokhraidze⁷, F. Lebel⁷, M. Socinski⁹, ¹MD Anderson Cancer Center, Houston, US, ²BC Cancer Agency - Vancouver, Vancouver, CA, ³H. Lee Moffitt Cancer Center & Research Institute, Tampa, US, ⁴The Ohio State University, Columbus, US, ⁵Seattle Cancer Care Alliance, Seattle, US, ⁶Karmanos Cancer Institute, Detroit, US, ⁷Spectrum Pharmaceuticals, Irvine, US, ⁸Spectrum Pharmaceuticals, Boston, US, ⁹AdventHealth Cancer Institute, Orlando, US

09:22 - 09:23

1173P - Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study

B.C. Cho¹, M.-J. Ahn², T.M. Kim³, C. Kim⁴, B. Shim⁵, J.-Y. Han⁶, A. Drilon⁷, H. Lena⁸, J. Gomez⁹, J.E. Gray¹⁰, M. Awad¹¹, J. Perez¹², M. Navas¹², M. Kaul¹², S. Patel¹², B. Gao¹², H. Magnan¹², P. Rietschel¹², ¹Yonsei Cancer Center, Seoul, KR, ²Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, ³Seoul National University Hospital, Seoul, KR, ⁴Georgetown University, Washington, US, ⁵Catholic University of Korea, Seoul, KR, ⁶National Cancer Center Korea, Goyang, KR, ⁷Memorial Sloan Kettering Cancer Center, New York, US, ⁸Centre Hospitalier Universitaire de Rennes, Rennes, FR, ⁹Mount Sinai Medical Center, New York, US, ¹⁰Moffitt Cancer Center, Tampa, US, ¹¹Dana-Farber Cancer Institute, Boston, US, ¹²Regeneron Pharmaceuticals, Inc., Tarrytown, US

09:23 - 09:24

1174P - The MET inhibitor ABN401 in combination with the third-generation EGFR-TKI is effective MET-amplified and EGFR-mutant NSCLC with acquired resistance to third-generation EGFR-TKI in preclinical models

M.R. Yu¹, M.R. Yun¹, S. Lee², N. Rajasekaran², K.E. Park², N.Y. Kim², S. Hong³, S.Y. Oh¹, Y.W. Lee¹, E.J. Lee¹, C.G. Kim⁴, S.M. Lim⁴, J. Choi², B.C. Cho⁴, ¹Yonsei University College of Medicine, Seoul, KR, ²Abion Inc., Seoul, KR, ³Seoul National University College of

Pharmacy, Seoul, KR, ⁴Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR

- 09:24 - 09:25 **1175P - Pharmacokinetics of ensartinib in advanced solid tumors and anaplastic lymphoma kinase-positive non-small cell lung cancer**
Y. Xu¹, D. Ji², P. Pan², T. Li², L.-X. Han², Z. Zhang², Y. Wang², H. Li², X.-F. Chen², X.-J. Zheng³, L. Xu⁴, H.-X. Liu⁴, Q.-H. Meng⁵, M.-Z. Wang¹, Q.-S. Zheng⁴, ¹Chinese Academy of Medical College & Peking Union Medical College Hospital, Beijing, CN, ²Betta Pharmaceuticals Co., Ltd. - Headquarters, Hangzhou, CN, ³Shanghai BioGuider Medical Technology Co. Ltd, Shanghai, CN, ⁴Shanghai University of Traditional Chinese Medicine, Shanghai, CN, ⁵Beijing BioVoice Technology Co. Ltd, Beijing, CN
- 09:25 - 09:26 **1176P - Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)**
J. Vansteenkiste¹, I. Demedts², E. Pons-Tostivint³, B. Biesma⁴, F. Borm⁵, B. Colinet⁶, K. Cuppens⁷, S. Derijcke⁸, L. Greillier⁹, J. Jürgens¹⁰, D. Moro-Sibilot¹¹, M. Pérol¹², M. Sebastian¹³, M. Skrzypski¹⁴, W. Theelen¹⁵, C. Van De Kerkhove¹⁶, M. Collodoro¹⁷, J. Plumas¹⁸, C. Debruyne¹⁷, A. Sibille¹⁹, ¹University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ²AZ Delta Campus Rumbeke, Roeselare, BE, ³CHU du Nantes - Hôtel-Dieu, Nantes, Cedex, FR, ⁴Jeroen Bosch Hospital, 's-Hertogenbosch, NL, ⁵LUMC - Universitair Medisch Centrum, Leiden, NL, ⁶GHdC - Grand Hopital de Charleroi - Site Notre Dame, Charleroi, BE, ⁷Virga Jesse Ziekenhuis, Hasselt, BE, ⁸AZ Groeninge - Campus Kennedylaan, Kortrijk, BE, ⁹Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ¹⁰Kliniken der Stadt Köln gGmbH, Köln, DE, ¹¹CHU Grenoble-Alpes - Le site nord à La Tronche - Hopital Michallon, La Tronche, FR, ¹²Centre Léon Bérard, Lyon, FR, ¹³Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, DE, ¹⁴Medical University of Gdańsk, Gdansk, PL, ¹⁵Netherlands Cancer Institute, Amsterdam, NL, ¹⁶Vitaz, Sint Niklaas, BE, ¹⁷PDC*line Pharma SA, Liège, BE, ¹⁸PDC*Line Pharma SAS - Grenoble Research Laboratory, La Tronche, FR, ¹⁹Centre Hospitalier Universitaire Sart Tilman, Liège, BE
- 09:26 - 09:27 **1177P - Clinical implications of TSC1/TSC2 variants on immunotherapy in NSCLC patients**
L. Chen, S. Yuan, H. Chen, X. Shi, D. Chen, J. Hu, Z. Yang, S. Zhang, C. Chen, L. Mei, Shanghai OrigiMed Co., Ltd, Shanghai, CN
- 09:27 - 09:28 **1178P - Integrated pathological analysis to develop a Gal-9 based immune survival stratification to predict the outcome of lung large cell neuroendocrine carcinoma**
Y. Che¹, Z. Luo², Y. Cao³, N. Sun¹, Q. Xue¹, J. He¹, ¹National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ²Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, ³National Cancer Center/National Clinical Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN

- 09:28 - 09:29 **1179P - Real-world insights into non-small cell lung cancer patients with MET exon 14 skipping mutations: A Swedish retrospective study from two university hospitals**
M. Skribek¹, H. Brunnstrom², O. Aricak³, M. Planck², K. Jatta⁴, G. Oskarsdottir², H. Naserhojati⁵, F. Haglund⁶, S. Ekman⁷, ¹Karolinska Institutet, Stockholm, SE, ²Lund University, Lund, SE, ³Karolinska University Hospital, Solna, SE, ⁴Karolinska University Hospital-Solna, Solna, SE, ⁵Karolinska University Hospital, Huddinge, SE, ⁶Karolinska Institute, Stockholm, SE, ⁷Karolinska Institutet, Solna, SE
- 09:29 - 09:30 **1180P - Treatment patterns and progression-free survival in MET exon 14 (METex14) skipping advanced non-small cell lung cancer (aNSCLC) in real-world clinical practice**
C. Ho¹, S. Wong¹, A. Hatswell², R. Slater², H. Vioix³, C. Chouaid⁴, ¹BC Cancer, Vancouver, Canada; University of British Columbia, Vancouver, CA, ²Delta Hat, Nottingham, GB, ³Merck Healthcare KGaA, Darmstadt, DE, ⁴CHI Créteil, Créteil, France; Institut Mondor de Recherche Biomédicale, U955 Inserm-Université Paris Est Créteil, Créteil, FR
- 09:30 - 09:31 **1181P - Heterogeneity and prognostic diagnosis of KRAS-mutated population and KRAS G12C subtype among patients (pts) with advanced NSCLC (aNSCLC): A real-world study aided by machine learning approaches**
H.H.F. Loong¹, T. Liu², T. Pattipaka³, R. Hong⁴, T. Smith⁵, S. Knoll⁵, V. Pretre⁵, R. Caparica Bitton⁶, F. Ye⁷, A. Farago⁸, ¹The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK, ²Brown University, Providence, US, ³Novartis International AG - Basel, Basel, CH, ⁴New York University Medical Center, New York, US, ⁵Novartis Pharmaceuticals Corporation, East Hanover, US, ⁶Novartis Pharma MCH, Basel, CH, ⁷Novartis AG - Novartis Corporation Branch Office, New York, US, ⁸Novartis Institutes for BioMedical Research, Cambridge, US
- 09:31 - 09:32 **1182P - US real-world (RW) patient characteristics with METex14 skipping advanced non-small cell lung cancer (aNSCLC)**
R. Kelly¹, X. Le², K. Luttrupp³, M. Yang⁴, F. Liu⁴, S. Huse⁵, M.L. Ganz⁵, B. Pfeiffer⁶, P. Paik⁷, ¹Baylor University Medical Center, Dallas, US, ²The University of Texas MD Anderson Cancer Center, Houston, US, ³Evidera, Stockholm, SE, ⁴an affiliate of Merck KGaA, located in Rockland, US, ⁵Evidera, Waltham, US, ⁶Merck Healthcare KGaA, Darmstadt, DE, ⁷Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, US
- 09:32 - 09:33 **1183P - Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 1 histology subgroups**
A. Sezer¹, S. Kilickap², M. Gumus³, I. Bondarenko⁴, M. Ozguroglu⁵, M. Gogishvili⁶, X. He⁷, G. Gullo⁷, P. Rietschel⁷, R. Quek⁷, ¹Başkent University, Adana, TR, ²Istinye University Faculty of Medicine, Istanbul, TR, ³School of Medicine, Istanbul Medeniyet University, Istanbul, TR, ⁴Dnipropetrovsk Medical Academy, Dnipro, UA, ⁵Istanbul University-Cerrahpaşa, Istanbul, TR, ⁶High Technology Medical Centre, University Clinic Ltd, Tbilisi, GE, ⁷Regeneron Pharmaceuticals, Inc., Tarrytown, US

- 09:33 - 09:34 **1184P - Improving the tolerability of osimertinib by identifying its toxic limit**
B. Agema¹, M. Veerman¹, D. Lanser¹, C. Steendam², T. Preijers³, C. Van Der Leest², B. Koch³, A.-M. Dingemans⁴, R. Mathijssen¹, S. Koolen¹, ¹Erasmus MC Cancer Institute, Rotterdam, NL, ²Amphia Ziekenhuis-location Molengracht, Breda, NL, ³Erasmus MC - Erasmus University Rotterdam, Rotterdam, NL, ⁴Erasmus MC - University Medical Center, Rotterdam, NL
- 09:34 - 09:35 **1185TiP - First-in-human phase I study of ABBV-637 as monotherapy and in combination in patients with relapsed and refractory solid tumors**
J. Rotow¹, K. Yoh², J. Powderly³, T. Yoshida⁴, T. Shimizu⁴, R. Perets⁵, L. Paz-Ares⁶, A. Phillips⁷, A. Souers⁷, P. Ansell⁷, J. Jin⁸, M. Badawi⁷, R. Saab⁸, G. Morrison-Thiele⁷, S. Jeffries⁷, M. Neagu Aristide⁷, B. Carneiro⁹, K. Papadopoulos¹⁰, ¹The Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, Boston, US, ²National Cancer Center Hospital East, Kashiwa, Japan, Kashiwa, JP, ³Carolina BioOncology Institute, Huntersville, US, ⁴National Cancer Center Research Institute - Tsukiji Campus, Chuo-ku, JP, ⁵Rambam Medical Center, Haifa, IL, ⁶Hospital Universitario 12 de Octubre, CNIO-H12O Lung Cancer Unit, Universidad Complutense & CiberOnc, Madrid, ES, ⁷Abbvie Inc. - Headquarters, North Chicago, US, ⁸Abbvie Inc., CA, US, ⁹The Warren Alpert Medical School of Brown University, Providence, US, ¹⁰South Texas Accelerated Research Therapeutics (START), San Antonio, US
- 09:35 - 09:36 **1186TiP - EPONA, efficacy of osimertinib with platinum and pemetrexed in EGFR mutant non-small cell lung cancer patients bearing CNS metastasis, and have systemic progression but stable intracranial disease on OsimertiNib resistAnce (TORG 1938)**
Y. Okuma¹, S. Nomura², K. Ninomiya³, H. Yamaguchi⁴, S. Murakami⁵, Y. Kogure⁶, D. Harada⁷, K. Okishio⁸, H. Okamoto⁹, Y. Goto¹⁰, ¹NCCH - National Cancer Center Hospital, Chuo-ku, JP, ²The University of Tokyo, Tokyo, JP, ³Okayama university of Science, Okayama, JP, ⁴Nagasaki University Hospital, Nagasaki, JP, ⁵Kanagawa Cancer Center, Yokohama, JP, ⁶National Hospital Organization, Nagoya Medical Center, Nagoya, JP, ⁷National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, ⁸National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, JP, ⁹Yokohama Municipal Citizen's Hospital, Yokohama, JP, ¹⁰National Cancer Center - Tsukiji Campus, Chuo-ku, JP
- 09:36 - 09:37 **1187TiP - Phase III study of tislelizumab (TIS) with sitravatinib versus chemotherapy (chemo) in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with chemo and an anti-programmed cell death protein 1/ligand 1 (PD-[L]1) antibody**
Z. Qing¹, J. Zhao², B. Gao³, M. Wang⁴, J. Chang⁵, J. Hu⁶, J. Li⁷, J. Zhang⁷, Q. Zhang⁷, C. Fei⁸, Y.-L. Wu¹, ¹Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, CN, ²Peking University Cancer Hospital & Institute, Beijing, CN, ³Blacktown Hospital, Blacktown, AU, ⁴Chinese Academy of Medical Sciences, Beijing, CN, ⁵Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, CN, ⁶Shanghai Respiratory Research Institute Zhongshan Hospital, Fudan University, Fudan, CN, ⁷BeiGene (Beijing) Co., Ltd., Beijing, CN, ⁸BeiGene (Shanghai) Co., Ltd., Shanghai, CN

- 09:37 - 09:38 **1188TiP - ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib**
- J. De Langen¹, B.C. Cho², Z. Piotrowska³, X. Le⁴, S. Goldberg⁵, J. Goldman⁶, I. Okamoto⁷, N. Hewson⁸, J. Maidment⁸, K.H. Tang⁹, N. Veney¹⁰, J. Cosaert⁸, J. Lau¹⁰, M. Dressman¹⁰, H. Ambrose⁸, J. Riess¹¹, H.A. Yu¹², ¹Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²Yonsei Cancer Center, Seoul, KR, ³Massachusetts General Hospital, Boston, US, ⁴The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁵Yale School of Medicine, New Haven, US, ⁶University of California, Los Angeles, US, ⁷Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, ⁸AstraZeneca, Cambridge, GB, ⁹AstraZeneca, Boston, US, ¹⁰AstraZeneca, Gaithersburg, US, ¹¹UC Davis Comprehensive Cancer Center, Sacramento, US, ¹²MSKCC - Memorial Sloan Kettering Cancer Center, New York, US
- 09:38 - 09:39 **1189TiP - Phase II study of anti-TIGIT GSK4428859A (GSK’859A)/EOS-448 + anti-CD96 GSK6097608 (GSK’608) + anti-PD-1 dostarlimab in non-small cell lung cancer (NSCLC)**
- D. Spigel¹, P. Garrido Lopez², S. Cousin³, P. Cheema⁴, L.M. Rodríguez⁵, M. Garassino⁶, M. Kijewska⁷, A. Majumdar⁸, D. Theti⁷, S. Roy-Ghanta⁹, M. Ballas⁹, M. Reck¹⁰, ¹Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ²Hospital Universitario Ramon y Cajal, Madrid, ES, ³Institut Bergonie, Bordeaux, FR, ⁴William Osler Health System - Brampton Civic Hospital, Brampton, CA, ⁵Hospital Regional y Virgen de la Victoria, IBIMA, Malaga, ES, ⁶National Cancer Institute of Milan, Milan, IT, ⁷GlaxoSmithKline GSK - UK, Greenford, GB, ⁸GlaxoSmithKline, Philadelphia, US, ⁹GlaxoSmithKline USA, Collegeville, US, ¹⁰Lung Clinic Grosshansdorf, Grosshansdorf, DE
- 09:39 - 09:40 **1190TiP - Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)**
- H.A. Yu¹, F. Cantero², B. Kim², M. Lee², E. Wu², D. Sternberg³, P. Jänne⁴, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²Daiichi Sankyo, Inc., Basking Ridge, US, ³Daiichi Sankyo Inc., Basking Ridge, US, ⁴Dana-Farber Cancer Institute, Boston, US
- 09:40 - 09:41 **1191TiP - Nivolumab-ipilimumab with cfDNA-guided treatment intensification as a chemotherapy-sparing strategy in metastatic non-small cell lung cancer (ATLAS)**
- L. Corke¹, M. García Pardo De Santayana¹, K. Meteleva², F. Shepherd¹, P. Bradbury¹, L. Eng¹, S. Kuang¹, M. Cabanero², P. Rogalla², G. Liu¹, M.-S. Tsao², T. Pugh¹, B. Wang², P. Ohashi², N. Leigh¹, A. Sacher¹, ¹Princess Margaret Cancer Centre, University Health Network, Toronto, CA, ²Princess Margaret Cancer Centre, Toronto, CA
- 09:41 - 09:42 **1192TiP - GALLANT-1: Galectin-3 (Gal-3) inhibitor, GB1211, plus atezolizumab (atz) in patients (pts) with non-small cell lung cancer (NSCLC) - a dose finding study followed by a randomised, double-blind, placebo-controlled trial**
- F. Ghiringhelli¹, P. Barre², E. Pichon³, S. Ponce Aix⁴, O.J. Juan Vidal⁵, E. Carcereny Costa⁶, T. Sethi⁷, B. Lindmark⁷, A. Mackinnon⁷, V. Aslanis⁷, D. Phung⁷, P. Jensen⁷, Z. Rajiwate⁷, G. Ross⁷, L. Basse⁷, ¹University of Burgundy, Genetic and Immunotherapy Medical Institute, Dijon, FR, ²Montpellier Regional University Hospital, Montpellier, FR, ³CHRU Bretonneau, Tours, FR, ⁴Hospital Universitario 12 de Octubre, Madrid, ES, ⁵La

Fe University Hospital, Valencia, ES, ⁶Catalan Institute of Oncology Badalona, Germans Trias i Pujol Hospital, Barcelona, ES, ⁷Galecto Biotech AB, Copenhagen, DK

- 09:42 - 09:43 **1193TiP - A phase II, multicenter, open-label, dose-finding study evaluating THIO sequenced with cemiplimab in patients with advanced NSCLC**
T.-E. Ciuleanu¹, R. Joshi², S. Gryaznov³, V. Vitoc³, M. Obrocea³, ¹IOCN - The Oncology Institute Prof. Dr. Ion Chiricuta, Cluj-Napoca, RO, ²Cancer Research SA, Adelaide, AU, ³MAIA Biotechnology, Inc., Chicago, US
- 09:43 - 09:44 **1194TiP - AdvanTIG-205: Phase II trial of ociperlimab (OCI) + tislelizumab (TIS) + chemotherapy (chemo) in first line (1L) treatment of patients (pts) with locally advanced (LA), unresectable, or metastatic non-small cell lung cancer (mNSCLC)**
B. Zhu¹, T.M. Kim², S. Patel³, S. Parakh⁴, J. Tang⁵, H. Wu⁶, N. Girard⁷, ¹Xinqiao Hospital, Third Military Medical University, Chongqing, CN, ²Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, ³University of North Carolina School of Medicine, Chapel Hill, US, ⁴Austin Hospital, Olivia Newton-John Cancer Research Institute, Melbourne, AU, ⁵BeiGene (Shanghai) Co., Ltd., Shanghai, CN, ⁶BeiGene USA, Inc., Ridgefield Park, US, ⁷Institut Curie, Paris, FR
- 09:44 - 09:45 **1195TiP - HERTHENA-Lung02: A randomized phase III study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR TKI**
T.S.K. Mok¹, Y.-L. Wu², M. Nishio³, M. Reck⁴, E. Wu⁵, D. Sternberg⁶, S. Esker⁵, H.A. Yu⁷, ¹State Key Laboratory of Translational Oncology and Chinese University of Hong Kong, Hong Kong, HK, ²Guangdong Province People's Hospital, Guangzhou, CN, ³The Cancer Institute Hospital of JFCR, Koto-ku, JP, ⁴LungenClinic Grosshandorf, Grosshansdorf, DE, ⁵Daiichi Sankyo, Inc., Basking Ridge, US, ⁶Daiichi Sankyo Inc., Basking Ridge, US, ⁷Memorial Sloan Kettering Cancer Center, New York, US
- 09:45 - 09:46 **1196TiP - LuCa-MERIT-1: First-in-human, open label, phase I dose confirmation trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer**
P. Forde¹, A. Atmaca², P. Brück³, N. Munshi⁴, M. Kaczorowska³, T. Schell³, Ö. Türeci³, U. Sahin³, ¹Johns Hopkins University SOM, Baltimore, US, ²KHNW - Krankenhaus Nordwest GmbH, Frankfurt am Main, DE, ³BioNTech SE, Mainz, DE, ⁴BioNTech US, Cambridge, US
- 09:46 - 09:47 **1197TiP - A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation**
D.H. Lee¹, A. Roohullah², B.C. Cho³, S.-H. Lee⁴, C. Lemech⁵, P. De Souza⁶, M. Millward⁷, J. Choi⁸, K.E. Park⁸, E. Kim⁸, N.Y. Kim⁸, Y.K. Shin⁹, J.-Y. Han¹⁰, ¹University of Ulsan College of Medicine, Asan Medical Center, Seoul, KR, ²Liverpool, Sydney, AU, ³Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁵Prince of Wales Clinical School, UNSW, Sydney, AU, ⁶Liverpool Hospital, Sydney, AU, ⁷University of

Western Australia, Consultant Medical Oncologist, Linear Clinical Research, Adjunct Professor, School of Medical and Health Sciences, Edith Cowan University, Perth, AU, ⁸Abion Inc., Seoul, KR, ⁹Seoul National University, Seoul, KR, ¹⁰National Cancer Center, Research institute and Hospital, National Cancer center, Goyang, KR

- 09:47 - 09:48 **1198TiP - A phase Ib/II open-label, nonrandomized study of FGFR inhibitor futibatinib in combination with MEK inhibitor binimetinib in patients with advanced KRAS-mutant cancer**
J. Rodon¹, B. O'Neil², V. Wacheck³, M. Liu³, L. Rosen⁴, ¹MD Anderson Cancer Center, Houston, US, ²Indiana University Health University Hospital, Indianapolis, US, ³Taiho Oncology, Princeton, US, ⁴UCLA, Santa Monica, US
- 09:48 - 09:49 **1199TiP - Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC**
A. Lisberg, B. Liu, R. Salehi-Rad, J. Lee, L. Tran, K. Krysan, R. Lim, C. Dumitras, Z. Jiang, F. Abtin, R. Suh, S. Genshaft, S. Oh, G.A. Fishbein, C.M. O'Higgins, D. Greenwald, J. Goldman, D. Elashoff, E. Garon, S. Dubinett, University of California, Los Angeles, ***, US
- 09:49 - 09:50 **1200TiP - Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)**
H.S. Ozer¹, G. Nomak², B. Oksuzoglu³, R. Senturk⁴, Y. Eralp⁵, F. Yumuk⁶, H. Nomak⁷, R. Sanyal⁸, ¹Koc University School of Medicine, Istanbul, TR, ²RS Research, Istanbul Asya, TR, ³University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, TR, ⁴University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, TR, ⁵Acibadem University Maslak Acibadem Hospital, Istanbul, TR, ⁶Koç University School of Medicine, Istanbul, TR, ⁷PDC Therapeutics, Lausanne, CH, ⁸RS Research, Istanbul, TR
- 09:50 - 09:51 **1201TiP - MINOVA: A phase II, open-label, single arm, multicenter, exploratory study with osimertinib plus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC) with uncommon EGFR mutations**
M. Huang, Y. Gong, Y. Liu, Y. Zhang, Y. Lu, Sichuan University West China Hospital, Chengdu, CN
- 09:51 - 09:52 **1202TiP - Evolution of the tumor immune microenvironment in hepatocellular carcinoma (HCC) and non-squamous non-small cell lung cancer (NSCLC) with liver metastases treated with atezolizumab and bevacizumab (INTEGRATE)**
A. Sacher¹, S. Lau², M. Allen¹, L. Corke¹, M. Makarem¹, E. Chen¹, R. Jang¹, E. Elimova¹, R. Grant¹, F. Shepherd¹, P. Bradbury¹, L. Eng¹, P. Rogalla³, G. Liu¹, M.-S. Tsao⁴, N. Leigh¹, R. Garonce-Hediger⁵, B. Wang⁶, P. Ohashi³, J. Knox¹, ¹Princess Margaret Cancer Centre, University Health Network, Toronto, CA, ²Laura & Issac Perlmutter Cancer Center, NYU Langone Health, New York, US, ³Princess Margaret Cancer Centre, Toronto, CA, ⁴UHN - Princess Margaret Cancer Research Tower - MaRS Discovery District, Toronto, CA, ⁵F. Hoffmann-La Roche AG, Basel, CH, ⁶UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

- 09:52 - 09:53 **1206P - HER2 copy number variation (CNV), HER2 expression and primary resistance mechanisms in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction cancer (mGC/GEJC) receiving first-line chemotherapy (CT) + trastuzumab (T) +/- pertuzumab (P) in the JACOB trial**
- F. Pietrantonio¹, E. Berrino², P. Manca¹, S. Bellomo³, A. Raimondi⁴, S. Corso², F. Morano⁴, C. Migliore³, M. Niger⁴, C. Marchiò², M. Di Bartolomeo⁴, E. Restuccia⁵, C. Lambertini⁶, J. Tabernero⁷, S. Giordano³, ¹Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ²Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Turin), IT, ³University of Turin, Torino, IT, ⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ⁵F. Hoffmann-La Roche AG, Basel, CH, ⁶F. Hoffmann- La Roche AG, Basel, CH, ⁷Vall d'Hebron University Hospital, Barcelona, ES
- 09:53 - 09:54 **1207P - Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study**
- Y. Li¹, A. Zhou¹, S. Liu², M. He³, K.-N. Chen⁴, Z. Tian⁵, H. Chen⁶, H. Tian⁷, Y. Yu¹, W. Qu¹, L. Xue⁸, S. Wang¹, F. Bie¹, B. Zhou¹, H. Huang¹, Y. Fang¹, B. Li⁹, X. Dai⁹, S. Gao¹, J. He¹, ¹National Cancer Center/National Clinical Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ²Fujian Provincial Cancer Hospital, Fuzhou, CN, ³Fourth Hospital of Hebei Medical University, Changan, CN, ⁴Peking University School of Oncology, Beijing Cancer Hospital, Beijing, CN, ⁵The Fourth Hospital of Hebei Medical University - North Gate, Shijiazhuang, CN, ⁶Fudan University Cancer Hospital, Shanghai, CN, ⁷Qilu Hospital of Shandong University, Jinan, CN, ⁸Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, ⁹Lee's Pharmaceutical Limited, Shenzhen, CN
- 09:54 - 09:55 **1209P - A phase II study of regorafenib in combination with nivolumab in patients with recurrent or metastatic solid tumors: Results of the ESCC cohort**
- L.-Y. Bai¹, C.-F. Chiu¹, S. Kadowaki², M. Robert³, H. Hara⁴, M.H. Hong⁵, F. Bergamo⁶, S. Pernot⁷, D. Cunningham⁸, C.-Y. Lin⁹, B. Keam¹⁰, Y. Matsumura¹¹, K. Enya¹¹, I. Waxman¹², L. Jin¹³, D. Ngo¹⁴, U. Drews¹⁵, C. Mancao¹⁶, M.-A. Le Berre¹⁷, K. Kato¹⁸, ¹China Medical University Hospital, Taichung City, TW, ²Aichi Cancer Center Hospital, Nagoya, JP, ³Institut de Cancérologie de l'Ouest, Saint Herblain, Saint Herblain, FR, ⁴Saitama Cancer Center, Kita-Adachigun, JP, ⁵Severance Hospital, Yonsei University Health System, Seoul, KR, ⁶Istituto Oncologico Veneto IRCCS (IOV), Padova, IT, ⁷Institut Bergonié, Bordeaux Cedex, FR, ⁸Royal Marsden Hospital, Sutton, GB, ⁹Chi-Mei Medical Center, Tainan City, TW, ¹⁰Seoul National University Hospital, Seoul, KR, ¹¹Ono Pharmaceutical Co., Ltd, Osaka, JP, ¹²Bristol-Myers Squibb, Princeton, US, ¹³Bristol-Myers Squibb, Lawrenceville, US, ¹⁴Bayer HealthCare Pharmaceuticals, Boston, US, ¹⁵Bayer AG, Berlin, DE, ¹⁶Bayer Consumer Care AG, Basel, CH, ¹⁷Bayer Healthcare SAS, Loos, FR, ¹⁸National Cancer Center Hospital, Tokyo, JP
- 09:55 - 09:56 **1210P - The preliminary efficacy and safety of KN026 combined with KN046 treatment in HER2-positive locally advanced unresectable or metastatic gastric/gastroesophageal junction cancer without prior systemic treatment in a phase II study**
- L. Shen¹, J. Gong¹, Z. Niu², R. Zhao³, L. Chen⁴, L. Liu⁵, T. Deng⁶, L. Lu⁷, Y. Zhang⁸, Z. Li⁹, X. Li¹⁰, B. Xia¹⁰, ¹Peking University Cancer Hospital and Institute, Beijing, CN, ²Shandong Cancer Hospital, Jinan, CN, ³Zibo city municipal hospital, Zibo, CN, ⁴The

First Affiliated Hospital of Xiamen University, Xiamen, CN, ⁵Suining Central Hospital, Suining, CN, ⁶Tianjin Medical University Cancer Institute and Hospital, tianjin, CN, ⁷Gansu Wuwei Tumor Hospital, Wuwei, CN, ⁸Linfen Central Hospital, Linfen, CN, ⁹Linyi Cancer Hospital, Linyi, CN, ¹⁰Alphamab Oncology, Suzhou, CN

- 09:56 - 09:57 **1211P - A multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (EPOC1802)**
H. Bando¹, S. Kumagai², D. Kotani¹, M. Saori¹, T. Habu², T. Tsushima³, H. Hara⁴, S. Kadowaki⁵, K. Kato⁶, K. Chin⁷, K. Yamaguchi⁷, S.-I. Kageyama¹, H. Hojo¹, M. Nakamura¹, H. Tachibana¹, M. Wakabayashi¹, M. Fukutani¹, N. Fuse¹, H. Nishikawa⁸, T. Kojima¹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²National Cancer Center Hospital East, Kashiwa, Chiba, JP, ³Shizuoka Cancer Center, Shizuoka, JP, ⁴Saitama Cancer Center, Ina, JP, ⁵Aichi Cancer Center Hospital, Nagoya, JP, ⁶National Cancer Center - Tsukiji Campus, Chuo-ku, JP, ⁷The Cancer Institute Hospital of JFCR, Koto-ku, JP, ⁸NCCH - National Cancer Center Hospital, Chuo-ku, JP
- 09:57 - 09:58 **1212P - Genomic subtypes of gastric cancer associated with response to chemoradiation therapy**
J.-S. Lee¹, Y.S. Jeong¹, S.H. Lee², S.-H. Kang³, J. Ajani⁴, ¹MD Anderson Cancer Center, Houston, US, ²CHA Bundang Medical Center, Seongnam, KR, ³Korea University College of Medicine-Guro Hospital, Seoul, KR, ⁴The University of Texas MD Anderson Cancer Center, Houston, US
- 09:58 - 09:59 **1213P - DKN-01 and tislelizumab + chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial**
S. Klempner¹, J. Chao², H. Uronis³, C. Sirard⁴, M. Kagey⁴, J. Baum⁴, J. Song⁵, J. Wang⁶, M. Sonbol⁷, Z. Wainberg⁸, J. Ajani⁹, ¹MGH - Massachusetts General Hospital, Boston, US, ²City of Hope Comprehensive Cancer Center, Duarte, US, ³Duke Cancer Center - Duke University Medical Center, Durham, US, ⁴Leap Therapeutics, Cambridge, US, ⁵BeiGene, Ltd., San Mateo, US, ⁶BeiGene, Ltd., Beijing, CN, ⁷Mayo Clinic Cancer Center, Phoenix, US, ⁸UCLA - David Geffen School of Medicine, Los Angeles, US, ⁹The University of Texas MD Anderson Cancer Center, Houston, US
- 09:59 - 10:00 **1214P - Prognostic value of 68Ga-FAPI PET/CT in esophageal squamous cell carcinoma: A pilot study**
L. Zhao, Y. Pang, S. Chen, H. Chen, Q. Lin, The First Affiliated Hospital of Xiamen University, Xiamen, CN
- 10:00 - 10:01 **1215P - Neoadjuvant concurrent chemoradiotherapy combined with immunotherapy in the treatment of adenocarcinoma of the oesophagogastric junction: A phase II study**
R. Du¹, J. Ming¹, J. Geng¹, X. Sui¹, S. Li¹, Z. Liu¹, X. Zhu¹, Y. Cai¹, Z. Wang¹, L. Tang², X. Zhang², Z. Peng², Y. Yan¹, Z. Li¹, Y. Peng¹, A. Wu¹, Y. Li¹, Z. Li¹, W. Wang¹, J. Ji², ¹Beijing Cancer Hospital & Institute, Beijing, CN, ²Peking University Cancer Hospital and Institute, Beijing, CN

- 10:01 - 10:02 **1216P - Prognostic potential of liquid biopsy in advanced HER2 positive esophagogastric adenocarcinoma under HER2 blockade and immune checkpoint therapy**
- L. Paschold¹, A. Stein², S. Henkes¹, J. Tintelnot³, E. Goekkurt², D. Simnica¹, C. Schultheiß¹, E. Willscher¹, M. Bauer⁴, C. Wickenhauser⁴, P. Thuss-Patience⁵, S. Lorenzen⁶, J. Riera Knorrenschild⁷, S. Kubicka⁸, A. Reinacher-Schick⁹, M. Sinn³, W. Hiegl¹⁰, A. Hinke¹¹, S. Hegewisch-Becker¹², M. Binder¹, ¹Martin Luther University Halle-Wittenberg, Halle (Saale), DE, ²Hematology-Oncology Practice Eppendorf (HOPE), Hamburg, DE, ³University Medical Center Hamburg-Eppendorf, Hamburg, DE, ⁴University Hospital, Martin-Luther University, Halle, Berlin, DE, ⁵Charité – University Medicine Berlin, Berlin, DE, ⁶Klinikum Rechts der Isar - Technische Universität München, Munich, DE, ⁷University Hospital, Philipps-Universität Marburg, Marburg, DE, ⁸Klinikum am Steinenberg Reutlingen, Reutlingen, DE, ⁹Katholisches Klinikum Bochum - St. Josef-Hospital, Bochum, DE, ¹⁰AIO Studien gGmbH Berlin, Berlin, DE, ¹¹CCRC - Cancer Clinical Research Consulting, Düsseldorf, DE, ¹²Hematological Oncology Practice Eppendorf HOPE, Hamburg, DE
- 10:02 - 10:03 **1217P - Profiling of myeloid cells associated with prognosis in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study)**
- H. Shoji¹, N. Boku¹, C. Kudo-Saito², K. Nagashima³, K. Tsugaru³, N. Takahashi⁴, T. Kawakami⁵, Y. Amanuma⁶, T. Wakatsuki⁷, N. Okano⁸, Y. Narita⁹, Y. Yamamoto¹⁰, R. Kizawa¹¹, H. Imazeki¹, K. Aoki², K. Muro⁹, ¹National Cancer Center Hospital, Tokyo, JP, ²National Cancer Center Research Institute, Tokyo, JP, ³Keio University Hospital, Tokyo, JP, ⁴Saitama Cancer Center, Saitama, JP, ⁵Shizuoka Cancer Center, Shizuoka, JP, ⁶Chiba Cancer Center, Chiba, JP, ⁷The Cancer Institute Hospital of JFCR, Tokyo, JP, ⁸Kyorin University of Faculty of Medicine, Tokyo, JP, ⁹Aichi Cancer Center Hospital, Aichi, JP, ¹⁰University of Tsukuba Hospital, Ibaraki, JP, ¹¹Toranomon Hospital, Tokyo, JP
- 10:03 - 10:04 **1218P - Long-term survivorship rates among chemotherapy refractory or intolerant advanced esophageal squamous cell carcinoma (aESCC) patients treated with nivolumab (NIVO)**
- J. Ajani¹, D. Sharpe², T. De³, I. Kim⁴, J. Gricar⁴, M. Kurt⁴, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²Parexel International, Uxbridge, GB, ³PAREXEL International, Billerica, US, ⁴Bristol Myers Squibb, Lawrenceville, US
- 10:04 - 10:05 **1219P - Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma: The PANDA study**
- M. Chalabi¹, Y. Verschoor², J. Van De Haar², J. Van Den Berg², L. Kodach², J. Van Sandick², J. Van Dieren², S. Balduzzi², M.C. Grootscholten², X. Veenhof², K. Hartemink², M. Vollebergh³, E. Owers², A. Bartels-Rutten², P. Den Hartog-Lievaart², M. Van Leerdam², T. Schumacher², J. Haanen², E. Voest², ¹Netherlands Cancer Institute, Amsterdam, NL, ²NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ³Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL
- 10:05 - 10:06 **1220P - Efficacy and safety of camrelizumab combined with FLOT versus FLOT alone as neoadjuvant therapy in patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical**

gastrectomy

L. Min, N. Liu, Y. Zhou, Z. Niu, The Affiliated Hospital of Qingdao University, Qingdao, CN

- 10:06 - 10:07 **1221P - Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): Results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6**
- Z. Wainberg¹, P. Enzinger², S. Qin³, K. Yamaguchi⁴, A. Gnanasakthy⁵, A. Jamotte⁶, I. Majer⁶, Y.-K. Kang⁷, ¹University of California at Los Angeles, Los Angeles, CA, Los Angeles, US, ²Dana Farber Cancer Institute, Boston, US, ³Jingling Hospital, Nanjing University of Chinese Medicine, Nanjing, CN, ⁴The Cancer Institute Hospital of JFCR, Koto-ku, JP, ⁵RTI Health Solutions, Durham, US, ⁶Amgen Inc, Thousand Oaks, US, ⁷Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR
- 10:07 - 10:08 **1222P - Predictiveness of Mandard score on recurrence patterns of esophageal adenocarcinoma after neoadjuvant therapy and surgery**
- D. Liu¹, S.P. Henckens², M. Kalff², M. Bijlsma¹, C. Oyarce¹, S. Gisbertz², H. Van Laarhoven², M. Van Berge Henegouwen², ¹Amsterdam UMC location University of Amsterdam, Amsterdam, NL, ²Academic Medical Center, University of Amsterdam, Amsterdam, NL
- 10:08 - 10:09 **1223P - First-line lenvatinib (Len) + pembrolizumab (Pembro) + chemotherapy (Chemo) vs chemo in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 safety run-in**
- K. Shitara¹, I. Ben-Aharon², C. Rojas³, D. Acosta Eyzaguirre⁴, A. Hubert⁵, H. Araya Moya⁶, D. Cohen⁷, L.-Y. Bai⁸, F. Ghiringhelli⁹, L. Wyrwicz¹⁰, Y. Janjigian¹¹, J. Tabernero¹², E. Van Cutsem¹³, S. Qin¹⁴, J. Xu¹⁵, A. Wang¹⁶, M.G. Miller¹⁶, C.-S. Shih¹⁶, P. Bhagia¹⁶, P. Yanez Weber¹⁷, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Rambam Health Care Campus, Haifa, IL, ³Bradford Hill, Recoleta, Santiago, CL, ⁴Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁵Hadassah-Hebrew University Hospital, Jerusalem, IL, ⁶Clinica Universidad Catolica del Maule, Maule, CL, ⁷Icahn School of Medicine at Mount Sinai, New York, US, ⁸China Medical University Hospital, Taichung, TW, ⁹Center Georges Francois Leclerc, Dijon, FR, ¹⁰Maria Sklodowska-Curie National Cancer Research Institute, Warsaw, PL, ¹¹Memorial Sloan Kettering Cancer Center, New York, US, ¹²Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, ES, ¹³University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, BE, ¹⁴Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, CN, ¹⁵The Fifth Medical Center, PLA General Hospital, Beijing, CN, ¹⁶Merck & Co., Inc., Rahway, US, ¹⁷Universidad de La Frontera, James Lind Cancer Research Center, Temuco, CL
- 10:09 - 10:10 **1224P - Final analysis of clinical outcomes in the DELIVER trial: Observational study of nivolumab treatment in advanced gastric cancer (JACCRO GC-08)**
- Y. Sunakawa¹, E. Inoue², Y. Sakamoto³, R. Kawabata⁴, A. Ishiguro⁵, Y. Akamaru⁶, Y. Kito⁷, M. Takahashi⁸, J. Matsuyama⁹, H. Yabusaki¹⁰, A. Makiyama¹¹, T. Suzuki¹², M. Tsuda¹³, H. Yasui¹⁴, H. Kawakami¹⁵, T. Nakajima¹⁶, K. Muro¹⁷, R. Matoba¹⁸, W. Ichikawa¹⁹, M. Fujii²⁰, ¹St. Marianna University School of Medicine, Kawasaki, JP, ²Showa University, Shinagawa-ku, JP, ³Osaki Citizen Hospital, Osaki, JP, ⁴Osaka Rosai Hospital, Sakai, JP,

⁵Teine Keijinkai Hospital, Sapporo, JP, ⁶Ikeda City Hospital, Ikeda, JP, ⁷Ishikawa Prefectural Central Hospital, Kanazawa, JP, ⁸Yokohama Municipal Citizen's Hospital, Yokohama, JP, ⁹Higashiosaka City Medical Center, Higashi-Osaka, JP, ¹⁰Niigata Cancer Center Hospital, Niigata, JP, ¹¹Gifu University Hospital, Gifu, JP, ¹²National Hospital Organization - Kure Medical Center and Chugoku Cancer Center, Kure, JP, ¹³Hyogo Cancer Center, Akashi, JP, ¹⁴Kobe City Medical Center General Hospital, Kobe, JP, ¹⁵Kindai University - Faculty of Medicine, Osaka, JP, ¹⁶Kyoto University, Kyoto, JP, ¹⁷Aichi Cancer Center Hospital, Nagoya, JP, ¹⁸DNA Chip Research Inc., Tokyo, JP, ¹⁹Showa University Fujigaoka Hospital, Yokohama, JP, ²⁰Nihon University School of Dentistry Medecine, Tokyo, JP

- 10:10 - 10:11 **1225P - Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC): Preliminary results of a preoperative phase exploratory clinical trial**
Y. Dong¹, J. Luo², S. Liu³, Y. Lin⁴, H. Han⁴, ¹Shandong Cancer Hospital and Institute Affiliated Shandong First Medical University and Shandong Academy of Medical Sciences, jinan, CN, ²Shandong Cancer Hospital, Jinan, CN, ³Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN, ⁴Jiangsu Hengrui Pharmaceutical Co., Ltd., Jinan, CN
- 10:11 - 10:12 **1226P - Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay**
C. Fong¹, S. Iyer², L. Potts¹, C. Peckitt¹, S. Cromarty¹, C. Saffery¹, S. Kidd¹, T. Rana¹, L. Ausec³, A. Gregorc³, D. Pointing³, M. Gombert⁴, K. Von Loga⁵, L. Benjamin², N. Starling¹, T. Waddell⁶, R. Petty⁷, M. Uhlik², I. Chau¹, D. Cunningham¹, ¹The Royal Marsden NHS Foundation Trust, London and Sutton, GB, ²OncXerna Therapeutics, Inc., Waltham, US, ³Genealis, Boston, US, ⁴QIAGEN GmbH, Hilden, DE, ⁵The Royal Marsden NHS Foundation Trust, Sutton, GB, ⁶The Christie NHS Foundation Trust, Manchester, GB, ⁷Clinical Research Centre - Ninewells Hospital - NHS Tayside, Dundee, GB
- 10:12 - 10:13 **1227P - Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC)**
S. Cytryn, S. Joshi, G. Ku, S. Maron, A. Desai, J. Yang, D. Rao, Z. Goldberg, R. Sugarman, A. Antoine, F. Socolow, J. Chou, M. Capanu, H. Gerdes, M. Simmons, V. Paroder, L. Tang, J. Shia, D. Ilson, Y. Janjigian, Memorial Sloan Kettering Cancer Center, New York, US
- 10:13 - 10:14 **1228P - Stage migration, changed treatment profile and survival impact in newly diagnosed oesophago-gastric cancer in Scotland during the COVID-19 pandemic: A national study**
M. Baxter¹, K. Khan², L. Gall², C. Samuelson³, L.R. Narramneni⁴, M. Al-Zuabi⁵, G. Bryce⁵, H. Shareef¹, R. Petty¹, M. Forshaw², ¹Clinical Research Centre - Ninewells Hospital - NHS Tayside, Dundee, GB, ²Glasgow Royal Infirmary - NHS Greater Glasgow and Clyde, Glasgow, GB, ³Edinburgh Cancer Centre - SCAN, Edinburgh, GB, ⁴Aberdeen Royal Infirmary, Aberdeen, GB, ⁵University Hospital Wishaw, Wishaw, GB
- 10:14 - 10:15 **1229P - A multicenter phase II study of sotigalimab (CD40 agonist) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers**

A. Ko¹, M. Noel², J. Chao³, D. Sohal⁴, M. Crow⁵, P. Oberstein⁶, A. Scott⁷, A. Mcree⁸, C. Rocha Lima⁹, L. Fong¹⁰, B. Keenan¹⁰, E. Filbert¹¹, F. Hsu¹¹, V. Shankaran¹², ¹UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US, ²Georgetown University, Washington, US, ³City of Hope Comprehensive Cancer Center, Duarte, US, ⁴University of Cincinnati Cancer Centre, Cincinnati, US, ⁵Renovatio Clinical, Houston, US, ⁶NYU Langone Health - Perlmutter Cancer Center - 34th Street, New York, US, ⁷University of Arizona Cancer Center, Tucson, US, ⁸University of North Carolina - Chapel Hill, Chapel Hill, US, ⁹Wake Forest University Comprehensive Cancer Center, Winston-Salem, US, ¹⁰UCSF - University of California San Francisco, San Francisco, US, ¹¹Apexigen Inc., San Carlos, US, ¹²University of Washington Seattle Cancer Care Alliance, Seattle, US

- 10:15 - 10:16 **1230P - Immunotherapies for gastric cancer with CLDN18-ARHGAP fusion gene**
Y. Wang, X. Song, T. Shi, H. Wang, X. Zhang, B. Liu, J. Wei, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, CN
- 10:16 - 10:17 **1231P - Phase I study to evaluate the safety, tolerability, and efficacy of VCN-01 in combination with durvalumab (MEDI4736) in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)**
M. Jove¹, I. Brana², M. Oliva Bernal¹, A. Hernando-Calvo³, C. Erasun Lecuona¹, J.D. Assaf Pastrana², M. Bazan Peregrino⁴, A. Mato-Berciano⁵, M.V. Maliandi⁵, S. Torres-Manjon⁶, J. Martinez De Villareal⁷, F.X. Real⁷, P. Nuciforo⁸, R. Alemany⁹, G. Capella⁹, E. Blasi⁵, C. Blasco⁴, M. Cascallo Piqueras⁴, R. Mesia Nin¹⁰, ¹ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Early Drug Development Unit, "La Caixa Research" UITM - Vall d'Hebron Institute of Oncology (VHIO). Vall D'Hebron, Barcelona, ES, ⁴VCN BIOSCIENCES SL, Barcelona, ES, ⁵VCN Biosciences SL, Sant Cugat del Valles, ES, ⁶Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat, Barcelona, ES, ⁷CNIO - Centro Nacional de Investigaciones Oncologicas, Madrid, ES, ⁸Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁹ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, ¹⁰ICO - Institut Català d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, ES
- 10:17 - 10:18 **1232P - CROSS protocol for esophageal cancer in India: Reality or pipe dream?**
K. Puja¹, M. Verma², D. Kukreja², M.L.B. Bhatt², ¹King George's Medical University, Lucknow, IN, ²KGMU - King George's Medical University, Lucknow, IN
- 10:18 - 10:19 **1233P - Real world outcomes of FLOT versus CROSS for patients with oesophageal or gastro-oesophageal junction cancer**
A. Shahnam¹, U. Nindra², N. Mcnamee¹, R. Yoon², G.R. Asghari³, W. Ng², D. Karikios⁴, M. Wong¹, ¹Crown Princess Mary Cancer Centre Westmead, Westmead, AU, ²Liverpool Cancer Therapy Centre, Liverpool, AU, ³Bankstown-Lidcombe Hospital, Bankstown, AU, ⁴Nepean Blue Mountains Local Health District, Penrith, AU
- 10:19 - 10:20 **1234P - Neoadjuvant camrelizumab plus docetaxel and carboplatin in locally advanced esophageal squamous cell carcinoma (ESCC): A prospective study**
R. Wang, G. Zhang, Q. Zhu, T. Ma, C. Weng, D. Zhang, H. Zeng, T. Wang, F. Gao, The Fourth Hospital of Hebei Medical University - North Gate, Shijiazhuang, CN

- 10:20 - 10:21 **1235P - Analytical performance of PD-L1 IHC 28-8 pharmDx in gastric, gastroesophageal junction (GEJ), and esophageal carcinoma evaluated using combined positive score (CPS)**
- T. Chan¹, B. Neill¹, A. Murga¹, K. Sojka¹, S. Thakrar², Q. Nguyen¹, C. Felten³, J. Blaustein⁴, D. Falconer¹, T. Marquez¹, K. Wakamiya⁵, S.C. Hsu¹, D. Houston¹, N. Hertle⁶, S. Tabuena-Frolli¹, M. Borgert¹, S. Smith¹, E. Oroudjev¹, ¹Agilent Technologies, Carpinteria, US, ²ICON plc, Dublin, IE, ³Gemini Diagnostics, Westlake Village, US, ⁴Caris Life Sciences - Lab & Specimen Receiving, Phoenix, US, ⁵Agilent Technologies, Goleta, US, ⁶Epsilon, Westlake Village, US
- 10:21 - 10:22 **1236P - Comorbidities and their association with the overall survival in a large European cohort with gastroesophageal cancer**
- H. Pühr, F. Selimi, K. Oberreiter, M.A. Dieterle, C.C. Weirauch, G. Jomrich, M. Paireder, S. Schoppmann, A.S. Berghoff, M. Preusser, A. Ilhan-Mutlu, Medical University of Vienna - Vienna General Hospital, Vienna, AT
- 10:22 - 10:23 **1237P - Phase I study to evaluate the safety, tolerability and preliminary efficacy of rivoceranib plus paclitaxel in advanced gastric or gastroesophageal junction (GEJ) cancer**
- M.H. Ryu¹, A. Pande², J.H. Kim², Y.-K. Kang¹, ¹Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ²Elevar Therapeutics, Salt Lake City, US
- 10:23 - 10:24 **1238P - Effect of a standardized nutritional support program on nutritional status, body composition, morbidity and mortality in patients with advanced upper gastrointestinal (UGI) cancer before and after neo-adjuvant radio-chemotherapy followed by surgery**
- C. Fottner¹, M. Silber¹, L. Bergholz¹, J. Gartenschläger¹, R. Gans¹, M. Ferrata¹, A. Zimmermann¹, M. Gartenschläger¹, T. Bostel¹, M. Moehler², P. Grimminger², M.M. Weber¹, ¹Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, ²Universitätsmedizin Mainz, Mainz, DE
- 10:24 - 10:25 **1239P - Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma**
- L. Aoude¹, V. Bonazzi¹, S. Brosda¹, B. Wong², H. Moradi³, J. Lonie¹, J. Bradford⁴, C. Bloxham³, V. Atkinson², P. Law², G. Lampe⁵, M. Smithers⁴, N. Waddell⁶, V. Vegh³, K. Miles², A. Barbour², ¹The University of Queensland, Woolloongabba, AU, ²Princess Alexandra Hospital - Metro South Health, Woolloongabba, AU, ³The University of Queensland, St Lucia, AU, ⁴The University of Queensland, Brisbane, AU, ⁵Royal Brisbane and Women's Hospital, Herston, AU, ⁶QIMR Berghofer Medical Research Institute, Brisbane, AU
- 10:25 - 10:26 **1240P - Activation status of CD8⁺ T and Treg cells in the tumor microenvironment potentially predicts the clinical efficacy of nivolumab in advanced esophageal squamous cell carcinoma**
- H. Mikuni¹, G. Watanabe², S. Kumagai², S. Yamamoto³, R. Sawada¹, K. Yokoyama³, Y. Honma⁴, S. Sekine³, T. Kashiwara⁴, K. Ishiyama⁴, J. Oguma⁴, H. Igaki⁴, M. Saruta¹, H. Daiko⁵, S. Koyama², H. Nishikawa², K. Kato³, ¹Jikei University School of Medicine,

Tokyo, JP, ²National Cancer Center Hospital East, Kashiwa, Chiba, JP, ³National Cancer Center Hospital, Tokyo, JP, ⁴NCCH - National Cancer Center Hospital, Chuo-ku, JP, ⁵National Cancer Center Hospital, Tokyo, Japan, Tokyo, JP

- 10:26 - 10:27 **1241P - Phase Ib study of futibatinib plus pembrolizumab in patients with advanced or metastatic solid tumors: Tolerability results and antitumor activity in esophageal carcinoma**
K. Muro¹, K. Kato², K. Chin³, K. Nishino⁴, M. Satouchi⁵, Y. Watanabe⁶, H. Kawakami⁷, T. Tsushima⁸, H. Hirai⁹, M. Chisamore¹⁰, T. Kojima¹¹, ¹Aichi Cancer Center Hospital, Nagoya, JP, ²National Cancer Center Hospital, Tokyo, JP, ³The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JP, ⁴Osaka International Cancer Institute, Osaka, JP, ⁵Hyogo Cancer Center, Akashi, JP, ⁶Saitama Cancer Center, Saitama, JP, ⁷Kindai University Faculty of Medicine, Osaka-Sayama, JP, ⁸Shizuoka Cancer Center, Shizuoka, JP, ⁹Taiho Pharmaceutical, Co., Ltd., Tsukuba, JP, ¹⁰Merck & Co., Inc., Kenilworth, US, ¹¹National Cancer Center Hospital East, Kashiwa, JP
- 10:27 - 10:28 **1242P - Thromboembolic events and their association with the overall survival in a large European cohort with gastroesophageal cancer**
H. Puhr, M.A. Dieterle, F. Selimi, K. Oberreiter, C.C. Weirauch, L. Eischer, S. Eichinger, A.S. Berghoff, M. Preusser, A. Ilhan-Mutlu, Medical University of Vienna - Vienna General Hospital, Vienna, AT
- 10:28 - 10:29 **1243P - Influence of home nutritional therapy on body weight in patients with esophageal cancer after surgery: A prospective observational study**
L. Dai¹, K.-N. Chen², Y. Wu¹, J. Ma³, S. Guo⁴, H. Tian⁵, G. Xiao⁶, W. Liu⁷, M. He⁸, C. Chen⁹, X. Shi¹⁰, Z. Wang¹¹, J. Liu¹², W. Guo¹³, Y. Cui¹⁴, T. Dai¹⁵, X. Fu¹⁶, W. Jiao¹⁷, ¹Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Peking University School of Oncology, Beijing, CN, ²Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Peking University School of Oncology, Beijing, CN, ³3rd Affiliated Hospital of Harbin Medical University, Harbin, CN, ⁴Shanxi Provincial Cancer Hospital, Taiyuan, CN, ⁵Qilu Hospital of Shandong University, Jinan, CN, ⁶Hunan Cancer Hospital, Changsha, CN, ⁷the Second Xiangya Hospital of Central South University, Changsha, CN, ⁸Fourth Hospital of Hebei Medical University, Shijiazhuang, CN, ⁹Fujian Medical University Union Hospital, Fuzhou, CN, ¹⁰Anyang Cancer Hospital, Anyang, CN, ¹¹Shandong Provincial Hospital, Jinan, CN, ¹²Shanxi Province Cancer Hospital, Xian, CN, ¹³Army Medical Center of PLA, Chongqing, CN, ¹⁴the First Bethune Hospital of Jilin University, Changchun, CN, ¹⁵The Affiliated Hospital of Southwest Medical University, Luzhou, CN, ¹⁶Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, CN, ¹⁷The Affiliated Hospital of Qingdao University, Qingdao, CN
- 10:29 - 10:30 **1244P - Prognostic impact of myeloid subsets in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study)**
N. Boku¹, C. Kudo-Saito², H. Imazeki¹, H. Shoji¹, K. Tsugaru³, N. Takahashi⁴, T. Kawakami⁵, Y. Amanuma⁶, T. Wakatsuki⁷, N. Okano⁸, Y. Narita⁹, Y. Yamamoto¹⁰, R. Kizawa¹¹, K. Nagashima³, K. Aoki², K. Muro⁹, ¹National Cancer Center Hospital, Tokyo, JP, ²National Cancer Center Research Institute, Tokyo, JP, ³Keio University Hospital, Tokyo, JP, ⁴Saitama Cancer Center, Saitama, JP, ⁵Shizuoka Cancer Center, Shizuoka, JP,

⁶Chiba Cancer Center, Chiba, JP, ⁷Cancer Institute Hospital of JFCR, Tokyo, JP, ⁸Kyorin University of Faculty of Medicine, Tokyo, JP, ⁹Aichi Cancer Center Hospital, Nagoya, JP, ¹⁰University of Tsukuba Hospital, Tsukuba, JP, ¹¹Toranomon Hospital, Tokyo, JP

- 10:30 - 10:31 **1245P - Outcomes and tolerability of neoadjuvant chemoradiation in elderly patients with oesophageal cancer: An Irish cancer centre retrospective analysis**
R. McLaughlin¹, M. Almeraikhi², H. Alkaabi², F. Bligh², C. Cluxton¹, D. McMahon¹, O. Fitzpatrick¹, M. Conroy¹, B. Hennessy¹, B. O'Neill¹, O. Breathnach¹, J. Naidoo¹, W. Grogan¹, A. Murphy¹, P. Morris¹, ¹Beaumont Hospital, Dublin, IE, ²RCSI - Royal College of Surgeons in Ireland, Dublin, IE
- 10:31 - 10:32 **1246P - Multicenter phase Ib/II study of second-line varlitinib and paclitaxel in patients with EGFR/HER2 co-expressing advanced gastric cancer (K-MASTER-13)**
M. Jung¹, Y.H. Kim², H.C. Jeung³, D.Y. Zang⁴, W.K. Bae⁵, D.-H. Koo⁶, H. Kim⁷, H.S. Kim⁸, C.-K. Lee⁷, H.C. Chung⁹, S.Y. Rha⁹, ¹Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ²Korea University Anam Hospital, Seoul, KR, ³Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, ⁴Hallym University Medical Center Hallym University College of Medicine, Anyang, KR, ⁵Chonnam National University Hwasun Hospital, Hwasun, KR, ⁶Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, KR, ⁷Yonsei Cancer Center Yonsei University, Seoul, KR, ⁸Yonsei University College of Medicine, Seoul, KR, ⁹Yonsei University, Seoul, KR
- 10:32 - 10:33 **1247P - Apatinib plus toripalima (anti-PD1 therapy, JS001) for advanced GC/EGJC patients: Results from a pilot phase II study**
J.-E. Ying¹, Q. Wei¹, Q. Xu², J. Li¹, C. Luo¹, ¹Zhejiang Cancer Hospital, Hangzhou, CN, ²Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN
- 10:33 - 10:34 **1248P - Identification of Epstein-Barr virus (EBV)-associated gastric cancer at RNA-level by evaluating transcriptional status of seven EBV crucial genes**
J. Yuan¹, W. Chen¹, L. Wang¹, C. Cao¹, X. Song¹, J. Zhao², F. Gai², H. Dong², C. Zhu², H. Shi¹, ¹Chinese PLA General Hospital (301 Military Hospital), Beijing, CN, ²Amoy Diagnostics Co., Ltd., Xiamen, CN
- 10:34 - 10:35 **1249P - Older patients experience similar toxicity and survival outcomes to FLOT chemotherapy compared to younger patients**
A. Lewis, B.S. Hapuarachi, A. Khan, F. Britton, N. Billy Graham Mariam, K. Connors, V. Kounnis, R. Lee, J. Weaver, K. Kamposioras, R. Hubner, T. Waddell, W. Mansoor, The Christie NHS Foundation Trust, Manchester, GB
- 10:35 - 10:36 **1250P - Camrelizumab plus apatinib combined with POF in patients with untreated advanced gastric cancer (UAGC): A single-center, open-label, single-arm, phase II trial (SYLT-017)**
L. Su, S. Zhao, P. Lin, Y. Yin, R. Lin, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN

10:36 - 10:37

1251P - CHARIOT: A phase I dose escalation study combining ATR inhibitor Berzosertib with chemoradiotherapy in oesophageal cancer using time to event continual reassessment (TiTE-CRM) method: Results from A1 cohort (combination with palliative RT)

S. Mukherjee¹, S. Lord², R. Harman², D. McIntosh³, A. Ooms⁴, M. Parkes⁴, G. Radhakrishna⁵, P. Shaw⁶, M. Hawkins⁷, ¹Oxford University Hospital NHS Foundation Trust, Oxford, GB, ²University of Oxford, Oxford, GB, ³BWSCC - Beatson West of Scotland Cancer Centre, Glasgow, GB, ⁴University of Oxford - NDORMS, Oxford, GB, ⁵The Christie NHS Foundation Trust, Manchester, GB, ⁶Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Milton Keynes, GB, ⁷UCL - University College London, London, GB

10:37 - 10:38 **1252P - Update results of anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase 2/3 clinical trial**

Y.-F. Zhang, X.-B. Li, Y.-G. Hong, X.-M. Li, W.-M. Liang, Z.-X. Zheng, G.-Y. Yang, Y.-Y. Wen, H. Cao, W.-L. Wu, W.-Z. Su, Anyang Tumour Hospital, Anyang, CN

09:00 - 13:00 **Type: Poster session** **Poster Area, Hall 4**
Title: Poster session 15

09:00 - 09:01 **1050P - Association of ctDNA quantification with prognosis and early prediction of response to first-line osimertinib in NSCLC patients**

M. Denis¹, G. Herbreteau², S. Charpentier², A. Vallée², J. Cadranel³, C. Audigier Valette⁴, P. Tomasini⁵, P. Masson⁶, E. Pons-Tostivint⁷, R. Gervais⁸, N. Girard⁹, A. Cortot¹⁰, O. Molinier¹¹, I. Monnet¹², M. Marcq¹³, T. Urban¹⁴, D. Moro-Sibilot¹⁵, H. Lena¹⁶, C. Sagan², J. Bennouna¹⁷, ¹CHU du Nantes - Hôtel-Dieu, Nantes, FR, ²CHU de Nantes, Nantes, FR, ³Hopital Tenon AP-HP, Paris, Cedex, FR, ⁴Hopital Sainte Musse, Toulon, FR, ⁵Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Marseilles, FR, ⁶CH Cholet, Cholet, FR, ⁷CHU du Nantes - Hôtel-Dieu, Nantes, Cedex, FR, ⁸Centre Francois Baclesse, Caen, FR, ⁹Institut du Thorax Curie-Montsouris, Institut Curie, Paris, FR, ¹⁰CHU Lille - Centre Hospitalier Régional Universitaire de Lille, Lille, FR, ¹¹Centre Hospitalier Du Mans, Le Mans, FR, ¹²CH Intercommunal de Créteil, Creteil, FR, ¹³CHD Vendée, La Roche / Yon, FR, ¹⁴CHU Angers, Angers, FR, ¹⁵CHU Grenoble-Alpes, La Tronche, FR, ¹⁶Hop Pontchaillou, Rennes, FR, ¹⁷Hopital Foch, Suresnes, FR

09:01 - 09:02 **1051P - Radiotherapy (RT) and efficacy of immune checkpoint inhibitors (ICI), chemotherapy (CTx) and chemoimmunotherapy (CIT) in patients with non-small cell lung cancer (NSCLC)**

A. Meisel¹, M. Mark², A. Haider³, L. Holer⁴, S. Hayoz⁴, C. Gebhard¹, S. Bengs¹, V. Treyer¹, S. Rothschild⁵, M. Hochmair⁶, D. Gandara⁷, F. Cappuzzo⁸, M. Reck⁹, F. Stenner-Liewen⁵, R. Von Moos², ¹USZ - University Hospital Zürich, Zurich, CH, ²KSGR - Kantonsspital Graubünden, Chur, CH, ³Harvard Medical School, Massachusetts General Hospital, Boston, US, ⁴Swiss Group for Clinical Cancer Research (SAKK), Bern, CH, ⁵University Hospital Basel, Basel, CH, ⁶Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, AT, ⁷University of California Davis Comprehensive Cancer Center, Sacramento, US, ⁸IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT, ⁹LungenClinic Grosshandorf, Grosshandorf, DE

- 09:02 - 09:03 **1052P - Comprehensive molecular profiling of squamous non-small cell lung cancer by smoking status**
J. Reuss¹, N. Gandhi², P. Walker², B. Halmos³, C. Aggarwal⁴, J. Xiu², S. Patel⁵, A. Vanderwalde², S. Ramalingam⁶, S. Liu¹, ¹Lombardi Cancer Center Georgetown University, Washington, US, ²Caris Life Sciences, Phoenix, US, ³Montefiore Medical Center, New York City, US, ⁴University Of Pennsylvania, Philadelphia, US, ⁵UCSD Moores Cancer Center, La Jolla, US, ⁶Winship Cancer Institute of Emory University, Atlanta, US
- 09:03 - 09:04 **1053P - Early prediction of non-response to immunotherapy by a combined serum tumor marker model in non-small cell lung cancer patients**
M. Schuurbijs¹, F. Van Delft², H. Koffijberg², S. Burgers³, M. Ijzerman², H. Van Rossum³, M. Van Den Heuvel¹, ¹Radboud University Medical Center, Nijmegen, NL, ²University of Twente, Enschede, NL, ³NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 09:04 - 09:05 **1054P - Impact of intratumoral microbiome on immunotherapy treatment outcomes in patients with advanced non-small cell lung cancer**
A. Elkrief, A. Bowman, H. Rizvi, M. Hellmann, G. Riely, A. Schoenfeld, M. Ladanyi, C. Vanderbilt, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US
- 09:05 - 09:06 **1055P - The gene landscape of lung adenocarcinoma patients with progressive disease of the leptomeninges**
H. Yang¹, L. Wen², C. Zhou³, ¹Tongji University School of Medicine, Shanghai, CN, ²Guangdong Sanjiu 999 Brain Hospital, Guangzhou, CN, ³Shanghai Pulmonary Hospital, Shanghai, CN
- 09:06 - 09:07 **1056P - KRAS and LKB1 mutation conferring prognostic and predictive role on liquid biopsy in advanced NSCLC**
A. Bottiglieri¹, L. Provenzano², A. Spagnoletti³, L. Mazzeo³, M. Ganzinelli², G. Lo Russo³, R. Ferrara², C. Proto², A. De Toma³, M. Brambilla², M. Occhipinti², S. Manglaviti², T. Beninato³, M. Garassino⁴, J. Filosa⁵, G. Di Guida⁵, F.G.M. De Braud², G. Viscardi⁶, C.M. Della Corte⁵, A. Prelaj², ¹Università degli Studi di Milano, Milan, IT, ²Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ³Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁴University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, ⁵Università degli Studi della Campania "Luigi Vanvitelli", Naples, IT, ⁶Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT
- 09:07 - 09:08 **1057P - Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations**
R. Ferrara¹, G. Lo Russo¹, C.M. Ciniselli¹, S. Di Gregorio¹, G. Calareso², B. Bassani², C. Proto¹, A. Prelaj¹, A. De Toma¹, M. Occhipinti¹, M. Brambilla¹, S. Manglaviti¹, L. Mazzeo¹, T. Beninato¹, M. Ganzinelli¹, F.G.M. De Braud¹, M. Garassino³, M. Colombo², P. Verderio¹, S. Sangaletti², ¹Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ²Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, IT, ³University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US

- 09:08 - 09:09 **1058P - Non-smokers with squamous lung cancers have a high incidence of HHV infections, DDR gene alterations and good prognosis**
S. Lau¹, M. Makarem², M. Cabanero³, M.-S. Tsao², P. Bradbury², F. Shepherd², G. Liu², N. Leigh², A. Sacher², ¹Laura & Issac Perlmutter Cancer Center, NYU Langone Health, New York, US, ²UHN - University Health Network - Princess Margaret Cancer Centre, Toronto, CA, ³UHN - University Health Network, Toronto, CA
- 09:09 - 09:10 **1059P - KRAS G12 subtypes with co-mutated TP53, LRP1B, STK11, KEAP1 in lung cancer and their impact on TMB levels, PD-L1 expression and overall survival**
Y. Zhao¹, X. Wu¹, H. Tang¹, Q. Qi¹, C. Zhang¹, X. Liu², M. Huang³, ¹Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, CN, ²3D Medicines, Shanghai, CN, ³3D Medicines, Inc., Shanghai, CN
- 09:10 - 09:11 **1060P - Impact of baseline clinicopathologic and genomic features on outcomes to KRAS G12C inhibitors in patients with NSCLC**
G. Lamberti¹, A.J. Cooper², B. Ricciuti¹, J. Alessi¹, A.P. De Castro Barrichello¹, F. Pecci¹, V. Vaz¹, M. Nishino³, L. Sholl³, R. Heist², M. Awad¹, ¹Dana-Farber Cancer Institute, Boston, US, ²Massachusetts General Hospital Cancer Center, Boston, US, ³Brigham and Women's Hospital, Boston, US
- 09:11 - 09:12 **1061P - Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC**
G. Mazzaschi, L. Moron Dalla Tor, M. Balbi, G. Milanese, D. Tognazzi, B. Lorusso, F. Trentini, G. Di Rienzo, M. Verzè, M. Pluchino, R. Minari, L. Leo, L. Gnetti, P. Bordi, A. Leonetti, L. Ampollini, G. Roti, F. Quaini, N. Sverzellati, M. Tiseo, University Hospital of Parma, Parma, IT
- 09:12 - 09:13 **1062P - Predictive impact of inflammation scores in non-small cell lung cancer patients treated with immunotherapy rechallenge**
C. Plazy¹, A.C. Toffart², D. Moro-Sibilot², E. Gobbini³, ¹CHU Grenoble Alpes, La Tronche, FR, ²CHU Grenoble-Alpes, La Tronche, FR, ³CHU Grenoble-Alpes, Corenc, FR
- 09:13 - 09:14 **1063P - Comprehensive genomic profiling of leptomeningeal metastases on NSCLC patients through circulating tumor DNA in cerebrospinal fluid**
Y. Sen¹, H. Tang², F. Xie², Y. Zhang², S. Jia², Q. Wang³, ¹Henan Cancer Hospital, Zhengzhou, CN, ²Huidu (Shanghai) Medical Technology Co., Ltd., Shanghai, CN, ³Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN
- 09:14 - 09:15 **1064P - Genomic characterization of first line advanced or metastatic non-small cell lung cancer (aNSCLC) patients (pts) subgroups associated with good/bad prognosis**
M. Provencio Pulla¹, D. Perez Parente², B. Campos Balea³, D. Rodriguez Abreu⁴, H. Hasan⁵, S. Olson², N. Pal⁵, S. Wilkinson⁶, F. De Oro Pulido², P. Ruiz Gracia², M. Cobo Dols⁷, ¹Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda, Majadahonda, ES, ²Roche Spain, Madrid, ES, ³Hospital Universitario Lucus Augusti (HULA), Lugo, ES, ⁴Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, ES,

⁵Genentech - Building 40, South San Francisco, US, ⁶Roche Products Limited, Welwyn Garden City, GB, ⁷Hospital Regional Universitario Málaga Carlos Haya, Malaga, ES

- 09:15 - 09:16 **1065P - The impact of pre-treatment plasma sex hormones on the immune checkpoint inhibitors response in patients with metastatic non-small cell lung cancer**
Y. Zhang¹, L. Darville¹, S. Hogue¹, J. Hallanger Johnson¹, Y. Kim¹, J.E. Gray², L. Robinson², ¹H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ²H. Lee Moffitt Cancer Center University of South Florida, Tampa, US
- 09:16 - 09:17 **1066P - Tumor microenvironment (TME) of HRAS mutated non-small cell lung cancer (NSCLC)**
A. Trabolsi¹, E. Rodriguez¹, S. Kareff¹, J.A. Ocejo Gallegos², J. Yin³, P. Walker⁴, H. Mamdani⁵, J.J. Nieva⁶, H. Borghaei⁷, C. Nabhan³, M. Nagasaka⁸, S. Puri⁹, S. Liu¹⁰, B. Halmos¹¹, G. Lopes¹, ¹Sylvester Comprehensive Cancer Center - University of Miami, Miami, US, ²Um Miller School of Medicine Jackson Memorial Hospital - Internal Medicine Program, Miami, US, ³Caris Life Sciences - Arizona Office, Phoenix, US, ⁴Caris Life Sciences - Headquarters, Irving, US, ⁵Karmanos Cancer Institute, Detroit, US, ⁶USC - University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, US, ⁷Fox Chase Cancer Center - Main Campus, Philadelphia, US, ⁸UCI Health - University of California Irvine, Orange, US, ⁹Huntsman Cancer Institute, Utah, US, ¹⁰Lombardi Cancer Center Georgetown University, Washington, US, ¹¹Montefiore Medical Center, New York City, US
- 09:17 - 09:18 **1067P - Discovery of a new CD4⁺ T cell cluster that correlates PD-1 blockade efficacy**
H. Kagamu¹, S. Yamasaki¹, K. Horimoto¹, S. Kitano², O. Yamaguchi¹, A. Mouri¹, A. Shiono¹, Y. Miura¹, K. Hashimoto¹, H. Imai¹, K. Kaira¹, K. Kobayashi¹, ¹Saitama Medical University International Medical Center, Hidaka, JP, ²The Cancer Institute Hospital of JFCR, Koto-ku, JP
- 09:18 - 09:19 **1068P - Predicting response to pembrolizumab in non-small cell lung cancer using spatial analysis of biopsy images by deep learning**
E. Ofek¹, J. Bar¹, A. Zer², C. Mayer¹, C. Sade Zaltz³, L. Litzky⁴, C. Langer⁴, C. Davis⁴, C. Solomides⁵, I. Micaily⁵, J. Johnson⁵, R. Stapp⁶, Z.L. Quinn⁵, Z. Rachmiel⁷, A. Laniado⁷, M. Matalon⁷, E. Markovits⁷, O. Zelichov⁷, M. Feinmesser³, I. Barshack¹, ¹Chaim Sheba Medical Center, Ramat Gan, IL, ²Rambam Health Care Campus, Haifa, IL, ³Rabin Medical Center, Petah Tikva, IL, ⁴Hospital of the University of Pennsylvania, Philadelphia, US, ⁵Thomas Jefferson University Hospital, Philadelphia, US, ⁶H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ⁷Nuclei, Tel Aviv, IL
- 09:19 - 09:20 **1069P - An immune-based score for the prediction of clinical outcome in patients with metastatic non-small cell lung cancer treated with first-line immunotherapy**
A. Sbrana¹, S. Cappelli², I. Petrini³, A. Chella², L. Carrozzi¹, ¹University of Pisa, Pisa, IT, ²Azienda Ospedaliero-Universitaria Pisana, Pisa, IT, ³AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT

- 09:20 - 09:21 **1070P - Previous viral infections assessed by pan-virus phage immunoprecipitation sequencing (PhIP-Seq) predict response to immune checkpoint blockers (ICBs) in non-small cell lung cancer (NSCLC)**
F. Dall'Olio¹, M. Lerousseau², G. Roman³, F.-X. Danlos⁴, M. Aldea¹, N. Chaput-Gras¹, D. Planchard¹, F. Barlesi², T. Hulett³, A. Marabelle⁵, B. Besse⁵, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Gustave Roussy - Cancer Campus, Villejuif, FR, ³CDI Laboratories, Baltimore, US, ⁴Gustave Roussy - INSERM U1015, Villejuif, FR, ⁵Institut Gustave Roussy, Villejuif, FR
- 09:21 - 09:22 **1071P - Trustworthy artificial intelligence models using real-world and circulating genomics data for the prediction of immunotherapy efficacy in non-small cell lung cancer patients**
A. Prelaj¹, A. Bottiglieri¹, L. Provenzano¹, A. Spagnoletti², L. Mazzeo², V. Miskovic³, M. Ganzinelli¹, G. Lo Russo¹, R. Ferrara¹, C. Proto¹, A. De Toma², M. Brambilla¹, M. Occhipinti¹, S. Manglaviti¹, T. Beninato¹, A. Rametta¹, M. Garassino⁴, F.G.M. De Braud¹, F. Trovò³, A. Pedrocchi³, ¹Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ²Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ³Politecnico di Milano, Milan, IT, ⁴University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US
- 09:22 - 09:23 **1072P - Prognostic role of immune checkpoints mRNA expression in peripheral blood of non-small cell lung cancer patients treated with immune checkpoint inhibitors**
C. Papadaki¹, A. Monastirioti², K. Rounis³, D. Kalapanida⁴, G. Kousoulis¹, K. Michaelidou¹, E. Vorrias¹, M. Papadaki², D. Mavroudis⁵, S. Agelaki⁵, ¹University of Crete - School of Medicine, Heraklion, GR, ²UOC - University of Crete, Heraklion, GR, ³Karolinska Institutet - Cancer Center Karolinska (CCK), Solna, SE, ⁴Private Address - Mrs. Despoina Kalapanida, Crete, GR, ⁵University General Hospital of Heraklion, Heraklion, GR
- 09:23 - 09:24 **1073P - Relationship between basal metabolism, nivolumab clearance and survival in metastatic non-small cell lung cancer patients of the ELY study**
A. Puszkiel¹, P. Boudou Rouquette², J. Arrondeau², M. Wislez³, E. Fabre-Guillevin⁴, G. Bianconi², X. Declèves¹, A. Jouinot², S. De Percin⁵, J. Alexandre⁶, F. Goldwasser⁷, B. Blanchet², ¹Université de Paris, Paris, FR, ²Hopital Cochin AP-HP, Paris, FR, ³Hopital Tenon AP-HP, Paris, Cedex, FR, ⁴HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, ⁵Assistance Publique - Hopitaux De Paris, Paris, FR, ⁶Cochin-Port Royal Hospital, Paris Cancer Institute CARPEM, AP-HP Centre - Université de Paris Cité, Paris, FR, ⁷Hopital Cochin - Port-Royal AP-HP, Paris, FR
- 09:24 - 09:25 **1074P - Peripheral low-density neutrophils identify a subset of NSCLC patients with high PD-L1 tumor expression that can benefit from chemo-immunotherapy**
H. Arasanz¹, A.I. Bocanegra Gondan², L. Teixeira¹, M. Garnica², I. Morilla Ruiz¹, L. Chocarro², M. Martínez-Aguillo¹, K. Ausin², E. Blanco², M. Zuazo², G. Fernandez-Hinojal³, M. Echaide², L. Fernández-Rubio², S. Pineiro-Hermida², P. Ramos², J. Fernández-Irigoyen², G. Kochan², R. Vera¹, D. Escors², ¹Hospital Universitario de Navarra, Pamplona, ES, ²Navarrabiomed, Pamplona, ES, ³Hospital Clinico Universitario San Carlos, Madrid, ES

- 09:25 - 09:26 **1075P - Tobacco smoking related mutational signatures (MS) in classifying smoking and non-smoking associated metastatic non-small cell lung cancer (mNSCLC)**
S. Ernst¹, J. Mankor¹, J. Van Riet², J. Von Der Thüsen², H.J. Dubbink², J. Aerts¹, J. De Langen³, E. Smit³, K. Monkhorst³, A.-M. Dingemans¹, ¹Erasmus MC - University Medical Center, Rotterdam, NL, ²Erasmus MC, Rotterdam, NL, ³NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 09:26 - 09:27 **1076P - Cancer cachexia associated with gut microbiota and clinical outcomes of patients with non-small cell lung cancer amenable to immunotherapy**
T. Hakoza¹, A. Nolin-Lapalme², M. Kogawa³, Y. Okuma⁴, S. Nakamura¹, T. Tamura¹, Y. Hosomi¹, H. Takeyama³, C. Richard², M. Hosokawa³, B. Routy², ¹Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, JP, ²CRCHUM - Centre de recherche du CHUM, Montreal, CA, ³Waseda University, Shinjuku-ku, JP, ⁴NCCH - National Cancer Center Hospital, Chuo-ku, JP
- 09:27 - 09:28 **1077P - An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of the advanced EGFR mutation positive non-small cell lung cancer**
Y. Qi¹, X. Xia¹, S. Wei¹, L. Shao¹, J. Tian², ¹Gansu Provincial Cancer Hospital, Lanzhou, CN, ²Lanzhou University, Lanzhou, CN
- 09:28 - 09:29 **1078P - Correlation between T cell immunity and EGFR-TKI treatment in patients harboring EGFR driver mutation**
A. Mouri, K. Kaira, O. Yamaguchi, A. Shiono, Y. Miura, K. Hashimoto, F. Nishihara, H. Imai, K. Kobayashi, H. Kagamu, Saitama Medical University International Medical Center, Hidaka city, JP
- 09:29 - 09:30 **1079P - Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with novel actionable oncogenic driver alterations**
T. Beninato¹, M. Brambilla¹, C.C. Pircher¹, L. Mazzeo¹, A. Rametta¹, S. Manglaviti¹, A. De Toma¹, G. Galli¹, A. Prelaj¹, R. Ferrara¹, C. Proto¹, G. Lo Russo¹, M. Ganzinelli¹, R. Di Mauro¹, A. Di Nucci¹, M. Garassino², P. Marchetti³, F.G.M. De Braud¹, M. Occhipinti¹, ¹Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ²University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, ³IRCCS Istituto Dermatologico dell'Immacolata IDI, Rome, IT
- 09:30 - 09:31 **1080P - Immune checkpoint blockade therapy affects circulating FLIP-expressing monocytic myeloid-derived suppressor cells (M-MDSC) in non-progressor non-small cell lung cancer patients**
L. Belluomini¹, C. Frusteri², A. Adamo², S. Pilotto¹, G. Sartori³, J. Insolda⁴, M. Sposito¹, S. Caligola¹, L. Giacobazzi², O. Poffe², D. Rizzini², A. Vella², C. Carbone⁵, G. Piro⁵, F. De Sanctis², S. Sartoris², S. Canè², M. Milella⁶, V. Bronte², S. Ugel², ¹University of Verona, Verona, IT, ²university of Verona, Verona, IT, ³Ospedale San Bortolo - AULSS8 Berica - Distretto EST, Vicenza, IT, ⁴AOU Integrata di Verona - Ospedale Borgo Trento, Verona, IT, ⁵Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, IT, ⁶University of Verona - Faculty of Medicine, Verona, IT
- 09:31 - 09:32

1081P - DNA damage response and repair (DDR) gene mutations as an alternative mechanism to generate high TMB in never smoker NSCLC patients

M. Filetti¹, M. Occhipinti², A. Cirillo³, F. Scirocchi⁴, A. Ugolini⁴, M. Petti⁵, R. Giusti⁶, P. Lombardi¹, A. Botticelli³, G. Lo Russo², F.G.M. De Braud², P. Marchetti⁷, M. Nuti⁴, E. Ferretti⁴, A. Rughetti⁴, L. Farina⁵, ¹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ²Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ³Sapienza University of Rome, Rome, IT, ⁴Sapienza Università di Roma - Dip. di Medicina Sperimentale, Rome, IT, ⁵Sapienza - Università di Roma, Rome, IT, ⁶AOU Sant'Andrea, Rome, IT, ⁷IRCCS Istituto Dermatologico dell'Immacolata IDI, Rome, IT

09:32 - 09:33

1082P - Improved response prediction to immune checkpoint inhibitors by combining TMB and WGS-driven genomic features in NSCLC

P. Nawrocka-Muszyńska¹, K. Pacewicz², M. Mędzin², P. Sztromwasser², M. Dabrowski², D. Sielski², W. Majer-Burman², R. Maltkowski³, P. Kasprzak³, S. Szymański⁴, M. Piernik², A. Wozna⁵, P. Zawadzki⁵, ¹Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznań, PL, ²MNM Diagnostics Sp. z o.o., Poznań, PL, ³Lower Silesian Oncology, Pulmonology and Hematology Center, Wrocław, PL, ⁴Pomeranian Medical University in Szczecin, Szczecin, PL, ⁵Adam Mickiewicz University, Poznań, PL

09:33 - 09:34

1083P - The analysis molecular characteristics, PD-L1, TMB and MSI in Chinese NF1-mutated NSCLC

J. Liu¹, Y. Zhao², D. Guo², S. Chen², G. Lu², W. Deng², F. Bu³, R. Ding³, ¹Affiliated Hospital of Nantong University, Nantong, CN, ²Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, CN, ³Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, CN

09:34 - 09:35

1084P - Predicting KRAS G12C subtype from non-small cell lung cancer H&E slides using deep learning

I. Soubeyran¹, R. Dubois², M. Jacquemin¹, K. Courtet¹, Y. Laizet¹, C. Lucchesi¹, B. Allard³, A. Rousset³, A. Jaeger², J. Moreira², E. Khalifa¹, B. Bonhomme¹, A. Italiano¹, ¹Institute Bergonié, Bordeaux, FR, ²OWKIN France, Paris, FR, ³Amgen France, BOULOGNE BILLANCOURT, FR

09:35 - 09:36

1085P - Evaluation of blood tumor mutation burden for efficacy of second-line atezolizumab treatment in non-small cell lung cancer: BUDDY

C.-K. Park¹, H.R. Jun², H.-J. Oh³, J.-Y. Lee², H. Cho⁴, Y.-C. Kim³, J.E. Lee⁵, S.H. Yoon⁶, C.M. Choi², J.C. Lee⁷, S.Y. Lee⁸, S.Y. Lee⁹, S.-M. Chun², I.-J. Oh⁴, ¹Chonnam National University Medical School and Hwasun Hospital, Hwasun, KR, ²Asan Medical Center - University of Ulsan, Seoul, KR, ³Chonnam National University Medical School & Chonnam National University Hwasun Hospital, Hwasun, KR, ⁴Chonnam National University Hwasun Hospital, Hwasun, KR, ⁵Chungnam National University, Daejeon, KR, ⁶Pusan National University Yangsan Hospital, Yangsan, KR, ⁷Asan Medical Center - Asan Institute for Life Science, Seoul, KR, ⁸Korea University Guro Hospital, Seoul, KR, ⁹KNUH-Kyungpook National University Medical Center Biobank - Chilgok Hospital, Daegu, KR

09:36 - 09:37

1086P - Advanced lung cancer inflammation index (ALI) association with increased risk of immune-related adverse events (irAEs) among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy

V. Bhat¹, M. Millward², E. Gray³, A. Abed³, ¹University of Western Australia, Perth, AU, ²University of Western Australia, Consultant Medical Oncologist, Linear Clinical Research, Adjunct Professor, School of Medical and Health Sciences, Edith Cowan University, Perth, AU, ³Edith Cowan University, Perth, AU

- 09:37 - 09:38 **1087P - Predictive value of Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D) in patients (pts) with EGFR exon 20 insertion (ex20ins)-positive metastatic non-small cell lung cancer (mNSCLC) receiving mobocertinib therapy**
P. Hofman¹, Z. Su², X. Tong², V. Bunn², S. Jin², S. Vincent², ¹University of Nice Sophia Antipolis, Nice, FR, ²Takeda Development Center Americas, Inc., Lexington, US
- 09:38 - 09:39 **1089P - Hepcidin expression as a predictive biomarker for anti-PD1/PDL1 antibody monotherapy for advanced non-small cell lung cancer**
M. Yamamoto¹, S. Kubo¹, N. Hirama¹, S. Teranishi¹, K. Tashiro¹, K. Seki¹, C. Maeda¹, S. Hiro¹, Y. Kajita¹, C. Sugimoto¹, W. Segawa¹, H. Nagayama¹, S. Nagaoka¹, M. Kudo¹, T. Kaneko², ¹Yokohama City University Medical Center, Yokohama, JP, ²Yokohama City University Hospital, Yokohama, JP
- 09:39 - 09:40 **1090P - HER2 copy number variation in non-small cell lung cancer (NSCLC)**
M. Tagliamento¹, E. Auclin², A. Valent¹, R. Ferrara³, S. Cotteret¹, E. Rouleau¹, C. Caramella⁴, M. Riudavets Melia¹, A. Gazzah¹, J. Adam¹, C. Jovelet¹, A. Bayle¹, L. Lacroix¹, N. Auger¹, F. Barlesi¹, D. Planchard¹, B. Besse¹, L. Mezquita⁵, ¹Gustave Roussy, Villejuif, FR, ²Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, ³Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁴Hôpital Marie Lannelongue, Le Plessis-Robinson, FR, ⁵Laboratory of Translational Genomic and Targeted Therapies in Solid Tumors, IDIBAPS, Hospital Clínic, Barcelona, ES
- 09:40 - 09:41 **1091P - Predictive and prognostic value of Patras Immunotherapy Score (PIOS) in patients with advanced NSCLC treated with immunotherapy/chemotherapy combination**
F.-I. Dimitrakopoulos¹, P. Christopoulos², M. Elshiaty², L. Daniello², I. Pyrousis³, A. Kottorou¹, T. Makatsoris¹, C. Kalofonos⁴, A. Koutras⁴, ¹University Hospital Patras, Patras, GR, ²Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, DE, ³University of Patras, Patras, GR, ⁴University Hospital Patras, Rion, Achaia, GR
- 09:41 - 09:42 **1092P - Clinical potential of circulating tumor DNA (ctDNA)-based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response to first-line (1L) chemoimmunotherapy in advanced squamous non-small cell lung cancer (sqNSCLC)**
F. Ciardiello¹, Z. Feng², N. Smith³, Z. Andric⁴, S. Shell⁵, A. Yablonovitch⁵, G. Guezel³, J. Scheuenpflug³, ¹The University of Campania Luigi Vanvitelli, Napoli, IT, ²EMD Serono Research & Development Institute Inc., (an affiliate of Merck KGaA), Billerica, US, ³Merck Healthcare KGaA, Darmstadt, DE, ⁴Clinical Hospital Center Bezanijska Kosa, Belgrade, RS, ⁵Guardant Health, Redwood City, US
- 09:42 - 09:43 **1093P - RET rearrangements detection by FISH in lung cancer, literature review and comparison with results from a French centre**

A. Mc Leer¹, J. Mondet¹, A. Mercier¹, M. Mersch¹, D. Benito², ¹CHU Grenoble Alpes - Site Nord (La Tronche), La Tronche, FR, ²Eli Lilly S.A - Dubai, Dubai, AE

09:43 - 09:44

1094P - The clinical potential of circulating-free DNA (cfDNA) for real-time longitudinally monitoring clinical outcomes in a real-world first-line non-small cell lung cancer (NSCLC) prospective study

V. Gristina¹, N. Barraco¹, A. Galvano¹, M. La Mantia¹, S. Cutaia¹, F. Iacono¹, C. Lisanti¹, S. Inguglia¹, D. Sardo¹, A. Perez¹, S. Cusenza¹, L. Castellana¹, T.D. Bazan Russo¹, S. Vieni¹, F. Fulfaro¹, L. Incorvaia¹, G. Badalamenti¹, V. Bazan², A. Russo¹, ¹University of Palermo, palermo, IT, ²University of Palermo, Palermo, IT

09:44 - 09:45

1095P - Concomitant genetic alterations predicted response to alectinib in patients with ALK-rearranged non-small cell lung cancer: A real word study in China

X. Chen¹, X. Yu², J. Huang³, J. Lai⁴, L. Ding⁵, L. Sheng⁴, S. Ma⁶, ¹Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, CN, ²Cancer Hospital Affiliated to the University of Chinese Academy of Sciences, Hangzhou, CN, ³Hangzhou Cancer Hospital, Hangzhou, CN, ⁴Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Hangzhou, CN, ⁵The Second Affiliated Hospital of Zhejiang Medical University School, Hangzhou, CN, ⁶Hangzhou Cancer Hospital, Cancer Center, Zhejiang University, Hangzhou, CN

09:45 - 09:46

1096P - Identifying predictive biomarkers for long term response on immunotherapy in non-small cell lung cancer (NSCLC)

L. Decoster¹, S. Nazari², K. De Ridder², P. Giron¹, K. Vekens¹, C. Goyvaerts², ¹UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE, ²Vrije Universiteit Brussel - Faculty of Medicine & Pharmacy, Brussels, BE

09:46 - 09:47

1097P - Impact of tumor and liquid rebiopsy in metastatic non-small cell lung cancer with EGFR/ALK/ROS oncogenic drivers, progressing after optimal target therapy

A. Bronstein¹, R. Gervais², I. Monnet³, C. Ricordel⁴, L. Bigay-Game⁵, M. Geier⁶, C. Decroisette⁷, C. Daniel⁸, F. Guisier⁹, A. Swalduz¹⁰, A.C. Toffart¹¹, H. Doubre¹², J.M. Pelsoni¹³, D. Arpin¹⁴, H. Morel¹⁵, R. Veillon¹⁶, B. Clarisse¹⁷, C. Chouaid¹⁸, L. Greillier¹⁹, O. Bylicki²⁰, ¹Hopital d'instruction des armées Saint ANNE, Toulon, FR, ²Comprehensive Cancer Centre François Baclesse, Caen, FR, ³CH Intercommunal de Créteil, Creteil, FR, ⁴CHU Rennes, Rennes, FR, ⁵CHU Toulouse-Hôpital Larrey, TOULOUSE, FR, ⁶CHU Brest, Brest, FR, ⁷CH Annecy-Genevois, Metz-Tessy, FR, ⁸Thorax Institute Curie Montsouris, Paris, FR, ⁹CHU Rouen, Rouen, FR, ¹⁰Comprehensive Cancer Centre Léon Bérard, Lyon, FR, ¹¹CHU Grenoble, La Tronche, FR, ¹²Hopital Foch, Suresnes, FR, ¹³Maison de Santé Protestant de Bordeaux-Bagatelle, Villenave-d'Ornon, FR, ¹⁴Hôpital Nord-Ouest, Gleizé, FR, ¹⁵CHR Orléans, Orleans, FR, ¹⁶Bordeaux University Hospital, Pessac, FR, ¹⁷Centre Francois Baclesse, Caen, Cedex, FR, ¹⁸CH Intercommunal de Créteil, Créteil, FR, ¹⁹Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ²⁰Hopital d'instruction des armées Sainte-Anne, Toulon, FR

09:47 - 09:48

1098P - Predictive factors of efficacy to pembrolizumab in advanced NSCLC patients with high PD-L1 expression.

A. Piedra¹, A. Barba Joaquín¹, J. Mosquera Martinez², M. Fernandez Bruno², P. Cordeiro González², I.G. Sullivan¹, M. Riudavets Melia¹, M. Aguado Sorolla¹, P. Gallardo Melo¹, B. Martin Cullell¹, J. Gavira¹, J. Tapia¹, A. Romano¹, F. Bosma¹, S. Sanchez Del Rio¹, J. Sanz Beltran¹, M. Molina Pérez¹, J. Serra López¹, M.R. Garcia Campelo³, M. Majem Tarruella¹, ¹Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ²CHUAC - Complexo Hospitalario Universitario A Coruña, A Coruña, ES, ³Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES

09:48 - 09:49 **1099P - Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients**

F. Parisi¹, G. De Luca¹, G. Rossi¹, S. Coco¹, C. Dellepiane¹, E. Bennicelli², L. Zinoli¹, L. Zullo¹, A. Alama¹, M. Mosconi¹, M. Mora¹, A. Ballestrero³, F. Montecucco⁴, S. Marconi¹, P. Pronzato¹, L. Del Mastro⁵, P. Nozza¹, A. Bellodi¹, M. Dono¹, C. Genova³, ¹IRCCS Ospedale Policlinico San Martino, Genova, IT, ²Ospedale Policlinico San Martino, Genova, IT, ³Università degli Studi di Genova e Ospedale Policlinico San Martino IRCCS - DiMI, Genova, IT, ⁴Department of Internal Medicine, Università degli Studi di Genova, Genova, IT, ⁵Università degli Studi di Genova, Genova, IT

09:49 - 09:50 **1100P - Association of clinical and molecular factors with immune checkpoint inhibitors efficacy in advanced non-small cell lung cancer: A systematic review and meta-analysis**

F. Li, Z. Lv, Y. Mao, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN

09:50 - 09:51 **1101P - Use of genomic sequencing for the determination of genomic alterations and new therapeutic opportunities in Spanish lung cancer (LC) patients (pts)**

M.R. Garcia Campelo¹, E. Arriola², D. Isla³, R. Bernabe Caro⁴, D. Perez Parente⁵, B. Moll⁵, J. Lavara Sanz⁵, S. Olson⁵, J. García González⁶, ¹Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES, ²Hospital del Mar - Parc de Salut Mar, Barcelona, ES, ³Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, ⁴Hospital Universitario Virgen del Rocio, Seville, ES, ⁵Roche Farma Spain, Madrid, ES, ⁶CHUS - Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES

09:51 - 09:52 **1102P - Genomic alterations correlated with the expression of PD-L1 based on the next-generation sequencing in Chinese non-small cell lung cancer**

X. Li¹, R. Feng², C. Xia², S. Ding², P. Luo², ¹Tianjin First Central Hospital, Tianjin, CN, ²Zhejiang Shaoxing Topgen Biomedical Technology Co., Ltd., Shanghai, CN

09:52 - 09:53 **1103P - Drug-related pneumonitis induced by osimertinib as first-line treatment for EGFR-positive non-small cell lung cancer: A real-world setting**

Y. Sato¹, H. Sumikawa², R. Shibaki³, T. Morimoto⁴, Y. Sakata⁵, Y. Oya⁶, M. Tamiya⁷, H. Suzuki⁸, H. Matsumoto⁹, T. Kijima⁴, K. Hashimoto¹⁰, H. Kobe¹¹, A. Hino¹², M. Inaba¹³, Y. Tsukita¹⁴, H. Ikeda¹⁵, D. Arai¹⁶, H. Maruyama¹⁷, S. Sakata¹⁸, D. Fujimoto³, ¹Kobe City Medical Center General Hospital, Kobe, JP, ²National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, JP, ³Wakayama Medical University, Wakayama, JP, ⁴Hyogo College of Medicine, Nishinomiya, JP, ⁵Saiseikai Kumamoto Hospital, Kumamoto, JP,

⁶Aichi Cancer Center Hospital, Nagoya, JP, ⁷Osaka International Cancer Institute, Osaka, JP, ⁸Osaka Prefectural Habikino Hospital, Habikino, JP, ⁹Hyogo Prefectural Amagasaki Hospital, Amagasaki, JP, ¹⁰National Hospital Organization Toneyama Hospital, Toyonaka, JP, ¹¹Kurashiki Central Hospital, Kurashiki, JP, ¹²Chiba University, School of Medicine, Chiba, JP, ¹³Kumamoto Chuo Hospital, Kumamoto, JP, ¹⁴Tohoku University, Sendai, JP, ¹⁵Kimitsu Chuo Hospital, Kisarazu, JP, ¹⁶Saiseikai Utsunomiya Hospital, Utsunomiya, JP, ¹⁷Kumamoto Rosai Hospital, Yatsushiro, JP, ¹⁸Kumamoto University, Kumamoto, JP

09:53 - 09:54

1104P - Health-related quality of life (HRQOL) in patients with ALK⁺ non-small cell lung cancer (NSCLC) in the phase III CROWN study

G. Liu¹, L. Iadeluca², A. Reisman², F. Blackhall³, J. Mazieres⁴, ¹Princess Margaret Cancer Centre, Toronto, CA, ²Pfizer Inc., New York, US, ³University of Manchester, Manchester, GB, ⁴Toulouse University Hospital, Toulouse, FR

09:54 - 09:55

1105P - Outcomes of real-world (RW) patients (pts) with advanced NSCLC (aNSCLC) and high programmed cell death-ligand 1 (PD-L1) expression receiving first line (1L) immune checkpoint inhibitor (ICI) therapy

M. Hsu¹, W. Ge², N. Wu², R. Quek², J. Liu³, J.J. Jalbert², P. Rietschel², J. Feliciano⁴, J. Harnett², ¹University Hospitals, Case Comprehensive Cancer Center, Cleveland, US, ²Regeneron Pharmaceuticals, Inc., Tarrytown, US, ³Genesis Research, Hoboken, US, ⁴Johns Hopkins Hospital, Baltimore, US

09:55 - 09:56

1106P - Capmatinib for METex14 non-small cell lung cancer patients: Results of the real-world study IFCT-2104 CapmATU

M. Ferreira¹, L. Greillier², A. Swalduz³, A.C. Toffart⁴, J. Raimbourg⁵, V. Gounant⁶, S. Couraud⁷, G. De Chabot⁸, S. Friard⁹, J. Hureauux¹⁰, L. Odier¹¹, M. Wislez¹², P. Missy¹³, F. Morin¹³, V. Westeel¹⁴, A. Cortot¹⁵, ¹CHRU Hopitaux de Tours - Hopital Bretonneau, Tours, cedex, FR, ²Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ³Centre Léon Bérard, Lyon, FR, ⁴CHU Grenoble-Alpes - Le site nord à La Tronche - Hopital Michallon, La Tronche, FR, ⁵ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁶Hopital Bichat Claude Bernard, Paris, FR, ⁷Lyon Sud Hospital Center - HCL, Pierre-Bénite, FR, ⁸Centre d'Oncologie Saint-Yves, Vannes, FR, ⁹Hopital Foch, Suresnes, FR, ¹⁰CHU Angers, Angers, FR, ¹¹Hopital Nord Ouest, Gleize, FR, ¹²Hopital Tenon AP-HP, Paris, Cedex, FR, ¹³French Cooperative Thoracic Intergroup, Paris, FR, ¹⁴CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, ¹⁵CHU Lille - Centre Hospitalier Régional Universitaire de Lille, Lille, FR

09:56 - 09:57

1107P - BRAF mutations and fusions in a real-world cohort of NSCLC patients

J. Niu¹, E. Mauer², A. Barrett², A. Ashok², ¹Banner MD Anderson Cancer Center - Main Campus, Gilbert, US, ²Tempus Labs, Inc., Chicago, US

09:57 - 09:58

1108P - Outcomes when stage IV non-small cell lung cancer (NSCLC-4) patients (pts) harboring oncogenic drivers (OD) are treated initially without tyrosine kinase inhibitors (TKI)

R. Choksi¹, R. Smith², M. Johnson³, L. Gordan⁴, M. Xue², P. Varughese², N. Dorrow², B. Wang², V. Vaidya⁵, A. Vasudevan², M. Gart², H. Gierman², J. Scott², ¹UPMC Hillman

Cancer Center, Pittsburgh, US, ²Integra Connect, West Palm Beach, US, ³Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ⁴Florida Cancer Specialists, Fort Myers, US, ⁵The University of Toledo - Health Science Campus, Toledo, US

- 09:58 - 09:59 **1109P - Amivantamab vs real-world (RW) therapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC) epidermal growth factor receptor (EGFR) exon-20 insertion mutation (E20i)**
T.M. Kim¹, N. Girard², G. Low Massin³, J. Zhou⁴, D.Y. Yu³, Y. Yang⁴, M. Murota⁵, C. Lim⁶, N. Kleinman⁷, B.C. Cho⁸, ¹Seoul National University Hospital, Seoul, KR, ²Institut Curie, Paris, FR, ³Janssen Asia Pacific, Singapore, SG, ⁴Janssen China, Shanghai, CN, ⁵Janssen Research & Development, Tokyo, JP, ⁶IQVIA Solutions Asia Pte Ltd, Singapore, SG, ⁷IQVIA Hong Kong, Kwai Fong, HK, ⁸Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, KR
- 09:59 - 10:00 **1110P - Clinical outcomes for EGFR/HER2 exon 20 insertion-mutated NSCLC**
K. Li, I. Bosdet, S. Yip, C. Ho, J. Laskin, B. Melosky, Y. Wang, S. Sun, BC Cancer Agency - Vancouver, Vancouver, CA
- 10:00 - 10:01 **1111P - Real-world treatment duration in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (EGFRex20ins) mutations receiving mobocertinib through the global Expanded Access Program (EAP)**
V. Lee¹, M. Lin², E. Curran², Y. Yin², E. Churchill², S. Allen², J. Abovich², N. Leigh³, ¹The University of Hong Kong - Li Ka Shing Faculty of Medicine, Hong Kong, HK, ²Takeda Development Center Americas, Inc., Lexington, US, ³Princess Margaret Cancer Centre, Toronto, CA
- 10:01 - 10:02 **1112P - Real-world treatment (tx) patterns and outcomes based on PD-L1 status in tx-naïve patients (pts) with METex14 advanced non-small cell lung cancer (aNSCLC)**
N. Leigh¹, M. Hampe², W.-H. Wu³, J. Kim³, V. Pretre⁴, F. Ye⁴, ¹Princess Margaret Cancer Center, Toronto, CA, ²Novartis Pharmaceuticals Canada Inc., Dorval, CA, ³Genesis Research, Hoboken, US, ⁴Novartis Pharmaceuticals Corporation, East Hanover, US
- 10:02 - 10:03 **1113P - Real-world multicentre cohort of 1L pembrolizumab alone or in combination with platinum-based chemotherapy in NSCLC PD-L1 ≥ 50%**
E. Pons-Tostivint¹, P. Hulo², V. Guardiolle³, L. Bodot⁴, A. Rabeau⁴, M. Porte⁵, S. Huret⁵, P. Demontrond⁶, H. Curcio⁶, A. Boudoussier⁷, R. Veillon⁷, M. Mayenga⁸, C. Dumenil⁹, P.-A. Gourraud³, J. Mazieres⁴, J. Bennouna⁸, ¹CHU du Nantes - Nantes Université - Hôpital Laennec, Nantes, Cedex, FR, ²Clinique Mutualiste de l'Estuaire, Saint Nazaire, FR, ³Nantes University, Centre Hospitalier Universitaire Nantes, Institute of Health and Medical Research, Nantes, Cedex, FR, ⁴Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR, ⁵institut de cancérologie de l'ouest, saint herblain, FR, ⁶Centre Francois Baclesse, Caen, FR, ⁷Bordeaux University Hospital, Pessac, FR, ⁸Hopital Foch, Suresnes, FR, ⁹Ambroise paré Hospital APHP, boulogne, FR
- 10:03 - 10:04 **1114P - Long-term outcome in Danish real-life patients with advanced non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors**
B. Bjornhart¹, M. Mouritzen², C. Kristiansen³, K. Holmskov⁴, K. Wedervang⁵, T.

Jorgensen⁴, J. Herrstedt⁶, M. Pohl⁷, T. Schytte⁴, ¹Faculty of Health Sciences, University of Southern Denmark, Odense, DK, ²Aalborg University Hospital, Clinical Cancer Research Center, Aalborg University, Aalborg, DK, ³Vejle Hospital, University Hospital of Southern Denmark, Vejle, DK, ⁴OUH - Odense University Hospital, Odense, DK, ⁵Sonderborg Sygehus, Sonderborg, DK, ⁶ZUH - Zealand University Hospital Roskilde - Region Sjælland, Roskilde, DK, ⁷Rigshospitalet, Copenhagen, DK

10:04 - 10:05

1115P - Amivantamab vs real-world (RW) therapies for advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutation (E20i) in Japan

M. Okahisa¹, H. Udagawa¹, S. Matsumoto¹, T. Kato², H. Yokouchi³, N. Furuya⁴, R. Kanemaru⁵, R. Toyozawa⁶, A. Nishiyama⁷, K. Ohashi⁸, S. Miyamoto⁹, K. Nishino¹⁰, H. Oi¹, G. Low Massin¹¹, J. Zhuo¹², D.Y. Yu¹¹, Y. Yang¹², C. Lim¹³, N. Kleinman¹⁴, K. Goto¹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Kanagawa Cancer Center, Yokohama, JP, ³Hokkaido Cancer Center, Sapporo, JP, ⁴St.Marianna University School of Medicine, Kawasaki, JP, ⁵Juntendo University Hospital, Bunkyo-ku, JP, ⁶National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, ⁷Kanazawa University Hospital, Kanazawa, JP, ⁸Okayama University Hospital, Okayama, JP, ⁹Japanese Red Cross Medical Center, Tokyo, JP, ¹⁰OICI - Osaka International Cancer Institute, Osaka, JP, ¹¹Janssen Asia Pacific, Singapore, SG, ¹²Janssen China, Shanghai, CN, ¹³IQVIA Solutions Asia Pte Ltd, Singapore, SG, ¹⁴IQVIA Hong Kong, Kwai Fong, HK

10:05 - 10:06

1116P - United Kingdom real-world experience of sotorasib in KRAS G12C mutant non-small cell lung cancer: A British thoracic oncology group review

M. Julve¹, O. Kennedy², C. Lindsay³, R. Walters-Davies⁴, M.R. Button⁵, N. Steele⁶, A. Mcgeogh⁷, A. Georgiou⁸, B. Goranov⁹, D. Farrugia¹⁰, L. Gorf¹¹, M. Remer¹², R. Shah¹³, S. Baijal¹⁴, S. Gennatas⁸, T. Geldart¹⁵, E. Daniels¹⁰, L. Watts¹³, A. Greystoke¹⁶, T. Newsom-Davis¹, ¹Chelsea and Westminster Hospital - NHS Trust, London, GB, ²Institute of Health and Society - Newcastle University, Newcastle-upon-Tyne, GB, ³Christie NHS Foundation Trust, Manchester, GB, ⁴Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff, GB, ⁵Velindre Cancer Centre, Cardiff, GB, ⁶BWSCC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, ⁷Hinchingbrooke Hospital, Peterborough, GB, ⁸Guy's and St. Thomas' Hospital NHS Trust, London, GB, ⁹Derriford Hospital Plymouth Hospitals NHS Trust, Plymouth, GB, ¹⁰Gloucestershire Oncology Centre - Cheltenham General Hospital - Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, GB, ¹¹Poole hospital NHS Foundation Trust, Poole, GB, ¹²Southampton General Hospital, Southampton, GB, ¹³Maidstone Hospital, Maidstone, GB, ¹⁴Heartlands Hospital - University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB, ¹⁵Royal Bournemouth Hospital, Bournemouth, GB, ¹⁶The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB

10:06 - 10:07

1117P - Amivantamab compared with European, real-world (RW) standard of care (SoC) in adults with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), after failure of platinum-based therapy

N. Girard¹, S. Popat², N. Rahhali³, B. Rodrigues⁴, C. Schioppa⁵, C. Pick-Lauer⁶, A. Adamczyk⁷, J. Sermon⁸, J. Diels⁸, J. Penton⁹, M. Thomas¹⁰, ¹Institut Curie, Paris, FR, ²The Royal Marsden Hospital, NHS Foundation Trust, London, GB, ³Janssen-Cilag, Île-de-

France, FR, ⁴Janssen-Cilag, Porto Salvo, PT, ⁵Janssen-Cilag NV, Beerse, BE, ⁶Janssen-Cilag GmbH, Neuss, DE, ⁷Janssen-Cilag, Madrid, ES, ⁸Janssen Pharmaceutica NV, Beerse, BE, ⁹Janssen-Cilag Ltd., High Wycombe, GB, ¹⁰Thoraxklinik Heidelberg gGmbH, Heidelberg, DE

- 10:07 - 10:08 **1118P - Real-world adjuvant treatment patterns in patients with stage I-III EGFR-mutated non-small cell lung cancer (NSCLC) in China: Interim analysis from the ADDRESS study**
- W. Liang¹, S. Jiang¹, Y. Chai², W. Liu³, L. Liu⁴, P. Song⁵, Z. Wang⁶, S. Zhang⁷, H. Xin⁸, X. Liu⁹, S. Xu¹⁰, H. Zhang¹¹, Y. Han¹², W. Shen¹³, Z. Peng¹⁴, M. Geng¹⁵, G. Yu¹⁶, X. Zhang¹⁷, J. He¹, ¹The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ²The Second Affiliated Hospital of Zhejiang University School of Medicine - East Gate 1, Hangzhou, CN, ³The First Hospital of Jilin University, Changchun, CN, ⁴SCU - Sichuan University - Huaxi Campus, Chengdu, CN, ⁵Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN, ⁶Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, CN, ⁷Shengjing Hospital of China Medical University - Nanhu Campus, Shenyang, CN, ⁸China-Japan Union Hospital of Jilin University/Third Hospital of Jilin University, Changchun, CN, ⁹Suzhou Municipal Hospital, Suzhou, CN, ¹⁰Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, ¹¹Shanxi Provincial Cancer Hospital, Taiyuan, CN, ¹²Sichuan Cancer Hospital and Institute/The Affiliated Cancer Hospital School of Medicine, UESTC, Chengdu, CN, ¹³Lihuili Hospital Ningbo Medical Treatment Center, Ningbo, CN, ¹⁴Shandong Provincial Hospital, Jinan, CN, ¹⁵Anyang Tumor Hospital, Anyang, CN, ¹⁶Shaoxing People's Hospital, Shaoxing, CN, ¹⁷Tianjin Chest Hospital, Tianjin, CN
- 10:08 - 10:09 **1119P - Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer**
- Q. Wang¹, C. Ma², T. Wang³, G. Chen⁴, H. Wang⁵, J. Mei⁶, ¹Henan Cancer Hospital, Zhengzhou, CN, ²Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou, CN, ³The First Affiliated Hospital of Henan University of traditional Chinese Medicine, Zhengzhou, CN, ⁴1st People's Hospital of Shangqiu, Shangqiu, CN, ⁵Anyang Cancer Hospital, Anyang, CN, ⁶People's Hospital of Zhengzhou, Zhengzhou, CN
- 10:09 - 10:10 **1120P - Medical practice analysis of sex-specific trends in advanced non-small cell lung cancer (NSCLC) in biomarker testing and treatment in Europe and Asia**
- C. Escorial¹, L. Mendoza², L. Schnetter¹, F. Tetzlaff³, ¹IQVIA Commercial GmbH & Co. OHG/IQVIA RDS GmbH - Zentrale, Frankfurt am Main, DE, ²IQVIA RDS Czech Republic s.r.o., Prague, CZ, ³IQVIA, Frankfurt am Main, DE
- 10:10 - 10:11 **1121P - Real-world (RW) data from the sotorasib French pre-market authorization early access program in patients (pts) with KRASG12C driven metastatic non-small cell lung cancer (mNSCLC): Clinical characteristics**
- J. Cadranel¹, X. Quantin², N. Girard³, F. Barlesi⁴, J.B. Auliac⁵, S. Couraud⁶, A.-C. Madroszyk Flandin⁷, L. Pabst⁸, C. Rieux⁹, H. Curcio¹⁰, R. Gille¹¹, A.-C. Métivier¹², C. Becht¹³, O. Bylicki¹⁴, P. Tomasini¹⁵, R. Veillon¹⁶, C. Damade¹⁷, C. Mourad¹⁸, C. Veillard¹⁷, H. Lena¹⁹, ¹Hopital Tenon AP-HP, Paris, Cedex, FR, ²ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, ³Institut Curie, Paris, FR, ⁴Gustave Roussy - Cancer Campus, Villejuif, FR, ⁵CHI - Centre Hospitalier Intercommunal de Créteil,

Créteil, Cedex, FR, ⁶Lyon Sud Hospital Center - HCL, Pierre-Bénite, FR, ⁷IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ⁸ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ⁹CHU Nimes - Hopital Universitaire Carémeau, Nimes, Cedex, FR, ¹⁰Centre Francois Baclesse, Caen, FR, ¹¹UNICANCER LYON - CENTRE LEON BERARD, Lyon, FR, ¹²Hopital Foch, Suresnes, FR, ¹³Clinique du Parc, Castelnau-le-Lez, FR, ¹⁴Hopital d'instruction des armées Sainte-Anne, Toulon, FR, ¹⁵Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Marseilles, FR, ¹⁶Hopital De Haut Leveque, Pessac, FR, ¹⁷Amgen France, Boulogne Billancourt, FR, ¹⁸Amgen France, Boulogne-Billancourt, FR, ¹⁹Hop Pontchaillou, Rennes, FR

10:11 - 10:12 **1122P - An adjusted comparison of amivantamab phase II data versus real-world clinical management in France of EGFR exon 20 insertion-mutated (ex20ins) advanced NSCLC patients**

C. Chouaid¹, N. Perualila², D. Debieuvre³, X. Quantin⁴, J. Diels⁵, N. Rahhali⁶, R. Toueg⁷, G. Simon⁸, L. Bosquet⁸, T. Filleron⁹, ¹CH Intercommunal de Créteil, Créteil, FR, ²Janssen EMEA, Beerse, BE, ³GHRMSA, Mulhouse, FR, ⁴ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, ⁵Janssen Pharmaceutica NV - Belgium, Beerse, BE, ⁶Janssen-Cilag SAS, Issy-les-Moulineaux, Cedex, FR, ⁷Janssen France, issy-les-moulineaux, FR, ⁸Unicancer, Paris, Cedex, FR, ⁹Institut Claudius Regaud IUCT-O, Toulouse, FR

10:12 - 10:13 **1123P - Real-world outcomes of first-line osimertinib for EGFR mutated advanced NSCLC patients in China: Interim analysis of the FLOURISH study**

J. Zhou¹, J. Zhou¹, J. Zheng¹, K. Wang², K. Tang³, D. Lü⁴, J. Cui⁵, D. Zhu⁶, Y. Wang⁷, Y. Zhao⁸, L. Xing⁹, L. Ding¹⁰, X. Shi¹¹, L. Shen¹, ¹The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CN, ²West China Hospital of Sichuan University, Chengdu, CN, ³The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, CN, ⁴Affiliated Taizhou Hospital of Zhejiang Province of Wenzhou Medical University, Taizhou, CN, ⁵The First Hospital of Jilin University, Changchun, CN, ⁶Jinhua Central Hospital, Jinhua, CN, ⁷Tumor Hospital affiliated to Harbin Medical University, Harbin, CN, ⁸Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ⁹Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN, ¹⁰The Second Affiliated Hospital of Zhejiang Medical University School, Hangzhou, CN, ¹¹Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN

10:13 - 10:14 **1124P - Pralsetinib in RET fusion-positive non-small cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)**

A. Passaro¹, G. Lo Russo², F. Passiglia³, M. D'Arcangelo⁴, A. Sbrana⁵, M. Russano⁶, L. Bonanno⁷, R. Giusti⁸, G. Metro⁹, F. Bertolini¹⁰, S. Grisanti¹¹, A. Carta¹², F.L. Cecere¹³, M. Montrone¹⁴, G. Massa², I. Attili¹, F. De Marinis¹⁵, ¹European Institute of Oncology IRCCS, Milan, IT, ²Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ³Università Degli Studi Di Torino - Orbassano, Orbassano, IT, ⁴Ospedale Santa Maria delle Croci, Ravenna, IT, ⁵Azienda Ospedaliero Universitaria Pisana - Stabilimento di Santa Chiara, Pisa, IT, ⁶Policlinico Universitario Campus Bio-Medico, Rome, IT, ⁷I OV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁸AOU Sant'Andrea, Rome, IT, ⁹Ospedale S. Maria della Misericordia, Perugia, IT, ¹⁰Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ¹¹Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT, ¹²Ospedale Oncologico "A. Businco", Cagliari, IT, ¹³IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT, ¹⁴IRCCS Istituto Tumori "Giovanni Paolo II", Bari, IT,

¹⁵European Institute of Oncology IRCCS, Milan, IT

- 10:14 - 10:15 **1125P - Real-world molecular testing and treatment patterns in epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic Chinese non-small cell lung cancer patients failing first-line EGFR-tyrosine kinase inhibitors**
- P. Tian¹, L. Wu², C. Zhou³, J. Tan⁴, K. Wang⁵, F. Luo⁵, Y. Liu⁵, Y. Guo⁶, Y. Li⁷, Z. Liu⁸, Y. Gong⁵, Y. Wang⁵, W. Li⁹, ¹West China Medical Center of Sichuan University, Chengdu, CN, ²Hunan Cancer Hospital, Changsha, CN, ³The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ⁴Suzhou Fourth People's Hospital/ Suzhou Municipal Hospital, Suzhou, CN, ⁵West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN, ⁶The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, ⁷Shenyang Chest Hospital, Shenyang, CN, ⁸Beijing Chest Hospital, Capital Medical University, Beijing, CN, ⁹SCU - Sichuan University - Huaxi Campus, Chengdu, CN
- 10:15 - 10:16 **1126P - Project LUMINATE-101: Real-world outcomes of EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (aNSCLC) patients receiving docetaxel post frontline (1L) platinum-based chemotherapy in combination with pembrolizumab**
- D.R. Camidge¹, S. Karve², Q. Xu², S. Ng², R. Kamalakar², C. Ratajczak², S. Lu³, ¹University of Colorado Cancer Center, Aurora, US, ²Abbvie Inc., North Chicago, US, ³Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai, CN
- 10:16 - 10:17 **1127P - Efficacy of current immunotherapies in patients (pt) with metastatic non-small cell lung cancer (NSCLC) harboring KRAS mutations**
- L. Notario Rincon¹, A. Pous¹, A. Lopez Paradis¹, A. Notario¹, M. Cucurull Salamero¹, A. Hernandez Gonzalez¹, M. Domenech Vinolas¹, E. Carcereny Costa¹, M.T. Moran Bueno¹, A. Muñoz², J.L. Mate², C. Sanz², M. Saigi Morgui¹, ¹Institut Catala d'Oncologia Badalona, Badalona, ES, ²Hospital Universitari Germans Trias i Pujol, Badalona, ES
- 10:17 - 10:18 **1128P - Efficacy of immunotherapy in Chinese patients with KRAS-mutant advanced NSCLC**
- Z. Wang¹, X. Han¹, L. Peng¹, J. Guo¹, L. Kong¹, Y. Huang¹, N. Tang¹, J. Zhang¹, M. Wang¹, X. He², Z. Li³, Y. Peng², ¹Shandong Cancer Hospital and Institute; Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CN, ²Berry Oncology Co. Ltd, Beijing, CN, ³Berry Oncology Co., Ltd, Beijing, CN
- 10:18 - 10:19 **1129P - Real-world outcomes of second-line osimertinib for advanced NSCLC patients with EGFR mutation in China**
- W. Ji¹, X. Li², S. Cang³, Y. Xiang⁴, X. Li⁵, J. Zhang⁶, J. Tan⁷, Q. Wang⁸, D. Jiang⁹, H. Zhang¹⁰, S. Lu¹, ¹Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, ²The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ³Henan Provincial People's Hospital, Zhengzhou, CN, ⁴Shanghai Ruijin - Ammed Cancer Centre, Shanghai, CN, ⁵Liaoning Cancer Hospital & Institute, Shenyang, CN, ⁶Shanxi Da Hospital, Taiyuan, CN, ⁷Suzhou Fourth People's Hospital/ Suzhou Municipal Hospital, Suzhou, CN, ⁸Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University,

Zhengzhou, CN, ⁹The Fourth Hospital of Hebei Medical University - North Gate, Shijiazhuang, CN, ¹⁰Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, CN

- 10:19 - 10:20 **1130P - Real-world data of osimertinib (osi) for the treatment of metastatic epidermal growth factor receptor (EGFR+) non-small cell lung cancer (NSCLC) patients (pts), with a focus on age, body mass index (BMI) and trough levels**
- A. Veelen¹, M. Veerman², M. Verschueren³, J. Gulikers¹, A. Brouns⁴, S. Dursun⁵, R. Mathijssen⁶, A.-M. Dingemans², V. Tjan-Heijnen¹, B. Peters³, P. Souverein⁷, A. Driessen¹, L. Hendriks⁸, R. Van Geel¹, S. Croes¹, ¹Maastricht University Medical Center (MUMC), Maastricht, NL, ²Erasmus MC - University Medical Center, Rotterdam, NL, ³St. Antonius Hospital, Nieuwegein, NL, ⁴Zuyderland Medical Center, Heerlen, NL, ⁵Academisch Ziekenhuis Maastricht (AZM), Maastricht, NL, ⁶Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ⁷Utrecht University - Faculty of Pharmaceutical Sciences, Utrecht, NL, ⁸Maastricht UMC, Maastricht, NL
- 10:20 - 10:21 **1131P - Overall survival after treatment with first-line crizotinib or alectinib in patients with stage IV NSCLC and ALK rearrangement: A real-world nationwide cohort study from the Netherlands**
- M. Tilkema-Tiebosch¹, R. Damhuis², S. Vijftigschild³, A.J. Van Der Wekken¹, ¹UMCG - University Medical Center Groningen, Groningen, NL, ²Comprehensive Cancer Centre the Netherlands, Utrecht, NL, ³IKNL - Netherlands Comprehensive Cancer Organisation, Utrecht, NL
- 10:21 - 10:22 **1132P - Prevalence of the synonymous EGFR Q787Q variant in Mexican patients with non-small cell lung cancer**
- M. Ramos-Ramirez¹, N.Y. Hernandez-Pedro², M. Arroyo-Hernández¹, A. Aviles-Salas¹, L. Cabrera Miranda¹, K. Martinez-Perez¹, S. Monraz-Perez³, O.G. Arrieta Rodriguez¹, ¹INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico, MX, ²INCAN - Instituto Nacional de Cancerologia, ciudad de México, MX, ³INER - Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Ciudad de Mexico, MX
- 10:22 - 10:23 **1133P - Additional practice-informing adverse event patterns and management in the KRYSTAL-1 phase II study of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC**
- J. Zhang¹, K. Leventakos², T. Leal³, N. Pennell⁴, M. Barve⁵, A. Paulson⁶, L. Bazhenova⁷, M. Johnson⁸, R. Chao⁹, K. Velastegui⁹, C. Qian⁹, W. Bleker⁹, A. Spira¹⁰, ¹University of Kansas Medical Center, Kansas City, US, ²Mayo Clinic, Rochester, US, ³Winship Cancer Institute, Emory University, Atlanta, US, ⁴Cleveland Clinic, Cleveland, US, ⁵Mary Crowley Cancer Research Center, Dallas, US, ⁶Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, US, ⁷UC San Diego Moores Cancer Center, La Jolla, US, ⁸Sarah Cannon Research Institute Tennessee Oncology, Nashville, US, ⁹Mirati Therapeutics, Inc., San Diego, US, ¹⁰Virginia Cancer Specialists, Fairfax, US
- 10:23 - 10:24 **1134P - Prevention of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small cell lung cancer by administration of ursodeoxycholic acid: Analysis from the monoinstitutional analysis**

A. Lugini¹, S. Verna¹, F. Buzzacchino², M. Minelli¹, L. Cristofani², ¹Azienda Ospedaliera San Giovanni Addolorata, Rome, IT, ²Policlinico Umberto I -, Rome, IT

- 10:24 - 10:25 **1135P - Adverse event (AE) burden of nivolumab-based immuno-oncology (IO) therapy with/without chemotherapy (chemo) for first-line (1L) advanced non-small cell lung cancer (aNSCLC)**
L. Schwartzberg¹, A. Wu², J. Hartman³, T. Wang⁴, X. Yin³, J. Chen⁴, K.A. Betts⁵, S. Lubinga³, ¹Renown Institute for Cancer, Reno, US, ²Inc., Los Angeles, US, ³Bristol Myers Squibb, Princeton, US, ⁴Inc., Boston, US, ⁵Analysis Group, Inc., Los Angeles, US
- 10:25 - 10:26 **1136P - Relationship between caloric intakes and sensitivity to immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients: The ELY-2 study**
M. Tiako Meyo¹, G. Ulmann², P. Boudou Rouquette³, J. Arrondeau¹, J. Chen³, L. Hirsch³, N. Neveux², C. Guidet³, H. Lawand³, M. Wislez⁴, J. Alexandre³, J.-P. Durand³, F. Goldwasser³, ¹Hopital Cochin - Port Royal AP-HP, Paris, FR, ²Hopital Cochin AP-HP, Paris, FR, ³Hopital Cochin - Port-Royal AP-HP, Paris, FR, ⁴Hopital Cochin - Port-Royal AP-HP, Paris Cedex, FR
- 10:26 - 10:27 **1138P - Alternate pembrolizumab dosing interval in advanced NSCLC with PD-L1 <math>\geq 50\%: 3 weekly compared to 6 weekly dosing**
L. Jones¹, R. Rittberg¹, B. Leung¹, A. Shokoohi², A. Pender³, S. Wong¹, Z. Al-Hashami⁴, Y. Wang¹, C. Ho¹, ¹BC Cancer Agency, Vancouver, CA, ²University of Alberta, Edmonton, CA, ³The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB, ⁴Sultan Qaboos University Hospital, Muscat, OM
- 10:27 - 10:28 **1139P - A CT-based radiomic readout on the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors**
F. Tohidinezhad¹, A. Traverso², D. Bontempi³, A. Dekker², D. De Ruysscher², ¹Maastricht University Medical Center (MUMC), Maastricht, NL, ²Maastro Clinic, Maastricht, NL, ³Maastricht University, Maastricht, NL
- 10:28 - 10:29 **1140P - A chemo-holiday immunotherapy regimen for advanced NSCLC**
F. Li, B. Wang, Y. Xiang, C.C. Li, R. Zhong, J. Li, S. Xiong, J. He, W. Liang, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN
- 10:29 - 10:30 **1141P - A multicenter study of incidence of drug-induced lung disease in first-line osimertinib therapy and continuation of osimertinib administration**
C. Mimura¹, M. Tachihara¹, K. Kaneshiro², Y. Kono², S. Fujimoto³, Y. Hatakeyama³, R. Dokuni⁴, N. Iwamoto⁵, K. Matsumura⁵, K. Kobayashi¹, ¹Kobe University Graduate School of Medicine, Kobe, JP, ²Kita-Harima Medical Center, Ono, JP, ³Akashi Medical Center, Akashi, JP, ⁴Awaji Medical Center, Sumoto, JP, ⁵Takatsuki General Hospital, Takatsuki, JP
- 10:30 - 10:31 **1142P - The influence of food with different fat concentrations on alectinib exposure: A randomized cross-over pharmacokinetic trial**
D. Lanser¹, M. Veerman², S. De Leeuw³, E. Oomen-De Hoop¹, M. Paats¹, S. Koolen², A.-

M. Dingemans², R. Mathijssen⁴, ¹Erasmus MC Cancer Institute, Rotterdam, NL, ²Erasmus MC - University Medical Center, Rotterdam, NL, ³Erasmus MC, Rotterdam, NL, ⁴Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL

- 10:31 - 10:32 **1143P - Effect of best response to first-line (1L) treatment (tx) on outcomes with second-line (2L) nintedanib (NIN) & docetaxel (DOC) for patients (pts) with lung adenocarcinoma after 1L immune checkpoint inhibitor (ICI) combination therapy**
- C. Grohe¹, T. Wehler², S. Henschke³, I. Dittrich⁴, S. Hammerschmidt⁵, C. Aulmann⁶, T. Dechow⁷, C. Schiefer⁸, E. Von Der Heyde⁹, W. Schuette¹⁰, J. Atz¹¹, R. Kaiser¹², ¹ELK Berlin, Berlin, DE, ²University Hospital Giessen, Giessen, DE, ³Universitätskliniken des Saarlandes, Homburg, DE, ⁴Lungenklinik Lostau, Lostau, DE, ⁵Klinikum Chemnitz GmbH, Chemnitz, DE, ⁶University Hospital Augsburg, Augsburg, DE, ⁷Private Oncology Practice Ravensburg, Ravensburg, DE, ⁸Pneumologische Praxis Markkleeberg, Markkleeberg, DE, ⁹Praxis Hämatologie und Onkologie, Hannover, DE, ¹⁰Krankenhaus Martha-Maria Halle-Dölau, Halle, DE, ¹¹Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, DE, ¹²Johannes Gutenberg University, Mainz, DE
- 10:32 - 10:33 **1144P - Clinical outcomes of NSCLC patients (pts) who had brain-only metastasis at time of stage IV diagnosis, by presence versus absence of EGFR/ALK mutations**
- S. Schmid¹, L.J. Zhan², M. Garcia³, S. Cheng², K. Khan², M. Chowdhury⁴, A. Sabouhanian⁵, J. Herman³, P. Walia³, E. Strom⁴, M.C. Brown³, D. Patel², W. Xu⁴, F. Shepherd⁴, A. Sacher⁴, N. Leighl⁴, P. Bradbury⁶, D. Shultz², G. Liu⁴, ¹Kantonsspital St. Gallen, St. Gallen, CH, ²Princess Margaret Cancer Centre, Toronto, CA, ³Princess Margaret Cancer Center, University Health Network, Toronto, CA, ⁴UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ⁵University of Toronto - St. George Campus, Toronto, CA, ⁶Princess Margaret Cancer Center, Toronto, CA
- 10:33 - 10:34 **1145P - Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: The ComIT-1 trial**
- H. Horndalsveen¹, T. Alver¹, A.M. Dalsgaard¹, Å.K. Öjlert¹, V. Haakensen¹, M. Bjaanaes², A. Helland³, ¹Oslo University Hospital, Oslo, NO, ²Oslo University Hospital - Ulleval Hospital, Oslo, NO, ³University of Oslo, Institute of Clinical medicine, Oslo, NO
- 10:34 - 10:35 **1146P - Correlation between different molecular states and liver metastasis in patients with non-small cell lung cancer**
- Y. Zhang, H. Guo, X. Jia, M.J. Liu, Y. Li, Z. Mao, First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, CN
- 10:35 - 10:36 **1147P - Effects of the use of antibiotics or antacids on chemoimmunotherapy prognostic factors in patients with advanced non-small cell lung cancer: A propensity-score-matched analysis**
- K. Tamura, Y. Okuma, A. Fukuda, K. Masuda, Y. Shinno, T. Yoshida, Y. Goto, H. Horinouchi, N. Yamamoto, Y. Ohe, National Cancer Center Hospital, Tokyo, JP
- 10:36 - 10:37 **1148P - The effects of statin use on lung cancer development in patients with idiopathic pulmonary fibrosis using clinical data warehouse**

K.Y. Kim¹, H.S. Kang², ¹The Catholic University of Korea Uijeongbu St. Mary's Hospital, Uijeongbu, KR, ²The Catholic University of Korea - Bucheon St. Mary's Hospital, Bucheon, KR

10:37 - 10:38 **1149P - Factors associated with not receiving first-line (1L) immune checkpoint inhibitor (ICI) treatment among patients (pts) with advanced NSCLC and high programmed cell death-ligand 1 (PD-L1) expression: An evaluation by age**
J. Feliciano¹, N. Wu², W. Ge², R. Quek², M. Gleeson³, J.J. Jalbert², M. Hsu⁴, J. Harnett²,
¹Johns Hopkins Hospital, Baltimore, US, ²Regeneron Pharmaceuticals, Inc., Tarrytown, US, ³Genesis Research, Hoboken, US, ⁴University Hospitals, Case Comprehensive Cancer Center, Cleveland, US

09:00 - 12:00 Type: Poster session Title: Poster session 14 Poster Area, Hall 4

09:00 - 09:01 **758P - A comprehensive analysis of tumor-infiltrating immune cells in HPV-associated cancers**
H. Yang, A. Lin, K. Wei, J. Zhang, P. Luo, Zhujiang Hospital of Southern Medical University, Guangzhou, CN

09:01 - 09:02 **759P - Preconditioning with irradiation enhances efficacy of B7-H3-CAR-T in treating solid tumor models**
T. Wang, F. You, Y. Li, S. Xiang, H. Wu, H. Meng, N. Yang, B. Zhang, L. Yang, PersonGen BioTherapeutics(Suzhou) Co., Ltd., Suzhou, CN

09:02 - 09:03 **760P - Acute toxicities of intravenous, intraperitoneal, or intratumoral injection of natural killer cells in human pancreatic adenocarcinoma-bearing mice: A randomized study**
L. Huang, Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, CN

09:03 - 09:04 **761P - Tumor infiltrating lymphocytes expressing membrane-bound IL-2 and IL-12 exhibit enhanced proliferation, function, and persistence without requiring exogenous IL-2 support**
R.J. Silver, M. Silva, M.F. Maloney, A.A. Brate, N. El-Sayes, E.I. Ozay, D. Parwanda, C. Bartlett, A. Sharei, S. Loughhead, J. Gilbert, D. Bridgen, SQZ Biotechnologies, Watertown, US

09:04 - 09:05 **762P - Personalized immunotherapy with encapsulated cell technology: Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors**
E. Fernandez¹, R. Vernet¹, E. Charrier², D. Migliorini³, M. Urwyler¹, M.-C. Belkouch¹, O. Von Rohr⁴, V. Saingier⁴, V. Ancrenaz¹, N. Grandjean¹, E. Lafferma¹, E. Lavalliere¹, O. Rubin⁴, J. Villard¹, J. Grogg⁵, N. Mach¹, ¹HUG - Hopitaux Universitaires de Geneve, Geneva, CH, ²UNIGE - Université de Genève - Centre Médical Universitaire (CMU), Geneva, CH, ³Hopitaux Universitaires de Geneve - HUG, Geneva, CH, ⁴HUG - Hopitaux Universitaires de Genève, Geneva, CH, ⁵MaxiVax SA, Geneva, CH

09:05 - 09:06 **763P - Combined gene signature (T-cell inflamed gene expression profile**

IMMUTOP (IMMUTOP: IMMUTOP) identifies a metabolic rewiring program, key for immune evasion

H. Oliveres¹, C. Foguet², M. Nebozhyn³, L. Pedrosa¹, I. Cirrincione⁴, P. Morales⁵, J. Lunceford⁶, T. Gorria¹, J. Maurel¹, M. Cascante⁷, ¹Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ²Department of Biochemistry and Molecular Biomedicine & Institute of Biomedicine of Universitat de Barcelona, Barcelona, ES, ³Merck & Co. Inc., Riverside, US, ⁴MSD, Barcelona, ES, ⁵MSD - Merck Sharp & Dohme de Espana S.A., Madrid, ES, ⁶Merck S.L.U., Washington, US, ⁷Barcelona University, Barcelona, ES

765P - Comprehensive analysis of the association between RAS mutation and immune checkpoint marker expression

H. Miyashita¹, R. Kurzrock², S. Lee³, S. Pabla⁴, M. Nesline⁴, S. Glenn⁴, J. Conroy⁴, P. Depietro⁴, S. Kato³, ¹Mount Sinai Beth Israel, New York, US, ²Medical College of Wisconsin, Milwaukee, US, ³University of California San Diego - UCSD, La Jolla, US, ⁴OmniSeq Inc., Buffalo, US

766P - Levels of serum EGF concentration as biomarker of response of CIMAvax-EGF vaccine: Survival evaluation of advanced NSCLC patients treated in primary health care scenario

R.A. Otiz Carrodegua¹, G. Lorenzo Monteagudo², P.P. Guerra³, L. Sanchez², L. Cárdenas⁴, I. Álvarez⁵, E.E. Salomón⁶, M. Díaz⁷, Y. Menéndez⁸, L. Lobaina⁹, J.C. Columbié¹⁰, K. Camacho¹¹, M. Corella¹², N. Fardales¹³, J. Parra³, C. Viada², D. Saavedra², O. Santos², T. Crombet Ramos², ¹Hospital Provincial Oncológico Universitario Celestino Hernández Robau, Santa Clara, CU, ²CIM - Center of Molecular Immunology, Havana, CU, ³National Coordinating Center for Clinical Trials, Havana, CU, ⁴Manuel Ascunse Hospital, Camagüey, CU, ⁵Maria Curie Hospital, Camagüey, CU, ⁶Joaquín Albarrán Hospital, La Habana, CU, ⁷Benéfico Jurídico Hospital, La Habana, CU, ⁸Enrique Cabrera Hospital, Havana, CU, ⁹Saturnino Lora Hospital, Santiago de Cuba, CU, ¹⁰Juan Bruno Zayas Hospital, Santiago de Cuba, CU, ¹¹Faustino Pérez Hospital, Matanzas, CU, ¹²Vladimir Ilich Lenin Hospital, Holguín, CU, ¹³Hospital Camilo Cienfuegos, Sancti Spiritus, CU

767P - Refining patients' selection for immunotherapeutic early-phase clinical trials (ieCTs): A single phase I unit experience

A. Losurdo, P. Persico, E. Lorenzi, A. Dipasquale, A. Di Muzio, L. Giordano, M. Simonelli, A. Santoro, IRCCS Humanitas Research Hospital, Rozzano, IT

768P - Investigation of CD73 expression in response to immunotherapy in pancreatic cancer

Y. Wang¹, M. Liu², X. Hu², ¹Hunan Provincial People's Hospital, Changsha, CN, ²3D Medicines, Inc., Shanghai, CN

769P - Analysis of PMS2 mutation as a potential biomarker for melanoma immunotherapy

J. Qiu¹, Q. Zhang², Y. Tan², Q. Duan², C. Qi², T. Sun², ¹ChangShu No.2 People's Hospital, Changshu, CN, ²Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, CN

770P - Comprehensive immune profiling of primary tumors, lymph nodes, and

peripheral blood after treatment with nivolumab and BMS 986205 in head and neck squamous cell carcinoma (HNSCC)

L. Harshyne¹, A. Linnenbach², M. Mahoney², A. South², U. Martinez-Outschoorn², J. Curry³, D. Cognetti², J. Johnson², M. Tuluc², A. Argiris⁴, A. Luginbuhl², ¹Kimmel Cancer Center-Thomas Jefferson University, Philadelphia, US, ²Thomas Jefferson University, Philadelphia, US, ³JEFFERSON UNIVERSITY-OTOLARYNGOLOGY, Philadelphia, US, ⁴Hygeia Hospital, Marousi, GR

09:12 - 09:13

771P - Correlation of gut microbiome composition with checkpoint inhibitor induced severe immune-related adverse events

R. Verheijden, J. Van De Wijgert, A. May, M. Viveen, M. Rogers, F. Paganelli, K. Suijkerbuijk, University Medical Center Utrecht, Utrecht, NL

09:13 - 09:14

772P - Discovery and exploration of a live bacterial consortium as co-therapy to enhance immune checkpoint inhibitor response in melanoma patients

M. Robinson¹, K. Vervier¹, S. Harris¹, A. Popple¹, D. Klisko¹, R. Hudson¹, G. Bakdash¹, C. Villemin¹, C. Booth², D. Adams³, S. Welsh⁴, P. Corrie², T. Lawley¹, ¹Microbiotica, Cambridge, GB, ²Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB, ³Wellcome Trust Sanger Institute, Cambridge, GB, ⁴Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB

09:14 - 09:15

773P - Differences between hyperprogressive disease and progressive disease in patients receiving immunotherapy

H. Yildirim¹, D.C. Guven¹, O.H. Aktepe¹, F. Yilmaz², B. Aktas¹, G. Guner¹, O. Dizdar², S. Aksoy², M. Erman³, S. Yalcin², S. Kilickap⁴, ¹Hacettepe University Oncology Hospital, Ankara, TR, ²Hacettepe University - Faculty of Medicine, Ankara, TR, ³Hacettepe University, Ankara, TR, ⁴Istinye University Faculty of Medicine, Istanbul, TR

09:15 - 09:16

774P - Immune checkpoint inhibitor monotherapy and the risk of venous thromboembolism in cancer: A systematic review and meta-analysis

N. Khan¹, S.A.A. Naqvi², H. Ijaz³, K.Z.R. Khakwani⁴, I. Riaz⁵, ¹AIMC - Allama Iqbal Medical College - Jinnah Hospital, Lahore, PK, ²Mayo Clinic Cancer Center, Phoenix, US, ³Nishtar Medical College and Hospital - NMC, Multan, PK, ⁴The University of Arizona, Tucson, US, ⁵Dana Farber Cancer Institute, Boston, US

09:16 - 09:17

775P - Treatment of Kaposi sarcoma with immune-checkpoint inhibitors: A systematic review and single-arm meta-analysis

M. Silveira Vilbert¹, I. Hirsch¹, E. Koch¹, T. Pimentel Muniz¹, D. Pinheiro Xavier², M.F. Silva Almeida Ribeiro¹, L. Mantle¹, S. Saibil¹, A. Spreafico¹, M. Butler¹, D. Hogg¹, ¹Princess Margaret Cancer Centre, Toronto, CA, ²Universidade Federal do Para-Health Science Institute, Belém, BR

09:17 - 09:18

776P - Early mortality in patients with cancer treated with immunotherapy in routine practice

J. Raphael¹, L. Richard², M. Lam², P. Blanchette¹, N. Leigh³, G. Rodrigues¹, M. Trudeau⁴, M. Krzyzanowska⁵, ¹London Regional Cancer Program (LRCP) - London Health Science Center (LHSC), London, CA, ²Institute for Clinical Evaluative Sciences,

Toronto, CA, ³Princess Margaret Cancer Centre, Toronto, ON, CA, ⁴Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA, ⁵UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

- 09:18 - 09:19 **777TiP - Phase I study of LYL797, a ROR1-targeted CAR T-cell therapy with genetic and epigenetic reprogramming for the treatment of advanced solid tumors**
- D. Spigel¹, H. Murthy², S. Chumsri², B. Ganguly³, L. Gong³, H. Hiraragi³, E. Larsen³, W. Liu³, L. Martell³, S. Zhu³, I.-M. Bornman³, S. Fitzsimmons³, E. Barnum³, S. Christiansen³, H. Gillenwater³, ¹Sarah Cannon Research Institute, Cancer Centre, and Tennessee Oncology, Nashville, US, ²Mayo Clinic Cancer Center, Jacksonville, US, ³Lyell Immunopharma, Seattle, US
- 09:19 - 09:20 **778TiP - A phase I/II trial investigating safety and efficacy of autologous TAC T-cells targeting HER2 in relapsed or refractory solid tumors**
- B. Schlechter¹, E. Ileana Dumbrava², D. Olson³, S. Saibil⁴, B. Pieke⁵, R. Bouvier¹, K. Moss⁶, N. Turnus⁶, A. Bader⁶, D. Adib⁶, ¹Dana Farber Cancer Institute, Boston, US, ²The University of Texas M. D. Anderson Cancer Center, Houston, US, ³The University of Chicago, Chicago, US, ⁴UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ⁵University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, ⁶Triumvira, Austin, US
- 09:20 - 09:21 **779TiP - Commencement of first-in-human phase I/II TCR-T clinical trial targeting shared tumor-specific hotspot mutations in solid tumors**
- M.P. Morelli¹, M. Negrao², A. Jazaeri³, B. Johnson¹, P. Kebriaei¹, D. Deniger⁴, M. Collinson-Pautz⁴, N. Demars⁴, J. Heymach², S. Kopetz¹, ¹MD Anderson Cancer Center, Houston, US, ²MD Anderson Cancer Center, University of Texas, Houston, US, ³The MD Anderson Cancer Center, Houston, US, ⁴Alaunos Therapeutics Inc., Houston, US
- 09:21 - 09:22 **780TiP - A phase I dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB Antibody) alone and in combination with pembrolizumab in patients with advanced malignancies**
- E. Hamilton¹, I. Melero², I. Lugowska³, A.M. Arance Fernandez⁴, L. Vila Martinez⁵, J. Powderly⁶, M. Gutierrez⁷, T. Serino⁸, N. Mehta⁸, I. Shapiro⁹, K. Whalen⁸, J. Michaelson⁸, J. Jones⁸, J. Janik⁹, V. Moreno Garcia¹⁰, ¹Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ²Clinica Universitaria de Navarra, Pamplona, ES, ³Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, ⁴Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁵Parc Tauli Hospital Universitari, Sabadell, ES, ⁶Carolina BioOncology Institute, Huntersville, US, ⁷John Theurer Cancer Center - Hackensack University Medical Center, Hackensack, US, ⁸Cullinan Oncology, LLC, Cambridge, US, ⁹Cullinan Oncology, Cambridge, US, ¹⁰Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES
- 09:22 - 09:23 **781TiP - AGADIR: A basket multicenter open-label phase II study evaluating the first in class TLR7/8 agonist BDB001 in combination with atezolizumab and stereotactic body radiation therapy in patients with advanced solid tumors**
- A. Italiano¹, C. Coutzac Bergouignan², D. Pasquier³, P. Rochigneux⁴, M.P. Sablin⁵, C.

Gomez-Roca⁶, F. Ghiringhelli⁷, J.-P. Metges⁸, M. Toulmonde⁹, S. Cousin¹⁰, S. Pernot¹¹, C. Auzanneau¹, B. Lortal¹, M. Kind¹, P. Sargos¹, S. Batard¹², A. Petit¹³, P. Gillon¹², S. Albert¹², M. Pulido¹², ¹Institute Bergonié, Bordeaux, FR, ²Centre Léon Bérard, Lyon, FR, ³Centre Oscar Lambret, Lille, FR, ⁴IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ⁵Dr. Marie Paule Sablin, La Défense, FR, ⁶Institut Universitaire du Cancer -Toulouse-Oncopole, Toulouse, FR, ⁷Centre Georges-François Leclerc (Dijon), Dijon, FR, ⁸CHU Morvan - Institut de Cancerologie et d'Hématologie, Brest, FR, ⁹Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ¹⁰Institut Bergonie, Bordeaux, FR, ¹¹Institut Bergonié, Bordeaux Cedex, FR, ¹²Institut Bergonie, BORDEAUX, FR, ¹³Institut Bergonié, Bordeaux, FR

09:23 - 09:24 **782TiP - Reduced frequency immune checkpoint inhibition in cancers (REFINE): A multi-arm phase II trial testing reduced intensity immunotherapy in different cancers**

S. Merrick¹, M. Nankivell¹, T. Griffiths¹, W. Hudson¹, C. Clarke², G. Bray², S. Forcat¹, M. Campos¹, H. Bryant¹, M. Quartagno¹, R. Langley¹, L. Pickering³, N. Vasudev⁴, D. Gilbert¹, ¹Medical Research Council Clinical Trials Unit, London, GB, ²Research Department of Primary Care and Population Health, London, GB, ³The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB, ⁴St. James's University Hospital, Leeds, GB

09:24 - 09:25 **783TiP - Phase I study of HFB301001, a novel OX40 agonist monoclonal antibody, in patients with solid tumors selected via Drug Intelligence Science (DIS)**

A. Spira¹, R. Mehra², C. Mantia³, H. Babiker⁴, M. Borad⁵, A. Cervantes⁶, E. Garralda⁷, A. Mahipal⁸, L. Paz-Ares⁹, C. Hatzis¹⁰, A. Liu¹⁰, A. Raue¹⁰, J. Gan¹⁰, F. Adrian¹⁰, L. Manenti¹⁰, A. El-Khoueiry¹¹, ¹Virginia Cancer Specialist, Fairfax, US, ²University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, US, ³Dana Farber Cancer Institute, Boston, US, ⁴Mayo Clinic Cancer Center, Jacksonville, US, ⁵Mayo Clinic Cancer Center, Scottsdale, US, ⁶Hospital Clinico Universitario de Valencia, Valencia, ES, ⁷Vall d'Hebron University Hospital, Barcelona, ES, ⁸Mayo Clinic, Rochester, US, ⁹Hospital Universitario 12 de Octubre, Madrid, ES, ¹⁰HiFiBiO Inc., Cambridge, US, ¹¹USC - University of Southern California - Keck School of Medicine, Los Angeles, US

09:25 - 09:26 **975P - Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial**

E. Smit¹, E. Felip², D. Uprety³, K. Nakagawa⁴, L. Paz-Ares⁵, J. Pacheco⁶, B. Li⁷, D. Planchard⁸, C. Baik⁹, Y. Goto¹⁰, H. Murakami¹¹, A. Saltos¹², K. Saxena¹³, R. Shiga¹³, Y. Cheng¹³, Q. Yan¹³, W. Feng¹³, P. Jänne¹⁴, ¹Netherlands Cancer Institute, Amsterdam, NL, ²Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES, ³Barbara Ann Karmanos Cancer Institute, Detroit, US, ⁴Kindai University Faculty of Medicine, Osaka, JP, ⁵Clinica Universidad de Navarra, University de Navarra, Navarra, ES, ⁶University of Colorado Anschutz, Aurora, US, ⁷Memorial Sloan Kettering Cancer Center, New York, US, ⁸Gustave Roussy, Thoracic Team, Villejuif, Cedex, FR, ⁹University of Washington, Seattle, US, ¹⁰National Cancer Center Hospital, Tokyo, JP, ¹¹Shizuoka Cancer Center, Shizuoka, JP, ¹²Moffitt Cancer Center, Tampa, US, ¹³Daiichi Sankyo, Inc., Basking Ridge, US, ¹⁴Dana-Farber Cancer Institute and Belfer Center for Applied Cancer

Science, Boston, US

09:26 - 09:27

976P - Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01

B. Li¹, E. Smit², Y. Goto³, K. Nakagawa⁴, K. Goto⁵, J. Mazieres⁶, D. Uprety⁷, L. Bazhenova⁸, A. Saltos⁹, E. Felip¹⁰, J. Pacheco¹¹, M. Pérol¹², L. Paz-Ares¹³, K. Saxena¹⁴, R. Shiga¹⁴, Y. Cheng¹⁴, Q. Yan¹⁴, D. Planchard¹⁵, P. Jänne¹⁶, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²Netherlands Cancer Institute, Amsterdam, NL, ³National Cancer Center Hospital, Tokyo, JP, ⁴Kindai University Hospital, Osaka, JP, ⁵National Cancer Center Hospital East, Chiba, JP, ⁶Hôpital Larrey (Centre Hospitalier Universitaire), Toulouse, FR, ⁷Karmanos Cancer Institute, Detroit, US, ⁸UC San Diego Moores Cancer Center, San Diego, US, ⁹Moffitt Cancer Center, Tampa, US, ¹⁰Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES, ¹¹University of Colorado, Aurora, US, ¹²Centre Léon Bérard, Lyon, FR, ¹³Hospital Universitario 12 de Octubre, Madrid, ES, ¹⁴Daiichi Sankyo, Inc., Basking Ridge, US, ¹⁵Gustave Roussy, Villejuif, Cedex, FR, ¹⁶Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, Boston, US

09:27 - 09:28

977P - Phase II study of brigatinib in patients with tyrosine kinase inhibitor (TKI)-naïve ROS1-rearranged advanced non-small cell lung cancer (NSCLC): Barossa cohort 1

R. Toyozawa¹, S. Niho², Y. Goto³, T. Takahashi⁴, K. Ohashi⁵, H. Daga⁶, H. Tanaka⁷, Y. Hattori⁸, M. Morise⁹, J. Sakakibara-Konishi¹⁰, M. Kodani¹¹, T. Ikeda¹², S. Matsumoto¹², K. Yoh¹², S. Nomura¹³, K. Goto¹², ¹National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, ²Dokkyo Medical University, Mibu, JP, ³National Cancer Center - Tsukiji Campus, Chuo-ku, JP, ⁴Shizuoka Cancer Center, Shizuoka, JP, ⁵Okayama University Hospital, Okayama, JP, ⁶Osaka City General Hospital, Osaka, JP, ⁷Niigata Cancer Center Hospital, Niigata, JP, ⁸Hyogo Cancer Center, Akashi, JP, ⁹Nagoya University Graduate School of Medicine, Nagoya, JP, ¹⁰Hokkaido University Hospital, Sapporo, JP, ¹¹Tottori University Hospital, Yonago, JP, ¹²National Cancer Center Hospital East, Kashiwa, JP, ¹³The University of Tokyo, Tokyo, JP

09:28 - 09:29

978P - Pertuzumab plus trastuzumab (P+T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study

A.K. Ganti¹, M. Rothe², P. Mangat², E. Garrett-Mayer², E. Dib³, H. Duvivier⁴, E. Ahn⁵, D. Behl⁶, H. Borghaei⁷, A. Balmanoukian⁸, A. Gaba⁹, R. Li¹⁰, K. Osei-Boateng¹¹, R. Thota¹², R. O'Lone², G. Grantham², S. Halabi¹³, R. Schilsky², ¹University of Nebraska Medical Center and VA-NWIIHCS, Omaha, US, ²American Society of Clinical Oncology (ASCO), Alexandria, US, ³Michigan Cancer Research Consortium, IHA Hematology Oncology, Ypsilanti, US, ⁴CTCA - Cancer Treatment Centers of America - Atlanta, Newnan, US, ⁵Cancer Treatment Centers of America, Zion, US, ⁶Sutter Institute for Medical Research, Sacramento, US, ⁷Fox Chase Cancer Center - Main Campus, Philadelphia, US, ⁸The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, US, ⁹Sanford Health, Fargo, US, ¹⁰Providence Cancer Institute, Providence Portland Medical Center, Portland, US, ¹¹Levine Cancer Institute, Charlotte, US, ¹²Intermountain Medical Center - Intermountain Healthcare, Murray, US, ¹³Duke University - Health System, Durham, US

- 09:29 - 09:30 **979P - Long-term intracranial safety and efficacy analyses from the phase III CROWN study**
A. Bearz¹, E. Felip², J. Mazieres³, F. De Marinis⁴, T. Bauer⁵, A. Polli⁶, R. Messina⁷, H. Thurm⁸, D. Thomaidou⁹, T.S.K. Mok¹⁰, B. Solomon¹¹, ¹Centro di Riferimento Oncologico - CRO, Aviano, IT, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR, ⁴IEO - Istituto Europeo di Oncologia, Milan, IT, ⁵Tennessee Oncology, Chattanooga, US, ⁶Pfizer Italy, Milan, IT, ⁷Pfizer - Italy, Rome, IT, ⁸Pfizer Inc - La Jolla Campus - CB10, San Diego, US, ⁹Pfizer Hellas S.A., Neo Psychiko, GR, ¹⁰State Key Laboratory of Translational Oncology and Chinese University of Hong Kong, Hong Kong, HK, ¹¹Peter MacCallum Cancer Center, Melbourne, AU
- 09:30 - 09:31 **980P - Continuation of selpercatinib beyond progression in RET fusion-positive NSCLC: Data from LIBRETTO-001 study**
A. Drilon¹, J. Chan², J. Sands³, D.S.W. Tan⁴, J. Weiss⁵, B. Solomon⁶, Y.J. Kim⁷, M. Johnson⁸, T. Puri⁹, M.A. Sarno⁹, S. Kang⁹, V. Soldatenkova⁹, C.-W. Duann⁹, S. Szymczak⁹, V. Subbiah¹⁰, B. Besse¹¹, ¹Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US, ²UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ³Dana-Farber Cancer Institute, Harvard Medical School, Boston, US, ⁴NCCS - National Cancer Centre Singapore, Singapore, SG, ⁵UNC - Lineberger Cancer Center, Chapel Hill, US, ⁶Peter MacCallum Cancer Centre, Melbourne, AU, ⁷SNUBH - Seoul National University Bundang Hospital, Seongnam, KR, ⁸Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, US, ⁹Eli Lilly and Company, Indianapolis, US, ¹⁰The University of Texas M. D. Anderson Cancer Center, Houston, US, ¹¹Institut Gustave Roussy, Villejuif, FR
- 09:31 - 09:32 **981P - A phase IIa study to evaluate safety and efficacy of rezivertinib (BPI-7711) in locally advanced or metastatic/recurrent treatment-naïve NSCLC patients with EGFR mutation**
Y.-K. Shi¹, J. Zhou², Y. Zhao³, B. Zhu⁴, L. Zhang⁵, X. Li⁶, J. Fang⁷, J. Shi⁸, Z. Zhuang⁹, S. Yang¹⁰, D. Wang¹¹, H. Yu¹¹, L. Zhang¹², R. Zheng¹³, M. Greco¹⁴, T. Wang¹⁵, F. Mo¹⁵, ¹Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center and National Clinical Research Center for Cancer and Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ²The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, CN, ³Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ⁴Cancer Center of People's Liberation Army, Xinqiao Hospital, Third Military Medical University, Chongqing, CN, ⁵Yantai Yuhuangding Hospital, Yantai, CN, ⁶The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ⁷Peking University Cancer Hospital and Institute, Beijing, CN, ⁸Linyi Cancer Hospital, Linyi, CN, ⁹The Second Affiliated Hospital of Soochow University, Suzhou, CN, ¹⁰National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ¹¹Chongqing Cancer Hospital, Chongqing, CN, ¹²The Affiliated Hospital of Xuzhou Medical University, Xuzhou, CN, ¹³The First Affiliated Hospital of Bengbu Medical College, Bengbu, CN, ¹⁴BetaPharma, Inc., Princeton, US, ¹⁵Beta Pharma (Shanghai) Co., Ltd., shanghai, CN
- 09:32 - 09:33 **982P - Final results and biomarker analysis of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated**

patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study

A. Nakamura¹, H. Kenmotsu², K. Sakai³, K. Mori², T. Kato⁴, K. Kiritani⁵, Y. Yoneshima⁶, K. Azuma⁷, K. Nishino⁸, S. Teraoka⁹, T. Shukuya¹⁰, K. Masuda¹¹, H. Hayashi¹², R. Toyozawa¹³, S. Miura¹⁴, D. Fujimoto¹⁵, K. Nakagawa¹², N. Yamamoto⁹, K. Nishio¹², T. Takahashi², ¹Sendai Kousei Hospital, Sendai, JP, ²Shizuoka Cancer Center, Shizuoka, JP, ³Kindai University - Faculty of Medicine, Osaka, JP, ⁴Kanagawa Cancer Center, Yokohama, JP, ⁵National Cancer Center Hospital East, Kashiwa, JP, ⁶Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, ⁷Kurume University, Kurume, JP, ⁸OICI - Osaka International Cancer Institute, Osaka, JP, ⁹Wakayama Medical University, Wakayama, JP, ¹⁰Juntendo University Hospital, Bunkyo-ku, JP, ¹¹Hiroshima City Hiroshima Citizens Hospital, Hiroshima, JP, ¹²Kindai University School of Medicine - Main Campus, Osaka, JP, ¹³National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, ¹⁴Niigata Cancer Center Hospital, Niigata, JP, ¹⁵Kobe City Medical Center General Hospital, Kobe, JP

09:33 - 09:34

984P - Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD)

S. Gadgeel¹, J. Gainor², F. Cappuzzo³, E. Garraza⁴, D.H. Lee⁵, J. Mazieres⁶, D.-W. Kim⁷, V. Zhu⁸, G. Lopes⁹, S. Miller¹⁰, M. Nowicka¹¹, H. Trinh¹², S.M. Arndorfer¹³, A. Rahman¹⁴, J. Noe¹¹, Q. Zhang¹², V. Subbiah¹⁵, ¹Henry Ford Cancer Institute, Henry Ford Health, Detroit, US, ²Massachusetts General Hospital, Boston, US, ³IRCCS Regina Elena National Cancer Institute, Rome, IT, ⁴Vall d'Hebron University Hospital, Barcelona, ES, ⁵University of Ulsan College of Medicine, Seoul, KR, ⁶Institut Universitaire du Cancer, Toulouse, FR, ⁷Seoul National University College of Medicine and Seoul National University Hospital, Seoul, KR, ⁸University of California Irvine, Orange, US, ⁹Miller School of Medicine and Sylvester Comprehensive Cancer Center, University of Miami, Miami, US, ¹⁰Blueprint Medicines, Cambridge, US, ¹¹F. Hoffmann-La Roche Ltd, Basel, CH, ¹²Genentech, Inc., South San Francisco, US, ¹³Genesis Research, Hoboken, US, ¹⁴F. Hoffmann-La Roche Ltd, Welwyn Garden City, GB, ¹⁵The University of Texas MD Anderson Cancer Center, Houston, US

09:34 - 09:35

985P - Tepotinib outcomes according to prior therapies in patients with MET exon 14 (METex14) skipping NSCLC

E. Smit¹, M. Garassino², E. Felip³, H. Sakai⁴, X. Le⁵, R. Veillon⁶, J. Mazieres⁷, A. Cortot⁸, J. Raskin⁹, M. Thomas¹⁰, S. Viteri Ramirez¹¹, K. Berghoff¹², R. Bruns¹², G. Otto¹², P. Paik¹³, ¹Leiden University Medical Centre, Leiden, NL, ²Section of Hematology/Oncology, Knapp Center for Biomedical Discovery, The University of Chicago, Chicago, US, ³Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁴Saitama Cancer Center, Kitaadachi-gun, JP, ⁵The University of Texas MD Anderson Cancer Center, Houston, US, ⁶Service des Maladies Respiratoires, Bordeaux, FR, ⁷Université Paul Sabatier, Toulouse, FR, ⁸CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020 - UMR-S 1277 - Canther, F-59000, Lille, FR, ⁹Antwerp University Hospital (UZA), Edegem, BE, ¹⁰Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), Heidelberg, DE, ¹¹Hospital Universitario Dexeus, Grupo Quironsalud, Barcelona, Spain; UOMI cancer center, Clínica Mi NovAliança, Lleida, ES, ¹²Merck Healthcare KGaA, Darmstadt, DE, ¹³Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York,

US

- 09:35 - 09:36 **986P - Response to capmatinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) and MET exon 14 skipping (METex14) mutation: Whole transcriptome analysis from phase II GEOMETRY Mono-1 study**
J. Wolf¹, H. Groen², D.S.W. Tan³, E. Garon⁴, D. Demanse⁵, A. Robeva⁶, A. Yovine⁵, L. Fairchild⁶, A. Boran⁷, R. Heist⁸, ¹University Hospital Cologne, Köln, DE, ²University Medical Center Groningen, Groningen, NL, ³National Cancer Centre, Singapore, SG, ⁴UCLA Hematology/Oncology, Santa Monica, US, ⁵Novartis Pharma AG, Basel, CH, ⁶Novartis Institutes for BioMedical Research, Cambridge, US, ⁷Novartis Pharmaceuticals Corporation, East Hanover, US, ⁸Massachusetts General Hospital, Boston, US
- 09:36 - 09:37 **987P - Sunvozertinib in NSCLC patients with EGFR exon 20 insertion mutations**
M. Wang¹, Y. Fan², M. Sun³, Y. Wang⁴, J. Fang⁵, Y. Zhao⁶, B. Jin⁷, Y. Hu⁸, Z. Han⁹, X. Song¹⁰, A. Liu¹¹, K. Tang¹², C. Ding¹³, L. Liang¹⁴, L. Wu¹⁵, J. Gao¹⁶, J. Wang¹⁷, J.C.-H. Yang¹⁸, P. Jänne¹⁹, L. Zheng²⁰, ¹PUMCH - Peking Union Medical College Hospital/Beijing Xiehe Hospital - Dongdan Campus, Beijing, CN, ²Zhejiang Cancer Hospital, Hangzhou, CN, ³Central Hospital Affiliated to Shandong First Medical University, Jinan, CN, ⁴West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN, ⁵Peking University School of Oncology, Beijing Cancer Hospital, Beijing, CN, ⁶The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ⁷The First Affiliated Hospital of China Medical University, Shenyang, CN, ⁸Beijing Chest Hospital - Capital Medical University, Beijing, CN, ⁹Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, CN, ¹⁰Shanxi Provincial Cancer Hospital, Taiyuan, CN, ¹¹The Second Affiliated Hospital of Nanchang University, Nanchang, CN, ¹²The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, CN, ¹³The Fourth Hospital of Hebei Medical University - North Gate, Shijiazhuang, CN, ¹⁴3rd Hospital Beijing University, Beijing, CN, ¹⁵Hunan Cancer Hospital, Changsha, CN, ¹⁶The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, CN, ¹⁷Chongqing Cancer Hospital, Chongqing, CN, ¹⁸NTUCC - National Taiwan University Cancer Center, Taipei City, TW, ¹⁹Dana Farber Cancer Institute, Boston, US, ²⁰Dizal pharmaceutical, Shanghai, CN
- 09:37 - 09:38 **988P - Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP)**
S. Ramalingam¹, C. Zhou², T.M. Kim³, J.C.-H. Yang⁴, G. Riely⁵, T. Mekhail⁶, D. Nguyen⁷, M.R. Garcia Campelo⁸, E. Felip⁹, D. Misch¹⁰, M. Kaur¹¹, V. Bunn¹¹, M. Lin¹¹, P. Zhang¹¹, P. Jänne¹², ¹Emory University, Atlanta, US, ²Shanghai Pulmonary Hospital, Shanghai, CN, ³Seoul National University Hospital, Seoul, KR, ⁴NTUCC - National Taiwan University Cancer Center, Taipei City, TW, ⁵Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ⁶AdventHealth Medical Group - Internal Medicine at Orlando, Orlando, US, ⁷City of Hope National Medical Center, Los Angeles, US, ⁸Complejo Hospitalario Universitario A Coruña, A Coruña, ES, ⁹Vall d'Hebron University Hospital, Barcelona, ES, ¹⁰HELIOS Klinikum Emil von Behring Berlin-Zehlendorf, Berlin, DE, ¹¹Takeda Development Center Americas, Inc., Lexington, US, ¹²Dana Farber Cancer Institute, Boston, US
- 09:38 - 09:39 **989P - Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): Safety and efficacy data from the global expanded access program**

(EAP)

M. Awad¹, G. Pelizzari², J. Stevenson³, M. Majem Tarruella⁴, C.G. Ferreira⁵, W. Petty⁶, E. Arriola⁷, J. De Castro⁸, I. Morbeck⁹, J. Bauman¹⁰, L. Toschi¹¹, A. Zer¹², G. Metro¹³, S. Kalmadi¹⁴, A. Azkárte Martínez¹⁵, C. Xia¹⁶, A. Meloni¹⁶, C. Obiozor¹⁶, N. Maimon¹⁷, S. Novello¹⁸, ¹Dana Farber Cancer Institute, Boston, US, ²Santa Maria della Misericordia Hospital, Azienda Sanitaria Universitaria Friuli Centrale, Udine, IT, ³Cleveland Clinic Taussig Cancer Institute, Cleveland, US, ⁴Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁵Oncoclinicas Institute for Research and Education, Rio de Janeiro, BR, ⁶Wake Forest University School of Medicine, North Carolina, US, ⁷Hospital del Mar - Parc de Salut Mar, Barcelona, ES, ⁸Hospital Universitario La Paz, Madrid, ES, ⁹Hospital Sírio-Libanês - Centro de Oncologia Asa Sul, Brasilia, BR, ¹⁰Fox Chase Cancer Center - Main Campus, Philadelphia, US, ¹¹Istituto Clinico Humanitas, Rozzano, IT, ¹²Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, IL, ¹³Ospedale S. Maria della Misericordia, Perugia, IT, ¹⁴Ironwood Cancer and Research Centers, Chandler, US, ¹⁵Hospital Universitario Son Espases, Palma de Mallorca, ES, ¹⁶Amgen Inc., Thousand Oaks, US, ¹⁷Meir Medical Center, Sackler School of Medicine, Rishon Le Zion, IL, ¹⁸Università Degli Studi Di Torino - Orbassano, Orbassano, IT

09:39 - 09:40 **990P - Osimertinib for RT-naïve CNS metastasis of EGFR mutation-positive NSCLC: Phase II OCEAN study (LOGIK 1603/WJOG 9116L), part of the first-line cohort**

H. Yamaguchi¹, K. Wakuda², M. Fukuda³, H. Kenmotsu², K. Ito⁴, Y. Tsuchiya-Kawano⁵, K. Tanaka⁶, T. Harada⁷, Y. Nakatani⁸, S. Miura⁹, T. Yokoyama¹⁰, T. Nakamura¹¹, M. Izumi¹², A. Nakamura¹³, S. Ikeda¹⁴, K. Takayama¹⁵, K. Yoshimura¹⁶, K. Nakagawa¹⁷, N. Yamamoto¹⁸, K. Sugio¹⁹, ¹Nagasaki University Hospital, Nagasaki, JP, ²Shizuoka Cancer Center, Shizuoka, JP, ³Nagasaki Prefecture Shimabara Hospital, Shimabara, JP, ⁴Matsusaka Municipal Hospital, Matsusaka, JP, ⁵Kitakyushu Municipal Medical Center, Kitakyushu, JP, ⁶Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, ⁷Japan Community Health Care Organization (JCHO) Kyushu Hospital, Kitakyushu, JP, ⁸Osaka City General Hospital, Osaka, JP, ⁹Niigata Cancer Center Hospital, Niigata, JP, ¹⁰Kurashiki Central Hospital, Kurashiki, JP, ¹¹Saga university, Saga, JP, ¹²National Hospital Organization Omuta National Hospital, Omuta, JP, ¹³Sendai Kousei Hospital, Sendai, JP, ¹⁴Kanagawa Cardiovascular and Respiratory Center, Yokohama, JP, ¹⁵Kyoto Prefectural University of Medicine, Kyoto, JP, ¹⁶Hiroshima University Hospital, Hiroshima, JP, ¹⁷Kindai University Faculty of Medicine, Osaka, JP, ¹⁸Wakayama Medical University, Wakayama, JP, ¹⁹Oita University Faculty of Medicine, Yufu, JP

09:40 - 09:41 **991P - EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)**

A. Kron¹, M. Scheffler¹, M. Ihle¹, S. Michels¹, J. Süptitz¹, D. Prang¹, F. Jakobs², L. Nogova³, R. Fischer³, A. Eisert¹, R. Riedel¹, F. Kron³, A. Hillmer¹, S. Loges⁴, S. Merkelbach-Bruse³, R. Büttner⁵, J. Wolf¹, ¹Universitätsklinikum Köln (AöR), Köln, DE, ²Universitätsklinikum Essen, Essen, DE, ³University Hospital Cologne, Köln, DE, ⁴University Hospital Mannheim, Mannheim, DE, ⁵University Hospital Cologne, Köln, DE

09:41 - 09:42 **992P - Updated analyses from the CROWN study of first-line lorlatinib vs crizotinib in Asian patients with ALK-positive non-small cell lung cancer (NSCLC)**

Z. Qing¹, H.R. Kim², R. Soo³, C.H. Chiu⁴, H. Hayashi⁵, S.-W. Kim⁶, S. Teraoka⁷, D.-W. Kim⁸, H. Zhan⁹, H. Zhao⁹, H. Li⁹, T.S.K. Mok¹⁰, Y.-L. Wu¹, ¹Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, CN, ²Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ³National University Cancer Institute, Singapore, SG, ⁴Taipei Veterans General Hospital, Taipei, TW, ⁵Kindai University Faculty of Medicine, Osaka-Sayama, JP, ⁶University of Ulsan College of Medicine, Seoul, KR, ⁷Wakayama Medical University, Wakayama, JP, ⁸Seoul National University Hospital, Seoul National University College of Medicine, Seoul, KR, ⁹Pfizer Inc., Shanghai, CN, ¹⁰State Key Laboratory of Translational Oncology and Chinese University of Hong Kong, Hong Kong, CN

09:42 - 09:43

994P - Efficacy and safety of capmatinib plus spartalizumab in treatment-naïve patients with advanced NSCLC harboring MET exon 14 skipping mutation

J. Wolf¹, R. Heist², T.M. Kim³, M. Nishio⁴, C. Doms⁵, R.R. Kanthala⁶, E. Leo⁷, E. Giorgetti⁷, Y. Wang⁸, F.I. Mardjuali⁸, A. Cortot⁹, ¹Universitätsklinikum Köln (AöR), Köln, DE, ²MGH - Massachusetts General Hospital, Boston, US, ³Seoul National University - College of Medicine - Yeongseon Medical Campus, Seoul, KR, ⁴The Cancer Institute Hospital of JFRC, Koto-ku, JP, ⁵UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁶Novartis Healthcare Pvt. Ltd., Hyderabad, IN, ⁷Novartis Pharma AG, Basel, CH, ⁸Novartis Institutes for BioMedical Research Co., Ltd., Shanghai, CN, ⁹Univ. Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020 - UMR-S 1277 - Canther, Lille, FR

09:43 - 09:44

995P - Effectiveness of combination of osimertinib with another targeted therapy in advanced EGFR mutated non-small cell lung cancer harbouring other oncogenic drivers: The real-world COMPOSIT study

C. Mehlman¹, A. Swalduz², I. Monnet³, C. Morin⁴, F. Guisier⁵, H. Curcio⁶, P. Du Rusquec⁷, A. Cortot⁸, V. Gounant⁹, B. Abbar¹⁰, B. Duchemann¹¹, E. Giroux-Leprieur¹², T. Pierret¹³, F.M. Quilot¹⁴, J. Cadranel¹, V. Fallet¹, ¹Tenon Hospital, Assistance Publique Hôpitaux de Paris and GRC 4, Therascan, Sorbonne Université, Paris, FR, ²Comprehensive Cancer Centre Léon Bérard, Lyon, FR, ³CH Intercommunal de Créteil, Creteil, FR, ⁴Toulouse University Hospital, Toulouse, FR, ⁵CHU Rouen Normandie, Rouen, FR, ⁶Centre Francois Baclesse, Caen, FR, ⁷Institut Curie, Paris, FR, ⁸Univ. Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020 - UMR-S 1277 - Canther, Lille, FR, ⁹Bichat-Claude Bernard Hospital, APHP Nord; Université Paris Cité, Paris, FR, ¹⁰Hopital Pitié Salpêtrière - Hopitaux Universitaires Pitié Salpêtrière - Charles Foix AP-HP, Paris, FR, ¹¹Hôpital Avicenne, Bobigny, FR, ¹²Hopital Ambroise Pare AP-HP, Boulogne-Billancourt, FR, ¹³Groupement Hospitalier Est, Hospices Civils de Lyon, Lyon, FR, ¹⁴CHU Dijon, Dijon, FR

09:44 - 09:45

996P - Activity of OsimeRTinib in NSCLC with UNcommon EGFR Mutations: Retrospective observational multicenter study (ARTICUNO)

E. Pizzutilo¹, G. Cerea², S. Oresti¹, A.G. Agostara¹, D. Signorelli², S. Stabile², C. Lauricella², M. Brambilla³, L. Mazzeo⁴, R. Giusti⁵, M. Montrone⁶, M. Russano⁷, C. Bennati⁸, A. Russo⁹, G. Viscardi¹⁰, E. Roca¹¹, A. Gelibter¹², D. Cortinovis¹³, A. Sartore Bianchi¹, S. Siena², ¹UNIMI - Università degli Studi di Milano Statale, Milano, IT, ²ASST Grande Ospedale Metropolitano Niguarda, Milan, IT, ³Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁴Istituto Nazionale dei Tumori di Milano - Fondazione

IRCCS, Milan, IT, ⁵AOU Sant'Andrea, Rome, IT, ⁶IRCCS Istituto Tumori "Giovanni Paolo II", Bari, IT, ⁷Policlinico Universitario Campus Bio-Medico, Rome, IT, ⁸Ospedale Santa Maria delle Croci, Ravenna, IT, ⁹Centro Oncologico Ospedale Papardo, Messina, IT, ¹⁰Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ¹¹Ospedale Pederzoli, Peschiera del Garda, IT, ¹²Umberto I - Policlinico di Roma, Rome, IT, ¹³Ospedale San Gerardo - ASST Monza, Monza, IT

- 09:45 - 09:46 **997P - Phase I study of brigatinib plus panitumumab in patients with advanced EGFR-mutated non-small cell lung cancer resistant to osimertinib (BEBOP): Early termination due to severe early onset pneumonitis by brigatinib**
H. Izumi¹, T. Sakamoto², K. Uchibori³, K. Nishino⁴, J. Sakakibara-Konishi⁵, S. Nomura¹, K. Ryohei⁶, H. Udagawa¹, Y. Shibata¹, T. Ikeda¹, S. Niho¹, T. Sakai¹, Y. Zenke¹, K. Nosaki¹, S. Matsumoto¹, K. Yoh¹, K. Goto¹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Tottori University Hospital, Yonago, JP, ³The Cancer Institute Hospital of JFCR, Koto-ku, JP, ⁴OICI - Osaka International Cancer Institute, Osaka, JP, ⁵Hokkaido University Hospital, Sapporo, JP, ⁶Japanese Foundation for Multidisciplinary Treatment of Cancer, Koto-ku, JP
- 09:46 - 09:47 **998P - A phase I study of CKD-702, an EGFR-cMET bispecific antibody, in advanced or metastatic non-small cell lung cancer (NSCLC)**
D.-W. Kim¹, S.-H. Lee², I.-J. Jang³, K.-J. Park⁴, D.H. Lee⁵, ¹Seoul National University College of Medicine and Seoul National University Hospital, Seoul, KR, ²Samsung Medical Center - Sungkyunkwan University School of Medicine, Seoul, KR, ³Seoul National University Hospital, Seoul, KR, ⁴CKD - Chong Kun Dang Research Institute (Hyojong), Yongin, KR, ⁵Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR
- 09:47 - 09:48 **999P - JIN-A02, a fourth-generation, highly effective tyrosine kinase inhibitor with intracranial activity, targeting EGFR C797S mutations in NSCLC**
M.R. Yun¹, M.R. Yu¹, K.B. Duggirala², K. Lee², S.M. Lim³, A. Jo⁴, E. Seah⁴, C. Kim⁴, B.C. Cho⁵, ¹Yonsei University College of Medicine, Seoul, KR, ²KRICT-Korea Research Institute of Chemical Technology, Daejeon, KR, ³Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ⁴J INTS BIO, Seoul, KR, ⁵Yonsei University, Seoul, KR
- 09:48 - 09:49 **1000P - Common and uncommon mutations in NSCLC: Differences in response to treatment with tyrosine kinase inhibitors: A single-center retrospective analysis**
C. Sciortino¹, B. Bovolenta¹, G. Marrocco¹, G. Martino¹, A. Neri¹, M. Nucci¹, L. Pappalardo¹, M.G. Polito¹, V. Vigliani¹, E. Cortesi², S. Caponnetto², ¹Sapienza - Università di Roma, Rome, IT, ²Umberto I - Policlinico di Roma, Rome, IT
- 09:49 - 09:50 **1001P - Epidermal growth factor receptor (EGFR) testing and treatment patterns associated with diagnosis of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) in the US**
Z. Piotrowska¹, M. Lin², Y. Yin², E. Curran², V. Crossland², Y. Wu², S.-H. Ou³, ¹Massachusetts General Hospital, Boston, US, ²Takeda Development Center Americas, Inc., Lexington, US, ³University of California Irvine, Chao Family Comprehensive Cancer Center, Orange, US

- 09:50 - 09:51 **1002P - Compared with the difference in efficacy between EGFR-TKIs alone and EGFR-TKIs combined with craniocerebral radiotherapy in EGFR mutant lung adenocarcinoma patients with brain metastasis. A propensity-score matched analysis**
G. Deng, Z. Li, Shandong Cancer Hospital Affiliated to Shandong University, Ji Nan, CN
- 09:51 - 09:52 **1004P - Efficacy and safety of anlotinib monotherapy or combination therapy as second-line therapy in EGFR-wild-type non-small cell lung cancer (NSCLC) patients**
J. Guo, X. Wang, F. Zheng, G. Zhao, Y. Wang, Y. Hu, P. Liu, C. Ma, Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou, CN
- 09:52 - 09:53 **1005P - Indirect treatment comparisons of relative efficacy for aumolertinib vs osimertinib in EGFR-positive non-small cell lung cancer (NSCLC)**
S. Popat¹, S. Stergiopoulos², S. King², M. Curtis², A. Dillon³, R. Akehurst⁴, D. Lee⁵, F. Guelfucci⁶, A. Ngami⁶, F. Bianic⁶, Y. Li², S. Ali⁷, V. Miller⁸, ¹The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ²EQRx, Inc., Cambridge, US, ³Imperial College London - South Kensington Campus, London, GB, ⁴BresMed Health Solutions Ltd, Sheffield, GB, ⁵Bresmed Health Solutions Ltd, Sheffield, GB, ⁶Syneos Health, Montrouge, FR, ⁷EQRx Inc., Cambridge, US, ⁸Foundation Medicine, Cambridge, US
- 09:53 - 09:54 **1006P - RANKL drives malignant phenotypes and poor prognosis in KRAS-mutated lung adenocarcinoma**
H.-S. Li, C. Liu, F. Xu, S.-Y. Lei, Y. Wang, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN
- 09:54 - 09:55 **1007P - Mechanisms of primary and secondary resistance to RET inhibitors in patients with RET-positive advanced NSCLC**
A. Marinello¹, D. Vasseur², N. Conci³, V. Fallet⁴, C. Audigier-Valette⁵, S. Cousin⁶, F. Tabbò⁷, F. Guisier⁸, A. Russo⁹, A. Calles Blanco¹⁰, G. Metro¹¹, G. Massa¹², F. Citarella¹³, A. Eisert¹⁴, P. Iranzo Gomez¹⁵, M. Tagliamento¹⁶, L. Mezquita¹⁷, C. Lindsay¹⁸, S. Ponce², M. Aldea¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Gustave Roussy - Cancer Campus, Villejuif, FR, ³University of Bologna - Alma Mater Studiorum, Bologna, IT, ⁴Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR, ⁵Hospital Sainte Musse, Toulon, FR, ⁶Institut Bergonie, Bordeaux, FR, ⁷Università Degli Studi Di Torino - Orbassano, Orbassano, IT, ⁸CHU de Rouen Normandie, Rouen, FR, ⁹Centro Oncologico Ospedale Papardo, Messina, IT, ¹⁰Hospital General Universitario Gregorio Marañón, Madrid, ES, ¹¹Ospedale S. Maria della Misericordia, Perugia, IT, ¹²Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ¹³Policlinico Universitario Campus Bio-Medico, Rome, IT, ¹⁴Universitätsklinikum Köln (AöR), Köln, DE, ¹⁵Vall d'Hebron University Hospital, Barcelona, ES, ¹⁶Gustave Roussy, Villejuif, FR, ¹⁷Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ¹⁸The Christie NHS Foundation Trust, Manchester, GB
- 09:55 - 09:56 **1008P - Resistance mechanisms to lorlatinib or crizotinib in treatment-naïve patients (pts) with ALK⁺; advanced non-small cell lung cancer (NSCLC)**
E. Felip¹, J.-F. Martini², J. Mazieres³, D.-W. Kim⁴, D. Shepard², A. Polli⁵, G. Liu⁶, F. De Marinis⁷, F. Toffalorio⁵, Y. Goto⁸, B. Solomon⁹, ¹Vall d'Hebron University Hospital and

Vall d'Hebron Institute of Oncology, Barcelona, ES, ²Pfizer Inc, La Jolla, US, ³Toulouse University Hospital, Toulouse, FR, ⁴Seoul National University College of Medicine and Seoul National University Hospital, Seoul, KR, ⁵Pfizer, Milan, IT, ⁶Princess Margaret Cancer Centre, Toronto, CA, ⁷European Institute of Oncology IRCCS, Milan, IT, ⁸National Cancer Center Hospital, Tokyo, JP, ⁹Peter MacCallum Cancer Centre, Melbourne, AU

09:56 - 09:57

1009P - Integrated biomarker analysis of brigatinib efficacy in anaplastic lymphoma kinase-positive (ALK⁺) non-small cell lung cancer (NSCLC) refractory to alectinib

S.-H. Ou¹, M. Nishio², T. Yoshida³, M.-J. Ahn⁴, T.S.K. Mok⁵, K. Kudou⁶, T. Asato⁷, H. Yang⁸, X. Tong⁸, P. Zhang⁸, N. Yamamoto⁹, E. Kim¹⁰, ¹Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, US, ²The Cancer Institute Hospital of JFCR, Koto-ku, JP, ³NCCH - National Cancer Center Hospital, Chuo-ku, JP, ⁴Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, ⁵State Key Laboratory of Translational Oncology and Chinese University of Hong Kong, Hong Kong, HK, ⁶Japan Development Centre, Takeda Pharmaceutical Company Limited, Osaka, JP, ⁷Oncology Therapeutic Area Unit for Japan and Asia, Takeda Pharmaceutical Company Limited, Osaka, JP, ⁸Takeda Development Center Americas, Inc., Lexington, US, ⁹Osaka International Cancer Institute, Osaka, JP, ¹⁰City of Hope National Medical Center, Duarte, US

09:57 - 09:58

1010P - Assessment of early resistance mechanisms to first-line osimertinib in EGFR-mutant NSCLC using spatial transcriptomics

G. Ruiz De Garibay¹, B. Roch², P. Garrido Lopez³, D. Isla⁴, C. Aguado⁵, A. Callejo Perez⁶, R. Marse Fabregat⁷, M.R. Garcia Campelo⁸, A. Blasco Cordellat⁹, J.M. Sanchez Torres¹⁰, R. Bernabe Caro¹¹, O.J. Juan Vidal¹², J. De Castro Carpeno¹³, F.F. Franco¹⁴, I. Ramos Garcia¹⁵, A. Gomez Rueda³, E. Conde Gallego¹⁶, S. Ponce Aix¹⁶, L. Paz-Ares¹⁶, J. Zugazagoitia¹⁶, ¹Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), Madrid, ES, ²Hopital Arnaud de Villeneuve, Montpellier, FR, ³Hospital Universitario Ramon y Cajal, Madrid, ES, ⁴Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, ⁵Hospital Clinico Universitario San Carlos, Madrid, ES, ⁶Vall d'Hebron University Hospital, Barcelona, ES, ⁷Hospital Universitario Son Espases, Palma de Mallorca, ES, ⁸Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES, ⁹CHGUV - Consorcio Hospital General Universitario de Valencia, Valencia, ES, ¹⁰Hospital Universitario de La Princesa, Madrid, ES, ¹¹Hospital Universitario Virgen del Rocio, Seville, ES, ¹²Hospital Universitari i Politècnic La Fe, Valencia, ES, ¹³Hospital Universitario La Paz, Madrid, ES, ¹⁴Hospital Puerta de Hierro-Majadahonda, Madrid, ES, ¹⁵Hospital Universitario Virgen de la Victoria, Málaga, ES, ¹⁶Hospital Universitario 12 de Octubre, Madrid, ES

09:58 - 09:59

1011P - MET and NF2 alterations confer early resistance to first-line alectinib treatment in ALK-rearranged non-small cell lung cancer

J. Hu¹, N. Ding¹, Y. Chen², J. Liu², J. Zhou¹, X. Xu¹, H. Bao², Y. Song¹, D. Zhang¹, Y. Shao², Y. Zhang¹, ¹Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, ²Nanjing Geneseeq Technology Inc., Nanjing, CN

09:59 - 10:00

1012P - Resistance mechanisms to dual EGFR and MET inhibition in patients with EGFR-mutant MET-amplified non-small cell lung cancer

K. Wang¹, R. Du², S. Roy³, N. Vokes², Y. Elamin², C. Bueno Hume², F. Skoulidis², C. Gay², G. Blumenschein², F. Fossella², A. Tsao², J.J. Lee², W. Rinsurongkawong¹, V. Rinsurongkawong¹, D. Gibbons², A. Vaporciyan¹, J. Zhang², J. Heymach², M. Altan², X. Le², ¹MD Anderson Cancer Center, Houston, US, ²The University of Texas M. D. Anderson Cancer Center, Houston, US, ³The University of Texas M.D. Anderson Cancer Center, Houston, US

- 10:00 - 10:01 **1013P - Utilizing a combined biomarker and therapeutic strategy to reverse TKI resistance in EGFR mutant non-small cell lung cancer**
K. O'Byrne¹, M. Adams², D. Richard², ¹Princess Alexandra Hospital - Metro South Health, Woolloongabba, AU, ²Queensland University of Technology, Brisbane, AU
- 10:01 - 10:02 **1014P - Resistance landscape to almonertinib in EGFR-mutated NSCLC**
M. Tian¹, Z. Lu², S. Chen², G. Lu², F. Bu², W. Deng², R. Ding², ¹The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, CN, ²Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, CN
- 10:02 - 10:03 **1015P - Phase III study of ramucirumab plus docetaxel versus atezolizumab for PD-L1 negative or weakly positive advanced non-small cell lung cancer after disease progression on platinum-based therapy: WJOG10317L study (EMERALD)**
Y. Zenke¹, S. Niho², A. Nakamura³, T. Okamoto⁴, S. Hara⁵, Y. Akazawa⁶, Y. Hosomi⁷, H. Hayashi⁸, S. Teraoka⁹, T. Yokoyama¹⁰, T. Ozaki¹¹, K. Ueno¹², H. Gytoku¹³, T. Misumi¹⁴, K. Nakagawa⁸, N. Yamamoto⁹, M. Tsuboi¹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Dokkyo Medical University, Mibu, JP, ³Sendai Kousei Hospital, Sendai, JP, ⁴National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, ⁵Itami City Hospital, Itami, JP, ⁶National Hospital Organization Toneyama Hospital, Toyonaka, JP, ⁷Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, JP, ⁸Kindai University School of Medicine - Main Campus, Osaka, JP, ⁹Wakayama Medical University, Wakayama, JP, ¹⁰Kurashiki Central Hospital, Kurashiki, JP, ¹¹Kishiwada City Hospital, Kishiwada, JP, ¹²Osaka General Medical Center, Osaka, JP, ¹³Nagasaki University Hospital, Nagasaki, JP, ¹⁴National Cancer Center Hospital East, Kashiwa, Japan, Kashiwa, JP
- 10:03 - 10:04 **1016P - GFPC 06-2018: A multicentre phase II, open-label, non-randomized study evaluating platinum-pemetrexed-atezolizumab (+/- bevacizumab) for patients with stage IIIB/IV non-squamous NSCLC with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies**
O. Bylicki¹, R. Gervais², I. Monnet³, C. Ricordel⁴, L. Bigay-Game⁵, M. Geier⁶, C. Decroisette⁷, C. Daniel⁸, F. Guisier⁹, A. Swalduz¹⁰, A.C. Toffart¹¹, H. Doubre¹², J.M. Pelsoni¹³, D. Arpin¹⁴, H. Morel¹⁵, R. Veillon¹⁶, B. Clarisse¹⁷, P.-H. Martins-Lavinas¹⁸, L. Greillier¹⁹, C. Chouaid²⁰, ¹Hopital d'instruction des armées Sainte-Anne, Toulon, FR, ²Comprehensive Cancer Centre François Baclesse, Caen, FR, ³CH Intercommunal de Créteil, Creteil, FR, ⁴CHU Rennes, Rennes, FR, ⁵CHU Toulouse-Hôpital Larrey, TOULOUSE, FR, ⁶CHU Brest, Brest, FR, ⁷CH Annecy-Genevois, Metz-Tessy, FR, ⁸Thorax Institute Curie Montsouris, Paris, FR, ⁹CHU Rouen, Rouen, FR, ¹⁰Comprehensive Cancer Centre Léon Bérard, Lyon, FR, ¹¹CHU Grenoble-Alpes - Le site nord à La Tronche - Hopital Michallon, La Tronche, FR, ¹²Hopital Foch, Suresnes, FR, ¹³Maison de Santé Protestant de Bordeaux-Bagatelle, Villenave-d'Ornon, FR, ¹⁴Hôpital Nord-Ouest, Gleizé, FR, ¹⁵CHR Orléans, Orleans, FR, ¹⁶Bordeaux University Hospital, Pessac, FR,

¹⁷Comprehensive Cancer Centre François Baclesse, Caen, Cedex, FR, ¹⁸Hospices Civils de Lyon, Bron, FR, ¹⁹Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ²⁰CH Intercommunal de Créteil, Créteil, FR

10:04 - 10:05

1017P - AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC)

Y. Yu¹, D. Huang², B. Gao³, J. Zhao⁴, Y. Hu⁵, W. Zhuang⁶, S. Kao⁷, W. Xu⁸, Y. Yao⁹, T.-Y. Yang¹⁰, Y. Lee¹¹, J.-S. Kim¹², H.-S. Shiah¹³, R. Wang¹⁴, H. Zheng¹⁵, W. Tan¹⁶, R. Gao¹⁴, H.R. Kim¹⁷, S. Lu¹⁸, ¹The Third Affiliated Hospital of Harbin Medical University, Harbin, CN, ²Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, CN, ³Blacktown Hospital, Western Sydney Local Health District, Blacktown, AU, ⁴Peking University Cancer Hospital & Institute, Beijing, CN, ⁵Hubei Cancer Hospital, Wuhan, CN, ⁶Fujian Provincial Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, CN, ⁷Chris O'Brien Lifehouse, Camperdown, AU, ⁸Princess Alexandra Hospital, Brisbane, AU, ⁹First Hospital, Medical College, Xi'an Jiaotong University, Xi'an, CN, ¹⁰Taichung Veterans General Hospital, Taichung, TW, ¹¹National Cancer Center, Goyang, KR, ¹²SMG-SNU Boramae Medical Center, Seoul, KR, ¹³Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, TW, ¹⁴BeiGene (Shanghai) Co., Ltd., Shanghai, CN, ¹⁵BeiGene USA, Inc., San Mateo, US, ¹⁶BeiGene (Beijing) Co., Ltd., Beijing, CN, ¹⁷Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, KR, ¹⁸Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN

10:05 - 10:06

1018P - Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients

R. Veluswamy¹, S. Bhalla², R. Samstein¹, T. Marron³, J. Gomez⁴, D. Doroshow⁴, J. Sabari⁵, E. Shum⁶, A. Saxena⁷, A. Namakydoust⁸, A. Chachoua⁶, J. Wisnivesky⁴, J. Mandeli¹, N. Bhardwaj¹, F. Hirsch³, M. Merad¹, E. Reddy⁴, ¹Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US, ²UT Southwestern Medical Center, Dallas, US, ³The Mount Sinai Hospital - Icahn School of Medicine, New York, US, ⁴Icahn School of Medicine at Mount Sinai, New York, US, ⁵NYU Langone Health - Perlmutter Cancer Center - 34th Street, New York, US, ⁶New York University Medical Center, New York, US, ⁷Weill Cornell Medicine, New York, US, ⁸Memorial Sloan Kettering Cancer Center, New York, US

10:06 - 10:07

1019P - Pattern of clinical activity of anticancer vaccine OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial

M.R. Garcia Campelo¹, E. Felip², B. Besse³, M. Cobo Dols⁴, E. Quoix⁵, A.-C. Madroszyk Flandin⁶, F. Cappuzzo⁷, F. Denis⁸, W. Hilgers⁹, G. Romano¹⁰, D. Debieuvre¹¹, D. Galetta¹², E. Baldini¹³, S. Viteri Ramirez¹⁴, M. Duc Phan¹⁵, W. Schuette¹⁶, A. Zer¹⁷, B. Vasseur¹⁸, R. Dziadziuszko¹⁹, G. Giaccone²⁰, ¹Complejo Hospitalario Universitario A Coruña, A Coruña, ES, ²Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES, ³Institut Gustave Roussy, Villejuif, FR, ⁴Hospital Regional Universitario Málaga Carlos Haya, Malaga, ES, ⁵Hopitaux Universitaires de Strasbourg -

Nouvel Hopital Civil, Strasbourg, FR, ⁶IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ⁷IRCCS Regina Elena National Cancer Institute, Rome, IT, ⁸Institut Inter-Régional de Cancérologie Jean Bernard-Elsan, Le Mans, FR, ⁹Sainte Catherine Cancer Center, AVIGNON, FR, ¹⁰Ospedale Vito Fazzi - ASL Lecce, Lecce, IT, ¹¹Groupe Hospitalier de la Région Mulhouse Sud Alsace, Mulhouse, FR, ¹²Istituto Tumori Bari Giovanni Paolo II - IRCCS, Bari, IT, ¹³Ospedale San Luca, Lucca, IT, ¹⁴Instituto Oncológico Dr. Rosell, Hospital Universitario Dexeus, Grupo Quironsalud, Barcelona, ES, ¹⁵University of Oklahoma Health Sciences Center, Oklahoma City, US, ¹⁶Martha-Maria City Hospital Halle-Doelau, Halle, DE, ¹⁷Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, IL, ¹⁸OSE Immunotherapeutics, Paris, FR, ¹⁹Medical University of Gdansk, Gdansk, PL, ²⁰Weill Cornell Medicine, New York, US

10:07 - 10:08 **1020P - Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in metastatic NSCLC patients: The RECLAIM study**

I. Bahce¹, F. Schneiders¹, S. Hashemi¹, J. Veltman¹, H. Daniels¹, M. Fransen¹, T. Radonic¹, E. Ulas¹, I. Houda¹, N. Barlo², M. Disselhorst³, M. Van Laren⁴, M. Tiemessen⁴, S. Tarasevych⁵, J.M. Van Haarst⁶, P. Van Tilburg⁷, P. Kunst⁸, A. Moons-Pasic⁹, T. De Gruijl¹, S. Senan¹, ¹Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, ²Noordwest Ziekenhuisgroep, Alkmaar, NL, ³Noordwest Ziekenhuisgroep - Alkmaar, Alkmaar, NL, ⁴Dijklander Hospital, Hoorn, NL, ⁵Zaans Medisch Centrum, Zaandam, NL, ⁶Tergooi Ziekenhuizen, Hilversum, NL, ⁷Tergooi Hospital - locatie Hilversum, Hilversum, NL, ⁸OLVG Hospital, Amsterdam, NL, ⁹OLVG - location West, Amsterdam, NL

10:08 - 10:09 **1021P - DURATION - a phase II randomized trial in older / frail patients (pts) with advanced non-small cell lung cancer (NSCLC) comparing chemotherapy (CTX, 4 cycles) with CTX (2 cycles) and consecutive durvalumab (D): Top-line early efficacy endpoints**

J. Kuon¹, M. Blasi², K. Kokowski³, M. Faehling⁴, W. Schuette⁵, D.C. Christoph⁶, M. Kimmich⁷, W. Engel-Riedel⁸, J. Fischer⁹, M. Lehmann¹⁰, M. Ulmer¹¹, P. Schuett¹², N. Moosmann¹³, C. Meyer Zum Bueschenfelde¹⁴, F. Griesinger¹⁵, M. Schneider², R. Behnisch¹⁶, A. Stenzinger¹⁷, P. Christopoulos¹⁸, M. Thomas¹⁸, ¹Thoraxklinik at Heidelberg University Hospital, Heidelberg, DE, ²Thoraxklinik Heidelberg, Heidelberg, DE, ³Krankenhaus München Bogenhausen II Med. Abteilung, Munich, DE, ⁴Klinikum Esslingen, Esslingen am Neckar, DE, ⁵Hospital Martha-Maria Halle-Doelau, Halle (Saale), DE, ⁶Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen, DE, ⁷Robert-Bosch-Krankenhaus, Stuttgart, DE, ⁸Krankenhaus Merheim, Köln, DE, ⁹SLK-Kliniken Heilbronn GmbH, Heilbronn, DE, ¹⁰Lungenklinik Hemer des Deutschen Gemeinschafts-Diakonieverbandes GmbH, Hemer, DE, ¹¹Klinikum Ludwigsburg Medizinische Klinik I, Ludwigsburg, DE, ¹²Onkologische Schwerpunktpraxis, Gütersloh, DE, ¹³Barmherzige Brüder Krankenhaus Regensburg, Regensburg, DE, ¹⁴St. Vincentius Hospital Medizinische Klinik II, Karlsruhe, DE, ¹⁵Pius Hospital, Oldenburg, DE, ¹⁶Heidelberg University Hospital, Heidelberg, DE, ¹⁷University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE, ¹⁸Thoraxklinik Heidelberg gGmbH, Heidelberg, DE

10:09 - 10:10 **1022P - A phase II study of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed first line treatment**

C. Zhou¹, A. Xiong¹, J. Fang², X. Li³, Y. Fan⁴, W. Zhuang⁵, Q. Xie⁶, Z. Ma⁷, M. Kang⁸, T.

Xu⁹, M. Xu⁹, L. Zhi⁹, Q. Liu⁹, N. Wang⁹, ¹Shanghai Pulmonary Hospital, Shanghai, CN, ²Peking University Cancer Hospital and Institute, Beijing, CN, ³The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ⁴Zhejiang Cancer Hospital, Hangzhou, CN, ⁵Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN, ⁶Fuzhou Pulmonary Hospital of Fujian, Fuzhou, CN, ⁷The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, CN, ⁸Affiliated Hospital of Guilin Medical University, Guilin, CN, ⁹Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, CN

10:10 - 10:11 **1023P - Relationship between 18F-FDG PET colonic uptake, resting energy expenditure and immune checkpoint inhibitors efficacy in metastatic non-small cell lung cancer (NSCLC) patients: Preliminary results of the MICROBIO-TEP study**

J. Chen, L. Hirsch, D. Dudoignon, M. Tiako Meyo, J. Zerbit, J. Arrondeau, P. Boudou Rouquette, M. Wislez, J. Alexandre, F. Goldwasser, M. Wartski, Hopital Cochin AP-HP, Paris, FR

10:11 - 10:12 **1024P - Net treatment benefit of OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial**

M. Buyse¹, F. Montestruc², J.-C. Chiem¹, V. Deltuvaite-Thomas¹, S. Salvaggio¹, M.R. Garcia Campelo³, M. Cobo Dols⁴, E. Quoix⁵, A.-C. Madroszyk Flandin⁶, F. Cappuzzo⁷, G. Romano⁸, S. Viteri Ramirez⁹, W. Schuette¹⁰, A. Zer¹¹, S. Comis¹², B. Vasseur¹², R. Dziadziuszko¹³, G. Giaccone¹⁴, B. Besse¹⁵, E. Felip¹⁶, ¹International Drug Development Institute, Louvain-la-Neuve, BE, ²eXYSTAT, Malakoff, FR, ³Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES, ⁴Hospital Regional Universitario Málaga Carlos Haya, Malaga, ES, ⁵Hopitaux Universitaires de Strasbourg - Nouvel Hopital Civil, Strasbourg, FR, ⁶IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ⁷IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT, ⁸Ospedale Vito Fazzi - ASL Lecce, Lecce, IT, ⁹Instituto Oncológico Dr. Rosell, Hospital Universitario Dexeus, Grupo Quironsalud, Barcelona, ES, ¹⁰Hospital Martha-Maria Halle-Doelau, Halle (Saale), DE, ¹¹Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, IL, ¹²OSE Immunotherapeutics, Paris, FR, ¹³Medical University of Gdansk, Gdansk, PL, ¹⁴Weill Cornell Medicine, New York, US, ¹⁵Institut Gustave Roussy, Villejuif, FR, ¹⁶Vall d'Hebron University Hospital, Barcelona, ES

10:12 - 10:13 **1025P - DOcetaxel (DOC) plus RAMucirumab (RAM) with pegylated Granulocyte-colONY stimulating factor (PEG-G-CSF) for elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial (DRAGON study: WJOG9416L)**

T. Tokito¹, A. Hata², S. Hara³, M. Tachihara⁴, H. Okada², H. Tanaka⁵, Y. Sato⁶, E. Tabata⁷, H. Watanabe⁸, Y. Takayama⁹, R. Toyozawa¹⁰, I. Okamoto¹¹, K. Wakuda¹², A. Nakamura¹³, M. Shimokawa¹⁴, N. Yamamoto¹⁵, K. Nakagawa¹⁶, ¹Kurume University, Kurume, JP, ²Kobe Minimally Invasive Cancer Center, Kobe, JP, ³Itami City Hospital, Itami, JP, ⁴Kobe University Graduate School of Medicine, Kobe, JP, ⁵Niigata Cancer Center Hospital, Niigata, JP, ⁶Kobe City Medical Center General Hospital, Kobe, JP, ⁷Ikeda City Hospital, Ikeda, JP, ⁸Saka General Hospital, Shiogama, JP, ⁹Hiroshima City Hiroshima Citizens Hospital, Hiroshima, JP, ¹⁰National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, ¹¹Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, ¹²Shizuoka Cancer Center, Shizuoka, JP, ¹³Sendai Kousei Hospital, Sendai,

JP, ¹⁴Yamaguchi University Graduate School of Medicine, Ube, JP, ¹⁵Wakayama Medical University, Wakayama, JP, ¹⁶Kindai University School of Medicine - Main Campus, Osaka, JP

- 10:13 - 10:14 **1026P - Treatment switching adjustment of overall survival in the CheckMate 227 clinical trial of nivolumab plus ipilimumab versus chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer**
M. Reck¹, T. De², L. Paz-Ares³, Y. Yuan⁴, A. Chaudhary⁴, A. Lee⁵, N. Varol⁵, J. Penrod⁴,
¹LungenClinic Grosshansdorf, Grosshansdorf, DE, ²PAREXEL International, Durham, US,
³Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Ciberonc and Universidad Complutense, Madrid, ES, ⁴BMS - Bristol-Myers Squibb, Princeton, US,
⁵Bristol-Myers Squibb Pharmaceuticals Limited - Uxbridge, Uxbridge, GB
- 10:14 - 10:15 **1027P - 1-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer**
C. Verschraegen¹, Z. Andric², T.-E. Ciuleanu³, F. Moiseenko⁴, T. Makharadze⁵, S. Shevnia⁶, A. Oleksienko⁷, E. Yanez Riuz⁸, S.H. Kim⁹, K.Y. Ahn⁹, T.H. Park⁹, S. Park⁹, E. Baek⁹, S. Kwon⁹, H.A. Ju⁹, S.J. Lee⁹, S.H. Kim⁹, H.A. Kim⁹, E.K. Lee⁹, Y. Ohe¹⁰, ¹OSUCCC - The Ohio State University Comprehensive Cancer Center - James, Columbus, US,
²University Clinical Hospital Center Bezanijska Kosa, Belgrade, RS, ³Oncology Institute "Prof. Dr. Ion Chiricuță", Cluj-Napoca, RO, ⁴GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology), Saint-Petersburg, RU, ⁵LTD "High Technology Hospital Medcenter", Batumi, GE, ⁶Communal Nonprofit Enterprise Podilsky Regional Center Of Oncology Of The Vinnytsia Regional Council, Vinnytsia, UA,
⁷Treatment and Diagnostic Center of LLC Specialized Clinic Prognosis Optima, Kyiv, UA, ⁸Instituto Clinico Oncológico del Sur, Temuco, CL, ⁹Celltrion Inc., Incheon, KR, ¹⁰National Cancer Center - Tsukiji Campus, Chuo-ku, JP
- 10:15 - 10:16 **1028P - BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort**
R. Fischer¹, J. George¹, A. Scheel¹, H. Schloesser², P. Brossart³, W. Engel-Riedel⁴, F. Griesinger⁵, C. Grohe⁶, J. Kern⁷, J. Panse⁸, M. Sebastian⁹, M. Serke¹⁰, R. Wiewrodt¹¹, S. Michels², L. Nogova¹, R. Riedel², J.-P. Weber¹², R. Büttner¹³, R. Thomas¹, J. Wolf²,
¹University Hospital Cologne, Köln, DE, ²Universitätsklinikum Köln (AÖR), Köln, DE, ³UKB - Universitätsklinikum Bonn, Bonn, DE, ⁴Krankenhaus Merheim, Köln, DE, ⁵Pius Hospital, Oldenburg, DE, ⁶Charité - Universitaetsmedizin Berlin, Berlin, DE, ⁷KWM Standort Missioklinik - Klinikum Würzburg Mitte gGmbH, Würzburg, DE, ⁸University Hospital RWTH Aachen, Aachen, DE, ⁹Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, DE, ¹⁰Lungenklinik Hemer des Deutschen Gemeinschafts-Diakonieverbandes GmbH, Hemer, DE, ¹¹UKM - University Hospital Muenster, Muenster, DE, ¹²Uniklinik Köln Bettenhaus, Köln, DE, ¹³University Hospital Cologne, Köln, DE
- 10:16 - 10:17 **1029P - Two-year follow-up from KN046 in combination with platinum doublet chemotherapy as first-line (1L) treatment for NSCLC: An open-label, multi-center phase II trial**
Y. Zhao¹, G. Chen¹, X. Li², J. Wu³, B. Chang⁴, S. Hu⁵, S. Yang⁶, Y. Liu⁷, N. Wang⁷, Y.

Huang¹, L. Zhang¹, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ³The First Affiliated Hospital of Xiamen University, Xiamen, CN, ⁴The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, CN, ⁵Hubei Cancer Hospital, Wuhan, CN, ⁶The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN, ⁷Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, CN

10:17 - 10:18 **1030P - Anlotinib plus docetaxel in the treatment of non-small cell lung cancer (NSCLC) after failure of previous immune checkpoint inhibitors (ICIs) therapy: Updated results from a pooled analysis of two phase II trials**

H. Pan¹, Y. Fang¹, L. Wu², ¹Sir Run Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, CN, ²Hunan Cancer Hospital, Changsha, CN

10:18 - 10:19 **1031P - Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian subgroup analysis of the RATIONALE-303 study**

C. Zhou¹, D. Huang², Y. Fan³, X. Yu³, Y. Liu⁴, Y. Shu⁵, Z. Ma⁶, Z. Wang⁷, Y. Cheng⁸, J. Wang⁹, S. Hu¹⁰, E. Poddubskaya¹¹, U. Disel¹², A. Akopov¹³, M. Dvorkin¹⁴, Y. Wang¹⁵, S. Ghassemifar¹⁶, S. Li¹⁷, G. Rivalland¹⁸, ¹Shanghai Pulmonary Hospital, Shanghai, CN, ²Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ³Zhejiang Cancer Hospital, Hangzhou, CN, ⁴The First Hospital of China Medical University, Shenyang, CN, ⁵Jiangsu Provincial People's Hospital, Nanjing, CN, ⁶The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, CN, ⁷Peking University Cancer Hospital and Institute, Beijing, CN, ⁸Jilin Cancer Hospital, Changchun, CN, ⁹Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, ¹⁰Hubei Cancer Hospital, Wuhan, CN, ¹¹VitaMed LLC, Moscow, RU, ¹²Acibadem Health Group Adana Acibadem Hospital, Adana, TR, ¹³Pavlov State Medical University, Saint-Petersburg, RU, ¹⁴BHIOR Clinical Oncology Dispensary, Omsk, RU, ¹⁵BeiGene (Beijing) Co., Ltd., Beijing, CN, ¹⁶BeiGene USA, Inc., San Mateo, US, ¹⁷BeiGene, Ltd., Ridgefield Park, US, ¹⁸Auckland City Hospital, Auckland, NZ

10:19 - 10:20 **1032P - ML41256: Phase II study of atezolizumab (atezo) in combination with bevacizumab (beva) in advanced non-squamous non-small cell lung cancer (nsqNSCLC) patients (pts) pretreated with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs)**

W.F. Fang¹, J. Fang², P. Tian³, Y. Fan⁴, Q. Yu⁵, X. Zhang⁶, Z. Wang⁷, L. Zhang¹, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Beijing Cancer Hospital, Beijing, CN, ³West China Hospital of Sichuan University, Chengdu, CN, ⁴Zhejiang Cancer Hospital, Hangzhou, CN, ⁵Guangxi Medical University Affiliated Tumor Hospital, Nanning, CN, ⁶The Affiliated Hospital of Qingdao University, Qingdao, CN, ⁷Shandong Cancer Hospital, Jinan, CN

10:20 - 10:21 **1033P - IMreal Cohort 2: Second interim analysis of efficacy and safety data in patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) under real-world conditions**

N. Girard¹, S. Popat², S. Shoshkova³, S. Fear⁴, J.L. Perez Gracia⁵, ¹Institut Curie, Paris, FR, ²Royal Marsden Hospital, London, GB, ³Roche Bulgaria EOOD, Sofia, BG, ⁴F. Hoffmann-La Roche Ltd, Basel, CH, ⁵Clínica Universidad de Navarra, Navarra, ES

- 10:21 - 10:22 **1034P - A phase II study of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed prior EGFR-TKIs**
C. Zhou¹, A. Xiong¹, J. Fang², X. Li³, Q. Xie⁴, Q. Yu⁵, L. Han⁶, Z. Ma⁷, J. Shi⁸, B. Wang⁹, M. Ji¹⁰, G. Yang¹¹, T. Xu¹², M. Xu¹², L. Zhi¹², Q. Liu¹², N. Wang¹², ¹Shanghai Pulmonary Hospital, Shanghai, CN, ²Peking University Cancer Hospital and Institute, Beijing, CN, ³The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ⁴Fuzhou Pulmonary Hospital of Fujian, Fuzhou, CN, ⁵Guangxi Medical University Affiliated Tumor Hospital, Nanning, CN, ⁶Xuzhou Central Hospital, Xuzhou, CN, ⁷The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, CN, ⁸Linyi Cancer Hospital, Linyi, CN, ⁹Xuzhou Mining Group General Hospital/The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, CN, ¹⁰The First people's hospital of Changzhou, Changzhou, CN, ¹¹The Second people's hospital of Weifang, Weifang, CN, ¹²Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, CN
- 10:22 - 10:23 **1035P - A phase II trial of nivolumab and denosumab association as second-line treatment for stage IV non-small-cell lung cancer (NSCLC) with bone metastases: DENIVOS study (GFPC 06-2017)**
C. Decroisette¹, I. Monnet², C. Ricordel³, A. Demaegd⁴, L. Falchero⁵, O. Bylicki⁶, M. Geier⁷, G. Justeaux⁸, M. Bernardi⁹, M. Andre¹⁰, F. Guisier¹¹, P. Fournel¹², S. Vieillot¹³, P.A. Hauss¹⁴, R. Schott¹⁵, J. Crequit¹⁶, J.B. Auliac¹⁷, C. Chouaid¹⁸, L. Greillier¹⁹, ¹Centre Hospitalier Annecy Genevois, Metz-Tessy, FR, ²CH De Creteil, Creteil, FR, ³Hopital Pontchaillou, Rennes, FR, ⁴CH de Bigorre, Tarbes, FR, ⁵L'Hopital Nord-Ouest, Gleizé, FR, ⁶Hopital d'instruction des armées Sainte-Anne, Toulon, FR, ⁷CHRU Morvan, University Hospital of Brest, Brest, FR, ⁸CHU Angers, Angers, Cedex, FR, ⁹CH du Pays d'Aix, Aix-en-Provence, FR, ¹⁰CHU Felix Guyon, Saint Denis La Réunion, FR, ¹¹CHU Rouen, Rouen, FR, ¹²CHU St Etienne, Saint-Priest-en-Jarez, Cedex, FR, ¹³CH de Perpignan, Perpignan, FR, ¹⁴CHI Elbeuf, Saint Aubin les Elbeuf, FR, ¹⁵ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ¹⁶CH Beauvais, Beauvais, FR, ¹⁷CHI - Centre Hospitalier Intercommunal de Créteil, Créteil, Cedex, FR, ¹⁸CH Intercommunal de Créteil, Créteil, FR, ¹⁹Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Marseille, FR
- 10:23 - 10:24 **1036P - Anlotinib plus docetaxel vs. docetaxel as 2nd-line treatment of advanced non-small cell lung cancer (NSCLC): Updated results from ALTER-L016**
Y. Fang¹, H. Pan¹, J. Shou², J. Chen³, Q. Guo⁴, W. Hong⁵, C. Rao⁶, Y. Wang⁷, L. Lu⁸, X. Yang⁹, D. Zhu¹⁰, F. Lan¹¹, ¹Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, CN, ²Sir Run Run Shaw Hospital - Zhejiang University School of Medicine - Xiasha Campus, Hangzhou, CN, ³The Affiliated People's Hospital of Ningbo University, Ningbo, CN, ⁴Taizhou Hospital of Zhejiang Province, Taizhou, CN, ⁵Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN, ⁶Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, CN, ⁷Lishui Municipal Central Hospital, lishui, CN, ⁸Zhejiang Provincial People's Hospital, Hangzhou, CN, ⁹The First Hospital of Jiaxing, Jiaxing, CN, ¹⁰Jinhua Central Hospital, Jinhua, CN, ¹¹The Second Affiliated Hospital of Zhejiang University School of Medicine - East Gate 1, Hangzhou, CN
- 10:24 - 10:25

1037P - Taxol-ramucirumab-pembrolizumab (TRP) for immuno-resistant/refractory NSCLC

J. Niu¹, A. Amado², J. Zhou², M. Hebert², T. Liu-Dumlao², M. Capozzi², S. Lindebak²,

¹Banner MD Anderson Cancer Center - Main Campus, Gilbert, US, ²Banner MD Anderson Cancer Center, Gilbert, US

10:25 - 10:26

1038P - Nanosomal docetaxel lipid suspension (NDLS) monotherapy is effective and well-tolerated in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy

C. Deshmukh¹, G. Biswas², A.B. Patel³, R. Naik⁴, S. Belagutti Jayappa⁴, L.C. Kuntegowdanahalli⁵, N. Khippal⁶, R. Nagarkar⁷, G. Mamillapalli⁸, V. Mahobia⁹, S. Bondarde¹⁰, J.G. Patel¹¹, A. Ahmad¹², S. Sheikh¹², S.M. Ali¹², M. Paithankar¹³, A. Rajani¹³, D. Bunker¹³, M. Khan¹³, I. Ahmad¹², ¹Lata Mangeshkar Medical Foundation's Deenanath Mangeshkar Hospital and Research Center, Pune, IN, ²Sparsh Hospitals & Critical Care (P) Ltd., Bhubaneswar, IN, ³Unique Hospital Multispecialty and Research Institute, Surat, IN, ⁴Healthcare Global Enterprises Limited, Bangalore, IN, ⁵Srinivasam Cancer Care Multi Speciality Hospital India Pvt. Ltd., Bangalore, IN, ⁶SMS Medical College and Hospital, Jaipur, IN, ⁷HCG Manavata Cancer Centre, Nasik, IN, ⁸City Cancer Center, Vijayawada, IN, ⁹Government Medical College and Hospital, Nagpur, IN, ¹⁰Shatabdi Super Speciality Hospital, Nasik, IN, ¹¹Apple Hospital and Nirmal Hospital Pvt. Ltd, Surat, IN, ¹²Jina Pharmaceuticals, Libertyville, US, ¹³Intas Pharmaceuticals Ltd., Ahmedabad, IN

10:26 - 10:27

1039P - Efficacy and safety of surufatinib (HMPL-012) as a third-line or further treatment for advanced non-small cell lung cancer (NSCLC)

Y. Zheng, F. Niu, P. Jiang, X. Zhu, J. Lin, X. Wu, L. Qin, Z. Liu, S. Fang, C. Jin, X. Yu, L. Zuo, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, CN

10:27 - 10:28

1040P - Nivolumab or atezolizumab in the second-line treatment of advanced non-small-cell lung cancer? Prognostic index based on real-world data

M. Knetki-Wroblewska, A. Płuzański, S. Tabor, K. Winiarczyk, M. Zaborowska-Szmit, K. Zajda, A. Janowicz Zebrowska, A. Piórek, P. Badurak, P. Jaśkiewicz, D. Kowalski, M. Krzakowski, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL

10:28 - 10:29

1041P - Efficacy and safety of chemotherapy after progression on immunotherapy: Results of a multicenter retrospective observational trial

A. Camerini¹, F. Mazzoni², V. Scotti², C. Tibaldi³, A. Sbrana⁴, L. Calabro⁵, E. Caliman², L.P. Ciccone⁶, M.A. Grosso¹, A. Chella⁷, D. Amoroso¹, E. Baldini³, ¹Ospedale "Versilia", Lido di Camaiore, IT, ²AOUC - Azienda Ospedaliero-Universitaria Careggi, Firenze, IT, ³Ospedale San Luca, Lucca, IT, ⁴Azienda Ospedaliero Universitaria Pisana - Stabilimento di Santa Chiara, Pisa, IT, ⁵AOU Senese - Santa Maria delle Scotte, Siena, IT, ⁶AOU Careggi Radiation Oncology Unit, Florence, IT, ⁷AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT

10:29 - 10:30

1042P - Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin first-line therapy for advanced non-small cell lung cancer

H. Huang, S. Fu, The First Affiliated Hospital of Nanchang University, Nanchang, CN

- 10:30 - 10:31 **1043P - Clinical predictors of benefit from pembrolizumab (pembro) or pembro-chemotherapy (CHT) in advanced non-small cell lung cancer (NSCLC)**
L. Zullo¹, E. Cella¹, D. Favero¹, F. Parisi¹, C. Dellepiane¹, G. Rossi¹, E. Bennicelli¹, G. Barletta¹, L. Zinoli¹, P. Pronzato¹, L. Del Mastro², C. Genova², ¹IRCCS Ospedale Policlinico San Martino, Genova, IT, ²Università degli Studi di Genova, Genova, IT
- 10:31 - 10:32 **1044P - Taxanes plus immunotherapy might be a potential option for HER2-altered NSCLC beyond first-line progression: A retrospective real-world study**
Y. Yang¹, G. Yang², H. Xu³, X. Hao¹, S. Zhang¹, X. Ai¹, S.-Y. Lei¹, Y. Wang¹, ¹National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ²Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CN, ³National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing, CN
- 10:32 - 10:33 **1045P - Comprehensive genomic profiling to guide immunotherapy in lung cancer**
J. Van De Haar¹, J. Mankor², K. Hummelink³, K. Monkhorst¹, E. Smit¹, L. Wessels¹, E. Cuppen⁴, J. Aerts⁵, E. Voest¹, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²Erasmus MC Cancer Institute, Rotterdam, NL, ³Netherlands Cancer Institute, Amsterdam, NL, ⁴Hartwig Medical Foundation, Amsterdam, NL, ⁵Erasmus MC - University Medical Center, Rotterdam, NL
- 10:33 - 10:34 **1046P - Homologous recombination deficiency (HRD) and genomic associations in non-small cell lung cancer (NSCLC) using a novel HRD signature (HRDsig)**
J. Riess¹, R. Madison², K. Tolba², A. Schrock³, G. Oxnard², E. Sokol², ¹UC Davis Comprehensive Cancer Center, Sacramento, US, ²Foundation Medicine, Inc, Cambridge, US, ³Foundation Medicine, Inc., Cambridge, US
- 10:34 - 10:35 **1047P - Lung-MAP S1800A: Exploratory analysis of prior immunotherapy outcomes on OS with ramucirumab plus pembrolizumab for NSCLC with PD on prior ICI**
K. Reckamp¹, M. Redman², K. Dragnev³, L. Villaruz⁴, B. Faller⁵, T. Al Baghdadi⁶, S. Hines⁷, K. Minichiello², D. Gandara⁸, K. Kelly⁹, R.S. Herbst¹⁰, ¹Cedars-Sinai Medical Center, LOS ANGELES, US, ²Fred Hutchinson Cancer Research Center, Seattle, US, ³Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, US, ⁴UPMC Hillman Cancer Center, Pittsburgh, US, ⁵Heartland Cancer Research NCORP, Decatur, US, ⁶Trinity Health Ann Arbor, Ypsilanti, US, ⁷Novant Health Cancer Institute - Mount Airy, Mt Airy, US, ⁸University of California Davis Cancer Center, Sacramento, US, ⁹UC Davis Comprehensive Cancer Center, Sacramento, US, ¹⁰Yale University School of Medicine, New heaven, US
- 10:35 - 10:36 **1048P - Molecular predictors of immunotherapy efficacy in lung squamous-cell carcinoma (LSCC): Results from the randomized prospective SQUINT trial**
F. Cappuzzo¹, A. Delmonte², L. Landi¹, K. Andrikou², A. Dal Maso³, G. Minuti¹, C. Lee⁴, X. Wang⁵, M. Papi⁶, G. Metro⁷, I. Attili⁸, F.V. Piantedosi⁹, S. Pilotto¹⁰, S. Gori¹¹, G. Rossi¹², S. Buglioni¹³, D. Giannarelli¹⁴, L. Bonanno³, ¹IRCCS Istituto Nazionale Tumori

Regina Elena (IRE), Rome, IT, ²IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS S.r.l., Meldola, IT, ³IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁴Vela Genomics Pte. Ltd. - Global Headquarters, Singapore, SG, ⁵Vela Diagnostics Germany GmbH, Hamburg, DE, ⁶Ospedale Infermi, Rimini, IT, ⁷Ospedale S. Maria della Misericordia, Perugia, IT, ⁸IEO - Istituto Europeo di Oncologia, Milan, IT, ⁹Azienda Ospedaliera Dei Colli-Monaldi, Napoli, IT, ¹⁰University of Verona, Verona, IT, ¹¹IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, IT, ¹²Fondazione Poliambulanza Istituto Ospedaliero, Brescia, IT, ¹³Istituto Nazionale Tumori "Regina Elena", Rome, IT, ¹⁴Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT

10:36 - 10:37

1049P - Clinical outcomes in patients (pts) with tumor PD-L1 <3%; 1% with first-line (1L) nivolumab (NIVO) & ipilimumab (IPI) & 2 cycles of chemotherapy (chemo) vs chemo alone for metastatic NSCLC (mNSCLC): Results from CheckMate 9LA

T. John¹, T.-E. Ciuleanu², M. Cobo Dols³, M. Schenker⁴, B. Zurawski⁵, J. Menezes⁶, E. Richardet⁷, J. Bennouna⁸, Y. Cheng⁹, E. Felip¹⁰, O.J. Juan Vidal¹¹, A. Alexandru¹², L. Paz-Ares¹³, S. Lu¹⁴, M. Reck¹⁵, N. Hu¹⁶, X. Zhang¹⁶, D. Grootendorst¹⁶, L. Eccles¹⁷, D. Carbone¹⁸, ¹Austin Hospital, Heidelberg, AU, ²Institutul Oncologic Prof Dr Ion Chiricuta and University of Medicine and Pharmacy Iulia Hatieganu, Cluj-Napoca, RO, ³Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, Malaga, ES, ⁴SF Nectarie Oncology Center, Craiova, RO, ⁵Ambulatorium Chemioterapii, Bydgoszcz, PL, ⁶Hospital Nossa Senhora da Conceição, Porto Alegre, BR, ⁷Instituto Oncológico de Córdoba, Córdoba, AR, ⁸University Hospital of Nantes and INSERM, CRCINA, Nantes, FR, ⁹Jilin Cancer Hospital, Changchun, CN, ¹⁰Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, ES, ¹¹Hospital Universitario La Fe, Valencia, ES, ¹²Institute of Oncology Prof Dr Alexandru Trestioreanu, Bucharest, RO, ¹³Universidad Complutense de Madrid, Madrid, ES, ¹⁴Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai, CN, ¹⁵Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE, ¹⁶Bristol Myers Squibb, Princeton, US, ¹⁷BGB Group, Princeton, US, ¹⁸The Ohio State University Comprehensive Cancer Center, Columbus, US

09:00 - 11:00

Type: Poster session
Title: Poster session 13

Poster Area, Hall 4

09:00 - 09:01

55P - Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)

C. Yoo¹, K.-P. Kim², I. Kim³, M.J. Kang³, J. Cheon⁴, B.W. Kang⁵, H. Ryu⁶, J. Jeong¹, J.S. Lee⁷, K.W. Kim⁷, B.-Y. Ryoo¹, G. Abou-Alfa⁸, ¹Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ²Asan Medical Center - Asan Institute for Life Science, Seoul, KR, ³Inje University Haeundae Paik Hospital, Busan, KR, ⁴Bundang CHA university hospital, seongnam, KR, ⁵KNUH-Kyungpook National University Medical Center Biobank - Chilgok Hospital, Daegu, KR, ⁶Chungnam National University Hospital, Daejeon, KR, ⁷Asan Medical Center - University of Ulsan, Seoul, KR, ⁸Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

09:01 - 09:02

56P - Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (& GC) in patients (pts) with advanced biliary tract cancer (BTC)

D.-Y. Oh¹, A.R. He², S. Qin³, L.-T. Chen⁴, T. Okusaka⁵, A. Vogel⁶, J.W. Kim⁷, T. Suksombooncharoen⁸, M.A. Lee⁹, M. Kitano¹⁰, H. Burris¹¹, M. Bouattour¹², S. Tanasanvimon¹³, R. Zaucha¹⁴, A. Avallone¹⁵, J. Cundom¹⁶, N. Rokutanda¹⁷, M. Watras¹⁸, G. Cohen¹⁷, J. Valle¹⁹, ¹Seoul National University Hospital, and Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, ²Georgetown University, Washington, US, ³Cancer Center of Nanjing, Jinling Hospital, Nanjing, CN, ⁴National Institute of Cancer Research, National Health Research Institutes, Zhunan, TW, ⁵National Cancer Center Hospital, Tokyo, JP, ⁶Hannover Medical School, Hannover, DE, ⁷Seoul National University Bundang Hospital, Seoul, KR, ⁸Chiang Mai University, Chiang Mai, TH, ⁹Seoul St. Mary's Hospital, Catholic University, Seoul, KR, ¹⁰Wakayama Medical University, Wakayama, JP, ¹¹Sarah Cannon Research Institute, Nashville, US, ¹²AP-HP Hôpital Beaujon, Paris, FR, ¹³Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, TH, ¹⁴Medical University of Gdańsk, Gdansk, PL, ¹⁵Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples, IT, ¹⁶Instituto de Investigaciones Metabólicas, Buenos Aires, AR, ¹⁷AstraZeneca, Gaithersburg, US, ¹⁸AstraZeneca, Warsaw, PL, ¹⁹University of Manchester and the Christie NHS Foundation Trust, Manchester, GB

09:02 - 09:03 **57P - Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in advanced biliary tract cancer (BTC)**

L. Antonuzzo¹, H. Takahashi², J.O. Park³, A. Sookprasert⁴, R. Gillmore⁵, S.-S. Yang⁶, J. Cundom⁷, M. Petrova⁸, G. Vaccaro⁹, M. Holmblad¹⁰, J. Xiong¹¹, K. Heider¹², N. Rokutanda¹⁰, D.-Y. Oh¹³, ¹Careggi University Hospital, and Department of Experimental and Clinical Medicine, University of Florence, Florence, IT, ²Osaka International Cancer Institute, Osaka, JP, ³Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁴Khon Kaen University, Khon Kaen, TH, ⁵Royal Free Hospital, London, GB, ⁶Taichung Veterans General Hospital, Taichung, TW, ⁷Instituto de Investigaciones Metabólicas, Buenos Aires, AR, ⁸MHAT Nadezhda, Sofia, BG, ⁹Providence Cancer Institute, Portland, US, ¹⁰AstraZeneca, Gaithersburg, US, ¹¹AstraZeneca, Waltham, US, ¹²AstraZeneca, Cambridge, GB, ¹³Seoul National University Hospital, and Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR

09:03 - 09:04 **58P - Spectrum of germline pathogenic mutations in 1087 Chinese patients with biliary tract cancer**

J. Shen¹, R. Kong², D. Guo², S. Chen², T. Han², M. Wang², G. Lu², W. Deng², R. Ding³, F. Bu³, ¹Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, Shanghai, CN, ²Jiangsu Sincere Diagnostics Co., Ltd., Nanjing, CN, ³Jiangsu Sincere Diagnostics Co., Ltd, Nanjing, CN

09:04 - 09:05 **59P - Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications**

M. Borad¹, M. Javle², W.L. Shaib³, K. Mody⁴, F. Bergamo⁵, W. Harris⁶, N. Damjanov⁷, T. Macarulla Mercade⁸, G. Brandi⁹, G. Masi¹⁰, M. Droz Dit Busset¹¹, A. Boncompagni¹², M. Dimova-Dobreva¹², M. Engelhardt¹³, M. Saulay¹², T. Halfdanarson¹⁴, J. Knox¹⁵, G. Abou-Alfa¹⁶, N. Personeni¹⁷, V. Mazzaferro¹⁸, ¹Mayo Clinic Cancer Center, Scottsdale, US, ²MD Anderson Cancer Center, Houston, US, ³Emory University, Atlanta, US, ⁴Mayo Clinic, Jacksonville, US, ⁵IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁶University

of Washington Medical Center, Seattle, US, ⁷Abramson Cancer Center at the University of Pennsylvania, Philadelphia, US, ⁸Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁹IRCCS Azienda Ospedaliero-Universitaria of Bologna, Bologna, IT, ¹⁰AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT, ¹¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ¹²Basilea Pharmaceutica Ltd., Basel, CH, ¹³Basilea Pharmaceutica AG, Basel, CH, ¹⁴Mayo Clinic, Rochester, US, ¹⁵Princess Margaret Cancer Center, Toronto, ON, CA, ¹⁶Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ¹⁷Istituto Clinico Humanitas, Rozzano, IT, ¹⁸Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, IT

- 09:05 - 09:06 **60P - A phase II trial of hepatic arterial infusion chemotherapy and bevacizumab in combination with toripalimab for advanced biliary tract cancers: Interim report**
X. Wang¹, S. Fu², K. Zheng², G. Cao², L. Xu¹, R. Yang¹, X. Zhu², P. Liu², S. Gao², H. Xu¹, J. Guo², H. Chen¹, K. Wang¹, J. Li¹, J. Zhou¹, X. Zhang¹, C. Hao¹, B. Xing¹, L. Shen¹, ¹Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, CN, ²Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, CN
- 09:06 - 09:07 **61P - Clinical and molecular characterisation of IDH1/2 mutant cholangiocarcinoma**
F. Castet¹, Q. Serra Camprubi², C. Fabregat-Franco¹, H. Verdaguer¹, G. Castillo¹, T. Tian², T. Macarulla Mercade¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES
- 09:07 - 09:08 **62P - Proteomic and single-cell landscape reveals novel pathogenic mechanisms of HBV-infected intrahepatic cholangiocarcinoma**
X. Shuaishuai, W. Wu, R. Chen, C. Ye, Q. Li, J. Chen, Q. Jiang, J. Ruan, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN
- 09:08 - 09:09 **63P - Intrahepatic cholangiocarcinoma (iCCA) genomic findings with high versus low tumor mutational burdens**
T.-Y. Tang¹, J. Ross², J. Rodon¹, M. Javle¹, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²Foundation Medicine, Inc, Cambridge, US
- 09:09 - 09:10 **64P - Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE)**
M. Ueno¹, C. Morizane², M. Ikeda³, M. Ozaka⁴, F. Nagashima⁵, T. Kataoka², J. Mizusawa², A. Ohba², S. Kobayashi¹, H. Imaoka³, A. Kasuga⁴, N. Okano⁵, Y. Nagasaka², K. Kurishita², S. Tomatsuri², M. Sasaki³, T. Shibata², K. Nakamura², J. Furuse¹, T. Okusaka², ¹Kanagawa Cancer Center, Yokohama, JP, ²National Cancer Center - Tsukiji Campus, Tokyo, JP, ³National Cancer Center Hospital East, Kashiwa, JP, ⁴The Cancer Institute Hospital of JFCR, Tokyo, JP, ⁵Kyorin university Faculty of Medicine, Tokyo, JP
- 09:10 - 09:11 **65P - A single-arm, open-label, phase II study of tislelizumab combined with lenvatinib and Gemox regimen for conversion therapy of potentially resectable locally advanced biliary tract cancers**

H. Li, Tianjin Cancer Hospital, Tianjin, CN

- 09:11 - 09:12 **461P - Overview of patients inclusions and outcomes into modern phase I trials at Gustave Roussy over the last 5 years, OVATION study**
E. Alouani¹, A. Gazzah¹, S. Mercier¹, R. Bahleda¹, A. Hollebecque¹, J.-M. Michot¹, C. Baldini¹, S. Champiat¹, A. Marabelle¹, S. Postel-Vinay¹, V. Ribrag¹, Y. Loriot², S. Ponce¹, L. Mahjoubi¹, ¹Gustave Roussy, Villejuif, FR, ²Institut Gustave Roussy, Villejuif, FR
- 09:12 - 09:13 **462P - TYRA-300: FGFR3 selective and gatekeeper agnostic**
J. Starrett, E. Allen, A. Balcer, D. Bensen, T. Burn, I. Hoffman, R. Hudkins, S. Iyer, M. Neal, K. Nelson, C. Occhino, P. Patel, R. Swanson, Q. Ye, Tyra Biosciences, Inc., Carlsbad, US
- 09:13 - 09:14 **463P - Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up**
R.S. McDermott¹, C. Van Tilburg², J. Lin³, S. Kummar⁴, D.S.W. Tan⁵, C.M. Albert⁶, J. Berlin⁷, U. Lassen⁸, F. Doz⁹, B. Geoerger¹⁰, L. Mascarenhas¹¹, N. Federman¹², R. Norenberg¹³, L. Dima¹⁴, C. Mussi¹⁵, E. De La Cuesta¹⁶, T. Laetsch¹⁷, D.S. Hong¹⁸, A. Drilon¹⁹, ¹St Vincent's University Hospital and Cancer Trials Ireland, Dublin, IE, ²Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, DE, ³Massachusetts General Hospital and Harvard Medical School, Boston, US, ⁴Oregon Health & Science University, Portland, US, ⁵National Cancer Centre Singapore, Duke-NUS Medical School, Singapore, SG, ⁶Seattle Children's Hospital and University of Washington School of Medicine, Seattle, US, ⁷Vanderbilt University Medical Center, Nashville, US, ⁸Rigshospitalet, Copenhagen, DK, ⁹SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), Institut Curie and Université Paris Cité, Paris, FR, ¹⁰Gustave Roussy Cancer Center, Université Paris-Saclay, INSERM, Villejuif, FR, ¹¹Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, US, ¹²David Geffen School of Medicine, University of California, Los Angeles, US, ¹³Chrestos Concept GmbH & Co. KG, Essen, DE, ¹⁴Bayer HealthCare SAS, La Garenne-Colombes, FR, ¹⁵Bayer S.p.A, Milan, IT, ¹⁶Bayer HealthCare Pharmaceuticals Inc., Whippany, US, ¹⁷The Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, US, ¹⁸The University of Texas MD Anderson Cancer Center, Houston, US, ¹⁹Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US
- 09:14 - 09:15 **464P - Intra-patient (Pt) comparison from larotrectinib (Laro) clinical trials in tropomyosin receptor kinase (TRK) fusion cancer: An expanded dataset**
A. Italiano¹, A. Drilon², L. Shen³, D.S. Hong⁴, C. Van Tilburg⁵, D.S.W. Tan⁶, J. Lin⁷, S. Kummar⁸, F. Doz⁹, B. Geoerger¹⁰, M. Brose¹¹, A. Briggs¹², U.N. Lassen¹³, G. Vassal¹⁴, K. Keating¹⁵, R. Norenberg¹⁶, L. Dima¹⁷, N. Brega¹⁸, T. Laetsch¹⁹, J. Garcia-Foncillas²⁰, ¹Institute Bergonié and University of Bordeaux, Bordeaux, FR, ²Memorial Sloan Kettering Cancer Center, New York, US, ³Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, CN, ⁴The University of Texas MD Anderson Cancer Center, Houston, US, ⁵Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, DE, ⁶National Cancer Centre Singapore and Duke-NUS Medical School, Singapore, SG, ⁷Massachusetts

General Hospital, Boston, US, ⁸Stanford University, Palo Alto, US, ⁹SIREDON Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), Institut Curie and Université Paris Cité, Paris, FR, ¹⁰Gustave Roussy Cancer Center, Université Paris-Saclay, INSERM U1015, Villejuif, FR, ¹¹University of Pennsylvania, Philadelphia, US, ¹²London School of Hygiene and Tropical Medicine, London, GB, ¹³Rigshospitalet, Copenhagen, DK, ¹⁴Institut Gustave Roussy, Villejuif, FR, ¹⁵Bayer HealthCare Pharmaceuticals Inc., Whippany, US, ¹⁶Chrestos Concept GmbH & Co. KG, Essen, DE, ¹⁷Bayer Consumer Care AG, LA GARENNE COLOMBES CEDEX, FR, ¹⁸Bayer Pharmaceuticals, Milan, IT, ¹⁹The Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, US, ²⁰University Hospital Fundación Jiménez, Madrid, ES

09:15 - 09:16

465P - Larotracking: Real-life study of locally advanced/metastatic solid tumor treated with larotrectinib in French expanded access program

A. Dufresne¹, O. Huillard², C. Dalban¹, M. Geier³, J. Wassermann⁴, S. Zanetta⁵, M. Cabourg⁶, B. Catargi⁷, C. El Kouri⁸, I. Hrab⁹, M. Laramas¹⁰, A. Moreira¹¹, E. Saada¹², C. Tournigand¹³, T. Valentin¹⁴, E. Vauleon¹⁵, R. Mayet¹, D. Perol¹, J.-Y. Blay¹, ¹Centre Léon Bérard, Lyon, FR, ²Hopital Cochin AP-HP, Paris, FR, ³CHRU Morvan, University Hospital of Brest, Brest, FR, ⁴Hôpital Pitié-Salpêtrière AP-HP, Paris, FR, ⁵Centre Georges-François Leclerc, Dijon, FR, ⁶Hospital Center Intercommunal of Elbeuf Louviers Val De Reuil, Saint-Aubin-lès-Elbeuf, FR, ⁷CHU Bordeaux - Hopital St. André, Bordeaux, FR, ⁸Centre Catherine de Sienne, Nantes, FR, ⁹Centre Francois Baclesse, Caen, FR, ¹⁰CHU Grenoble Alpes - Site Nord, La Tronche, FR, ¹¹CHU Amiens, Amiens, FR, ¹²Centre Antoine Lacassagne, Nice, FR, ¹³Centre Hospitalier Universitaire Henri-Mondor AP-HP, Creteil, FR, ¹⁴Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, FR, ¹⁵Centre Eugene Marquis, Rennes, FR

09:16 - 09:17

466P - Efficacy of BRAF inhibitor FORE8394 in BRAF V600E patients

E. Sherman¹, F. Tsai², F. Janku³, C. Allen⁴, R. Yaeger⁵, N. Ammakkanavar⁶, N. Butowski⁷, G. Michelson⁸, M. Paz⁸, A. Tussay-Lindenberg⁸, K. Wang⁸, S. Shepherd⁸, E. Dehan⁸, M. De La Fuente⁹, J. Rodon³, ¹MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ²HonorHealth Research Institute, Scottsdale, US, ³The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁴Baylor College of Medicine, Houston, US, ⁵Memorial Sloan Kettering Cancer Center, New York, US, ⁶Community Cancer Center, Anderson, US, ⁷UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US, ⁸Fore Biotherapeutics Inc., Philadelphia, US, ⁹Sylvester Comprehensive Cancer Center - University of Miami, Miami, US

09:17 - 09:18

467P - Dose escalation of TAS-117 in patients with advanced solid tumors

J. Rodon¹, H.-T. Arkenau², P. Funchain³, A. Hervieu⁴, L. Gao⁵, M. Liu⁵, A. Halim⁵, M. Mina⁵, O. Takahashi⁵, K. Benhadji⁵, S. Delaloge⁶, ¹MD Anderson Cancer Center, Houston, US, ²Sarah Cannon Research Institute, London, GB, ³Cleveland Clinic, Cleveland, US, ⁴Centre Georges-François Leclerc, Dijon, FR, ⁵Taiho Oncology, Inc., Princeton, US, ⁶Institut Gustave Roussy, Villejuif, FR

09:18 - 09:19

468P - Clinical benefit of alpelisib in pediatric patients with PIK3CA-related overgrowth spectrum (PROS): An EPIK-P1 analysis

G. Canaud¹, A. Irvine², D. Adams³, N. Ankrah⁴, P. O'Connell⁵, J.C. López Gutiérrez⁶, ¹Hôpital Necker-Enfants Malades, Paris, FR, ²Trinity College Dublin, Dublin, IE,

³Children's Hospital of Philadelphia, Philadelphia, US, ⁴Novartis Pharmaceuticals Corporation, East Hanover, US, ⁵Novartis Pharmaceuticals, dublin, IE, ⁶La Paz Children's Hospital, Madrid, ES

- 09:19 - 09:20 **469P - A phase I study of palbociclib in combination with cisplatin or carboplatin in advanced solid malignancies**
O. Alese¹, M. Bilen¹, E. Hitron¹, C. Lewis¹, H. Collins¹, S. Scott¹, B. Carthon¹, Y. Cao¹, J. Switchenko¹, R.D. Harvey¹, T. Owonikoko², ¹Winship Cancer Institute of Emory University, Atlanta, US, ²University of Pittsburgh and Hillman Cancer Center, Pittsburgh, US
- 09:20 - 09:21 **470P - Preclinical assessment of the pharmacokinetics, disposition, and duration of action of the dual alphav-integrin and neuropilin-1 targeting peptide CEND-1**
H. Järveläinen¹, C. Schmithals², M. Von Harten², T.J. Vogl², C. Henson³, G. Bullen-Clerkson³, S. Harris³, A. Piiper², ¹University of Helsinki - Faculty of Pharmacy, Helsinki, FI, ²University Hospital Frankfurt, Frankfurt am Main, DE, ³Pharmaron UK, Northamptonshire, GB
- 09:21 - 09:22 **472P - Prognostic markers in patients (pts) with solid tumors submitted to bispecific T-cell engagers in phase I (pH1) clinical trials**
M. Cunha, S. Ammari, J.-M. Michot, A. Laparra, A. Geraud, P. Martin Romano, P. Vuagnat, C. Sarkozy, A. Gazzah, R. Bahleda, K. Ouali, F.-X. Danlos, V. Goldschmidt, A. Hollebecque, A. Marabelle, S. Postel-Vinay, C. Massard, S. Ponce Aix, S. Champiat, C. Baldini, Institut Gustave Roussy, Villejuif, FR
- 09:22 - 09:23 **473P - Phase I study of GFH018, a small molecular TGF- β 2;RI inhibitor, in patients (pts) with advanced solid tumors**
Y. Guo¹, W. Zishu², H. Zhou², H. Pan³, W. Han³, Y. Deng⁴, Y. Zhang⁵, H. Ren⁶, H. Zhang⁶, S. Wang⁶, Y. Zhang⁶, J. Li¹, ¹Shanghai East Hospital (South Division), Shanghai, CN, ²The First Affiliated Hospital of Bengbu Medical College, Bengbu, CN, ³Sir Run Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, CN, ⁴The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN, ⁵Harbin Medical University Cancer Hospital, Harbin, CN, ⁶GenFleet Therapeutics (Shanghai) Inc., Shanghai, CN
- 09:23 - 09:24 **474P - Evaluation of gelatinase-responsive copolymeric nanoparticles targeting PD-1 and TGF- β 2; pathways for treating immune-resistant tumor**
Y. Yen¹, A. Chen², Z. Zhang¹, Q. Wang¹, C. Li², Z. Wei², X. Li¹, X. Wang¹, F. Meng¹, J. Shao¹, L. Yu¹, B. Liu¹, R. Li¹, ¹The Affiliated Hospital of Nanjing University Medical School, Nanjing, CN, ²The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, CN
- 09:24 - 09:25 **475P - Safety and efficacy of vimseltinib in tenosynovial giant cell tumour (TGCT): Long-term phase I update**
H. Gelderblom¹, A. Abdul Razak², J. Martin-Broto³, B. Wilky⁴, P. Rutkowski⁵, S. Narasimhan⁶, M. Vallee⁶, M. Sharma⁶, R. Ruiz-Soto⁶, M.L. Sherman⁶, W.D. Tap⁷, ¹Leiden University Medical Centre, Leiden, NL, ²Princess Margaret Cancer Centre, Toronto, CA, ³Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, ⁴University of Colorado Cancer Center, Aurora, US, ⁵Maria Sklodowska-Curie National Research Institute of

Oncology, Warsaw, PL, ⁶Deciphera Pharmaceuticals, LLC, Waltham, US, ⁷Memorial Sloan Kettering Cancer Center, New York, US

- 09:25 - 09:26 **476P - First-in-human, dose-escalation phase I trial of intratumoral (IT) CyPep-1 in patients (pts) with advanced solid tumors**
F. Eskens¹, F. Opdam², E. Gort³, H. Gelderblom⁴, L. Prestegarden⁵, C. Pico-Navarro⁶,
¹Erasmus MC - University Medical Center, Rotterdam, NL, ²NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ³UMC - University Medical Center Utrecht, Utrecht, NL, ⁴LUMC - Leids Universitair Medisch Centrum, Leiden, NL, ⁵Cytovation AS, Bergen, NO, ⁶Cytovation AS, Madrid, ES
- 09:26 - 09:27 **477P - MTL-STING increases STING expression and potentiates efficacy of checkpoint inhibitor in murine preclinical model**
C.P. Tan¹, B. Ryan¹, V. Gomez¹, R. Hodgson¹, L. Sinigaglia¹, G. Pizza¹, K. Stathaki¹, S. Hegre², R. Habib¹, J. Rossi³, N. Habib⁴, ¹MiNA Therapeutics, London, GB, ²Norwegian University of Science and Technology, Trondheim, NO, ³City of Hope Comprehensive Cancer Center, Duarte, US, ⁴Hammersmith Hospital, London, GB
- 09:27 - 09:28 **478P - Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): Results of the tumor mutational burden-high (TMB-h) and/or microsatellite instability-high (MSI-h) cohort of the MOVIE study**
A. Hervieu¹, J. Guigay², E. Borcoman³, P. Lavaud⁴, E. Coquan⁵, J.-S. Frenel⁶, T. De La Motte Rouge⁷, P. Augereau⁸, C. Cropet⁹, F. Legrand¹⁰, A. Goncalves¹¹, ¹Centre Georges-François Leclerc (Dijon), Dijon, FR, ²Centre Anticancer Antoine Lacassagne, Nice, FR, ³Institut Curie, Paris, FR, ⁴Institut Gustave Roussy, Villejuif, Cedex, FR, ⁵Centre Francois Baclesse, Caen, Cedex, FR, ⁶ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁷Centre Eugene - Marquis, Rennes, FR, ⁸Centre Paul Papin, Angers, FR, ⁹Centre Léon Bérard, Lyon, FR, ¹⁰UNICANCER, Paris, FR, ¹¹Institute Paoli Calmettes, Marseille, FR
- 09:28 - 09:29 **479P - Synergistic anti-tumor effect of Allocetra-OTS in combination with immune checkpoint inhibitors (ICI)/chemotherapy/CAR T, through in-vivo reprogramming of macrophages**
D. Mevorach¹, E. Yalon², E. Regev³, C. Ankri², O. HersHKovitz², Y. Shabat², B. Reicher²,
¹Hadassah-Hebrew University Medical Center, Jerusalem, IL, ²Enlivex, Nes Ziona, IL, ³Hadassah University Hospital - Ein Kerem, Jerusalem, IL
- 09:29 - 09:30 **480P - CATRIPCA – A phase I of pembrolizumab (P) combined with Xevinapant (Debio 1143, (X)) in patients (pts) with non MSI-high advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) or colorectal cancer (CRC)**
P. Cassier¹, C. Terret¹, A. Voisin², C. Schiffler¹, A.-S. Bidaux¹, H. Vanacker³, L. Eberst⁴, M.W. Lepercq³, A. D'Argenio³, M. Bernardin⁵, A. Bouhamama³, L. Gilles-Afchain³, I. Treilleux³, S. Tabone-Eglinger³, D. Spaggiari⁶, S. Chabaud⁷, Y. Grinberg-Bleyer⁸, G. Garin³, D. Perol³, A. Vinceneux³, ¹Centre Léon Bérard, LYON, FR, ²CRCL - Centre de recherche en cancerologie de Lyon, LYON, FR, ³Centre Léon Bérard, Lyon, FR, ⁴ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ⁵Center Leon Berard, LYON, FR, ⁶Debiopharm International S.A., Lausanne, CH, ⁷Centre de recherche en

cancerologie de Lyon (CRCL), Lyon, FR, ⁸CRCL - Centre de recherche en cancerologie de Lyon, Lyon, Cedex, FR

- 09:30 - 09:31 **481P - A phase I first-in-human study of XL092 in patients (pts) with locally advanced or metastatic solid tumors: Results from dose-escalation of XL092 alone and in combination with atezolizumab**
- M. Sharma¹, V. Subbiah², G. Shapiro³, S. Pal⁴, N. Agarwal⁵, K. Wentzel⁶, B. Fang⁷, N. Zhang⁸, M. Schwickart⁸, Z. Wang⁸, D. Curran⁸, A. Patnaik⁹, ¹START Midwest, Grand Rapids, US, ²The University of Texas M. D. Anderson Cancer Center, Houston, US, ³Dana Farber Cancer Institute, Boston, US, ⁴City of Hope Comprehensive Cancer Center, Duarte, US, ⁵Huntsman Cancer Institute, University of Utah, Salt Lake City, US, ⁶The Angeles Clinic and Research Institute, Los Angeles, US, ⁷Astera Cancer Care, East Brunswick, US, ⁸Exelixis, Inc., Alameda, US, ⁹START San Antonio, San Antonio, US
- 09:31 - 09:32 **482P - Safety, pharmacokinetic (PK), and pharmacodynamic profiles of the WEE1 inhibitor IMP7068 in patients (pts) with advanced solid tumors**
- C.-C. Lin¹, J. Grewal², D. Sommerhalder³, L.-Y. Bai⁴, G. Li⁵, R. Schneider⁶, L. Shen⁷, Y.-M. Yeh⁸, R. Yin⁹, H.-C. Hsu¹⁰, J. Baranda¹¹, C.-Y. Hsieh¹², S.X. Cai¹², Y.E. Tian¹², N. Ma¹², H. Xia¹², C. Zhang¹², B. Li¹², M. Zhang¹², Z. Yu¹², ¹NTUH - National Taiwan University Hospital, Taipei City, TW, ²Norton Cancer Institute, Louisville, US, ³NEXT Oncology, San Antonio, US, ⁴China Medical University Hospital, New Taipei City, TW, ⁵Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ⁶Mary Crowley Cancer Research Center, Dallas, US, ⁷Beijing Cancer Hospital, Beijing, CN, ⁸NCKUH - National Cheng Kung University Hospital, Tainan City, TW, ⁹West China Second University Hospital, Sichuan University/ West China Women's and Children's Hospital, Chengdu, CN, ¹⁰Chang Gung Medical Foundation - Linkou Branch, Taoyuan City, TW, ¹¹KUMC - University of Kansas Clinical Research Center, Kansas City, US, ¹²IMPACT Therapeutics, Inc. (Shanghai), Shanghai, CN
- 09:32 - 09:33 **483P - Pre-clinical and early clinical assessment of the safety and anti-tumor activity of RP12146, a PARP1/2 inhibitor in solid tumors**
- P. Tomczak¹, M. Kwiatek¹, D. Chraniuk², M. Kmiecik², I. Lugowska³, M. Chelstowska³, S. Eleswarapu⁴, S. Veeraraghavan⁴, K. Routhu⁵, P. Barde⁵, A. Nair⁵, ¹Pratia Poznań Medical Center, Poznan, PL, ²Clinical Trials Site Nasz Lekarz, Toruń, PL, ³Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL, ⁴Incozen Therapeutics Pvt. Ltd., Hyderabad, IN, ⁵Rhizen Pharmaceuticals AG, Basel, CH
- 09:33 - 09:34 **484P - CHARIOT trial (cohort A2): A phase I dose-escalation study combining the ATR inhibitor berzosertib with cisplatin and capecitabine**
- S. El Badri¹, S. Lord¹, R. Harman¹, D. McIntosh², S. Mukherjee³, A. Ooms⁴, M. Parkes⁴, G. Radhakrishna⁵, P. Shaw⁶, M. Hawkins⁷, ¹University of Oxford, Oxford, GB, ²BWSCC - Beatson West of Scotland Cancer Centre, Glasgow, GB, ³Oxford Institute for Radiation Oncology, Oxford, GB, ⁴University of Oxford - NDORMS, Oxford, GB, ⁵The Christie NHS Foundation Trust, Manchester, GB, ⁶Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff, GB, ⁷UCL - University College London, London, GB
- 09:34 - 09:35 **485P - Correlation of clinical, genomic and hematological parameters with ATR inhibitor (ATRI) outcomes in phase I/II clinical trials**

N. Ngoi¹, H. Lin¹, E. Ileana Dumbrava¹, S. Fu¹, D. Karp¹, A. Naing¹, S. Pant¹, J. Rodon¹, S. Piha-Paul¹, V. Subbiah¹, A.M. Tsimberidou¹, E. Campbell¹, S. Urrutia², D.S. Hong¹, F. Meric-Bernstam¹, Y. Yuan¹, T. Yap¹, ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²MD Anderson Cancer Center, Houston, US

09:35 - 09:36

486P - AK130, a first-in-class Fc-mutant anti-TIGIT antibody fused with TGF- β 2;RII protein, elicits potent anti-tumor efficacy in pre-clinical studies

J. Min, Z. Huang, X. Pang, T. Zhong, C. Jin, N. Chen, D. Xia, P. Zhang, Z.M. Wang, Y. Xia, B. Li, Akeso Biopharma Inc., Zhongshan, CN

09:36 - 09:37

487P - Randomized phase II study of trabectedin/olaparib compared to physician's choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies

C. Heilig¹, M.-V. Teleanu¹, I. Bhatti¹, S. Richter², J. Siveke³, S. Wagner⁴, H.-G. Kopp⁵, T. Kindler⁶, L. Illert⁷, A. Golf⁸, K. Dormann⁹, A. Benner¹⁰, H. Süsse¹, A. Freitag¹, C. Von Kalle¹¹, H. Glimm¹², D. Hübschmann¹⁰, S. Fröhling¹, R. Schlenk¹, ¹NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE, ²Universitätsklinikum Carl Gustav Carus Dresden, Dresden, DE, ³West German Cancer Center, University Hospital Essen, Essen, DE, ⁴Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, DE, ⁵Robert-Bosch-Center for Tumor Diseases, Stuttgart, DE, ⁶Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, ⁷Universitätsklinikum Freiburg Klinik für Innere Medizin Hämatologie, Onkologie und Stammzelltransplantation, Freiburg im Breisgau, DE, ⁸Universitätsklinikum Tübingen, Tuebingen, DE, ⁹LMU - Ludwig Maximilians University of Munich, Munich, DE, ¹⁰DKFZ - German Cancer Research Center, Heidelberg, DE, ¹¹Berlin Institute of Health, Berlin, DE, ¹²National Center for Tumor Diseases, Partner site Dresden (NCT), Dresden, DE

09:37 - 09:38

488P - Phase I trial of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in follicular lymphoma (FL), small cell lung cancer (SCLC) and castration-resistant prostate cancer (CRPC)

M. Schweizer¹, K. Penkov², A. Tolcher³, A. Choudhury⁴, V. Doronin⁵, R. Aljumaily⁶, E. Calvo⁷, R. Frank⁸, J. Hamm⁹, V. Moreno Garcia¹⁰, V. Vorobyev¹¹, S. Billotte¹², T. Bowler¹³, J. Chen¹⁴, T. Lin¹³, L. Liu¹⁵, A. Maity¹², S. Sharma¹², M. Johnson¹⁶, ¹University of Washington, Seattle, US, ²Private Medical Institution "Euromedservice", Saint-Petersburg, RU, ³NEXT Oncology, San Antonio, US, ⁴Dana Farber Cancer Institute, Boston, US, ⁵State Budgetary Healthcare Institute of Moscow City Clinical Hospital No 40, Moscow, RU, ⁶Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, ⁷START Madrid Group, Madrid, ES, ⁸Norwalk Hospital, Nuvance Health, Norwalk, US, ⁹Norton Cancer Institute, Louisville, US, ¹⁰Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, ¹¹Botkin Hospital, Moscow, RU, ¹²Pfizer, San Diego, US, ¹³Pfizer, New York, US, ¹⁴Pfizer Inc - USA, San Francisco, US, ¹⁵Pfizer Inc - La Jolla Campus - CB10, San Diego, US, ¹⁶Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, US

09:38 - 09:39

489P - Analysis of 3-dimensional volumetric distribution and dispersion of the radioenhancer NBTXR3 in various solid malignancies

T. De Baere¹, C. Shen², A. Ducassou³, S. Bonvalot⁴, E. Chajon⁵, L. Farber⁶, O. Vivar⁷, P. Tyan⁸, E. Koay⁹, S. Lin⁹, Z. Liao⁹, A. Dicker¹⁰, C. Hoffmann⁴, C. Le Tourneau¹¹, ¹Institut Gustave Roussy, Villejuif, FR, ²UNC - The University of North Carolina at Chapel Hill -

School of Medicine, Chapel Hill, US, ³IUCT - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, FR, ⁴Institut Curie, Paris, FR, ⁵Centre Eugene - Marquis, Rennes, FR, ⁶Nanobiotix Corp., Cambridge, US, ⁷Nanobiotix, Paris, FR, ⁸Nanobiotix, Munich, DE, ⁹The University of Texas MD Anderson Cancer Center, Houston, US, ¹⁰Thomas Jefferson University, Philadelphia, US, ¹¹Paris Saclay University; Institut Curie, Paris, FR

09:39 - 09:40

490P - Safety and efficacy of tusamitamab ravtansine in patients with colorectal or gastric cancer expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)

A. Italiano¹, A. Gazzah², J. Tabernero³, Y.-K. Kang⁴, E. Calvo⁵, M. Provencio Pulla⁶, Y.-J. Bang⁴, F. Barlesi⁷, P. Bedard⁸, J.O. Park⁹, J.-S. Kim¹⁰, M. Chadja¹¹, S. Yoruk¹², J.-P. Delord¹³, ¹Institute Bergonié, Bordeaux, FR, ²Gustave Roussy, Villejuif, FR, ³Vall d'Hebron University Hospital and Institute of Oncology, IOB-Quiron, UVic-UCC, Barcelona, ES, ⁴Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁵Centro Integral Oncológico Clara Campal, Madrid, ES, ⁶Hospital Universitario Puerta de Hierro, Madrid, ES, ⁷Aix-Marseille University, INSERM, CNRS, CRCM, APHM, Gustave Roussy, Villejuif, FR, ⁸Princess Margaret Cancer Centre-University Health Network, University of Toronto, Toronto, CA, ⁹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ¹⁰Seoul National University Boramae Medical Center, Seoul, KR, ¹¹Sanofi, Inc., Vitry-sur-Seine, FR, ¹²Sanofi, Inc., Istanbul, TR, ¹³IUCT-Oncopole, Toulouse, FR

09:40 - 09:41

491TiP - A first-in-human phase I/II study of BLU-222, a potent, selective CDK2 inhibitor in patients with CCNE1-amplified or CDK4/6 inhibitor-resistant advanced solid tumors

T. Yap¹, K. Moore², M. Patel³, B. Henick⁴, D. Do⁵, A. Iheanacho⁵, H. Zhang⁵, M. Roche⁵, K. Newberry⁵, A. Hsieh⁵, D. Juric⁶, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²University of Oklahoma Health Sciences Center, Oklahoma City, US, ³Sarah Cannon Research Institute, Sarasota, US, ⁴Columbia University Irving Medical Center, New York, US, ⁵Blueprint Medicines Corporation, Cambridge, US, ⁶Massachusetts General Hospital, Boston, US

09:41 - 09:42

492TiP - A phase I study of synthetic lethal, IDE397 (MAT2A inhibitor) as a monotherapy and in combination with chemotherapy in advanced solid tumors harboring MTAP deletion

M. Johnson¹, J. Rodon², R. Aljumaily³, M. Villalona-Calero⁴, E. Borazanci⁵, M. Pishvaian⁶, A. Turk⁷, R. Carvajal⁸, C. Mantia⁹, G. Giaccone¹⁰, Z. Mounir¹¹, A. Patel¹¹, M. Maurer¹¹, C. Neilan¹¹, D. Rajendran¹¹, U. Ganesan¹¹, J. Hinkle¹², A. Tolcher¹³, ¹Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ²The University of Texas M. D. Anderson Cancer Center, Houston, US, ³Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, ⁴City of Hope National Medical Center, Duarte, US, ⁵HonorHealth Research Institute, Scottsdale, US, ⁶Johns Hopkins University, Baltimore, US, ⁷Indiana University Simon Cancer Center, Indianapolis, US, ⁸Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, ⁹Dana Farber Cancer Institute, Boston, US, ¹⁰Weill Cornell Medicine, New York, US, ¹¹IDEAYA Biosciences, South San Francisco, US, ¹²EarlyPhase Sciences, Inc., Magnolia, US, ¹³NEXT OncologyTM, San Antonio, US

09:42 - 09:43

493TiP - A CRUK phase I/IIA, first in human dose-escalation and expansion trial

of HMBD-001 (an anti-HER-3 antibody) in patients with advanced HER3-positive solid tumours

J. De Bono¹, S. Lord², C. Yap³, E.K. Rowinsky⁴, N. Gandhi⁴, D. Thakkar⁵, P. Ingram⁵, N. Padmanabhan⁵, K. Chandran⁶, A. Paschalis¹, L. McGuigan⁷, P. Neal⁷, D. Paisley⁷, H. Walter⁷, F. Kelly⁷, J. Craigan⁷, N. Westwood⁷, G. Halbert⁷, J. Boyd-Kirkup⁵, S. Halford⁷,
¹ICR - Institute of Cancer Research, London, GB, ²University of Oxford, Oxford, GB, ³ICR - The Institute of Cancer Research - North Site, Sutton, GB, ⁴Hummingbird Bioscience, Houston, US, ⁵Hummingbird Bioscience Pte. Ltd. - Temasek Lifescience Laboratories, Singapore, SG, ⁶The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB, ⁷CRUK - Cancer Research UK, London, GB

09:43 - 09:44 **494TiP - Phase Ib study of elimusertib (ATRI; BAY 1895344) in combination with niraparib (PARPi) in patients with advanced solid tumors**

T. Yap¹, P. Konstantinopoulos², R. Grisham³, D. Gupta⁴, G. Wilkinson⁵, A. Cao⁶, M. Jeffers⁶, N. Sharma⁶,
¹The University of Texas MD Anderson Cancer Center, Houston, US, ²Dana Farber Cancer Institute, Boston, US, ³Memorial Sloan Kettering Cancer Center, New York, US, ⁴GlaxoSmithKline, Waltham, US, ⁵Bayer Pharma AG, Berlin, DE, ⁶Bayer HealthCare Pharmaceuticals Inc., Whippany, US

09:44 - 09:45 **495TiP - A phase II study evaluating the safety and efficacy of ENV-101 (taladegib) in patients with advanced solid tumors harboring PTCH1 loss of function mutations**

J. Luke¹, S. Pendyala², A. Di Francesco², S. Kim², L. Dellamary², S. Kc², H. Humphreys², M. De Los Rios², J. Pitman², J. Hood², D.S. Hong³,
¹University of Pittsburgh Cancer Institute, Pittsburgh, US, ²Endeavor Biomedicines, San Diego, US, ³The University of Texas MD Anderson Cancer Center, Houston, US

09:45 - 09:46 **500P - The impact of COVID-19 on the management and outcome of oncology patients: The results of the Middle East and North African (MENA) COVID-19 and Cancer Registry (MCCR)**

A.R. Jazieh¹, H. Abdel-Razeq², E. K  ksoy³, A. Bounedjar⁴, A. Tafayli⁵, E. Tashkandi⁶, W. Jastaniah⁷, J. Ansari⁸, M. Alorabi⁹, A. Darwish¹⁰, A. Rabea¹⁰, A. Alolayan¹¹, F. Ibnshamsa¹², H. Errihani¹³, M. Alkaiyat¹⁴, E. Garrett-Mayer¹⁵, S.S. Bruinooge¹⁵, F. Hussain¹⁶, H. Tamim¹⁶, K. Alkattan¹⁶,
¹Cincinnati Cancer Advisors, Cincinnati, US, ²KHCC - King Hussein Cancer Center, Amman, JO, ³Ankara University Medical School, Ankara, TR, ⁴CHU de Blida, Blida, DZ, ⁵AUBMC - American University of Beirut Medical Center, Beirut, LB, ⁶King Abdulaah Medical City-Makkah, Makkah, SA, ⁷King Faisal Specialist Hospital & Research Centre - Jeddah (KFSHRC-J), Jeddah, SA, ⁸Tawam Hospital, Al Ain, AE, ⁹Ain Shams University - Faculty of Medicine, Cairo, EG, ¹⁰National Cancer Institute - Cairo University, Cairo, EG, ¹¹King Abdulaziz Medical City, Riyadh, SA, ¹²KFSH-D - King Fahad Specialist Hospital - Dammam, Dammam, SA, ¹³National institut of oncology, Rabat, MA, ¹⁴King Abdulaziz Medical Cities (KAMC) - National Guard Hospital, Hofuf, SA, ¹⁵American Society of Clinical Oncology (ASCO), Alexandria, US, ¹⁶Alfaisal University, Riyadh, SA

09:46 - 09:47 **501P - A prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19**

S. Halabi¹, B. Luo¹, H. Dzimitrowicz², C. Hwang³, T. Wise-Draper⁴, C. Labaki⁵, R.R.

Mckay⁶, E. Ruiz⁷, C. Rangel-Escareño⁸, D. Farmakiotis⁹, E. Griffiths¹⁰, C. Jani¹¹, M. Accordino¹², C. Friese¹³, E. Wulff-Burchfield¹⁴, M. Puc¹⁵, P. Yu¹⁶, U. Topaloglu¹⁷, S. Mishra¹⁸, J. Warner¹⁹, ¹Duke University Medical Center, Durham, US, ²Duke Cancer Center - Duke University Medical Center, Durham, US, ³Henry Ford Cancer Institute-Henry Ford Health, Detroit, US, ⁴University of Cincinnati Cancer Centre, Cincinnati, US, ⁵Dana Farber Cancer Institute, Boston, US, ⁶Moore's Cancer Center - UC San Diego Health, La Jolla, US, ⁷INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico, MX, ⁸National Institute of Genomic Medicine, Mexico City, MX, ⁹Lifespan Cancer Institute - Rhode Island Hospital, Providence, US, ¹⁰Roswell Park Comprehensive Cancer Center, Buffalo, US, ¹¹Mount Auburn Hospital - Harvard Medical School, Cambridge, US, ¹²HICCC - Herbert Irving Comprehensive Cancer Center - Columbia University, New York, US, ¹³Michigan Medicine University of Michigan, Ann Arbor, US, ¹⁴KUMC - University of Kansas Medical Center, Kansas City, US, ¹⁵Virtua Health, Marlton, US, ¹⁶Hartford Health Care Cancer Institute, Hartford, US, ¹⁷Wake Forest University Comprehensive Cancer Center, Winston-Salem, US, ¹⁸Vanderbilt University Medical Center, Nashville, US, ¹⁹Vanderbilt Ingram Cancer Center, Nashville, US

09:47 - 09:48

502P - Association of immunotherapy and immunosuppression with severe COVID-19 disease in patients with cancer

Z. Bakouny¹, P. Grover², C. Labaki³, J. Awosika⁴, S. Gulati², C.-Y. Hsu⁵, M. Bilen⁶, O. Eton⁷, L. Fecher⁸, C. Hwang⁹, H. Khan¹⁰, R. Mckay¹¹, E. Ruiz¹², L. Weissmann¹³, M. Thompson¹⁴, D. Shah¹⁵, J. Warner¹⁶, Y. Shyr¹⁷, T. Choueiri³, T. Wise-Draper¹⁸, ¹Dana-Farber Cancer Institute, Boston, US, ²UCCI - University of Cincinnati Cancer Institute, Cincinnati, US, ³Dana Farber Cancer Institute, Boston, US, ⁴University of Cincinnati Cancer Centre, Cincinnati, US, ⁵Vanderbilt University Medical Center, Nashville, US, ⁶Winship Cancer Institute of Emory University, Atlanta, US, ⁷Hartford HealthCare Cancer Institute, Hartford, US, ⁸Michigan Medicine University of Michigan, Ann Arbor, US, ⁹Henry Ford Cancer Institute-Henry Ford Health, Detroit, US, ¹⁰Brown University, Providence, US, ¹¹University of California San Diego - UCSD, La Jolla, US, ¹²INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico, MX, ¹³Mount Auburn Hospital - Harvard Medical School, Cambridge, US, ¹⁴Tempus Labs, Chicago, US, ¹⁵Mays Cancer Center - UT Health San Antonio MD Anderson Cancer Center, San Antonio, US, ¹⁶Vanderbilt Ingram Cancer Center, Nashville, US, ¹⁷Vanderbilt University - Department of Biostatistics, Nashville, US, ¹⁸Vontz Center for Molecular Studies, Cincinnati, US

09:48 - 09:49

503P - The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway

A. Helland¹, K. Tasken², H.E.G. Russnes³, L. Fagereng⁴, E.S. Blix⁵, S. Brabrand⁶, T. Donnem⁵, Å. Flobak⁷, B.T. Gjertsen⁸, A. Haug⁹, R. Hovland⁸, G. Inpred¹, P.E. Lonning¹⁰, P. Niehusmann¹, K. Puco¹¹, E.S. Samdal⁹, S. Smeland², ¹Oslo University Hospital, Oslo, NO, ²Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, ³Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, NO, ⁴Oslo University Hospital - Radiumhospitalet, Oslo, NO, ⁵University Hospital of North Norway, Tromsø, NO, ⁶University of Oslo, Institute of Clinical medicine, Oslo, NO, ⁷St. Olavs Hospital HF, Trondheim, NO, ⁸Haukeland University Hospital, Bergen, NO, ⁹Haukeland Universitetssykehus, Bergen, NO, ¹⁰University of Bergen, Bergen, NO, ¹¹Lovisenberg Diakonale Sykehus AS, Oslo, NO

09:49 - 09:50

504P - SARS-CoV-2 Omicron (B.1.1.529) variant infection leads to high morbidity

and mortality in unvaccinated patients with cancer

D. Pinato¹, J. Aguilar-Company², A. Bertuzzi³, G. Hanbury⁴, M. Bower⁵, R. Salazar⁶, M. Lambertini⁷, P. Pedrazzoli⁸, A. Lee⁹, A. Sinclair¹⁰, S. Townsend¹¹, A. Plaja Salarich¹², A. Sita-Lumsden¹³, U. Mukherjee¹⁴, N. Diamantis¹⁴, R. Sharkey⁵, G. Gaidano¹⁵, A. Gennari¹⁶, J. Tabernero¹⁷, A. Cortellini¹⁸, ¹Imperial College London - Hammersmith Hospital, London, GB, ²Hospital Universitario Vall d'Hebron, Barcelona, ES, ³Humanitas Research Hospital, Rozzano, IT, ⁴St. Mary's Hospital Imperial College Healthcare NHS Trust, London, GB, ⁵Chelsea and Westminster Hospital - NHS Trust, London, GB, ⁶Institut Català d'Oncologia-Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ⁷IRCCS Ospedale Policlinico San Martino, Genova, IT, ⁸Fondazione IRCCS Policlinico San Matteo, Pavia, IT, ⁹UCL Cancer Institute - Paul O'Gorman Building, London, GB, ¹⁰UCLH - University College London Hospitals NHS Foundation Trust, London, GB, ¹¹Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff, GB, ¹²HUGTP - Hospital Universitario Germans Trias i Pujol, Badalona, ES, ¹³London Bridge Hospital - Private Care at Guys - HCA Healthcare UK, London, GB, ¹⁴St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, ¹⁵Amedeo Avogadro University, Novara, IT, ¹⁶Università Degli Studi Del Piemonte Orientale - Scuola di Medicina, Novara, IT, ¹⁷Vall d'Hebron University Hospital, Barcelona, ES, ¹⁸Imperial College London, London, GB

09:50 - 09:51

505P - The impact of COVID-19 on the wellness and resilience of the Canadian medical oncology workforce: A Canadian Association of Medical Oncologists survey

L. Jones¹, B. Colwell², D. Hao³, S. Welch⁴, A. Campbell⁵, S. Gill¹, ¹BC Cancer Agency - Vancouver, Vancouver, CA, ²Dalhousie University, Halifax, CA, ³Tom Baker Cancer Centre, Calgary, CA, ⁴London Regional Cancer Program (LRCP) - London Health Science Center (LHSC), London, CA, ⁵Canadian Association of Medical Oncologists (CAMO), Ottawa, CA

09:51 - 09:52

506P - The prognostic utility of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in carcinoma of unknown primary (CUP): An experience from a tertiary UK cancer centre

J.A. Scott¹, N. Peters¹, C. Harman², C. Mitchell¹, A.-M. Conway³, N. Cook¹, ¹The Christie NHS Foundation Trust, Manchester, GB, ²The University of Manchester, Manchester, GB, ³Cancer Research UK Manchester Institute The University of Manchester, Alderley Edge, GB

09:52 - 09:53

507P - Clinical characteristics and survival outcomes in neuroblastoma: A single center study at a regional cancer center

A. Padakanti¹, V. Toka², K.C. Puligundla³, R. Parimkayala³, S. Attili⁴, ¹Osmania Medical College, Hyderabad, IN, ²Mnj institute of oncology & Regional Cancer Center, Hyderabad, IN, ³MNJ Institute of Oncology & Regional Cancer Center, Hyderabad, IN, ⁴Omega Hospitals, Hyderabad, IN

09:53 - 09:54

508P - High prevalence of clonal hematopoiesis of indeterminate potential (CHIP) associated mutations in elderly patients with solid tumors

J. Rodriguez¹, A. Bayle¹, A. Pages¹, F.-X. Danlos², D. Vasseur³, E. Rouleau³, L. Lacroix³, V. Goldschmidt¹, L. Seknazi⁴, A. Hollebecque¹, J.-M. Michot⁵, S. Champiat³, A. Marabelle⁵, S. Postel-Vinay⁵, K. Ouali³, C. Marzac¹, S. Ponce¹, A. Italiano¹, J. Baptiste Micol¹, C.

Baldini³, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Gustave Roussy - INSERM U1015, Villejuif, FR, ³Gustave Roussy - Cancer Campus, Villejuif, FR, ⁴UPMC Université Pierre et Marie Curie, Paris, FR, ⁵Institut Gustave Roussy, Villejuif, FR

- 09:54 - 09:55 **509P - COVID-19 disease among lung cancer (LC) patients: Data from a real-life prospective multicentric study**
O. Molinier¹, L. Falchero², I. Monnet³, C. Decroisette⁴, A.-C. Neidhart⁵, E. Redureau⁶, A.-M. Chiappa⁷, F. Bigot⁸, A. Bedossa⁹, K. Amrane¹⁰, S. Jeandeau¹¹, C. Dujon¹², A.-S. Bugnet¹³, P. Bonnefoy¹⁴, C. Alizon¹⁵, N. Meyer¹⁶, S. Couraud¹⁷, A. Cortot¹⁸, A. Letierce¹⁹, D. Debieuvre²⁰, ¹Centre Hospitalier Du Mans, Le Mans, FR, ²Hospital Center De Villefranche-Sur-Saône, Gleizé, FR, ³CH Intercommunal de Créteil, Creteil, FR, ⁴Le Centre Hospitalier Annecy Genevois, Metz-Tessy, FR, ⁵Centre Hospitalier de Colmar, Colmar, FR, ⁶CHD Vendee - Hopital Les Oudairies, La Roche-sur-Yon, FR, ⁷CH de Cornouaille, Quimper, FR, ⁸Centre Hospitalier de Cholet, Cholet, FR, ⁹Grand Hôpital de l'Est Francilien - Site de Marne-la-Vallée, Jossigny, FR, ¹⁰Hospital Center Des Pays De Morlaix, Morlaix, FR, ¹¹Etablissement de santé MGEN Sainte-Feyre, Sainte-Feyre, FR, ¹²Centre Hospitalier de Versailles - Hopital Andre Mignot, Le Chesnay, FR, ¹³Centre Hospitalier de Thonon (du Lemman), Thonon-les-Bains, FR, ¹⁴Hôpital de Jonzac, Jonzac, FR, ¹⁵Centre Hospitalier Lannion-Trestel, Lannion, FR, ¹⁶CHU de Strasbourg, Strasbourg, FR, ¹⁷Lyon Sud Hospital Center - HCL, Pierre-Bénite, FR, ¹⁸CHU Lille - Centre Hospitalier Régional Universitaire de Lille, Lille, FR, ¹⁹Qualitystat, MORANGIS, FR, ²⁰GHRMSA, Mulhouse, FR
- 09:55 - 09:56 **510P - Long-term outcomes of COVID-19 infection in patients with solid tumors before vaccination**
O. Yazici, O. Ünsal, Ö.F. Özkan, N. Ozdemir, G. Tahtaci, A. Uner, N. Günel, A. Özet, Gazi University - Faculty of Medicine, Ankara, TR
- 09:56 - 09:57 **511P - HIV impact in localized anal carcinoma: A matched cohort study**
A. Acioli De Almeida¹, E. Rocha¹, R. Colombo Bonadio¹, D. Galhera¹, M.I. Braghiroli¹, L. Alban¹, C. Victor¹, A. Dornellas², M. Polo Mingueti E Silva¹, C. Araujo De Carvalho¹, A. Bueno¹, C. Nahas¹, K. Ibrahim¹, A. Chen¹, P. Hoff², C. Motta Venchiarutti Moniz², ¹ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR, ²University of Sao Paulo - Faculty of Medicine, Sao Paulo, BR
- 09:57 - 09:58 **514P - Nerve sparing retroperitoneal lymph node dissection for clinical stage IIA/B seminomas: A clinical phase II trial**
A. Heidenreich¹, P. Paffenholz², T. Nestler¹, D. Pfister³, ¹Universitätsklinikum Köln (AöR), Köln, DE, ²University Hospital Cologne, Köln, DE, ³University Hospital Cologne, Cologne, DE
- 09:58 - 09:59 **515P - Prognostic significance of elevated serum tumor markers (STM) after the first cycle of chemotherapy in patients with intermediate and poor risk non seminomatous testicular germ cell tumors (NSGCT)**
A. Batra, B. Nayak, P. Singh, R.K. Sahoo, H. Kunhiparambath, S. Kaushal, A. Seth, A. Varshney, A. Raj, AIIMS - All India Institute of Medical Sciences, New Delhi, IN
- 09:59 - 10:00 **516P - Early relapse in seminoma is associated with reduced overall survival**

P. Paffenholz¹, T. Nestler², F. Seelemeyer³, M. Von Brandenstein¹, B. Köditz³, D. Pfister¹, A. Heidenreich⁴, ¹University Hospital Cologne, Cologne, DE, ²Bundeswehrzentral Krankenhaus Koblenz, Koblenz, DE, ³University Hospital Cologne, Köln, DE, ⁴Uniklinik Köln, Cologne, DE

- 10:00 - 10:01 **709P - Real-world systemic treatment patterns of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma (HCC)**
A. Singal¹, K. Ozgurdal², X. Fan³, Z. Vassilev³, C.-C. Chen⁴, J. Multani⁵, Z. Zhou⁴, J. He⁴, F. Pisa⁶, ¹University of Texas Southwestern Medical Center, Dallas, US, ²Bayer Consumer Care AG, Basel, CH, ³Bayer HealthCare Pharmaceuticals Inc., Whippany, US, ⁴IQVIA US, Plymouth Meeting, US, ⁵IQVIA US, Falls Church, US, ⁶Bayer AG, Berlin, DE
- 10:01 - 10:02 **710P - Neoadjuvant tislelizumab for resectable recurrent hepatocellular carcinoma: A non-randomized control, phase II trial (TALENT)**
S. Chen¹, Y. Wang², W. Xie², S. Shen², S. Peng², M. Kuang², ¹First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, ²The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN
- 10:02 - 10:03 **711P - Sintilimab combined with bevacizumab biosimilar as a conversion therapy in potentially resectable intermediate stage hepatocellular carcinoma (HCC): A phase II trial**
H. Sun¹, X. Zhu¹, Q. Gao¹, S. Qiu¹, Y. Shi¹, X. Wang¹, X. Huang¹, X. Yang¹, Y. Ji², Y. Pang², Y. He¹, Y. Xu¹, M. Li¹, J. Zhu¹, Y. Shen¹, C. Huang¹, J. Zhou¹, J. Fan¹, ¹Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, CN, ²Zhongshan Hospital, Fudan University, Shanghai, CN
- 10:03 - 10:04 **712P - CAPT: A multicenter randomized controlled trial of perioperative versus postoperative camrelizumab plus apatinib for resectable hepatocellular carcinoma**
X. Bai¹, Y. Chen¹, X. Zhang¹, F. Zhang², X. Liang³, C. Zhang⁴, X. Wang⁵, B. Lu⁶, S. Yu⁷, T. Liang¹, ¹The First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, CN, ²Taizhou Hospital of Zhejiang Province, Taizhou, CN, ³Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, CN, ⁴Zhejiang Provincial People's Hospital, Hangzhou, CN, ⁵Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN, ⁶Shaoxing People's Hospital, Shaoxing, CN, ⁷Jinhua Central Hospital, Jinhua, CN
- 10:04 - 10:05 **713P - Pembrolizumab (Pembro) vs placebo (Pbo) as second-line treatment for sorafenib-treated advanced hepatocellular carcinoma (aHCC): 4.5-year follow-up from KEYNOTE-240**
J. Edeline¹, R. Finn², M. Bouattour³, A.-L. Cheng⁴, L. Chan⁵, T. Yau⁶, M. Garrido⁷, J. Knox⁸, B. Daniele⁹, V. Breder¹⁰, H.Y. Lim¹¹, S. Ogasawara¹², A. Odeleye-Ajakaye¹³, I. Martinez-Forero¹³, A. Siegel¹³, P. Merle¹⁴, ¹Centre Eugène Marquis, Rennes, FR, ²David Geffen School of Medicine at UCLA, Los Angeles, US, ³Hôpital Beaujon, Assistance Publique Hôpitaux de Paris, Clichy, FR, ⁴National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, TW, ⁵Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Hong Kong, CN, ⁶The University of Hong Kong, Hong Kong, CN, ⁷Pontificia Universidad Catolica de Chile, Santiago, CL, ⁸UHN Princess

Margaret Cancer Centre, University of Toronto, Toronto, CA, ⁹Ospedale del Mare, Napoli, IT, ¹⁰N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ¹¹Samsung Medical Center, Sungkyunkwan University, Seoul, KR, ¹²Graduate School of Medicine, Chiba University, Chiba, JP, ¹³Merck & Co., Inc., Rahway, US, ¹⁴Hôpital de la Croix-Rousse, Hospices Civils de Lyon, and Centre de Recherche en Cancerologie de Lyon, Lyon, FR

10:05 - 10:06

714P - Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

L. Chan¹, M. Kudo², B. Sangro³, R.K. Kelley⁴, J. Furuse⁵, J.-W. Park⁶, P. Sunpaweravong⁷, A. Fasolo⁸, T. Yau⁹, T. Kawaoka¹⁰, A.-L. Cheng¹¹, S. Azevedo¹², M.E. Reig Monzon¹³, E. Assenat¹⁴, M. Yarchoan¹⁵, A.R. He¹⁶, M. Makowsky¹⁷, D. Ran¹⁷, A. Negro¹⁷, G. Abou-Alfa¹⁸, ¹Department of Clinical Oncology, Sir Yue-Kong Pao Center for Cancer, The Chinese University of Hong Kong, Hong Kong SAR, CN, ²Kindai University Faculty of Medicine, Osaka, JP, ³Clínica Universidad de Navarra and CIBEREHD, Pamplona, ES, ⁴University of California, San Francisco, US, ⁵Kanagawa Cancer Center, Yokohama, JP, ⁶National Cancer Center, Goyang, KR, ⁷Prince of Songkla University Hospital, Songkhla, TH, ⁸Fondazione Michelangelo, Milan, IT, ⁹Queen Mary Hospital, Pok Fu Lam, Hong Kong SAR, CN, ¹⁰Hiroshima University, Hiroshima, JP, ¹¹National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, TW, ¹²UPCO- Hospital de Clínicas de Porto Alegre, Porto Alegre, BR, ¹³Hospital Clinic de Barcelona, IDIBAPS, CIBEREHD, University of Barcelona, Barcelona, ES, ¹⁴Saint Eloi Hospital, Montpellier University, Montpellier, FR, ¹⁵Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, ¹⁶Georgetown University, Washington, US, ¹⁷AstraZeneca, Gaithersburg, US, ¹⁸Memorial Sloan Kettering Cancer Center & Weill Medical College, Cornell University, New York, US

10:06 - 10:07

715P - The safety and efficacy of lenvatinib combined with TACE and PD-1 inhibitors (Len-TAP) versus TACE alone in the conversion resection for initially unresectable hepatocellular carcinoma: Interim results from a multicenter prospective cohort study

Z. Xiaoyun¹, X. Zhu¹, X. Feng², W. Han³, M.-L. Yan⁴, F. Xie⁵, S. Zhang⁶, Y. Zhang⁷, X. Jiang⁸, W. Peng¹, C. Li¹, W. Lu¹, C. Liu¹, Q. Li¹, W. Chen¹, S. Cheng⁹, T. Wen¹, ¹SCU - Sichuan University - Huaxi Campus, Chengdu, CN, ²Sichuan Cancer Hospital and Institute/The Affiliated Cancer Hospital School of Medicine, UESTC, Chengdu, CN, ³Beijing Luhe Hospital, Beijing, CN, ⁴Fujian Provincial Hospital, Fuzhou, CN, ⁵NeiJiang first people's hospital, neijiang, CN, ⁶chengdu second people's hospital, chengdu, CN, ⁷Sichuan Provincial People's Hospital, sichuan chengdu, CN, ⁸yibing second hospital, Chengdu, CN, ⁹Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, Shanghai, CN

10:07 - 10:08

716P - Impact of COVID-19 pandemic on clinical outcomes in hepatocellular carcinoma: A multicentre cohort study

S. De Souza¹, J. Kahol De Jong¹, R. Jones², H. Reeves³, S. Shetty⁴, J. Orr⁵, D. Bettinger⁶, V. Yip⁷, L. Temperley⁸, D. Geh⁹, M. Qurashi⁴, B. Allen⁵, L. Sturm⁶, A. Banerjee⁷, P. Ross¹⁰, R. Sharma¹¹, ¹Imperial College London - Hammersmith Campus, London, GB, ²The Royal Liverpool University Hospital, Liverpool, GB, ³Northern Institute for Cancer Research, Newcastle-upon-Tyne, GB, ⁴Queen Elizabeth Hospital - University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB, ⁵University Hospitals Bristol NHS

Foundation Trust, Bristol, GB, ⁶University Medical Center Freiburg, Freiburg im Breisgau, DE, ⁷Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB, ⁸King's College Hospital - NHS Foundation Trust, London, GB, ⁹Newcastle University, Newcastle upon Tyne, GB, ¹⁰Guy's & St Thomas NHS Foundation Trust, London, GB, ¹¹Hammersmith Hospital, London, GB

- 10:08 - 10:09 **717P - Phase II study of transhepatic artery chemoembolization (TACE) combined with tislelizumab (TIS) and lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma(uHCC)**
X. Nong, J.-L. Xie, Y.-M. Zhang, J.-C. Liang, Z.-L. Pan, Z.-M. Zhang, Guangxi Tumor Hospital and Oncology Medical Center Medical University Affiliated, Nanning, CN
- 10:09 - 10:10 **718P - Prognosis-related molecular subtypes and immune features associated with hepatocellular carcinoma**
J. Ye, Y. Lin, X. Gao, L. Lu, X. Huang, S. Huang, T. Bai, G. Wu, Y. Li, X. Luo, R. Liang, Guangxi Tumor Hospital and Oncology Medical Center Medical University Affiliated, Nanning, CN
- 10:10 - 10:11 **719P - Tyrosine kinase inhibitors and/or immune checkpoint inhibitors is required for improving efficacy of transarterial chemoembolization for hepatocellular carcinoma: A large-scale multicenter real-world study of 582 patients**
G. Yuan¹, R. Li², M. Zang¹, Q. Li¹, X. Hu¹, W. Fan³, W. Huang⁴, J. Ruan⁵, H. Pang², J. Chen¹, ¹Nanfang Hospital, Southern Medical University, Guangzhou, CN, ²Nanfang Hospital of Southern Medical University, Guangzhou, CN, ³1st Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, ⁴Shunde Hospital, Southern Medical University, Shunde, CN, ⁵The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN
- 10:11 - 10:12 **720P - Integrative genomic analysis of matched primary and recurrent tumors reveals molecular characteristics of hepatocellular carcinoma with short-term recurrence**
J. Cao¹, K. Liu¹, K. Li¹, W. Hu¹, J. Pang¹, P. Sun¹, S. Zhang², X. Zhang², F. Pang², D. You², ¹The Affiliated Hospital of Qingdao University, Qingdao, CN, ²Shanghai Origimed Co., Ltd, Shanghai, CN
- 10:12 - 10:13 **721P - Molecular alterations as predictors of response to immunotherapy in hepatocellular carcinoma**
J. Chang¹, K. Fowler¹, S. Ting¹, P. Tamayo¹, A. Burgoyne², ¹University of California San Diego - UCSD, La Jolla, US, ²Moore's Cancer Center - UC San Diego Health, La Jolla, US
- 10:13 - 10:14 **722P - Modeling of tumor control probability (TCP) and normal tissue complications in individualized hypofractionated radiotherapy (IHRT) for large, advanced hepatocellular carcinoma (HCC)**
S.M. Wong¹, C.L. Chiang², W.S. Wu¹, N.Y. Chan¹, W.Y. Lee¹, H.M. Ho¹, W.L. Yip¹, S.Y. Yeung¹, A.S. Lee¹, M.K.H. Chan³, C.S.F. Wong¹, ¹Tuen Mun Hospital, Tuen Mun, HK, ²Queen Mary Hospital, Hong Kong, HK, ³University of Groningen, University Medical Center Groningen, Groningen, NL

- 10:14 - 10:15 **723P - Medical expenditures and treatment efficacy of patients who had initial hepatocellular carcinoma and underwent surgery or radiofrequency ablation: Accompanying research of the SURF trial**
Y. Kawaguchi¹, R. Kita², T. Kimura², R. Goto³, T. Takayama⁴, N. Izumi⁵, M. Kudo⁶, S. Kaneko⁷, N. Yamanaka⁸, M. Inomata⁹, M. Shimada¹⁰, H. Baba¹¹, K. Koike¹, M. Omata¹², M. Makuuchi¹³, Y. Matsuyama¹, Y. Yamada¹⁴, N. Kokudo¹⁴, K. Hasegawa¹⁵, ¹The University of Tokyo, Bunkyo-ku, JP, ²Osaka Red Cross Hospital, Osaka, JP, ³Keio University, Yokohama, JP, ⁴Nihon University School of Medicine, Tokyo, JP, ⁵Japanese Red Cross Musashino Hospital, Musashino, JP, ⁶Kindai University - Faculty of Medicine, Osaka, JP, ⁷Kanazawa University, Kanazawa, JP, ⁸Meiwa Hospital, Nishinomiya, JP, ⁹Oita University Faculty of Medicine, Yufu, JP, ¹⁰Tokushima University Graduate School, Tokushima, JP, ¹¹Kumamoto University, Kumamoto, JP, ¹²Yamanashi Prefectural Central Hospital, Kofu, JP, ¹³Koto Hospital, Koto-ku, JP, ¹⁴NCGM - National Center for Global Health and Medicine, Shinjuku-ku, JP, ¹⁵The University of Tokyo Graduate School of Medicine, Tokyo, JP
- 10:15 - 10:16 **724P - Anti-PD-1 antibody SHR-1210 combined with apatinib as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: Preliminary results from a multicenter, randomized, controlled phase II trial**
H. Zhao¹, S. Du², Z. Zhu³, L. Jiang⁴, X. Che⁵, H. Qian⁶, J. Song⁷, D. Liu⁸, Y. Zhang⁹, P. Zhang¹⁰, Y. Sun¹, W. Zhang¹, Y. Tang¹, ¹National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ²Peking Union Medical College Hospital, Chinese Academy of Medical College & Peking Union Medical College Hospital, Beijing, CN, ³The Fifth Medical Center of PLA General Hospital, Beijing, CN, ⁴Beijing Ditan Hospital, Capital Medical University, Beijing, CN, ⁵Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, CN, ⁶Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, CN, ⁷Beijing Hospital, Beijing, CN, ⁸Xuanwu Hospital Capital Medical University, Beijing, CN, ⁹Harbin Medical University Cancer Hospital, Harbin, CN, ¹⁰the First Bethune Hospital of Jilin University, Changchun, CN
- 10:16 - 10:17 **725P - Identification of cuproptosis-related subtypes, the development of a prognosis model and drug candidates in HCC**
Y. Wang¹, Y. Zhang², L. Wang³, N. Zhang¹, W. Xu¹, J. Zhou¹, Y. Zhao¹, W. Zhu¹, T. Zhang¹, L. Wang¹, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²Fudan University Shanghai Cancer Center, Qingdao City, CN, ³Fudan University Shanghai Cancer Center, Shanghai, CN
- 10:17 - 10:18 **726P - Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study)**
M. Zang¹, Q. Li², H. Pang², X. Hu², R. Li², G. Yuan¹, W. Li², Y. Guo¹, J. Chen², ¹Nanfang Hospital, Southern Medical University, Guangzhou, CN, ²Nanfang Hospital of Southern Medical University, Guangzhou, CN
- 10:18 - 10:19 **727TiP - A randomised phase III study of tremelimumab (T) plus durvalumab (D) with or without lenvatinib combined with concurrent transarterial**

chemoembolisation (TACE) versus TACE alone in patients (pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-3

G. Abou-Alfa¹, J. Fan², J. Heo³, Y. Arai⁴, J. Erinjeri¹, C. Kuhl⁵, R. Lencioni⁶, Z. Ren², A. Zeng⁷, B. Evans⁷, G. Cohen⁷, M. Kudo⁸, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²Zhongshan Hospital, Fudan University, Shanghai, CN, ³Pusan National University Hospital, Busan, KR, ⁴National Cancer Center, Chuo-ku, Tokyo, JP, ⁵University Hospital of Aachen, Aachen, DE, ⁶University of Pisa School of Medicine, Pisa, IT, ⁷AstraZeneca, Gaithersburg, US, ⁸Kindai University Faculty of Medicine, Osaka, JP

10:19 - 10:20

738P - Combined ipilimumab and nivolumab in previously treated patients with cancer of unknown primary: Results of the CheCUP trial

M. Pouyiourou¹, B. Kraft¹, T. Wohlfrohm², M. Stahl³, B. Kubuschok⁴, H. Löffler⁵, U. Hacker⁶, G. Huebner⁷, C.B. Westphalen⁸, M. Bitzer⁹, T. Ernst¹⁰, P. Schuett¹¹, T. Hielscher¹², S. Delorme¹², A. Stenzinger¹³, T. Bochtler¹, A. Krämer¹, ¹German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, DE, ²DKFZ - German Cancer Research Center, Heidelberg, DE, ³Evangelische Kliniken Essen Mitte, Essen, DE, ⁴Augsburg University Medical Center, Augsburg, DE, ⁵Marienhospital Stuttgart, Stuttgart, DE, ⁶University of Leipzig Faculty of Medicine, Leipzig, DE, ⁷Ameos Krankenhausgesellschaft Ostholstein, Oldenburg, DE, ⁸Hospital of the University of Munich, Munich, DE, ⁹University Hospital Tuebingen, Tuebingen, DE, ¹⁰Jena University Hospital, Jena, DE, ¹¹Onkologische Schwerpunktpraxis, Gütersloh, DE, ¹²German Cancer Research Center (DKFZ), Heidelberg, DE, ¹³University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE

10:20 - 10:21

739P - Patient preference for subcutaneous nivolumab (NIVO) with/without recombinant human hyaluronidase PH20 (rHuPH20) vs intravenous NIVO: An exploratory analysis of a phase I/II pharmacokinetic multi-tumor study

S. Lonardi¹, B. Bennett², M. Dixon³, ¹Veneto Institute of Oncology IOV-IRCSS, Padova, IT, ²Bristol Myers Squibb, Uxbridge, GB, ³Bristol Myers Squibb, Princeton, NJ, US

10:21 - 10:22

740P - Anti-cytotoxic T-lymphocyte antigen-4 (CTLA 4) probody BMS-986249 ± nivolumab (NIVO) in patients (pts) with advanced cancers: Updated phase I results

M. Gutierrez¹, C. Friedman², G. Long³, P. Ascierto⁴, I. Melero⁵, D. Richards⁶, B. Bastos⁷, V. Moreno Garcia⁸, M. Uemura⁹, P. Conkling¹⁰, B. Corr¹¹, A. Kim¹², L. Zhu¹², A. Hammell¹², D. Perumal¹², A. Chouzy¹³, F. Benavente¹², O. Awosemo¹², A. Hannah¹⁴, D. Le¹⁵, ¹John Theurer Cancer Center - Hackensack University Medical Center, Hackensack, US, ²Memorial Sloan Kettering Cancer Center, New York, US, ³The University of Sydney, and Royal North Shore and Mater Hospitals, Wollstonecraft, AU, ⁴Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁵Clinica Universitaria de Navarra, Pamplona, ES, ⁶Texas Oncology-Tyler Medical Records Coordinator, Tyler, US, ⁷Miami Cancer Institute - Baptist Health South Florida, Miami, US, ⁸Fundacion Jimenez Diaz University Hospital, Madrid, ES, ⁹Willamette Valley Cancer Institute and Research Center, Eugene, US, ¹⁰Virginia Oncology Associates, Norfolk, US, ¹¹University of Colorado Denver - Anschutz Medical Campus, Aurora, US, ¹²Bristol Myers Squibb, Princeton, US, ¹³Bristol Myers Squibb, Boudry, CH, ¹⁴CytomX Therapeutics, South San Francisco, US, ¹⁵Johns Hopkins University School of Medicine, Baltimore, US

- 10:22 - 10:23 **741P - Phase I results demonstrate highly differentiated safety and PK profile of ADG126, a masked anti-CTLA-4 SAFEbody in patients with advanced solid tumors**
G. Richardson¹, A. Tolcher², M. Morris³, P. De Souza⁴, A. Hamid⁵, X. She⁶, L. Zhu⁶, S. Zheng⁶, G. Liu⁶, Y. Li⁶, F. Du⁶, S. Fischkoff⁶, H. Gong⁶, J. Zha⁶, P. Luo⁶, ¹Oncology Clinics Victoria - Cabrini Malvern Hospital, Malvern, AU, ²NEXT Oncology, San Antonio, US, ³Sunshine Coast University Hospital, Birtinya, AU, ⁴Western Sydney University - School of Medicine, Campbelltown, AU, ⁵Cabrini Malvern Hospital, Malvern, AU, ⁶Adagene Inc., San Diego, US
- 10:23 - 10:24 **742P - First-in-human phase I study of INCAGN02385, a LAG-3 monoclonal antibody antagonist in patients with advanced malignancies**
J. Powderly¹, O. Hamid², M. Gutierrez³, A. Balmanoukian⁴, J. Janik⁵, P. Hoyle⁵, Z. Dong⁵, W. Wei⁵, X. Chen⁵, N. Bourayou⁵, L. Horn⁶, ¹Carolina BioOncology Institute, Huntersville, US, ²The Angeles Clinic and Research Institute, A Cedars Sinai Affiliate, Los Angeles, US, ³Hackensack University Medical Center, Hackensack, US, ⁴The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, US, ⁵Incyte Corporation, Wilmington, US, ⁶Vanderbilt University Medical Center - Preston Cancer Research Building, Nashville, US
- 10:24 - 10:25 **743P - A phase Ib dose escalation study of CD137 mAb agonist OC-001 as monotherapy in patients with advanced or metastatic cancer**
W. Miller¹, D. Provencher², Q.S.-C. Chu³, D. Jonker⁴, A. Oza⁵, G. Batist¹, R. Jamal⁶, R. Goel⁴, J. Hilton⁴, J. Spratlin⁷, P. Smith⁸, I. Darling⁹, J. Stille⁸, C. Fortier¹⁰, R. Mangat¹¹, J. Polzer¹⁰, ¹Jewish General Hospital McGill University, Montreal, CA, ²CRCHUM - Centre de recherche du CHUM, Montreal, CA, ³Cross Cancer Institute, Edmonton, CA, ⁴The Ottawa Hospital Regional Cancer Centre, Ottawa, CA, ⁵UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ⁶CHUM - Centre Hospitalier de l'Université de Montréal, Montreal, CA, ⁷Alberta Health Services - Holy Cross Centre, Calgary, CA, ⁸Eli Lilly and Company, New York, US, ⁹Cognigen, Buffalo, US, ¹⁰Ocellaris Pharma Inc., Montreal, CA, ¹¹Ozmosis Reseach Inc., Toronto, CA
- 10:25 - 10:26 **744P - Safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of adebrelimab: A phase I trial**
X. Hu¹, Y. Fan², W. Jing³, Y. Shen³, X. Ma³, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²Zhejiang Cancer Hospital, Hangzhou, CN, ³Jiangsu Hengrui Pharmaceutical Co., Ltd., Shanghai, CN
- 10:26 - 10:27 **745P - Clinical activity, safety, and PK/PD from the first in human study (NP41300) of RO7247669, a PD1-LAG3 bispecific antibody**
K. Rohrberg¹, E. Garralda², E. Calvo³, V. Moreno Garcia⁴, M. Guidi⁵, D. Kraus⁵, C. McIntyre⁶, H. Kao⁵, L. Codarri Deak⁷, F. Michielin⁵, T. Liu⁵, M. Muecke⁵, C. Markert⁸, I. Melero⁹, ¹Rigshospitalet, Copenhagen, DK, ²Hospital Universitario Vall d'Hebron, Barcelona, ES, ³START Madrid Group, Madrid, ES, ⁴START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, ES, ⁵F. Hoffmann-La Roche Ltd, Basel, CH, ⁶Roche Products Limited, Welwyn Garden City, GB, ⁷Roche Glycart AG, Schlieren, CH, ⁸Roche Diagnostics GmbH, Penzberg, DE, ⁹Clinica Universitaria de Navarra, Pamplona, ES

- 10:27 - 10:28 **746P - Synergistic antitumor efficacy of INV-71 ROR gamma agonist with immune checkpoint inhibitor anti-PD-1 in a murine orthotopic 4T1 breast cancer model**
C. Sebesta¹, V. Chung², A. El-Khoueiry³, J. Tilley⁴, W. Windsor⁵, T. Stouch⁴, J. Ellingboe⁴, C. Zhang¹, A. Gaweco⁴, ¹Klinik Donaustadt, Vienna, AT, ²City of Hope Comprehensive Cancer Center, Duarte, US, ³USC - University of Southern California - Keck School of Medicine, Los Angeles, US, ⁴Innovimmune Biotherapeutics, New York, US, ⁵Stevens Institute of Technology, Hoboken, US
- 10:28 - 10:29 **747P - Phase I study of SAR444245 (SAR#x2019;245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors**
G. Falchook¹, S. Fu², C. Lemech³, M. Mckean⁴, A. Azad⁵, H. Gan⁶, D. Sommerhalder⁷, J. Wang⁸, T. Tan⁹, C.E. Chee¹⁰, M. Barve¹¹, J. Moser¹², J. Mooney¹³, N. Acuff¹³, R. Wang¹⁴, N. Marina¹⁴, G. Abbadessa¹⁴, M. Streit¹⁴, S. Ramusovic¹⁵, T. Meniawy¹⁶, ¹Sarah Cannon Research Institute, Denver, US, ²The University of Texas M. D. Anderson Cancer Center, Houston, US, ³Scientia Clinical Research, Randwick, AU, ⁴Sarah Cannon Research Institute, Nashville, US, ⁵Peter MacCallum Cancer Centre, Melbourne, AU, ⁶Austin Health, Heidelberg, AU, ⁷NEXT Oncology, San Antonio, US, ⁸Florida Cancer Specialists & Research Institute - Lake Mary Cancer Center, Lake Mary, US, ⁹NCCS - National Cancer Centre Singapore, Singapore, SG, ¹⁰NCIS - National University Cancer Institute Singapore, Singapore, SG, ¹¹Mary Crowley Cancer Research Center, Dallas, US, ¹²Honor Health Research and Innovative Institute, Scottsdale, US, ¹³Synthorx, A Sanofi Company, La Jolla, US, ¹⁴Sanofi, Cambridge, US, ¹⁵Sanofi, Berlin, DE, ¹⁶Linear Clinical Research & University of Western Australia Hospital, Nedlands, AU
- 10:29 - 10:30 **748P - Development of a CCR8 monoclonal antibody for the treatment of cancer**
G. Fan, Nanjing Immunophage Biotech Co., Ltd., Nanjing, CN
- 10:30 - 10:31 **749P - ANV419, a selective IL-2R-beta-gamma targeted antibody-IL-2 fusion protein, in patients with advanced solid tumors, a phase I/II study**
H. Läubli¹, G. Alonso², J. Lopez³, E. Calvo⁴, M. Joerger⁵, V. Perez⁶, D. Di Blasi⁷, A. Nair⁷, K. Richter⁷, C. Huber⁷, J. Mouton⁷, S. Costanzo⁷, S. Jethwa⁷, C. Bucher⁷, E. Garralda⁸, ¹Universitatsspital Basel, Basel, CH, ²Vall d'Hebron Institute of Oncology, Barcelona, ES, ³The Royal Marsden Hospital NHS Foundation Trust, Sutton, GB, ⁴START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, ES, ⁵Kantonsspital St. Gallen, St. Gallen, CH, ⁶Royal Marsden Hospital Institute of Cancer Research, Sutton, GB, ⁷Anaveon AG, Basel, CH, ⁸Vall d'Hebron University Hospital, Barcelona, ES
- 10:31 - 10:32 **750P - Phase I study of TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa (BA) in patients (pts) with metastatic/locally advanced solid unresectable tumours**
L. Siu¹, M. Mckean², A. Tolcher³, A. Victor⁴, T. Kitzing⁴, V. Pierre⁵, S. Gleicher⁴, D. Holland⁴, E. Richter⁴, A. Naing⁶, ¹Princess Margaret Cancer Centre, Toronto, CA, ²Sarah Cannon Research Institute, Nashville, US, ³NEXT Oncology and Texas Oncology, San Antonio, US, ⁴Merck Healthcare KGaA, Darmstadt, DE, ⁵EMD Serono Research & Development Institute Inc., (an affiliate of Merck KGaA), Billerica, US, ⁶The University of Texas M. D. Anderson Cancer Center, Houston, US

- 10:32 - 10:33 **751P - Preclinical evaluation of SG-3-06686, a positive allosteric modulator of CXCR3**
H. Kiefel, J. Guagua, D. Haria, J. Lee, E. Casey, K. Roskamp, M. Willcoxon, K. Dabbagh, J. Dal Porto, Second Genome, South San Francisco, US
- 10:33 - 10:34 **752P - Novel CEAxCD3 (NILK-2301) and CEAxCD28 (NILK-3301) bispecific antibodies for next generation immunotherapy of CEA-expressing cancer**
A. Seckinger¹, S. Majocchi², V. Moine², L. Nouveau², B. Daubeuf², V. Buatois², F. Gueneau², U. Ravn², K. Masternak², Y. Poitevin², G. Magistrelli², P. Malinge², L. Shang², N. Fischer², K. Strein¹, W. Ferlin², D. Hose¹, ¹LamKap Bio Group, Pfäffikon, CH, ²Light Chain Bioscience, Plan-les-Ouates, CH
- 10:34 - 10:35 **753P - Targeting solid tumors with IMA402, a next-generation bispecific T cell engaging receptor against PRAME**
S. Missel¹, S. Bunk¹, M. Hofmann¹, G. Pszolla¹, M. Hutt¹, F. Schwoebel¹, F. Unverdorben¹, C. Wagner¹, M. Jaworski¹, H. Schuster¹, F. Schwoerer¹, C. Schraeder¹, O. Schoor¹, T. Weinschenk², D. Maurer¹, C. Reinhardt², ¹Immatics Biotechnologies GmbH, Tuebingen, DE, ²Immatics N.V., Tuebingen, DE
- 10:35 - 10:36 **754P - A phase I/IIa dose escalation study of AFM24 in patients with epidermal growth factor receptor-expressing (EGFR) solid tumors: Results from phase I**
A. El-Khoueiry¹, J. Lopez², O. Saavedra³, M. Awad⁴, J. Thomas¹, C. Tiu⁵, E. Garralda³, B. Rehbein⁶, G. Hintzen⁶, K. Pietzko⁶, C. Raab⁶, E. Rajkovic⁶, P. Ravenstijn⁶, D. Rivas⁶, M. Emig⁶, ¹USC - University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, US, ²Royal Marsden NHS foundation trust and the Institute of Cancer Research, Sutton, GB, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Dana Farber Cancer Institute, Boston, US, ⁵Royal Marsden Hospital Institute of Cancer Research, Sutton, GB, ⁶Affimed GmbH, Heidelberg, DE
- 10:36 - 10:37 **755P - B7H3-targeted tri-specific killer engagers deliver IL-15 to NK cells but not T-cells, and specifically target solid tumors as a pan-tumor antigen strategy mediated through NK cells**
J. Miller¹, N. Zorko¹, A. Merino¹, G. Phung¹, M. Khaw¹, P. Howard¹, H. Hamsher¹, Z. Davis¹, F. Cichocki¹, G. Berk², M. Felices¹, ¹Masonic Cancer Center - University of Minnesota, Minneapolis, US, ²Gregory Berk, MD, Dover, US
- 10:37 - 10:38 **756P - Glypican-3 (GPC3) and NKp46 directed FLEX-NK engager antibody (CYT-303) recruits natural killer (NK) cells to tumors in a preclinical hepatocellular carcinoma (HCC) mouse model**
A. Arulanandam¹, H. Potu¹, V. Khairnar¹, D. Zou¹, M. Triggiano¹, N. Dilmac¹, L. Lin¹, H.-M. Chang¹, A. Welch¹, O. Mandelboim², Y. Ilan³, D. Teper¹, S. Frankel¹, J. Kadouche¹, W. Li¹, ¹Cytovia Therapeutics, Aventura, US, ²Hebrew University of Jerusalem, Jerusalem, IL, ³Hadassah-Hebrew University Medical Center, Jerusalem, IL
- 10:38 - 10:39 **757P - USFDA authorized compassionate use of SNK01 (autologous non-**

genetically modified natural killer cells with enhanced cytotoxicity) and checkpoint inhibitors in advanced heavily pre-treated sarcoma: A promising regimen

V. Chua¹, S. Chawla¹, E. Gordon¹, T. Kim¹, B. Gibson², P. Chang², P. Song², ¹Sarcoma Oncology Research Center, Santa Monica, US, ²NKGen Biotech, Santa Ana, US

09:00 - 17:00 **Type: Poster session** **Poster Area, Hall 4**
Title: Poster session 12

- 09:00 - 09:01 **1719P - Predictive value of DNA repair gene alterations for the response to platinum-based chemotherapy and immunotherapy in advanced solid tumors patients: Results from a single center molecular screening program**
C. Chabot¹, S. Cousin¹, E. Khalifa², M. Spalato Ceruso², I. Soubeyran², Y. Laizet¹, A. Crombe³, A. Italiano⁴, ¹Institut Bergonie, Bordeaux, FR, ²Institute Bergonié, Bordeaux, FR, ³Bergonie Institute, Bordeaux, FR, ⁴Institute Bergonié and University of Bordeaux, Bordeaux, FR
- 09:01 - 09:02 **1720P - VIPR1 as a novel prognostic biomarker and its correlation with immune infiltrates in lung adenocarcinoma**
L. Al-Kraimeen¹, O. Ababneh¹, Y. Al-Kraimeen², N. Ayoub³, ¹Jordan University of Science and Technology, Irbid, JO, ²Université Salah Boubnider Constantine 03, Constantine, DZ, ³JUST - Jordan University of Science and Technology, Irbid, JO
- 09:02 - 09:03 **1721P - Hereditary component of HER2-positive breast cancer**
M. Iglesias Campos¹, A. Jimena Márquez¹, R.J. Peralta Linero¹, E. Alba Conejo², ¹Medical Oncology Intercenter Unit. Regional and Virgen de la Victoria University Hospitals. IBIMA. Málaga. Spain, Malaga, ES, ²Hospital Universitario Virgen de la Victoria, Malaga, ES
- 09:03 - 09:04 **1722P - The subtype-specific cell fitness of head and neck cancer is regulated by the YBX1 integration of oncogenic PI3K/mTOR signalling**
Y. Bai, C. Darido, Peter MacCallum Cancer Centre, Melbourne, AU
- 09:04 - 09:05 **1723P - CLEC3B mRNA expression levels are linked to distinct genetic backgrounds, transcriptomic signatures and survival in NSCLC**
A. Seeber¹, Y. Baca², J. Xiu², S. Puri³, T. Owonikoko⁴, T. Oliver⁵, K. Kerrigan⁵, S. Patel⁵, D. Uprety⁶, H. Mamdani⁶, A. Kulkarni⁷, G. Lopes⁸, B. Halmos⁹, H. Borghaei¹⁰, W. Akerley³, S. Liu¹¹, W.M. Korn², A. Pircher¹, D. Wolf¹, F. Kocher¹, ¹Medical University of Innsbruck, Innsbruck, AT, ²Caris Life Sciences, Phoenix, US, ³Huntsman Cancer Institute, Utah, US, ⁴University of Pittsburgh and Hillman Cancer Center, Pittsburgh, US, ⁵University of Utah Health, Salt Lake City, US, ⁶Karmanos Cancer Institute, Detroit, US, ⁷Masonic Cancer Center - University of Minnesota, Minneapolis, US, ⁸Sylvester Comprehensive Cancer Center - University of Miami, Miami, US, ⁹Montefiore Medical Center, New York City, US, ¹⁰Fox Chase Cancer Center - Main Campus, Philadelphia, US, ¹¹Lombardi Cancer Center Georgetown University, Washington, US
- 09:05 - 09:06 **1724P - Secreted kinase FAM20C promotes stromal remodeling via inflammatory cancer-associated fibroblast activation in pancreatic cancer microenvironment**

M.R. Lee¹, Y.-S. Lee², S. Kang¹, H.W. Shon¹, S.M. Woo³, Y.-H. Kim², ¹National Cancer Center - Graduate School of Cancer Science and Policy, Goyang, KR, ²NCC - National Cancer Center, Goyang, KR, ³National Cancer Center, Goyang, KR

- 09:06 - 09:07 **1725P - Metastasis-resident bacteria in advanced hormone receptor-positive breast cancer are related to primary tumor microbiota and show distinct composition**
C. Araya¹, S. Contreras-Riquelme², B. Mino¹, F. Perez¹, A. Martin², D. Carvajal-Hausdorf¹, ¹Facultad de Medicina - Clinica Alemana Universidad del Desarrollo, Santiago, CL, ²Facultad de Ciencias, Ingeniería y Tecnología, Universidad Mayor, Santiago, CL
- 09:07 - 09:08 **1726P - Investigating adipocytes-tumor cells interaction and its effect on disease progression in lobular breast cancer with spatial transcriptomics**
M. Serra¹, L. Collet¹, M. Rediti¹, F. Lifrange², D. Venet¹, N. Occelli¹, D. Vincent¹, G. Rouas¹, D. Larsimont¹, L. Craciun¹, X. Wang¹, D. Gacquer¹, M. Vikkula³, F. Duhoux⁴, F. Rothé¹, C. Sotiriou¹, ¹Institute Jules Bordet, Brussels, BE, ²CHU de Liège, Liège, BE, ³De Duve Institute UCLouvain, Woluwe-Saint-Lambert, BE, ⁴King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE
- 09:08 - 09:09 **1727P - Trametinib enhances PD-L1 expression in KRAS-mutant NSCLC via Id1 downregulation**
A. Puyalto¹, M. Rodríguez-Remírez¹, I. López², M. Olmedo López-Frías¹, A. Vilalta¹, C. Welch², S. Vicent², A. Calvo², I. Gil Bazo¹, ¹Clinica Universidad de Navarra, Pamplona, ES, ²University of Navarra, Center for Applied Medical Research, Pamplona, ES
- 09:09 - 09:10 **1728P - Hypoxia in the tumor microenvironment and its use for in-silico drug repurposing**
S. Becker, Justus-Liebig-Universität, Gießen, DE
- 09:10 - 09:11 **1729P - The biological effect of small-scale ROS1 aberrations: An in silico analysis**
M. Glaser¹, C. Von Levetzow¹, S. Michels¹, L. Nogova¹, M. Katzenmeier¹, C. Wömpner¹, J. Schmitz¹, E. Bitter¹, I. Terjung¹, E. Passmann¹, D. Schaufler¹, A. Eisert¹, R. Fischer¹, R. Riedel¹, J.-P. Weber¹, S. Hahne¹, S. Merkelbach-Bruse², R. Büttner², J. Wolf¹, M. Scheffler¹, ¹University Hospital Cologne, Köln, DE, ²University Cologne, Köln, DE
- 09:11 - 09:12 **1730P - The variation of T cell receptor (TCR) diversity and genomic human leukocyte antigen-I (HLA-I) among non-small cell lung cancer (NSCLC) patients expressing high PDL1 versus those with low or no PDL1**
A. Abed¹, A. Beasley¹, C. Leslie¹, A. Reid¹, M. Millward², E. Gray¹, ¹Edith Cowan University, Perth, AU, ²University of Western Australia, Perth, AU
- 09:12 - 09:13 **1731P - Lung cancer predisposition in Li-Fraumeni syndrome: Cohort from Gustave Roussy Institute**
H. Sassi¹, D. Vasseur¹, L. Mezquita², D. Planchard¹, B. Besse¹, B. Bressac¹, A. Fievet¹, O. Cabaret¹, M.A. Robert De Rancher¹, S. Cotteret¹, V. Goldbarg¹, O. Caron¹, J.-Y. Scoazec¹,

L. Lacroix¹, E. Rouleau¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Hospital Clinic y Provincial de Barcelona, Barcelona, ES

09:13 - 09:14 **1732P - Cancer-associated fibroblasts correlates with immune phenotypes in human tumors**

A. Italiano¹, J.-P. Guegan², X. Sher³, L. Dillon³, T. Schürpf³, G. Clifton³, ¹Institute Bergonié, Bordeaux, FR, ²Explicyte, Bordeaux, FR, ³Parthenon Therapeutics, Cambridge, US

09:00 - 16:00 Type: Poster session Title: Poster session 11 Poster Area, Hall 4

09:00 - 09:01 **1393P - Comparison of genomic alterations (GA) landscape in SPOP mutated (SPOPmut) and SPOP wild type (SPOPwt) clinically advanced prostate cancer (CAPC)**

G. Bratslavsky¹, P. Spiess², P. Grivas³, J. Jacob¹, A. Necchi⁴, N. Danziger⁵, D. Pavlick⁵, H. Tukachinsky⁶, R. P. Graf⁷, J. Ross¹, ¹SUNY Upstate Medical University, Syracuse, US, ²H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ³University of Washington Seattle Cancer Care Alliance, Seattle, US, ⁴IRCCS Ospedale San Raffaele, Milan, IT, ⁵Foundation Medicine, Inc, Cambridge, US, ⁶Foundation Medicine, Boston, US, ⁷Foundation Medicine Inc., Cambridge, US

09:01 - 09:02 **1394P - Alkaline phosphatase (ALP) decline and pain response as markers for overall survival (OS) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra) in the REASSURE study**

J. O'Sullivan¹, D. Heinrich², E. Castro Marcos³, S. George⁴, D. Song⁵, S. Dizdarevic⁶, S. Baldari⁷, M. Essler⁸, I. Jan De Jong⁹, S. Lastoria¹⁰, P. Hammerer¹¹, B. Tombal¹², N. James¹³, F. Verholen¹⁴, J. Meltzer¹⁵, P. Sandström¹⁵, O. Sartor¹⁶, ¹Queen's University Belfast and Northern Ireland Cancer Centre, Belfast, GB, ²Innlandet Hospital Trust, Gjøvik, NO, ³Virgen de la Victoria University Hospital, Malaga, ES, ⁴Roswell Park Comprehensive Cancer Center, Buffalo, US, ⁵Johns Hopkins University School of Medicine, Baltimore, US, ⁶University of Sussex and Brighton, Brighton, GB, ⁷University of Messina, Messina, IT, ⁸University Hospital Bonn, Bonn, DE, ⁹University Medical Center Groningen, Groningen, NL, ¹⁰Fondazione Senatore G. Pascale, Naples, IT, ¹¹Academic Hospital, Braunschweig, DE, ¹²Cliniques Universitaires Saint-Luc, Brussels, BE, ¹³The Institute of Cancer Research, London, GB, ¹⁴Bayer Consumer Care AG, Basel, CH, ¹⁵Bayer HealthCare Pharmaceuticals Inc., Whippany, US, ¹⁶Tulane Medical School, New Orleans, US

09:02 - 09:03 **1395P - Real-world association between bone targeted agents and palliative bone radiation in prostate cancer decedents: A province-wide study**

W. Phillips¹, A. Jooya², R. Mahdavi², J. Leigh², K. Tawagi², C. Webber², C. Milani², S. Morgan², R. Macrae², J.-M. Bourque², P. Tanuseputro², M. Ong², ¹University of Ottawa Faculty of Medicine, Ottawa, CA, ²The Ottawa Hospital Regional Cancer Centre, Ottawa, CA

09:03 - 09:04 **1396P - Phase II study of AZD4635 in combination with durvalumab or oleclumab in patients (pts) with metastatic castrate-resistant prostate cancer**

(mCRPC)

E. Lim¹, J. Reeves², S. Gandhi³, D. Spiegel⁴, E. Arrowsmith⁵, D. George⁶, J. Karlix⁷, G. Pouliot⁸, M. Hattersley⁹, E. Gangl¹⁰, G. James¹¹, J. Thompson⁹, D. Russell⁹, B. Patel¹², R. Kumar¹³, G. Falchook¹⁴, ¹HICCC - Herbert Irving Comprehensive Cancer Center - Columbia University, New York, US, ²Sarah Cannon Research Institute, Fort Myers, US, ³Sarah Cannon Research Institute, St. Petersburg, US, ⁴Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ⁵Tennessee Oncology, Nashville, US, ⁶Duke University Medical Center, Durham, US, ⁷Sarah Cannon Research Institute, Nashville, US, ⁸AstraZeneca, South San Francisco, US, ⁹AstraZeneca, Waltham, US, ¹⁰AstraZeneca, Boston, US, ¹¹AstraZeneca, London, GB, ¹²AstraZeneca, Cambridge, GB, ¹³AstraZeneca Pharmaceuticals LP, Gaithersburg, US, ¹⁴Sarah Cannon Research Institute, Denver, US

09:04 - 09:05

1397P - Phase I results of exicorilant plus enzalutamide in patients with castration-resistant prostate cancer

M. Linch¹, G. Liu², S. Crabb³, T. Beer⁴, E. Heath⁵, M. Gordon⁶, J. De Bono⁷, H. Pashova⁸, I.C. Tudor⁸, J. Custodio⁸, G. Mann⁸, M. Morris⁹, ¹UCL Cancer Institute, London, GB, ²University of Wisconsin Carbone Cancer Center, Madison, US, ³Southampton Experimental Cancer Medicine Centre, Southampton, GB, ⁴OHSU Knight Cancer Institute, Portland, US, ⁵Karmanos Cancer Institute, Detroit, US, ⁶HonorHealth Research Institute, Scottsdale, US, ⁷The Institute of Cancer Research and The Royal Marsden Hospital, London, GB, ⁸Corcept Therapeutics, Menlo Park, US, ⁹MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

09:05 - 09:06

1398P - Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES

D. Petrylak¹, A. Azad², R. Szmulewitz³, T. Iguchi⁴, N. Shore⁵, J. Holzbeierlein⁶, B. Alekseev⁷, N. El-Chaar⁸, B. Rosbrook⁹, J. Ma⁸, F. Zohren⁹, G. Haas⁸, A. Stenzl¹⁰, A. Armstrong¹¹, ¹Yale Cancer Center, New Haven, US, ²Peter MacCallum Cancer Centre, Melbourne, AU, ³The University of Chicago, Chicago, US, ⁴Kanazawa Medical University, Ishikawa, JP, ⁵Carolina Urologic Research Center, Myrtle Beach, US, ⁶The University of Kansas Medical Center, Kansas City, US, ⁷Hertzen Moscow Cancer Research Institute, Moscow, RU, ⁸Astellas Pharma Inc., Northbrook, US, ⁹Pfizer Inc., San Diego, US, ¹⁰University Hospital, Eberhard Karls University of Tübingen, Tübingen, DE, ¹¹Duke Cancer Institute Center for Prostate & Urologic Cancers, Durham, US

09:06 - 09:07

1399P - Androgen receptor (AR) alterations on circulating tumor DNA (ctDNA) sequencing and response to the first-line androgen-receptor targeted agent (ARAT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

N. Tripathi¹, B. Chigarira¹, N. Sayegh¹, V. Mathew Thomas¹, S. Adidam Kumar¹, D. Goel¹, C. Tandar¹, T. Mcfarland¹, R. Nussenzveig¹, D. Sirohi², U. Swami¹, B. Maughan¹, N. Agarwal¹, ¹University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US, ²University of Utah and ARUP Laboratories, Salt Lake City, US

09:07 - 09:08

1400P - Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC): Initial results from SPLASH

A. Hansen¹, S. Probst², R. Tutrone³, M. Osman⁴, E. Delpassand⁵, L. Nordquist⁶, B. Viglianti⁷, J. Michalski⁸, J.-M. Beauregard⁹, O. Oz¹⁰, K. Courtney¹⁰, J. Jensen¹¹, W. Wu¹¹, N. Fleshner¹², O. Sartor¹³, K. Chi¹⁴, S. Tagawa¹⁵, ¹UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ²Jewish General Hospital McGill University, Montreal, CA, ³Carolina Urologic Research Center, LLC, Myrtle Beach, US, ⁴SSM Health Saint Louis University Hospital - West Pavilion, St. Louis, US, ⁵EXCEL DIAGNOSTICS & NUCLEAR ONCOLOGY CENTER, Houston, US, ⁶Urology Cancer Center and GU Research Network, Omaha, US, ⁷University of Michigan Health System, Ann Arbor, US, ⁸Washington University School of Medicine in St. Louis - Siteman Cancer Center, St. Louis, US, ⁹CHU de Québec - Université Laval, Quebec City, CA, ¹⁰UT Southwestern Medical Center, Dallas, US, ¹¹POINT Biopharma, Indianapolis, US, ¹²Princess Margaret Cancer Centre, Toronto, CA, ¹³Tulane University, New Orleans, US, ¹⁴BC Cancer Agency - Vancouver, Vancouver, CA, ¹⁵NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US

09:08 - 09:09 **1401P - Quality of life across three countries using a large-scale, fully digital survey of patients with prostate cancer**

J. O'Sullivan¹, B. Gonzalez², L. Gudenkauf³, R. Lehmann⁴, S. Allen⁵, C. Ernst-Guenther⁶, H. Wolinsky⁷, A. Poschenrieder⁸, O. Mirante⁸, A. Morgans⁹, ¹Queen's University Belfast, Belfast, GB, ²Moffitt Cancer Center, Tampa, US, ³H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ⁴DontBePatient Intelligence GmbH, Munchen, DE, ⁵Tackle Prostate Cancer, London, GB, ⁶Europa Uomo - Bundesverband Prostatakrebs Selbsthilfe e. V. (BPS), Tornesch, DE, ⁷AnCan Virtual Support Group for Active Surveillance, Des Plaines, US, ⁸AAA - Advanced Accelerator Applications SA - a Novartis Company, Geneva, CH, ⁹Dana Farber Cancer Institute, Boston, US

09:09 - 09:10 **1402P - Initial results of a cohort of advanced prostate cancer patients in a phase Ia study of NGM120, a first-in-class anti-GDNF family receptor alpha like (GFRAL) antibody**

I. Medic¹, S. Gulati², H.-J. Lenz³, D. Mahalingam⁴, J. Thomas⁵, J. Luo⁶, J. Zha⁶, A. Depaoli⁶, C. Tran-Muchowski⁶, C. Tseng⁶, H. Lieu⁶, ¹Sharp Grossmont Hospital, La Mesa, US, ²UCCI - University of Cincinnati Cancer Institute, Cincinnati, US, ³University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, ⁴Robert. H. Lurie Cancer Center of Northwestern University, Chicago, US, ⁵USC - University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, US, ⁶NGM Biopharmaceuticals Inc, South San Francisco, US

09:10 - 09:11 **1403P - Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in men with metastatic castration-resistant prostate cancer (mCRPC) in a phase I/II trial**

R. Jones¹, D. Pinato², A. Joshua³, M. Forster⁴, C. Morton⁵, K. Aboud⁶, J. Liu⁷, C. Fulgenzi⁸, J. Kefas⁹, S. Edmondson¹⁰, N. Main¹⁰, J. Paull¹⁰, J. Fairley¹⁰, J. Spicer¹¹, ¹Velindre NHS University Trust - NHS Wales, Cardiff, GB, ²Imperial College London - Hammersmith Hospital, London, GB, ³The Kinghorn Cancer Centre, Sydney, AU, ⁴UCL - University College London, London, GB, ⁵Guy's and St Thomas' NHS Foundation Trust, London, GB, ⁶Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff, GB, ⁷St Vincent's Hospital Sydney, Darlinghurst, AU, ⁸Imperial College London - Hammersmith Campus, London, GB, ⁹NIHR UCLH Clinical Research Facility (CRF),

London, GB, ¹⁰Starpharma PTY Ltd., Abbotsford, AU, ¹¹KCL - King's College London, London, GB

- 09:11 - 09:12 **1404P - A phase II study of ZEN-3694 (ZEN), enzalutamide (ENZ), and pembrolizumab (P) in metastatic castration resistant prostate cancer (mCRPC): Interim safety results**
T. Jindal¹, H. Han², P. Deshmukh³, I. De Kouchkovsky³, D. Kwon³, H. Borno³, V. Koshkin⁴, A. Desai⁵, R. Bose³, J. Chou³, T. Friedlander³, E. Small⁴, A. Angelidakis³, M. Johnson⁶, S. Feng³, A. Patnaik⁷, L. Fong³, J. Alumkal⁸, R. Aggarwal¹, ¹UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US, ²Dana Farber Cancer Institute, Boston, US, ³UCSF - University of California San Francisco, San Francisco, US, ⁴UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ⁵University of California San Francisco, San Francisco, US, ⁶UCSF Medical Center at Mission Bay, San Francisco, US, ⁷The University of Chicago, Chicago, US, ⁸University of Michigan Health System, Ann Arbor, US
- 09:12 - 09:13 **1405P - Circulating tumor DNA in advanced prostate cancer: Focus on high blood tumor mutational burden (h-bTMB)**
Z. Guillaume¹, A. Bayle², C. Pobel², L. Lacroix³, D. Vasseur³, L. Albiges², E. Colomba⁴, R. Flippot⁵, N. Naoun⁵, A. Patrikidou², V. Goldschmidt¹, P. Vuagnat², C. Massard⁶, S. Ponce³, K. Fizazi², Y. Loriot², C. Baldini², A. Italiano¹, A. Bernard-Tessier², ¹Gustave Roussy, Villejuif, FR, ²Institut Gustave Roussy, Villejuif, Cedex, FR, ³Gustave Roussy - Cancer Campus, Villejuif, FR, ⁴Gustave Roussy, Université Paris-Saclay, Villejuif, FR, ⁵Institut Gustave Roussy, Villejuif, FR, ⁶Eugène Marquis center, Rennes, FR
- 09:13 - 09:14 **1406P - Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)**
J. Lang¹, S. Tagawa², S. Slovin³, H. Enamekhoo¹, D. Rathkopf³, W. Abida⁴, K. Autio⁴, H. Xiao⁴, A. Molina², J. Eickhoff¹, J. Sperger¹, S. Dehm⁵, D. Nanus⁶, C. Kyriakopoulos⁷, ¹University of Wisconsin Carbone Cancer Center, Madison, US, ²NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US, ³MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ⁴Memorial Sloan Kettering Cancer Center, New York, US, ⁵Masonic Cancer Center - University of Minnesota, Minneapolis, US, ⁶Weill Cornell Medical College, New York, US, ⁷UW Carbone Cancer Center, Madison, US
- 09:14 - 09:15 **1407P - Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and tumors with androgen receptor (AR) 878/875 mutations**
T. Stewart¹, R. Gedrich², J. Saha³, D. Chirnomas², M. Edwards², J. Lang⁴, ¹UC San Diego Health, La Jolla, US, ²Arvinas, Inc., New Haven, US, ³Guardant Health, Inc., Redwood City, US, ⁴Carbone Cancer Center, University of Wisconsin-Madison, Madison, US
- 09:15 - 09:16 **1408P - Comparative transcriptomic analyses of 100,691 primary tumors from East Asian (EA) and North American (NA) men with prostate cancer (PCa)**
M.L.K. Chua¹, A. Sim¹, A. Hakansson², E. Ong¹, K.P. Low¹, C. Tan¹, J. Tan¹, A.S.Y. Lau¹, J. Tuan¹, T.W.K. Tan¹, M.L.C. Wang¹, J.P.S. Yeong³, M.C.S. Tan⁴, L.S. Lee⁵, R. Kanesvaran¹, K.J. Tay³, S. Liu², L.Y. Khor³, E. Davicioni², ¹NCCS - National Cancer Centre Singapore,

Singapore, SG, ²Veracyte, Inc. - Headquarters, South San Francisco, US, ³SGH - Singapore General Hospital, Singapore, SG, ⁴Changi General Hospital, Singapore, SG, ⁵Sengkang General Hospital, Singapore, SG

- 09:16 - 09:17 **1409P - Development of a clinically accessible, circulating prognostic lipid biomarker panel in men with mCRPC to guide potential metabolic intervention**
T. Scheinberg¹, M. Fitzpatrick², H.-M. Lin³, A. Azad⁴, P. Bonnitcha², A. Davies⁵, G. Heller⁶, K. Huynh⁷, B. Mak¹, K. Mahon¹, P. Meikle⁷, D. Sullivan², L. Horvath¹, ¹Chris O'Brien Lifehouse, Camperdown, AU, ²New South Wales Health Pathology, Camperdown, AU, ³Garvan Institute of Medical Research, Darlinghurst, AU, ⁴Peter MacCallum Cancer Centre, Melbourne, AU, ⁵Monash Health - Monash Medical Centre, Clayton, AU, ⁶University of Sydney, Sydney, AU, ⁷Baker Heart and Diabetes Institute, Melbourne, AU
- 09:17 - 09:18 **1410P - Real-world first-line (1L) treatment patterns in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC)**
S. Gupta¹, A. Hong², N. El-Chaar², C. Young², K. Ramaswamy³, B. Xie², S. Bunner⁴, B. Diessner⁴, U. Swami¹, ¹Huntsman Cancer Institute, University of Utah, Salt Lake City, US, ²Astellas Pharma Inc., Northbrook, US, ³Pfizer Inc., New York, US, ⁴Optum, Eden Prairie, US
- 09:18 - 09:19 **1411P - Development and validation of a novel six-gene signature to accurately risk stratify men with early-stage prostate cancer to aid in treatment decision making**
A. Krzyzanowska¹, S. Barron², T. Loughman², D.F. Higgins², K. Sheehan³, A. Chan-Ju Wang², B. Fender², L.M. McGuire², A. O'Neill⁴, J. Fay³, T. O'Grady³, D. O'Leary², A. Bjartell¹, R.W.G. Watson⁴, W. Gallagher⁴, ¹Lund University - Faculty of Medicine, Malmö, SE, ²NovaUCD, Dublin, IE, ³RCSI Education & Research Centre, Beaumont Hospital, Dublin, IE, ⁴National University of Ireland - University College Dublin, Dublin, IE
- 09:19 - 09:20 **1412P - Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC)**
R. Madan¹, R. Donahue², Y.-T. Tsai², F. Karzai², S. Gandhi¹, M. Bilusic¹, P. Arlen², M. Theoret¹, J. Marte¹, L. Cordes¹, A. Couvillon¹, A. Hankin², M. Williams², S. McMahon¹, W. Figg³, W. Dahut¹, J. Schlom², J. Gulley¹, ¹National Cancer Institute, Bethesda, US, ²National Cancer Institute - Center for Cancer Research, Bethesda, US, ³National Cancer Institute at Shady Grove, Bethesda, US
- 09:20 - 09:21 **1413P - Tumor transcriptomic profiling of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) who do not achieve optimal PSA response to intensified androgen deprivation therapy (ADT-I)**
V. Mathew Thomas¹, B. Chigarira¹, N. Sayegh¹, E. Hernandez², N. Tripathi¹, S. Adidam Kumar¹, D. Goel¹, C. Tandar¹, T. McFarland¹, M. Yandell², R. Nussenzweig¹, D. Sirohi³, U. Swami¹, B. Maughan¹, N. Agarwal¹, ¹University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US, ²University of Utah, Salt Lake City, US, ³University of Utah and ARUP Laboratories, Salt Lake City, US
- 09:21 - 09:22 **1414P - Treatment efficacy and safety of 177Lu-PSMA radioligand therapy in**

octogenarians with metastatic castration-resistant prostate cancer

R. Tauber¹, M. Retz¹, K. Knorr¹, C. D'Alessandria¹, S. Grigorascu¹, K. Hansen¹, H.-J. Wester², J. Gschwend¹, W. Weber¹, M. Eiber¹, T. Langbein¹, ¹Klinikum Rechts der Isar - Technische Universität München, Munich, DE, ²TUM - Technical University of Munich, Munich, DE

09:22 - 09:23 **1415P - Phase II trial of a DNA vaccine with nivolumab in patients with PSA-recurrent, castration-sensitive prostate cancer (nmCSPC)**

D. Mcneel¹, H. Emamekhoo², J. Eickhoff², E. Wargowski², G. Liu², ¹WIMR - Wisconsin Institutes for Medical Research - University of Wisconsin, Madison, US, ²University of Wisconsin Carbone Cancer Center, Madison, US

09:23 - 09:24 **1416P - Associations between metformin and mortality risks in Asian diabetic patients with prostate cancer undergoing androgen deprivation therapy: A retrospective cohort study**

Y.H.A. Lee¹, J.M.H. Hui², J.S.K. Chan², K. Liu¹, E.C. Dee³, K. Ng⁴, P. Tang², G. Tse⁵, A.C.F. Ng⁶, ¹The Chinese University of Hong Kong - Prince of Wales Hospital, Hong Kong, HK, ²Cardiovascular Analytics Group, Hong Kong, HK, ³Memorial Sloan Kettering Cancer Center, New York, US, ⁴University College London Hospitals NHS Foundation Trust, London, GB, ⁵The Second Hospital of Tianjin Medical University, Tianjin, CN, ⁶The Chinese University of Hong Kong, Hong Kong, HK

09:24 - 09:25 **1417P - Mixed treatment comparisons evaluating contemporary therapies in metastatic castration sensitive prostate cancer (mCSPC): A living systematic review**

I. Riaz¹, S.A.A. Naqvi², H. He³, N. Asghar⁴, R. Siddiqi⁵, K.Z.R. Khakwani⁴, H. Liu³, S. Hussain⁶, P. Singh², M. Murad³, A. Bryce², ¹Dana Farber Cancer Institute, Boston, US, ²Mayo Clinic Cancer Center, Phoenix, US, ³Mayo Clinic, Rochester, US, ⁴The University of Arizona, Tucson, US, ⁵Dow University of Health Sciences, Karachi, PK, ⁶University of Sheffield Medical School, Sheffield, GB

09:25 - 09:26 **1418P - Extensive alteration of androgen precursor levels after castration in prostate cancer patients and their association with active androgen level: Importance for treatment intensification**

F. Pouliot¹, M. Rouleau², B. Neveu², P. Caron², F. Morin², P. Toren², L. Lacombe¹, V. Turcotte², E. Lévesque², C. Guillemette², ¹Université Laval, CHU de Québec, Québec City, CA, ²CHU de Québec - Université Laval, Québec City, CA

09:26 - 09:27 **1419P - Radiobiological parameters for the assessment of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer**

J. Hu¹, S. Xue¹, L. Mercolli¹, S. Hasan², A. Rominger¹, A. Afshar-Oromieh¹, K. Shi¹, ¹University Hospital Inselspital Bern, Bern, CH, ²Siemens Healthcare AG, Bern, CH

09:27 - 09:28 **1420P - The pharmacokinetics and the pharmacodynamic effect of ODM-208, an inhibitor of cholesterol side-chain cleavage enzyme (CYP11A1)**

A. Bernard-Tessier¹, P. Nykanen², T. Utriainen³, N. Cook⁴, P. Barthelemy⁵, C. Baldini¹, N. Peters⁴, T. Ikonen², P. Pohjanjousi², M. Karimaa², J. Malkki², P. Toivanen², C. Garratt⁶, K.

Fizazi¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Orion Corporation Orion Pharma, Espoo, FI, ³Helsinki University Central Hospital, Helsinki, FI, ⁴The Christie NHS Foundation Trust, Manchester, GB, ⁵Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ⁶Orion Corporation Orion Pharma, Newbury, GB

09:28 - 09:29

1421P - Effect of abiraterone-prednisone in metastatic castration-sensitive prostate cancer (mCSPC) with neuroendocrine and very high-risk features in the PEACE-1 trial

A. Bernard-Tessier¹, M. Cancel², B. Tombal³, G. Roubaud⁴, J. Carles Galceran⁵, A. Flechon⁶, R.S. Mcdermott⁷, S. Supiot⁸, D. Berthold⁹, R. Philippe¹⁰, G. Kacso¹¹, G. Gravis Mescam¹², F. Calabro¹³, J. Berdah¹⁴, A. Hasbini¹⁵, F. Ricci¹⁶, C. Hennequin¹⁷, H. Ribault¹⁸, S. Foulon¹⁹, K. Fizazi²⁰, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²CHRU Hopitaux de Tours - Hopital Bretonneau, Tours, cedex, FR, ³Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE, ⁴Institute Bergonié, Bordeaux, FR, ⁵Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁶Centre Léon Bérard, Lyon, FR, ⁷St Vincent's University Hospital and Cancer Trials Ireland, Dublin, IE, ⁸ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁹CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ¹⁰Centre Azureen Cancerologie, Mougins, FR, ¹¹Amethyst Radiotherapy Center, Bucharest, RO, ¹²Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, Cedex, FR, ¹³Azienda Ospedaliera San Camillo Forlanini, Rome, IT, ¹⁴Hopital Privé Toulon Hyeres St Jean, Toulon, FR, ¹⁵Clinique Pasteur Lanroze, Brest, FR, ¹⁶Institut Curie, Paris, FR, ¹⁷Hopital Saint Louis AP-HP, Paris, FR, ¹⁸Unicancer, Paris, Cedex, FR, ¹⁹Gustave Roussy - Cancer Campus, Villejuif, FR, ²⁰Institut Gustave Roussy, University of Paris-Saclay, Villejuif, Cedex, FR

09:29 - 09:30

1422P - Validation of the prognostic value of the early modeled longitudinal PSA kinetics (KELIM and KPROD) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with taxanes in FIRSTANA

A. Carrot¹, S. Oudard², O. Colombari³, K. Fizazi⁴, O. Sartor⁵, G. Freyer⁶, B. You⁷, ¹Université Claude Bernard Lyon 1, Villeurbanne, Cedex, FR, ²HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, ³Université Claude Bernard Lyon 1 - Campus Rockefeller, Lyon, FR, ⁴Institut Gustave Roussy, Villejuif, Cedex, FR, ⁵Tulane University, New Orleans, US, ⁶Lyon Sud Hospital Center - HCL, Pierre Benite (Lyon), FR, ⁷(5) Institut de cancérologie des Hospices Civils de Lyon (IC-HCL), Oncologie médicale, CITOHL, Lyon, France, Pierre Benite (Lyon), FR

09:30 - 09:31

1423TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)

R. McKay¹, N. Agarwal², N. Matsubara³, J.M. Piulats Rodriguez⁴, M. Smith⁵, T. Todenhöfer⁶, T. Zhang⁷, A. Balar⁸, C. Schaverien⁸, S. Sherwood⁸, E. Johnston⁸, A. Lithio⁸, K. Nacerddine⁸, C. Sweeney⁹, ¹University of California San Diego, La Jolla, US, ²University of Utah, Salt Lake City, US, ³National Cancer Center Hospital East, Kashiwa, JP, ⁴Hospitalet de Llobregat, Barcelona, ES, ⁵Massachusetts General Hospital, Boston, US, ⁶Studienpraxis Urologie, Nuertingen, DE, ⁷University of Texas Southwestern Medical Center, Dallas, US, ⁸Eli Lilly and Company, Indianapolis, US, ⁹Dana Farber Cancer Institute, Boston, US

- 09:31 - 09:32 **1494P - Regomune - a phase II study of regorafenib + avelumab in solid tumors: Results of the soft tissue sarcoma (STS) cohort**
S. Cousin¹, C. Bellera², J.-P. Guegan³, T. Valentin⁴, R. Bahleda⁵, J.-P. Metges⁶, P. Cassier⁷, C. Cantarel⁸, M. Spalato Ceruso⁹, M. Kind⁹, I. Soubeyran⁹, J. Palussiere¹⁰, A. Bessedé³, A. Italiano⁹, ¹Institut Bergonie, Bordeaux, FR, ²Institut Bergonie, BORDEAUX, FR, ³Explicyte, Bordeaux, FR, ⁴Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, FR, ⁵Gustave Roussy - Cancer Campus, Villejuif, FR, ⁶CHU Morvan - Institut de Cancerologie et d'Hématologie, Brest, FR, ⁷Centre Léon Bérard, Lyon, FR, ⁸Institut Bergonié, Bordeaux, FR, ⁹Institute Bergonié, Bordeaux, FR, ¹⁰Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR
- 09:32 - 09:33 **1495P - SAKK 57/16 nab-paclitaxel and gemcitabine in soft tissue sarcoma (NAPAGE): Final results from the phase Ib/II trial with >2y median follow up**
A. Digklia¹, A. Kollar², M.-N. Kronig², C. Britschgi³, T. Rordorf³, M. Joerger⁴, F. Krasniqi⁵, Y. Metaxas⁶, I. Colombo⁷, D. Dietrich⁸, S. Chiquet⁸, K. Ribi⁹, C. Rothermundt⁴, ¹CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ²Inselspital - Universitatsspital Bern - Kinderklinik, Bern, CH, ³USZ - University Hospital Zürich, Zurich, CH, ⁴Kantonsspital St. Gallen, St. Gallen, CH, ⁵Universitatsspital Basel, Basel, CH, ⁶KSGR - Kantonsspital Graubünden, Chur, CH, ⁷EOC - Ospedale Regionale di Bellinzona e Valli, San Giovanni, Bellinzona, CH, ⁸SAKK - Swiss Group for Clinical Cancer Research, Bern, CH, ⁹IBCSG - International Breast Cancer Study Group, Bern, CH
- 09:33 - 09:34 **1496P - Trabectedin for patients with advanced soft tissue sarcoma: A non-interventional, prospective, multicenter study**
V. Gruenwald¹, D. Pink², G. Egerer³, E. Schalk⁴, M. Augustin⁵, C.K. Deinzer⁶, V. Kob⁷, D. Reichert⁸, M. Kebenko⁹, S. Brandl¹⁰, D. Hahn¹¹, L. Lindner¹², M. Hoiczky¹³, U. Ringsdorf¹⁴, L. Hanker¹⁵, D. Hempel¹⁶, M.J. Pontes¹⁷, T. Wismann¹⁸, P. Ivanyi¹⁹, ¹University Hospital Essen, Essen, DE, ²Helios Klinikum Bad-Saarow, Klinik für Onkologie und Palliativmedizin, Bad Saarow, DE, ³Universitätsklinikum Heidelberg, Heidelberg, DE, ⁴Universitätsklinikum Magdeburg A. ö. R. - Medizinische Fakultät, Magdeburg, DE, ⁵Klinikum Nuernberg Nord, Paracelsus Medizinische Privatuniversität, Nürnberg, DE, ⁶University Clinic Würzburg-Medizinische Klinik und Poliklinik II Zentrum fuer Innere Medizin (ZIM), Wuerzburg, DE, ⁷Schwerpunktpraxis Hämatologie/Onkologie Volksdorf, MVZ für Immunologie Lokstedt GmbH, Hamburg, DE, ⁸Gemeinschaftspraxis für Hämatologie und Onkologie, Westerstede, DE, ⁹UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE, ¹⁰Überörtliche Gemeinschaftspraxis Bergedorf, Hamburg, DE, ¹¹Klinikum Stuttgart - Katharinenhospital (KH), Stuttgart, DE, ¹²LMU Klinikum der Universität München, Munich, DE, ¹³Marien-Hospital Wesel, Wesel, DE, ¹⁴Lahn-Dill-Kliniken GmbH, Wetzlar, DE, ¹⁵Universitätsklinikum Schleswig-Holstein, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, DE, ¹⁶Center of Oncology, Donauwörth, DE, ¹⁷PharmaMar S.A., Colmenar Viejo, ES, ¹⁸Praxisgemeinschaft für Onkologie und Urologie, Wilhelmshaven, DE, ¹⁹Medizinische Hochschule Hannover, Claudia von Schilling Zentrum Comprehensive Cancer Center, Hannover, DE
- 09:34 - 09:35 **1497P - Safety and efficacy of [90Y]Y-FAPI-46 radioligand therapy in patients with advanced sarcomas and other cancer entities**

R. Hamacher¹, K.M. Pabst¹, L. Kessler¹, P. Costa¹, J. Ferdinandus¹, M. Weber¹, M. Lippert¹, K. Lueckerath¹, N. Hirmas¹, K. Kostbade¹, I. Mavroei¹, M. Schuler¹, M. Ahrens², C. Rischpler¹, S. Bauer¹, K. Herrmann¹, J. Siveke¹, W. Fendler¹, ¹West German Cancer Center, University Hospital Essen, Essen, DE, ²University Hospital Frankfurt, Frankfurt am Main, DE

- 09:35 - 09:36 **1498P - Phase I/II study to evaluate penpulimab combined with anlotinib and epirubicin in the first-line treatment of soft tissue sarcoma: Phase I dose escalation results**
Y. Zhou, Y. Feng, W. Li, R. Zhuang, Y. You, C. Zhang, Z. Wang, W. Liu, Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN
- 09:36 - 09:37 **1499P - Phase I clinical & immunologic data of SQ3370 in advanced solid tumors**
S. Chawla¹, K. Batty², M. Alečković³, V. Bhadri⁴, N. Bui⁵, A. Guminski⁶, J. Mejía Oneto³, S. Srinivasan³, J. Strauss⁷, V. Subbiah⁸, M. Weiss⁹, R. Wilson³, N. Yee³, M. Zakharian³, V. Kwatra¹⁰, ¹Sarcoma Oncology Research Center, Santa Monica, US, ²University of Sydney, Wollstonecraft, AU, ³Shasqi, Inc., San Francisco, US, ⁴Chris O'Brien Lifehouse, Camperdown, AU, ⁵Stanford Cancer Center, Palo Alto, US, ⁶Royal North Shore Hospital, St Leonards, AU, ⁷Mary Crowley Cancer Research Center, Dallas, US, ⁸The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁹Washington University School of Medicine, St. Louis, US, ¹⁰Cancer Research SA, Adelaide, AU
- 09:37 - 09:38 **1500P - Radiochemotherapy with gemcitabine as a radiosensitizer in patients with soft tissue sarcomas**
L. Schneider¹, C. Albrecht², C. Grehn², T. Gryc², S. Knop³, G. Siegler³, A. Bott³, M. Rottmann³, M. Blos³, U. Linnemann³, J. Köhler³, J. Jakob⁴, P. Hohenberger⁵, T. Papadopoulos³, C. Meyer³, V. Mordstein³, B. Stein³, L. Gazdag³, B. Reichert³, M. Augustin³, ¹Paracelsus Medical University, Nürnberg, DE, ²Praxis für Strahlentherapie Nordstrahl, Nürnberg, DE, ³Klinikum Nuernberg, Paracelsus Medical University, Nürnberg, DE, ⁴Sarcoma Unit , Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, Mannheim, DE, ⁵UMM - Universitaetsklinikum Mannheim, Mannheim, DE
- 09:38 - 09:39 **1501P - Preliminary analysis of a single-arm, multi-center study of anlotinib combined with toripalimab in first-line treatment of unresectable or metastatic undifferentiated pleomorphic sarcoma**
D. Wu, S. Lan, Z. Guo, N. Niu, Y. Zhang, J. Gui, The First Hospital of Jilin University, Changchun, CN
- 09:39 - 09:40 **1502P - Heavy pre-treatment is associated with microbiome dysbiosis, reduced immune infiltration, and potential resistance to immune checkpoint inhibitors in metastatic sarcoma**
Q. Bao¹, W. Zhang², J. Wen¹, Y. Shen¹, ¹Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, CN, ²Shanghai Ruijin Hospital, Shanghai Jiao Tong University, College of Medicine, Shanghai, CN
- 09:40 - 09:41 **1503P - Prevalence and clinical characteristics of metastatic synovial sarcoma (mSS) patients with tumours expressing NY-ESO-1 antigen (NY+) and who**

are HLA-A*02:01, *02:05 or *02:06 allele positive (HLA*02b): Cohort study from the French sarcoma group

A. Dufresne¹, A. Meurgey¹, S. Chabaud¹, J. Bollard¹, M. Jean-Denis¹, L. Tonon¹, N. Gadot¹, C. Le Neve¹, J.-Y. Blay¹, M. Woessner², E. Klohe², T. Thayaparan², K. Blouch², I. Eleftheriadou², M.J. Nathenson², S. Pokras², ¹Centre Léon Bérard, Lyon, FR, ²GSK, Collegeville, US

09:41 - 09:42 **1504P - Real-world treatment patterns and outcomes of metastatic synovial sarcoma over the last decade in England**

S. Strauss¹, P. Hindocha², S. Hitov², S. Benson², H. Galante², S. Georgiev², S. Lay-Flurrie², M. Schoemaker², S. McGuigan³, C. Lunt³, E. Van Winkle⁴, S. Biswas³, ¹University College London Hospitals NHS Foundation Trust, London, GB, ²IQVIA, London, GB, ³Adaptimmune, Abingdon, GB, ⁴Adaptimmune, Philadelphia, US

09:42 - 09:43 **1505P - Risk factors for metastatic disease at presentation with synovial sarcoma**

Y. Kong, R. Agrawal, G. Hanna, Rutgers New Jersey Medical School, Newark, US

09:43 - 09:44 **1506P - Role of 18F-FDG PET/CT in the initial staging of very high risk Ewing sarcoma in a prospective multicentric phase II study: Is there still a place for bone marrow sampling?**

N. Jehanno¹, N. Corradini², N. Gaspar³, C. Chevreau⁴, J.-C. Gentet⁵, C. Lervat⁶, S. Taque⁷, N. Entz-Werle⁸, L. Mansuy⁹, D. Plantaz¹⁰, M. Rios¹¹, L. Saumet¹², C. Verite¹³, M.-P. Castex¹⁴, E. Thebaud¹⁵, T. Cassou-Mounat¹⁶, V. Mosseri¹, M. Brahmi¹⁷, C. Cordero¹, V. Laurence¹, ¹Institut Curie, Paris, FR, ²IHOPE - Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, FR, ³Institut Gustave Roussy, Villejuif, Cedex, FR, ⁴Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ⁵CHU de Marseille - Hôpital de la Timone, Marseille, FR, ⁶Centre Oscar Lambret, Lille, FR, ⁷CHU de Rennes - Hopital Pontchaillou, Rennes, Cedex, FR, ⁸University Hospital of Strasbourg, Strasbourg, FR, ⁹CHRU Nancy, Nancy, FR, ¹⁰CHU Grenoble-Alpes - Le site nord à La Tronche - Hopital Michallon, La Tronche, FR, ¹¹Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, ¹²CHU de Montpellier - Hopital Gui de Chauliac, Montpellier, Cedex, FR, ¹³CHU - Centre Universitaire Hospitalier de Bordeaux, Bordeaux, FR, ¹⁴Centre Hospitalier Universitaire de Toulouse - Hopital Purpan, Toulouse, FR, ¹⁵CHU du Nantes - Hôtel-Dieu, Nantes, Cedex, FR, ¹⁶IUCT - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, FR, ¹⁷Centre Léon Bérard, Lyon, FR

09:44 - 09:45 **1507P - Distinct enomic features between osteosarcomas initially metastasing to bone and to lung**

L. Xie, Peking University People's Hospital, Beijing, CN

09:45 - 09:46 **1508P - Pre-treatment high serum alkaline phosphatase level as a prognostic factor for patients with localized extremity osteosarcoma: A retrospective analysis of adolescent and adult patients**

A. Durnali¹, N. Alkış¹, A. Inal², F. Ardiç Yükrük¹, M.M. Seker³, T. Akman⁴, M. Polat Inanc⁵, O. Bal⁶, B. Oksuzoglu¹, ¹Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, TR, ²Mersin City Hospital, Mersin, TR, ³Koru Ankara Hospital, Ankara, TR, ⁴Tınaztepe University, Izmir, TR, ⁵Erciyes University Medical

Faculty - Mehmet Kemal Dedeman Hematoloji - Oncology Hospital, Kayseri, TR, ⁶Ankara City Hospital, Ankara, TR

09:46 - 09:47

1509P - Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase II expansion

J.-Y. Blay¹, H. Gelderblom², P. Rutkowski³, A. Wagner⁴, M. Van De Sande², A. Falcon Gonzalez⁵, S. Stacchiotti⁶, A. Le Cesne⁷, T. Alcindor⁸, C. Serrano⁹, E. Palmerini¹⁰, V. Ravi¹¹, A. Casado Herraiz¹², B. Seddon¹³, M. Vallee¹⁴, R. Jarecha¹⁴, M. Sharma¹⁴, R. Ruiz-Soto¹⁴, M.L. Sherman¹⁴, W.D. Tap¹⁵, ¹Centre Léon Bérard, Lyon, FR, ²Leiden University Medical Centre, Leiden, NL, ³Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL, ⁴Dana-Farber Cancer Institute, Boston, US, ⁵Hospital Universitario Virgen del Rocío, Seville, ES, ⁶Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ⁷Gustave Roussy, Villejuif, FR, ⁸McGill University Health Centre, Cedars Cancer Centre, Montreal, CA, ⁹Vall d'Hebron Institute of Oncology, Barcelona, ES, ¹⁰Istituto Ortopedico Rizzoli, Bologna, IT, ¹¹The University of Texas MD Anderson Cancer Center, Houston, US, ¹²Hospital Clinico Universitario San Carlos, Madrid, ES, ¹³University College London Hospitals NHS Foundation Trust, London, GB, ¹⁴Deciphera Pharmaceuticals, LLC, Waltham, US, ¹⁵Memorial Sloan Kettering Cancer Center, New York, US

09:47 - 09:48

1510P - Selective intra-arterial doxorubicin-eluting embolization for desmoid fibromatosis: A combined prospective and retrospective study

E. Elnekave¹, E. Ben Ami², S. Shamai³, I. Peretz⁴, J. Erinjeri⁵, A. Stemmer⁶, J. Ricke⁷, M. Seidensticker⁷, M. Wildgruber⁸, S. Ash⁹, A. Zer⁹, ¹Rabin Medical Center, Petah Tikva, IL, ²Sheba Medical Center, Ramat Gan, IL, ³Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL, ⁴Davidoff Cancer Center - Rabin Medical Center, Petah Tikva, IL, ⁵MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ⁶Chaim Sheba Medical Center, Ramat Gan, IL, ⁷LMU Klinikum der Universität München, Munich, DE, ⁸LMU - Ludwig Maximilians University of Munich, Munich, DE, ⁹Rambam Health Care Campus, Haifa, IL

09:48 - 09:49

1511P - Efficacy and toxicity of sorafenib in desmoid type fibromatosis: A real-world experience

V. Garg, S. Rastogi, B. Bharath, AIIMS - All India Institute of Medical Sciences, New Delhi, IN

09:49 - 09:50

1512P - Pain in patients with desmoid fibromatosis (DF)

N. Penel¹, S. Bonvalot², A.-M. Bimbai¹, A. Italiano³, D. Orbach², B. Verret⁴, M. Toulmonde⁵, A. Dufresne⁶, J.-O. Bay⁷, L. Chaigneau⁸, J.E. Kurtz⁹, E. Bompas¹⁰, S. Salas¹¹, F. Bertucci¹², C. Guillemet¹³, T. Ryckewaert¹, J. Thery¹, M.-C. Le Deley¹, J.-Y. Blay⁶, A. Le Cesne¹⁴, ¹Centre Oscar Lambret, Lille, FR, ²Institut Curie, Paris, FR, ³Institut Bergonie, Bordeaux, FR, ⁴Institut Gustave Roussy, VILLEJUIF, FR, ⁵Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ⁶Centre Léon Bérard, Lyon, FR, ⁷CHU de Clermont-Ferrand, Clermont-Ferrand, FR, ⁸CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, ⁹CHU Haute-pierre, Strasbourg, FR, ¹⁰ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ¹¹AP-HM - CHU La Timone Enfants, Marseille, FR, ¹²IPC - Institut Paoli-Calmettes, Marseille, FR, ¹³Centre Henri Becquerel, Rouen, FR, ¹⁴Gustave Roussy - Cancer Campus, Villejuif, FR

- 09:50 - 09:51 **1513P - Impact of mutational status on long-term treatment outcomes in patients with advanced gastrointestinal stromal tumors (GIST) treated in the first line with imatinib**
P. Sobczuk¹, E. Bylina¹, A. Klimczak¹, P. Rutkowski², ¹Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, ²Maria Sklodowska Curie National Research Institute of Oncology, Warsaw, PL
- 09:51 - 09:52 **1514P - Anti-tumor effects of the novel KIT mutant inhibitor M4205 in gastrointestinal stromal tumor (GIST) xenograft models**
L. De Sutter¹, A. Wozniak¹, J. Verreet¹, U. Vanleeuw¹, L. De Cock¹, N. Linde², C. Drechsler², C. Esdar², R. Sciot³, P. Schoeffski³, ¹KU Leuven - Laboratory of Experimental Oncology, Leuven, BE, ²Merck KGaA - Germany, Darmstadt, DE, ³UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE
- 09:52 - 09:53 **1515P - Nationwide management of soft tissue sarcoma (STS) in France, before (2019) versus during COVID-19 pandemic (2020)**
N. Penel¹, A. Giraud², C. Chemin³, C. Cantarel², F. Ducimetiere³, C. Honoré⁴, A. Le Cesne⁴, F. Gouin³, M. Toulmonde⁵, G. Decanter¹, S. Bonvalot⁶, C. Chevreau⁷, P. Anract⁸, N. Firmin⁹, F. Duffaud¹⁰, J.E. Kurtz¹¹, E. Bompas¹², M. Ropars¹³, J.-Y. Blay³, S. Mathoulin-Pelissier², ¹Centre Oscar Lambret, Lille, FR, ²Institut Bergonié, Bordeaux, FR, ³Centre Léon Bérard, Lyon, FR, ⁴Gustave Roussy - Cancer Campus, Villejuif, FR, ⁵Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ⁶Institut Curie, Paris, FR, ⁷Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ⁸Hopital Cochin AP-HP, Paris, FR, ⁹Icm Val D Aurelle, Montpellier, FR, ¹⁰CHU La Timone Adultes, Marseille, FR, ¹¹CHU Hautepierre, Strasbourg, FR, ¹²ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ¹³CHU de Rennes - Hopital Pontchaillou, Rennes, Cedex, FR
- 09:53 - 09:54 **1516P - Diagnostic delay due to COVID-19 pandemic in sarcoma patients: Single-centre retrospective SarCorD study (COMETA Project)**
A. Cosimati¹, C.E. Onesti², S. Vari², F. Nardozza², G. Maggi², D. Minghelli², B. Rossi², F. Sperati², E. Checcucci², W. Faltyn², M.C. Cercato², F. Salvatori¹, F. Riva¹, R. Biagini², G. Ciliberto², V. Ferraresi², ¹Sapienza - Università di Roma, Rome, IT, ²IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT
- 09:54 - 09:55 **1517P - Role of geriatric assessment and oncological multidimensional prognostic index (onco-MPI) in older patients (age >70 years) with advanced soft tissue sarcoma in a real-world setting**
B. Chiusole¹, I. Tortorelli¹, A. Galiano¹, F. Murtas¹, S. Ahcene Djaballah¹, G. Tierno¹, A. Banzato¹, M. Gatti², A. Di Maggio¹, G. Sergi³, M. Rastrelli¹, M. Sbaraglia³, V. Zagonel¹, A. Brunello¹, ¹Veneto Institute of Oncology IOV - IRCCS, Padova, IT, ²IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ³University of Padua, Padova, IT
- 09:55 - 09:56 **1518P - An individualized model-based risk score is the best prognostic tool for localized soft tissue sarcoma (STS) cases, but clinical status cannot be neglected**
P. Teterycz¹, H. Kosela Paterczyk¹, P. Jagodzinska-Mucha¹, A. Mariuk-Jarema¹, P. Sobczuk¹, K. Kozak¹, P. Rogala¹, M. Wagrodzki¹, T. Switaj¹, W. Łysikowska², A. Klimczak¹, P. Rutkowski¹, ¹Maria Sklodowska-Curie National Research Institute of

Oncology, Warsaw, PL, ²Medical University of Warsaw, Warsaw, PL

- 09:56 - 09:57 **1520P - Preferences on treatment decision making in sarcoma patients. Prevalence and associated factors: Results from the PROSa study**
H. Salm¹, M. Eichler², L. Hentschel³, S. Richter², P. Hohenberger⁴, B. Kasper⁴, D. Andreou⁵, D. Pink⁶, L. Mütze⁷, K. Arndt⁸, M. Bornhaeuser², J. Schmitt⁹, M. Schuler²,
¹University Hospital Greifswald, Germany, Greifswald, DE, ²Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE, ³National Center for Tumor Diseases (NCT/UCC), Dresden, DE, ⁴UMM - Universitaetsklinikum Mannheim, Mannheim, DE, ⁵UKM - University Hospital Muenster, Muenster, DE, ⁶HELIOS Klinikum Bad Saarow, Bad Saarow, DE, ⁷Hospital Emmaus Niesky, Niesky, DE, ⁸German Sarcoma Foundation, Woelfersheim, DE, ⁹University Hospital Carl Gustav Carus, Dresden, DE
- 09:57 - 09:58 **1521P - Comprehensive genomic profiling (CGP) of epithelioid hemangioendothelioma (EHE) and liver angiosarcomas (LAS)**
A. Shreenivas¹, R. Kurzrock¹, H.-Z. Chen¹, A. Clark², K. Dougherty³, N. Danziger³, S. Chakrabarti¹, J. Charlson¹, J. Ross³, ¹Medical College of Wisconsin, Milwaukee, US, ²Foundation Medicine Inc., Cambridge, US, ³Foundation Medicine, Inc, Cambridge, US
- 09:58 - 09:59 **1522P - Is it safe to discontinue the tyrosine kinase inhibitors in advanced sarcoma following a favorable tumor response to antiangiogenics therapy?**
Q. Bao¹, Z. Zhang¹, J. Wen¹, Y. Shen¹, W. Zhang², ¹Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, CN, ²Shanghai Ruijin Hospital, Shanghai Jiao Tong University, College of Medicine, Shanghai, CN
- 09:59 - 10:00 **1523P - Incidence and geographic distribution of bone and soft tissue sarcoma in Japan using a nationwide population-based analysis: 69,734 cases**
T. Shimoi¹, A. Saito¹, H. Charvat², T. Matsuda³, K. Yonemori¹, ¹National Cancer Center Hospital, Tokyo, JP, ²Juntendo University, Tokyo, JP, ³National Cancer Center Research Institute - Tsukiji Campus, Chuo-ku, JP
- 10:00 - 10:01 **1524P - Epidemiology and demography of gynecological sarcoma: Results of the prospective intergroup registry for gynecological sarcoma REGSA (NOGGO RU1)**
E. Roser¹, A.-S. Noack², D. Zocholl³, S. Kommoss⁴, P. Harter⁵, M. Kalder⁶, E. Egger⁷, P. Buderath⁸, C. Marth⁹, U. Ulrich¹⁰, M. Klar¹¹, M. Weigel¹², L. Traub¹³, H.-G. Strauß¹⁴, L. Hanker¹⁵, M. Pölcher¹⁶, P. Wimberger¹⁷, F. Beck¹, K. Pietzner¹, J. Sehouli¹⁸, ¹Charité-Universitaetsmedizin Berlin - Campus Virchow Klinikum (CVK), Berlin, DE, ²Charité - Universitätsmedizin Berlin, Berlin, DE, ³Charité - Universitaetsmedizin Berlin, Berlin, DE, ⁴Universitaetsklinikum Tuebingen Medizinische Universitaetsklinik, Tuebingen, DE, ⁵Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen, DE, ⁶UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE, ⁷University of Bonn, Bonn, DE, ⁸Universitätsklinikum Essen, Essen, DE, ⁹Universitätsklinikum Innsbruck, Innsbruck, AT, ¹⁰Martin-Luther-Krankenhaus, Berlin, DE, ¹¹Universitätsklinikum Freiburg - Klinik für Frauenheilkunde, Freiburg im Breisgau, DE, ¹²Leopoldina Krankenhaus Medizinische Klinik II, Schweinfurt, DE, ¹³Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE, ¹⁴UKH - Universitätsklinikum Halle (Saale), Halle (Saale), DE, ¹⁵University SH.-Lübeck, Lübeck, DE, ¹⁶Rotkreuzklinikum München - Frauenklinik,

Munich, DE, ¹⁷Universitätsklinikum Carl Gustav Carus Dresden, Dresden, DE,
¹⁸Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE

- 10:01 - 10:02 **1525TiP - TORNADO: A randomized multicenter open-label phase II study evaluating retifanlimab in combination with neoadjuvant chemotherapy in patients with selected retroperitoneal sarcomas**
S. Albert¹, A. Italiano², M. Toulmonde³, S. Cousin⁴, R. Bahleda⁵, M. Brahmi⁶, S. Watson⁷, C. Auzanneau², N. Douiri¹, L. Poignie¹, B. Lortal², F. Le Loarer⁴, C. Bellera¹, ¹Institut Bergonie, BORDEAUX, FR, ²Institute Bergonié, Bordeaux, FR, ³Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ⁴Institut Bergonie, Bordeaux, FR, ⁵Gustave Roussy - Cancer Campus, Villejuif, FR, ⁶Centre Léon Bérard, Lyon, FR, ⁷Institut Curie, Paris, FR
- 10:02 - 10:03 **1526TiP - TOLERANCE: An EORTC STBSG-QLG-ETF 3-arm randomized study on health-related quality of life of elderly patients with advanced soft tissue sarcoma undergoing doxorubicin alone three weekly or doxorubicin weekly or cyclophosphamide plus predniso(lo)ne treatment**
W. Van Der Graaf¹, G. Marquina², A. Brunello³, C. Coens⁴, G. Farro⁴, L. Meirsmann⁴, O. Husson¹, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²Hospital Clinico Universitario San Carlos, Department of Medicine, School of Medicine, Universidad Complutense de Madrid (UCM), IdISSC, Madrid, ES, ³IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁴EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, BE
- 10:03 - 10:04 **1527TiP - CONGRATS-combination of nivolumab plus relatlimab in patients with advanced or metastatic soft-tissue sarcoma: A proof-of-concept randomized phase II study**
M. Spalato Ceruso¹, S. Albert², A. Italiano¹, M. Toulmonde³, S. Cousin⁴, T. Grellety¹, J.-Y. Blay⁵, B. Verret⁶, C. Auzanneau¹, V. Valade², L. Poignie², B. Lortal¹, M. Kind¹, F. Le Loarer⁴, M. Pulido², ¹Institute Bergonié, Bordeaux, FR, ²Institut Bergonie, BORDEAUX, FR, ³Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ⁴Institut Bergonie, Bordeaux, FR, ⁵Centre Léon Bérard, Lyon, FR, ⁶Gustave Roussy, VILLEJUIF, FR
- 10:04 - 10:05 **1528TiP - A phase II/III study evaluating the efficacy and safety of unesbulin in advanced leiomyosarcoma (SUNRISELMs)**
M. Ingham¹, J.-Y. Blay², J. Baird³, D. D'Silva³, K. O'Keefe³, R. Kong³, R. Spiegel³, M. Wahba³, M. Weetall³, ¹Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, ²Centre Léon Bérard, Lyon, FR, ³PTC Therapeutics, Inc., South Plainfield, US
- 10:05 - 10:06 **1648P - Deep learning identifies oncogenic genetic alterations in BRAF and NTRK in H&E whole slide images from thyroid carcinomas**
M. Williams¹, V. Pelekanou², J. Hoehne³, J.D. Zoete³, A. Schmitz³, T. Bal⁴, T. Banerji⁴, J. Ferrer⁴, V. Bernard-Gauthier⁵, M. Rudolph³, M. Theron⁶, M. Cabanillas¹, M. Lenga³, E. Di Tomaso², ¹UT MD Anderson Cancer Center, Houston, US, ²Bayer Pharmaceuticals-US, Cambridge, US, ³Bayer AG, Berlin, DE, ⁴Bayer Pharmaceuticals-US, Whippany, US, ⁵Bayer Pharmaceuticals, Quebec, CA, ⁶Bayer Consumer Care AG, Basel, CH

- 10:06 - 10:07 **1649P - A proof-of-concept study for detecting ctDNA in rare thyroid cancers**
D. Vodopivec Kuri¹, Y.H. Chen¹, M. Cabanillas¹, M. Hu¹, N. Busaidy¹, R. Dadu¹, G. Budde², M. Malhotra³, J. Diersing¹, M. Zafereo¹, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²Natera, Inc., San Carlos, US, ³Natera, San Carlos, US
- 10:07 - 10:08 **1650P - The interplay of peripheral circulating free DNA and platelet-to-lymphocyte ratio in patients with differentiated thyroid cancer with/without type 2 diabetes mellitus undergoing radioiodine therapy**
A.E. Stanciu¹, L.M. Bolovan¹, M.M. Stanciu², A. Zamfirescu¹, ¹Institute of Oncology Professor Doctor Alexandru Trestioreanu Bucharest, Bucharest, RO, ²Politehnica University of Bucharest, Bucharest, RO
- 10:08 - 10:09 **1651P - Comparison of surgical outcomes between synchronous lateral neck dissection and metachronous lateral neck dissection for clinically N1b papillary thyroid cancer**
H.J. Yun¹, J.S. Lee¹, J.S. Lee¹, S.-M. Kim¹, H.J. Chang¹, Y.S. Lee², H.S. Chang¹, C.S. Park³, ¹Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, ²Yonsei University, Seoul, KR, ³CHA Ilisan Medical Center, Goyang-si, KR
- 10:09 - 10:10 **1652P - Molecular and pathological patterns of treatment failure in patients treated by RET selective inhibitors for metastatic medullary thyroid carcinoma**
J. Hadoux¹, A. Al Ghuzlan², L. Lamartina¹, M. Attard², J.-Y. Scoazec², D. Hartl³, M. Aldea³, L. Friboulet⁴, A. Italiano², B. Besse⁵, L. Lacroix², E. Baudin¹, ¹Gustave Roussy, Villejuif, Cedex, FR, ²Gustave Roussy, Villejuif, FR, ³Institut Gustave Roussy, Villejuif, Cedex, FR, ⁴Gustave Roussy - Cancer Campus, Villejuif, FR, ⁵Institut Gustave Roussy, Villejuif, FR
- 10:10 - 10:11 **1653P - Cabozantinib (C) vs placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: Outcomes by duration of prior lenvatinib (L) treatment**
M. Brose¹, J. Krajewska², F. Vaisman³, A. Hoff⁴, E. Hitre⁵, J. Oliver⁶, D. Williamson⁶, N. Berry⁶, J. Capdevila Castillon⁷, ¹Abramson Cancer Center, University of Pennsylvania, Philadelphia, US, ²Maria Sklodowska-Curie Institute - Oncology Center (MSCI), Gliwice Branch, Gliwice, PL, ³Instituto Nacional de Câncer, Rio de Janeiro, BR, ⁴Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, BR, ⁵Országos Onkológiai Intézet, Budapest, HU, ⁶Exelixis, Inc., Alameda, US, ⁷Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES
- 10:11 - 10:12 **1654P - Updated ARROW data: Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC)**
M. Hu¹, V. Subbiah², A. Mansfield³, M. Taylor⁴, M. Schuler⁵, V. Zhu⁶, J. Hadoux⁷, G. Curigliano⁸, L. Wirth⁹, E. Garralda¹⁰, D. Adkins¹¹, Y. Godbert¹², M.-J. Ahn¹³, P. Cassier¹⁴, B.C. Cho¹⁵, C.-C. Lin¹⁶, T. Barata¹⁷, A. Zalutskaya¹⁸, A. Scalori¹⁹, M. Brose²⁰, ¹University of Texas MD Anderson Cancer Center, Houston, US, ²University of Texas M. D. Anderson Cancer Center, Houston, US, ³Mayo Clinic, Rochester, US, ⁴Providence Portland Medical Center, Portland, US, ⁵University Hospital Essen, Essen, DE, ⁶University of California Irvine, Orange, US, ⁷Institut Gustave Roussy, Villejuif, FR, ⁸IRCCS, and University of

Milano, Milan, IT, ⁹Massachusetts General Hospital, Boston, US, ¹⁰Hospital Universitario Vall d'Hebron, Barcelona, ES, ¹¹and Washington University School of Medicine, St. Louis, US, ¹²Bergonié Institute Cancer Center, Bordeaux, FR, ¹³Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ¹⁴Centre Léon Bérard, Lyon, FR, ¹⁵Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, KR, ¹⁶National Taiwan University Hospital, Taipei, TW, ¹⁷F. Hoffmann-La Roche Ltd, Basel, CH, ¹⁸Blueprint Medicines Corporation, Cambridge, US, ¹⁹F. Hoffmann-La Roche Ltd, Welwyn Garden City, GB, ²⁰Sydney Kimmel Cancer Center, Jefferson University, Philadelphia, US

- 10:12 - 10:13 **1655P - Dabrafenib and trametinib in patients with metastatic BRAFV600E-mutated thyroid cancer**
Y.-K. Jeon¹, H.A. Jung², S. Park³, S.-H. Lee², T.H. Kim¹, S.W. Kim¹, J.H. Chung¹, M.-J. Ahn³, ¹Samsung Medical Center (SMC), Seoul, KR, ²Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ³Samsung Medical Center, Seoul, KR
- 10:13 - 10:14 **1656P - Durable efficacy of selpercatinib in patients (pts) with medullary thyroid cancer (MTC): Update of the LIBRETTO-001 trial**
M. Kroiss¹, E. Sherman², L. Wirth³, M. Cabanillas⁴, B. Robinson⁵, V. Subbiah⁶, A. Drilon⁷, Y. Godbert⁸, N. Fasnacht⁹, V. Soldatenkova⁹, M.S. Xia⁹, C.-W. Duann⁹, J. Wright⁹, D. Weiler-Bisig¹⁰, M. Shah¹¹, ¹University Hospital Würzburgniversity of Munich, Würzburg, DE, ²MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ³MGH - Massachusetts General Hospital, Boston, US, ⁴The University of Texas, Houston, US, ⁵Royal North Shore Hospital, St Leonards, AU, ⁶The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁷Memorial Sloan Kettering and Weill Cornell Medical College, New York, US, ⁸Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ⁹Eli Lilly and Company, Inianapolis, US, ¹⁰Luzern Cantonal Hospital, Luzern, CH, ¹¹The Ohio State University James Cancer Hospital, Columbus, US
- 10:14 - 10:15 **1657P - Clinical and molecular profiles of radioiodine refractory differentiated thyroid cancer**
Y. Lin¹, X. Zhang¹, H. He², L. Huang², S. Ding², Z. Kai², R. Lin³, P. Luo², ¹Peking Union Medical College Hospital, Beijing, CN, ²Zhejiang Shaoxing Topgen Biomedical Technology Co., Ltd., Shanghai, CN, ³Zhejiang Topgen Biomedical Technology Co., Ltd., Huzhou, CN
- 10:15 - 10:16 **1658P - rs4646 is found to be associated with the efficacy of radioiodine (RAI) uptake on thyroid carcinomas: A retrospective study**
X. Zhang¹, Y. Lin¹, Z. Kai², H. He², L. Huang², R. Lin³, P. Luo², ¹Peking Union Medical College Hospital, Beijing, CN, ²Zhejiang Shaoxing Topgen Biomedical Technology Co., Ltd., Shanghai, CN, ³Zhejiang Topgen Biomedical Technology Co., Ltd., Huzhou, CN
- 10:16 - 10:17 **1659TiP - A Spanish observational study for MOLEcular characterization of THYroid carcinoma: MOLTHY Project – TTCC-2020-02**
N. Baste Rotllan¹, J. Martinez Trufero², C. Alvarez Escola³, T. Alonso Gordoa⁴, E. Gallardo Diaz⁵, J. Rubió-Casadevall⁶, C. Vila⁷, M. Plana Serrahima⁸, A. Cunqueiro Tomas⁹, C. Lopez

Lopez¹⁰, A. Segura Huerta¹¹, J. Hernando Cubero¹², M. Durán¹³, C. Teixido¹⁴, E. Ortega Izquierdo¹⁵, R.M. Regojo³, I. Ruz-Caracuel¹⁶, T. Bonfill Abella¹⁷, J. Grau¹⁸, R. Mesia Nin¹⁹, ¹Hospital Clinic y Provincial de Barcelona, IDIBAPS, Barcelona, ES, ²Hospital Universitario Miguel Servet, Zaragoza, ES, ³Hospital Universitario La Paz, Madrid, ES, ⁴Hospital Universitario Ramon y Cajal, Madrid, ES, ⁵Parc Tauli Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, ES, ⁶Institut Català d'Oncologia Girona, Girona Biomedical Research Institute (IDIBGI), Girona, ES, ⁷Xarxa Assistencial Universitària Althaia Manresa, Manresa, ES, ⁸Institut Català d'Oncologia (ICO-Hospitalet), IDIBELL, L'Hospitalet de Llobregat, ES, ⁹General University Hospital of Valencia, EOM Group, Valencia, ES, ¹⁰Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, ES, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, ES, ¹²Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ¹³TTCC-Grupo Español de Tratamiento de Tumores de Cabeza y Cuello, Madrid, ES, ¹⁴Hospital Clinic y Provincial de Barcelona, Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, ES, ¹⁵Hospital Universitario Miguel Servet, Zaragoza, ES, ¹⁶Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, ES, ¹⁷Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, ES, ¹⁸Hospital Clinic Barcelona, Barcelona, ES, ¹⁹Institut Català d'Oncologia Badalona, B-ARGO Group, BADALONA, ES

10:17 - 10:18

1697P - Drug-induced evolutionary dynamics in BRCA-mutant/non-mutant ovarian cancer models

A. Ingles Russo Garces¹, S. Milite², E. Oliveira³, J. Fernandez-Mateos³, B. Chen³, L. Pickard³, A. Stewart³, R. Lau³, A. De Haven Brandon³, E. Paranjape³, A. Sottoriva⁴, S. Banerjee⁵, U. Banerji⁶, ¹The Institute of Cancer Research/The Royal Marsden Foundation Trust, London, GB, ²Fondazione Human Technopole, Milan, IT, ³ICR - Institute of Cancer Research, London, GB, ⁴Fondazione Human Technopole and The Institute of Cancer Research, Milan, IT, ⁵The Royal Marsden Hospital - Chelsea, London, GB, ⁶The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB

10:18 - 10:19

1698P - Correlation between sex steroid hormone receptors expression in prostate cancer (PCa)

M. Puchinskaya, Minsk City Clinical Oncologic Centre, Minsk, BY

10:19 - 10:20

1699P - Real-life molecular testing in lung cancer patients in a French non-academic public hospitals network: Results of a cohort of 9,000 lung cancer patients

A. Cortot¹, S. Couraud², O. Molinier³, P. Slaouti⁴, C. Delmas⁵, E. Maetz⁶, O. Leleu⁷, P. Kuntz⁸, S. Loutski Vettese⁹, V. Levrat¹⁰, H. Rabut¹¹, J.-M. Dot¹², J.-P. Kraemer¹³, S. Larive¹⁴, J.M. Peloni¹⁵, F. El Khanjari¹⁶, J. Obert¹⁷, P. Beynel¹⁸, A. Letierce¹⁹, D. Debieuvre²⁰, ¹CHU Lille - Centre Hospitalier Régional Universitaire de Lille, Lille, FR, ²Lyon Sud Hospital Center - HCL, Pierre-Bénite, FR, ³Centre Hospitalier Du Mans, Le Mans, FR, ⁴CENTRE MEDICAL NATIONAL MGEN, Sainte-Feyre, FR, ⁵CENTRE HOSPITALIER SAVERNE, Saverne, FR, ⁶Hospital Center De Douai, Douai, FR, ⁷CH Abbeville, Abbeville, FR, ⁸GROUPE HOSPITALIER DE LA HAUTE SAONE, Vesoul, FR, ⁹Centre Hospitalier de Compiègne, Compiègne, FR, ¹⁰Hopital Saint Louis - Groupe Hospitalier La Rochelle-Ré-Aunis, La Rochelle, FR, ¹¹Hôpital Louis Pasteur, Le coudray, FR, ¹²Médipole Hopital Mutualiste Lyon-Villeurbanne, Villeurbanne, FR, ¹³Centre Hospitalier Intercommunal Frejus Saint Raphael, Frejus, FR, ¹⁴Centre Hospitalier les

Chanaux-Macon, Macon, FR, ¹⁵Hospital Instruction Armed Robert Picqué, Villenave-d'Ornon, FR, ¹⁶Centre Hospitalier Simone Veil de Blois, Blois, Cedex, FR, ¹⁷Centre hospitalier intercommunal Le Raincy-Montfermeil, Montfermeil, FR, ¹⁸Centre Hospitalier de Bourg-en-Bresse (Fleyriat) CH De Fleyriat, Bourg en Bresse, FR, ¹⁹Qualitystat, MORANGIS, FR, ²⁰GHRMSA, Mulhouse, FR

- 10:20 - 10:21 **1700P - Radiation therapy elicits a consistent myeloid and lymphoid immune response in breast and rectal cancer**
S. Becker¹, M. Suffiotti², ¹Justus-Liebig-Universität, Gießen, DE, ²Idorsia Pharmaceuticals Ltd, Allschwil, CH
- 10:21 - 10:22 **1701P - Consensus molecular subtypes in late-stage colorectal cancer**
A. Bjerrum, T.O. Stannius, L. Belcaid, K. Rohrberg, I. Spanggaard, M. Hoejgaard, F.C. Nielsen, F.O. Bagger, C. Qvortrup, Rigshospitalet, Copenhagen, DK
- 10:22 - 10:23 **1702P - Comutations in DNA damage repair pathway and its correlations with potential biomarkers for colorectal cancer immunotherapy in a Chinese cohort**
G. Shi¹, J. Xu², C. Xia², S. Ding², P. Luo², ¹The Second Hospital of Tianjin Medical University, Tianjin, CN, ²Zhejiang Shaoxing Topgen Biomedical Technology Co., Ltd., Shanghai, CN
- 10:23 - 10:24 **1703P - The effect of CA4 on lung adenocarcinoma immune microenvironment**
L. Al-Kraimeen¹, O. Ababneh², Y. Al-Kraimeen³, N. Ayoub¹, ¹JUST - Jordan University of Science and Technology, Irbid, JO, ²Jordan University of Science and Technology, Irbid, JO, ³Université Salah Boubnider Constantine 03, Constantine, DZ
- 10:24 - 10:25 **1704P - Multimodal approach to discover novel targets for antibody-drug conjugates by analyzing distinct expression patterns of frequent copy number aberration**
J. Moon¹, H.-G. Cho², S. Kim³, S. Kim², G. Park², S. Song², W. Jung², C.-Y. Ock², ¹Korea University, Seoul, KR, ²Lunit Inc., Seoul, KR, ³Ajou University School of Medicine, Suwon, KR
- 10:25 - 10:26 **1705P - HER2 intratumoral genetic and non-genetic heterogeneity in metastatic colorectal cancer**
K. Sawada¹, H. Nitta², Y. Nakamura³, W. Okamoto⁴, H. Taniguchi⁵, Y. Komatsu⁶, H. Hara⁷, T. Kato⁸, T. Nishina⁹, T. Ohta¹⁰, T. Esaki¹¹, T. Yoshino³, S. Fujii¹², ¹Kushiro Rosai Hospital, Kushiro, JP, ²Roche Tissue Diagnostics, Tucson, US, ³National Cancer Center Hospital East, Kashiwa, JP, ⁴Hiroshima University Hospital, Hiroshima, JP, ⁵Aichi Cancer Center Hospital, Nagoya, JP, ⁶Hokkaido University Hospital, Sapporo, JP, ⁷Saitama Cancer Center, Ina, JP, ⁸National Hospital Organization Osaka National Hospital, Osaka, JP, ⁹Shikoku Cancer Center, Matsuyama, JP, ¹⁰Kansai Rosai Hospital, Amagasaki, JP, ¹¹National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, ¹²Yokohama City University Hospital, Yokohama, JP
- 10:26 - 10:27 **1706P - Artificial intelligence-powered tumor purity assessment from H&E whole slide images associates with variant allele frequency of somatic mutations**

across 23 cancer types in TCGA cohorts

S. Kim¹, G. Park², S. Kim², S. Song², H. Song², J. Ryu², S. Park², S. Pereira², K. Paeng², C.-Y. Ock², ¹Ajou University School of Medicine, Suwon, KR, ²Lunit Inc., Seoul, KR

- 10:27 - 10:28 **1707P - The landscape of PALB2 alteration in Chinese solid tumor patients**
Z. Cui¹, H. Li², S. Gao³, D. Li⁴, C. Liu⁵, Y. Zhang⁵, F. Meng⁵, L. Li⁶, ¹Baoding NO.1 Hospital, Baoding, CN, ²Rongcheng County People's Hospital, Baoding, CN, ³The Second Hospital of Hebei Medical University, Shijiazhuang, CN, ⁴Jingxing County Hospital of Hebei Province, Shijiazhuang, CN, ⁵Yinfeng Gene Technology Co Ltd, Jinan, CN, ⁶Clinical Oncology Research Alliance, Tianjin, CN
- 10:28 - 10:29 **1708P - SMARCA4/SMARCB1 alterations detected through tissue comprehensive genomic profiling (CGP): A single-center study of prevalence and clinical characteristics**
J. Bartolomé Arcilla, G. Fernandez-Hinojal, A. Manzano Fernández, M. Paz Cabezas, A. Ocana Fernandez, P. Pérez Segura, Hospital Clinico Universitario San Carlos, Madrid, ES
- 10:29 - 10:30 **1709P - Cascade genetic testing utilized only in 31% of initial families with pathogenic variants in breast cancer genes**
D. Ziogas¹, K. Agiannitopoulos², G. Pepe², K. Potska², G. Tsaousis², D. Apostolopoulou², N. Tsoulos², V. Venizelos³, C. Markopoulos⁴, R. Iosifidou⁵, S. Karageorgopoulou⁶, S. Giassas⁶, I. Natsiopoulou⁷, K. Papazisis⁸, M. Vasilaki-Antonatou⁹, A. Psyrri¹⁰, A. Koumariannou¹¹, C. Papadimitriou¹², E. Papadopolou², G. Nasioulas², ¹Laiko General Hospital of Athens, Athens, GR, ²Genekor Medical S.A, ATHENS, GR, ³Metropolitan Hospital, Athens, GR, ⁴Athens Medical Center, Athens, GR, ⁵Theagenio Cancer Hospital of Thessaloniki, Thessaloniki, GR, ⁶IASO S.A., Athens, GR, ⁷Interbalkan Medical Center of Thessaloniki, Thessaloniki, GR, ⁸Euromedica General Clinic, Thessaloniki, GR, ⁹IASO General Hospital, Cholargos/Holargos, GR, ¹⁰Attikon University Hospital, Athens, GR, ¹¹Attikon University Hospital, Haidari, GR, ¹²Alexandra Hospital, Athens, GR
- 10:30 - 10:31 **1710P - Genomic landscape (GL) with potential of methylthioadenosine phosphorylase (MTAP) loss in clinically advanced breast cancer (CABC)**
M. Bou Zerdan¹, P. Ashok Kumar¹, E. Sokol², D. Pavlick², M. Levy², N. Danziger², J. Ross¹, A. Sivapiragasam¹, ¹SUNY Upstate Medical University, Syracuse, US, ²Foundation Medicine, Inc, Cambridge, US
- 10:31 - 10:32 **1711P - Spatial transcriptomics reveals substantial heterogeneity in TNBC tumor and stroma compartments with potential clinical implications**
X. Wang¹, D. Venet¹, F. Lifrange², D. Larsimont¹, M. Rediti¹, L. Stenbeck³, D. Gacquer¹, F. Dupont¹, G. Rouas¹, M. Serra¹, J. Lundeborg³, F. Rothé¹, C. Sotiriou¹, ¹Institut Jules Bordet, Brussels, BE, ²CHU de Liège, Liège, BE, ³Science for Life Laboratory (SciLifeLab), Solna, SE
- 10:32 - 10:33 **1712P - Usefulness of schlafen-11 expression level in cstage II/III esophageal squamous cell carcinoma**
T. Yamamura, K. Hatanaka, K. Harada, Y. Kawamoto, R. Watanabe, T. Nakamura, S. Yuki, T. Mitsuhashi, Y. Hatanaka, Y. Komatsu, Hokkaido University Hospital, Sapporo, JP

- 10:33 - 10:34 **1713P - Single-cell transcriptomic analysis of appendiceal cancer peritoneal disease**
M. Strach¹, N. Yeung², E. Apostolov², H.-M. Lin², R. Nagaraju³, N. Ansari⁴, C. Koh⁴, J.-S. Shin⁴, J. Kench⁴, O. Aziz⁵, A. Swarbrick², L. Horvath⁶, J. Barriuso⁵, K. Mahon⁶, ¹The University of Sydney, Sydney, AU, ²Garvan Institute of Medical Research, Darlinghurst, AU, ³The University of Manchester, Manchester, GB, ⁴Royal Prince Alfred Hospital, Camperdown, AU, ⁵The Christie NHS Foundation Trust, Manchester, GB, ⁶Chris O'Brien Lifehouse, Camperdown, AU
- 10:34 - 10:35 **1714P - Single-cell RNA sequencing and proteomic analysis reveals dedifferentiation-immunosuppression loop formed by malignant cell and macrophage in intrahepatic cholangiocarcinoma**
Q. Li, C. Ye, Q. Jiang, R. Chen, W. Wu, F. Yan, X. Shuaishuai, X. Zhang, J. Ruan, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN
- 10:35 - 10:36 **1715P - The landscape of SMAD4 alteration in Chinese solid tumor patients**
H. Xu¹, X. Liu¹, Y. Zhang², C. Liu², F. Meng², P. Du², L. Li³, ¹363 Hospital, Chengdu, CN, ²Yinfeng Gene Technology Co Ltd, Jinan, CN, ³Clinical Oncology Research Alliance, Tianjin, CN
- 10:36 - 10:37 **1716P - Prognostic value and immune characteristics of CYP4B1 in lung squamous cell carcinoma: A bioinformatics analysis**
O. Ababneh¹, L. Al-Kraimeen², Y. Al-Kraimeen³, N. Ayoub², ¹Jordan University of Science and Technology, Irbid, JO, ²JUST - Jordan University of Science and Technology, Irbid, JO, ³Université Salah Boubnider Constantine 03, Constantine, DZ
- 10:37 - 10:38 **1717P - Biomarker potential of collagens linked to fibroblast subtypes in pancreatic ductal adenocarcinoma (PDAC)**
J. Thorlacius-Ussing¹, C. Jensen², M. Karsdal², N. Willumsen², ¹University of Copenhagen, Copenhagen, DK, ²Nordic Bioscience A/S, Herlev, DK
- 10:38 - 10:39 **1718P - Transcriptomic expression of immunological markers associated with pathological complete response in patients with triple negative breast cancer in NACATRINE trial**
A.J. De Freitas, C.R. Nunes, R.L. Causin, M.A. De Oliveira, C.P. Souza, M.M.C. Marques, Barretos Cancer Hospital, Barretos, BR

09:00 - 15:00 **Type: Poster session** **Poster Area, Hall 4**
Title: Poster session 10

- 09:00 - 09:01 **672P - Nivolumab (Nivo) and ipilimumab (Ipi) combined with radiotherapy (RT) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): Updated results on efficacy and correlative analysis**
I. Vathiotis¹, J. Johnson¹, L. Harshyne², A. Luginbuhl¹, J. Curry¹, D. Cognetti¹, R. Axelrod¹, V. Bar-Ad³, A. Argiris⁴, ¹Thomas Jefferson University, Philadelphia, US, ²Kimmel Cancer Center-Thomas Jefferson University, Philadelphia, US, ³Sidney Kimmel Cancer Center - Thomas Jefferson University, Philadelphia, US, ⁴Hygeia Hospital,

Marousi, GR

- 09:01 - 09:02 **673P - A prospective comparative study on biweekly docetaxel, cisplatin, 5-fluorouracil, leucovorin (TPFL) versus triweekly TPF as an induction chemotherapy in locally advanced squamous cell carcinoma of head and neck**
S. Anantharamu, L.A. Jacob, L. Dasappa, M.C. Suresh Babu, K.N. Lokesh, A. Rudresha, R. Lakkavalli Krishnappa, S. Saldanha, Kidwai Memorial Institute of Oncology, Bangalore, IN
- 09:02 - 09:03 **674P - Initial curative management for localized/locally advanced head and neck squamous cell carcinomas (LAHNSCC): Exclusive (chemo)radiation (CRT) or S/IC (surgery or induction chemotherapy) – The EPOCKS study**
J. Fayette¹, C. Dalban¹, P. Zrounba², S. Racadot², D. Girodet², S. Chabaud³, E. Reyt⁴, M. Poupard⁵, J.M. Prades⁶, M. Burgy⁷, D. Cellier², P. Ceruse⁸, J. Leval⁹, P. Muller¹⁰, P. Manipoud¹¹, I. Ray-Coquard¹, G. Thibault², ¹Centre Léon Bérard, Lyon, FR, ²Léon-Bérard Cancer Center, Lyon, FR, ³Centre de recherche en cancerologie de Lyon (CRCL), Lyon, FR, ⁴CHU Grenoble Alpes - Site Nord (La Tronche), La Tronche, FR, ⁵Hospices Civiles de Lyon - HCL - Lyon University Hospital Center, Lyon, FR, ⁶CHU de Saint Etienne, Hôpital du Nord, Saint-Priest-en-Jarez, FR, ⁷ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ⁸Lyon-Nord University Hospital, Lyon, FR, ⁹Clinique Charcot, Sainte-Foy-lès-Lyon, FR, ¹⁰Centre Hospitalier de Romans sur Isère, Romans-sur-Isère, FR, ¹¹Centre Hospitalier Metropole Savoie - Chambéry, Chambéry, Cedex, FR
- 09:03 - 09:04 **675P - Patterns of radiological responses to anti-PD1 in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in TOPNIVO (T) study**
C. Even¹, A. Bernard-Tessier¹, M. Texier², O. Ben Said³, M. Iacob⁴, A. Daste⁵, J. Fayette⁶, S. Zanetta⁷, G. Lefebvre⁸, M. Vinches⁹, A. Johnson¹⁰, L. Bozec Le Moal¹¹, E. Saada¹², I. Jallut¹³, F. Garic¹³, L. Monard¹⁴, J. Bourhis¹⁵, J. Guigay¹², A. Auperin³, S. Ammari³, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Institut Gustave Roussy, Villejuif, FR, ³Gustave Roussy - Cancer Campus, Villejuif, FR, ⁴IRO - Regional Institute of Oncology, Villejuif, FR, ⁵CHU Bordeaux Hopital St. André, Bordeaux, FR, ⁶Centre Léon Bérard, Lyon, FR, ⁷Centre Georges-François Leclerc (Dijon), Dijon, FR, ⁸Centre Oscar Lambret, Lille, FR, ⁹ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, ¹⁰Centre Francois Baclesse, Caen, FR, ¹¹Institut Curie - Hôpital René Huguenin, Saint Cloud, FR, ¹²Centre Anticancer Antoine Lacassagne, Nice, FR, ¹³Unicancer, Paris, Cedex, FR, ¹⁴UNICANCER, Paris, FR, ¹⁵UNIL CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, CH
- 09:04 - 09:05 **676P - ATHENA: A multicenter phase II of atezolizumab (A) and bevacizumab (B) in patients (pts) with recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M HNSCC) - The HPV-negative cohort**
J. Fayette¹, E. Saada², A. Demontfort¹, A. Karabajakian¹, E.M. Neidhardt¹, C. Borel³, M. Burgy⁴, H. Carinato³, J.-P. Delord⁵, S. Betrian⁶, P. Toussaint¹, T. Chatellier⁷, T. Lharidon⁷, G. Garin¹, M. Bernardin⁸, L. Jaouen⁸, I. Sondarjee⁸, D. Perol¹, J.-Y. Blay¹, ¹Centre Léon Bérard, Lyon, FR, ²Centre Anticancer Antoine Lacassagne, Nice, FR, ³Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, ⁴ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ⁵IUCT - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, FR, ⁶Institut Claudius Regaud, Toulouse, FR,

⁷Clinique Mutualiste de l'Estuaire, Saint-Nazaire, FR, ⁸Center Leon Berard, Lyon, FR

- 09:05 - 09:06 **677P - A phase I study of the CDK4/6 inhibitor, palbociclib in combination with cetuximab and intensity modulated radiation therapy (IMRT) for locally advanced squamous cell carcinoma of the head and neck (SCCHN): An expansion cohort**
- N. Ngamphaiboon¹, T. Siripoon¹, S. Lukerak¹, A. Jinawath², L. Arsa², P. Shantavasinkul¹, N. Taonam¹, N. Jinawath², A. Kositwattanarerk², T. Sananmuang², P. Pattaranutaporn², C. Jiarpinitnun², ¹Mahidol University - Faculty of Medicine - Ramathibodi Hospital, Bangkok, TH, ²Mahidol University - Faculty of Medicine Ramathibodi Hospital, Bangkok, TH
- 09:06 - 09:07 **678P - Real-world evidence of first-line cetuximab (CX) plus paclitaxel (PX) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)**
- B. Cirauqui Cirauqui¹, J. Martinez Trufero², M. Plana Serrahima³, A. García Castaño⁴, J. Rubió-Casadevall⁵, A. Carral Maseda⁶, L. Iglesias Docampo⁷, P. Pérez Segura⁸, I. Ceballos Lenza⁹, V. Gutierrez Calderon¹⁰, J. Fuster Salva¹¹, C. Pena Álvarez¹², V. Arrazubi Arrula¹³, E. Del Barco Morillo¹⁴, M. Chaves Conde¹⁵, J. Martínez Galán¹⁶, M. Durán Sánchez¹⁷, V. Quiroga¹, E. Ortega², R. Mesia Nin¹⁸, ¹Institut Català d'Oncologia Badalona, B-ARGO Group, Badalona, ES, ²Hospital Universitario Miguel Servet, Zaragoza, ES, ³Institut Català d'Oncologia (ICO-Hospitalet), IDIBELL, L'Hospitalet de Llobregat, ES, ⁴Hospital Universitario Marqués de Valdecilla, Santander, ES, ⁵Institut Català d'Oncologia Girona. Girona Biomedical Research Institute (IDIBGI), Girona, ES, ⁶Hospital Universitario Lucus Augusti, Lugo, ES, ⁷Hospital Universitario 12 de Octubre, Madrid, ES, ⁸Hospital Clínico San Carlos, IdISSC, Madrid, ES, ⁹Hospital Universitario de Canarias, San Cristóbal de La Laguna, ES, ¹⁰Hospital Universitario Regional y Virgen Victoria. IBIMA., Malaga, ES, ¹¹Hospital Universitario Son Espases, Palma de Mallorca, ES, ¹²Centro Oncológico Galicia, A Coruña, ES, ¹³Centro Hospitalario de Navarra, Pamplona, ES, ¹⁴Hospital Universitario de Salamanca. IBSAL., Salamanca, ES, ¹⁵Hospital Universitario Virgen de Valme, Sevilla, ES, ¹⁶Hospital Universitario Virgen Nieves, Granada, ES, ¹⁷Spanish Group of Head and Neck Cancer Treatment (TTCC), Madrid, ES, ¹⁸Institut Català d'Oncologia Badalona, B-ARGO Group, Badalona. On behalf of the Spanish Group of Head and Neck Cancer Treatment (TTCC), Madrid, ES
- 09:07 - 09:08 **679P - Clinical outcomes in patients with recurrent or metastatic head and neck squamous cell carcinoma after failure of platinum and nivolumab: A multicenter retrospective study**
- H. Oka¹, K. Nagashima², H. Nishi³, Y. Kumai³, H. Iijima⁴, K. Okami⁴, Y. Shimizu⁵, S. Kano⁵, K. Ito⁶, T. Yamazaki⁷, H. Takahashi⁸, N. Oridate⁸, T. Yokota⁹, T. Koyama¹⁰, N. Kiyota¹⁰, K. Kato¹¹, S. Kadowaki¹¹, Y. Honma¹, ¹National Cancer Center - Tsukiji Campus, Chuo-ku, JP, ²Keio University Hospital, Tokyo, JP, ³Nagasaki University Hospital, Nagasaki, JP, ⁴Tokai University Hospital, Isehara, JP, ⁵Hokkaido University Hospital, Sapporo, JP, ⁶Miyagi Cancer Center, Natori, JP, ⁷Saitama Medical University International Medical Center, Saitama, JP, ⁸Yokohama City University Hospital, Yokohama, JP, ⁹Shizuoka Cancer Center, Shizuoka, JP, ¹⁰Kobe University Hospital, Kobe, JP, ¹¹Aichi Cancer Center Hospital, Nagoya, JP
- 09:08 - 09:09 **680P - HANNA: Real-world data of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), including first-**

line population, treated with nivolumab in Germany

C. Langer¹, E. Von Der Heyde², D. Hahn³, B. Kubuschok⁴, U. Bockmühl⁵, H. Mueller-Huesmann⁶, G. Klautke⁷, J. Von Der Grün⁸, D. Beutner⁹, J. Büntzel¹⁰, C.-J. Busch¹¹, B. Tamaskovics¹², J. Riera Knorrenschild¹³, K. Gutsche¹⁴, M. Welslau¹⁵, T. Gauler¹⁶, D. Waldenberger¹⁷, A. Dietz¹⁸, ¹Universitätsklinikum Gießen und Marburg, Giessen, DE, ²Onkologische Praxis am Raschplatz, Hannover, DE, ³Klinikum der Landeshauptstadt Stuttgart, Stuttgart, DE, ⁴Universitätsklinikum Augsburg, Augsburg, DE, ⁵Klinikum Kassel, Kassel, DE, ⁶Brüderkrankenhaus St. Josef Paderborn, Paderborn, DE, ⁷Klinikum Chemnitz gGmbH, Chemnitz, DE, ⁸Universitätsklinikum Frankfurt, Frankfurt, DE, ⁹Universitätsmedizin Göttingen, Göttingen, DE, ¹⁰Südharz Klinikum Nordhausen gGmbH, Nordhausen, DE, ¹¹Universitätsmedizin Greifswald, Greifswald, DE, ¹²Heinrich Heine University, Düsseldorf, DE, ¹³Philipps-Universität Marburg, Marburg, DE, ¹⁴Carl-Thiem-Klinikum Cottbus gGmbH, Cottbus, DE, ¹⁵Klinikum Aschaffenburg, Aschaffenburg, DE, ¹⁶Universitätsklinikum Essen, Essen, DE, ¹⁷Bristol Myers Squibb, München, DE, ¹⁸Universitätsklinikum Leipzig, Leipzig, DE

09:09 - 09:10

681P - OPTIM: A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck – AIO-KHT-0117

V. Gruenwald¹, J. Alt², M. Tometten³, M. Haenel⁴, P. Ivanyi⁵, G. Schuch⁶, K. Klinghammer⁷, K. Gutsche⁸, J. Hasenkamp⁹, G. Hapke¹⁰, M. Mänz¹¹, W. Weichert¹², D. Hahn¹³, ¹University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ²Universitätsmedizin Mainz, Mainz, DE, ³Uniklinik RWTH Aachen, Aachen, DE, ⁴Klinikum Chemnitz gGmbH, Chemnitz, DE, ⁵MHH - Medizinische Hochschule Hannover, Hannover, DE, ⁶Hämatologisch-Onkologische Praxis Altona (HOPA), Hamburg, DE, ⁷Charite, Campus Benjamin Franklin Medizinische Klinik III, Berlin, DE, ⁸Hospital Carl-Thiem-Klinikum Cottbus, Cottbus, DE, ⁹University Hospital Goettingen, Goettingen, DE, ¹⁰Marienkrankenhaus, Hamburg, DE, ¹¹AIO - Arbeitsgemeinschaft Internistische Onkologie in der Deutschen Krebsgesellschaft e.V., Berlin, DE, ¹²Technische Universität München-Institute of Pathology, Munich, DE, ¹³Klinikum Stuttgart - Katharinenhospital (KH), Stuttgart, DE

09:10 - 09:11

682P - Patient characteristics and treatment patterns of newly diagnosed locally advanced head and neck squamous cell carcinoma (LA HNSCC): A retrospective cohort analysis of real-world data in England

A. Kong¹, G. Chiu², S. Shah², J. Bolodeoku², C. Casey³, O. Massey³, A. Patel³, C. Black⁴, ¹KCL - King's College London, London, GB, ²MSD - Merck Sharp & Dohme Limited, Hoddesdon, GB, ³Adelphi Real World - Adelphi Group, Bollington, GB, ⁴Merck & Co., Inc. - Corporate Headquarters, Kenilworth, US

09:11 - 09:12

683P - Pembrolizumab plus nabpaclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II study

L. Gui, X. He, J. Yang, P. Liu, Q. Yan, Y.-K. Shi, Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, Beijing, CN

09:12 - 09:13

684P - Liquid biopsy for detection of molecular residual disease and recurrence in head and neck squamous cell carcinoma

S. Flach¹, K. Howarth², S. Hackinger², C. Pipinikas², P. Ellis², K. Mclay², G. Marsico², C.

Walz¹, L. Käsmann¹, C.A. Reichel¹, O. Gires¹, M. Canis¹, P. Baumeister¹, ¹LMU Klinikum der Universität München, Munich, DE, ²Inivata Limited, Cambridge, GB

09:13 - 09:14

685P - Genomic characteristics and immunotherapy outcomes in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)

J.C. Park¹, M. Useche Cortes², J. Durbeck², J. Clark¹, Y. Zhao², S. Saladi², ¹Massachusetts General Hospital Cancer Center, Boston, US, ²Massachusetts Eye and Ear Infirmary, Boston, US

09:14 - 09:15

686P - Next generation sequencing (NGS) helps predict response to immunotherapy (IO) in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)

O. Mirallas¹, D. Marmolejo Castaneda¹, D. Illescas¹, D. Gómez-Puerto¹, R. Berché², A. Calvo³, M. Vieito Villar¹, L. Lorini⁴, V. Navarro², J.D. Assaf Pastrana¹, O. Saavedra¹, G. Alonso⁵, S. Aguilar Izquierdo¹, C. Bescós¹, J. Lorente¹, J. Giralt¹, R. Dienstmann⁶, E. Garralda¹, E. Felip¹, I. Brana¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ³Princess Margaret Cancer Centre, Toronto, CA, ⁴Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT, ⁵Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁶Grupo Oncoclinicas, Sao Paulo, BR

09:15 - 09:16

687P - Differential expression of PDL-1 between primary and recurrent/metastatic head and neck squamous cell carcinoma: Analysis of concordance and factors impacting on variations

P. Bossi¹, D. Mattavelli², S. Battocchio³, M. Martini⁴, S. Calza², L. Lorini⁵, D. Baldassarra³, G. Zigliani³, C. Piazza², P. Morbini⁶, ¹University of Brescia, ASST Spedali Civili, Brescia, IT, ²University of Brescia, Brescia, IT, ³ASST Spedali Civili di Brescia, Brescia, IT, ⁴Università Cattolica del Sacro Cuore, Rome, IT, ⁵Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT, ⁶Università Degli Studi di Pavia - Polo Scientifico, Pavia, IT

09:16 - 09:17

688P - Transcriptional profile changes in matched paired tumor samples after PARP inhibitor treatment in head and neck squamous cell carcinoma (HNSCC)

M. Moutafi¹, P. Economopoulou², I. Kotsantis², M. Anastasiou³, P. Foukas², G. Fountzilas⁴, D. Rimm⁵, A. Psyrri², ¹Yale University, NEW HAVEN, US, ²Attikon University Hospital, Haidari, GR, ³Attikon University Hospital, Athens, GR, ⁴Aristotle University of Thessaloniki - School of Medicine, Thessaloniki, GR, ⁵Yale University School of Medicine - Yale Cancer Center, New Haven, US

09:17 - 09:18

689P - Effects of durvalumab-metformin on head and neck squamous cell carcinoma (HNSCC) as revealed by digital spatial profiling (DSP)

J. Riordan, A. Linnenbach, A. Alnemri, R. Philips, S. Awosanya, S. Sussman, A. Luginbuhl, D. Cognetti, L. Harshyne, M. Mahoney, A. South, D. Whitaker-Menezes, M. Tuluc, A. Argiris, U. Martinez-Outschoorn, J. Johnson, J. Curry, Thomas Jefferson University, Philadelphia, US

09:18 - 09:19

690P - Early response to leukocyte interleukin Injection (LI) immunotherapy extends overall survival (OS) in locally advanced primary squamous cell carcinoma of the head & neck (SCCHN): The IT-MATTERS study

P. Lavin¹, E. Talor², D. Markovic³, J. Cipriano², ¹Boston Biostatistics Research Foundation, Framingham, US, ²CEL-SCI Corporation, Vienna, US, ³Ergomed d.o.o. Beograd, Belgrade, RS

09:19 - 09:20

691P - DNA-based peripheral blood epigenetic immuno-profiling of recurrent/metastatic (R/M) squamous cell carcinoma of head and neck (SCCHN) treated with anti-programmed death (PD)-1 therapy

K. Sehgal¹, Z. Zhang², K. Shirai³, S. Donnelly¹, R. Butler⁴, M.K. Lee², A. Molinaro⁵, J. Wiencke⁵, D. Koestler⁶, L. Salas², B. Christensen², K. Kelsey⁴, R. Haddad¹, ¹Dana Farber Cancer Institute, Boston, US, ²Geisel School of Medicine at Dartmouth, Hanover, US, ³Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, US, ⁴Brown University, Providence, US, ⁵UCSF - University of California San Francisco, San Francisco, US, ⁶KUMC - University of Kansas Medical Center, Kansas City, US

09:20 - 09:21

692P - Copy number alterations and response to radiotherapy + cisplatin vs radiotherapy + cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer

J.L. García¹, A. Olivares Hernandez¹, N. Alonso¹, L.A. Corchete Sánchez¹, J. Fernandez-Mateos², J. Perez García¹, M.A. Hernández¹, R. Seijas Tamayo³, R. Mesia Nin⁴, J. Rubió-Casadevall⁵, C. Garcia Giron⁶, L. Iglesias⁷, A. Carral Maseda⁸, J. Adansa Klain³, M. Taberna Sanz⁹, S. Vazquez¹⁰, A. Gómez Muñoz³, E. Del Barco¹¹, R. González Sarmiento¹², J.J. Cruz Hernandez¹, ¹IBSAL - Instituto de Investigación Biomédica de Salamanca, Salamanca, ES, ²Biomedical Research Institute of Salamanca (IBSAL), SACYL-University of Salamanca., London, GB, ³University Hospital of Salamanca, Salamanca, ES, ⁴ICO - Institut Català d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ⁵ICO Girona - Institut Català d'Oncologia Girona, Girona, ES, ⁶Complejo Hospitalario de Burgos -Hospital General Yagüe, Burgos, ES, ⁷Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), Madrid, ES, ⁸Hospital Universitario Lucus Augusti (HULA), Lugo, ES, ⁹Institut Català d'Oncologia-Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ¹⁰ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ¹¹HOSP. CLINICO UNIVERSITARIO SALAMANCA, Salamanca, ES, ¹²USAL - Universidad de Salamanca, Salamanca, ES

09:21 - 09:22

693P - Impact of one-week hydration after each three-weekly concurrent cisplatin on the tolerance among locally advanced head and neck cancer patients receiving chemoradiotherapy

C. Billard-Sandu, E. Rassy, G. Dumitrescu, S. Akla, T. Bathily, E. Deutsch, Gustave Roussy - Cancer Campus, Villejuif, FR

09:22 - 09:23

694P - Prognostic impact of facial nerve resection in patients treated for a primary parotid cancer abutting the facial nerve without preoperative paralysis: A multicentric study of the REFCOR group with propensity score matching analysis

F. Chatelet¹, N. Fakhry², R. Garrel³, E. De Monès⁴, N. Saroul⁵, F. Mouawad⁶, J. Thariat⁷, C. Even⁸, V. Costes Martineau⁹, P. Herman¹, S. Chevreton¹⁰, B. Verillaud¹¹, ¹Hôpital Lariboisière AP-HP, Paris, FR, ²Assistance Publique Hopitaux de Marseille, Marseille, FR, ³Gui de Chauliac Hospital, Montpellier, FR, ⁴CHU - Centre Universitaire Hospitalier de

Bordeaux, Bordeaux, FR, ⁵Centre Jean PERRIN, Clermont-Ferrand, Cedex, FR, ⁶CHU Lille - Centre Hospitalier Régional Universitaire de Lille, Lille, FR, ⁷Centre Francois Baclesse, Caen, Cedex, FR, ⁸Gustave-Roussy Cancer Campus, Villejuif, FR, ⁹CHU de Montpellier - Hopital Gui de Chauliac, Montpellier, Cedex, FR, ¹⁰Hopital Saint Louis AP-HP, Paris, FR, ¹¹Université de Paris - Faculté de Médecine, Paris, Cedex, FR

09:23 - 09:24

695P - Effectiveness and quality-of-life (QoL) data from real-world study (ProNiHN) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) treated with nivolumab (nivo) in France

C. Le Tourneau¹, S. Salas², Y. Pointreau³, P. Ceruse⁴, E. Babin⁵, V. Rondeau⁶, J. Guigay⁷, M. Rotarski⁸, M. Chehimi⁹, C. Toullec¹⁰, G. Marie¹¹, C. Sire¹², A. Darut Jouve¹³, A. Theron¹⁴, B. Calderon¹⁵, A. Houessinon¹⁶, F.-E. Cotté¹⁷, M. Lavignon¹⁸, C. Even¹⁹, J. Fayette²⁰, ¹Paris Saclay University; Institut Curie, Paris, FR, ²AP-HM, AMU Aix Marseille University, Marseille, FR, ³Jean Bernard Centre, (3) Inter-regional Cancer Institute, Le Mans, FR, ⁴Lyon-Nord University Hospital, Lyon, FR, ⁵Caen Normandie University Hospital, Caen, FR, ⁶University of Bordeaux, bordeaux, FR, ⁷Antoine Lacassagne Center, Nice, FR, ⁸Radiation Oncology Center, Bayonne, FR, ⁹Saint-Quentin Hospital, Saint-Quentin, FR, ¹⁰Avignon-Provence Cancer Institut, Avignon, FR, ¹¹Boulogne-sur-mer Hospital, Boulogne Sur Mer, FR, ¹²Scorff - Bretagne Sud Hospital, Lorient, FR, ¹³Bourgogne Cancerology Institute, Dijon, FR, ¹⁴Bretonneau University hospital, Tours, cedex, FR, ¹⁵Sainte-Catherine Institut, Avignon, FR, ¹⁶Amiens University Hospital, Amiens, FR, ¹⁷Bristol-Myers Squibb, Rueil-Malmaison, FR, ¹⁸Bristol Myers Squibb, Rueil-Malmaison, FR, ¹⁹Gustave-Roussy Cancer Campus, Villejuif, FR, ²⁰Léon Bérard Center, Lyon, FR

09:24 - 09:25

696P - Geriatric nutritional risk index as a prognostic factor in elderly patients with locally advanced head and neck cancer receiving definitive chemoradiotherapy with cisplatin

Y. Fujiwara¹, Y. Sato², N. Fukuda², N. Hayashi², X. Wang², K. Nakano², A. Ohmoto², T. Urasaki², M. Ono², J. Tomomatsu², T. Toshiyasu², H. Mitani², S. Takahashi², ¹Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York, US, ²The Cancer Institute Hospital of JFCR, Tokyo, JP

09:25 - 09:26

697P - Lipid profile as a new diagnostic marker in head and neck cancer

T. Castro¹, G. Polachini¹, L.F. Smarra², T. Henrique¹, R. López³, A.C. Zeri⁴, I. Silva⁵, M. Vandenbosch⁶, R. Heeren⁶, E. Tajara Da Silva¹, ¹Faculdade de Medicina de São José do Rio Preto, Sao Jose do Rio Preto, BR, ²Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, BR, ³ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR, ⁴Laboratório Nacional de Luz Síncrotron, Campinas, BR, ⁵UNIFESP - Federal University of Sao Paulo - Campus Sao paulo, Sao Paulo, BR, ⁶Maastricht University, Maastricht, NL

09:26 - 09:27

698P - Bilateral nodal drainage in early-stage oral cancers: The case for lymphatic mapping

K. King, Rush University Medical Center - Woman's Board Center for Radiation Therapy, Chicago, US

09:27 - 09:28

699P - The molecular and immune landscape of recurrent head and neck

squamous cell carcinoma (HNSCC) in patients undergoing definitive therapy

A. Alloghbi¹, J. McGrath², I. Aijazuddin¹, T. Wise-Draper³, J. Leddon⁴, P. Walker⁵, M. Oberley⁵, A. Sukari⁶, ¹Wayne State University, Detroit, US, ²Caris Life Sciences - Arizona Office, Phoenix, US, ³Vontz Center for Molecular Studies, Cincinnati, US, ⁴University of Cincinnati Cancer Centre, Cincinnati, US, ⁵Caris Life Sciences - Headquarters, Irving, US, ⁶Karmanos Cancer Institute, Detroit, US

09:28 - 09:29

700P - Prognostic miRNA signature score in patients with HNSCC

T. Siripoon¹, W. Worakitchanon², W. Panvongsa², L. Arsa³, N. Trachu¹, A. Wongpan², N. Jinawath³, A. Chairoungdua², N. Ngamphaiboon¹, ¹Mahidol University - Faculty of Medicine - Ramathibodi Hospital, Bangkok, TH, ²Mahidol University - Faculty of Science, Bangkok, TH, ³Mahidol University - Faculty of Medicine Ramathibodi Hospital, Bangkok, TH

09:29 - 09:30

701P - Genomic alteration relationships with toxicity to TPF induction chemotherapy in head and neck squamous cell carcinoma patients participating in a clinical trial

A. Olivares Hernandez¹, J.L. García¹, N. Alonso², L.A. Corchete Sánchez², J. Perez García², R. Mesia Nin³, J. Rubió-Casadevall⁴, C. Garcia Giron⁵, L. Iglesias Docampo⁶, A. Carral Maseda⁷, M. Taberna Sanz⁸, S. Vazquez⁹, A. Gómez Muñoz¹⁰, E. Del Barco¹¹, R. González Sarmiento¹², J.J. Cruz Hernandez¹, ¹IBSAL - Instituto de Investigación Biomédica de Salamanca, Salamanca, ES, ²IBSAL - Instituto de Investigación Biomédica de Salamanca, Soria, ES, ³Institut Català d'Oncologia Badalona, B-ARGO Group, BADALONA, ES, ⁴Institut Català d'Oncologia Girona, Girona Biomedical Research Institute (IDIBGI), Girona, ES, ⁵Complejo Hospitalario de Burgos -Hospital General Yagüe, Burgos, ES, ⁶Hospital Universitario 12 de Octubre, Madrid, ES, ⁷Hospital Universitario Lucus Augusti (HULA), Lugo, ES, ⁸ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, ⁹ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ¹⁰University Hospital of Salamanca, Salamanca, ES, ¹¹HOSP. CLINICO UNIVERSITARIO SALAMANCA, Salamanca, ES, ¹²USAL - Universidad de Salamanca, Salamanca, ES

09:30 - 09:31

702P - Genomic alterations in epigenetic modifiers and response to epigenetic-targeted agents (ETAs) in patients (pts) with recurrent/metastatic (R/M) salivary gland tumours (SGTs)

M. Rezgallah Aron¹, A. Hernando-Calvo¹, V. Galvao De Aguiar¹, O. Saavedra Santa Gadea¹, J.D. Assaf Pastrana², M.J. Lostes Bardaji¹, K. Rojas Laimito¹, S. Aguilar Izquierdo³, R. Berché¹, T. Tian⁴, C. Bescós⁵, J. Lorente⁵, J. Giralt³, J. Temprana-Salvador⁵, M. Alberola⁵, R. Dienstmann³, E. Felip², E. Garralda¹, M. Vieito Villar¹, I. Brana¹, ¹Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron, Barcelona, ES, ²Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, ES, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁵Vall d'Hebron University Hospital, Barcelona, ES

09:31 - 09:32

703TiP - A randomised, double-blind, placebo-controlled phase II study of setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (rmSCCHN)

A. Rullan¹, D. Adkins², P. Bossi³, E. Cohen⁴, A. Daste⁵, K. Harrington⁶, C. Le Tourneau⁷,

L. Licitra⁸, N. Little⁹, T. Morris⁹, C. Ottensmeier¹⁰, M. Reinwald¹¹, T. Rutkowski¹², ¹The Royal Marsden NHS Foundation Trust, London, GB, ²Washington University School of Medicine, St. Louis, US, ³University of Brescia, Brescia, IT, ⁴UC San Diego, San Diego, US, ⁵CHU de Bordeaux, Bordeaux, FR, ⁶The Institute of Cancer Research, London, GB, ⁷Institut Curie, Paris, FR, ⁸Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ⁹Calliditas Therapeutics AB, Stockholm, SE, ¹⁰University of Liverpool, Liverpool, GB, ¹¹Brandenburg Medical School Theodor Fontane, Brandenburg an der Havel, DE, ¹²Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, PL

09:32 - 09:33

704TiP - SAR445256 (KY1044) in combination with atezolizumab in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)

M. Patel¹, P. Ascierto², F. Thistlethwaite³, D. Adkins⁴, V. Meucci Villaflor⁵, D. Galizia⁶, L. Calabro⁷, M. Di Maio⁸, C. D'Ambrosio⁹, A. Bertolini¹⁰, A. Damato¹¹, C. Deantonio¹², Y. Yang¹³, D. Kurup¹³, G. Abbadessa¹³, ¹Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, US, ²Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, IT, ³The Christie NHS Foundation Trust and University of Manchester, Manchester, GB, ⁴Washington University School of Medicine, St. Louis, US, ⁵City of Hope Comprehensive Cancer Center, California, US, ⁶IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, ⁷Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Meldola, IT, ⁸Azienda Ospedaliera Ordine Mauriziano di Torino, Torino, IT, ⁹Istituto Nazionale Tumori Regina Elena, Rome, IT, ¹⁰Ospedale Civile di Sondrio, Sondrio, IT, ¹¹Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, IT, ¹²Sanofi, Cambridge, GB, ¹³Sanofi, Cambridge, US

09:33 - 09:34

705TiP - Phase II trial of retifanlimab (anti-PD-1) in combination with INCAGN02385 (anti-LAG-3) and INCAGN02390 (anti-TIM-3) as first-line treatment in patients with PD-L1-positive recurrent/metastatic squamous cell carcinoma of the head and neck

L. Licitra¹, C. Le Tourneau², N. Bourayou³, R. Schaub³, M. Bartenstein⁴, W. Wei³, E. Cohen⁵, ¹Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ²Paris Saclay University; Institut Curie, Paris, FR, ³Incyte Corporation, Wilmington, US, ⁴Incyte Biosciences International Sàrl, Epalinges, CH, ⁵Moore's Cancer Center - UC San Diego Health, La Jolla, US

09:34 - 09:35

706TiP - Phase III study assessing the best of radiotherapy compared to the best of surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0-N1 oropharyngeal, supraglottic carcinoma and with T1, N0 hypopharyngeal carcinoma

C. Simon¹, C. Fortpied Lefevre², A.-S. Govaerts², T. Raveloarivahy², J. Bourhis¹, M. Evans³, J.P. Klussmann⁴, C.R. Leemans⁵, K. Hunter⁶, S. Singer⁷, S. Nuyts⁸, E. Willemse⁹, M. Ansarin¹⁰, G. Spriano¹¹, W. Golusinski¹², R. Giger¹³, A. Boehm¹⁴, F. Lopez¹⁵, V. Grégoire¹⁶, ¹CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ²EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, BE, ³University Hospital of Wales (UHW) - Cardiff and Vale University Health Board (CVUHB) - NHS Wales, Cardiff, GB, ⁴Universitätsklinikum Köln (AöR), Köln, DE, ⁵Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, ⁶University of Sheffield, Sheffield, GB, ⁷JGU - Johannes Gutenberg University, Mainz, DE, ⁸University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁹Institute Jules Bordet, Brussels, BE, ¹⁰European Institute of Oncology, Milan, IT, ¹¹Humanitas University, Milan, IT, ¹²Greater Poland Cancer Center in Poznan, Poznan, PL, ¹³Inselspital, Bern, CH,

¹⁴Klinikum St. Georg gGmbH, Leipzig, DE, ¹⁵Hospital Universitario Central de Asturias, Oviedo, ES, ¹⁶Centre Léon Bérard, Lyon, FR

09:35 - 09:36 **707TiP - Postoperative adjuvant radiochemotherapy (aRCH) with cisplatin versus aRCH with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma: The ADRISK trial**

S. Wiegand¹, B. Tamaskovics², P. Brossart³, H. Kaftan⁴, V. Lewitzki⁵, M. Muentner⁶, G. Maschmeyer⁷, N. Rotter⁸, C. Stromberger⁹, M. Beck¹⁰, T. Gauler¹¹, U. Schroeder¹², M. Görner¹³, M. Hautmann¹⁴, O. Guntinas-Lichius¹⁵, G. Hapke¹⁶, S. Dommerich¹⁷, A. Schmiedeknecht¹, G. Wichmann¹, A. Dietz¹⁸, ¹UKL - Universitätsklinikum Leipzig, Leipzig, DE, ²UKD - Universitätsklinikum Düsseldorf, Düsseldorf, DE, ³UKB - Universitätsklinikum Bonn, Bonn, DE, ⁴Helios Klinikum Erfurt, Erfurt, DE, ⁵UKW - University Hospital Würzburg, Würzburg, DE, ⁶Klinikum Stuttgart - Katharinenhospital (KH), Stuttgart, DE, ⁷Ernst von Bergmann Klinikum Potsdam, Potsdam, DE, ⁸UMM - Universitätsklinikum Mannheim, Mannheim, DE, ⁹Vivantes Klinikum Neukoelln, Berlin, DE, ¹⁰Charité - Universitätsmedizin Berlin, Berlin, DE, ¹¹WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, ¹²UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE, ¹³State Medical Hospital Bielefeld, Bielefeld, DE, ¹⁴UKR - University Hospital Regensburg, Regensburg, DE, ¹⁵Universitätsklinikum Jena, Jena, DE, ¹⁶Marienkrankenhaus, Hamburg, DE, ¹⁷Charite Berlin Mitte, Berlin, DE, ¹⁸Universitätsklinikum Leipzig, Leipzig, DE

09:36 - 09:37 **708TiP - BD4QoL: A multicenter randomized trial for monitoring quality of life (QoL) by intelligent tools in head and neck cancer (HNC) survivors after curative treatment**

S. Cavaliere¹, C. Vener², M. Leblanc³, L. Lopez Perez⁴, G. Fico⁴, C. Resteghini⁵, D. Monzani², G. Marton², M. Moreira-Soares³, D.E. Filippidou⁶, A. Almeida⁷, A. Bilbao⁷, H. Mehanna⁸, S. Singer⁹, S. Thomas¹⁰, L. Lacerenza¹¹, A. Manfuso¹¹, F. Mercalli¹², E. Martinelli², L. Licitra¹³, ¹Fondazione IRCCS Istituto Nazionale dei Tumori di Milano & University of Milan, Milan, IT, ²University of Milan, Milan, IT, ³University of Oslo, Oslo, NO, ⁴UPM - Universidad Politecnica de Madrid - ETSIT, Madrid, ES, ⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ⁶DOTSOFT, Thessaloniki, GR, ⁷Universidad de Deusto, Bilbao, ES, ⁸The University of Birmingham - Institute for Cancer Studies, Birmingham, GB, ⁹JGU - Johannes Gutenberg University, Mainz, DE, ¹⁰University of Bristol - Bristol Medical School, Bristol, GB, ¹¹Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, IT, ¹²Multimed Engineers srls, Parma, IT, ¹³Fondazione IRCCS Istituto Nazionale dei Tumori & University of Milan, Milan, IT

09:37 - 09:38 **891P - Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: Outcomes from the first prespecified analyses of the Pivotal 201 Trial**

J. Mora¹, M. Bear², G. Chan³, D. Morgenstern⁴, K. Nysom⁵, K. Tornøe⁶, P. Sørensen⁶, B. Kushner⁷, ¹Hospital Sant Joan de Déu Barcelona, Esplugues de Llobregat, ES, ²Indiana University Simon Cancer Center, Indianapolis, US, ³The University of Hong Kong - Queen Mary Hospital, Hong Kong, HK, ⁴The Hospital for Sick Children, Toronto, CA, ⁵Rigshospitalet, Copenhagen, DK, ⁶Y-mAbs Therapeutics A/S, Hørsholm, DK, ⁷Memorial Sloan Kettering Cancer Center, New York, US

09:38 - 09:39 **892P - Hedgehog (Hh) activation in neuroendocrine neoplasms (NENs)**

C. Blanco Abad¹, P. Saiz Lopez², R. Alcaraz Ortega², E. Garcia Toro², C. Garcia Giron¹, P. Muñoz Rodriguez², J.L. Catoya Villa², S. De La Torre Lazaro², B. De Frutos Gonzalez², I. Rodriguez Ledesma², C. Gutierrez Perez², M. Vela², M. Pumares Gonzalez², N. Espinosa Cabria², G. Crespo Herrero², ¹Complejo Hospitalario de Burgos -Hospital General Yagüe, Burgos, ES, ²Hospital Universitario de Burgos (HUBU), Burgos, ES

09:39 - 09:40 **893P - Autophagy flux is induced in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)**

I. Angelioudaki¹, M. Theochari², E. Koniaris³, A. Katakaki¹, L. Stoupis¹, A. Mitrousias¹, A.-G. Tzingounis¹, N. Dafnios¹, G. Zografos¹, G. Kafiri³, M. Konstadoulakis¹, ¹National & Kapodistrian University of Athens (NKUA), Athens, GR, ²"Laiko" General Hospital, Athens, GR, ³"Hippokration" General Hospital of Athens, Athens, GR

09:40 - 09:41 **894P - Utility of histopathological revision in the management of gastro-entero-pancreatic neuroendocrine neoplasia**

L. Magi, M. Marasco, E. Rogges, E. Dell'Unto, M. Rinzivillo, E. Pillozzi, B. Annibale, F. Panzuto, Sant'Andrea University Hospital, Sapienza- University of Rome, Rome, IT

09:41 - 09:42 **895P - Correlating peptidylglycine alpha-amidating monooxygenase (PAM) expression with clinicopathologic variables in gastrointestinal (GI) neuroendocrine tumors (NETs)**

J. Sim¹, H. Marginean², A. Jirovec³, M. Vickers⁴, E. Marginean⁵, T. Asmis⁴, B. Marginean⁶, R. Goodwin², ¹University of Ottawa, Dept of Pathology, Ottawa, CA, ²The Ottawa Hospital Cancer Centre, Ottawa, CA, ³Ottawa Hospital Research Institute, Ottawa, CA, ⁴The Ottawa Hospital Regional Cancer Centre, Ottawa, CA, ⁵Baylor College of Medicine, Houston, US, ⁶UBC - The University of British Columbia, Vancouver, CA

09:42 - 09:43 **896P - Multiple radiomic biomarkers-based machine learning model to predict responses of surufatinib-treated advanced neuroendocrine tumor (NET): A multicenter exploratory study**

J. Xu¹, C. Zhao², J. Zhou², X. Luo², S. Fan², W. Su², K. Nie³, C. Lin³, J. Yang³, ¹The Fifth Medical Center of Chinese PLA General Hospital, Beijing, CN, ²Hutchison MediPharma Limited, Shanghai, CN, ³Taimei Medical Technology, Shanghai, CN

09:43 - 09:44 **897P - HORMONET: Phase II trial of tamoxifen for patients (pts) with estrogen/progesterone receptor (ER/PR)-positive neuroendocrine tumors (NET)**

R. Riechelmann¹, J. Strosberg², T. Al-Toubah², L. Durant³, M.D. Spina Donadio⁴, C.A.L.D. Mello⁴, V. De Jesus⁵, T. Felismino¹, R. Taboada⁴, L. De Brot Andrade³, M. Barros⁶, ¹A.C. Camargo Cancer Center - Unidade Antonio Prudente, Sao Paulo, BR, ²H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ³AC Camargo Cancer Center, Sao Paulo, BR, ⁴A.C. Camargo Cancer Center - Fundacao Antonio Prudente, Sao Paulo, BR, ⁵Roche Diagnostica Brasil Ltda., Sao Paulo, BR, ⁶A. C. Camargo Cancer Center - Fundacao Antonio Prudente, Sao Paulo, BR

09:44 - 09:45 **898P - The safety and efficacy of surufatinib for the treatment of advanced neuroendocrine tumors: A prospective, multicenter, real-world study**

J. Long¹, C. Wu¹, B. Hu¹, C. Tao¹, H. Gu¹, H. Dong¹, J. Yan¹, Z. Qi¹, C. Zhao², J. Zhou²,

¹Shanghai First People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine - North Campus, Shanghai, CN, ²HUTCHMED (China) Limited, Shanghai, CN

- 09:45 - 09:46 **899P - Molecular characterization of gastro-entero-pancreatic advanced mixed adeno-neuroendocrine carcinomas: NIRVANA sub-study**
F. Spada¹, L. Gervaso², E. Pisa¹, A. Ranghiero³, M. Rubino³, N. Fazio¹, ¹Istituto Europeo di Oncologia (IEO), IRCCS,, Milan, IT, ²IEO - Istituto Europeo di Oncologia, Milan, IT, ³Istituto Europeo di Oncologia (IEO), IRCCS, Milan, IT
- 09:46 - 09:47 **900P - AI-powered analyzer reveals enrichment of intra-tumoral tumor-infiltrating lymphocytes in high-grade neuroendocrine neoplasms**
H.-G. Cho¹, S. Kim², S. Choi³, S.I. Cho¹, W. Jung¹, S. Kim¹, G. Park¹, S. Song¹, S. Pereira¹, H. Song¹, S. Park¹, M. Mostafavi¹, K. Paeng¹, C.-Y. Ock¹, ¹Lunit, Seoul, KR, ²Ajou University School of Medicine, Suwon, KR, ³Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR
- 09:47 - 09:48 **901P - Cisplatin vs carboplatin in extrapulmonary neuroendocrine carcinoma**
N. McLaughlin¹, P. Mcgarrah¹, R. Eiring¹, K. Leventakos¹, M. Sonbol², J. Starr³, T. Hobday¹, T. Halfdanarson¹, ¹Mayo Clinic, Rochester, US, ²Mayo Clinic Cancer Center, Phoenix, US, ³Mayo Clinic, Jacksonville, US
- 09:48 - 09:49 **902TiP - COMPOSE: Pivotal phase III trial to compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumours**
T. Halfdanarson¹, D. Halperin², D. Reidy-Lagunes³, G. Kong⁴, J. Mailman⁵, K. Herrmann⁶, R. Sri Rajaskanthan⁷, S. Leyden⁴, J. Capdevila Castillon⁸, C. Sierras⁹, P. Harris⁹, ¹Mayo Clinic, Rochester, US, ²MD Anderson Cancer Center, Houston, US, ³Memorial Sloan Kettering Cancer Center, New York, US, ⁴Peter MacCallum Cancer Centre, Melbourne, AU, ⁵NorCal CarciNET Community, Ripon, US, ⁶University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ⁷King's College Hospital - NHS Foundation Trust, London, GB, ⁸Vall d'Hebron University Hospital, Barcelona, ES, ⁹ITM Isotopen Technologien Muenchen AG, Garching bei Munich, DE
- 09:49 - 09:50 **906P - A pilot study of a lung cancer screening program with low-dose computed tomography in high-risk individuals in Greece**
S. Lampaki¹, E. Fountzilas², A. Vagionas³, I. Filippou¹, G. Mountzios⁴, G. Koliou⁵, N. Pastelli¹, T. Karaiskos⁶, D. Spyros¹, ¹G. Papanikolaou Hospital, Thessaloniki, GR, ²Euromedica General Clinic, Thessaloniki, GR, ³General Hospital of Kavala, Kavala, GR, ⁴Henry Dunant Hospital Centre, Athens, GR, ⁵HeCOG - Hellenic Cooperative Oncology Group, Athens, GR, ⁶G. Papanikolaou General Hospital, Thessaloniki, GR
- 09:50 - 09:51 **907P - A real-time histologic evaluation of gastric cancer tissue by using confocal laser endomicroscopic system**
S. Kim¹, H. Bae², J. Chu³, H. Cho⁴, S. Choi², K. Hwang⁵, Y. Jo⁵, S.A. Kim⁵, ¹Ajou University School of Medicine, Suwon, KR, ²Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ³Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, KR, ⁴Asan Medical Center -

University of Ulsan, Seoul, KR, ⁵VPIX Medical Inc., Daejeon, KR

- 09:51 - 09:52 **908P - Evaluation of anxiety, distress and satisfaction with a multi-cancer early detection test**
D. Schrag¹, T. Beer², C. McDonnell³, L. Nadauld⁴, C. Dilaveri⁵, E. Klein⁶, R. Reid⁷, C. Marinac⁸, K. Chung⁹, M. Lopatin⁹, E. Fung⁹, D. Patrick¹⁰, ¹MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ²OHSU - Center for Health & Healing Building 2, Portland, US, ³Sutter Institute for Medical Research, Sacramento, US, ⁴Intermountain Healthcare - Intermountain Cancer Center of St George, St. George, US, ⁵Mayo Clinic, Rochester, US, ⁶Stanford Comprehensive Cancer Institute, Stanford, US, ⁷US Oncology, Inc., Thornton, US, ⁸Dana Farber Cancer Institute, Boston, US, ⁹GRAIL, Inc., Menlo Park, US, ¹⁰University of Washington, Seattle, US
- 09:52 - 09:53 **909P - A multi-cancer early detection model based on liquid biopsy of multi-omics biomarkers: A proof of concept study (PROMISE study)**
Q. Gao¹, C. Wang², X. Yang², S. Fang², Y. Zhang², G. Wang², F. Liu², X. Wen², J. Zhao², G. Zhou², B. Li², S. Cai², Z. Zhang², J. Fan³, ¹Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, CN, ²Burning Rock Biotech, Guangzhou, CN, ³Zhongshan Hospital, Fudan University, Shanghai, CN
- 09:53 - 09:54 **910P - Assessment of early detection by multi-omics-based liquid biopsy in lung cancer: A prospective study (ASCEND-LUNG)**
K. Chen¹, H. Kou², K. Zhang¹, Y. Jin¹, C. Wang², Y. Zhang², G. Wang², X. Yang², G. Zhou², S. Cai², F. Yang¹, ¹Peking University People's Hospital, Beijing, CN, ²Burning Rock Bioengineering Ltd, Guangzhou, CN
- 09:54 - 09:55 **911P - The development and application of a baseline-agnostic minimal residual disease assay**
R. Li¹, G. Bonora², C. Dai², B. Xiang², T. Zheng², W. Mo², X. Wang², K. Zhou², S. Jia², S. Luo², P. Du², ¹H. Lee Moffitt Cancer Center & Research Institute, Tampa, US, ²Predicine, Inc., Hayward, US
- 09:55 - 09:56 **912P - Metabolomic profiling for the early detection of lung cancer**
P. Joubert¹, D. Wishart², J.-F. Haince³, H. Bach⁴, R. Bux³, P. Tappia⁵, B. Ramjiawan⁵, ¹Universite Laval, CHU de Quebec, Quebec City, CA, ²University of Alberta, Edmonton, CA, ³BioMark Diagnostics Inc, Richmond, CA, ⁴UBC - The University of British Columbia, Vancouver, CA, ⁵St. Boniface Hospital, Winnipeg, CA
- 09:56 - 09:57 **914P - Early cancer detection using circulating extracellular vesicles**
R. Kurzrock¹, P. Billings², H. Balcer³, J. Hinestrosa², ¹Medical College of Wisconsin, Milwaukee, US, ²Biological Dynamics, San Diego, US, ³Biological Dynamics, Inc., San Diego, US
- 09:57 - 09:58 **915P - EMLI-ICC: An ensemble machine learning-based proteome and transcriptome integration algorithm for metastasis prediction and risk-stratification in intrahepatic cholangiocarcinoma**
C. Ye, R. Chen, Q. Jiang, W. Wu, F. Yan, Q. Li, X. Shuaishuai, Y. Wang, Y. Jia, X. Zhang, P.

Shen, J. Ruan, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN

- 09:58 - 09:59 **916P - Deep learning-based multimodal ensemble algorithm for multi-cancer detection and classification using cf-WGS**
J. Lee¹, T.-R. Lee², G. Kim³, J.M. Ahn², S.R. Park⁴, K.-B. Song⁵, E. Jun⁵, D. Oh⁶, J.-W. Lee⁶, Y.S. Park⁷, G.-W. Song⁸, J.-S. Byeon⁴, B.H. Kim⁹, J. Lee², D. Kim², C.-S. Ki², E. Cho², J.K. Choi³, ¹Soongsil University, Seoul, KR, ²GC Genome, yongin, KR, ³KAIST, Daejeon, KR, ⁴Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ⁵Asan Medical Center - University of Ulsan, Seoul, KR, ⁶Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ⁷Seoul National University Hospital, Seoul, KR, ⁸Asan Medical Center, Seoul, KR, ⁹National Cancer Center, Goyang, KR
- 09:59 - 10:00 **917P - OPTIMA: Improve care for patients with prostate, breast, and lung cancer through artificial intelligence**
J. N'Dow¹, E.J. Smith², K. Polychronopoulos³, A. Cannon⁴, M. Roobol⁵, S. Auweter⁶, M. Thomas⁷, A. Kremer⁸, B. De Meulder⁹, D. Dellamonica¹⁰, D.P. Alhambra¹¹, A. Asimwe¹², M. Bussmann¹³, X. Ji¹⁴, P. Torremante¹⁵, S. Keller¹⁶, F. Kube¹⁷, H. Krueger¹⁶, ¹University of Aberdeen, Aberdeen, GB, ²EAU - European Association of Urology, Arnhem, NL, ³University of Vienna, Vienna, AT, ⁴Genentech Inc., Hillsboro, US, ⁵Erasmus University Medical Center, Rotterdam, NL, ⁶Smart Reporting GmbH, Munich, DE, ⁷F. Hoffmann-La Roche AG, Basel, CH, ⁸Information Technology for Translational Medicine, Luxembourg, LU, ⁹Association EISBM, Vourles, FR, ¹⁰AstraZeneca AG, Zug, CH, ¹¹University of Oxford, Oxford, GB, ¹²Bayer AG, Leverkusen, DE, ¹³Helmholtz-Zentrum Dresden-Rossendorf, Dresden, DE, ¹⁴Pfizer Inc, Collegeville, US, ¹⁵ARTTIC Innovation GmbH, Munich, DE, ¹⁶Pfizer Pharma GmbH, Berlin, DE, ¹⁷Pfizer Pharma GmbH, Karlsruhe, DE
- 10:00 - 10:01 **918P - Improving TNM staging predictive value with PET/CT imaging features and deep learning model in non-small cell lung cancer**
E. Giovannini¹, G. Giovacchini¹, F. Tutino¹, L. Florimonte², A. Milano¹, L. Dellavedova³, C. Bareggi⁴, A. Castello², C. Aschele¹, M. Castellani², A. Ciarmiello¹, ¹Ospedale Civile Sant'Andrea di La Spezia - ASL5 Spezzino, La Spezia, IT, ²Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Milan, IT, ³Ospedale di Legnano - ASST Ovest Milanese, Legnano, IT, ⁴IRCCS Ospedale Maggiore Policlinico, Milan, IT
- 10:01 - 10:02 **919P - Artificial intelligence supporting lung cancer screening: Computer aided diagnosis of lung lesions driven by morphological feature extraction**
F. Grossi¹, V.-K. Le², P. Baudot², C. Voyton², D. Francis², E. Munoz², B. Huet², ¹University of Insubria, Varese, IT, ²Median Technologies, Valbonne, FR
- 10:02 - 10:03 **920P - Blind validation of MSIntuit, an AI-based pre-screening tool for MSI detection from colorectal cancer H&E slides**
M. Svrcek¹, C. Saillard², R. Dubois², N. Loiseau², P. Mespoulhe³, F. Brulport², J. Guillon², M. Auffret², M. Sefta², A. Kamoun², P. Courtiol², S. Rossat³, F. Renaud⁴, A. Fouillet², G. Wainrib², ¹Saint-Antoine Hospital, Sorbonne Université, AP-HP, Paris, FR, ²Owkin France, Paris, FR, ³Medipath France, Fréjus, FR, ⁴CHU Lille - Lille University Hospital, Lille, FR

- 10:03 - 10:04 **921P - Application of machine learning algorithm for cytological diagnosis of thyroid cancer**
E. Lee¹, Y.K. Lee¹, H.-S. Min², S.-Y. Park³, H.Y. Lee¹, J. Park⁴, Y. Park⁵, ¹National Cancer Center, Goyang, KR, ²Tomocube, Daejeon, KR, ³NCC - National Cancer Center, Goyang, KR, ⁴KAIST, Daejeon, KR, ⁵Korea Advanced Institute of Science and Technology, Daejeon, KR
- 10:04 - 10:05 **922P - Automated and rapid KRAS mutation testing in non-small cell lung cancer**
G. Recondo¹, S. Akselrad², F. Jauk³, P. Teves², J. Pandolfi³, L. Basbus³, C.A. Franco Cortes³, H. Garcia Rivello³, R. Sanchez Marull², Y. Powazniak¹, J. Calderazzo², M. Bluthgen⁴, S. Sena⁴, A. Perfetti⁵, P. Levit⁵, N. Castagneris⁶, M. Rizzo⁷, L. Lupinacci³, J.N. Minatta³, ¹Centro de Educacion Medica e Investigaciones Clinicas (CEMIC), Buenos Aires, AR, ²CEMIC - Centro de Educacion Medica e Investigacones Clinicas Dr Norberto Quirno, Buenos Aires, AR, ³Hospital Italiano de Buenos Aires, Buenos Aires, AR, ⁴Hospital Aleman, Buenos Aires, AR, ⁵Centro Medico Accor, Buenos Aires, AR, ⁶Clinica Universitaria Reina Fabiola, Cordoba, AR, ⁷Hospital Universitario Austral, Pilar, AR
- 10:05 - 10:06 **923P - Molecular classification of cancers of unknown primary expands and refines treatment options**
D. George¹, E. Moore², G. Blobe³, N. Devito⁴, B. Hanks⁵, M. Harrison⁶, C. Hoimes³, J. Jia⁷, M. Morse⁷, P. Jayaprakasan⁸, A. Mackelfresh¹, H. Mulder⁸, K. Beauchamp², J. Michuda², M. Stumpe⁹, E. Perakslis⁸, T. Taxter⁹, ¹Duke University Medical Center, Durham, US, ²Tempus Labs, Inc., Chicago, US, ³Duke Cancer Institute, Durham, US, ⁴Duke University, Durham, US, ⁵Duke Cancer Center - Duke University Medical Center, Durham, US, ⁶Snyderman Genome Science Research Building, Durham, US, ⁷Duke Cancer Center, Durham, US, ⁸Duke Clinical Research Institute, Durham, US, ⁹Tempus Labs, Chicago, US
- 10:06 - 10:07 **924P - BLEACH&STAIN, a novel multiplex fluorescence immunohistochemistry framework that facilitates a fast high-throughput analysis of >15 biomarkers in more than 3000 human carcinomas**
E. Bady, K. Möller, N. Debatin, T. Mandelkow, C. Hube-Magg, N. Blessin, University Medical Center Hamburg-Eppendorf, Hamburg, DE
- 10:07 - 10:08 **925P - Analytical performance of a next-generation sequencing (NGS) assay kit for assessing homologous recombination deficiency (HRD) from solid tumor samples**
L. Liu, K. Roessler, S. Bilke, Y. Ding, D. Erlandson, Y. Fu, B. Hariharan, S. Katz, J. Lee, C. Schulman, F. Song, R. Vijayaraghavan, P. Wenz, E. Xia, H. Yan, Y. Zhu, C. Zhao, J. Dockter, T. Pawlowski, J. Day, Illumina, Inc., San Diego, US
- 10:08 - 10:09 **926P - Utility of point-of-care genomic profiling in the diagnosis and treatment of cancer of unknown primary**
X. Wang¹, A. Beharry², B.S. Sheffield², P. Cheema², ¹UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ²William Osler Health System - Brampton Civic Hospital, Brampton, CA

- 10:09 - 10:10 **927P - Awareness & obscurity: Demystifying genomic profiling in real-world practice for the members of Turkish Society of Medical Oncology (TSMO)**
E. Bayram¹, B. Sahin¹, T. Koseci¹, A. Bisgin², ¹Cukurova University, ADANA, TR, ²Cukurova University, Adana, TR
- 10:10 - 10:11 **1365P - The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC)**
S. Gupta¹, Q. Yang², S. Halabi³, A. Tubbs¹, Y. Gore¹, D. George², D. Nanus⁴, E. Antonarakis⁵, D. Danila⁶, R. Szmulewitz⁷, R. Wenstrup⁸, A. Armstrong⁹, ¹Epic Sciences Inc., San Diego, US, ²Duke University Medical Center, Durham, US, ³Duke University - Health System, Durham, US, ⁴Weill Cornell Medical College, New York, US, ⁵Johns Hopkins University, Baltimore, US, ⁶MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ⁷The University of Chicago Medical Centre, Chicago, US, ⁸Epic Sciences, San Diego, US, ⁹Duke Cancer Center, Durham, US
- 10:11 - 10:12 **1366P - Impact of COVID-19 on prostate cancer diagnosis and treatment**
R. Leszczynski¹, N. Norori¹, S. Beecroft², J. Wallace², B. Levick², M. Hobbs¹, T. Harding¹, G. Hall³, ¹Prostate Cancer UK, London, GB, ²OPEN Health - Holborn, London, GB, ³ghepi, BARNET, GB
- 10:12 - 10:13 **1367P - JNJ-70218902 (JNJ-902), a TMEFF2 x CD3 bispecific antibody, in prostate cancer: Initial results from a phase I dose escalation study**
E. Calvo¹, B. Doger De Spéville², J. Carles Galceran³, A. Peer⁴, D. Sarid⁵, B. Eigl⁶, A. Avadhani⁷, D. Yao⁸, V. Lin⁸, S. Wu⁸, P. Jaiprasart⁸, J. Loffredo⁸, M. Tamegnon⁸, H. Xie⁸, A. Hansen⁹, ¹START Madrid-CIOCC, Madrid, ES, ²START Madrid-FJD, Madrid, ES, ³Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁴Rambam Health Care Center, Haifa, IL, ⁵Tel Aviv Sourasky Medical Center-Ichilov, Tel Aviv, IL, ⁶BC Cancer Center - Vancouver, Vancouver, CA, ⁷Tempus Labs, Chicago, US, ⁸Janssen R&D, Raritan, US, ⁹Queensland Health, Brisbane, AU
- 10:13 - 10:14 **1368P - TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) – Exploration of tumor genetics associated with prolonged benefit**
J. De Bono¹, E. Castro Marcos², D. Laird³, K. Fizazi⁴, T. Dorff⁵, S. Zhao⁶, I.M. Van Oort⁷, D. Gasparro⁸, F. Calabro⁹, S. Pignata¹⁰, L. Geczi¹¹, P. Barthelemy¹², D. Kilari¹³, J.F. Hopkins¹⁴, H.-C. Chen³, C.G. Healy¹⁵, J. Chelliserry³, G. Scagliotti¹⁶, N. Mehra⁷, ¹The Institute of Cancer Research and The Royal Marsden Hospital, London, GB, ²Hospital Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Malaga, ES, ³Pfizer Inc., La Jolla, US, ⁴Institut Gustave Roussy, University of Paris-Saclay, Villejuif, FR, ⁵City of Hope Comprehensive Cancer Center, Duarte, US, ⁶Swedish Cancer Institute, Seattle, US, ⁷Radboud University Medical Center, Nijmegen, NL, ⁸Azienda Ospedaliero-Universitaria di Parma, Parma, IT, ⁹Azienda Ospedaliera San Camillo Forlanini, Rome, IT, ¹⁰Istituto Nazionale Tumori di Napoli IRCCS, Fondazione G Pascale, Naples, IT, ¹¹National Institute of Oncology, Budapest, HU, ¹²Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ¹³Medical College of Wisconsin, Milwaukee, US, ¹⁴Foundation Medicine Inc., Cambridge, US, ¹⁵Pfizer Inc., Collegeville, US, ¹⁶University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, IT

- 10:14 - 10:15 **1369P - Biochemical outcomes from ARTO trial (NCT03449719) a phase II randomized trial testing association between abiraterone acetate and stereotactic body radiation therapy in castrate-resistant prostate cancer patients**
G. Francolini¹, B. Detti¹, V. Di Cataldo¹, S. Caini², A.R. Alitto³, S. Parisi⁴, C. Demofonti⁵, A. Bruni⁶, G. Ingrosso⁷, G. Timon⁸, A.G. Allegra⁹, L. Burchini⁹, V. Salvestrini⁹, G. Frosini⁹, C. Cerbai⁹, L. Visani⁹, C. Becherini¹, I. Desideri⁹, I. Meattini⁹, L. Livi⁹, ¹Azienda Ospedaliero-Universitaria Careggi, Firenze, IT, ²Institute for Cancer Research, Prevention and Clinical Network, Cancer Risk Factors and Life-Style Epidemiology Unit,, Firenze, IT, ³Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ⁴Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, IT, ⁵Radiotherapy Unit, Department of Oncology and Hematology, Tor Vergata General Hospital, Rome, IT, ⁶Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ⁷Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia, Perugia, IT, ⁸Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, ⁹University of Florence, Firenze, IT
- 10:15 - 10:16 **1370P - Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial**
A. Armstrong¹, F. Saad², A. Thiery-Vuillemin³, M. Oya⁴, N. Shore⁵, N. Mehra⁶, M. Ozguroglu⁷, C. Gedye⁸, O. Sartor⁹, C. Poehlein¹⁰, P. Qiu¹¹, Y.-Z. Liu¹², L. Riva¹³, L. Harrington¹³, L. Barker¹³, P.M. Del Rosario¹³, A. Barnicle¹³, N. Clarke¹⁴, ¹Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, US, ²Centre Hospitalier de l'Université de Montréal/CRCHUM, Université de Montreal, Montreal, CA, ³CHRU Besançon Hôpital J.Minjoz, Besancon, FR, ⁴Keio University School of Medicine, Tokyo, JP, ⁵Carolina Urologic Research Center, Myrtle Beach, US, ⁶Istituto Nazionale Per Cura Tumori Milano, Milan, IT, ⁷Cerrahpaşa School of Medicine, Istanbul University-Cerrahpaşa, Istanbul, TR, ⁸Calvary Mater Newcastle, Waratah, AU, ⁹Tulane Medical School, New Orleans, US, ¹⁰Merck & Co., Inc., Rahway, US, ¹¹Merck & Co., Inc., Kenilworth, US, ¹²Astrazeneca, Cambridge, GB, ¹³AstraZeneca, Cambridge, GB, ¹⁴The Christie and Salford Royal NHS Foundation Trusts, Manchester, GB
- 10:16 - 10:17 **1371P - Assessment of whether time to docetaxel impacts outcome when given in metastatic hormone-sensitive prostate cancer (MHSPC) setting**
S. George¹, R. Gosain², K. Yendamuri¹, J.M. Boher³, G. Gravis Mescam⁴, C. Sweeney⁵, A. Hutson¹, ¹Roswell Park Comprehensive Cancer Center, Buffalo, US, ²University of Pittsburgh, Pittsburgh, US, ³Unicancer, Paris, Cedex, FR, ⁴Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, Cedex, FR, ⁵Dana Farber Cancer Institute, Boston, US
- 10:17 - 10:18 **1372P - Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial**
A. Armstrong¹, O. Sartor², F. Saad³, J. Czernin⁴, N. Shore⁵, A. Kendi⁶, T. Beer⁷, N. Vaishampayan⁸, G. El-Haddad⁹, J. Wu¹⁰, O. Mirante¹¹, M. Morris¹², ¹Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, US, ²Tulane University, New Orleans, US, ³Hospital St. Luc du CHUM, Montreal, CA, ⁴University of California Los Angeles, Los Angeles, US, ⁵Atlantic Urology Clinics, LLC, Myrtle Beach, US, ⁶Mayo Clinic, Rochester, US, ⁷OHSU Knight Cancer Institute, Portland, US, ⁸Wayne State

University, Detroit, US, ⁹H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, US, ¹¹AAA - Advanced Accelerator Applications SA - a Novartis Company, Geneva, CH, ¹²MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

- 10:18 - 10:19 **1373P - SPOP mutations (mtSPOP) are a treatment-selection biomarker in patients (pts) with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC)**
- U. Swami¹, R. P. Graf², R. Nussenzweig³, V. Fisher², H. Tukachinsky⁴, G. Li⁵, N. Sayegh³, N. Tripathi³, V. Mathew Thomas³, G. Oxnard², E. Antonarakis⁶, N. Agarwal³, ¹Huntsman Cancer Institute, University of Utah, Salt Lake City, US, ²Foundation Medicine Inc., Cambridge, US, ³University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US, ⁴Foundation Medicine, Boston, US, ⁵Foundation Medicine, Inc, Cambridge, US, ⁶University of Minnesota Masonic Cancer Center, Minneapolis, US
- 10:19 - 10:20 **1374P - Radiographic progression-free survival correlation with time-to-event endpoints: A post hoc analysis of the VISION trial**
- M. Morris¹, J. De Bono², J. Nagarajah³, X. Wei⁴, L. Nordquist⁵, V. Koshkin⁶, A. Vickers⁷, O. Mirante⁸, R. Ghouse⁹, S. Tagawa¹⁰, K. Fizazi¹¹, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²Institute of Cancer Research, London, GB, ³Radboud University Medical Center, Nijmegen, NL, ⁴Dana Farber Cancer Institute, Boston, US, ⁵Urology Cancer Center and GU Research Network, Omaha, US, ⁶UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ⁷RTI Health Solutions, Manchester, GB, ⁸AAA - Advanced Accelerator Applications SA - a Novartis Company, Geneva, CH, ⁹AAA - Advanced Accelerator Applications International SA, Geneva, CH, ¹⁰New York-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US, ¹¹Institut Gustave Roussy, Villejuif, Cedex, FR
- 10:20 - 10:21 **1375P - Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)**
- S. Halabi¹, A. Roy², L. Rydzewska³, P. Godolphin⁴, M. Parmar⁵, M. Hussain⁶, C. Tangen⁷, I. Thompson⁸, W. Xie⁹, M. Carducci¹⁰, M. Smith¹¹, M. Morris¹², G. Gravis Mescam¹³, D. Dearnaley¹⁴, P. Verhagen¹⁵, T. Goto¹⁶, N. James¹⁴, M. Buyse¹⁷, J. Tierney³, C. Sweeney⁹, ¹Duke University Medical Center, Durham, US, ²Duke University School of Medicine, Durham, US, ³UCL - University College London, London, GB, ⁴University College London, London, GB, ⁵Institute of Clinical Trials and Methodology-UCL, London, GB, ⁶Northwestern University Feinberg School of Medicine, Chicago, US, ⁷Fred Hutchinson Cancer Research Center, Seattle, US, ⁸Christus Health, San Antonio, US, ⁹Dana Farber Cancer Institute, Boston, US, ¹⁰Johns Hopkins University, Baltimore, US, ¹¹Massachusetts General Hospital, Boston, US, ¹²MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ¹³IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ¹⁴ICR - Institute of Cancer Research, London, GB, ¹⁵Erasmus MC, Rotterdam, NL, ¹⁶Kyoto University, Kyoto, JP, ¹⁷International Drug Development Institute, Louvain-la-Neuve, BE
- 10:21 - 10:22 **1376P - Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer: Exploratory analysis of LATITUDE study**

S. Roy¹, C. Wallis², S. Morgan³, Y. Sun⁴, A. Kishan⁵, D. Mukherjee⁶, D. Spratt⁴, F. Saad⁷, S. Malone³, ¹Rush University Medical Center - Woman's Board Center for Radiation Therapy, Chicago, US, ²Mount Sinai Hospital-University of Toronto, Toronto, CA, ³The Ottawa Hospital Regional Cancer Centre, Ottawa, CA, ⁴Case Western Reserve University / University Hospitals, Cleveland, US, ⁵Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US, ⁶Bangalore University, Bangalore, IN, ⁷Hospital St. Luc du CHUM, Montreal, CA

10:22 - 10:23

1377P - Transcriptomic based indicators of potential therapeutic response to targeted therapy among 50,000 men with localized prostate cancer

E. Schaeffer¹, J. Proudfoot², E. Li¹, A. Weiner¹, J. Aguiar¹, A. Hakansson², X. Zhao², Y. Liu², E. Davicioni², A. Ross¹, ¹Northwestern University Feinberg School of Medicine, Chicago, US, ²Veracyte, Inc. - Headquarters, South San Francisco, US

10:23 - 10:24

1378P - Biopsy-based basal-luminal subtyping classifier in high-risk prostate cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 randomized phase III trials

P. Nguyen¹, V. Liu², J. Proudfoot², E. Davicioni², Y. Liu², A. Dal Pra³, D. Spratt⁴, H. Sandler⁵, J. Efsthathiou⁶, C. Lawton⁷, J. Simko⁸, S. Rosenthal⁹, K. Zeitzer¹⁰, L. Mendez¹¹, A. Hartford¹², W. Hall¹³, A. Desai¹⁴, S. Pugh¹⁵, P. Tran¹⁶, F. Feng¹⁷, ¹Dana Farber Cancer Institute, Boston, US, ²Veracyte, Inc., San Diego, US, ³UH Health - University of Miami Health System - Miller School of Medicine, Coral Gables, US, ⁴Case Western Reserve University / University Hospitals, Cleveland, US, ⁵Cedars Sinai Medical Center, Los Angeles, US, ⁶Massachusetts General Hospital Cancer Center, Boston, US, ⁷University of Wisconsin Carbone Cancer Center, Madison, US, ⁸UCSF Medical Center at Mission Bay, San Francisco, US, ⁹CPMC - California Campus - Sutter Health, San Francisco, US, ¹⁰Albert Einstein College of Medicine, Bronx, US, ¹¹London Regional Cancer Program (LRCP) - London Health Science Center (LHSC), London, CA, ¹²Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, US, ¹³Froedtert Hospital & Medical College of Wisconsin, Milwaukee, US, ¹⁴Summa Health System, Akron, US, ¹⁵NRG Oncology Statistics and Data Management Center, Philadelphia, US, ¹⁶Maryland Proton Treatment Center, Baltimore, US, ¹⁷UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US

10:24 - 10:25

1379P - A phase Ib study of a single priming dose of 177Lu-PSMA-617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC)

R. Aggarwal¹, L. Trihy², E. Hernandez Romero², S. Luch Sam¹, M. Rastogi¹, I. De Kouchkovsky², E. Small³, F. Feng¹, D. Kwon², T. Friedlander², H. Borno², R. Bose², J. Chou², V. Koshkin³, A. Desai⁴, S. Feng², A. Angelidakis², M. Johnson⁵, L. Fong⁶, T. Hope², ¹UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US, ²UCSF - University of California San Francisco, San Francisco, US, ³UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ⁴University of California San Francisco, San Francisco, US, ⁵UCSF Medical Center at Mission Bay, San Francisco, US, ⁶UCSF Diabetes Teaching Center, San Francisco, US

10:25 - 10:26

1380P - High Sonic Hedgehog (HH) signalling activity, low androgen receptor activity and clonal evolution are associated with resistance to androgen-receptor axis inhibitors in patients with metastatic prostate cancer

N. Menssouri¹, Y. Wesseling-Rozendaal², L. Poiraudau¹, C. Helissey³, L. Bigot⁴, J. Sabio⁵, T. Ibrahim¹, C. Nicotra⁵, L. Tselikas⁵, E. Colomba⁵, P. Lavaud⁵, B. Besse⁴, J.-Y. Scoazec⁴, E. Den Biezen⁶, S. Neerken⁶, K. Fizazi⁵, D. Gautheret⁵, P. Van De Wiel⁶, Y. Lorient⁵, ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²InnoSIGN B.V, Eindhoven, NL, ³Bégin Military Teaching Hospital, Saint-Mandé, FR, ⁴Institut Gustave Roussy, Villejuif, FR, ⁵Institut Gustave Roussy, Villejuif, Cedex, FR, ⁶Philips Healthcare, Eindhoven, NL

10:26 - 10:27 **1381P - A transcriptomic signature of AR activity prognosticates development of castration-resistance following metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer**

P. Tran¹, P. Sutera², M. Deek³, K. Van Der Eecken⁴, A. Hakansson⁵, S. Liu⁵, J. Chang¹, V. Fonteyne⁶, A. Mendes², N. Lumen⁴, L. Delrue⁴, S. Verbeke⁷, K. De Man⁸, D. Song², C. Paller², E. Davicioni⁵, S. Joniau⁹, G. De Meerleer¹⁰, T. Lotan², P. Ost¹¹, ¹University of Maryland, Baltimore, US, ²Johns Hopkins Hospital, Baltimore, US, ³Rutgers Cancer Institute of New Jersey, New Brunswick, US, ⁴UZ Gent - University Hospital Ghent, Gent, BE, ⁵Veracyte, Inc. - Headquarters, South San Francisco, US, ⁶Ghent University - Campus Ufo, Gent, BE, ⁷N.V. Roche S.A. - Belgium, Brussels, BE, ⁸UZ Gent - Universitair Ziekenhuis Gent, Gent, BE, ⁹UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ¹⁰University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ¹¹UZ Gent - University Hospital Ghent, Ghent, BE

10:27 - 10:28 **1382P - FDG-positive/PSMA-negative PET lesion prevalence in metastatic castration-resistant prostate cancer and its correlation with lines of systemic therapy: Results from the prospective 3TMPO imaging study**

F. Pouliot¹, F. Saad², P. Richard³, E. Rousseau³, S. Probst⁴, E. Levesque⁵, V. Castonguay⁶, N. Marcoux⁷, M. Lodde¹, D. Juneau⁸, Z. Hamilou⁸, J.-B. Lattouf⁸, F.-A. Buteau⁵, M. Pavic³, J.-F. Castilloux⁹, B. Neveu⁵, G. Bouvet⁵, A. Tetu³, B. Guérin³, J.-M. Beaugregard⁵, ¹Université Laval, CHU de Québec, Québec City, CA, ²Hospital St. Luc du CHUM, Montreal, CA, ³CIUSSS de l'Estrie - CHUS Hopital Fleurimont (Sherbrooke), Sherbrooke, CA, ⁴Jewish General Hospital McGill University, Montreal, CA, ⁵CHU de Québec - Université Laval, Québec City, CA, ⁶CHU de Québec - Hotel Dieu de Québec et CRCEO, Québec City, CA, ⁷Centre Hospitalier Universitaire Pavillon l'Hôtel-Dieu de Québec, Québec City, CA, ⁸CHUM - Centre Hospitalier de l'Université de Montréal, Montreal, CA, ⁹Sherbrooke University CHU - Hôpital Fleurimont, Sherbrooke, CA

10:28 - 10:29 **1383P - Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA)**

R. Reisinger¹, U. Swami¹, E. Hernandez¹, N. Sayegh¹, S. Wesolowski², L. Kiedrowski³, P.M. Coelho Barata⁴, R. Nussenzeig¹, G. Lemmon², M. Bilen⁵, E. Heath⁶, L. Nandagopal⁷, H. Babiker⁸, S. Pal⁹, M. Lilly¹⁰, B. Maughan¹, M. Yandell², O. Sartor⁴, N. Agarwal¹¹, ¹University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US, ²University of Utah, Salt Lake City, US, ³Guardant Health, Inc., Redwood City, US, ⁴Tulane University, New Orleans, US, ⁵Winship Cancer Institute of Emory University, Atlanta, US, ⁶Karmanos Cancer Institute, Detroit, US, ⁷University of Alabama at Birmingham, Birmingham, US, ⁸Mayo Clinic Cancer Center, Phoenix, US, ⁹City of Hope Comprehensive Cancer Center, Duarte, US, ¹⁰Medical University of South Carolina, Charleston, US, ¹¹Huntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, US

- 10:29 - 10:30 **1384P - Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2010 to 2019**
- D. George¹, R. Sandin², N. Agarwal³, S. Tagawa⁴, Z. Klaassen⁵, R. Bitting⁶, K. Ramaswamy⁷, B. Emir⁷, C. Bland⁸, A. Hong⁹, L. Shi¹⁰, H. Yang¹¹, W. Gao¹², W. Song¹², S. Freedland¹³, ¹Duke University Medical Center, Durham, US, ²Pfizer AB, Sollentuna, SE, ³University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US, ⁴Weill Cornell Medicine / New York Presbyterian Hospital, New York, US, ⁵Georgia Cancer Center - Augusta University Health, Augusta, US, ⁶Durham VA Health Care System / Duke University Medical Center, Durham, US, ⁷Pfizer Inc, New York, US, ⁸Pfizer Inc, Collegeville, US, ⁹Astellas Pharma, Northbrook, US, ¹⁰Tulane University, New Orleans, US, ¹¹Analysis Group, Inc, Boston, US, ¹²Analysis Group, Inc., Boston, US, ¹³and Durham, NC VA Medical Center, Los Angeles, US
- 10:30 - 10:31 **1385P - Transcriptome-based prognostic and predictive biomarker analysis of ENACT: A randomized controlled trial of enzalutamide (ENZA) in men undergoing active surveillance (AS)**
- A. Ross¹, K. Iwata², D. Elsouda², J. Hairston², D. Russell³, E. Davicioni⁴, J. Proudfoot⁴, N. Shore⁵, M. Cooperberg⁶, E. Schaeffer¹, ¹Northwestern University Feinberg School of Medicine, Chicago, US, ²Astellas Pharma Inc., Northbrook, US, ³Pfizer Inc., New York, US, ⁴Veracyte, Inc., San Francisco, US, ⁵Carolina Urologic Research Center, Myrtle Beach, US, ⁶University of California, San Francisco, San Francisco, US
- 10:31 - 10:32 **1386P - 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate in patients with prostate cancer (NCT04729114)**
- J. Avitia¹, J. Bailen Md², N. Shore³, R. Tutrone⁴, L. Nordquist⁵, J. Walling⁶, L. Peterson⁶, R. Schotzinger⁶, W. Moore⁶, ¹New Mexico Cancer Center, Albuquerque, US, ²First Urology Research, Jeffersonville, US, ³Carolina Urologic Research Center/GenesisCare, Myrtle Beach, US, ⁴Chesapeake Urology Research Associates, Towson, US, ⁵Urology Cancer Center and GU Research Network, Omaha, US, ⁶Propella Therapeutics, Inc., Pittsboro, US
- 10:32 - 10:33 **1387P - Final analysis of the phase Ib/II study of sabizabulin in men with metastatic castration-resistant prostate cancer who progressed on an androgen receptor targeting agent**
- M. Markowski¹, M. Eisenberger², C. Pieczonka³, D. Rodriguez⁴, K.G. Barnette⁴, R. Getzenberg⁴, M. Steiner⁴, D. Saltzstein⁵, E. Antonarakis⁶, R. Tutrone⁷, ¹Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US, ²Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, US, ³Associated Medical Professionals of NY, Syracuse, US, ⁴Veru Inc., Miami, US, ⁵Urology San Antonio, San Antonio, US, ⁶University of Minnesota, Minneapolis, US, ⁷Chesapeake Urology Research Associates, Towson, US
- 10:33 - 10:34 **1388P - Interim safety analysis of nivolumab 3mg/kg and ipilimumab 1mg/kg (nivo3/ipi1) in molecular-selected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)**
- S. Van Wilpe¹, H. Westdorp¹, I. Kloots¹, P. Sloombeek¹, M. Den Brok¹, G. Adema¹, L. Kerkmeijer¹, R.J. Smeenk¹, M. Coskunturk¹, H. Bloemendal¹, J. Schalken², N. Van Erp¹,

W. Gerritsen¹, N. Mehra¹, ¹Radboud University Medical Center, Nijmegen, NL, ²Radboud University Medical Center, Nijmegen, Nijmegen, NL

- 10:34 - 10:35 **1389P - Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC)**
- M. Linch¹, C. Ferrario², M. Stoeckle³, B. Laguerre⁴, J. Arranz Arijia⁵, T. Todenhöfer⁶, P. Fong⁷, J.M. Piulats Rodriguez⁸, W. Berry⁹, U. Emmenegger¹⁰, L. Mourey¹¹, N. Mar¹², L. Appleman¹³, A. Joshua¹⁴, H. Conter¹⁵, X.T. Li¹⁶, C. Schloss¹⁶, C. Poehlein¹⁶, J. De Bono¹⁷, E. Yu¹⁸, ¹University College London Hospital, London, GB, ²Jewish General Hospital, Montreal, CA, ³Saarland University, Homburg, DE, ⁴Eugene Marquis Center, Rennes, FR, ⁵Hospital General Universitario Gregorio Maranon, Madrid, ES, ⁶Studienpraxis Urologie, Nuertingen, DE, ⁷Auckland City Hospital, Auckland, NZ, ⁸Catalàn Institute of Oncology and i Reynals, Barcelona, ES, ⁹Duke Cancer Center Cary, Cary, US, ¹⁰Sunnybrook Odette Cancer Centre and Research Institute, Toronto, CA, ¹¹IUCT - Oncopole, Toulouse, FR, ¹²University of California Irvine, Orange, US, ¹³UPMC, Pittsburgh, US, ¹⁴St. Vincent's Hospital Sydney, Sydney, AU, ¹⁵William Osler Health System, University of Western Ontario, Brampton, CA, ¹⁶Merck & Co., Inc., Rahway, US, ¹⁷The Royal Marsden NHS Foundation Trust, London, GB, ¹⁸University of Washington, Seattle, US
- 10:35 - 10:36 **1390P - Circulating tumor DNA (ctDNA) and prognosis with PSMA-targeted radionuclide therapy (TRT)**
- M. Sun¹, C. Thomas¹, F. Orlando², M. Sigouros³, J. Osborne¹, J. Nauseef¹, A. Molina³, C. Sternberg⁴, M. Bissassar¹, S. Singh¹, F. Khani³, D. Nanus³, K. Ballman¹, N. Bander³, F. Demichelis⁵, H. Beltran⁶, S. Tagawa³, ¹Weill Cornell Medicine, New York, US, ²University of Trento, Povo, IT, ³Weill Cornell Medicine, Meyer Cancer Center, New York, US, ⁴Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York, US, ⁵University of Trento, Trento, IT, ⁶Dan Farber Cancer Institute, Boston, MA, US
- 10:36 - 10:37 **1391P - Tumor-first mutation-specific risk approach to trigger germline testing in castration-resistant prostate cancer**
- I. Kloots¹, M. Kets¹, J. Schuurs-Hoeijmakers², H. Westdorp², M. Coskunturk², H. Bloemendal¹, W. Gerritsen¹, I.M. Van Oort², M. Ligtenberg¹, N. Mehra¹, ¹Radboud University Medical Center, Nijmegen, Nijmegen, NL, ²Radboud University Medical Center, Nijmegen, NL
- 10:37 - 10:38 **1392P - Lutetium-177-prostate-specific membrane antigen therapy (177Lu-PSMA) in patients (Pts) with prior radium-223 (223Ra): Safety and effectiveness outcomes**
- K. Rahbar¹, M. Essler², M. Eiber³, C. La Fougère⁴, V. Prasad⁵, W. Fendler⁶, P. Rassek¹, E. Hasa³, H. Dittmann⁴, R. Bundschuh², K.M. Pabst⁶, M. Kurtinecz⁷, A. Schmall⁸, F. Verholen⁸, O. Sartor⁹, ¹University of Münster Medical Center, Muenster, DE, ²University Hospital Bonn, Bonn, DE, ³Technical University of Munich, Munich, DE, ⁴University Hospital Tübingen, Tübingen, DE, ⁵University of Ulm, Ulm, DE, ⁶German Cancer Consortium (DKTK) University Hospital Essen, Essen, DE, ⁷Bayer HealthCare Pharmaceuticals Inc., Whippany, US, ⁸Bayer Consumer Care AG, Basel, CH, ⁹Tulane University, New Orleans, US

09:00 - 14:00 Type: Poster session
Title: Poster session 09
Poster Area, Hall 4

- 09:00 - 09:01 **549P - Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study**
T. André¹, D. Berton-Rigaud², G. Curigliano³, R. Sabatier⁴, A. Tinker⁵, A. Oaknin⁶, F.G.M. De Braud⁷, S. Ellard⁸, H.-T. Arkenau⁹, J. Trigo Perez¹⁰, J. Brown¹¹, A. Jewell¹², J. Pikiel¹³, M.R. Mirza¹⁴, T. Duan¹⁵, G. Antony¹⁶, S. Zildjian¹⁷, E. Zografos¹⁸, J. Veneris¹⁷, S. Banerjee¹⁹, ¹Sorbonne University and Saint-Antoine Hospital, Paris, FR, ²GINECO & Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain, FR, ³IEO, European Institute of Oncology IRCCS, and University of Milano, Milan, IT, ⁴Institut Paoli Calmettes, Aix-Marseille University, Marseille, FR, ⁵British Columbia Cancer, Vancouver Centre, University of British Columbia, Vancouver, CA, ⁶Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, ⁷Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Milan, IT, ⁸BC Cancer, Kelowna, CA, ⁹Sarah Cannon Research Institute UK Limited, London, GB, ¹⁰Hospital Virgen de la Victoria IBIMA, Malaga, ES, ¹¹Levine Cancer Institute, Carolinas HealthCare System, Charlotte, US, ¹²University of Kansas Medical Center, Kansas City, US, ¹³Regional Center of Oncology, Gdansk, PL, ¹⁴Rigshospitalet, Copenhagen University Hospital, Nordic Society of Gynaecologic Oncology-Clinical Trial Unit, Copenhagen, DK, ¹⁵GlaxoSmithKline, Pennington, US, ¹⁶GlaxoSmithKline, Hertfordshire, GB, ¹⁷GlaxoSmithKline, Waltham, US, ¹⁸GlaxoSmithKline, London, GB, ¹⁹The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, GB
- 09:01 - 09:02 **550P - Immunoprofiling of mismatch repair-deficient (MMRd) endometrial cancer (EC) patients (pts): Immune checkpoint inhibitor (ICI)-responders (R) versus non-responders (NR)**
J.F. Grau Béjar¹, E. Yaniz Galende¹, C. Genestie², J.-Y. Scoazec², E. Edmond², A. Le Formal¹, F. Blanc-Durand², J. Michels², M. Kfoury², P. Morice¹, P. Pautier², E. Colomba², A. Leary¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Institut Gustave Roussy, Villejuif, Cedex, FR
- 09:02 - 09:03 **551P - Genomic DNA analysis of cervical smear samples of endometrial cancer with next-generation sequencing: A prospective study**
N. Kim, Y.-N. Kim, Y.J. Lee, S.W. Kim, S.H. Kim, J.R. Choi, J.-Y. Lee, S.-T. Lee, Yonsei University College Of Medicine, Seoul, KR
- 09:03 - 09:04 **552P - The prognostic evaluation of lymph-vascular space invasion to patients with endometrioid cancer and non-endometrioid cancer**
J. Feng, K. Song, R. Chu, Qilu Hospital of Shandong University, Jinan, CN
- 09:04 - 09:05 **553P - Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: Descriptive analysis of the French cohort temporary authorization of use (ATU)**
M. Rodrigues¹, L. Eberst², P. Follana³, V. Brunel⁴, L. Gauthier⁵, V. Jacquemin⁵, C. Tessier⁵, N. El Mouaddin⁵, P. Boudier², F. Fiteni⁶, E. Angeli⁷, S. Roche⁸, I. Bonnet⁹, C.

Deldycke¹⁰, N. Delanoy¹¹, R. Sabatier¹², R. Flippot¹³, T. De La Motte Rouge¹⁴, ¹Institut Curie, Paris, FR, ²Institut de Cancerologie de Strasbourg Europe, Strasbourg, FR, ³Centre Antoine Lacassagne, Nice, FR, ⁴Hôpital Européen, Marseille, FR, ⁵GlaxoSmithKline, Rueil-Malmaison, FR, ⁶Centre Hospitalier Universitaire de Nîmes, Nîmes, FR, ⁷Hôpital Avicenne, Bobigny, FR, ⁸Centre Jean Bernard, Le Mans, FR, ⁹Centre François Baclesse, Caen, FR, ¹⁰Centre Hospitalier Universitaire de Poitiers, Poitiers, FR, ¹¹CARPEM, AP-HP, APHP.Centre, Department of Medical Oncology, Hôpital Européen Georges-Pompidou, Paris, FR, ¹²Institut Paoli-Calmettes, Marseille, FR, ¹³Gustave Roussy Institute, Villejuif, FR, ¹⁴Centre Eugène Marquis, Région de Rennes, FR

09:05 - 09:06 **554P - Does the type of hysterectomy affect the survival of patients with clinical IA endometrial cancer: A multicenter and retrospective study**

C. Liu, K. Song, R. Chu, Qilu Hospital of Shandong University, Jinan, CN

09:06 - 09:07 **555P - TQB2450 injection combined with anlotinib hydrochloride capsule in the treatment of advanced, recurrent or metastatic endometrial cancer: A multicohort, open label, multicenter phase II clinical trial - The TQB2450-II-08 trial**

X. Wu¹, S. Liang¹, X. Chen², J. Hou³, K. Wang⁴, D. Wang⁵, R. An⁶, A. Zang⁷, X. Li⁸, B. Zhang⁹, P. Qu¹⁰, W. Duan¹¹, G. Yu¹², D. Wang¹³, D. Yan¹⁴, J. Wang¹⁵, D. Yao¹⁶, S. Wang¹⁷, W. Zhao¹⁸, H. Lou¹⁹, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²Obstetrics & Gynecology Hospital of Fudan University, Shanghai, CN, ³Yantai Yuhunagding Hospital, Yantai, CN, ⁴TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ⁵Liaoning Cancer Hospital & Institute, Shenyang, CN, ⁶First Affiliated Hospital Of Xian Jiaotong University, Xian, CN, ⁷Baoding Third Hospital/Baoding Tumor Hospital, Baoding, CN, ⁸Linyi Cancer Hospital, Linyi, CN, ⁹2nd Affiliated Hospital/Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, CN, ¹⁰Tianjin Central Hospital Of Gynecology Obstetrics, Tianjin, CN, ¹¹Beijing Obstetrics and Gynecology Hospital, Capital Medical University - East Courtyard, Beijing, CN, ¹²Weifang People Hospital, Weifang, CN, ¹³Chongqing University Cancer Hospital, Chongqing, CN, ¹⁴Beijing Luhe Hospital, Beijing, CN, ¹⁵Hunan Cancer Hospital, Changsha, CN, ¹⁶Oncology Medical College Guuangxi Cancer Institute, Nanning, CN, ¹⁷Beijing Chaoyang Hospital - Capital Medical University, Beijing, CN, ¹⁸The First Affiliated Hospital of USTC/ Anhui Provincial Hospital, Hefei, CN, ¹⁹Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN

09:07 - 09:08 **556P - Prognostic significance of positive peritoneal cytology in endometrial carcinoma based on ESGO/ESTRO/ESP risk classification: A multicenter retrospective study**

Y. Zhang, K. Song, R. Chu, Qilu Hospital of Shandong University, Jinan, CN

09:08 - 09:09 **557P - Tumour mutation burden is a dispensable test in endometrial carcinoma patients whose molecular classification is known**

H. Jiang, S. Chen, Q. Wang, Y. Deng, S. Wang, The Third Affiliated Hospital of Southern Medical University, Guangzhou, CN

09:09 - 09:10 **558P - Molecular subtyping endometrial carcinoma in Chinese population applying an NGS-based classifier and its association with prognosis**

Q. Zhang¹, X. Ma¹, W. Cao¹, H. Wu¹, K. Song¹, C. Sun¹, H. Liu², F. Gai², C. Zhu², B.

Kong¹, ¹Qilu Hospital of Shandong University, Jinan, CN, ²Amoy Diagnostics Co., Ltd., Xiamen, CN

09:10 - 09:11

559P - Neratinib in HER2-mutant, recurrent/metastatic cervical cancer (R/M CC): Updated findings from the phase 2 SUMMIT basket trial

C. Friedman¹, A. D'Souza², A. Tinker³, E. Corral⁴, V. Gambardella⁵, J. Goldman⁶, S. Loi⁷, M. Melisko⁸, A. Oaknin⁹, I. Spanggaard¹⁰, A. Vanderwalde¹¹, A. Frazier¹², B. Zhang¹³, L. Eli¹³, D. Solit¹, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, ³British Columbia Cancer Center, Vancouver, CA, ⁴START Madrid - Hospital Universitario Madrid Sanchinarro, Madrid, ES, ⁵Hospital Clinico Universitario de Valencia, Valencia, ES, ⁶UCLA Hematology/Oncology Santa Monica, Santa Monica, US, ⁷Peter MacCallum Cancer Centre, Melbourne, AU, ⁸University of California San Francisco, San Francisco, US, ⁹Vall d'Hebron University Hospital, Barcelona, ES, ¹⁰Copenhagen University Hospital, Rigshospitalet, Copenhagen, DK, ¹¹West Cancer Center, Germantown, US, ¹²Puma Biotechnology, Inc., Los Angeles, US, ¹³Puma Biotechnology, Inc., San Francisco, US

09:11 - 09:12

560P - Neoadjuvant camrelizumab plus chemotherapy in patients with locally advanced cervical cancer (NACI): A prospective, single-arm, phase II trial

J. Chen¹, K. Li¹, Y. Han¹, Y. Shen², Y. Wang³, K. Song⁴, X. Chen⁵, B. Xia⁶, D. Zou⁷, Y. Wang⁸, D. Ma¹, ¹Huazhong University of Science and Technology, Wuhan, CN, ²Zhejiang University Medical College Affiliated Obstetrics and Gynecology Hospital, Hangzhou, CN, ³Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, CN, ⁴Qilu Hospital of Shandong University, Jinan, CN, ⁵Obstetrics & Gynecology Hospital of Fudan University, Shanghai, CN, ⁶The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, CN, ⁷Chongqing Cancer Hospital, Chongqing, CN, ⁸Tianjin Medical University General Hospital, Tianjin, CN

09:12 - 09:13

561P - When to treat the pelvis in node-positive vulvar cancer: Results from the AGO-VOP.2 QS vulva study

M. Hampf¹, A. Jaeger², C. Eulenburg³, K. Prieske⁴, J. Hambrecht⁵, S. Fuerst⁶, R. Klapdor⁷, S. Heublein⁸, P. Gass⁹, A. Rohner¹⁰, U. Canzler¹¹, S. Becker¹², M. Bommert¹³, D. Bauerschlag¹⁴, A. Denecke¹⁵, L. Hanker¹⁶, J. Sehouli¹⁷, C. Dannecker¹⁸, S. Mahner¹⁹, L. Woelber⁵, ¹UKD - Universitätsklinikum Düsseldorf, Düsseldorf, DE, ²UKE Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE, ³UMCG - University Medical Center Groningen, Groningen, NL, ⁴Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE, ⁵AGO & Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE, ⁶LMU Klinikum der Universität München, Munich, DE, ⁷Hannover Medical School, Klinik für Dermatologie, Allergologie und Venerologie, Hannover, DE, ⁸Heidelberg University - Faculty of Medicine in Mannheim, Mannheim, DE, ⁹Universität Erlangen-Nürnberg, Nürnberg, DE, ¹⁰Universitätsklinikum Tuebingen Medizinische Universitätsklinik, Tuebingen, DE, ¹¹Technische Universität Dresden - Carl Gustav Carus Faculty of Medicine, Dresden, DE, ¹²Goethe-University Frankfurt am Main - Campus Westend, Frankfurt am Main, DE, ¹³KEM | Evang. Kliniken Essen-Mitte gGmbH, Essen, DE, ¹⁴University Hospital UKSH, Kiel, DE, ¹⁵Klinikum Wolfsburg, Wolfsburg, DE, ¹⁶University SH.-Lübeck, Lübeck, DE, ¹⁷Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, ¹⁸Universitätsklinikum Augsburg, Augsburg, DE, ¹⁹University

Hospital, LMU Munich, München, DE

- 09:13 - 09:14 **562P - Camrelizumab plus concurrent chemoradiotherapy for locally advanced cervical cancer: Preliminary results of a single-arm, open-label, phase II trial**
Y. Xiao¹, H. Cheng², L. Wang¹, L. Yang¹, X. Yu¹, ¹Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ²The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN
- 09:14 - 09:15 **563P - Single-cell profiling analysis reveals that AIF1-induced M2-to-M1 transition of macrophages suppresses the expression of HPV oncogenes and the progression of cervical carcinoma**
Y. Wei, P. Wu, C. Cao, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan City, CN
- 09:15 - 09:16 **564P - Efficacy and safety of tislelizumab plus anlotinib in the treatment of cervical cancer resistant to standard therapy: A prospective, single-arm, open labelled phase II clinical trial**
M. Zheng¹, Y. Zhou², J. Zhou¹, Y. Jiang¹, ¹Sun Yat-Sen University Cancer Center, Guangzhou, CN, ²Sun Yat-sen University Cancer Center, Guangdong, CN
- 09:16 - 09:17 **565P - Survival analysis of patients with locally advanced cervical cancer treated with cisplatin and gemcitabine concomitantly to radiotherapy followed by consolidation chemotherapy**
F. Alencar¹, A. Costa¹, F. Cruz², D. Alencar³, A.A. Da Costa⁴, ¹Santa Casa de Misericórdia de Maceió, Maceio, BR, ²Santa Casa de Misericórdia de Maceió, Maceió, BR, ³Santa Casa de Misericórdia de Maceió - Nossa Senhora da Guia, Maceio, BR, ⁴A.C. Camargo Cancer Center - Unidade Antonio Prudente, Sao Paulo, BR
- 09:17 - 09:18 **566P - Stage IVB cervical cancer: Does definitive chemoradiation effect oncological outcomes?**
S. Peleg Hasson¹, S. Felder², S. Baor², S. Abuakar², R. Shapira-Frommer², J. Goldstein¹, A. Saad², ¹Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL, ²Chaim Sheba Medical Center, Ramat Gan, IL
- 09:18 - 09:19 **567P - Phase Ib study of Intraperitoneal (IP) administration of nivolumab plus ipilimumab in patients with recurrent gynaecologic malignancies with peritoneal involvement**
E. Hinchcliff¹, A. Mosely², S. Hull², S. Westin³, A. Sood³, K. Schmeler³, J. Taylor², S. Huang⁴, R. Sheth⁴, K. Lu², A. Jazaeri³, ¹Northwestern University, Chicago, US, ²MD Anderson Cancer Center, Houston, US, ³The MD Anderson Cancer Center, Houston, US, ⁴The University of Texas MD Anderson Cancer Center, Houston, US
- 09:19 - 09:20 **568P - First-in-human anti-ALPP CAR-T cell immunotherapy for ovarian and endometrial cancer**
B. Zhu¹, Q. Jia¹, R. Chen², G. Chen³, L. Zhao², N. Palmer², D. Xiang⁴, F. Chen¹, Y. Duan¹, H. Wang⁵, J. Shan¹, L. Xiong⁶, R. Xie¹, G. Li¹, L. Yan¹, R. Li⁷, L. Xia⁸, Z. Su⁹, P. Alexander², S. Li¹⁰, ¹Xinqiao Hospital of Army Medical University, Chongqing, CN,

²TCRCure Biopharma Corp., Durham, US, ³Xinqiao Hospital of Army Medical University, Chongqing, CN, ⁴Jiangjin Distit Central Hospital, Chongqing, CN, ⁵Chongqing Traditional Chinese Medicine Hospital, Chongqing, CN, ⁶the People's Hospital of Kaizhou District, Chongqing, CN, ⁷Chongqing University Cancer Hospital, Chongqing, CN, ⁸Daping Hospital/Third Affiliated Hospital of People's Liberation Army Military Medical University, Chongqing, CN, ⁹Guangdong TCRCure Biopharma Technology Co., Ltd, GuangZhou, CN, ¹⁰TCRCure Biopharma Corp., Los Angeles, US

- 09:20 - 09:21 **569P - Pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: Real-life clinical experience**
S. Poblete, M. Caulkins, C. Roche, A. Loecher, K. Attwood, N. Gaulin, K. Mager, P. Frederick, E. Zsiros, Roswell Park Comprehensive Cancer Center, Buffalo, US
- 09:21 - 09:22 **570P - Hypomethylating agents synergistically combine with PARP inhibitors in ovarian cancer**
J. Hong¹, M. Vernon¹, P. Pandya², M. Mcdermott¹, P. Mokhtar³, G. Konecny⁴, ¹David Geffen School of Medicine at UCLA - Translational Oncology Research Laboratory (TORL), Santa Monica, US, ²Mayo Clinic, Rochester, US, ³UCLA, Los Angeles, US, ⁴UCLA Westwood Oncology Hematology - Oncology Community Practice Group, Los Angeles, US
- 09:22 - 09:23 **571P - BRCA and beyond: Wider genetic testing of women with epithelial ovarian cancer**
N. Flaum¹, E. Van Veen², W. Newman¹, E. Crosbie³, R. Edmondson³, M. Smith¹, E. Woodward⁴, F. Lalloo⁴, G. Evans⁴, ¹University of Manchester, Manchester, GB, ²Radboud University Medical Center, Nijmegen, Nijmegen, NL, ³The University of Manchester, Manchester, GB, ⁴Manchester Royal Infirmary - Manchester University NHS Foundation Trust, Manchester, GB
- 09:23 - 09:24 **572P - High concordance of different molecular assays in the determination of HRD associated GIS in high grade epithelial ovarian cancer**
W. Weichert¹, S. Bartels², I. Braicu³, Y. Christinat⁴, M. Demes⁵, V. Endris⁶, S. Herold⁷, L. Heukamp⁸, M. Hummel⁹, U. Lehmann², S. Merkelbach-Bruse¹⁰, N. Pfarr¹, R. Rad¹¹, J. Sehouli³, J. Siemanowski¹⁰, A. Stenzinger⁶, K. Von Schwarzenberg¹, C. Vollbrecht⁹, P. Wild⁵, D. Zocholl¹², ¹Technische Universität München-Institute of Pathology, Munich, DE, ²MHH - Medizinische Hochschule Hannover, Hannover, DE, ³Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, ⁴HUG - Hopitaux Universitaires de Geneve, Geneva, CH, ⁵Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, DE, ⁶University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE, ⁷Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE, ⁸Hematopathology Hamburg, Hamburg, DE, ⁹Charité - Universitätsmedizin Berlin, Berlin, DE, ¹⁰University Hospital Cologne, Köln, DE, ¹¹Technical University of Munich-TUM, Munich, DE, ¹²Charité - Universitaetsmedizin Berlin, Berlin, DE
- 09:24 - 09:25 **573P - Role of CA125 in patients included in the DESKTOP III/ENGOT-ov20 trial**
F. Lecuru¹, J. Sehouli², I. Vergote³, A. Reuss⁴, J.-M. Classe⁵, P. Hillemanns⁶, S. Greggi⁷, M.R. Mirza⁸, P.E. Brachet⁹, P. Follana¹⁰, N. Raban¹¹, A. Hasenburg¹², R. Zang¹³, K. Lindemann¹⁴, J.-W. Kim¹⁵, A. Poveda¹⁶, F. Raspagliesi¹⁷, C.A. Haslund¹⁸, A. Du Bois¹⁹, P.

Harter¹⁹, ¹GINECO & Institut Curie & Université Paris Cité, Paris, FR, ²AGO & Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, ³University Hospital Leuven, Leuven Cancer Institute, and BGOG, Leuven, BE, ⁴AGO & Philipps-University Marburg, Marburg, DE, ⁵GINECO & ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁶AGO & MHH - Medizinische Hochschule Hannover, Hannover, DE, ⁷Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli, Naples, IT, ⁸Rigshospitalet, Copenhagen, DK, ⁹GINECO & Centre Francois Baclesse, Caen, FR, ¹⁰GINECO & Centre Anticancer Antoine Lacassagne, Nice, FR, ¹¹GINECO & CHU Poitiers - Jean Bernard Hôpital, Poitiers, FR, ¹²AGO & Universitätsmedizin Mainz, Mainz, DE, ¹³SGOG & Zhongshan Hospital - Fudan University, Shanghai, CN, ¹⁴NSGO & Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, ¹⁵KGOG & Seoul National University Hospital, Seoul, KR, ¹⁶Initia Oncology, Hospital Quirónsalud,, Valencia, ES, ¹⁷Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ¹⁸Aalborg University Hospital, Aalborg, DK, ¹⁹AGO & Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE

09:25 - 09:26

574P - Myriad MyChoice plus intermediate performance to discriminate platinum-resistant high-grade ovarian cancer patients

F. Blanc-Durand¹, S. Cotteret², C. Genestie¹, E. Rouleau³, J. Michels¹, E. Colomba¹, M. Kfoury¹, P. Pautier¹, A. Leary⁴, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Institut Gustave Roussy, Villejuif, FR, ³Gustave Roussy - Cancer Campus, Villejuif, FR, ⁴Institut Gustave Roussy, and GINECO, Villejuif, FR

09:26 - 09:27

575P - Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade serous or endometrioid ovarian cancer: A multi-national observational study

R. Morgan¹, A. Clamp¹, B. Barnes², H. Schlecht³, L. Yarram-Smith⁴, Y. Wallis⁵, S. Morgan⁶, M. Valganon⁷, E. Hudson⁸, S. Mckenna⁹, S. Sundar¹⁰, S. Nicum¹¹, J. Brenton¹², R. Kristeleit¹³, S. Banerjee¹⁴, I. Mcneish¹⁵, J. Ledermann¹¹, S. Taylor², G. Evans¹⁶, G. Jayson¹, ¹The Christie NHS Foundation Trust, Manchester, GB, ²The University of Manchester, Manchester, GB, ³Manchester University NHS Foundation Trust, Manchester, GB, ⁴North Bristol NHS Trust, Bristol, GB, ⁵Birmingham Women's and Children's NHS Foundation Trust, Birmingham, GB, ⁶University Hospital Wales, Cardiff, GB, ⁷The Royal Marsden Hospital NHS Foundation Trust, Sutton, GB, ⁸Velindre Cancer Centre, Cardiff, GB, ⁹Belfast City Hospital, Belfast, GB, ¹⁰University of Birmingham, Birmingham, GB, ¹¹University College London Hospitals NHS Foundation, London, GB, ¹²University of Cambridge, Cambridge, GB, ¹³Guys and St Thomas NHS Trust, London, GB, ¹⁴The Royal Marsden Hospital, London, GB, ¹⁵Imperial College London, London, GB, ¹⁶Manchester University NHS Foundation Trust, Manchester, GB

09:27 - 09:28

576P - Genome instability index used for the optimization of molecular classification of endometrial carcinoma

M. Gao, W. Wang, N. Song, H. Zheng, N. Zhang, W. Gao, T. Shu, N. Zhang, H. Wang, Q. Li, Y. Gao, Peking University Cancer Hospital and Institute, Beijing, CN

09:28 - 09:29

577P - Impact of homologous recombination deficiency (HRD) on outcomes with intraperitoneal (IP) and intravenous (IV) chemotherapy in ovarian cancer: Analyses from the translational iPocc study (TriPocc)

S. Wijaya¹, T.Z. Tan², N. Ngoi¹, A. Yabuno³, K. Takehara⁴, H. Nakazawa⁵, T. Hirasawa⁶,

H. Fujiwara⁷, M. Yasuda³, Y.-H. Jan⁸, S.-J. Chen⁸, R. Huang⁹, K. Fujiwara³, K. Hasegawa³, D.S. Tan¹⁰, ¹NCIS - National University Cancer Institute Singapore, Singapore, SG, ²Cancer Science Institute (CSI) - National University of Singapore (NUS), Singapore, SG, ³Saitama Medical University International Medical Center, Saitama, JP, ⁴Shikoku Cancer Center, Matsuyama, JP, ⁵Hyogo Cancer Center, Akashi, JP, ⁶Tokai University School of Medicine Isehara Campus, Isehara, JP, ⁷Jichi Medical University Hospital, Shimotsuke, JP, ⁸ACT Genomics Headquarters, Taipei City, TW, ⁹NTU - National Taiwan University - College of Medicine, Taipei City, TW, ¹⁰National University Cancer Institute of Singapore, National University Hospital, Yong Loo Lin School of Medicine, and Cancer Science Institute of Singapore, Singapore, SG

09:29 - 09:30

578P - Genotype-phenotype correlation in diverse pathogenic variants in BRCA genes in patients with ovarian cancer: Focusing in prognosis and predictive role of each one

E.M. Gomez Garcia¹, N.L. Hernandez-Martinez², L. Lechuga-Becerra³, D. Trujillo-Gomez¹, J. Valdez-Andrade¹, ¹Centro Oncológico Estatal ISSEMYM, Toluca de Lerdo, MX, ²Instituto Nacional de Pediatría, Ciudad de Mexico, MX, ³UNAM - Universidad Nacional Autónoma de Mexico, Ciudad de Mexico, MX

09:30 - 09:31

579P - A multicenter evaluation of a low pass whole genome sequencing-based solution for homologous recombination deficiency detection

A. Buisson¹, P. Saintigny¹, E. Pujade-Lauraine², C. Montoto Grillot², D. Varcica³, M. Barberis⁴, N. Colombo⁴, A. Harlé⁵, P. Gilson⁶, C. Roma⁷, F. Bergantino⁸, P. Harter⁹, S. Pignata¹⁰, A.J. Gonzalez Martin¹¹, C. Schauer¹², K. Fujiwara¹³, I. Vergote¹⁴, T. Juhler-Nottrup¹⁵, P.-A. Just¹⁶, I. Ray-Coquard¹, ¹Centre Léon Bérard, Lyon, FR, ²ARCAGY-GINECO, Paris, FR, ³European Institute of Oncology, Milan, IT, ⁴IEO - Istituto Europeo di Oncologia, Milan, IT, ⁵Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, ⁶Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, ⁷Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁸Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁹Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen, DE, ¹⁰Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ¹¹Clinica Universidad de Navarra, Madrid, ES, ¹²Barmherzige Brüder Krankenhaus Graz, Graz, AT, ¹³Saitama Medical University International Medical Center, Saitama, JP, ¹⁴UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ¹⁵Copenhagen University Hospital, Copenhagen, DK, ¹⁶Hopital Cochin AP-HP, Paris, FR

09:31 - 09:32

580P - Physician behaviour and perceptions of genetic biomarker test use for the management of newly diagnosed advanced ovarian cancer patients

G. Valabrega¹, R. Eskander², T. Bailey³, W. Ambler³, S. Volpe⁴, O. Ozgoren⁴, N. Alam⁴, G. Long⁴, S. Banerjee⁵, ¹University of Turin, Ordine Mauriziano Hospital, Turin, IT, ²University of California San Diego - UCSD, La Jolla, US, ³Adelphi Real World, Bollington, GB, ⁴AstraZeneca PLC, Cambridge, GB, ⁵The Royal Marsden Hospital - Chelsea, London, GB

09:32 - 09:33

581P - Homologous recombination deficiency (HRD) in 543 ovarian cancer samples: A single center hands-on experience

A. Kotsakis¹, P. Konstantoulakis², G. Christopoulou², S. Samara², A. Oikonomaki², K.

Roumelioti², F. Pachitsa², F. Koinis³, V. Georgoulas⁴, ¹University General Hospital of Larissa, Larissa, GR, ²Genotypos Science Labs, Athens, GR, ³University Hospital of Larissa, Larissa, GR, ⁴Metropolitan General Hospital, Heraklion, GR

- 09:33 - 09:34 **582P - Longitudinal, multi-sample characterization of HGSC from DECIDER: A Finnish observational study**
J. Oikkonen¹, A. Virtanen¹, Y. Li¹, V.-M. Isoviita¹, K. Zhang¹, S. Jamalzadeh¹, G. Marchi¹, A. Häkkinen¹, T. Muranen¹, A. Lahtinen¹, S. Hietanen², K. Huhtinen³, J. Hynninen⁴, S. Hautaniemi¹, ¹University of Helsinki - Faculty of medicine, Helsinki, FI, ²Turku University Hospital (Tyks), Turku, FI, ³University of Turku, Turku, FI, ⁴Turku University Hospital TYKS, Turku, FI
- 09:34 - 09:35 **583P - Aurora kinase overexpression may play a role in PARPi resistance in tumor samples of patients with high grade ovarian cancer and its inhibition with alisertib overcomes resistance to olaparib in a PARPi-resistant cell line model**
J.A. Perez Fidalgo¹, J.J. Martinez Pretel², V. Heredia³, M. Romeo Marin⁴, M. Mendiola³, J. Hochstadt², A. Bernat⁵, P. Sanchez-Serrano², A. Redondo Sanchez³, M. Gil Martín⁶, S. Guerra Ojeda⁷, I. Teruel⁴, O. Burgués¹, A. Cervantes¹, B. Pineda Merlo⁸, ¹Hospital Clínico Universitario de Valencia, Valencia, ES, ²INCLIVA - Fundación Investigación del Hospital Clínico Universitario de Valencia, Valencia, ES, ³Hospital Universitario La Paz, Madrid, ES, ⁴ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ⁵FIGTP - Fundacio Institut d'Investigacio Germans Trias i Pujol, Badalona, ES, ⁶ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ⁷University of Valencia, Valencia, ES, ⁸INCLIVA Instituto de Investigación Sanitaria, Valencia, ES
- 09:35 - 09:36 **584P - Mutation analysis of ovarian carcinoma patients presenting optimal response to neoadjuvant chemotherapy**
E. Dos Santos¹, E. Yaniz Galende², S. Caputo³, A.A. Da Costa⁴, M. Nashvi⁵, F. Maella⁵, L. Lacroix⁶, A. Auguste⁶, A. Le Formal⁷, L. De Brot Andrade⁸, V. Miranda⁹, M. Diz⁹, M. Vasconcelos¹⁰, P. Pautier⁵, P. Morice², C. Genestie⁵, A. Leary², E. Rouleau⁶, ¹Hospital AC Camargo, SAO PAULO, BR, ²Institut Gustave Roussy, Villejuif, FR, ³Institut Curie, Paris, FR, ⁴A.C. Camargo Cancer Center - Unidade Antonio Prudente, Sao Paulo, BR, ⁵Institut Gustave Roussy, Villejuif, Cedex, FR, ⁶Gustave Roussy - Cancer Campus, Villejuif, FR, ⁷Institut Gustave Roussy - INSERM UMR 981, Villejuif, FR, ⁸AC Camargo Cancer Center, Sao Paulo, BR, ⁹ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR, ¹⁰Hospital Alemao Oswaldo Cruz - Paulista, Sao Paulo, BR
- 09:36 - 09:37 **585P - Trabectedin induces apoptosis regardless of acquired resistance to PARP inhibitors in BRCA2 mutant high grade ovarian cancer cell lines**
J.A. Perez Fidalgo¹, P. Sanchez-Serrano², V. Heredia³, J.J. Martinez Pretel², J. Hochstadt², M. Mendiola³, A. Redondo Sanchez³, O. Burgués¹, B. Pineda Merlo⁴, ¹Hospital Clínico Universitario de Valencia, Valencia, ES, ²INCLIVA - Fundación Investigación del Hospital Clínico Universitario de Valencia, Valencia, ES, ³Hospital Universitario La Paz, Madrid, ES, ⁴INCLIVA Instituto de Investigación Sanitaria, Valencia, ES
- 09:37 - 09:38 **586P - BRCA1, BRCA2 and RAD51C somatic RNAseq study in ovarian cancer: A**

description of physiological and pathogenic splicing patterns

M. Sebai¹, R. Tang², A. Le Formal¹, M. Nashvi², A. Leary¹, E. Rouleau¹, ¹Institut Gustave Roussy, Paris-Saclay University, Villejuif, Cedex, FR, ²Institut Gustave Roussy, Villejuif, Cedex, FR

09:38 - 09:39 **587P - Sequential approach to determine the HRD status with BRCA1 promotor methylation status and shallow whole genome sequencing (sWGS)**

E. Rouleau¹, F. Blanc-Durand², M. Nashvi², S. Cotteret³, C. Genestie², A. Le Formal³, M. Pommier⁴, D. Vasseur¹, Y. Adnani², L. Lacroix⁵, A. Leary³, R. Tang⁶, ¹Institut Gustave Roussy, Paris-Saclay University, Villejuif, Cedex, FR, ²Institut Gustave Roussy, Villejuif, Cedex, FR, ³Institut Gustave Roussy, Villejuif, FR, ⁴Paris University, Paris, FR, ⁵Gustave Roussy, Villejuif, FR, ⁶Institut Gustave Roussy, Villejuif, FR

09:39 - 09:40 **588P - Prognostic value of circulating tumor DNA (ctDNA) in ovarian cancer**

J. Heo, Y.-N. Kim, J.-Y. Lee, S.-T. Lee, S. Shin, K. Lee, Y.J. Lee, S.W. Kim, J.R. Choi, S. Kim, Severance Hospital, Yonsei University College of Medicine, Seoul, KR

09:40 - 09:41 **589P - Circulating tumour DNA as prognostic factor in endometrial cancer: Updated results from an international multicenter study**

F. Siegenthaler¹, K. Teien Lande², C. Krakstad³, E. Høivik³, M. Mueller¹, T. Sorlie², K. Lindemann⁴, ¹Bern University Hospital and University of Bern, Bern, CH, ²Institute for Cancer Research, Oslo University Hospital, Oslo, NO, ³Haukeland University Hospital, Bergen, NO, ⁴Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO

09:41 - 09:42 **590P - Ki67 as a predictor of response to PARP inhibitors in platinum sensitive BRCA wild type ovarian cancers: MITO 37 retrospective study**

V. Tuninetti¹, E. Ghisoni², S. Pignata³, E. Picardo⁴, F. Raspagliesi⁵, C. Andreetta⁶, E. Maldi⁷, G. Artioli⁸, S. Mammoliti⁹, M. Roccio¹⁰, A. Sikokis¹¹, N. Biglia¹, A. Parisi¹², V.D. Mandato¹³, C. Carella¹⁴, G. Cormio¹⁵, M. Marinaccio¹⁵, G. Scotto¹, M. Di Maio¹, G. Valabrega¹, ¹University of Turin, Ordine Mauriziano Hospital, Turin, IT, ²Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne, CH, ³Istituto Nazionale Tumori di Napoli IRCCS, Fondazione G Pascale, Naples, IT, ⁴Ospedale Sant'Anna di Torino, Torino, IT, ⁵Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁶Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, IT, ⁷IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, ⁸ULSS 2 UOC Oncologia Manca Trevigiana, Mirano, IT, ⁹IRCCS Ospedale Policlinico San Martino, Genova, IT, ¹⁰Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy, Pavia, IT, ¹¹Ospedal Maggiore di Parma, Parma, IT, ¹²University of L'Aquila, L'Aquila, IT, ¹³Azienda Unità Sanitaria Locale - IRCCS, Reggio Emilia, Reggio Emilia, IT, ¹⁴Istituto Tumori Giovanni Paolo II, Bari, IT, ¹⁵Policlinico di Bari - Ospedale Giovanni XXIII, Bari, IT

09:42 - 09:43 **591P - Feasibility of longitudinal monitoring of whole blood-based circulating tumour DNA (ctDNA) in patients with endometrial cancer**

Y.-N. Kim, N. Kim, Y.J. Lee, S.W. Kim, J.R. Choi, S.H. Kim, S.-T. Lee, J.-Y. Lee, Yonsei University College Of Medicine, Seoul, KR

09:43 - 09:44 **592P - Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor α 1; (FR α 1)-**

positive cancer

U. Matulonis¹, K. Moore², D. Lorusso³, A. Oaknin⁴, S. Pignata⁵, H. Denys⁶, N. Colombo⁷, T. Van Gorp⁸, J. Konner⁹, M. Romeo Marin¹⁰, P. Harter¹¹, C. Murphy¹², Y. Tu¹³, F. Zhu¹³, B. Esteves¹³, M. Method¹³, M. Birrer¹⁴, R. Coleman¹⁵, D. O'Malley¹⁶, ¹Dana Farber Cancer Institute, Boston, US, ²Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, ³Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome, Rome, IT, ⁴Vall d'Hebron University Hospital, Barcelona, ES, ⁵Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ⁶UZ Gent - Universitair Ziekenhuis Gent, Gent, BE, ⁷European Institute of Oncology, and MANGO, Milan, IT, ⁸University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁹Memorial Sloan Kettering Cancer Center, New York, US, ¹⁰ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ¹¹Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen, DE, ¹²Bon Secours Hospital, Cork, IE, ¹³ImmunoGen, Inc., Waltham, US, ¹⁴UAMS - University of Arkansas for Medical Sciences, Little Rock, US, ¹⁵Texas Oncology-The Woodlands, The Woodlands, US, ¹⁶The Ohio State University and the James Cancer Center, Columbus, US

09:44 - 09:45 **593P - AI-powered analysis of nuclear morphology associated with prognosis in high-grade serous carcinoma**

C. Michener¹, C. Kirkup², B. Rahsepar², J. Iyer², J. Abel², K. Leidal², A. Khosla², B. Trotter², M. Lin², M. Resnick², B. Glass², I. Wapinski², F. Najdawi², ¹Cleveland Clinic, Cleveland, US, ²PathAI, Inc., Boston, US

09:45 - 09:46 **594P - The heterogeneous molecular landscape of ovarian cancer metastases (OCM)**

M. Hadfield¹, S. Wu², P. Thaker³, A. Farrell², M. Oberley², N. Jones⁴, T. Herzog⁵, D. Dizon⁶, ¹Warren Alpert Medical School of Brown University, Providence, US, ²Caris Life Sciences - Headquarters, Irving, US, ³Washington University School of Medicine in St. Louis, St. Louis, US, ⁴University of South Alabama, Mobile, US, ⁵UCCI - University of Cincinnati Cancer Institute, Cincinnati, US, ⁶Women & Infants Hospital - Warren Alpert Medical School of Brown Univ, Providence, US

09:46 - 09:47 **595P - Multi-marker liquid biopsy for detection of early-stage ovarian cancer**

R. Eskander¹, J. Lewis², J. Hinestrosa², G. Schroeder², H. Balcer², P. Billings³, ¹University of California San Diego - UCSD, La Jolla, US, ²Biological Dynamics, Inc., San Diego, US, ³Biological Dynamics, San Diego, US

09:47 - 09:48 **596P - CA125 longitudinal decline kinetic is complementary to BRCA testing in first-line high grade serous ovarian carcinoma (HGSOC) patients (pts)**

O. Becker¹, M. Chevrier¹, L. Gladieff², F. Joly Lobbedez³, I. Ray-Coquard⁴, A. Floquet⁵, C. Pomel⁶, H. Costaz⁷, P. Pautier⁸, T. De La Motte Rouge⁹, R. Sabatier¹⁰, J.-M. Classe¹¹, E. Leblanc¹², F. Marchal¹³, P.-E. Colombo¹⁴, E. Barranger¹⁵, O. Colombari¹⁶, L. Bosquet¹⁷, B. You¹⁸, M. Rodrigues¹, ¹Institut Curie, Paris, FR, ²Institut Universitaire du Cancer - Toulouse- Oncopole, Toulouse, FR, ³Centre Francois Baclesse, Caen, Cedex, FR, ⁴Centre Léon Bérard, Lyon, FR, ⁵Institute Bergonié, Bordeaux, FR, ⁶Université Auvergne, Clermont-Ferrand, FR, ⁷Centre Georges-François Leclerc (Dijon), Dijon, FR, ⁸Institut Gustave Roussy, Villejuif, Cedex, FR, ⁹Centre Eugene - Marquis, Rennes, FR, ¹⁰IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ¹¹ICO Institut de Cancerologie de l'Ouest

René Gauducheau, Saint-Herblain, FR, ¹²Centre Oscar Lambret, Lille, FR, ¹³Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, ¹⁴ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, ¹⁵Centre Anticancer Antoine Lacassagne, Nice, FR, ¹⁶Université Claude Bernard Lyon 1 - Campus Rockefeller, Lyon, FR, ¹⁷Unicancer, Paris, Cedex, FR, ¹⁸Lyon Sud Hospital Center - HCL, Pierre-Bénite, FR

09:48 - 09:49

597P - Endometrial carcinoma and mismatch repair deficiency: Clinical association and universal screening for Lynch syndrome

S. Puglisi¹, M. Ponzano¹, M. Perachino¹, C. Pirrone¹, A. Damassi¹, G. Bregni², A. Puccini¹, M. Grassi¹, L. Trevisan¹, V. Gismondi¹, M. Dono¹, S. Lastraioli¹, P. Fedele³, M. Cremante¹, A. Gandini¹, F. Giannelli¹, S. Mammoliti¹, V.G. Vellone⁴, M.S. Sciallero¹, M.L. Iaia¹, ¹IRCCS Ospedale Policlinico San Martino, Genova, IT, ²Institut Jules Bordet, Brussels, BE, ³Ospedale Dario Camberlingo, Francavilla Fontana, IT, ⁴IRCCS Ospedale Policlinico San Martino, Pathology Unit, Genova, IT

09:49 - 09:50

598P - Can circulating PD-L1 levels, age at diagnosis and peritoneal carcinomatosis act as survival predictors in patients with advanced high-grade serous ovarian cancer?

D. Fanale¹, C. Brando², L.R. Corsini², S. Cutaia², M.C. Di Donna², C. Filorizzo², L. Magrin², U. Randazzo², M. Di Piazza², V. Gurrera², A. Fiorino², E. Pedone², R. Scalia², R. Romano², T.D. Bazan Russo², A. Dimino², V. Chiantera², A. Russo², V. Bazan², J.L. Iovanna³, ¹AOU Policlinico Paolo Giaccone, Palermo, IT, ²University of Palermo, Palermo, IT, ³Aix-Marseille Université and Institut Paoli-Calmettes, Marseille, France, Marseille, FR

09:50 - 09:51

599P - Tumor mutation burden is a predictive biomarker for survival to patients with ovarian carcinoma

N. Liu¹, C. Huang¹, J. He¹, J. Lu¹, S. Wang², ¹Nanfang Hospital of Southern Medical University, Guangzhou, CN, ²3D Medicines, GuangZhou, CN

09:51 - 09:52

600P - Ethnic and socio-economic status in ovarian cancer patients recruited to clinical trials

K. Palmer¹, K. El-Shakankery², J. Kefas², K. Gao³, S. Cruz¹, M. Flynn², L. Jonathan², M. Lockley², M. McCormack², N. Macdonald², S. Nicum², M.-J. Devlin¹, R. Miller², ¹St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, ²UCH - University College Hospital, London, GB, ³QMUL - Queen Mary University of London - Charterhouse Square, London, GB

09:52 - 09:53

601P - Treatment patterns and outcomes of patients with locally advanced vulvar or vaginal cancer in British Columbia

E. Leung¹, C. Tremblay¹, D. Liao², L. Huang³, S. Sun³, J. Ko⁴, ¹University of British Columbia, Vancouver, CA, ²University of Toronto, Toronto, CA, ³University of the Fraser Valley, Abbotsford, CA, ⁴Abbotsford Regional Hospital and Cancer Centre, Abbotsford, CA

09:53 - 09:54

602P - Using scenarios to explain survival times – attitudes of women with gynaecological cancer

K. Lindemann¹, H. Liland², M. Paus Reinertsen², A. Jabri Haug³, J. Deu Martinez⁴, M.R. Stockler⁵, G. Aune⁶, B.E. Kiely⁵, I. Vistad⁷, T. Paulsen², ¹Oslo University Hospital - The

Norwegian Radium Hospital, Oslo, NO, ²Oslo University Hospital - Radiumhospitalet, Oslo, NO, ³Akershus University Hospital HF, Lorenskog, NO, ⁴Sykehuset Telemark HF, Skien, NO, ⁵NHMRC Clinical Trials Centre, Camperdown, AU, ⁶NTNU - Norwegian University of Science and Technology, Trondheim, NO, ⁷Sørlandet Hospital HF, Kristiansand, NO

09:54 - 09:55

603P - Multi-cancer early detection in gynaecological malignancies based on integrating multi-omics assays by liquid biopsy: A prospective study

H. Wen¹, Z. Feng¹, H. Ge¹, C. Quan¹, X. Zhou¹, B. Yang², F. Liu², J. Wang², Y. Wang², J. Zhao², G. Zhou², X. Wen², Y. Liu², X. Zhu², G. Wang², Y. Zhang², B. Li², S. Cai², Z. Zhang², X. Wu¹, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²Burning Rock Bioengineering Ltd, Guangzhou, CN

09:55 - 09:56

604P - T cell density and immune phenotypes at the invasive margin correlate with prognosis in epithelial vulvar cancer

L. Woelber¹, N. Blessin², A.-C. Rolschewski³, F. Lutz³, T. Mandelkow³, C. Yang³, E. Bady³, V. Reischwich³, R. Simon³, G. Sauter², S. Mahner⁴, N. De Gregorio⁵, M. Kalder⁶, R. Klapdor⁷, I. Braicu⁸, S. Fuerst⁹, M. Klar¹⁰, H.-G. Strauß¹¹, E. Burandt³, K. Prieske¹², ¹AGO & Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE, ²University Medical Center Hamburg-Eppendorf, Hamburg, DE, ³UKE Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE, ⁴University Hospital, LMU Munich, München, DE, ⁵Uniklinik Ulm, Ulm, DE, ⁶UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE, ⁷Hannover Medical School, Hannover, DE, ⁸Universitätsklinik Charité - Campus Virchow Klinikum, Berlin, DE, ⁹LMU Klinikum der Universität München, Munich, DE, ¹⁰Universitätsklinikum Freiburg - Klinik für Frauenheilkunde, Freiburg im Breisgau, DE, ¹¹UKH - Universitätsklinikum Halle (Saale), Halle (Saale), DE, ¹²Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE

09:56 - 09:57

605P - Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor α -positive cancer

K. Moore¹, D. Lorusso², A. Oaknin³, S. Pignata⁴, H. Denys⁵, N. Colombo⁶, T. Van Gorp⁷, J. Konner⁸, M. Romeo Marin⁹, P. Harter¹⁰, C. Murphy¹¹, Y. Tu¹², F. Zhu¹², B. Esteves¹², M. Method¹², M. Birrer¹³, R. Coleman¹⁴, U. Matulonis¹⁵, D. O'Malley¹⁶, ¹Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome, Rome, IT, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ⁵UZ Gent - Universitair Ziekenhuis Gent, Gent, BE, ⁶IEO - Istituto Europeo di Oncologia, Milan, IT, ⁷University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁸Memorial Sloan Kettering Cancer Center, New York, US, ⁹ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ¹⁰Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen, DE, ¹¹Bon Secours Hospital, Cork, IE, ¹²ImmunoGen, Inc., Waltham, US, ¹³UAMS - University of Arkansas for Medical Sciences, Little Rock, US, ¹⁴US Oncology Research, The Woodlands, US, ¹⁵Dana Farber Cancer Institute, Boston, US, ¹⁶Ohio State University Medical Center, Columbus, US

09:57 - 09:58

606P - Development and validation of a nomogram for predicting survival in patients with serous ovarian cancer: A population-based analysis

X. Peng, Xiegang District, Dongguan Municipal People's Hospital, Guangdong Province,

Dongguan City, CN

- 09:58 - 09:59 **607P - Prognostic and reproductive assessment of omentectomy for patients with clinically apparent early-stage (I, II) malignant ovarian germ cell tumors**; A multicenter and retrospective study
K. Song, P. Liu, Z. Li, Qilu Hospital of Shandong University, Jinan, CN
- 09:59 - 10:00 **608P - The socio-economic burden of endometrial, ovarian, cervical, and vaginal cancer survivorship**
J.C. Michaeli¹, D. Michaeli², T. Boch³, S. Albers¹, T. Michaeli⁴, ¹Asklepios Klinik Altona - Asklepios Kliniken, Hamburg, DE, ²Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, DE, ³Heidelberg University - Faculty of Medicine in Mannheim, Mannheim, DE, ⁴UMM - Universitaetsklinikum Mannheim, Mannheim, DE
- 10:00 - 10:01 **609P - Effect of lymphadenectomy on fertility and prognostic outcomes in adult patients with clinically early-stage malignant ovarian germ cell tumours during fertility-sparing surgery: A retrospective multicenter study**
K. Song, P. Liu, R. Chu, Qilu Hospital of Shandong University, Jinan, CN
- 10:01 - 10:02 **610P - Physical activity and fitness levels in women with ovarian cancer shortly after diagnosis**
Y. Hartman¹, S. Stelten¹, G. Kenter², L. Van Lonkhuizen³, P.B. Ottevanger⁴, W. Driel⁵, M. Hoedjes⁶, L. Buffart⁴, ¹Radboud University Medical Center, Nijmegen, NL, ²Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, ³Academic Medical Center, University of Amsterdam, Amsterdam, NL, ⁴Radboud University Medical Center, Nijmegen, Nijmegen, NL, ⁵NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁶Tilburg University, Tilburg, NL
- 10:02 - 10:03 **611P - Clinical characteristics and outcomes in ultra high-risk gestational trophoblastic neoplasia: Experience from an Indian cancer center**
D. Mondal, U. Palo, J. Ghosh, S. Ganguly, S. Roy, B. Biswas, A. Ghosh, B. Chakraborti, J. Bhaumik, TMC - Tata Medical Center, Kolkata, IN
- 10:03 - 10:04 **612P - Sentinel lymph node detection and accuracy in vulvar cancer: Meta-analysis and systemic review**
H.-W. Cho, Korea University Guro Hospital, Seoul, KR
- 10:04 - 10:05 **613P - Clinical characteristics and treatment outcomes of women with recurrent uterine leiomyosarcoma**
H. Yuan, National Cancer Center/National Clinical Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN
- 10:05 - 10:06 **614P - Tolerance and preliminary efficacy of intraperitoneal (IP) nivolumab after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients (pts) with advanced ovarian carcinoma: A phase I study with expansion cohort (ICONIC)**

P. Corbaux¹, B. You², V. Kepenekian³, N. Bakrin⁴, A. Gelot⁵, D. Dayde⁵, C. Sajous⁶, M. Lamuraglia⁷, J. Peron⁸, O. Glehen⁹, G. Freyer⁴, ¹Université Claude Bernard Lyon 1, Villeurbanne, Cedex, FR, ²Lyon Sud Hospital Center - HCL, Pierre-Bénite, FR, ³Hospices Civils de Lyon - HCL - Lyon University Hospital Center, Pierre-Bénite, FR, ⁴Lyon Sud Hospital Center - HCL, Pierre Benite, FR, ⁵Hospices Civiles de Lyon - HCL - Lyon University Hospital Center, Lyon, FR, ⁶Hospices civils de lyon Hôpital neurologique pierre wertheimer, Bron, FR, ⁷Institut de Cancérologie et Hématologie Universitaire du CHU de Saint Etienne, Saint-Priest-en-Jarez, FR, ⁸Ch Lyon Sud, Pierre Benite, FR, ⁹Hospices Civils de Lyon, Pierre-Bénite, FR

- 10:06 - 10:07 **615TiP - NIRVANA-1: A multicentre randomized study comparing carboplatin-paclitaxel (CP) followed by niraparib (nira) to CP–bevacizumab (bev) followed by nira-bev in patients with FIGO stage III ovarian high-grade epithelial cancer and no residual disease after upfront surgery**
G. Freyer¹, A.J. Gonzalez Martin², F. Raspagliesi³, J. Peron⁴, E. Van Nieuwenhuysen⁵, K. Hasegawa⁶, M.-C. Lim⁷, I. Ray-Coquard⁸, ¹Lyon Sud Hospital Center - HCL, Pierre Benite, FR, ²Clinica Universidad de Navarra, Madrid, ES, ³Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁴Ch Lyon Sud, Pierre Benite, FR, ⁵University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁶Saitama Medical University International Medical Center, Saitama, JP, ⁷National Cancer Center - Graduate School of Cancer Science and Policy, Goyang, KR, ⁸Centre Léon Bérard, Lyon, FR
- 10:07 - 10:08 **616TiP - Intra-tumor injection of H101 combined with or without radiotherapy in refractory/recurrent/metastatic gynecological malignancies: A prospective, open-label, multi-center, single-arm study**
Z. Liu, T. Wang, J. Wang, F. Shi, J. Su, Q.-Y. Zhang, J. Zhang, F. Wang, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, CN
- 10:08 - 10:09 **628P - Infection-related hospitalization and overall survival with primary prophylaxis for febrile neutropenia in patients with diffuse large B-cell lymphoma treated with R-CHOP: A nationwide population-based study**
M. Kim¹, Y. Ahn¹, H.-J. Ahn¹, S.-W. Yi², ¹Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, KR, ²Catholic Kwandong University International St. Mary's Hospital, Incheon, KR
- 10:09 - 10:10 **629P - Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays**
L. Chen, A. Eriksson, S. Weström, T. Pandzic, S. Lehmann, L. Cavelier, U. Landegren, Uppsala University, Uppsala, SE
- 10:10 - 10:11 **630P - Comparison of different bone marrow detection methods in the diagnosis and prognosis of bone marrow involvement in diffuse large b cell lymphoma**
K. Zhao, Shanxi Provincial Cancer Hospital, Taiyuan, CN
- 10:11 - 10:12 **631P - A meta-analysis of the outcome of post-transplant lymphoproliferative disorder in adult patients after hematopoietic stem cell transplant**
L. Kantamneni¹, R. Khanam², Z. Shah³, B. Laek⁴, M. Ebad⁵, Z. Roksana⁶, D. Franco⁷, F. Anwer⁸, ¹University of Alabama Huntsville Regional Campus, Huntsville, US, ²Baystate Medical Center, Springfield, US, ³Weiss Memorial Hospital, Chicago, US, ⁴University of

Pittsburgh, Pittsburgh, US, ⁵Rawalpindi Medical University, Rawalpindi, PK, ⁶Feni Sardar Hospital, Feni, BD, ⁷Loyola Mcneal Hospital, Berwyn, US, ⁸Taussig Cancer Center-Cleveland Clinic, Cleveland, US

- 10:12 - 10:13 **632P - Prognostic relevance of pre-treatment c-reactive protein to albumin ratio in patients with diffuse large b cell lymphoma**
T.-M. Nicolaescu¹, A. Abu Sabaa², K. Hedell², C. Morth¹, A. Valachis³, G. Enblad²,
¹Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden and Center for Clinical Research of Uppsala University, Vastmanland, Vasteras Hospital, Vasteras, SE, ²Experimental and Clinical Oncology, Uppsala University, Uppsala, SE, ³Örebro University, Örebro, SE
- 10:13 - 10:14 **633P - Determining the prognostic value of end of treatment (EOT) 18F-choline positron emission tomography (PET) in patients treated with primary central nervous system lymphoma (PCNSL) who respond to first-line therapy: A single centre retrospective study at the Royal Marsden Hospital (RMH)**
S. Li¹, B. Sharma², Y. Du², D. El-Sharkawi², S. Iyengar², E. Nicholson², M. Potter², M. Ethell², C. Arias², S. Easdale², E. Alexander², D. Cunningham¹, I. Chau³, ¹The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ²The Royal Marsden Hospital (Sutton), Sutton, GB, ³The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB
- 10:14 - 10:15 **634P - Real-world (RW) health-related quality of life (QoL) in patients (pts) with follicular lymphoma (FL): Comparisons by line of therapy (LOT) and region (Europe vs United States (US))**
P.C. Johnson¹, A. Bailey², N. Milloy², E. Clayton², R. Quek³, Q. Ma³, ¹MGH - Massachusetts General Hospital, Boston, US, ²Adelphi Real World, Bollington, GB, ³Regeneron Pharmaceuticals Inc., New York, US
- 10:15 - 10:16 **635P - The treatment patterns and outcomes in patients with AL amyloidosis: A multi-center, retrospective, observational, real-world study in Sichuan province, China**
H. Yu¹, C. Zhang¹, Q. Liu¹, Y. Yang¹, J. Li², K. Wan¹, B. Cao¹, Y. Chen¹, H. Shang¹, Z. Hu¹, W. Liu¹, Y. Wu¹, ¹West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN, ²West China School of Public Health and West China Fourth Hospital - Sichuan University, Chengdu, CN
- 10:16 - 10:17 **636P - Development of radiolabelled plerixafor as a theranostic tool for malignant lymphomas**
T. Lakhanpal, J. Shukla, R. Kumar, P. Malhotra, G. Prakash, A. Bal, Y. Rathore, A. Khadwal, H. Singh, B.R. Mittal, PGIMER - Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, IN
- 10:17 - 10:18 **637P - Multiple myeloma: Effect of changing treatment landscape on population mortality in United States**
N. Kahlon, Z. Abuhelwa, T. Sheikh, S. Doddi, D. Hamouda, The University of Toledo - Health Science Campus, Toledo, US

- 10:18 - 10:19 **638P - Burden of infection in patients with multiple myeloma and secondary immunodeficiencies: A retrospective cohort study**
J. Richter¹, C. Anderson-Smits², K. Ren², M. Kamieniak³, D. Shah², C. Siffel², ¹Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US, ²Takeda Development Center Americas, Inc., Lexington, US, ³Takeda Pharma Sp.z.o.o, Warsaw, PL
- 10:19 - 10:20 **639P - Conditional survival in MM and impact of prognostic factors over time**
N. Abdallah, A. Smith, S. Geyer, M. Binder, P. Greipp, P. Kapoor, A. Dispenzieri, M. Gertz, L. Baughn, M. Lacy, S. Hayman, F. Buadi, D. Dingli, Y. Hwa, Y. Lin, T. Kourelis, R. Warsame, R. Kyle, S.V. Rajkumar, S. Kumar, Mayo Clinic, Rochester, US
- 10:20 - 10:21 **640P - Healthcare resource consumption, autologous stem cell transplantation and direct costs of multiple myeloma: An Italian real-world picture**
I. Esposito¹, S. Calabria², G. Ronconi², C. Piccinni², L. Dondi², L. Dondi², A. Addesi³, A. Pedrini², A.P. Maggioni², N. Martini², ¹Drugs & Health srl, Roma, IT, ²Fondazione ReS (Ricerca e Salute) - Research and Health Foundation, Roma, IT, ³Drugs & Health srl, Rome, IT
- 10:21 - 10:22 **641P - The burden of frailty in chronic myeloid leukemia: Evidence from 2016-2018 nationwide inpatient sample of the US**
H.-E. Tzeng¹, K.-D. Lee², H.-T. Lin³, ¹Taichung Veterans General Hospital, Taichung, TW, ²Taichung Veterans General Hospital, Taichung City, TW, ³Taipei Medical University Hospital, Taipei City, TW
- 10:22 - 10:23 **642P - Frequency and impact of retreatment in relapsed refractory multiple myeloma (RRMM): Real-world survey conducted in 5 European countries (United Kingdom, France, Germany, Italy, Spain)**
A. Bailey¹, S. Perera², T. D'Estrube², A. Ribbands¹, E. Luke¹, P. Feng Wang³, ¹Adelphi Real World, Bollington, GB, ²GlaxoSmithKline, London, GB, ³GlaxoSmithKline, Collegeville, US
- 10:23 - 10:24 **643P - Efficacy of CAR-T therapy for relapse or refractory multiple myeloma in the Chinese population: A systematic literature review and meta-analysis**
J. Xu¹, Y. Wang¹, M. Gao², C. Cui³, C. Liu⁴, J. Ma⁴, J.-Q. Mi¹, ¹Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, CN, ²Xian-Janssen Pharmaceutical Co., Ltd. - Beijing Headquarters, Shanghai, CN, ³Xian-Janssen Pharmaceutical Co., Ltd. - Beijing Headquarters, Beijing, CN, ⁴Legend Biotech China, Nanjing, CN
- 10:24 - 10:25 **644P - Treatment patterns, outcomes, and physician decision-making in multiple myeloma: A real-world European study**
A. Ribbands¹, S. Perera², T. D'Estrube², A. Bailey¹, E. Luke¹, P. Feng Wang³, ¹Adelphi Real World, Bollington, GB, ²GlaxoSmithKline, London, GB, ³GlaxoSmithKline, Collegeville, US

- 10:25 - 10:26 **646TiP - VITALIZE: A phase IIb, open-label, multicenter, randomized parallel-group, two-stage, study of maveropepimut-S, pembrolizumab, with or without intermittent low-dose cyclophosphamide, in r/r DLBCL**
M. Matasar¹, J. Teti², K. Mody², S. Fiset³, J. Graff², ¹MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ²IMV inc., Cambridge, US, ³IMV Inc., Quebec, CA
- 10:26 - 10:27 **647TiP - A multi-center phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2**
S. Iyer¹, I. Greenwell², L. Shea³, J.-H. Lee⁴, M. Muller⁵, ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²Medical University of South Carolina, Charleston, US, ³University of Alabama at Birmingham - School of Medicine, Birmingham, US, ⁴Gachon University Gil Hospital, Incheon, KR, ⁵INNATE PHARMA, Marseille, FR
- 10:27 - 10:28 **648TiP - Reduction of methotrexate (MTX) levels after glucarpidase in patients with diffuse large b cell lymphoma (DLBCL) at risk of central nervous system (CNS) involvement who receive cycles of HDMTX: An open-label, interventional, non-randomized, phase II, pilot, multicenter study**
A. De La Fuente Burguera¹, F.J. Peñalver Parraga², R. Cordoba Mascunano³, P. Herrera⁴, M.T. Olave⁵, C. Martiniez Chamorro⁶, I. Jarque⁷, M. Estevez Fernandez¹, ¹MD Anderson Cancer Center Madrid, Madrid, ES, ²Hospital Universitario Fundación Alcorcón, Alcorcon, ES, ³University Hospital Fundacion Jimenez Diaz, Madrid, ES, ⁴Hospital Universitario Ramon y Cajal, Madrid, ES, ⁵Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, ⁶Quironsalud Madrid, Madrid, ES, ⁷La Fe - Hospital Universitari i Politècnic, Valencia, ES
- 10:28 - 10:29 **649TiP - A phase I/Ib study evaluating the safety, pharmacokinetics, and preliminary efficacy of LP-118 in subjects with relapsed or refractory haematological malignancies**
E. Curran¹, J. Byrd¹, W. Stock², M. Foster³, F. Tan⁴, Y. Chen⁴, S. Anthony⁴, A. Chen⁴, ¹University of Cincinnati Cancer Centre, Cincinnati, US, ²University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, ³UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US, ⁴Newave Pharmaceutical Inc., Pleasanton, US
- 10:29 - 10:30 **662P - Deep learning-enabled precise recurrence detection in nasopharyngeal carcinoma: A multicentre study**
Y. Huang, Y. Deng, C. Li, X. Guo, X. Lv, Sun Yat-sen University Cancer Center, Guangzhou, CN
- 10:30 - 10:31 **663P - Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II study**
X. Ding¹, W. Zhang², R. You¹, X. Zou¹, Z. Wang³, Y.-F. Ouyang¹, Y.-L. Liu¹, L. Peng¹, L. You-Ping¹, C.-Y. Duan⁴, Q. Yang¹, C. Lin¹, X. Yulong¹, S.-Y. Chen¹, C.-M. Gu¹, P.Y. Huang¹, Y. Hua¹, M. Chen¹, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Sun Yat-Sen University Cancer Center, Guangzhou, CN, ³The First Affiliated Hospital of Kunming Medical University, Kunming, CN, ⁴Southern Medical University, Guangzhou, CN

- 10:31 - 10:32 **664P - A multicentre retrospective analysis of recurrent/metastatic (RM) nasopharyngeal cancer (NPC) from non-endemic areas: Results in the pre-immunotherapy era**
- P. Bossi¹, A. Alberti¹, M. Zamparini¹, E. Orlandi², S. Grisanti¹, A. Trama³, C. Resteghini³, R. Mesia Nin⁴, I. Mohamad⁵, E. Ozyar⁶, M. Buglione⁷, M. Airolidi⁸, S. Vecchio⁹, L. Livi¹⁰, B. Cirauqui Cirauqui¹¹, M. El-Sherify¹², S. Ursino¹³, A. Argiris¹⁴, I. Linares Galiana¹⁵, L. Licitra³, ¹University of Brescia, ASST Spedali Civili, Brescia, IT, ²Centro Nazionale di Adroterapia Oncologica - CNAO, Pavia, IT, ³Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁴ICO - Institut Català d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ⁵KHCC - King Hussein Cancer Center, Amman, JO, ⁶Acibadem Mehmet Ali Aydinlar University, Istanbul, TR, ⁷University of Brescia, ASST Spedali Civili, Brescia, Brescia, IT, ⁸AOU Città della Salute e della Scienza Torino, Torino, IT, ⁹IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ¹⁰Azienda Ospedaliera Universitaria Careggi, Firenze, IT, ¹¹ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ¹²Damitta Oncology Center, Damietta, EG, ¹³AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT, ¹⁴Hygeia Hospital, Marousi, GR, ¹⁵Hospital Universitario Virgen de las Nieves, Granada, ES
- 10:32 - 10:33 **665P - Retinal vessels characteristics analysis as a predictive tool for post-radiation neurocognitive impairment in patients with nasopharyngeal cancer**
- J. Chow¹, J. Lee², M.M.P. Lai², S.X.X. Li², A.Y.L. Lau², B.S.Y. Ng¹, G.G. Leung¹, S.T.Y. Li¹, K.M. Cheung¹, A.M.C. Lau¹, K.H. Au¹, B.C.Y. Zee², ¹Queen Elizabeth Hospital, Kowloon, HK, ²The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK
- 10:33 - 10:34 **666P - Circulating CX3CR1+CD8 T and Th17 cells and immunotherapy response in recurrent or metastatic NPC**
- D. Zheng¹, C.L. Chiang², T.-C. Lam³, S.K. Chan⁴, A. Lee⁵, F. Kong³, ¹HKU - The University of Hong Kong, Hong Kong, HK, ²Queen Mary Hospital, Hong Kong, HK, ³HKU - The University of Hong Kong, HK, CN, ⁴The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, HK, ⁵The University of Hong Kong - Shenzhen Hospital, Shenzhen, CN
- 10:34 - 10:35 **667P - Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours**
- D.S. Hong¹, M. Tahara², C. Baik³, J. Bauman⁴, J. Gilbert⁵, M. Brose⁶, J.E. Grilley-Olson⁷, T. Patil⁸, R. Mcdermott⁹, L. Raez¹⁰, J.M. Johnson¹¹, L. Shen¹², R. Norenberg¹³, L. Dima¹⁴, C. Mussi¹⁵, X. Le¹, A. Drilon¹⁶, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²National Cancer Center Hospital East, Kashiwa, JP, ³University of Washington/Seattle Cancer Care Alliance, Seattle, US, ⁴Fox Chase Cancer Center, Philadelphia, US, ⁵Vanderbilt University Medical Center, Nashville, US, ⁶Sidney Kimmel Cancer Center of Jefferson University Health, Philadelphia, US, ⁷Duke University, Durham, US, ⁸University of Colorado, Aurora, US, ⁹St Vincent's University Hospital and Cancer Trials Ireland, Dublin, IE, ¹⁰Memorial Cancer Institute, Florida International University, Pembroke Pines, US, ¹¹Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, US, ¹²Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, CN, ¹³Chrestos Concept GmbH & Co. KG,

Essen, DE, ¹⁴Bayer HealthCare Pharmaceuticals, Inc., Basel, CH, ¹⁵Bayer S.p.A, Milan, IT, ¹⁶Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US

- 10:35 - 10:36 **668P - Comprehensive analysis of the tumor immune microenvironment (TIM) in advanced adenoid cystic (ACC) and non-adenoid cystic salivary gland cancers (SGC)**
D. Rieke¹, E. Blanc², B. Von Der Emde¹, I. Piwonski¹, F. Klauschen³, I. Tinhofer-Keilholz¹, A. Mock⁴, P. Horak⁴, U. Keller¹, D. Beule², K. Klinghammer¹, S. Fröhling⁴, S. Ochsenreither¹, U. Keilholz¹, ¹Charité - Universitätsmedizin Berlin, Berlin, DE, ²Berlin Institute of Health, Berlin, DE, ³German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Berlin Institute of Health, Berlin, DE, ⁴NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE
- 10:36 - 10:37 **669P - Neoadjuvant chemotarget therapy with cetuximab, docetaxel, and cisplatin in locally advanced resectable oral/oropharyngeal squamous cell carcinoma: A multicenter phase III trial (Eagle trial)**
L.-P. Zhong, Shanghai Ninth People's Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, CN
- 10:37 - 10:38 **670P - Discordant pathologic tumor response in primary tumors and lymph nodes after neoadjuvant immune checkpoint inhibition (ICI) in head and neck squamous cell carcinoma (HNSCC)**
A. Luginbuhl¹, E. Scott¹, L. Harshyne¹, E. Flerova¹, M. Tuluc¹, S. Gargano¹, J. Curry², D. Cognetti¹, A. Argiris¹, J. Johnson¹, ¹Thomas Jefferson University, Philadelphia, US, ²JEFFERSON UNIVERSITY-OTOLARYNGOLOGY, Philadelphia, US
- 10:38 - 10:39 **671P - Postoperative chemoradiation in combination with cetuximab followed by 6-months cetuximab maintenance in squamous cell carcinoma of the head and neck with high risk of locoregional recurrence**
B. Tamaskovics¹, C. Matuschek¹, J. Haussmann¹, J. Debus², T. Held², M. Henke³, S. Kirste³, M. Bamberg⁴, W. Stefan⁵, C. Belka⁶, U. Ganswindt⁷, T. Wiegel⁸, M. Mäurer⁹, V. Budach¹⁰, M. Stuschke¹¹, J. Schipper¹, E. Boelke¹, W. Budach¹, ¹Heinrich Heine University Düsseldorf, Düsseldorf, DE, ²University Hospital Heidelberg, Heidelberg, DE, ³University Medical Center Freiburg, Freiburg im Breisgau, DE, ⁴Eberhard Karl University of Tübingen, Tuebingen, DE, ⁵Marienhospital Stuttgart, Stuttgart, DE, ⁶University of Munich LMU, Munich, DE, ⁷Medical University of Innsbruck, Innsbruck, AT, ⁸Ulm Medical University, Ulm, DE, ⁹Jena University Hospital, Friedrich-Schiller, Jena, DE, ¹⁰Charité - Universitätsmedizin Berlin, Berlin, DE, ¹¹WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE

09:00 - 13:00 Type: Poster session Title: Poster session 08 Poster Area, Hall 4

- 09:00 - 09:01 **372P - Microsatellite instability testing practices in colorectal cancer patients, in Europe and Asia**
K. Jindal¹, L. Mendoza², J.-L. Merot³, C. Anger¹, A. Pino⁴, ¹IQVIA Solutions UK Ltd, London, GB, ²IQVIA RDS Czech Republic s.r.o., Prague, CZ, ³IQVIA - France, La Defense Cedex, FR, ⁴IQVIA - Madrid, Madrid, ES

- 09:01 - 09:02 **373P - The role of concomitant RAS and BRAF mutations in influencing clinical outcome during BRAF-targeted treatment for metastatic colorectal cancer**
A. Pretta¹, P. Ziranu², D. Spanu², E. Lai², M. Dettori³, C. Manai⁴, F. Balconi², R. Intini⁴, S. Murgia², A.G. Leone⁵, M. Pozzari², C. Rasola⁶, F. Bardanzellu², G. Maddalena⁶, V. Pusceddu², M. Puzzoni², F. Pietrantonio⁵, F. Bergamo⁴, S. Lonardi⁷, M. Scartozzi²,
¹Medical Oncology Unit, University Hospital and University of Cagliari, Monserrato, IT, ²University Hospital and University of Cagliari, Cagliari, IT, ³Armando Businco Hospital, Cagliari, IT, ⁴IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Milan, IT, ⁶Veneto Institute of Oncology IOV - IRCCS; University of Padua, Padua, IT, ⁷Veneto Institute of Oncology IOV-IRCCS, Padova, IT
- 09:02 - 09:03 **374P - Influence of sex on safety and efficacy in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with encorafenib-cetuximab +/- binimetinib (E-C+/-B)**
F.J. Ros Montana¹, V. Navarro², R. Comas², A. Garcia Rodriguez¹, D. Gomez¹, N. Saoudi Gonzalez¹, P. Vicente³, J.L. Cuadra⁴, D. Paez⁵, V. Alonso⁶, A. Hernandez Martinez⁷, D. López Valbuena¹, I. Baraibar Argota¹, F. Salvà Ballabrera¹, J. Tabernero¹, M.E. Elez Fernandez¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ³Hospital General de Granollers, Barcelona, ES, ⁴Hospital Quironsalud Barcelona, Barcelona, ES, ⁵Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁶Hospital Universitario Miguel Servet, Zaragoza, ES, ⁷ICO Girona - Institut Català d'Oncologia Girona, Barcelona, ES
- 09:03 - 09:04 **375P - The co-mutations and genetic features of BRAF-mutated gene mutations in a large Chinese MSS colorectal cancer cohort**
S. Chen¹, Z. Su¹, S. Ma¹, Z. Sun¹, X. Liu², M. Huang², ¹GDPU - Guangdong Pharmaceutical University, Guangzhou, CN, ²3D Medicines, Inc., Shanghai, CN
- 09:04 - 09:05 **376P - Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer (HER2+ mCRC): A systematic literature review and meta-analysis of clinical outcomes**
T. Bekaii-Saab¹, K. Lach², L.-I. Hsu³, M.F. Siadak³, M. Stecher³, J. Ward³, R. Beckerman², J. Strickler⁴, ¹Mayo Clinic Cancer Center, Phoenix, US, ²Maple Health Group, New York, US, ³Seattle Genetics, Seattle, US, ⁴Duke Cancer Center, Durham, US
- 09:05 - 09:06 **377P - Intraindividual tumor heterogeneity of mismatch repair status in metastatic colorectal cancer**
G. Liu, Q. Huang, Q. Zhang, K. Li, S. Zhang, T. Liu, Tianjin Medical University General Hospital, Tianjin, CN
- 09:06 - 09:07 **378P - Liquid biopsy detects early molecular response and predicts benefit to first-line chemotherapy plus cetuximab in metastatic colorectal cancer: PLATFORM-B study**
J. Vidal Barrull¹, M. Nieva Munoz¹, C. Fernandez-Rodriguez², P. García-Alfonso³, D. Paez⁴, V. Alonso-Orduna⁵, M.T. Cano Osuna⁶, C. Santos Vivas⁷, G. Duran⁸, M.E. Elez Fernandez⁹, J.L. Manzano Mozo¹⁰, R. Garcia-Carbonero¹¹, E. Pineda¹², J. Sastre Varela¹³,

F. Rivera Herrero¹⁴, B. Bellosillo Paricio², J. Tabernero⁹, E. Aranda Aguilar⁶, R. Salazar⁷, C. Montagut Viladot¹, ¹Hospital del Mar, Institut Mar Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra, CIBERONC, Barcelona, ES, ²Hospital del Mar - IMIM, Barcelona, ES, ³Hospital General Universitario Gregorio Marañón, Madrid, ES, ⁴Hospital de la Santa Creu i Sant Pau, U705. CIBERER, Barcelona, ES, ⁵Hospital Universitario Miguel Servet, Zaragoza, ES, ⁶IMIBIC, Reina Sofía Hospital, University of Cordoba, CIBERONC, Cordoba, ES, ⁷Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), CIBERONC, L'Hospitalet de Llobregat, ES, ⁸Unidad de Gestión Clínica Intercentros de Oncología Médica. Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Malaga, ES, ⁹Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, ES, ¹⁰ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ¹¹Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12), UCM, Madrid, ES, ¹²Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ¹³Hospital Universitario Clínico San Carlos, CIBERONC, Madrid, ES, ¹⁴Hospital Marqués de Valdecilla, IDIVAL, Santander, ES

09:07 - 09:08

379P - Whole exome sequencing of plasma circulating tumor DNA identifies dynamic mutational changes to guide targeted therapies in colon cancer patients

J. Martín-Arana¹, F. Gimeno-Valiente², R. Tébar-Martínez¹, B. García-Mico¹, V. Gambardella³, M. Huerta¹, C. Martínez-Ciarpaglini⁴, J. Carbonell-Asins⁵, M. Cabeza Segura¹, J. Martín-Arévalo⁶, D. Casado⁶, V. Pla⁶, L. Pérez⁶, P. Rentero-Garrido⁷, S. Rosello Keranen¹, T. Fleitas¹, J. Castillo⁸, D. Roda Perez³, A. Cervantes³, N. Tarazona Llaverro³, ¹Biomedical Research Institute INCLIVA, Hospital Clínico, University of Valencia, Valencia, ES, ²University College London Cancer Institute, London, GB, ³Biomedical Research Institute INCLIVA, Hospital Clínico, University of Valencia. CIBERONC, Instituto de Salud Carlos III, Madrid, Spain, Valencia, ES, ⁴Biomedical Research Institute INCLIVA, Hospital Clínico, University of Valencia. CIBERONC, Instituto de Salud Carlos III, Madrid, Spain, Valencia, ES, ⁵Biomedical Research Institute INCLIVA, Valencia, ES, ⁶Hospital Clinico Universitario de Valencia, Valencia, ES, ⁷INCLIVA Biomedical Research Institute, Valencia, ES, ⁸Universitat de Valencia, Valencia, ES

09:08 - 09:09

380P - Tumour naïve circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial

D. Day¹, A. Starus², A. Lamik³, O. Sieber⁴, S. Begbie⁵, A. Bonaventura⁶, S. Rai⁷, N. Karanth⁸, C. Underhill⁹, L. Nott¹⁰, G. Van Hazel¹¹, T. Van Hagen¹², M. Wong¹³, A. Saqib¹⁴, M. Eastgate¹⁵, R. Srivastav¹⁶, J. Chia¹⁷, H.C. Toh¹⁷, F. Jones², E. Segelov¹, ¹Monash Health - Monash Medical Centre, Clayton, AU, ²Sysmex-Inostics, Inc., Baltimore, US, ³Sysmex Inostics GmbH, Hamburg, DE, ⁴WEHI - Walter and Eliza Hall Institute of Medical Research, Parkville, AU, ⁵Port Macquarie Base Hospital, Port Macquarie, AU, ⁶Newcastle Private Hospital, Newcastle, AU, ⁷North West Cancer Centre, Tamworth Hospital, Tamworth, AU, ⁸Royal Darwin Hospital, Darwin, AU, ⁹Border Medical Oncology & Haematology, Albury Wodonga Regional Cancer Centre, Albury, AU, ¹⁰Royal Hobart Hospital, Hobart, AU, ¹¹Sir Charles Gairdner Hospital, Nedlands, AU, ¹²St John of God Subiaco, Subiaco, AU, ¹³Gosford Hospital, Gosford, AU, ¹⁴Goulburn Valley Health, Shepparton, AU, ¹⁵Royal Brisbane and Women's Hospital, Herston, AU, ¹⁶The Tweed Hospital, Tweed Heads, AU, ¹⁷NCCS - National Cancer Centre Singapore, Singapore, SG

- 09:09 - 09:10 **381P - A tumor-informed, hybrid-capture based ctDNA assay for minimal residual disease (MRD) detection in colorectal cancer (CRC) patients after curative surgery**
S.-W. Han¹, S. Heo², Y. Lim², W. Lee², H.-P. Kim², S.Y. Kim², D. Bang³, K.J. Park¹, S.T. Oh⁴, C.S. Yoo⁵, S.-B. Kang⁶, Y.-J. Kim³, T.-Y. Kim¹, ¹Seoul National University Hospital, Seoul, KR, ²IMBdx, Seoul, KR, ³Yonsei University, Seoul, KR, ⁴The Catholic University of Korea Uijeongbu St. Mary's Hospital, Uijeongbu, KR, ⁵Asan Medical Center - University of Ulsan, Seoul, KR, ⁶Seoul National University Bundang Hospital, Seongnam, KR
- 09:10 - 09:11 **382P - Sequential RAS mutation status evaluation in circulating free DNA (cfDNA) in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) starting first-line (1L) treatment with panitumumab (P) and chemotherapy (CT). PERSEIDA (Idylla Cohort) study**
M. Valladares¹, M.J. Safont Aguilera², E. González-Flores³, P. García-Alfonso⁴, A.M. López Muñoz⁵, E. Aranda Aguilar⁶, E. Falco Ferrer⁷, N. Rodríguez-Salas⁸, L. Cirera⁹, M. Llanos-Munoz¹⁰, J. Aparicio¹¹, P. Pimentel¹², A. Castillo Trujillo¹³, M. Salgado Fernandez¹⁴, M.A. Salud Salvia¹⁵, R. Vidal Tocino¹⁶, B. Massuti Sureda¹⁷, R. Garcia-Carbonero¹⁸, M.A. Vicente Conesa¹⁹, A. Lloansi Vila²⁰, ¹Hospital Universitario Virgen del Rocío and Instituto de Biomedicina (IBIS), Sevilla, ES, ²General Universitario, CIBERONC, Universidad de Valencia, Valencia, ES, ³Hospital Universitario Virgen de las Nieves, Granada, ES, ⁴Hospital General Universitario Gregorio Marañón, Madrid, ES, ⁵Hospital Universitario de Burgos (HUBU), Burgos, ES, ⁶Hospital Universitario Reina Sofía. IMIBIC. UCO. CIBERONC, Cordoba, ES, ⁷Hospital Son Llatzer, Palma de Mallorca, ES, ⁸Hospital Universitario La Paz, Madrid, ES, ⁹Hospital Mutua de Terrassa, Terrassa, ES, ¹⁰Hospital Universitario de Canarias, San Cristobal de la Laguna, ES, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, ES, ¹²Hospital Universitario Santa Lucia, Cartagena, ES, ¹³HUCA - Hospital Universitario Central de Asturias, ISPA, Oviedo, ES, ¹⁴Complejo Hospitalario Universitario de Ourense, Ourense, ES, ¹⁵Hospital Universitario Arnau de Vilanova, Lleida, ES, ¹⁶Hospital Universitario de Salamanca. IBSAL, Salamanca, ES, ¹⁷Hospital General Universitario de Alicante, Alicante, ES, ¹⁸University Hospital 12 De Octubre, Madrid, ES, ¹⁹Hospital General Universitario Jose Maria Morales Meseguer, Murcia, ES, ²⁰AMGEN - Spain, Barcelona, ES
- 09:11 - 09:12 **383P - An exosome-based liquid biopsy assay for predicting therapeutic outcomes in patients with metastatic colorectal cancer treated with anti-EGFR therapy: Results from prospective, first-line, PULSE and POSIBA trials**
A. Goel¹, C. Xu¹, S. Roy¹, F. Esposito², O. Helena³, V. Alonso⁴, A. Yubero Esteban⁵, F.-M. Carlos⁶, M.A. Salud Salvia⁷, J. Gallego Plazas⁸, J.R. Rodriguez Monwbray⁹, M.M.-R. Marta¹⁰, J. Fernandez¹¹, H. Manzano¹², J. Aparicio¹³, J. Feliu¹⁴, J. Maurel², ¹City of Hope Comprehensive Cancer Center, Duarte, US, ²Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ³Hospital Clinic of Barcelona, Barcelona, ES, ⁴Hospital Universitario Miguel Servet, Zaragoza, ES, ⁵Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, ⁶IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, ⁷Hospital Universitario Arnau de Vilanova, Lleida, ES, ⁸Hospital General Universitario de Elche, Elche, ES, ⁹Hospital Universitario Infanta Cristina, Parla, ES, ¹⁰Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹¹Hospital Mutua de Terrassa, Terrassa, ES, ¹²Hospital Universitario Son Espases, Palma de Mallorca, ES, ¹³Hospital Universitari i Politècnic La Fe, Valencia, ES, ¹⁴Hospital Universitario La Paz, Madrid, ES

- 09:12 - 09:13 **384P - Concordance of genomic alterations in tumour tissue and ctDNA in patients with colorectal cancer referred for early phase trials**
N. Ramchander¹, N. Billy Graham Mariam¹, S. Rack¹, K. Shohdy², A. Ortega Franco¹, F. Thistlethwaite¹, D. Graham¹, L. Carter², S. Dransfield¹, A. Henshaw¹, E. Darlington¹, D. Rothwell³, G. Burghel⁴, C. Dive³, M. Krebs², N. Cook², ¹The Christie NHS Foundation Trust, Manchester, GB, ²The University of Manchester, Manchester, GB, ³Cancer Research UK Manchester Institute, Manchester, GB, ⁴Manchester Foundation Trust, Manchester, GB
- 09:13 - 09:14 **385P - The prognostic value of circulating in blood tumor DNA after surgery in I-III stages colorectal cancer**
E. Polyanskaya¹, M. Fedyanin¹, B. Uliana², A. Kechin², E. Moroz³, E. Khrapov², I. Oskorobin², S. Darya², V. Aliev³, A. Tryakin⁴, M. Filipenko⁵, S. Tjulandin⁴, ¹N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ²The Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of ICBFM RAS, Novosibirsk, RU, ³N.N. Blokhin Russian Cancer Research Center, Moscow, RU, ⁴National Medical Research Center of Oncology named after N.N. Blokhin, Moscow, RU, ⁵Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, RU
- 09:14 - 09:15 **386P - Methylated circulating tumor DNA in plasma as a biomarker for treatment efficacy in metastatic colorectal cancer**
L. Raunkilde¹, T. Hansen¹, R.F. Andersen², L.H. Jensen¹, ¹Danish Colorectal Cancer Center South, Vejle, DK, ²Sygehus Lillebaelt - Vejle Sygehus, Vejle, DK
- 09:15 - 09:16 **387P - Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Final results of the randomized phase II TIME-PRODIGE 28 UNICANCER study**
V. Boige¹, E. Francois², H. Blons³, M. Ben Abdelghani⁴, J.M. Phelip⁵, V. Ly Lebrun⁶, L. Mineur⁷, M.P. Galais⁸, A.-L. Villing⁹, V. Hautefeuille¹⁰, L. Miglianico¹¹, C. De La Fouchardiere¹², D. Genet¹³, N. Levasseur¹⁴, N. Lachaux¹⁵, S. Gourgou¹⁶, F. Castan¹⁶, O. Bouche¹⁷, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Centre Anticancer Antoine Lacassagne, Nice, FR, ³Hopital Europeen Georges-Pompidou - APHP, Paris, FR, ⁴Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, ⁵CHU Saint Etienne - Hopital Nord, Saint-Étienne, FR, ⁶CHU Limoges - Hopital Dupuytren, Limoges, FR, ⁷Institut Ste Catherine, Avignon, FR, ⁸Centre Francois Baclesse, Caen, FR, ⁹CH Auxerre, Auxerre, FR, ¹⁰CHU Amiens-Picardie - Site Nord, Amiens, FR, ¹¹Centre Hospitalier Privé Saint-Grégoire, Saint-Grégoire, FR, ¹²Centre Léon Bérard, Lyon, FR, ¹³Polyclinique de Limoges - Francois Chénieux, Limoges, FR, ¹⁴Centre Hospitalier Jean Rougier Cahors, Cahors, FR, ¹⁵UNICANCER, Paris, FR, ¹⁶ICM - Institut régional du Cancer de Montpellier, Val d'Aurelle, Montpellier, Cedex, FR, ¹⁷CHU de Reims - Hôpital Robert Debré, Reims, Cedex, FR
- 09:16 - 09:17 **388P - Early tumor shrinkage (ETS) and depth of response (DpR) analyses in metastatic colorectal cancer (mCRC) treated with first-line mFOLFOX6 plus panitumumab (PAN) or bevacizumab (BEV): Results from the phase III PARADIGM trial**
K. Muro¹, J. Watanabe², K. Shitara³, K. Yamazaki⁴, H. Ohori⁵, M. Shiozawa⁶, H. Yasui⁴, E.

Oki⁷, T. Sato⁸, T. Naitoh⁸, Y. Komatsu⁹, T. Kato¹⁰, M. Hihara¹¹, J. Soeda¹², K. Yamamoto¹³, K. Akagi¹⁴, A. Ochiai¹⁵, H. Uetake¹⁶, K. Tsuchihara¹⁵, T. Yoshino³, ¹Aichi Cancer Center Hospital, Nagoya, JP, ²Yokohama City University Medical Center, Yokohama, JP, ³National Cancer Center Hospital East, Kashiwa, JP, ⁴Shizuoka Cancer Center, Shizuoka, JP, ⁵Japanese Red Cross Ishinomaki Hospital, Miyagi, Miyagi, JP, ⁶Kanagawa Cancer Center, Yokohama, JP, ⁷Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, ⁸KUSM - Kitasato University School of Medicine, Sagamihara, JP, ⁹Hokkaido University Hospital, Sapporo, JP, ¹⁰National Hospital Organization Osaka National Hospital, Osaka, JP, ¹¹Takeda Pharmaceutical Company Limited, Chuo-ku, JP, ¹²Takeda Pharmaceutical Company Limited, Tokyo, JP, ¹³Yokohama City University, School of Medicine, Yokohama, JP, ¹⁴Saitama Cancer Center, Saitama, JP, ¹⁵National Cancer Center, Chiba, JP, ¹⁶National Hospital Organization, Disaster Medical Center, Tokyo, JP

09:17 - 09:18

389P - Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)

Y. Kito¹, K. Yamazaki², H. Shoji³, T. Yamada⁴, T. Tsushima², S. Mitani⁵, K. Shiraishi⁶, H. Yasui⁷, H. Hara⁸, K. Shimosaki⁹, T. Esaki¹⁰, H. Shimokawa¹¹, S. Kajiura¹², T. Masuishi¹³, E. Baba¹⁴, K. Yoshimura¹⁵, H. Kawakami⁵, S. Hironaka¹⁶, K. Muro¹³, ¹Ishikawa Prefectural Central Hospital, Kanazawa, JP, ²Shizuoka Cancer Center, Shizuoka, JP, ³National Cancer Center - Tsukiji Campus, Chuo-ku, JP, ⁴Nippon Medical School Main Hospital, Tokyo, JP, ⁵Kindai University - Faculty of Medicine, Osaka, JP, ⁶National Hospital Organization, Nagoya Medical Center, Nagoya, JP, ⁷Kobe City Medical Center General Hospital, Kobe, JP, ⁸Saitama Cancer Center, Ina, JP, ⁹Keio University School of Medicine, Shinjuku-ku, JP, ¹⁰National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, ¹¹JCHO - Japan Community Healthcare Organization Kyushu Hospital, Kitakyushu, JP, ¹²Toyama University Hospital, Toyama, JP, ¹³Aichi Cancer Center Hospital, Nagoya, JP, ¹⁴Kyushu University - Graduate School of Medical Sciences - Faculty of Medical Sciences, Fukuoka, JP, ¹⁵Hiroshima University Hospital, Hiroshima, JP, ¹⁶Saitama Medical University International Medical Center, Saitama, JP

09:18 - 09:19

390P - Impact of age on treatment strategies in RAS/BRAF wild-type metastatic colorectal cancer (mCRC): A prespecified subgroup analysis of the GERCOR-PRODIGE STRATEGIC-1 phase III study

E. Carola¹, B. Chibaudel², R. Boulahssass³, L.M. Dourthe⁴, T. André⁵, J. Henriques⁶, V. Bourgeois⁷, P.-L. Etienne⁸, J. Desrame⁹, O. Dupuis¹⁰, N. Baba-Hamed¹¹, D. Auby¹², C. Louvet¹³, E. Maillard¹⁴, C. Tournigand¹⁵, M.-L. Garcia-Larnicol¹⁶, E. Shacham Shmueli¹⁷, B. Bird¹⁸, F. Ghiringhelli¹⁹, A. De Gramont²⁰, ¹GHPSO, Creil, FR, ²HFB - Hopital Franco-Britannique, Levallois-Perret, FR, ³Centre Anticancer Antoine Lacassagne, Nice, FR, ⁴Clinique Saint Anne, Strasbourg, FR, ⁵Hopital Saint-Antoine, Paris, FR, ⁶CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, ⁷CH de Boulogne sur Mer - Hopital Duchenne, Boulogne Sur Mer, FR, ⁸Hôpital Privé des Côtes d'Armor, Plérin, FR, ⁹Hôpital privé Jean Mermoz, Lyon, FR, ¹⁰Clinique Victor Hugo - ELSAN, Le Mans, Cedex, FR, ¹¹Groupe Hospitalier Paris Saint-Joseph, Paris, FR, ¹²Hospital Layné, Mont-de-Marsan, FR, ¹³IMM - Institut Mutualiste Montsouris, Paris, FR, ¹⁴CH Annecy-Genevois, Epagny Metz-Tessy, FR, ¹⁵Centre Hospitalier Universitaire Henri-Mondor AP-HP, Creteil, FR, ¹⁶GERCOR, Paris, FR, ¹⁷Chaim Sheba Medical Center, Ramat Gan, IL, ¹⁸Bon Secours Hospital, Cork, IE, ¹⁹Center Georges Francois Leclerc, Dijon, FR, ²⁰Franco-britannique hospital, paris, FR

- 09:19 - 09:20 **391P - Traditional Chinese medicine jianpi-bushen formula enhancing completion rate of adjuvant chemotherapy for stage II and III colon cancer: A multi-center randomized placebo-controlled clinical trial in China**
L. Sun¹, Y. Yang², ¹Xiyuan Hospital CACMS, Beijing, CN, ²Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, CN
- 09:20 - 09:21 **392P - Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas**
V. Moreno Garcia¹, P. Cassier², B. Doger De Spéville³, E. Calvo⁴, M.J. De Miguel⁵, R. Garcia-Carbonero⁶, C. Gomez-Roca⁷, C. Jungels⁸, P. Erbs⁹, S. Sainte-Croix⁹, A. Sadoun⁹, K. Bendjama⁹, ¹Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, ²Centre Léon Bérard, Lyon, FR, ³University Hospital Fundacion Jimenez Diaz, Madrid, ES, ⁴START Madrid-CIOCC, Madrid, ES, ⁵Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES, ⁶University Hospital 12 De Octubre, Madrid, ES, ⁷Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ⁸Institute Jules Bordet, Brussels, BE, ⁹Transgene SA, Illkirch-Graffenstaden, FR
- 09:21 - 09:22 **393P - Adherence to treatment recommendations from multidisciplinary tumor boards: Initial data from 562 colorectal cancer cases**
J. Wagner¹, J. Roeper¹, L. Ansmann², F. Griesinger¹, ¹Pius Hospital, Oldenburg, DE, ²Carl von Ossietzky University Oldenburg, Oldenburg, DE
- 09:22 - 09:23 **394P - Impact of gender on demographics, resectability, resections, systemic treatment, adverse events and outcomes in metastatic colorectal cancer (mCRC) patients (RAXO-study)**
P. Osterlund¹, T. Salminen², K. Lehtomaki³, E. Österlund⁴, A. Uutela⁵, P. Halonen⁶, L.-M. Soveri⁶, H. Stedt⁷, A.-M. Lamminmaki⁸, S. Aho², T. Muhonen⁹, A. Algars¹⁰, R. Kallio¹¹, E. Heervä¹², A. Nordin¹³, L. Aroviita¹⁴, P. Nyandoto¹⁵, J. Kononen¹⁶, R. Ristamäki¹², H. Isoniemi¹³, ¹Tampere and Karolinska University Hospital (Tays), Tampere, FI, ²Tampere University Hospital and University of Tampere, Tampere, FI, ³Tampere University Hospital (Tays), Tampere, FI, ⁴Uppsala University - Rudbecklaboratoriet, Uppsala, SE, ⁵Helsinki University Central Hospital, Helsinki, FI, ⁶Helsinki University Central Hospital (HUCH), Helsinki, FI, ⁷Kuopio University Hospital, Kuopio, FI, ⁸Kuopio University Hospital - Auditorium 1, Kuopio, FI, ⁹South Carelia Central Hospital, Lappeenranta, FI, ¹⁰Turku University Hospital, Turku, FI, ¹¹OYS - Oulu University Hospital, Oulu, FI, ¹²Turku University Hospital (Tyks), Turku, FI, ¹³Helsinki University Hospital, Helsinki, FI, ¹⁴Kanta-Häme Central Hospital, Hämeenlinna, FI, ¹⁵Paijat-Häme Central Hospital, Lahti, FI, ¹⁶Central Hospital of Central Finland, Jyväskylä, FI
- 09:23 - 09:24 **395P - Prevalence of clinically diagnosed depression among patients undergoing treatment for bowel cancer**
G. Delanerolle¹, H. Cavalini², ¹University of Oxford, Oxford, GB, ²University of Pernambuco, Petrolina, BR
- 09:24 - 09:25 **396P - Impact of depth of response of induction therapy on consecutive maintenance therapy in patients with RAS wild-type metastatic colorectal**

cancer: An analysis of the PanaMa trial (AIO KRK 0212)

G. Sommerhäuser¹, A. Kurreck¹, U. Fehrenbach², A. Beck², M. Karthaus³, S. Fruehauf⁴, U. Graeven⁵, L. Müller⁶, A.O. Koenig⁷, L. Fischer Von Weikersthal⁸, E. Goekkurt⁹, S. Haas¹⁰, A. Stahler¹, V. Heinemann¹¹, S. Held¹², A. Alig¹³, S. Kasper¹⁴, S. Stintzing¹³, T. Trarbach¹⁵, D. Modest¹, ¹Charité-Universitätsmedizin Berlin - Campus Virchow Klinikum (CVK) / Campus Mitte (CCM), Berlin, DE, ²Charité-Universitätsmedizin Berlin - Campus Virchow Klinikum (CVK), Berlin, DE, ³Klinikum Neuperlach-Städtisches Klinikum München, Munich, DE, ⁴Klinik Dr. Hancken GmbH, Stade, DE, ⁵Kliniken Maria Hilf GmbH - Klinik für Hämatologie, Onkologie und Gastroenterologie, Mönchengladbach, DE, ⁶Praxis Onkologie Unterems/ Onkologie und Hämatologie, Leer, DE, ⁷Universitätsmedizin Göttingen, Goettingen, DE, ⁸Klinikum St. Marien Amberg, Amberg, DE, ⁹Facharztzentrum Eppendorf, Hamburg, DE, ¹⁰FEK - Friedrich-Ebert-Krankenhaus, Neumünster, DE, ¹¹LMU Klinikum der Universität München, Munich, DE, ¹²ClinAssess Klinische Forschungs GmbH, Leverkusen, DE, ¹³Charité-Universitätsmedizin Berlin - Campus Virchow Klinikum (CVK) / Campus Mitte (CCM), Berlin, DE, ¹⁴WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, ¹⁵Reha-Zentrum am Meer, Bad Zwischenahn, DE

09:25 - 09:26 **397P - Early decreases in KRAS mutant allele frequency (MAF) predicts clinical benefit to the PLK1 inhibitor onvansertib in combination with FOLFIRI/bev in 2L treatment of metastatic colorectal carcinoma (mCRC)**

H.-J. Lenz¹, M. Ridinger², E. Samuels³, T. Smeal³, D. Ahn⁴, ¹University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, ²Cardiff Oncology Inc., San Diego, US, ³Cardiff Oncology, San Diego, US, ⁴Mayo Clinic Cancer Center, Phoenix, US

09:26 - 09:27 **398P - Effectiveness and safety of regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A real-world multicenter retrospective study with focus on sequential treatment**

C. Signorelli¹, M. Schirripa¹, M.G. Chilelli¹, M.A. Calegari², M. Basso², A. Anghelone², J. Lucchetti³, A. Minelli³, L. Angotti³, C. Morelli⁴, E. Dell'Aquila⁵, A. Cosimati⁵, D. Gemma⁶, M. Ribelli⁷, D. Corsi⁷, G. Arrivi⁸, F. Zoratto⁹, M.G. Morandi¹⁰, F. Santamaria¹¹, R. Saltarelli¹², E. Ruggeri¹, ¹Medical Oncology Unit, Belcolle Hospital, ASL Viterbo, Viterbo, IT, ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ³Division of Medical Oncology, Policlinico Universitario Campus Bio-Medico, Rome, IT, ⁴Policlinico Tor Vergata, Rome, IT, ⁵Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, IT, ⁶Ospedale SS Trinità, Sora, IT, ⁷U.O.C. Oncology, San Giovanni Calibita Fatebenefratelli Isola Tiberina Hospital, Rome, IT, ⁸Azienda Ospedaliera Sant'Andrea, Rome, IT, ⁹Ospedale Santa Maria Goretti - ASL Latina, Latina, IT, ¹⁰Medical Oncology Unit, San Camillo de Lellis Hospital, ASL Rieti, Rieti, IT, ¹¹UOC Oncology A, Policlinico Umberto I, Rome, IT, ¹²UOC Oncology, San Giovanni Evangelista Hospital, ASL RM5, Tivoli, IT

09:27 - 09:28 **399P - Role of geriatric assessment and oncological multidimensional prognostic index in elderly patients with metastatic colorectal cancer in a real-world setting**

F. Bergamo¹, A. Brunello¹, L. Procaccio¹, G. Sergi², M. Gatti¹, E. Bergo¹, A. Galiano¹, G. Tierno¹, B. Chiusole¹, A. Feltrin¹, F. Daniel¹, A. Prete¹, M.C. De Grandis³, V.M. Piva³, G. Barsotti³, C. Rasola³, G. Maddalena³, K. Cerma⁴, S. Lonardi⁵, V. Zagonel¹, ¹Veneto Institute of Oncology IOV - IRCCS, Padua, IT, ²University of Padua, Padova, IT, ³Veneto

Institute of Oncology IOV – IRCCS; University of Padua, Padua, IT, ⁴Veneto Institute of Oncology IOV – IRCCS; University Hospital of Modena, Padua, IT, ⁵Veneto Institute of Oncology IOV – IRCCS, Castelfranco Veneto, IT

- 09:28 - 09:29 **400P - Impact of regorafenib dose optimization on comparative outcomes in the treatment of relapsed/refractory metastatic colorectal cancer (mCRC)**
H. Burnett¹, I. Proskorovsky¹, S. Yoon², Y. Wang¹, H. Ostojic³, L. Gaiuanu⁴, Y. Su³,
¹Evidera, St-Laurent, CA, ²Evidera, San Francisco, US, ³Bayer HealthCare Pharmaceuticals Inc., Whippany, US, ⁴Bayer Public Limited Company, Reading, GB
- 09:29 - 09:30 **401P - PROMETCO study: Metastatic colorectal cancer treatment patterns of the first 531 enrolled patients**
J.-B. Bachet¹, C. Pinto², G.M. Bodoky³, F. Marti⁴, A. Mitroshkin⁵, E. Choucair⁶, M. Fazilleau⁷, A. Sullivan⁸, R. Garcia-Carbonero⁹, M. Koopman¹⁰, ¹Groupe Hospitalier Pitié Salpetrière, Paris, FR, ²Clinical Cancer Centre Azienda USL – IRCCS di Reggio Emilia, Reggio Emilia, IT, ³South-Pest Hospital Centre - National Institute for Infectology and Haematology - Szent Istvan Site, Budapest, HU, ⁴The Christie NHS Foundation Trust, Manchester, GB, ⁵Klinikum Freudenstadt, akademisches Lehrkrankenhaus der Universität Tübingen, Freudenstadt, DE, ⁶Servier, Suresnes, FR, ⁷Servier, Suresnes, Cedex, FR, ⁸Servier Pharmaceuticals - Corporate Headquarters, Boston, US, ⁹University Hospital 12 De Octubre, Madrid, ES, ¹⁰UMC - University Medical Center Utrecht, Utrecht, NL
- 09:30 - 09:31 **402P - Updated results from the multicenter phase II, ALTER-C001 trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC**
Y. Jin¹, Y. Han², L. Zhang³, Y. Jin¹, H. Sun⁴, ¹Sichuan Cancer Hospital and Institute/The Affiliated Cancer Hospital School of Medicine, UESTC, Chengdu, CN, ²The Affiliated Hospital of Southwest Medical University, Luzhou, CN, ³Chongqing University Three Gorges Hospital, Chongqing, CN, ⁴Chongqing University Cancer Hospital, Chongqing, CN
- 09:31 - 09:32 **403P - First-line anti-EGFR therapy, patient characteristics and survival: Results from South Australian (SA) metastatic colorectal registry (mCRCR)**
T. Price¹, C. Karapetis², B. Geerinckx³, A. Roy⁴, D. Roder⁵, R. Padbury⁴, A. Townsend⁶,
¹The Queen Elizabeth Hospital - University of Adelaide, Woodville, AU, ²Flinders Centre for Innovation in Cancer, Bedford Park, AU, ³University of Antwerp, Antwerpen, BE, ⁴FCIC - Flinders Centre for Innovation in Cancer, Bedford Park, AU, ⁵University of South Australia School of Nursing and Midwifery, Adelaide, AU, ⁶The University of Adelaide, Adelaide, AU
- 09:32 - 09:33 **404P - A quantitative synthesis of disparities in the inclusion of younger adults and racial/ethnic minorities in colorectal cancer clinical trials**
I. Riaz¹, S.A.A. Naqvi², M. Islam³, W. Ikram², U. Raza³, A. Ayaz⁴, A. Riaz⁵, H. Amna⁶, H. Maqsood⁷, Z. Jin⁸, M. Sonbol², ¹Dana Farber Cancer Institute, Boston, US, ²Mayo Clinic Cancer Center, Phoenix, US, ³Dow University of Health Sciences, Karachi, Karachi, PK, ⁴Beth Israel Deaconess Medical Center, Boston, US, ⁵Midwestern University - Downers Grove Campus, Glendale, US, ⁶Liaquat National Hospital (LNH), Karachi, PK, ⁷Nishtar

Medical College and Hospital - NMC, Multan, PK, ⁸Mayo Clinic, Rochester, US

- 09:33 - 09:34 **405P - Repurposing disulfiram as treatment for irinotecan-resistant metastatic colorectal cancer: An investigator-initiated clinical phase II trial**
L. Tarpgaard¹, I.C. Elle¹, J. Bartek², P. Pfeiffer¹, ¹Odense University Hospital, Odense, DK, ²The Danish Cancer Society, Copenhagen, DK
- 09:34 - 09:35 **406P - Real-world evidence of efficacy and safety in first-line cetuximab treatment of RAS wild-type metastatic colorectal cancer: A multicenter retrospective study in Taiwan**
C.-C. Chen¹, S.-C. Chang², Y.-Y. Chang³, B.-W. Lin⁴, H.-H. Chen⁵, Y.-Y. Hsieh⁶, H.-C. Hsu⁷, M.-C. Hsieh⁸, F.-C. Kuan⁹, C.C. Wu¹⁰, W.-C. Lu¹¹, Y.-L. Su⁵, Y.-H. Liang¹², C. Chen¹, S.-Y. Huang³, C.Y. Wang¹³, ¹Taichung Veterans General Hospital, Taichung City, TW, ²Taipei Veterans General Hospital, Taipei City, TW, ³Changhua Christian Hospital, Changhua City, TW, ⁴National Cheng Kung University Hospital, Tainan, TW, ⁵Chang Gung Memorial Hospital, Kaohsiung City, TW, ⁶Shuang Ho Hospital, Taipei Medical University, New Taipei City, TW, ⁷Chang Gung Memorial Hospital at Linkou, Taoyuan City, TW, ⁸E-Da Hospital, I-Shou University, Kaohsiung City, TW, ⁹Chang Gung Memorial Hospital, Chiayi, TW, ¹⁰Kaohsiung Veterans General Hospital, Kaohsiung City, TW, ¹¹National Taiwan University Hospital Yunlin Branch, Yunlin, TW, ¹²National Taiwan University Hospital, Taipei City, TW, ¹³Kaohsiung Medical University Hospital, Kaohsiung City, TW
- 09:35 - 09:36 **407P - Cross-sectoral colorectal cancer care in Germany in the context of the COVID-19 pandemic and scarcity of resources**
C. Luginier¹, T. Birkner², S. Sommerlatte³, H. Hense⁴, A.-L. Kraeft¹, J. Christmann⁵, S. Foerster⁵, O. Schoffer², A. Stein⁶, R. Reichelt⁷, W. Knauf⁸, C. Biermann⁹, O. Overheu¹, A. Tannapfel⁵, J. Schildmann³, A. Reinacher-Schick¹, J. Schmitt², ¹Katholisches Klinikum Bochum - St. Josef-Hospital, Bochum, DE, ²University Hospital Carl Gustav Carus, Dresden, DE, ³Martin Luther Universität Halle-Wittenberg, Halle (Saale), DE, ⁴Technische Universität Dresden - Carl Gustav Carus Faculty of Medicine, Dresden, DE, ⁵Georgius Agricola Stiftung Ruhr - Institut für Pathologie - Ruhr-Universität Bochum, Bochum, DE, ⁶UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ⁷alanta health service GmbH, Hamburg, DE, ⁸Centrum for Hematology and Oncology Bethanien, Frankfurt/Main, DE, ⁹MVZ Bocholt, Bocholt, DE
- 09:36 - 09:37 **408P - Prediction of survival using the G8 scale frailty scale in a prospective series of elderly patients with colon cancer**
G. Soler Gonzalez¹, L. Raventos², R. Legido-Diaz², C. Martínez³, F. Torrent⁴, M. Martinez Villacampa⁵, F. Losa³, C. Santos Vivas¹, J. Ruffinelli Rodriguez⁶, A. Teule⁷, M.R. Gallego², A. Manzana³, A. Rios³, S. Sánchez³, A. Piera³, C. Boixareu⁸, R. Salazar⁹, J. Saldaña Cañada², ¹ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ²ICO - Institut Català d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ³Hospital de Sant Joan Despi Moisès Broggi, Sant Joan Despi, ES, ⁴Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat, Barcelona, ES, ⁵Hospital ICO Bellvitge, Hospitalet de Llobregat, ES, ⁶ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, ⁷ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ⁸Hospital Universitari de Bellvitge, Hospitalet de Llobregat, ES,

⁹Institut Català d'Oncologia-Hospital Duran i Reynals, Hospitalet de Llobregat, ES

- 09:37 - 09:38 **409P - Preliminary results of bevacizumab plus raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): A multicenter phase II trial**
S. Li¹, L. Zhu¹, C. Zhu², ¹Jiangsu Institute of Cancer Research, the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, CN, ²The First Affiliated Hospital of Soochow University, Suzhou, CN
- 09:38 - 09:39 **410P - Prognostic value of baseline ECOG performance status, frailty phenotype, and geriatric screening tools (G8 and VES-13) in vulnerable older patients with metastatic colorectal cancer: The randomized NORDIC9-study**
G. Liposits¹, J. Ryg¹, H. Skuladottir², S. Winther¹, S. Möller³, E. Hofslid⁴, C.-H. Shah⁵, L. Poulsen Oestergaard⁶, A. Berglund⁷, C. Qvortrup⁸, P. Osterlund⁹, B. Glimelius¹⁰, H. Sorbye¹¹, P. Pfeiffer¹, ¹OUH - Odense University Hospital, Odense, DK, ²Regional Hospital Gødstrup, Herning, DK, ³University of Southern Denmark, Odense, DK, ⁴St. Olavs Hospital HF, Trondheim, NO, ⁵Karolinska University Hospital and Karolinska Institute, Stockholm, SE, ⁶Aalborg University Hospital, Aalborg, DK, ⁷University Hospital Uppsala/Akademiska Sjukhuset, Uppsala, SE, ⁸Copenhagen University Hospital, Copenhagen, DK, ⁹Tampere University Hospital (Tays), Tampere, FI, ¹⁰Akademiska Sjukhuset Uppsala, Uppsala, SE, ¹¹Haukeland University Hospital, Bergen, NO
- 09:39 - 09:40 **411P - Laparoscopic versus open liver resection for colorectal cancer liver metastases: Five-year actual survival of the previously reported randomized controlled trial – The OSLO-COMET Trial**
D. Aghayan¹, Å. Fretland¹, A. Kazaryan², V. Dagenborg³, M. Fagerland¹, K. Flatmark³, B. Edwin¹, ¹Oslo University Hospital - Rikshospitalet, Oslo, NO, ²Sykehuset Ostfold Kalnes, Gralum, NO, ³Oslo University Hospital - Radiumhospitalet, Oslo, NO
- 09:40 - 09:41 **412P - Phase I study of intraperitoneal irinotecan in combination with standard systemic chemotherapy in patients with extensive peritoneal metastases of colorectal origin: The INTERACT trial**
R. Van Eerden¹, N. De Boer¹, J. Van Kooten¹, C. Bakkers², M. Dietz¹, G.-J. Creemers², S. Buijs¹, R. Bax², F. De Man¹, R. Lurvink², M. Diepeveen¹, A. Brandt - Kerkhof¹, E. Van Meerten¹, S. Koolen¹, I. De Hingh², K. Verhoef¹, R. Mathijssen¹, P. Burger², ¹Erasmus MC Cancer Institute, Rotterdam, NL, ²Catharina Cancer Institute, Eindhoven, NL
- 09:41 - 09:42 **413P - Primary tumor resection (PTR) in metastatic colorectal cancer (mCRC) patients (pts) treated with upfront chemotherapy (CT) – bevacizumab (BEV): A pooled analysis of TRIBE and TRIBE2 studies**
V. Fanotto¹, A. Boccaccino², M. Casagrande¹, F. Bergamo³, A. Spagnoletti⁴, D. Santini⁵, C. Antoniotti², G. Allegrini⁶, F. Daniel³, V. Nasca⁴, D. Rossini², A. Zaniboni⁷, B. Borelli², M. Carullo², V. Conca², A. Passardi⁸, E. Tamburini⁹, G. Masi², C. Cremolini², N. Pella¹, ¹ASUFC University Hospital of Udine, Udine, IT, ²University of Pisa, Pisa, IT, ³Veneto Institute of Oncology IOV - IRCCS, Padua, IT, ⁴Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, IT, ⁵University Campus Biomedico, Rome, IT, ⁶Division of Medical Oncology, Azienda USL Toscana Nord Ovest, Livorno, IT, ⁷Istituto Ospedaliero Fondazione Poliambulanza, Brescia, IT, ⁸IRCCS Istituto Romagnolo per lo Studio dei

Tumori (IRST) "Dino Amadori", Meldola, IT, ⁹Cardinale Panico Tricase City Hospital, Tricase, IT

- 09:42 - 09:43 **414P - Long-term follow-up of the randomized trial of the conventional technique versus the no-touch isolation technique for primary tumor resection in patients with colon cancer (JCOG1006)**
Y. Takii¹, J. Mizusawa², Y. Kanemitsu³, K. Komori⁴, M. Shiozawa⁵, M. Ohue⁶, S. Ikeda⁷, N. Takiguchi⁸, T. Kobatake⁹, H. Ike¹⁰, T. Sato¹¹, N. Tomita¹², M. Ota¹³, E. Sunami¹⁴, T. Hamaguchi¹⁵, D. Shida¹⁶, H. Katayama¹⁶, Y. Shimada¹⁷, H. Fukuda¹⁶, ¹Niigata Cancer Centre, Niigata, JP, ²National Cancer Center - Tsukiji Campus, Chuo-ku, JP, ³National Cancer Center Hospital-Tsukiji Campus, Tokyo, JP, ⁴Aichi Cancer Center Hospital, Nagoya, JP, ⁵Kanagawa Cancer Center, Yokohama, JP, ⁶OICI - Osaka International Cancer Institute, Osaka, JP, ⁷Hiroshima Prefectural Hospital, Hiroshima, JP, ⁸Chiba Cancer Center Hospital, Chiba, JP, ⁹National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, ¹⁰Saiseikai Yokohama-shi Nanbu Hospital, Yokohama, JP, ¹¹Yamagata Prefectural Central Hospital, Yamagata, JP, ¹²Hyogo College of Medicine, Nishinomiya, JP, ¹³Yokohama City University Medical Center, Yokohama, JP, ¹⁴Kyorin University Faculty of Medicine, Mitaka, JP, ¹⁵Saitama Medical University International Medical Center, Hidaka, JP, ¹⁶NCCH - National Cancer Center Hospital, Chuo-ku, JP, ¹⁷Kochi Health Sciences Center, Kochi, JP
- 09:43 - 09:44 **415P - Metachronous peritoneal metastases in patients with pT4b colon cancer: An international multicenter analysis of intraperitoneal versus retroperitoneal tumor invasion**
E. Zwanenburg¹, P. Tanis², ¹Amsterdam University Medical Center (UMC) - locatie Academic Medical Center (AMC), Amsterdam, NL, ²Erasmus MC Cancer Institute, Rotterdam, NL
- 09:44 - 09:45 **416P - A randomized controlled trial to compare laparoscopic surgery with open surgery for symptomatic, non-curable stage IV colorectal cancer (CRC): First efficacy results from Japan clinical oncology group study JCOG1107**
T. Akagi¹, M. Inomata¹, R. Kanzaka², H. Katayama², H. Fukuda², A. Shiomi³, M. Ito⁴, J. Watanabe⁵, K. Murata⁶, Y. Hirano⁷, M. Shimomura⁸, T. Shunsuke², T. Hamaguchi⁹, Y. Kanemitsu¹⁰, ¹Oita University Faculty of Medicine, Yufu, JP, ²NCCH - National Cancer Center Hospital, Chuo-ku, JP, ³Shizuoka Cancer Center, Shizuoka, JP, ⁴National Cancer Center Hospital East, Kashiwa, JP, ⁵Yokohama City University Medical Center, Yokohama, JP, ⁶Kansai Rosai Hospital, Amagasaki, JP, ⁷Saitama Medical University International Medical Center, Saitama, JP, ⁸Hiroshima City Asa Citizens Hospital, Hiroshima, JP, ⁹Saitama Medical University International Medical Center, Hidaka, JP, ¹⁰National Cancer Center Hospital-Tsukiji Campus, Tokyo, JP
- 09:45 - 09:46 **417P - Randomized phase II trial of upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy versus preoperative chemoradiotherapy followed by surgery and adjuvant chemotherapy in locally advanced rectal cancer: KCSG-CO14-10**
S.-H. Beom¹, S.H. Park², J.B. Ahn¹, H.S. Kim¹, S.J. Shin², K.Y. Lee³, B.S. Min³, N.K. Kim², T. Kim⁴, ¹Yonsei University, Seoul, KR, ²Yonsei University College of Medicine, Seoul, KR, ³Yonsei Cancer Center Yonsei University, Seoul, KR, ⁴Severance Hospital - Yonsei University College of Medicine, Seoul, KR

- 09:46 - 09:47 **418P - Colorectal cancer lung metastases resection and its impact on survival in the oligometastatic setting**
J. Ruffinelli Rodriguez¹, E. Guinó¹, A. Ruiz Valderrama¹, G. Ibañez², I. Macia Vidueira², S. Padrones Sanchez², A. Navarro Martin³, C. Santos Vivas⁴, ¹Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat, Barcelona, ES, ²Hospital Universitari de Bellvitge, Hospitalet de Llobregat, ES, ³ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, ⁴Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), CIBERONC, L'Hospitalet de Llobregat, ES
- 09:47 - 09:48 **419P - Transanal endoscopic microsurgery for local regrowth after curative radio-chemotherapy for rectal cancer**
A. Larsen¹, L. Poulsen Oestergaard², M. Mikalonis¹, J.D. Nielsen¹, L.H. Jensen³, ¹Aalborg Universitetshospital - Region Nordjylland, Aalborg, DK, ²Aalborg University Hospital, Aalborg, DK, ³Vejle Hospital, University Hospital of Southern Denmark, Vejle, DK
- 09:48 - 09:49 **420P - The role of HIPEC in the management of gastrointestinal and biliary tract malignancies: Systematic review and meta-analysis of randomized data**
P. Filis¹, A. Kanellopoulou², A. Gogadis¹, N. Filis², K. Kamposioras³, F. Kapoulitsa¹, D. Mauri¹, ¹University Hospital of Ioannina, Ioannina, GR, ²UOI - University of Ioannina, Ioannina, GR, ³The Christie NHS Foundation Trust, Manchester, GB
- 09:49 - 09:50 **421P - Ghost stoma – solving the dilemma of diversion after anterior resection: A single centre experience from India**
N. Sharma¹, S. Patni², N. Modi², ¹All India Institute of Medical Sciences, Jodhpur, Jodhpur, IN, ²BMCHRC - Bhagwan Mahaveer Cancer Hospital and Research Centre, Jaipur, IN
- 09:50 - 09:51 **422P - Nivolumab (NIV) plus FOLFOXIRI/bevacizumab (BEV) as first-line (1L) in metastatic colorectal cancer (mCRC) RAS/BRAF mutated (mut) patients, regardless of microsatellite status: Results of phase II NIVACOR Trial (GOIRC-03-2018)**
A. Damato¹, F. Bergamo², L. Antonuzzo³, G. Nasti⁴, F. Pietrantonio⁵, G. Tonini⁶, E. Maiello⁷, R. Bordonaro⁸, D. Bilancia⁹, A. Romagnani¹, F. Iachetta¹, M. Larocca¹, G. Maglietta¹⁰, N. Normanno¹¹, C. Pinto¹, ¹Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, IT, ²IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ³AOUC - Azienda Ospedaliero-Universitaria Careggi, Firenze, IT, ⁴Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁵Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁶Policlinico Universitario Campus Bio-Medico, Rome, IT, ⁷IRCCS Fondazione Casa Solievo della Sofferenza, San Giovanni Rotondo, IT, ⁸Azienda Ospedaliera ARNAS Garibaldi, Catania, IT, ⁹Azienda Ospedaliera Regionale S. Carlo di Potenza, Potenza, IT, ¹⁰Azienda Ospedaliero Universitaria di Parma, Parma, IT, ¹¹Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT
- 09:51 - 09:52 **423P - Fruquintinib plus sintilimab in refractory repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Preliminary clinical results and biomarker analyses from a phase II study**

W. Zhang¹, Y. Sun¹, Z. Jiang¹, T. Liu¹, C. Gong¹, L. Yang¹, Y. Xin², D. Huang², A. Zhou¹,
¹Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, ²3D Medicines Inc., Shanghai, CN

09:52 - 09:53

424P - Avelumab added to FOLFIRI plus cetuximab followed by avelumab maintenance in patients with previously untreated RAS wild-type colorectal cancer: The phase-II FIRE-6 (AIO KRK-0118)

S. Stintzing¹, T. Dechow², U. Vehling-Kaiser³, S. Lorenzen⁴, C.-V. Hannig⁵, I. Schwaner⁶, L. Fischer Von Weikersthal⁷, G. Puchtler⁸, M. Binder⁹, S. Held¹⁰, K. Heinrich¹¹, V. Heinemann¹², ¹Charité - Universitätsmedizin Berlin, Berlin, DE, ²Oncology, Ravensburg, DE, ³ÜBAG-MVZ Dr. Vehling-Kaiser GmbH, Landshut, DE, ⁴Klinikum Rechts der Isar, Technische Universität München, Munich, DE, ⁵Schwerpunktpraxis Haematologie / Onkologie, Bottrop, DE, ⁶Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, DE, ⁷Klinikum St. Marien Amberg, Amberg, DE, ⁸RoMed Klinikum Rosenheim, Rosenheim, DE, ⁹Martin Luther University of Halle, Halle (Saale), DE, ¹⁰ClinAssess Klinische Forschungs GmbH, Leverkusen, DE, ¹¹Hospital Munich Grosshadern - Ludwig-Maximilians-University (LMU), Munich, DE, ¹²University Hospital, LMU Munich, Munich, DE

09:53 - 09:54

425P - Novel CoupledCAR technology for treating colorectal cancer

J. Cui¹, N. Chen¹, C. Pu², L. Zhao¹, C. Wang¹, R. Zhu², T. Liang¹, X. Huang², H. Tang², Y. Wang¹, H. Yang², B. Jia², W. Wang², D. Chen², E. Kennedy³, G. Cui¹, Z. Wu², L. Xiao²,
¹The First Hospital of Jilin University, Changchun, CN, ²Innovative Cellular Therapeutics (ICT), Shanghai, CN, ³Innovative Cellular Therapeutics (ICT), Maryland, US

09:54 - 09:55

426P - Assessing nivolumab in class II expressing microsatellite stable (pMMR) colorectal cancer (CRC): Results of the ANICCA-Class II trial

G. Middleton¹, W. Liu¹, J. Savage¹, J. Bridgewater², P. Ross³, M. Saunders⁴, R. Plummer⁵, S. Clive⁶, V. Coyle⁷, A. Thomas⁸, P. Tanriere⁹, L. Billingham¹, ¹University of Birmingham, Birmingham, GB, ²University College London, London, GB, ³Guy's & St Thomas NHS Foundation Trust, London, GB, ⁴The Christie NHS Foundation Trust, Manchester, GB, ⁵Newcastle University, Newcastle-upon-Tyne, GB, ⁶Western General Hospital, Edinburgh, GB, ⁷Queen's University Belfast, Belfast, GB, ⁸University of Leicester, Leicester, GB, ⁹University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB

09:55 - 09:56

427P - Targeting adenosine (ADO) to improve the efficacy of combinations of cetuximab (CET) and immunotherapy in EGFRvIII MSS colorectal cancer (CRC)

M. Shi¹, F. Sun¹, F. Yao¹, S. Li¹, Y. Zhao², B. Liang¹, Q. Wu¹, X. Rong¹, Z. Yao¹, X. Xu¹, J. Wang¹, C. Zeng¹, G. Chen¹, Q. Huang¹, W. Liao¹, ¹Nanfang Hospital of Southern Medical University, Guangzhou, CN, ²The University of Texas MD Anderson Cancer Center, Houston, US

09:56 - 09:57

428P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Preliminary results of TRAP study

J. Zhang¹, Q. Dong¹, Y. Wang¹, Y. Diao¹, X. Cui², L. Man³, J. Zhang⁴, Y. Zhang⁵, T. Wu⁶, Y. Dong³, J. Zhang⁷, Y. Huang⁸, S. Wang⁹, ¹Liaoning Cancer Hospital & Institute, Shenyang,

CN, ²Chaoyang Central Hospital, Chaoyang, CN, ³Anshan Cancer Hospital, Anshan, CN, ⁴Liaoyang Central Hospital of China Medical University, Liaoyang, CN, ⁵General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fushun, CN, ⁶the Second Hospital of Dalian Medical University, Dalian, CN, ⁷Panjin Central Hospital, Panjin, CN, ⁸Liaoyang county Central Hospital, Liaoyang, CN, ⁹Shengjing Hospital of China Medical University, Shenyang, CN

09:57 - 09:58

429P - Management of localized anal cancer and prognostic factors in the elderly: Results of the French multicenter cohort FFCD 2013; ANABASE

C. Gouriou¹, C. Lemanski², P. Pommier³, K. Le Malicot⁴, A. Saint⁵, E. Rivin Del Campo⁶, C. Evin⁶, L. Quero⁷, P. Regnault De La Motte⁸, N. Baba Hamed⁹, R. Philippe¹⁰, G. Crehange¹¹, D. Tougeron¹², E. Menager-Tabourel¹³, O. Diaz¹⁴, M. Hummelsberger¹⁵, A. De La Rochefordière¹¹, F. Drouet¹⁶, V. Vendrely¹⁷, A. Lievre¹, ¹CHU de Rennes - Hopital Pontchaillou, Rennes, Cedex, FR, ²ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ³CRCL - Centre de recherche en cancerologie de Lyon, Lyon, Cedex, FR, ⁴Fédération Francophone de Cancérologie Digestive, Dijon, FR, ⁵Hopital del l'Archet, Nice, FR, ⁶Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR, ⁷Hopital Saint Louis AP-HP, Paris, FR, ⁸Clinique Tivoli Ducos, Bordeaux, FR, ⁹ONCO CARC CANCER, Issy-les-Moulineaux, FR, ¹⁰Centre Azureen Cancerologie, Mougins, FR, ¹¹Institut Curie, Paris, FR, ¹²CHU Poitiers - Jean Bernard Hôpital, Poitiers, FR, ¹³CHD Vendee - Hopital Les Oudairies, La Roche-sur-Yon, FR, ¹⁴Institut Daniel Hollard, Grenoble, FR, ¹⁵Oncodoc, Béziers, FR, ¹⁶Clinique Mutualiste de l'Estuaire, Saint-Nazaire, FR, ¹⁷CHU de Bordeaux, Hôpital Haut-Lévêque, PESSAC, FR

09:58 - 09:59

430P - Prediction of pathologic complete response to preoperative (chemo)radiotherapy and/or chemotherapy in rectal cancer using clinical and imaging parameters

M. Karimi¹, P. Osterlund², K. Hammarström³, I. Imam³, J.-E. Froedin⁴, B. Glimelius⁵, ¹Karolinska University Hospital-Solna, Solna, SE, ²Tampere University Hospital (Tays), Tampere, FI, ³Uppsala University, Uppsala, SE, ⁴Tema Cancer, Karolinska University Hospital, Solna, SE, ⁵Uppsala Universitet, Uppsala, SE

09:59 - 10:00

431P - Neoadjuvant treatment with regorafenib and capecitabine combined with radiotherapy in locally advanced rectal cancer: A multicenter phase Ib trial (RECAP) SAKK 41/16

S. Bastian¹, M. Joerger², D. Baertschi³, L. Holer³, M. Guckenberger⁴, W. Jochum², D. Koeberle⁵, A. Siebenhüner⁶, M. Berger⁷, R. Winterhalder⁸, C. Largiadèr⁹, M. Löffler-Baumann¹⁰, K. Mosna- Firlejczyk⁵, A. Wicki¹¹, A. Fischer Maranta¹², R. Von Moos¹², ¹Kantonsspital Graubünden, Chur, CH, ²Kantonsspital St. Gallen, St. Gallen, CH, ³SAKK - Swiss Group for Clinical Cancer Research, Bern, CH, ⁴University Hospital of Zurich, University of Zurich, Zurich, CH, ⁵St. Claraspital AG, Basel, CH, ⁶Kantonsspital Schaffhausen, Schaffhausen, CH, ⁷Inselspital - Universitätsklinik für Medizinische Onkologie, Bern, CH, ⁸Luzerner Kantonsspital, Luzern, CH, ⁹Inselspital, Bern, CH, ¹⁰St. Claraspital, Basel, CH, ¹¹University Hospital Basel - Department of Oncology, Basel, CH, ¹²KSGR - Kantonsspital Graubünden, Chur, CH

10:00 - 10:01

432P - Determinants of pre-surgical treatment in primary rectal cancer: A population-based study

I. Imam¹, K. Hammarström¹, B. Glimelius², ¹Uppsala University, Uppsala, SE, ²University Hospital Uppsala/Akademiska Sjukhuset, Uppsala, SE

- 10:01 - 10:02 **433P - Pre-treatment and post-treatment MRI extramural venous invasion, predicts disease-free survival and overall survival, in locally advanced rectal cancer**
L. Fernández Mañas, F.J. Muñoz I Carrillo, C. Perez-Serrano, H. Oliveres, F.B. De Lacy, A. Otero, R. Bravo, R. Almenara, M. Pages, M.J. Moreno, M. Cuatrecasas, M. Pellise, C. Conill, A. De Lacy, J. Maurel, J.-R. Ayuso, Hospital Clinic y Provincial de Barcelona, Barcelona, ES
- 10:02 - 10:03 **434P - Cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma: A single center experience**
M. Valery, B. Cervantes, C. Smolenschi, V. Boige, A. Boileve, D. Malka, A. Hollebecque, M. Ducreux, Gustave Roussy, Villejuif, FR
- 10:03 - 10:04 **435P - Cisplatin versus mitomycin plus fluoropyrimidine and radiation for localized squamous cell carcinoma of the anus (SCCA): Final results of GTG-LACOG 1318 real-world data study**
R. Riechelmann¹, A. Kruschewsky Coutinho Araujo², G. Dos Santos Fernandes³, R. Weschenfelder⁴, D. Rocha Filho⁵, L.A. Schlittler⁶, J. Rego⁷, G. Prolla⁸, R. De Jesus⁹, G. Gössling⁹, R. D'Alpino Peixoto¹⁰, ¹A.C. Camargo Cancer Center - Unidade Antonio Prudente, Sao Paulo, BR, ²Clinica AMO Itaigara, Salvador, BR, ³Hospital Sirio-Libanes - Centro de Oncologia Asa Sul, Brasilia, BR, ⁴Hospital Moinhos de Vento, Porto Alegre, BR, ⁵Fujiday Cancer Center and Hematology - Oncologia D'Or, Fortaleza, BR, ⁶Hospital São Vicente de Paulo, Passo Fundo, BR, ⁷Hospital Universitário Onofre Lopes, Natal, BR, ⁸Hospital Sao Lucas da PUCRS, Porto Alegre, BR, ⁹Latin American Cooperative Oncology Group (LACOG), Porto Alegre, BR, ¹⁰Hospital Alemão Oswaldo Cruz, Sao Paulo, BR
- 10:04 - 10:05 **436TiP - COLSTAR: Randomized, open-label, multicentre, phase III study comparing futuximab/modotuximab plus trifluridine/tipiracil to trifluridine/tipiracil in KRAS/NRAS and BRAF wild type (wt) metastatic colorectal cancer (mCRC) previously treated with both standard and anti-EGFR treatment**
F. Ciardiello¹, T. Yoshino², D. Modest³, L. Martin Fernandez⁴, L. Roby⁴, R. Fougerey⁴, B. Lockhart⁴, J. Tabernero⁵, ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²National Cancer Center Hospital East, Kashiwa, JP, ³Charité - Universitätsmedizin Berlin, Berlin, DE, ⁴Institut de Recherches Internationales Servier, Suresnes, FR, ⁵Vall d'Hebron University Hospital, Barcelona, ES
- 10:05 - 10:06 **437TiP - Trial in progress: A phase III global study of sotorasib, a specific KRAS G12C inhibitor, in combination with panitumumab versus investigator's choice in chemorefractory metastatic colorectal cancer (CodeBreak 300)**
D. Paez¹, F. Meriggi², C. Cremolini³, G. Folprecht⁴, I. Korantzis⁵, E. Chan⁶, Q. Tran⁶, M. Fakih⁷, ¹Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ²Fondazione Poliambulanza Istituto Ospedaliero, Brescia, IT, ³Azienda Ospedaliera Universitaria Pisana, Pisa, IT, ⁴Universitätsklinikum Carl Gustav Carus, Dresden, DE, ⁵St Luke's Hospital-Agios Loukas Clinic, Thessaloniki, GR, ⁶Amgen Inc., Thousand Oaks, US, ⁷City of Hope Comprehensive Cancer Center, Duarte, US

- 10:06 - 10:07 **438TiP - MOUNTAINEER-03: Phase III study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2⁺ metastatic colorectal cancer (trial in progress)**
T. André¹, T. Bekaii-Saab², J. Tabernero³, S. Siena⁴, T. Yoshino⁵, K. Norwood⁶, D. Adelberg⁷, J. Ward⁸, S. Yang⁸, J. Strickler⁹, E. Van Cutsem¹⁰, ¹Hopital Saint-Antoine, Paris, FR, ²Mayo Clinic Cancer Center, Phoenix, US, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴ASST Grande Ospedale Metropolitano Niguarda, Milan, IT, ⁵National Cancer Center Hospital East, Kashiwa, JP, ⁶MSD-Merck Sharp & Dohme, Kenilworth, US, ⁷Merck & Co., Inc., North Wales, US, ⁸Seagen Inc., Bothell, US, ⁹Duke Cancer Center, Durham, US, ¹⁰UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE
- 10:07 - 10:08 **439TiP - A phase II (ph2), randomized study of magrolimab with bevacizumab and FOLFIRI in previously treated patients with advanced inoperable metastatic colorectal cancer (mCRC)**
M. Fakih¹, M. Tejani², X. Ren³, D. Landes³, S. Werneke³, K. Curtis³, J. Hecht⁴, ¹City of Hope Comprehensive Cancer Center, Duarte, US, ²AdventHealth Cancer Institute, Orlando, US, ³Gilead Sciences, Inc., Foster City, US, ⁴David Geffen School of Medicine at UCLA, Santa Monica, US
- 10:08 - 10:09 **440TiP - TRESBIEN (OGSG 2101): Encorafenib, binimetinib and cetuximab for early relapse stage II/III BRAF V600E-mutated CRC**
S. Boku¹, H. Satake², T. Ohta³, S. Mitani⁴, K. Kawakami⁵, T. Matsumoto¹, E. Yamazaki⁶, H. Hasegawa⁷, T. Ikoma¹, M. Uemura⁸, T. Yamaguchi⁹, Y. Ishizuka¹⁰, Y. Kurokawa⁸, D. Sakai¹¹, H. Kawakami⁴, T. Shimokawa¹², T. Tsujinaka¹³, T. Kato¹⁴, T. Satoh¹⁵, Y. Kagawa¹⁶, ¹Kansai Medical University, Hirakata, JP, ²Kochi Medical School, Kochi, JP, ³Kansai Rosai Hospital, Amagasaki, JP, ⁴Kindai University - Faculty of Medicine, Osaka, JP, ⁵Keiyukai Sapporo Hospital, Sapporo, JP, ⁶Osaka Medical and Pharmaceutical University Hospital, Takatsuki, JP, ⁷National Hospital Organization, Osaka National Hospital, Osaka, JP, ⁸Graduate School of Medicine / Faculty of Medicine, Osaka University, Suita, JP, ⁹Osaka Medical and Pharmaceutical University Hospital, Osaka, JP, ¹⁰Osaka International Cancer Institute, Osaka, JP, ¹¹Osaka University Hospital, Osaka, JP, ¹²Wakayama Medical University, Wakayama, JP, ¹³Izumi Municipal Hospital Cancer Center, Izumi, JP, ¹⁴National Hospital Organization Osaka National Hospital, Osaka, JP, ¹⁵Osaka University Hospital, Suita, JP, ¹⁶Osaka General Medical Center, Osaka, JP
- 10:09 - 10:10 **441TiP - A multicenter, randomized, open-label, phase III study of anlotinib plus CAPEOX versus bevacizumab plus CAPEOX as first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer**
K. Ding¹, Y. Liu¹, Y. Song¹, D. Xu¹, J. Li¹, J. Wang², X. Chen³, R. Lin⁴, Y. Jiang⁵, Y. Zhang⁶, W. Zhang⁷, Y. Cheng⁸, X. Wu⁹, Y. Yuan¹, ¹The Second Affiliated Hospital of Zhejiang University School of Medicine - East Gate 1, Hangzhou, CN, ²Affiliated Hospital of Jining Medical College, Jining, CN, ³Henan Cancer Hospital, Zhengzhou, CN, ⁴Fujian Provincial Tumor Hospital, Fuzhou, CN, ⁵Cancer Hospital of Shantou University Medical College, Shantou, CN, ⁶The Affiliated Tumour Hospital of Harbin Medical University, Harbin, CN, ⁷Gansu Province People Hospital, Lanzhou, CN, ⁸Jilin Cancer Hospital, Changchun, CN, ⁹Affiliated Hospital of Jiangnan University, Wuxi, CN

- 10:10 - 10:11 **442TiP - A multicenter phase II clinical study evaluating the efficacy and safety of perioperative encorafenib, binimetinib plus cetuximab combination treatment in patients with surgically resectable BRAF V600E-mutant colorectal oligometastases (NEXUS)**
S. Kobayashi¹, H. Bando¹, A. Taketomi², T. Takamoto³, E. Shinozaki⁴, M. Shiozawa⁵, H. Hara⁶, K. Yamazaki⁷, K. Komori⁸, N. Matsushashi⁹, T. Kato¹⁰, Y. Kagawa¹¹, M. Yokota¹², E. Oki¹³, S. Takahashi¹⁴, T. Yoshino¹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Hokkaido University Hospital, Sapporo, JP, ³NCCH - National Cancer Center Hospital, Chuo-ku, JP, ⁴The Cancer Institute Hospital of JFCR, Koto-ku, JP, ⁵Kanagawa Cancer Center, Yokohama, JP, ⁶Saitama Cancer Center, Ina, JP, ⁷Shizuoka Cancer Center, Shizuoka, JP, ⁸Aichi Cancer Center Hospital, Nagoya, JP, ⁹Gifu University Hospital, Gifu, JP, ¹⁰National Hospital Organization Osaka National Hospital, Osaka, JP, ¹¹Osaka General Medical Center, Osaka, JP, ¹²Kurashiki Central Hospital, Kurashiki, JP, ¹³Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, ¹⁴Tokai University Hospital, Isehara, JP
- 10:11 - 10:12 **443TiP - Impact of a centralized tumour board on secondary intervention rate in patients with RAS mutant metastatic colorectal cancer after first-line treatment with FOLFOXIRI plus bevacizumab (FIRE-7, AIO-KRK-0120)**
A. Stahler¹, K. Heinrich², S. Stintzing¹, I. Jelas¹, J. Pratschke¹, W. Schöning¹, M. Angele³, J. D'Haese³, B. Gebauer¹, M. Seidensticker⁴, F. Streitparth⁴, W. Kunz⁴, S. Corradini⁴, C. Stromberger⁵, U. Vehling-Kaiser⁶, D. Zhang², A. Kurreck¹, A. Alig¹, D. Modest¹, V. Heinemann², ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, DE, ²University Hospital, LMU Munich, Munich, DE, ³LMU - Ludwig Maximilians University of Munich, Munich, DE, ⁴LMU Klinikum der Universität München, Munich, DE, ⁵Vivantes Klinikum Neukoelln, Berlin, DE, ⁶ÜBAG-MVZ Dr. Vehling-Kaiser GmbH, Landshut, DE
- 10:12 - 10:13 **444TiP - Trial in progress: A phase Ib study of sotorasib, a selective KRAS G12C inhibitor, in combination with panitumumab and FOLFIRI in treatment-naïve and previously treated metastatic colorectal cancer (CodeBreak 101)**
T. Masuishi¹, Y. Kuboki², M. Fakih³, J. Strickler⁴, M. Furqan⁵, E. Kim⁶, P. Cardona⁷, Q. Tran⁷, E. Chan⁷, D.S. Hong⁸, ¹Aichi Cancer Center Hospital, Nagoya, JP, ²National Cancer Center Hospital East, Kashiwa, JP, ³City of Hope Comprehensive Cancer Center, Duarte, US, ⁴Duke University Medical Center, Durham, US, ⁵University of Iowa, Iowa City, US, ⁶UC Davis Comprehensive Cancer Center, Sacramento, US, ⁷Amgen Inc., Thousand Oaks, US, ⁸University of Texas MD Anderson Cancer Center, Houston, US
- 10:13 - 10:14 **445TiP - VIVA trial: A randomized phase II study of adjuvant regorafenib plus durvalumab in stage IV colorectal cancer patients achieving the no evidence of disease state**
A. Pastorino¹, A. Puccini¹, V. Martelli¹, M. Grassi¹, M. Cremante¹, A. Gandini¹, S. Puglisi¹, F. Catalano¹, V. Murianni¹, A. Pessino¹, V. Andretta¹, S. Mammoliti¹, M.S. Sciallero¹, D. Comandini¹, G. Fornarini¹, F. Caprioni¹, G. Bregni², S. Barni³, R. Labianca⁴, A. Sobrero¹, ¹IRCCS Ospedale Policlinico San Martino, Genova, IT, ²Institut Jules Bordet, Brussels, BE, ³ASST Bergamo Ovest, Bergamo, IT, ⁴GISCAD Foundation, Vanzago, IT
- 10:14 - 10:15 **446TiP - Randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI)**

plus bevacizumab (BEV) vs. FTD/TPI for chemorefractory metastatic colorectal cancer (mCRC): ROBiTS/JCOG2014

K. Yamazaki¹, H. Satake², A. Takashima³, J. Mizusawa⁴, T. Kataoka⁴, H. Fukuda⁵, Y. Ishizuka⁶, Y. Suwa⁷, K. Numata⁸, N. Shibata², M. Asayama⁹, M. Yokota¹⁰, T. Tsushima¹, T. Ohta¹¹, T. Yamaguchi¹², T. Hamaguchi¹³, Y. Kanemitsu¹⁴, ¹Shizuoka Cancer Center, Shizuoka, JP, ²Kansai Medical University, Hirakata, JP, ³NCCH - National Cancer Center Hospital, Chuo-ku, JP, ⁴National Cancer Center - Tsukiji Campus, Chuo-ku, JP, ⁵NCCH - National Cancer Center Hospital, Tokyo, JP, ⁶Osaka International Cancer Institute, Osaka, JP, ⁷Yokohama City University Medical Center, Yokohama, JP, ⁸Kanagawa Cancer Center, Yokohama, JP, ⁹Saitama Cancer Center, Ina, JP, ¹⁰Kurashiki Central Hospital, Kurashiki, JP, ¹¹Kansai Rosai Hospital, Amagasaki, JP, ¹²Osaka Medical and Pharmaceutical University Hospital, Osaka, JP, ¹³Saitama Medical University International Medical Center, Hidaka, JP, ¹⁴National Cancer Center Hospital-Tsukiji Campus, Tokyo, JP

10:15 - 10:16 **447TiP - Neoadjuvant long-course chemoradiation plus tislelizumab (anti-PD1) for MMR-status-unscreened locally advanced rectal cancer: Study protocol for a phase II, 3-arm, randomized trial**

Y. Yang, K. Pang, Z. Zhang, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, CN

10:16 - 10:17 **448TiP - A multicenter single arm phase II trial evaluating the safety and the efficacy of panitumumab and irinotecan for patients with NeoRAS wild-type metastatic colorectal cancer (C-PROWESS trial)**

H. Osumi¹, N. Ishizuka², A. Takashima³, Y. Kumeoka⁴, D. Nakano⁵, M. Shiozawa⁶, T. Denda⁷, R. Sawada⁸, K. Ouchi⁹, T. Wakatsuki¹, N. Boku¹⁰, K. Kato³, K. Yamaguchi¹, E. Shinozaki¹, ¹The Cancer Institute Hospital of JFCR, Koto-ku, JP, ²Cancer Institute Hospital of the Japanese Foundation for Cancer Therapy, Tokyo, JP, ³NCCH - National Cancer Center Hospital, Chuo-ku, JP, ⁴Saitama Cancer Center Clinical Oncology Research Institute, Ina, JP, ⁵Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, JP, ⁶Kanagawa Cancer Center, Yokohama, JP, ⁷Chiba Cancer Center, Chiba, JP, ⁸Jikei University School of Medicine, Tokyo, JP, ⁹Tohoku University Hospital, Sendai, JP, ¹⁰IMS Hospital, Institute of Medical Science, University of Tokyo, Tokyo, JP

10:17 - 10:18 **449TiP - Evaluation of regorafenib treatment PERSONalization based on therapeutic drug monitoring in patients with metastatic colorectal cancer (mCRC): RePERSO study**

C. Tron¹, F. Lemaitre¹, C. Locher¹, T. Lecomte², C. Tournigand³, K. Bouhier Leporrier⁴, S. Le Sourd⁵, J.-P. Metges⁶, D. Tougeron⁷, F. Di Fiore⁸, C. Hervé⁹, M. Heran¹⁰, Y. Toucheffu¹¹, B. Rousseau¹², A. Hulin¹³, A. Lievre¹, ¹CHU de Rennes - Hopital Pontchaillou, Rennes, Cedex, FR, ²CHU de Tours, Hôpital Trousseau, Chambray-lès-Tours, FR, ³Henri Mondor University Hospital, Créteil, FR, ⁴CHU de Caen - Hopital Cote de Nacre, Caen, FR, ⁵Centre Eugène Marquis, Rennes, FR, ⁶CHU Morvan - Institut de Cancerologie et d'Hématologie, Brest, FR, ⁷CHU Poitiers - Jean Bernard Hôpital, Poitiers, FR, ⁸CHU de Rouen Normandie, Rouen, FR, ⁹Institut Daniel Hollard, Grenoble, FR, ¹⁰Hôpital Saint-Antoine, Paris, FR, ¹¹CHU du Nantes - Hôtel-Dieu, Nantes, Cedex, FR, ¹²MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ¹³Centre Hospitalier Universitaire Henri-Mondor AP-HP, Creteil, FR

- 10:18 - 10:19 **497P - Prognostic impact of venous and lymphatic invasion of pancreatic neuroendocrine neoplasm in patients undergoing resection**
J. Arita, S. Kiritani, A. Ichida, Y. Kawaguchi, N. Akamatsu, J. Kaneko, K. Hasegawa, The University of Tokyo, Bunkyo-ku, JP
- 10:19 - 10:20 **498P - Generation of CAR T cells expressing a scFV targeting the hTSHR in thyroid cancer**
M. Ali¹, L. Paschold¹, M. Bauer², C. Schultheiß¹, D. Owczarek¹, L. Müller¹, K. Lorenz³, B. Edemir¹, C. Wickenhauser², R. Latif⁴, S. Hüttelmaier⁵, C. Dierks¹, M. Binder¹, ¹Martin Luther University Halle-Wittenberg, Halle (Saale), DE, ²UKH - Universitätsklinikum Halle (Saale), Halle (Saale), DE, ³Department of Visceral, Vascular, and Endocrine Surgery, halle, DE, ⁴Icahn School of Medicine at Mount Sinai, James J. Peters VA Medical Center, New York, US, ⁵Martin Luther University Halle-Wittenberg, halle, DE
- 10:20 - 10:21 **499TiP - Surufatinib combined with sintilimab and IBI310 in the treatment of high-grade advanced-neuroendocrine neoplasm: A single arm, open-label, multicenter study**
M. Lu¹, Y. Wang², P. Zhang², L. Shen¹, ¹Peking University Cancer Hospital and Institute, Beijing, CN, ²Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN
- 10:21 - 10:22 **530P - PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety**
A.J. Gonzalez Martin¹, B. Pothuri², I. Vergote³, W. Graybill⁴, M.R. Mirza⁵, C. McCormick⁶, D. Lorusso⁷, G. Freyer⁸, F. Backes⁹, K. Baumann¹⁰, A. Redondo Sanchez¹¹, R. Moore¹², C. Vulsteke¹³, R. O'Cearbhaill¹⁴, I. Malinowska¹⁵, L. Shtessel¹⁵, N. Compton¹⁵, B. Monk¹⁶, ¹Grupo Español de Investigación en Cáncer de Ovario (GEICO), Clínica Universidad de Navarra, Madrid, ES, ²Gynecologic Oncology Group (GOG), Perlmutter Cancer Center, NYU Langone Health, New York, US, ³Belgium and Luxembourg Gynaecological Oncology Group (BGOG), University Hospitals Leuven, Leuven Cancer Institute, Leuven, BE, ⁴GOG, Medical University of South Carolina, Charleston, US, ⁵NSGO, Rigshospitalet-Copenhagen University Hospital, Copenhagen, DK, ⁶Legacy Medical Group, Portland, Or, US, ⁷Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO), Fondazione Policlinico Gemelli IRCCS National Cancer Institute of Milan, Milan, IT, ⁸Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), HCL Cancer Institute Lyon University, Lyon, FR, ⁹Ohio State University, Columbus, US, ¹⁰Arbeitsgemeinschaft Gynäkologische Onkologie (AGO), Klinikum der Stadt Ludwigshafen, Ludwigshafen, DE, ¹¹GEICO, Hospital Universitario La Paz-IdiPAZ, Madrid, ES, ¹²USOR, Division of Gynecologic Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, US, ¹³BGOG, AZ Maria Middelaers, Center for Oncological Research, Antwerp University, Antwerp, BE, ¹⁴GOG, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, US, ¹⁵GlaxoSmithKline, Middlesex, GB, ¹⁶University of Arizona College of Medicine, Phoenix Creighton University,, Phoenix, US
- 10:22 - 10:23 **531P - Maintenance olaparib monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) without a germline BRCA1/BRCA2 mutation (non-gBRCAm): Final overall survival (OS) results from the OPINION trial**
A.M. Poveda Velasco¹, S. Lheureux², N. Colombo³, D. Cibula⁴, M. Elstrand⁵, J. Weberpals⁶, M. Bjurberg⁷, A. Oaknin⁸, M. Sikorska⁹, A.J. Gonzalez Martin¹⁰, R. Madry¹¹,

M.J. Rubio Perez¹², J. Ledermann¹³, O. Ozgoren¹⁴, A. Barnicle¹⁴, H. Marshall¹⁴, Z. Bashir¹⁴, E. Skof¹⁵, ¹Initia Oncology, Valencia, ES, ²Princess Margaret Hospital, Toronto, CA, ³University of Milan-Bicocca, European Institute of Oncology IRCCS, Milan, IT, ⁴General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, CZ, ⁵Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NO, ⁶Ottawa Hospital Research Institute, Ottawa, CA, ⁷Skåne University Hospital, Lund University, Lund, SE, ⁸Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, ⁹Olsztyn Provincial Specialist Hospital, Olsztyn, PL, ¹⁰Clinica Universidad de Navarra, Madrid, ES, ¹¹Poznan University of Medical Sciences, and PGOG, Poznań, PL, ¹²Hospital Universitario Reina Sofía, Cordoba, ES, ¹³University College London and UCL Hospitals, London, GB, ¹⁴AstraZeneca, Cambridge, GB, ¹⁵Institute of Oncology Ljubljana, Ljubljana, SI

10:23 - 10:24

532P - Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)

K. Moore¹, A. Oza², N. Colombo³, A. Oaknin⁴, G. Scambia⁵, D. Lorusso⁶, S. Banerjee⁷, C. Murphy⁸, J. Konner⁹, P. Lim¹⁰, M. Prasad-Hayes¹¹, B. Monk¹², J. Wang¹³, M. Birrer¹⁴, I. Vergote¹⁵, ¹Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, ²UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ³IEO - Istituto Europeo di Oncologia, Milan, IT, ⁴Vall d'Hebron University Hospital, Barcelona, ES, ⁵Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ⁶Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome, Rome, IT, ⁷The Royal Marsden Hospital - Chelsea, London, GB, ⁸Bon Secours Hospital, Cork, IE, ⁹Memorial Sloan Kettering Cancer Center, New York, US, ¹⁰Center of Hope Reno, Reno, US, ¹¹Mount Sinai Hospital, Chicago, US, ¹²Arizona Oncology (US Oncology Network), Phoenix, US, ¹³ImmunoGen, Inc., Waltham, US, ¹⁴UAMS - University of Arkansas for Medical Sciences, Little Rock, US, ¹⁵UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

10:24 - 10:25

533P - Real-world data of treatment and outcome of patients with relapsed ovarian cancer (OC) in Germany (QS ovar of the AGO study group)

P. Harter¹, A. Du Bois¹, F. Hilpert², M. Kerkmann³, J. Sehouli⁴, S. Mahner⁵, N. De Gregorio⁶, L. Hanker⁷, F. Heitz¹, F. Marmé⁸, L. Woelber⁹, L. Holtmann³, G. Elser¹⁰, J. Pfisterer¹¹, ¹Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen, DE, ²Krankenhaus Jerusalem, Hamburg, DE, ³MMF Münster, Münster, DE, ⁴Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, ⁵University Hospital, LMU Munich, München, DE, ⁶SLK-Kliniken Heilbronn GmbH, Heilbronn, DE, ⁷University SH.-Lübeck, Lübeck, DE, ⁸Heidelberg University, University Hospital Mannheim, Mannheim, DE, ⁹AGO & Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE, ¹⁰AGO Research GmbH, Wiesbaden, DE, ¹¹Gynäkologie und Gynäkologische Onkologie Kiel - Prof. Dr. Jacobus Pfisterer, Kiel, DE

10:25 - 10:26

534P - A pilot study of neoadjuvant olaparib for patients with HRD-positive advanced ovarian cancer

K. Harano¹, T. Nakao¹, S. Nishio², T. Katsuda², K. Tasaki², K. Takehara³, T. Yokoyama³, H. Furuya¹, K. Hongo¹, M. Asano¹, T. Ikeno¹, M. Wakabayashi¹, A. Sato¹, H. Tanabe¹, T. Taki¹, R. Watanabe¹, G. Ishii¹, T. Mukohara¹, ¹National Cancer Center Hospital East,

Kashiwa, JP, ²Kurume University, Kurume, JP, ³National Hospital Organization Shikoku Cancer Center, Matsuyama, JP

10:26 - 10:27 **535P - Long term quality of life after chemotherapy among nonepithelial ovarian cancer survivors: The case-control vivrovaire rare tumours study**

F. Joly Lobbedez¹, I. Ray-Coquard², S. Lefevre Arbogast¹, J.-M. Grellard¹, B. Clarisse³, A. Floquet⁴, F. Selle⁵, D. Berton-Rigaud⁶, S. Frank⁷, T. De La Motte Rouge⁸, E. Kalbacher⁹, M. Provansal Gross¹⁰, A. Lortholary¹¹, H. Orfeuvre¹², J. Alexandre¹³, P. Augereau¹⁴, J.E. Kurtz¹⁵, C. Nadeau¹⁶, P. Pautier¹⁷, F. Gernier¹, ¹Centre Francois Baclesse, Caen, Cedex, FR, ²Centre Léon Bérard, and GINECO, Lyon, FR, ³Comprehensive Cancer Centre François Baclesse, Caen, Cedex, FR, ⁴Institut Bergonié, Comprehensive Cancer Centre and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Bordeaux, FR, ⁵Groupe Hospitalier Diaconesses Croix Saint-Simon, and GINECO, Paris, FR, ⁶GINECO & Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain, FR, ⁷Institut Curie, Paris, FR, ⁸UNICANCER/Centre Eugene - Marquis/GINECO, Rennes, FR, ⁹CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, ¹⁰Institute Paoli Calmettes, Marseille, FR, ¹¹Centre Catherine de Sienne, Hopital privé du Confluent, and GINECO, Nantes, FR, ¹²Ch Fleyriat, Bourg En Bresse, FR, ¹³Hopital Cochin - Site Port-Royal AP-HP, Paris, FR, ¹⁴ICO - Institut de Cancerologie de l'Ouest - Site Paul Papin, ANGERS, FR, ¹⁵ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ¹⁶CHU Poitiers - Jean Bernard Hôpital, Poitiers, FR, ¹⁷Institut Gustave Roussy, Villejuif, Cedex, FR

10:27 - 10:28 **536P - Relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: Phase II subgroup analysis mirroring the patient population of an upcoming phase III study**

N. Colombo¹, T. Van Gorp², U. Matulonis³, A. Oaknin⁴, R. Grisham⁵, G. Fleming⁶, A. Olawaiye⁷, I.C. Tudor⁸, H. Pashova⁸, D. Lorusso⁹, ¹University of Milan-Bicocca, European Institute of Oncology IRCCS, Milan, IT, ²University Hospitals Leuven - Leuven Cancer Institute, Leuven, BE, ³Dana Farber Cancer Institute, Boston, US, ⁴Vall d'Hebron University Hospital, Barcelona, ES, ⁵Memorial Sloan Kettering Cancer Center, New York, US, ⁶University of Chicago, Chicago, US, ⁷University of Pittsburgh - Magee-Women's Hospital, Pittsburgh, US, ⁸Corcept Therapeutics, Menlo Park, US, ⁹Fondazione Universitario A. Policlinico Gemelli IRCCS and Catholic University of Sacred Heart, Rome, IT

10:28 - 10:29 **537P - A phase I/II study of oral chk1 inhibitor LY2880070 in combination with low-dose gemcitabine in patients with advanced or metastatic ovarian cancer**

W. Miller¹, A. Shields², D. Provencher³, L. Gilbert⁴, G. Shapiro⁵, A. Oza⁶, J. Spratlin⁷, S. Lheureux⁶, G. Bhat⁶, S. Salvador¹, P. Nunes³, S. Lau¹, I. Weiner², J. Keene², S. Zaknoen⁸, P. Smith⁹, J. Stille⁹, D. Vincett¹⁰, Q.S.-C. Chu¹¹, ¹Jewish General Hospital McGill University, Montreal, CA, ²Karmanos Cancer Institute, Detroit, US, ³CRCHUM - Centre de recherche du CHUM, Montreal, CA, ⁴McGill University Health Centre - Cedars Cancer Center, Montreal, CA, ⁵Dana Farber Cancer Institute, Boston, US, ⁶UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ⁷Alberta Health Services - Holy Cross Centre, Calgary, CA, ⁸Esperas Pharma Inc, Montreal, US, ⁹Eli Lilly and Company, New York, US, ¹⁰Ozmosis Reseach Inc., Toronto, CA, ¹¹Cross Cancer Institute, Edmonton, CA

- 10:29 - 10:30 **538P - Adding plasmid encoding p62/SQSTM1 to gemcitabine chemotherapy increases PFS for patients with platinum-resistant ovarian cancer (updated data)**
Y. Baranau¹, S. Polyakov², V. Gabai³, K. Zharkova², A. Filimonava¹, V. Siarheyeva², A. Khorau², S. Kazlouskaya², S. Krasny², A. Shneider³, ¹Minsk City Clinical Oncologic Centre, Minsk, BY, ²N. N. Alexandrov National Cancer Centre of Belarus, Minsk, BY, ³CureLab Oncology, Inc., Dedham, US
- 10:30 - 10:31 **540P - Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: A systematic review and meta-analysis of randomized trials**
D. Mauri¹, P. Filis¹, G. Markozannes², N. Filis³, K. Tsilidis², ¹University Hospital of Ioannina, Ioannina, GR, ²St. Mary's Hospital Imperial College Healthcare NHS Trust, London, GB, ³UOI - University of Ioannina, Ioannina, GR
- 10:31 - 10:32 **541P - Efficacy of various anticancer agents after failure of maintenance olaparib: A retrospective study**
A. Rumyantsev¹, A. Tyulyandina¹, E. Glazkova², I. Pokataev¹, S. Tjulandin³, ¹N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ²N.N. Blokhin Russian Cancer Research Center, Moscow, RU, ³National Medical Research Center of Oncology named after N.N. Blokhin, Moscow, RU
- 10:32 - 10:33 **542P - Efficacy of PARPi monotherapy and the impact of subsequent platinum-based chemotherapy in BRCA1/2 mutant ovarian cancer patients with secondary platinum-sensitive relapse**
K. Song¹, Y. Ma¹, N. Li², H. Bu¹, Y. Huang³, C. Jin⁴, H. Wen⁵, S. Feng⁶, H. Zhang⁷, L. Wu⁸, ¹Qilu Hospital of Shandong University, Jinan, CN, ²Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, ³Sun Yat-sen University Cancer Center, Guangzhou, CN, ⁴Shanghai First People's Hospital - Southern Division, Shanghai, CN, ⁵Fudan University Shanghai Cancer Center, Shanghai, CN, ⁶Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN, ⁷The Fourth Hospital of Hebei Medical University, Shijiazhuang, CN, ⁸National Cancer Center/National Clinical Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN
- 10:33 - 10:34 **543P - Can we predict the long and short-term survivors with advanced ovarian cancer?**
E. Shachar¹, Y. Raz², S. Peleg Hasson¹, B. Levy¹, L. Adar³, Z.G. Honig⁴, N. Mischon², I. Laskov², D. Grisaru², I. Wolf¹, T. Safra⁴, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, IL, ²Tel Aviv Sourasky Medical Center - Ichilov, Tel Aviv, IL, ³Technion - Israel Institute of Technology, Haifa, IL, ⁴Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL
- 10:34 - 10:35 **544P - Feasibility of two different first-line carboplatin plus paclitaxel regimens in elderly women with ovarian cancer: A retrospective study**
N. Delanoy¹, E. Ashton¹, S. Mebarki², M. Gisselbrecht², B. Nicaise¹, H. Azais³, M. Koual³, A.-S. Bats Mongardon³, L. Fournier³, M.-A. Le Frère-Belda³, J. Medioni¹, E. Paillaud², S. Oudard¹, ¹Hopital European George Pompidou, Paris, FR, ²Hopital European Georges Pompidou, Paris, FR, ³HEGP - Hopital European Georges-Pompidou -

AP-HP, Paris, FR

- 10:35 - 10:36 **545P - The synergistic effect of treosulfan and irinotecan in the treatment of platinum-resistant ovarian cancer**
- N. Konoplya¹, K. Zharkova², U. Korsik¹, V. Kalenik³, ¹State Institution "N. N. Alexandrov National Cancer Centre of Belarus", Minsk, BY, ²State Institution N. N. Alexandrov National Cancer Centre of Belarus, Lesnoy - Minsk District, BY, ³N.N. Alexandrov National Cancer Center of Belarus, Minsk, BY
- 10:36 - 10:37 **546P - Pembrolizumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer: Long-term follow-up results from KEYNOTE-158**
- D. O'Malley¹, G. Bariani², P. Cassier³, A. Marabelle⁴, A. Hansen⁵, A. De Jesus-Acosta⁶, W. Miller⁷, T. Safra⁸, A. Italiano⁹, L. Mileschkin¹⁰, L. Yao¹¹, A. Gozman¹¹, F. Jin¹¹, M. Maio¹², ¹The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, Columbus, US, ²Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, BR, ³Centre Léon Bérard, 69008, Lyon, FR, ⁴Gustave Roussy, Institut National de la Santé et de la Recherche Médicale (INSERM) U1015, Université Paris Saclay, Villejuif, FR, ⁵Princess Margaret Cancer Centre, Toronto, CA, ⁶Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, US, ⁷Jewish General Hospital, Rossy Cancer Network and Departments of Oncology and Medicine, McGill University, Montreal, CA, ⁸Tel Aviv Medical Center, Tel Aviv and Sackler School of Medicine, Tel Aviv University, Tel Aviv, IL, ⁹Institut Bergonie, Bordeaux, FR, ¹⁰The University of Melbourne, Melbourne, AU, ¹¹Merck & Co., Inc., Rahway, US, ¹²University of Siena and Center for Immuno-Oncology, University Hospital, Siena, IT
- 10:37 - 10:38 **547P - Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study**
- A. Oaknin¹, B. Pothuri², L. Gilbert³, R. Sabatier⁴, J. Brown⁵, S. Ghamande⁶, C. Mathews⁷, D. O'Malley⁸, V. Boni⁹, A. Gravina¹⁰, S. Banerjee¹¹, R. Miller¹², J. Pikiel¹³, M.R. Mirza¹⁴, T. Duan¹⁵, X. Han¹⁵, S. Zildjian¹⁶, N. Dewal¹⁶, J. Veneris¹⁶, A. Tinker¹⁷, ¹Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, ²Gynecologic Oncology Group (GOG), Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, US, ³McGill University Health Centre - Cedars Cancer Center, Montreal, CA, ⁴Institut Paoli Calmettes, Aix-Marseille University, Marseille, FR, ⁵Levine Cancer Institute, Carolinas HealthCare System, Charlotte, US, ⁶Georgia Cancer Center, Augusta University, Augusta, US, ⁷Women & Infants Hospital - Warren Alpert Medical School of Brown Univ, Providence, US, ⁸The Ohio State University and the James Cancer Center, Columbus, US, ⁹*At the time of study START Madrid CIOCC, Currently NEXT Oncology Hospital Universitario Quirónsalud Madrid, Madrid, ES, ¹⁰Clinical Trial Unit, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, IT, ¹¹The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, GB, ¹²University College London, St. Bartholomew's Hospitals London, London, GB, ¹³Regional Center of Oncology, Gdansk, PL, ¹⁴Rigshospitalet, Copenhagen University Hospital, Denmark, Nordic Society of Gynaecologic Oncology-Clinical Trial Unit, Copenhagen, DK, ¹⁵GlaxoSmithKline, Pennington, US, ¹⁶GlaxoSmithKline, Waltham, US, ¹⁷British Columbia Cancer, Vancouver Centre, University of British Columbia, Vancouver, CA

- 10:38 - 10:39 **548P - Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study**
- A. Tinker¹, B. Pothuri², L. Gilbert³, R. Sabatier⁴, J. Brown⁵, S. Ghamande⁶, C. Mathews⁷, D. O'Malley⁸, V. Boni⁹, A. Gravina¹⁰, S. Banerjee¹¹, R. Miller¹², J. Pikiel¹³, M.R. Mirza¹⁴, T. Duan¹⁵, G. Antony¹⁶, S. Zildjian¹⁷, E. Zografos¹⁸, J. Veneris¹⁷, A. Oaknin¹⁹, ¹British Columbia Cancer, Vancouver Centre, University of British Columbia, Vancouver, CA, ²Gynecologic Oncology Group (GOG), Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, US, ³McGill University Health Centre, Montreal, CA, ⁴Institut Paoli Calmettes, Aix-Marseille University, Marseille, FR, ⁵Levine Cancer Institute, Atrium Health, Charlotte, US, ⁶Georgia Cancer Center, Augusta University, Augusta, US, ⁷Women and Infants Hospital of Rhode Island, Providence, US, ⁸The Ohio State University and the James Cancer Center, Columbus, US, ⁹At the time of study START Madrid CIOCC, Currently NEXT Oncology Hospital Universitario Quirónsalud Madrid, Madrid, ES, ¹⁰Clinical Trial Unit, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, IT, ¹¹The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, GB, ¹²University College London, St. Bartholomew's Hospitals London, London, GB, ¹³Regional Center of Oncology, Gdansk, PL, ¹⁴Rigshospitalet, Copenhagen University Hospital, Denmark, Nordic Society of Gynaecologic Oncology-Clinical Trial Unit, Copenhagen, DK, ¹⁵GlaxoSmithKline, Pennington, US, ¹⁶GlaxoSmithKline, Hertfordshire, GB, ¹⁷GlaxoSmithKline, Waltham, US, ¹⁸GlaxoSmithKline, London, GB, ¹⁹Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES

09:00 - 16:00 **Type: Poster session** **Poster Area, Hall 4**
Title: Poster session 18

- 09:00 - 09:01 **1751P - Impact of squamous histology on clinical outcomes and molecular profiling in metastatic urothelial carcinoma (mUC) patients (pts) treated with newer therapies**
- P. Deshmukh¹, I. De Kouchkovsky¹, L. Zhang¹, T. Jindal¹, K. Reyes¹, E. Hernandez Romero¹, E. Chan¹, A. Desai², H. Borno¹, D. Kwon¹, A. Wong¹, R. Bose¹, R. Aggarwal³, S. Porten¹, L. Fong¹, E. Small⁴, J. Chou¹, T. Friedlander¹, V. Koshkin⁴, ¹UCSF - University of California San Francisco, San Francisco, US, ²University of California San Francisco, San Francisco, US, ³UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US, ⁴UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
- 09:01 - 09:02 **1752P - Post hoc analysis of pembrolizumab efficacy in potentially platinum ineligible patients with urothelial carcinoma enrolled in KEYNOTE-052 and LEAP-011**
- Y. Loriot¹, T. Csomos², N. Matsubara³, S.J. Shin⁴, S.H. Park⁵, V. Atduev⁶, M. Gumus⁷, B. Karaca⁸, P. Grivas⁹, R. De Wit¹⁰, A. Siefker-Radtke¹¹, D. Castellano Gauna¹², P. O'Donnell¹³, T. Powles¹⁴, J. Vuky¹⁵, Y. Zhao¹⁶, K. O'Hara¹⁷, S. Franco¹⁶, B. Homety Moreno¹⁶, J. Zolnierak¹⁸, ¹Gustave Roussy, Université Paris-Saclay, Villejuif, FR, ²Jász-Nagykúnszabolcs County Hospital, Szabolcs, HU, ³National Cancer Center Hospital East, Chiba, JP, ⁴Severance Hospital, Seoul, KR, ⁵Samsung Medical Center, Seoul, KR, ⁶Volga District Medical Center, Federal Medical-Biological Agency, Nizhny Novgorod, RU, ⁷Istanbul Medeniyet University, Istanbul, TR, ⁸Tulay Aktas Onkoloji Hastanesi, Izmir

Bornova, TR, ⁹University of Washington and Fred Hutchinson Cancer Center, Seattle, US, ¹⁰Erasmus MC Cancer Institute, Rotterdam, NL, ¹¹The University of Texas MD Anderson Cancer Center, Houston, US, ¹²Hospital Universitario 12 de Octubre, Madrid, ES, ¹³The University of Chicago, Chicago, US, ¹⁴Barts Cancer Institute, Queen Mary University of London, London, GB, ¹⁵Oregon Health & Science University, Knight Cancer Institute, Portland, US, ¹⁶Merck & Co., Inc., Rahway, US, ¹⁷Eisai Inc., Nutley, US, ¹⁸LUXMED Oncology, Warsaw, PL

- 09:02 - 09:03 **1753P - Cost-effectiveness (CE) of nivolumab (NIVO) as adjuvant treatment of muscle invasive urothelial carcinoma at high risk of recurrence (MIUC-HR) in France**
S. Negrier¹, F. Colrat², J. Bonastre³, C. Chamielec⁴, S. Teitsson⁵, C. Knight⁶, L. Ni⁶, J. Chevalier⁴, A.-F. Gaudin², M. Roupert⁷, S. Branchoux², ¹CENTRE LEON BERARD, Lyon Cedex, FR, ²Bristol-Myers Squibb SARL, Rueil-Malmaison, FR, ³Institut Gustave Roussy, Villejuif, FR, ⁴Vyoo Agency, Paris, FR, ⁵Bristol Myers Squibb Pharmaceuticals Limited - Uxbridge, Uxbridge, GB, ⁶RTI Health Solutions, Manchester, GB, ⁷Sorbonne Université - Site Saint-Antoine, Paris, Cedex, FR
- 09:03 - 09:04 **1754P - Association between body mass index (BMI) and anti-PD1/L1 immune checkpoint inhibitor (ICI) outcomes in patients with metastatic urothelial carcinoma (mUC)**
S. Labidi¹, N. Meti², R. Barua³, J. Riromar⁴, A. Hansen⁵, D.M. Jiang⁵, N. Fallah-Rad⁵, S. Sridhar⁵, C. Ferrario¹, R. Pezo⁶, S. Cheng⁶, A. Sacher⁵, A. Rose¹, ¹Jewish General Hospital, Montreal, CA, ²St Mary's Hospital, Montreal, CA, ³Michael Garron Hospital, Toronto, CA, ⁴Royal hospital, Muscat, OM, ⁵UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ⁶Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA
- 09:04 - 09:05 **1755P - The impact of upfront transurethral resection of bladder tumor (TURBT) and intravesical BCG versus radical cystectomy on survival outcomes of high-risk non-muscle invasive bladder cancer: A meta-analysis of comparative studies**
P. Haddad¹, N. Khater², ¹LSU Feist Weiller Cancer Center/Overton Brooks VAMC, Shreveport, US, ²LSU Feist Weiller Cancer Center, Shreveport, US
- 09:05 - 09:06 **1756P - Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a nationwide, longitudinal, retrospective study in Hungary**
A.C. Maraz¹, B. Nagy², T. Macher², J. Jeskó², E. Tischler³, C. Csongvai³, M. Kearney⁴, ¹University of Szeged, Szeged, HU, ²Healthware Consulting Ltd., Budapest, HU, ³Merck Kft., Budapest, Hungary, an affiliate of Merck KGaA, Darmstadt, DE, ⁴Merck Healthcare KGaA, Darmstadt, DE
- 09:06 - 09:07 **1757P - Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC)**
P. Barthelemy¹, C. Thibault², E. Voog³, J.-C. Eymard⁴, A. Ravaud⁵, A. Flechon⁶, C.

Abraham Jaillon⁷, W. Hilgers⁸, S. Le Moulec⁹, M. Chasseray¹⁰, D. Pouessel¹¹, Y.E. Amela¹², V. Lorgis¹³, E. Nicolas¹⁴, E. Kazan¹⁵, G. Denechere¹⁶, M.-N. Solbes¹⁷, P. Lambert¹⁶, Y. Loriot¹⁸, ¹Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ²Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, FR, ³ILC groupe, Le Mans, Cedex, FR, ⁴Institut de Cancérologie Jean-Godinot, Reims, FR, ⁵Bordeaux University Hospital, Bordeaux University, Bordeaux, FR, ⁶Centre Leon Berard, Lyon, FR, ⁷Foch Hospital, Suresnes, FR, ⁸Avignon-Provence Cancer Institute, Avignon, FR, ⁹Groupe de radiothérapie et d'oncologie des pyrénées, clinique Marzet, Pau, FR, ¹⁰Clinique Pasteur, Brest, FR, ¹¹Institut Claudius Régaud-IUCT Oncopole, Toulouse, FR, ¹²Hôpital privé Le bois, Lille, FR, ¹³Institut de Cancérologie de Bourgogne, Dijon, FR, ¹⁴University Hospital of Nimes, Nimes, FR, ¹⁵Ramsay Health Group-Private Hospital Villeneuve d'Ascq, Villeneuve-d'Ascq, FR, ¹⁶Pfizer Oncology, Paris, FR, ¹⁷Merck Santé SAS, Lyon, France, an affiliate of Merck KGaA, Darmstadt, DE, ¹⁸Gustave Roussy, Université Paris-Saclay, Villejuif, FR

09:07 - 09:08

1758P - Characteristics, management and survival outcomes of French patients (pts) with muscle invasive bladder cancer (MIBC) at high risk of recurrence (MIBC-HR): A study based on the COBLAnCE cohort

A. Frasin¹, F. Colrat², M. Karimi³, J. Bonastre³, G. Karine⁴, S. Teitsson⁵, A. Prudent², S. Branchoux², F. Radvanyi⁶, S. Benhamou⁷, Y. Allory⁶, T. Lebreton⁸, ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Bristol-Myers Squibb SARL, Rueil-Malmaison, FR, ³Institut Gustave Roussy, Villejuif, FR, ⁴INSERM 1018, Villejuif, FR, ⁵Bristol Myers Squibb Pharmaceuticals Limited - Uxbridge, Uxbridge, GB, ⁶Institut Curie, Paris, FR, ⁷UVSQ Paris-Saclay, Versailles, FR, ⁸Hopital Foch, Suresnes, FR

09:08 - 09:09

1759P - Enfortumab vedotin in metastatic urothelial carcinoma: Retrospective multicentre patient cohort

C. Darr¹, S. Zschäbitz², G. Niegisch³, F. Roghmann⁴, P. Ivanyi⁵, F. Zengerling⁶, P. Paffenholz⁷, N. Biernath⁸, M. Klee⁹, N. Klümper¹⁰, R. Tauber¹¹, B. Hadaschik¹, T. Hilser¹², V. Gruenwald¹³, ¹University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ²NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE, ³Heinrich-Heine-University Düsseldorf, Düsseldorf, DE, ⁴Marienhospital Herne, Herne, DE, ⁵MHH - Medizinische Hochschule Hannover, Hannover, DE, ⁶Ulm Medical University Hospital, Ulm, DE, ⁷University Hospital Cologne, Köln, DE, ⁸Charité University Hospital Berlin, Berlin, DE, ⁹Universitätsklinik Schleswig-Holstein, Lübeck, DE, ¹⁰University Hospital Bonn, Bonn, DE, ¹¹Klinikum Rechts der Isar - Technische Universität München, Munich, DE, ¹²WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, ¹³University Hospital Essen, Essen, DE

09:09 - 09:10

1760P - Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Results from patients with ≥12 mo of treatment in JAVELIN Bladder 100

J. Aragon-Ching¹, P. Grivas², Y. Loriot³, J. Bellmunt⁴, J. Wang⁵, E. Michelon⁶, A. Di Pietro⁷, T. Powles⁸, S. Sridhar⁹, ¹Inova Schar Cancer Institute, Fairfax, US, ²University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, US, ³Gustave Roussy, INSERMU981, Université Paris-Saclay, Villejuif, FR, ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, US, ⁵Pfizer, Cambridge, US, ⁶Pfizer, New York, US, ⁷Pfizer srl, Milano, IT, ⁸Barts Cancer Institute,

Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew's Hospital, London, GB, ⁹Princess Margaret Cancer Center, University Health Network, Toronto, CA

- 09:10 - 09:11 **1761P - Clinicopathological features of FGFR3-mutated upper tract urothelial carcinoma: A genomic database analysis**
A. Rizzo¹, V. Mollica², M. Santoni³, F. Massari⁴, ¹I.R.C.C.S. Istituto Tumori "Giovanni Paolo II, Bari, IT, ²IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, IT, ³Macerata Hospital, Macerata, IT, ⁴University of Bologna, Bologna, IT
- 09:11 - 09:12 **1762P - MERINOS: Metastatic non muscle invasive urothelial carcinoma - An observational study**
M. Haberstick¹, G. Pignot², J. Rigaud³, M. Cancel⁴, D. Maillet⁵, S. Oudard⁶, D. Pouessel⁷, C. Serrate⁸, L. Campedel⁹, C. Dumont¹⁰, D. Borchellini¹¹, P. Barthelemy¹², E. Boughalem¹³, E. Colomba¹⁴, O. Huillard¹⁵, H. Boyle¹⁶, F. Lefort¹⁷, F. Constans Schlurmann¹⁸, F. Audenet¹, C. Thibault¹, ¹HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, ²IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ³CHU de Nantes, Hôtel Dieu, Nantes, FR, ⁴CHRU Hopitaux de Tours - Hopital Bretonneau, Tours, cedex, FR, ⁵Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices de Lyon, Pierre Benite, FR, ⁶HEGP - Hopital Europeen Georges-Pompidou - APHP - University de Paris, Paris, FR, ⁷Institut Claudius Régaud-IUCT Oncopole, Toulouse, FR, ⁸Groupe hospitalier Diaconesses Croix Saint-Simon, Paris, FR, ⁹Hôpitaux Universitaires Pitié Salpêtrière, Paris, FR, ¹⁰Hopital Saint Louis, Paris, FR, ¹¹Centre Anticancer Antoine Lacassagne, Nice, FR, ¹²Strasbourg Europe Cancer Institute, Strasbourg, FR, ¹³ICO - Institut de Cancerologie de l'Ouest - Site Paul Papin, Angers, FR, ¹⁴Gustave Roussy, Université Paris-Saclay, Villejuif, FR, ¹⁵Hopital Cochin AP-HP, Paris, FR, ¹⁶Centre Léon Bérard, Lyon, FR, ¹⁷CHU Bordeaux - Hopital St. André, Bordeaux, FR, ¹⁸Centre Hospitalier de Cornouaille, Quimper, FR
- 09:12 - 09:13 **1763P - Real-world outcomes before and after the access to immune-checkpoint inhibitors (ICI) in advanced urothelial carcinoma (aUC)**
J. Tapia, G. Anguera Palacios, J. Gavira, F. Bosma, S. Sanchez Del Rio, J. Sanz Beltran, M. Molina Pérez, M. Aguado Sorolla, A. Piedra, J.P. Maroto Rey, Hospital de la Santa Creu i Sant Pau, Barcelona, ES
- 09:13 - 09:14 **1764P - The vanishing clinical value of PD-L1 status as predictive biomarker in first-line treatment of urothelial carcinoma of the bladder**
A. Tamalunas, M. Götz, S. Rodler, C. Stief, J. Casuscelli, University Hospital Munich, LMU Munich, Munich, DE
- 09:14 - 09:15 **1765P - Undertreatment rates, associated factors, and survival among patients with locally advanced or metastatic urothelial cancer (la/mUC): A systematic literature review**
T. Wilke¹, L. Zhang², E. Hubscher², M. Musat², S. Harricharan², M. Kearney³, ¹University of Wismar, Wismar, DE, ²Cytel, Waltham, US, ³Merck Healthcare KGaA, Darmstadt, DE
- 09:15 - 09:16 **1766P - Urachal cancer: A population-based study of 315 cases in California from 1988-2019**

D. Benjamin¹, A. Shrestha², D. Fellman², R. Cress², A. Rezazadeh Kalebasty¹, ¹UCI Health - University of California Irvine, Orange, US, ²Cancer Registry of Greater California, Sacramento, US

09:16 - 09:17 **1767P - Outcomes after first line therapy in metastatic bladder and upper tract cancer**

L. Furtado O'Mahony¹, F. Jackson-Spence², C. Toms², L. Flanders¹, H. Hockings¹, J. Choy³, T. Powles¹, B. Szabados³, ¹St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, ²Barts Cancer Institute, London, GB, ³Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB

09:17 - 09:18 **1768P - Clinical outcomes with platinum-based chemotherapy after progression on frontline immunotherapy in metastatic urothelial cancer (mUC)**

B. Szabados¹, C. Stockem², D. Castellano Gauna³, A. Gomez De Liano Lista⁴, M. Rey Cardenas⁵, B. Perez Valderrama⁶, T. Powles⁷, M. Van Der Heijden⁸, ¹Barts Cancer Institute - Queen Mary University of London, London, GB, ²NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ³Hospital Universitario 12 de Octubre, Madrid, ES, ⁴Complejo Hospitalario Universitario Insular - Materno Infantil, Las Palmas de Gran Canaria, ES, ⁵Hosp. Doce de Octubre, Madrid, ES, ⁶Hospital Universitario Virgen del Rocio, Seville, ES, ⁷St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, ⁸Netherlands Cancer Institute, Amsterdam, NL

09:18 - 09:19 **1769P - KDM6A mutation act as a potential immunotherapy biomarker in urothelial carcinoma**

W. Xiao¹, L. Chen², T. Xuan³, X. He¹, H. Yu¹, X. Zhu⁴, N. Luo⁴, M. Li⁴, Y. Qi⁴, T. Sun⁴, C. Qi⁴, ¹The Affiliated Hospital of Qingdao University, Qingdao, CN, ²Qingdao Municipal Hospital, Qingdao, CN, ³Qilu Hospital of Shandong University (Qingdao), Qingdao, CN, ⁴Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, CN

09:19 - 09:20 **1770P - Updated follow-up data and biomarker analysis of pre-operative ipilimumab and nivolumab in locoregional advanced urothelial cancer (NABUCCO)**

C. Stockem¹, A. Gil Jimenez¹, J. Van Dorp¹, N. Van Dijk², M. Alkemade², I. Seignette², C. Pipinikas³, G. Jones³, N. Rosenfeld³, M. Van Montfoort¹, K. Hendricksen¹, J. De Feijter¹, R. Meijer⁴, A. Van Der Heijden⁵, N. Mehra⁶, B. Suelmann⁴, B. Van Rhijn¹, M. Van Der Heijden², ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²Netherlands Cancer Institute, Amsterdam, NL, ³Inivata Limited, Cambridge, GB, ⁴UMC - University Medical Center Utrecht, Utrecht, NL, ⁵Radboud University Medical Center, Nijmegen, NL, ⁶Radboud University Medical Center, Nijmegen, NL

09:20 - 09:21 **1771P - Genomic characteristics and clinical outcomes of HRAS-mutated urothelial bladder cancer**

J.A. Ocejó Gallegos¹, E. Rodriguez², A. Trabolsi², S. Kareff², J. Yin³, P. Walker⁴, W. El-Deiry⁵, B. Carneiro⁶, C. Nabhan³, G. Lopes², J. Merchan⁷, ¹Um Miller School of Medicine Jackson Memorial Hospital - Internal Medicine Program, Miami, US, ²Sylvester Comprehensive Cancer Center - University of Miami, Miami, US, ³Caris Life Sciences - Arizona Office, Phoenix, US, ⁴Caris Life Sciences - Headquarters, Irving, US, ⁵Brown

University, Providence, US, ⁶The Warren Alpert Medical School of Brown University, Providence, US, ⁷University of Miami Health System, Miami, US

- 09:21 - 09:22 **1772P - Characterisation of a DNA repair deficiency (DRD) biomarker phenotype in metastatic urothelial carcinoma (mUC) within the ATLANTIS clinical trial platform**
S. Crabb¹, L. Dempsey², E. Soulis², S. Hinsley², Y.P. Song³, J. Barber⁴, J. Frew⁵, J. Gale⁶, G. Faust⁷, S. Brock⁸, U. McGovern⁹, O. Parikh¹⁰, D. Enting¹¹, S. Sundar¹², G. Ratnayake¹³, K. Lees¹³, S. Hussain¹⁴, T. Powles¹⁵, R. Jones², W. Tapper¹, ¹University of Southampton, Southampton, GB, ²University of Glasgow, Glasgow, GB, ³The Christie NHS Foundation Trust, Manchester, GB, ⁴Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff, GB, ⁵The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, ⁶St. Mary's Hospital Portsmouth Oncology Centre, Portsmouth, GB, ⁷Leicester Royal Infirmary - University Hospitals of Leicester NHS Trust, Leicester, GB, ⁸University Hospitals Dorset, Poole, GB, ⁹UCLH - University College London Hospitals NHS Foundation Trust, London, GB, ¹⁰Royal Preston Hospital-Lancashire Teaching Hospitals NHS Foundation Trust, Preston, GB, ¹¹Guy's and St. Thomas' NHS Foundation Trust, London, GB, ¹²Nottingham City Hospital, Nottingham, GB, ¹³Musgrove Park Hospital - Taunton and Somerset NHS Foundation Trust, Taunton, GB, ¹⁴University of Sheffield, Sheffield, GB, ¹⁵St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB
- 09:22 - 09:23 **1773P - Prediction of neoadjuvant chemotherapy response in muscle-invasive bladder cancer: A machine learning approach**
E. Shkolyar¹, H. Bhambhani², E. Tiu², V. Krishna², V. Krishna², V. Nimgaonkar², R. Krishnan², O. O'Donoghue², D. Vrabac², C.-S. Kao¹, A. Joshi², J. Shah¹, ¹Stanford University School of Medicine, Stanford, US, ²Valar Labs Inc., Palo Alto, US
- 09:23 - 09:24 **1774P - Association of CREBBP mutation with favorable outcome with immune checkpoint inhibitors in bladder cancer**
W. Sheng¹, Q. Zhang², Q. Duan², Y. Tan², T. Sun², C. Qi², ¹The First Affiliated Hospital of Xiamen University, Xiamen, CN, ²Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, CN
- 09:24 - 09:25 **1775P - Prevalence of PD-L1 high expression in advanced urothelial carcinoma (aUC): Results from the PREVAIL prospective cohort study**
P. Grivas¹, P. Agarwal², H. Al-Ahmadie³, T. Friedlander⁴, D. Geynisman⁵, I. Hussain⁶, Y. Lotan⁷, A. Morgans⁸, M. Tesic-Schnell⁹, J. Meeks¹⁰, ¹University of Washington Seattle Cancer Care Alliance, Seattle, US, ²The University of Chicago, Chicago, US, ³Memorial Sloan Kettering Cancer Center, New York, US, ⁴UCSF - University of California San Francisco, San Francisco, US, ⁵Fox Chase Cancer Center - Main Campus, Philadelphia, US, ⁶AstraZeneca, Phoenix, US, ⁷UTSW - University of Texas Southwestern Medical Center, Dallas, US, ⁸Dana Farber Cancer Institute, Boston, US, ⁹AstraZeneca USA, Gaithersburg, US, ¹⁰Northwestern University Feinberg School of Medicine, Chicago, US
- 09:25 - 09:26 **1776P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan**
J.-R. Li¹, Y.-H. Feng², C.-H. Chen³, W.-H. Ku⁴, H.-L. Huang⁵, W.J.-S. Huang⁶, ¹Department of Surgery, Taichung Veterans General Hospital, Taichung, TW, ²Department of Internal

Medicine, Chi Mei Medical Center, Tainan, TW, ³National Taiwan University Hospital, Taipei, TW, ⁴Taipei Institute of Pathology, Taipei, TW, ⁵Janssen, Taipei, TW, ⁶Taipei Veterans General Hospital, Taipei, TW

- 09:26 - 09:27 **1777P - 13 genes panel validation to assess minimal residual disease through urinary tumor DNA in muscle-invasive bladder cancer patients**
G. De Renzi¹, F. Belardinilli¹, V. Magri², C.M. Scornajenghi³, E. De Berardinis³, P. Gazzaniga¹, C. Nicolazzo¹, ¹Sapienza Università di Roma, Rome, IT, ²Sapienza Università di Roma, Roma, IT, ³Sapienza - Università di Roma, Rome, IT
- 09:27 - 09:28 **1778P - Comparative genomic alterations (GA) landscape in urothelial carcinoma of the bladder (UCB) in patients of South Asian ancestry (SAS)**
P. Spiess¹, G. Bratslavsky², P. Grivas³, J. Jacob², A. Necchi⁴, N. Danziger⁵, D. Pavlick⁵, H. Tukachinsky⁶, R. P. Graf⁷, J. Ross⁵, ¹H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ²SUNY Upstate Medical University, Syracuse, US, ³University of Washington Seattle Cancer Care Alliance, Seattle, US, ⁴IRCCS Ospedale San Raffaele, Milan, IT, ⁵Foundation Medicine, Inc, Cambridge, US, ⁶Foundation Medicine, Boston, US, ⁷Foundation Medicine Inc., Cambridge, US
- 09:28 - 09:29 **1779TiP - Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001)**
V. Koshkin¹, T. Powles², G. Iyer³, Y. Loriot⁴, A. Drakaki⁵, I. Duran Martinez⁶, M. De Santis⁷, M. Retz⁸, R. Jain⁹, S. Chan¹⁰, M. Ichimaru¹⁰, M. Galsky¹¹, ¹UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ²Barts Health NHS Trust, London, GB, ³Memorial Sloan Kettering Cancer Center, New York, US, ⁴Institut Gustave Roussy, Villejuif, Cedex, FR, ⁵David Geffen School of Medicine at UCLA, Los Angeles, US, ⁶Hospital Universitario Marques de Valdecilla, Santander, ES, ⁷Charité Universitätsmedizin, Berlin, DE, ⁸Rechts der Isar Medical Center, Technical University Munich, München, DE, ⁹H. Lee Moffitt Cancer Center & Research Institute, Tampa, US, ¹⁰Seagen Inc., Bothell, US, ¹¹Icahn School of Medicine at Mount Sinai, New York, US
- 09:29 - 09:30 **1780TiP - A phase II clinical study to assess efficacy of induction ipilimumab/nivolumab to spare the bladder in urothelial bladder cancer (INDI-BLADE)**
C. Stockem¹, B. Van Rhijn¹, T. Boellaard¹, M. Van Montfoort¹, S. Balduzzi¹, J. Boormans², M. Franckena², R. Meijer³, J. Noteboom³, D. Robbrecht², B. Suelmann³, E. Schaake¹, M. Van Der Heijden⁴, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²Erasmus MC, Rotterdam, NL, ³UMC - University Medical Center Utrecht, Utrecht, NL, ⁴Netherlands Cancer Institute, Amsterdam, NL
- 09:00 - 17:00 Type: Poster session**
Title: Poster session 06
Poster Area, Hall 4
- 09:00 - 09:01 **1641TiP - Adjuvant nivolumab with chemotherapy in pleural mesothelioma: The NICITA trial**
R. Shah, Thoraxklinik Heidelberg, Heidelberg, DE

- 09:01 - 09:02 **1642TiP - ENSURE: Dendritic cell therapy (MesoPher) in combination with extended-pleurectomy/decortication after chemotherapy in subjects with resectable mesothelioma: A feasibility study**
- L. Cantini¹, M. Dietz¹, R.A. Belderbos¹, R. Cornelissen¹, D. Dumoulin¹, M. Vink¹, K. Bezemer¹, A. Langerak¹, J. Von Der Thüsen², E. Mahtab¹, L. Maat¹, R. Stadhouders¹, R. Hendriks¹, M. Willemsen¹, J. Aerts¹, ¹Erasmus MC, Rotterdam, NL, ²Erasmus MC - Erasmus University Rotterdam, Rotterdam, NL
- 09:02 - 09:03 **1643TiP - First-in-human dose-escalation and expansion study (MITOPE) to evaluate mitochondrial PRX3 inhibition by RSO-021 in patients with mesothelioma and other advanced solid tumors**
- S. Dulloo¹, D. Fennell¹, P. Szlosarek², F. Thistlethwaite³, S. Lord⁴, N. Rahman⁴, A. Greystoke⁵, B. Cunniff⁶, J. Dzalo⁷, C. Poile⁷, R. Panchal¹, J. Duncan⁸, P. Graham⁸, A. Bexon⁹, G. Naumov⁸, J. Spicer¹⁰, ¹Leicester Royal Infirmary - University Hospitals of Leicester NHS Trust, Leicester, GB, ²St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, ³The Christie NHS Foundation Trust, Manchester, GB, ⁴University of Oxford, Oxford, GB, ⁵The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, ⁶University of Vermont College of Medicine, Burlington, US, ⁷University of Leicester - Leicester Cancer Research Centre, Leicester, GB, ⁸RS Oncology LLC, Cambridge, US, ⁹Bexon Clinical Consulting LLC, Montclair, US, ¹⁰KCL - King's College London, London, GB
- 09:03 - 09:04 **1665P - Genomic mutational landscape of solid tumors: Preliminary results from ROME trial**
- A. Botticelli¹, S. Scagnoli¹, P.F. Conte², C. Cremolini³, P. Ascierto⁴, F. Cappuzzo⁵, M. Aglietta⁶, F. Mazzuca⁷, E. Capoluongo⁸, G. Blandino⁵, U. Malapelle⁹, M. Nuti¹, G. D'Amati¹, B. Cerbelli¹, G. Prunerì¹⁰, M. Biffoni¹¹, G. Giannini¹², F. Cognetti⁵, G. Curigliano¹³, P. Marchetti¹⁴, ¹Sapienza University of Rome, Rome, IT, ²IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ³University of Pisa, Pisa, IT, ⁴Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁵IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT, ⁶IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, ⁷AOU Sant'Andrea - Università Sapienza di Roma, Rome, IT, ⁸Università degli Studi di Napoli Federico II, Napoli, IT, ⁹Università degli Studi di Napoli Federico II - Scuola di Medicina e Chirurgia, Napoli, IT, ¹⁰Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ¹¹Istituto Superiore di Sanità (ISS), Rome, IT, ¹²Sapienza - Università di Roma, Rome, IT, ¹³IRCCS European Institute of Oncology - University of Milano, Milan, IT, ¹⁴IRCCS Istituto Dermopatologico dell'Immacolata IDI, Rome, IT
- 09:04 - 09:05 **1666P - Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients**
- Y. Debie¹, J. Van Audenaerde¹, T. Vandamme², L. Croes³, L.-A. Teuwen², L. Verbruggen², G. Vanhoutte², E. Marcq¹, D. Le Blon¹, B. Peeters⁴, M. Goossens⁵, K. Arien⁶, S. Anguille², E. Smits¹, C. Vulsteke³, E. Lion¹, M. Peeters², P. Van Dam², ¹University of Antwerp, Wilrijk, BE, ²UZA - University Hospital Antwerp, Edegem, BE, ³AZ Maria Middelaers, Gent, BE, ⁴Antwerp University Hospital, Edegem, BE, ⁵Sciensano, Brussel, BE, ⁶Institute of Tropical Medicine Antwerp (ITM), Antwerpen, BE
- 09:05 - 09:06 **1667P - Multiplexed spatial analysis by imaging mass cytometry to**

immunologically characterize checkpoint inhibitor colitis

M. Van Eijs¹, J. Ter Linde¹, M. Baars¹, M. Amini¹, M. Laclé¹, E. Brand¹, B. Oldenburg¹, Y. Vercoulen¹, K. Suijkerbuijk², F. Van Wijk¹, ¹UMC - University Medical Center Utrecht, Utrecht, NL, ²UMC-University Medical Center Utrecht, Utrecht, NL

09:06 - 09:07 **1668P - Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction**

X. Chen¹, E. Sifakis¹, S. Robertson¹, S.Y. Neo¹, S.-H. Jun², L. Tong¹, J. Lövrot¹, A. Tay¹, R. Hellgren³, S. Margolin⁴, J. Bergh¹, T. Foukakis¹, J. Lagergren², A. Lundqvist¹, R. Ma¹, J. Hartman¹, ¹Karolinska Institutet, Stockholm, SE, ²Science for Life Laboratory (SciLifeLab), Solna, SE, ³Södersjukhuset, Stockholm, SE, ⁴Karolinska University Hospital and Karolinska Institute - Huddinge, Stockholm, SE

09:07 - 09:08 **1669P - Monitoring immune checkpoint inhibition in advanced solid tumors using genome-wide cfDNA fragmentomes**

J. Medina¹, E. Roussos Torres², A. Leal¹, V. Adleff¹, K. Lumbard³, L. Keefer³, J. Carey³, A. Brufsky⁴, P. Lorusso⁵, J.P. Eder⁶, V. Chung⁷, M. Downs¹, A. O'Connor¹, R. Piekarz⁸, H. Streicher⁸, E. Jaffee¹, R. Scharpf¹, V. Stearns¹, R. Connolly⁹, V. Velculescu¹, ¹Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, ²USC - University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, US, ³Delfi Diagnostics, Inc., Baltimore, US, ⁴Comprehensive Breast Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, US, ⁵Yale School of Medicine - Radiology and Biomedical Imaging, New Haven, US, ⁶Yale University School of Medicine - Yale Cancer Center, New Haven, US, ⁷City of Hope Comprehensive Cancer Center, Duarte, US, ⁸National Cancer Institute (NCI)/National Institute of Health (NIH), Bethesda, US, ⁹University College Cork, Cork, IE

09:08 - 09:09 **1670P - Circulating tumor DNA (ctDNA) dynamics of response and resistance in BRAF V600E mutant (mt) metastatic colorectal (mCRC) and other cancers: Data from EVICT (erlotinib and vemurafenib in combination trial)**

L. Tan¹, B. Tran¹, J. Tie¹, E. Link¹, S. Wong¹, S. Chandrashekar¹, J. Guinto¹, B. Markman², S. Ananda¹, N. Tebbutt³, M. Michael¹, B. Solomon¹, G. Mcarthur¹, P. Gibbs⁴, S.-J. Dawson¹, J. Desai¹, ¹Peter MacCallum Cancer Centre, Melbourne, AU, ²Monash Health - Monash Cancer Centre, Bentleigh East, AU, ³Olivia Newton John Cancer Wellness and Research Centre, Heidelberg, AU, ⁴WEHI - Walter and Eliza Hall Institute of Medical Research, Parkville, AU

09:09 - 09:10 **1671P - PRECISEKIDS: A nation-wide project for the comprehensive genomic profiling of paediatric solid tumours in Portugal**

J. Lima¹, J. Pinheiro², H. Barroca², S. Nunes², A. Fernandes², A. Carvalho³, M. Jeronimo³, I. Luz³, C. Mendes⁴, S. Nunes⁴, P. Soares⁵, J.C. Machado⁵, M. Gil-Da-Costa², M. Bom-Sucesso², ¹IPATIMUP - Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, PT, ²CHUSJ - Centro Hospitalar Sao Joao E.P.E - SNS - Polo Porto, Porto, PT, ³CHUC - Centro Hospitalar e Universitário de Coimbra, Coimbra, PT, ⁴Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, PT, ⁵Instituto de Investigacao e Inovacao em Saude (i3S), Porto, PT

09:10 - 09:11 **1672P - Tumor and immune cell dynamics at single-cell resolution on combined**

PARP inhibition and anti-PD-L1 therapy

J. Vibert¹, C. Henon², P. Martin Romano¹, L. Tselikas², L. Colmet-Daage², R. Chabanon², N. Dorvault², A. Gazzah¹, F. Bouquet³, N. Droin², K. Fizazi², D. Vasseur⁴, E. Rouleau⁴, S. Postel-Vinay¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Institut Gustave Roussy, Villejuif, Cedex, FR, ³Roche S.A.S - France, Basel, CH, ⁴Gustave Roussy - Cancer Campus, Villejuif, FR

09:11 - 09:12 **1673P - Exploring different strategies to incorporate germline analysis in tumor whole genome sequencing**

R. Koster¹, L. Schipper¹, D. Van Beek², M. Mendeville², K. Samsom¹, E. Rosenberg¹, F. Hogervorst¹, P. Roepman², G. Meijer¹, E. Voest¹, T. Van Wezel¹, L. Van Der Kolk¹, K. Monkhorst¹, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²Hartwig Medical Foundation, Amsterdam, NL

09:12 - 09:13 **1674P - NT-I7 plus pembrolizumab combination treatment enhances infiltration of PD-1+ T cells and provides a more immunogenic tumor microenvironment: Biomarker data from the NIT-110 study**

A. Naing¹, S. Ferrando-Martinez², A. Wolfarth², M. Xu¹, J. Goon², M. Ware², C. Haymaker¹, M. Raso¹, M. Chaney³, U. Ezeanya², S. Dhar², H. Lee⁴, T. Lee⁴, T. Adebajo², J. Fan², S.H. Yang², B.H. Lee², R. Kim⁵, ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²NeoImmuneTech, Inc., Rockville, US, ³Merck & Co., Inc., North Wales, US, ⁴Geninus, Inc., Seoul, KR, ⁵H. Lee Moffitt Cancer Center University of South Florida, Tampa, US

09:13 - 09:14 **1676P - Active immunization with a multi-peptide B cell vaccine, targeting trastuzumab and pertuzumab binding sites, prevents the formation of HER-2/neu expressing lung metastases**

J. Tobias¹, M. Drinic², S. Högl³, A. Schmid², E. Garner-Spitzer¹, L. Kenner¹, M. Kundi¹, C. Zieleinski⁴, U. Wiedermann⁵, ¹Medical University of Vienna, Vienna, AT, ²Medical University of Vienna, Wien, AT, ³University of Veterinary Medicine, Vienna, Vienna, AT, ⁴Cecog Central European Cooperative Oncology Group, Vienna, AT, ⁵MedUni Wien - Institute of Specific Prophylaxis and Tropical Medicine, Wien, AT

09:14 - 09:15 **1677P - Risk factors predicting immune checkpoint inhibitors (ICIs) toxicity using machine learning computer algorithm**

R. Holland, K. Miron, T. Goshen - Lago, N. Gordon, A. Zer, I. Ben-Aharon, Rambam Health Care Campus, Haifa, IL

09:15 - 09:16 **1678P - The interaction between cancer cells and cancer-associated fibroblasts promotes RAS signalling in squamous cell carcinoma, resulting in an immune-suppressive tumour microenvironment and poorer survival outcomes**

A. Rullan¹, G. Giangreco², Y. Naito³, S. Hooper², P. Chakravarty², E. Hirata⁴, K. Harrington¹, E. Sahai², ¹The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB, ²The Francis Crick Institute, London, GB, ³Nippon Medical School Main Hospital, Tokyo, JP, ⁴Kanazawa Medical University, Uchinada, JP

09:16 - 09:17 **1679P - A comparative analysis of cancer NGS reporting practices between Europe and North America**

B. Pitel¹, S. Rao², I. King³, J. Saliba⁴, D. Sonkin⁵, M. Griffith⁶, A.H. Wagner⁷, D. Beule⁸, U. Keilholz⁹, M. Benary⁹, ¹Mayo Clinic, Rochester, US, ²Georgetown University, Washington, US, ³University Health Network, Toronto, CA, ⁴Washington University School of Medicine in St. Louis, St. Louis, US, ⁵National Cancer Institute, Rockville, MD, US, ⁶Washington University, St. Louis, US, ⁷Nationwide Children's Hospital; the Ohio State University College of Medicine, Columbus, US, ⁸Berlin Institute of Health, Berlin, DE, ⁹Charité - Universitätsmedizin Berlin, Berlin, DE

09:17 - 09:18

1680P - An activator of GPX4 protects against doxorubicin-induced cardiomyopathy

C. Huang¹, L. Wang², G. Sun², ¹Enshi Tujia and Miao Autonomous Prefecture Central Hospital, Enshi, CN, ²Enshi Tujia and Miao Autonomous Prefecture Central Hospital/Enshi Clinical College of Wuhan University, Enshi, CN

09:18 - 09:19

1681P - Testing the generalizability of cfDNA fragmentomic features across different studies for cancer early detection

S. Su¹, Y. Xuan¹, X. Fan², H. Bao², H. Tang², X. Lv¹, W. Ren¹, F. Chen¹, X. Wu³, Y. Shao², T. Wang¹, L. Wang¹, ¹Nanjing Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, CN, ²Nanjing GENESSEEQ Technology Inc., Nanjing, CN, ³Nanjing Geneseeq Technology Inc., Nanjing, CN

09:19 - 09:20

1682P - Development of an ex vivo RNA-based predictive assay for tumor tissue explants

E. Imyanitov, P. Kaidun, A. Ivantsov, A. Venina, S. Baskina, A. Togo, S. Aleksakhina, N.N. Petrov Institute of Oncology, Saint-Petersburg, RU

09:20 - 09:21

1683P - Implementing next generation sequencing (NGS)/molecular tumor board (MTB)-based precision oncology practice: One-year experience at the Verona University Hospital

S.T. Riva¹, C. Luchini¹, F. Zacchi¹, A. Mafficini¹, M. Borghesani¹, M. Mongillo¹, I. Scaglione¹, S. Manduca¹, E. Lucin¹, V. Moscarda¹, S. Pafumi¹, L. Leta¹, A. Dodi¹, A. Reni¹, L. Messineo¹, C. Chiamulera¹, E. Urso², A. Scarpa¹, R. Lawlor¹, M. Milella¹, ¹University of Verona - Faculty of Medicine, Verona, IT, ²University of Padua - Faculty of Medicine, Padova, IT

09:21 - 09:22

1684P - Genetic alterations as independent prognostic factors to predict the type of recurrence of lung cancer

A. Valter¹, L. Luhari², H. Pisarev³, B. Truumees¹, A. Planken¹, O.-P. Smolander², K. Oselin¹, ¹North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla), Tallinn, EE, ²TalTech - Tallinn University of Technology, Tallinn, EE, ³University of Tartu, Tartu, EE

09:22 - 09:23

1685P - Oncogenic activity of recurrent ERBB4 mutations and their sensitivity to neratinib

V. Ojala¹, A. Tuohisto-Kokko¹, S. Ahonen¹, A. Jokilampi¹, O. Esparta Gonzalez¹, P. Suominen¹, D. Chakroborty¹, T. Airene², M. Johnson², L. Eli³, K. Kurppa¹, K. Elenius¹, ¹University of Turku - Institute of Biomedicine, Turku, FI, ²Abo Akademi University,

Turku, FI, ³Puma Biotechnology Inc., South San Francisco, US

- 09:23 - 09:24 **1686P - Evaluating the relationship between BRAF mutation class and patient demographics in an international cancer cohort**
S. Kazandjian¹, A. Rose², ¹McGill University Health Center, Montreal, CA, ²Jewish General Hospital McGill University, Montreal, CA
- 09:24 - 09:25 **1687P - Targeted metabolomics reveals dynamic changes and potential therapeutic targets in the serum metabolome of patients receiving adoptive cell therapy with tumor infiltrating lymphocytes**
L. Mantle¹, D. Millar², R. Laister², V. Sotov², L. Nguyen², C. Robert², M. Vilbert¹, T. Pimentel Muniz¹, I. Hirsch¹, M.F. Silva Almeida Ribeiro¹, E. Koch¹, P. Ohashi¹, M. Butler¹, S. Saibil¹, ¹Princess Margaret Cancer Centre, Toronto, CA, ²Princess Margaret Cancer Center, University Health Network, Toronto, CA
- 09:25 - 09:26 **1688P - Selection of PD-L1 escape variants in microsatellite stable metastatic colorectal cancer on avelumab treatment**
C. Schultheiß¹, L. Claaß², R. Scholz², L. Paschold¹, D. Simnica¹, V. Heinemann³, S. Stintzing⁴, M. Binder¹, ¹Martin Luther University Halle-Wittenberg, Halle (Saale), DE, ²Martin Luther Universität Halle-Wittenberg, Halle (Saale), DE, ³LMU Klinikum der Universität München, Munich, DE, ⁴Charité - Universitätsmedizin Berlin, Berlin, DE
- 09:26 - 09:27 **1689P - OATD-02 validates the benefits of pharmacological inhibition of arginase 1 and 2 in cancer**
M. Grzybowski, R. Blaszczyk, P. Pomper, P. Stanczak, B. Borek, A. Gzik, J. Nowicka, K. Jędrzejczak, T. Rejczak, M. Młacki, N.C. Guner-Chalimoniuk, A. Kikulska, J. Olczak, J. Pęczkowicz-Szyska, K. Dzwonek, P. Dobrzanski, A. Gołębiowski, Z. Zasłona, Molecure SA, Warsaw, PL
- 09:27 - 09:28 **1690P - Anticancer effects of PARP1 hyperactivation by a new generation of decoy oligodeoxynucleotide**
W. Jdey, C. Doizelet, A. Pinheiro, Onxeo, Paris, FR
- 09:28 - 09:29 **1692P - ImmTAC redirect T cells against patient-derived tumour organoids and three-dimensional melanospheres: Effects augmented by type I interferons**
P. Kirk, D. Gascoyne, J. Clubley, C. Britton-Rivet, E. Guc, E. Leach, J. Houghton, J. Newton, S. Stanhope, A. Benlahrech, Immunocore Limited, Abingdon-on-Thames, GB
- 09:29 - 09:30 **1693P - Incidence of NTRK genes fusion in adult brain tumours: A prospective cohort of 140 patients with cerebral gliomas and brain metastases**
P. Métellus¹, C. Camilla², E. Bialecki¹, N. Beauvils², C. Vellutini³, E. Pellegrino², P. Tomasini⁴, I. Nanni², L. Ouafik², ¹Ramsay santé - Hopital Privé Clairval, Marseille, FR, ²Assistance Publique Hopitaux de Marseille, Marseille, FR, ³Aix Marseille University, Marseille, Cedex, FR, ⁴Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Marseilles, FR

- 09:30 - 09:31 **1694P - Single cell characterization of longitudinal biopsies from breast cancer patients treated with the aromatase inhibitor letrozole and the CDK4/6 inhibitor ribociclib**
X. Tekpli¹, S. Ghannoum¹, C. Steen¹, M. Fongård¹, B. Holm², T. Bosnjak³, L. Reitsma⁴, S. Geisler⁵, M. Seyedzadeh⁴, U.-C. Buvarp⁴, M. Loeng⁴, M. Lyngra⁴, V. Kristensen¹, J. Geisler⁵, ¹Oslo University Hospital, Oslo, NO, ²Novartis Sverige AB, Taby, SE, ³Novartis Oncology, Oslo, NO, ⁴Akershus University Hospital HF, Lorenskog, NO, ⁵Akershus universitetssykehus HF, Lorenskog, NO
- 09:31 - 09:32 **1695P - Neutralizing anti-FGFR1 antibody as a combined partner of anti-PD-1 antibodies in tumor models**
I. Tsimafeyeu¹, J. Smith², W. Yin², A. Fanelli², A. Olshanskaya³, D. Khochenkov⁴, ¹Bureau of Cancer Research, New York, US, ²Altogen Labs, Austin, US, ³Moscow Clinical Oncology Hospital #1, Moscow, RU, ⁴N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU
- 09:00 - 10:00 Type: Poster session Title: Poster session 01 Poster Area, Hall 4**
- 09:00 - 09:01 **70P - Fluoropyrimidine (FP) dose individualization based on pretreatment uracil levels: Safety and pharmacokinetic (PK) analysis from the Alpe2U study**
M. De With¹, J. Knikman², A. Baars³, G.-J. Creemers⁴, H. Droogendijk⁵, E. Fiets⁶, A. Imholz⁷, L. Valkenburg-Van Iersel⁸, F.J.F. Jeurissen⁹, C. Mandigers¹⁰, R. Van Schaik¹¹, B. Van Den Bosch¹², H. Rosing¹³, J. Beijnen¹⁴, J. Swen¹⁵, H. Gelderblom¹⁶, J. Schellens¹⁷, R. Mathijssen¹, H.-J. Guchelaar¹⁵, A. Cats², ¹Erasmus MC Cancer Institute, Rotterdam, NL, ²Netherlands Cancer Institute, Amsterdam, NL, ³Hospital Gelderse Vallei, Ede, NL, ⁴Catharina Hospital Eindhoven, Eindhoven, NL, ⁵Bravis Ziekenhuis-Roosendaal, Roosendaal, NL, ⁶Medical Center Leeuwarden, Leeuwarden, NL, ⁷Deventer Ziekenhuis, Deventer, NL, ⁸Maastricht Universitair Medisch Centrum, Maastricht, NL, ⁹HMC - Haaglanden Medisch Centrum - Westeinde, Den Haag, NL, ¹⁰Canisius Wilhelmina Hospital, Nijmegen, NL, ¹¹Erasmus University Medical Center, Rotterdam, NL, ¹²Maastricht University Medical Center (MUMC), Maastricht, NL, ¹³titute, Amsterdam, NL, ¹⁴Netherlands Cancer Institute and Utrecht University, Amsterdam, NL, ¹⁵Leiden University Medical Center and Leiden Network for Personalised Therapeutics, Leiden, NL, ¹⁶Leiden University Medical Center, Leiden, NL, ¹⁷Utrecht University - Faculty of Pharmaceutical Sciences, Utrecht, NL
- 09:01 - 09:02 **71P - Capecitabine-induced adverse events: A pharmacogenetic study beyond DPYD**
M. De With¹, L. Van Doorn¹, D. Maasland¹, T. Mulder², S. El Bouazzaoui², R. Mathijssen¹, R. Van Schaik², S. Bins¹, ¹Erasmus MC Cancer Institute, Rotterdam, NL, ²Erasmus MC, Rotterdam, NL
- 09:02 - 09:03 **72P - Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET#x2b; colorectal carcinoma as a unique molecular subset of CRC**
M. Nagasaka¹, D. Brazel², Y. Baca³, J. Xiu³, M.N. Al-Hallak⁴, C. Kim⁵, J.J. Nieva⁶, J.J. Swensen³, D. Spetzler³, W.M. Korn⁷, M. Socinski⁸, B. Halmos⁹, S.-H. Ou¹⁰, ¹UCI Health - University of California Irvine, Orange, US, ²UC Irvine Medical Center, Orange, US,

³Caris Life Sciences, Phoenix, US, ⁴Karmanos Cancer Institute, Detroit, US, ⁵Georgetown Lombardi Comprehensive Cancer Center, Washington DC, US, ⁶USC - University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, US, ⁷UCSF-Diller Cancer Research Building, Mount Zion, San Francisco, US, ⁸Florida Hospital Cancer Institute, Orlando, US, ⁹Montefiore Medical Center, New York City, US, ¹⁰UCI Health Chao Family Comprehensive Cancer Center, Orange, US

- 09:03 - 09:04 **73P - Multi-cancer early detection through evaluation of aneuploidy, methylation, and protein biomarkers in plasma**
C. Douville¹, C. Nobles², H.J. Hwang², V.E. Katerov², V. Gainullin², J. Tong², K. Ushakov², A. Koenig², H. Guttman², M. Jaime², J. Wang², W. Ault², M. Gray², G. Cerqueira², C. Lengauer², J. Garces², A. Mcelhinny², H. Allawi², F. Diehl², ¹Johns Hopkins University, Baltimore, US, ²Exact Sciences Corporation, Madison, US
- 09:04 - 09:05 **75P - Comprehensive assessment of 18F-FDG PET/CT images of cancer patients improves predictions of survival**
G. Liu¹, M. La Fontaine², A. Weisman², S. Houshmandi², O. Lokre², R. Jeraj³, T. Perk², ¹University of Wisconsin Carbone Cancer Center, Madison, US, ²AIQ Solutions, Madison, US, ³University of Wisconsin-Madison, Madison, US
- 09:05 - 09:06 **76P - Second interim analysis of INFINITY: A registry on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice**
U. Martens¹, J. Schröder², L. Sellmann³, M. Reiser⁴, S. Frank-Gleich⁵, T. Decker⁶, A. Schneeweiss⁷, M. Schuler⁸, S. Grebhardt⁹, S. Woerner⁹, S. Zacharias⁹, N. Marschner⁹, B. Kasenda¹⁰, C. Vannier⁹, ¹SLK-Kliniken Heilbronn GmbH, Heilbronn, DE, ²MVZ für Hämatologie und Onkologie in Mülheim an der Ruhr, Mülheim, DE, ³Praxis für Onkologie - Sellmann & Bartels, Mönchengladbach, DE, ⁴PIOH (Köln Zentrum) - Praxis Internistischer Onkologie und Hämatologie, Köln, DE, ⁵Gemeinschaftspraxis und Tagesklinik - Innere Medizin, Hämatologie, Onkologie, Gastroenterologie, Palliativmedizin, Halle/Saale, DE, ⁶Gemeinschaftspraxis für Hämatologie und Onkologie, Ravensburg, DE, ⁷Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg, DE, ⁸Universitätsklinikum Essen, Essen, DE, ⁹iOMEDICO AG, Freiburg im Breisgau, DE, ¹⁰Universitätsklinikum Basel, Basel, CH
- 09:06 - 09:07 **77P - Hypermethylation of genes HIST1H4F, Septin9 and RASSF1 as the potential biomarker for nasopharyngeal carcinoma screening**
D. Wen, GDPU - Guangdong Pharmaceutical University, Guangzhou, CN
- 09:07 - 09:08 **78P - Association between obesity, sex, and overall survival in patients with metastatic cancers treated with first- or second-line immune checkpoint inhibitors**
M. Li¹, S. Zhao², J. Guo², M. Husain¹, J. Schafer², K. Chakravarthy², G. Lopez¹, D. Spakowicz¹, L. Wei², E. Bertino¹, A. Alahmadi¹, R. Memmott¹, J. Kaufman¹, K. He¹, C. Presley¹, P. Shields¹, D. Carbone¹, G. Otterson¹, D. Owen¹, ¹The Ohio State University - OSU Wexner Medical Center, Columbus, US, ²OSUCCC - The Ohio State University Comprehensive Cancer Center - James, Columbus, US

- 09:08 - 09:09 **79P - Molecular characterization of KRAS NSCLC all stages: A single-center cohort**
C. Climent Vicente¹, N. Lopez Zurita¹, J. Giner Joaquin¹, S. Soriano¹, P. Ribera Fernandez¹, M. Rodriguez², P. Andreu Cobo¹, M. Busquets Godall¹, M. Frago Gil¹, O. Cano I Cano¹, A. Carrasco Navas¹, M. Sierra Boada¹, L. Vila Martinez¹, ¹Parc Tauli Hospital Universitari, Sabadell, ES, ²Hospital de Sabadell Corporacis Parc Tauli, Sabadell, ES
- 09:09 - 09:10 **80P - The analysis of ROS1 fusions characteristics in Chinese solid tumor patients**
Y. Lin¹, Y. Zhao², D. Guo², G. Lu², W. Deng², F. Bu³, R. Ding³, ¹The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, CN, ²Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, CN, ³Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, CN
- 09:10 - 09:11 **81P - NF1 mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in gastroesophageal cancers**
H. Xiao¹, L. Zhao², M.Z. Xiao², C. Qi², ¹First affiliated hospital of Guangdong College of Pharmacy, Guangzhou, CN, ²Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, CN
- 09:11 - 09:12 **82P - Exploring the prognostic role of DNA damage sensing deficiency for immune checkpoint blockade in diverse cancer types**
Y. Shao¹, X. Chen², X. Wu², Q. Ou², J. Yin², X. Wu², ¹Nanjing Medical University, Nanjing, CN, ²Nanjing Geneseeq Technology Inc., Nanjing, CN
- 09:12 - 09:13 **83P - Patterns of trophoblast cell surface antigen 2 (TROP2) and epithelial cell adhesion molecule (EPCAM) expression in human tumors: A tissue microarray study on 14,766 tumors**
D. Dum¹, C. Hube-Magg¹, R. Simon², E. Bady¹, T. Mandelkow¹, N. Blessin¹, M. Lennartz¹, G. Sauter¹, S. Minner¹, A. Luebke³, ¹University Medical Center Hamburg-Eppendorf, Hamburg, DE, ²UKE Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE, ³Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE
- 09:13 - 09:14 **84P - Pharmacodynamic marker modulation of the selective WEE1 inhibitor Debio 0123 in patient biopsies from phase I clinical trial**
H. Gelderblom¹, N. Luong², J. Gietema³, I. Desar⁴, O. Saavedra⁵, M. Jalving³, J. Kroep¹, A. Bellon², J. Nowakowska², M. Jonnaert², E. Rodrigo Imedio², ¹LUMC - Leids Universitair Medisch Centrum, Leiden, NL, ²Debiopharm International S.A., Lausanne, CH, ³UMCG - University Medical Center Groningen, Groningen, NL, ⁴Radboud University Medical Center, Nijmegen, Nijmegen, NL, ⁵Vall d'Hebron University Hospital, Barcelona, ES
- 09:14 - 09:15 **85P - A circulating, surrogate-systemic biomarker correlates with anti-tumor benefit on LNS8801 therapy**
J. Cohen¹, C. Natale², J. Lin³, P. Lorusso⁴, A. Mita⁵, M. Mita⁵, C. Muller⁶, M. Orloff⁷, K. Papadopoulos⁸, J. Rodon⁹, T. Garyantes², ¹Abramson Cancer Center - University of Pennsylvania, Philadelphia, US, ²Linnaeus Therapeutics, Haddonfield, US,

³Massachusetts General Hospital and Harvard Medical School, Boston, US, ⁴Yale School of Medicine - Radiology and Biomedical Imaging, New Haven, US, ⁵Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center, Los Angeles, US, ⁶University of New Mexico, Albuquerque, US, ⁷Thomas Jefferson Univ Hospital, Philadelphia, US, ⁸South Texas Accelerated Research Therapeutics (START), San Antonio, US, ⁹The University of Texas M. D. Anderson Cancer Center, Houston, US

- 09:15 - 09:16 **86P - Plasma exosomal AKR1C3 mRNA expression is a predictive and prognostic biomarker in metastatic castration-resistant prostate cancer patients**
S. Zhu¹, Y. Ni², G. Sun¹, H. Zeng¹, ¹West China Hospital of Sichuan University, Chengdu, CN, ²West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN
- 09:16 - 09:17 **87P - ctDNA analysis as a prognostic factor for early-stage and oligometastatic patients treated with radiotherapy**
G. Alvarez Cifuentes¹, A. Santiago¹, L. Mendez¹, M. Fueyo¹, E. López Martínez¹, R. Soria¹, I. Martín López¹, N. Durán¹, R. Álvarez¹, C. Lago¹, A. Otero Gonzalez¹, M. Diñeiro¹, R. Capín¹, J. Cadiñanos¹, R. Cabanillas², ¹IMOMA - Instituto de Medicina Oncologica y Molecular de Asturias, Oviedo, ES, ²Cabanillas Precision Consulting, Wetzikon, CH
- 09:17 - 09:18 **88P - DNA-methylome derived epigenetic fingerprint as an immunophenotype indicator prompts durable clinical immunotherapeutic benefits in head and neck squamous cell carcinoma**
R. Li¹, X.-R. Tang¹, Y.-K. Wang¹, X. Wen¹, X.-Y. Ren², R.-X. Lv¹, F. Zhao¹, ¹Nanfang Hospital of Southern Medical University, Guangzhou, CN, ²Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, CN
- 09:18 - 09:19 **89P - Novel resistance mechanisms to second-generation EGFR tyrosine kinase inhibitor afatinib in non-small cell lung cancer**
Q. Ding¹, Y. Shao², X. Wu², Q. Hu², Q. Meng², J. Yin², Q. Ou², X. Wu², ¹Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University, Nanjing, CN, ²Nanjing Geneseeq Technology Inc., Nanjing, CN
- 09:19 - 09:20 **91P - Liquid biopsy, a tool to detect genetic alterations with therapeutic impact in international patients: Prospective data on 47 patients from Gustave Roussy**
T. Assi¹, T. Ibrahim¹, C. Chahine¹, N. Lezghed¹, N. Masri¹, E. Rouleau¹, O. Caron², A. Le Cesne¹, ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Institut Gustave Roussy, Villejuif, Cedex, FR
- 09:20 - 09:21 **92P - Analysis of standard serum biomarker levels in patients with non-specific symptoms seen at Guy's rapid diagnostic clinic**
M. Monroy Iglesias, KCL - King's College London, London, GB
- 09:21 - 09:22 **93P - An AI-driven computational biomarker from H&E slides recovers cases with low levels of HER2 from immunohistochemically HER2-negative breast cancers**
A. Marra¹, M. Goldfinger², E. Millar³, M. Hanna¹, B. Rothrock², M. Lee², Y. Wang², A.

Van Eck², L. Trlifaj Tydlitova², J. Sue², H. Wen¹, J. Stefanelli², J. Retamero², P. Hamilton², T. Fuchs², D. Klimstra², S. Chandarlapaty⁴, J. Reis-Filho⁴, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²Paige, New York, US, ³Garvan Institute of Medical Research, Darlinghurst, AU, ⁴MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

- 09:22 - 09:23 **94P - Performance validation of an artificial intelligence-powered programmed death-ligand 1 (PD-L1) combined positive score analyzer in urothelial cancer**
J.H. Park¹, S.I. Cho², K.S. Lee³, E. Choi⁴, W. Jung², S. Kim², G. Park², S. Song², C. Kang², M. Ma², D. Yoo², K. Paeng², C.-Y. Ock², ¹Boramae Medical Center, Seoul, KR, ²Lunit, Seoul, KR, ³Seoul National University Bundang Hospital, Seongnam-si, KR, ⁴Ewha Womans University Mokdong Hospital, Seoul, KR
- 09:23 - 09:24 **95P - Serum-based colorectal cancer detection using orphan noncoding RNAs**
H. Goodarzi¹, J. Wang², O. Afolabi², L. Fish², H. Li², K. Chau³, P. Arensdorf², F. Hormozdiari², B. Alipanahi², ¹UCFS - University of California San Francisco, San Francisco, US, ²Exai Bio Inc, Palo Alto, US, ³Exai Bio, Inc, Palo Alto, US
- 09:24 - 09:25 **96P - Use of computational algorithms to predict mutation effect in clinical setting**
E. Ignatova¹, V. Yakushina², A. Lebedeva², G. Timokhin², E. Veselovsky², V. Mileyko², M. Ivanov², ¹Research Centre for Medical Genetics, Moscow, RU, ²Atlas Oncodiagnostics, LLS, Moscow, RU
- 09:25 - 09:26 **97P - Pan-cancer landscape of clonal tumor mutational burden (cTMB)**
A. Parikh¹, K. Murugesan², J.F. Hopkins², Z. Arshad³, D. Jin², S. Klempner⁴, D. Fabrizio², G. Frampton², J. He², M. Montesion², ¹Harvard Medical School, Charlestown, US, ²Foundation Medicine, Inc, Cambridge, US, ³Georgia Institute of Technology, Atlanta, US, ⁴MGH - Massachusetts General Hospital, Boston, US
- 09:26 - 09:27 **98P - Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study**
E. Ahn¹, M. Rothe², P. Mangat², E. Garrett-Mayer², T. Al Baghdadi³, A. Baron⁴, J. Krauss⁵, A. Balmanoukian⁶, J. Bauman⁷, M. Hameed⁸, K. Mileham⁹, R. Thota¹⁰, P. Gold¹¹, F. Meric-Bernstam¹², S. Powell¹³, E. Yang¹⁴, R. O'Lone², G. Grantham², S. Halabi¹⁵, R. Schilsky², ¹Cancer Treatment Centers of America, Zion, US, ²American Society of Clinical Oncology (ASCO), Alexandria, US, ³Michigan Cancer Research Consortium, IHA Hematology Oncology, Ypsilanti, US, ⁴California Pacific Medical Center, San Francisco, US, ⁵University of Michigan Rogel Comprehensive Cancer Center, Ann Arbor, US, ⁶The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, US, ⁷Fox Chase Cancer Center, Philadelphia, US, ⁸Ascension Borgess Cancer Center, Kalamazoo, US, ⁹Levine Cancer Institute - Morehead, Charlotte, US, ¹⁰Intermountain Medical Center - Intermountain Healthcare, Murray, US, ¹¹Swedish Cancer Institute - Medical Oncology - First Hill, Seattle, US, ¹²The University of Texas MD. Anderson Cancer Center, Houston, US, ¹³Sanford Health, Sioux Falls, US, ¹⁴University of Alabama at Birmingham - School

of Medicine, Birmingham, US, ¹⁵Duke University - Health System, Durham, US

- 09:27 - 09:28 **99P - Landscape of homologous recombination repair gene mutations in different molecular subtypes of NSCLC**
L. Liu¹, F. Xu¹, W. Sun², Y. He², ¹Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN, ²Geneplus-Beijing Institute, Beijing, CN
- 09:28 - 09:29 **100P - Co-mutational landscape of key fibroblast growth factor receptor (FGFR) alterations in intra-hepatic cholangiocarcinoma (iCCA), bladder cancer (BC) and glioma**
A. Necchi¹, K. Murugesan², T. Burn³, O. Gjoerup², R. Greenstein², J. López⁴, M. Montesion², H. Nimeiri², A. Parikh⁵, S. Roychowdhury⁶, S. Schwemmers⁴, I. Silverman⁷, A. Vogel⁸, ¹IRCCS San Raffaele Hospital and Scientific Institute, Vita-Salute San Raffaele University, Milan, IT, ²Foundation Medicine, Inc, Cambridge, US, ³Tyra Biosciences, Carlsbad, US, ⁴F. Hoffmann-La Roche Ltd, Basel, CH, ⁵Jefferson Health, Philadelphia, US, ⁶Ohio State University, Columbus, US, ⁷Repare Therapeutics, Cambridge, US, ⁸Hannover Medical School, Hannover, DE
- 09:29 - 09:30 **101P - Real-world prevalence of MSI-H/dMMR across 6 different tumor types in Asia**
D.S. Tan¹, Y.M. Kim², M.-C. Lim³, M. Sho⁴, C.-H. Lu⁵, S. Nagao⁶, S. Kubo⁷, B.-G. Kim⁸, L.-T. Chen⁹, M. Kanai¹⁰, P.-H. Wang¹¹, S.Y. Rha¹², R. Ramar¹³, M. Wong¹³, T. Sasaki¹⁴, ¹National University Cancer Institute of Singapore, National University Hospital, Yong Loo Lin School of Medicine, and Cancer Science Institute of Singapore, Singapore, SG, ²Asan Medical Center, Seoul, KR, ³National Cancer Center, Goyang, KR, ⁴Nara Medical University Hospital, Kashihara, JP, ⁵Taichung Veterans General Hospital, Taichung, TW, ⁶Hyogo Cancer Center, Akashi, JP, ⁷Osaka Metropolitan University, Osaka, JP, ⁸Samsung Medical Center, Seoul, KR, ⁹National Cheng Kung University Hospital, Tainan, TW, ¹⁰Kyoto University Hospital, Kyoto, JP, ¹¹Taipei Veterans General Hospital, Taipei, TW, ¹²Yonsei Cancer Center, Yonsei University Health System, Seoul, KR, ¹³MSD International GmbH, Singapore, SG, ¹⁴The Cancer Institute Hospital of JFCR, Tokyo, JP
- 09:30 - 09:31 **102P - Clinical analysis of patients with different KRAS mutations in NSCLC: Different entities analyzed by NGS**
J. Rubio Perez¹, M. Fernández Ochoa¹, P. Villalba Cuesta¹, M. Avedillo Ruidiaz¹, F. Rojo², M. Domine Gomez¹, ¹Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, ²University Hospital Fundacion Jimenez Diaz, Madrid, ES
- 09:31 - 09:32 **103P - Next generation sequencing (NGS) for the identification of PARP inhibitors; predictive biomarkers**
T. Floros¹, E. Papadopoulou², V. Metaxa-Mariatou², A. Tsantikidi², G. Kapetsis², C. Florou-Chatzigiannidou², A. Meintani², N. Touroutoglou³, I. Boukovinas⁴, F. Stavridi⁵, C. Papadimitriou⁶, D. Ziogas⁷, M. Theochari⁷, E. Timotheadou⁸, A. Fassas⁹, Z. Saridaki-Zoras¹⁰, M. Ozdogan¹¹, U. Demirci¹², G. Nasioulas², ¹NNA - Naval and Veterans Hospital of Athens, Athens, GR, ²Genekor Medical S.A, ATHENS, GR, ³European Interbalkan Medical Center, Thessaloniki, GR, ⁴Bioclinic Oncology Unit of Thessaloniki, Thessaloniki, GR, ⁵Hygeia Hospital, Marousi, GR, ⁶Alexandra Hospital, Athens, GR, ⁷Laiko General Hospital of Athens, Athens, GR, ⁸Aristotle University of Thessaloniki - School of

Medicine, Thessaloniki, GR, ⁹St Luke's Hospital-Agios Loukas Clinic, Thessaloniki, GR, ¹⁰Asklepios Oncology Unit, Heraklion, GR, ¹¹Medstar Yildiz Hastanesi, GERA KAS ATHENS, GR, ¹²Memorial Ankara Hospital, Ankara, TR

- 09:32 - 09:33 **104P - NTRK3 mutation affects the efficacy of immune checkpoint inhibitors in patients with advanced cancer**
H. Tian¹, Y. Qi², X. Zhu², N. Luo², M. Li², T. Sun², C. Qi², ¹Qilu Hospital of Shandong University, Jinan, CN, ²Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, CN
- 09:33 - 09:34 **105P - Pan-tumor survey of ROS1 fusions detected by next-generation RNA sequencing**
S. Zhang¹, M. Nagasaka¹, Y. Baca², J. Xiu², J.J. Nieva³, A. Vanderwalde², J.J. Swensen², D. Spetzler², W.M. Korn⁴, S. Liu⁵, S.-H. Ou⁶, ¹UCI Health - University of California Irvine, Orange, US, ²Caris Life Sciences, Phoenix, US, ³USC - University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, US, ⁴UCSF-Diller Cancer Research Building, Mount Zion, San Francisco, US, ⁵Lombardi Cancer Center Georgetown University, Washington, US, ⁶UCI Health Chao Family Comprehensive Cancer Center, Orange, US
- 09:34 - 09:35 **106P - Comparative analysis of urinary and tissue tumor DNA in muscle-invasive bladder cancer by boosted whole-exome sequencing**
J. Zang¹, R. Zhang¹, F. Xie², Y. Zhang², P. Du², S. Jia³, H. Chen¹, G. Zhuang¹, ¹Shanghai Jiao Tong University School of Medicine, Shanghai, CN, ²Huidu Shanghai Medical Sciences Ltd, Shanghai, CN, ³Huidu Shanghai Medicinal Sciences Ltd, Shanghai, CN
- 09:35 - 09:36 **107P - Systematic characterization of MET activating mutations in non-small cell lung cancer**
Y. Yu¹, Y. Shao², J. Zhang², H. Bao², J. Pang², R. Guo², J. Yin², Q. Ou², X. Wu², ¹The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN, ²Nanjing Geneseeq Technology Inc., Nanjing, CN
- 09:36 - 09:37 **108P - Copy loss enrichment at metastatic disease progression in hormone receptor-positive (HR⁺)/HER2-negative metastatic breast cancer patients treated with endocrine therapy and CDK4/6 inhibition**
A. Davis¹, J. Luo¹, T. Zheng², C. Dai², R. Suresh¹, F. Ademuyiwa³, C. Rigden⁴, K. Clifton¹, K. Weillbaecher¹, A. Frith¹, P. Tandra⁵, T. Summa¹, S. Thomas¹, L. Peterson¹, X. Wang², P. Du², S. Jia², B. King², J. Krishnamurthy⁵, C. Ma¹, ¹Washington University School of Medicine in St. Louis, St. Louis, US, ²Predicine, Inc., Hayward, US, ³Washington University School of Medicine, St. Louis, US, ⁴Washington University School of Medicine in St. Louis - Siteman Cancer Center, St. Louis, US, ⁵UNMC - 986840 Nebraska Medical Center, Omaha, US
- 09:37 - 09:38 **109P - Improved accuracy of somatic variant detection from high throughput sequencing (HTS) data via site-specific noise estimation**
E. Ignatova¹, M. Ivanov², V. Yakushina², V. Mileyko², ¹Research Centre for Medical Genetics, Moscow, RU, ²Atlas Oncodiagnosics, LLS, Moscow, RU

- 09:38 - 09:39 **110P - Characteristics and survival outcomes of patients (pts) with RET fusion-positive (RET-fp) solid tumours receiving non-RET inhibitor (RETi) therapy in a real-world setting**
P. Garrido Lopez¹, S. Siena², M. Taylor³, A. Beringer⁴, W. Bordogna⁴, O. Fajardo⁵, C. Nikolaidis⁴, ¹Ramón y Cajal University Hospital, Madrid, ES, ²Università degli Studi di Milano, and Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, IT, ³Providence Portland Medical Center, Portland, US, ⁴F. Hoffmann-La Roche Ltd, Basel, CH, ⁵F. Hoffmann-La Roche AG, Basel, CH
- 09:39 - 09:40 **111P - Interim biomarker analysis of a phase Ib/II study of anti-TIGIT etigilimab (MPH313) and nivolumab in subjects with select locally advanced or metastatic solid tumors (ACTIVATE)**
G. Sarikonda¹, B. Wallace¹, C. Wiesner², S. Krishnan¹, J. Lewicki¹, A. Kapoun¹, ¹Mereo Biopharma, Redwood City, US, ²Wiesner Consulting LLC, Livermore, US
- 09:40 - 09:41 **112P - Beyond BRAF V600: Characterizing the genomic landscape of non-BRAF V600 mutations and BRAF fusions in 121,221 in adult patients with cancer**
N. Coleman, M. Gouda, J. Roszik, V. Subbiah, The University of Texas M. D. Anderson Cancer Center, Houston, US
- 09:41 - 09:42 **113P - Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial**
M. Maio¹, P. Ascierto², D. Motola Kuba³, N. Penel⁴, P. Cassier⁵, G. Bariani⁶, A. De Jesus-Acosta⁷, T. Doi⁸, F. Longo Muñoz⁹, W. Miller¹⁰, D.-Y. Oh¹¹, M. Gottfried¹², L. Yao¹³, F. Jin¹³, A. Gozman¹³, A. Marabelle¹⁴, ¹University of Siena and Center for Immuno-Oncology, Siena, IT, ²Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Napoli, IT, ³COMOP A.C., Clinical Investigation, Mexico City, MX, ⁴Centre Oscar Lambret and Lille University, Lille, FR, ⁵Centre Léon Bérard, Lyon, FR, ⁶Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, BR, ⁷Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, US, ⁸National Cancer Center Hospital East, Kashiwa, JP, ⁹Hospital Universitario Ramon y Cajal, Madrid, ES, ¹⁰Jewish General Hospital McGill University, Montreal, CA, ¹¹Seoul National University Hospital and Cancer Research Institute, Seoul, KR, ¹²Meir Medical Center, Kfar Saba, IL, ¹³Merck & Co., Inc., Rahway, US, ¹⁴Gustave Roussy, Institut National de la Santé et de la Recherche Médicale (INSERM) U1015, Université Paris Saclay, Villejuif, FR
- 09:42 - 09:43 **114P - Clinical interchangeability of programmed cell death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays for the treatment of first-line (1L) non-small cell lung cancer (NSCLC) with cemiplimab**
K. Kerr¹, J. Perez², K. McGuire², B. Baker², F. Fang³, J. Li³, G. Wlasiuk⁴, S. Li², B. Gao², J.-F. Pouliot², F. Seebach², I. Lowy², G. Gullo², P. Rietschel², ¹Aberdeen University Medical School, University of Aberdeen, Aberdeen, GB, ²Regeneron Pharmaceuticals, Inc., Tarrytown, US, ³Roche Molecular Solutions, Pleasanton, US, ⁴Roche Tissue Diagnostics, Tuscon, US
- 09:43 - 09:44 **115P - Combination of two distinct subsets of peripheral blood CD8+ T cells from patients with NSCLC predicts response outcome to immune**

checkpoint inhibitor therapy

J.-H. Cho¹, S.-W. Lee¹, J.S. Yun¹, H.-O. Kim², H. Cho¹, S.Y. Song¹, I.-J. Oh¹, ¹Chonnam National University Medical School & Chonnam National University Hwasun Hospital, Hwasun, KR, ²Selecine, Seoul, KR

09:44 - 09:45

116P - Any regression of tumor (ART) as an intermediate endpoint in patients (pts) treated with immune checkpoint inhibitors (ICI): A pan-cancer analysis

T. El Zarif¹, G. Pond², A. Nassar³, E. Adib³, D. Freeman¹, J. Thomas⁴, U. Kalluri¹, A. Matar⁵, E. Kelly¹, C. Curran¹, A. Kadamkulam Syriac⁶, H. McClure¹, M. Davidsohn¹, C. Labaki¹, R.M. Saliby¹, C. Hobeika³, P.V. Nuzzo¹, J. Berchuck¹, T. Choueiri¹, G. Sonpavde¹, ¹Dana Farber Cancer Institute, Boston, US, ²McMaster University Medical Centre - Hamilton Health Sciences, Hamilton, CA, ³Brigham and Women's Hospital, Boston, US, ⁴Beth Israel Deaconess Medical Center, Boston, US, ⁵AUBMC - American University of Beirut Medical Center, Beirut, LB, ⁶St. Elizabeth's Medical Center, Brighton, US

09:45 - 09:46

117P - BiomeOne: Multi-centric validation of a novel microbiome-based biomarker to predict response to cancer immunotherapy

I. Robinson¹, M. Schmidinger², M. Hochmair¹, L. Ay¹, G. Absenger³, M. Pichler³, V.A. Nguyen⁴, E. Richtig⁵, B. Rainer⁵, C. Jansen⁶, B. Sladek⁶, A. Knabl⁶, N. Gasche⁶, A. Valipour¹, ¹Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, AT, ²Vienna General Hospital (AKH), Vienna Medical University, Vienna, AT, ³Medical University of Graz, Graz, AT, ⁴Landeskrankenhaus - Universitaetskliniken Innsbruck, Innsbruck, AT, ⁵Universitätsklinik für Dermatologie und Venerologie, Graz, AT, ⁶Biome Diagnostics GmbH, Wien, AT

09:46 - 09:47

118P - Predictive role of neutrophil lymphocyte ratio (NLR) in metastatic solid tumour patients receiving immune checkpoint inhibitors (ICI)

A. Mehta¹, S. Almel¹, M. Shaikh², ¹P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, IN, ²Max Institute of Cancer Care, New Delhi, IN

09:47 - 09:48

119P - Characterisation of distinct subgroups of BRCA1-like triple-negative breast cancers with multiomics data analysis

T.W.S. Chan, M. Opdam, P. Schouten, L. De Boo, F. Hilbers, S. Linn, R. De Menezes, Netherlands Cancer Institute, Amsterdam, NL

09:48 - 09:49

120P - The predictive value of LATS1 mutation for immune checkpoint inhibitors therapy in bladder cancer

J. Li¹, Q. Zhang², Y. Tan², Q. Duan², T. Sun², C. Qi², ¹Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN, ²Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, CN

09:49 - 09:50

121P - Spectrum of druggable gene fusions in microsatellite-unstable colorectal tumors

E. Imyanitov, A. Anuskina, A. Iyevleva, N. Mitiushkina, R. Mulkidzhan, E. Preobrazhenskaya, A. Romanko, E. Saitova, V. Tiurin, N.N. Petrov Institute of Oncology, Saint-Petersburg, RU

09:50 - 09:51

122P - Can circulating PD-1, PD-L1, pan-BTN3As, BTN3A1, BTN2A1 and BTLA

levels enhance prognostic power of serum CA125 in patients with advanced high-grade serous ovarian cancer?

L.R. Corsini¹, D. Fanale¹, C. Brando¹, S. Cutaia¹, M.C. Di Donna¹, U. Randazzo¹, L. Magrin¹, C. Filorizzo¹, V. Gurrera¹, A. Fiorino¹, E. Pedone¹, M. Di Piazza¹, A. Dimino¹, R. Scalia¹, R. Romano¹, T.D. Bazan Russo¹, V. Chiantera¹, A. Russo¹, V. Bazan¹, J.L. Iovanna², ¹University of Palermo, Palermo, IT, ²Aix-Marseille Université and Institut Paoli-Calmettes, Marseille, France, Marseille, FR

09:51 - 09:52 **123P - Correlation between MSI, TMB and BLM gene mutation in solid tumors**

Y. Jinhai¹, H. Hu², Z. Bian², J. Ma², S. Chen², G. Lu², W. Deng², R. Ding², F. Bu², ¹The First Hospital of Jilin University, Jilin Province, CN, ²Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, CN

09:52 - 09:53 **124P - Durvalumab in advanced, pre-treated microsatellite instability-high solid tumors: Results of a tumor-agnostic DRUP trial cohort**

B. Geurts¹, T. Battaglia¹, J. Van Berge Henegouwen², L. Zevenijn¹, L. Hoes¹, H. Van Der Wijngaart³, G. De Wit¹, P. Roepman⁴, A. Jansen⁵, W. De Leng⁵, V. Van Der Noort¹, F. Opdam¹, A. Bins⁶, J.W. De Groot⁷, M. Labots³, H. Gelderblom², H. Verheul⁸, E. Voest¹, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²LUMC - University Medical Center, Leiden, NL, ³Amsterdam University Medical Center (UMC), location Vrije Universiteit Amsterdam, Amsterdam, NL, ⁴Hartwig Medical Foundation, Amsterdam, NL, ⁵UMC-University Medical Center Utrecht, Utrecht, NL, ⁶Amsterdam University Medical Center (UMC) - location University of Amsterdam, Amsterdam, NL, ⁷Isala, Zwolle, NL, ⁸Radboud University Medical Center, Nijmegen, Nijmegen, NL

09:53 - 09:54 **125P - Assessing the accuracy of multiple prognostic scores for immune checkpoint inhibitors (ICI) in patients with advanced solid tumors**

J. Garcia-Corbacho¹, A. Indacochea², A. Gonzalez³, I. Victoria Ruiz³, D. Moreno Fernández³, D. Pesantez Coronel³, L. Angelats³, A. Modrego⁴, E. Sanfeliu Torres³, O. Castillo⁵, P. Blasco⁵, L. Mezquita³, N. Vinolas Segarra³, M. Nogue Aliguer⁶, B. Adamo³, N. Baste Rotllan³, T. Sauri Nadal³, M. Juan³, A. Prat⁵, F. Schettini⁵, ¹Hospitales Universitarios Virgen de la Victoria y Regional, Málaga, ES, ²Hospital Clinic y Provincial de Barcelona / H Granollers, Barcelona, ES, ³Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁴Hospital Universitario 12 de Octubre, Madrid, ES, ⁵Hospital Clinic y Provincial de Barcelona / IDIBAPS, Barcelona, ES, ⁶Hospital General de Granollers, Granollers, ES

09:54 - 09:55 **126P - The HLA I composite score and VHIO immune gene-expression signature (VIGex) as selection tools to explore the tumor microenvironment (TME) in patients (pts) treated with immunotherapy (IT)**

O. Saavedra Santa Gadea¹, M. Vila Casadesus², O. Mirallas¹, A. Calvo³, F.J. Ros Montana¹, I. Baraibar Argota¹, C. Suarez Rodriguez¹, A. Oberoi², R. Morales Barrera¹, P. Iranzo Gomez¹, G. Alonso⁴, I. Brana¹, A. Cabrera Navarro¹, E. Hernández-Illán², M. Vieito Villar¹, M.E. Elez Fernandez¹, M. Gonzalez Rodriguez¹, E. Felip¹, E. Garralda¹, A. Vivancos¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ³Princess Margaret Cancer Centre, Toronto, CA, ⁴Vall d'Hebron Institute of Oncology, Barcelona, ES

- 09:55 - 09:56 **127P - Better than RECIST and faster than iRECIST: Defining the immunotherapy progression decision score to better manage progressive tumors on immunotherapy**
Y. Belkouchi¹, H. Talbot¹, N. Lassau², L. Lawrance², S. Farhane², R. Feki-Mkaouar², J. Vibert³, P.-H. Cournede⁴, A. Marabelle⁵, S. Ammari², S. Champiat², ¹CentraleSupélec - Paris-Saclay campus, Gif sur Yvette, FR, ²Gustave Roussy - Cancer Campus, Villejuif, FR, ³Institut Gustave Roussy, Villejuif, Cedex, FR, ⁴CentraleSupélec - Paris-Saclay campus, Gif-Sur-Yvette, FR, ⁵Institut Gustave Roussy, Villejuif, FR
- 09:56 - 09:57 **128P - Histopathology (HP) biomarkers confirm leukocyte interleukin injection (LI) treatment (Tx) outcome in naïve locally advanced primary head & neck squamous cell carcinoma (SCCHN) the IT-MATTERS study**
J. Timar¹, E. Talor², P. Lavin³, A. Ladanyi⁴, I. Kenessey¹, A. Kiss¹, D. Markovic⁵, J. Cipriano², ¹Semmelweis University - Faculty of Medicine, Budapest, HU, ²CEL-SCI Corporation, Vienna, US, ³Boston Biostatistics Research Foundation, Framingham, US, ⁴National Institute of Oncology, Budapest, HU, ⁵Ergomed d.o.o. Beograd, Belgrade, RS
- 09:57 - 09:58 **129P - Association of clinico-pathological markers with longitudinal liquid biopsy (LB) results predicts outcome in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs)**
L. Bonanno¹, E. Zulato², P. Del Bianco², A. Boscolo Bragadin², I. Attili³, A. Pavan², G. Nardo², A. Dal Maso¹, A. Ferro¹, S. Frega², G. Pasello⁴, M. Fassan⁵, F. Calabrese⁵, V. Guarneri⁴, S. Indraccolo⁴, ¹Veneto Institute of Oncology - IRCCS, Padova, IT, ²IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ³IEO - Istituto Europeo di Oncologia, Milan, IT, ⁴University of Padua, Padova, IT, ⁵University of Padova, Padova, IT
- 09:58 - 09:59 **130P - Autoantibodies as potential biomarkers of high grade immune-related adverse events (irAEs) in metastatic melanoma patients treated with check point inhibitors (ICIs)**
A. Gandhi¹, J. Taylor², M. Morici², A. Reid², T. Meniawy¹, M. Khattak³, M. Millward⁴, E. Gray², P. Zaenker², ¹Sir Charles Gairdner Hospital, Perth, AU, ²Edith Cowan University, Perth, AU, ³Fiona Stanley hospital, Perth, AU, ⁴University of Western Australia, Perth, AU
- 09:59 - 10:00 **131P - Frequency of germline testing after tumor sequencing by cancer type**
H. Karpel¹, B. Pothuri², ¹New York University Grossman School of Medicine, New York, US, ²NYU Langone Laura and Isaac Perlmutter Cancer Center, New York, US
- 10:00 - 10:01 **132TiP - Biomarker assessments in daNIS-3: A phase II study of NIS793 and other new investigational drug combinations with standard-of-care (SoC) therapy vs SoC alone for the second-line treatment of patients (pts) with metastatic colorectal adenocarcinoma (mCRC)**
S. Kasper¹, N. Segal², F. Rivera³, C. Tournigand⁴, Y. Cheng⁵, P. Deshpande⁶, N. Amirouchene Angelozzi⁷, A. Bento Pereira Da Silva⁷, A. St-Pierre⁷, S. Kopetz⁸, ¹West German Cancer Center, Essen, DE, ²Memorial Sloan Kettering Cancer Center, New York, US, ³University Hospital Marqués de Valdecilla, IDIVAL, Santander, ES, ⁴Henri Mondor University Hospital, Créteil, FR, ⁵Novartis AG, East Hanover, US, ⁶Novartis Pharmaceuticals Corporation, East Hanover, US, ⁷Novartis AG, Basel, CH, ⁸The

University of Texas M. D. Anderson Cancer Center, Houston, US

- 10:01 - 10:02 **142P - Effectiveness and safety of pegylated liposomal doxorubicin-cyclophosphamide vs. epirubicin-cyclophosphamide as adjuvant chemotherapy for stage I and II HER2-negative breast cancer: An interim analysis of phase II randomized trial**
- L.-M. Tseng¹, F.-M. Chen², S.-T. Chen³, T.-F. Cheng⁴, T.-Y. Chao⁵, M.-S. Dai⁶, W.-Y. Kao⁷, D.-R. Chen⁸, L.-C. Liu⁹, H.C. Wang⁹, H.-T. Chang¹⁰, B.W. Wang¹¹, J.-C. Yu¹², S.C. Chen¹³, K.-H. Liao¹², M.-F. Hou¹⁴, ¹Taipei Veterans General Hospital, Taipei City, TW, ²Kaohsiung Medical University Hospital, Kaohsiung, TW, ³Changhua Christian Hospital - Changji Campus - General Hospital, Changhua City, TW, ⁴Shin Kong Wu Ho-Su Memorial Hospital, Taipei City, TW, ⁵Shuang Ho hospital, New Taipei City, TW, ⁶Tri-Service General Hospital - National Defense Medical Center, Taipei City, TW, ⁷Taipei Buddhist Tzu Chi General Hospital, New Taipei City, TW, ⁸Changhua Christian Hospital, Changhua city, TW, ⁹China Medical University Hospital, New Taipei City, TW, ¹⁰Shin-Huey-Shin Hospital, Kaohsiung, TW, ¹¹Veteran General Hospital-Kaohsiung, Kaohsiung, TW, ¹²Tri-Service General Hospital, National Defense Medical Center, Taipei City, TW, ¹³Chang Gung Medical Foundation- Taipei Chang Gung Memorial Hospital, Taipei City, TW, ¹⁴Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, TW
- 10:02 - 10:03 **143P - Efficacy and safety of anthracyclines in neoadjuvant therapy in HER2-negative breast cancer. A systematic review and network meta-analysis (NMA)**
- G. Villacampa Javierre¹, T. Pascual², A. Matikas³, A. Papakonstantinou⁴, ¹Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ²Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ³Karolinska Institutet, Huddinge, SE, ⁴Karolinska Institutet and Vall D'Hebron Institute of Oncology (VHIO), Solna, Barcelona, SE
- 10:03 - 10:04 **144P - Neoadjuvant giredestrant (GDC-9545) vs palbociclib (P) vs anastrozole (A) vs P in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER-positive/HER2-negative; eBC): Biomarker subgroup analysis of the randomised, phase II coopERA BC study**
- A. Bardia¹, T. Fernando², P.A. Fasching³, V. Quiroga Garcia⁴, Y.H. Park⁵, J. Giltane², C. Xue⁶, V. Lopez Valverde⁷, J. Steinseifer-Szabo⁷, P. Pérez-Moreno², H. Moore², S. Hurvitz⁸, ¹Harvard Medical School, Boston, US, ²Genentech, Inc., South San Francisco, US, ³University Hospital Erlangen, Comprehensive Cancer Center (CCC) Erlangen-EMN, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, DE, ⁴GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Madrid, ES, ⁵Samsung Medical Center, Seoul, KR, ⁶F. Hoffmann-La Roche Ltd, Mississauga, CA, ⁷F. Hoffmann-La Roche Ltd, Basel, CH, ⁸University of California, Los Angeles/Jonsson Comprehensive Cancer Center (UCLA/JCCC), Los Angeles, US
- 10:04 - 10:05 **145P - Prognostic value of tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade: A TRAIN-2 sub study**
- M. Liefwaard¹, A. Van Der Voort¹, M. Van Seijen², J. Sanders¹, S. Vonk¹, L. De Munck³, A.E. Van Leeuwen-Stok⁴, H. Horlings¹, R. Salgado⁵, E. Lips¹, G. Sonke¹, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL,

²Amsterdam UMC - VUmc, Amsterdam, NL, ³IKNL - Netherlands Comprehensive Cancer Organisation, Utrecht, NL, ⁴BOOG Study Center, Amsterdam, NL, ⁵GZA-ZNA Ziekenhuizen, Antwerp, BE

- 10:05 - 10:06 **146P - HRD/TIL-low high-risk breast cancer is characterized by good prognosis (the RADIMMUNE trial)**
- B. Pellegrino¹, A. Llop-Guevara², C. Solinas³, N. Campanini⁴, C. Tommasi⁴, M. Michiara⁵, D. Boggiani⁶, A. Sikokis⁵, A. Frassoldati⁷, C. Casarini⁸, E. Cretella⁹, G. Zoppoli¹⁰, M. Lambertini¹¹, M.V. Dieci¹², L. Cortesi¹³, E. Silini⁴, J. Balmaña¹⁴, K. Willard-Gallo³, V. Serra², A. Musolino⁵, ¹Azienda Ospedaliero-Universitaria di Parma, Parma, IT, ²Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ³Institute Jules Bordet, Brussels, BE, ⁴Università Degli Studi Di Parma - Facoltà di Medicina e Chirurgia, Parma, IT, ⁵Ospedal Maggiore di Parma, Parma, IT, ⁶University Hospital of Parma, Parma, IT, ⁷Azienda Ospedaliera di Ferrara St. Anna, Ferrara, IT, ⁸Nuovo Ospedale di Sassuolo, Sassuolo, IT, ⁹Ospedale Centrale di Bolzano ASDAA/SABES, Bolzano, IT, ¹⁰University of Genova-DIMI, Genova, IT, ¹¹IRCCS AOU San Martino, Genoa, IT, ¹²University of Padua, Padova, IT, ¹³Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ¹⁴Hospital General Vall d'Hebron, Barcelona, ES
- 10:06 - 10:07 **147P - Blind validation of an AI-based tool for predicting distant relapse from breast cancer HES stained slides**
- I. Garberis¹, V. Gaury², V. Aubert², D. Drubay³, C. Saillard², K. Elgui², F. Bernigole³, A. Jacquet⁴, F. André⁵, M. Lacroix-Triki⁶, ¹Institut Gustave Roussy - INSERM UMR 981, Villejuif, FR, ²OWKIN France, Paris, FR, ³Institut Gustave Roussy, Villejuif, Cedex, FR, ⁴Unicancer, Paris, FR, ⁵Gustave Roussy - Cancer Campus, Villejuif, FR, ⁶Institut Gustave Roussy, Villejuif, FR
- 10:07 - 10:08 **148P - Serum metabolomics based risk assessment of disease recurrence in elderly patients with early breast cancer (eBC)**
- E. Risi¹, A. Vignoli², C. Lisanti³, C. Biagioni¹, A. Paderi¹, S. Cappadona Sciammetta¹, F. Del Monte¹, E. Moretti¹, G. Sanna¹, L. Livraghi¹, L. Malorni¹, M. Benelli¹, F. Puglisi³, C. Luchinat², L. Tenori², L. Biganzoli¹, ¹Hospital of Prato, Prato, IT, ²University of Florence, Florence, IT, ³CRO Aviano - Centro di Riferimento Oncologico - IRCCS, Aviano, IT
- 10:08 - 10:09 **149P - Clinical outcomes in ER⁺ breast cancer patients with recurrence score 26-30-guided therapy: Real-world data**
- O. Rotem¹, I. Peretz¹, M. Levirov², I. Kuchuk³, A. Itay⁴, M. Tokar⁵, S. Paluch-Shimon⁶, O. Maimon⁶, R. Yerushalmi¹, K. Drumea², E. Evron⁷, A. Sonnenblick⁸, E. Nili Gal Yam⁴, H. Goldvaser⁹, S. Yosef¹⁰, R. Meroze¹¹, A. Bareket-Samish¹², L. Soussan-Gutman¹³, S. Stemmer¹, ¹Rabin Medical Center, Petah Tikva, IL, ²LIN Medical Center, Haifa, IL, ³Meir Medical Center, Kfar Saba, IL, ⁴Chaim Sheba Medical Center, Ramat Gan, IL, ⁵Soroka University Medical Center, Beer Sheva, IL, ⁶Hadassah University Hospital - Ein Kerem, Jerusalem, IL, ⁷Kaplan Medical Center Oncology Institute, Rehovot, IL, ⁸Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL, ⁹Shaare Zedek Medical Center, Jerusalem, IL, ¹⁰Emek Medical Center, Afula, IL, ¹¹Yizhak Shamir Medical Center - Assaf HaRofeh Campus, Be'er-Yaakov, IL, ¹²BioInsight Ltd., Binyamina, IL, ¹³Rhenium-Oncotest, Modi'in, IL

- 10:09 - 10:10 **150P - Assessment of high Ki67 ($\geq 20\%$) ER$^+$HER2- breast cancer with a 21-gene multigene assay**
S.G. Ahn, S.J. Bae, J.S. Jang, J. Jeong, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR
- 10:10 - 10:11 **151P - Tumor biology and immunology in patients (pts) with breast cancer occurring during pregnancy (BCP) compared to non-pregnant breast cancer pts**
K. Galas¹, M. Gleitsmann², J. Rey³, C. Solbach⁴, I. Witzel⁵, B. Seliger⁶, T. Karn⁷, S. Schmatloch⁸, A. Schneeweiss⁹, B. Sinn¹⁰, T. Fehm¹¹, C. Denkert², A.-S. Litmeyer², P. Jank², J. Furlanetto³, O. Ortmann¹², M.T. Van Mackelenbergh¹³, V. Nekljudova³, S. Loibl³,
¹German Breast Group and Institut für Pathologie, Philipps Universität Marburg, Universitätsklinikum Marburg (UKGM), Neu-Isenburg, Marburg, DE, ²Philipps Universität Marburg und Universitätsklinikum Marburg (UKGM), Marburg, DE, ³German Breast Group, Neu-Isenburg, DE, ⁴University Hospital Frankfurt, Frankfurt am Main, DE, ⁵Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE, ⁶Martin Luther University Halle-Wittenberg and Fraunhofer Institut für Zelltherapie und Immunologie, Leipzig, Halle (Saale), Leipzig, DE, ⁷Goethe University Hospital, Frankfurt am Main, DE, ⁸Elisabeth Krankenhaus, Kassel, DE, ⁹Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg, Heidelberg, DE, ¹⁰Charité Berlin, Berlin, DE, ¹¹Universitätsklinikum Düsseldorf, Düsseldorf, DE, ¹²University Medical Center, Regensburg, DE, ¹³Universitätsklinikum Schleswig-Holstein, Kiel, DE
- 10:11 - 10:12 **152P - Molecular characterization by the 21-gene breast cancer (BC) Recurrence Score (RS) test of BRCA1/2 mutation carriers (mBRCA1/2) versus the general BC patient (pt) population**
R. Yerushalmi¹, A. Pomerantz¹, R. Lewin², S. Paluch-Shimon³, L. Soussan-Gutman⁴, F.L. Baehner⁵, H. Voet⁶, A. Bareket-Samish⁷, I. Kedar¹, L. Kaduri⁸, ¹Rabin Medical Center, Petah Tikva, IL, ²Chaim Sheba Medical Center, Ramat Gan, IL, ³Hadassah University Hospital - Ein Kerem, Jerusalem, IL, ⁴Rhenium-Oncotest, Modi'in, IL, ⁵Exact Sciences Corporation, Madison, US, ⁶The Hebrew University of Jerusalem, Rehovot, IL, ⁷BioInsight Ltd., Binyamina, IL, ⁸Hadassah-Hebrew University Medical Center, Jerusalem, IL
- 10:12 - 10:13 **153P - HER2DX risk-score in the context of the PREDICT online-tool: A correlative analysis of the Short-HER clinical trial in early-stage HER2-positive (HER2$^+$) breast cancer (BC)**
P.F. Conte¹, L. Pare Brunet², F. Brasó-Maristany³, N. Chic⁴, O. Martinez Saez⁵, M.V. Dieci⁶, M. Marin², V. Guarneri⁶, A. Vivancos⁷, P. Villagrasa Gonzalez², J. Parker⁸, C. Perou⁹, A. Prat², ¹IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ²Reveal Genomics, S.L., Barcelona, ES, ³IDIBAPS - Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES, ⁴Hospital Clinic de Barcelona, Barcelona, ES, ⁵Hospital Clinic of Barcelona, Barcelona, ES, ⁶University of Padua, Padova, IT, ⁷Vall d'Hebron University Hospital, Barcelona, ES, ⁸UNC - Lineberger Cancer Center, Chapel Hill, US, ⁹UNC - Lineberger Comprehensive Cancer Center, Chapel Hill, US
- 10:13 - 10:14 **154P - Prognosis of pregnancy after breast cancer diagnosis according to the type of treatment: A population-based study in Korea by the SMARTSHIP group**
S. Park¹, S.Y. Bae², J. Lee³, ¹Chungbuk National University Hospital, Cheongju, KR, ²The Catholic University of Korea - College of Medicine - Songeui Medical Campus, Seoul, KR,

³Soonchunhyang University Hospital Seoul, Seoul, KR

- 10:14 - 10:15 **155P - Artificial Intelligence (AI) - powered human epidermal growth factor receptor-2 (HER2) and tumor-infiltrating lymphocytes (TIL) analysis for HER2-positive early breast cancer patients treated with HER2-targeted neoadjuvant chemotherapy (NAC)**
S.Y. Cho¹, Y. Lim², S.I. Cho², S. Kim², G. Park², S. Song², H. Song², S. Park², M. Ma², W. Jung², K. Paeng², C.-Y. Ock², E.Y. Cho¹, S.Y. Song¹, ¹Samsung Medical Center (SMC), Seoul, KR, ²Lunit Inc., Seoul, KR
- 10:15 - 10:16 **156P - Low CD2 expression in sentinel lymph nodes of early breast cancer patients is associated with postoperative tumor recurrence or metastasis**
S.Y. Kang, T.-H. Kim, M.S. Ahn, Y.W. Choi, M. Kwon, H.W. Lee, J.-H. Choi, J.-H. Kim, Ajou University School of Medicine, Suwon, KR
- 10:16 - 10:17 **157P - Prognostic role of BRCA mutation in patients with breast cancer**
S. Endo, K. Kida, M. Suzuki, C. Fukano, A. Yoshida, N. Hayashi, J. Takei, H. Yamauchi, St. Luke's International Hospital, Chuo-ku, JP
- 10:17 - 10:18 **158P - The impact of tumor microenvironment on pathologic complete response after neoadjuvant chemotherapy of early breast cancer**
C. Grasic Kuhar¹, B. Gazić¹, A. Klevišar Ivančič¹, P. Drev¹, M. Vetter², C. Kurzeder³, K. Geršak¹, ¹Institute of Oncology Ljubljana, Ljubljana, SI, ²KSBL - Kantonsspital Baselland Liestal, Liestal, CH, ³Universitatsspital Basel, Basel, CH
- 10:18 - 10:19 **159P - Peripheral T-lymphocytes senescence and response to neoadjuvant therapy (NAT) in operable breast cancer (BC)**
F. D'Avanzo¹, V. Rossi¹, C. Saggia¹, F. Platini¹, G. Borra¹, V. Martini¹, A. Rua², E. Gioffi², C. Branni¹, P.M. Maggiora², A. Tassone¹, F.M. Varughese², A. Ram Vachanaram², R. Ben Ayed², C. Angelillo², A. Barcellini², R. Boldorini¹, I. Dodaro¹, D. Ferrante², A. Gennari³, ¹AOU Maggiore della Carità di Novara, Novara, IT, ²Università del Piemonte Orientale, Novara, IT, ³Università Degli Studi Del Piemonte Orientale - Scuola di Medicina, Novara, IT
- 10:19 - 10:20 **160P - Is it possible to omit axillary surgery in patients with cN0, postmenopausal ER⁺/HER2- breast cancer who perform breast-conserving surgery?**
Y. Kwon¹, J. Kim¹, J.H. Im¹, S. Kim², Y.A. Im¹, H.-J. Kang¹, J. Lee¹, ¹Hallym University Medical Center (HUMC)-Dongtan Sacred Heart Hospital, Hwaseong, KR, ²HUMC - Hallym University Sacred Heart Hospital (HUSHH), Anyang, KR
- 10:20 - 10:21 **161P - MammaPrint and Blueprint diagnostic tests can be robustly assessed on Whole-Transcriptome NGS platform**
M. Liefwaard¹, R. Bhaskaran², Y. Bijl², D. Israeli², S. Jong-Raadsen², E. Van Montfort², S. Bao³, S. Mee³, T. Cavness³, A. Gallagher², J. Falk³, T. Piel², A. Witteveen², A. Van Der Voort¹, S. Vonk¹, E. Lips¹, G. Sonke¹, M. Kleijn², A. Glas², L. Mittempergher², ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²Agendia NV, Amsterdam, NL, ³Agendia Inc., Irvine, US

- 10:21 - 10:22 **162P - MammaPrint 10-year follow up results from a German breast cancer cohort study**
C. Jackisch¹, D. Pronin², T. Dimpfl³, R. Büttner⁴, G. Kunz⁵, C. Langwieder⁵, M. Rees³, T. Anzeneder⁶, ¹Sana Klinikum Offenbach, Offenbach am Main, DE, ²Agendia Inc., Amsterdam, NL, ³Klinikum Kassel, Kassel, DE, ⁴University Hospital Cologne, Köln, DE, ⁵St.-Johannes-Hospital Dortmund, Dortmund, DE, ⁶Biobank der Stiftung PATH, München, DE
- 10:22 - 10:23 **163P - Development and validation of the prognostic HER2RI assay for predicting recurrence and survival in early HER2-positive breast cancer**
Y.-K. Kang¹, P. Yuan¹, B. Xu¹, H. Wang², T.-H. Chen³, X. Zhang², ¹Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, ²Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, CN, ³Amwise Diagnostics Pte. Ltd., Singapore, SG
- 10:23 - 10:24 **164P - Current use of breast cancer multigene signatures in clinical practice among European experts: Results from the PROCURE Project**
G. Curigliano¹, F. Cardoso², M. Gnant³, N. Harbeck⁴, J. King⁵, A.-V. Laenkholm⁶, F. Penault-Llorca⁷, A. Prat⁸, ¹European Institute of Oncology, Milan, IT, ²Champalimaud Foundation - Champalimaud Clinical Center, Milano, IT, ³Universitätskliniken der MedUni Wien - AKH Wien, Milano, IT, ⁴LMU Klinikum München, München, DE, ⁵UCLH - University College London Hospitals NHS Foundation Trust, Milano, IT, ⁶Slagelse Hospital, Milano, IT, ⁷Jean Perrin Center, Clermont-Ferrand, FR, ⁸SOLTI / IDIBAPS/ Hospital Clinic of Barcelona, Barcelona, ES
- 10:24 - 10:25 **165P - EPclin, OncotypeDx and Prosigna in lobular breast cancer (ILC): Is there an association with Ki67?**
I. Leao¹, E. Zamora², R. Cayuela³, G. Villacampa Javierre⁴, P. Gomez Pardo², M. Arumi De Dios², I. Pimentel², S. Escrivá De Romani², C. Ortiz Velez², M. Cruellas Lapena², L. Sanz², M. Borrell Puy², J. De La Torre⁵, M. Espinosa-Bravo⁵, T. Gorria³, M. Oliveira², C. Saura Manich², V. Peg⁶, M.J. Vidal Losada³, M. Bellet Ezquerro², ¹Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, PT, ²Vall d'Hebron University Hospital / Institute of Oncology (VHIO), Barcelona, ES, ³Hospital Clinic of Barcelona, Barcelona, ES, ⁴Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁵Breast Cancer Center Vall d'Hebron University Hospital, Barcelona, ES, ⁶Vall d'Hebron University Hospital, Barcelona, ES
- 10:25 - 10:26 **166P - Adjuvant trastuzumab plus pertuzumab (TP) versus trastuzumab (T) alone in patients achieving pathologic complete response after chemotherapy with TP**
J.H. Kim¹, Y. Kook¹, J.S. Jang¹, S.J. Bae¹, B.J. Chae², D. Shin³, J.M. Ryu², J. Sohn⁴, J. Jeong¹, S.G. Ahn¹, ¹Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, ²Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ³Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ⁴Yonsei University, Seoul, KR
- 10:26 - 10:27 **167P - The prognostic importance of high HER2 copy numbers and high**

HER2/CEP17 ratio in trastuzumab-treated early breast cancer

C. Rönnlund¹, S. Robertson¹, E. Sifakis¹, I. Fredriksson², T. Foukakis¹, J. Hartman¹,
¹Karolinska Institutet, Solna, SE, ²Karolinska Institutet, Stockholm, SE

- 10:27 - 10:28 **168P - Long-term survival of a randomised, open-label, phase II study comparing the efficacy and safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)**
- J. Huober¹, W. Janni², M. Untch³, J.-U. Blohmer⁴, D.-M. Zahm⁵, C. Hanusch⁶, C. Jackisch⁷, G. Heinrich⁸, A. Schneeweiss⁹, C. Denkert¹⁰, T. Link¹¹, K. Rhiem¹², J. Furlanetto¹³, C. Solbach¹⁴, P. Klare¹⁵, V. Nekljudova¹³, N. Filmann¹³, S. Loibl¹³, ¹Kantonsspital St.Gallen, Brustzentrum, St. Gallen, CH, ²Universitätsklinikum Ulm, Ulm, DE, ³Helios Klinikum Berlin-Buch, Berlin, DE, ⁴Charité – Universitätsmedizin Berlin, Berlin, DE, ⁵SRH Wald-Klinikum Gera GmbH, Gera, DE, ⁶Rotkreuzklinikum München, Munich, DE, ⁷Sana Klinikum Offenbach, Offenbach am Main, DE, ⁸Schwerpunktpraxis der Gynäkologie und Onkologie, Fürstenwalde/Spree, DE, ⁹Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg, Heidelberg, DE, ¹⁰Philipps Universität Marburg und Universitätsklinikum Marburg (UKGM), Marburg, DE, ¹¹Technische Universität Dresden, Dresden, DE, ¹²Universitätsklinikum Köln, Köln, DE, ¹³German Breast Group, Neu-Isenburg, DE, ¹⁴University Hospital Frankfurt, Frankfurt am Main, DE, ¹⁵Praxisklinik Berlin, Berlin, DE
- 10:28 - 10:29 **169P - Neoadjuvant pembrolizumab & chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis**
- J. Cortés¹, A. Haiderali², M. Huang², W. Pan², G.E. Fox³, J. Park³, A. Frederickson³, P.A. Fasching⁴, J. O'Shaughnessy⁵, ¹International Breast Cancer Center (IBCC), Barcelona, ES, ²Merck & Co., Inc., Rahway, US, ³PRECISIONtheor, New York, US, ⁴Department of Gynecology and Obstetrics, Erlangen, DE, ⁵Baylor University Medical Center, Texas Oncology and US Oncology, Dallas, US
- 10:29 - 10:30 **170P - Phase II study of camrelizumab plus chemotherapy as neoadjuvant therapy in patients with early triple-negative breast cancer**
- Y. Wang¹, Y. Liu¹, S. Zhu², X. Bi², ¹Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CN, ²Yantai Yuhuangding Hospital, Yantai, CN
- 10:30 - 10:31 **171P - Association of breast cancer therapy with cognitive decline in older women with early breast cancer: Findings from the CLIMB study**
- J. Baltussen¹, M.G.M. Derks¹, A.A. Lemij¹, N.A. De Glas¹, M. Fiocco¹, E. Linthorst-Niers², A. Vulink³, L. Van Gerven⁴, O.R. Guicherit⁵, T. Van Dalen⁶, J.W.S. Merkus⁷, T. Lans⁸, C.C. Van Der Pol⁹, S.P. Mooijaart¹, J.E.A. Portielje¹, G.J. Liefers¹⁰, ¹LUMC-Leiden University Medical Center, Leiden, NL, ²Groene Hart Ziekenhuis, Gouda, NL, ³Reinier de Graaf Hospital, Delft, NL, ⁴Het LangeLand Ziekenhuis, Zoetermeer, NL, ⁵HMC - Haaglanden Medical Center, Den Haag, NL, ⁶Diakonessenhuis Utrecht, Utrecht, NL, ⁷Hagaziekenhuis, Den Haag, NL, ⁸Adrz-Admiraal de Ruijter Hospital-Goes, Goes and Vlissingen, NL, ⁹Alrijne Hospital Leiderdorp, Leiderdorp, NL, ¹⁰LUMC - Leiden University Medical Center, Leiden, NL

- 10:31 - 10:32 **172P - Prediction of persistent taxane-induced peripheral neuropathy among early-stage breast cancer survivors using whole-exome sequencing**
K. Engvall, N. Björn, E. Avall-Lundqvist, H. Gréen, LiU - Linköping University, Linköping, SE
- 10:32 - 10:33 **173P - A deep learning model to predict competing cancer and cardiac risks after anthracycline exposure for early breast cancer**
C. Mclean¹, P. Hall², ¹Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, GB, ²Cancer Research UK Edinburgh Centre, Edinburgh, GB
- 10:33 - 10:34 **174P - Breast cancer (BC) and severe COVID-19 (C-19) outcomes: A matched analysis**
M. Chavez Mac Gregor¹, X. Lei², H. Zhao¹, C. Malinowski¹, S. Giordano¹, ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²American Society of Clinical Oncology (ASCO), Alexandria, US
- 10:34 - 10:35 **175P - Patients' experiences of a supported self-managed pathway in breast cancer (PRAGMATIC): Quality of life results**
M. Teoh¹, I. Solis-Trapala², L. Matthews³, S. May⁴, M. Kothari⁵, D. Bloomfield⁶, C. Zammit⁶, D. Betal⁷, R. Santos⁵, E. Stewart⁵, J. Finlay⁷, K. Nicholson⁷, D. Elwell-Sutton⁶, H. Gage⁸, S. Bell⁹, F. Mckinna¹⁰, V. Jenkins⁴, ¹Ashford and St Peter's NHS Foundation Trust, Ashford, GB, ²Keele University, Newcastle-under-Lyme, GB, ³University of Sussex, Brighton, GB, ⁴Brighton and Sussex Medical School - University of Sussex, Brighton, GB, ⁵St Peter's Hospital - Ashford and St. Peter's Hospitals NHS Foundation Trust, Chertsey, GB, ⁶University Hospitals Sussex, Brighton, GB, ⁷Worthing Hospital, Worthing, GB, ⁸University of Surrey, Guildford, GB, ⁹Surrey Technology Centre, Guildford, GB, ¹⁰Surrey and Sussex Cancer Alliance, Guildford, GB
- 10:35 - 10:36 **176P - The effectiveness of long-term physical activity after exercise and educational programs on breast cancer-related lymphoedema: Secondary analyses from a randomized controlled trial: The Setouchi Breast Project 10**
S. Nakamoto¹, N. Taira¹, K. Kawada², D. Takabatake³, Y. Miyoshi⁴, S. Kubo⁵, Y. Suzuki¹, M. Yamamoto⁵, Y. Ogasawara², S. Yoshitomi⁶, K. Hara⁶, T. Shien¹, T. Iwamoto¹, S. Ohsumi⁴, M. Ikeda⁵, Y. Mizota⁷, S. Yamamoto⁷, H. Doihara¹, ¹Okayama University Hospital, Okayama, JP, ²Kagawa Prefectural Center Hospital, Takamatsu, JP, ³Kochi Health Science Center, Kochi, JP, ⁴National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, ⁵Fukuyama City Hospital, Fukuyama, JP, ⁶Japanese Red Cross Okayama Hospital, Okayama, JP, ⁷National Cancer Center - Tsukiji Campus, Chuo-ku, JP
- 10:36 - 10:37 **177P - Health related quality of life in older breast cancer survivors**
S. Giordano¹, K. Liao¹, L. Li², D. Zorzi¹, H. Holmes³, M. Chavez Mac Gregor¹, S. Peterson², ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²MD Anderson Cancer Center, Houston, US, ³UT Health - University of Texas at Houston - UT Professional Building, Houston, US
- 10:37 - 10:38 **178P - Awareness of modifiable lifestyle risk factors and acceptability of secondary risk reduction services amongst Irish breast cancer survivors and**

oncology clinicians

C. Steele¹, S. O'Reilly², J. Harrington¹, ¹UCC - University College Cork, Cork, IE, ²CUH - Cork University Hospital, Cork, IE

09:00 - 16:00 **Type: Poster session** **Poster Area, Hall 4**
Title: Poster session 05

09:00 - 09:01 1533P - Atezolizumab (ATZ) plus carboplatin (Cb) and etoposide (eto) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC): Results from the interim analysis of MAURIS trial

E. Bria¹, M. Garassino², E. Del Signore³, F. Morgillo⁴, F. Spinnato⁵, A. Morabito⁶, M. Iero⁷, A. Ardizzoni⁸, ¹Università Cattolica del Sacro Cuore - Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ²University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, ³IRCCS Istituto Europeo Di Oncologia IEO, Milan, IT, ⁴Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ⁵Azienda Ospedaliera "Ospedali Riuniti Villa Sofia-Cervello", Palermo, IT, ⁶Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ⁷Roche S.p.A., Monza, IT, ⁸Azienda Ospedaliero-Universitaria S. Orsola -Malpighi, Bologna, IT

09:01 - 09:02 1534P - Phase II study of berzosertib + topotecan in patients with relapsed platinum (Pt)-resistant SCLC (DDRiver SCLC 250): Japanese safety run-in

T. Yoshida¹, Y. Fujisaka², T. Kurata³, N. Yamamoto¹, A. Thomas⁴, B. Sarholz⁵, R. Hallwachs⁵, J. Bolleddula⁶, T. Kuronita⁷, C. Moulin Correa⁸, L. Paz-Ares⁹, ¹National Cancer Center Hospital, Tokyo, JP, ²Osaka Medical and Pharmaceutical University Hospital, Osaka, JP, ³Kansai Medical University Hospital, Osaka, JP, ⁴National Cancer Institute, Bethesda, US, ⁵Merck Healthcare KGaA, Darmstadt, DE, ⁶EMD Serono Research & Development Institute Inc., (an affiliate of Merck KGaA), Billerica, US, ⁷Merck Biopharma Co., Ltd., (an affiliate of Merck KGaA), Tokyo, JP, ⁸Ares Trading SA, (an affiliate of Merck KGaA), Eysins, CH, ⁹Hospital Universitario 12 de Octubre, Madrid, ES

09:02 - 09:03 1535P - Efficacy and safety of amrubicin after treatment with immune checkpoint inhibitor combined with chemotherapy in extensive-stage small cell carcinoma: MiSSION1

T. Nishimura¹, H. Fujimoto², T. Fujiwara², K. Ito³, A. Fujiwara⁴, H. Yuda⁵, H. Itani⁶, C.N. D'Alessandro-Gabazza², E.C. Gabazza², T. Kobayashi², ¹Mie Chuo Medical Center, Tsu, JP, ²Mie University Faculty and Graduate School of Medicine, Tsu, JP, ³Matsusaka City Hospital, Matsusaka, JP, ⁴Mie Prefectural General Medical Center, Yokkaichi, JP, ⁵Kuwana city medical center, Kuwana, JP, ⁶Ise Red Cross Hospital, Ise, JP

09:03 - 09:04 1536P - Synthetic control arm (SCA) analysis of lurbinectedin compared to the standard of care (SoC) among patients with small cell lung cancer (SCLC) previously treated with platinum-based chemotherapy

D. Boyne¹, H. Shakir¹, O. Joe-Uzuegbu¹, D. Dawe², A. Pabani¹, E. Farah¹, C. Baratta³, W. Cheung¹, D. Brenner¹, ¹University of Calgary, Calgary, CA, ²CancerCare Manitoba, Winnipeg, CA, ³Jazz Pharmaceuticals Canada, Inc., Mississauga, CA

09:04 - 09:05 1538P - Prognostic impact of leptin (LEP)-mediated meta-inflammation (MI) in

patients (pts) receiving maintenance immunotherapy (IT) for extensive-stage small cell lung cancer (ES-SCLC)

E. Vita, A. Stefani, G. Piro, I. Sparagna, F. Monaca, M. Di Salvatore, M. Ferrara, D. Barone, E. D'Argento, C. Carbone, G. Tortora, E. Bria, Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, IT

09:05 - 09:06 **1539P - Real-world (RW) outcomes of second-line (2L) small cell lung cancer (SCLC) patients treated with lurbinectedin**

A. Estrin¹, X. Wang², A. Boccuti³, P. Prince¹, N. Gautam¹, B. Rengarajan³, W. Li², T. Lu³, Y. Cao², N. Naveh², R. D'Agostino⁴, R. Ben-Joseph³, A.K. Ganti⁵, ¹Aetion Inc., New York, US, ²Jazz Pharmaceuticals, Philadelphia, US, ³Jazz Pharmaceuticals, Palo Alto, US, ⁴Wake Forest University School of Medicine, Winston-Salem, US, ⁵VA Nebraska Western Iowa Health Care System/University of Nebraska Medical Center, Omaha, US

09:06 - 09:07 **1540P - Real-world analysis of outcomes of first-line chemo-immunotherapy in patients with extensive disease small cell lung cancer (ED-SCLC)**

N. Zellweger¹, S. Schmid², M. Bertschinger³, C. Waibel⁴, F. Cerciello⁵, P. Froesch⁶, M. Mark⁷, A. Bettini⁸, P. Häuptle⁹, V. Blum¹⁰, T. Litke¹¹, F. Helfenstein¹¹, M. Frueh², L. Mauti³, S. Rothschild¹², ¹Universitätsspital Basel, Basel, CH, ²Kantonsspital St. Gallen, St. Gallen, CH, ³KSW - Kantonsspital Winterthur, Winterthur, CH, ⁴Kantonsspital Baden, Baden, CH, ⁵Inselspital - Universitätsklinik für Medizinische Onkologie, Bern, CH, ⁶EOC - Ospedale Regionale di Locarno - Istituto Oncologico Svizzera Italiana (IOSI), Locarno, CH, ⁷KSGR - Kantonsspital Graubünden, Chur, CH, ⁸HFR - Hopital Cantonal, Fribourg, CH, ⁹Kantonsspital Liestal Medizinische Universitätsklinik, Liestal, CH, ¹⁰Luzerner Kantonsspital, Luzern, CH, ¹¹University Hospital Basel, Basel, CH, ¹²Universitätsspital Basel, Basel, CH

09:07 - 09:08 **1541P - Real-world data of atezolizumab plus carboplatin-etoposide for patients with extensive stage SCLC: The UK experience**

L. Moliner¹, L. Woodhouse¹, S. Ahmed², S. Bhagani², P. Sevak², A. Vijay², N. Steele³, H.-L. Gray³, S. Robinson⁴, M. Davidson⁴, M. O'Brien⁴, S. Cox⁵, C. Powell⁵, T. Khalid⁶, T. Geldart⁶, L. Hennah⁷, T. Newsom-Davis⁷, A. Denton⁸, F. Blackhall⁹, R. Califano⁹, ¹The Christie NHS Foundation Trust, Manchester, GB, ²Leicester Royal Infirmary - University Hospitals of Leicester NHS Trust, Leicester, GB, ³Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, ⁴The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ⁵Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff, GB, ⁶University Hospitals Dorset NHS Foundation Trust, Poole, GB, ⁷Chelsea and Westminster Hospital NHS Foundation Trust, London, GB, ⁸Northwick Park Hospital - London North West University Healthcare NHS Trust, Harwood, GB, ⁹The Christie NHS Foundation Trust and Division of Cancer Sciences, The University of Manchester, Manchester, GB

09:08 - 09:09 **1542P - First real-world outcome data of SCLC in Germany: Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315)**

M. Sebastian¹, M. Reck², R. Fischer³, D.C. Christoph⁴, C. Bernhardt⁵, E. Von Der Heyde⁶, A. Nusch⁷, P. Ludwig⁸, A. Hipper⁸, J. Hanselmann⁹, T. Medinger⁹, A. Binninger⁹, M. Jänicke¹⁰, P. Christopoulos¹¹, C. Elender¹², A. Bethge¹³, B. Seese¹⁴, T. Gauler¹⁵, C.

Waller¹⁶, ¹Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, DE, ²LungenClinic Grosshandorf, Grosshansdorf, DE, ³University Hospital Cologne, Köln, DE, ⁴Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen, DE, ⁵Private Practice - Christiane Bernhardt, Dortmund, DE, ⁶Private practice Dr Von der heyde, hannover, DE, ⁷Praxis, Ratingen, DE, ⁸AIO-Studien-gGmbH, Berlin, DE, ⁹iOMEDICO AG, Freiburg im Breisgau, DE, ¹⁰iOMEDICO AG, Freiburg, DE, ¹¹Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, DE, ¹²Medizinische Klinik Mitte Klinikum Dortmund GmbH, Dortmund, DE, ¹³Klinikum Bremen-Ost - Gesundheit Nord - Klinikverbund Bremen, Bremen, DE, ¹⁴Thoraxzentrum Bezirk Unterfranken, Münnerstadt, DE, ¹⁵Universitätsklinikum Essen, Essen, DE, ¹⁶University Medical Centre Freiburg and Faculty of Medicine, University of Freiburg, Freiburg, DE

09:09 - 09:10 **1543P - A retrospective cross-sectional study of treatment patterns in small cell lung cancer (SCLC) in Europe 2018–2021**

N. Reguart Aransay¹, S. Puntis², K. Ohrling³, A. Abbasi², K. Louie², M. Sebastian⁴, ¹Hospital Clinic, IDIBAPS, Barcelona, ES, ²Amgen Ltd, Uxbridge, GB, ³Amgen (Europe) GmbH, Rotkreuz, CH, ⁴University Hospital Frankfurt, Frankfurt, DE

09:10 - 09:11 **1544P - Pre-treatment CT radiomics predicts survival in chemo-immunotherapy-treated small cell lung cancer**

J. Bae¹, P. Prasanna¹, S. Gadgil², ¹SUNY Stony Brook University, Stony Brook, US, ²Henry Ford Cancer Institute-Henry Ford Health, Detroit, US

09:11 - 09:12 **1545P - A multicenter prospective observational study of pre-existing autoantibodies in patients with small cell lung cancer treated with ICI**

Y. Sato¹, S. Fujiwara¹, A. Hata², Y. Kida³, T. Masuda³, H. Amimoto⁴, H. Matsumoto⁵, K. Miyoshi⁶, K. Otsuka⁶, K. Tomii¹, ¹Kobe City Medical Center General Hospital, Kobe, JP, ²Kobe Minimally Invasive Cancer Center, Kobe, JP, ³Kobe City Nishi-Kobe Medical Center, Kobe, JP, ⁴Kobe City Medical Center West Hospital, Kobe, JP, ⁵Hyogo Prefectural Amagasaki Hospital, Amagasaki, JP, ⁶Shinko Hospital, Kobe, JP

09:12 - 09:13 **1546P - Impact of stratification factors on outcomes in limited-stage small cell lung cancer: Analysis of CALGB 30610 (Alliance)/RTOG 0538**

J. Bogart¹, X. Wang², G. Masters³, J. Gao², R. Komaki⁴, L. Gaspar⁵, J. Heymach⁶, J.A. Bonner⁷, C. Kuzma⁸, S.N. Waqar⁹, W. Petty¹⁰, T. Stinchcombe¹¹, J. Bradley¹², E. Vokes¹³, ¹SUNY Upstate Medical University, Syracuse, US, ²Duke Cancer Center - Duke University Medical Center, Durham, US, ³Helen F. Graham Cancer Center, Newark, US, ⁴The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁵UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, ⁶MD Anderson Cancer Center, Houston, US, ⁷University of Alabama at Birmingham Hospital, Birmingham, US, ⁸FirstHealth Outpatient Cancer Center, Pinehurst, US, ⁹Washington University School of Medicine in St. Louis - Siteman Cancer Center, St. Louis, US, ¹⁰Wake Forest University School of Medicine, North Carolina, US, ¹¹Duke Cancer Center, Durham, US, ¹²Winship Cancer Institute of Emory University, Atlanta, US, ¹³University of Chicago - Department of Medicine, Chicago, US

09:13 - 09:14 **1547P - Predictors of short-, medium-, and long-term survival with limited stage**

small cell lung cancer in the real-world

D. Dawe¹, R. Rittberg², O. Bucher¹, K. Galloway¹, I. Syed³, D. Moldaver³, K. Reynolds⁴, J. Paul¹, C. Harlos¹, S. Banerji¹, ¹CancerCare Manitoba, Winnipeg, CA, ²University of Manitoba - Faculty of Medicine - Internal Medicine, Winnipeg, CA, ³AstraZeneca Canada, Inc., Mississauga, CA, ⁴UBC - The University of British Columbia, Vancouver, CA

09:14 - 09:15 **1548P - Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy**

M. Shirasawa¹, T. Yoshida¹, K. Shiraishi², A. Takigami³, D. Takayanagi², T. Imabayashi², Y. Matsumoto¹, K. Masuda¹, Y. Shinno¹, Y. Okuma¹, Y. Goto¹, H. Horinouchi¹, T. Tsuchida², R. Hamamoto², N. Yamamoto¹, N. Motoi⁴, S.-I. Watanabe⁵, Y. Ohe¹, ¹National Cancer Center Hospital, Tokyo, Japan, Tokyo, JP, ²National Cancer Center - Tsukiji Campus, Chuo-ku, JP, ³Jichi Medical University Hospital, Shimotsuke, JP, ⁴Saitama Cancer Center Clinical Oncology Research Institute, Ina, JP, ⁵NCCH - National Cancer Center Hospital, Chuo-ku, JP

09:15 - 09:16 **1549TiP - DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC)**

S. Gadgeel¹, J. Al-Mondhiry², M.-J. Ahn³, S.-W. Kim⁴, L. Paz-Ares⁵, H. Prenen⁶, M. Boyer⁷, J. Bustamante Alvarez⁸, B. Solomon⁹, S. Huang¹⁰, M. Minocha¹⁰, M. Kistler¹⁰, N. Hashemi Sadraei¹⁰, ¹Henry Ford Cancer Institute, Detroit, US, ²University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, US, ³Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, ⁴Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁵Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Ciberonc and Universidad Complutense, Madrid, ES, ⁶UZA - University Hospital Antwerp, Edegem, BE, ⁷Chris O'Brien Lifecare, Camperdown, AU, ⁸West Virginia University, Morgantown, US, ⁹Avera McKennan Hospital & University Health Center, Sioux Falls, US, ¹⁰Amgen Inc., Thousand Oaks, US

09:16 - 09:17 **1550TiP - Phase II, multicenter, randomized, open-label study of DS-7300 in patients (pts) with pre-treated extensive-stage small cell lung cancer (ES-SCLC)**

L. Paz-Ares¹, M. Johnson², N. Girard³, C. Hann⁴, M.-J. Ahn⁵, M. Nishio⁶, J. Godard⁷, A. Laadem⁸, N. Yoshizuka⁸, M. Qian⁸, B. Cheng⁹, C. Rudin¹⁰, ¹Hospital Universitario 12 de Octubre, Madrid, ES, ²Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ³Institut Curie, Paris, FR, ⁴Johns Hopkins University School of Medicine, Baltimore, US, ⁵Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ⁶The Cancer Institute Hospital of JFCR, Koto-ku, JP, ⁷Daiichi Sankyo, Inc., Rueil-Malmaison, FR, ⁸Daiichi Sankyo, Inc., Basking Ridge, US, ⁹Daiichi Sankyo Inc., Basking Ridge, US, ¹⁰Memorial Sloan-Kettering Cancer Center, New York, US

09:17 - 09:18 **1559P - Towards more efficient multi-arm exercise trials in oncology: Application of a Bayesian adaptive decision-theoretic approach**

L. Buffart¹, A. Bassi², M. Stuijver³, N. Aaronson⁴, G. Sonke⁴, J. Berkhof², P. Van De Ven⁵, ¹Radboud University Medical Center, Nijmegen, Nijmegen, NL, ²Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, ³Netherlands Cancer Institute,

Amsterdam, NL, ⁴NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁵UMC - University Medical Center Utrecht, Utrecht, NL

- 09:18 - 09:19 **1560P - Barriers, facilitators, and preferences to exercise interventions in patients with metastatic breast cancer: A qualitative study in four European countries**
J. Depenbusch¹, M. Sweegers², N. Aaronson², Y. Wengström³, M. Backman³, J.I. Arraras⁴, M. Schranz⁵, B. Büchler⁵, M. Lachowicz⁶, A. May⁷, K. Steindorf¹, M. Stuiver², ¹DKFZ - German Cancer Research Center, Heidelberg, DE, ²NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ³Karolinska Institute, Huddinge, SE, ⁴Hospital Universitario de Navarra, Pamplona, ES, ⁵University Medical Center of the Johannes Gutenberg University Mainz, Mainz, DE, ⁶Medical University of Gdansk, Gdansk, PL, ⁷UMC - University Medical Center Utrecht, Utrecht, NL
- 09:19 - 09:20 **1561P - Changes of muscle mass, muscle strength and fatigue symptom scale during three cycles of chemotherapy in adult women breast cancer**
A. Kurniawan¹, N. Sutandyo², S.S. Panigoro³, R.D. Hatma⁴, R. Sumantri⁵, A. Adisasmita⁶, D.S. Rivami⁷, S. Budianto⁷, ¹Trainee Hematology and Medical Oncology, Faculty of Medicine, Universitas Indonesia; Faculty of Medicine, Pelita Harapan University, Tangerang, ID, ²RS Kanker Dharmais, West Jakarta, ID, ³RS Umum Pusat Nasional Dr Cipto Mangunkusumo, Faculty of Medicine, Universitas Indonesia, Jakarta, ID, ⁴Faculty of Public Health, Universitas Indonesia, North Jakarta, ID, ⁵RSUP Dr Hasan Sadikin Hospital Bandung, Bandung, ID, ⁶Faculty of Public Health, Universitas Indonesia, Depok, ID, ⁷UPH - Pelita Harapan University, Tangerang, ID
- 09:20 - 09:21 **1562P - Inpatient cancer rehabilitation for survivorship fatigue patients improves all outcomes, whereas fatigue response seems related to improved anxiety and creative therapies**
F. Strasser¹, V. Wen², J. Wiskemann³, ¹Cantonal Hospital St. Gallen & Cancer Fatigue Clinic, St. Gallen, CH, ²German Cancer Research Center - National Center for Tumor Diseases (NCT), Heidelberg, DE, ³NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE
- 09:21 - 09:22 **1563P - Cancer-related fatigue: Identification of hallmarks that could guide refined treatment approaches**
M. Schmidt, P. Blicke, K. Steindorf, DKFZ - German Cancer Research Center, Heidelberg, DE
- 09:22 - 09:23 **1564P - Cancer-related fatigue in colorectal cancer patients at the time of diagnosis**
A. Ruiz-Casado¹, F.F. Franco², M. Romero-Elias³, C. Fiuxa⁴, L. Gutiérrez Sanz¹, A. Alvarez-Bustos⁵, A. Sanchez Ruiz⁶, D. Garcia Gonzalez⁷, D. Gonzalez-Cutre³, H. Cebolla⁸, ¹University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES, ²Hospital Puerta de Hierro-Majadahonda, Madrid, ES, ³Universidad Miguel Hernández de Elche, Elche, ES, ⁴Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), Madrid, ES, ⁵HU de Getafe, Getafe, ES, ⁶Puerta de Hierro, Madrid, ES, ⁷Universidad Autonoma de Madrid, Madrid, ES, ⁸CSIC, Madrid, ES

- 09:23 - 09:24 **1565P - Predictive elements of cancer treatment symptom burden and the effectiveness of symptom treatment approaches**
K. Mooney¹, E. Iacob², G. Donaldson², ¹Huntsman Cancer Institute, Salt Lake City, US, ²University of Utah, Salt Lake City, US
- 09:24 - 09:25 **1566P - Sleep quality and depression in cancer patients receiving systemic chemotherapy: A prospective study**
C. Charonpongsuntorn, P. Tiranaprakij, S. Wangtawesap, P. Muangnoi, Srinakharinwirot University - Faculty of Medicine - Ongkharak Campus, Nakhon Nayok, TH
- 09:25 - 09:26 **1567P - Comparison of sociodemographic characteristics and physical and psychological health of adolescent and young adult (AYA) cancer survivors with those of the general population**
S. Kim¹, J. Cho², D. Kang², ¹SAIHST - Samsung Advanced Institute for Health Sciences & Technology, SKKU, Seoul, KR, ²Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR
- 09:26 - 09:27 **1568P - Physical condition in patients with a recent diagnosis of colorectal cancer**
M. Romero-Elias¹, A. Alvarez-Bustos², D. Garcia Gonzalez³, F.F. Franco⁴, R. Aguado⁵, L. Gutierrez Sanz⁵, A. Sanchez Ruiz⁶, H. Cebolla⁷, D. Gonzalez-Cutre¹, A. Ruiz-Casado⁵, ¹Universidad Miguel Hernández de Elche, Elche, ES, ²HU de Getafe, Getafe, ES, ³Universidad Autonoma de Madrid, Madrid, ES, ⁴Hospital Puerta de Hierro-Majadahonda, Madrid, ES, ⁵University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES, ⁶Puerta de Hierro, Madrid, ES, ⁷CSIC, Madrid, ES
- 09:27 - 09:28 **1570P - A deep learning model for prediction of chemotherapy infusion related symptoms using continuous heart rate variability**
H. Ahn¹, J.-H. Park¹, K.H. Yoo¹, J.H. Yeo¹, S.J. Lee², J.S. Park³, J. Um³, ¹Gachon University Gil Medical Center, Incheon, KR, ²EWHA Womans University Seoul Hospital, Seoul, KR, ³Kyung Hee University-Global Campus, Yongin, KR
- 09:28 - 09:29 **1571P - Cancer-related neuropathic pain (CRNP) in Europe: Impact of cancer stage on diagnosis and treatment of patients**
D. Dupoirion¹, S. Brill², C. Eeeltink³, D. Bell⁴, B. Barragán⁵, G. Petersen⁶, M. Eerdekens⁶, D. Ryan⁷, M. Rakuša⁸, ¹ICO - Institut de Cancerologie de l'Ouest - Site Paul Papin, Angers, FR, ²Tel Aviv Medical Center, Tel Aviv, IL, ³Dijklander Hospital, Hoorn, NL, ⁴Macmillan Cancer Support, Glasgow, GB, ⁵GEPAC, Madrid, ES, ⁶Grünenthal GmbH, Aachen, DE, ⁷Pain Alliance Europe, Brussels, BE, ⁸University Medical Centre Maribor, Maribor, SI
- 09:29 - 09:30 **1572P - Real-world evidence based on big data on the effects of opioids on chemotherapy-induced ulcerative mucositis in patients hospitalized for cancer treatment**
S.K. Poolakkad Sankaran¹, M. Ponnammah Mohan², ¹Roswell Park Comprehensive Cancer Center, Buffalo, US, ²Boston University - BioSquare, Boston, US
- 09:30 - 09:31 **1573P - Developing a patient-related predictive model for the occurrence of**

CINV (NOGGO-EMRISK trial): Prospective, multicentre study in Germany

J. Sehouli¹, G. Oskay-Öczelik², D. Zocholl¹, A.-S. Klemm³, N. Bangemann⁴, O. Albrecht⁵, H.-J. Strittmatter⁶, P. Wimberger⁷, A. Kaczerowsky⁸, R. Lorenz⁹, W. Ruhwedel¹⁰, T. Fehm¹¹, A. Zahn¹², O. Tome¹³, M. Markert¹⁴, D. Hager¹⁵, A. Zorr¹⁶, M. Keller¹⁷, H. Rittmeister¹, J. Grabowski¹, ¹Charité - Universitätsmedizin Berlin, Berlin, DE, ²MediOnko-Institut GbR, Berlin, DE, ³University Clinic Tübingen, Tübingen, DE, ⁴Hospital Carl-Thiem-Klinikum Cottbus, Cottbus, DE, ⁵St. Franziskus Hospital Münster, Münster, DE, ⁶Rems-Murr-Kliniken gGmbH, Winnenden, DE, ⁷Universitätsklinikum Carl Gustav Carus Dresden, Dresden, DE, ⁸Katholisches Marienkrankenhaus, Hamburg, DE, ⁹Frauenärztliche Gemeinschaftspraxis, Braunschweig, DE, ¹⁰State Hospital Gütersloh, Gütersloh, DE, ¹¹Heinrich-Heine-University Düsseldorf, Düsseldorf, DE, ¹²Elisabeth Krankenhaus Essen, Essen, DE, ¹³St.-Vincentius-Kliniken Frauenklinik, Karlsruhe, DE, ¹⁴ViDia Karlsruhe Diakonissenkrankenhaus, Karlsruhe, DE, ¹⁵Thüringer Kliniken "Georgius Agricola", Saalfeld, DE, ¹⁶Klinikum Konstanz, Konstanz, DE, ¹⁷Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie, Berlin, DE

09:31 - 09:32 **1574P - Randomized study to assess effect of L-carnitine on multiple toxicities caused by chemoradiation in head and neck cancer**

K. Puja¹, I. Yadav², K. Singh³, B.S. Chahar⁴, A.K. Arya³, ¹King George's Medical University, Lucknow, IN, ²VCSGG Institute of medical sciences and research, Srinagar, IN, ³S.N Medical college, Agra, IN, ⁴District Hospital Agra, Agra, IN

09:32 - 09:33 **1575P - Preservation of intercostobrachial nerve during axillary lymph node dissection in breast cancer patients positively impacts chronic pain, sensory changes, and quality of life: Should it be the new standard?**

A. Sasidhar, J. Ram Vishnoi, AIIMS - All India Institute of Medical Sciences, Jodhpur, Jodhpur, IN

09:33 - 09:34 **1576P - Efficacy of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A network meta-analysis**

M. Filetti¹, P. Lombardi², R. Falcone¹, D. Giannarelli¹, A. Carcagnì³, R. Giusti⁴, G. Scambia⁵, G. Daniele¹, ¹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ²Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, IT, ³Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, IT, ⁴AOU Sant'Andrea, Rome, IT, ⁵U.O. di Ginecologia Oncologica - Fondazione Policlinico Universitario Gemelli Università Cattolica del Sacro Cuore di Roma, and MITO, Rome, IT

09:34 - 09:35 **1577P - Optimizing the management of PARP inhibitors in clinical practice: Results of a DELPHI French consensus**

F. Selle¹, F. Scotté², J.-J. Boffa³, G. Etienne⁴, A. Angelergues⁵, P. Augereau⁶, D. Berton-Rigaud⁷, P. Dielenseger², M. Fabbro⁸, C. Falandry⁹, P. Follana¹⁰, L. Gladieff¹¹, F. Joly Lobbedez¹², J.E. Kurtz¹³, C. Matta¹⁴, M.A. Mouret Reynier¹⁵, A. Schmitt¹⁶, C. Marjollet¹⁷, A. Floquet¹⁸, ¹Groupe Hospitalier Diaconesses Croix Saint-Simon, and GINECO, Paris, FR, ²Institut Gustave Roussy, Villejuif, Cedex, FR, ³Hopital Tenon AP-HP, Paris, Cedex, FR, ⁴Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ⁵Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, FR, ⁶Centre Paul Papin, Angers, FR, ⁷ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁸ICM - Institut du Cancer de Montpellier, Montpellier,

Cedex, FR, ⁹Lyon Sud Hospital Center, Pierre Benite, FR, ¹⁰Centre Anticancer Antoine Lacassagne, Nice, FR, ¹¹Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ¹²Centre Francois Baclesse, Caen, Cedex, FR, ¹³ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ¹⁴Institut Curie, Paris, FR, ¹⁵Jean Perrin Center, Clermont-Ferrand, FR, ¹⁶Centre Georges-François Leclerc (Dijon), Dijon, FR, ¹⁷IMAGYN, Paris, FR, ¹⁸Institute Bergonié, Bordeaux, FR

- 09:35 - 09:36 **1578P - Scalp cooling system for prevention of chemotherapy induced alopecia: A single center one-year prospective observational study**
V. Agarwala¹, C. Mv¹, A. Daga¹, M. Basu¹, M. Ganguly¹, S. Kumar², K. Mandal¹, S. Chakraborty¹, D. Sunani¹, N. Choudhary¹, K. Basu¹, S. Das¹, S. Mallik¹, ¹Narayana Superspeciality Hospital & Cancer Institute, Howrah, IN, ²MMC&H - Malda Medical College & Hospital, Malda, IN
- 09:36 - 09:37 **1579P - Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: A meta-analysis of randomized controlled trials**
J.G. Pandey¹, P. Franco², ¹St. Luke's Medical Center - Quezon City, Quezon, PH, ²St. Luke's Medical Center - Global City, Taguig City, PH
- 09:37 - 09:38 **1580P - Effect of combined use of proton pump inhibitors with cisplatin on platinum nephrotoxicity**
T. Ugur¹, O. Sutcuoglu¹, A. Özet¹, N. Ozdemir², O. Yazici¹, ¹Gazi University - Faculty of Medicine, Ankara, TR, ²Ankara Numune Education and Research Hospital, Ankara, TR
- 09:38 - 09:39 **1581P - Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors (ICIs): Pooled analysis of individual cases from multiple institutions and literature**
A. Boutros¹, A. Bottini², G. Rossi², E.T. Tanda², F. Spagnolo², G. Barletta², P. Fava³, A. Parisi⁴, F. De Rosa⁵, M. Palla⁶, R. Marconcini⁷, M. Grandis⁸, P. Spallarossa², M. Sarocchi², E. Arboscello², L. Del Mastro⁹, P. Pronzato², C. Genova¹⁰, ¹Medical Oncology 2, IRCCS Ospedale Policlinico San Martino, Genova, IT, ²IRCCS Ospedale Policlinico San Martino, Genova, IT, ³Dermatologic Clinic, University of Turin, Torino, IT, ⁴University of L'Aquila, L'Aquila, IT, ⁵IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, IT, ⁶Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ⁷AOU Pisana, Pisa, IT, ⁸University of Genova, Genova, IT, ⁹Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genoa, Genova, IT, ¹⁰Università degli Studi di Genova e Ospedale Policlinico San Martino IRCCS - DiMI, Genova, IT
- 09:39 - 09:40 **1582P - Real-world management of immune-related adverse events in the community setting**
D. Johnson¹, D. Bruno², M. Rioth³, C. Zhang³, J. Palaia⁴, R. Pisupati⁵, C. Bond⁴, L. Rosenblatt⁶, R. Broome³, M. Teka³, H. Kluger⁷, ¹Vanderbilt University Medical Center, Nashville, US, ²Case Western Reserve University / University Hospitals, Cleveland, US, ³Syapse, San Francisco, US, ⁴BMS - Bristol-Myers Squibb, Princeton, US, ⁵Bristol Myers Squibb, Princeton, US, ⁶Bristol-Myers Squibb, Lawrenceville, US, ⁷Yale Cancer Center Breast Center, New Haven, US

- 09:40 - 09:41 **1583P - Evaluation of immune checkpoint inhibitors rechallenge after immune-related adverse events in patients with cancer**
X.-R. Tang, R. Li, F. Zhao, X. Wen, Y.-K. Wang, R.-X. Lv, Nanfang Hospital of Southern Medical University, Guangzhou, CN
- 09:41 - 09:42 **1584P - Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) in a real-world analysis: A risk prediction nomogram**
A. Ferro¹, F. Girardi¹, G. Pretelli², C. Mulargiu², M.V. Resi², B. Benetti², G.M. Marinato², M. Lorenzi², A. Dal Maso², S. Frega¹, G. Pasello², V. Guarneri², L. Bonanno¹, ¹Veneto Institute of Oncology - IRCCS, Padova, IT, ²University of Padua, Padova, IT
- 09:42 - 09:43 **1585P - Thromboprophylaxis “challenge” in oncology patients with high burden for thrombosis: Real-world data from GMaT and ACT4CAT studies**
N. Tsoukalas, A. Christopoulou, E. Timotheadou, A. Koumarianou, A. Ardavanis, I. Athanasiadis, M. Demiri, A. Bokas, G. Samelis, S. Peroukidis, G. Papatsimpas, C. Andreadis, A. Nikolakopoulos, A. Psyrri, N. Kapodistrias, P. Papakostas, G. Aravantinos, A. Athanasiadis, P. Papakotoulas, I. Boukovinas, On behalf of the Hellenic Society of Medical Oncology, Athens, GR
- 09:43 - 09:44 **1586P - Improving the management of anaemia in cancer patients receiving chemotherapy: ESMO clinical practice guidelines in action**
J. Broadfoot, K. Teasdale, L. Nolan, Southampton General Hospital, Southampton, GB
- 09:44 - 09:45 **1587P - Joint effect of cardiovascular disease and cancer: Analysis of national health insurance data of cancer patients who had cardiovascular disease before cancer diagnosis**
J. Lee¹, J. Cho¹, D. Kang², S. Kim¹, ¹SAIHST - Samsung Advanced Institute for Health Sciences & Technology, SKKU, Seoul, KR, ²Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR
- 09:45 - 09:46 **1588P - Clinical evaluation of plinabulin’s granulocyte-monocyte progenitor (GMP) stem cell effects for the prevention of chemotherapy-induced neutropenia (CIN)**
D. Blayney¹, R. Mohanlal², L. Huang³, ¹Stanford Comprehensive Cancer Institute, Stanford, US, ²BeyondSpring Pharmaceuticals, New York, US, ³BeyondSpring Pharmaceuticals, Bronx, US
- 09:46 - 09:47 **1589P - Chronological pattern of venous thromboembolism (VTE) occurrence impacts in survival of pancreatic ductal adenocarcinoma (PDAC)**
I. Gonzalez Caraballo¹, R. Martín Lozano¹, R. Jiménez Rodríguez¹, B. Lobato Delgado², M.A. Cañete Muñoz³, M. Benavente³, M. Palma⁴, M. De Toro Carmena⁵, B. Morón⁴, V. Tirado Anula⁴, J. Soto Alsar⁵, M. Bringas Beranek⁵, N. Gutierrez Alonso⁵, C. López Jiménez³, A. Gutiérrez Ortiz De La Tabla³, D. Juliao Caamaño³, L. Ortega Morán³, J.M. Soria Fernandez², M. Martin Jimenez⁴, A. Munoz Martin³, ¹Hospital General Universitario Gregorio Marañón, Madrid, ES, ²Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ³Hospital General Universitario Gregorio Marañón, Madrid, ES, ⁴Hospital General Universitario Gregorio Marañón, Madrid, ES, ⁵Hospital General Universitario Gregorio Marañón - Fundación Investigación Biomedica, Madrid, ES

- 09:47 - 09:48 **1590P - Interest of preventive treatment with anticoagulant in older patients with cancer on venous thrombo-embolic events (ANTIGONE study): Design and baseline results**
O. Hanon¹, E. Paillaud², A. Baudin², S. Chaoui³, J. Canovas², L. Iratni², P. Lucas³, H. Mabungu³, M. Villebrun¹, C. Chambraud², F. Rollot-Trad⁴, M. Bringuier⁴, A. Broussier², N. Spiess⁵, I. Elalamy¹, F. Canouï-Poitaine², ¹Assistance Publique - Hopitaux De Paris, Paris, FR, ²Assistance Publique - Hopitaux De Paris, Créteil, FR, ³Gérond'if, Paris, FR, ⁴Institut Curie, Paris, FR, ⁵LEO PHARMA, Voisins Le Bretonneux, FR
- 09:48 - 09:49 **1591P - Swedish national population-based study of direct oral anticoagulants and low molecular weight heparin treatment for thromboembolism in cancer patients: The OSCAR SWE study**
M. Linder, Karolinska Institutet, Stockholm, SE
- 09:49 - 09:50 **1592P - Cardiovascular toxicity in patients treated with a PARP inhibitor for solid tumors: A meta-analysis**
M.C. Cannizzaro¹, C. Ciccarese², A. Palazzo², M. Pasqualoni¹, L. Pontolillo¹, R. Iacovelli², E. Bria¹, G. Tortora¹, ¹Università Cattolica del Sacro Cuore - Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT
- 09:50 - 09:51 **1593P - Real-world data on anemia management in patients with solid tumors and malignant lymphoma in Germany**
H. Link¹, M. Kerkmann², L. Holtmann², ¹Private Practice - Dr. Hartmut Link, Kaiserslautern, DE, ²MMF Münster, Münster, DE
- 09:51 - 09:52 **1594P - Outcome, mortality and 30-day readmission of pericardial effusion in cancer patients**
J. Kaur¹, P. Singh², S. Mehta¹, A. Morani¹, Y. Nadeem¹, T. Mir³, ¹Saint Joseph Mercy Oakland Hospital, Pontiac, US, ²Karmanos Cancer Institute, Detroit, US, ³Wayne State University, Detroit, US
- 09:52 - 09:53 **1595P - QTc-prolonging drug-drug interactions related to CDK4/6 inhibitors**
E. Giraud¹, J. Chiong², J. Martin², D. Burger¹, N. Van Erp¹, E. Smolders³, ¹Radboud University Medical Center, Nijmegen, Nijmegen, NL, ²University of Liverpool, Liverpool, GB, ³Isala Hospital, Zwolle, NL
- 09:53 - 09:54 **1596P - The G8 screening tool as an independent predictor of survival in elderly cancer patients**
A. Mennitto¹, F. Biello¹, L.G. Forti¹, G. Siffredi¹, A. Mokhtar Mahmoud², F. Invernizzi², P.M. Maggiora², A. Rua², C. Branni¹, E. Gioffi², V. Martini¹, S. Gobbato², C. Pisani¹, E. Ferrara¹, M. Cappelli¹, E. Catania¹, D. Ferrante², G. Gaidano², M. Krengli², A. Gennari³, ¹AOU Maggiore della Carità di Novara, Novara, IT, ²Università del Piemonte Orientale, Novara, IT, ³Università Degli Studi Del Piemonte Orientale - Scuola di Medicina, Novara, IT

- 09:54 - 09:55 **1597P - Improving hospitality for cancer patients at the hospital**
K. Lê Van¹, F. Ninane¹, L. Terrier², C. Arditi³, A. Savoie¹, S. Rochat⁴, I. Peytremann Bridevaux³, M. Eicher¹, B. Schaad³, ¹CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ²EHL Hospitality Business School, HES-SO, University of Applied Sciences and Arts Western Switzerland, Lausanne, CH, ³University of Lausanne, Lausanne, CH, ⁴Patient representative, Neuchâtel, CH
- 09:55 - 09:56 **1598P - Results and feasibility of a pragmatic designed onco-geriatric assessment (POgA)**
A.F. Ferreira Filho¹, D.S. Daniela Lessa¹, R. Van Der Ham², B. Caroline³, K. Luisa³, ¹Oncosinos & Feevale University, Porto Alegre, BR, ²Oncosinos Clinica de Oncologia, Novo Hamburgo, BR, ³Oncosinos Clinica de Oncologia, Porto Alegre, BR
- 09:56 - 09:57 **1599P - Intrapericardial cisplatin as treatment for malignant pericardial effusion: 13-year experience at Hospital Clinic of Barcelona**
F.J. Muñoz I Carrillo, P. Amorós, D. Pesantez Coronel, R. Reyes, T. Barreto Zambrano, G. Carrera Domenech, E. Cascos, P. Castro, S. Fernández-Méndez, M.C. Font Puig, L. González-Aguado, I. Monge, J. Padrosa, N. Reguart Aransay, A. Téllez, A. Tuca, M. Viladot, C. Zamora, J. Marco Hernández, Hospital Clinic y Provincial de Barcelona, Barcelona, ES
- 09:57 - 09:58 **1600P - The role of C-reactive protein/albumin ratio in predicting 90-day mortality in patients with febrile neutropenia**
O. Yazici¹, O. Sutcuoglu¹, N. Rustamova², A. Uner³, A. Özet¹, N. Ozdemir¹, ¹Gazi University - Faculty of Medicine, Ankara, TR, ²Gazi University - Faculty of Medicine, Istanbul, TR, ³Gazi University Medical School, Ankara, TR
- 09:58 - 09:59 **1601P - Predictors of in-hospital mortality after unplanned admissions among adults with cancer aged 80 years and older**
F. Lazar Neto, C.M. Hidalgo Filho, J.W. Rocha, V. Sobottka, L. Stangler, G. Benfatti, H. Guedes, M. Claro, R. Bonadio, M. Diz, P. Hoff, ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR
- 09:59 - 10:00 **1602P - Causes of unplanned hospitalizations and factors associated with in-hospital mortality among patients receiving chemotherapy treatment**
C.M. Hidalgo Filho, F. Lazar Neto, J.W. Rocha, V. Sobottka, L. Stangler, G. Benfatti, H. Guedes, M. Claro, R. Bonadio, M. Diz, P. Hoff, ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR
- 10:00 - 10:01 **1603P - An evaluation of Cancer Aging Research Group (CARG) score to predict chemotherapy toxicity in Iranian older cancer patients**
A. Ameri¹, N. Rahnema², F. Talebi², A. Sourati³, F. Taghizadeh-Hesary⁴, ¹Imam Hossein Hospital, Tehran, IR, ²Shahid Beheshti University of Medical Sciences, Tehran, IR, ³Emam Hosein Hospital, Tehran, IR, ⁴Iran University of Medical Sciences, Tehran, IR
- 10:01 - 10:02 **1604P - Assessing lung cancer patients' unplanned hospitalizations, a cohort study to find care gaps: Tracking what is trackable**

J. Sanchez, B. Nunez Garcia, M. Blanco Clemente, B. Cantos, V. Calvo De Juan, M. Mendez Garcia, R. Aguado, D. Ruiz De Domingo, M. Sánchez Del Corral, M. Provencio Pulla, Puerta de Hierro-Majadahonda University Hospital, Majadahonda, ES

- 10:02 - 10:03 **1605P - Comparison of the prognostic value of comorbidities in older patients with colorectal, breast, prostate or lung cancer: The ELCAPA cohort study**
M.-A. Benders¹, A. Gonzalez-Serrano², E. Paillaud³, C. Martinez-Tapia², T. Cudennec⁴, C. Chouaid⁵, E. Lorisson², A. De La Taille², M. Laurent³, E. Brain⁶, M. Bringuier⁷, J. Gligorov⁸, P. Caillet⁹, F. Canouï-Poitrine⁹, ¹Hopital Tenon AP-HP, Paris, Cedex, FR, ²Université Paris Est Créteil, Créteil, FR, ³Assistance Publique - Hopitaux De Paris, Paris, FR, ⁴Hopital Ambroise Pare AP-HP, Boulogne-Billancourt, FR, ⁵CH Intercommunal de Créteil, Créteil, FR, ⁶Hopital René Huguenin - Institut Curie, Saint-Cloud, FR, ⁷Institut Curie, Paris, FR, ⁸Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR, ⁹Centre Hospitalier Universitaire Henri-Mondor AP-HP, Creteil, FR
- 10:03 - 10:04 **1606P - Health care literacy impact on Portuguese cancer patients' perceived information**
B. Lima, J. Barbosa-Martins, A. Barbosa, J. Mendonca, A. Rolo Dos Santos, L. Oliveira, C. Carvalho, I. Faustino, A. Teixeira, C. Coutinho, Hospital Da Senhora Da Oliveira Guimaraes EPE - SNS, Guimaraes, PT
- 10:04 - 10:05 **1607P - Evaluation of scientific reliability and popularity of YouTube videos on cancer and nutrition**
O. Sutcuoglu, Z.İ. Özey, A. Özet, O. Yazici, N. Ozdemir, Gazi University - Faculty of Medicine, Ankara, TR
- 10:05 - 10:06 **1608P - Feasibility of the PENS approach for breaking bad news (BBN) in the Indian oncology outpatient setting**
S. Mailankody¹, S. Lewis Salins¹, A. Pai², K. Udupa², R. Shenoy², P. Sherigar¹, S.R. Rao³, ¹Kasturba Medical College and Hospital - Shirdi Sai Baba Cancer Center, Manipal, IN, ²KMC - Kasturba Medical College, Manipal, Manipal, IN, ³Karunashraya Hospice - Bangalore Hospice Trust, Bangalore, IN
- 10:06 - 10:07 **1609P - Cannabis impacts on serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer**
A. Zer, T. Goshen - Lago, I. Ben-Aharon, M. Passhak, Rambam Health Care Campus, Haifa, IL
- 10:07 - 10:08 **1610P - Humoral immune response to COVID-19 vaccination in patients with cancer: The ANRS0001S COV-POPART study**
L.B. Luong Nguyen¹, M. Chalouni², P. Loubet³, N. Dohollou⁴, O. Tredan⁵, M. Veyri⁶, Z. Maakaroun-Vermesse⁷, I. Ben Ghezala⁸, E. Fourn⁹, D. Merrien¹⁰, C. Cracowski¹¹, A. Barquin², A. Levier¹², L. Wittkop², O. Launay¹³, J.-Y. Blay¹⁴, J.-P. Spano¹⁵, ¹Assistance Publique - Hopitaux De Paris, Hôpital Cochin, Paris, France, Paris, FR, ²University of Bordeaux-Bordeaux Population Health, Bordeaux, Cedex, FR, ³Infectious disease department, CHU Nimes, Université de Montpellier, Nimes, Nimes, FR, ⁴Unicancer Bordeaux, France, Bordeaux, FR, ⁵Medical Oncology, Lyon, FR, ⁶Sorbonne Université, INSERM, IPLESP, Paris, FR, ⁷CHRU Hopitaux de Tours - Hopital Bretonneau, Tours,

cedex, FR, ⁸CHU Dijon, Dijon, FR, ⁹Hopital Foch, Suresnes, FR, ¹⁰CHD Vendee - Hopital Les Oudairies, La Roche-sur-Yon, FR, ¹¹CHU Grenoble Alpes, La Tronche, FR, ¹²ANRS | MIE - Agence Nationale de Recherche sur le SIDA, les hépatites virales et maladies infectieuses émergentes, Paris, FR, ¹³Assistance Publique - Hopitaux De Paris, Paris, FR, ¹⁴Centre Léon Bérard, Lyon, FR, ¹⁵Hopital Pitié Salpêtrière AP-HP, Paris, FR

- 10:08 - 10:09 **1611P - Clinical determinants of SARS-CoV-2 vaccine response in adults with cancer**
E. Segelov¹, A. Body¹, L. Lal¹, H. Abdulla¹, S. Turville², Z. Naing³, S. Opat¹, M. Leahy⁴, J. Balendra⁴, N. Hamad⁵, R. Mccuaig⁶, S. Rao⁷, K. Lineburg⁸, C. Smith⁸, C.R. Macintyre², V. Milch⁹, L. Busija¹⁰, E. Ahern¹, ¹Monash Health - Monash Medical Centre, Clayton, AU, ²The Kirby Institute - UNSW Sydney, Sydney, AU, ³New South Wales Health Pathology, Camperdown, AU, ⁴Royal Perth Hospital, Perth, AU, ⁵St Vincent's Hospital Sydney, Darlinghurst, AU, ⁶QIMR Berghofer, Brisbane, AU, ⁷QIMR Berghofer, Herston, AU, ⁸QIMR Berghofer Medical Research Institute, Brisbane, AU, ⁹Cancer Australia, Surry Hills, AU, ¹⁰Monash University, Prahran, AU
- 10:09 - 10:10 **1612P - Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy**
D.C. Guven¹, F.G. Gulbahce Incesu², H. Yildirim¹, E. Erul², E. Chalabiyev¹, B. Aktas¹, D. Yuce², Z. Arik¹, S. Kilickap¹, S. Aksoy¹, M. Erman², K.M. Hayran², S. Unal³, A. Alp², O. Dizdar², ¹Hacettepe University Oncology Hospital, Ankara, TR, ²Hacettepe University - Faculty of Medicine, Ankara, TR, ³Hacettepe University Faculty of Medicine, Ankara, TR
- 10:10 - 10:11 **1613P - Prevalence and predictive value for 6-month mortality of four criteria for assessment of sarcopenia in older patients with cancer: NutriAgeCancer national prospective cohort study**
C. Martinez-Tapia¹, K. Rougette², V. Fossey-Diaz³, T. Cudennec⁴, C. Taleb⁵, B. Beauplet⁶, L. Balardy⁷, C. Mertens⁸, N. Mitha⁹, M. Bringuier¹⁰, E. Cotto¹¹, S. Estivin¹², V. Quipourt¹³, F. Canoui-Poitaine¹⁴, C. Baldini¹⁵, E. Paillaud¹⁶, ¹Université Paris Est Créteil, Créteil, FR, ²HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, ³Hopital Bretonneau AP-HP, Paris, FR, ⁴Hopital Ambroise Pare AP-HP, Boulogne-Billancourt, FR, ⁵Hopital René Muret - AP HP, Sevran, FR, ⁶Chu De Caen Normandie - Hôpital Clemenceau (CHR), Caen, Cedex, FR, ⁷Centre Hospitalier Universitaire de Toulouse - Hopital Purpan, Toulouse, FR, ⁸Institute Bergonié, Bordeaux, FR, ⁹CHU Grenoble Alpes - Site Nord (La Tronche), La Tronche, FR, ¹⁰Institut Curie, Paris, FR, ¹¹Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, FR, ¹²CHRU Brest - Hopital Augustin Morvan, Brest, FR, ¹³CHU Dijon, Dijon, FR, ¹⁴Centre Hospitalier Universitaire Henri-Mondor AP-HP, Créteil, FR, ¹⁵Institut Gustave Roussy, Villejuif, Cedex, FR, ¹⁶Assistance Publique - Hopitaux De Paris, Georges Pompidou European Hospital, Paris, FR
- 10:11 - 10:12 **1614P - Influence of cancer on COVID-19 vaccine beliefs, attitudes and uptake**
M. Nguyen¹, N. Bain¹, L. Grech², A. Kwok¹, N. Hamad³, A. Tognela⁴, B. Chan⁵, L. Nott⁶, S. Harris⁷, N. Chau⁸, C. Underhill⁹, D. Day¹, A. McCartney¹, K. Webber¹, E. Segelov¹, ¹Monash Health - Monash Medical Centre, Clayton, AU, ²Monash University, Clayton, AU, ³St Vincent's Hospital Sydney, Darlinghurst, AU, ⁴Macarthur Cancer Therapy Centre, Campbelltown, AU, ⁵Sunshine Coast University Hospital, Birtinya, AU, ⁶Icon Cancer

Centre, Hobart, AU, ⁷Bendigo Health, Bendigo, AU, ⁸Latrobe Regional Hospital, Traralgon, AU, ⁹Border Medical Oncology Murray Valley Private Hospital, Wodonga, AU

- 10:12 - 10:13 **1615P - The association of social distancing and obligatory face masks during COVID-19 era with the rates of febrile neutropenia in patients with solid tumors receiving antineoplastic therapy**
T. Shentzer Kutiel, A. Stern, M. Moskovits, Rambam Health Care Campus, Haifa, IL
- 10:13 - 10:14 **1616P - The mortality burden of cachexia in patients with non-small cell lung cancer: A systematic literature review**
P. Bonomi¹, J. Crawford², R. Dunne³, K. Smoyer⁴, T.D. Mcrae⁵, M. Rossulek⁶, J. Revkin⁶, L. Tarasenko⁵, ¹Rush University Medical Center, Chicago, US, ²Duke University Medical Center, Durham, US, ³University of Rochester Medical Center, Rochester, US, ⁴Envision Pharma Group, Philadelphia, US, ⁵Pfizer Inc, New York, US, ⁶Pfizer Inc, Cambridge, US
- 10:14 - 10:15 **1617P - Impact of nutritional counselling (NC) on CT-based body composition in patients with oncogene addicted advanced non-small cell lung cancer (aNSCLC)**
A.M. Morelli¹, M. Bungaro², I. Capizzi³, E. Parlagreco², F. Solitro³, L. Eletti³, S. Martinetto³, A. Veltri³, M. Tinivella³, P. Pedrazzoli⁴, R. Caccialanza⁴, V. Bertaglia², E. Capelletto², M.L. Reale², S. Novello², M. Tampellini¹, ¹ASL TO3 Rivoli Hospital, Rivoli, IT, ²University of Turin, San Luigi Gonzaga Hospital, Orbassano, IT, ³University of Turin, San Luigi Hospital, Orbassano, IT, ⁴Fondazione IRCCS Policlinico San Matteo, Pavia, IT
- 10:15 - 10:16 **1618P - Impact of body composition phenotypes on outcome of non-small cell lung cancer patients treated with immunotherapy**
I. Trestini¹, A. Caldart¹, A. Dodi¹, M. Cintoni², M. Sposito¹, L. Belluomini¹, J. Menis¹, E. Vita², I. Sperduti³, A. Drudi¹, G. Aluffi¹, M. Todesco¹, D. Tregnago¹, A. Avancini⁴, M. D'Onofrio¹, M.C. Mele², G. Tortora², M. Milella¹, E. Bria², S. Pilotto¹, ¹University Hospital Trust of Verona, Verona, IT, ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ³IRCCS Regina Elena National Cancer Institute, Rome, IT, ⁴University of Verona - Faculty of Medicine, Verona, IT
- 10:16 - 10:17 **1619P - Assessment of the pharmacokinetic interaction of enzalutamide with oxycodone in men with prostate cancer: The ENZYME study**
S. Detert Oude Weme, W. Vervenne, A. Imholz, R. Cremers, I. Van Berlo - Van De Laar, F. Jansman, G. Benoist, Deventer Ziekenhuis, Deventer, NL
- 10:17 - 10:18 **1620P - Return to work trajectories after early breast cancer diagnosis: A population-based cohort study in the French National Healthcare Insurance database**
R. Varnier, A. Moskal, A. Dima, C. Bodelet, J. Peron, M. Lamort-Bouché, J.-B. Fassier, M. Viprey, Université Claude Bernard Lyon 1, Lyon, FR
- 10:18 - 10:19 **1621P - miRNA signature as early predictor of hyponatremia and survival in lung cancer: Preliminary results from the ISA retrospective study**
G. Mentrasti¹, E. Ambrosini², L. Giuliani¹, N. Chiodi², C. Liguori¹, M. Gualtieri¹, F. Bianchi², F. Barbisan², G. Goteri², M.B.L. Rocchi³, R. Berardi¹, ¹Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, Torrette di Ancona, IT, ²Università

Politecnica delle Marche, Ancona, IT, ³Università degli Studi di Urbino, Urbino, IT

- 10:19 - 10:20 **1622P - A comparative study of the impact of countries' health expenditure on the support experiences of patients with lymphoma and CLL in Europe**
O. Bamigbola, L. Warwick, Lymphoma Coalition - Head Office, Mississauga, CA
- 10:20 - 10:21 **1623P - Drug-drug interactions with tyrosine kinase inhibitors**
N. Janus, LEO Pharma, Voisins-le-Bretonneaux, FR
- 10:21 - 10:22 **1624P - Do external factors such as weather affect patient reported outcomes of patients with malignant diseases?**
D. Pink¹, J. Bahr², D. Andreou³, M. Eichler⁴, H. Salm², ¹HELIOS Klinikum Bad Saarow, Bad Saarow, DE, ²University Hospital Greifswald, Germany, Greifswald, DE, ³Sarcoma Center Berlin-Brandenburg, Helios Hospital, Bad Saarow, DE, ⁴National Center for Tumor Diseases (NCT/UCC), Dresden, DE
- 10:22 - 10:23 **1625P - Cyclin-dependent kinase 4/6 inhibitors (CDKI)-associated venous thromboembolism in patients with hormone receptor (HR)-positive breast cancer**
K. Thein¹, T. Win Htut², Y. Myat¹, M. Han³, T. Oo⁴, ¹OHSU - Oregon Health Science University, Portland, US, ²Aberdeen Royal Infirmary, Scotland, GB, ³Interfaith Medical Center, Brooklyn, US, ⁴UT MD Anderson Cancer Center, Houston, US
- 10:23 - 10:24 **1626P - Time trends (2012-2016 vs 2017-2021) in health-related quality of life (QoL) assessment and reporting in oncology: A systematic review of randomized phase III trials**
L. Marandino¹, F. Trastu², E. Ghisoni³, P. Lombardi⁴, A. Mariniello⁵, M.L. Reale⁵, G. Aimar⁶, M. Audisio⁵, M. Bungaro⁵, A. Caglio², R. Di Liello⁷, T. Gamba², P. Gargiulo⁷, C. Paratore⁵, A. Rossi⁸, V. Tuninetti², F. Turco⁵, F. Perrone⁷, M. Di Maio², ¹IRCCS Ospedale San Raffaele, Milano, IT, ²University of Turin, Ordine Mauriziano Hospital, Turin, IT, ³Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne, CH, ⁴Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, IT, ⁵University of Turin, San Luigi Gonzaga Hospital, Orbassano, IT, ⁶University of Turin; Santa Croce e Carle Hospital, Turin; Cuneo, IT, ⁷Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, IT, ⁸"La Sapienza" University of Rome, Azienda Ospedaliera Sant'Andrea, Rome, IT
- 10:24 - 10:25 **1627TiP - Impact of patient education on immune-related adverse events (irAEs) during immune checkpoint inhibitor (ICI)**
V. Berger¹, C. Jubé², A. Forestier³, C. Mitonneau⁴, H. Humeau⁴, S. Limouzin⁵, M. Tiercin⁶, L. Morlière⁷, L. Geoffrois⁸, M. Cabart⁹, M. Bertholet¹⁰, C. Llambrich-Molines¹¹, S. Breysse¹², S. Laghouati¹³, N. Beaumont¹, ¹Institut de Cancérologie de l'Ouest, Angers, FR, ²Institut de Cancérologie de l'Ouest, St Herblain cedex, FR, ³Centre Oscar Lambret, Lille, FR, ⁴CHU Angers, Angers, Cedex, FR, ⁵CHD Vendée, La Roche / Yon, FR, ⁶CH St Malo, ST MALO, FR, ⁷Centre Léon Bérard, Lyon, FR, ⁸Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, ⁹Institute Bergonié - Centre

Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ¹⁰CHU Saint Etienne - Hopital Nord, Saint-Étienne, FR, ¹¹Institut Curie, Paris, FR, ¹²CH Emile Roux, Le Puy en Velay, FR, ¹³Institut Gustave Roussy, Villejuif, Cedex, FR

10:25 - 10:26

1628TiP - Romiplostim for chemotherapy-induced thrombocytopenia (CIT) in solid tumors: Two phase III, international, randomized controlled trials (RCT)

H. Al-Samkari¹, C. Geredeli², C. Arslan³, I. Korantzis⁴, G. Dogu⁵, M. Nechaeva⁶, M. Salgado Fernandez⁷, B. Gonzalez Astorga⁸, V. Yordanov⁹, T.-E. Ciuleanu¹⁰, C. Bowers¹¹, A. Armas¹¹, F. Scotté¹², J. Camargo¹³, C.G. Munoz Sanchez-Miguel¹⁴, P. Bunn¹⁵, D. Kuter¹, G. Soff¹⁶, ¹Massachusetts General Hospital Cancer Center, Boston, US, ²Health Sciences University, Prof. Dr. Cemil Taşcıoğlu City Hospital, Istanbul, TR, ³Izmir Economy University Medical Park Hospital, Izmir, TR, ⁴St Luke's Hospital-Agios Loukas Clinic, Thessaloniki, GR, ⁵Pamukkale University - Faculty of Medicine, Denizli, TR, ⁶Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, RU, ⁷Complejo Hospitalario Universitario de Ourense, Ourense, ES, ⁸Hospital Clinico Universitario San Cecilio, Granada, ES, ⁹Complex Oncology Centre-Ruse, Ruse, BG, ¹⁰IOCN - The Oncology Institute Prof. Dr. Ion Chiricuta, Cluj-Napoca, RO, ¹¹Amgen, Thousand Oaks, US, ¹²Institut Gustave Roussy, Villejuif, FR, ¹³IOP - Instituto de Oncologia do Paraná, Curitiba, BR, ¹⁴HM Hospitales, Madrid, ES, ¹⁵UC Health University of Colorado Hospital, Aurora, US, ¹⁶University of Miami Health System/Sylvester Comprehensive Cancer Center, Miami, US

10:26 - 10:27

1629P - Increased incidence of thymic epithelial tumors during COVID-19 pandemic: A retrospective analysis from the French RYTHMIC network

J.C. Benitez¹, J. Florez-Arango¹, M.-E. Boucher¹, E. Dansin², M. Kerjouan³, L. Bigay-Game⁴, E. Pichon⁵, F. Thillays⁶, P.-E. Falcoz⁷, S. Lyubimova⁸, Y. Oulkhovir⁹, F. Calcagno¹⁰, L. Thiberville¹¹, C. Clément-Duchêne¹², V. Westeel¹⁰, P. Thomas¹³, J.-M. Maury¹⁴, T. Molina¹⁵, B. Besse¹⁶, N. Girard¹⁷, ¹Gustave Roussy - Cancer Campus, Villejuif, Cedex, FR, ²Centre Oscar Lambret, Lille, FR, ³CHU de Rennes - Hopital Pontchaillou, Rennes, FR, ⁴CHU Toulouse-Hôpital Larrey, TOULOUSE, FR, ⁵CHRU Hopitaux de Tours - Hopital Bretonneau, Tours, cedex, FR, ⁶Centre Henri Becquerel, Rouen, FR, ⁷Hopitaux Universitaires de Strasbourg - Nouvel Hopital Civil, Strasbourg, FR, ⁸CHU de Montpellier - Hopital Gui de Chauliac, Montpellier, Cedex, FR, ⁹Chu De Caen Normandie - Hôpital Clemenceau (CHR), Caen, Cedex, FR, ¹⁰CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, ¹¹CHU de Rouen Normandie, Rouen, FR, ¹²CHRU Nancy, Nancy, FR, ¹³Assistance Publique Hopitaux de Marseille, Marseille, FR, ¹⁴CHU Lyon, Lyon, Cedex, FR, ¹⁵Hôpital Necker et Enfants, Paris, FR, ¹⁶Institut Gustave Roussy, Villejuif, FR, ¹⁷Institut Curie, Paris, FR

10:27 - 10:28

1630P - Effectivity and safety of anti-SARS-CoV2 vaccination in patients with lung cancer: The VAC-CaP observational study (GECP 21/01)

E. Nadal¹, M.T. Moran Bueno², D. Rodriguez Abreu³, Z. Vidales Sepulveda¹, M.A. Sala Gonzalez⁴, M. Antonanzas Basa⁵, J.J. Garcia Gonzalez⁶, P. Diz Tain⁷, M. Martinez Kareaga⁸, G. Lopez Vivanco⁹, J. Baena Espinar¹⁰, B. Campos Balea¹¹, D. Cumplido Buron¹², S. Cerezo Gonzalez¹³, A. Diaz¹⁴, M. Guirado¹⁵, X. Mielgo Rubio¹⁶, O.J. Juan Vidal¹⁷, M. Saigi Morgui², M. Provencio Pulla¹⁸, ¹ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ²ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ³Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-

Insular, Las Palmas de Gran Canaria, ES, ⁴Hospital Universitario de Basurto, Bilbao, ES, ⁵Hospital Clinico Universitario San Carlos, Madrid, ES, ⁶CHUS - Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, ⁷Complejo Asistencial Universitario de León - Hospital de León, León, ES, ⁸HUA - Hospital Universitario Araba - Txagorritxu, Vitoria-Gasteiz, ES, ⁹Hospital de Cruces, Barakaldo, ES, ¹⁰Hospital Universitario 12 Octubre, Madrid, ES, ¹¹Hospital Universitario Lucus Augusti (HULA), Lugo, ES, ¹²Hospital de Torrevieja, Alicante, ES, ¹³Hospital General Mancha Centro, Alcazar de San Juan, ES, ¹⁴Complejo Asistencial de Zamora, Zamora, ES, ¹⁵Hospital General Universitario de Elche, Elche, ES, ¹⁶Hospital Universitario Fundación Alcorcón, Alcorcon, ES, ¹⁷Hospital Universitari i Politècnic La Fe, Valencia, ES, ¹⁸Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda, Majadahonda, ES

- 10:28 - 10:29 **1631P - The efficacy and safety of anlotinib alone and in combination with other drugs in previously treated advanced thymic epithelia tumors: A retrospective analysis**
S. Li¹, X. Zhang², H. Zhou¹, H. Zhang¹, J. Yu¹, ¹Shandong Cancer Hospital and Institute Affiliated Shandong First Medical University and Shandong Academy of Medical Sciences, jinan, CN, ²Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN
- 10:29 - 10:30 **1632P - Analysis of penpulimab plus anlotinib in pleural mesothelioma or thymic carcinoma patients who have received at least one line of chemotherapy**
C. Zhang¹, Y.-K. Shi², Q. Liu³, K. Wu⁴, X. Li⁵, J. Cui⁶, Y.-M. Jia⁷, ¹Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, ²Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, Beijing, CN, ³Shenyang Chest hospital, Shenyang, CN, ⁴Fudan University Shanghai Cancer Center, Shanghai, CN, ⁵The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ⁶The First Hospital of Jilin University, Changchun, CN, ⁷The Second People's Hospital Of Yibin, Yibin, CN
- 10:30 - 10:31 **1633P - The correlation between the geographical distribution of asbestos-exposed workplaces and the increased risk of developing malignant mesothelioma, lung cancer, laryngeal cancer, and ovarian cancer: A nationwide population-based analysis in Japan**
A. Saito¹, H. Charvat², T. Shimoi¹, T. Matsuda³, K. Yonemori¹, ¹National Cancer Center Hospital, Tokyo, JP, ²Juntendo University, Tokyo, JP, ³National Cancer Center Research Institute - Tsukiji Campus, Chuo-ku, JP
- 10:31 - 10:32 **1634P - Patterns of disease recurrence in relation to the extent of lymph node sampling in patients with resected lung carcinoid: A population-based study**
J. Derks¹, L. Moonen¹, L. Hillen¹, R.J. Van Suylen², M. Den Bakker³, J. Von Der Thüsen⁴, R. Damhuis⁵, W. Buikhuisen⁶, E. Van Den Broek⁷, J. Maessen¹, L. Maat⁸, P. Van Schil⁹, E.-J. Speel¹, A.-M. Dingemans¹⁰, ¹Maastricht University Medical Center (MUMC), Maastricht, NL, ²Jeroen Bosch Hospital, 's-Hertogenbosch, NL, ³Maasstad Ziekenhuis, Rotterdam, NL, ⁴Erasmus MC - Erasmus Medical Center Rotterdam, Rotterdam, NL, ⁵Comprehensive Cancer Centre the Netherlands, Utrecht, NL, ⁶The Netherlands Cancer Institute, Amsterdam, NL, ⁷PALGA (Dutch Nationwide Pathology Databank), Houten, NL, ⁸Erasmus MC, Rotterdam, NL, ⁹UZA - University Hospital Antwerp, Edegem, BE,

¹⁰Erasmus MC - University Medical Center, Rotterdam, NL

- 10:32 - 10:33 **1635P - Impact of treatment sequence on clinical outcomes in patients with thymic carcinoma**
A. Tateishi, Y. Okuma, Y. Goto, M. Arakaki, Y. Shinno, T. Yoshida, H. Horinouchi, N. Yamamoto, Y. Ohe, NCCH - National Cancer Center Hospital, Chuo-ku, JP
- 10:33 - 10:34 **1636P - Prognostic indication for malignant peritoneal mesothelioma with tumor-specific and inflammatory biomarkers**
K. Yerigeri¹, B. Morrow², S. Steinberg², R. Hassan², J. Puthiamadathil³, ¹Case Western Reserve University / MetroHealth, Cleveland, US, ²Center for Cancer Research-National Cancer Institute, Bethesda, US, ³US FDA - Federal Drug Administration, Silver Spring, US
- 10:34 - 10:35 **1637P - Impact of immune-related adverse events (irAEs) and survival (OS) in a cohort of MPM patients (p) treated with immunotherapy (IT)**
S. Cedres Perez¹, A. Valdivia¹, J.D. Assaf¹, P. Iranzo Gomez¹, A. Callejo¹, N. Pardo Aranda¹, A. Navarro Mendivil¹, A. Martinez-Marti¹, G. Molina¹, V. Navarro¹, J. Gonzalo¹, M. Soleda¹, J. Frigola², C. Carbonell², R. Amat¹, R. Dienstmann¹, E. Felip³, ¹Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, ES, ²Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ³Vall d'Hebron University Hospital, Barcelona, ES
- 10:35 - 10:36 **1638P - Risk and prognosis of secondary lung cancer after radiation therapy for thoracic malignancies**
Y. Zheng, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN
- 10:36 - 10:37 **1639P - MACADAM (Mesothelioma Clinical Data platform): A reference database as a tool for large-scale collaborative research**
L. Cerbone¹, G. Cuniatti², S. Delfanti¹, A.M. De Angelis¹, M. Lia³, M. Venturelli⁴, A. Mazzucco⁴, D. Ricci², F. Grosso¹, ¹SSD Mesotelioma, Alessandria, IT, ²Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, IT, ³AOU Ospedale Policlinico san Martino, Genova, IT, ⁴Reply, Turin, IT
- 10:37 - 10:38 **1640TiP - PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced b3-thymoma (B3-T) and thymic carcinoma (TC)**
J. Remon Masip¹, N. Girard², P. Bironzo³, S. Novello⁴, J. De Castro Carpeno⁵, L. Bigay-Game⁶, R. Bernabe Caro⁷, L. Greillier⁸, J. Mosquera Martinez⁹, S. Cousin¹⁰, O.J. Juan Vidal¹¹, M. Sampayo-Cordero¹², B. Besse¹³, ¹HM CIOCC - Centro Integral Oncológico Clara Campal, Barcelona, ES, ²Institut Curie, Paris, FR, ³Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT, ⁴Università Degli Studi Di Torino - Orbassano, Orbassano, IT, ⁵Hospital Universitario La Paz, Madrid, ES, ⁶CHU RANGUEIL, TOULOUSE, FR, ⁷Hospital Universitario Virgen del Rocío, Seville, ES, ⁸Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ⁹CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, ¹⁰Institut Bergonie,

Bordeaux, FR, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, ES, ¹²MEDSIR - Medica Scientia Innovation Research, Barcelona, ES, ¹³Institut Gustave Roussy, Villejuif, FR

09:00 - 15:00 **Type: Poster session** **Poster Area, Hall 4**
Title: Poster session 17

- 09:00 - 09:01 **1253P - Safety and efficacy of Wnt inhibition with a DKK1 inhibitor, DKN-01, in combination with atezolizumab in patients with advanced oesophagogastric adenocarcinoma: Phase IIa results of the WAKING trial**
F. Turkes, R. Crux, A. Tran, E. Cartwright, I. Rana, E. Johnston, A. Dunlop, J. Thomas, A. Smith, E. Smyth, C. Fribbens, S. Rao, D. Watkins, I. Chau, N. Starling, D. Cunningham, The Royal Marsden Hospital (Sutton), Sutton, GB
- 09:01 - 09:02 **1254P - Updated report of a phase I study of TST001, a humanized anti-CLDN18.2 monoclonal antibody, in combination with capecitabine and oxaliplatin (CAPOX) as a first-line treatment of advanced G/GEJ cancer**
L. Shen¹, J. Gong², N. Li³, W. Guo⁴, J. Zhang⁴, Q. Fan³, T. Liu⁵, Z. Xia⁶, Y. Shen⁶, J. Wang⁷, L. Lu⁷, C. Qi⁶, J. Yao⁷, X. Qian⁶, M. Shi⁷, ¹Peking University Cancer Hospital & Institute, Beijing, CN, ²Peking University Cancer Hospital and Institute, Beijing, CN, ³The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ⁴Fudan University Shanghai Cancer Center, Shanghai, CN, ⁵Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, ⁶Suzhou Transcenta Therapeutics Co., Ltd., Suzhou, CN, ⁷Transcenta Therapeutics Inc., Princeton, US
- 09:02 - 09:03 **1255P - da VINci: Safety and efficacy of the OTSGC-A24 vaccine and nivolumab in metastatic gastric cancer**
J. Choo¹, S.Y. Rha², M. Jung³, H.L. Tan⁴, G. Chan⁵, J.S. Ho⁴, R. Walsh⁵, C.E. Chee¹, R. Sundar⁴, W.P. Yong⁴, ¹NCIS - National University Cancer Institute Singapore, Singapore, SG, ²Yonsei University, Seoul, KR, ³Yonsei Cancer Center Yonsei University, Seoul, KR, ⁴NUHS - National University Health System, Singapore, SG, ⁵NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG
- 09:03 - 09:04 **1256P - Three courses of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma (ESCC): A prospective phase II clinical trial**
G. Yang¹, X. Sun², H. Yang¹, G. Luo¹, Y. Zheng³, M. Huang³, Z. Wang¹, P. Cai², H. He², J. Xiang², M. Cai², J. Fu¹, Q. Liu¹, H. Yi¹, J. Zhong¹, Y. Huang¹, Q. Guo¹, X. Zhang¹, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Sun Yat-Sen University Cancer Center, Guangzhou, CN, ³3D Medicines, Inc., Shanghai, CN
- 09:04 - 09:05 **1257P - Apatinib plus POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC): Update from the phase I study (SYLT 007)**
S. Zhao¹, L. Su², R. Lin³, ¹Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN, ²Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, FUZHOU, CN, ³Fujian Provincial Tumor Hospital, Fuzhou, CN
- 09:05 - 09:06 **1258P - HJM-353: A potent, selective and orally bioavailable EED inhibitor with**

robust anti-tumor activities

X. Ma¹, W. Qi², Y. Du¹, D. Kong¹, Y. Geng¹, L. Zeng¹, ¹Jing Medicine Technology (Shanghai) Ltd., Shanghai, CN, ²ShanghaiTech University - Zhangjiang Campus, Shanghai, CN

09:06 - 09:07

1259TiP - Investigator-initiated phase II study of nivolumab plus low-dose ipilimumab as first-line therapy for microsatellite instability-high advanced gastric or esophagogastric junction cancer (NO LIMIT, WJOG13320G/CA209-7W7)

H. Kawakami¹, S. Kadowaki², K. Hirata³, M. Tsuda⁴, T. Esaki⁵, N. Sugimoto⁶, A. Makiyama⁷, N. Machida⁸, H. Hirano⁹, H. Hara¹⁰, T. Kawakami¹¹, W. Okamoto¹², H. Yabusaki¹³, Y. Komatsu¹⁴, S. Hironaka¹⁵, K. Muro², ¹Kindai University - Faculty of Medicine, Osaka, JP, ²Aichi Cancer Center Hospital, Nagoya, JP, ³Keio University School of Medicine, Shinjuku-ku, JP, ⁴Hyogo Cancer Center, Akashi, JP, ⁵National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, ⁶OICI - Osaka International Cancer Institute, Osaka, JP, ⁷Gifu University Hospital, Gifu, JP, ⁸Kanagawa Cancer Center, Yokohama, JP, ⁹National Cancer Center Research Institute - Tsukiji Campus, Chuo-ku, JP, ¹⁰Saitama Cancer Center, Ina, JP, ¹¹Shizuoka Cancer Center, Shizuoka, JP, ¹²Hiroshima University Hospital, Hiroshima, JP, ¹³Niigata Cancer Center Hospital, Niigata, JP, ¹⁴Hokkaido University Hospital, Sapporo, JP, ¹⁵Saitama Medical University International Medical Center, Saitama, JP

09:07 - 09:08

1260TiP - The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: A randomized multi-center study in resectable HER2 overexpressing adenocarcinoma of the esophagus or gastroesophageal junction (TRAP-2)

D. Blangé¹, M. Hulshof², M. Van Berge Henegouwen³, B. Mostert⁴, M. Slingerland⁵, N. Haj Mohammad⁶, M.C. Grootsholten⁷, G.-J. Creemers⁸, L. Mekenkamp⁹, E. Fiets¹⁰, J. De Haan¹¹, P. Jeene¹², T. Rozema¹³, M. Berbee¹⁴, A. Beeker¹⁵, L. Beerepoot¹⁶, S. Derks¹⁷, M. Bijlsma¹⁸, N. Van Grieken³, H. Van Laarhoven¹⁹, ¹Amsterdam University Medical Center (UMC) - locatie Academic Medical Center (AMC), Amsterdam, NL, ²Amsterdam University Medical Center (UMC) locatie Academic Medical Center (AMC), Amsterdam, NL, ³Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, ⁴Erasmus MC Cancer Institute, Rotterdam, NL, ⁵LUMC - Leids Universitair Medisch Centrum, Leiden, NL, ⁶University Medical Center Utrecht, Utrecht, NL, ⁷NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁸Catharina Hospital Eindhoven, Eindhoven, NL, ⁹MST - Medisch Spectrum Twente, Enschede, NL, ¹⁰Medical Center Leeuwarden, Leeuwarden, NL, ¹¹UMCG - University Medical Center Groningen, Groningen, NL, ¹²Radiotherapiegroep, Arnhem, NL, ¹³Dr. Bernard Verbeeten Instituut, Tilburg, NL, ¹⁴Maastricht Clinic, Maastricht, NL, ¹⁵Spaarne Ziekenhuis, Hoofddorp, NL, ¹⁶ETZ Elisabeth Hospital, Tilburg, NL, ¹⁷VU University Medical Centre, Amsterdam, NL, ¹⁸Amsterdam UMC location University of Amsterdam, Amsterdam, NL, ¹⁹Academic Medical Center, University of Amsterdam, Amsterdam, NL

09:08 - 09:09

1261TiP - CARMEN-GC01: Phase II, open-label, single-arm study of tusamitamab ravtansine in combination with ramucirumab in pretreated patients with gastric or gastroesophageal junction adenocarcinoma (GA/GEJA)

F. Esposito¹, J. Lee², S.Y. Rha³, K. Penkov⁴, A. Moisseev⁵, M. Van Den Eynde⁶, H.

Prenen⁷, M. Díez García⁸, M. Gumus⁹, T. Sagawa¹⁰, M. Nechaeva¹¹, T. Kajiwarra¹², H. Harputluoglu¹³, L. Charbonnier¹⁴, S. Bensfia¹⁵, N. Yang¹⁶, D.-Y. Oh¹⁷, ¹Hospital Clínic de Barcelona, Barcelona, ES, ²Samsung Medical Center, Seoul, KR, ³Yonsei Cancer Center, Yonsei University Health System, Seoul, KR, ⁴Euromedservice, St. Petersburg, RU, ⁵Medical Clinic of NACPP, Moscow, RU, ⁶Cliniques Universitaires Saint-Luc, Brussels, BE, ⁷UZA, Edegem, BE, ⁸Hospital Universitario Vall d'Hebron, Barcelona, ES, ⁹Istanbul Medeniyet University, Istanbul, TR, ¹⁰National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, JP, ¹¹State Budgetary Healthcare Institution of Arkhangelsk Region, Arkhangelsk, RU, ¹²National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, JP, ¹³Inonu University, Turgut Ozal Medical Center, Malatya, TR, ¹⁴Sanofi, Chilly-Mazarin, FR, ¹⁵Sanofi, Cambridge, US, ¹⁶Sanofi, Shanghai, CN, ¹⁷Seoul National University Hospital, Seoul, KR

09:09 - 09:10 **1262TiP - Efficacy and safety of consolidative camrelizumab following definitive concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell cancer**

J. Wang, Y. Cheng, Y. Wu, F. Cao, Q. Liu, G. Gao, The Fourth Hospital of Hebei Medical University - North Gate, Shijiazhuang, CN

09:10 - 09:11 **1297P - Adjuvant gemcitabine is as efficient as mFOLFIRINOX in patients with GemPred+ tumor signature and resected pancreatic adenocarcinoma (PDAC): An ancillary study of the PRODIGE-24 clinical trial**

R. Nicolle¹, J.-B. Bachet², A. Harlé³, J.L. Iovanna⁴, P. Hammel⁵, V. Rebours⁶, A. Turpin⁷, M. Ben Abdelghani⁸, A. Wei⁹, E. Mitry¹⁰, A. Lopez¹¹, J. Biagi¹², E. Francois¹³, P. Artru¹⁴, A. Lambert¹⁵, D. Renouf¹⁶, M. Mauduit¹⁷, N. Dussetti¹⁸, T. Conroy³, J. Cros⁶, ¹Université Paris Cité, INSERM, CNRS ERL 8252, Paris, FR, ²Groupe Hospitalier Pitié Salpetriere, Paris, FR, ³Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, ⁴Aix-Marseille Université and Institut Paoli-Calmettes, Marseille, France, Marseille, FR, ⁵Assistance Publique - Hopitaux De Paris, Paris, FR, ⁶Beaujon Hospital AHP, Clichy, FR, ⁷CHU Lille - Hopital Claude Huriez, Lille, FR, ⁸Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, ⁹MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ¹⁰IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ¹¹CHU Brabois, Vandoeuvre-lès-Nancy, FR, ¹²Cancer Centre of Southeastern Ontario, Kingston, CA, ¹³Centre Anticancer Antoine Lacassagne, Nice, FR, ¹⁴Hôpital privé Jean Mermoz, Lyon, FR, ¹⁵Icl Alexis Vautrin, Vandoeuvre Les Nancy, FR, ¹⁶BC Cancer Agency - Vancouver, Vancouver, CA, ¹⁷Unicancer, Paris, FR, ¹⁸CRCM centre de recherche en cancérologie de marseille, Marseille, FR

09:11 - 09:12 **1298P - Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation**

P. Hamme¹, T. Golan², M. Reni³, E. Van Cutsem⁴, T. Macarulla Mercade⁵, M. Hall⁶, J.O. Park⁷, D. Hochhauser⁸, D. Arnold⁹, D.-Y. Oh¹⁰, A. Reinacher-Schick¹¹, G. Tortora¹², H. Algül¹³, E. O'Reilly¹⁴, K. Sharan¹⁵, X. Ou¹⁶, K. Cui¹⁷, G. Locker¹⁸, H. Kindler¹⁹, ¹Assistance Publique - Hopitaux De Paris, Paris, FR, ²Chaim Sheba Medical Center, Ramat Gan, IL, ³IRCCS Ospedale San Raffaele, Milan, IT, ⁴UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁵Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁶Fox Chase Cancer Center - Main Campus, Philadelphia, US, ⁷Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ⁸UCL Cancer Institute - Paul O'Gorman Building, London,

GB, ⁹Asklepios Klinik Altona - Asklepios Kliniken, Hamburg, DE, ¹⁰Seoul National University Hospital, Seoul, KR, ¹¹Katholisches Klinikum Bochum - St. Josef-Hospital, Bochum, DE, ¹²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ¹³TUM - Technical University of Munich, Munich, DE, ¹⁴Memorial Sloan Kettering Cancer Center, New York, NY, US, ¹⁵Merck & Co., Inc. - Rahway, Rahway, US, ¹⁶AstraZeneca, Cambridge, GB, ¹⁷AstraZeneca US, Gaithersburg, US, ¹⁸AstraZeneca USA, Gaithersburg, US, ¹⁹University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US

- 09:12 - 09:13 **1299P - PD-1 blockade plus chemotherapy followed by concurrent hypofractionated radiotherapy with simultaneous integrated boost as induction therapy for patients with borderline resectable and locally advanced pancreatic cancer: A phase II clinical trial**
J. Du¹, C. Lu², W. Kong¹, Y. Zhu¹, Q. Xin², H. Cheng¹, G. Li¹, M. Tang¹, J. Chen¹, Q. Li¹, A. Li¹, Q. Gu³, Q. Xiaoping¹, S. Bao¹, L. Wang¹, Y. Qiu¹, B. Liu¹, ¹Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, CN, ²Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, CN, ³Nanjing University, Nanjing, CN
- 09:13 - 09:14 **1300P - Exploration of a novel HRD signature (HRDsig) as a biomarker of first line FOLFIRINOX benefit in metastatic pancreatic cancer**
A. Singhi¹, T. Chen², R. Madison³, N. Bhardwaj², D. Jin², Z. Fleischmann², J. Newberg², J. Moore², G. Frampton², P. Hegde², D. Fabrizio³, J. He³, A. Schrock², E. Ebot², E. Sokol³, ¹University of Pittsburgh, Pittsburgh, US, ²Foundation Medicine, Inc., Cambridge, US, ³Foundation Medicine, Inc, Cambridge, US
- 09:14 - 09:15 **1301P - Sequential therapy of metastatic pancreatic ductal adenocarcinoma (PDAC) after failure of gemcitabine plus nab-paclitaxel with either 5-FU/folinic acid (5FU/LV) plus irinotecan (FOLFIRI) followed by 5FU/LV plus oxaliplatin (OFF) or the reverse sequence: The PANTHEON trial (AIO PAK 0116)**
D. Modest¹, V. Heinemann², P. Schütt³, S. Angermeier⁴, M. Haberkorn⁵, O. Waidmann⁶, U. Graeven⁷, K. Wille⁸, V. Kunzmann⁹, L. Henze¹⁰, C. Constantin¹¹, M. De Wit¹², C. Denzlinger¹³, A. Kurreck¹, A. Alig¹, A. Stahler¹, U. Pelzer¹, S. Stintzing¹, H. Oettle¹⁴, ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, DE, ²LMU Klinikum der Universität München, Munich, DE, ³Gütersloh, Gütersloh, DE, ⁴Klinikum Ludwigsburg Medizinische Klinik I, Ludwigsburg, DE, ⁵Praxis Dr. Vehling-Kaiser, Landshut, DE, ⁶Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, DE, ⁷Kliniken Maria Hilf GmbH - Klinik für Haematologie, Onkologie und Gastroenterologie, Mönchengladbach, DE, ⁸Johannes Weseling klinikum, Minden, DE, ⁹University Clinic Würzburg-Medizinische Klinik und Poliklinik II Zentrum fuer Innere Medizin (ZIM), Wuerzburg, DE, ¹⁰Universitätsklinikum Rostock, Rostock, DE, ¹¹Klinikum Lippe-Lemgo, Lemgo, DE, ¹²Vivantes Hospital Neukoelln, Berlin, DE, ¹³Marienhospital Stuttgart, Stuttgart, DE, ¹⁴Praxis für Innere Medizin Friedrichshafen - Prof. Dr. Oettle & Prof. Dr. Mayer, Friedrichshafen, DE
- 09:15 - 09:16 **1302P - Gender differences in tumor characteristics, treatment allocation and survival in patients in a real-world non-metastatic pancreatic cancer cohort**
A. Gehrels¹, H. Wilmink¹, A. Wagner², M.G. Besselink³, R. Verhoeven⁴, H.C. Van

Santvoort⁵, B. Groot Koerkamp⁶, H. Van Laarhoven¹, L. Van Der Geest⁴, ¹Amsterdam UMC location University of Amsterdam, Amsterdam, NL, ²Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, CH, ³Amsterdam UMC - University of Amsterdam, Amsterdam, NL, ⁴IKNL - Netherlands Comprehensive Cancer Organisation, Utrecht, NL, ⁵UMC - University Medical Center Utrecht, Utrecht, NL, ⁶Erasmus MC University Medical Center, Rotterdam, NL

- 09:16 - 09:17 **1303P - Feasibility of endoscopic ultrasound-guided fine needle biopsy tissue sampling for whole exome sequencing in pancreatic cancer**
S. Yang, E. Jeon, K. Jung, J.H. Jung, J. Ahn, B. Kim, J.-C. Lee, J. Kim, J.-H. Hwang, SNUBH - Seoul National University Bundang Hospital, Seongnam, KR
- 09:17 - 09:18 **1304P - Characterizing the clinico-genomic landscape and outcomes of KRAS G12C mutated pancreas cancer**
F. Keane¹, W. Park¹, A. Varghese¹, F. Balogun¹, K. Yu², I. El Dika¹, D. Khalil¹, D. Kelsen¹, D. Reidy-Lagunes¹, G. Ku³, N. Raj¹, J. Chou¹, M. Capanu¹, N. Schultz¹, R. Yaeger¹, E. O'Reilly⁴, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²Memorial Sloan Kettering 60th Street Outpatient Center, New York, US, ³MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ⁴Memorial Sloan Kettering Cancer Center, New York, NY, US
- 09:18 - 09:19 **1305P - Landscape and clinical significance of germline pathogenic variants (PV) in pancreatic cancer (PC)-predisposing genes in PC patients**
A. Gandini¹, L. Pastorino², M. Ponzano¹, S. Puglisi¹, R. Borea¹, M. Cremante¹, M. Grassi¹, W. Bruno², B. Dalmasso², V. Andreotti², I. Vanni², E. Allavena², F. Catalano¹, V. Martelli¹, A. Pastorino¹, M.L. Iaia³, G. Fornarini¹, M.S. Sciallero¹, A. Puccini¹, P. Ghiorzo², ¹IRCCS Ospedale Policlinico San Martino, Genova, IT, ²Genetics of Rare Cancers, IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy, Genova, IT, ³D. Camberlingo Hospital, brindisi, IT
- 09:19 - 09:20 **1306P - Early-stage pancreatic cancer detection using extracellular vesicles**
R. Sears¹, J. Hinestrosa², G. Schroeder², J. Lewis², H. Balcer², R. Kurzrock³, S. Lippman⁴, A. Lowy⁴, P. Billings⁵, ¹OHSU - Oregon Health Science University, Portland, US, ²Biological Dynamics, Inc., San Diego, US, ³Medical College of Wisconsin, Milwaukee, US, ⁴UCSD Moores Cancer Center, La Jolla, US, ⁵Biological Dynamics, San Diego, US
- 09:20 - 09:21 **1307P - Real-world impact of olaparib use in advanced pancreatic cancer (PC) patients (pts) harboring germline BRCA1/2 (gBRCA) mutations**
M. Milella¹, G. Orsi², A. Palloni³, L. Salvatore⁴, L. Procaccio⁵, S. Noventa⁶, S. Bozzarelli⁷, I. Garajova⁸, E. Vasile⁹, G. Giordano¹⁰, M. Macchini², A. Cavaliere¹¹, M. Gaule¹, S. Lonardi⁵, M.C. Di Marco¹², G. Tortora⁴, I. Sperduti¹³, M. Reni², ¹University of Verona - School of Medicine, Verona, IT, ²IRCCS San Raffaele Hospital - Vita e Salute University, Milan, IT, ³IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, IT, ⁴Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ⁵IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁶Fondazione Poliambulanza Istituto Ospedaliero, Brescia, IT, ⁷Humanitas Research Hospital, Rozzano, IT, ⁸University Hospital of Parma, Parma, IT, ⁹University of Pisa - DAM, Pisa, IT, ¹⁰Unit of Medical Oncology and

Biomolecular Therapy, Policlinico Riuniti - University of Foggia, Foggia, IT, ¹¹IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, ¹²S. Orsola-Malpighi University Hospital, Bologna, IT, ¹³IRCCS Regina Elena National Cancer Institute, Rome, IT

- 09:21 - 09:22 **1308P - Comparison of tumour size on outcomes for patients with unresectable locally advanced pancreatic adenocarcinoma (LAPC) receiving P-32 microparticles with standard-of-care chemotherapy (SoC CT)**
P. Ross¹, H. Wasan², D. Croagh³, M. Nikfarjam⁴, N. Nguyen⁵, M. Aghmesheh⁶, A. Nagrial⁷, D. Bartholomeusz⁸, A. Hendlisch⁹, T. Ajithkumar¹⁰, C. Iwuji¹¹, D. Turner¹², D. James¹³, M. Harris¹⁴, ¹Guy's Hospital, London, GB, ²Hammersmith Hospital - Imperial College Healthcare NHS Trust, London, GB, ³Monash Health - Moorabbin Hospital, Bentleigh East, AU, ⁴University of Melbourne Centre for Cancer Research (UMCCR) - Victorian Comprehensive Cancer Centre, Parkville, AU, ⁵University of Adelaide, Adelaide, AU, ⁶Southern Medical Day Care Centre, Wollongong, AU, ⁷Westmead Hospital, Sydney, AU, ⁸RAH - Royal Adelaide Hospital, Adelaide, AU, ⁹Institute Jules Bordet, Brussels, BE, ¹⁰Cambridge Clinical Trials Unit - Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB, ¹¹Leicester Royal Infirmary - University Hospitals of Leicester NHS Trust, Leicester, GB, ¹²OncoSil Medical Ltd, North Sydney, AU, ¹³OncoSil Medical Limited, North Sydney, AU, ¹⁴Monash Health - Monash Medical Centre, Melbourne, AU
- 09:22 - 09:23 **1309P - CD8⁺ T cell infiltration is associated with improved survival in advanced pancreatic cancer**
G. O'Kane¹, Y. Wang², R. Gonzalez³, G. Jang⁴, A. Zhang⁴, A. Dodd³, S. Ramotar³, S. Hutchinson³, F. Vyas³, N. Chan³, M. Tehfe⁵, R. Ramjeesingh⁶, J. Biagi⁷, J. Wilson⁴, S. Fischer⁸, R. Grant⁹, G. Zogopoulos², S. Gallinger³, B. Grunwald³, J. Knox¹⁰, ¹St James's Hospital, Dublin, IE, ²McGill University, Montreal, CA, ³Princess Margaret Cancer Center, University Health Network, Toronto, CA, ⁴Ontario Institute for Cancer Research, Toronto, CA, ⁵CHUM - Centre Hospitalier de l'Université de Montréal, Montreal, CA, ⁶Nova Scotia Cancer Centre & Dalhousie University, Halifax, CA, ⁷Cancer Centre of Southeastern Ontario, Kingston, CA, ⁸University of Toronto - Leslie Dan Faculty of Pharmacy, Toronto, CA, ⁹Princess Margaret Cancer Centre, Toronto, CA, ¹⁰Princess Margaret Cancer Center, University Health Network, Toronto, ON, CA
- 09:23 - 09:24 **1311P - Penile cancer in North-West England: A 5-year analysis of epidemiology, risk factors and outcomes in a supraregional centre**
N. Peters, J.A. Scott, A. Issa, C. Fankhauser, E. Lee, J. Churchill, P. Oliveria, A. Tran, M. Lau, A. Parnham, V. Sangar, D. Graham, The Christie NHS Foundation Trust, Manchester, GB
- 09:24 - 09:25 **1323P - Towards the development of a German instrument to measure financial effects of a tumor disease: First results**
S. Pauge¹, B. Surmann¹, A. Züger², V. Mathies³, L. Richter⁴, K. Mehlis², T. Ernst³, W. Greiner¹, N. Menold⁴, E. Winkler², ¹Bielefeld University, Bielefeld, DE, ²NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE, ³Jena University Hospital, Jena, DE, ⁴Dresden University, Dresden, DE
- 09:25 - 09:26 **1324P - Metastatic breast cancer at initial diagnosis in the United States: Racial differences in prevalence, clinical characteristics, and survival**

S. Hammad¹, M. Gouda², M. Khalafallah³, ¹MFM - Menoufia University - Faculty of Medicine, Shebin Elkom, EG, ²The University of Texas MD Anderson Cancer Center - Breast Medical Oncology, Houston, US, ³University of Alabama at Birmingham (UAB), Birmingham, US

09:26 - 09:27 **1325P - The analysis of clinical trials in medical oncology: A shared risk tool for the change towards the sustainability of the system**

D. Sánchez¹, F. Salas-Lucia², H. Jian², P. Ruiz-Carreño¹, J.L. Alonso¹, ¹Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, ES, ²University of Chicago - Department of Medicine, Chicago, US

09:27 - 09:28 **1326P - Oncology under attack by predatory journals: A global survey**

K. El Bairi¹, D. Trapani², S. Nidhamalddin³, S. Zeb Khan⁴, A.R. Chowdhury⁵, C. Lengyel⁶, S. Hussain⁷, B. Habibe⁸, A. Petrillo⁹, N. Omar¹⁰, S. Altuna¹¹, F. Seid¹², E. Elfaham¹³, A. Seeber¹⁴, F. Roitberg¹⁵, A. Burguete¹⁶, S. Elkefi¹⁷, N. Hammad¹⁸, O. Al Jarroudi¹⁹, S. Afqir²⁰, ¹Faculty of Medicine and Pharmacy of Oujda, Oujda, MA, ²Dana Farber Cancer Institute, Boston, US, ³Hiwa Cancer Hospital, Sulaymaniyah, IQ, ⁴Binor Cancer Hospital Bannu, Bannu, PK, ⁵Delta Medical College and Hospital, Dhaka, BD, ⁶National Institute of Oncology, Budapest, HU, ⁷Leicester Royal Infirmary - University Hospitals of Leicester NHS Trust, Leicester, GB, ⁸Shaqlawah Hospital, Erbil, IQ, ⁹Ospedale del Mare, Napoli, IT, ¹⁰Hamad Medical Corporation (HMC)-National Center for Cancer Care and Research (Al Amal Hospital), Doha, QA, ¹¹Oncomédica C.A., Caracas, VE, ¹²Addis Ababa University - College of Health Sciences, Addis Ababa, ET, ¹³Alexandria Faculty of Medicine, Alexandria, EG, ¹⁴Landeskrankenhaus - Universitaetskliniken Innsbruck, Innsbruck, AT, ¹⁵ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR, ¹⁶CUCC - Centro Universitario Contra el Cáncer - Universidad Autónoma de Nuevo León (UANL), Monterrey, MX, ¹⁷Stevens Institute of Technology, Hoboken, US, ¹⁸Queen's University, Kingston, CA, ¹⁹CHU Mohammed VI-Oujda, Oujda, MA, ²⁰Hassan II Oncology RegionalCenter, Oujda, MA

09:28 - 09:29 **1328P - Association of socioeconomic disparities with nasopharyngeal carcinoma survival in an endemic area, China**

D.-F. Meng¹, J. Ma², L. Fu¹, ¹Shandong Cancer Hospital and Institute Affiliated Shandong First Medical University and Shandong Academy of Medical Sciences, jinan, CN, ²The People's Hospital of Leling, Leling, CN

09:29 - 09:30 **1330P - Organizational impact of immune-checkpoint inhibitors in advanced cancers in France: Final analysis**

I. Borget¹, C. Chouaid², F.-E. Cotté³, A.-F. Gaudin⁴, V. Grumberg⁴, ¹Institut Gustave Roussy, Villejuif, FR, ²CH Intercommunal de Créteil, Créteil, FR, ³Bristol Myers Squibb, Rueil-Malmaison, FR, ⁴Bristol Myers Squibb, Rueil, FR

09:30 - 09:31 **1331P - Regional variation in early diagnosis, multimorbidity and death in English males and females of different ethnicity with incident lung cancer from 2014-2019**

S. Paul¹, S. Jose², S. Hori³, A. Krishna³, ¹AstraZeneca PLC, London, GB, ²HDI - Health Data Insight CIC, Cambridge, GB, ³AstraZeneca UK Ltd., Luton, GB

- 09:31 - 09:32 **1333P - S1 Guideline for prioritisation in gastrointestinal cancer care: Scarcity of resources in the pandemic context**
A. Reinacher-Schick¹, C. Lugnier¹, S. Sommerlatte², T. Birkner³, O. Schoffer³, A.-L. Kraeft¹, S. Foerster⁴, W. Knauf⁵, B.O. Maier⁶, E. Fokas⁷, M. Ebert⁸, P. Piso⁹, K.-S. Monika¹⁰, J. Christmann⁴, R.D. Hofheinz⁸, A. Tannapfel⁴, B. Woermann¹¹, J. Schmitt³, J. Schildmann², ¹Katholisches Klinikum Bochum - St. Josef-Hospital, Bochum, DE, ²Martin Luther Universität Halle-Wittenberg, Halle (Saale), DE, ³University Hospital Carl Gustav Carus, Dresden, DE, ⁴Georgius Agricola Stiftung Ruhr - Institut für Pathologie - Ruhr-Universität Bochum, Bochum, DE, ⁵Centrum for Hematology and Oncology Bethanien, Frankfurt/Main, DE, ⁶St. Josef Hospital Wiesbaden, Wiesbaden, DE, ⁷Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, ⁸UMM - Universitaetsklinikum Mannheim, Mannheim, DE, ⁹Barmherzige Brüder Krankenhaus Regensburg, Regensburg, DE, ¹⁰University Medical Center, Regensburg, Regensburg, DE, ¹¹DGHO - Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V., Berlin, DE
- 09:32 - 09:33 **1334P - Objective response rates of placebo in randomized controlled trials of anticancer medicines: 2015 – 2019**
A. Sachdev, I. Sharpe, M. Bowman, B. Gyawali, C. Booth, Queen's University, Kingston, CA
- 09:33 - 09:34 **1335P - Using adaptive health technology assessment (aHTA) to assess the potential cost-effectiveness of pembrolizumab and palbociclib in the Indian context**
M. Sengar¹, P. Ranganathan¹, A. Ashok¹, J. Thorat¹, P. Nayak¹, T. Wahid¹, C. Nemzoff², S. Ghosh³, F. Ruiz², A. Mehndiratta⁴, C. Pramesh¹, ¹Tata Memorial Centre, Mumbai, IN, ²London School of Hygiene and Tropical Medicine, London, GB, ³Centre for Global Development, London, GB, ⁴Centre for Global Development, London, IN
- 09:34 - 09:35 **1336P - Epidemiology of rare cancers in South Asian Association for Regional Cooperation (SAARC) countries: Remembering the forgotten**
J. Bajpai¹, S. Mailankody², A. Budukh¹, R. Swaminathan³, R. Dikshit¹, S. Perera⁴, M. Dhimal⁵, U. Tshomo⁶, S. Bagal⁷, M. Bhise⁷, S. Banavali¹, S. Gupta¹, P. Chaturvedi⁸, R. Badwe⁹, A. Trama¹⁰, ¹Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, ²Kasturba Medical College and Hospital - Shirdi Sai Baba Cancer Center, Manipal, IN, ³Cancer Institute (WIA), Adyar, Chennai, Chennai, IN, ⁴National Cancer Control Programme Ministry of Health, Colombo, LK, ⁵Nepal Health Research Council (NHRC), Kathmandu, NP, ⁶JDWNR Hospital, Thimphu, Bhutan, Thimpu, BT, ⁷ACTREC Tata Memorial Centre, Mumbai, IN, ⁸Tata Memorial Hospital - Parel, Mumbai, IN, ⁹Tata Memorial Centre, Mumbai, IN, ¹⁰Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT
- 09:35 - 09:36 **1337P - Implementation of precision oncology in clinical practice: A nationwide survey in Italy**
G. Fasola¹, M.C. Barducci¹, G. Pelizzari¹, G. Aprile², F. Grossi³, C. Pinto⁴, B. Daniele⁵, M. Giordano⁶, C. Ortega⁷, R.R. Silva⁸, V. Tozzi⁹, L. Cavanna¹⁰, ¹ASU FC - University Hospital S. Maria della Misericordia, Udine, IT, ²Ospedale San Bortolo - AULSS8 Berica - Distretto EST, Vicenza, IT, ³University of Insubria, Busto Arsizio, IT, ⁴Clinical Cancer Centre

Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, IT, ⁵Ospedale del Mare, Napoli, IT, ⁶Azienda Ospedaliera Sant'Anna-Como, Como, IT, ⁷Ospedale Michele e Pietro Ferrero - ASL CN2 Alba e Bra, Verduno, IT, ⁸Ospedale E. Profili U.O. Oncologia Medica, Fabriano, IT, ⁹SDA Bocconi School of Management, Milan, IT, ¹⁰AUSL di Piacenza - Ospedale Guglielmo da Saliceto, Piacenza, IT

- 09:36 - 09:37 **1338P - Cost-effectiveness and direct impact analysis of clinical research in the clinical approach of metastatic renal cell carcinoma and neuroendocrine tumors in a large public Spanish university hospital**
S. García-Garro¹, P. Gajate Borau¹, E. Gómez De Salazar¹, T. Alonso Gordoa¹, M.Á. Rodríguez Sagrado¹, J. Molina Cerrillo¹, L. Manzano Espinosa¹, T. Bermejo Vicedo¹, A. Carrato Mena¹, J.J. Díez Gómez², E. Grande Pulido³, ¹Hospital Universitario Ramon y Cajal, Madrid, ES, ²University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES, ³MD Anderson Cancer Center Madrid, Madrid, ES
- 09:37 - 09:38 **1339P - Crowd funding in cancer in India: A much needed financial therapy but needs checkpoints**
K. Kalpathi¹, M. Krishnamani², K. Mathi³, ¹NIMS - Nizam's Institute of Medical Sciences, Hyderabad, IN, ²C Path Labs, Hyderabad, IN, ³Stanford University School of Medicine, Stanford, US
- 09:38 - 09:39 **1340P - Trends in access to early phase clinical trials in underserved populations during the COVID-19 pandemic**
J. Balmaceda, D.P. Mudaranthakam, G. Doolittle, W. Sun, H. Krebill, T. Lin, A. Jewell, A. Saeed, S. Abbasi, R. Jensen, J. Baranda, KUMC - University of Kansas Medical Center, Kansas City, US
- 09:39 - 09:40 **1341P - Correlation between psychological resilience and burnout syndrome in oncologists**
A. Budisavljevic¹, R. Kelemenic-Drazin², T. Silovski³, N. Dedic Plavetic³, ¹General Hospital Pula, Pula, HR, ²General Hospital Varazdin, Varazdin, HR, ³KBC - University Hospital Centre Zagreb, Zagreb, HR
- 09:40 - 09:41 **1342P - Pharmacoeconomics in the antineoplastic therapy sector of a public hospital in the Brazilian Amazon aiming at cost minimization: Quantitative analysis**
K. Borges¹, B. Almeida¹, G. Almeida², C. Borges Junior², S. Queiroz², J. Quaresma³, E. Negrão³, K. Penalber², ¹Oncológica do Brasil Santarém - Unidade Tapajós, SANTAREM, BR, ²Oncológica do Brasil Santarém - Unidade Tapajós, Santarém, BR, ³UFPA - Universidade Federal do Pará, Belém, BR
- 09:41 - 09:42 **1343P - NCRI's Consumer Forum: Patients promoting evidence-based medicine and evidence-based policy**
E. Kinloch¹, R. Stephens², ¹NCRI - National Cancer Research Institute, London, GB, ²National Cancer Research Institute, London, GB
- 09:42 - 09:43 **1344P - Impact of COVID-19 pandemic on cancer care provision: A cross-sectional study of Egyptian patients' perspectives and concerns**

A.M. Abdou¹, S. Khalil², M. Yassin³, M. Amin⁴, S. Alyamani⁵, A. Abdelaziz⁶, ¹Ministry of Health and Population, Cairo, EG, ²Ain Shams University - Faculty of Medicine, Cairo, EG, ³Ain Shams Hospital, Cairo, EG, ⁴Shefaa El Orman Oncology Hospital (SOH), Luxor, EG, ⁵Dar El Shefaa, Cairo, EG, ⁶Ain Shams University Hospital - Faculty of Clinical Medicine and Radiation Oncology, Cairo, EG

09:43 - 09:44 **1345P - Immunotherapy vs chemotherapy in social media: A real-world exploratory analysis**

J. Blanco Avila¹, S. Bernabé¹, R. Sanchez Bayona², M.A. Alvarez De Mon Gonzalez³, M. Alvarez De Mon⁴, C. Donat Vargas⁵, ¹Clinica Universidad de Navarra, Madrid, ES, ²Hospital Universitario 12 de Octubre, Madrid, ES, ³Hospital Universitario Infanta Leonor, Madrid, ES, ⁴Hospital Principe de Asturias, Alcalá de Henares, ES, ⁵Karolinska Institutet, Solna, SE

09:44 - 09:45 **1346P - Diagnosis of early-stage cancers in carriers of BRCA1/2 pathogenetic variants: Two years of activity of the multidisciplinary team for hereditary cancers**

M. Pensabene¹, S. Greggi¹, S. Visconti¹, M.S. Gallo¹, S. Pignata¹, S. Mori², F. Avino¹, R. Saponara¹, U. Marone¹, C. Siani¹, E. Esposito¹, M.L. Barretta¹, L. Formisano¹, C. Roma¹, D. Barberio¹, M. De Laurentiis¹, N. Normanno¹, ¹Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ²Istituto Nazionale Tumori di Napoli, Naples, IT

09:45 - 09:46 **1347P - Onco-geriatric assessment can be used to detect social disparities between populations of older patients with cancer**

D.S. Daniela Lessa¹, A.F. Ferreira Filho¹, R. Van Der Ham², B. Caroline², V. Kipper², B. Estela², ¹Oncosinos & Feevale University, Porto Alegre, BR, ²Oncosinos Clinica de Oncologia, Porto Alegre, BR

09:46 - 09:47 **1348P - The main challenges and potential solutions to improving patient access to oncology combination therapies in Europe**

M. Pistollato, T. Wilsdon, C. Poon, T. Veale, Charles River Associates, London, GB

09:47 - 09:48 **1349P - A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products between Swissmedic, EMA and FDA**

U.-P. Rohr¹, M. Iovino¹, L. Rudofsky¹, Q. Li¹, S. Juritz¹, A. Gircys¹, O. Wildner¹, M. Bujar², S. Dalla-Torre¹, A. Wolfer¹, ¹Swissmedic Swiss Agency for Therapeutic Products, Bern, CH, ²Centre for Innovation in Regulatory Science, London, GB

09:48 - 09:49 **1350P - Bridging the platforms of adaptive clinical trials in oncology and accelerating clinical research in rare genomic aberrations**

S. Van Waalwijk Van Doorn-Khosrovani¹, L. Zeverijn², B. Geurts², G. De Wit², I.A.C. Spiekman³, A. Pisters¹, A.M.G. Pasmooij⁴, L. Timmers⁵, H. Nygren⁶, K. Rohrberg⁷, K. Peltola⁸, M. Mustonen⁸, U. Lassen⁷, A. Helland⁹, H. Gelderblom¹⁰, H. Verheul³, K. Tasken¹¹, E. Voest², ¹CZ Health Insurance, Tilburg, NL, ²NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ³Radboud University Medical Center, Nijmegen, Nijmegen, NL, ⁴Dutch Medicines Evaluation Board, Utrecht, NL, ⁵Dutch National Health Care Institute, Diemen, NL, ⁶Uppsala University -

Rudbecklaboratoriet, Uppsala, SE, ⁷Rigshospitalet, Copenhagen, DK, ⁸Comprehensive Cancer Center - Helsinki University Central Hospital, Helsinki, FI, ⁹University of Oslo, Institute of Clinical medicine, Oslo, NO, ¹⁰LUMC - Leids Universitair Medisch Centrum, Leiden, NL, ¹¹Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO

- 09:49 - 09:50 **1351P - Indirect costs due to lung cancer-related premature mortality in four European countries**
G. Bencina¹, N. Chami², R. Hughes², G. Weston², C. Baxter³, S. Salomonsson⁴, I. Demedts⁵, ¹MSD, Madrid, ES, ²Adelphi Values, Bollington, GB, ³MSD - Merck Sharp & Dohme (UK) Limited, London, GB, ⁴MSD - Merck Sharp & Dohme (Sweden) A B, Sollentuna, SE, ⁵AZ Delta, Roeselare, BE
- 09:50 - 09:51 **1352P - Real-world use of genomic profiling and genetic testing and implications for clinicians, providers and insurers**
C. Mikropoulos, J. Benfield, T. Woodman, Bupa UK Insurance, Salford, GB
- 09:51 - 09:52 **1353P - Prediction of the risk of recurrence in patients with non-small cell lung cancer using an integrated claims and electronic medical record database**
T. Delea¹, A. Moynahan¹, Z. Cong², K. Chung², ¹PAI - Policy Analysis Inc., Chestnut Hill, US, ²GRAIL LLC a subsidiary of Illumina Inc. currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission dated 29 October 2021, Menlo Park, US
- 09:52 - 09:53 **1354P - Delay of diagnoses, increase of advanced stages, and worse overall survival in patients with thoracic malignancies because of the COVID-19 pandemic**
A. Sbrana¹, S. Cappelli², I. Petrini³, A. Chella², L. Carrozzi¹, ¹University of Pisa, Pisa, IT, ²Azienda Ospedaliero-Universitaria Pisana, Pisa, IT, ³AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT
- 09:53 - 09:54 **1355P - Clinical trial enrollment among lung cancer patients: A real-world multicenter analysis**
M.L. Reale¹, E. Capelletto¹, C. Buttigliero¹, P. Bordi², S. Ricciardi³, L. Belluomini⁴, E. Garbo¹, A. Leonetti², A. Lombardi³, A. Dodi⁴, V. Napoli¹, M. Casali², D. Soregaroli³, J. Insolda⁴, P. Bironzo¹, M. Tiseo², M.R. Migliorino³, S. Pilotto⁴, F. Passiglia¹, S. Novello¹, ¹San Luigi Gonzaga Hospital, Orbassano, IT, ²Azienda Ospedaliero-Universitaria di Parma, Parma, IT, ³Azienda Ospedaliera S. Camillo Forlanini, Rome, IT, ⁴University of Verona, Verona, IT
- 09:54 - 09:55 **1356P - Socioeconomic vulnerabilities (SEV) and cancer-related mortality in United States (US): A cross-sectional analysis**
S.A.A. Naqvi¹, Y. Saleem², A. Ayaz³, M. Islam², Z.B. Riaz⁴, Z. Kazmi², S. Khan⁵, I. Riaz⁶, ¹Mayo Clinic Cancer Center, Phoenix, US, ²Dow University of Health Sciences, Karachi, Karachi, PK, ³Beth Israel Deaconess Medical Center, Boston, US, ⁴Rashid Latif Medical College, Lahore, PK, ⁵Houston Methodist, Houston, US, ⁶Dana Farber Cancer Institute, Boston, US
- 09:55 - 09:56 **1453P - Phase II study of belzutifan plus cabozantinib for previously treated**

advanced renal cell carcinoma (RCC): Update from cohort 2 of LITESPARK-003

D. McDermott¹, T. Choueiri², S. Tykodi³, J. Merchan⁴, A. Roy⁵, R. Perini⁵, D. Vickery⁵, T. Bauer⁶, ¹Beth Israel Deaconess Medical Center, Boston, US, ²Dana Farber Cancer Institute, Boston, US, ³University of Washington and Fred Hutchinson Cancer Center, Seattle, US, ⁴University of Miami Health System, Miami, US, ⁵Merck & Co., Inc., Rahway, US, ⁶Sarah Cannon Research Institute and Tennessee Oncology, Nashville, US

09:56 - 09:57

1454P - Optimizing ipilimumab in RCC: Results from SAKK 07/17 (CM-980) nivolumab (N) + ipilimumab (Ipi) in mRCC

F. Stenner-Liewen¹, R. Cathomas², C. Rothermundt³, J. Beyer⁴, N. Mach⁵, D. Zihler⁶, A. Erdmann⁷, M. Kueng⁸, D. Dietrich⁹, J. Glaus Garzon⁹, A. Lorch¹⁰, D. Berthold¹¹, H. Läubli¹, ¹Universitätsklinik Basel, Basel, CH, ²Kantonsspital Graubünden, Chur, CH, ³Kantonsspital St. Gallen, St. Gallen, CH, ⁴University Hospital Inselspital Bern, Bern, CH, ⁵HUG - Hopitaux Universitaires de Geneve, Geneva, CH, ⁶Kantonsspital Aarau, Aarau, CH, ⁷Kantonsspital Baden, Baden, CH, ⁸HFR - Hopital Cantonal, Fribourg, CH, ⁹SAKK - Swiss Group for Clinical Cancer Research, Bern, CH, ¹⁰USZ, Zurich, CH, ¹¹CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

09:57 - 09:58

1455P - Characterization of patients with metastatic renal cell carcinoma achieving complete response to first-line therapies: Results from the international metastatic renal cell carcinoma database consortium (IMDC)

K. Takemura¹, V. Navani¹, M. Ernst¹, J.C. Wells², T. Choueiri³, L. Meza⁴, S. Pal⁴, J.-L. Lee⁵, H. Li⁶, N. Agarwal⁶, A. Alva⁷, A. Hansen⁸, N. Basappa⁹, B. Szabados¹⁰, T. Powles¹⁰, B. Tran¹¹, C. Hocking¹², B. Beuselinck¹³, T. Yuasa¹⁴, D. Heng¹, ¹Tom Baker Cancer Centre - University of Calgary, Calgary, CA, ²BC Cancer Agency, Vancouver, CA, ³Dana-Farber Cancer Institute, Boston, US, ⁴City of Hope Comprehensive Cancer Center, Duarte, US, ⁵Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ⁶Huntsman Cancer Institute - University of Utah, Salt Lake City, US, ⁷University of Michigan, Ann Arbor, US, ⁸Princess Margaret Cancer Centre - University Health Network, Toronto, CA, ⁹Cross Cancer Institute - University of Alberta, Edmonton, CA, ¹⁰Barts Cancer Institute - Queen Mary University of London, London, GB, ¹¹Peter MacCallum Cancer Centre, Melbourne, AU, ¹²Lyell McEwin Hospital, Adelaide, AU, ¹³University Hospitals Leuven - KU Leuven, Leuven, BE, ¹⁴Cancer Institute Hospital - Japanese Foundation for Cancer Research, Tokyo, JP

09:58 - 09:59

1456P - Long-term survivorship rates for first-line intermediate or poor (I/P) risk advanced renal cell carcinoma (aRCC) patients achieving objective response (OR) with nivolumab plus ipilimumab (N+I)

S. George¹, M. Hunger², O. Hughes³, J. May⁴, M. Dyer⁴, F. Ejzykowicz⁵, M. Kurt⁵, ¹Roswell Park Comprehensive Cancer Center, Buffalo, US, ²ICON plc, Munich, DE, ³ICON plc, Blue Bell, US, ⁴Bristol Myers Squibb, Uxbridge, GB, ⁵Bristol Myers Squibb, Lawrenceville, US

09:59 - 10:00

1457P - A UK multicentre retrospective review of metastatic renal cell carcinoma (mRCC) patients (pts) outcomes with brain metastases (BM) in the modern era

G. Ratnayake¹, A. Challapalli², J. Mcgrane³, R. Frazer⁴, S. Gupta⁵, D. Parslow⁶, S. Kingdon⁶, A. Lydon⁷, A. Sharma⁸, M. Tuthill⁹, T. McCartney¹⁰, R. Jabbar¹¹, N. Charnley¹², J. Malik¹³, D. Abhi¹⁴, C. Chau¹⁵, T. Geldart¹⁶, A. Halstead¹⁷, U. Anuforom¹⁸,

A. Bahl¹⁹, ¹Musgrove Park Hospital - Taunton and Somerset NHS Foundation Trust, Taunton, GB, ²Bristol Haematology and Oncology Centre - NHS Foundation Trust, Bristol, GB, ³Royal Cornwall Hospital, Truro, GB, ⁴Singleton Hospital, Swansea, GB, ⁵Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff, GB, ⁶Derriford Hospital Plymouth Hospitals NHS Trust, Plymouth, GB, ⁷Torbay Hospital - South Devon Healthcare NHS Foundation Trust, Torquay, GB, ⁸Mount Vernon Cancer Centre, Northwood, GB, ⁹Charing Cross Hospital - Imperial College Healthcare NHS Trust, London, GB, ¹⁰Belfast City Hospital - Belfast Health & Social Care Trust, Belfast, GB, ¹¹RD&E - Royal Devon and Exeter Hospital (Wonford), Exeter, GB, ¹²Royal Preston Hospital-Lancashire Teaching Hospitals NHS Foundation Trust, Preston, GB, ¹³NHS Lothian, Edinburgh, GB, ¹⁴Western General Hospital, Edinburgh, GB, ¹⁵University Hospital Southampton, SOUTHAMPTON, GB, ¹⁶University Hospitals Dorset, Poole, GB, ¹⁷University of Southampton, Southampton, GB, ¹⁸Weston Park Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, ¹⁹BHOC - Bristol Haematology and Oncology Centre, Bristol, GB

- 10:00 - 10:01 **1458P - Association between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced first-line (1L) renal cell carcinoma (aRCC): Exploratory analyses from CheckMate 9ER (CM 9ER)**
- D. Cella¹, C.G. Porta², M. Hamilton³, F. Ejzykowicz⁴, S. Blum⁴, C. Ivanescu⁵, C. Suarez Rodriguez⁶, T. Choueiri⁷, R. Motzer⁸, ¹Northwestern University, Chicago, US, ²University of Bari 'A. Moro', Bari, IT, ³Bristol Myers Squibb, Lawrenceville, US, ⁴Bristol Myers Squibb, Princeton, US, ⁵IQVIA Nederland, Amsterdam, NL, ⁶Vall d'Hebron University Hospital, Barcelona, ES, ⁷Dana-Farber Cancer Institute, Boston, US, ⁸Memorial Sloan Kettering Cancer Center, New York, US
- 10:01 - 10:02 **1459P - Analysis of long-term efficacy outcomes from the CheckMate 025 (CM 025) trial comparing nivolumab (NIVO) vs everolimus (EVE) based on 7 years (yrs) of follow-up in pre-treated patients (pts) with advanced renal cell carcinoma (aRCC)**
- B. Escudier¹, R. Motzer², M. Dyer³, J. May³, F. Ejzykowicz⁴, M. Kurt⁴, C.-W. Lee⁵, P. Wang⁶, E. Testa⁷, D. Sharpe⁸, S. George⁹, N. Tannir¹⁰, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ³Bristol Myers Squibb, Uxbridge, GB, ⁴Bristol Myers Squibb, Princeton, US, ⁵Bristol Myers Squibb, Lawrenceville, US, ⁶Bristol Myers Squibb, San Diego, US, ⁷Parexel, Stockholm, SE, ⁸Parexel, Uxbridge, GB, ⁹Roswell Park Comprehensive Cancer Center, Buffalo, US, ¹⁰The M.D. Anderson Cancer Center, Houston, US
- 10:02 - 10:03 **1460P - IO-Synthesise RCC: Analysis of real-world (RW) health-related quality of life (HRQoL) outcomes with nivolumab for previously treated metastatic renal cell carcinoma (mRCC) using pooled data from France and Germany**
- G. Mouillet¹, J. Bedke², L. Albiges³, P. Barthelemy⁴, B. Escudier³, V. Gruenwald⁵, P. Ivanyi⁶, H. Mueller-Huesmann⁷, Y.-A. Vano⁸, E. Von Der Heyde⁹, F. Ejzykowicz¹⁰, F. Brellier¹¹, M. Herber¹², C. Quentric¹³, B. Bennett¹¹, S. Nere¹³, A. Autengruber¹², A. Thiery-Vuillemin¹⁴, M.-O. Grimm¹⁵, ¹University Hospital of Besançon, Besancon, FR, ²Tübingen University Hospital, Tübingen, DE, ³Gustave Roussy, Villejuif, FR, ⁴Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ⁵West-German Cancer Center Essen, University Hospital Essen, Essen, DE, ⁶Hannover Medical School, Hannover, DE, ⁷Brüderkrankenhaus St. Josef Paderborn, Paderborn, DE, ⁸Hôpital Européen Georges

Pompidou, APHP-Centre, Université de Paris-Cité,, Paris, FR, ⁹Onkologische Praxis am Raschplatz, hannover, DE, ¹⁰Bristol Myers Squibb, Princeton, US, ¹¹Bristol Myers Squibb, Uxbridge, GB, ¹²Bristol Myers Squibb, Munich, DE, ¹³Bristol Myers Squibb, Rueil-Malmaison, FR, ¹⁴CHRU Jean Minjoz, Besancon, FR, ¹⁵Jena University Hospital, Jena, DE

10:03 - 10:04 **1461P - Impact of first-line (1L) therapy on outcomes of adult patients (pts) with metastatic MiT family translocation renal cell carcinomas (TRCC) treated in the contemporary immune checkpoint therapy (ICT) era**

J. Thouvenin¹, O. Alhalabi², M. Carlo³, L. Carril Ajuria⁴, Z. Bakouny⁵, N. Martinez Chanza⁶, S. Negrier⁷, L. Campedel⁸, M. Bilen⁹, D. Borchellini¹⁰, J. Chahoud¹¹, Y.-A. Vano¹², M. Lodi¹³, P. Barthelemy¹⁴, S.R. Viswanathan⁵, P. Msaouel¹⁵, T. Choueiri¹⁶, L. Albiges¹⁷, N. Tannir¹⁸, G. Malouf¹³, ¹Hospices Civils de Lyon - HCL - Lyon University Hospital Center, Pierre-Bénite, FR, ²The University of Texas M. D. Anderson Cancer Center, Houston, US, ³Memorial Sloan Kettering Cancer Center, New York, US, ⁴Institut Gustave Roussy, Villejuif, FR, ⁵Dana Farber Cancer Institute, Boston, US, ⁶Institute Jules Bordet, Brussels, BE, ⁷Centre Léon Bérard, Lyon, FR, ⁸Hôpitaux Paris Centre AP-HP, Paris, FR, ⁹Winship Cancer Institute of Emory University, Atlanta, US, ¹⁰Centre Anticancer Antoine Lacassagne, Nice, FR, ¹¹H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ¹²Georges Pompidou European Hospital, Paris, FR, ¹³Institut de Cancérologie de Strasbourg, Strasbourg, FR, ¹⁴ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ¹⁵MD Anderson Cancer Center, Houston, US, ¹⁶Dana-Farber Cancer Institute, Boston, US, ¹⁷Gustave Roussy Cancer Campus, Villejuif, Cedex, FR, ¹⁸The M.D. Anderson Cancer Center, Houston, US

10:04 - 10:05 **1462P - Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a)**

M. Stellato¹, S. Buti², M. Maruzzo³, M. Bersanelli², P. Ermacora⁴, B.A. Maiorano⁵, V. Prati⁶, U. De Giorgi⁷, F. Pierantoni⁸, A. Malgeri⁹, A. Mennitto¹⁰, A. Cavo¹¹, M.G. Vitale¹², M. Santoni¹³, C. Carella¹⁴, G. Procopio¹, E. Verzoni¹, D. Santini⁹, ¹Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, IT, ²University Hospital of Parma, Parma, IT, ³Istituto Oncologico Veneto IOV IRCCS, Padova, IT, ⁴University and General Hospital, Udine, IT, ⁵Foundation Casa Sollievo della Sofferenza IRCCS,, San Giovanni Rotondo, IT, ⁶Ospedale Michele e Pietro Ferrero - ASL CN2 Alba e Bra, Verduno, IT, ⁷IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, IT, ⁸Istituto Oncologico Veneto IOV IRCCS, Padova, IT, ⁹Fondazione Policlinico Campus Bio-Medico di Roma, Rome, IT, ¹⁰"Maggiore della Carità" University Hospital, Novara, IT, ¹¹Ospedale Villa Scassi ASL 3 Genovese, Genova, IT, ¹²University Hospital Modena, Modena, IT, ¹³Macerata Hospital, Macerata, IT, ¹⁴IRCCS Istituto Tumori Giovanni Paolo II, Bari, IT

10:05 - 10:06 **1463P - Patterns of care and outcomes of metastatic renal cell carcinoma (mRCC) patients (pts) with bone metastases (BM): A UK multicenter review**

A. Challapalli¹, G. Ratnayake², J. Mcgrane³, R. Frazer⁴, S. Gupta⁵, D. Parslow⁶, S. Kingdon⁷, A. Lydon⁸, A. Sharma⁹, M. Tuthill¹⁰, C. Mccusker¹¹, V. Ford¹², A. Ferrera¹³, J. Malik¹⁴, Z. Boh¹⁵, E. Jones¹⁶, T. Geldart¹⁷, S. Nelmes¹⁷, J. Brown¹⁸, A. Bahl¹, ¹BHOC - Bristol Haematology and Oncology Centre, Bristol, GB, ²Musgrove Park Hospital - Taunton and Somerset NHS Foundation Trust, Taunton, GB, ³Royal Cornwall Hospital,

Truro, GB, ⁴Singleton Hospital, Swansea, GB, ⁵Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff, GB, ⁶University Hospital Plymouth NHS Trust, Plymouth, GB, ⁷Derriford Hospital Plymouth Hospitals NHS Trust, Plymouth, GB, ⁸Torbay Hospital - South Devon Healthcare NHS Foundation Trust, Torquay, GB, ⁹Mount Vernon Cancer Centre, Northwood, GB, ¹⁰Churchill Hospital, Oxford, GB, ¹¹Northern Ireland Cancer Centre - Belfast Health & Social Care Trust, Belfast, GB, ¹²Royal Devon and Exeter NHS Hospital (Wonford) - Royal Devon and Exeter Foundation Trust, Exeter, GB, ¹³Royal Preston Hospital, Preston, GB, ¹⁴NHS Lothian, Edinburgh, GB, ¹⁵ECC - Edinburgh Cancer Centre - SCAN, Edinburgh, GB, ¹⁶University of Southampton - Cancer Research UK Centre, Southampton, GB, ¹⁷University Hospitals Dorset, Poole, GB, ¹⁸University of Sheffield Medical School, Sheffield, GB

- 10:06 - 10:07 **1464P - The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international metastatic RCC database consortium (IMDC)**
- V. Navani¹, M. Ernst¹, K. Takemura¹, S. Pal², T. Powles³, F. Donskov⁴, J.C. Wells⁵, C. Kollmannsberger⁶, B. Beuselinck⁷, A. Alva⁸, A. Weickhardt⁹, A.-K. Lalani¹⁰, D.S. Ernst¹¹, N. Agarwal¹², T. Choueiri¹³, D. Heng¹, ¹Tom Baker Cancer Centre - University of Calgary, Calgary, CA, ²City of Hope Comprehensive Cancer Center, Duarte, US, ³Barts Cancer Institute - Queen Mary University of London, London, GB, ⁴Aarhus University Hospital, Aarhus, DK, ⁵BC Cancer Agency, Vancouver, CA, ⁶BC Cancer Agency - Vancouver, Vancouver, CA, ⁷University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁸University of Michigan, Ann Arbor, US, ⁹Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, AU, ¹⁰JCC - Juravinski Cancer Centre - Hamilton Health Sciences, Hamilton, CA, ¹¹London Health Sciences Centre (LHSC) - London Regional Cancer Program (LRCP), London, CA, ¹²University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US, ¹³Dana Farber Cancer Institute, Boston, US
- 10:07 - 10:08 **1465P - Real-world (RW) outcomes in metastatic renal cell carcinoma (mRCC) patients treated with first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) in the United States**
- D. Geynisman¹, P. Chan², N. Robert², L. Chen², V. Del Tejo³, L. Rosenblatt³, S. Huo³, G. Doshi⁴, ¹Fox Chase Cancer Center - Main Campus, Philadelphia, US, ²Ontada LLC, The Woodlands, US, ³Bristol-Myers Squibb, Lawrenceville, US, ⁴US Oncology, Inc., Thornton, US
- 10:08 - 10:09 **1466P - Efficacy of immune checkpoint inhibitors (ICI) in renal cell carcinoma (RCC) venous tumor thrombus (VTT) shrinkage**
- J. Thouvenin¹, P. Bigot², N. Martinez Chanza³, V. Gaillard⁴, R. Cazzato⁵, P. Boudier⁶, D. Mailet⁷, R. Boissier⁸, P. Barthelemy⁹, ¹Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices de Lyon, Pierre-Bénite, FR, ²Angers University Hospital, Angers, FR, ³Institute Jules Bordet, Brussels, BE, ⁴Hopitaux Universitaires de Strasbourg - Nouvel Hopital Civil, Strasbourg, FR, ⁵Nouvel Hôpital Civil, Strasbourg, FR, ⁶ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ⁷Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices de Lyon, Pierre Benite, FR, ⁸Hopital de la Conception Assistance Publique des Hopitaux de Marseille, Marseille, FR, ⁹Institut de Cancérologie Strasbourg Europe, Strasbourg, FR

- 10:09 - 10:10 **1467P - Optimal neoadjuvant treatment choice for localised renal cell carcinoma**
L. Jurascheck¹, Y.-H. Yang¹, F. Jackson-Spence², C. Toms², C. Sng¹, L. Flanders¹, T. Powles², B. Szabados², ¹St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, ²Barts Cancer Institute, London, GB
- 10:10 - 10:11 **1468P - IO-synthesise RCC: Real-world outcomes of nivolumab in patients (pts) with previously treated advanced non-clear cell renal cell carcinoma (nccRCC) – A pooled analysis from France and Germany**
P. Barthelemy¹, J. Bedke², L. Albiges³, V. Gruenwald⁴, B. Escudier⁵, H. Mueller-Huesmann⁶, Y.-A. Vano⁷, P. Ivanyi⁸, P. Bigot⁹, E. Von Der Heyde¹⁰, B. Narciso¹¹, H. Belz¹², S. Nere¹³, C. Quentric¹⁴, F. Brellier¹⁵, M. Herber¹⁶, A. Thiery-Vuillemin¹⁷, M.-O. Grimm¹⁸, ¹Strasbourg Europe Cancer Institute, Strasbourg, FR, ²Eberhard Karls University, Tübingen, DE, ³Gustave Roussy Cancer Campus, Villejuif, Cedex, FR, ⁴University Hospital Essen, Essen, DE, ⁵Gustave Roussy Cancer Campus, Villejuif, FR, ⁶Brüderkrankenhaus St. Josef, Paderborn, DE, ⁷Georges Pompidou European Hospital, Paris, FR, ⁸Claudia-von-Schelling Center, Comprehensive Cancer Center Hannover, Hannover Medical School, Hannover, DE, ⁹Angers University Hospital, Angers, FR, ¹⁰Private practice Dr Von der heyde, hannover, DE, ¹¹Tours university hospital, Tours, FR, ¹²Zeisigwaldkliniken Bethanien Chemnitz, Chemnitz, DE, ¹³Bristol-Myers Squibb, Rueil-Malmaison, FR, ¹⁴Bristol-Myers Squibb, Princeton, US, ¹⁵Bristol Myers Squibb, Uxbridge, GB, ¹⁶Bristol-Myers Squibb, Munich, DE, ¹⁷University hospital of Besançon, Besancon, FR, ¹⁸Jena University Hospital, Jena, DE
- 10:11 - 10:12 **1469P - Efficacy and safety of pembrolizumab/axitinib combination in metastatic renal cell carcinoma (mRCC): A multicentric prospective analysis (ProPAXI study)**
A. Guida¹, M. Maruzzo², E. Lai², D. Bimbatti², F. Pierantoni², M. Dionesi², C. Caserta¹, C. Mosillo¹, M.L. Calandrella¹, S. Macrini¹, G. Fornarini³, E. Zanardi³, A. Damassi³, F. Calabro⁴, L. Cerbone⁴, S. Astore⁴, L. Galli⁵, S. Bracarda¹, ¹Azienda Ospedaliera Santa Maria, Terni, IT, ²Istituto Oncologico Veneto, IOV - IRCCS, Padova, IT, ³IRCCS Ospedale Policlinico San Martino, Genova, IT, ⁴Azienda Ospedaliera San Camillo Forlanini, Rome, IT, ⁵Azienda Ospedaliero-Universitaria Pisana, Pisa, IT
- 10:12 - 10:13 **1470P - Transcriptomic signature and immune infiltrate in metastatic collecting duct renal cell carcinoma patients treated with first-line cabozantinib: Results of exploratory endpoints from BONSAI trial (Meeturo 2)**
E. Verzoni¹, K. Todoerti¹, L. Rivoltini², V. Huber¹, M. Rodolfo³, L. Agnelli¹, A. Devecchi¹, A. Busico⁴, F. Perrone¹, G. Centonze¹, L. De Cecco², M. Claps¹, V. Guadalupi², M. Stellato⁵, P. Giannatempo¹, F.G.M. De Braud¹, G. Procopio¹, P. Sepe¹, ¹Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ²Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ⁴Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, IT, ⁵Policlinico Universitario Campus Bio-Medico, Milan, IT
- 10:13 - 10:14 **1471P - Plasma KIM-1 for preoperative identification and risk stratification of renal cell carcinoma**
W. Xu¹, V. Gaborieau², S. Niman¹, A. Mukeriyar³, D. Zaridze³, N. Singla⁴, M. Freedman¹, D. McDermott⁵, T. Choueiri¹, P. Catalano¹, V. Sabbisetti⁶, P. Brennan⁷, R. Bhatt⁵, ¹Dana

Farber Cancer Institute, Boston, US, ²IARC - International Agency for Research on Cancer, Lyon, FR, ³N.N. Blokhin Russian Cancer Research Center, Moscow, RU, ⁴Johns Hopkins Hospital, Baltimore, US, ⁵Beth Israel Deaconess Medical Center, Boston, US, ⁶Brigham and Women's Hospital, Boston, US, ⁷International Agency for Research on Cancer, Lyon, FR

- 10:14 - 10:15 **1472P - Biomarkers of the response in metastatic papillary renal cell carcinoma**
M. De Vries-Brilland¹, N. Rioux-Leclercq², E. Blanc³, G. Fromont⁴, G. Gravis Mescam⁵, L. Geoffrois⁶, C. Chevreau⁷, M. Gross Goupil⁸, B. Escudier⁹, S. Negrier³, L. Albiges¹⁰, ¹ICO - Institut de Cancerologie de l'Ouest - Site Paul Papin, Angers, FR, ²CHU de Rennes - Hopital Pontchaillou, Rennes, Cedex, FR, ³Centre Léon Bérard, Lyon, FR, ⁴University of Tours, Tours, cedex, FR, ⁵IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ⁶Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, ⁷Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ⁸CHU Bordeaux - Hopital St. André, Bordeaux, FR, ⁹Gustave Roussy - Cancer Campus, Villejuif, FR, ¹⁰Institut Gustave Roussy, Villejuif, Cedex, FR
- 10:15 - 10:16 **1473P - A prognostic microRNA-based signature for relapse risk prediction and definition of therapeutic targets in patients with high-risk localized clear cell renal cell carcinoma**
A. Pinto Marin¹, L. Trilla¹, J. Miranda², N. Vasudev³, E. García¹, R. López-Vacas¹, N. Miranda⁴, M. Wilson³, E. López-Camacho¹, A. Pertejo-Fernández¹, M.I. Lumbreras Herrera¹, J. Brown³, A. Zapater Moros¹, G.A. De Velasco Oria⁴, D. Castellano Gauna⁴, M.P. González-Peramato¹, E. Espinosa¹, R. Banks³, J.Á. Fresno-Vara¹, A. Gámez¹, ¹Hospital Universitario La Paz, Madrid, ES, ²QuironSalud Hospitales, Madrid, ES, ³St. James's University Hospital, Leeds, GB, ⁴Hospital Universitario 12 de Octubre, Madrid, ES
- 10:16 - 10:17 **1474P - Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study)**
C. Iglesias Gómez¹, V. Blanco Lorenzo¹, R. Garcia Dominguez², I. García Carbonero³, E. Feliciangeli⁴, S. Galvan Ruiz⁵, A. Gómez De Liaño⁶, B. Perez Valderrama⁷, A. Rodriguez Sanchez⁸, R. Sánchez-Escribano⁹, C. Suarez Rodriguez¹⁰, M. Lázaro Quintela¹¹, E. Gallardo Diaz¹², J. Guma I Padro¹³, J. Puente¹⁴, J.C. Villa Guzman¹⁵, J. García Sanchez¹⁶, M. Martinez Kareaga¹⁷, M.D.C. Beato Zambrano¹⁸, J. Molina-Cerrillo¹⁹, ¹HUCA - Hospital Universitario Central de Asturias, Oviedo, ES, ²University Hospital of Salamanca, Salamanca, ES, ³Hospital Virgen de la Salud, Toledo, ES, ⁴Hospital Universitario Santa Lucia, Cartagena, ES, ⁵Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, ES, ⁶Complejo Hospitalario Universitario Insular - Materno Infantil (CHUIMI), las Palmas de Gran Canaria, ES, ⁷Hospital Universitario Virgen del Rocio, Seville, ES, ⁸Complejo Asistencial Universitario de León - Hospital de León, León, ES, ⁹University Clinical Hospital of Valladolid, Valladolid, ES, ¹⁰Vall d'Hebron University Hospital, Barcelona, ES, ¹¹Hospital Alvaro Cunqueiro, Pontevedra, ES, ¹²Parc Tauli Hospital Universitari, Sabadell, ES, ¹³Hospital Universitari Sant Joan de Reus, Reus, ES, ¹⁴Hospital Clinico Universitario San Carlos, Madrid, ES, ¹⁵Hospital General Ciudad Real, Ciudad Real, ES, ¹⁶Hospital Arnau de Vilanova, Valencia, ES, ¹⁷Hospital Txagorritxu, Vitoria, ES, ¹⁸Hospital Universitario Virgen Macarena, Seville, ES, ¹⁹Hospital Universitario Ramon y Cajal, Madrid, ES

- 10:17 - 10:18 **1475P - Association of circulating tumor cells (CTCs) with immune checkpoint inhibitor (ICI) responses in metastatic renal cell carcinoma (mRCC)**
T. Zhang¹, M. Poellmann², S.-J. Park², J. Bu², R. Zhao¹, Q. Zhou¹, A. Agarwal³, J. Parks⁴, M. Reyes-Martinez⁴, A. Armstrong⁵, D. George⁴, A. Wang¹, S. Hong², ¹UTSW - University of Texas Southwestern Medical Center, Dallas, US, ²University of Wisconsin, Madison, US, ³University of North Carolina - Chapel Hill, Chapel Hill, US, ⁴Duke Cancer Center - Duke University Medical Center, Durham, US, ⁵Duke Cancer Center, Durham, US
- 10:18 - 10:19 **1476P - Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study**
S.E. Rebuzzi¹, P. Rescigno², A. Signori³, M. Brunelli⁴, F. Galuppini⁵, V.G. Vellone⁶, G. Gaggero⁶, M. Maruzzo⁷, M. Milella⁴, F. Vignani⁸, A. Cavo⁹, U. Basso⁷, F. Catalano⁶, V. Murianni⁶, M. Cremante⁶, A. Damassi⁶, M.A. Llaja Obispo⁶, G.L. Banna², S. Buti¹⁰, G. Fornarini⁶, ¹Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, IT, ²IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, ³University of Genova, Genova, IT, ⁴University and Hospital Trust of Verona, Verona, IT, ⁵University of Padua, Padua, IT, ⁶IRCCS Ospedale Policlinico San Martino, Genova, IT, ⁷Istituto Oncologico Veneto IOV - IRCCS, Padua, IT, ⁸Ordine Mauriziano Hospital, Torino, IT, ⁹Villa Scassi Hospital, ASL 3 Genovese, Genova, IT, ¹⁰Department of Medicine and Surgery, University of Parma, Parma, IT
- 10:19 - 10:20 **1477P - Molecular epidemiology of somatic VHL alterations in Chinese patients with solid tumors**
H. Zhang¹, M. Hu², D. Zhang², ¹Huadong Hospital affiliated to Fudan University, Shanghai, CN, ²3D Medicines, Shanghai, CN
- 10:20 - 10:21 **1478P - Clearseq1-4 classifier in localized and metastatic clear-cell renal cell carcinoma (ccRCC)**
L. Kinget¹, E. Roussel², A. Verbiest¹, D. Lambrechts³, B. Boeckx³, J. Zucman-Rossi⁴, G. Couchy⁴, S. Caruso⁴, M. Baldewijns¹, L. De Wever¹, M. Albersen², B. Beuselinck¹, ¹UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ²University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ³VIB-KU Leuven Center for Cancer Biology (CCB), Leuven, BE, ⁴Centre de Recherche des Cordeliers, INSERM1138, Paris, FR
- 10:21 - 10:22 **1479P - Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC)**
A. Chehrazi-Raffle¹, R. Muddasani¹, N. Dizman¹, J. Hsu¹, L. Meza¹, Z. Zengin¹, J. Malhotra¹, N. Chawla¹, Y. Lyou¹, T. Dorff¹, T. Contente-Cuomo², D. Dinwiddie², B. McDonald³, J. Trent², M. Murtaza³, S. Pal¹, ¹City of Hope Comprehensive Cancer Center, Duarte, US, ²TGen - The Translational Genomics Research Institute, Phoenix, US, ³University of Wisconsin, Madison, US
- 10:22 - 10:23 **1480P - Baseline levels of proinflammatory cytokines according to body mass**

index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (NIVO) within the NIVOREN trial

E. Colomba¹, L. Carril Ajuria¹, C. Dalban², L. Derosa¹, C. Alves Costa Silva³, E. Rassy¹, S. Negrier², C. Chevreau⁴, G. Gravis Mescam⁵, S. Oudard⁶, B. Laguerre⁷, P. Barthelemy⁸, M. Gross Goupil⁹, L. Geoffrois¹⁰, A. Thiery-Vuillemin¹¹, F. Joly Lobbedez¹², S. Ladoire¹³, F. Tantot¹⁴, B. Escudier¹⁵, L. Albiges³, ¹Gustave Roussy - Cancer Campus, Villejuif, Cedex, FR, ²Centre Léon Bérard, Lyon, FR, ³Institut Gustave Roussy, Villejuif, Cedex, FR, ⁴Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ⁵Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, Cedex, FR, ⁶HEGP - Hopital Europeen Georges-Pompidou - APHP - University de Paris, Paris, FR, ⁷Eugene Marquis Center, Rennes, FR, ⁸Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ⁹CHU Bordeaux - Hopital St. André, Bordeaux, FR, ¹⁰Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, ¹¹CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, ¹²Centre Francois Baclesse, Caen, Cedex, FR, ¹³Centre Georges-François Leclerc (Dijon), Dijon, FR, ¹⁴Unicancer, Paris, Cedex, FR, ¹⁵Gustave Roussy Cancer Campus, Villejuif, FR

10:23 - 10:24 **1481TiP - A prospective, randomized phase II trial of neoadjuvant immunotherapy in primary clear cell renal cancer at risk for recurrence or distant metastases: The NESICIO trial**

F. Burgers¹, N. Graafland¹, B. Lagerveld², A. Ruiter², H. Beerlage³, J. Van Moorselaar³, P. Zondervan³, C. Mellema⁴, S. Rynja⁴, M. Van Montfoort¹, S. Zerp¹, M. Lopez-Yurda¹, C. Blank¹, A. Bex⁵, J. Haanen¹, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²OLVG, Amsterdam, NL, ³Amsterdam UMC, Amsterdam, NL, ⁴Spaarne Hospital, Hoofddorp, NL, ⁵Royal Free London NHS Foundation Trust, London, GB

10:24 - 10:25 **1738P - Three-year follow-up update and survival outcomes of the PURE-01 study**

T. Padua¹, G. Basile¹, M. Bandini¹, D. Raggi¹, L. Marandino¹, P. Giannatempo², R. Colombo¹, M. Colecchia¹, R. Lucianò¹, M. Moschini¹, A. Briganti³, F. Montorsi³, A. Necchi³, ¹San Raffaele Hospital, Milan, IT, ²Istituto Nazionale dei Tumori, Milan, IT, ³San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, IT

10:25 - 10:26 **1739P - Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)**

A. Weickhardt¹, F. Foroudi¹, J. Xie², K. Kanojia², M. Sidhom³, A. Pal³, P. Grimison⁴, A. Zhang⁵, S. Ng⁶, C. Tang⁶, E. Hovey⁷, C. Chen⁷, G. Hruby⁸, A. Guminski⁸, M. Mcjannett⁹, C. Conduit², N. Lawrentschuk², B. Tran¹⁰, I. Davis¹¹, D. Hayne¹², ¹Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, AU, ²Peter MacCallum Cancer Center, Melbourne, AU, ³Liverpool Hospital - South Western Sydney Local Health District, Liverpool, AU, ⁴Chris O'Brien Lifehouse, Camperdown, AU, ⁵Chris O'Brien Lifehouse, Camperdown, AU, ⁶Sir Charles Gairdner Hospital, Nedlands, AU, ⁷Prince of Wales Hospital - Nelune Comprehensive Cancer Centre, Randwick, AU, ⁸Royal North Shore Hospital, St Leonards, AU, ⁹ANZUP Cancer Clinical Trials, Camperdown, AU, ¹⁰Peter MacCallum Cancer Centre, Melbourne, AU, ¹¹Monash University Eastern Health Clinical School, Box Hill, AU, ¹²Fiona Stanley Hospital, Murdoch, AU

- 10:26 - 10:27 **1740P - Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART): An open-label, single-arm, multicenter, phase II trial**
- Y. Nagumo¹, T. Kimura¹, H. Ishikawa², Y. Sekino³, K. Maruo¹, B. J. Mathis⁴, M. Takemura¹, Y. Kageyama⁵, H. Ushijima⁵, T. Kawai⁶, H. Yamashita⁶, H. Azuma⁷, T. Naiki⁸, Y. Kobayashi⁹, J. Inokuchi¹⁰, T. Osawa¹¹, Y. Kita¹², T. Tsuzuki¹³, K. Hashimoto¹, H. Nishiyama¹, ¹University of Tsukuba, Tsukuba, JP, ²National Institutes for Quantum and Radiological Science and Technology, Chiba, JP, ³NCCH - National Cancer Center Hospital, Chuo-ku, JP, ⁴University of Tsukuba Hospital, Tsukuba, JP, ⁵Saitama Prefectural Cancer Center, Ina, JP, ⁶The University of Tokyo, Meguro-ku, JP, ⁷Osaka Medical and Pharmaceutical University Hospital, Takatsuki, JP, ⁸Nagoya City University Hospital, Nagoya, JP, ⁹Okayama University Graduate School of Medicine, Okayama, JP, ¹⁰Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, ¹¹Hokkaido University, Sapporo, JP, ¹²Graduate School of Medicine and Faculty of Medicine Kyoto University, Kyoto, JP, ¹³Aichi Medical University, Nagakute, JP
- 10:27 - 10:28 **1741P - Atezolizumab (ATZ) with split-doses of cisplatin plus gemcitabine in patients with locally advanced or metastatic urothelial carcinoma (SOGUG-AUREA): A multicentre, single-arm phase II trial**
- G.A. De Velasco Oria¹, I. García-Carbonero², E. Esteban-Gonzalez³, A. Pinto⁴, D. Lorente⁵, A. Gómez De Liaño⁶, E. Martínez Ortega⁷, L. Jimenez Colomo⁸, J. Puente⁹, I. Gonzalez¹⁰, O. Fernández¹¹, G. Anguera¹², ¹Hospital Universitario 12 de Octubre, Madrid, ES, ²Hospital Hospital Virgen de la Salud, Toledo, ES, ³Hospital Universitario Central de Asturias, Oviedo, ES, ⁴Hospital Universitario La Paz - IdiPAZ, Madrid, ES, ⁵Hospital Provincial de Castellón, Castellón, ES, ⁶Complejo Hospitalario Universitario Insular - Materno Infantil (CHUIMI), las Palmas de Gran Canaria, ES, ⁷Hospital Universitario de Jaén, Jaén, ES, ⁸Institut Català d'Oncologia (ICO) Hospitalet, L'Hospitalet de Llobregat, ES, ⁹Hospital Clinico Universitario San Carlos, Madrid, ES, ¹⁰Hospital Son Llàtzer, Mallorca, ES, ¹¹Complejo Hospitalario Universitario Ourense, Ourense, ES, ¹²Hospital de la Santa Creu i Sant Pau, Barcelona, ES
- 10:28 - 10:29 **1742P - Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC)**
- P. Martin Romano¹, G. Roubaud², P. Lavaud³, M. Cabart⁴, A. Pages³, D. Vasseur⁵, E. Colomba³, S. Cousin⁶, M. Toulmonde⁴, T. Grellety², Z. Castel Ajgal⁷, R. Chabanon³, A. Parpaleix³, G. Buzzatti⁸, K. Fizazi³, C. Gomez-Roca⁹, A. Italiano², Y. Lorient³, S. Postel-Vinay¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Institute Bergonié, Bordeaux, FR, ³Institut Gustave Roussy, Villejuif, Cedex, FR, ⁴Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ⁵Gustave Roussy - Cancer Campus, Villejuif, FR, ⁶Institut Bergonie, Bordeaux, FR, ⁷INSTITUT CURIE, PARIS, FR, ⁸IRCCS Ospedale Policlinico San Martino, Genova, IT, ⁹Institut Universitaire du Cancer - Toulouse- Oncopole, Toulouse, FR
- 10:29 - 10:30 **1743P - ALTN-AK105-II-02 cohort 4: A phase II study of penpulimab plus anlotinib in patients (pts) with previously treated locally advanced or metastatic urothelial carcinoma (UC)**
- Y. Sun¹, W. Qu¹, M. Sun², J. Zhou³, X. Bi¹, A. Zhou¹, ¹National Cancer Center/National

Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ²Jinan Central Hospital Affiliated to Shandong University; Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, CN, ³Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN

- 10:30 - 10:31 **1744P - Camrelizumab plus nab-paclitaxel in platinum-resistant patients with unresectable locally advanced or metastatic urothelial carcinoma: A multicentre, single-arm, phase II study**
- H. Li¹, M. Chen¹, C. Xue¹, L. Li¹, A. Hu¹, W. Yang¹, Z. Zheng², M. Ni¹, L. Zhang¹, Y. Zeng¹, J. Peng¹, K. Yao¹, F. Zhou¹, Z. Liu³, X. An¹, Y. Shi¹, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, ³Sun Yat-sen University Cancer Center, Guangzhou, CN
- 10:31 - 10:32 **1745P - Phase II study of neoadjuvant chemotherapy with 4 cycles of dose dense MVAC followed by radical surgery in Korean patients with MIBC and locally advanced urothelial carcinoma of bladder (NCT04047693)**
- K. Park¹, J.K. Nam², H.J. Lee², T.U. Kim², H. Ryu², Y.K. Ki², J.-J. Kim¹, S.B. Oh¹, S.Y. Oh¹, Y.J. Hong³, ¹Pusan National University Yangsan Hospital, Yansan-si, KR, ²Pusan National University Yangsan Hospital, Yangsan, KR, ³The Catholic University of Korea - College of Medicine, Seoul, KR
- 10:32 - 10:33 **1746P - Disease-free survival (DFS) and distant metastasis-free survival (DMFS) as surrogates for overall survival (OS) in adjuvant treatment of muscle-invasive bladder cancer (MIBC)**
- C. Sternberg¹, P. Squifflet², S. Burdett³, D. Fisher⁴, E. Saad⁵, M. Kurt⁶, S. Teitsson⁷, J. May⁸, M. Stoeckle⁹, F. Torti¹⁰, R. Cote¹¹, S. Groshen¹², E. Ruggeri¹³, A. Zhegalik¹⁴, J. Tierney¹⁵, L. Collette⁵, T. Burzykowski², M. Buyse⁵, ¹Weill Cornell Medicine, New York, US, ²IDDI, Ottignies (Céroux-Mousty), BE, ³Institute of Clinical Trials and Methodology-UCL, London, GB, ⁴MRC - Medical Research Council Clinical Trials Unit - University College London (UCL), London, GB, ⁵International Drug Development Institute, Louvain-la-Neuve, BE, ⁶Bristol Myers Squibb, Lawrenceville, US, ⁷Bristol Myers Squibb Pharmaceuticals Limited - Uxbridge, Uxbridge, GB, ⁸Bristol-Myers Squibb Pharmaceuticals Limited - Uxbridge, Uxbridge, GB, ⁹Saarland University Medical Center - Universitaetsklinikum des Saarlande (UKS), Homburg, DE, ¹⁰University of Connecticut Health Center, Farmington, US, ¹¹Washington University in St. Louis, St. Louis, US, ¹²USC - University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, US, ¹³Ospedale Belcolle - ASL Viterbo, Viterbo, IT, ¹⁴N. N. Alexandrov National Cancer Centre, Lesnoy - Minsk District, BY, ¹⁵UCL - University College London, London, GB
- 10:33 - 10:34 **1747P - Impact of prior chemotherapy (Chemo) on pembrolizumab (Pembro) response in urothelial cancer (UC): Exploratory analysis of the phase III KEYNOTE-045 study**
- R. De Wit¹, D. Vaughn², Y. Fradet³, L. Fong⁴, N. Vogelzang⁵, M.A. Climent Duran⁶, A. Necchi⁷, D. Petrylak⁸, W. Gerritsen⁹, H. Gurney¹⁰, D. Quinn¹¹, S. Culine¹², C. Sternberg¹³, D. Bajorin¹⁴, T. Choueiri¹⁵, J. Xu¹⁶, K. Imai¹⁶, B. Homet Moreno¹⁶, J. Bellmunt¹⁷, J.-L. Lee¹⁸, ¹Erasmus MC Cancer Institute, Rotterdam, NL, ²Abramson Cancer Center, Penn Medicine, Philadelphia, US, ³CHU de Québec-Laval University,

Québec, CA, ⁴University of California San Francisco, San Francisco, US, ⁵Comprehensive Cancer Centers of Nevada, Las Vegas, US, ⁶Valencian Institute of Oncology (IVO Foundation), València, ES, ⁷Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ⁸Yale University School of Medicine, New Haven, US, ⁹Radboud University Medical Center, Nijmegen, NL, ¹⁰Westmead Hospital and Macquarie University, Sydney, AU, ¹¹USC Norris Comprehensive Cancer Center, Keck Medicine of USC, Los Angeles, US, ¹²Saint-Louis Hospital, Paris, FR, ¹³Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian, New York, US, ¹⁴Memorial Sloan Kettering Cancer Center, New York, US, ¹⁵Dana-Farber Cancer Institute and Harvard Medical School, Boston, US, ¹⁶Merck & Co., Inc., Rahway, US, ¹⁷Beth Israel Deaconess Medical Center/IMIM Research Institute, Harvard Medical School, Boston, US, ¹⁸Asan Medical Center and University of Ulsan College of Medicine, Seoul, KR

- 10:34 - 10:35 **1748P - 4-factor model to predict response and survival benefit with durvalumab (D) in previously treated metastatic urinary tract carcinoma (mUTC)**
G. Sonpavde¹, C. Sternberg², J.-L. Lee³, U. Emeribe⁴, S.M. Oh⁴, A.R. Dantas De Lima⁴, S. Hotte⁵, ¹Dana Farber Cancer Institute, Boston, US, ²Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York, NY, US, ³Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ⁴AstraZeneca, Gaithersburg, US, ⁵JCC - Juravinski Cancer Centre - Hamilton Health Sciences, Hamilton, CA
- 10:35 - 10:36 **1749P - Association between immune-mediated adverse events (imAEs) and outcomes in metastatic urothelial cancer (mUC) treated with durvalumab (D) alone or in combination with tremelimumab (T) in the DANUBE study**
O. Abdeljalil¹, C. Stecca¹, C. Lu², H. Zhang³, E. Goluboff⁴, S. Sridhar⁵, ¹Princess Margaret Cancer Centre, Toronto, CA, ²AstraZeneca, Gaithersburg, US, ³AstraZeneca, Phoenix, US, ⁴AstraZeneca Global Medicines Development, Gaithersburg, US, ⁵Princess Margaret Cancer Center, Toronto, CA
- 10:36 - 10:37 **1750P - Factors associated with the receipt of systemic treatment (tx) for metastatic urothelial carcinoma (mUC) in England**
C. Knott¹, M. Kearney², H. Mahmoudpour², P. Verpillat², ¹Health Data Insight CIC; NHS Digital, Leeds, GB, ²Merck Healthcare KGaA, Darmstadt, DE

09:00 - 13:00 Type: Poster session Poster Area, Hall 4
Title: Poster session 03

- 09:00 - 09:01 **299P - Integrative analysis of longitudinal genomic and non-genetic mechanisms of radiotherapy resistance**
E. Kocakavuk, F. Varn, K. Johnson, R. Verhaak, The Jackson Laboratory for Genomic Medicine, Farmington, US
- 09:01 - 09:02 **300P - The clinical results of an investigator initiated trial of allogeneic CAR-T cells targeting IL13R α 2 in the treatment of high-grade glioma**
Y. Huang¹, X. Li¹, X. Shang², ¹The Dushu Lake Affiliated Hospital of Suzhou (Soochow) University, Suzhou, CN, ²JIANGSU T-MAXIMUM BIOTECH CO., LTD., Suzhou, CN

- 09:02 - 09:03 **301P - Hypofractionated radiotherapy for the treatment of newly diagnosed high-grade gliomas in younger and good performance status patients during COVID-19 pandemic**
A.C. Valente¹, C. Lopes Almeida¹, M. Costa¹, I. Nogueira Costa², J. Reis¹, M. Freitas³, C. Teixeira⁴, M. Gonçalves³, A. Fernandes¹, A. Costa⁵, C. Caeiro⁵, L. Osório⁶, I. Augusto¹, M. Barbosa¹, ¹CHUSJ - Centro Hospitalar Sao Joao E.P.E - SNS - Polo Porto, Porto, PT, ²CHUSJ - Centro Hospitalar Sao Joao E.P.E - Polo Porto, Porto, PT, ³Centro Hospitalar Sao Joao E.P.E - Polo Porto, Porto, PT, ⁴são joão university hospital center, Porto, PT, ⁵HSJ - Hospital de Sao Joao Centro Hospitalar Universitario, EPE - SNS, Porto, PT, ⁶Centro Hospitalar e Universitário São João - Porto, Porto, PT
- 09:03 - 09:04 **302P - A multicenter, open-label, dose-escalation (DE), first-in-human study of VEGFRs and CSF1R inhibitor SYHA1813 in patients (pts) with recurrent high-grade gliomas (HGG) or advanced solid tumors**
W. Li¹, Z. Kang¹, S. Li¹, Y. Lin¹, Y. Li², Y. Mao³, J. Zhang³, T. Lei⁴, H. Wang⁵, Y. Su⁵, Y. Yang⁵, J. Qiu⁵, ¹Beijing Tiantan Hospital, Capital Medical University, Beijing, CN, ²Chongqing Cancer Hospital, Chongqing, CN, ³Huashan Hospital Affiliated to Fudan University, Shanghai, CN, ⁴Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan City, CN, ⁵CSPC Pharmaceutical Group Co., Ltd., Shijiazhuang, CN
- 09:04 - 09:05 **303P - EO2401 (EO) therapeutic vaccine for patients (pts) with recurrent glioblastoma (GB): Phase I/II ROSALIE study**
D. Reardon¹, A. Idbaih², M. Vieito Villar³, G. Tabatabai⁴, A. Stradella⁵, F. Ghiringhelli⁶, M. Burger⁷, M. Gonzalez Rodriguez³, A. Hervieu⁶, I. Mildenerberger⁸, M. Gil Martín⁵, M. Renovanz⁴, M. Touat⁹, P. Wen¹, A. Wick¹⁰, C. Gouttefangeas¹¹, A. Maia¹¹, C. Bonny¹², J. Fagerberg¹², W. Wick¹³, ¹Dana Farber Cancer Institute, Boston, US, ²Sorbonne Université, AP-HP, ICM, Hôpital Universitaire La Pitié-Salpêtrière, Paris, FR, ³Hospital Universitari Vall d'Hebron, Barcelona, ES, ⁴Universitätsklinikum, Tübingen, DE, ⁵Institut Català d'Oncologia, Barcelona, ES, ⁶Centre Georges-François Leclerc, Dijon, FR, ⁷Universitätsklinikum Frankfurt Goethe-Universität, Frankfurt, DE, ⁸Medizinische Fakultät, Mannheim, DE, ⁹Hôpital Universitaire La Pitié-Salpêtrière, Paris, FR, ¹⁰Universitätsklinikum, Heidelberg, DE, ¹¹Eberhard-Karls-University, Tuebingen, DE, ¹²Enterome, Paris, FR, ¹³Universitätsklinikum Heidelberg and German Cancer Research Center, Heidelberg, DE
- 09:05 - 09:06 **304P - A phase II study of anlotinib in the treatment of recurrent high-grade glioma: Updated results**
H. Dai, M. Zhang, S. Zhao, Q. Zhang, Hangzhou Cancer Hospital, Hangzhou, CN
- 09:06 - 09:07 **305P - The role of surgery in addition to chemotherapy in the second-line treatment of glioblastomas**
A.S. Mendes¹, H. Pereira², P. Liu³, H. Miranda¹, R. Romao¹, C. Noronha⁴, L. Rocha⁴, C. Pinheiro⁴, E. Rosendo¹, M.J. Freitas Magalhães¹, R. Moreira², M.J. Pereira Amorim², M. Sousa³, T. Malheiro Sarmiento³, A.M. Ferreira Araujo¹, ¹Hospital Geral de Santo António (Centro Hospitalar Universitario do Porto, EPE-SNS), Porto, PT, ²Hospital de Braga EPE - SNS, Braga, PT, ³Centro Hospitalar Tras-os-Montes e Alto Douro, EPE-SNS, Vila Real, PT, ⁴Hospital Geral de Santo António (CHPORTO - Centro Hospitalar Universitario do Porto,

EPE-SNS), Porto, PT

- 09:07 - 09:08 **306P - Different dosage of bevacizumab treatment in recurrent IDHwt glioblastoma/IDHmut grade 4 astrocytoma and its impact on outcome**
A. Bosio, M. Caccese, M. Padovan, G. Cerretti, V. Zagonel, G. Lombardi, Veneto Institute of Oncology IOV-IRCCS, Padova, IT
- 09:08 - 09:09 **307P - Incidence of neurological symptoms in brain metastases from breast cancer and its impact on prognosis: An analysis of 968 patients with brain metastases**
A. Steindl¹, K. Schweighart¹, C. Zach¹, A. Grisold¹, B. Gatterbauer¹, K. Dieckmann², Z. Bago-Horvath¹, R. Exner¹, F. Fitzal¹, G. Pfeiler³, C. Singer³, G. Widhalm¹, R. Bartsch¹, M. Preusser¹, A.S. Berghoff⁴, ¹MedUni Wien - Medical University of Vienna, Vienna, AT, ²Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT, ³Medizinische Universitaet Wien, Vienna, AT, ⁴Medical University of Vienna, Vienna, AT
- 09:09 - 09:10 **309P - Patients with relapsed adult medulloblastoma (MB) treated by the GEINO (Spanish cooperative group for research in neuro-oncology) group oncologists: Natural history and patterns of care**
M. Vieito Villar¹, R. Luque Caro², M.C. Martín Soberon³, S. Del Barco Berron⁴, E. Pineda⁵, M.Á. Vaz Salgado⁶, M.T. Tuñon⁷, A. Herrero Ibañez⁸, T. Quintanar Verduguez⁹, J. Diaz Santos¹⁰, R. Girones Sarrio¹¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Hospital Universitario Virgen de las Nieves, Granada, ES, ³Hospital Universitario 12 de Octubre, MADRID, ES, ⁴Fundació Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Salt, ES, ⁵Hospital Clinic de Barcelona, Barcelona, ES, ⁶Hospital Universitario Ramon y Cajal, Madrid, ES, ⁷Complejo Hospitalario de Navarra - Royal Navarre Hospital, Pamplona, ES, ⁸Hospital Universitario Miguel Servet, Zaragoza, ES, ⁹Hospital General Universitario de Elche, Elche, ES, ¹⁰Hospital Universitario Regional de Malaga, Malaga, ES, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, ES
- 09:10 - 09:11 **310P - Bevacizumab in meningiomas: A monocentric experience**
G. Cerretti, A. Bosio, M. Maccari, M. Padovan, M. Caccese, V. Zagonel, G. Lombardi, Veneto Institute of Oncology IOV-IRCCS, Padova, IT
- 09:11 - 09:12 **311P - Differences in stromal component of chordoma are associated with contrast enhancement in MRI and differential gene expression in RNA sequencing**
Y.J. Cha, M. Park, I. Park, J.H. Kim, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR
- 09:12 - 09:13 **312TiP - Impact of early palliative care integration on quality of life and symptom burden in patients with high-grade glioma**
J. Reis¹, I. Nogueira Costa², C. Caeiro², A. Costa², A. Fernandes¹, E. Gonçalves², T. Tavares¹, C. Moreira¹, M. Barbosa¹, A.C. Valente¹, M. Costa¹, ¹CHUSJ - Centro Hospitalar Sao Joao E.P.E - SNS - Polo Porto, Porto, PT, ²HSJ - Hospital de Sao Joao Centro Hospitalar Universitario, EPE - SNS, Porto, PT
- 09:13 - 09:14 **313TiP - Phase II study on the safety and efficacy of fluzoparib and**

temozolomide in primary glioblastoma

H. Zhang¹, R. Tao², J. Meng², Y. Wang³, J. Yang³, H. Zhang⁴, ¹Shandong Provincial Hospital, Jinan, CN, ²Department of Neurosurgery, Shandong Cancer Hospital Affiliated to Shandong University, ShanDong, CN, ³Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN, ⁴Jiangsu Hengrui medicine Co., Ltd, Lianyungang, CN

09:14 - 09:15 **793P - NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma**

G. Long¹, A. Spillane², T. Pennington¹, K. Shannon¹, J. Stretch¹, M. Gonzalez¹, R. Saw³, S. Lo⁴, R. Scolyer³, A. Menzies¹, ¹Melanoma Institute Australia, Wollstonecraft, AU, ²University of Sydney, Sydney, AU, ³Royal Prince Alfred Hospital, Camperdown, AU, ⁴The University of Sydney School of Public Health, Sydney, AU

09:15 - 09:16 **794P - Efficacy and tolerability of neoadjuvant treatment with T-VEC in difficult to resect primary basal cell carcinoma: A phase II clinical trial (NeoBCC)**

J. Ressler¹, A. Kusienicka¹, R. Silmbrod¹, T. Silly¹, V. Bachmayr¹, M. Plaschka², L.E. Shaw¹, N. Zila¹, A. Stepan¹, P. Tschandl¹, J. Tittes¹, F. Roka¹, W. Haslik³, F. Koenig⁴, R. Kunstfeld¹, P. Petzelbauer¹, F. Halbritter², W. Weninger¹, M. Farlik¹, C. Hoeller¹, ¹Medical University of Vienna, Vienna, AT, ²St. Anna Children's Cancer Research Institute, Vienna, AT, ³Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT, ⁴MedUni Wien - Medical University of Vienna, Vienna, AT

09:16 - 09:17 **795P - A phase Ib trial of neoadjuvant oncolytic virus OrienX010 (ori) and anti-PD-1 toripalimab (tori) combo in patients (pts) with resectable stage IIIb-IV (M1a) acral melanoma**

X. Wei¹, X. Wang¹, X. Bai¹, C. Li¹, L. Mao¹, Z. Chi¹, B. Lian¹, T. Bixia¹, Y. Kong¹, J. Dai¹, R. Andtbacka², J. Guo¹, C.-L. Cui¹, L. Si¹, ¹Peking University Cancer Hospital and Institute, Beijing, CN, ²Seven & Eight Biopharma, New Jersey, US

09:17 - 09:18 **796P - Neoadjuvant toripalimab plus axitinib in patients (pts) with resectable mucosal melanoma (MuM): Updated findings of a single-arm, phase II trial**

C.-L. Cui¹, Z. Li¹, N. Wu¹, M. Li¹, X. Chen², H. Zheng¹, M. Gao¹, D. Wang³, B. Lian¹, X. Wang¹, H. Tian¹, L. Si¹, Z. Chi¹, X. Sheng¹, Y. Lai¹, T. Sun⁴, Q. Zhang⁴, Y. Kong¹, J. Guo¹, ¹Peking University Cancer Hospital and Institute, Beijing, CN, ²Beijing Tongren Hospital, Capital Medical University, Beijing, CN, ³Peking University School of Stomatology, Beijing, CN, ⁴Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, CN

09:18 - 09:19 **797P - Relapse-free survival (RFS) update and first translational analyses of DONIMI, a study testing personalized neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage III melanoma patients (pts) based on the interferon-gamma signature (IFN- γ signature) algorithm**

I. Reijers¹, A. Menzies², J. Versluis¹, P. Dimitriadis¹, M. Wouters¹, R. Saw², M. Klop¹, T. Pennington², W. Van Houdt¹, L. Bosch¹, S. Cornelissen¹, M. Lopez-Yurda³, L. Griepink-Ongering¹, R. Rawson², A. Spillane², R. Scolyer², B. Van De Wiel³, A. Van Akkooi², G. Long², C. Blank³, ¹Netherlands Cancer Institute, Amsterdam, NL, ²Melanoma Institute Australia, Wollstonecraft, AU, ³NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

- 09:19 - 09:20 **798P - NeoTrio – Optimal neoadjuvant (NAT) sequencing of anti-PD-1 and BRAF targeted therapy (TT) in BRAF mutant stage III melanoma: Results of histopathological analysis**
J. Braden¹, A. Potter¹, E. Paver¹, R. Rawson², A. Menzies³, M. Carlino⁴, G. Au-Yeung⁵, R. Saw², A. Spillane¹, K. Shannon¹, T. Pennington¹, S. Ch'Ng¹, D. Gyorki⁶, J. Howle⁴, D. Daneshvar⁷, J. Wilmott⁷, S. Lo⁸, I. Pires Da Silva¹, R. Scolyer², G. Long¹, ¹Melanoma Institute Australia, Wollstonecraft, AU, ²Royal Prince Alfred Hospital, Camperdown, AU, ³Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, New South Wales, AU, ⁴Crown Princess Mary Cancer Centre Westmead, Westmead, AU, ⁵Peter MacCallum Cancer Centre, East Melbourne, AU, ⁶Olivia Newton-John Cancer Centre, Victoria, AU, ⁷University of Sydney, Sydney, AU, ⁸The University of Sydney School of Public Health, Sydney, AU
- 09:20 - 09:21 **799P - A pilot study of the neo-adjuvant use of vemurafenib plus cobimetinib in patients with BRAF mutant melanoma with palpable lymph node metastases**
T. Petrella¹, C. Mihalciou², C. Nessim³, A. Spatz⁴, I. Watson⁵, F. Wright⁶, ¹Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA, ²McGill University Health Centre (Glen Site), Montreal, CA, ³The Ottawa Hospital - General Campus, Ottawa, CA, ⁴Lady Davis Institute, Montreal, FR, ⁵McGill University, Montreal, CA, ⁶Sunnybrook Health Sciences Centre, Toronto, CA
- 09:21 - 09:22 **800P - Number needed to treat (NNT) and number needed to harm (NNH) to estimate clinical efficacy and safety of new adjuvant (Adj) therapies for resected stage (St) II-III melanoma**
D. Zara¹, B. Pastò¹, M. Garutti², M. Bartoletti², L. Palmero¹, E. Bertoli¹, C. Noto¹, L. Cucciniello¹, F. Totaro¹, M. Rizzetto¹, T. Pivetta¹, A. Membrino¹, A. Freschi², S. Bolzonello², F. Puglisi³, ¹Department of Medicine (DAME), University of Udine, Udine, UD, Italy, Udine, IT, ²CRO Aviano - Centro di Riferimento Oncologico - IRCCS, Aviano, IT, ³CRO di Aviano, National Cancer Institute, IRCCS; Department of Medicine (DAME), University of Udine, Udine, IT
- 09:22 - 09:23 **801P - Neoadjuvant checkpoint inhibitor immunotherapy (IMT) for resectable mucosal melanoma (MM)**
J. Ho¹, J. Mattei², M. Tetzlaff³, M. Williams¹, M. Davies¹, A. Diab¹, I. Glitza¹, J. Mcquade¹, S. Patel¹, H. Tawbi¹, M. Wong¹, C. Yee¹, S. Fisher¹, E. Hanna¹, E. Keung¹, M. Ross⁴, S. Su¹, S. Faria¹, P. Nagarajan¹, R. Amaria¹, ¹MD Anderson Cancer Center, Houston, US, ²Hospital Moinhos de Vento, Porto Alegre, BR, ³UCSF - University of California San Francisco, San Francisco, US, ⁴The University of Texas M. D. Anderson Cancer Center, Houston, US
- 09:23 - 09:24 **802P - Demography and clinical outcomes of adjuvant therapy in Spain: Results from GEM 1801 study**
S. Martin Algarra¹, A. Piñero Madrona², M.-Á. Berciano-Guerrero³, E. Muñoz Couselo⁴, A. Soria Rivas⁵, J.L. Manzano⁶, L. Gutiérrez Sanz⁷, G. Crespo⁸, T. Puértolas⁹, A. García Castaño¹⁰, C. Aguado De La Rosa¹¹, E. Espinosa¹², M. Majem¹³, R. López Castro¹⁴, P. Ayala De Miguel¹⁵, J. Medina Martínez¹⁶, L.A. Fernández-Morales¹⁷, L. Bellido¹⁸, P. Cerezuela-Fuentes², I. Márquez-Rodas¹⁹, ¹Clinica Universidad de Navarra, Madrid, ES, ²Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Ciudad de Murcia, ES, ³Hospitales Universitarios Regional y Virgen de la Victoria (HURyVV). Instituto de

Investigaciones Biomédicas de Málaga (IBIMA), Malaga, ES, ⁴Hospital Universitari Vall d'Hebron y Vall Hebrón Institute of Oncology (VHIO), Barcelona, ES, ⁵Hospital Universitario Ramón y Cajal, Madrid, ES, ⁶Instituto Catalán de Oncología, ICO-Badalona, H. Germans Trias i Pujol, Badalona, ES, ⁷Hospital Universitario Puerta de Hierro, Madrid, ES, ⁸Hospital Universitario de Burgos, Burgos, ES, ⁹Hospital Universitario Miguel Servet, Zaragoza, ES, ¹⁰Hospital Universitario Marqués de Valdecilla, Santander, ES, ¹¹Hospital Universitario Clínico San Carlos, Madrid, ES, ¹²Hospital Universitario La Paz - CIBERONC, Madrid, ES, ¹³Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹⁴Hospital Clínico Universitario de Valladolid, Valladolid, ES, ¹⁵Hospital Universitario San Pedro de Alcántara, Cáceres, ES, ¹⁶Hospital Universitario Toledo, Toledo, ES, ¹⁷Parc Taulí Sabadell Hospital Universitari, Sabadell, ES, ¹⁸Hospital Universitario Salamanca, Salamanca, ES, ¹⁹Hospital General Universitario Gregorio Marañón, Madrid, ES

09:24 - 09:25

803P - Patient-reported outcomes in patients with resected, stage III BRAF V600E melanoma treated with adjuvant dabrafenib & trametinib: COMBI-APlus study

J.J. Grob¹, C. Dutriaux², M. Del Vecchio³, B. Ryll⁴, C. Robert⁵, H. Gogas⁶, A. Menzies⁷, A. Gupta⁸, H. Banerjee⁹, M. Lau¹⁰, V. Atkinson¹¹, ¹Timone Hospital AP-HM, Aix-Marseille University, Marseille, FR, ²CHU Bordeaux - Hopital St. André, Bordeaux, FR, ³Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁴Melanoma Patient Network Europe MPNE, Uppsala, SE, ⁵Gustave Roussy, Villejuif, FR, ⁶Laiko General Hospital of Athens, Athens, GR, ⁷Melanoma Institute Australia, Wollstonecraft, AU, ⁸The Christie NHS Foundation Trust, Manchester, GB, ⁹Novartis Pharmaceuticals Corporation, East Hanover, US, ¹⁰Novartis Pharma AG - Novartis Campus, Basel, CH, ¹¹Princess Alexandra Hospital - Metro South Health, Woolloongabba, AU

09:25 - 09:26

804P - Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial

A. Eggermont¹, M. Kicinski², C. Blank³, M. Mandala⁴, G. Long⁵, V. Atkinson⁶, S. Dalle⁷, A. Haydon⁸, A. Meshcheryakov⁹, A. Khattak¹⁰, M. Carlino¹¹, S. Sandhu¹², S. Puig Sarda¹³, P. Ascierto¹⁴, P. Lorigan¹⁵, D. Grebennik¹⁶, N. Ibrahim¹⁶, S. Marreaud¹⁷, S. Suciu², C. Robert¹⁸, ¹Comprehensive Cancer Center Munich (CCCM), Munich, Germany, and University Medical Center Utrecht, Utrecht, NL, ²European Organisation for Research and Treatment of Cancer, Brussels, BE, ³NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁴Università degli Studi di Perugia, Perugia, IT, ⁵Melanoma Institute Australia, Wollstonecraft, AU, ⁶Princess Alexandra Hospital - Metro South Health, Woolloongabba, AU, ⁷Lyon Sud Hospital Center, Pierre Benite, FR, ⁸Alfred Hospital, Melbourne, AU, ⁹N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ¹⁰Fiona Stanley Hospital, Murdoch, AU, ¹¹Westmead Hospital - Crown Princess Mary Cancer Center, Westmead, AU, ¹²Peter Maccallum Cancer Institute, Melbourne, AU, ¹³Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ¹⁴IRCCS - Fondazione G. Pascale, Napoli, IT, ¹⁵The Christie NHS Foundation Trust, Manchester, GB, ¹⁶Merck & Co., Inc., Rahway, US, ¹⁷EORTC - European Organisation for Research and Treatment of Cancer, Brussels, BE, ¹⁸Gustave Roussy Cancer Campus Grand Paris & University Paris-Saclay, Villejuif, FR

09:26 - 09:27

805P - Predicting recurrence-free survival for patients with stage II melanoma: A validated tool to guide selection for adjuvant systemic therapy

A. Valey¹, M.-A. El Sharouni², J. Simon³, J. Gershenwald⁴, G. Long¹, R. Scolyer⁵, J. Thompson¹, S. Lo⁶, ¹Melanoma Institute Australia, Wollstonecraft, AU, ²UMC - University Medical Center Utrecht, Utrecht, NL, ³The University of Texas MD Anderson Cancer Center, Houston, US, ⁴MD Anderson Cancer Center, Houston, US, ⁵Royal Prince Alfred Hospital, Camperdown, AU, ⁶The University of Sydney School of Public Health, Sydney, AU

09:27 - 09:28

806P - Updated toxicity profile and relapse-free survival outcomes using an adapted pyrexia management algorithm in patients with resected stage III BRAF V600E/K-mutant melanoma treated with adjuvant dabrafenib plus trametinib in COMBI-APlus

M. Del Vecchio¹, V. Atkinson², B. Ryll³, A. Menzies⁴, F. Aubin⁵, V. Chiarion Sileni⁶, V. Ferraresi⁷, T. Lesimple⁸, G. Rinaldi⁹, P. Saiag¹⁰, C. Robert¹¹, C. Dutriaux¹², H. Gogas¹³, L. Demidov¹⁴, A. Gupta¹⁵, H. Banerjee¹⁶, S. Sudhir¹⁷, F. Miranda¹⁸, M. Lau¹⁹, J.J. Grob²⁰, ¹Unit of Melanoma Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ²Princess Alexandra Hospital - University of Queensland, Queensland, AU, ³Melanoma Patient Network Europe MPNE, Uppsala, SE, ⁴Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, New South Wales, AU, ⁵University Hospital and Inserm, Besançon, FR, ⁶Di Padova, Padova, IT, ⁷IRCCS Regina Elena National Cancer Institute (IRE), Rome, IT, ⁸CLCC Eugène Marquis,, RENNES CEDEX, FR, ⁹Section of Oncology, University of Palermo, Palermo, IT, ¹⁰Hôpital A Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, FR, ¹¹Gustave Roussy and Paris-Saclay University,, Villejuif, FR, ¹²University Hospital of Bordeaux / CHU De Bordeaux Hospital Saint-André,, Bordeaux, FR, ¹³Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, GR, ¹⁴N.N. Blokhin Russian Cancer Research Center, Moscow, RU, ¹⁵The Christie NHS Foundation Trust, Manchester, GB, ¹⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, US, ¹⁷Novartis Healthcare Private Limited, Hyderabad, IN, ¹⁸Novartis Pharmaceuticals Corporation, East Hanover NJ, US, ¹⁹Novartis Pharma AG, Basel, CH, ²⁰Aix-Marseille University,, Marseille, FR

09:28 - 09:29

807P - Adjuvant anti-PD-1 monotherapy benefit varies across different ethnicities and melanoma subtypes

X. Bai¹, S. Gerstberger², B. Park³, S. Jung³, R. Johnson⁴, N. Yamazaki⁵, D. Ogata⁶, Y. Umeda⁷, C. Li⁸, L. Si⁸, K. Flaherty⁹, Y. Nakamura¹⁰, K. Namikawa⁶, G. Long⁴, A. Menzies⁴, D. Johnson³, R. Sullivan¹¹, G. Boland¹², J. Guo⁸, ¹Peking University Cancer Hospital and Institute/Massachusetts General Hospital, Beijing, CN, ²Massachusetts General Hospital Cancer Center, boston, US, ³Vanderbilt University Medical Center, Nashville, US, ⁴Melanoma Institute Australia, Wollstonecraft, AU, ⁵National Cancer Center - Tsukiji Campus, Chuo-ku, JP, ⁶NCCH - National Cancer Center Hospital, Chuo-ku, JP, ⁷Saitama Medical University International Medical Center, Saitama, JP, ⁸Peking University Cancer Hospital and Institute, Beijing, CN, ⁹MGH - Massachusetts General Hospital, boston, US, ¹⁰Saitama Medical University International Medical Center, Hidaka, JP, ¹¹Mass General Cancer Center, Boston, MA, US, ¹²Massachusetts General Hospital - Surgical Oncology Division, Boston, US

09:29 - 09:30

808P - Postoperative adjuvant radiotherapy can reduce the local recurrence of nasal cavity and paranasal sinus mucosal melanoma: A prospective design, retrospective analysis and case–control study

B. Lian, Y. Yang, L. Si, L. Zhou, Z. Chi, X. Sheng, L. Mao, X. Wang, C.-L. Cui, J. Guo, B.

Zheng, Peking University Cancer Hospital and Institute, Beijing, CN

09:30 - 09:31

809P - Outcomes of patients with resected stage III/IV acral or mucosal melanoma treated with adjuvant anti-PD-1 therapy

S.K. Jacques¹, J. Mckeown², P. Grover², B. Park³, A. Zaremba⁴, F. Dimitriou⁵, M.F. Harunal Rashid⁶, K. Namikawa⁷, M. Mooradian⁸, J. Placzke⁹, C. Allayous¹⁰, I. Mehmi¹¹, D. Depalo¹², A. Wicky¹³, J. Schwarze¹⁴, Y. Nakamura¹⁵, N. Benannoune¹⁶, A. Menzies², S. Lo¹⁷, M. Carlino¹, ¹Crown Princess Mary Cancer Centre Westmead, Westmead, AU, ²Melanoma Institute Australia, Wollstonecraft, AU, ³Vanderbilt University Medical Center, Nashville, US, ⁴Universitätsklinikum Essen, Essen, DE, ⁵USZ - University Hospital Zürich, Zurich, CH, ⁶NCCS - National Cancer Centre Singapore, Singapore, SG, ⁷NCCCH - National Cancer Center Hospital, Chuo-ku, JP, ⁸Massachusetts General Hospital Cancer Center, Boston, US, ⁹Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, ¹⁰Hopital Saint Louis AP-HP, Paris, FR, ¹¹The Angeles Clinic & Research Institute, Los Angeles, CA, USA, Santa Monica, US, ¹²H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ¹³CHUV - Centre Hospitalier Universitaire Vaudois - Batiment Agora, Lausanne, CH, ¹⁴UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE, ¹⁵Saitama Medical University International Medical Center, Hidaka, JP, ¹⁶Gustave Roussy - Cancer Campus, Villejuif, FR, ¹⁷The University of Sydney School of Public Health, Sydney, AU

09:31 - 09:32

810P - PRESERV MEL: Real-world outcomes and health-related quality of life (HRQoL) in patients receiving adjuvant nivolumab for melanoma in Belgium and Luxembourg

A. Rogiers¹, L. Willemot², L. Mcdonald³, H. Van Campenhout⁴, K. Vouk⁵, G. Berchem⁶, C. Jacobs⁷, A. Rorive⁸, B. Neyns⁹, ¹CHU Brugmann UVB, Brussels, BE, ²Bristol Myers Squibb Belgium SA/NV, Braine L'Alleud, BE, ³Bristol Myers Squibb Pharmaceuticals Limited - Uxbridge, Uxbridge, GB, ⁴Bristol Myers Squibb, Braine-l'Alleud, BE, ⁵Syneos Health Germany GmbH, Munich, DE, ⁶Centre Hospitalier de Luxembourg, Luxembourg, LU, ⁷UZ Gent - Universitair Ziekenhuis Gent, Gent, BE, ⁸Centre Hospitalier Universitaire Sart Tilman, Liège, BE, ⁹UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE

09:32 - 09:33

811P - Three-years real-world evidence of adjuvant dabrafenib plus trametinib (DT) in patients with resected melanoma in Spain (GEM 1901 - DESCRIBE-AD)

P. Cerezuela-Fuentes¹, J. Martín-Liberal², L.A. Fernández-Morales³, G. Benítez⁴, J. Medina Martinez⁵, M. Quindós⁶, A. García Castaño⁷, T. Puértolas⁸, R. Vilchez Simo⁹, O. Fernández¹⁰, M. Majem¹¹, L. Bellido Hernández¹², P. Ayala De Miguel¹³, B. Campos¹⁴, E. Espinosa¹⁵, J.A. Macías Cerrolaza¹⁶, A. Rodríguez-Lescure¹⁷, L. Espasa Font¹⁸, G. Belaustegui Ferrández¹⁹, J.L. Manzano Mozo²⁰, ¹Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Ciudad de Murcia, ES, ²Catalan Institute of Oncology (ICO) L'Hospitalet, L'Hospitalet de Llobregat, ES, ³Parc Taulí Sabadell Hospital Universitari, Sabadell, ES, ⁴Hospital Universitario Insular de Gran Canaria, Las Palmas, ES, ⁵Hospital Universitario Toledo, Toledo, ES, ⁶Complejo Hospitalario Universitario A Coruña, La Coruña, ES, ⁷Hospital Universitario Marqués de Valdecilla, Santander, ES, ⁸Hospital Universitario Miguel Servet, Zaragoza, ES, ⁹Hospital Arquitecto Marcide, Ferrol, ES, ¹⁰Complejo Hospitalario Universitario de Ourense, Ourense, ES, ¹¹Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹²Complejo Asistencial Universitario de Salamanca,

Salamanca, ES, ¹³Hospital San Pedro de Alcántara, Caceres, ES, ¹⁴Hospital Universitario Lucus Augusti de Lugo, Lugo, ES, ¹⁵Hospital Universitario La Paz - CIBERONC, Madrid, ES, ¹⁶Hospital General Universitario Morales Meseguer, Murcia, ES, ¹⁷Hospital General Universitario de Elche, Alicante, ES, ¹⁸Novartis Farmacéutica S.A., Barcelona, ES, ¹⁹Novartis Farmaceutica S.A., Barcelona, ES, ²⁰Instituto Catalán de Oncología, ICO-Badalona, H. Germans Trias i Pujol, Badalona, Barcelona, ES

09:33 - 09:34 **812P - Early experiences in adjuvant treatment of melanoma: Real-world data on tolerability, safety and efficacy**

S. Van Laar¹, E. Kapiteijn², K. Gombert³, H.-J. Guchelaar¹, J. Zwaveling¹, ¹LUMC-Leiden University Medical Center, Leiden, NL, ²Leiden University Medical Center (LUMC), Leiden, NL, ³LUMC - Leids Universitair Medisch Centrum, Leiden, NL

09:34 - 09:35 **813P - Time to development of central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with vemurafenib (V) + cobimetinib (C): Updated results from the phase III IMspire150 study**

K. Lewis¹, C. Robert², R. Ramella Munhoz³, G. Liskay⁴, L. De La Cruz Merino⁵, J. Olah⁶, P. Queirolo⁷, J. Mackiewicz⁸, H. Li⁹, Q. Zhu¹⁰, C. Hertig¹¹, N. Paranthaman¹⁰, E. Mckenna¹⁰, R. Gutzmer¹², G. Mcarthur¹³, P. Ascierto¹⁴, ¹University of Colorado Comprehensive Cancer Center, Aurora, US, ²Gustave Roussy and Université Paris-Saclay, Villejuif, FR, ³Instituto do Câncer do Estado de São Paulo, Sao Paulo, BR, ⁴Országos Onkológiai Intézet, Budapest, HU, ⁵Hospital Universitario Virgen Macarena, Seville, ES, ⁶University of Szeged Szent-Györgyi Medical University, Szeged, HU, ⁷IRCCS Istituto Europeo di Oncologia, Milano, IT, ⁸Institute of Oncology, Poznan University of Medical Sciences, Poznan, PL, ⁹Hoffmann-La Roche Ltd., Mississauga, CA, ¹⁰Genentech, Inc., South San Francisco, US, ¹¹F. Hoffmann-La Roche Ltd., Basel, CH, ¹²Johannes Wesling Medical Center, Bochum, DE, ¹³Peter MacCallum Cancer Centre, Melbourne, AU, ¹⁴Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, IT

09:35 - 09:36 **814P - Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3**

M. Migden¹, C. Schmults², N. Khushanlani³, A. Guminski⁴, A.L. Chang⁵, K. Lewis⁶, G. Ansstas⁷, S. Bowyer⁸, B. Hughes⁹, D. Schadendorf¹⁰, B. Modi¹¹, L. Dunn¹², L. Flatz¹³, A. Hauschild¹⁴, S.-Y. Yoo¹⁵, J. Booth¹⁵, F. Seebach¹⁵, I. Lowy¹⁵, M. Fury¹⁵, D. Rischin¹⁶, ¹University of Texas MD Anderson Cancer Center, Houston, US, ²Brigham and Women's Hospital, Harvard Medical School, Boston, US, ³Moffitt Cancer Center, Tampa, US, ⁴Royal North Shore Hospital, St Leonards, AU, ⁵Stanford University School of Medicine, Stanford, US, ⁶University of Colorado Denver, Aurora, US, ⁷Washington University School of Medicine, St. Louis, US, ⁸University of Western Australia, Nedlands, AU, ⁹Royal Brisbane & Women's Hospital and University of Queensland, Brisbane, AU, ¹⁰University Hospital Essen, Essen and German Cancer Consortium, Essen, DE, ¹¹City of Hope, Duarte, US, ¹²Memorial Sloan Kettering Cancer Center, New York, US, ¹³University Hospital Tübingen, Tübingen, DE, ¹⁴Schleswig-Holstein University Hospital, Kiel, DE, ¹⁵Regeneron Pharmaceuticals, Inc., Tarrytown, US, ¹⁶Peter MacCallum Cancer Centre, Melbourne, AU

09:36 - 09:37 **815P - A single-arm, phase II clinical study of imatinib mesylate/toripalimab combo in patients (pts) with advanced melanoma harboring c-Kit mutation or**

amplification

L. Si, Z. Qi, J. Dai, X. Bai, L. Mao, C. Li, X. Wei, C.-L. Cui, Z. Chi, X. Sheng, Y. Kong, T. Bixia, L. Zhou, B. Lian, X. Wang, R. Duan, J. Guo, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, CN

- 09:37 - 09:38 **816P - Investigating surrogate endpoints (SE) for overall survival (OS) in first-line (1L) advanced melanoma: A pooled-analysis of immune checkpoint inhibitor (ICI) trials**
- J. Larkin¹, P. Squifflet², E. Saad³, P. Mohr⁴, M. Kurt⁵, A. Moshyk⁵, M. Hamilton⁵, S. Kotapati⁵, M. Buyse³, ¹The Royal Marsden Hospital, London, GB, ²IDDI, Ottignies (Céroux-Mousty), BE, ³International Drug Development Institute, Louvain-la-Neuve, BE, ⁴Elbe-Klinikum Buxtehude, Buxtehude, DE, ⁵Bristol Myers Squibb, Lawrenceville, US
- 09:38 - 09:39 **817P - Nivolumab (NIVO) + relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047**
- F.S. Hodi¹, H. Tawbi², E. Lipson³, D. Schadendorf⁴, P. Ascierto⁵, L. Matamala⁶, P. Salman⁶, E. Gutierrez⁷, P. Rutkowski⁸, H. Gogas⁹, C. Lao¹⁰, J. Menezes¹¹, S. Dalle¹², A.M. Arance Fernandez¹³, J.J. Grob¹⁴, S. Keidel¹⁵, S. Rodriguez¹⁶, P. Wang¹⁶, S. Dolfi¹⁶, G. Long¹⁷, ¹Dana-Farber Cancer Institute, Boston, US, ²The University of Texas MD Anderson Cancer Center, Houston, US, ³Sidney Kimmel Comprehensive Cancer Center, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, US, ⁴University Hospital Essen, Essen, DE, ⁵Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, IT, ⁶Instituto Oncológico Fundación Arturo López Pérez, Santiago, CL, ⁷FAICIC Clinical Research, Veracruz, MX, ⁸Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL, ⁹National and Kapodistrian University of Athens, Athens, GR, ¹⁰Michigan Medicine, Rogel Cancer Center, Ann Arbor, US, ¹¹Hospital Nossa Senhora da Conceição, Porto Alegre, BR, ¹²Hospices Civils de Lyon, Cancer Research Center of Lyon, Pierre Benite, FR, ¹³Hospital Clinic Barcelona and IDIBAPS, Barcelona, ES, ¹⁴Aix-Marseille University, CHU Timone, Marseille, FR, ¹⁵Bristol Myers Squibb, Uxbridge, GB, ¹⁶Bristol Myers Squibb, Princeton, US, ¹⁷Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, AU
- 09:39 - 09:40 **818P - Phase II confirmatory study of cemiplimab (350mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6**
- B. Hughes¹, J.J. Grob², S. Bowyer³, F. Day⁴, R. Ladwa⁵, B. Stein⁶, E. Muñoz Couselo⁷, N. Basset-Seguín⁸, A. Guminski⁹, L. Mortier¹⁰, A. Hauschild¹¹, M. Migden¹², C. Schmults¹³, S.-Y. Yoo¹⁴, J. Booth¹⁴, F. Seebach¹⁵, I. Lowy¹⁵, M. Fury¹⁶, D. Rischin¹⁷, ¹and the University of Queensland, Brisbane, AU, ²Hôpital de la Timone, Marseille, FR, ³Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, AU, ⁴Calvary Mater Newcastle, Newcastle, AU, ⁵and University of Queensland, Brisbane, AU, ⁶Adelaide Cancer Centre, Adelaide, AU, ⁷Medical Oncology Department, Melanoma and Other Skin Tumors Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁸Hôpital Saint Louis, Paris, FR, ⁹Royal North Shore Hospital, St Leonards, AU, ¹⁰CARADERM and University of Lille, INSERM U1189, Lille Hospital-Claude Huriez Hospital, Lille, FR, ¹¹University Hospital (UKSH), Kiel, DE, ¹²University of Texas MD

Anderson Cancer Center, Houston, US, ¹³Brigham and Women's Hospital, Harvard Medical School, Boston, US, ¹⁴Regeneron Pharmaceuticals, Inc., Basking Ridge, US, ¹⁵14Regeneron Pharmaceuticals, Inc., Tarrytown, US, ¹⁶Regeneron Pharmaceuticals, Inc., Tarrytown, US, ¹⁷Peter MacCallum Cancer Centre, Melbourne, AU

09:40 - 09:41

819P - Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Post hoc analysis of phase III COMBI-i trial

P. Nathan¹, J.J. Grob², R. Dummer³, P. Ascierto⁴, A. Ribas⁵, C. Robert⁶, D. Schadendorf⁷, K. Flaherty⁸, H. Tawbi⁹, A. Hauschild¹⁰, M. Mandala¹¹, R. Shah¹², H. Banerjee¹², R. Sarkar¹³, M. Lau¹⁴, G. Long¹⁵, ¹Mount Vernon Cancer Centre, East and North Herts NHS Trust, Northwood, GB, ²Timone Hospital AP-HM, Aix-Marseille University, Marseille, FR, ³University Hospital Zürich, Skin Cancer Center, Zurich, CH, ⁴Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁵Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, US, ⁶Gustave Roussy Cancer Campus Grand Paris & University Paris-Saclay, Villejuif, FR, ⁷University Hospital Essen and German Cancer Consortium, Essen, DE, ⁸Harvard Medical School and Massachusetts General Hospital, Boston, US, ⁹The University of Texas MD Anderson Cancer Center, Houston, US, ¹⁰University Hospital Schleswig-Holstein, Kiel, DE, ¹¹University of Perugia and Papa Giovanni XXIII Cancer Center Hospital, Perugia, IT, ¹²Novartis Pharmaceuticals Corporation, East Hanover, US, ¹³Novartis Healthcare Pvt Ltd., Hyderabad, IN, ¹⁴Novartis Pharma AG, Basel, CH, ¹⁵Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, North Sydney, AU

09:41 - 09:42

820P - Nivolumab (NIVO) +/- relatlimab (RELA) or ipilimumab (IPI) for patients (pts) with advanced treatment-naïve or -refractory basal cell carcinoma (BCC)

K. Schenk¹, J. Deutsch², M. Schollenberger¹, W. Sharfman³, P. Brothers⁴, A. Pons⁵, J. Scott⁶, K. Bibee⁶, J. Taube⁴, S. Topalian¹, E. Lipson⁵, ¹Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, ²Johns Hopkins Hospital, Baltimore, US, ³Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Lutherville, US, ⁴Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US, ⁵Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, ⁶Johns Hopkins University School of Medicine, Baltimore, US

09:42 - 09:43

821P - Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma

M. Schlaak¹, R. Dummer², J. Kirkwood³, A. Joshua⁴, M. Milhem⁵, L. Gastaud⁶, C. Mauch⁷, M. Yushak⁸, S. Lockwood⁹, C. Hayes⁹, A. Shoushtari¹⁰, ¹University Hospital LMU Munich, Munich, DE, ²Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, ³UPMC Hillman Cancer Center, Pittsburgh, US, ⁴Saint Vincent's Hospital, Sydney, AU, ⁵University of Iowa Hospitals and Clinics, Iowa City, US, ⁶Centre Anticancer Antoine Lacassagne, Nice, FR, ⁷University Hospital Cologne, Köln, DE, ⁸Winship Cancer Institute of Emory University, Atlanta, US, ⁹Immunocore Limited, Abingdon-on-Thames, GB, ¹⁰MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

09:43 - 09:44

822P - Phase II clinical trial: Safety and efficacy study of tocilizumab (Toci) in

combination with ipilimumab (Ipi) 3mg/kg plus nivolumab (Nivo) 1mg/kg in patients (pts) with metastatic melanoma (MM)

N. Abdel-Wahab¹, E.J. Montazari¹, C. Spillson¹, R. Amaria¹, I. Glitza¹, S. Patel¹, M. Awiwi¹, A. Hassan¹, N. Tahon¹, K.M. Elsayes¹, M. Altan², M. Wong¹, J. Mcquade¹, H. Tawbi¹, M. Davies¹, C. Yee¹, P. Sharma³, J. Allison², D. Johnson⁴, A. Diab¹, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²The University of Texas M. D. Anderson Cancer Center, Houston, US, ³The University of Texas MD Anderson Cancer Center, TX, US, ⁴Ochsner Medical Center - Ochsner Health, New Orleans, US

09:44 - 09:45

823P - A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma

J.M. Piulats Rodriguez¹, S. Piperno-Neumann², P. Rutkowski³, P. Nathan⁴, J. Hassel⁵, E. Espinosa⁶, L. De La Cruz Merino⁷, S. Ochsenreither⁸, A. Shoushtari⁹, M. Orloff¹⁰, A. Salama¹¹, C. Watkins¹², H. Goodall¹³, J.-F. Baurain¹⁴, ¹ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, ²Institut Curie, Paris, FR, ³Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, ⁴Mount Vernon Cancer Centre - East and North Herts NHS Trust, Northwood, GB, ⁵NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE, ⁶Hospital Universitario La Paz, Madrid, ES, ⁷Hospital Universitario Virgen Macarena, Seville, ES, ⁸Charité - Universitätsmedizin Berlin, Berlin, DE, ⁹MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ¹⁰Thomas Jefferson Univ Hospital, Philadelphia, US, ¹¹Duke University, Durham, US, ¹²Immunocore Limited, Abingdon-on-Thames, GB, ¹³Immunocore Ltd, Abingdon-on-Thames, GB, ¹⁴Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE

09:45 - 09:46

824P - Patterns of response/progression and management following progressive disease (PD) with anti-PD-(L)1 (PD(L)1) in patients (pts) with advanced Merkel cell carcinoma (MCC)

J. Mo¹, A. Zaremba², A.-J. Inderjeeth³, P. El Zenaity⁴, A. Li⁵, A. Wicky⁶, N. Della Marta⁷, C. Gaudy Marqueste⁸, A.-S. Bohne⁹, L. Festino¹⁰, C. Chen¹¹, S. Lo¹², A. Guminski¹³, O. Michielin¹⁴, W. Xu⁵, C. Lebbe¹⁵, S. Sandhu¹⁶, L. Zimmer², M. Carlino¹⁷, I. Pires Da Silva⁷, ¹Crown Princess Mary Cancer Centre Westmead, Westmead, AU, ²Universitätsklinikum Essen, Essen, DE, ³Peter MacCallum Cancer Center, Melbourne, AU, ⁴Assistance Publique - Hopitaux De Paris AP-HP, Paris, FR, ⁵Princess Alexandra Hospital - Metro South Health, Woolloongabba, AU, ⁶CHUV - Centre Hospitalier Universitaire Vaudois - Batiment Agora, Lausanne, CH, ⁷Melanoma Institute Australia, Wollstonecraft, AU, ⁸AP-HM - CHU La Timone Enfants, Marseille, FR, ⁹UKSH - Universitätsklinikum Schleswig-Holstein - Campus Kiel, Kiel, DE, ¹⁰Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ¹¹Blacktown Hospital, Blacktown, AU, ¹²The University of Sydney School of Public Health, Sydney, AU, ¹³Royal North Shore Hospital, ST LEONARDS, AU, ¹⁴Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ¹⁵Hopital Saint Louis AP-HP, Paris, FR, ¹⁶Peter MacCallum Cancer Centre, Melbourne, AU, ¹⁷Westmead Hospital - Crown Princess Mary Cancer Center, Westmead, AU

09:46 - 09:47

825P - CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting

G. Rabinowits¹, J. Homsy², S. Park³, N. Khushanlani⁴, T. Panella⁵, D. Ellison⁶, R. Gentry⁷,

S. Venna⁸, J. Strasswimmer⁹, R. Zuniga¹⁰, S. Chandra¹¹, E. Ruiz¹², M. Migden¹³, S. Ibrahim¹⁴, N. Mehta¹⁵, X. He¹⁶, H. Zhang¹⁶, K. Gillis¹⁶, J.-F. Pouliot¹⁶, ¹Miami Cancer Institute/Baptist Health South Florida, Miami, US, ²University of Texas Southwestern Medical Center, Dallas, US, ³University of California San Diego, San Diego, US, ⁴Moffitt Cancer Center, Tampa, US, ⁵University of Tennessee Medical Center, Knoxville, US, ⁶Charleston Oncology, Charleston, US, ⁷CARTI Cancer Center, Little Rock, US, ⁸Inova Schar Cancer Institute, Fairfax, US, ⁹Florida Atlantic University, Boca Raton, US, ¹⁰New York Cancer and Blood Specialists, Port Jefferson, US, ¹¹Northwestern University Feinberg School of Medicine, Chicago, US, ¹²Brigham and Women's Hospital, Boston, US, ¹³University of Texas MD Anderson Cancer Center, Houston, US, ¹⁴Rochester Dermatologic Surgery, PC, Victor, US, ¹⁵Sanofi, Cambridge, US, ¹⁶Regeneron Pharmaceuticals, Inc., Tarrytown, US

09:47 - 09:48

826P - Encorafenib and binimetinib followed by radiotherapy for patients with symptomatic BRAF mutated melanoma brain metastases: GEM1802/E-BRAIN clinical trial

I. Marquez-Rodas¹, A.M. Arance Fernandez², M.A. Berciano Guerrero³, A. Garcia Castano⁴, M.D.C. Alamo De La Gala⁵, M. Gonzalez Cao⁶, P. Sanchez Mauriño⁷, R. Diaz Beveridge⁸, I. Valduvico⁹, R. Delgado¹⁰, P.J. Prada⁴, E. Puertas⁶, J.L. Romero¹¹, A. Conde⁸, A. Alvarez¹², A. Berrocal¹³, ¹Hospital General Universitario Gregorio Marañón - Fundación Investigación Biomedica, Madrid, ES, ²Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ³Hospital Regional Universitario Málaga Carlos Haya, Malaga, ES, ⁴HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES, ⁵Hospital Universitario Virgen Macarena, Seville, ES, ⁶Hospital Universitari Dexeus, Barcelona, ES, ⁷Hospital Universitario Reina Sofía, Cordoba, ES, ⁸Hospital Universitari i Politènic La Fe, Valencia, ES, ⁹Hospital Clinic of Barcelona, Barcelona, ES, ¹⁰Hospital Universitario Regional de Malaga, Malaga, ES, ¹¹Hospital Reina Sofia, Tudela, ES, ¹²Hospital General Universitario Gregorio Marañón, Madrid, ES, ¹³Hospital General Universitario Valencia, Valencia, ES

09:48 - 09:49

827P - An open-label, multicenter, phase I study of RP2 as a single agent and in combination with nivolumab in patients with solid tumors: Safety, efficacy, and biomarker results

K. Harrington¹, J. Sacco², A. Olsson-Brown³, T. Chan⁴, P. Nenclares¹, I. Leslie¹, P. Bommarreddy⁵, C. Ahlers⁵, J. Wolff⁵, M. Middleton⁶, ¹ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB, ²Clatterbridge Cancer Center - NHS Foundation Trust, Wirral, GB, ³The Clatterbridge Cancer Centre - Liverpool, Liverpool, GB, ⁴Royal Liverpool University Hospital, Liverpool, GB, ⁵Replimune Inc., Woburn, US, ⁶Churchill Hospital, Oxford, GB

09:49 - 09:50

828P - Effectiveness and safety of dabrafenib and trametinib in patients with BRAFV600 mutated metastatic melanoma in the real-world setting: Final results of the non-interventional COMBI-r study

C. Berking¹, E. Livingstone², M. Weichenthal³, U. Leiter-Stopcke⁴, J. Remy⁵, T. Eigentler⁶, P. Mohr⁷, F. Kiecker⁸, C. Loquai⁹, D. Debus¹⁰, R. Gutzmer¹¹, ¹Universitätsklinik Erlangen, Erlangen, DE, ²University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ³Christian-Albrechts-University Kiel, Kiel, DE, ⁴Universitäts-Hautklinik Tuebingen, Tuebingen, DE, ⁵Novartis Pharma GmbH, Nuremberg, DE, ⁶Universitätsklinikum Tübingen, Tuebingen, DE, ⁷Dermatologic Center Buxtehude,

Buxtehude, DE, ⁸Vivantes Klinikum Neukoelln, Berlin, DE, ⁹Gesundheit Nord - Klinikverbund Bremen, Bremen, DE, ¹⁰Klinikum Nuernberg Nord, Nürnberg, DE, ¹¹Ruhr University Bochum Medizinische Universitätsklinik, Bochum, DE

- 09:50 - 09:51 **829P - A proof of concept study of sequential treatment with the HDAC inhibitor vorinostat plus BRAF and MEK inhibitors in BRAFV600 mutated melanoma**
A. Embaby¹, S. Huijberts¹, L. Wang¹, R. Leite De Oliveira¹, H. Rosing¹, B. Nuijen¹, C. Blank¹, H. Van Thienen¹, A. Meerveld-Eggink¹, J. Haanen¹, J. Beijnen¹, A. Huitema¹, R. Bernards¹, J. Schellens², S. Wilgenhof¹, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²Utrecht University - Faculty of Pharmaceutical Sciences, Utrecht, NL
- 09:51 - 09:52 **830P - Efficacy of immunotherapy in melanoma patients with symptomatic brain metastases treated with steroids: Initial report from the MEMBRAINS trial**
T. Borch¹, H. Schmidt², L. Bastholt³, E. Ellebæk⁴, M. Donia¹, I.-M. Svane¹, ¹National Center for Cancer Immune Therapy, Herlev, DK, ²Aarhus University Hospital, Aarhus, DK, ³OUH - Odense University Hospital, Odense, DK, ⁴Copenhagen University Hospital, Herlev, Herlev, DK
- 09:52 - 09:53 **831P - Outcomes of immune checkpoint inhibitors in patients with metastatic uveal melanoma treated with tebentafusp**
E. Koch¹, D. Arteaga Ceballos², M. Vilbert¹, K. Lajkosz¹, T. Pimentel Muniz¹, I. Hirsch¹, M.F. Silva Almeida Ribeiro¹, L. Mantle¹, M. Anczurowski³, D. Hogg¹, S. Saibil¹, A. Spreafico¹, H. Krema⁴, M. Butler¹, ¹Princess Margaret Cancer Centre, Toronto, CA, ²University of Western Ontario, London, CA, ³University of Toronto, Toronto, CA, ⁴UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA
- 09:53 - 09:54 **832P - Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM)**
F. Dimitriou¹, J. Hassel², M. Orloff³, I. Hughes⁴, E. Kapiteijn⁵, I. Mehmi⁶, K. Montazeri⁷, D. Johnson⁸, P. Grover⁹, C. Gerard¹⁰, E. Simeone¹¹, C. Gaudy Marqueste¹², P. Cheng¹, G. Long⁹, R. Carvajal¹³, R. Dummer¹⁴, ¹USZ - University Hospital Zürich, Zurich, CH, ²University Hospital Heidelberg, Heidelberg, DE, ³Thomas Jefferson Univ Hospital, Philadelphia, US, ⁴HICCC - Herbert Irving Comprehensive Cancer Center - Columbia University, New York, US, ⁵Leiden University Medical Center (LUMC), Leiden, NL, ⁶The Angeles Clinic and Research Institute, Los Angeles, US, ⁷Beth Israel Deaconess Med. Center, Boston, US, ⁸Vanderbilt University Medical Center, Nashville, US, ⁹Melanoma Institute Australia, Wollstonecraft, AU, ¹⁰CHUV - Centre Hospitalier Universitaire Vaudois - Batiment Agora, Lausanne, CH, ¹¹Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ¹²AP-HM - CHU La Timone Enfants, Marseille, FR, ¹³Columbia University Medical Center, New York, US, ¹⁴Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH
- 09:54 - 09:55 **833P - Longer follow up of a real-world study of cemiplimab in advanced cutaneous squamous cell carcinoma: Focus on late toxicities and long term benefit**
P. Quaglino¹, A. Baggi², R. Depenni³, M. Guida⁴, P. Ascierto⁵, P. Queirolo⁶, K. Peris⁷, F.

Spagnolo⁸, L. Bianchi⁹, F. De Galitiis¹⁰, M. Zamparini², I. Proietti¹¹, R. Marconcini¹², A. Botticelli¹³, V. Barbieri¹⁴, S. Alfieri¹⁵, M. Fagnoli¹⁶, M. Occeci¹⁷, P. Bossi², ¹AOU Città della Salute e della Scienza Torino, Torino, IT, ²University of Brescia, ASST Spedali Civili, Brescia, IT, ³Modena University Hospital, Modena, IT, ⁴IRCCS Istituto Tumori Giovanni Paolo II, Bari, IT, ⁵Istituto Nazionale Tumori, IRCCS, Fondazione "G. Pascale," Naples, Italy, ⁶European Institute of Oncology IRCCS, Milan, IT, ⁷Università Cattolica del Sacro Cuore, Rome, IT, ⁸IRCCS Ospedale Policlinico San Martino, Genova, IT, ⁹University of Rome Tor Vergata - School of Medicine and Surgery, Rome, IT, ¹⁰IDI - Istituto dermatologico dell'Immacolata - IRCCS, Rome, IT, ¹¹Sapienza University of Rome, Polo Pontino, Terracina, IT, ¹²AOU Pisana, Pisa, IT, ¹³Sapienza University of Rome, Rome, IT, ¹⁴Azienda Ospedaliera di Catanzaro Pugliese Ciaccio, Catanzaro, IT, ¹⁵Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ¹⁶University of L'Aquila; San Salvatore Hospital, Coppito, IT, ¹⁷Azienda Ospedaliera Santa Croce and Carle University Teaching Hospital, Cuneo, IT

09:55 - 09:56 **834P - Intracranial disease control and survival in patients with melanoma brain metastases (MBM) treated with radiation and immune checkpoint inhibitors (IO)**

M.F. Silva Almeida Ribeiro¹, T. Pimentel Muniz¹, P. Jablonska², I. Hirsch¹, M. Vilbert¹, E.C. Koch¹, L. Mantle¹, S. Saibil³, A. Spreafico³, D. Hogg¹, D. Shultz², M. Butler¹, ¹Princess Margaret Cancer Centre, Toronto, CA, ²Princess Margaret Cancer Center, University Health Network, Toronto, CA, ³UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

09:56 - 09:57 **835P - Efficacy of checkpoint inhibitors and targeted therapy depending on the line of treatment in patients with advanced / metastatic melanoma**

B. Cybulska-Stopa¹, A. Czarnecka², K. Ostaszewski², K. Piejko³, M. Ziętek⁴, R. Dziura⁵, L. Galus⁶, B. Ziolkowska², J. Seredynska⁷, A. Kamycka⁸, W. Bal⁹, T. Kubiakowski¹⁰, T. Switaj², N. Kempa-Kaminska¹¹, E. Rutkowska¹², P. Rogala², G. Kamińska-Winciorek¹³, R. Suwinski¹⁴, J. Mackiewicz⁶, P. Rutkowski², ¹Department of Clinical Oncology, Cracow, PL, ²Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL, ³Maria Skłodowska-Curie National Research Institute of Oncology, Cracow Branch, Cracow, PL, ⁴Wrocław Comprehensive Cancer Center, Wrocław, PL, ⁵Świętokrzyskie Centrum Onkologii, Kielce, PL, ⁶University of Medical Sciences, Poznań, PL, ⁷Maria Skłodowska-Curie National Research Institute of Oncology, Cracow Branch, Kraków, PL, ⁸Podkarpackie Centrum Onkologii w Rzeszowie, Rzeszów, PL, ⁹National Oncology Institute Maria Skłodowskiej-Curie National Research Institute, Gliwice Branch, Gliwice, PL, ¹⁰Warmian-Masurian Cancer Center of The Ministry of The Interior and Administration's Hospital, Olsztyn, PL, ¹¹Dolnośląskie Centrum Chorób Płuc-Lower Silesian Centre of Lung Diseases, Wrocław, PL, ¹²Holycross Cancer Centre - SCO Kielce, Kielce, PL, ¹³Maria Skłodowska Curie National Research Institute of Oncology Gliwice Branch, Gliwice, PL, ¹⁴Maria Skłodowska-Curie Institute - Oncology Center (MSCI), Gliwice Branch, Gliwice, PL

09:57 - 09:58 **836P - Outcome of PD-1 inhibitor therapy of advanced melanoma patients according to demographic factors in a real-world setting across Europe**

M. Weichenthal¹, I.-M. Svane², L. Kandolf Sekulovic³, J. Mangana⁴, I. Lugowska⁵, P. Mohr⁶, E. Espinosa⁷, H. Gogas⁸, M. Bender⁹, E. Ellebæk¹⁰, I. Gavrilova¹¹, D. Herceg¹², E. Muñoz Couselo¹³, H. Schmidt¹⁴, D. Stulhofer Buzina¹², P. Rutkowski⁵, P. Ascierto¹⁵, R. Dummer⁴, D. Schadendorf¹⁶, L. Bastholt¹⁷, ¹Christian-Albrechts-University Kiel, Kiel,

DE, ²Copenhagen University Hospital Herlev, Herlev, DK, ³Military Medical Academy VMA, Belgrade, RS, ⁴Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, ⁵Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, ⁶Dermatologic Center Buxtehude, Buxtehude, DE, ⁷Hospital Universitario La Paz, Madrid, ES, ⁸Laiko General Hospital of Athens, Athens, GR, ⁹EUMelaReg, Berlin, DE, ¹⁰Herlev and Gentofte Hospital, Herlev, DK, ¹¹Bulgarian National Cancer Registry, Sofia, BG, ¹²KBC - University Hospital Centre Zagreb, Zagreb, HR, ¹³Vall d'Hebron University Hospital, Barcelona, ES, ¹⁴Aarhus University Hospital, Aarhus, DK, ¹⁵Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ¹⁶University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ¹⁷OUH - Odense University Hospital, Odense, DK

09:58 - 09:59

837P - Real-world evidence of encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma in Spain (GEM 2002 - BECARE)

A. Soria Rivas¹, P. Sánchez Mauriño², J.J. Serrano¹, S. Sequero³, J. Fra Rodríguez⁴, V. Amezcua⁵, G. Benítez⁶, E. Espinosa⁷, C. Aguayo⁸, R. García Galindo⁹, R. Díaz-Beveridge¹⁰, T. Puértolas¹¹, A. Cunqueiro-Tomás¹², R. López Castro¹³, G. Crespo¹⁴, P. López¹⁵, L. Gutiérrez Sanz¹⁶, B. Campos¹⁷, L. García¹⁸, P. Cerezuela-Fuentes¹⁹, ¹Hospital Universitario Ramón y Cajal, Madrid, ES, ²Hospital Universitario Reina Sofia, Córdoba, ES, ³Hospital Universitario San Cecilio, Granada, ES, ⁴Hospital Universitario Río Hortega, Valladolid, ES, ⁵Hospital Universitario Virgen de las Nieves, Granada, ES, ⁶Complejo Hospitalario Universitario Insular-Materno infantil de Gran Canaria, las Palmas de Gran Canaria, ES, ⁷Hospital Universitario La Paz - CIBERONC, Madrid, ES, ⁸Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, ES, ⁹Hospital Universitario de Jerez de la Frontera, Jerez de la Frontera, ES, ¹⁰Hospital Universitario y Politécnico la Fe de Valencia, Valencia, ES, ¹¹Hospital Universitario Miguel Servet, Zaragoza, ES, ¹²Hospital General Universitario de Valencia, Valencia, ES, ¹³Hospital Clínico Universitario de Valladolid, Valladolid, ES, ¹⁴Hospital Universitario de Burgos, Burgos, ES, ¹⁵Complejo Hospitalario de Jaén, Jaén, ES, ¹⁶Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, ES, ¹⁷Hospital Universitario Lucus Augusti de Lugo, Lugo, ES, ¹⁸Hospital General de Segovia, Segovia, ES, ¹⁹Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Ciudad de Murcia, ES

09:59 - 10:00

838P - Patterns of response/progressive disease (PD) and management following PD with anti-PD-1 (PD1) in patients (pts) with advanced cutaneous squamous cell carcinoma (cSCC)

J. Mo¹, A.-S. Bohne², C. Gaudy Marqueste³, N. Della Marta⁴, L. Festino⁵, C. Chen⁶, S. Lo⁷, J. Park⁸, P. Ascierto⁹, R. Ladwa¹⁰, W. Xu¹⁰, J.J. Grob¹¹, A. Hauschild¹², A. Menzies⁴, G. Long⁴, M. Carlino¹³, I. Pires Da Silva⁴, ¹Crown Princess Mary Cancer Centre Westmead, Westmead, AU, ²UKSH - Universitätsklinikum Schleswig-Holstein - Campus Kiel, Kiel, DE, ³AP-HM - CHU La Timone Enfants, Marseille, FR, ⁴Melanoma Institute Australia, Wollstonecraft, AU, ⁵Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ⁶Blacktown Hospital, Blacktown, AU, ⁷The University of Sydney School of Public Health, Sydney, AU, ⁸Macquarie University, Macquarie Park, AU, ⁹Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ¹⁰Princess Alexandra Hospital - Metro South Health, Woolloongabba, AU, ¹¹Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ¹²UK-SH, Campus Kiel, Kiel, DE,

13Westmead Hospital - Crown Princess Mary Cancer Center, Westmead, AU

- 10:00 - 10:01 **839P - A retrospective study on the long-term survival and incidence of metachronous malignancies in advanced melanoma patients treated with immune checkpoint blockade (ICB)**
F. Verschaeve¹, N. Vandelaer¹, A.-S. Vander Mijnsbrugge¹, J. Tijtgat¹, J.K. Schwarze¹, G. Awada¹, J. Kessels¹, S. Aspeslagh¹, W. Cools², A. Rogiers³, B. Neyns¹, ¹UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE, ²Vrije Universiteit Brussel - Faculty of Medicine & Pharmacy, Brussels, BE, ³CHU Brugmann UVB, Brussels, BE
- 10:01 - 10:02 **840P - Electronic patient-reported outcomes (ePROs) of adults with BRAF V600E mutant stage III-IV melanoma treated with dabrafenib & trametinib (D & T) collected using the Kaiku Health digital patient (pt) monitoring platform**
J. Lijnsvelt¹, A. Addeo², M.G. Vitale³, P. Mohr⁴, P. Queirolo⁵, J. Ekström⁶, J. Vainio⁶, V. Kataja⁶, F. Calado⁷, A. Fagan⁸, M. Lau⁷, T. Romero Salas⁹, H. Thole-Glettig⁷, C. Blank¹, P. Ascierto³, ¹Netherlands Cancer Institute, Amsterdam, NL, ²University Hospital of Geneva, Geneva, CH, ³Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, IT, ⁴Elbe Klinikum Buxtehude, Buxtehude, DE, ⁵European Institute of Oncology IRCCS, Milan, IT, ⁶Kaiku Health, Helsinki, FI, ⁷Novartis Pharma AG, Basel, CH, ⁸Novartis Ireland Ltd, Dublin, IE, ⁹Novartis Pharmaceuticals Corporation, East Hanover, US
- 10:02 - 10:03 **841P - Effects of immune checkpoint inhibitor-based combination therapies on the gut microbiota in advanced melanoma patients**
J. Li¹, L. Xu², Z. Peng³, H. Jiang¹, F. Chao², Y. Ding¹, J.M. Moll⁴, D. Li¹, X. Wen¹, J. Wang¹, Q. Ding¹, L. Zhang³, K. Kristiansen⁵, S. Brix⁴, X. Zhang¹, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²BGI-Shenzhen, Shenzhen, CN, ³University of Chinese Academy of Sciences, Beijing, CN, ⁴Technical University of Denmark, Kongens Lyngby, DK, ⁵University of Copenhagen, Copenhagen, DK
- 10:03 - 10:04 **842P - A phase II trial of AU-011, an investigational, virus-like drug conjugate (VDC) for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM) using suprachoroidal administration**
H. Demirci¹, A. Narvekar², C. Murray², C. Rich², ¹Michigan Medicine University of Michigan, Ann Arbor, US, ²Aura Biosciences, Cambridge, US
- 10:04 - 10:05 **843P - Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma**
T. Sato¹, A. Ikeguchi², P. Nathan³, R. Carvajal⁴, A. Shoushtari⁵, T. Gajewski⁶, J. Hassel⁷, M. Rioth⁸, S. Leyvraz⁹, G. Daniels¹⁰, L. Hernandez-Aya¹¹, D. Johnson¹², K. Kim¹³, J.M. Piulats Rodriguez¹⁴, C.L. Cowey¹⁵, S. Lockwood¹⁶, L. Collins¹⁶, O. Karakuzu¹⁷, J. Sacco¹⁸, M. Butler¹⁹, ¹Thomas Jefferson Univ Hospital, Philadelphia, US, ²Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, ³Mount Vernon Cancer Centre - East and North Herts NHS Trust, Northwood, GB, ⁴Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, ⁵MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ⁶The University of Chicago, Chicago, US, ⁷Heidelberg University Hospital, Heidelberg, DE, ⁸University of Colorado Denver, Denver, US, ⁹Charité - Universitätsmedizin Berlin, Berlin, DE,

¹⁰University of California San Diego - UCSD, La Jolla, US, ¹¹Washington University School of Medicine in St. Louis, St. Louis, US, ¹²Vanderbilt University Medical Center, Nashville, US, ¹³California Pacific Medical Center, San Francisco, US, ¹⁴ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, ¹⁵Baylor Scott & White Health, Dallas, US, ¹⁶Immunocore Limited, Abingdon-on-Thames, GB, ¹⁷Immunocore LLC, Conshohocken, US, ¹⁸Clatterbridge Cancer Center - NHS Foundation Trust, Wirral, GB, ¹⁹UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

10:05 - 10:06

844P - Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody

J. Larkin¹, S. Dalle², M. Sanmamed³, M. Wilson⁴, J. Hassel⁵, H. Kluger⁶, M. Orloff⁴, J. Weber⁷, F. Graf Finckenstein⁸, P. Hari⁸, M. Jagasia⁸, H. Yin⁸, W. Shi⁸, G. Sulur⁸, X. Wu⁸, V. Gontcharova⁸, K. Lewis⁹, ¹The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ²Centre Hospitalier Lyon Sud, Pierre Benite, FR, ³Clinica Universidad de Navarra, Pamplona, ES, ⁴Thomas Jefferson Kimmel Cancer Center, Philadelphia, US, ⁵University Hospital Heidelberg, Heidelberg, DE, ⁶Yale University School of Medicine, Smilow Cancer Hospital, New Haven Hospital, New Haven, US, ⁷Laura and Isaac Perlmutter Cancer Center, New York City, US, ⁸Iovance Biotherapeutics, Inc., San Carlos, US, ⁹University of Colorado Cancer Center, Aurora, US

10:06 - 10:07

845P - Vidutolimod + pembrolizumab as 2L+ treatment in patients with anti–PD-1–refractory melanoma and adrenal insufficiency: Subgroup analyses of a phase Ib study

J. Kirkwood¹, Y. Zakharia², D. Davar¹, E. Buchbinder³, T. Medina⁴, A. Daud⁵, A. Ribas⁶, B. Chmielowski⁶, J. Niu⁷, G. Gibney⁸, K. Margolin⁹, A. Olszanski¹⁰, I. Mehmi¹¹, T. Sato¹², M. Shaheen¹³, L. Zhao¹⁴, D. Bobilev¹⁴, A. Krieg¹⁴, J. Wooldridge¹⁴, M. Milhem², ¹University of Pittsburgh Medical Center, Pittsburgh, US, ²University of Iowa, Iowa City, US, ³Dana Farber Cancer Institute, Boston, US, ⁴University of Colorado Denver, Aurora, US, ⁵University of California San Francisco, San Francisco, US, ⁶University of California Los Angeles, Los Angeles, US, ⁷Banner MD Anderson Cancer Center, Gilbert, US, ⁸Georgetown Lombardi Comprehensive Cancer Center, Washington DC, US, ⁹City of Hope Comprehensive Cancer Center, Santa Monica, US, ¹⁰Fox Chase Cancer Center, Philadelphia, US, ¹¹The Angeles Clinic and Research Institute, Los Angeles, US, ¹²Thomas Jefferson University, Philadelphia, US, ¹³University of Arizona, Tucson, US, ¹⁴Checkmate Pharmaceuticals, Inc., Cambridge, US

10:07 - 10:08

846P - Triple combination of ipilimumab + nivolumab + anti-TNF in treatment naive melanoma patients: Final analysis of TICIMEL, a phase Ib prospective clinical trial

N. Meyer¹, A. Lusque², M. Virazels³, T. Filleron², C. Colacios³, A. Montfort³, B. Ségui³, ¹IUC et CHU de Toulouse, Toulouse, FR, ²Institut Claudius Regaud IUCT-O, Toulouse, FR, ³Centre de Recherche en Cancérologie de Toulouse, Toulouse, FR

10:08 - 10:09

847P - Precision oncology for resistant acral, mucosal and cutaneous melanomas: A prospective broad high throughput genomics feasibility study

S. Leyvraz¹, M. Schütte², T. Kessler³, M. Lamping¹, S. Burock¹, S. Ochsenreither¹, V. Amstislavskiy⁴, T. Risch⁴, I. Jelas⁵, C. Ulrich⁵, G. Dobos¹, F. Klauschen⁶, R. Schäfer¹, B.

Lange², K. Klinghammer¹, M.-L. Yaspo⁴, U. Keilholz¹, ¹Charité - Universitätsmedizin Berlin, Berlin, DE, ²Alacris Theranostics GmbH, Berlin, DE, ³MGZ - Medical Genetics Center, Munich, DE, ⁴Max Planck Institute for Molecular Genetics, Berlin, DE, ⁵Charité - Universitätsmedizin Berlin, Berlin, DE, ⁶University of Munich, Munich, DE

10:09 - 10:10

848P - Second-line systemic treatment for patients with advanced melanoma: Results from the prospective real-world study GEM1801

I. Marquez-Rodas¹, M.A. Berciano Guerrero², E. Muñoz Couselo³, A. Soria Rivas⁴, P. Cerezuela-Fuentes⁵, J.L. Manzano Mozo⁶, L. Gutierrez Sanz⁷, G. Crespo⁸, T. Puértolas⁹, A. Garcia Castano¹⁰, C. Aguado De La Rosa¹¹, E. Espinosa¹², M. Majem Tarruella¹³, R. López Castro¹⁴, P. Ayala De Miguel¹⁵, J. Medina Martinez¹⁶, L.A. Fernández Morales¹⁷, L. Bellido Hernández¹⁸, A. Berrocal¹⁹, S. Martin Algarra²⁰, ¹Hospital General Universitario Gregorio Marañón - Fundación Investigación Biomedica, Madrid, ES, ²Hospital Regional Universitario Málaga Carlos Haya, Malaga, ES, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Hospital Universitario Ramon y Cajal, Madrid, ES, ⁵Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, ES, ⁶ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ⁷University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES, ⁸Hospital Universitario de Burgos (HUBU), Burgos, ES, ⁹Hospital Universitario Miguel Servet, Zaragoza, ES, ¹⁰HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES, ¹¹Hospital Clínico Universitario San Carlos, Madrid, ES, ¹²Hospital Universitario La Paz, Madrid, ES, ¹³Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹⁴Hospital Clínico Universitario De Valladolid, Valladolid, ES, ¹⁵Hospital San Pedro De Alcantara, Caceres, ES, ¹⁶Hospital Universitario Toledo, Toledo, ES, ¹⁷Parc Tauli Hospital Universitari, Sabadell, ES, ¹⁸IBSAL - Instituto de Investigación Biomédica de Salamanca, Salamanca, ES, ¹⁹Hospital General Universitario Valencia, Valencia, ES, ²⁰Clinica Universidad de Navarra, Madrid, ES

10:10 - 10:11

849P - Time from primary melanoma to first distant recurrence in relation to survival outcomes in metastatic melanoma

I. Van Duin¹, S. Elias¹, F. Van Den Eertwegh², J.W. De Groot³, W. Blokk¹, O. Van Not¹, M. Aarts⁴, C. Blank⁵, J. Haanen⁵, G. Hospers⁶, D. Piersma⁷, R. Van Rijn⁸, M. Stevensen-Den Boer⁹, A. Van Der Veldt¹⁰, G. Vreugdenhil¹¹, M. Wouters⁵, F. Van Den Berkmortel¹², M. Boers-Sonderen¹³, E. Kapiteijn¹⁴, K. Suijkerbuijk¹⁵, ¹UMC - University Medical Center Utrecht, Utrecht, NL, ²Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, ³Isala ziekenhuis, Zwolle, NL, ⁴Maastricht University Medical Centre+, Maastricht, NL, ⁵NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁶UMCG - University Medical Center Groningen, Groningen, NL, ⁷Medisch Spectrum Twente (MST) - Radiology, Enschede, NL, ⁸MCL - Medisch Centrum Leeuwarden, Leeuwarden, NL, ⁹Amphia Ziekenhuis-location Molengracht, Breda, NL, ¹⁰Erasmus MC - University Medical Center, Rotterdam, NL, ¹¹Maxima Medisch Centrum -Veldhoven, Veldhoven, NL, ¹²Zuyderland Medical Center, Heerlen, NL, ¹³Radboud University Medical Center, Nijmegen, Nijmegen, NL, ¹⁴Leiden University Medical Center (LUMC), Leiden, NL, ¹⁵UMC-University Medical Center Utrecht, Utrecht, NL

10:11 - 10:12

850P - A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma

A. Taylor¹, C. Galea¹, A. Varey¹, K. Shannon¹, S. Ch'Ng¹, R. Saw¹, T. Pennington¹, J. Stretch¹, A. Spillane¹, A. Van Akkooi¹, I. Pires Da Silva¹, M. Carlino², R. Scolyer¹, G. Long¹, S. Lo¹, A. Menzies¹, ¹Melanoma Institute Australia, Wollstonecraft, AU, ²Westmead Hospital - Crown Princess Mary Cancer Center, Westmead, AU

- 10:12 - 10:13 **851P - Frequency and clinical significance of homologous recombination deficiency gene mutations in non-cutaneous melanoma**
Y. Yang, B. Lian, L. Si, Z. Chi, X. Sheng, Y. Kong, C.-L. Cui, J. Guo, Peking University Cancer Hospital and Institute, Beijing, CN
- 10:13 - 10:14 **852P - Does sex affect the efficacy of immune checkpoint inhibitors? A national Danish melanoma study**
S. Petersen¹, H. Schmidt², E. Ellebæk³, C.A. Haslund⁴, C.R. Hansen¹, L. Bastholt¹, ¹Odense University Hospital, Odense, DK, ²Aarhus University Hospital, Aarhus, DK, ³Copenhagen University Hospital, Herlev, Herlev, DK, ⁴Aalborg University Hospital, Aalborg, DK
- 10:14 - 10:15 **853P - TNF plasma levels in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study**
M. Virazels¹, A. Montfort¹, A. Lusque², T. Filleron², C. Colacios¹, B. Ségui¹, N. Meyer³, ¹Centre de Recherche en Cancérologie de Toulouse, Toulouse, FR, ²Institut Claudius Regaud IUCT-O, Toulouse, FR, ³IUC et CHU de Toulouse, Toulouse, FR
- 10:15 - 10:16 **854P - Clinical features of acquired resistance (AR) in stage IV melanoma patients (pts) treated with immune checkpoint inhibition (ICI)**
J. Versluis, E. Alocs, H. Van Thienen, S. Wilgenhof, A. Meerveld-Eggink, H. Mallo, W. Uytterlinde, J. Lijnsvelt, J. Haanen, C. Blank, Netherlands Cancer Institute, Amsterdam, NL
- 10:16 - 10:17 **855P - Whole blood transcriptomic profiling to predict response to immunotherapy in metastatic melanoma**
R. Hassaïne¹, E. Durandau², L. Ciarloni², N. Hadadi², S. Hosseinian Ehrensberger², S. Van Wilpe¹, B. De Vet¹, N. Mehra¹, ¹Radboud University Medical Center, Nijmegen, NL, ²Novigenix, Epalinges, CH
- 10:17 - 10:18 **856P - Characterization of patients with brain metastases from metastatic uveal melanoma**
T. Pimentel Muniz¹, E. Koch¹, M.F. Silva Almeida Ribeiro¹, M. Silveira Vilbert¹, D. Arteaga Ceballos², P.A. Jablonska¹, L. Mantle¹, I. Hirsch¹, H. Krema¹, A. Spreafico¹, S. Saibil¹, D. Hogg¹, D. Shultz¹, M. Butler¹, ¹Princess Margaret Cancer Centre, Toronto, CA, ²University of Western Ontario, London, CA
- 10:18 - 10:19 **857P - Precision oncology and tumor mutational burden (TMB) in Merkel cell carcinoma (MCC): An analysis of the AACR Project Genie real-world database**
J. Moyers¹, D. Brazel², P. Kumar², ¹UCI Health - University of California Irvine, Orange, US, ²UC Irvine Medical Center, Orange, US

- 10:19 - 10:20 **858P - Automated detection of melanoma: Comparing a convolutional neural network (CNN) approach with an algorithm assessing disorder in the pattern of pigmented lesions, intended to mimick onco-dermatologists' visual analysis**
- J. Monnier¹, A.C. Gouabou Foahom², M. Serdi², J. Collenne², R. Iguernaissi², C. Gaudy Marqueste³, J.-L. Damoiseaux², J.J. Grob³, D. Merad², ¹Dermatology and skin cancers department, La Timone hospital, AP-HM, Aix-Marseille University, Marseille, FR, ²Aix-Marseille University -Faculté des Sciences de Luminy, Marseille, FR, ³Aix-Marseille University, Marseille, FR
- 10:20 - 10:21 **859P - The influence of hematologic malignancies on response to immune checkpoint inhibition in patients with advanced melanoma**
- O. Van Not¹, F. Van Den Eertwegh², J. Haanen³, R. Van Rijn⁴, M. Aarts⁵, F. Van Den Berkmortel⁶, C. Blank³, M. Boers-Sonderen⁷, J.W. De Groot⁸, G. Hospers⁹, E. Kapiteijn¹⁰, M. De Meza³, D. Piersma¹¹, M. Stevense-Den Boer¹², A. Van Der Veldt¹³, G. Vreugdenhil¹⁴, M. Wouters³, W. Blokk¹⁵, K. Suijkerbuijk¹, ¹UMC-University Medical Center Utrecht, Utrecht, NL, ²Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, ³NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁴MCL - Medisch Centrum Leeuwarden, Leeuwarden, NL, ⁵Maastricht University Medical Centre+, Maastricht, NL, ⁶Zuyderland Medical Center, Heerlen, NL, ⁷Radboud University Medical Center, Nijmegen, Nijmegen, NL, ⁸Isala ziekenhuis, Zwolle, NL, ⁹UMCG - University Medical Center Groningen, Groningen, NL, ¹⁰Leiden University Medical Center (LUMC), Leiden, NL, ¹¹Medisch Spectrum Twente (MST) - Radiology, Enschede, NL, ¹²Amphia Ziekenhuis-location Molengracht, Breda, NL, ¹³Erasmus MC - University Medical Center, Rotterdam, NL, ¹⁴Maxima Medisch Centrum -Veldhoven, Veldhoven, NL, ¹⁵UMC - University Medical Center Utrecht, Utrecht, NL
- 10:21 - 10:22 **860P - The IOpener study: Tyrosine kinase activity in peripheral lymphocytes to predict durable response to immune checkpoint inhibition in patients with advanced melanoma**
- K. De Joode¹, K. Suijkerbuijk², J.W. De Groot³, A. Van Der Veldt¹, H. Westgeest⁴, R. De Wijn⁵, D. Hurkmans¹, D. Van Den Heuvel⁵, K. Schmidt⁵, T. Van Doorn⁵, H. Pinedo⁶, J.P. Groten⁵, E. Verdegaal⁷, S.H. Van Der Burg⁷, J. Aerts⁸, R. Debets¹, E. Kapiteijn⁷, R. Mathijssen¹, ¹Erasmus MC Cancer Institute - University Medical Center, Rotterdam, NL, ²University Medical Center Utrecht, Utrecht, NL, ³Isala ziekenhuis, Zwolle, NL, ⁴Amphia Hospital, Breda, NL, ⁵PamGene International B.V., 's-Hertogenbosch, NL, ⁶Amsterdam University Medical Center, location VUmc, Amsterdam, NL, ⁷Leiden University Medical Center, Leiden, NL, ⁸Erasmus MC - University Medical Center, Rotterdam, NL
- 10:22 - 10:23 **861P - Association of genetic variants in JAK/STAT signaling pathway with cutaneous melanoma susceptibility**
- C. Passos Lima¹, G. Gomez¹, G. Lourenço¹, L. Monteiro², R. Rocha², K. Fernández³, J. Recio³, J. Carron¹, C. Torricelli¹, L. Coser¹, A. Oliveira¹, A. Moraes¹, ¹UNICAMP - Universidade Estadual de Campinas, Sao Paulo, BR, ²Ribeirao Preto Medical School - USP, Ribeirao Preto, BR, ³Hospital Universitari Vall d'Hebron,, Barcelona, ES
- 10:23 - 10:24 **862P - Incidence of hypothyroidism following the use of various immune**

checkpoint inhibitor regimens in melanoma patients: Meta-analysis

V. Urbonas¹, I. Grigorjeva², V. Norvaisa², S. Valinskas², D. Dabkeviciene¹, ¹National Cancer Institute, Vilnius, LT, ²Vilnius University, Vilnius, LT

10:24 - 10:25

863P - Elderly patients (pts) with advanced melanoma: Results from the prospective real-world study GEM1801

E. Muñoz Couselo¹, C. Ortiz Vélez¹, M.-Á. Berciano-Guerrero², A. Soria Rivas³, P. Cerezuela-Fuentes⁴, J.L. Manzano⁵, L. Gutiérrez Sanz⁶, G. Crespo⁷, T. Puértolas⁸, A. García Castaño⁹, C. Aguado De La Rosa¹⁰, E. Espinosa¹¹, M. Majem¹², R. López Castro¹³, P. Ayala De Miguel¹⁴, J. Medina Martínez¹⁵, L.A. Fernández-Morales¹⁶, L. Bellido¹⁷, S. Martin Algarra¹⁸, I. Márquez-Rodas¹⁹, ¹Hospital Universitari Vall d'Hebron y Vall Hebrón Institute of Oncology (VHIO), Barcelona, ES, ²Hospitales Universitarios Regional y Virgen de la Victoria (HURyVV). Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Málaga, ES, ³Hospital Universitario Ramón y Cajal, Madrid, ES, ⁴Hospital Clínico Universitario Virgen de la Arrixaca, IMIB Arrixaca, Ciudad de Murcia, ES, ⁵Instituto Catalán de Oncología, ICO-Badalona, H. Germans Trias i Pujol, Badalona, ES, ⁶Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, ES, ⁷Hospital Universitario de Burgos, Burgos, ES, ⁸Hospital Universitario Miguel Servet, Zaragoza, ES, ⁹Hospital Universitario Marqués de Valdecilla, Santander, ES, ¹⁰Hospital Universitario Clínico San Carlos, Madrid, ES, ¹¹Hospital Universitario La Paz, CIBERONC, Madrid, ES, ¹²Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹³Hospital Clinico Universitario De Valladolid, Valladolid, ES, ¹⁴Hospital Universitario San Pedro de Alcántara, Cáceres, ES, ¹⁵Hospital Universitario Toledo, Toledo, ES, ¹⁶Parc Taulí Sabadell Hospital Universitari, Sabadell, ES, ¹⁷Hospital Universitario Salamanca, Salamanca, ES, ¹⁸Clínica Universidad de Navarra, Madrid, ES, ¹⁹Hospital General Universitario Gregorio Marañón, Madrid, ES

10:25 - 10:26

864P - Prognostic impact of MARCO and OAS1 expression in metastatic melanoma patients treated with anti-PD1: A proteomics and transcriptomics retrospective analysis

D. Mallardo¹, C. Messner², M. Capone¹, J. Vowinkel², A. Sorrentino¹, K. Novy², V. Vanella¹, K. Kakalacheva - Beeler², S. Warren³, P. Ascierto¹, ¹Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ²Biognosys AG, Schlieren, CH, ³NanoString Technologies, Inc., Seattle, US

10:26 - 10:27

865P - TNFRSF1B gene variants on susceptibility, clinicopathological aspects, and prognosis of patients with cutaneous melanoma

C. Passos Lima¹, B. Carvalho¹, G. Gomez¹, J. Carron¹, L. Traldi Macedo¹, G. Gonçalves², V. Vazquez², S. Serrano², G. Lourenço¹, ¹UNICAMP - Universidade Estadual de Campinas, Sao Paulo, BR, ²Hospital De Cancer De Barretos - Hospital de Amor, Barretos, BR

10:27 - 10:28

866P - Inflammation proteins associated with worse clinical outcome to treatment with anti-PD1 in metastatic cutaneous melanoma

F. Costa Svedman, H. Helgadottir, S. Egyhazi Brage, Karolinska Institutet - Bioclinicum, Solna, SE

- 10:28 - 10:29 **867P - The association between polygenic risk of autoimmune disease, progression-free survival (PFS), and pathway-level transcriptomic signatures predictive of anti-PD1 response in melanoma**
C. Owen, G. Richenberg, V. Gray, A. Nounu, T. Robinson, S. Kar, University of Bristol, Bristol, GB
- 10:29 - 10:30 **868P - System biology approach to normal tissue protection in cytotoxic cancer therapy: Experimentally validated gene/signaling basis – melanoma as case study**
B. Kumari¹, C. Sakode², L. Raghavendran³, P. Roy⁴, ¹Indian Institute of Technology, I.I.T BHU, Varanasi, IN, ²Indian Institute of Information Technology, Nagpur, IN, ³JNU - Jawaharlal Nehru University, New Delhi, IN, ⁴Indian Institute of Technology, BHU, Varanasi, IN
- 10:30 - 10:31 **869P - PAK4 as a potential marker for poor response to immunotherapy in melanoma patients**
M.P. Levesque¹, J. Martinez¹, J. Kuo², H. Nunns², T. Treiber³, K. Kakalacheva - Beeler³, J. Vowinkel³, A. Juncker-Jensen⁴, ¹USZ - University Hospital Zürich, Zurich, CH, ²Neogenomics Laboratories, Fort Myers, US, ³Biognosys AG, Schlieren, CH, ⁴NeoGenomics Laboratories, Aliso Viejo, US
- 10:31 - 10:32 **870P - Systemic levels of the soluble co-inhibitory and co-stimulatory immune checkpoint molecules in basal cell carcinoma**
B. Rapoport¹, N. Malinga¹, S. Siwele¹, H. Steel¹, L. Kwofie¹, P. Meyer¹, T. Smit², R. Anderson¹, M. Kgokolo¹, ¹University of Pretoria, Pretoria, ZA, ²The Medical Oncology Centre of Rosebank, Johannesburg, ZA
- 10:32 - 10:33 **871P - Predictive role of neutrophil-lymphocyte ratio (NLR) in patients (pts) with metastatic melanoma: A post hoc exploratory analysis from phase III COMBI-i trial**
D. Schadendorf¹, K. Flaherty², H. Tawbi³, C. Robert⁴, P. Nathan⁵, R. Dummer⁶, G. Long⁷, P. Ascierto⁸, M. Mandala⁹, A. Hauschild¹⁰, J.J. Grob¹¹, R. Shah¹², B. Gopal Sahoo¹³, M. Lau¹⁴, A. Ribas¹⁵, ¹University Hospital Essen, Essen and German Cancer Consortium, Essen, DE, ²MGH - Massachusetts General Hospital, Boston, US, ³The University of Texas MD Anderson Cancer Center, Houston, US, ⁴Gustave Roussy Cancer Campus Grand Paris & University Paris-Saclay, Villejuif, FR, ⁵Mount Vernon Cancer Centre, East and North Herts NHS Trust, Northwood, GB, ⁶University Hospital Zürich, Skin Cancer Center, Zurich, CH, ⁷Melanoma Institute Australia, Wollstonecraft, AU, ⁸Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, IT, ⁹University of Perugia and Papa Giovanni XXIII Cancer Center Hospital, Perugia, IT, ¹⁰University Hospital Schleswig-Holstein, Kiel, DE, ¹¹Timone Hospital AP-HM, Aix-Marseille University, Marseille, FR, ¹²Novartis Pharmaceuticals Corporation, East Hanover, US, ¹³Novartis Healthcare Pvt. Ltd., Hyderabad, IN, ¹⁴Novartis Pharma AG, Basel, CH, ¹⁵Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, US
- 10:33 - 10:34 **872P - Ipilimumab-induced gastrointestinal and hepatic immune-related adverse events: A national cohort**
B. Langbein¹, M. Labban¹, X. Chen¹, S. Reese¹, S. Lipsitz¹, J. McNabb-Baltar¹, M. Sun², A. Cole¹, Q.-D. Trinh¹, ¹Brigham and Women's Hospital, Boston, US, ²Dana-Farber

Cancer Institute, Boston, US

- 10:34 - 10:35 **873P - Feasibility of a comprehensive ambulatory monitoring platform during immunotherapy for advanced melanoma: CAMP-IT trial**
M. Kos¹, L. Buffart², H. Westgeest³, J.W. De Groot⁴, M. Boers-Sonderen², H. Van Laarhoven⁵, M. Van Oijen¹, ¹Amsterdam UMC, locations University of Amsterdam, Amsterdam, NL, ²Radboud University Medical Center, Nijmegen, Nijmegen, NL, ³Amphia Hospital, Breda, NL, ⁴Isala Oncology Center, Zwolle, NL, ⁵Amsterdam UMC location University of Amsterdam, Amsterdam, NL
- 10:35 - 10:36 **874P - The economic burden of surviving malignant melanoma**
D. Michaeli¹, J.C. Michaeli², T. Boch³, S. Albers², T. Michaeli⁴, ¹Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, DE, ²Asklepios Klinik Altona - Asklepios Kliniken, Hamburg, DE, ³Heidelberg University - Faculty of Medicine in Mannheim, Mannheim, DE, ⁴UMM - Universitaetsklinikum Mannheim, Mannheim, DE
- 10:36 - 10:37 **875P - Trends in melanoma incidence among women living in North-East Italy 2000-2020: Population-based study**
D. Serraino, F. Toffolutti, L. Dal Maso, T. Angelin, L. Fratino, M.A. Pizzichetta, A. Palumbo, O. Forgiarini, E. De Santis, E. Bidoli, CRO Aviano - Centro di Riferimento Oncologico - IRCCS, Aviano, IT
- 10:37 - 10:38 **876P - An observational retrospective study on microsatellite instability (MSI) in metastatic melanoma**
G. Targato¹, E. Poletto², S. Buriolla¹, M. De Scordilli¹, F. Pravisan¹, G. Pascoletti², G. De Maglio², M. Battiston², V. Angione², M. Turina², S. Pizzolitto², D. Cesselli², M. Bulfoni², C.A. Scott², S. Marzinotto², C. Di Loreto², F. Puglisi³, G. Fasola², A.M. Minisini², ¹University of Udine, Udine, IT, ²Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, IT, ³Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, IT
- 10:38 - 10:39 **877P - Characteristics of malignant cutaneous adnexal tumors in a single-institution study**
E. Koch, M. Vilbert, T. Pimentel Muniz, D. Ghazarian, I. Hirsch, M.F. Silva Almeida Ribeiro, L. Mantle, D. Hogg, S. Saibil, A. Spreafico, M. Butler, Princess Margaret Cancer Centre, Toronto, CA

09:00 - 12:00 Type: Poster session Poster Area, Hall 4
Title: Poster session 02

- 09:00 - 09:01 **179P - Does undertreatment of elderly patients with early breast cancer impact outcome?**
J. Monteiro Vasconcellos, R. Colombo Bonadio, S. Vidaurre Mendes, B. Zanin Orsi, L. Vecchi Leis, A.P. Messias, O.A. Moreira, M. Baptista Pereira, P.J. Galvão Freire, A. Rodrigues De Araujo Neto, E. Andrade Rocha, V. Petry, L. Testa, ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR

- 09:01 - 09:02 **180P - Impact of Out-Of-Pocket (OOP) cost on breast cancer (BC) treatment persistence in the US: A systematic literature review (SLR)**
S. Attri, N. Kaur, B. Singh, Pharmacovidence Private Limited, Sahibzada Ajit Singh Nagar, IN
- 09:02 - 09:03 **181P - A randomized controlled trial on the efficacy of supervised exercise training in reducing IGF-1 levels in breast cancer survivors of the Movis2019 cohort**
M. Bocconcelli¹, V. Natalucci¹, C. Ferri Marini¹, G. Annibalini¹, D. Sisti¹, F. Lucertini¹, L. Vallorani¹, M. De Santi¹, M.B.L. Rocchi¹, S. Barocci², M. Flori², G. Brandi¹, V. Catalano², A. Villarini³, E. Barbieri¹, R. Emili², ¹Università degli Studi di Urbino, Urbino, IT, ²Ospedale Santa Maria della Misericordia di Urbino, Urbino, IT, ³Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT
- 09:03 - 09:04 **182P - Trends and variations of endocrine treatment in "in situ" breast cancer in Europe**
L. Van Walle¹, D. Verhoeven², L. Marotti³, A. Ponti³, M. Tomatis³, I.T. Rubio⁴, ¹Belgian Cancer Registry, Brussels, BE, ²University of Antwerp; Breast Clinic Voorkempen, Brasschaat, BE, ³European Society of Breast Cancer Specialists (EUSOMA), Florence, IT, ⁴Clinica Universidad de Navarra, Madrid, ES
- 09:04 - 09:05 **183P - Rates of risk-reduction mastectomy among women with inherited breast cancer**
S. Reid¹, M. Roberson², J. Whisenant¹, T. Shah², L. Venton², A. Weidner², T. Pal², ¹Vanderbilt Ingram Cancer Center, Nashville, US, ²Vanderbilt University Medical Center, Nashville, US
- 09:05 - 09:06 **184P - Comparison of survival outcomes between repeat sentinel lymph node biopsy and axillary lymph node dissection among patients with ipsilateral breast tumor recurrence: A SEER population-based study**
Z. Gou¹, X. Lu², ¹West China Hospital, Sichuan University, chengdu, CN, ²West China Hospital, Sichuan University, Chengdu, CN
- 09:06 - 09:07 **185P - Prospective study to evaluate pathological complete response after neoadjuvant therapy in breast cancer: Are we ready to avoid surgery?**
D.E.M.C. Rossi¹, A.M. De Scalzi¹, A. Girardi¹, F. Pesapane¹, A. Invento², V. Dominelli¹, F. De Lorenzi¹, V. Sacchini³, P. Veronesi¹, ¹IEO - Istituto Europeo di Oncologia, Milan, IT, ²AOU Integrata di Verona - Ospedale Borgo Trento, Verona, IT, ³Memorial Sloan Kettering Cancer Center, New York, US
- 09:07 - 09:08 **186P - Evaluation of event-free survival as a surrogate for overall survival in early-stage triple-negative breast cancer following neoadjuvant therapy**
P.A. Fasching¹, M. Huang², A. Haiderali², W. Xue³, W. Pan², V. Karantza², F. Yang³, J. Truscott³, Y. Xin³, J. O'Shaughnessy⁴, ¹University Hospital Erlangen, Comprehensive Cancer Center (CCC) Erlangen-EMN, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, DE, ²Merck Research Laboratories - Merck & Co., Inc., Rahway, US, ³Analysis Group Ltd., London, GB, ⁴Texas Oncology - Baylor Sammons Cancer Center, Dallas, US

- 09:08 - 09:09 **187P - Routine care of early breast cancer (stage I-III) in Germany: Data of the prospective, intersectoral research platform OPAL**
A. Welt¹, M.-O. Zahn², A. Wöckel³, E. Stickeler⁴, M. Thoma⁵, A. Nusch⁶, S. Fuxius⁷, L. Müller⁸, D. Reschke⁹, M. Chiabudini¹⁰, L. Hillebrand¹⁰, L. Kruggel¹⁰, M. Jänicke¹⁰, N. Marschner¹¹, M. Thill¹², N. Harbeck¹³, T. Decker¹⁴, ¹Universitätsklinikum Essen, Essen, DE, ²MVZ Onkologische Kooperation Harz, Goslar, DE, ³Universitätsklinikum Würzburg, Würzburg, DE, ⁴Universitätsklinikum Aachen (UKA), Aachen, DE, ⁵Ammerland-Klinik, Westerstede, DE, ⁶Praxis, Ratingen, DE, ⁷Praxis, Heidelberg, DE, ⁸Praxis, Leer, DE, ⁹Praxis, Oldenburg, DE, ¹⁰iOMEDICO AG, Freiburg im Breisgau, DE, ¹¹Praxis für interdisziplinäre Onkologie & Hämatologie, Freiburg, DE, ¹²Agaplesion Markus Krankenhaus, Frankfurt am Main, DE, ¹³LMU Klinikum München, München, DE, ¹⁴Studienzentrum Onkologie Ravensburg, Ravensburg, DE
- 09:09 - 09:10 **188P - Characteristics of second primary breast cancer after ovarian cancer: A Korea central cancer registry retrospective study**
E.-G. Lee¹, S.-Y. Jung², Y.-J. Won³, J. Lim⁴, H.I. Ha⁵, M.-C. Lim⁶, Y.J. Chang¹, ¹NCC - National Cancer Center, Goyang, KR, ²National Cancer Center, Goyang, KR, ³Yonsei University, Wonju, KR, ⁴NCC-National Cancer Center, Goyang, KR, ⁵Pusan National University Yangsan Hospital, Yangsan, KR, ⁶National Cancer Center - Graduate School of Cancer Science and Policy, Goyang, KR
- 09:10 - 09:11 **189P - Characteristics and prognosis of breast cancer patients who have experienced hormone replacement therapy: From the Korean Breast Cancer Society Registry database**
C.W. Kim, S.Y. Bae, W.C. Park, C.I. Yoon, Y.J. Lee, D.R. Kim, The Catholic University of Korea - Seoul St.Mary Hospital, Seoul, KR
- 09:11 - 09:12 **190P - Staging strategies of newly diagnosed triple-negative breast cancer (TNBC): Comparison between CT scan and 18F-FDG-PET/CT**
B. Riccò, B. Meduri, M. Venturelli, L. Cortesi, E. Barbieri, O. Ponzoni, L. Moscetti, C. Omarini, F. Piacentini, M. Dominici, A. Toss, Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT
- 09:12 - 09:13 **191P - Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026)**
M. Hennesy¹, J. Leal², C.-Y. Huang³, L. Solnes², R. Denbow², V. Abramson⁴, L. Carey⁵, M. Liu⁶, M. Rimawi⁷, J. Specht⁸, A.M. Storniolo⁹, V. Valero¹⁰, C. Vaklavas¹¹, E. Winer¹², I. Krop¹², A. Wolff², A. Cimino-Mathews², R. Wahl¹³, V. Stearns², R. Connolly¹, ¹University College Cork, Cork, IE, ²Johns Hopkins, Baltimore, US, ³UCSF - University of California San Francisco, San Francisco, US, ⁴Vanderbilt Ingram Cancer Center, Nashville, US, ⁵Alliance Breast Committee / UNC - Lineberger Comprehensive Cancer Center, Chapel Hill, US, ⁶Mayo Clinic, Rochester, US, ⁷Baylor College of Medicine, Houston, US, ⁸University of Washington Seattle Cancer Care Alliance, Seattle, US, ⁹Indiana University, Indianapolis, US, ¹⁰The University of Texas MD Anderson Cancer Center - Main Building, Houston, US, ¹¹University of Alabama at Birmingham, Birmingham, US, ¹²Yale University School of Medicine, New Haven, US, ¹³Washington University School of Medicine in St. Louis, St. Louis, US

- 09:13 - 09:14 **192P - A phase II single-arm clinical study of neoadjuvant treatment with pegylated liposomal doxorubicin (PLD) plus cyclophosphamide (C) combined with trastuzumab (H) and pertuzumab (P) in HER2-positive (HER2⁺) breast cancer (BC)**
Y. Yang, L. Jin, N. Rao, C. Gong, S. Li, Y. Li, J. Wu, J. Zhao, L. Ding, Q. Liu, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN
- 09:14 - 09:15 **193P - Pathologic complete response, long-term outcomes, and recurrence patterns in HER2-low vs HER2-zero breast cancer after neoadjuvant chemotherapy**
S. Kang¹, S.H. Lee², H.J. Lee², H. Jeong², J.-H. Jeong², J.E. Kim², J.-H. Ahn², K. Jung², G. Gong², H.H. Kim², S. Lee³, J. Lee³, S.-B. Kim², ¹Chungnam National University Hospital, Daejeon, KR, ²Asan Medical Center - University of Ulsan, Seoul, KR, ³Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR
- 09:15 - 09:16 **194P - Clinical feasibility and oncological safety of targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: A prospective registry study**
S. Wu¹, J. Li¹, Y. Wang², G. Liu¹, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CN
- 09:16 - 09:17 **195P - Breast cancer molecular subtypes markers in subpopulations of circulating tumor cells**
E. Grigoryeva¹, O. Savelieva¹, L. Tashireva¹, V. Alifanov¹, V. Yakushina², N. Tarabanovskaya¹, N. Cherdyntseva¹, V. Perelmuter¹, ¹Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RU, ²Research Centre for Medical Genetics, Moscow, RU
- 09:17 - 09:18 **196P - Molecular profiling to identify recurrent mutations comparing pre and post-neoadjuvant chemotherapy tumour specimens of TNBC patients with residual disease**
J. Georgy, A. Singh, D. Sakthi, E. Sigamani, A. Joel, D.B. Thumaty, A. John, J.P. Wisely, P. Kumar M, H. Kovilapu, P. Jambunathan, S. Backianathan, J. Chandramohan, M. Therese Manipadam, G. Rebekah, R.T. Chacko, R. Pai, CMC - Christian Medical College Hospital, Vellore, IN
- 09:18 - 09:19 **197P - Long-term effects of physical exercise on self-reported cognitive function, fatigue, and quality of life in chemotherapy-treated breast cancer patients**
E. Monninkhof¹, E. Koevoets¹, M. De Leede¹, M. De Ruiter², S. Schagen², A. May¹, ¹UMC - University Medical Center Utrecht, Utrecht, NL, ²Netherlands Cancer Institute, Amsterdam, NL
- 09:19 - 09:20 **198P - Cosmesis (CA), late effects (LE) and Patient reported outcome measures (PROM) in high risk breast cancer (BC) treated with hypo-fractionated radiotherapy (RT): Real world outcome from a developing country**
S. Agrawal¹, C. Mishra¹, P. Lal², G. Chand¹, G. Agarwal², ¹SGPGIMS - Gandhi Post Graduate Institute of Medical Sciences, Lucknow, IN, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, IN

- 09:20 - 09:21 **199P - Breast cancer overdiagnosis in England, 1995-2019**
P. Autier¹, M. Bota², ¹International Prevention Research Institute, Lyon, FR, ²IPRI, Dardilly, FR
- 09:21 - 09:22 **200TiP - A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)- GeparPiPPa**
S. Loibl¹, M. Reinish², C. Denkert³, P.A. Fasching⁴, S. Seiler¹, T. Link⁵, C. Hanusch⁶, V. Bjelic-Radisic⁷, A. Schneeweiss⁸, J. Huober⁹, C. Jackisch¹⁰, K. Rhiem¹¹, M. Untch¹², C. Solbach¹³, J.-U. Blohmer¹⁴, T. Buechele¹, V. Nekljudova¹, S. Loi¹⁵, ¹German Breast Group, Neu-Isenburg, DE, ²Evang. Kliniken Essen-Mitte, Essen, DE, ³Philipps Universität Marburg und Universitätsklinikum Marburg (UKGM), Marburg, DE, ⁴Erlangen, Erlangen, DE, ⁵Technische Universität Dresden, Dresden, DE, ⁶Rotkreuzklinikum München, Munich, DE, ⁷Helios Universitätsklinik Wuppertal, Universität Witten/Herdecke, Wuppertal, DE, ⁸Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg, Heidelberg, DE, ⁹Kantonsspital St.Gallen, Brustzentrum, St. Gallen, CH, ¹⁰Sana Klinikum Offenbach, Offenbach am Main, DE, ¹¹Universitätsklinikum Köln, Köln, DE, ¹²Helios Klinikum Berlin-Buch, Berlin, DE, ¹³University Hospital Frankfurt, Frankfurt am Main, DE, ¹⁴Charité - Universitätsmedizin Berlin, Berlin, DE, ¹⁵Victoria Centre, Melbourne, AU
- 09:22 - 09:23 **201TiP - Density lowering effect of ovarian function suppression in premenopausal breast cancer patients who had no density change with one year of tamoxifen treatment (DELFINO study)**
H.-K. Kim¹, E.-S. Lee², C. Lim¹, Y. Han¹, J. Kim¹, J.-H. Cheun³, H.-B. Lee¹, H.-G. Moon¹, W. Han², ¹Seoul National University Hospital, Seoul, KR, ²Korea University Anam Hospital, Seoul, KR, ³Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, KR
- 09:23 - 09:24 **202TiP - SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naïve, early breast cancer**
M. Oliveira¹, J.M. Cejalvo Andujar², M. Margeli Vila³, P. Tolosa Ortega⁴, O. Martinez Saez⁵, F.J. Salvador Bofill⁶, J. Cruz Jurado⁷, A.M. Luna Barrera⁸, M. Arumi De Dios⁹, M.J. Vidal Losada⁵, J.A. Guerra¹⁰, S. Pernas Simon¹¹, G. Villacampa Javierre¹², B. Gonzalez-Farre¹³, E. Sanfeliu Torres¹³, A. Santhanagopal¹⁴, C. Falato¹⁵, J. Ferrero Cafiero¹⁶, T. Pascual¹⁶, A. Prat¹⁷, ¹SOLTI / Vall d'Hebron University Hospital, Barcelona, ES, ²SOLTI / Hospital Clínico Universitario de Valencia, Valencia, ES, ³SOLTI / ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ⁴SOLTI / Hospital Universitario 12 de Octubre, Madrid, ES, ⁵SOLTI / Hospital Clinic of Barcelona, Barcelona, ES, ⁶Hospital Universitario Virgen de Valme, Seville, ES, ⁷Hospital Universitario de Canarias, San Cristobal de la Laguna, ES, ⁸Hospital Clinico Universitario San Carlos, Madrid, ES, ⁹Universitat de Barcelona - Facultat de Medicina, Barcelona, ES, ¹⁰Hospital Universitario de Fuenlabrada, Fuenlabrada, ES, ¹¹SOLTI / ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ¹²SOLTI / Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ¹³Hospital Clinic of Barcelona, Barcelona, ES, ¹⁴Daiichi Sankyo, Inc., Basking Ridge, US, ¹⁵SOLTI / IDIBAPS - August Pi i Sunyer Biomedical Research

Institute, Barcelona, ES, ¹⁶SOLTI HQ, Barcelona, ES, ¹⁷SOLTI / IDIBAPS/ Hospital Clinic of Barcelona, Barcelona, ES

- 09:24 - 09:25 **203TiP - SOLTI-1911: Neoadjuvant and adjuvant ribociclib and endocrine therapy for clinically high-risk estrogen receptor-positive and HER2-negative breast cancer (RIBOLARIS)**
- P. Cottu¹, A. Prat², T. Pascual³, J. Lemonnier⁴, H. Hu⁵, E. Roux⁶, A. Thuerigen⁷, R. Connolly⁸, C. Ma⁹, T. Antonioli Crestani¹⁰, P. Tolosa Ortega¹¹, F. Salvador¹², T. De La Motte Rouge¹³, J. Gavila Gregori¹⁴, ¹UNICANCER/Institut Curie, Paris, FR, ²SOLTI / IDIBAPS/ Hospital Clinic of Barcelona/University of Barcelona, Barcelona, ES, ³SOLTI/Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁴UCBG UNICANCER, Paris, FR, ⁵Novartis Pharmaceuticals Corp., East Hanover, US, ⁶Novartis Pharmaceuticals Corporation, East Hanover, US, ⁷Novartis Pharma AG, Basel, CH, ⁸UCC - University College Cork, Cork, IE, ⁹Washington University School of Medicine in St. Louis, St. Louis, US, ¹⁰Breast International Group (BIG) - AISBL, Brussels, BE, ¹¹SOLTI/Hospital Universitario 12 de Octubre, Madrid, ES, ¹²SOLTI HQ, Barcelona, ES, ¹³UNICANCER/Centre Eugene - Marquis/GINECO, Rennes, FR, ¹⁴SOLTI/IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES
- 09:25 - 09:26 **204TiP - Low-dose 5-azacitadine to Promote Immunogenicity of the Breast Tumor Microenvironment**
- V. Gadi, A. Kodali, K. Hoskins, O. Danciu, A. Ibraheem, University of Illinois at Chicago (UIC), Chicago, US
- 09:26 - 09:27 **205P - Pooled exploratory analysis of survival in patients (pts) with HR⁺/HER2⁻ advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) & endocrine therapy (ET) in the MONALEESA (ML) trials**
- D. Yardley¹, Y.S. Yap², H. Azim³, R. De Boer⁴, M. Campone⁵, A. Ring⁶, M. De Laurentiis⁷, J. O'Shaughnessy⁸, J. Cortés⁹, Y. Chattar¹⁰, A. Thuerigen¹¹, J.P. Zarate¹², A. Nusch¹³, ¹Tennessee Oncology, Nashville, US, ²NCCS - National Cancer Centre Singapore, Singapore, SG, ³Cairo Oncology Center Cairo Hospital-CairoCure, Giza, EG, ⁴Peter MacCallum Cancer Centre, Victoria, AU, ⁵ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁶Royal Marsden Hospital Institute of Cancer Research, Surrey, GB, ⁷Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Naples, IT, ⁸Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, ⁹International Breast Cancer Center (IBCC), Grupo Quiron, Madrid & Barcelona, ES, ¹⁰Novartis Healthcare Pvt Ltd., Hyderabad, IN, ¹¹Novartis Pharma AG, Basel, CH, ¹²Novartis Pharmaceuticals Corporation, East Hanover, US, ¹³Practice for Hematology and Internal Oncology, Velbert, DE
- 09:27 - 09:28 **206P - HER2-low inflammatory breast cancer (IBC): Clinicopathologic features and prognostic implications**
- P. Tarantino¹, S.L. Niman¹, T. Erick¹, N. Priedigkeit¹, B. Harrison¹, A. Giordano¹, F. Nakhli¹, J.R. Bellon¹, T. Parker¹, S. Strauss¹, Q. Jin¹, T.A. King¹, B. Overmoyer¹, G. Curigliano², M. Regan¹, S. Tolaney¹, F. Lynce¹, ¹Dana Farber Cancer Institute, Boston, US, ²IEO - Istituto Europeo di Oncologia, Milan, IT

- 09:28 - 09:29 **207P - Comparison of CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors in the second-line treatment of hormone receptor-positive, HER2-negative advanced breast cancer: A network meta-analysis**
Y. Fan, D. Ji, Y. Luo, J. Wang, S. Chen, B. Lan, B. Xu, National Cancer Center/National Clinical Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN
- 09:29 - 09:30 **208P - Automated prognosis marker assessment in 2019 breast cancers using an artificial intelligence-based framework for BLEACH&STAIN mFIHC**
T. Mandelkow, E. Bady, J.H. Müller, N. Debatin, M.C.J. Lurati, C. Hube-Magg, G. Sauter, N. Blessin, University Medical Center Hamburg-Eppendorf, Hamburg, DE
- 09:30 - 09:31 **209P - Efficacy and feasibility of long acting every three months goserelin for premenopausal breast cancer patients during COVID pandemic**
S.F. El Zawawy¹, G. Khedr², ¹University of Alexandria - Faculty of Medicine, Alexandria, EG, ²Alexandria University - Clinical Oncology and Nuclear Medicine Department, Alexandria, EG
- 09:31 - 09:32 **218P - Patient-reported quality of life in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (ABC) treated with palbociclib (PAL) plus letrozole (LET): Results from PALOMA-4**
X. Hu¹, E. Broughton², W. Li³, T. Sun⁴, K. Shen⁵, C. Huang⁶, V. Sriuranpong⁷, K.C.R. Ngan⁸, Y.H. Chia⁹, H. Bhattacharyya², H. Zhao¹⁰, J. Shen¹⁰, B. Xu¹¹, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²Pfizer Inc - USA, New York, US, ³The First Hospital of Jilin University, Changchun, CN, ⁴Cancer Hospital of China Medical University/Liaoning Cancer Hospital, Shenyang, CN, ⁵Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, CN, ⁶National Taiwan University Hospital, Taipei City, TW, ⁷King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, TH, ⁸The University of Hong Kong, Hong Kong, HK, ⁹Tan Tock Seng Hospital, Singapore, SG, ¹⁰Pfizer (China) Research and Development Co., Ltd., Shanghai, CN, ¹¹Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN
- 09:32 - 09:33 **219P - UK survey measuring informational needs & QoL in women living with metastatic breast cancer (LIMBER)**
V. Jenkins¹, S. Russ¹, R. Starkings¹, A. Tait², L. Stephen², S. May¹, C. Palmieri³, L. Fallowfield¹, ¹Brighton and Sussex Medical School - University of Sussex, Brighton, GB, ²PPI, Edinburgh, GB, ³NHS Liverpool Clinical Laboratories - Royal Liverpool University Hospital NHS Trust, Liverpool, GB
- 09:33 - 09:34 **220P - Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD**
P. Aftimos¹, J. Cortés², F.C. Bidard³, V. Kaklamani⁴, A. Bardia⁵, P. Neven⁶, G. Streich⁷, A. Montero⁸, F. Forget⁹, M.A. Mouret Reynier¹⁰, J. Sohn¹¹, D. Taylor¹², K. Harnden¹³, H. Khong¹⁴, J. Kocsis¹⁵, F. Dalenc¹⁶, P. Dillon¹⁷, G. Tonini¹⁸, K. Grzegorzewski¹⁹, J. Lu²⁰,

¹Institute Jules Bordet, Brussels, BE, ²International Breast Cancer Center (IBCC), Quiron Group, Madrid & Barcelona, Barcelona, ES, ³Institut Curie, Paris, FR, ⁴UTHSCSA - University of Texas Health Science Center at San Antonio, San Antonio, US, ⁵Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US, ⁶University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁷Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Buenos Aires, AR, ⁸Case Western Reserve University / University Hospitals, Cleveland, US, ⁹Centre Hospitalier de l'Ardenne, Libramont, BE, ¹⁰Jean Perrin Center, Clermont-Ferrand, FR, ¹¹Yonsei University, Seoul, KR, ¹²CHU-UCL-Namur - Site Sainte-Elisabeth, Namur, BE, ¹³Inova Schar Cancer Institute, Fairfax, US, ¹⁴H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ¹⁵Bács-Kiskun County Teaching Hospital, Kecskemet, HU, ¹⁶Centre Claudius-Regaud, Toulouse, FR, ¹⁷UVA - University of Virginia - School of Medicine - Division of Hematology & Oncology, Charlottesville, US, ¹⁸Menarini Silicon Biosystems, Inc. - North American Operations, Huntingdon Valley, US, ¹⁹Stemline Therapeutics, Inc., New York, US, ²⁰USC - University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, US

09:34 - 09:35 **221P - Early prediction of efficacy of endocrine therapy (ET) in metastatic breast cancer (MBC): Pilot study with [18F]fluoro-estradiol-17β; (18F-FES) PET/CT**

A. Gennari¹, E. Brain², O. Nanni³, N. Harbeck⁴, J. Cortés⁵, A. De Censi⁶, A. Piccardo⁶, J.L. Alberini⁷, F. Matteucci⁸, G. Sacchetti⁹, H. Ilhan¹⁰, M. Monti⁸, R. Wuerlestein¹¹, C. Saggia⁹, V. Rossi⁹, F. D'Avanzo⁹, P.M. Maggiora¹², M. Iacozzi⁶, A. Frassoldati¹³, L. Boni¹⁴, ¹Università Degli Studi Del Piemonte Orientale - Scuola di Medicina, Novara, IT, ²Hopital René Huguenin - Institut Curie, Saint-Cloud, FR, ³IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l., Meldola, IT, ⁴Ludwig Maximilians University Hospital of Munich, Munich, DE, ⁵Hospital Ruber Internacional, Madrid, ES, ⁶Ente Ospedaliero Ospedali Galliera, Genova, IT, ⁷Centre Georges-François Leclerc (Dijon), Dijon, FR, ⁸IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS S.r.l., Meldola, IT, ⁹AOU Maggiore della Carità di Novara, Novara, IT, ¹⁰ISAR-Klinikum, Munchen, DE, ¹¹LMU - Ludwig Maximilians University of Munich, Munich, DE, ¹²Università degli Studi del Piemonte Orientale - Amedeo Avogadro, Novara, IT, ¹³Azienda Ospedaliera di Ferrara St. Anna, Ferrara, IT, ¹⁴IRCCS Ospedale Policlinico San Martino, Genova, IT

09:35 - 09:36 **223P - Gene expression profiles in endocrine-resistant breast cancer**

C. Schagerholm¹, S. Robertson¹, E. Sifakis¹, L. Hases², C. Williams³, J. Hartman¹, ¹Karolinska Institutet, Stockholm, SE, ²The Salk Institute for Biological Studies, La Jolla, US, ³Science for Life Laboratory (SciLifeLab), Solna, SE

09:36 - 09:37 **224P - Efficacy and safety of tenalisib, a PI3K delta/gamma and SIK3 inhibitor in patients with locally advanced or metastatic breast cancer: Results from a phase II study**

T. Makharadze¹, I. Kiladze², G. Dzagnidze³, N. Semionova-Peskova⁴, L. Katselashvili², N. Vekua⁵, K. Routhu⁶, P. Barde⁶, A. Nair⁶, ¹LTD "High Technology Hospital Medcenter", Batumi, GE, ²CMC - Caucasus Medical Centre, Tbilisi, GE, ³Simon Khechinashvili University Hospital, Tbilisi, GE, ⁴LTD High Technology Hospital Medcenter, Batumi, GE, ⁵S.Khechinashvili Hospital, Tbilisi, GE, ⁶Rhizen Pharmaceuticals AG, Basel, CH

- 09:37 - 09:38 **225P - MET-enriched circulating tumor cells and cell-free DNA concentration as significant independent predictors for progression in HR-positive HER2-negative metastatic breast cancer**
J. Park¹, E.S. Chang², J.-Y. Kim³, C. Chelakkot⁴, M. Sung⁵, J.-Y. Song⁵, K. Jung⁵, N.Y. Kim⁶, Y.H. Park³, Y.K. Shin¹, Y.-L. Choi⁵, ¹Seoul National University (SNU) - Main Campus, Seoul, KR, ²SAIHST - Samsung Advanced Institute for Health Sciences & Technology, SKKU, Seoul, KR, ³Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ⁴Genobio Corp., Seoul, KR, ⁵Samsung Medical Center (SMC), Seoul, KR, ⁶ABION - Perpetual Pharmaceutical Pearl Provider, Seoul, KR
- 09:38 - 09:39 **226P - Exploring the impact of first-line therapies on the metastatic behavior of luminal-like metastatic breast cancer (mBC)**
R. Mazzeo¹, B. Pastò¹, D. Basile², L. Bortot¹, L. Cucciniello¹, A. Dri¹, C. Noto¹, S. Buriolla¹, L. Palmero¹, A. Membrino¹, M. Bonotto³, C. Lisanti⁴, S. Russo³, A.M. Minisini³, G. Fasola³, L. Gerratana⁴, F. Puglisi¹, ¹University of Udine, Udine, IT, ²San Giovanni di Dio Hospital, Crotone, IT, ³Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, IT, ⁴Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, IT
- 09:39 - 09:40 **227P - Peripheral blood lymphocyte counts predict clinical outcomes in patients with hormone receptor-positive HER2-negative advanced breast cancer treated with CDK4/6 inhibitors**
C. Vernieri¹, E. Zattarin¹, L. Mariani², A. Menichetti³, R. Leporati¹, F. Ligorio¹, G. Fuca¹, R. Lobefaro¹, G. Griguolo³, M. Sirico⁴, O. Bernocchi⁵, A. Marra⁶, E. Agostinetto⁷, F. Jacobs⁸, P. Di Mauro⁹, G. Curigliano¹⁰, R. Pedersini⁹, A. Losurdo⁸, D. Generali¹¹, M.V. Dieci³, ¹Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ²Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Milano, IT, ³IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁴Istituto tumori della Romagna IRST IRCCS, Meldola, IT, ⁵Department of Medical, Surgery and Health Sciences, University of Trieste, 34147 Trieste, Italy., Trieste, IT, ⁶Memorial Sloan Kettering Cancer Center, New York, US, ⁷Institute Jules Bordet, Bruxelles, BE, ⁸Humanitas University, Milan, IT, ⁹Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT, ¹⁰IEO - Istituto Europeo di Oncologia, Milan, IT, ¹¹Breast Cancer Unit & Translational Research Unit, ASST Cremona, Cremona, Italy., Cremona, IT
- 09:40 - 09:41 **228P - Fulvestrant with additional palbociclib in advanced or metastatic hormone receptor-positive HER2-negative breast cancer after progression to fulvestrant monotherapy: JBCRG- M07 (FUTURE trial)**
K. Watanabe¹, N. Niikura², Y. Kikawa³, M. Oba⁴, K. Kobayashi⁵, H. Tada⁶, S. Ozaki⁷, U. Toh⁸, Y. Yamamoto⁹, M. Tsuneizumi¹⁰, T. Okuno¹¹, N. Iwakuma¹², T. Takeshita¹³, T. Iwamoto¹⁴, H. Ishiguro¹⁵, N. Masuda¹⁶, S. Saji¹⁷, ¹Hokkaido Cancer Center, Sapporo, JP, ²Tokai University School of Medicine, Isehara, JP, ³Kansai Medical University Hospital, Hirakata, JP, ⁴National Center of Neurology and Psychiatry, Kodaira, JP, ⁵Cancer Institute Hospital of JFCR, Tokyo, JP, ⁶Graduate School of Dentistry, Tohoku University, Sendai, JP, ⁷Hiroshima Prefectural Hospital, Hiroshima, JP, ⁸Kurume University Hospital, Kurume, JP, ⁹Kumamoto University Hospital, Kumamoto, JP, ¹⁰Shizuoka General Hospital, Shizuoka, JP, ¹¹Kobe City Nishi-Kobe Medical Center, Kobe, JP, ¹²National Hospital Organization Kyushu Medical Center, Fukuoka, JP, ¹³Kumamoto City Hospital (Kumamotoshimin Hospital), Kumamoto, JP, ¹⁴Okayama University Hospital, Okayama, JP, ¹⁵Saitama

Medical University International Medical Center, Saitama, JP, ¹⁶Nagoya University Hospital, Nagoya, JP, ¹⁷Fukushima Medical University, Fukushima, JP

- 09:41 - 09:42 **229P - Dabpoliciclib plus fulvestrant in HR⁺/HER2⁻ advanced breast cancer (ABC): Updated analysis from the phase III DAWNA-1 trial**
P. Zhang¹, Q.Y. Zhang², X. Hu³, W. Li⁴, Z. Tong⁵, T. Sun⁶, Y. Teng⁷, X. Wu⁸, Q. Ouyang⁹, X. Yan¹⁰, J. Cheng¹¹, Q. Liu¹², J. Feng¹³, X. Wang¹⁴, G. Xu¹⁵, F. Wu¹⁵, B. Xia¹⁵, B. Xu¹,
¹Cancer Hospital/National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ²Harbin Medical University Cancer Hospital, Harbin, CN, ³Fudan University Shanghai Cancer Center, Shanghai, CN, ⁴The First Hospital of Jilin University, Changchun, CN, ⁵Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ⁶Cancer Hospital of China Medical University/Liaoning Cancer Hospital, Shenyang, CN, ⁷The First Affiliated Hospital of China Medical University, Shenyang, CN, ⁸Hubei Cancer Hospital, Wuhan, CN, ⁹Hunan Cancer Hospital, Changsha, CN, ¹⁰West China Hospital, Sichuan University, Chengdu, CN, ¹¹Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, CN, ¹²Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, CN, ¹³Jiangsu Cancer Hospital, Nanjing, CN, ¹⁴Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, CN, ¹⁵Jiangsu Hengrui Pharmaceutical Co., Ltd., Shanghai, CN
- 09:42 - 09:43 **230P - Early metabolic response by FDG-PET scan predicts survival in patients with metastatic breast cancer receiving CDK4/6 inhibitors: Preliminary results from the PUCCINI study**
E. Agostinetto¹, C. De Angelis², M. Brandão¹, P. Flamen¹, M. Piccart¹, E. De Azambuja¹, G. Gebhart¹, ¹Institute Jules Bordet, Bruxelles, BE, ²AOU Careggi Firenze, Firenze, IT
- 09:43 - 09:44 **231P - Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer**
L. Visani¹, C. Becherini¹, E. Scoccimarro¹, M. Valzano¹, C. Saieva², I. Ratosa³, D. Ribnikar³, M. Orazem³, T. Marinko³, I. Desideri⁴, V. Scotti¹, A. Morandi⁴, M. Lambertini⁵, I. Meattini⁴, L. Livi⁴, ¹Azienda Ospedaliero-Universitaria Careggi, Florence, IT, ²Istituto per lo Studio, la Prevenzione e la rete Oncologica (ISPRO), Florence, IT, ³Institute of Oncology Ljubljana, Ljubljana, SI, ⁴University of Florence, Florence, IT, ⁵IRCCS Ospedale Policlinico San Martino, Genova, IT
- 09:44 - 09:45 **232P - Second-line therapies of patients with early progression under CDK4/6-inhibitor in first-line – data from the registry platform OPAL**
N. Marschner¹, N. Harbeck², M. Thill³, E. Stickeler⁴, M. Zaiss¹, A. Nusch⁵, J. Rauh⁶, H. Schulz⁷, K. Engelken⁸, L. Kruggel⁹, M. Jänicke¹⁰, M.-O. Zahn¹¹, A. Wöckel¹², A. Welt¹³, T. Decker¹⁴, ¹Praxis, Freiburg im Breisgau, DE, ²LMU Klinikum München, München, DE, ³Agaplesion Markus Krankenhaus, Frankfurt am Main, DE, ⁴Universitätsklinikum Aachen (UKA), Aachen, DE, ⁵Praxis, Ratingen, DE, ⁶Praxis, Witten, DE, ⁷PIOH (Frechen) - Praxis Internistischer Onkologie und Hämatologie, Frechen, DE, ⁸Klinik Dr. Hancken GmbH, Stade, DE, ⁹iOMEDICO AG, Freiburg im Breisgau, DE, ¹⁰iOMEDICO AG, Freiburg, DE, ¹¹MVZ Onkologische Kooperation Harz, Goslar, DE, ¹²Universitätsklinikum Würzburg, Würzburg, DE, ¹³Universitätsklinikum Essen, Essen, DE, ¹⁴Studienzentrum

Onkologie Ravensburg, Ravensburg, DE

- 09:45 - 09:46 **233P - Decision-making criteria for the choice of 1st line CDK4/6-inhibitor therapy for HR⁺/Her2- breast cancer in Germany: DECISIONext**
D. Finas, Gemeinschaftskrankenhaus Havelhöhe, Berlin, DE
- 09:46 - 09:47 **234P - CDK 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (mBC): The Likelihood of being Helped or Harmed (LHH) as a patient-centred tool to assess clinical impact and safety**
L. Mastrantonì¹, A. Orlandi², A. Palazzo², G. Garufi¹, A. Fabi³, G. Daniele³, D. Giannarelli³, G. Tortora³, E. Bria³, ¹Università Cattolica del Sacro Cuore, Rome, IT, ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, IT, ³Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT
- 09:47 - 09:48 **235P - The impact of body mass index (BMI) on the progression-free survival of CDK4/6 inhibitors in metastatic breast cancer patients (MBC)**
M. Artac¹, D. Cağlayan¹, M.Z. Koçak¹, C. Geredeli², A.M. Tatli³, S. Sezgin Goksu³, M. Karakurt Eryılmaz¹, M. Araz¹, ¹Necmettin Erbakan University - Meram Medical Faculty, Konya, TR, ²Okmeydanı Training and Research Hospital, Istanbul, TR, ³Akdeniz University - Faculty of Medicine, Antalya, TR
- 09:48 - 09:49 **236P - Subgroup analysis by disease history and prior treatments of patients (pts) with HER2-positive (HER2⁺) metastatic breast cancer (MBC) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1)**
J. Cortés¹, S.-A. Im², H. Iwata³, E. Hamilton⁴, S. Hurvitz⁵, A. Egorov⁶, J. Cathcart⁷, Y. Liu⁸, E. Bako⁹, G. Curigliano¹⁰, ¹Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, ES, ²Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, ³Aichi Cancer Center Hospital, Nagoya, JP, ⁴Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, ⁵David Geffen School of Medicine at UCLA and Jonsson Comprehensive Cancer Center, Los Angeles, US, ⁶Daiichi Sankyo, Inc., Rueil-Malmaison, FR, ⁷Daiichi Sankyo Inc., Basking Ridge, US, ⁸Daiichi Sankyo, Inc., Basking Ridge, US, ⁹Daiichi Sankyo, Inc., Wilsonville, US, ¹⁰Department of Oncology and Hemato-Oncology, University of Milan and Division of Early Drug Development, European Institute of Oncology, IRCCS, Milan, IT
- 09:49 - 09:50 **237P - HER2DX genomic assay in advanced HER2-positive (HER2⁺) breast cancer treated with T-DM1**
F. Brasó-Maristany¹, G. Griguolo², N. Chic¹, L. Pare Brunet³, P. Galván⁴, M.V. Dieci⁵, F. Miglietta⁶, T. Giarratano⁶, O. Martínez-Sáez⁷, M. Marin³, M.J. Vidal Losada⁷, B. Adamo⁸, M. Muñoz⁷, A. Vivancos⁹, P. Villagrasa Gonzalez³, J. Parker¹⁰, C. Perou¹¹, P.F. Conte⁶, A. Prat⁸, V. Guarneri⁵, ¹IDIBAPS - Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES, ²University of Padova, Padova, IT, ³Reveal Genomics, S.L., Barcelona, ES, ⁴IDIBAPS - August Pi i Sunyer Biomedical Research Institute, Barcelona, ES, ⁵University of Padua, Padova, IT, ⁶IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁷Hospital Clinic of Barcelona, Barcelona, ES, ⁸Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁹Vall d'Hebron University Hospital, Barcelona, ES, ¹⁰UNC - Lineberger Cancer

Center, Chapel Hill, US, ¹¹UNC - Lineberger Comprehensive Cancer Center, Chapel Hill, US

- 09:50 - 09:51 **238P - Clinical safety and pharmacokinetics (PK) data of DZD1516, an BBB-penetrant selective HER2 inhibitor for the treatment of HER2-positive metastatic breast cancer**
J. Zhang¹, N. Mcandrew², W. Yu³, X. Pan³, X. Hu¹, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²David Geffen School of Medicine at UCLA, Santa Monica, US, ³Dizal Pharmaceutical, Shanghai, CN
- 09:51 - 09:52 **239P - Pyrotinib in combination with docetaxel as first-line treatment for HER2-positive metastatic breast cancer (PANDORA): A single-arm, multicenter phase II trial**
X. Wang, J. Huang, Zhejiang Cancer Hospital - Cancer Research Institute, Hangzhou, CN
- 09:52 - 09:53 **240P - Prognostic impact of extracranial disease control in HER2-positive breast cancer-related brain metastases**
M. Bottosso¹, G. Griguolo¹, L. Sinoquet², M.C. Guarascio¹, V. Aldegheri³, F. Miglietta¹, C. Barbieri¹, F. Girardi³, W. Jacot², V. Guarneri¹, A. Darlix², M.V. Dieci¹, ¹University of Padova, Padova, IT, ²ICM - Institut du Cancer de Montpellier, Montpellier, FR, ³Istituto Oncologico Veneto - IRCCS, Padova, IT
- 09:53 - 09:54 **241P - Genomic analysis of plasma cell-free DNA in patients with heavily pretreated HER2-positive metastatic breast cancer (MBC)**
K. Lee¹, J. Lee², J. Choi², S.H. Sim³, J.E. Kim⁴, M.H. Kim⁵, Y.H. Park⁶, J.H. Kim⁷, S. Koh⁸, K.H. Park⁹, M.J. Kang¹⁰, M.S. Ahn¹¹, K.-E. Lee¹², H.J. Kim¹³, H. Ahn¹⁴, H.J. Kim¹⁵, K.U. Park¹⁶, I.H. Park¹, ¹Korea University Guro Hospital, Seoul, KR, ²Korea University College of Medicine, Seoul, KR, ³NCC - National Cancer Center, Goyang, KR, ⁴Asan Medical Center - University of Ulsan, Seoul, KR, ⁵Yonsei University, Seoul, KR, ⁶Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ⁷Seoul National University Bundang Hospital, Seongnam, KR, ⁸Ulsan University Hospital, Ulsan, KR, ⁹Korea University Anam Hospital, Seoul, KR, ¹⁰Inje University Haeundae Paik Hospital, Busan, KR, ¹¹Ajou University Hospital School of Medicine, Suwon, KR, ¹²Ewha Womans University Mokdong Hospital, Seoul, KR, ¹³Chung-Ang University Hospital, Seoul, KR, ¹⁴Gachon University Gil Hospital, Incheon, KR, ¹⁵Soonchunhyang University Cheonan Hospital, Cheonan-si, KR, ¹⁶Keimyung University Dongsan Hospital, Daegu, KR
- 09:54 - 09:55 **242P - Investigating the risk of drug-induced interstitial lung disease in patients with metastatic breast cancer treated with antiHER2 regimens through a network meta-analysis approach**
L. Palmero¹, M. Siciliano², P. Di Nardo³, D. Basile², L. Cucciniello¹, B. Pastò¹, C. Lisanti³, A. Membrino¹, C. Noto¹, S. Spazzapan³, L. Gerratana³, F. Puglisi⁴, ¹Department of Medicine (DAME), University of Udine, Udine, UD, Italy, Udine, IT, ²San Giovanni di Dio Hospital, Crotone, IT, ³CRO Aviano - Centro di Riferimento Oncologico - IRCCS, Aviano, IT, ⁴CRO di Aviano, National Cancer Institute, IRCCS; Department of Medicine (DAME), University of Udine, Udine, IT
- 09:55 - 09:56 **243P - Tumor-infiltrating lymphocytes (TILs) in paired samples from patients**

with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer

S. Morganti¹, A. Marra², K. Venetis³, E. Sajjadi³, L. Ascione⁴, C. Corti⁴, P. Zagami⁵, M. Ivanova³, L. Zattoni³, G. Curigliano⁴, N. Fusco³, C. Criscitiello⁴, ¹Dana-Farber Cancer Institute, Harvard Medical School, Boston, US, ²Memorial Sloan Kettering Cancer Center, New York, US, ³IEO - Istituto Europeo di Oncologia; Department of Pathology, Milan, IT, ⁴IEO - Istituto Europeo di Oncologia; Division of New Drugs and Early Drug Development, Milan, IT, ⁵Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, US

09:56 - 09:57 **244P - Eribulin combined with anlotinib for patients with HER2-negative metastatic breast cancer: A single-arm, multicenter, phase II study**

Y. Yin, X. Wu, X. Huang, W. Li, Y. Hua, Y. Liang, Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN

09:57 - 09:58 **245P - Impact of regular intensive imaging surveillance on survival after recurrence in patients with early breast cancer; a propensity score matching study**

C.S. Park¹, H.-A. Kim¹, M.K. Seong¹, I.C. Park², H.J. Kim¹, S.W. Kim¹, J.H. Lee¹, J. Kim³, G. Gwak³, ¹Korea Cancer Center Hospital, Seoul, KR, ²Korea institute of radiological & medical science, Seoul, KR, ³Sanggye Paik Hospital - Inje University College of Medicine, Seoul, KR

09:58 - 09:59 **246P - Nanosomal paclitaxel lipid suspension demonstrates better tumor response and safety versus conventional paclitaxel in patients with metastatic breast cancer**

S. Chiradoni Thungappa¹, R. Taran², J.K. Singh³, S.P. Shrivastav⁴, N.K. Vithalani⁵, K. Mukherjee⁶, R. Nagarkar⁷, T. Maksud⁸, A. Mehta⁹, K. Srinivasan¹⁰, M. Vikranth¹¹, S.R. Sonawane¹², A. Ahmad¹³, S. Sheikh¹³, S.M. Ali¹³, M. Paithankar¹⁴, A. Rajani¹⁴, D. Bunker¹⁴, M. Khan¹⁴, I. Ahmad¹³, ¹Sri Venkateshwara Hospital, Bangalore, IN, ²Convenient Hospital Ltd., CHL-Hospital & CHL- CBCC Cancer Center, Indore, IN, ³MCSRC - Mahavir Cancer Sansthan and Research Centre, Patna, IN, ⁴Kiran Multi Super Speciality Hospital & Research Centre, Surat, IN, ⁵Unique Hospital Multispecialty and Research Institute, Surat, IN, ⁶CNCI - Chittaranjan National Cancer Institute, Kolkata, IN, ⁷Curie Manavata Cancer Centre, Nasik, IN, ⁸Bharat Cancer Hospital and Research Institute, Surat, IN, ⁹Central India Cancer Research Institute, Nagpur, IN, ¹⁰Dr. Rai Memorial Medical Centre, Chennai, IN, ¹¹City Cancer Center, Vijayawada, IN, ¹²Anandrishiji Hospital and Medical Research Centre, Ahmed Nagar, IN, ¹³Jina Pharmaceuticals, Libertyville, US, ¹⁴Intas Pharmaceuticals Ltd., Ahmedabad, IN

09:59 - 10:00 **247P - Apatinib combined with chemotherapy versus single chemotherapy in advanced HER-2-negative breast cancer: A randomized, controlled, open-label phase II study**

Z.-H. Chen, X. Wang, Zhejiang Cancer Hospital - Cancer Research Institute, Hangzhou, CN

10:00 - 10:01 **248P - Sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments**

B. Xu¹, F. Ma¹, S. Wang², Z. Tong³, W. Li⁴, X. Wu⁵, X. Wang⁶, T. Sun⁷, Y. Pan⁸, H. Yao⁹, X. Wang¹⁰, T. Luo¹¹, J. Yang¹², X. Zeng¹³, W. Zhao¹⁴, X. Cong¹⁵, J. Chen¹⁵, ¹Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, ²Sun Yat-sen University Cancer Center, Guangzhou, CN, ³TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ⁴The First Hospital of Jilin University, Changchun, CN, ⁵Hubei Cancer Hospital, Wuhan, CN, ⁶Zhejiang Cancer Hospital - Cancer Research Institute, Hangzhou, CN, ⁷Liaoning Cancer Hospital & Institute, Shenyang, CN, ⁸Anhui Provincial Hospital, Hefei, CN, ⁹2nd Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, ¹⁰Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, CN, ¹¹West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN, ¹²First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, CN, ¹³Chongqing Cancer Hospital, Chongqing, CN, ¹⁴Chinese PLA General Hospital (301 Military Hospital), Beijing, CN, ¹⁵Everest Medicines, Shanghai, CN

10:01 - 10:02 **249P - A retrospective analysis on capecitabine and vinorelbine combination in metastatic breast cancer: The MARCELLINO study**

M. De Scordilli¹, L. Bortot¹, L. Cucciniello¹, F. Totaro¹, R. Mazzeo¹, M. Alberti¹, L. Palmero¹, G. Targato¹, A. Dri¹, F. Pravisano¹, G. Zapelloni¹, C. Lisanti², S. Spazzapan², A.M. Minisini³, M. Mansutti³, M. Bonotto³, L. Gerratana², G. Fasola³, F. Puglisi⁴, ¹University of Udine, Udine, IT, ²CRO Aviano - Centro di Riferimento Oncologico - IRCCS, Aviano, IT, ³Santa Maria della Misericordia Academic Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, IT, ⁴Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, IT

10:02 - 10:03 **250P - Association between progression free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: Evidence from the ESME real-world database**

C. Courtinard¹, S. Gourgou², W. Jacot³, M. Carton⁴, T. Filleron⁵, D. Couch⁶, B. Asselain⁷, M.-C. Le Deley⁸, L. Vacher⁹, A. Antoine¹⁰, D. Parent¹¹, R. Schiappa¹², M. Breton¹³, S. Michiels¹⁴, E. Brain¹⁵, O. Guérin¹⁶, A. Loeb¹⁷, G. Perrocheau¹⁸, G. Simon¹⁹, C. Bellera¹, ¹INSERM U1219 - Bordeaux Population Health - ISPED University of Bordeaux, Bordeaux, Cedex, FR, ²ICM - Institut régional du Cancer de Montpellier, Val d'Aurelle, Montpellier, Cedex, FR, ³ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ⁴Institut Curie, Paris, FR, ⁵Institut Claudius Regaud, Toulouse, FR, ⁶Unicancer, Paris, FR, ⁷ARCAGY-GINECO, Paris, FR, ⁸Centre Oscar Lambret, Lille, FR, ⁹Centre Jean PERRIN, Clermont-Ferrand, Cedex, FR, ¹⁰Center Leon Berard, Lyon, FR, ¹¹Institu Jean Godinot, Reims, Cedex, FR, ¹²Centre Anticancer Antoine Lacassagne, Nice, FR, ¹³Centre Eugene - Marquis, Rennes, FR, ¹⁴Institut Gustave Roussy, Villejuif, Cedex, FR, ¹⁵Hopital René Huguenin - Institut Curie, Saint-Cloud, FR, ¹⁶ICO - Institut de Cancerologie de l'Ouest - Site Paul Papin, Angers, FR, ¹⁷Centre Henri Becquerel, Rouen, FR, ¹⁸ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ¹⁹Unicancer, Paris, Cedex, FR

10:03 - 10:04 **251P - Real-world clinical outcomes of palbociclib plus endocrine therapy (ET) in hormone receptor-positive advanced breast cancer: Results from the POLARIS trial**

D. Tripathy¹, G. Rocque², J. Blum³, M. Karuturi¹, S. Mccune⁴, S. Kurian⁵, M. Moezi⁶, D.

Anderson⁷, E. Gauthier⁸, Z. Zhang⁹, M. Montelongo¹⁰, Y. Wang¹¹, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²University of Alabama at Birmingham, Birmingham, US, ³Texas Oncology, Dallas, US, ⁴Wellstar Health System, Marietta, US, ⁵West Virginia University Cancer Institute, Morgantown, US, ⁶Cancer Specialists of North Florida, Fleming Island, US, ⁷Health Partners Institute, Saint Paul, US, ⁸Pfizer Inc., San Francisco, US, ⁹Pfizer Inc, San Diego, US, ¹⁰ICON plc, Blue Bell, US, ¹¹Pfizer Inc, New York, US

- 10:04 - 10:05 **252P - Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience**
C. Labaki¹, Z. Bakouny², T. Sanglier³, A. Schmidt¹, J. Shim⁴, D. Braun⁵, F. Bouquet⁶, M. Joyce⁷, W. Xie¹, S. Tolaney¹, T. Choueiri¹, ¹Dana Farber Cancer Institute, Boston, US, ²Dana-Farber Cancer Institute, Boston, US, ³F. Hoffmann-La Roche AG, Basel, CH, ⁴F. Hoffmann-La Roche AG Undo, Basel, CH, ⁵Yale University School of Medicine - Yale Cancer Center, New Haven, US, ⁶Roche S.A.S - France, Boulogne-Billancourt, FR, ⁷Genentech, Basel, CH
- 10:05 - 10:06 **253P - Unmet need in heavily pre-treated patients with HR⁺/HER2⁻ metastatic breast cancer (mBC) in the US: A ConcertAI analysis**
A. Waks¹, M. Gharaibeh², N. Sjekloca³, N. Poluparthi², A. Shah², E. Bergamaco², T. Maccannell², G. Leung², I. Ntalla³, H. Oko-Osi², S. Tolaney¹, ¹Dana-Farber Cancer Institute, Boston, US, ²Gilead Sciences, Inc., Foster City, US, ³Gilead Sciences Europe Ltd., Stockley Park, GB
- 10:06 - 10:07 **254P - Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer**
L. Wyrwicz¹, C. Rodríguez Sanchez², P. Sanchez-Rovira³, S. Lewis⁴, D. Sandschafer⁴, T. San⁵, ¹Maria Skłodowska Curie National Cancer Research Institute, Warsaw, PL, ²Hospital Universitario de Salamanca-IBSAL, Salamanca, ES, ³Complejo Hospitalario de Jaén, Jaén, ES, ⁴Amgen Inc., Thousand Oaks, US, ⁵Centre Oncologie et Radiothérapie, Chambray-lès-Tours, FR
- 10:07 - 10:08 **255P - Challenges to assess bone metastases in Blinded Independent Central Review (BICR) of breast cancer trials using RECIST 1.1**
S. Bodard¹, C. Ojango², A. Iannessi², L. Balcells², J. He³, Y. Liu², ¹GH Necker - Enfants Malades, Paris, FR, ²Median Technologies, Valbonne, FR, ³Median Medical Technology Shanghai, Shanghai, CN
- 10:08 - 10:09 **256P - Difference of immunological status and response to immune checkpoint inhibitor between recurrent and de novo stage IV HER2-negative breast cancer in NEWBEAT trial (WJOG9917BTR)**
Y. Ozaki¹, S. Kitano¹, M. Yamashita², D. Ikarashi³, J. Tsurutani⁴, T. Iwasa⁵, M. Takahashi⁶, T. Mukohara⁷, N. Masuda⁸, M. Futamura⁹, H. Minami¹⁰, K. Matsumoto¹¹, Y. Tanabe Hashimoto¹², H. Kawabata¹², K. Yoshimura¹³, T. Takano¹, ¹The Cancer Institute Hospital of JFCR, Koto-ku, JP, ²Japanese Foundation for Cancer Research Cancer Institute Hospital, Koto-ku, JP, ³Iwate Medical University School of Medicine, Morioka, JP, ⁴Showa University, Shinagawa-ku, JP, ⁵Kindai University - Faculty of Medicine, Osaka, JP

⁶Hokkaido University Hospital, Sapporo, JP, ⁷National Cancer Center Hospital East, Kashiwa, JP, ⁸Nagoya University Hospital, Nagoya, JP, ⁹Gifu University Hospital, Gifu, JP, ¹⁰Kobe University Hospital, Kobe, JP, ¹¹Hyogo Cancer Center, Akashi, JP, ¹²Toranomon Hospital, Minato-ku, JP, ¹³Hiroshima University Hospital, Hiroshima, JP

- 10:09 - 10:10 **257P - Efficacy of pembrolizumab in pre-treated breast cancer harboring high mutational load 140-290 – results from the Drug Rediscovery Protocol (DRUP)**
- L. Zeverijn¹, B. Geurts¹, J. Van Berge Henegouwen², L. Hoes¹, H. Van Der Wijngaart³, G. De Wit¹, P. Roepman⁴, A. Jansen⁵, W. De Leng⁵, V. Van Der Noort¹, A. Van Ommen-Nijhof¹, H. Gelderblom², H. Verheul⁶, E. Voest¹, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²LUMC - Universitair Medisch Centrum, Leiden, NL, ³Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, ⁴Hartwig Medical Foundation, Amsterdam, NL, ⁵UMC-University Medical Center Utrecht, Utrecht, NL, ⁶Radboud University Medical Center, Nijmegen, Nijmegen, NL
- 10:10 - 10:11 **258P - Immune checkpoint inhibitors addition to chemotherapy in older patients with metastatic triple-negative breast cancer: A systematic review and meta-analysis**
- M. Pagliuca¹, L. Bencivenga², K. Komici³, C. De Angelis², R. Caputo⁴, F. Napolitano², D. Cianniello⁴, V. Di Lauro⁴, G. Rengo⁵, S. De Placido², F. André⁶, M. De Laurentiis⁴, ¹Gustave Roussy, Villejuif, FR, ²Università degli Studi di Napoli Federico II, Napoli, IT, ³Unimol - Università degli Studi del Molise, Campobasso, IT, ⁴Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ⁵Università degli Studi di Napoli Federico II - Scuola di Medicina e Chirurgia, Napoli, IT, ⁶Gustave Roussy - Cancer Campus, Villejuif, FR
- 10:11 - 10:12 **259P - Efficacy of eribulin mesylate in HER2-low metastatic breast cancer (MBC): Results from three phase III studies**
- P. Kaufman¹, C. Twelves², A. Awada³, S.-A. Im⁴, L. Vahdat⁵, B. Xu⁶, P. Yuan⁶, W. Hauck⁷, R. Xie⁷, B. Lalayan⁷, J. Cortés⁸, ¹University of Vermont Cancer Center, Burlington, US, ²University of Leeds and Leeds Teaching Hospitals Trust, Leeds, GB, ³Institut Jules Bordet, Université Libre de Bruxelles, Brussels, BE, ⁴Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, ⁵Dartmouth Cancer Center, Lebanon, US, ⁶National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ⁷Eisai Inc., Nutley, US, ⁸International Breast Cancer Center (IBCC), Madrid & Barcelona, ES
- 10:12 - 10:13 **260P - Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial**
- N. Epailard¹, A. Lusque², B. Pistilli³, F. André⁴, T. Bachelot⁵, J.-Y. Pierga⁶, A. Ducoulombier⁷, C. Jouannaud⁸, F. Viret⁹, L. Salabert¹⁰, A. Johnson¹¹, E. Deluche¹², X. Durando¹³, T. Petit¹⁴, T. Filleron², C. Mahier Ait Oukhatar¹⁵, V. Dieras¹⁶, M.F. Mosele⁴, ¹Institut Gustave Roussy, Villejuif, FR, ²Institut Claudius Regaud, Toulouse, FR, ³Institut Gustave Roussy, Villejuif, Cedex, FR, ⁴Gustave Roussy - Cancer Campus, Villejuif, FR, ⁵Centre Léon Bérard, Lyon, FR, ⁶Institut Curie, Paris, FR, ⁷Centre Anticancer Antoine Lacassagne, Nice, FR, ⁸Institut Jean Godinot, Reims, FR, ⁹IPC - Institut Paoli-Calmettes,

Marseille, FR, ¹⁰Institute Bergonié, Bordeaux, FR, ¹¹Centre Francois Baclesse, Caen, FR, ¹²CHU Limoges - Hopital Dupuytren, Limoges, FR, ¹³Jean Perrin Center, Clermont-Ferrand, FR, ¹⁴Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, ¹⁵UNICANCER, Paris, FR, ¹⁶Centre Eugene - Marquis, Rennes, FR

- 10:13 - 10:14 **261P - Liquid biopsy-based biomarkers for the characterization of hormone receptor-positive (HR⁺) HER2-Low metastatic breast cancer (mBC)**
 L. Bortot¹, D. Basile², L. Palmero¹, A. Dri¹, L. Cucciniello¹, S. Buriolla¹, B. Pastò¹, R. Mazzeo¹, M. Bonotto³, S. Bolzonello⁴, A. Franzoni⁵, L. Allegri⁵, B. Belletti⁶, G. Damante¹, L. Gerratana⁴, A.M. Minisini³, F. Puglisi¹, ¹University of Udine, Udine, IT, ²San Giovanni di Dio Hospital, Crotone, IT, ³Santa Maria della Misericordia Academic Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, IT, ⁴Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, IT, ⁵Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, IT, ⁶Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, IT
- 10:14 - 10:15 **262P - Niraparib plus aromatase inhibitors (AI) for germinal mutated BRCA1/2 (gBRCAm) or homologous recombination-deficient (HRd), hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR⁺/HER2-) advanced breast cancer (ABC): LUZERN interim analysis**
 I. Pimentel¹, L. Lema Roso², M. Ramos Vazquez³, J.Á. García Saenz⁴, P. Palacios-Ozores⁵, J. De La Haba Rodriguez⁶, S. Blanch⁷, A. Prat⁸, J.E. Ales Martínez⁹, E. Alba Conejo¹⁰, J. Balmaña¹¹, J.M. Perez Garcia¹², M. Sampayo-Cordero¹³, A. Malfettone¹⁴, J. Cortés¹⁵, A. Llombart Cussac¹⁶, ¹Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ²Hospital Universitario 12 de Octubre, Madrid, ES, ³Centro Oncologico de Galicia, A Coruña, ES, ⁴Hospital Clinico Universitario San Carlos, Madrid, ES, ⁵CHUS - Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, ⁶Hospital Universitario Reina Sofía, Cordoba, ES, ⁷IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, ⁸Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁹Hospital Nuestra Señora de Sonsoles, Ávila, ES, ¹⁰Hospital Universitario Virgen de la Victoria, Malaga, ES, ¹¹Hospital General Vall d'Hebron, Barcelona, ES, ¹²International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, ES, ¹³MEDSIR - Medica Scientia Innovation Research, Barcelona, ES, ¹⁴Medica Scientia Innovation Research, Barcelona, ES, ¹⁵International Breast Cancer Center (IBCC), Quiron Group, Barcelona, ES, ¹⁶Hospital Arnau de Vilanova, Valencia, ES
- 10:15 - 10:16 **263P - Clinical outcomes in patients with germline pathogenic variants in homologous recombination repair (HRR) genes treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET)**
 A. Rodriguez Hernandez¹, O. Martinez Saez², F. Brasó-Maristany³, B. Pastor², M. Potrony⁴, L. Moreno², E. Grau², J. Puig-Butille¹, A. Sánchez², F. Schettini⁵, B. Conte⁶, N. Chic¹, M.J. Vidal Losada², M. Munoz², F. Balaguer², A. Prat⁷, B. Adamo¹, ¹Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ²Hospital Clinic of Barcelona, Barcelona, ES, ³IDIBAPS - Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES, ⁴IDIBAPS, Barcelona, ES, ⁵IDIBAPS - August Pi i Sunyer Biomedical Research Institute, Barcelona, ES, ⁶IRCCS Ospedale Policlinico San Martino, Genova, IT, ⁷Translational Genomics and Targeted Therapies in Solid Tumors, Barcelona, ES

- 10:16 - 10:17 **264P - Increased membrane HER3 expression in brain metastases compared to primary tumors in breast cancer**
S. Kusuhara¹, T. Kogawa¹, M. Shimokawa², C. Funasaka¹, C. Kondoh¹, K. Harano¹, N. Matsubara¹, Y. Naito¹, A. Hosono¹, K. Satomi³, M. Yoshida³, S. Fujii⁴, T. Ohnishi¹, A. Suto⁵, K. Yonemori⁶, K. Koyama⁷, N. Maeda⁷, Y. Narita³, T. Mukohara¹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Yamaguchi University Graduate School of Medicine, Ube, JP, ³National Cancer Center - Tsukiji Campus, Chuo-ku, JP, ⁴Yokohama City University Hospital, Yokohama, JP, ⁵National Cancer Center Hospital, Tokyo, JP, ⁶National Cancer Center Hospital, Chuo-ku, JP, ⁷Daiichi Sankyo Co., Ltd. - Shinagawa R&D Center, Tokyo, JP
- 10:17 - 10:18 **265P - Phase II study of DHP107 oral paclitaxel compared to IV paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer (MBC): Opera (NCT03326102)**
H. Rugo¹, T. Pluard², P. Sharma³, M. Melisko¹, G. Al-Jazayrly⁴, Y. Ji⁵, N. Vidula⁶, J. Ellerton⁷, M. Smakal⁸, M. Zimovjanova⁹, D. Weng¹⁰, K.E. Yoon¹¹, H.J. Cho¹¹, ¹University of California San Francisco, San Francisco, US, ²Saint Luke's Hospital of Kansas City - Saint Luke's Health System, Kansas City, US, ³University of Kansas Medical Center, Westwood, US, ⁴HPMC - Hollywood Presbyterian Medical Center, Los Angeles, US, ⁵University of Minnesota, Minneapolis, US, ⁶Massachusetts General Hospital - Surgical Oncology Division, Boston, US, ⁷Nevada NCORP, Las Vegas, US, ⁸Hospital Horovice, a.s., Horovice, CZ, ⁹General Teaching Hospital and The First Faculty of Medicine of Charles University in Prague, Prague, CZ, ¹⁰Anne Arundel Medical Center, Annapolis, US, ¹¹Daehwa Pharmaceutical Co., Ltd., Seoul, KR
- 10:18 - 10:19 **266P - Real-world quality of life (QoL) in patients with HR⁺/HER2-advanced breast cancer (ABC) treated with palbociclib: Final clinical outcome assessment (COA) analysis from POLARIS**
G. Rocque¹, J. Blum², Y. Ji³, T. Pluard⁴, J. Migas⁵, S. Lakhanpal⁶, E. Jepsen⁷, E. Gauthier⁸, Y. Wang⁹, M. Montelongo¹⁰, J. Cappelleri¹¹, M. Karuturi¹², D. Tripathy¹², ¹University of Alabama at Birmingham, Birmingham, US, ²Texas Oncology, Dallas, US, ³HealthPartners, St. Paul, US, ⁴Saint Luke's Cancer Institute, Kansas City, US, ⁵Mid-Illinois Hematology and Oncology Associates, Ltd, NORMAL, US, ⁶St. Vincent's Birmingham, Birmingham, US, ⁷Novant Health Cancer Institute, Winston-Salem, US, ⁸Pfizer Inc, San Francisco, US, ⁹Pfizer Inc, New York, US, ¹⁰ICON plc, Blue Bell, US, ¹¹Pfizer Inc., Groton, US, ¹²The University of Texas MD Anderson Cancer Center, Houston, US
- 10:19 - 10:20 **267P - AB-ITALY: The impact of drug-drug interaction on abemaciclib treatment in Italian real world experience**
A. Botticelli¹, S. Scagnoli¹, S. Pisegna¹, A. Toss², A. Fabi³, C. Criscitiello⁴, G. D'Auria⁵, M.A. Fabbri⁶, A. Orlandi³, V. Barberi⁷, R. Caputo⁸, P. Vici⁹, M. Palleschi¹⁰, D. Santini¹¹, G. Tomasello¹², E. Ricevuto¹³, M. Simmaco¹⁴, R. Preissner¹⁵, E. Cortesi¹⁶, P. Marchetti¹⁷, ¹Sapienza University of Rome, Rome, IT, ²Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ³Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ⁴IEO - Istituto Europeo di Oncologia, Milan, IT, ⁵ASL Roma 2 Ospedale Pertini - S Eugenio, Rome, IT, ⁶Ospedale Belcolle - ASL Viterbo, Viterbo, IT, ⁷Università degli Studi di Roma la Sapienza, Latina, IT, ⁸Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ⁹IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT, ¹⁰IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS S.r.l., Meldola,

IT, ¹¹Policlinico Universitario Campus Bio-Medico, Rome, IT, ¹²Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Milan, IT, ¹³Ospedale San Salvatore dell'Aquila, L'Aquila, IT, ¹⁴Azienda Ospedaliera Sant'Andrea, Rome, IT, ¹⁵Charité - Universitaetsmedizin Berlin, Berlin, DE, ¹⁶Sapienza - Università di Roma, Rome, IT, ¹⁷IRCCS Istituto Dermatologico dell'Immacolata IDI, Rome, IT

10:20 - 10:21

268P - Results from a real-world study of patients (pts) with hormone-receptor (HR)-positive HER2-negative metastatic breast cancer (MBC) treated with CDK4/6 inhibitors (CDK 4/6i) in three institutions

H. Pla¹, S. Recalde Penabad², G. Vinas Villaro¹, M. Margeli Vila³, V.L. Obadia Gil², B. Cirauqui Cirauqui³, S. Del Barco Berron¹, M. Gil², V. Quiroga Garcia³, I. Teruel-Garcia³, S. Pernas Simon², A. Stradella², A.M. Esteve Gomez³, E. Felip³, ¹ICO Girona - Institut Català d'Oncologia Girona (Hospital Josep Trueta), Girona, ES, ²ICO Hospitalet - Institut Català d'Oncologia (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ³ICO Badalona - Institut Català d'Oncologia (Hospital Universitario Germans Trias i Pujol), Badalona, ES

10:21 - 10:22

269P - Long-term survival of HER2-positive breast cancer patients with brain metastases: Subanalysis of the BMBC registry

E. Laakmann¹, K. Riecke¹, T. Neunhöffer², T.-W. Park-Simon³, R. Weide⁴, A. Polasik⁵, M. Schmidt⁶, J. Puppe⁷, P.A. Fasching⁸, T. Hesse⁹, T. Decker¹⁰, C. Denkert¹¹, T. Fehm¹², V. Nekljudova¹³, J. Rey¹³, S. Loibl¹⁴, V. Mueller¹, I. Witzel¹, ¹University Medical Center Hamburg-Eppendorf, Hamburg, DE, ²Helios Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, DE, ³MHH - Medizinische Hochschule Hannover, Hannover, DE, ⁴Institut für Versorgungsforschung in der Onkologie, Koblenz, DE, ⁵Universitätsfrauenklinik Ulm, Ulm, DE, ⁶Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, ⁷Gynecology and Obstetrics University Hospital of Cologne, Köln, DE, ⁸Universitätsklinikum Erlangen, Erlangen, DE, ⁹Agaplesion Diakonieklinikum Rotenburg GmbH, Rotenburg an der Wümme, DE, ¹⁰Onkologie Hamatologie Ravensburg, Ravensburg, DE, ¹¹UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE, ¹²Heinrich-Heine-University Düsseldorf, Düsseldorf, DE, ¹³GBG Forschungs GmbH, Neu-Isenburg, DE, ¹⁴German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

10:22 - 10:23

270P - Defining clinico-pathological characteristics of HER2 positive metastatic breast cancer (MBC) patients experiencing radiologic complete response (rCR) in a nationwide real-world cohort

L. Cucciniello¹, E. Blondeaux², C. Bighin², M.S. Gasparro³, S. Russo⁴, A. Dri¹, P. Pugliese⁵, A. Fontana⁶, G. Naso⁷, A. Ferzi⁸, F. Riccardi⁹, V. Sini¹⁰, A. Fabi¹¹, F. Montemurro¹², M. De Laurentiis¹³, G. Arpino¹⁴, L. Del Mastro¹⁵, L. Gerratana¹⁶, F. Puglisi¹⁷, ¹University of Udine, Udine, IT, ²IRCCS Ospedale Policlinico San Martino, Genova, IT, ³IRCCS Regina Elena National Cancer Institute (IRE), Rome, IT, ⁴ASUIUD - Azienda Sanitaria Universitaria Integrata di Udine, Udine, IT, ⁵Poliambulatorio di Via Napoleona - Como, Como, IT, ⁶Azienda Ospedaliero Universitaria Pisana - Stabilimento di Santa Chiara, Pisa, IT, ⁷Policlinico Umberto I - Università La Sapienza, Roma, Rome, IT, ⁸Mater Salutis Hospital Legnano, Legnano, IT, ⁹Università degli Studi di Napoli Federico II, Napoli, IT, ¹⁰ASL Roma1, Rome, IT, ¹¹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ¹²IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, ¹³Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ¹⁴Università degli Studi della

Campania Luigi Vanvitelli, Napoli, IT, ¹⁵Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genoa, Genova, IT, ¹⁶CRO Aviano - Centro di Riferimento Oncologico - IRCCS, Aviano, IT, ¹⁷Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, IT

- 10:23 - 10:24 **271P - Eribulin (E) plus endocrine therapy (ET) in patients (pts) with HR[+]/HER2[-] metastatic breast cancer (mBC) after progression on previous ET: The REVERT study**
- A. Lopez Gonzalez¹, S. Del Barco Berron², I. Garau Llinas³, M. Galan Gramaje³, B. Castelo⁴, A. Cortes Salgado⁵, P. Sanchez-Rovira⁶, A. Martinez Bueno⁷, A. García⁸, P. Gener⁸, L. Mina⁸, D. Alcalá⁸, M. Sampayo-Cordero⁸, J. Cortés⁹, J.M. Perez Garcia¹⁰, A. Llombart Cussac¹¹, E. Lopez Miranda⁵, ¹Complejo Asistencial Universitario de León - Hospital de León, León, ES, ²Fundació Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Salt, ES, ³Hospital Son Llatzer, Palma de Mallorca, ES, ⁴Hospital Universitario La Paz, Madrid, ES, ⁵Hospital Universitario Ramon y Cajal, Madrid, ES, ⁶Hospital Universitario de Jaén, Jaén, ES, ⁷Instituto Universitario Dexeus, Barcelona, ES, ⁸MEDSIR - Medica Scientia Innovation Research, Barcelona, ES, ⁹International Breast Cancer Center (IBCC), Quiron Group, Madrid & Barcelona, Barcelona, ES, ¹⁰International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, ES, ¹¹Hospital Arnau de Vilanova, Valencia, ES
- 10:24 - 10:25 **272TiP - HARMONIA SOLTI-2101 / AFT-58: A head-to-head phase III study comparing ribociclib (RIB) and palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+)/HER2-/HER2-E) advanced breast cancer (ABC)**
- T. Pascual¹, D. Stover², A. Thuerigen³, C. Perou⁴, E. Ciruelos⁵, A. Casas Fernandez Tejerina¹, P. Spears⁶, E. Roux⁷, H. Hu⁸, Y.-S. Lu⁹, S. Tolaney¹⁰, A. Partridge¹⁰, G. Villacampa Javierre¹¹, J. Ferrero Cafiero¹, L. Carey¹², A. Prat¹³, ¹SOLTI HQ, Barcelona, ES, ²Stefanie Spielman Comprehensive Breast Center, Columbus, US, ³Novartis Pharma AG, Basel, CH, ⁴UNC - Lineberger Comprehensive Cancer Center, Chapel Hill, US, ⁵SOLTI / Hospital Universitario 12 de Octubre, Madrid, ES, ⁶UNC - Lineberger Cancer Center, Chapel Hill, US, ⁷Novartis Pharmaceuticals Corporation, East Hanover, US, ⁸Novartis Pharmaceuticals Corp., East Hanover, US, ⁹NTUH - National Taiwan University Hospital, Taipei City, TW, ¹⁰Dana Farber Cancer Institute, Boston, US, ¹¹SOLTI / Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ¹²Alliance Breast Committee / UNC - Lineberger Comprehensive Cancer Center, Chapel Hill, US, ¹³SOLTI / IDIBAPS/ Hospital Clinic of Barcelona, Barcelona, ES
- 10:25 - 10:26 **273TiP - ACE-Breast-03: A phase II study patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens treated with ARX788**
- S. Hurvitz¹, K. Kalinsky², D. Tripathy³, G. Sledge⁴, W. Gradishar⁵, J. O'Shaughnessy⁶, S. Modi⁷, H. Park⁸, A. McCartney⁹, S. Frentzas¹⁰, C. Shannon¹¹, K. Cuff¹², R. Eek¹³, M. Martin Jimenez¹⁴, G. Curigliano¹⁵, G. Jerusalem¹⁶, C. Huang¹⁷, M. Press¹⁸, J. Lu¹⁹, ¹UCLA Hematology/Oncology Santa Monica, Santa Monica, US, ²Columbia University Vagelos College of Physicians and Surgeons, New York, US, ³The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁴Stanford University, Stanford, US, ⁵Northwestern University Feinberg School of Medicine, Chicago, US, ⁶Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, ⁷Memorial Sloan Kettering Cancer Center,

New York, NY, US, ⁸Washington University School of Medicine, St. Louis, US, ⁹Monash Health - Monash Medical Centre, Clayton, AU, ¹⁰Monash Health - Monash Cancer Centre, Bentleigh East, AU, ¹¹Mater Cancer Care Centre, Brisbane, AU, ¹²Princess Alexandra Hospital, Brisbane, AU, ¹³Border Medical Oncology Murray Valley Private Hospital, Wodonga, AU, ¹⁴Hospital General Universitario Gregorio Marañón, Madrid, ES, ¹⁵IEO - Istituto Europeo di Oncologia, Milan, IT, ¹⁶Centre Hospitalier Universitaire Sart Tilman, Liège, BE, ¹⁷NTUH - National Taiwan University Hospital, Taipei City, TW, ¹⁸Keck School of Medicine - University of Southern California USC, Los Angeles, US, ¹⁹USC - University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, US

- 10:26 - 10:27 **274TiP - Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigator's choice of chemotherapy (ICC) in previously-treated, inoperable or metastatic hormone-receptor (HR) positive, HER2-negative (HR⁺/HER2⁻) breast cancer: TROPION-Breast01**
A. Bardia¹, K. Kalinsky², J. Tsurutani³, E. Hamilton⁴, S. Johnston⁵, J. Sohn⁶, K.H. Park⁷, Y.H. Park⁸, S.-A. Im⁹, K.S. Lee¹⁰, D. Dastur¹¹, V. Haddad¹², S. Khan¹³, B. Xu¹⁴, B. Pistilli¹⁵, H. Rugo¹⁶, ¹Massachusetts General Hospital Cancer Center, Boston, US, ²Winship Cancer Institute at Emory University, Atlanta, US, ³Showa University Hospital, Tokyo, JP, ⁴Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, ⁵Royal Marsden Hospital, London, GB, ⁶Yonsei University College of Medicine, Seoul, KR, ⁷Korea University Anam Hospital, Seoul, KR, ⁸Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁹Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, ¹⁰National Cancer Center, Goyang, KR, ¹¹AstraZeneca Canada, Inc., Missauga, CA, ¹²AstraZeneca, Cambridge, GB, ¹³AstraZeneca, Gaithersburg, US, ¹⁴National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Beijing, CN, ¹⁵Institut Gustave Roussy, Villejuif, FR, ¹⁶University of California San Francisco Comprehensive Cancer Center, San Francisco, US
- 10:27 - 10:28 **275TiP - ASCENT-03: Phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC)**
A. Bardia¹, K. Punie², C. Barrios³, A. Schneeweiss⁴, X. Zhai⁵, D. Huynh⁵, N. Vaksman⁵, C. Lai⁵, S. Tolaney⁶, ¹Harvard Medical School, Boston, US, ²Leuven, Leuven, BE, ³São Lucas, Porto Alegre, BR, ⁴and German Cancer Research Center, Heidelberg, DE, ⁵Inc., Foster City, US, ⁶Cancer Institute, Boston, US
- 10:28 - 10:29 **276TiP - ASCENT-04/KEYNOTE-D19: Phase III study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician's choice (TPC) plus pembro in first-line (1L) programmed death-ligand 1-positive (PD-L1⁺) metastatic triple-negative breast cancer (mTNBC)**
S. Tolaney¹, E. De Azambuja², L. Emens³, S. Loi⁴, W. Pan⁵, J. Huang⁶, S. Sun⁶, C. Lai⁶, P. Schmid⁷, ¹Cancer Institute, Boston, US, ²Jules Bordet, Brussels, BE, ³Medical Center, Pittsburgh, US, ⁴Division of Cancer Research, Melbourne, AU, ⁵Corporation Inc., Rahway, US, ⁶Inc., Foster City, US, ⁷Hospital, London, GB
- 10:29 - 10:30 **290P - Potential enrichment strategies for next-generation sequencing (NGS) in primary brain cancers (pBCs) in a clinical series according to ESMO scale for clinical actionability of molecular targets (ESCAT)**

O. Mirallas¹, D. López Valbuena¹, J. Yaringaño¹, B. Martin Cullell², D. Illescas¹, S. Aguilar Izquierdo¹, E. Martínez-Sáez³, A. Pedrola⁴, A. Vivancos¹, N. Saoudi Gonzalez¹, F.J. Ros Montana¹, M. Gonzalez Rodriguez¹, R. Dienstmann⁵, J. Mateo¹, J. Tabernero¹, E. Garralda¹, J. Carles Galceran⁶, M. Vieito Villar¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ³Hospital Universitario Vall d'Hebron, Barcelona, ES, ⁴Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁵Grupo Oncoclinicas, Sao Paulo, BR, ⁶Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES

10:30 - 10:31 **291P - Prognosis of glioblastoma according to different TERT promoter mutations**

A. Hernandez Gonzalez¹, C. Sanz², C. Mariño Siancas³, M. Domenech Vinolas¹, G. Parra⁴, A.M. Esteve³, C. Carrato², B. Melendez⁵, A. Esteve Codina⁴, A. Martinez-Cardús⁶, F. Alameda⁷, E. Pineda⁸, A. Muñoz², R. Lopez², C. Balana¹, ¹Institut Catala d'Oncologia Badalona, Badalona, ES, ²Hospital Universitari Germans Trias i Pujol, Badalona, ES, ³Hospital Germans Trias i Pujol, Badalona, ES, ⁴Barcelona Institute of Science and Technology, Barcelona, ES, ⁵Hospital Universitario de Toledo, Toledo, ES, ⁶Badalona-Applied Research Group in Oncology (B-ARGO, Badalona, ES, ⁷Hospital del Mar - Parc de Salut Mar, Barcelona, ES, ⁸Hospital Clinic de Barcelona, Barcelona, ES

10:31 - 10:32 **292P - Androgen receptor signalling is associated with resistance to temozolomide and tumour growth in glioblastoma**

C. Birzu¹, J. Boussier², L. Belin³, N. Lemaire⁴, T. Da Costa Pereira⁴, K. Mokhtari⁵, M. Verreault⁶, A. Idbaih¹, ¹AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Département de Neurologie, Paris, FR, ²Hopital Pitié Salpêtrière - Hopitaux Universitaires Pitié Salpêtrière - Charles Foix AP-HP, Paris, FR, ³INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Unité de Recherche Clinique PSL-CFX, CIC-1901, Paris, FR, ⁴Paris Brain Institute, Paris, FR, ⁵AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Département de Neuropathologie, Paris, FR, ⁶Hopital Pitié Salpêtrière AP-HP, Paris, FR

10:32 - 10:33 **293P - Molecular biomarkers correlation in symptomatic tumor-related epilepsy: A preliminary study on 151 cases of brain tumors**

E. Cella¹, S. Mambriani², A. Donniaquio¹, F. Hasanzadeh², P. Nozza¹, E. Bennicelli³, D. Arnaldi¹, ¹IRCCS Ospedale Policlinico San Martino, Genova, IT, ²Università di Genova, Genova, IT, ³Ospedale Policlinico San Martino, Genova, IT

10:33 - 10:34 **294P - Adult population with BRAF-mutated (BRAFmut) and NF1-mutated (NF1mut) gliomas. Analysis of the potential role of targeted therapy (TT) in these patients (pts)**

M.J. Lostes Bardaji¹, M. Rezaqallah Aron², M. Gonzalez Rodriguez², G. Villacampa Javierre³, E. Martinez Saez⁴, C. Auger⁴, X. Maldonado⁵, F. Martinez Ricarte⁴, J. Tabernero⁶, J. Carles Galceran², E. Garralda², M. Vieito Villar⁶, ¹Vall d'Hebron Institute of Oncology (VHIO). Vall D'Hebron, Barcelona, ES, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁴Hospital Universitari Vall d'Hebron,, Barcelona, ES, ⁵Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁶Vall d'Hebron University Hospital, BARCELONA, ES

10:34 - 10:35	<p>295P - PIK3CA in Asia: A landscape analysis of 1974 Chinese glioma samples</p> <p><u>Y. Gao</u>¹, D. Guo², S. Chen², T. Han², Y. Zhao², J. Ma², G. Lu², W. Deng², R. Ding³, F. Bu³, ¹The Fourth Affiliated Hospital of China Medical University, Shenyang city, CN, ²Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, CN, ³Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, CN</p>
10:35 - 10:36	<p>296P - Isocitrate dehydrogenase mutation and risk of venous thromboembolism in glioma: A systematic review and meta-analysis</p> <p><u>S.K. Low</u>, Z. Anjum, U. Joshi, A. Mahmoud, P. Kouides, Rochester General Hospital, Rochester, US</p>
10:36 - 10:37	<p>297P - The genetic profile of primary and recurrent gliomas: A mono-institutional experience using next-generation sequencing</p> <p><u>M. Padovan</u>, M. Maccari, S. Vizzaccaro, I. Cestonaro, A. Bosio, V. Zagonel, G. Lombardi, Veneto Institute of Oncology IOV-IRCCS, Padova, IT</p>
10:37 - 10:38	<p>298P - Stable, controllable, and scalable manufacturing of B7-H3 UCAR-T, an allogeneic CAR-T product for advanced glioma, from healthy donors</p> <p><u>H. Jiang</u>, D. Wang, J. Li, X. Shang, JIANGSU T-MAXIMUM BIOTECH CO., LTD., Suzhou, CN</p>
09:00 - 15:00	<p>Type: Poster session Title: Poster session 04</p> <p style="text-align: right;">Poster Area, Hall 4</p>
09:00 - 09:01	<p>878P - Improved proteome coverage for cancer plasma-derived extracellular vesicles (pEVs) using high-resolution isoelectric focusing (HiRIEF) LC-MS</p> <p><u>N. Sharma</u>¹, G. Mermelekas², J. Lehtiö³, O. Wiklander⁴, A. Gorgens², S. Andaloussi², M. Pernemalm², H. Eriksson⁴, ¹Karolinska Institute, Solna, Stockholm, SE, ²Karolinska Institute, Stockholm, SE, ³Karolinska Institutet, Huddinge, SE, ⁴Karolinska University Hospital-Solna, Solna, SE</p>
09:01 - 09:02	<p>879P - Whole-genome landscape of head and neck melanomas in East Asia (China)</p> <p><u>X. Wang</u>¹, W. Wu², X. Wu¹, L. Si¹, Z. Chi¹, X. Sheng¹, L. Li², W. Han², H. Li², B. Lian¹, L. Zhou¹, L. Mao¹, X. Bai¹, T. Bixia¹, X. Wei¹, C.-L. Cui¹, Y. Kong¹, J. Guo¹, ¹Peking University Cancer Hospital and Institute, Beijing, CN, ²Berry Oncology Corporation, Fuzhou, CN</p>
09:02 - 09:03	<p>880P - Phase II trial of the cyclin dependent kinase 4/6 inhibitor SHR6390 in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification</p> <p><u>C. Shi</u>¹, J. Houyu¹, R. Zhou¹, Y. Wu¹, H. Li², Y. Wang², S. Xu¹, Z. Gu¹, J. Li¹, Z. Zhang¹, G. Ren¹, ¹Shanghai Ninth People's Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, CN, ²Jiangsu Hengrui pharmaceuticals Co., Ltd., Shanghai, CN</p>
09:03 - 09:04	<p>881TiP - NEOplus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma</p>

L. Mao, X. Bai, X. Wei, J. Dai, C.-L. Cui, Z. Chi, X. Sheng, B. Lian, X. Wang, T. Bixia, L. Si, J. Guo, Peking University Cancer Hospital and Institute, Beijing, CN

- 09:04 - 09:05 **882TiP - Subcutaneous vs intravenous nivolumab in patients with melanoma following complete resection**
P. Ascierto¹, P. Mohr², R. Dronca³, S. Harris⁴, M. Wilson⁵, B. Gurm⁶, M. Howansky⁷, W.-T. Ng⁸, S. Ravimohan⁶, H. Vezina⁶, M. Pe Benito⁶, P. Gurman⁶, ¹Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Napoli, IT, ²Dermatologic Center Buxtehude, Buxtehude, DE, ³Mayo Clinic, Jacksonville, US, ⁴Bendigo Health, Bendigo, AU, ⁵St. Luke's University Health Network, Easton, US, ⁶Bristol Myers Squibb, Princeton, US, ⁷Bristol Myers Squibb, New Brunswick, US, ⁸Bristol Myers Squibb, Boudry, Neuchâtel, CH
- 09:05 - 09:06 **883TiP - A phase I/II open-label study (IOV-GM1-201) of TALEN-mediated PD-1 inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC**
J. Chesney¹, T. Wise-Draper², A. Sarnaik³, F. Graf Finckenstein⁴, P. Hari⁴, M. Jagasia⁴, A. Desai⁴, A. Suzuki⁴, X. Wu⁴, A. Betof Warner⁵, ¹Brown Cancer Center University of Louisville, Louisville, US, ²Vontz Center for Molecular Studies, Cincinnati, US, ³H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ⁴Iovance Biotherapeutics, San Carlos, US, ⁵Memorial Sloan Kettering Cancer Center, New York, US
- 09:06 - 09:07 **884TiP - A phase Ib/II multicenter, randomized, umbrella study evaluating novel treatment combinations in melanoma (MORPHEUS-MELANOMA)**
G. Long¹, R. Amaria², A. Tarhini³, P. Ascierto⁴, E. Cha⁵, O. Cirovic⁶, D. Cotting⁶, V. Teichgräber⁶, C. Blank⁷, ¹Melanoma Institute Australia, Wollstonecraft, AU, ²University of Texas MD Anderson Cancer Center, Houston, US, ³H. Lee Moffitt Cancer Center and Research Institute, Tampa, US, ⁴Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, IT, ⁵Genentech, Inc., South San Francisco, US, ⁶F. Hoffmann-La Roche AG, Basel, CH, ⁷The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 09:07 - 09:08 **886TiP - Recombinant human adenovirus type 5 combined with anti-PD-1 monoclonal antibody in the treatment of patients with advanced melanoma with previous immunotherapy failure: A single-site, single-arm, prospective study**
J. Lin, B. Lan, L. Chen, L. Chen, Y. Huang, M. You, J. Liu, J. Xiong, H. Zhang, Y. Chen, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, CN
- 09:08 - 09:09 **934P - Clinical and genomic characteristics of non-small cell lung cancer in young patients under 40 years old**
T. Yao, C. Chen, Y. Fenglei, L. Wenliang, L. Guangjun, H. Xiaojie, The Second Xiangya Hospital of Central South University, Changsha, CN
- 09:09 - 09:10 **935P - Demographics, clinical characteristics, treatment patterns and clinical outcomes of patients with stages I-III resected NSCLC without known EGFR mutations**
N. Altorki¹, R. Salomonsen², N. Georgoulia², I. Diaz Perez², A. Wang², L. Cai², G. Wetherill³, Y. Xiao², C. Fielden³, J.E. Gray⁴, ¹Weill Cornell Medicine, New York, US,

²AstraZeneca, Gaithersburg, US, ³AstraZeneca, Cambridge, GB, ⁴H. Lee Moffitt Cancer Center and Research Institute, Tampa, US

09:10 - 09:11 **936P - Analysis of different EGFR mutations affecting the efficacy of postoperative adjuvant therapy for resectable non-small cell lung cancer**

C. Xu¹, H. Zhang², D. Liu³, ¹GuiZhou Provincial People's Hospital, Guiyang, CN, ²The Medical Department, 3D Medicines Inc., Shanghai, 201114, PR China, Shanghai, CN, ³Guizhou Provincial People's Hospital, Guiyang, CN

09:11 - 09:12 **937P - Incidence and outcomes of EGFR mutated non-small cell lung cancer treated with surgery: EXERPOS GFPC study**

J.B. Auliac¹, Y. Simmoneau², P. Thomas³, F. Guisier⁴, O. Bylicki⁵, H. Curcio⁶, A. Swalduz⁷, M. Wislez⁸, M. Geier⁹, J. Letreut¹⁰, C. Decroisette¹¹, L. Falchero¹², J. Tricard², D. Moreau¹³, E. Huchot¹⁴, G. De Chabot¹⁵, K. Leroy¹⁶, A. Lupo Mansuet¹⁷, C. Chouaid¹⁸, L. Greillier¹⁹, ¹CHI - Centre Hospitalier Intercommunal de Créteil, Créteil, Cedex, FR, ²CHU Limoges - Hopital Dupuytren, Limoges, FR, ³Assistance Publique Hopitaux de Marseille, Marseille, FR, ⁴CHU Rouen, Rouen, FR, ⁵Hopital d'instruction des armées Sainte-Anne, Toulon, FR, ⁶Centre Francois Baclesse, Caen, FR, ⁷Comprehensive Cancer Centre Léon Bérard, Lyon, FR, ⁸Hopital Tenon AP-HP, Paris, Cedex, FR, ⁹CHRU Morvan Brest, Brest, FR, ¹⁰Hopital Européen Marseille, Marseille, FR, ¹¹Le Centre Hospitalier Annecy Genevois, Metz-Tessy, FR, ¹²Hospital Center De Villefranche-Sur-Saône, Gleizé, FR, ¹³Centre Hospitalier Universitaire Felix-Guyon, Saint DENIS, FR, ¹⁴Centre Hospitalier Universitaire de Saint Pierre de la Réunion, Saint-Pierre, RE, ¹⁵Centre Hospitalier Bretagne Atlantique, Vannes, FR, ¹⁶HEGP Biochimie, Paris, FR, ¹⁷Hopital Cochin AP-HP, Paris, FR, ¹⁸CH Intercommunal de Créteil, Créteil, FR, ¹⁹Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR

09:12 - 09:13 **939P - Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial**

M. Casarrubios¹, A. Cruz-Bermudez¹, B. Sierra-Rodero¹, C. Martinez¹, E. Nadal², M.A. Insa Molla³, J. Mosquera Martinez⁴, C. Gonzalez Ojea⁵, M. Domine Gomez⁶, M. Majem Tarruella⁷, D. Rodriguez Abreu⁸, A. Martinez-Marti⁹, J. De Castro Carpeno¹⁰, M. Cobo Dols¹¹, G. Lopez Vivanco¹², R. Bernabe Caro¹³, N. Vinolas Segarra¹⁴, I.C. Barneto Aranda¹⁵, B. Massuti Sureda¹⁶, M. Provencio Pulla¹, ¹Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda, Majadahonda, ES, ²ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ³Hospital Clinico Universitario de Valencia, Valencia, ES, ⁴CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, ⁵Hospital Universitario Alvaro Cunqueiro, Vigo, ES, ⁶Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁸Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, ES, ⁹Vall d'Hebron University Hospital, Barcelona, ES, ¹⁰Hospital Universitario La Paz, Madrid, ES, ¹¹Hospital Regional Universitario Málaga Carlos Haya, Malaga, ES, ¹²Hospital de Cruces, Barakaldo, ES, ¹³Hospital Universitario Virgen del Rocio, Seville, ES, ¹⁴Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ¹⁵Hospital Universitario Reina Sofía, Cordoba, ES, ¹⁶Hospital General Universitario de Alicante, Alicante, ES

09:13 - 09:14 **940P - Programmed death-ligand 1 (PDL1) expression and real-world outcomes**

in resected, early-stage non-small cell lung cancer (NSCLC)

P. Cheema¹, I. Syed², F. Gwadry-Sridhar³, M. Rakibuz-Zaman³, R. Sachdeva⁴, A. Pencz⁴, L.J. Zhan⁵, K. Hueniken⁵, D. Patel⁵, K. Balaratnam⁵, K. Khan⁵, B. Grant⁵, S. Noy¹, K. Singh¹, B.S. Sheffield¹, B. Locke³, D. Moldaver², M.K. Shanahan², G. Liu⁶, M. Kuruvilla⁷,
¹William Osler Health System - Brampton Civic Hospital, Brampton, CA, ²AstraZeneca Canada, Inc., Mississauga, CA, ³Pulse Infoframe Inc., London, CA, ⁴London Health Sciences Centre, London, CA, ⁵Princess Margaret Cancer Centre, Toronto, CA, ⁶UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ⁷London Health Sciences Centre, London, CA

09:14 - 09:15

941P - PET-derived parameters for response assessment in neoadjuvant atezolizumab: A secondary analysis of PRINCEPS phase II trial

F. Dall'Olio¹, L. Mabile², C. Garcia³, J. Adam¹, M.R. Ghigna⁴, N. Cozic⁴, C. Caramella⁵, N. Chaput-Gras¹, D. Planchard¹, L. Mezquita⁶, J. Remon Masip⁷, P. Lavaud¹, C. Naltet⁸, A. Gazzah³, V. Thomas De Montpreville², O. Mercier², F. Barlesi⁴, B. Besse⁵,
¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson, FR, ³Gustave Roussy, Villejuif, FR, ⁴Gustave Roussy - Cancer Campus, Villejuif, FR, ⁵Institut Gustave Roussy, Villejuif, FR, ⁶Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁷HM CIOCC - Centro Integral Oncológico Clara Campal, Barcelona, ES, ⁸Groupe Hospitalier Paris Saint-Joseph, Paris, FR

09:15 - 09:16

942P - Camrelizumab combined with albumin paclitaxel and platinum in perioperative treatment of resectable squamous cell lung cancer: A single-arm, open-label, phase II clinical trial

Y. Zhang, S. Liu, L. Yang, Y. Liu, C. Wang, Y. Han, B. Xiao, D. Yan, C. Gong, F. Wang, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, CN

09:16 - 09:17

943P - Association between event-free survival and overall survival following neoadjuvant therapy for non-small-cell lung cancer

G. Ostoros¹, M. Berktaş², P. Chander³, I. Diaz Perez³, N. Georgoulia³, R. Hettle², P. Morten², A.-M. Couto⁴, C. Eichinger⁴, P. Field⁴, B. Massuti Sureda⁵,
¹OKTPI-Korányi National Institute for Tuberculosis and Pulmonology, Budapest, HU, ²AstraZeneca UK, Cambridge, GB, ³AstraZeneca Pharmaceuticals LP, Gaithersburg, US, ⁴Oxford PharmaGenesis Ltd, Oxford, GB, ⁵Hospital General Universitario de Alicante, Alicante, ES

09:17 - 09:18

944P - Hazard function analysis of recurrence in patients with curatively resected lung cancer: Results from the Japanese Lung Cancer Registry in 2010

Y. Yamauchi¹, M. Kawamura¹, J. Okami², Y. Shintani³, H. Ito⁴, T. Ohtsuka⁵, S. Toyooka⁶, T. Mori⁷, S.-I. Watanabe⁸, H. Asamura⁹, M. Chida¹⁰, S. Endo¹¹, M. Kadokura¹², R. Nakanishi¹³, E. Miyaoka¹⁴, I. Yoshino¹⁵, H. Date¹⁶,
¹Teikyo University School of Medicine, Tokyo, JP, ²Osaka International Cancer Institute, Osaka, JP, ³Graduate School of Medicine / Faculty of Medicine, Osaka University, Suita, JP, ⁴Kanagawa Cancer Center, Yokohama, JP, ⁵Jikei University School of Medicine, Tokyo, JP, ⁶Okayama University Graduate School of Medicine, Okayama, JP, ⁷Japanese Red Cross Kumamoto Hospital, Kumamoto, JP, ⁸NCCH - National Cancer Center Hospital, Chuo-ku, JP, ⁹Keio University School of Medicine, Shinjuku-ku, JP, ¹⁰Dokkyo Medical University, Mibu, JP, ¹¹Jichi Medical School, Shimotsuke, JP, ¹²Showa University School of Medicine, Shinagawa-ku,

JP, ¹³Nagoya City University Graduate School of Medical Sciences, Nagoya, JP, ¹⁴Tokyo University of Science, Tokyo, JP, ¹⁵Chiba University, School of Medicine, Chiba, JP, ¹⁶Kyoto University, Kyoto, JP

- 09:18 - 09:19 **945P - Respiratory and cardiometabolic comorbidities and stage I-III non-small cell lung cancer (NSCLC) survival: A pooled analysis from the International Lung Cancer Consortium (ILCCO)**
- M. García Pardo De Santayana¹, A. Chang¹, S. Schmid², M. Dong¹, D. Christiani³, H. Tindle⁴, P. Brennan⁵, C. Chen⁶, Z. Jie⁷, B. Ryan⁸, D. Zaridze⁹, M. Schabath¹⁰, R.M. Reis¹¹, A. Tardon¹², S. Shete¹³, A. Andrew¹⁴, H. Brenner¹⁵, W. Xu¹⁶, R. Hung¹⁷, G. Liu¹⁸, ¹Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, CA, ²Kantonsspital St. Gallen, St. Gallen, CH, ³Harvard T.H. Chan School of Public Health, Boston, US, ⁴Vanderbilt Ingram Cancer Center, Nashville, US, ⁵International Agency for Research on Cancer, Lyon, FR, ⁶Fred Hutchinson Cancer Research Center, Seattle, US, ⁷Fudan University Shanghai Cancer Center, Shanghai, CN, ⁸NIH - National Institutes of Health, Bethesda, US, ⁹N.N. Blokhin Russian Cancer Research Center, Moscow, RU, ¹⁰H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ¹¹Barretos Cancer Hospital, Barretos, BR, ¹²University of Oviedo, Oviedo, ES, ¹³The University of Texas MD Anderson Cancer Center, Houston, US, ¹⁴Dartmouth-Hitchcock Medical Center, Lebanon, US, ¹⁵DKFZ - German Cancer Research Center, Heidelberg, DE, ¹⁶UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ¹⁷Dalla Lana School of Public Health, University of Toronto and Lunenfeld-Tanenbaum Research Institute, Sinai Health Systems, Toronto, CA, ¹⁸Princess Margaret Cancer Centre, Toronto, CA
- 09:19 - 09:20 **946P - Non-examination of lymph nodes (LN) in early-stage non-small cell lung cancer (eNSCLC) is associated with wedge resections and underutilization of adjuvant (adv) chemotherapy**
- J. Lee¹, C. Meyer², T.M. To², C.-W. Lin², S. Wang³, M. Kent³, A. Johnson², J. Lee², ¹UCLA - David Geffen School of Medicine, Los Angeles, US, ²Genentech, Inc., South San Francisco, US, ³Genesis Research, Hoboken, US
- 09:20 - 09:21 **947P - Follow-up tests’ profitability in NSCLC: Experience of a tertiary hospital**
- V. Calvo De Juan¹, F. Cano¹, Y. Garitaonaindía Díaz¹, A. Collazo Lorduy², F.F. Franco³, M. Blanco Clemente¹, M. Martinez Cutillas¹, C. Traseira Puchol¹, R. Aguado¹, M. Provencio Pulla¹, ¹University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES, ²Centro Integral Oncologico Clara Campal, Madrid, ES, ³Hospital Puerta de Hierro-Majadahonda, Madrid, ES
- 09:21 - 09:22 **948TiP - Efficacy and safety of almonertinib in the adjuvant treatment of resectable stage I non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-sensitizing mutations in solid and/or micropapillary components**
- B. Han¹, V. Fang², F. Yao³, P. Song⁴, D. Yue⁵, Y. Qi⁶, B. Zhang⁷, W. Zhang², Y. Zhang³, L. Tan⁸, ¹Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN, ²Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, ³Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CN, ⁴Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN, ⁵Tianjin

Medical University Cancer Institute & Hospital, Tianjin, CN, ⁶The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ⁷Shanghai Chest Hospital, Shanghai, CN, ⁸Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN

- 09:22 - 09:23 **949TiP - Neoadjuvant durvalumab in non-surgical early stage/locally advanced non-small cell lung cancer (NSCLC) followed by radical RT/CRT (IDEAR) study concept of a phase II investigator initiated clinical trial**
C. Fava Gaspar¹, J. Oliveira², ¹Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE (IPO-Porto), Águas Santas, PT, ²Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE (IPO-Porto), Porto, PT
- 09:23 - 09:24 **951P - Induction osimertinib followed by definitive sequential radiation therapy and/or surgery in unresectable EGFR-mutant stage III NSCLC: An open-label, single-arm, phase II study**
N. Peled¹, L. C. Roisman¹, J. Dudnik², E. Dudnik³, E. Chernomordikov², S. Keren Rosenberg⁴, W. Shalata², V. Hannes⁵, S. Tsuriet⁵, R. Lichtenburg², A. Allen⁶, D. Hershkowitz⁷, P. Blumenfeld⁸, K. Lavrenkov², W. Kian⁹, ¹Shaare Zedek Medical Center, Jerusalem, IL, ²Soroka University Medical Center, Beer Sheva, IL, ³Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL, ⁴LIN Medical Center, Haifa, IL, ⁵Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL, ⁶Roche Pharmaceuticals (Israel) Ltd, Hod Hasharon, IL, ⁷Rambam Health Care Campus, Haifa, IL, ⁸Hadassah University Hospital - Ein Kerem, Jerusalem, IL, ⁹Ben-Gurion University of the Negev, Beer Sheva, IL
- 09:24 - 09:25 **952P - Effect of thoracic radiotherapy timing on prognosis for patients with late-staged lung adenocarcinoma harboring EGFR mutations**
Q. Wang¹, Z. Li², ¹Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, CN, ²Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CN
- 09:25 - 09:26 **953P - EGFR mutation testing from pleural effusions of advanced lung adenocarcinoma patients in Serbia**
M. Cavic, A. Damjanovic, I. Boljevic, M. Pavlovic, A. Stefanovic, K. Zivic, M. Vukovic, M. Tanic, R. Jankovic, Institute for Oncology and Radiology of Serbia, Belgrade, RS
- 09:26 - 09:27 **954P - Cemiplimab with platinum-based chemotherapy (chemo) for first-line (1L) locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 3 subgroup analysis**
E. Kalinka¹, M. Gogishvili², T. Makharadze³, M. Dvorkin⁴, K. Penkov⁵, K. Laktionov⁶, M. Nechaeva⁷, I. Rozhkova⁸, X. He⁹, R. Quek⁹, J.-F. Pouliot⁹, F. Seebach⁹, I. Lowy⁹, G. Gullo⁹, P. Rietschel⁹, ¹Polish Mother's Memorial Hospital - Research Institute, Łódź, PL, ²High Technology Medical Centre, University Clinic Ltd, Tbilisi, GE, ³LTD High Technology Hospital Med Center, Batumi, GE, ⁴State Budgetary Healthcare Institution of Omsk Region, Omsk, RU, ⁵Private Medical Institution "Euromedservice", Saint-Petersburg, RU, ⁶"N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, RU, ⁷Chelyabinsk Regional Clinical Oncology Center, Chelyabinsk, RU, ⁸State Budgetary Healthcare Institution of Kaluga Region, Kaluga, RU, ⁹Regeneron Pharmaceuticals, Inc.,

Tarrytown, US

- 09:27 - 09:28 **955P - Updated event-free survival of neoadjuvant toripalimab with chemotherapy for resectable stage III NSCLC (NeoTAP01 study)**
Z.-R. Zhao, H. Long, Sun Yat-sen University Cancer Center, Guangzhou, CN
- 09:28 - 09:29 **956P - Computed tomography and radiation dose images-based deep-learning model for predicting radiation pneumonitis in lung cancer patients after radiation therapy: A pilot study with external validation**
Z. Zhang¹, L. Wee¹, A. Dekker¹, L. Zhao², ¹Maastricht Clinic, Maastricht, NL, ²Tianjin Cancer Hospital, Tianjin, CN
- 09:29 - 09:30 **957P - Proton-therapy and concurrent chemotherapy in stage III NSCLC: Effects on toxicity and immune therapy**
F. Cortiula¹, L. Hendriks², R. Wijsman³, S. Debakker², M. Steens⁴, S. Peeters⁵, A. Michelotti⁶, N. Sijtsema³, S. Urban⁶, A. Niezink³, S. Dursun², G. Bootsma⁴, R. Canters⁵, F. Tohidinezhad⁷, G. Fasola¹, I. Rinaldi⁵, V. Taasti⁵, R. Houben⁵, D. De Ruysscher⁵, ¹ASU Friuli Centrale - Ospedale S. Maria della Misericordia, Udine, IT, ²Maastricht UMC, Maastricht, NL, ³UMCG - University Medical Center Groningen, Groningen, NL, ⁴Zuyderland Medical Center, Heerlen, NL, ⁵Maastricht Clinic, Maastricht, NL, ⁶University of Udine, Udine, IT, ⁷Maastricht University Medical Center (MUMC), Maastricht, NL
- 09:30 - 09:31 **958P - Intensity-modulated radiotherapy (IMRT)-adapted chemoradiotherapy (CRT) followed by durvalumab for locally advanced non-small cell lung cancer (NSCLC): A multicenter prospective observational study (WJOG12019L)**
N. Mamesaya¹, H. Harada¹, A. Hata², M. Konno¹, K. Nakamatsu³, H. Hayashi⁴, T. Yamamoto⁵, R. Saito⁶, H. Mayahara², M. Kokubo⁷, Y. Sato⁸, K. Yoshimura⁹, Y. Nishimura⁴, N. Yamamoto¹⁰, K. Nakagawa⁴, ¹Shizuoka Cancer Center, Shizuoka, JP, ²Kobe Minimally Invasive Cancer Center, Kobe, JP, ³Kindai University - Faculty of Medicine, Osaka, JP, ⁴Kindai University School of Medicine - Main Campus, Osaka, JP, ⁵Graduate School of Dentistry, Tohoku University, Sendai, JP, ⁶Tohoku University Hospital, Sendai, JP, ⁷Institute of Biomedical Research and Innovation, Kobe, JP, ⁸Kobe City Medical Center General Hospital, Kobe, JP, ⁹Hiroshima University Hospital, Hiroshima, JP, ¹⁰Wakayama Medical University, Wakayama, JP
- 09:31 - 09:32 **959P - The association of GTV and brain metastasis development in patients with stage III NSCLC**
H. Zeng¹, Y. Willems¹, F. Cortiula², G. Bootsma³, A. Traverso¹, D. De Ruysscher¹, L. Hendriks⁴, ¹Maastricht Clinic, Maastricht, NL, ²ASU Friuli Centrale - Ospedale S. Maria della Misericordia, Udine, IT, ³Zuyderland Medical Center, Heerlen, NL, ⁴Maastricht University Medical Center+, Maastricht, the Netherlands, Maastricht, NL
- 09:32 - 09:33 **960P - Beyond PACIFIC: Real-world outcomes of adjuvant durvalumab according to treatment received and PD-L1 expression**
M.-H. Denault, J. Feng, S. Kuang, A. Shokoohi, B. Leung, M. Liu, E. Berthelet, J. Laskin, S. Sun, T. Zhang, C. Ho, B. Melosky, BC Cancer Agency - Vancouver, Vancouver, CA

09:33 - 09:34

961P - Prospective real-world data of immuno(chemo)therapy (IO) prior to resection, definitive chemo-radiotherapy (CRT), or palliative therapy in patients with non-small cell lung cancer (NSCLC) without a primary curative option

K. Lehrach¹, S. Fallscheer², B. Schwenk², S. Kramberg², S. Eschmann³, J. Sträter⁴, F. Heinzelmann¹, R. Sätzler¹, M. Faehling², ¹Klinikum Esslingen, Esslingen am Neckar, DE, ²Klinikum Esslingen, Esslingen, DE, ³Marienhospital Stuttgart, Stuttgart, DE, ⁴Institut, Esslingen am Neckar, DE

09:34 - 09:35

962P - Quality of life at diagnosis for unresectable stage III NSCLC: Initial results from the national prospective study OBSTINATE (GFPC 06-2019)

C. Ricordel¹, A. Anota², M. Bernardi³, L. Falchero⁴, J.B. Auliac⁵, L. Greillier⁶, O. Bylicki⁷, G. De Chabot⁸, A. Demaegd⁹, A. Vergnenegre¹⁰, C. Decroisette¹¹, I. Martel-Lafay¹², C. Chouaid¹³, F. Guisier¹⁴, ¹Hopital Pontchaillou, Rennes, FR, ²Centre Léon Bérard, Lyon, France; French National Platform Quality of life and Cancer, France, Lyon cedex, FR, ³CH du Pays d'Aix, Aix-en-Provence, FR, ⁴Hospital Center De Villefranche-Sur-Saône, Gleizé, FR, ⁵CHI - Centre Hospitalier Intercommunal de Créteil, Créteil, Cedex, FR, ⁶Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ⁷Hopital d'instruction des armées Sainte-Anne, Toulon, FR, ⁸Centre Hospitalier Bretagne Atlantique, Vannes, FR, ⁹CH de Bigorre, Tarbes, FR, ¹⁰CHU Limoges - Hopital Dupuytren, Limoges, FR, ¹¹CH Annecy-Genevois, Metz-Tessy, FR, ¹²Center Leon Berard, Lyon, FR, ¹³CH Intercommunal de Créteil, Créteil, FR, ¹⁴CHU de Rouen Normandie, Rouen, FR

09:35 - 09:36

963P - Clinical research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-world evidence of NSCLC patients treated with radiochemotherapy in Germany – AIO-TRK-0315

W. Eberhardt¹, B. Passlick², M. Stuschke³, A. Groeschel⁴, P. Christopoulos⁵, M. Reck⁶, P. Ludwig⁷, A. Hipper⁷, M. Chiabudini⁸, L. Spring⁸, M. Jänicke⁸, A. Andres-Pons⁸, D. Christoph⁹, C. Bernhardt¹⁰, M. Reiser¹¹, M. Sebastian¹², F. Griesinger¹³, M. Thomas⁵, ¹University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ²Universitätsklinikum Freiburg - Klinik für Innere Medizin I/Klinik für Tumorbologie, Freiburg im Breisgau, DE, ³Universitätsklinikum Essen, Essen, DE, ⁴Clemenshospital Muenster, Muenster, DE, ⁵Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, DE, ⁶LungenClinic Grosshandorf, Grosshansdorf, DE, ⁷AIO-Studien-gGmbH, Berlin, DE, ⁸iOMEDICO, Freiburg im Breisgau, DE, ⁹Medizinisches Versorgungszentrum Hämatologie und Onkologie Essen gGmbH, Essen, DE, ¹⁰Private Practice - Christiane Bernhardt, Dortmund, DE, ¹¹PIOH (Köln Zentrum) - Praxis Internistischer Onkologie und Hämatologie, Köln, DE, ¹²Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, DE, ¹³Pius Hospital, Oldenburg, DE

09:36 - 09:37

964P - PACIFIC on the West Coast: Exploring reasons for not receiving consolidative durvalumab in the treatment of locally advanced lung cancer

J. Feng, M.-H. Denault, S. Kuang, A. Shokoohi, B. Leung, M. Liu, E. Berthelet, J. Laskin, S. Sun, T. Zhang, C. Ho, B. Melosky, BC Cancer Agency - Vancouver, Vancouver, CA

09:37 - 09:38

965P - Real-world toxicity of consolidation durvalumab following chemoradiotherapy (CRT) in elderly and comorbid patients (pts) with unresectable stage III NSCLC: A multi-centre, Australian experience

S. Stevens¹, U. Nindra², A. Shahnam³, V. Bray², A. Pal², P.Y. Yip⁴, T. Adam⁵, A. Nagrial³, J. Lee¹, M. Boyer¹, S. Kao¹, ¹Chris O'Brien Lifehouse, Camperdown, AU, ²Liverpool Cancer Therapy Centre, Liverpool, AU, ³Crown Princess Mary Cancer Centre Westmead, Westmead, AU, ⁴Macarthur Cancer Therapy Centre, Campbelltown, AU, ⁵Bankstown-Lidcombe Hospital, Bankstown, AU

09:38 - 09:39 **966P - Evaluation of the prognostic marker of PD-L1 expression after combined radio-chemotherapy in patients with non-small cell lung cancer (NSCLC) stage III**

K. Willborn¹, J. Wagner¹, J. Roeper¹, M. Falk², L. Heukamp², F. Griesinger¹, ¹Pius Hospital, Oldenburg, DE, ²Hematopathology Hamburg, Hamburg, DE

09:39 - 09:40 **967TiP - An open-label, prospective, phase II, umbrella study of precise neoadjuvant therapy for patients with stage II-IIIB resectable non-small cell lung cancer (PURPOSE)**

Y. Wang¹, V. Fang², ¹Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CN, ²Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN

09:40 - 09:41 **968TiP - A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial)**

S.Y. Lee¹, J.E. Lee², C.-M. Choi³, I.-J. Oh⁴, K. Lee⁵, T. Jang⁶, S.H. Lee⁷, E.Y. Kim⁸, D.W. Park⁹, S.H. Park¹⁰, ¹Korea University Guro Hospital, Seoul, KR, ²Chungnam National University, Daejeon, KR, ³Asan Medical Center - Asan Institute for Life Science, Seoul, KR, ⁴Chonnam National University Hwasun Hospital, Hwasun, KR, ⁵Konkuk University School of Medicine, Seoul, KR, ⁶Kosin University Gospel Hospital, Busan, KR, ⁷Kyung Hee University - Seoul Campus, Seoul, KR, ⁸Severance Hospital - Yonsei University College of Medicine, Seoul, KR, ⁹Hanyang University Hospital, Seoul, KR, ¹⁰Keimyung University Dongsan Hospital, Daegu, KR

09:41 - 09:42 **969TiP - Randomized, phase III study of MK-7684A plus concurrent chemoradiotherapy (cCRT) followed by MK-7684A vs cCRT followed by durvalumab for unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYVIBE-006**

S. Jabbour¹, B. Lu², X. Fu³, T. Goksel⁴, S. Sugawara⁵, A. Song⁶, S. Quinn⁶, P. Yang⁷, M. Reck⁸, ¹Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, US, ²Thomas Jefferson University, Philadelphia, US, ³Shanghai Jiao Tong University, Shanghai, CN, ⁴Ege University School of Medicine, Izmir, TR, ⁵Sendai Kousei Hospital, Sendai, JP, ⁶Merck & Co., Inc., Rahway, US, ⁷MSD China, Shanghai, CN, ⁸German Center for Lung Research, Grosshansdorf, DE

09:42 - 09:43 **970TiP - SKYSCRAPER-05: Phase II study of neoadjuvant atezolizumab (Atezo) + tiragolumab (Tira) with or without platinum-based chemotherapy (CT) in patients (Pts) with locally advanced resectable stage II‒IIIB NSCLC**

H. Pass¹, A.W. Kim², E. Felip³, C.A. Shu⁴, A. Ferris⁵, M. Frueh⁶, B. Gitlitz⁷, S. Troutman⁷, H. Petrek⁷, X. Liu⁷, J. Hsu⁷, N. Patil⁷, R. Meng⁷, ¹NYU Langone Health, New York, US, ²Keck School of Medicine - University of Southern California USC, Los Angeles, US, ³Vall

d'Hebron University Hospital, Barcelona, ES, ⁴Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, ⁵LUNGEvity Foundation, Chicago, US, ⁶Kantonsspital St. Gallen, St. Gallen, CH, ⁷Genentech, Inc., South San Francisco, US

- 09:43 - 09:44 **971TiP - Phase III trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)**
M. Ozguroglu¹, B. Levy², H. Horinouchi³, J. Yu⁴, E. Grainger⁵, P. Phuong⁶, D. Peterson⁷, M. Newton⁸, A. Spira⁹, ¹Istanbul University—Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, TR, ²Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, Washington, D.C., US, ³National Cancer Center Hospital, Tokyo, JP, ⁴Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, CN, ⁵AstraZeneca, Cambridge, GB, ⁶Arcus Biosciences, Hayward, US, ⁷AstraZeneca, Waltham, US, ⁸AstraZeneca, Gaithersburg, US, ⁹Virginia Cancer Specialists Research Institute and US Oncology Research, Fairfax, US
- 09:44 - 09:45 **1266P - Identifying Dutch hospitalized cancer patients with a limited life expectancy**
A. Van Der Velden¹, A. De Heij², A. Oosten³, P. De Graeff², A. Reyners⁴, ¹UMCG, Groningen, NL, ²The University Medical Center - UMCG, Groningen, NL, ³Erasmus MC, Rotterdam, NL, ⁴UMCG - University Medical Center Groningen, Groningen, NL
- 09:45 - 09:46 **1267P - Whether hospice-based palliative care is cost-effective in resource-limited settings of the Republic of Kazakhstan**
I. Salikhanov¹, S. Wieser², B. Crape³, M. Katapodi⁴, ¹University of Basel - Medizinische Fakultät, Basel, CH, ²ZHAW - Zurich University of Applied Sciences, Jona, CH, ³Nazarbayev University, Nur-Sultan, KZ, ⁴University of Basel - Faculty of Medicine - Institut für Pflegewissenschaft - Nursing Science (INS), Basel, CH
- 09:46 - 09:47 **1268P - Associations between psycho-social-spiritual interventions, reduced aggressive end-of-life measures, and increased time after final oncologic treatment**
G. Bar-Sela¹, M. Schultz², S. Baziliansky², I. Mitnik², D. Zalman², ¹Haemek Medical Center, Afula, IL, ²Rambam Health Care Campus, Haifa, IL
- 09:47 - 09:48 **1269P - Early interdisciplinary palliative care in patients with non-small-cell lung cancer: A 24-weeks randomised controlled trial in Southwest China**
M. Chen, H. Yu, Chongqing Cancer Hospital, Chongqing, CN
- 09:48 - 09:49 **1270P - Clinical outcomes in treatments of intensive care unit for lung cancer patients**
Y. Hong¹, J. Park², ¹Kangwon National University Hospital, Chuncheon, KR, ²Kyung Hee University Hospital at Gangdong, Seoul, KR
- 09:49 - 09:50 **1271P - A phase II study of high-flow nasal cannula as palliative care in advanced cancer patients**
E. Takase¹, H. Akamatsu¹, S. Teraoka¹, K. Nakaguchi¹, M. Tanaka¹, T. Kaki¹, K. Furuta¹,

K. Sato¹, E. Murakami¹, T. Sugimoto¹, R. Shibaki¹, D. Fujimoto¹, A. Hayata¹, N. Tokudome¹, Y. Ozawa¹, M. Nakanishi¹, Y. Koh¹, K. Kanai², T. Shimokawa¹, N. Yamamoto¹,
¹Wakayama Medical University, Wakayama, JP, ²Naga Municipal Hospital, Wakayama, JP

- 09:50 - 09:51 **1272P - Living with brain metastases: A longitudinal qualitative study of patient experiences from time of diagnosis**
T. Lundebj, T.E. Wester, N. Aass, M. Hjermstad, O. Yri, A. Bye, S. Kaasa, Oslo University Hospital, Oslo, NO
- 09:51 - 09:52 **1273P - Early integration between oncologic treatment and palliative care: Experience of the simultaneous care outpatient clinic at Veneto Institute of Oncology, ESMO Designated Center**
A. Brunello¹, A. Galiano¹, S. Schiavon², I. Guglieri¹, D. Nucci², A. Pambuku², A. Dal Col², F. Bergamo¹, S. Finotto¹, M. Bolshinsky¹, S. Stragliotto³, M.D. Rizzato¹, S. Lonardi³, V. Zagonel¹, ¹Veneto Institute of Oncology IOV - IRCCS, Padova, IT, ²Veneto Institute of Oncology IOV - IRCCS, Padua, IT, ³Veneto Institute of Oncology IOV - IRCCS, Castelfranco Veneto, IT
- 09:52 - 09:53 **1274P - Performance status (PS) and end-of-life (EOL) care in patients (pts) with metastatic prostate cancer (mPC) treated with androgen receptor targeted (ART) therapy**
G. Mellgard¹, Z. Chakrani¹, S. Mccroskery¹, N. Saffran¹, N. Taylor¹, B. Liaw¹, M. Galsky², W. Oh³, C.-K. Tsao¹, V. Patel¹, ¹Icahn School of Medicine at Mount Sinai, New York, US, ²The Mount Sinai Hospital - Icahn School of Medicine, New York, US, ³Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US
- 09:53 - 09:54 **1275P - Chemotherapy at the end of life: The reality of an oncological centre**
R. Fontes, J. Rodrigues, C. Oliveira, M. Peixoto, S. Doria, S. Martins, R. Silva, A. Marques, R. Nabico, Hospital de Braga EPE - SNS, Braga, PT
- 09:54 - 09:55 **1276P - Analysis of palliative care duration in advanced lung cancer: A 10-year retrospective study**
P. Gallardo Melo, J. Tapia, B. Martin Cullell, M. Prada, I. Gich, Hospital de la Santa Creu i Sant Pau, Barcelona, ES
- 09:55 - 09:56 **1277P - The role of palliative care in patients with glioblastoma multiforme: A single centre review**
A. McGarry¹, A. Ni Nualláin¹, T. Byrne¹, J. O'Brien¹, C. Rice¹, O. Breathnach¹, W. Grogan¹, C. Mcaleer¹, R. Mcquillan¹, S. McNally², E. Cowie², ¹Beaumont RCSI Cancer Centre, Dublin, IE, ²Beaumont Hospital, Dublin, IE
- 09:56 - 09:57 **1278P - How do hospitalized patients with chronic liver disease, with and without hepatocellular carcinoma, die? End-of-life quality analysis**
A.C. Bravo, C. Nascimento, B. Abreu, J. Revés, B. Morão, C. Frias-Gomes, M. Canhoto, L. Glória, C. Fidalgo, Hospital Beatriz Ângelo, Loures, PT
- 09:57 - 09:58 **1279P - Changes in vital signs of end-of-life patients with advanced cancer: A**

prospective cohort study

S. Hiramoto¹, A. Kikuchi², K. Oya¹, A. Sakashita³, S. Ito⁴, T. Ito⁵, ¹Peace Home Care Clinic, Otsu, JP, ²Mitsubishi Kyoto Hospital, Kyoto, JP, ³Hyogo Prefectural Harima Himeji General Medical Center, Himeji, JP, ⁴Japan Baptist Hospital, Kyoto, JP, ⁵Japanese Red Cross Medical Center, Shibuya-ku, JP

09:58 - 09:59

1280P - Validation of HAplog, an app for advanced cancer outpatient prognostication in routine practice

D. Preto, M. Guimarães, E. Gonçalves, T. Alencar, G. Zulli, A. De Melo, C. Barone, M. Freire, B. Paiva, C. Paiva, Barretos Cancer Hospital, Barretos, BR

09:59 - 10:00

1281P - Attitude toward palliative care among Panamanian physicians: A national questionnaire-based study

O. Castillo Fernandez, M. Lim Law, L. Montano, Y. Pereira, Instituto Oncologico Nacional, Panama City, PA

10:00 - 10:01

1282P - An interim report on the piloting of care of the dying patient guidance in an acute hospital

O. Mc Carthy, Marymount University Hospital & Hospice, Cork, IE

10:01 - 10:02

1283P - Psychiatric disorders associated with immune checkpoint inhibitors

C. Zhou, A. Lin, T. Gu, J. Zhang, P. Luo, Zhujiang Hospital of Southern Medical University, Guangzhou, CN

10:02 - 10:03

1284P - Detection and evaluation of immune-related adverse event signals: A nationwide, population-based study

E.J. Kim¹, Y.-J. Kim², M. Kim², H. Lee³, S.-H. Lee⁴, S. Seo⁵, J. Myung³, J.S. Oh³, S.R. Park⁵, ¹Kangbuk Samsung Hospital, Seoul, KR, ²Asan Medical Center - University of Ulsan, Seoul, KR, ³Asan Medical Center - Asan Institute for Life Science, Seoul, KR, ⁴Korea University College of Medicine, Seoul, KR, ⁵Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR

10:03 - 10:04

1285P - Risk of immune-related adverse events associated with adjuvant antiPD-1/PDL-1 in solid tumors

C. Serrano¹, R. Irene², D. Jiménez Duque³, G.A. De Velasco Oria¹, ¹Hospital Universitario 12 de Octubre, Madrid, ES, ²Hospital Virgen de la Salud, Toledo, ES, ³Hospital General Ciudad Real, Ciudad Real, ES

10:04 - 10:05

1287P - A clinical controlled study of fecal microbiota transplantation in the treatment of advanced cancer with cachexia

Y. Hu¹, M. Wang², J. Liu², H. Jiang², ¹Dalian Medical University, Dalian, CN, ²The Second People's Hospital of Changzhou, Changzhou, CN

10:05 - 10:06

1288P - Efficacy and safety of palliative procedures for malignant gastric outlet obstruction: A systematic review and network meta-analysis

K. Tran, N.-P. Vo, S.H. Nguyen, K.-W. Tam, TMU - Taipei Medical University, Taipei City, TW

- 10:06 - 10:07 **1289P - Quality of death in cancer patients managed by gastroenterologists**
C. Nascimento, A.C. Bravo, M. Canhoto, L. Glória, C. Fidalgo, Hospital Beatriz Ângelo, Loures, PT
- 10:07 - 10:08 **1290P - The effect of electric massage chair on chemotherapy-induced nausea and vomiting in cancer patients**
J.W. Kim, A. Lim, J.Y. Lee, S. Lee, Y.J. Choi, Y.H. Kim, K.H. Park, Korea University Anam Hospital, Seoul, KR
- 10:08 - 10:09 **1291P - Efficacy of honey, triphala and turmeric mouthwash on mucosal pain management in palliative care patients**
J. Acharya, Sardar Patel Medical College, Bikaner, Bikaner, IN
- 10:09 - 10:10 **1292P - A review of in-hospital end-of-life care (EOLC) for oncology patients during the COVID-19 pandemic**
H.K. Carroll¹, A. Broderick¹, O. McCarthy², M. Kennedy², R. Bambury¹, D. Power¹, D. Collins¹, R. Connolly¹, S. Noonan¹, D. Collins¹, E. Cunningham², K. O'Driscoll¹, D. Nuzum¹, K. Twomey¹, A. O'Riordan¹, F. O'Sullivan¹, C. Roe¹, M.J. O'Leary², A. Lowney², S. O'Reilly¹, ¹CUH - Cork University Hospital, Cork, IE, ²Marymount University Hospital & Hospice, Cork, IE
- 10:10 - 10:11 **1293P - Impact of COVID epidemic on palliative care referrals in a national cancer center**
M. Ebert Moltara, M. Bernot, J. Benedik, N. Golob, M. Ivanetič, Institute of Oncology Ljubljana, Ljubljana, SI
- 10:11 - 10:12 **1294TiP - Olanzapine for anorexia in cancer cachexia patients: A placebo-controlled randomized trial**
N. Osman¹, D.E. Faheem¹, W. El-Sherief¹, H. Abdel-Aal¹, S. Alsirafy², ¹Cairo University - Faculty of Medicine (Kasr Alainy School), Cairo, EG, ²NEMROCK Cairo University, Cairo, EG
- 10:12 - 10:13 **1295TiP - Investigation of calcium electroporation (CaEP) therapy in malignant cutaneous and subcutaneous tumours: A non-randomized phase II clinical trial of a novel palliative therapy**
M. Pervan¹, M. Vissing², H. Princk¹, J. Ploeen³, K. Vestergaard⁴, M. Schnefeldt⁵, S. Rafaelsen⁵, C. Lindhardt⁵, L.H. Jensen⁶, A. Rody⁷, J. Gehl², ¹UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE, ²ZUH - Zealand University Hospital Roskilde - Region Sjælland, Roskilde, DK, ³Vejle Hospital, University Hospital of Southern Denmark, Vejle, DK, ⁴University College Absalon, Soro, DK, ⁵University of Southern Denmark, Odense, DK, ⁶Vejle Sygehus Hospital, Vejle, DK, ⁷University SH.-Lübeck, Lübeck, DE
- 10:13 - 10:14 **1426P - Depression and genetic variants related to cortisol levels may influence the vulnerability of head and neck cancer-related post-traumatic stress disorder**
D. Pequeno¹, J. Carron¹, K. Gaspar¹, C. Passos Lima¹, C. Dantas¹, G. Lourenço², ¹UNICAMP - Universidade Estadual de Campinas, Sao Paulo, BR, ²University of

Campinas (UNICAMP), Campinas, BR

- 10:14 - 10:15 **1427P - The role of anxiety and self-isolation in seropositivity for COVID-19 in actively treated cancer patients in Sweden**
B. Ginman¹, S. Pahnke¹, E. Freyhult², T. Hoffman³, L. Kolstad³, B. Rönnerberg³, Å. Lundkvist³, K. Hamberg⁴, G. Enblad⁵, I. Glimelius¹, ¹University Hospital Uppsala/Akademiska Sjukhuset, Uppsala, SE, ²Department of Medical Sciences, Cancer Pharmacology and Computational Medicine, Uppsala, SE, ³Department of Medical Biochemistry and Microbiology, Uppsala, SE, ⁴Department of Public Health and Caring Sciences, Uppsala University, Uppsala, SE, ⁵Akademiska Sjukhuset Uppsala, Uppsala, SE
- 10:15 - 10:16 **1428P - Suicidal outcomes among cancer survivors: Examining associations with depression and non-medical pain prescriptions**
N. Osazuwa-Peters¹, O. Osazuwa-Peters², E. Adjei Boakye³, D. Abouelella¹, J. Barnes⁴, N. Bates⁵, K. Ramos¹, ¹Duke University Medical Center, Durham, US, ²Duke University School of Medicine, Durham, US, ³Henry Ford Hospital - Henry Ford Health System, Detroit, US, ⁴Washington University School of Medicine in St. Louis - Siteman Cancer Center, St. Louis, US, ⁵University of Washington Seattle Cancer Care Alliance, Seattle, US
- 10:16 - 10:17 **1429P - Impact of previous health-related events on coping with cancer**
M. Homa¹, M. Ziarko², M. Litwiniuk³, ¹Greater Poland Cancer Centre, Poznan, PL, ²Adam Mickiewicz University, Poznan, PL, ³Poznan University of Medical Sciences and Greater Poland Cancer Centre, Poznan, PL
- 10:17 - 10:18 **1430P - Psychological status and patient perception during the SARS-CoV-2 vaccination campaign in active oncological patients (pts)**
T. Daniela¹, A. Avancini¹, L. Belluomini¹, I. Trestini¹, S. Zuliani¹, T. Sava², C. Gaiani², A. Caldart¹, M. Casali¹, L. Benini¹, F. Zacchi¹, E. Trevisani¹, F. Bianchi¹, S.T. Riva¹, L. Del Piccolo³, A. Tfaily⁴, M. Rimondini³, G. Verlato⁴, S. Pilotto¹, M. Milella¹, ¹Verona University Hospital Trust, Verona, IT, ²Ospedale di Camposampiero, Camposampiero, IT, ³AOU Integrata di Verona - Ospedale Borgo Roma, Verona, IT, ⁴Università degli studi di Verona, Verona, IT
- 10:18 - 10:19 **1431P - Improving psycho-oncologic attention by adding first psychological evaluation to a screening for psychosocial distress tool in recently diagnosed cancer patients**
G. Simó¹, E. Bailles², E. Mahia¹, S. Albiol Rodriguez¹, C. De Miguel¹, J. Pujadas Olano³, F. Cobo³, ¹Hospital Nostra Senyora de Meritxell, Escaldes-Engordany, AD, ²Hospital Universitario Vall d'Hebron, Barcelona, ES, ³Instituto Oncologico Teknon, Barcelona, ES
- 10:19 - 10:20 **1432P - Incorporating psycho-social factors in cancer treatment adverse events studies**
C. Casini¹, D. Monzani², M. Masiero², K. Mazzocco¹, R. Grasso², D. Fotiadis³, N. Memos⁴, K. Keramida⁵, G. Curigliano¹, C. Cipolla⁶, D. Cardinale¹, A. Papakonstantinou⁷, A. Constantinidou⁸, C. Conti⁹, G. Pravettoni¹, ¹IEO - Istituto Europeo di Oncologia, Milan, IT, ²University of Milan, Milan, IT, ³UOI - University of Ioannina, Ioannina, GR, ⁴Aretaieio Hospital, Strovolos, CY, ⁵Attikon University Hospital, Haidari, GR, ⁶European Institute of

Oncology, Milan, IT, ⁷Karolinska University Hospital-Solna, Solna, SE, ⁸Bank of Cyprus Oncology Centre, Nicosia, CY, ⁹IMS - Istituto di Management Sanitario, Milan, IT

- 10:20 - 10:21 **1433P - Screening for mental health disorders and neurochemical correlates in gynecology cancer survivors: A cross-sectional study from a tertiary care center in India**
N. Singh¹, S. Singh², R. Quraishi², J. Meena², S. Pandey², D. Sharma², K. Roy², N. Bhatla³, ¹All India Institute of Medical Sciences, New Delhi, IN, ²AIIMS - All India Institute of Medical Sciences, New Delhi, IN, ³All India Institute of Medical Sciences, Delhi, IN
- 10:21 - 10:22 **1434P - Understanding the treatment experiences of adults diagnosed with early-onset colorectal cancer: A qualitative study**
A. Hamilton, H. Reid, H. Coleman, O. Santin, Queen's University, Belfast, GB
- 10:22 - 10:23 **1435P - Living with a metastatic breast cancer: A qualitative study on altered psychological needs and life goals after the diagnosis**
I. Durosini¹, L. Savioni¹, S. Triberti², V. Sebrì¹, A.V. Giudice¹, G. Pravettoni¹, ¹IEO, European Institute of Oncology IRCCS, Milano, IT, ²University of Milan, Milan, IT
- 10:23 - 10:24 **1436P - Genotoxic effect of bullying in children and adolescents with and without central nervous system cancer**
C.B. Gonzalez-Alcorta, C. Burciaga-Flores, F. Alcorta-Nuñez, M.D.R. Velazco-Campos, L. Rojas-Patlán, D. Pérez-Ibave, J. Gonzalez Guerrero, O. Vidal-Gutiérrez, L.E. Martínez-De Villarreal, A. Alcorta-Garza, Hospital Universitario Dr José Eleuterio Gonzalez, Monterrey, MX
- 10:24 - 10:25 **1437P - Does subjective cognitive impairment reflect objective cognitive impairment in cervical cancer survivors?**
E. Areklett¹, S. Andersson², J. Stubberud², K. Bruheim¹, E. Fagereng³, K. Lindemann¹, ¹Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, ²University of Oslo, Oslo, NO, ³Sunnaas Rehabilitation hospital, Bjørnemyr, NO
- 10:25 - 10:26 **1438P - Effects of tamoxifen on cognitive functions in premenopausal patients with breast cancer: A cross-sectional study**
V. Ferencz¹, E. Tóth-Fáber², D. Németh³, L. Landherr⁴, M. Tóth¹, ¹Semmelweis University, Budapest, HU, ²Eötvös Lóránd University, Budapest, HU, ³Lyon University, Lyon, FR, ⁴Uzsoki Hospital, Budapest, HU
- 10:26 - 10:27 **1439P - Sexual health in long-term breast cancer survivors: A comparative study**
S.K. Smedsland¹, R.S. Falk², K. Vandraas¹, C. Kiserud¹, M. Brekke³, R. Reidunsdatter⁴, J. Horn⁴, K.V. Reinertsen⁵, ¹Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, ²Oslo University Hospital - Rikshospitalet, Oslo, NO, ³University of Oslo, Oslo, NO, ⁴NTNU - Norwegian University of Science and Technology, Trondheim, NO, ⁵Oslo University Hospital - Radiumhospitalet, Oslo, NO
- 10:27 - 10:28 **1440P - Experience of Tunisian young adult cancer patients**

A.A. Haouari, Y. Berrazaga, S. Fendri, H. Rachdi, N. Daoud, M. Saadi, N. Mejri, H. Boussen, University of medicine Tunis El Manar, Tunis, TN

- 10:28 - 10:29 **1441P - Young females at risk for pre-donation worries and lower psychological well-being before haematopoietic stem cell donation**
J. Winterling¹, S. Pahnke², H. Häggglund², G. Larfors², S. Lennhof³, A. Kisch³, ¹Karolinska Institutet, Huddinge, SE, ²Unit of haematology, UPPSALA, SE, ³Skåne University Hospital, Lund, SE
- 10:29 - 10:30 **1442P - Prevalence and factors associated with professional burnout in Polish oncologists: A nationwide survey by Young Oncologists Section of Polish Society of Clinical Oncology**
P. Sobczuk¹, A. Gawlik-Urban², D. Sigorski³, A. Brodziak¹, J. Kiszka⁴, M. Osmola⁵, K. Machulska-Ciuraj⁶, M. Wilk⁷, ¹Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL, ²Maria Skłodowska-Curie National Research Institute of Oncology, Cracow, PL, ³SP ZOZ of the Ministry of the Interior with the Warmian-Masurian Oncology Center, Olsztyn, PL, ⁴Subcarpathian Cancer Center, Brzozów, PL, ⁵Medical University of Warsaw, Warsaw, PL, ⁶Independent Public Clinical Hospital No. 4 in Lublin, Lublin, PL, ⁷ECZ - Postgraduate Medical Center European Health Center, Otwock, PL
- 10:30 - 10:31 **1443P - Intimate partner violence in cancer patients: An SOS call**
I. Lajnef¹, M. Nesrine², M. Bohli³, Y. Berrazaga⁴, H. Rachdi², H. Boussen², ¹abderrahmen mami hospital, ariana, TN, ²Hopital Abderrahmen Mami de Pneumo-Phistiologie, Ariana, TN, ³Abderrahmen Mami, Ariana, TN, ⁴Hopital Abderrahmane Mami de Pneumophistiologie, Ariana, TN
- 10:31 - 10:32 **1444P - Cancer diagnosis communication: The perspective of oncologists, patients and caregivers**
C. Paratore¹, M.V. Pacchiana Parravicini¹, O. Cantale¹, F. Carfi¹, C. Zichi², T. Gamba², D. Pignataro³, A. Samuelly¹, M. Tucci³, M. Di Maio², S. Novello¹, ¹University of Turin, San Luigi Hospital, Orbassano, IT, ²University of Turin, Ordine Mauriziano Hospital, Turin, IT, ³Cardinal Massaia Hospital, Asti, IT
- 10:32 - 10:33 **1445P - Family dynamics of pediatric oncology patients in a level III clinic in the city of Cali**
V. Santa Ovalles¹, L. Agudelo Campiño¹, M. Guerrero¹, A. Botero Carvajal², A. Jimenez Urrego¹, A. Guerrero Benitez³, ¹Universidad de San Buenaventura de Cali, Cali, CO, ²Universidad Santiago de Cali, Cali, CO, ³Clinica de Occidente, Cali, CO
- 10:33 - 10:34 **1446P - Barriers and facilitators for genetic/epigenetic screening trials attendance in healthy populations at high-risk for cancer: A qualitative study**
S. Oliveri¹, G. Ongaro¹, C. Cincidda¹, I. Cutica², G. Pravettoni³, ¹IEO - Istituto Europeo di Oncologia, Milan, IT, ²Università degli Studi di Milano, Milan, IT, ³IEO, European Institute of Oncology IRCCS, Milano, IT
- 10:34 - 10:35 **1530P - Durvalumab (D) + platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in**

CASPIAN

N. Reinmuth¹, J. Goldman², Y. Chen³, K. Hotta⁴, G. Statsenko⁵, M. Hochmair⁶, M. Ozguroglu⁷, J.H. Ji⁸, M. Garassino⁹, A. Poltoratskiy¹⁰, F. Verderame¹¹, L. Havel¹², I. Bondarenko¹³, G. Losonczy¹⁴, N. Conev¹⁵, H. Mann¹⁶, P. Chugh¹⁷, T. Dalvi¹⁸, L. Paz-Ares¹⁹, ¹Asklepios Lung Clinic, Munich-Gauting, DE, ²David Geffen School of Medicine at UCLA, Los Angeles, US, ³Cancer & Hematology Centers of Western Michigan, Grand Rapids, US, ⁴Okayama University Hospital, Okayama, JP, ⁵Omsk Regional Cancer Center, Omsk, RU, ⁶Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, AT, ⁷Istanbul University—Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, TR, ⁸Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, KR, ⁹Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy and The University of Chicago, Chicago, US, ¹⁰Petrov Research Institute of Oncology, St Petersburg, RU, ¹¹AO Ospedali Riuniti PO Vincenzo Cervello, Palermo, IT, ¹²Thomayer Hospital, First Faculty of Medicine, Charles University, Prague, CZ, ¹³Dnipropetrovsk Medical Academy, Dnipro, UA, ¹⁴Semmelweis University, Budapest, HU, ¹⁵UMHAT St Marina, Varna, BG, ¹⁶AstraZeneca, Cambridge, GB, ¹⁷AstraZeneca, Waltham, US, ¹⁸AstraZeneca, Gaithersburg, US, ¹⁹Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, ES

10:35 - 10:36

1531P - Primary results from IMfirst, a phase IIIb open label safety study of atezolizumab (ATZ) & carboplatin (CB)/cisplatin (CP) & etoposide (ET) in an interventional real-world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain

M.R. Garcia Campelo¹, M. Domine Gomez², J. De Castro Carpeno³, A.L. Moreno Vega⁴, S. Ponce Aix⁵, E. Arriola⁶, E. Carcereny Costa⁷, M. Majem Tarruella⁸, G. Huidobro Vence⁹, E. Esteban Gonzalez¹⁰, J. Fuentes Pradera¹¹, A.L. Ortega Granados¹², M. Guillot Morales¹³, B. Massuti Sureda¹⁴, L. Vila Martinez¹⁵, A. Blasco Cordellat¹⁶, C. Fajardo¹⁷, L. Crama¹⁷, N. Leronés Laborda¹⁷, M. Cobo Dols¹⁸, ¹Complejo Hospitalario Universitario A Coruña, A Coruña, ES, ²Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, ³Hospital Universitario La Paz, Madrid, ES, ⁴Hospital Universitario Reina Sofía, Cordoba, ES, ⁵Hospital Universitario 12 de Octubre, Madrid, ES, ⁶Hospital del Mar - CIBERONC, Barcelona, ES, ⁷ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ⁸Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁹CHUVI - Complejo Hospitalario Universitario de Vigo, Vigo, ES, ¹⁰Hospital Universitario Central de Asturias, Oviedo, ES, ¹¹Hospital Universitario Virgen de Valme, Seville, ES, ¹²Hospital Universitario de Jaén, Jaén, ES, ¹³Hospital Universitario Son Espases, Palma de Mallorca, ES, ¹⁴Hospital General Universitario de Alicante, Alicante, ES, ¹⁵Parc Tauli Hospital Universitari, Sabadell, ES, ¹⁶Hospital General Universitario de Valencia-CIBERONC, Valencia, ES, ¹⁷Roche Farma S.A., Madrid, ES, ¹⁸Hospital Regional Universitario Málaga Carlos Haya, Malaga, ES

10:36 - 10:37

1532P - Phase IIIb study of durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Preliminary efficacy results

D. Isla¹, E. Arriola², M.R. Garcia Campelo³, P. Diz Tain⁴, C. Marti Blanco⁵, M. Lopez-Brea Piqueras⁶, A.L. Moreno Vega⁷, L.A. Leon Mateos⁸, J. Oramas Rodriguez⁹, V. Gutierrez Calderon¹⁰, M. Majem Tarruella¹¹, A. Sanchez Hernandez¹², C. Aguado De La Rosa¹³, R. Alvarez Cabellos¹⁴, J.L. Marti Ciriquian¹⁵, A. Moreno Paul¹⁶, J.L. Firvida Perez¹⁷, Á. Callejo Mellén¹⁸, L. Baez¹⁸, L. Paz-Ares¹⁹, ¹Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, ²Hospital del Mar - Parc de Salut Mar, Barcelona, ES, ³Instituto de

Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES, ⁴Complejo Asistencial Universitario de León - Hospital de León, León, ES, ⁵Hospital Universitari Sant Joan de Reus, Reus, ES, ⁶HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES, ⁷Hospital Universitario Reina Sofía, Cordoba, ES, ⁸Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, ES, ⁹Hospital Universitario de Canarias, San Cristobal de la Laguna, ES, ¹⁰Hospital Regional Universitario Málaga Carlos Haya, Malaga, ES, ¹¹Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹²Consorcio Hospitalario Provincial de Castellón, Castellon de la Plana, ES, ¹³Hospital Clinico Universitario San Carlos, Madrid, ES, ¹⁴Hospital Virgen de la Salud, Toledo, ES, ¹⁵Hospital General Universitario de Alicante, Alicante, ES, ¹⁶Hospital Galdakao - Usansolo, Galdakao, ES, ¹⁷Centro Médico El Carmen, Ourense, ES, ¹⁸AstraZeneca Farmaceutica Spain S A, Madrid, ES, ¹⁹Hospital Universitario 12 de Octubre, Madrid, ES

09:00 - 10:00	Type: Controversy session Title: Does hyperprogression exist? Chair(s): Marleen Kok, NL	7.2.F - Fécamp Auditorium
09:00 - 09:05	Introduction by the Chair <u>M. Kok</u> , Netherlands Cancer Institute, Amsterdam, NL	
09:05 - 09:06	Polling 1 (led by chair) <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
09:06 - 09:21	Pro: Does hyperprogression exist? <u>C. Ottensmeier</u> , University of Liverpool - School of Medicine, Liverpool, GB	
09:21 - 09:36	Contra: Does hyperprogression exist? <u>C. Le Tourneau</u> , Paris, FR	
09:36 - 09:37	Polling 2 (led by chair)	
09:37 - 09:57	Q&A	

09:00 - 10:00 **Type: Multidisciplinary session** **7.1.D - Dijon Auditorium**
Title: Management of adrenocortical carcinoma
Chair(s): Alfredo Berruti, IT

09:00 - 09:05 **Presentation of case/condition**
A. Berruti, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT

09:05 - 09:20 **The place of surgery, interventional radiology and radiation**
A. Frilling, London, GB

09:20 - 09:35 **Systemic therapy**
E. Baudin, Gustave Roussy - Cancer Campus, Villejuif, FR

09:35 - 09:50 **Novel compounds including immunotherapy**
M. Kroiss, LMU - Ludwig Maximilians University of Munich, Munich, DE

09:50 - 10:00 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

09:00 - 10:00 **Type: Challenge your Expert** **7.3.G - Grenoble Auditorium**
Title: Management of 21st century CRPC after upfront treatment: Men progressing after androgen deprivation and second generation therapies
Chair(s): Cora Sternberg, US

09:00 - 09:15 **Presentation by Expert**
R. De Wit, Erasmus MC, Rotterdam, NL

09:15 - 10:00 **Discussion led by Chair**
C. Sternberg, Weill Cornell Medicine - Belfer Research Building, New York, US

09:00 - 10:00 **Type: Challenge your Expert** **7.3.H - Honfleur Auditorium**
Title: Immunotherapy for lung cancer: The longer the better? The more the better?
Chair(s): Tony S.K. Mok, HK

09:00 - 09:15 **Presentation by Expert**
S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

09:15 - 10:00 **Discussion led by Chair**
T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

09:00 - 10:00	Type: Challenge your Expert Title: What every oncologist should know about palliative sedation? Chair(s): Giovanni Boniolo, IT	7.3.O - Orléans Auditorium
----------------------	--	-----------------------------------

09:00 - 09:15 **Presentation by Expert**
N. Cherny, Shaare Zedek Medical Center, Jerusalem, IL

09:15 - 10:00 **Discussion led by Chair**
G. Boniolo, Ferrara, IT

09:00 - 10:00	Type: Challenge your Expert Title: Can we cure oligometastatic disease in sarcoma patients? Chair(s): Armelle Dufresne, FR	7.3.T - Toulouse Auditorium
----------------------	--	------------------------------------

09:00 - 09:15 **Presentation by Expert**
A. Gronchi, Milan, IT

09:15 - 10:00 **Discussion led by Chair**
A. Dufresne, Centre Léon Bérard, Lyon, FR

10:15 - 11:45	Type: Special symposium Title: Slicing the pie: Advances in targeted therapy for oncogene-addicted NSCLC Chair(s): Zofia Piotrowska, US; Jarushka Naidoo, IE	4.A - Antibes Auditorium
10:15 - 10:20	Introduction and scientific background <u>J. Naidoo</u> , Beaumont Hospital, Dublin, IE	
10:20 - 10:35	New therapies and questions for EGFR, Exon 20 and HER2 mutation <u>Z. Piotrowska</u> , MGH - Massachusetts General Hospital, Boston, US	
10:35 - 10:50	Targeting KRAS: Current knowledge and future directions <u>A. Calles Blanco</u> , Hospital General Universitario Gregorio Marañón, Madrid, ES	
10:50 - 11:05	How to address resistance <u>J. De Langen</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL	
11:05 - 11:20	Where does IO fit in? <u>R. Hui</u> , Westmead Hospital, Sydney, AU	
11:20 - 11:25	Conclusions and perspectives <u>Z. Piotrowska</u> , MGH - Massachusetts General Hospital, Boston, US	
11:25 - 11:45	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
10:15 - 11:45	Type: Proffered Paper session Title: Proffered Paper session 1: GU tumours, non-prostate Chair(s): Thomas Powles, GB; Rana McKay, US	4.B - Brest Auditorium
10:15 - 10:25	LBA66 - IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection <u>A. Bex</u> ¹ , R. Uzzo ² , J.A. Karam ³ , V. Master ⁴ , F. Donskov ⁵ , C. Suárez ⁶ , L. Albiges ⁷ , B. Rini ⁸ , Y. Tomita ⁹ , A. Kann ¹⁰ , G. Procopio ¹¹ , F. Massari ¹² , M. Zibelman ² , I. Antonyan ¹³ , M. Huseni ¹⁴ , D. Basu ¹⁵ , B. Ci ¹⁴ , W. Leung ¹⁴ , O. Khan ¹⁶ , S. Pal ¹⁷ , ¹ The Royal Free London NHS Foundation Trust, University College London Division of Surgery and Interventional Science, London, UK & The Netherlands Cancer Institute, Amsterdam, NL, ² Fox Chase Cancer Center, Philadelphia, US, ³ The University of Texas MD Anderson Cancer Center, Houston, US, ⁴ Winship Cancer Institute, Emory University School of Medicine, Atlanta, US, ⁵ Aarhus University Hospital, Aarhus, Denmark & University Hospital of Southern Denmark, Esbjerg, DK, ⁶ Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, ⁷ Gustave Roussy, Université Paris-Saclay, Villejuif, FR, ⁸ Vanderbilt University Medical	

Center, Nashville, US, ⁹Graduate School of Medical and Dental Sciences, Niigata University, Niigata, JP, ¹⁰Hospital Alemão Oswaldo Cruz, São Paulo, BR, ¹¹Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, IT, ¹²University of Bologna, Bologna, IT, ¹³Regional Medical Clinical Center of Urology and Nephrology n.a. V.I.Shapoval, Kharkiv, UA, ¹⁴Genentech, Inc., South San Francisco, US, ¹⁵F. Hoffmann-La Roche Ltd, Welwyn Garden City, GB, ¹⁶Roche Products Ltd, Welwyn Garden City, GB, ¹⁷City of Hope Comprehensive Cancer Center, Duarte, US

- 10:25 - 10:35 **LBA67 - Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial**
- M. Allaf¹, S.E. Kim², L. Harshman³, D. Mcdermott⁴, V. Master⁵, S. Signoretti⁶, S. Cole⁷, H. Moon⁸, N. Adra⁹, E. Singer¹⁰, J. Gills¹¹, T. Choueiri², B. Leibovich¹², M.D. Michaelson¹³, B. Shuch¹⁴, P. Lara¹⁵, D. Heng¹⁶, A. Kapoor¹⁷, M. Carducci¹⁸, N. Haas¹⁹, ¹Johns Hopkins University School of Medicine, Boston, US, ²Dana Farber Cancer Institute, Boston, US, ³Surface Oncology Inc, Cambridge, US, ⁴Beth Israel Deaconess Medical Center, Boston, US, ⁵Emory University - Rollins School of Public Health, Atlanta, US, ⁶Brigham and Women's Hospital, Boston, US, ⁷UTSW - University of Texas Southwestern Medical Center, Dallas, US, ⁸Kaiser Permanente - Riverside Medical Center, Riverside, US, ⁹Indiana University Simon Cancer Center, Indianapolis, US, ¹⁰Rutgers Cancer Institute of New Jersey, New Brunswick, US, ¹¹LSU Healthcare Network, Metairie Multispeciality Clinic, Metairie, US, ¹²Mayo Clinic, Rochester, US, ¹³MGH - Massachusetts General Hospital, Boston, US, ¹⁴UCLA - David Geffen School of Medicine, Los Angeles, US, ¹⁵University of California Davis Cancer Center, Sacramento, US, ¹⁶Tom Baker Cancer Centre, Calgary, CA, ¹⁷St. Joseph's Healthcare Hamilton, Hamilton, CA, ¹⁸Johns Hopkins University, Baltimore, US, ¹⁹Abramson Cancer Center - University of Pennsylvania, Philadelphia, US
- 10:35 - 10:45 **Invited Discussant LBA66 and LBA67**
- T. Powles, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB
- 10:45 - 11:00 **Q&A**
- A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH
- 11:00 - 11:10 **17350 - PD-L1 expression on immune cells by SP142 co-localises with dendritic cells and is associated with improved overall survival (OS) with atezolizumab in patients with untreated metastatic urothelial cancer (mUC)**
- E. Grande Pulido¹, M. Galsky², R. Van Elzen³, R. Banchereau⁴, M. Peterson⁴, C. Sedano⁴, H. Koeppen⁵, H. Li⁶, A. Bamias⁷, J. Arranz Arija⁸, E. Kikuchi⁹, M. De Santis¹⁰, I. Davis¹¹, I. Mellman⁴, S. Oh⁴, P. Williams⁴, S. Bernhard¹², C. Lee¹², M. Kockx³, S. Mariathasan⁴, ¹MD Anderson Cancer Center Madrid, Madrid, ES, ²Icahn School of Medicine at Mount Sinai, New York, US, ³CellCarta, Antwerpen, BE, ⁴Genentech, Inc., South San Francisco, US, ⁵Genentech Inc., South San Francisco, US, ⁶Hoffmann-La Roche Ltd, Mississauga, CA, ⁷National & Kapodistrian University of Athens, Athens, GR, ⁸Gregorio Maranon Hospital, Madrid, ES, ⁹St. Marianna University School of Medicine, Kawasaki, JP, ¹⁰Charité Universitätsmedizin, Berlin, Germany & Medical University of Vienna, Vienna, AT, ¹¹Monash University Eastern Health Clinical School, Box Hill, AU, ¹²Roche Products Limited, Welwyn Garden City, GB

- 11:10 - 11:20 **LBA74 - Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)**
- T. Powles¹, S. Sridhar², J. Bellmunt³, C. Sternberg⁴, P. Grivas⁵, E. Hunter⁶, M. Dezfouli⁶, M. Salter⁶, R. Powell⁶, A. Dring⁶, J. Green⁶, A. Akoulitchev⁷, R. Amezquita⁸, K. Ching⁹, J. Pu¹⁰, S. Deng⁹, A. Di Pietro¹¹, C. Davis⁸, ¹Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew's Hospital, London, GB, ²Princess Margaret Cancer Centre, University Health Network, Toronto, CA, ³Dana Farber Cancer Institute, Harvard Medical School, Boston, US, ⁴Weill Cornell Medicine, New York, US, ⁵University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, US, ⁶Oxford BioDynamics Plc, Oxford, GB, ⁷Oxford Biodynamics Plc, Oxford, GB, ⁸Pfizer, La Jolla, US, ⁹Pfizer, San Diego, US, ¹⁰Pfizer, Tucson, US, ¹¹Pfizer srl, Milano, IT
- 11:20 - 11:30 **Invited Discussant 1735O and LBA74**
- R. Mckay, University of California San Diego - UCSD, La Jolla, US
- 11:30 - 11:45 **Q&A**

10:15 - 11:45	Type: Special symposium Title: Lessons learned and new horizons and other hepatobiliary/pancreatic malignancies Chair(s): Angela Lamarca, ES; Arndt Vogel, DE	7.1.C - Cannes Auditorium
----------------------	---	----------------------------------

10:15 - 10:20	Introduction and scientific background <u>A. Lamarca</u> , Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES	
10:20 - 10:35	Approach to inhibition of activating FGFR2 fusions <u>F. Facchinetti</u> , Institut Gustave Roussy - INSERM UMR 981, Villejuif, FR	
10:35 - 10:50	IDH1 and IDH2 <u>M. Lowery</u> , Trinity College Dublin, Dublin, IE	
10:50 - 11:05	The role of immunotherapy and other targeted treatments <u>A. Vogel</u> , MHH - Medizinische Hochschule Hannover, Hannover, DE	
11:05 - 11:20	The role of KRAS inhibitor and other new treatment options in pancreatic cancer <u>E. O'Reilly</u> , New York, NY, US	
11:20 - 11:25	Conclusions and perspectives <u>A. Vogel</u> , MHH - Medizinische Hochschule Hannover, Hannover, DE	
11:25 - 11:45	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

10:15 - 11:45	Type: Proffered Paper session Title: Proffered Paper session: Breast cancer, early stage Chair(s): Peter Dubsy, CH; Ana Bosch, SE	7.2.E - Évry Auditorium
----------------------	---	--------------------------------

10:15 - 10:25	1330 - Extended adjuvant aromatase inhibition after sequential endocrine therapy: Final results of the phase III DATA trial <u>V. Tjan-Heijnen</u> ¹ , S. Lammers ¹ , S. Geurts ¹ , I. Vriens ¹ , A. Swinkels ² , C. Smorenburg ³ , M. Van Der Sangen ⁴ , J. Kroep ⁵ , H. De Graaf ⁶ , A. Honkoop ⁷ , F. Erdkamp ⁸ , W. De Roos ⁹ , S. Linn ³ , A. Imholz ¹⁰ , ¹ Maastricht University Medical Centre, Maastricht, NL, ² Netherlands Comprehensive Cancer Organisation (IKNL), Nijmegen, NL, ³ Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Amsterdam, NL, ⁴ Catharina Hospital, Eindhoven, NL, ⁵ Leiden University Medical Centre, Leiden, NL, ⁶ Medical Centre Leeuwarden, Leeuwarden, NL, ⁷ Isala Clinics, Zwolle, NL, ⁸ Zuyderland Medical Centre, Sittard-Geleen, NL, ⁹ Gelderse Vallei Hospital, Ede, NL, ¹⁰ Deventer Ziekenhuis, Deventer, NL	
10:25 - 10:35	LBA13 - Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial	

M. Kok¹, I. Nederlof¹, O. Isaeva¹, N. Bakker¹, M. De Graaf¹, R. Salgado², N. Klioueva³, K. Van De Vijver⁴, F. Van Duijnhoven⁵, E. Kalashnikova⁶, S. Willingham⁶, S. Luykx⁷, C.E. Loo⁵, E. Kerver³, G. Sonke⁵, C. Blank⁵, R. Mann⁵, S. Linn⁵, D. Lambrechts⁸, H. Horlings¹, ¹Netherlands Cancer Institute, Amsterdam, NL, ²GZA Ziekenhuizen Campus Sint-Augustinus, Wilrijk, BE, ³OLVG Hospital, Amsterdam, NL, ⁴UZ Gent - Universitair Ziekenhuis Gent, Gent, BE, ⁵NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁶Natera, Inc., Austin, US, ⁷Tergooi Hospital - locatie Hilversum, Hilversum, NL, ⁸VIB-KULeuven, Leuven, BE

10:35 - 10:45 **Invited Discussant 1330 and LBA13**

L. Del Mastro, IRCCS Ospedale Policlinico San Martino, Genova, IT

10:45 - 11:00 **Q&A**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

11:00 - 11:10 **LBA14 - Impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTCycle trials**

O. Gluz¹, U. Nitz¹, M. Christgen², S. Kuemmel³, M. Braun⁴, M. Thill⁵, B. Aktas⁶, P. Wimberger⁷, K. Luedtke-Heckenkamp⁸, M. Zaiss⁹, M. Warm¹⁰, C. Schumacher¹¹, C. Schem¹², M. Graeser¹, A. Hartkopf¹³, R. Kates¹⁴, C. Zu Eulenburg¹⁵, P. Schmid¹⁶, H. Kreipe¹⁷, N. Harbeck¹⁸, ¹Evangelical Johanniter Bethesda Clinics and West German Study Group, Mönchengladbach, DE, ²MHH - Medizinische Hochschule Hannover, Hannover, DE, ³Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE, ⁴Rotkreuzklinikum München - Frauenklinik, Munich, DE, ⁵Kliniken Markus-Krankenhaus, Agaplesion, Frankfurt am Main, DE, ⁶Universitätsklinikum Leipzig - Klinik und Poliklinik für Frauenheilkunde, Leipzig, DE, ⁷Universitätsklinikum Carl Gustav Carus Dresden, Dresden, DE, ⁸Franziskus-Hospital Harderberg - Niels-Stensen-Kliniken GmbH, Georgsmarienhütte, DE, ⁹Praxis für Interdisziplinäre Onkologie, Freiburg im Breisgau, DE, ¹⁰City Hospital Köln-Holweide, Köln, DE, ¹¹St. Elisabeth Krankenhaus Köln-Hohenlind, Köln, DE, ¹²Krankenhaus Jerusalem, Hamburg, DE, ¹³University Clinics Tuebingen, Tübingen, DE, ¹⁴West German Study Group, Mönchengladbach, DE, ¹⁵Westdeutsche Studiengruppe GmbH, Mönchengladbach, DE, ¹⁶Queen Mary University of London, London, GB, ¹⁷Hannover Medical School, Hannover, DE, ¹⁸Ludwig Maximilians University Hospital of Munich, Munich, DE

11:10 - 11:20 **1340 - Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)**

L. Del Mastro¹, F. Poggio¹, E. Blondeaux¹, S. De Placido², M. Giuliano³, M. De Laurentiis⁴, G. Bisagni⁵, M. Cantore⁶, A. Turletti⁷, C. Nisticò⁸, Y. Urracci⁹, O. Garrone¹⁰, C. Bighin¹, M. Mansutti¹¹, F. Montemurro¹², G. Colantuoni¹³, M. Lambertini¹, L. Boni¹, ¹IRCCS Ospedale Policlinico San Martino, Genova, IT, ²Azienda Ospedaliera Universitaria Federico II, Napoli, IT, ³University "Federico II", Napoli, IT, ⁴Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁵Azienda Ospedaliera - Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, ⁶Azienda Ospedaliera Carlo Poma, Mantova, IT, ⁷POEV ASL TO1, Torino, IT, ⁸IRCCS Regina Elena National Cancer Institute (IRE), Rome, IT,

⁹Ospedale Oncologico "A. Businco", Cagliari, IT, ¹⁰Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Milan, IT, ¹¹ASU Friuli Centrale - Ospedale S. Maria della Misericordia, Udine, IT, ¹²IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, ¹³Azienda Ospedaliera S. Giuseppe Moscati, Avellino, IT

11:20 - 11:30 **Invited Discussant LBA14 and 1340**
P. Dubsky, Onkozentrum Luzern Hirslanden-Klinik St. Anna, Luzern, CH

11:30 - 11:45 **Q&A**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

10:15 - 11:45 **Type: Special symposium** **7.2.F - Fécamp Auditorium**
Title: Is heterogeneity the limitation of precision oncology in melanoma?
Chair(s): Caroline Robert, FR; Dirk Schadendorf, DE

10:15 - 10:20 **Introduction and scientific background**
C. Robert, Institut Gustave Roussy, Villejuif, Cedex, FR

10:20 - 10:35 **Plasticity: The door for tumour escape?**
C. Vallot, Institut Curie, Paris, FR

10:35 - 10:50 **Discovery of new metabolic pathways and liabilities in cancer cells**
A. Tasdogan, Universitätsklinikum Essen, Essen, DE

10:50 - 11:05 **Single cell dynamics**
B. Raphael, San Diego, CA, US

11:05 - 11:20 **How to target invisible melanoma cells**
C. Robert, Institut Gustave Roussy, Villejuif, Cedex, FR

11:20 - 11:25 **Conclusions and perspectives**
D. Schadendorf, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

11:25 - 11:45 **Discussion**

10:15 - 11:45 **Type: Mini Oral session** **7.1.D - Dijon Auditorium**
Title: Mini Oral session: Head & neck cancer
Chair(s): Ana Martins Ferreira Varges Gomes, PT; Sandra Schmitz, BE; Sjoukje Oosting, NL

10:15 - 10:20 **655MO - Quality of life in patients with p16⁺ oropharyngeal cancer receiving accelerated radiotherapy (RT) with either cisplatin or cetuximab in NRG/RTOG 1016**

J. Ringash¹, L. Demora², M. Gillison³, D. Adelstein⁴, P. Harari⁵, E. Sturgis⁶, E. Basch⁷, S. Koyfman⁸, G. Kreml⁹, D. Blakaj¹⁰, J. Bates¹¹, T. Galloway¹², C. Jones¹³, B. Beadle¹⁴, P. Torres-Saavedra², Q.-T. Le¹⁵, B. Movsas¹⁶, ¹The Princess Margaret Cancer Centre/UHN & The University of Toronto, Toronto, CA, ²NRG Oncology Statistics and Data Management Center, Philadelphia, US, ³MD Anderson Cancer Center, Houston, US, ⁴Cleveland Clinic - Cancer Center, Cleveland, US, ⁵University of Wisconsin Carbone Cancer Center, Madison, US, ⁶Jamail Specialty Center, Houston, US, ⁷UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US, ⁸Cleveland Clinic Main Campus, Cleveland, US, ⁹University of Oklahoma Health Sciences Center, Oklahoma City, US, ¹⁰OSUCCC - The Ohio State University Comprehensive Cancer Center - James, Columbus, US, ¹¹Winship Cancer Institute of Emory University, Atlanta, US, ¹²Fox Chase Cancer Center - Main Campus, Philadelphia, US, ¹³Sutter Cancer Center, Sacramento, US, ¹⁴Stanford Cancer Center Palo Alto, Palo Alto, US, ¹⁵Stanford University, Stanford, US, ¹⁶Henry Ford Cancer Institute-Henry Ford Health, Detroit, US

10:20 - 10:25

656MO - Phase I study of M6620 (VX-970, berzosertib) in combination with cisplatin and XRT in patients with locally advanced head and neck squamous cell carcinoma

A. Bhatia¹, Z. Chen², J. Bruce³, C. Steuer⁴, D. Zandberg⁵, J. Riess⁶, D. Mitchell⁷, T. Davis⁸, M. Patel⁹, V. Kaur¹⁰, S. Arnold¹¹, T. Owonikoko¹², ¹Yale University School of Medicine - Yale Cancer Center, New Haven, US, ²UIC - University of Illinois Chicago - Student Center West, Chicago, US, ³University of Wisconsin Carbone Cancer Center, Madison, US, ⁴Winship Cancer Institute of Emory University, Atlanta, US, ⁵University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Pittsburgh, US, ⁶UC Davis Comprehensive Cancer Center, Sacramento, US, ⁷OSUCCC - The Ohio State University Comprehensive Cancer Center - James, Columbus, US, ⁸Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, US, ⁹Rutgers Cancer Institute of New Jersey, New Brunswick, US, ¹⁰UVA - University of Virginia - School of Medicine - Division of Hematology & Oncology, Charlottesville, US, ¹¹UK - University of Kentucky - Markey Cancer Center, Lexington, US, ¹²University of Pittsburgh and Hillman Cancer Center, Pittsburgh, US

10:25 - 10:30

657MO - Effectiveness of geriatric assessment-driven interventions on quality of life for 2 years in older patients with head and neck cancer: Results from the EGeSOR trial

C. Lafont¹, E. Paillaud², C. Bertolus³, M. Baron⁴, P. Caillet², E. Bouvard⁵, M. Laurent⁶, D. Salvan⁷, L. Chaumette⁸, L. De Decker Lemarcis⁹, B. Piot¹⁰, B. Barry¹¹, A. Raynaud-Simon¹², E. Sauvaget¹³, A. Minard¹⁴, A. Anota¹⁵, H. Panjo¹⁶, L. Brugel¹⁷, F. Canoui-Poitrine¹, ¹Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France; AP-HP, hôpital Henri-Mondor, Service de Santé Publique, F-94010, Créteil, France, Creteil, FR, ²Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France; AP-HP, Paris Cancer Institute CARPEM, hôpital Européen Georges Pompidou, département de gériatrie, F-75015 Paris, France, Creteil, FR, ³AP-HP, Sorbonne université, Hôpital Pitié Salpêtrière, service de chirurgie maxillo-faciale, F-75013 Paris, France, Paris, FR, ⁴AP-HP, Sorbonne université, hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Service de Soins de Suites et de Réadaptation Gériatrique, F-94205 Ivry sur Seine, France, Ivry sur Seine, FR, ⁵AP-HP, hôpital Tenon, service de gériatrie, F-75020 Paris, France, Paris, FR, ⁶Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France; AP-HP, hôpital Henri-Mondor, Département de Gériatrie, F-94010 Créteil, France, Creteil, FR, ⁷Centre Hospitalier Sud Francilien, Service ORL et cervico-facial, F-91100 Corbeil-Essonnes, France, Corbeil-

Essonne, FR, ⁸Centre Hospitalier Sud Francilien, Service de court séjour gériatrique, F-91100 Corbeil-Essonnes, France, Corbeil-Essonnes, FR, ⁹Centre Hospitalier Universitaire de Nantes, service de gériatrie, F-44093 Nantes, France, Nantes, FR, ¹⁰Centre Hospitalier Universitaire de Nantes, service de chirurgie maxillo-faciale et stomatologie, F-44093 Nantes, France, Nantes, FR, ¹¹AP-HP, Université de Paris, hôpital Bichat, Service ORL et chirurgie cervico-faciale, F-75018 Paris, France, Paris, FR, ¹²AP-HP, Université Paris Cité, hôpital Bichat, service de gériatrie, F-75018 Paris, France, Paris, FR, ¹³Groupe Hospitalier Paris-Saint Joseph, service ORL et chirurgie cervico-faciale, F-75014 Paris, France, Paris, FR, ¹⁴Hôpital Léopold Bellan, Service de gériatrie, F-75014 Paris, France, Paris, FR, ¹⁵Clinical Research and Innovation Department & Department of Human and Social Sciences, Centre Léon Bérard, Lyon, France; French National Platform Quality of life and Cancer, France, Lyon cedex, FR, ¹⁶Université Paris-Saclay, UVSQ, Inserm, CESP, 94807 Villejuif, France, Villejuif, FR, ¹⁷Centre Hospitalier Intercommunal de Créteil, Service d'ORL et Chirurgie Cervico-faciale, F-94010 Créteil, France, Créteil, FR

10:30 - 10:45 **Invited Discussant 655MO, 656MO and 657MO**

S. Oosting, Groningen, NL

10:45 - 10:50 **658MO - Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040**

D. Soulieres¹, K. Harrington², C. Le Tourneau³, J.D. Silva⁴, L. Licitra⁵, M.-J. Ahn⁶, A. Soria Rivas⁷, J.-P. Machiels⁸, N. Mach⁹, R. Mehra¹⁰, B. Burtness¹¹, J. Lin¹², N. Lerman¹², B. Gumuscu¹², E. Cohen¹³, ¹CHUM (Centre Hospitalier de l'Université de Montréal), Montreal, CA, ²The Institute of Cancer Research, London, GB, ³Institut Curie, Paris, FR, ⁴Instituto Português de Oncologia do Porto Francisco Gentil, Porto, PT, ⁵Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, IT, ⁶Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁷Hospital Universitario Ramón y Cajal, Madrid, ES, ⁸Cliniques Universitaires Saint-Luc, Brussels, BE, ⁹Geneva University Hospital, Geneva, CH, ¹⁰University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, US, ¹¹Yale School of Medicine, New Haven, US, ¹²Merck & Co., Inc., Rahway, US, ¹³Moore's Cancer Center, UC San Diego Health, La Jolla, US

10:50 - 10:55 **659MO - Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048**

M. Tahara¹, R. Greil², D. Rischin³, K. Harrington⁴, B. Burtness⁵, G. De Castro Jr.⁶, A. Psyrri⁷, I. Brana⁸, P. Neupane⁹, Å. Bratland¹⁰, T. Fuereder¹¹, B. Hughes¹², R. Mesia Nin¹³, N. Ngamphaiboon¹⁴, T. Rordorf¹⁵, W.Z. Wan Ishak¹⁶, J. Lin¹⁷, B. Gumuscu¹⁷, N. Lerman¹⁷, D. Soulieres¹⁸, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Paracelsus Medical University Salzburg Cancer Research Institute and Cancer Cluster, Salzburg, AT, ³Peter MacCallum Cancer Institute University of Melbourne, Melbourne, AU, ⁴The Institute of Cancer Research, London, GB, ⁵Yale School of Medicine, New Haven, US, ⁶Instituto do Cancer de Sao Paulo—ICESP, Sao Paulo, BR, ⁷National and Kapodistrian University of Athens, Attikon University Hospital, Athens, GR, ⁸Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁹University of Kansas Medical Center, Kansas City, US, ¹⁰Oslo University Hospital, Oslo,

NO, ¹¹Medical University of Vienna/General Hospital Vienna, Vienna, AT, ¹²Royal Brisbane & Women's Hospital, and University of Queensland, Herston, AU, ¹³Catalan Institute of Oncology, Badalona, ES, ¹⁴Ramathibodi Hospital, Mahidol University, Ratchatewi, Bangkok, TH, ¹⁵University Hospital, Zurich, CH, ¹⁶University Malaya, Kuala Lumpur, Wilayah Persekutuan, MY, ¹⁷Merck & Co., Inc., Rahway, US, ¹⁸CHUM, Montréal, CA

- 10:55 - 11:00 **LBA33 - 5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in a randomized, phase II study**
- J. Bourhis¹, C. Le Tourneau², B. Calderon³, L. Martin⁴, C. Sire⁵, Y. Pointreau⁶, J.-F. Ramee⁷, A. Coutte⁸, P. Boisselier⁹, M.-C. Kaminsky-Forrett¹⁰, J.-P. Delord¹¹, F. Clatot¹², X. Sun¹³, J. Villa¹⁴, N. Magne¹⁵, O. Elicin¹⁶, L. Damstrup¹⁷, K. Gollmer¹⁷, P. Crompton¹⁷, Y. Tao¹⁸, ¹Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ²Institut Curie, Paris, FR, ³Avignon-Provence Cancer Institute, Avignon, FR, ⁴William the Conqueror Center, Le Havre, FR, ⁵Hôpital du Scorff, South Brittany Hospital Group, Lorient, FR, ⁶Institut Inter-Régional de Cancérologie, Centre Jean Bernard, Le Mans, FR, ⁷CHD Vendée, La Roche Sur Yon, FR, ⁸CHU Amiens Picardie, Amiens, FR, ⁹Montpellier Cancer Institute, Val d'Aurelle, Montpellier, FR, ¹⁰The Cancer Institute, de Lorraine Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, ¹¹Institut Claudius Regaud, IUCT-Oncopole, Toulouse, FR, ¹²Henri Becquerel Centre, Rouen, FR, ¹³Nord Franche-Comté de Montbéliard and CHRU de Besançon, Montbéliard, FR, ¹⁴CHU Grenoble, Grenoble, FR, ¹⁵Institut de Cancérologie Lucien Neuwirth, Saint Etienne, FR, ¹⁶Inselspital, Bern University Hospital, University of Bern, Bern, CH, ¹⁷Debiopharm International SA, Lausanne, CH, ¹⁸Institut Gustave Roussy, Villejuif, FR
- 11:00 - 11:15 **Invited Discussant 658MO, 659MO and LBA33**
- A. Martins Ferreira Varges Gomes, Centro Hospitalar Universitário do Algarve - Hospital de Faro EPE-SNS, Faro, PT
- 11:15 - 11:20 **660MO - Molecular targets in salivary gland cancers: A comprehensive genomic analysis of 1,666 cases**
- A. Sivapiragasam¹, P. Ashok Kumar¹, M. Bou Zerdan¹, D. Zaccarini¹, N. Danziger², J. Ross², ¹SUNY Upstate Medical University, Syracuse, US, ²Foundation Medicine, Inc, Cambridge, US
- 11:20 - 11:25 **654MO - High dimensional immuno-phenotyping of immunotherapy response in head and neck cancer**
- K. O'Byrne¹, N. Ma², H. Sadeghirad³, N. Jhaveri², J. Monkman³, A. Pratapa², B. Ben Cheikh², R. Ladwa¹, B. Hughes⁴, O. Braubach², A. Kulasinghe⁵, ¹Princess Alexandra Hospital - Metro South Health, Woolloongabba, AU, ²Akoya Biosciences - East Coast, Hopkinton, US, ³The University of Queensland, St Lucia, AU, ⁴Royal Brisbane and Women's Hospital, Herston, AU, ⁵University of Queensland, Brisbane, AU
- 11:25 - 11:30 **661MO - Evaluation of the DNA damage response (DDR) network as predictor of nivolumab efficacy in head and neck squamous cell carcinoma (HNSCC)**
- P. Economopoulou¹, C. Papanikolaou², A. Spathis¹, I. Kotsantis¹, N. Gavrielatou³, M.

Anastasiou³, D. Stellas², I. Panayiotides¹, P. Foukas⁴, V.L. Souliotis², A. Psyrri¹, ¹Attikon University Hospital, Haidari, GR, ²National Hellenic Research foundation, Athens, GR, ³Attikon University Hospital, Athens, GR, ⁴CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

11:30 - 11:45 **Invited Discussant 660MO, 654MO and 661MO**

S. Schmitz, Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE

10:15 - 11:45 Type: Educational session 7.3.G - Grenoble Auditorium
Title: Insight the new CNS WHO classification: Novel concepts and therapeutic implications for gliomas
 Chair(s): Pieter Wesseling, NL; Enrico Franceschi, IT

10:15 - 10:40 **Update on diagnosis: Novel concepts of WHO**

P. Wesseling, Amsterdam, NL

10:40 - 11:05 **Therapeutic implications for gliomas**

C. Balana, Badalona, ES

11:05 - 11:30 **Are molecular subtypes also radiologic subtypes? Radiogenomic mapping of brain tumours**

M. Smits, Rotterdam, NL

11:30 - 11:45 **Discussion**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

10:15 - 11:45 Type: Proffered Paper session 7.3.O - Orléans Auditorium
Title: Proffered Paper session: Developmental therapeutics
 Chair(s): Alexander Drilon, US; Shivaani Kummar, US

10:15 - 10:25 **451O - Preliminary evidence of clinical activity from phase I and Ib trials of the CLK/DYRK inhibitor cirtuvivint (CIRT) in subjects with advanced solid tumors**

A. Scott¹, J. Call², S. Chandana³, E. Borazanci⁴, G. Falchook⁵, R. Bordoni⁶, S. Richey⁷, A. Starodub⁸, V. Chung⁹, N. Lakhani¹⁰, E. Lam¹¹, K. Schaffer¹², J. Wang¹³, G. Shapiro¹⁴, J. Sachdev¹⁵, D. Beaupre¹⁵, A. Tolcher¹⁶, ¹University of Arizona Cancer Center, Tucson, US, ²South Texas Accelerated Research Therapeutics (START), San Antonio, US, ³START - Midwest, Grand Rapids, US, ⁴HonorHealth Research Institute, Scottsdale, US, ⁵Sarah Cannon Research Institute, denver, US, ⁶Georgia Cancer Specialists affiliated with Northside Hospital Cancer Institute, Atlanta, US, ⁷US Oncology, Inc., Fort Worth, US, ⁸The Christ Hospital - Hematology & Oncology, Cincinnati, US, ⁹City of Hope Comprehensive Cancer Center, Duarte, US, ¹⁰START Midwest, Grand Rapids, US, ¹¹UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, ¹²Vanderbilt University Medical Center, Nashville, US, ¹³Florida Cancer Specialists & Research Institute - Lake Mary Cancer Center, Lake Mary, US, ¹⁴Dana Farber Cancer Institute, Boston, US, ¹⁵Biosplice Therapeutics, Inc., SAN DIEGO,

US, 16NEXT Oncology™, San Antonio, US

- 10:25 - 10:35 **4520 - A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumours**
P. Schoeffski¹, N. Yamamoto², T. Bauer³, M. Patel⁴, M. Gounder⁵, J. Geng⁶, R. Sailer⁷, G. Jayadeva⁷, P. Lorusso⁸, ¹Leuven Cancer Institute, University Hospitals Leuven, Leuven, BE, ²National Cancer Center Hospital, Tokyo, JP, ³Tennessee Oncology, Nashville, US, ⁴Florida Cancer Specialists & Research Institute, Sarasota, US, ⁵Memorial Sloan Kettering Cancer Center, New York, US, ⁶Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, US, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, DE, ⁸Yale Cancer Center, New Haven, US
- 10:35 - 10:45 **4530 - DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study**
T. Doi¹, M. Patel², G. Falchook³, T. Koyama⁴, C. Friedman⁵, S. Piha-Paul⁶, M. Gutierrez⁷, R. Abdul-Karim⁸, M. Awad⁹, D. Adkins¹⁰, S. Takahashi¹¹, S. Kadowaki¹², B. Cheng¹³, N. Ikeda¹⁴, A. Laadem¹⁴, N. Yoshizuka¹⁴, M. Qian¹⁴, O. Dosunmu¹⁵, H.-T. Arkenau¹⁶, M. Johnson¹⁵, ¹National Cancer Center Hospital East, Kashiwa, Chiba, JP, ²Florida Cancer Specialists & Research Institute, Sarasota, US, ³Sarah Cannon Research Institute, Denver, US, ⁴National Cancer Center Hospital, Chuo City, Tokyo, JP, ⁵Memorial Sloan Kettering Cancer Center, New York, US, ⁶The University of Texas, MD Anderson Cancer Center, Houston, US, ⁷Hackensack University Medical Center, Hackensack, US, ⁸Henry Ford Cancer Institute-Henry Ford Health, Detroit, US, ⁹Dana Farber Cancer Institute, Boston, US, ¹⁰Washington University School of Medicine, St Louis, US, ¹¹Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, JP, ¹²Aichi Cancer Center Hospital, Nagoya, JP, ¹³Daiichi Sankyo Inc., Basking Ridge, US, ¹⁴Daiichi Sankyo, Inc., Basking Ridge, US, ¹⁵Sarah Cannon Research Institute, Nashville, US, ¹⁶Sarah Cannon Research Institute, London, GB
- 10:45 - 10:55 **Invited Discussant 4510, 4520 and 4530**
P. Cassier, Centre Léon Bérard, Lyon, FR
- 10:55 - 11:05 **Q&A**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH
- 11:05 - 11:15 **4500 - Initial monotherapy results of a phase I first-in-human study of ULK1/2 inhibitor DCC-3116 alone and in combination with MAPK pathway inhibition**
A. Tolcher¹, D.S. Hong², A. Vandross³, R. Amaravadi⁴, C. Psoinos⁵, D. Brennan⁵, M.L. Sherman⁵, R. Ruiz-Soto⁵, L. Viswanathan⁵, K. Sprott⁵, F.J. Reu⁵, C. Weekes⁶, ¹Texas Oncology-San Antonio Babcock NEXT Oncology, San Antonio, US, ²The University of Texas MD Anderson Cancer Center, Houston, US, ³Texas Oncology-Austin North NEXT Oncology, Austin, US, ⁴Abramson Cancer Center, University of Pennsylvania, Philadelphia, US, ⁵Deciphera Pharmaceuticals, LLC, Waltham, US, ⁶Massachusetts General Hospital, Boston, US

- 11:15 - 11:25 **4540 - A phase (Ph) I/II trial of the CXCR2 antagonist AZD5069 in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)**
C. Guo¹, A. Sharp¹, U. Vogl², I. Colombo², A. Stathis², S. Jain³, K. Chandran¹, C. Tiu¹, A. Paschalis¹, R. Matthews⁴, I. Figueiredo⁵, J. Rekowski⁴, C. Yap⁴, M. De Los Dolores Fenor De La Maza⁶, A. Turner⁴, H. Badham⁴, M. Parmar⁴, F. Raynaud⁴, A. Alimonti², J. De Bono¹, ¹Institute of Cancer Research and Royal Marsden Hospital, London, GB, ²EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH, ³Belfast City Hospital - Belfast Health & Social Care Trust, Belfast, GB, ⁴Institute of Cancer Research, London, GB, ⁵The Institute of Cancer Research, Sutton, GB, ⁶The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB
- 11:25 - 11:35 **Invited Discussant 4500 and 4540**
C.-C. Lin, NTUH - National Taiwan University Hospital, Taipei City, TW
- 11:35 - 11:45 **Q&A**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH
- 10:15 - 11:45 Type: Proffered Paper session 7.3.T - Toulouse Auditorium**
Title: Proffered Paper session: Sarcoma
 Chair(s): Breelyn Wilky, US; Tom Wei-Wu Chen, TW
- 10:15 - 10:25 **14820 - A phase III study comparing methotrexate (M), adriamycin (A) and cisplatin (P) with MAP + ifosfamide (MAP + IF) for the treatment of osteosarcoma: JCOG0905**
H. Hiraga¹, R. Machida², A. Kawai², Y. Matsumoto³, T. Yonemoto⁴, Y. Nishida⁵, A. Nagano⁶, K. Ae⁷, S. Yoshida⁸, K. Asanuma⁹, J. Toguchida¹⁰, D. Huruta¹¹, R. Nakayama¹², T. Akisue¹³, T. Hiruma¹⁴, T. Morii¹⁵, K. Tanaka¹⁶, T. Kataoka¹⁷, H. Fukuda², T. Ozaki¹⁸, ¹National Hospital Organization, Hokkaido Cancer Center, Sapporo, JP, ²NCCCH - National Cancer Center Hospital, Tokyo, JP, ³Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, ⁴Chiba Cancer Center Hospital, Chiba, JP, ⁵Nagoya University Hospital, Nagoya, JP, ⁶Gifu University School of Medicine, Gifu, JP, ⁷Cancer Institute Hospital of JFCR, Tokyo, JP, ⁸Tohoku University Hospital, Sendai, JP, ⁹Mie University Hospital, Tsu, JP, ¹⁰Kyoto University, Kyoto, JP, ¹¹Hiroshima University Hospital, Hiroshima, JP, ¹²Keio University School of Medicine, Shinjuku-ku, JP, ¹³Kobe University Graduate School of Medicine, Kobe, JP, ¹⁴Kanagawa Cancer Center, Yokohama, JP, ¹⁵Kyorin University Faculty of Medicine, Mitaka, JP, ¹⁶Oita University Faculty of Medicine, Yufu, JP, ¹⁷National Cancer Center - Tsukiji Campus, Tokyo, JP, ¹⁸Faculty of Medicine Dentistry and Pharmaceutical Sciences Okayama University, Okayama, JP
- 10:25 - 10:35 **14830 - Results of a phase I/II combination regimen with ipilimumab (I), nivolumab (N) and trabectedin (T) as first line therapy for advanced leiomyosarcoma**
E. Gordon¹, W.A. Tellez², D. Brigham², C. Valencia², S. Chawla³, V. Chua-Alcala², A. Moradkhani², ¹Sarcoma Oncology Research Center, Monterey, US, ²Sarcoma Oncology Center, Santa Monica, US, ³Sarcoma Oncology Research Center, Santa Monica, US
- 10:35 - 10:45 **Invited Discussant 14820 and 14830**

K. Boye, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO

10:45 - 11:00 **Q&A**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

11:00 - 11:10 **14850 - Percutaneous uterine needle biopsy with microscopic and array-CGH analyses in patients with suspicious myometrial tumors on MRI: A prospective study**

J. Smadja¹, V. Servois¹, G. Pierron², S. El Zein², E. Laas², T. Ramtohul², D. Tzanis², S. Watson², S. Bonvalot², ¹Institut Curie, PARIS, FR, ²Institut Curie, Paris, FR

11:10 - 11:20 **14840 - Deep learning predicts patients' outcome and mutations from H&E slides in gastrointestinal stromal tumor (GIST)**

A. Italiano¹, Y. Fu², M. Karanian³, R. Perret⁴, A. Camara², F. Le Loarer⁴, M. Jean-Denis³, I. Hostein⁴, A. Michot⁴, F. Ducimetiere³, A. Giraud⁵, J.-B. Courreges⁴, K. Courtet⁶, Y. Laizet⁶, J.O. Du Terrail², B. Schmauch², C. Maussion², J.-Y. Blay³, J.M. Coindre⁴, ¹Institute Bergonié, Bordeaux, FR, ²OWKIN France, Paris, FR, ³Centre Léon Bérard, Lyon, FR, ⁴Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ⁵Institut Bergonié, Bordeaux, FR, ⁶Institut Bergonie, Bordeaux, FR

11:20 - 11:30 **Invited Discussant 14850 and 14840**

J. Kather, Uniklinik RWTH Aachen, Aachen, DE

11:30 - 11:45 **Q&A**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

10:15 - 11:45	Type: Educational session Title: Complex technologies for diagnosis: How do we implement and use them globally? Chair(s): Joaquin Mateo, ES; Christoph Benedikt Westphalen, DE	7.3.M - Marseille Auditorium
10:15 - 10:20	Introduction <u>C.B. Westphalen</u> , LMU Klinikum der Universität München, Munich, DE	
10:20 - 10:40	Applying the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) <u>J. Mateo</u> , Vall d'Hebron University Hospital, Barcelona, ES	
10:40 - 11:00	The ESMO survey on availability and accessibility of biomolecular technologies in oncology <u>A. Bayle</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
11:00 - 11:20	Is drug access the bottleneck of precision medicine? <u>D. Horgan</u> , European Alliance for Personalised Medicine, Brussels, BE	
11:20 - 11:25	Conclusions and perspectives <u>J. Mateo</u> , Vall d'Hebron University Hospital, Barcelona, ES	
11:25 - 11:45	Discussion	

10:15 - 11:45	Type: Special session Title: De-escalation of treatment in medical oncology Chair(s): Hendrik van Halteren, NL; Michiel Strijbos, BE	7.3.U - Urval Auditorium
----------------------	--	---------------------------------

10:15 - 10:20	Introduction <u>H. Van Halteren</u> , Adrz-Admiraal de Ruijter Hospital-Goes, Goes, NL	
10:20 - 10:35	An ESMO framework for de-escalation of antineoplastic therapies: Principles and considerations <u>D. Trapani</u> , Dana Farber Cancer Institute, Boston, US	
10:35 - 10:50	Fundamentals of de-escalation <u>M. Strijbos</u> , GZA Ziekenhuizen Campus Sint-Augustinus, Wilrijk, BE	
10:50 - 11:05	The use of biomarkers in de-escalation <u>A. Stenzinger</u> , University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE	
11:05 - 11:20	De-escalation from a patients' perspective <u>T. Spanic</u> , Europa Donna Slovenia, Ljubljana, SI	
11:20 - 11:35	Challenges in de-escalation trials <u>H. Van Halteren</u> , Adrz-Admiraal de Ruijter Hospital-Goes, Goes, NL	
11:35 - 11:45	Discussion and Q&A	

10:15 - 11:45	Type: EONS session Title: Health promotion, prevention, and screening Chair(s): Amanda Drury, IE	7.3.S - Strasbourg Auditorium
----------------------	--	--------------------------------------

10:15 - 10:30	EONS focus on cancer prevention <u>L. Sharp</u> , RCC Stockholm-Gotland, HSF, Stockholm, SE	
10:30 - 10:45	Physical activity and cancer <u>M. Himberg</u> , Turku University Hospital (Tyks), Turku, FI	
10:45 - 11:00	Prevention and early detection for hereditary breast and ovarian cancer syndromes <u>E. O'Donovan</u> , Hermitage Medical Clinic, Dublin, IE	
11:00 - 11:10	CN12 - Impact of diet on immune checkpoint blockade: Nurse-directed dietary intervention <u>J. Malo</u> ¹ , M. Benlaïfaoui ¹ , K. Diop ¹ , M. Messaoudene ¹ , W. Belkaid ¹ , A. Elkrief ² , N. Blais ³ , M. Tehfe ³ , M. Florescu ³ , A. Al-Saleh ¹ , A. Leblanc ² , V. Marcil ⁴ , B. Routy ³ , C. Richard ¹ ,	

¹Université de Montreal, Montreal, CA, ²McGill University Healthcare Centre, Montreal, CA, ³CHUM - Centre Hospitalier de l'Université de Montréal, Montreal, CA, ⁴Research Centre, Sainte-Justine University Health Center, Montreal, CA

- 11:10 - 11:20 **CN13 - Nutriscore: Nutritional screening in colorectal cancer patients previous to cancer-specific treatment**
R. Legido-Diaz¹, L. Raventos¹, M. Bellver¹, A.R. Gonzalez¹, L. Hurtos¹, I. Peiró Martínez², L. Arribas³, ¹ICO - Institut Català d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ²ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, ³Institut Català D'Oncologia, Barcelona, ES
- 11:20 - 11:30 **CN15 - Individual factors leading to delay in diagnosis in patients with colorectal cancer and their illness perceptions**
Ü. Ege Tanrıku¹, S. Kav², ¹Baskent University - Ankara Hospital, Ankara, TR, ²Baskent University, Ankara, TR
- 11:30 - 11:40 **CN14 - Cancer prevention awareness among Croatian AYA population**
N. Dodlek¹, S. Islamčević², J. Miličević², M. Vukoje², A. Sajnic², S. Karabatic³, D. Anić⁴, A. Perković², M. Šušnjara², T. Ladenhauser⁵, I. Jelinčić⁶, ¹University Hospital Center Osijek, Osijek, HR, ²KBC - University Hospital Centre Zagreb, Zagreb, HR, ³KBC Zagreb - Clinic for Lung Diseases Jordanovac, Zagreb, HR, ⁴Osijek-Baranja County Health Center, Osijek, HR, ⁵KBC Osijek - Clinical Medical Center Osijek, Osijek, HR, ⁶Faculty for Medicine and Dental Health Osijek, Osijek, HR
- 11:40 - 11:45 **Q&A and discussion**

10:30 - 11:30 **Type: Multidisciplinary session** **7.3.H - Honfleur Auditorium**
Title: Let's talk about sex and cancer
 Chair(s): Matteo Lambertini, IT

10:30 - 10:35 **Presentation of case/condition**
M. Lambertini, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

10:35 - 10:50 **Implementing onco-fertility care to allow patient access to fertility preservation**
M. Lambertini, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

10:50 - 11:05 **Sexual health: If you don't address it, patients don't ask**
S. Bober, Boston, MA, US

11:05 - 11:20 **Onco-fertility care is not only fertility preservation: Counseling patients about pregnancy and contraception**
I. Demeestere, Brussels, LU

11:20 - 11:30 **Discussion**

10:30 - 11:30 **Type: Challenge your Expert** **7.3.Q - Quimper Auditorium**
Title: Treating KRAS mutant tumour
 Chair(s): Ben Solomon, AU

10:30 - 10:45 **Treating KRAS mutant tumour**
J. Downward, London, GB

10:45 - 11:30 **Discussion led by Chair**
B. Solomon, Peter MacCallum Cancer Center, Melbourne, AU

11:00 - 11:45 **Type: Young Oncologist session** **7.3.R - Rennes Auditorium**
Title: Young Oncologist Brunch 1: Integrating Patient Reported Outcomes in clinical practice
 Chair(s): Claudia Cardone, IT

11:00 - 11:15 **Integrating Patient Reported Outcomes in clinical practice**
M. Di Maio, Azienda Ospedaliera Ordine Mauriziano - Presidio Umberto I, Torino, IT

11:15 - 11:45 **Discussion led by Chair**
C. Cardone, Istituto Nazionale Tumori—IRCCS Fondazione Pascale, Napoli, IT

12:00 - 12:30	Type: Keynote lecture Title: What is the future of digital medicine for cancer patients? Chair(s): Fabrice André, FR	4.B - Brest Auditorium
12:00 - 12:05	Introduction by the Chair <u>F. André</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
12:05 - 12:30	What is the future of digital medicine for cancer patients? <u>D. Schrag</u> , MSKCC - Memorial Sloan Kettering Cancer Center, New York, US	
12:00 - 13:30	Type: EONS Industry Satellite Symposium Title: AstraZeneca, Eli Lilly, Novartis - Experience of living with Early Breast Cancer, treatment and beyond: What are we missing Chair(s): Theresa Wiseman, GB	7.3.S - Strasbourg Auditorium
12:00 - 12:05	Welcome <u>T. Wiseman</u> , The Royal Marsden Hospital - NHS Foundation Trust, London, GB	
12:05 - 12:20	FILM (pre-recorded): How people experience of early breast cancer, impact of diagnosis and treatment <u>T. Wiseman</u> , The Royal Marsden Hospital - NHS Foundation Trust, London, GB	
12:20 - 12:40	Evidence re unmet need for people with early breast cancer in Europe <u>A. Shewbridge</u> , Private Practice, London, GB	
12:40 - 12:55	FILM (pre-recorded): How people experience of early breast cancer, end of treatment and living well <u>T. Wiseman</u> , The Royal Marsden Hospital - NHS Foundation Trust, London, GB	
12:55 - 13:15	Discussion concerning patient film and evidence <u>M. Van Klinken</u> ¹ , <u>E. Wiseman</u> ² , <u>C. Díez De Los Ríos De La Serna</u> ³ , <u>A. Shewbridge</u> ⁴ , ¹ Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL, ² AstraZeneca, Northolt, GB, ³ Vall d'Hebron University Hospital, Barcelona, ES, ⁴ Private Practice, London, GB	
13:15 - 13:25	Recommendations for future practice <u>M. Van Klinken</u> ¹ , <u>T. Wiseman</u> ² , <u>C. Díez De Los Ríos De La Serna</u> ³ , <u>A. Shewbridge</u> ⁴ , ¹ Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL, ² The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ³ Vall d'Hebron University Hospital, Barcelona, ES, ⁴ Private Practice, London, GB	
13:25 - 13:30	Conclusion remarks <u>T. Wiseman</u> , The Royal Marsden Hospital - NHS Foundation Trust, London, GB	

12:00 - 13:00	Type: Special session Title: ONSITE ONLY: Patient guide: How can cancer affect bone health?	Networking Hub
---------------	--	-----------------------

12:00 - 13:00	Speaker panel <u>E. Trigos Arjona</u> ¹ , <u>N. Dodlek</u> ² , <u>C. Ernst-Guenther</u> ³ , <u>A. Deschamps</u> ⁴ , ¹ Hospital Universitari i Politècnic La Fe, Valencia, ES, ² KBC Osijek - Clinical Medical Center Osijek, Osijek, HR, ³ Europa Uomo - Bundesverband Prostatakrebs Selbsthilfe e. V. (BPS), Bonn, DE, ⁴ Europa Uomo - The European Prostate Cancer Coalition, Antwerpen, BE
---------------	---

13:00 - 14:30	Type: Industry Satellite Symposium Title: Incyte Biosciences International Sàrl - Targeting FGFR alterations in cholangiocarcinoma and other solid tumours: A new frontier in personalised medicine Chair(s): David Malka, FR; Juan Valle, GB	7.2.F - Fécamp Auditorium
13:00 - 13:05	Welcome and introduction <u>J. Valle</u> , The Christie NHS Foundation Trust, Manchester, GB	
13:05 - 13:18	Cholangiocarcinoma: The little-known, rare cancer of the biliary tract <u>F.G.M. De Braud</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT	
13:18 - 13:31	The challenges associated with diagnosing intrahepatic cholangiocarcinoma for targeted therapies <u>J. Valle</u> , The Christie NHS Foundation Trust, Manchester, GB	
13:31 - 13:44	Optimising molecular profiling and the multidisciplinary team approach in cholangiocarcinoma <u>A. Lamarca</u> , Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES	
13:44 - 13:58	Clinical practice guidelines for biliary tract cancer: Updates for the management of patients with locally advanced or metastatic intrahepatic cholangiocarcinoma <u>D. Malka</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
13:58 - 14:11	Targeting FGFR alterations in cholangiocarcinoma and other solid tumours <u>A. Hollebecque</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
14:11 - 14:29	Panel discussion <u>J. Valle</u> ¹ , <u>D. Malka</u> ² , <u>F.G.M. De Braud</u> ³ , <u>A. Lamarca</u> ⁴ , <u>A. Hollebecque</u> ² , ¹ The Christie NHS Foundation Trust, Manchester, GB, ² Institut Gustave Roussy, Villejuif, Cedex, FR, ³ Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁴ Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES	
14:29 - 14:30	Closing remarks <u>D. Malka</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	

13:00 - 14:29	Type: Industry Satellite Symposium Title: MSD - Navigating through the rapidly evolving treatment landscape for GI Cancers - A Clinical & Patient Centric Approach towards implementing Immunotherapy Chair(s): Michel Ducreux, FR	7.1.D - Dijon Auditorium
13:00 - 13:05	Introduction and Welcome <u>M. Ducreux</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
13:05 - 13:20	Moving the Needle in HER2 Positive Gastroesophageal Cancer <u>Y. Janjigian</u> , MSKCC - Memorial Sloan Kettering Cancer Center, New York, US	
13:20 - 13:35	Changing GEC Patient Care with IO plus Chemotherapy in First-Line <u>M. Moehler</u> , Universitätsmedizin Mainz, Mainz, DE	
13:35 - 13:47	The IO Revolution of Patient Treatment in HCC <u>R. Finn</u> , UCLA - David Geffen School of Medicine, Los Angeles, US	
13:47 - 13:59	Changing the Treatment Paradigm in First-Line Biliary Tract Cancers <u>A. Vogel</u> , MHH - Medizinische Hochschule Hannover, Hannover, DE	
13:59 - 14:09	Treating GI Patients in Europe Based on Tumor Characteristics <u>M. Ducreux</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
14:09 - 14:24	Final Q&A and Discussion Session <u>M. Ducreux</u> ¹ , <u>Y. Janjigian</u> ² , <u>M. Moehler</u> ³ , <u>R. Finn</u> ⁴ , <u>A. Vogel</u> ⁵ , ¹ Gustave Roussy - Cancer Campus, Villejuif, FR, ² MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ³ Universitätsmedizin Mainz, Mainz, DE, ⁴ UCLA - David Geffen School of Medicine, Los Angeles, US, ⁵ MHH - Medizinische Hochschule Hannover, Hannover, DE	
14:24 - 14:29	Summary and Adjournment <u>M. Ducreux</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	

13:00 - 14:30	Type: Industry Satellite Symposium Title: Pfizer Oncology - Journey through patient care: Long-term experience in advanced breast cancer Chair(s): Paul Cottu, FR	7.3.G - Grenoble Auditorium
13:00 - 13:05	Welcome and Introduction <u>P. Cottu</u> , Institut Curie, Paris, FR	
13:05 - 14:05	Navigating aBC case loads: Balancing evidence with experience <u>P. Cottu</u> ¹ , <u>N. Harbeck</u> ² , <u>N. Turner</u> ³ , ¹ Institut Curie, Paris, FR, ² Ludwig Maximilians University - Grosshadern, Munich, DE, ³ London, GB	
14:05 - 14:25	Questions and discussion <u>P. Cottu</u> ¹ , <u>N. Harbeck</u> ² , <u>N. Turner</u> ³ , ¹ Institut Curie, Paris, FR, ² Ludwig Maximilians University - Grosshadern, Munich, DE, ³ London, GB	
14:25 - 14:30	Summary and close <u>P. Cottu</u> , Institut Curie, Paris, FR	

13:00 - 14:30	Type: ESMO Colloquium Title: ESMO Colloquium Supported by Lilly and Thermo Fisher Scientific: The practice and promise of NGS tissue testing for tumour-agnostic precision therapeutics Chair(s): Vivek Subbiah, US; Javier Hernandez-Losa, ES	7.3.H - Honfleur Auditorium
13:00 - 13:05	Introduction <u>J. Hernandez-Losa</u> , Vall d'Hebron University Hospital, Barcelona, ES	
13:05 - 13:20	Tumour-agnostic precision therapeutics in molecular oncology: Target versus tissue context: Evidence for benefit and taxonomy considerations <u>V. Subbiah</u> , The University of Texas M. D. Anderson Cancer Center, Houston, US	
13:20 - 13:35	NGS tissue testing in the search of actionable biomarkers in solid tumours: When is it indicated? <u>C.B. Westphalen</u> , LMU Klinikum der Universität München, Munich, DE	
13:35 - 13:50	Optimally integrating tumour tissue NGS in the care pathway: Preanalytics, analytics, cost and reimbursement <u>J. Hernandez-Losa</u> , Vall d'Hebron University Hospital, Barcelona, ES	
13:50 - 14:05	The non-small cell lung cancer paradigm in translating NGS information to clear actionable insights: Standardised reporting, molecular tumour boards and decision-support systems <u>O. Gautschi</u> , Luzerner Kantonsspital, Sursee, CH	
14:05 - 14:25	Q&A and discussion	
14:25 - 14:30	Concluding remarks <u>V. Subbiah</u> , The University of Texas M. D. Anderson Cancer Center, Houston, US	

13:00 - 14:30	Type: Industry Satellite Symposium Title: GSK - Avant-garde: Reframing the art of first-line maintenance therapy to optimise long-term outcomes in advanced ovarian cancer Chair(s): Gilles Freyer, FR	7.3.O - Orléans Auditorium
13:00 - 13:10	Welcome and introduction <u>G. Freyer</u> , Hôpital de la Croix-Rousse, Lyon, FR	
13:10 - 13:30	State of the art: What are the most current data and updates to treatment guidelines for first-line maintenance in ovarian cancer <u>D. Lorusso</u> , Rome, IT	
13:30 - 13:50	The art of treatment selection: Importance and impact of early treatment planning <u>C. Gourley</u> , Cancer Research UK Edinburgh Centre, Edinburgh, GB	
13:50 - 14:20	Articles of individualised treatment: How can we begin to individualise treatment using biomarkers and available therapies <u>G. Freyer</u> , Hôpital de la Croix-Rousse, Lyon, FR	
14:20 - 14:30	Closing remarks <u>G. Freyer</u> , Hôpital de la Croix-Rousse, Lyon, FR	

13:00 - 14:30	Type: Industry Satellite Symposium Title: Janssen-Cilag International NV - Precision approaches in EGFR-mutant NSCLC: Optimising outcomes for patients Chair(s): David Planchard, FR; Maria Rosario Garcia Campelo, ES	7.3.Q - Quimper Auditorium
13:00 - 13:05	Welcome & Introduction <u>D. Planchard</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
13:05 - 13:15	Updates in precision approaches to the molecular diagnosis of NSCLC <u>P. Hofman</u> , CHU Nice - Hopital Pasteur, Nice, FR	
13:15 - 13:25	Discussion: How can we address diagnostic challenges of NSCLC in clinical practice? <u>D. Planchard</u> ¹ , <u>M.R. Garcia Campelo</u> ² , <u>S. Popat</u> ³ , <u>A.-M. Dingemans</u> ⁴ , <u>P. Hofman</u> ⁵ , ¹ Institut Gustave Roussy, Villejuif, Cedex, FR, ² Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES, ³ The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ⁴ Erasmus MC - University Medical Center, Rotterdam, NL, ⁵ CHU Nice - Hopital Pasteur, Nice, FR	
13:25 - 13:40	New and emerging therapies for EGFR-mutant NSCLC <u>A.-M. Dingemans</u> , Erasmus MC - University Medical Center, Rotterdam, NL	
13:40 - 13:50	Discussion: What does the future hold for the management of EGFR-mutant NSCLC? <u>D. Planchard</u> ¹ , <u>M.R. Garcia Campelo</u> ² , <u>S. Popat</u> ³ , <u>A.-M. Dingemans</u> ⁴ , <u>P. Hofman</u> ⁵ , ¹ Institut Gustave Roussy, Villejuif, Cedex, FR, ² Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES, ³ The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ⁴ Erasmus MC - University Medical Center, Rotterdam, NL, ⁵ CHU Nice - Hopital Pasteur, Nice, FR	
13:50 - 14:00	Emerging treatment options for EGFR exon 20 insertions <u>S. Popat</u> , The Royal Marsden Hospital - NHS Foundation Trust, London, GB	
14:00 - 14:25	Q&A <u>D. Planchard</u> ¹ , <u>M.R. Garcia Campelo</u> ² , <u>S. Popat</u> ³ , <u>A.-M. Dingemans</u> ⁴ , <u>P. Hofman</u> ⁵ , ¹ Institut Gustave Roussy, Villejuif, Cedex, FR, ² Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES, ³ The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ⁴ Erasmus MC - University Medical Center, Rotterdam, NL, ⁵ CHU Nice - Hopital Pasteur, Nice, FR	
14:25 - 14:30	Key learnings and closing remarks <u>M.R. Garcia Campelo</u> , Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES	

13:00 - 14:30	Type: Industry Satellite Symposium Title: Bristol Myers Squibb - The Treatment Paradigm Shift: Unlocking New Chapters with I-O in Thoracic Cancers Chair(s): Virginie Westeel, FR	7.3.T - Toulouse Auditorium
13:00 - 13:05	Welcome and Introductions <u>V. Westeel</u> , CHRU Besancon - Hopital Jean Minjoz, Besancon, FR	
13:05 - 13:35	Multidisciplinary Conversation: Putting I-O on the Table for Patients with Resectable NSCLC <u>J. Spicer</u> , McGill University, Montreal, CA	
13:35 - 14:00	Considering the Options: Survivorship in Metastatic NSCLC and Potential Approaches for I-O-Experienced Patients <u>V. Westeel</u> , CHRU Besancon - Hopital Jean Minjoz, Besancon, FR	
14:00 - 14:15	Making Progress for Patients: How I-O Has Changed Outcomes in Unresectable MPM <u>D. Fennell</u> , Leicester Royal Infirmary - University Hospitals of Leicester NHS Trust, Leicester, GB	
14:15 - 14:30	Live Q&A and Closing Remarks <u>V. Westeel</u> ¹ , <u>J. Spicer</u> ² , <u>D. Fennell</u> ³ , ¹ CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, ² McGill University, Montreal, CA, ³ Leicester Royal Infirmary - University Hospitals of Leicester NHS Trust, Leicester, GB	

13:00 - 14:30	Type: Patient Advocacy session Title: Patient involvement in clinical research: Placing the patient at the centre Chair(s): Gilliosa Spurrier-Bernard, FR; Jana Pelouchova, CZ	7.3.M - Marseille Auditorium
13:00 - 13:15	The importance of joining clinical research to improve cancer research outcomes <u>W. Van Der Graaf</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL	
13:15 - 13:30	How can patients get involved in clinical trials? <u>E. Verschuur-Van Der Voort</u> , Dutch Breast Cancer Coalition, Bloemendaal, NL	
13:30 - 13:45	How is patient data crucial to advance scientific research? <u>T. Willgoss</u> , EFPIA - European Federation of Pharmaceutical Industries and Associations, Brussels, BE	
13:45 - 14:00	How can patients' involvement in clinical trial design save lives? <u>G. Spurrier-Bernard</u> , MelanomeFrance and Melanoma Patients Network Europe, Teilhet, FR	
14:00 - 14:15	Case study: Patients being involved in clinical research <u>E. Lacointe Artzner</u> , InfoSarcomes, Rennes, FR	
14:15 - 14:25	Discussion	
14:25 - 14:30	Conclusion	

13:00 - 14:30	Type: Industry Satellite Symposium Title: Merck Pfizer Alliance - New approaches to optimize treatment outcomes in advanced urothelial carcinoma Chair(s): Joaquim Bellmunt, US	7.3.U - Urval Auditorium
13:00 - 13:15	Recent milestones in the evolution of Standard of Care treatment in advanced urothelial carcinoma <u>J. Bellmunt</u> , Boston, US	
13:15 - 13:35	Sequencing anticancer agents across lines of therapy in advanced urothelial carcinoma <u>S. Sridhar</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
13:35 - 13:55	Learnings from real-world data to optimize treatment in advanced urothelial carcinoma <u>A. Merseburger</u> , UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE	
13:55 - 14:25	Mini-debates on 'hot topics' in advanced urothelial carcinoma <u>J. Bellmunt</u> ¹ , <u>S. Sridhar</u> ² , <u>A. Merseburger</u> ³ , ¹ Boston, US, ² UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ³ UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE	
14:25 - 14:30	Closing remarks <u>J. Bellmunt</u> , Boston, US	

13:45 - 14:45	Type: EONS session Title: eHealth and digital innovations Chair(s): Wendy Oldenmenger, NL	7.3.S - Strasbourg Auditorium
13:45 - 14:00	Efficiency of eHealth and digital innovations in cancer care <u>A. Charalambous</u> , Cyprus University of Technology - Nursing Science, Limassol, CY	
14:00 - 14:15	Development and implementation of virtual pre-chemotherapy consultations <u>C. Oakley</u> , Guy's Hospital, London, GB	
14:15 - 14:25	CN1 - Patient-reported symptom monitoring improves health-related quality of life in lung cancer patients: The SYMPRO-Lung trial <u>N. Billings</u> ¹ , V. Tromp ¹ , A. Becker ¹ , R. Hoek ¹ , N. Aaronson ² , H.-J. Bogaard ¹ , J. Hugtenburg ¹ , B. Onwuteaka-Philipsen ¹ , L. Van De Poll-Franse ² , J. Belderbos ² , C. Van Den Hurk ³ , I. Walraven ⁴ , ¹ Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, ² NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ³ IKNL - Netherlands Comprehensive Cancer Organisation, Utrecht, NL, ⁴ Radboud University Medical Center, Nijmegen, Nijmegen, NL	
14:25 - 14:35	CN2 - A public involvement process to enhance diversity in technology clinical trials <u>L. Goodwin</u> ¹ , A. Keane ² , K. Harrigan ² , P. Contributors ² , M. Syed Ali ² , L. Lavery ² , S. Saeed ¹ , B. Starling ² , D. Graham ³ , ¹ The Christie NHS Foundation Trust, Manchester, GB, ² The University of Manchester, Manchester, GB, ³ Christie Hospital NHS Foundation Trust, Manchester, GB	
14:35 - 14:45	Q&A and discussion	

14:45 - 16:15	Type: Educational session Title: Is immunotherapy changing the standard of care in gynaecological cancers? Chair(s): Ana Oaknin, ES; Alexandra Leary, FR	4.A - Antibes Auditorium
----------------------	--	---------------------------------

14:45 - 15:10 **Endometrial cancer**
D. Lorusso, Rome, IT

15:10 - 15:35 **Cervical cancer**
A. Oaknin, Vall d'Hebron University Hospital, Barcelona, ES

15:35 - 16:00 **Ovarian cancer**
E. Pujade-Lauraine, ARCAGY-GINECO, Paris, FR

16:00 - 16:15 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

14:45 - 16:15	Type: Mini Oral session Title: Mini Oral session: Breast cancer, metastatic Chair(s): Shaheenah Dawood, AE; Sung-Bae Kim, KR; Shom Goel, AU	7.2.E - Évry Auditorium
----------------------	---	--------------------------------

14:45 - 14:50 **LBA18 - Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+,, HER2+ advanced breast cancer (monarchHER): A randomized, open-label, phase II trial**
F. André¹, J. Nadal², H. Denys³, S. Goel⁴, L. Litchfield⁵, A. Appiah⁵, Y. Chen⁵, S. Tolaney⁶,
¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Instituto Alexander Fleming, Buenos Aires, AR, ³UZ Gent - Universitair Ziekenhuis Gent, Gent, BE, ⁴Peter MacCallum Cancer Centre, Melbourne, AU, ⁵Eli Lilly and Company - Global Headquarters, Indianapolis, US, ⁶Dana Farber Cancer Institute, Boston, US

14:50 - 14:55 **LBA19 - Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial**
B. Xu¹, M. Yan², F. Ma¹, W. Li³, Q. Ouyang⁴, Z. Tong⁵, Y. Teng⁶, S. Wang⁷, Y. Wang⁸, C. Geng⁹, T. Luo¹⁰, J. Zhong¹¹, Q. Zhang¹², Q. Liu¹³, X. Zeng¹⁴, T. Sun¹⁵, Q. Mo¹⁶, F. Dong¹⁷, S. Wu¹⁷, X. Zhu¹⁷, ¹Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ²Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN, ³The First Hospital of Jilin University, Changchun, CN, ⁴Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN, ⁵Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, ⁶The First Hospital of China Medical University, Shenyang, CN, ⁷Sun Yat-sen University Cancer Center, Guangzhou, CN, ⁸Shandong Cancer Hospital & Institute, Jinan, CN, ⁹The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital, Shijiazhuang, CN, ¹⁰West China Hospital, Sichuan University, Chengdu, CN, ¹¹The First Affiliated Hospital of Guangxi Medical University, Nanning, CN, ¹²Cancer Hospital Harbin Medical University, Harbin, CN, ¹³Sun Yat-sen Memorial Hospital, Sun Yat-sen University,

Guangzhou, CN, ¹⁴Affiliated Cancer Hospital of Chongqing University, Chongqing, CN, ¹⁵Liaoning Cancer Hospital & Institute, Shenyang, CN, ¹⁶Guangxi Medical University Affiliated Tumor Hospital, Nanning, CN, ¹⁷Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, CN

14:55 - 15:05 **Invited Discussant LBA18 and LBA19**

S.-B. Kim, Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR

15:05 - 15:10 **LBA20 - Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER⁺/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors**

M. Goetz¹, P. Plourde², D. Stover³, N. Bagegni⁴, G. Vidal⁵, A. Brufsky⁶, H. Rugo⁷, D. Portman², E. Gal-Yam⁸, ¹Mayo Clinic, Rochester, US, ²Sermonix Pharmaceuticals, Columbus, US, ³OSUCCC - The Ohio State University Comprehensive Cancer Center - James, Columbus, US, ⁴Washington University School of Medicine in St. Louis - Siteman Cancer Center, St. Louis, US, ⁵West Cancer Center and Research Institute - East Campus, Germantown, US, ⁶Comprehensive Breast Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, US, ⁷UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ⁸Chaim Sheba Medical Center, Ramat Gan, IL

15:10 - 15:15 **211MO - Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER⁺, HER2⁻; locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acELERA BC study**

M. Martin Jimenez¹, E. Lim², M. Chavez Mac Gregor³, A. Bardia⁴, J. Wu⁵, Q. Zhang⁶, Z. Nowecki⁷, F. Cruz⁸, R. Safin⁹, S.-B. Kim¹⁰, C. Schem¹¹, A. Montero¹², S. Khan¹³, R. Bandyopadhyay¹⁴, M. Shivhare¹⁵, M. Patre¹⁶, J. Martinalbo¹⁶, L. Roncoroni¹⁶, P. Pérez-Moreno¹⁴, J. Sohn¹⁷, ¹Hospital General Universitario Gregorio Marañón, Madrid, ES, ²St Vincent's Clinical School, Darlinghurst, AU, ³MD Anderson Cancer Center, Houston, US, ⁴Harvard Medical School, Boston, US, ⁵Fudan University Cancer Institute, Shanghai, CN, ⁶Harbin Medical University Cancer Hospital, Harbin, CN, ⁷Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL, ⁸De Controle Do Cancer-IBCC Nucleo De Pesquisa Sao-Camilo, São Paulo, BR, ⁹Ministry of Health of the Republic of Tatarstan, Kazan, RU, ¹⁰University of Ulsan College of Medicine, Seoul, KR, ¹¹Mammazentrum Hamburg, Hamburg, DE, ¹²University Hospitals Seidman Cancer Center, Cleveland, US, ¹³City Hospital Campus, Nottingham, GB, ¹⁴Genentech, Inc., South San Francisco, US, ¹⁵Roche Products Limited, Welwyn Garden City, GB, ¹⁶F. Hoffmann-La Roche Ltd, Basel, CH, ¹⁷Yonsei University College of Medicine, Seoul, KR

15:15 - 15:20 **212MO - AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician's choice (TPC) in patients (pts) with endocrine-resistant ER⁺/HER2⁻; advanced breast cancer (aBC)**

S. Tolaney¹, A. Chan², K. Petrakova³, S. Delaloge⁴, M. Campone⁵, H. Iwata⁶, P. Peddi⁷, P. Kaufman⁸, E. De Kermadec⁹, Q. Liu⁹, P. Cohen¹⁰, G. Paux⁹, S.-A. Im¹¹, ¹Dana Farber Cancer Institute, Boston, US, ²Curtin University, Perth, AU, ³Masaryk Memorial Cancer Institute, Brno, CZ, ⁴Institut Gustave Roussy, Villejuif, FR, ⁵Institut de cancérologie de l'Ouest, Saint-Herblain, FR, ⁶Aichi Cancer Center Hospital, Nagoya, JP, ⁷Providence Saint

John's Cancer Institute, Santa Monica, US, ⁸University of Vermont - Larner College of Medicine, Burlington, US, ⁹Sanofi, Cambridge, US, ¹⁰Sanofi, Vitry-sur-Seine, FR, ¹¹Seoul National University Hospital, Seoul National University College of Medicine, Seoul, KR

- 15:20 - 15:35 **Invited Discussant LBA20, 211MO and 212MO**
S. Dawood, Mediclinic City Hospital, Dubai, AE
- 15:35 - 15:40 **213MO - Primary endpoint analysis of a randomized phase II of darolutamide or capecitabine in patients with triple-negative androgen receptor-positive advanced breast cancer (UCBG3-06 START trial)**
M. Arnedos¹, A. Goncalves², M. Pulido³, F. Lerebours⁴, O. Tredan⁵, F. Dalenc⁶, S. Guiu⁷, D. Mollon Grange⁸, L. Teixeira⁹, C. Levy¹⁰, B. Verret¹¹, H. Dawood¹², P. Augereau¹³, L. Deiana¹⁴, S. Ladoire¹⁵, E. Carola¹⁶, M.A. Mouret Reynier¹⁷, C. Guyonneau¹⁸, G. Macgrogan¹⁹, H. Bonnefoi¹⁹, ¹Institute Bergonié, Bordeaux, FR, ²Institute Paoli Calmettes, Marseille, FR, ³Institut Bergonie, BORDEAUX, FR, ⁴Hôpital René Huguenin - Institut Curie, St. Cloud, FR, ⁵Centre Léon Bérard, Lyon, FR, ⁶Centre Claudius-Régaud, Toulouse, FR, ⁷ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, ⁸Centre Hospitalier de Cornouaille - Site de Laennec, Quimper, Cedex, FR, ⁹Hopital Saint Louis AP-HP, Paris, FR, ¹⁰Centre Francois Baclesse, Caen, FR, ¹¹Gustave Roussy, VILLEJUIF, FR, ¹²CHR Orléans, Orléans, FR, ¹³Centre Paul Papin, Angers, FR, ¹⁴CHRU Brest - Hopital Augustin Morvan, Brest, FR, ¹⁵Centre Georges-François Leclerc (Dijon), Dijon, FR, ¹⁶GHPSO, Creil, FR, ¹⁷Jean Perrin Center, Clermont-Ferrand, FR, ¹⁸Unicancer, Paris, FR, ¹⁹Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR
- 15:40 - 15:45 **214MO - Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR⁺/HER2⁻) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study**
P. Schmid¹, J. Cortés², F. Marmé³, H. Rugo⁴, S. Tolaney⁵, M. Oliveira⁶, D. Loirat⁷, K. Jhaveri⁸, O.K. Yoon⁹, M. Motwani⁹, H. Wang⁹, R. Delaney⁹, A. Bardia¹⁰, ¹Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB, ²International Breast Cancer Center (IBCC), Quiron Group, Madrid & Barcelona, Barcelona, ES, ³Heidelberg University, University Hospital Mannheim, Mannheim, DE, ⁴University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ⁵Dana Farber Cancer Institute, Boston, US, ⁶Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁷Institut Curie, Paris, FR, ⁸Memorial Sloan Kettering, New York, NY, US, ⁹Gilead Sciences, Inc., Foster City, US, ¹⁰Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US
- 15:45 - 15:50 **215MO - ICON [®]; a randomized phase IIb study evaluating chemotherapy combined with ipilimumab and nivolumab in metastatic hormone receptor-positive breast cancer**
J.A. Kyte¹, N. Andresen¹, C. Quaghebeur², B. Gilje³, B. Boge⁴, A. Gombos⁵, A. Røssevold¹, R. Mathiesen⁶, E. Borgen⁷, R.S. Falk⁸, L. Julsrud⁷, H.G. Russnes⁹, O.C. Lingjærde⁷, B. Naume¹, ¹Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, ²CHR - Centre Hospitalier Régional de Namur, Namur, BE, ³Stavanger University Hospital - Helse Stavanger HF, Stavanger, NO, ⁴Sørlandet Hospital HF, Kristiansand, NO, ⁵Institute

Jules Bordet, Brussels, BE, ⁶Oslo University Hospital, Ulleval, Oslo, NO, ⁷Oslo University Hospital, Oslo, NO, ⁸Oslo University Hospital - Rikshospitalet, Oslo, NO, ⁹Oslo University Hospital - Radiumhospitalet, Oslo, NO

15:50 - 15:55 **216MO - A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER⁺/HER2- metastatic breast cancer (MBC): The METEORA-II trial (IBCSG 54-16)**
E. Munzone¹, M. Regan², S. Cinieri³, E. Montagna¹, L. Orlando³, R. Shi², E. Campadelli⁴, L. Gianni⁵, U. De Giorgi⁶, C. Bengala⁷, D. Generali⁸, E. Collova⁹, F. Puglisi¹⁰, E. Cretella¹¹, C. Zamagni¹², C. Chini¹³, A. Goldhirsch¹, M. Colleoni¹, ¹IEO - Istituto Europeo di Oncologia, Milan, IT, ²Dana Farber Cancer Institute, Boston, US, ³Ospedale A. Perrino, Brindisi, IT, ⁴Ospedale degli Infermi - AUSL Romagna, Faenza, IT, ⁵Ospedale Infermi, Rimini, IT, ⁶IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, IT, ⁷Ospedale della Misericordia, Grosseto, IT, ⁸Università di Trieste, Trieste, IT, ⁹Ospedale Civile di Legnano, Legnano, IT, ¹⁰CRO di Aviano, National Cancer Institute, IRCCS; Department of Medicine (DAME), University of Udine, Udine, IT, ¹¹Ospedale Centrale di Bolzano ASDAA/SABES, Bolzano, IT, ¹²IRCCS Azienda-ospedaliero-universitaria di Bologna, Bologna, IT, ¹³ASST - Sette Laghi, Varese, IT

15:55 - 16:10 **Invited Discussant 213MO, 214MO, 215MO and 216MO**
S. Goel, Peter MacCallum Cancer Centre, Melbourne, AU

14:45 - 16:15	Type: Proffered Paper session Title: Proffered Paper session 1: Melanoma and other skin tumours Chair(s): Caroline Robert, FR; Ryan Sullivan, US	7.2.F - Fécamp Auditorium
---------------	--	----------------------------------

14:45 - 14:55 **784O - Adjuvant nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma with no evidence of disease (NED): Overall survival (OS) results of IMMUNED, a randomized, double-blind multi-center phase II DeCOG trial**
D. Schadendorf¹, J. Hassel², M. Fluck³, T. Eigentler⁴, C. Loquai⁵, S. Haferkamp⁶, R. Gutzmer⁷, F. Meier⁸, P. Mohr⁹, A. Hauschild¹⁰, C. Menzer¹¹, F. Kiecker¹², E. Dippel¹³, J.-C. Simon¹⁴, B. Conrad³, C. Garbe¹⁵, S. Körner¹⁶, J.C. Becker¹⁷, L. Zimmer¹, E. Livingstone¹, ¹University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ²NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE, ³Fachklinik Hornheide, Münster, DE, ⁴Charité - Universitätsmedizin Berlin, Berlin, DE, ⁵Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, ⁶UKR - University Hospital Regensburg, Regensburg, DE, ⁷Ruhr University Bochum Medizinische Universitätsklinik, Bochum, DE, ⁸Universitätsklinikum Carl Gustav Carus Dresden, Dresden, DE, ⁹Dermatologic Center Buxtehude, Buxtehude, DE, ¹⁰UK-SH Campus Kiel, Kiel, DE, ¹¹Heidelberg University Hospital, Heidelberg, DE, ¹²Vivantes Klinikum Neukoelln, Berlin, DE, ¹³Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, DE, ¹⁴Universitätsklinikum Leipzig Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Leipzig, DE, ¹⁵Universitäts-Hautklinik Tuebingen, Tuebingen, DE, ¹⁶University Hospital Heidelberg, Heidelberg, DE, ¹⁷DKFZ - German Cancer Research Center, Heidelberg, DE

- 14:55 - 15:05 **LBA39 - Final 5-year results of the phase II, multicenter, randomized, open-label trial of talimogene laherparepvec (T-VEC) neoadjuvant treatment (Tx) plus surgery vs immediate surgery in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL)**
- R. Dummer¹, D. Gyorki², J. Hyngstrom³, A. Berger⁴, R. Conry⁵, L. Demidov⁶, L. Ning⁷, T. Lawrence⁸, M. Faries⁹, M. Ross¹⁰, ¹Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, ²Olivia Newton-John Cancer Centre, Victoria, AU, ³University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US, ⁴Rutgers Cancer Institute of New Jersey, New Brunswick, US, ⁵University of Alabama at Birmingham - School of Medicine, Birmingham, US, ⁶N.N. Blokhin Russian Cancer Research Center, Moscow, RU, ⁷Parexel China Co. Ltd., Guangzhou, CN, ⁸AMGEN (Headquarters) - USA, Thousand Oaks, US, ⁹The Angeles Clinic and Research Institute, Los Angeles, US, ¹⁰MD Anderson Cancer Center, Houston, US
- 15:05 - 15:15 **Invited Discussant 7840 and LBA39**
- C. Robert, Institut Gustave Roussy, Villejuif, Cedex, FR
- 15:15 - 15:30 **Q&A**
- 15:30 - 15:40 **LBA40 - Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600- or NRAS-mutant melanoma**
- C. Lebbe¹, G. Long², C. Robert³, O. Hamid⁴, V. Atkinson⁵, A. Shoushtari⁶, A. Daud⁷, O. Bechter⁸, D. Schadendorf⁹, R. Sullivan¹⁰, R. Dummer¹¹, J.J. Grob¹², N. Lewis¹³, L. Fan¹³, S. Basu¹³, G. Caponigro¹³, V. Cooke¹³, A. Lau¹³, R. Amaria¹⁴, ¹Université Paris Cité, AP-HP Hôpital Saint-Louis, Paris, FR, ²Melanoma Institute Australia, University of Sydney and Royal North Shore and Mater Hospitals, Sydney, AU, ³Institut Gustave Roussy, Villejuif, FR, ⁴The Angeles Clinic and Research Institute, A Cedars Sinai Affiliate, Los Angeles, CA, US, ⁵Princess Alexandra Hospital, University of Queensland, Brisbane, AU, ⁶Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US, ⁷University of California, San Francisco, CA, US, ⁸University Hospital Leuven, Leuven, BE, ⁹University Hospital Essen, Essen, DE, ¹⁰Massachusetts General Hospital, Boston, MA, US, ¹¹University Hospital Zürich, Zurich, CH, ¹²Timone AP-HM Hospital, Marseille, FR, ¹³Novartis Institutes for BioMedical Research, Cambridge, US, ¹⁴University of Texas M.D. Anderson Cancer Center, Houston, US
- 15:40 - 15:50 **7850 - PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL)**
- A. Diab¹, H. Gogas², S. Sandhu³, G. Long⁴, P. Ascierto⁵, J. Larkin⁶, M. Sznol⁷, F. Franke⁸, T.-E. Ciuleanu⁹, E. Muñoz Couselo¹⁰, A. Perfetti¹¹, C. Lebbe¹², F. Meier¹³, B. Curti¹⁴, C. Rojas¹⁵, H. Yang¹⁶, M. Zhou¹⁶, S. Ravimohan¹⁶, M. Tagliaferri¹⁷, N. Khushanlani¹⁸, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²National and Kapodistrian University of Athens, Athens, GR, ³Peter MacCallum Cancer Centre, Melbourne, AU, ⁴Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, AU, ⁵Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, IT, ⁶The Royal Marsden Hospital, London, GB, ⁷Yale Cancer Center, Yale University School of Medicine and Smilow Cancer Hospital Yale New Haven Health, New

Haven, US, ⁸Oncosite Centro de Pesquisa Clínica, Ijuí, BR, ⁹Institutul Prof Dr Ion Chiricuță, Cluj-Napoca, RO, ¹⁰Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology VHIO, Barcelona, ES, ¹¹Clínica Adventista Belgrano, Buenos Aires, AR, ¹²Université Paris Cité, APHP Dermatology and CIC Paris, Paris, FR, ¹³Skin Cancer Center at the University Cancer Centre Dresden and National Center for Tumor Diseases Dresden, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, DE, ¹⁴Providence Portland Medical Center, Portland, US, ¹⁵Bradford Hill Clinical Research Center, Santiago, CL, ¹⁶Bristol Myers Squibb, Princeton, US, ¹⁷Nektar Therapeutics, San Francisco, US, ¹⁸Moffitt Cancer Center, Tampa, US

15:50 - 16:00 **Invited Discussant LBA40 and 785O**

O. Michielin, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

16:00 - 16:15 **Q&A**

14:45 - 16:15 Type: Mini Oral session 7.3.O - Orléans Auditorium
Title: Mini Oral session: Investigational immunotherapy
 Chair(s): Inge-Marie Svane, DK; Alessandra Curioni, CH

14:45 - 14:50 **729MO - Final results of the first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in combination with nivolumab in subjects with solid tumors relapsed/refractory to prior anti-PD1/PD-L1 treatment**

I. Melero¹, M.J. De Miguel², G. Alonso Casal³, M.-E. Goebeler⁴, E. Ramelyte⁵, E. Calvo⁶, E. Garralda³, R. Dummer⁵, M. Rodríguez-Ruiz⁷, C.M. Sayehli⁴, M. Sanmamed⁷, J. Ramón⁸, M.J. Lostes Bardaji³, T. Gromke⁹, M. Schuler⁹, P. Fettes¹⁰, K. Klar¹⁰, C. Schuberth-Wagner¹⁰, J. Wischhusen¹¹, E. Leo¹⁰, ¹Clinica Universitaria de Navarra, Pamplona, ES, ²START MADRID, Hospital Universitario HM Sanchinarro - CIOCC, Madrid, ES, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴UKW - University Hospital Wuerzburg, Wuerzburg, DE, ⁵Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, ⁶HM Sanchinarro University Hospital, Madrid, ES, ⁷Clinica Universidad de Navarra, Pamplona, ES, ⁸HM University Sanchinarro Hospital, Madrid, ES, ⁹University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ¹⁰Catalym GmbH, Martinsried Planegg, DE, ¹¹University of Würzburg, Wuerzburg, DE

14:50 - 14:55 **730MO - First-in-human phase I study of INCAGN02390, a TIM-3 monoclonal antibody antagonist in patients with advanced malignancies**

M. Gutierrez¹, S.-C. Tang², J. Powderly³, A. Balmanoukian⁴, J. Janik⁵, P. Hoyle⁵, W. Wei⁵, X. Gong⁵, O. Hamid⁶, ¹Hackensack University Medical Center, Hackensack, US, ²University of Mississippi Medical Center, Jackson, US, ³Carolina BioOncology Institute, Huntersville, US, ⁴The Angeles Clinic and Research Institute - West Los Angeles, Los Angeles, US, ⁵Incyte Corporation, Wilmington, US, ⁶The Angeles Clinic and Research Institute, A Cedars Sinai Affiliate, Los Angeles, CA, US

14:55 - 15:00 **731MO - A phase I trial of the bifunctional EGFR/TGFβ2; fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors**

G. Hanna¹, A. Hernando Calvo², V. Morris³, R. Carvajal⁴, P. Paik⁵, D. Zandberg⁶, J. Kaczmar⁷, L. Niculescu⁸, R. Reiners⁸, D. Bohr⁸, E. Gharakhani⁸, R. Salazar⁸, S. Bilic⁹, P. Bedard², ¹Dana Farber Cancer Institute, Boston, US, ²UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ³The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁴Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, ⁵MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ⁶UPMC Hillman Cancer Center, Pittsburgh, US, ⁷MUSC Health Hollings Cancer Center, Charleston, US, ⁸Bicara Therapeutics, Inc., Cambridge, US, ⁹Vanadro, LLC., Waukegan, US

- 15:00 - 15:15 **Invited Discussant 729MO, 730MO and 731MO**
I.-M. Svane, Herlev and Gentofte Hospital, Herlev, DK
- 15:15 - 15:20 **732MO - The combination of ICT01, a β 3 β 4;2 T cell-activating mAb, plus pembrolizumab induces a broad antitumor immune response and disease control in patients with CPI-failure melanoma, NSCLC and bladder cancer: EVICTION trial**
S. Champiat¹, M. Wermke², C. Vicier³, J. De Bono⁴, C. Jungels⁵, N. Vey³, N. Kotecki⁵, K. Wetzko⁶, L. Ruhnke², E. Garralda⁷, V. Galvao De Aguiar⁸, P. Lorusso⁹, A. De Gassart¹⁰, E. Valentin¹⁰, P. Brune¹⁰, M. Iche¹¹, C. Leparquier¹¹, D. Olive¹², A. Marabelle¹³, P. Frohna¹⁴, ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE, ³IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ⁴The Institute of Cancer Research and The Royal Marsden Hospital, London, GB, ⁵Institute Jules Bordet, Brussels, BE, ⁶Universitätsklinikum Carl Gustav Carus Dresden - Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Dresden, DE, ⁷Hospital Universitario Vall d'Hebron, Barcelona, ES, ⁸Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁹Yale Cancer Center, New Haven, US, ¹⁰ImCheck Therapeutics SAS, Marseille, Cedex, FR, ¹¹Ilife Consulting, Argenteuil, FR, ¹²CRCM centre de recherche en cancérologie de marseille, Marseille, FR, ¹³Institut Gustave Roussy, Villejuif, Cedex, FR, ¹⁴IMCHECK THERAPEUTICS SAS, Marseille, FR
- 15:20 - 15:25 **733MO - β 3 β 4;T cells are effectors of immune checkpoint blockade in mismatch repair-deficient colon cancers with antigen presentation defects**
J. Van De Haar¹, N. De Vries², V. Veninga¹, M. Chalabi¹, M. Ijsselsteijn², M. Van Der Ploeg², J. Van Den Bulk², D. Ruano², J. Haanen¹, T. Schumacher¹, L. Wessels¹, F. Koning², N. De Miranda², E. Voest¹, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²LUMC-Leiden University Medical Center, Leiden, NL
- 15:25 - 15:30 **734MO - Deep sequencing of the T-cell receptor reveals common and reproducible CD8 T-cell receptor signatures of response to checkpoint immunotherapy**
R. Watson¹, C. Taylor¹, O. Tong¹, R. Cooper¹, I. Nassiri¹, E. Jungkurth¹, P.K. Sharma¹, A. Verge De Los Aires¹, E. Ieremia², M. Middleton³, B. Fairfax⁴, ¹The MRC Weatherall Institute of Molecular Medicine Oxford, Oxford, GB, ²Oxford University Hospitals NHS Foundation Trust, Oxford, GB, ³Churchill Hospital, Oxford, GB, ⁴University of Oxford, Oxford, GB

15:30 - 15:45	Invited Discussant 732MO, 733MO and 734MO <u>S. Kobold</u> , LMU Klinikum der Universität München, Munich, DE	
15:45 - 15:50	735MO - Updated safety and efficacy from SURPASS, the phase I trial of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in previously treated patients with unresectable or metastatic tumors <u>D.S. Hong</u> ¹ , A. Asch ² , E. Calvo ³ , J. Zugazagoitia ⁴ , J. Charlson ⁵ , M. Butler ⁶ , V. Moreno Garcia ⁷ , A. Cervantes ⁸ , B. Van Tine ⁹ , D. Lawrence ¹⁰ , M. Johnson ¹¹ , Q. Lin ¹² , T. Annareddy ¹² , F. Brophy ¹² , R. Broad ¹³ , A. Derrac Soria ¹³ , J.-M. Navenot ¹² , J. Saro ¹³ , E. Norry ¹² , J. Clarke ¹⁴ , ¹ The University of Texas MD Anderson Cancer Center, Houston, US, ² Stephenson Cancer Center, Oklahoma University Health Science Center, Oklahoma City, US, ³ START Madrid-CIOCC, Madrid, ES, ⁴ Hospital Universitario 12 de Octubre, Madrid, ES, ⁵ Medical College of Wisconsin, Milwaukee, US, ⁶ Princess Margaret Cancer Centre, Toronto, CA, ⁷ START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, ES, ⁸ University of Valencia, Valencia, ES, ⁹ Washington University School of Medicine, St. Louis, US, ¹⁰ Massachusetts General Hospital, Boston, US, ¹¹ Sarah Cannon Research Institute, Nashville, US, ¹² Adaptimmune, Philadelphia, US, ¹³ Adaptimmune, Abingdon, Oxfordshire, GB, ¹⁴ Duke Cancer Center, Durham, US	
15:50 - 15:55	736MO - Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS) <u>C. Kyi</u> ¹ , A. Spira ² , D. Carbone ³ , M. Johnson ⁴ , B. Henick ⁵ , B. Johnson ⁶ , H. Borghaei ⁷ , A. Mahipal ⁸ , J. Hecht ⁹ , D. Catenacci ¹⁰ , C.-Y. Liao ¹¹ , A. Shergill ¹¹ , R. Memmott ³ , C. Presley ³ , J. Jaroslavsky ¹² , D. Schenk ¹² , K. Jooss ¹² , A. Ferguson ¹² , J. Goldman ⁹ , ¹ Memorial Sloan Kettering Cancer Center, New York, US, ² Virginia Cancer Specialist, Fairfax, US, ³ The Ohio State University - OSU Wexner Medical Center, Columbus, US, ⁴ Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ⁵ Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, ⁶ MD Anderson Cancer Center, Houston, US, ⁷ Fox Chase Cancer Center - Main Campus, Philadelphia, US, ⁸ Mayo Clinic, Rochester, US, ⁹ UCLA Hematology/Oncology Santa Monica, Santa Monica, US, ¹⁰ Catenacci Consulting Ltd, Chicago, IL, US, ¹¹ University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, ¹² Gritstone bio, Inc., Emeryville, US	
15:55 - 16:00	737MO - EpCAM-targeted CAR-T cell therapy in patients with advanced colorectal and gastric cancers <u>W. Fang</u> ¹ , T. Luo ² , Z. Lu ² , H. Zhang ¹ , C. Tong ¹ , S. Wang ³ , F. Tang ³ , G. Ai ³ , ¹ The First Affiliated Hospital of Zhejiang University, Hangzhou, CN, ² The First Affiliated Hospital of Naval Medical University/Changhai Hospital of Shanghai, Shanghai, CN, ³ Suzhou Immunofoco Biotechnology Co., Ltd, Suzhou, CN	
16:00 - 16:15	Invited Discussant 735MO, 736MO and 737MO <u>A. Curioni</u> , USZ - University Hospital Zürich, Zurich, CH	
14:45 - 16:15	Type: Proffered Paper session Title: Proffered Paper session: Haematological malignancies	7.3.Q - Quimper Auditorium

Chair(s): Catherine Thieblemont, FR; Thomas Cluzeau, FR

- 14:45 - 14:55 **6170 - Lemzoparlimab, a differentiated anti-CD47 monoclonal antibody, in combination with azacitidine (AZA) in patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS): Initial clinical results**
C. Chang¹, Z. Xiao², Q. Li³, X. Yan⁴, T. Qin², H. Tong⁵, M. Dai⁶, Y. He⁷, J. Weng⁸, J. Li⁹, S. Gao¹⁰, R. Fu¹¹, X. Wei¹², X. Ma¹³, Y. Zhang¹³, W. Huang¹³, Q. Wang¹³, L. Gu¹³, Y. Meng¹³, A. Zhu¹³, ¹Shanghai Sixth People's Hospital, Shanghai, CN, ²Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin, CN, ³Union Hospital affiliated to Tongji Medical, College of Huazhong University of Science and Technology, Wuhan, CN, ⁴The First Affiliated Hospital of China Medical University, Shenyang, CN, ⁵the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN, ⁶Nanfang Hospital of Southern Medical University, Guangzhou, CN, ⁷Zhujiang Hospital of Southern Medical University, Guangzhou, CN, ⁸Guangdong Provincial People's Hospital, Guangzhou, CN, ⁹Peking Union Medical College Hospital, Beijing, CN, ¹⁰The First Hospital of Jilin University, Changchun, CN, ¹¹Tianjin Medical University General Hospital, Tianjin, CN, ¹²Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ¹³I-Mab Biopharma Co., Ltd. - Headquarter, Shanghai, CN
- 14:55 - 15:05 **Invited Discussant 6170**
T. Cluzeau, Hopital del l'Archet, Nice, FR
- 15:05 - 15:15 **Q&A**
- 15:15 - 15:25 **6180 - A phase I study of TRS005: An anti-CD20-MMAE antibody-drug conjugate, in relapsed or refractory b cell non-Hodgkin lymphoma**
Y.-K. Shi¹, Z.-M. Li², Y. Qing³, H. Zhang⁴, Y. Jia⁵, H. Jing⁶, Y. Li⁷, X. Tong⁸, H. Liu⁹, L. Li¹⁰, ¹Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, Beijing, CN, ²Sun Yat-sen University Cancer Center, Guangzhou, CN, ³cancer hospital Chinese academy of medical sciences, Beijing, CN, ⁴TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ⁵Affiliated Hospital of Hebei University, Baoding, CN, ⁶Peking University Third Hospital, Beijing, CN, ⁷Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ⁸Zhejiang Provincial People's Hospital, Hangzhou, CN, ⁹Beijing Hospital, Beijing, CN, ¹⁰The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN
- 15:25 - 15:35 **6190 - shRNA-mediated PD1 gene knock-down anti-CD19 CAR-T cell therapy for relapsed/refractory b cell malignancies**
H. Cen, Q. Ke, Z. Li, D. Zhou, M. Wang, J. Sun, C. Liao, Guangxi Medical University Affiliated Tumor Hospital and Oncology Medical Center, Nanning, CN
- 15:35 - 15:45 **6200 - CART-ddBCMA for multiple myeloma: Interim results from phase I study**
M. Frigault¹, J. Rosenblatt², N. Raje¹, D. Cook¹, M. Gaballa³, E. Emmanuel-Alejandro¹, C. Cornwell⁴, K. Banerjee⁴, A. Rotte⁴, C. Heery⁴, D. Avigan², A. Jakubowiak⁵, M. Bishop⁵, ¹MGH - Massachusetts General Hospital, Boston, US, ²Beth Israel Deaconess Medical Center, Boston, US, ³Massachusetts General Hospital - Surgical Oncology Division,

Boston, US, ⁴Arcellx, Gaithersburg, US, ⁵University of Chicago Medicine, Chicago, US

15:45 - 16:00 **Invited Discussant 6180, 6190 and 6200**

C. Thieblemont, Hopital Saint Louis AP-HP, Paris, FR

16:00 - 16:10 **Q&A**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

14:45 - 16:15 Type: Mini Oral session 7.3.T - Toulouse Auditorium
Title: Mini Oral session: GI, upper digestive

Chair(s): Maeve Lowery, IE; Florian Lordick, DE; Teresa Macarulla Mercade, ES

14:45 - 14:50 **LBA61 - HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: A multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC)**

L. Wang¹, S. Qin², Y. Zhou³, S. Zhang⁴, X. Sun⁵, Z. Chen⁶, J. Cui⁷, P. Zhao⁸, K. Gu⁹, Z. Li¹⁰, J. Wang¹¹, X. Chen¹¹, J. Yao¹², L. Shen¹³, J. Zhou¹³, G. Wang¹⁴, Y. Bai¹⁵, Q. Wang¹⁶, H. Wang¹⁶, ¹Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, CN, ²Nanjing Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, CN, ³Zhongshan Hospital Affiliated with Fudan University, Shanghai, CN, ⁴West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN, ⁵Jiangsu Cancer Hospital, Nanjing, CN, ⁶The Second Affiliated Hospital of Anhui Medical University, Hefei, CN, ⁷Bethune First Hospital of Jilin University, Changchun, CN, ⁸The First Affiliated Hospital, Zhejiang University School Of Medicine, Hangzhou, CN, ⁹The First Affiliated Hospital of Anhui Medical University, Hefei, CN, ¹⁰Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN, ¹¹Henan Cancer Hospital, Zhengzhou, CN, ¹²The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, CN, ¹³Beijing Cancer Hospital, Beijing, CN, ¹⁴The First Affiliated Hospital of USTC, Hefei, CN, ¹⁵Harbin Medical University Cancer Hospital, Harbin, CN, ¹⁶Jiangsu Hengrui Pharmaceutical Co., Ltd, Shanghai, CN

14:50 - 14:55 **1296MO - PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC)**

M. Ducreux¹, R. Desgrippes², Y. Rinaldi³, F. Di Fiore⁴, R. Guimbaud⁵, P. Follana⁶, J.-B. Bachet⁷, P. Vanelslender⁸, T. Lecomte⁹, O. Capitain¹⁰, A. Parzy¹¹, M. Bolliet¹², P.-L. Etienne¹³, J. Forestier¹⁴, F. El Hajbi¹⁵, A.L. Bignon Bretagne¹⁶, V. Ly Lebrun¹⁷, N. De Sousa Carvalho¹⁸, M. Texier¹⁹, O. Bouche²⁰, ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²C.H. Broussais, Saint-Malo, FR, ³Hopital Européen Marseille, Marseille, FR, ⁴CHU de Rouen Normandie, Rouen, FR, ⁵Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil, Toulouse, FR, ⁶Centre Anticancer Antoine Lacassagne, Nice, FR, ⁷Groupe Hospitalier Pitié Salpetriere, Paris, FR, ⁸Hôpital Saint Claude, Saint-Quentin, FR, ⁹CHU de Tours, Hôpital Trousseau, Chambray-lès-Tours, FR, ¹⁰Centre Paul Papin, Angers, FR, ¹¹Centre Francois Baclesse, Caen, FR, ¹²Hopitaux Civils de Colmar, Colmar, FR, ¹³Hôpital Privé des Côtes d'Armor, Plérin sur mer, FR, ¹⁴Hopital Edouard Herriot, Lyon, FR, ¹⁵Centre Oscar Lambret, Lille, FR, ¹⁶CHU de Caen - Hopital Cote de Nacre, Caen, FR, ¹⁷CHU Limoges - Hopital Dupuytren, Limoges, FR, ¹⁸Unicancer, Paris, Cedex, FR,

¹⁹Institut Gustave Roussy, Villejuif, FR, ²⁰CHU de Reims - Hôpital Robert Debré, Reims, Cedex, FR

14:55 - 15:10 **Invited Discussant LBA61 and 1296MO**

T. Macarulla Mercade, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

15:10 - 15:15 **52MO - A randomized phase II trial of durvalumab and tremelimumab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladder Carcinoma (IMMUCHEC)**

A. Vogel¹, S. Boeck², O. Waidmann³, M. Bitzer⁴, P. Wenzel⁵, S. Belle⁶, C. Springfield⁷, K. Schulze⁸, A. Weinmann⁹, U. Lindig¹⁰, C. Trautwein¹¹, T. Dechow¹², F. Lammert¹³, R. Plentz¹⁴, C.-H. Koehne¹⁵, V. Kunzmann¹⁶, M. Maenz¹⁷, M.M. Kirstein¹, A. Saborowski¹, ¹MHH - Medizinische Hochschule Hannover, Hannover, DE, ²LMU - Ludwig Maximilians University of Munich, Munich, DE, ³Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, DE, ⁴Universitätsklinikum Tuebingen Medizinische Universitätsklinik, Tuebingen, DE, ⁵Klinikum Rechts der Isar - Technische Universität München, Munich, DE, ⁶UMM - Universitätsklinikum Mannheim, Mannheim, DE, ⁷NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE, ⁸UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ⁹Universitätsmedizin Mainz, Mainz, DE, ¹⁰Jena University Hospital, Friedrich-Schiller, Jena, DE, ¹¹Uniklinik RWTH Aachen, Aachen, DE, ¹²Onkologie Hamatologie Ravensburg, Ravensburg, DE, ¹³UKS - Klinik für Innere Medizin II - Gastroenterologie und Endokrinologie, Homburg, DE, ¹⁴Gesundheit Nord-Klinikverbund Bremen - Klinikum Bremen Nord, Bremen, DE, ¹⁵Klinikum Oldenburg, Oldenburg, DE, ¹⁶University Clinic Würzburg-Medizinische Klinik und Poliklinik II Zentrum fuer Innere Medizin (ZIM), Würzburg, DE, ¹⁷CORBIN - Clinical Oncology Resources Berlin GmbH, Berlin, DE

15:15 - 15:20 **53MO - Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC – AIO-HEP-0116)**

A. Vogel¹, P. Wenzel², G. Folprecht³, P. Schütt⁴, H. Wege⁵, A. Kretschmar⁶, L. Jacobasch⁷, N. Ziegenhagen⁸, S. Boeck⁹, S. Kanzler¹⁰, J. Mohm¹¹, S. Belle¹², D. Pink¹³, T. Götze¹⁴, E. Goekkurt¹⁵, U. Graeven¹⁶, M. Schaaf¹⁷, M. Kirstein¹⁸, A. Saborowski¹, ¹Hannover Medical School, Hannover, DE, ²University Hospital rechts der Isar, Munich, DE, ³Universitätsklinikum Carl Gustav Carus, Dresden, DE, ⁴Oncodoc GmbH, Gütersloh, DE, ⁵University Medical Center Hamburg-Eppendorf, Hamburg, DE, ⁶Medical Care Center MVZ Mitte, Leipzig, DE, ⁷Gemeinschaftspraxis BAG- Joint Practice for Oncology, Dresden, DE, ⁸HELIOS Hospital Berlin-Buch, Berlin, DE, ⁹LMU - Ludwig Maximilians University of Munich, Munich, DE, ¹⁰Leopoldina Hospital, Schweinfurt, DE, ¹¹Onkopraxis, Dresden, DE, ¹²University of Heidelberg, Mannheim, DE, ¹³University Medicine Greifswald, Bad Saarow, DE, ¹⁴University Cancer Center Frankfurt- Marburg, Frankfurt am Main, DE, ¹⁵Hematological Oncology, Hamburg, DE, ¹⁶Kliniken Maria Hilf - St. Franziskus Hospital, Mönchengladbach, DE, ¹⁷KHNW - Krankenhaus Northwest GmbH, Frankfurt am Main, DE, ¹⁸University Medical Center Schleswig-Holstein, Campus Luebeck, Luebeck, DE

15:20 - 15:25 **54MO - Quality of life (QoL) and value of health (V-He) in advanced biliary**

cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial

A. Lamarca¹, D. Palmer², H. Wasan³, P. Ross⁴, Y.T. Ma⁵, A. Arora⁶, S. Falk⁷, R. Gillmore⁸, J. Wadsley⁹, K. Patel¹⁰, A. Anthoney¹¹, A. Maravellas¹², J. Waters¹³, C. Hoobs¹⁴, T. Macdonald¹⁵, D. Ryder¹⁵, J. Ramage¹⁶, L. Davies¹⁵, J. Bridgewater¹⁷, J. Valle¹⁵, ¹The Christie NHS Foundation Trust, Manchester, GB, ²The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, GB, ³Hammersmith Hospital - Imperial College Healthcare NHS Trust, London, GB, ⁴Guy's Hospital, London, GB, ⁵The University of Birmingham - Institute for Cancer Studies, Birmingham, GB, ⁶City Hospital Campus - Nottingham University Hospitals NHS Trust, Nottingham, GB, ⁷NHS, Bristol, GB, ⁸Royal Free Hospital, London, GB, ⁹Weston Park Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, ¹⁰John Radcliffe Hospital University of Oxford, Oxford, GB, ¹¹St. James's University Hospital - Leeds Teaching Hospitals NHS Trust, Leeds, GB, ¹²Castle Hill Hospital - Hull University Teaching Hospitals NHS Trust, Cottingham, GB, ¹³Maidstone Hospital - Maidstone and Tunbridge NHS Trust, Maidstone, GB, ¹⁴The Great Western Hospital, Swindon, GB, ¹⁵The University of Manchester, Manchester, GB, ¹⁶NHS Hampshire Hospitals Foundation Trust - Basingstoke and North Hampshire Hospital, Basingstoke, GB, ¹⁷UCL Cancer Institute - Paul O'Gorman Building, London, GB

15:25 - 15:40 **Invited Discussant 52MO, 53MO, 54MO**

M. Lowery, Trinity College Dublin, Dublin, IE

15:40 - 15:45 **1204MO - PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma**

D. Tougeron¹, L. Dahan², F. El Hajbi³, K. Le Malicot⁴, L. Evesque⁵, T. Aparicio⁶, O. Bouche⁷, N. Bonichon Lamichhane⁸, B. Chibaudel⁹, A. Angelergues¹⁰, A. Bodere¹¹, J.M. Phelip¹², M. Mabro¹³, P. Artru¹⁴, C. Louvet¹⁵, ¹CHU Poitiers - Jean Bernard Hôpital, Poitiers, FR, ²AP-HM - CHU La Timone Enfants, Marseille, FR, ³Centre Oscar Lambret, Lille, FR, ⁴Fédération Francophone de Cancérologie Digestive, Dijon, FR, ⁵Centre Anticancer Antoine Lacassagne, Nice, FR, ⁶Hopital Saint Louis AP-HP, Paris, FR, ⁷CHU de Reims - Hôpital Robert Debré, Reims, Cedex, FR, ⁸Tivoli Ducos Clinique, Bordeaux, FR, ⁹Franco-britannique hospital, paris, FR, ¹⁰Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, FR, ¹¹Saint Malo hospital, Saint Malo, FR, ¹²CHU Saint Etienne - Hopital Nord, Saint-Étienne, FR, ¹³Hopital Foch, Suresnes, FR, ¹⁴Hôpital privé Jean Mermoz, Lyon, FR, ¹⁵IMM - Institut Mutualiste Montsouris, Paris, FR

15:45 - 15:50 **1205MO - Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen**

G. Ku¹, M. Di Bartolomeo², E. Smyth³, I. Chau⁴, H. Park⁵, S. Siena⁶, S. Lonardi⁷, Z. Wainberg⁸, J. Ajani⁹, J. Chao¹⁰, F. Barlaskar¹¹, Y. Kawaguchi¹¹, A. Qin¹¹, J. Singh¹¹, G. Meinhardt¹¹, E. Van Cutsem¹², ¹Memorial Sloan Kettering Cancer Center, New York, US, ²Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ³Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB, ⁴The Royal Marsden Hospital, London, GB, ⁵Siteman Cancer Center, Washington University, St. Louis, US, ⁶Università degli

Studi di Milano and Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, IT, ⁷Veneto Institute of Oncology IOV-IRCCS, Padova, IT, ⁸UCLA, Los Angeles, US, ⁹The University of Texas MD Anderson Cancer Center, Houston, US, ¹⁰City of Hope Medical Center, Duarte, US, ¹¹Daiichi Sankyo, Basking Ridge, US, ¹²University Hospital Gasthuisberg, Leuven and KU Leuven, Leuven, BE

15:50 - 16:05 **Invited Discussant 1204MO and 1205MO**

F. Lordick, Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, DE

14:45 - 16:15 **Type: Proffered Paper session** **7.3.M - Marseille Auditorium**
Title: Proffered Paper session: Policy and preventive strategies
 Chair(s): Ravindran Kanesvaran, SG; Christophe Massard, FR

14:45 - 14:55 **1312O - From regulating off-label use to creating an environment for drug repurposing in oncology**

S. Van Waalwijk Van Doorn-Khosrovani¹, A. Pisters¹, E. Breugel², L. Timmers³, E. Voest⁴, H. Bloemendal⁵, F. Eskens⁶, M. Wymenga⁷, ¹CZ Health Insurance, Tilburg, NL, ²VGZ Health Insurance, Eindhoven, NL, ³Dutch National Health Care Institute, Diemen, NL, ⁴NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁵Radboud University Medical Center, Nijmegen, Nijmegen, NL, ⁶Erasmus MC - University Medical Center, Rotterdam, NL, ⁷Hospital Medisch Spectrum Twente, Enschede, NL

14:55 - 15:05 **1313O - Assessment of investigational new drugs (INDs) approved in USA and Europe after early phase trials using the ESMO-magnitude of clinical benefit scale (ESMO-MCBS)**

J. Moyers¹, D. Benjamin¹, D. Brazel², P. Kumar², V. Subbiah³, ¹UCI Health - University of California Irvine, Orange, US, ²UC Irvine Medical Center, Orange, US, ³The University of Texas M. D. Anderson Cancer Center, Houston, US

15:05 - 15:15 **Invited Discussant 1312O and 1313O**

P. Kanavos, The London School of Economics and Political Science, London, GB

15:15 - 15:25 **Q&A**

15:25 - 15:35 **1314O - Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer: The MetAction precision medicine study**

A. Ree¹, G.M. Mælandsmo², K. Flatmark², H.G. Russnes², M. Gómez Castañeda³, E. Aas³, ¹Akershus University Hospital HF, Lorenskog, NO, ²Oslo University Hospital - Radiumhospitalet, Oslo, NO, ³University of Oslo, Oslo, NO

15:35 - 15:45 **1315O - Key learnings from building: A precision cancer medicine implementation initiative for Norway**

K. Tasken¹, H.G. Russnes², E. Aas³, L. Bjorge⁴, E.S. Blix⁵, E. Enerly⁶, L. Fagereng², Å.

Flobak⁷, B. Gilje⁸, B.T. Gjertsen⁹, T.K. Guren¹, J. Heix¹⁰, E. Hovig², R. Hovland⁹, P.E. Lonning⁹, P.M. Mæhle¹¹, H.L. Nilsen¹², S. Thoresen¹³, S. Smeland¹, A. Helland¹⁴, ¹Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, ²Oslo University Hospital - Radiumhospitalet, Oslo, NO, ³University of Oslo, Oslo, NO, ⁴Helse Bergen HF, Bergen, NO, ⁵University Hospital of North Norway, Tromsø, NO, ⁶Cancer Registry of Norway, Oslo, NO, ⁷St. Olavs Hospital HF, Trondheim, NO, ⁸Stavanger University Hospital - Helse Stavanger HF, Stavanger, NO, ⁹Haukeland University Hospital, Bergen, NO, ¹⁰Oslo Cancer Cluster, Oslo, NO, ¹¹Oslo University Hospital, Oslo, NO, ¹²Akershus University Hospital HF, Lorenskog, NO, ¹³Merck AB Norway, Oslo, NO, ¹⁴University of Oslo, Institute of Clinical medicine, Oslo, NO

15:45 - 15:55

1316O - Improved nationwide survival of sarcoma patients 10 years after establishment of the NETSARC+ reference center network

J.-Y. Blay¹, A. Italiano², N. Penel³, E. Bompas⁴, F. Duffaud⁵, C. Chevreau⁶, P. Anract⁷, C. Perrin⁸, N. Firmin⁹, M. Toulmonde¹⁰, S. Piperno-Neumann¹¹, S. Watson¹¹, M. Rios¹², J.E. Kurtz¹³, F. Bertucci¹⁴, F. Le Loarer¹⁵, C. Chemin¹, M. Morelle¹⁶, F. Gouin¹, A. Le Cesne¹⁷, ¹Centre Léon Bérard, Lyon, FR, ²Institute Bergonié, Bordeaux, FR, ³Centre Oscar Lambret, Lille, FR, ⁴ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁵CHU La Timone Adultes, Marseille, FR, ⁶Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ⁷Hopital Cochin AP-HP, Paris, FR, ⁸Centre Eugene - Marquis, Rennes, FR, ⁹Icm Val D Aurelle, Montpellier, FR, ¹⁰Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ¹¹Institut Curie, Paris, FR, ¹²Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, ¹³CHU Hautepierre, Strasbourg, FR, ¹⁴IPC - Institut Paoli-Calmettes, Marseille, FR, ¹⁵Institut Bergonie, Bordeaux, FR, ¹⁶Center Leon Berard, Lyon, FR, ¹⁷Gustave Roussy - Cancer Campus, Villejuif, FR

15:55 - 16:05

Invited Discussant 1314O, 1315O and 1316O

C. Massard, Gustave Roussy - Cancer Campus, Villejuif, FR

16:05 - 16:15

Q&A

14:45 - 16:15	Type: Special session Title: Elements to build a Molecular Tumour Board Chair(s): Alice Indini, IT; Michiel Strijbos, BE	7.3.U - Urval Auditorium
14:45 - 14:50	Introduction <u>M. Strijbos</u> , GZA Ziekenhuizen Campus Sint-Augustinus, Wilrijk, BE	
14:50 - 15:10	Defining the role of the pathologist in the era of Next Generation Sequencing <u>G. Pruneri</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT	
15:10 - 15:30	Next Generation Sequencing: Power and pitfalls <u>A. Czarnecka</u> , Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL	
15:30 - 15:50	Novel therapeutic targets and tumour agnostic treatment <u>A. Italiano</u> , Institute Bergonié, Bordeaux, FR	
15:50 - 16:10	Challenges in the clinical application of Molecular Tumour Boards <u>A. Indini</u> , Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Milan, IT	
16:10 - 16:15	Discussion and Q&A	

15:00 - 16:15	Type: Multidisciplinary session Title: Management of challenging situation in urinary cancers Chair(s): Robert Huddart, GB	7.1.C - Cannes Auditorium
----------------------	--	----------------------------------

15:00 - 15:05	Presentation of case/condition <u>A. Fay</u> , PUCRS - Escola de Medicina, Porto Alegre, BR	
15:05 - 15:20	Rare variants of bladder cancer management: The role of radiation therapy <u>R. Huddart</u> , Royal Marsden Hospital Institute of Cancer Research, Sutton, GB	
15:20 - 15:35	Emerging systemic therapies in rare urothelial cancer variants <u>B. McGregor</u> , Boston, MA, US	
15:35 - 15:50	The role of systemic therapy in brain metastases from RCC: Targeted therapy and immunotherapy <u>S. Negrier</u> , Lyon, FR	
15:50 - 16:05	The emerging role of SBRT in treating the primary and distant metastases from Renal cancer <u>S. Siva</u> , Melbourne, AU	
16:05 - 16:15	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

15:00 - 16:00	Type: Challenge your Expert Title: HIPEC for peritoneal carcinomatosis Chair(s): Cornelis Punt, NL	7.1.D - Dijon Auditorium
----------------------	--	---------------------------------

15:00 - 15:15	Presentation by Expert <u>D. Goéré</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
15:15 - 16:00	Discussion led by Chair <u>C. Punt</u> , Utrecht, NL	

15:00 - 16:10 **Type: Multidisciplinary session** **7.3.G - Grenoble Auditorium**
Title: How can we collaborate better as a multidisciplinary team to develop novel therapeutics?
 Chair(s): Eric Deutsch, FR

15:00 - 15:15 **Can novel radiotherapy techniques pave the way for new combinations?**
E. Deutsch, Institut Gustave Roussy, Villejuif, FR

15:15 - 15:30 **Building infrastructure in academia for truly translational clinical research: going from bedside to the bench (reverse translation)**
S. Turajlic, The Royal Marsden Hospital - Chelsea, London, GB

15:30 - 15:45 **COVID as a catalyst for remodelling approaches to early phase clinical trial development in a resource challenged environment**
E. Calvo, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES

15:45 - 16:05 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

15:00 - 16:00 **Type: Multidisciplinary session** **7.3.H - Honfleur Auditorium**
Title: Locally advanced N2/stage III NSCLC
 Chair(s): Myung-Ju Ahn, KR

15:00 - 15:05 **Presentation of case/condition**
M.-J. Ahn, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR

15:05 - 15:20 **Systemic approaches in locally advanced N2/stage III NSCLC: EGFR mutation versus wildtype**
M.-J. Ahn, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR

15:20 - 15:35 **Radiotherapy approaches in locally advanced N2/stage III NSCLC**
S. Senan, Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL

15:35 - 15:50 **Considerations for staging and surgical intervention**
E. Lim, London, GB

15:50 - 16:00 **Discussion**

15:00 - 16:30	Type: EONS Industry Satellite Symposium Title: Bristol Myers Squibb - Cancer Nursing Considerations for comprehensive care in CAR T-Cell Therapy Chair(s): Johan De Munter, BE	7.3.S - Strasbourg Auditorium
----------------------	--	--------------------------------------

15:00 - 15:05	Introduction <u>J. De Munter</u> , UZ Gent - Universitair Ziekenhuis Gent, Gent, BE	
15:05 - 15:30	CART, IEC, BITE - what does the new technology mean for patients with solid malignancies <u>S. Rottey</u> , UZ Gent - University Hospital Ghent, Gent, BE	
15:30 - 15:55	Prehab to rehab for patients with CAR T cell therapy - optimising health and wellbeing <u>M. De Ruijter</u> , VU University Medical Centre, Amsterdam, NL	
15:55 - 16:20	What supportive care do patients need? <u>M. Hellberg-Nägele</u> , USZ - University Hospital Zürich, Zurich, CH	
16:20 - 16:30	Q&A and Conclusion remarks <u>J. De Munter</u> , UZ Gent - Universitair Ziekenhuis Gent, Gent, BE	

15:00 - 16:00	Type: Young Oncologist session Title: ON-SITE ONLY: Medical student session Chair(s): Andres Cervantes, ES	7.3.L - Lyon
----------------------	--	---------------------

15:00 - 15:15	How to prepare and present your first poster at a congress <u>P. Sobczuk</u> , Medical University of Warsaw, Warsaw, PL	
15:15 - 16:00	Poster walk <u>K.H.J. Lim</u> ¹ , <u>P. Sobczuk</u> ² , <u>R. Sanchez Bayona</u> ³ , <u>E. Connolly</u> ⁴ , <u>M. Kfoury</u> ⁵ , ¹ The Francis Crick Institute, London, GB, ² Medical University of Warsaw, Warsaw, PL, ³ Hospital Universitario 12 de Octubre, Madrid, ES, ⁴ Chris O'Brien Lifehouse, Camperdown, AU, ⁵ Institut Gustave Roussy, Villejuif, Cedex, FR	

16:30 - 18:00	Type: Proffered Paper session Title: Presidential Symposium I Chair(s): Solange Peters, CH; Fabrice André, FR	6.P - Paris Auditorium
----------------------	---	-------------------------------

16:30 - 16:45	LBA1 - Mechanism of action and an actionable inflammatory axis for air pollution induced non-small cell lung cancer: Towards molecular cancer prevention <u>C. Swanton</u> ¹ , W. Hill ¹ , E. Lim ² , C. Lee ¹ , C. Weeden ² , M. Augustine ³ , K. Chen ⁴ , F.-C. Kuan ⁵ , F. Marongiu ⁶ , F. Rodrigues ² , H. Cha ⁷ , T. Jacks ⁸ , M. Luchtenborg ⁹ , I. Malanchi ¹ , J. Downward ² , C. Carlsten ¹⁰ , A. Hackshaw ¹¹ , K. Litchfield ¹² , J. Degregori ⁶ , M. Jamal-	
---------------	---	--

Hanjani¹³, ¹Francis Crick Institute, London, GB, ²The Francis Crick Institute, London, GB, ³UCL - University College London, London, GB, ⁴Peking University People's Hospital, Beijing, CN, ⁵Chang Gung Medical Foundation - Chiayi Chang Gung Memorial Hospital, Puzi City, TW, ⁶UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, ⁷Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ⁸Koch Institute For Integrative Cancer Research at MIT, Cambridge, US, ⁹Public Health England, London, GB, ¹⁰UBC - The University of British Columbia, Vancouver, CA, ¹¹Cancer Research UK & University College London Cancer Trials Centre, London, GB, ¹²UCL Cancer Institute - UCL - London's Global University, London, GB, ¹³UCL Cancer Institute - Paul O'Gorman Building, London, GB

16:45 - 16:55 **Invited Discussant LBA1**

S. Delaloge, Institut Gustave Roussy, Villejuif, FR

16:55 - 17:10 **LBA2 - DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT)**

B. Kasper¹, R. Ratan², T. Alcindor³, P. Schoeffski⁴, W. Van Der Graaf⁵, B. Wilky⁶, R. Riedel⁷, A. Lim⁸, L.M. Smith⁸, S. Moody⁹, S. Attia¹⁰, S. Chawla¹¹, G. D'Amato¹², N. Federman¹³, P. Merriam¹⁴, B. Van Tine¹⁵, B. Vincenzi¹⁶, S. Kummar¹⁷, M. Gounder¹⁸, ¹UMM - Universitaetsklinikum Mannheim, Mannheim, DE, ²MD Anderson Cancer Center, Houston, US, ³McGill University Health Centre - Glen Site - Royal Victoria Hospital, Montreal, CA, ⁴KU Leuven - Laboratory of Experimental Oncology, Leuven, BE, ⁵NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁶University of Colorado Anschutz Medical Campus, Aurora, CO, US, ⁷Duke Cancer Center, Durham, US, ⁸SpringWorks Therapeutics, Stamford, US, ⁹PharPoint Research, Inc., Durham, US, ¹⁰Mayo Clinic Cancer Center, Phoenix, US, ¹¹Sarcoma Oncology Research Center, Santa Monica, US, ¹²Sylvester Comprehensive Cancer Center - University of Miami, Miami, US, ¹³UCLA - David Geffen School of Medicine, Los Angeles, US, ¹⁴Dana Farber Cancer Institute, Boston, US, ¹⁵Washington University School of Medicine in St. Louis, St. Louis, US, ¹⁶Policlinico Universitario Campus Bio-Medico, Rome, IT, ¹⁷Oregon Health & Science University, Portland, US, ¹⁸Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

17:10 - 17:20 **Invited Discussant LBA2**

J.-Y. Blay, Centre Léon Bérard, Lyon, FR

17:20 - 17:35 **LBA3 - Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial**

J. Haanen¹, M. Rohaan¹, T. Borch², J. Van Den Berg¹, Ö. Met², M. Geukes Foppen¹, J. Stolténborg Granhøj², B. Nuijen¹, C. Nijenhuis¹, J. Beijnen¹, I. Jedema¹, M. Van Zon¹, I. Mansfield Noringriis², R. Kessels¹, S. Wilgenhof¹, H. Van Thienen¹, F. Lalezari¹, A. Van Akkooi¹, M. Donia², I.-M. Svane², ¹Netherlands Cancer Institute, Amsterdam, NL, ²National Center for Cancer Immune Therapy, Herlev, DK

17:35 - 17:45 **Invited Discussant LBA3**

I. Melero, Clinica Universitaria de Navarra, Pamplona, ES

17:45 - 18:00 **Q&A and discussion**

16:30 - 18:00 **Type: Educational session** **7.1.C - Cannes Auditorium**
Title: The three “Ws” of early breast cancer management
 Chair(s): Evandro de Azambuja, BE; Nadia Harbeck, DE

16:30 - 16:55 **Gene expression profiling and chemotherapy: Who to test, which test, and when**
A. Prat, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

16:55 - 17:20 **Neo-adjuvant therapy in luminal breast cancer: Who to treat, which regimen, and what duration?**
N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE

17:20 - 17:45 **Adjuvant endocrine therapy: Who needs more than 5 years, which regimen, and what duration beyond 5 years?**
E. De Azambuja, Institute Jules Bordet, Brussels, BE

17:45 - 18:00 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

16:30 - 18:00	Type: Special symposium Title: New avenues for targeting biological mechanisms in sarcoma Chair(s): Breelyn Wilky, US; Paul Huang, GB	7.1.D - Dijon Auditorium
----------------------	---	---------------------------------

16:30 - 16:35	Introduction and scientific background <u>B. Wilky</u> , UCHHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US	
16:35 - 16:50	Targeting the “crack” DNA damage repair deficiency in sarcomas <u>P. Huang</u> , ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB	
16:50 - 17:05	Understanding the sarcoma genome <u>F. Amary</u> , The Royal National Orthopaedic Hospital - RNOH - NHS Trust, Stanmore, GB	
17:05 - 17:20	Targeting the epigenetics regulatory machinery in sarcoma <u>A. Italiano</u> , Institute Bergonié, Bordeaux, FR	
17:20 - 17:35	Defining molecular targets for immunotherapy <u>B. Wilky</u> , UCHHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US	
17:35 - 17:40	Conclusions and perspectives <u>P. Huang</u> , ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB	
17:40 - 18:00	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

16:30 - 18:00	Type: Mini Oral session Title: Mini Oral session: Supportive and palliative care Chair(s): Antonio Di Meglio, FR; Gudrun Kreye, AT; Maryam Lustberg, US	7.3.G - Grenoble Auditorium
----------------------	---	------------------------------------

16:30 - 16:35	1425MO - Use of psychosocial services and 1-year mortality among newly diagnosed and distressed cancer patients: A real-world study <u>J. Cho</u> ¹ , D. Kang ¹ , S. Kim ² , J. Lee ² , J.S. Ahn ¹ , ¹ Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ² SAIHST - Samsung Advanced Institute for Health Sciences & Technology, SKKU, Seoul, KR	
16:35 - 16:40	1554MO - Perspectives of patients with metastatic breast cancer on exercise interventions: Results from a survey in five European countries <u>M. Sweegers</u> ¹ , J. Depenbusch ² , N. Aaronson ¹ , Y. Wengström ³ , M. Backman ³ , N. Gunasekara ⁴ , D. Clauss ⁴ , M. Pelaez ⁵ , M. Lachowicz ⁶ , A. May ⁷ , K. Steindorf ² , M. Stuiver ¹ , ¹ NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ² DKFZ - German Cancer Research Center, Heidelberg, DE, ³ Karolinska Institute,	

Huddlinge, SE, ⁴German Sport University Cologne, Cologne, DE, ⁵Onkologikoa Fundazioa, Donostia, ES, ⁶Medical University of Gdansk, Gdansk, PL, ⁷University Medical Center Utrecht, Utrecht, NL

- 16:40 - 16:45 **1555MO - Effects of exercise on sleep quality and cancer-related fatigue during neurotoxic chemotherapy**
J. Müller¹, C. Kreutz², A. Schneeweiss³, G.M. Haag⁴, K. Steindorf², M. Weiler⁴, J. Wiskemann¹, ¹Heidelberg University Hospital - National National Center for Tumor Diseases (NCT), Heidelberg, DE, ²DKFZ - German Cancer Research Center, Heidelberg, DE, ³Heidelberg University Hospital and German Cancer Research Center, Heidelberg, DE, ⁴Heidelberg University Hospital, Heidelberg, DE
- 16:45 - 17:00 **Invited Discussant 1425MO, 1554MO and 1555MO**
A. Di Meglio, Institut Gustave Roussy - INSERM UMR 981, Villejuif, FR
- 17:00 - 17:05 **1556MO - The iBLAD study: Patient-reported outcomes in bladder cancer during oncological treatment: A multicenter national randomized controlled trial**
G.A. Taarnhøj¹, C. Johansen², A. Carus³, R.H. Dahlrot⁴, L. Dohn⁵, H. Lindberg⁵, H. Pappot¹, ¹University Hospital Copenhagen, Rigshospitalet, Copenhagen, DK, ²University of Copenhagen - Faculty of Health and Medical Sciences, Copenhagen, DK, ³Aalborg University Hospital, Aalborg, DK, ⁴Odense University Hospital, Odense, DK, ⁵Herlev and Gentofte Hospital, Herlev, DK
- 17:05 - 17:10 **1557MO - Phase II trial evaluating effect of gonyautoxins (GTX), a paralytic shellfish poisoning (PSP) on objective and subjective symptoms of chemotherapy-induced peripheral neuropathy (CIPN)**
M. Dias¹, L. Landeiro², R. Cunha Guimaraes³, F. Copati⁴, M. Mano⁵, F. Souza Lima⁶, C. Naurath⁷, C. Orellana⁸, F. Rondao⁹, R. Dienstmann⁹, J. Canedi⁹, B. Ferrari⁹, C.G. Ferreira¹, ¹Grupo Oncoclinicas Botafogo, Rio de Janeiro, BR, ²NOB - Nucleo de Oncologia da Bahia - Grupo Oncoclinicas, Salvador, BR, ³Grupo Oncoclinicas - Oncocentro, Belo Horizonte, BR, ⁴UFU - Universidade Federal de Uberlandia - Faculdade de Medicina (FAMED), Uberlandia, BR, ⁵Hospital Sirio Libanes - Complexo Hospitalar Bela Vista, Sao Paulo, BR, ⁶HUPE - Hospital Universitário Pedro Ernesto - UERJ, Rio de Janeiro, BR, ⁷Brazilian National Cancer Institute, Rio de Janeiro, BR, ⁸Algenis SpA, Santiago, CL, ⁹Grupo Oncoclinicas, Sao Paulo, BR
- 17:10 - 17:15 **1558MO - Dissecting sexual health after breast cancer (BC) by longitudinal assessment of patient reported outcomes**
M.A. Franzoi¹, M. Aupomerol², J. Havas¹, H. Hang¹, A. Di Meglio¹, M. Lambertini³, C. Massarotti³, C. Coutant⁴, O. Tredan⁵, F. Joly Lobbedez⁶, P. Cottu⁷, D. Soldato³, M.-A. Mouret⁸, C. Tarpin⁹, A. Arnaud¹⁰, L. Fasse², S. Everhard¹¹, A.-L. Martin¹¹, B. Pistilli², I. Vaz Luis¹, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Institut Gustave Roussy, Villejuif, FR, ³IRCCS Ospedale Policlinico San Martino, Genova, IT, ⁴Centre Georges Francois Leclerc, Dijon, FR, ⁵Medical Oncology, Lyon, FR, ⁶Centre Francois Baclesse, Caen, Cedex, FR, ⁷Institut Curie, Paris, FR, ⁸Centre Jean PERRIN, Clermont-Ferrand, Cedex, FR, ⁹IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ¹⁰Institut Sainte-Catherine, Avignon, FR, ¹¹UNICANCER, Paris, FR

- 17:15 - 17:30 **Invited Discussant 1556MO, 1557MO and 1558MO**
M. Lustberg, Yale University School of Medicine, New Heaven, US
- 17:30 - 17:35 **LBA70 - COVID-19 in cancer patients: Update from the joint analysis of ESMO-CoCARE, BSMO, PSMO international databases**
E. Romano¹, L. Castelo-Branco², Z. Tsourti³, E. De Azambuja⁴, S. Gennatas⁵, J. Oliveira⁶, J. Rogado⁷, M. Sekacheva⁸, S. Susnjar⁹, D. Vinal Lozano¹⁰, R. Lee¹¹, S. Khallaf¹², G. Dimopoulou¹³, S. Pradervand¹⁴, D. Arnold¹⁵, K. Harrington¹⁶, O. Michielin¹⁷, U. Dafni¹⁸, G. Pentheroudakis², S. Peters¹⁴, ¹Institut Curie, Paris, FR, ²ESMO - European Society for Medical Oncology, Lugano, CH, ³Frontier Science Foundation Hellas, Athens, GR, ⁴Institute Jules Bordet, Brussels, BE, ⁵The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB, ⁶Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE (IPO-Porto), Porto, PT, ⁷Hospital Universitario Infanta Leonor, Madrid, ES, ⁸Sechenov First Moscow State Medical University, Moscow, RU, ⁹Institute for Oncology and Radiology of Serbia, Belgrade, RS, ¹⁰Hospital Universitario La Paz, Madrid, ES, ¹¹The University of Manchester, Manchester, GB, ¹²SECI - South Egypt Cancer Institute - Assiut University, Assiut, EG, ¹³FSF-H - Frontier Science Foundation Hellas, Athens, GR, ¹⁴CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ¹⁵Asklepios Klinik Altona - Asklepios Kliniken, Hamburg, DE, ¹⁶The Royal Marsden/The Institute of Cancer Research NIHR Biomedical Research Centre, London, GB, ¹⁷Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ¹⁸National and Kapodistrian University of Athens, Athens, GR
- 17:35 - 17:40 **1264MO - Development and validation of a unifying pre-treatment decision tool for intracranial and extracranial metastasis-directed radiotherapy**
R. Kowalchuk¹, T. Mullikin², W. Breen¹, H. Gits¹, M. Florez³, B. De³, W. Harmsen¹, P. Rose¹, B. Siontis¹, B. Costello¹, J. Morris¹, J. Lucido¹, K. Olivier¹, B. Stish¹, N. Laack¹, S. Park¹, D. Owen¹, A. Ghia³, P. Brown¹, K. Merrell⁴, ¹Mayo Clinic, Rochester, US, ²Duke Cancer Center - Duke University Medical Center, Durham, US, ³MD Anderson Cancer Center, Houston, US, ⁴Mayo Clinic Cancer Center, Rochester, US
- 17:40 - 17:45 **1265MO - Cause and place of death in older patients with cancer: Results from a large cohort study using linked clinical and population-based data**
V. Depoorter¹, K. Vanschoenbeek², L. Decoster³, H. De Schutter², P. Debruyne⁴, I. De Groof⁵, D. Bron⁶, F. Cornelis⁷, S. Luce⁸, C. Focan⁹, V. Verschaeve¹⁰, G. Debugne¹¹, C. Langenaeken¹², H. Van Den Bulck¹³, J.-C. Goeminne¹⁴, K. Milisen¹⁵, J. Flamaing¹⁵, C. Kenis¹⁵, F. Verdoodt², H. Wildiers¹⁶, ¹KU Leuven, Leuven, BE, ²Belgian Cancer Registry, Brussels, BE, ³UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE, ⁴Medical Technology Research Institute (MTRI), School of Life Sciences, Anglia Ruskin University, Cambridge, GB, ⁵AZ Sint-Augustinus - Oncologisch Centrum GZA - Iridium Kankernetwerk, Antwerpen, BE, ⁶Institute Jules Bordet - ULB, Brussels, BE, ⁷Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE, ⁸Erasmus University Hospital-(Universite Libre de Bruxelles), Brussels, BE, ⁹Clinique CHC-MontLégia, Groupe Santé CHC-Liège, Liège, BE, ¹⁰GHdC - Grand Hopital de Charleroi, Charleroi, BE, ¹¹Centre Hospitalier de Mouscron, Mouscron, BE, ¹²AZ Klina, Brasschaat, BE, ¹³Imelda Hospital, Bonheiden, BE, ¹⁴CHU-UCL-Namur, Namur, BE, ¹⁵University Hospitals Leuven - KU Leuven, Leuven, BE, ¹⁶University Hospitals Leuven - KU Leuven, Leuven, BE

17:45 - 18:00 **Invited Discussant LBA70, 1264MO and 1265MO**

G. Kreye, Universitätsklinikum Krems, Krems an der Donau, AT

16:30 - 17:30 **Type: Multidisciplinary session** **7.3.H - Honfleur Auditorium**
Title: Treating oligometastatic oesophagogastric cancer
 Chair(s): Hanneke van Laarhoven, NL

16:30 - 16:35 **Presentation of case/condition**

H. Van Laarhoven, Academic Medical Center, University of Amsterdam, Amsterdam, NL

16:35 - 16:50 **The surgical oncologist perspective**

R. Van Hillegersberg, UMC - University Medical Center Utrecht, Utrecht, NL

16:50 - 17:05 **The radiation oncologist perspective**

M. Hawkins, UCL - University College London, London, GB

17:05 - 17:20 **The medical oncologist perspective**

S. Lorenzen, Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE

17:20 - 17:30 **Discussion**

16:30 - 18:00 **Type: Mini Oral session** **7.3.U - Urval Auditorium**
Title: Mini Oral session: CNS tumours
 Chair(s): Enrico Franceschi, IT; Patrick Roth, CH; Monika Hegi, CH

16:30 - 16:35 **281MO - Quality of life and neurocognitive function in patients with active brain metastases of HER2-positive breast cancer treated with trastuzumab-deruxtecan: Secondary endpoint analysis of the prospective single-arm phase II TUXEDO-1 trial**

A.M. Starzer¹, A.S. Berghoff¹, J. Furtner¹, M. Marhold¹, E. Bergen¹, S. Roider-Schur², H. Forstner¹, B. Rottenmanner¹, K. Dieckmann¹, Z. Bago-Horvath¹, G. Widhalm¹, A. Ilhan-Mutlu¹, C. Minichsdorfer¹, T. Fuereder¹, B. Gruenberger³, C. Singer¹, A. Weltermann⁴, R. Puhr¹, M. Preusser¹, R. Bartsch¹, ¹Medical University of Vienna, Vienna, AT, ²St. Joseph's Hospital, Vienna, AT, ³Landesklinikum Wiener Neustadt, Wiener Neustadt, AT, ⁴Ordensklinikum Linz Elisabethinen, Linz, AT

16:35 - 16:40 **282MO - Brain metastases: Real-life treatment patterns, survival and patient-reported outcomes – Results from a population-based, prospective study in 914 patients**

O. Yri¹, G. Astrup¹, A. Karlsson¹, Ø. Paulsen², R. Van Helvoirt³, J.-Å. Lund⁴, M.-I. Taran⁵, M. Jensen Hjermstad¹, M. Birketvedt¹, E. Bjerkeset¹, N. Aass¹, S. Kaasa¹, ¹Oslo University Hospital, Oslo, NO, ²Sykehuset Telemark HF, Skien, NO, ³Sorlandet Hospital, Kristiansand, NO, ⁴Helse More og Romsdal HF, Alesund, NO, ⁵Sykehuset i Vestfold HF,

Tonsberg, NO

- 16:40 - 16:45 **283MO - Leptomeningeal disease (LMD) in patients (pts) with metastatic melanoma (MM): Survival analysis of a contemporary cohort**
I. Glitza¹, C. Saberian¹, J. Simon², S. Duncan¹, R. Amaria², M. Davies¹, A. Diab¹, J. Mcquade¹, S. Patel¹, H. Tawbi¹, C. Yee¹, M. Wong¹, I. Mccutcheon¹, D. Milton², S. Ferguson¹, ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²University of Texas MD Anderson Cancer Center, Houston, US
- 16:45 - 17:00 **Invited Discussant 281MO, 282MO and 283MO**
E. Franceschi, Ospedale Bellaria Carlo Alberto Pizzardi, Bologna, IT
- 17:00 - 17:05 **284MO - Targeting the tumor microenvironment of glioblastoma multiforme using a macrophage-based treatment for the local delivery of immune-therapeutic payload: The TEM-GBM study (NCT03866109)**
G. Finocchiaro¹, M. Eoli², F. Farina¹, B. Gentner¹, A. Capotondo¹, E. Anghileri², M. Bruzzzone³, Q.G. D'Alessandris⁴, A. Franzin⁵, P. Ferroli², F. Gagliardi¹, F. Legnani², S. Mazzoleni⁶, A. Olivi⁴, R. Pallini⁴, M. Saini², A. Zambanini⁶, L. Naldini¹, C. Russo⁷, F. Ciceri¹, ¹IRCCS Ospedale San Raffaele, Milan, IT, ²Fondazione IRCCS - Istituto Neurologico C.Besta, Milan, IT, ³Istituto Neurologico Carlo Besta, Milan, IT, ⁴Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ⁵Fondazione Poliambulanza Istituto Ospedaliero, Brescia, IT, ⁶Genenta Science, Milan, IT, ⁷Genenta Science, New York, US
- 17:05 - 17:10 **285MO - The combination of lomustine and antibody-based targeted TNF (L19TNF) as a promising treatment for recurrent glioblastoma**
T. Weiss¹, T. Look¹, E. Puca², T. Hemmerle², R. De Luca³, R. Stucchi³, P. Roth⁴, D. Neri⁵, M. Weller⁴, ¹Universitätsspital Zürich - Klinik für Neurologie, Zurich, CH, ²Philogen S.p.A., Sovicille, IT, ³Philochem AG, Otelfingen, CH, ⁴USZ - Universitätsspital Zürich - Klinik für Neurologie, Zurich, CH, ⁵ETH Zurich - Institut für Mikrobiologie, Zurich, CH
- 17:10 - 17:15 **286MO - Radiomics-based prediction of lymphocyte infiltration in IDH-wildtype glioblastoma**
M. Mair, J. Leitner, M. Zvonek, H. Windhager, K. Häller, G.J. Kührer, C. Paiato, B. Kiesel, A. Wöhrer, G. Widhalm, K.-H. Nennig, G. Langs, M. Preusser, J. Furtner, A.S. Berghoff, Medical University of Vienna, Vienna, AT
- 17:15 - 17:30 **Invited Discussant 284MO, 285MO and 286MO**
M. Hegi, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH
- 17:30 - 17:35 **287MO - A phase 0 ‘trigger’ trial of pamiparib in newly diagnosed and recurrent glioblastoma patients**
N. Sanai¹, S. Mehta¹, Y.-W. Chang¹, J. Jiang², J. Molloy¹, C. Pennington-Krygier¹, J. Harmon¹, A. Hong¹, J. Wanebo¹, W. Kennedy¹, M. Garcia¹, I. Barani¹, W. Yoo¹, A. Tovmasyan¹, A.-C. Tien³, J. Li², ¹Barrow Neurological Institute, Phoenix, US, ²Wayne State University School of Medicine; Barbara Ann Karmanos Cancer Institute, Detroit, US, ³Barrow Brain and Spine, Phoenix, US

- 17:35 - 17:40 **288MO - Brain-only oligometastatic cancer patients present with longer overall survival than patients with extracranial involvement**
A. Steindl¹, A.Z. Ahmadi², G. Moser¹, B. Gatterbauer², K. Dieckmann³, G. Widhalm², M. Hoda³, M. Preusser¹, A.S. Berghoff¹, ¹Medical University of Vienna, Vienna, AT, ²MedUni Wien - Medical University of Vienna, Vienna, AT, ³Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT
- 17:40 - 17:45 **289MO - Next-generation sequencing (NGS) for identifying actionable molecular alterations in newly diagnosed and recurrent IDHwt-glioblastoma (GBM) patients: A large mono institutional experience**
M. Padovan¹, M. Maccari¹, A. Bosio¹, S. Vizzaccaro¹, I. Cestonaro¹, M. Corrà¹, M. Caccese¹, G. Cerretti¹, M. Fassan², V. Zagonel¹, G. Lombardi¹, ¹Veneto Institute of Oncology IOV-IRCCS, Padova, IT, ²University of Padova, Padova, IT
- 17:45 - 18:00 **Invited Discussant 287MO, 288MO and 289MO**
P. Roth, USZ - Universitätsspital Zürich - Klinik für Neurologie, Zurich, CH

16:45 - 17:45	Type: EONS session Title: Supportive care: Adapting to advances in oncology for better patient outcomes Chair(s): Mary Tanay, GB	7.3.S - Strasbourg Auditorium
16:45 - 17:00	Supportive care in cancer makes excellent cancer care possible! Recent developments (MASCC) <u>E. Tomlins</u> , Southampton General Hospital, Southampton, GB	
17:00 - 17:15	Cognition, sleep and the daily functioning of patients with cancer: A time for multi-modal management interventions <u>G. Kotronoulas</u> , University of Glasgow, Glasgow, GB	
17:15 - 17:25	CN61 - Patients' experiences of a supported self-management pathway In breast Cancer (PRAGMATIC): Interview results <u>L. Matthews</u> ¹ , M. Teoh ² , S. May ³ , C. Zammit ⁴ , D. Bloomfield ⁴ , M. Kothari ⁵ , D. Betal ⁶ , R. Santos ⁵ , E. Stewart ⁵ , J. Finlay ⁶ , K. Nicholson ⁶ , D. Elwell-Sutton ⁴ , F. Mckinna ⁷ , H. Gage ⁸ , S. Bell ⁷ , V. Jenkins ³ , ¹ University of Sussex, Brighton, GB, ² Ashford and St Peter's NHS Foundation Trust, Ashford, GB, ³ Brighton and Sussex Medical School - University of Sussex, Brighton, GB, ⁴ University Hospitals Sussex, Brighton, GB, ⁵ St Peter's Hospital - Ashford and St. Peter's Hospitals NHS Foundation Trust, Chertsey, GB, ⁶ Worthing Hospital, Worthing, GB, ⁷ Surrey and Sussex Cancer Alliance, Guildford, GB, ⁸ University of Surrey, Guildford, GB	
17:25 - 17:35	CN58 - Mapping the measurement of lymphoma survivors' unmet needs and quality of life outcomes: Evidence for a lymphoma-specific questionnaire <u>V. Boland</u> ¹ , A. Drury ² , A.-M. Brady ¹ , ¹ Trinity College Dublin, Dublin, IE, ² University College Dublin, Dublin, IE	
17:35 - 17:45	Q&A and discussion	

18:15 - 19:45	Type: Patient Advocacy session Title: The loved ones' perspective and role: Best practices to support cancer caregiver Chair(s): Tanja Spanic, SI; Vlad Voiculescu, RO	7.3.M - Marseille Auditorium
18:15 - 18:30	Caregiver story, the lost voice <u>A. Hyde</u> , The Swallows Head & Neck cancer Charity, Lincolnshire, GB	
18:30 - 18:45	Patients and caregivers are on the same journey but on different tracks: the importance of family-focused education <u>G. Graffigna</u> , Università Cattolica del Sacro Cuore, Rome, IT	
18:45 - 19:00	Psycho-oncology service caregivers in the UK <u>A. King</u> , St. Mary's Hospital Imperial College Healthcare NHS Trust, London, GB	
19:00 - 19:15	A multidisciplinary approach to support families in managing cancer repercussions <u>L. Travado</u> , Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT	
19:15 - 19:30	Connecting for caregivers' empowerment <u>K. Oliver</u> , IBTA - International Brain Tumour Alliance, Tadworth, GB	
19:30 - 19:40	Discussion	
19:40 - 19:45	Conclusion	

18:30 - 20:00	Type: Industry Satellite Symposium Title: Janssen-Cilag International NV - Exploring questions in metastatic prostate cancer Chair(s): Laura-Maria Krabbe, DE; Gerhardt Attard, GB	7.2.F - Fécamp Auditorium
18:30 - 18:35	Welcome and introduction <u>L.-M. Krabbe</u> , UKM - University Hospital Muenster, Muenster, DE	
18:35 - 18:55	Question 1: How should we manage oligometastatic disease? <u>J. O'Sullivan</u> , Northern Ireland Cancer Centre - Belfast Health & Social Care Trust, Belfast, GB	
18:55 - 19:15	Question 2: What is the role of chemotherapy alongside hormonal treatments in mHSPC? <u>G. Attard</u> ¹ , <u>L.-M. Krabbe</u> ² , ¹ UCL Cancer Institute - UCL - London's Global University, London, GB, ² UKM - University Hospital Muenster, Muenster, DE	
19:15 - 19:55	Question 3: How do we choose treatment options for patients with mCRPC? <u>E. Efstathiou</u> , The M.D. Anderson Cancer Center, Houston, US	
19:55 - 20:00	Close <u>G. Attard</u> , UCL Cancer Institute - UCL - London's Global University, London, GB	

18:30 - 19:40	Type: Industry Satellite Symposium Title: BeiGene Switzerland GmbH - Standard of Care is Not Enough! Talking Immunotherapy Clinical Trials in GI Cancers Chair(s): Lesley Fallowfield, GB; Elizabeth Smyth, GB	7.1.D - Dijon Auditorium
18:30 - 18:35	Welcome to the Conversation <u>L. Fallowfield</u> , Brighton and Sussex Medical School - University of Sussex, Brighton, GB	
18:35 - 18:45	What Now Doc? A Patient's Perspective <u>T. Gašpert</u> , University Hospital KBC Rijeka, Rijeka, HR	
18:45 - 19:05	GI Cancers: Checkpoint Inhibitors and Beyond <u>E. Smyth</u> , Addenbrooke's Hospital, Cambridge, GB	
19:05 - 19:25	Talking With Patients About Clinical Trials: How, What, Why, When and Where? <u>L. Fallowfield</u> , Brighton and Sussex Medical School - University of Sussex, Brighton, GB	
19:25 - 19:35	Questions about Trials? Connect With your Expert! <u>E. Smyth</u> ¹ , <u>E. Van Cutsem</u> ² , <u>M. Ducreux</u> ³ , <u>S. Lorenzen</u> ⁴ , <u>S. Cascinu</u> ⁵ , ¹ Addenbrooke's Hospital, Cambridge, GB, ² UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ³ Gustave Roussy - Cancer Campus, Villejuif, FR, ⁴ Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE, ⁵ Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT	
19:35 - 19:40	Chairs' Conclusions <u>L. Fallowfield</u> ¹ , <u>E. Smyth</u> ² , ¹ Brighton and Sussex Medical School - University of Sussex, Brighton, GB, ² Addenbrooke's Hospital, Cambridge, GB	

18:30 - 20:00	Type: Industry Satellite Symposium Title: Thermo Fisher Scientific - Connecting patients everywhere to precision oncology Chair(s): Silvia Novello, IT	7.3.G - Grenoble Auditorium
18:30 - 18:45	The Evolving Paradigm of Precision Medicine in Lung Cancer: what Oncologist and Advocacies can do <u>S. Novello</u> , Università Degli Studi Di Torino - Orbassano, Orbassano, IT	
18:45 - 19:00	Lung Cancer: How do I ask for and use molecular profiling results to guide everyday treatment decisions? <u>E. Arriola</u> , Hospital del Mar - Parc de Salut Mar, Barcelona, ES	
19:00 - 19:15	Next generation sequencing solution for every laboratory: My experience <u>B. Bellosillo Paricio</u> , Hospital del Mar - Parc de Salut Mar, Barcelona, ES	
19:15 - 19:30	Circulating tumour DNA for monitoring of response to neoadjuvant chemotherapy in patients with high grade serous ovarian carcinoma <u>E. Gray</u> , Edith Cowan University, Perth, AU	
19:30 - 19:45	Fully automated end to end IVD solution for ultra fast NGS results? Yes, we can <u>C. Rolando</u> , University of Milan, Milan, IT	
19:45 - 20:00	Q&A and closing remarks <u>S. Novello</u> , Università Degli Studi Di Torino - Orbassano, Orbassano, IT	

18:30 - 19:55	Type: Industry Satellite Symposium Title: PeerVoice - Contemporary Management of Prostate Cancer: Updated Approaches for Improved Outcomes in nmCRPC and mHSPC Chair(s): Karim Fizazi, FR	7.3.H - Honfleur Auditorium
18:30 - 18:35	Welcome, Faculty Introductions, and Overview of Agenda <u>K. Fizazi</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
18:35 - 19:05	State-of-the-Art Interventions in mHSPC: New Evidence, New Expectations <u>K. Fizazi</u> ¹ , <u>A. Morgans</u> ² , <u>B. Tombal</u> ³ , ¹ Institut Gustave Roussy, Villejuif, Cedex, FR, ² Dana Farber Cancer Institute, Boston, US, ³ Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE	
19:05 - 19:35	Modernising the Standard of Care in nmCRPC: What Are We Waiting For? <u>K. Fizazi</u> ¹ , <u>A. Morgans</u> ² , <u>B. Tombal</u> ³ , ¹ Institut Gustave Roussy, Villejuif, Cedex, FR, ² Dana Farber Cancer Institute, Boston, US, ³ Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE	
19:35 - 19:50	Key Questions and Expert Discussion With Programme Faculty <u>K. Fizazi</u> ¹ , <u>A. Morgans</u> ² , <u>B. Tombal</u> ³ , ¹ Institut Gustave Roussy, Villejuif, Cedex, FR, ² Dana Farber Cancer Institute, Boston, US, ³ Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE	
19:50 - 19:55	Final Remarks, Conclusions, and Closing <u>K. Fizazi</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	

18:30 - 20:00	Type: Industry Satellite Symposium Title: Sanofi and Regeneron - Evolving Treatment Roadmap for Advanced and High-risk NMSC Chair(s): Paolo Ascierto, IT	7.3.O - Orléans Auditorium
18:30 - 18:35	Welcome and Introductions <u>P. Ascierto</u> , Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT	
18:35 - 18:55	Current landscape in the immuno-oncology treatment of patients with NMSC <u>P. Ascierto</u> , Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT	
18:55 - 19:10	How to treat difficult cases with advanced CSCC <u>D. Rischin</u> , Peter MacCallum Cancer Centre, Melbourne, AU	
19:10 - 19:25	How to treat difficult cases with advanced BCC <u>J.J. Grob</u> , Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR	
19:25 - 19:45	What are the remaining unmet needs in clinical management of NMSC? <u>D. Schadendorf</u> , University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE	
19:45 - 20:00	Interactive Panel Discussion <u>P. Ascierto</u> ¹ , <u>D. Rischin</u> ² , <u>J.J. Grob</u> ³ , <u>D. Schadendorf</u> ⁴ , ¹ Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ² Peter MacCallum Cancer Centre, Melbourne, AU, ³ Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ⁴ University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE	

18:30 - 20:00	Type: Industry Satellite Symposium Title: Boehringer Ingelheim International GmbH - Breaking Through the Firewall: New Therapeutic Strategies to Disrupt Cancer's Operating Systems Chair(s): Martin Reck, DE	7.3.Q - Quimper Auditorium
18:30 - 18:35	Welcome and Introductions <u>M. Reck</u> , Krankenhaus Grosshansdorf, Grosshansdorf, DE	
18:35 - 19:05	Development of an MDM2-p53 Antagonist for STS and Other Indications <u>P. Schoeffski</u> , KU Leuven - Laboratory of Experimental Oncology, Leuven, BE	
19:05 - 19:25	Targeting HER2 and KRAS to Deliver Breakthrough Therapies <u>E. Smit</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL	
19:25 - 19:45	T-cell Engagers: Change of the Treatment Paradigm in Solid Tumors <u>M. Reck</u> , Krankenhaus Grosshansdorf, Grosshansdorf, DE	
19:45 - 19:55	Expert Panel Q&A <u>M. Reck</u> ¹ , <u>P. Schoeffski</u> ² , <u>E. Smit</u> ³ , ¹ Krankenhaus Grosshansdorf, Grosshansdorf, DE, ² KU Leuven - Laboratory of Experimental Oncology, Leuven, BE, ³ NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL	
19:55 - 20:00	Closing Remarks <u>M. Reck</u> , Krankenhaus Grosshansdorf, Grosshansdorf, DE	

18:30 - 20:00	Type: Industry Satellite Symposium Title: Pfizer Oncology - Is it time to raise the bar for ALK+ NSCLC patients? Chair(s): Ben Solomon, AU	7.3.T - Toulouse Auditorium
18:30 - 18:35	Welcome and introduction <u>B. Solomon</u> , Peter MacCallum Cancer Center, Melbourne, AU	
18:35 - 18:52	New data and updated expectations for 1L therapy <u>B. Solomon</u> , Peter MacCallum Cancer Center, Melbourne, AU	
18:52 - 19:10	Managing AEs and keeping patients on treatment <u>E. Felip</u> , Vall d'Hebron University Hospital, Barcelona, ES	
19:10 - 19:27	What next? Options after progression on 2nd and 3rd generation TKIs <u>N. Girard</u> , Institut Curie, Paris, FR	
19:27 - 19:45	The future of ALK+ NSCLC <u>N. Girard</u> , Institut Curie, Paris, FR	
19:45 - 19:55	Q&A <u>B. Solomon</u> ¹ , <u>E. Felip</u> ² , <u>N. Girard</u> ³ , ¹ Peter MacCallum Cancer Center, Melbourne, AU, ² Vall d'Hebron University Hospital, Barcelona, ES, ³ Institut Curie, Paris, FR	
19:55 - 20:00	Summary and close <u>B. Solomon</u> , Peter MacCallum Cancer Center, Melbourne, AU	

18:30 - 20:00 **Type: Industry Satellite Symposium** **7.3.U - Urval Auditorium**
Title: Medscape Oncology Global - Improving Outcomes in Patients With High-Risk HR+/HER2- EBC: Keeping the Patient Central
 Chair(s): Joyce O'Shaughnessy, US

- 18:30 - 18:35 **Welcome and introduction**
J. O'Shaughnessy, Texas Oncology - Baylor Sammons Cancer Center, Dallas, US
- 18:35 - 19:00 **How Would You Assess Risk of Recurrence in This Patient With HR+/HER2-EBC? Patient video will be included**
W. Janni, Ulm Medical University, Ulm, DE
- 19:00 - 19:30 **Treatment Considerations for Patients With High-Risk HR+/HER2- EBC: What do the Latest Data Show?**
M. Martin Jimenez, Hospital General Universitario Gregorio Marañón, Madrid, ES
- 19:30 - 19:55 **Keeping the Patient Central: Discussing Adherence and Persistence and the Role of the MDT Patient**
S. Donahue, UCSF - University of California San Francisco, San Francisco, US
- 19:55 - 20:00 **Concluding Remarks**
J. O'Shaughnessy, Texas Oncology - Baylor Sammons Cancer Center, Dallas, US

11.09.2022

08:30 - 10:00 **Type: Proffered Paper session** **4.A - Antibes Auditorium**
Title: Proffered Paper session: GU tumours, prostate
 Chair(s): Elena Castro Marcos, ES; Karim Fizazi, FR

08:30 - 08:40 **LBA62 - Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): Overall survival (OS) results of 2 randomised phase III trials from the STAMPEDE protocol**

G. Attard¹, L. Murphy², N. Clarke³, W. Cross⁴, S. Gillessen⁵, C. Amos², C. Brawley², R. Jones⁶, C. Pezaro⁷, Z. Malik⁸, A. Montazeri⁹, R. Millman², A. Cook², D. Gilbert², R. Langley², C. Parker¹⁰, M. Sydes², L. Brown², M. Parmar², N. James¹¹, ¹UCL Cancer Institute - UCL - London's Global University, London, GB, ²UCL, Institute of Clinical Trials & Methodology, London, GB, ³The Christie and Salford Royal NHS Foundation Trusts, Manchester, GB, ⁴University of Leeds - Leeds Institute of Molecular Medicine (LIMM), Leeds, GB, ⁵EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH, ⁶Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, GB, ⁷Weston Park Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, ⁸The Royal Liverpool University Hospital - Liverpool University Hospitals NHS Foundation Trust, Liverpool, GB, ⁹Clatterbridge Cancer Center, Wirral - NHS Foundation Trust, Metropolitan Borough of Wirral, GB, ¹⁰The Royal Marsden Hospital (Sutton) - NHS Foundation Trust, Sutton, GB, ¹¹ICR - Institute of Cancer Research, London, GB

08:40 - 08:50 **1358O - Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial**

M. Parry¹, E. Grist¹, C. Brawley², J. Proudfoot³, L. Mendes¹, S. Lall¹, A. Hoyle⁴, A. Sachdeva⁴, Y. Liu³, C. Amos⁵, M. Sydes², R. Jones⁶, M. Parmar⁷, F. Feng⁸, C. Sweeney⁹, N. Clarke¹⁰, E. Davicioni³, N. James¹¹, L. Brown¹², G. Attard¹, ¹UCL Cancer Institute - Paul O'Gorman Building, London, GB, ²Medical Research Council Clinical Trials Unit, London, GB, ³Veracyte, Inc. - Headquarters, South San Francisco, US, ⁴The Christie NHS Foundation Trust, Manchester, GB, ⁵Cancer Research UK & University College London Cancer Trials Centre, London, GB, ⁶MVLS - Medical, Veterinary and Life Sciences College - University of Glasgow, Glasgow, GB, ⁷Institute of Clinical Trials and Methodology-UCL, London, GB, ⁸JLABS @ MBC BioLabs, San Francisco, US, ⁹Dana Farber Cancer Institute, Boston, US, ¹⁰The University of Manchester, Manchester, GB, ¹¹ICR - Institute of Cancer Research, London, GB, ¹²MRC - Medical Research Council Clinical Trials Unit - University College London (UCL), London, GB

08:50 - 09:00 **Invited Discussant LBA62 and 1358MO**
E. Castro Marcos, Hospital Universitario 12 de Octubre, Madrid, ES

09:00 - 09:15 **Q&A**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

- 09:15 - 09:25 **13570 - Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)**
- F. Saad¹, A. Armstrong², A. Thiery-Vuillemin³, M. Oya⁴, N. Shore⁵, G. Procopio⁶, C. Arslan⁷, N. Mehra⁸, F. Parnis⁹, E. Brown¹⁰, F. Constans Schlurmann¹¹, J.Y. Joung¹², M. Sugimoto¹³, O. Sartor¹⁴, Y.-Z. Liu¹⁵, C. Poehlein¹⁶, C. Desai¹⁷, P.M. Del Rosario¹⁷, N. Clarke¹⁸, ¹Centre Hospitalier de l'Université de Montréal/CRCHUM, Université de Montréal, Montreal, CA, ²Duke Cancer Institute Center, Durham, US, ³CHRU Besançon Hôpital J.Minjoz, Besancon, FR, ⁴Keio University School of Medicine, Tokyo, JP, ⁵Carolina Urologic Research Center, Myrtle Beach, US, ⁶Istituto Nazionale Per Cura Tumori Milano, Milan, IT, ⁷Izmir Economy University Medical Park Hospital, Karsiyaka, TR, ⁸Radboud Universitair Medisch Centrum, Nijmegen, NL, ⁹Ashford Cancer Centre Research, Kurralt Park, AU, ¹⁰University Hospital Southampton, Southampton, GB, ¹¹Centre Hospitalier de Cornouaille, Quimper, FR, ¹²National Cancer Center, Goyang-si, KR, ¹³Kagawa University Hospital, Kagawa, JP, ¹⁴Tulane Cancer Center, New Orleans, US, ¹⁵Astrazeneca, Cambridge, GB, ¹⁶Merck & Co., Inc., Rahway, US, ¹⁷AstraZeneca, Cambridge, GB, ¹⁸The Christie and Salford Royal NHS Foundation Trusts, Manchester, GB
- 09:25 - 09:35 **LBA63 - PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19)**
- R. Aggarwal¹, G. Heller², D. Hillman³, H. Xiao², J. Picus⁴, J. Wang⁵, M.E. Taplin⁶, T. Dorff⁷, L. Appleman⁸, D. Weckstein⁹, A. Patnaik¹⁰, A. Bryce¹¹, D. Shevrin¹², J. Mohler¹³, D. Anderson¹⁴, A. Rao¹⁵, S. Tagawa¹⁶, A. Tan¹⁷, S. Eggener¹⁰, M. Morris¹⁸, ¹UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US, ²Memorial Sloan Kettering Cancer Center, New York, US, ³Mayo Clinic - Rochester, Rochester, US, ⁴Washington University School of Medicine in St. Louis, St. Louis, US, ⁵MD Anderson Cancer Center, Houston, US, ⁶Dana Farber Cancer Institute, Boston, US, ⁷City of Hope Comprehensive Cancer Center, Duarte, US, ⁸University of Pittsburgh Cancer Institute, Pittsburgh, US, ⁹NH Oncology Hematology PA, Concord, US, ¹⁰The University of Chicago, Chicago, US, ¹¹Mayo Clinic Cancer Center, Phoenix, US, ¹²NorthShore University HealthSystem-Evanston Hospital, Evanston, US, ¹³Roswell Park Comprehensive Cancer Center, Buffalo, US, ¹⁴Colorado Springs Health Partners, PC, Colorado Springs, US, ¹⁵Baylor College of Medicine, Houston, US, ¹⁶NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US, ¹⁷Rush University Medical Center, Chicago, US, ¹⁸MSKCC - Memorial Sloan Kettering Cancer Center, New York, US
- 09:35 - 09:45 **Invited Discussant 13570 and LBA63**
- J. De Bono, ICR - Institute of Cancer Research, London, GB
- 09:45 - 10:00 **Q&A**

08:30 - 10:00	Type: Proffered Paper session Title: Proffered Paper session: Non-metastatic NSCLC and other thoracic malignancies Chair(s): Nicolas Girard, FR; Noemi Reguart Aransay, ES	4.B - Brest Auditorium
----------------------	--	-------------------------------

- 08:30 - 08:40 **LBA47 - Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA**
M. Tsuboi¹, Y.-L. Wu², C. Grohe³, T. John⁴, M. Majem Tarruella⁵, J. Wang⁶, T. Kato⁷, J. Goldman⁸, S.-W. Kim⁹, C.-J. Yu¹⁰, H. Vinh Vu¹¹, G. Mukhametshina¹², C. Akewanlop¹³, F. De Marinis¹⁴, F. Shepherd¹⁵, D. Urban¹⁶, M. Stachowiak¹⁷, A. Bolanos¹⁸, X. Huang¹⁹, R.S. Herbst²⁰, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, ³Evangelische Lungenklinik Berlin Buch, Berlin, DE, ⁴Austin Health, Melbourne, AU, ⁵Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁶Chinese Academy of Medical Sciences, Beijing, CN, ⁷Kanagawa Cancer Center, Asahi Ward, Yokohama, JP, ⁸University of California Los Angeles, Los Angeles, US, ⁹Asan Medical Center, Seoul, KR, ¹⁰National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TW, ¹¹Cho Ray Hospital, Ho Chi Minh City, VN, ¹²Kazan, Republic of Tatarstan, RU, ¹³Siriraj Hospital, Bangkok, TH, ¹⁴European Institute of Oncology (IEO), IRCCS, Milan, IT, ¹⁵University Health Network, Princess Margaret Cancer Centre, Toronto, CA, ¹⁶Sheba Medical Center, Tel Hashomer, Israel and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IL, ¹⁷AstraZeneca, Warsaw, PL, ¹⁸AstraZeneca, Mississauga, CA, ¹⁹AstraZeneca, Cambridge, GB, ²⁰Yale School of Medicine and Yale Cancer Center, New Haven, US
- 08:40 - 08:50 **LBA48 - Community-based mass screening with low-dose CT for lung cancer in Guangzhou**
W. Liang, C.C. Li, J. Li, S. Xiong, B. Cheng, H. Liang, N. Zhong, J. He, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN
- 08:50 - 09:00 **Invited Discussant LBA47 and LBA48**
S. Popat, The Royal Marsden Hospital - NHS Foundation Trust, London, GB
- 09:00 - 09:15 **Q&A**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH
- 09:15 - 09:25 **9500 - Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable lung cancer: The INCREASE trial**
I. Bahce¹, C. Dickhoff², F. Schneiders², J. Veltman², D. Heineman², S. Hashemi², M. Fransen², A. Vrijmoet², I. Houda³, E. Ulas², P. Van De Ven², N. Bouwhuis², L. Meijboom², D. Oprea-Lager¹, J. Garcia Vallejo², T. De Gruijl², T. Radonic², S. Senan¹, ¹Amsterdam UMC - Vrije Universiteit Medical Center (VUmc), Amsterdam, NL, ²Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, ³Vrije Universiteit, Amsterdam, NL
- 09:25 - 09:35 **LBA49 - CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)**
E. Garon¹, S. Lu², Y. Goto³, P.R. De Marchi⁴, L. Paz-Ares⁵, D. Spigel⁶, M. Thomas⁷, J.C.-H. Yang⁸, A. Ardizzoni⁹, F. Barlesi¹⁰, S. Khanna¹¹, C. Bossen¹², M. Carhini¹², A. Yovine¹², B.C. Cho¹³, ¹David Geffen School of Medicine at UCLA/TRIO-US/TRIO-Global Network, Los Angeles, US, ²Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai,

CN, ³National Cancer Center - Tsukiji Campus, Chuo-ku, JP, ⁴Oncoclínicas, Rio de Janeiro, BR, ⁵Hospital Universitario 12 de Octubre, Madrid, ES, ⁶Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ⁷Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, and Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DLZ), Heidelberg, DE, ⁸NTUCC - National Taiwan University Cancer Center, Taipei City, TW, ⁹University of Bologna - Alma Mater Studiorum, Bologna, IT, ¹⁰Gustave Roussy, Villejuif, FR, ¹¹Novartis Pharma S.A.S, Rueil-Malmaison, FR, ¹²Novartis Pharma AG, Basel, CH, ¹³Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, KR

09:35 - 09:45 **Invited Discussant 9500 and LBA49**

N. Reguart Aransay, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

09:45 - 10:00 **Q&A**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

08:30 - 10:00 Type: Special symposium
Title: Application of novel technologies in head & neck cancer

7.2.E - Évry Auditorium

Chair(s): Ingeborg Tinhofer-Keilholz, DE; Lillian Siu, CA

08:30 - 08:35 **Introduction and scientific background**

L. Siu, Princess Margaret Cancer Centre, Toronto, CA

08:35 - 08:50 **Multi-omic profiling in H&N cancer: Clinical applications**

I. Tinhofer-Keilholz, Charité - Universitätsmedizin Berlin, Berlin, DE

08:50 - 09:05 **Circulating biomarker assays in individualizing targeted therapy and IO for HN cancers: ctDNA**

R. Galot, Brussels,

09:05 - 09:20 **New promising targets on the horizon: HRAS, PI3KCA, NTRK, RET, NOTCH1, BRAF...etc**

C. Le Tourneau, Paris, FR

09:20 - 09:35 **Novel platforms to identify neoantigens in personalised immunotherapy**

E. Cohen, Moores Cancer Center - UC San Diego Health, La Jolla, US

09:35 - 09:40 **Conclusions and perspectives**

I. Tinhofer-Keilholz, Charité - Universitätsmedizin Berlin, Berlin, DE

09:40 - 10:00 **Discussion**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

08:30 - 10:00	Type: Special symposium Title: Interplay between host biology and treatment Chair(s): Sandra Demaria, US; Christian Ottensmeier, GB	7.1.D - Dijon Auditorium
----------------------	---	---------------------------------

08:30 - 08:35	Introduction and scientific background <u>S. Demaria</u> , Weill Cornell Medical College, New York, US	
08:35 - 08:55	Germline make-up and immune landscape/response to immunotherapy <u>D. Bedognetti</u> , Doha, QA	
08:55 - 09:15	Targeting the adenosine immune checkpoint to overcome treatment resistance <u>J. Stagg</u> , University of Montreal Health Center, Montreal, CA	
09:15 - 09:35	Radiotherapy shapes the tumor antigenic repertoire <u>S. Demaria</u> , Weill Cornell Medical College, New York, US	
09:35 - 09:40	Conclusions and perspectives <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
09:40 - 10:00	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

08:30 - 10:00	Type: Special session Title: ESMO adaptation of an existing framework for determining Line of Therapy: A designation ecosystem for oncology practice Chair(s): George Pentheroudakis, CH; Christopher Twelves, GB	7.3.T - Toulouse Auditorium
08:30 - 08:45	Line of Therapy: Definitions and guidelines <u>K. Saini</u> , Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB	
08:45 - 09:00	Line of Therapy in the curative setting, challenges and solutions: Clinical vignettes <u>J. Remon Masip</u> , HM CIOCC - Centro Integral Oncológico Clara Campal, Barcelona, ES	
09:00 - 09:15	Line of Therapy in the non-curative setting, challenges and solutions: Clinical vignettes <u>C. Twelves</u> , St. James's University Hospital, Leeds, GB	
09:15 - 09:30	Perspectives from the Investigator: Landscape and impact on clinical research <u>V. Golfopoulos</u> , EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, BE	
09:30 - 09:45	Perspectives from the regulator: Landscape and unmet needs <u>O. Tenhunen</u> , Finnish Medicines Agency, Helsinki, FI	
09:45 - 09:55	Q&A <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
09:55 - 10:00	Conclusions <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

08:30 - 10:00	Type: Educational session Title: The road towards clinical implementation of artificial intelligence (AI) in oncology Chair(s): Rudolf Fehrmann, NL; Nathalie Lassau, FR	7.3.M - Marseille Auditorium
----------------------	--	-------------------------------------

08:30 - 08:50	What is AI? <u>J. Kather</u> , Uniklinik RWTH Aachen, Aachen, DE	
08:50 - 09:05	AI applied to radiology <u>N. Lassau</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
09:05 - 09:20	AI applied to pathology <u>E. Golomb</u> , Shaare Zedek Medical Center, Jerusalem, IL	
09:20 - 09:40	Key challenges for delivering clinical impact with artificial intelligence <u>J. Reis-Filho</u> , MSKCC - Memorial Sloan Kettering Cancer Center, New York, US	
09:40 - 09:55	Perspectives: Which transformations are expected? <u>R. Fehrmann</u> , UMCG - University Medical Center Groningen, Groningen, NL	
09:55 - 10:05	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

08:30 - 10:00	Type: Proffered Paper session Title: Proffered Paper session: Supportive and palliative care Chair(s): Karin Jordan, DE; Matteo Lambertini, IT	7.3.U - Urval Auditorium
----------------------	--	---------------------------------

08:30 - 08:40	1551O - Factors associated with chemotherapy (CT)-related amenorrhea (CRA) and its relationship with quality of life (QOL) in premenopausal women with early breast cancer (BC): Results from the prospective CANTO cohort study <u>R. Kabirian</u> ¹ , J. Havas ¹ , M.A. Franzoi ¹ , C. Coutant ² , O. Tredan ³ , C. Levy ⁴ , P. Cottu ⁵ , A. Dhaini Merimeche ⁶ , S. Guillermet ⁷ , J.-M. Ferrero ⁸ , S. Giacchetti ⁹ , T. Petit ¹⁰ , F. Dalenc ¹¹ , P. Rouanet ¹² , O. Querel ¹³ , A.-L. Martin ¹⁴ , B. Pistilli ¹ , M. Lambertini ¹⁵ , I. Vaz Luis ¹ , A. Di Meglio ¹ , ¹ Institut Gustave Roussy, Villejuif, Cedex, FR, ² Centre Georges Francois Leclerc, Dijon, FR, ³ Centre Léon Bérard, Lyon, FR, ⁴ Centre Francois Baclesse, Caen, FR, ⁵ Institut Curie, Paris, FR, ⁶ Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, ⁷ Centre Eugene - Marquis, Rennes, FR, ⁸ Centre Antoine Lacassagne, Nice, FR, ⁹ Hopital Saint Louis - Groupe Hospitalier La Rochelle-Ré-Aunis, La Rochelle, FR, ¹⁰ Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, ¹¹ Centre Claudius-Regaud, Toulouse, FR, ¹² CRLC Val d'Aurelle, Montpellier, FR, ¹³ Unicancer, Paris, Cedex, FR, ¹⁴ UNICANCER, Paris, FR, ¹⁵ IRCCS Ospedale Policlinico San Martino, Genova, IT	
08:40 - 08:50	1263O - Evaluation of weight gain and overall survival of male vs. female patients with advanced non-small cell lung cancer (NSCLC) receiving first-line	

chemotherapy

E. Roeland¹, F.J. Fintelmann², R. Yang³, L. Tarasenko³, T.D. Mcrae³, J. Revkin⁴, P. Bonomi⁵, ¹Oregon Health and Science University, Portland, US, ²Massachusetts General Hospital, Boston, US, ³Pfizer Inc, New York, US, ⁴Pfizer Inc, Cambridge, US, ⁵Rush University Medical Center, Chicago, US

08:50 - 09:00 **Invited Discussant 15510 and 12630**

K. Jordan, Ernst von Bergmann Klinikum Potsdam, Potsdam, DE

09:00 - 09:10 **Q&A**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

09:10 - 09:20 **15520 - Chemotherapy-induced peripheral neuropathy (CIPN) prevention trial evaluating the efficacy of hand-cooling and compression in patients undergoing taxan-based (neo-)adjuvant chemotherapy for primary breast cancer: First results of the prospective, randomized POLAR trial**

L. Michel¹, P. Romar¹, M. Feisst², D. Hamberger³, D. Schwarz⁴, E. Kurre¹, E. Klein¹, M. Breckwoldt⁴, A. Priester⁴, M. Weiler⁴, K. Smetanay⁴, C. Fremd¹, D. Jäger¹, M. Bendszus⁴, F. Marmé⁵, A. Schneeweiss¹, ¹University Hospital and German Cancer Research Center, Heidelberg, DE, ²University of Heidelberg, Heidelberg, DE, ³Asklepios-Fachklinikum, Gauting, DE, ⁴Heidelberg University Hospital, Heidelberg, DE, ⁵Heidelberg University, Mannheim University Hospital, Mannheim, DE

09:20 - 09:30 **15530 - Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2- metastatic breast cancer (MBC)**

H. Rugo¹, P. Schmid², S. Tolaney³, F. Dalenc⁴, F. Marmé⁵, L. Shi⁶, W. Verret⁷, M. Gharaibeh⁷, A. Bardia⁸, J. Cortés⁹, ¹University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ²Queen Mary University of London, London, GB, ³Dana-Farber Cancer Institute, Boston, US, ⁴Institut Claudius Regaud, Toulouse, FR, ⁵Heidelberg University, University Hospital Mannheim, Mannheim, DE, ⁶Evidera PPD, Waltham, US, ⁷Gilead Sciences, Inc., Foster City, US, ⁸Massachusetts General Hospital Cancer Center, Boston, US, ⁹International Breast Cancer Center, Quironsalud Group, Madrid & Barcelona, Spain Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain, Barcelona, ES

09:30 - 09:40 **2170 - Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)**

N. Ueno¹, W. Jacot², T. Yamashita³, J. Sohn⁴, E. Tokunaga⁵, A. Prat⁶, J. Tsurutani⁷, Y.H. Park⁸, H. Rugo⁹, B. Xu¹⁰, F. Cardoso¹¹, Z. Mitri¹², R. Mahtani¹³, K. Dunton¹⁴, Y. Wang¹⁵, D. Gambhire¹⁵, F. Cottone¹⁶, N. Harbeck¹⁷, D. Cameron¹⁸, S. Modi¹⁹, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²Institut du Cancer de Montpellier, Montpellier University, INSERM U1194, Montpellier, FR, ³Kanagawa Cancer Center, Yokohama, JP, ⁴Yonsei Cancer Center, Yonsei University Health System, Seoul, KR, ⁵National Hospital Organization (NHO) Kyushu Cancer Center, Fukuoka, JP, ⁶Translational Genomics and Targeted Therapies in Solid Tumors, Barcelona, ES, ⁷Showa

University, Shinagawa-ku, JP, ⁸Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ⁹UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ¹⁰Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ¹¹Champalimaud Clinical Center/Champalimaud, Lisbon, PT, ¹²Oregon Health & Science University, Portland, US, ¹³Baptist Health Miami Cancer Institute, Miami, US, ¹⁴Daiichi Sankyo, Uxbridge, GB, ¹⁵Daiichi Sankyo, Basking Ridge, US, ¹⁶Daiichi Sankyo, Rome, IT, ¹⁷LMU University Hospital, Munich, DE, ¹⁸Institute of Genetics and Cancer, University of Edinburgh, EDINBURGH, GB, ¹⁹Memorial Sloan Kettering Cancer Center, New York, US

09:40 - 09:50

Invited Discussant 15520, 15530 and 2170

G. Velikova, St. James's University Hospital, Leeds, GB

09:50 - 10:00

Q&A

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

08:30 - 10:00

Type: Young Oncologist session

Title: YO Fellowship Session: Despite COVID-19 the ESMO Fellowship programme did not stop and research continued

Chair(s): Teresa Amaral, DE; Evandro de Azambuja, BE

7.3.R - Rennes Auditorium

08:30 - 08:35

Introduction

E. De Azambuja, Institute Jules Bordet, Brussels, BE

08:35 - 08:55

ESMO Research Fellowship Programme: Supporting young oncologists and enhancing careers for more than 30 years

A. Lamarca, Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES

08:55 - 09:10

Best paper derived from an ESMO Fellowship

E. Ghisoni, UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Epalinges, CH

09:10 - 09:25

Best Fellowship project

B. Pellegrino, Azienda Ospedaliero-Universitaria di Parma, Parma, IT

09:25 - 09:55

ESMO Fellowship awards ceremony (Research Fellowship, José Baselga, Best Exam)

T. Amaral¹, E. De Azambuja², ¹Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE, ²Institute Jules Bordet, Brussels, BE

09:55 - 10:00

Conclusion

T. Amaral, Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE

08:30 - 10:00	Type: EONS session Title: Patient and occupational safety Chair(s): Gianluca Catania, IT	7.3.S - Strasbourg Auditorium
08:30 - 08:45	Advanced nursing practice in cancer <u>M. Fowler</u> , Heartlands Hospital - University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB	
08:45 - 09:00	Can we address the problem of the nurses shortage post COVID-19? <u>M. Foulkes</u> , Royal Berkshire Hospital - NHS Foundation Trust, Reading, GB	
09:00 - 09:15	Cancer nurses and safety around hazardous drugs, outcome of European Oncology Nursing Society advocacy work <u>H. Ullgren</u> , Karolinska University Hospital-Solna, Solna, SE	
09:15 - 09:25	CN30 - Three stage capacity: Consent process for systemic anti-cancer therapy <u>F. Barrett</u> ¹ , O. Fitzpatrick ¹ , T. Doyle ¹ , W. Grogan ¹ , D. McMahon ¹ , N. Cooley ¹ , A. Murphy ¹ , M. Conroy ¹ , L. Judge ¹ , J. Naidoo ¹ , R. McLaughlin ¹ , C. Matassa ¹ , P. Morris ¹ , B. Hennessy ¹ , M. Breathnach ² , K. Egan ¹ , D. O'Doherty ¹ , O. Breathnach ¹ , ¹ Beaumont RCSI Cancer Centre, Dublin, IE, ² National University of Ireland - University College Dublin, Dublin, IE	
09:25 - 09:35	CN32 - Cancer nurses' experiences and perceptions of potential occupational exposure to cytotoxic drugs: Systematic review utilising framework analysis <u>K. Campbell</u> , J. Afseth, M. Dunham, Edinburgh Napier University, Edinburgh, GB	
09:35 - 09:45	CN33 - How to work with swiptests in an oncology outpatient ward: An occupational safety project A. Stridsberg, <u>S. Wallberg</u> , Karolinska University Hospital-Solna, Solna, SE	
09:45 - 09:55	CN31 - Project bedside handover 2022 (a tool for health care professionals to increase patient participation in bedside report) <u>L. Matarlo Solvebrand</u> , Karolinska Institutet - Cancer Center Karolinska (CCK), Solna, SE	
09:55 - 10:00	Q&A and discussion	

09:00 - 10:00	Type: Multidisciplinary session Title: Multidisciplinary management of brain metastases with or without driver oncogene Chair(s): Rafal Dziadziuszko, PL	7.1.C - Cannes Auditorium
09:00 - 09:05	Presentation of case/condition <u>R. Dziadziuszko</u> , Medical University of Gdansk, Gdansk, PL	
09:05 - 09:20	Optimizing local treatment for brain metastasis in lung cancer <u>M. Guckenberger</u> , Zurich, CH	
09:20 - 09:35	Role and reliability of systemic treatment for brain metastasis in lung cancer <u>L. Hendriks</u> , Maastricht, NL	
09:35 - 09:50	Molecular features of brain metastasis and considerations for precision management <u>P. Brastianos</u> , Massachusetts General Hospital, Boston, US	
09:50 - 10:00	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
09:00 - 10:00	Type: Challenge your Expert Title: Selection of first-line and subsequent treatments in HCC Chair(s): Robin Katie Kelley, US	7.2.F - Fécamp Auditorium
09:00 - 09:15	Presentation by Expert <u>A. Forner</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, ES	
09:15 - 10:00	Discussion led by Chair <u>R.K. Kelley</u> , UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US	
09:00 - 10:00	Type: Challenge your Expert Title: How to incorporate digital medicine in survivorship care after breast cancer Chair(s): Ines Vaz Luis, FR	7.3.G - Grenoble Auditorium
09:00 - 09:15	How to incorporate digital medicine in survivorship care after breast cancer <u>A. Partridge</u> , Dana Farber Cancer Institute, Boston, US	
09:15 - 10:00	Discussion led by Chair <u>I. Vaz Luis</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	

09:00 - 10:00	Type: Challenge your Expert Title: Chronic lymphocytic leukemia (CLL): What is the optimal first-line therapy?	7.3.H - Honfleur Auditorium
	Chair(s): Carol Moreno, ES	
09:00 - 09:15	Presentation by Expert <u>C.-M. Wendtner</u> , Universitätsklinikum Köln (AöR), Köln, DE	
09:15 - 10:00	Discussion led by Chair <u>C. Moreno</u> , Barcelona, ES	
09:00 - 10:00	Type: Challenge your Expert Title: Should all advanced ovarian cancer patients receive a PARPi in first-line therapy?	7.3.O - Orléans Auditorium
	Chair(s): Frederik Marmé, DE	
09:00 - 09:15	Presentation by Expert <u>D.S. Tan</u> , NUHS - National University Health System, Singapore, SG	
09:15 - 10:00	Discussion led by Chair <u>F. Marmé</u> , UMM - Universitaetsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE	
09:00 - 10:00	Type: Challenge your Expert Title: Germ cell tumors: Prognostic factors, managing poor-risk and progressive/refractory disease	7.3.Q - Quimper Auditorium
	Chair(s): Anja Lorch, CH	
09:00 - 09:15	Presentation by Expert <u>G. Baciarello</u> , Azienda Ospedaliera San Camillo Forlanini, Rome, IT	
09:15 - 10:00	Discussion led by Chair <u>A. Lorch</u> , Zurich, CH	
10:15 - 11:45	Type: Proffered Paper session Title: Proffered Paper session 1: GI, lower digestive	4.A - Antibes Auditorium
	Chair(s): Andrea Cercek, US; Marco Gerlinger, GB	
10:15 - 10:25	LBA21 - FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group	
	<u>M. Bond</u> ¹ , K. Bolhuis ² , O. Loosveld ³ , H. Droogendijk ⁴ , J.W. De Groot ⁵ , M. Hendriks ⁶ , B. De Valk ⁷ , M. Liem ⁸ , A. Rijken ³ , K. Verhoef ⁹ , J. De Wilt ¹⁰ , K. De Jong ¹¹ , G. Kazemier ² , M. Van Amerongen ¹² , M. Engelbrecht ¹³ , J. Klaase ¹¹ , A. Komurcu ¹⁴ , M. Lopez-Yurda ¹⁵ , R.-J. Swijnenburg ² , C. Punt ¹ , ¹ University Medical Center Utrecht, Utrecht, NL, ² Amsterdam	

UMC, Amsterdam, NL, ³Amphia Ziekenhuis, Breda, NL, ⁴Bravis Ziekenhuis, Roosendaal, NL, ⁵Isala, Zwolle, NL, ⁶Northwest Clinics, Alkmaar, NL, ⁷Spaarne Hospital, Hoofddorp, NL, ⁸Medisch Spectrum Twente, Enschede, NL, ⁹Erasmus MC, Rotterdam, NL, ¹⁰Radboud University Medical Center, Nijmegen, NL, ¹¹UMCG - University Medical Center Groningen, Groningen, NL, ¹²Sint Maartenskliniek, Woerden, NL, ¹³Amsterdam University Medical Center (UMC), Amsterdam, NL, ¹⁴IKNL - Netherlands Comprehensive Cancer Organisation, Utrecht, NL, ¹⁵Netherlands Cancer Institute, Amsterdam, NL

10:25 - 10:35

LBA22 - Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study

C. Pinto¹, A. Orlandi², N. Normanno³, E. Maiello⁴, M.A. Calegari², L. Antonuzzo⁵, R. Bordonaro⁶, M.G. Zampino⁷, S. Pini⁸, F. Bergamo⁹, G. Tonini¹⁰, A. Avallone¹¹, T. Latiano¹², G. Rosati¹³, A. Pazzola¹⁴, A. Ballestrero¹⁵, A. Zaniboni¹⁶, M. Roselli¹⁷, S. Tamberi⁸, C. Barone², ¹Clinical Cancer Centre Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, IT, ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ³Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ⁴IRCCS Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, IT, ⁵Careggi University Hospital, and Department of Experimental and Clinical Medicine, University of Florence, Florence, IT, ⁶Azienda Ospedaliera ARNAS Garibaldi, Catania, IT, ⁷IEO - Istituto Europeo di Oncologia, Milan, IT, ⁸Opsedale degli Infermi - AUSL Romagna, Faenza, IT, ⁹IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ¹⁰Policlinico Universitario Campus Bio-Medico, Rome, IT, ¹¹Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples, IT, ¹²Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, IT, ¹³Ospedale San Carlo, Potenza, IT, ¹⁴Oncologia Universitaria Sassari, Sassari, IT, ¹⁵Università degli Studi di Genova e Ospedale Policlinico San Martino IRCCS - DiMI, Genova, IT, ¹⁶Fondazione Poliambulanza, Brescia, IT, ¹⁷Policlinico Tor Vergata, Rome, IT

10:35 - 10:45

Invited Discussant LBA21 and LBA22

J. Taieb, Hopital European George Pompidou, Paris, FR

10:45 - 10:55

Q&A

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

10:55 - 11:05

3140 - Adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colon cancer (HIPECT4): A randomized phase III study

A. Arjona-Sanchez¹, M.T. Cano-Osuna¹, A. Gutierrez², J.J. Segura³, E. Perez⁴, V. Concepcion⁵, S. Sanchez⁶, A. Garcia⁷, I. Prieto⁸, P. Barrios Sanchez⁹, J. Torres¹⁰, M. Ramirez¹¹, A. Prada¹², J. Carrasco¹³, M. Artiles¹⁴, P. Villarejo¹⁵, G. Ortega¹⁶, E. Boldo¹⁷, E. Aranda¹⁸, S. Rufian¹, ¹Hospital Universitario Reina Sofía, Cordoba, ES, ²UAH - Universidad de Alcalá, Alcalá de Henares, ES, ³Hospital Universitario Son Espases, Palma de Mallorca, ES, ⁴Hospital Universitario de Fuenlabrada, Fuenlabrada, ES, ⁵Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, ES, ⁶Hospital General Ciudad Real, Ciudad Real, ES, ⁷IIVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, ⁸Hospital Universitario La Paz, Madrid, ES, ⁹Hospital de Sant Joan Despi Moisès Broggi, Sant Joan Despí, ES, ¹⁰Hospital Torrecardenas, Almeria, ES, ¹¹Hospital Reina Sofia, Murcia, ES, ¹²Hospital Universitario Badajoz (Hospital Infanta Cristina), Badajoz, ES, ¹³Hospital Universitario Regional de Malaga, Malaga, ES,

¹⁴Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, ES, ¹⁵Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, ¹⁶MD Anderson Cancer Center Madrid, Madrid, ES, ¹⁷Hospital Provincial de Castellón, Castellón de La Plana, ES, ¹⁸Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) Hospital Universitario Reina Sofía, Córdoba, ES

- 11:05 - 11:15 **LBA23 - Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): The SAMCO-PRODIGE 54 randomised phase II trial**
J. Taieb¹, O. Bouche², T. André³, E. Barbier⁴, P. Laurent-Puig⁵, J. Bez⁴, C. Toullec⁶, C. Borg⁷, V. Randrian⁸, L. Evesque⁹, S. Corbinais¹⁰, B. Buecher¹¹, H. Perrier¹², F. Di Fiore¹³, C. Gallois¹⁴, C. Lepage¹⁵, F. El Hajbi¹⁶, D. Tougeron⁸, ¹Hopital European George Pompidou, Paris, FR, ²CHU de Reims - Hôpital Robert Debré, Reims, Cedex, FR, ³Hopital Saint-Antoine, Paris, FR, ⁴Fédération Francophone de Cancérologie Digestive, Dijon, FR, ⁵Paris Descartes University, Paris, FR, ⁶Avignon-Provence Cancer Institute, Avignon, FR, ⁷CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, ⁸CHU Poitiers - Jean Bernard Hôpital, Poitiers, FR, ⁹Centre Anticancer Antoine Lacassagne, Nice, FR, ¹⁰Centre Francois Baclesse, Caen, FR, ¹¹Institut Curie, Paris, FR, ¹²Fondation Hôpital Saint Joseph, Marseille, FR, ¹³CHU de Rouen Normandie, Rouen, FR, ¹⁴Centre de Recherche des Cordeliers - Université Paris Cité, Paris, FR, ¹⁵CHU Dijon, Dijon, FR, ¹⁶Centre Oscar Lambret, Lille, FR
- 11:15 - 11:25 **Invited Discussant 3140 and LBA23**
A. Cercek, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US
- 11:25 - 11:35 **Q&A**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH
- 10:15 - 11:45 Type: Educational session Title: Non-clear cell renal cell carcinoma: Best practices** **4.B - Brest Auditorium**
 Chair(s): Daniel Heng, CA; Cristina Suarez Rodriguez, ES
- 10:15 - 10:40 **Papillary renal cell carcinoma**
S. Pal, City of Hope Comprehensive Cancer Center, Duarte, US
- 10:40 - 11:05 **Translocation renal cell carcinoma**
G. Malouf, ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR
- 11:05 - 11:30 **Sarcomatoid renal cell carcinoma**
D. Heng, Tom Baker Cancer Centre, Calgary, CA
- 11:30 - 11:45 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

10:15 - 11:45	Type: Special session Title: ESMO Clinical Practice Guidelines session 1 Chair(s): Giuseppe Curigliano, IT; Emanuela Romano, FR	7.1.C - Cannes Auditorium
10:15 - 10:25	Early breast cancer: Clinical case <u>C. Valenza</u> , IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT	
10:25 - 10:35	Early breast cancer: Discussant <u>G. Curigliano</u> , IEO - Istituto Europeo di Oncologia, Milan, IT	
10:35 - 10:45	Early breast cancer: Discussion / Q&A <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
10:45 - 10:55	Cancer of Unknown Primary site (CUP): Clinical case <u>R. Pihlak</u> , The Christie NHS Foundation Trust, Manchester, GB	
10:55 - 11:05	Cancer of Unknown Primary site (CUP): Discussant <u>A. Krämer</u> , DKFZ - German Cancer Research Center, Heidelberg, DE	
11:05 - 11:15	Cancer of Unknown Primary site (CUP): Discussion / Q&A <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
11:15 - 11:25	Biliary tract cancer: Clinical case <u>E. Mariamidze</u> , Todua Clinic, Tbilisi, GE	
11:25 - 11:35	Biliary tract cancer: Discussant <u>A. Vogel</u> , MHH - Medizinische Hochschule Hannover, Hannover, DE	
11:35 - 11:45	Biliary tract cancer: Discussion / Q&A <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

10:15 - 11:45 **Type: Special symposium** **7.2.E - Évry Auditorium**
Title: New classification and staging of breast cancer
 Chair(s): Carsten Denkert, DE; Barbara Pistilli, FR

10:15 - 10:20 **Introduction and scientific background**

B. Pistilli, Institut Gustave Roussy, Villejuif, Cedex, FR

10:20 - 10:35 **Rethinking tumor subtype classification: Learning from RNA expression**

C. Denkert, UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE

10:35 - 10:50 **Special subtypes of breast cancer**

C. Marchiò, Candiolo, IT

10:50 - 11:05 **The microenvironment in early breast cancer: TILS and beyond**

S. Loi, Peter MacCallum Cancer Centre, Melbourne, AU

11:05 - 11:20 **Detecting minimal residual disease for new staging methods**

N. Turner, London, GB

11:20 - 11:25 **Conclusions and perspectives**

C. Denkert, UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE

11:25 - 11:45 **Discussion**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

10:15 - 11:45 **Type: Mini Oral session** **7.2.F - Fécamp Auditorium**
Title: Mini Oral session: NSCLC, metastatic
 Chair(s): Laura Mezquita, ES; Tony S.K. Mok, HK; Mary O'Brien, GB

10:15 - 10:20 **LBA55 - Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial**

K. Goto¹, K. Sang-We², T. Kubo³, Y. Goto⁴, M.-J. Ahn⁵, D. Planchard⁶, D.-W. Kim⁷, J.C.-H. Yang⁸, T.-Y. Yang⁹, K. Pereira¹⁰, K. Saxena¹⁰, R. Shiga¹⁰, Y. Cheng¹⁰, M. Aregay¹⁰, P. Jänne¹¹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ³Okayama University Hospital, Okayama, JP, ⁴National Cancer Center Hospital, Tokyo, JP, ⁵Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, ⁶Gustave Roussy, Villejuif, FR, ⁷Seoul National University Hospital, Seoul National University College of Medicine, Seoul, KR, ⁸National Taiwan University Hospital, Taipei City, TW, ⁹Taichung Veterans General Hospital, Taichung, TW, ¹⁰Daiichi Sankyo, Inc., Basking Ridge, US, ¹¹Dana-Farber Cancer Institute, Boston, US

10:20 - 10:25 **LBA56 - MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in**

treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial

M.-J. Ahn¹, S.-W. Kim², E. Carcereny Costa³, L.M. Rodríguez⁴, J. Oliveira⁵, M.A. Insa Molla⁶, M. Majem⁷, L. Costa⁸, W.-C. Su⁹, K. Lee¹⁰, J.C.-H. Yang¹¹, D. Spigel¹², E.K. Cho¹³, M. D'Arcangelo¹⁴, M.R. Garcia Campelo¹⁵, A. Delmonte¹⁶, P. Mitchell¹⁷, I. Achour¹⁷, D. Subramaniam¹⁷, E. Felip¹⁸, ¹Sungkyunkwan University School of Medicine, Seoul, KR, ²University of Ulsan College of Medicine, Seoul, KR, ³B-ARGO Group, Badalona, ES, ⁴Hospital Universitario Virgen de la Victoria, Malaga, ES, ⁵Portuguese Oncology Institute of Porto, Porto, PT, ⁶Hospital Clínico Universitario de Valencia, Valencia, ES, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁸Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, PT, ⁹National Cheng Kung University Hospital College of Medicine, Tainan City, TW, ¹⁰Chungbuk National University, Cheong-ju, KR, ¹¹National Taiwan University Hospital, Taipei City, TW, ¹²Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, ¹³Gachon University, Incheon, KR, ¹⁴AUSL di Romagna, Ravenna, IT, ¹⁵University Hospital A Coruna, Madrid, ES, ¹⁶Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" - IRCCS, Meldola, IT, ¹⁷AstraZeneca, Gaithersburg, US, ¹⁸Vall d'Hebron University Hospital, Barcelona, ES

10:25 - 10:40 **Invited Discussant LBA55 and LBA56**

L. Mezquita, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

10:40 - 10:45 **LBA57 - Sintilimab plus anlotinib versus platinum-based chemotherapy as first-line therapy in metastatic NSCLC (SUNRISE): An open label, multi-center, randomized, phase II study**

B. Han¹, T. Chu¹, Z. Yu², J. Wang², Y. Zhao³, X. Mu³, X. Yu⁴, X. Shi⁴, Q. Shi⁵, M. Guan⁵, C. Ding⁶, N. Geng⁶, ¹Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN, ²The Affiliated Hospital of Qingdao University, Qingdao, CN, ³Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ⁴Cancer Hospital Affiliated to the University of Chinese Academy of Sciences, Hangzhou, CN, ⁵AnHui Chest Hospital, Hefei, CN, ⁶The Fourth Hospital of Hebei Medical University, Shijiazhuang, CN

10:45 - 10:50 **LBA58 - Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated non-squamous non-small cell lung cancer (EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: Second interim analysis of phase III ORIENT-31 study**

S. Lu¹, L. Wu², H. Jian¹, Y. Cheng³, Q. Wang⁴, J. Fang⁵, Z. Wang⁵, Y. Hu⁶, L. Han⁷, M. Sun⁸, L. Miao⁹, C. Ding¹⁰, J. Cui¹¹, K. Wang¹², B. Li¹³, X. Li¹⁴, F. Ye¹⁵, A. Liu¹⁶, Y. Pan¹⁷, S. Cang¹⁸, ¹Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CN, ²Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN, ³Jilin Cancer Hospital, Changchun, CN, ⁴Henan Cancer Hospital, Zhengzhou, CN, ⁵Peking University Cancer Hospital, Beijing Cancer Hospital, Beijing, CN, ⁶Hubei Cancer Hospital, Wuhan, CN, ⁷Xuzhou Central Hospital, Xuzhou, CN, ⁸Jinan Central Hospital affiliated to Shandong University, Jinan, CN, ⁹Nanjing University Medical School affiliated Nanjing Drum Tower Hospital, Nanjing, CN, ¹⁰Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, CN, ¹¹The First Hospital of Jilin University, Changchun, CN, ¹²West China Hospital of Sichuan University, Chengdu, CN, ¹³Beijing

Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, CN, ¹⁴The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ¹⁵The First Affiliated Hospital of Xiamen University, Xiamen, CN, ¹⁶The Second Affiliated Hospital of Nanchang University, Nanchang, CN, ¹⁷Anhui Provincial Hospital, Hefei, CN, ¹⁸Henan Provincial People's Hospital, Zhengzhou, CN

10:50 - 11:05 **Invited Discussant LBA57 and LBA58**

T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

11:05 - 11:10 **LBA59 - Durvalumab (D) + tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)**

M. Johnson¹, B.C. Cho², A. Luft³, J. Alatorre-Alexander⁴, S.L. Geater⁵, K. Laktionov⁶, S.-W. Kim⁷, G. Ursol⁸, M. Hussein⁹, F.L. Lim¹⁰, C.T. Yang¹¹, L.H. Araujo¹², H. Saito¹³, N. Reinmuth¹⁴, Z. Lai¹⁵, H. Mann¹⁶, X. Shi¹⁷, S. Peters¹⁸, E. Garon¹⁹, T.S.K. Mok²⁰, ¹Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, US, ²Yonsei Cancer Center, Seoul, KR, ³Leningrad Regional Clinical Hospital, Saint-Petersburg, RU, ⁴Health Pharma Professional Research, Mexico City, MX, ⁵Prince of Songkla University, Amphoe Hat Yai, TH, ⁶Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, RU, ⁷Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁸Acinus, Kropyvnytskyi, UA, ⁹Florida Cancer Specialists - Sarah Cannon Research Institute, Leesburg, US, ¹⁰Queen Mary University of London, London, GB, ¹¹Chang Gung Memorial Hospital, Taoyuan City, TW, ¹²Instituto Nacional de Cancer-INCA, Rio de Janeiro, BR, ¹³Kanagawa Cancer Center, Yokohama, JP, ¹⁴Asklepios Lung Clinic, Munich-Gauting, DE, ¹⁵AstraZeneca, Waltham, US, ¹⁶AstraZeneca, Cambridge, GB, ¹⁷AstraZeneca, Gaithersburg, US, ¹⁸Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, CH, ¹⁹David Geffen School of Medicine at UCLA, Los Angeles, US, ²⁰Chinese University of Hong Kong, Hong Kong, HK

11:10 - 11:15 **973MO - KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC**

M. Garassino¹, S. Gadgeel², G. Speranza³, E. Felip⁴, E. Esteban Gonzalez⁵, M. Domine Gomez⁶, M. Hochmair⁷, S. Powell⁸, H. Bischoff⁹, N. Peled¹⁰, F. Grossi¹¹, R. Jennens¹², M. Reck¹³, R. Hui¹⁴, E. Garon¹⁵, T. Kurata¹⁶, J.E. Gray¹⁷, P. Schwarzenberger¹⁸, E. Jensen¹⁸, D. Rodriguez Abreu¹⁹, ¹Knapp Center for Biomedical Discovery, Chicago, US, ²Henry Ford Cancer Institute/Henry Ford Health, Detroit, US, ³Hôpital Charles-Le Moyne, Greenfield Park, CA, ⁴Vall d'Hebron University, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁵Hospital Universitario Central de Asturias, Oviedo, ES, ⁶Hospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, ES, ⁷Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, AT, ⁸Sanford Cancer Center, Sioux Falls, US, ⁹Thoraxklinik, Heidelberg, DE, ¹⁰Shaare Zedek Medical Center, Jerusalem, IL, ¹¹University of Insubria, Varese, IT, ¹²Epworth Healthcare, Richmond, AU, ¹³Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE, ¹⁴Westmead Hospital and University of Sydney, Sydney, AU, ¹⁵David Geffen School of Medicine at UCLA, Los Angeles, US, ¹⁶Kansai Medical University Hospital, Osaka, JP, ¹⁷Moffitt Cancer Center, Tampa, US, ¹⁸Merck & Co., Inc., Rahway, US, ¹⁹Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, ES

- 11:15 - 11:20 **974MO - 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC)**
- S. Novello¹, D. Kowalski², A. Luft³, M. Gumus⁴, D. Vicente Baz⁵, J. Mazieres⁶, J. Rodriguez Cid⁷, A. Tafreshi⁸, Y. Cheng⁹, K. Lee¹⁰, A. Golf¹¹, S. Sugawara¹², A. Robinson¹³, B. Halmos¹⁴, E. Jensen¹⁵, P. Schwarzenberger¹⁵, M.C. Pietanza¹⁵, L. Paz-Ares¹⁶, ¹University of Turin, Azienda Ospedaliero Universitaria San Luigi, Turin, IT, ²Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, ³Leningrad Regional Clinical Hospital, St Petersburg, RU, ⁴Istanbul Medeniyet University, Istanbul, TR, ⁵Hospital Universitario Virgen Macarena, Seville, ES, ⁶Hôpital Larrey, Centre Hospitalier Universitaire Toulouse, Toulouse, FR, ⁷Medica Sur Hospital, Mexico City, MX, ⁸Wollongong Private Hospital and Wollongong Oncology, Wollongong, AU, ⁹Jilin Cancer Hospital, Changchun, CN, ¹⁰Chungbuk National University College of Medicine, Cheong-ju, KR, ¹¹Universitätsklinikum Tübingen, Tuebingen, DE, ¹²Sendai Kousei Hospital, Sendai, Miyagi, JP, ¹³Kingston General Hospital, Kingston, CA, ¹⁴Albert Einstein College of Medicine, Bronx, US, ¹⁵Merck & Co., Inc., Rahway, US, ¹⁶Hospital Universitario 12 de Octubre, H12o-CNIO Lung Cancer Unit, Universidad Complutense & Ciberonc, Madrid, ES
- 11:20 - 11:35 **Invited Discussant LBA59, 973MO and 974MO**
- M. O'Brien, The Royal Marsden Hospital - Chelsea, London, GB

10:15 - 11:45	Type: Special symposium Title: Lessons learned and new horizons for treatment of primary brain tumours Chair(s): Susan Chang, US; Anna Sophie Berghoff, AT	7.1.D - Dijon Auditorium
10:15 - 10:20	Introduction and scientific background <u>A.S. Berghoff</u> , Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT	
10:20 - 10:35	Emerging role of RANO: From idea to practice <u>S. Chang</u> , University of California San Francisco, San Francisco, US	
10:35 - 10:50	Novel and less conventional treatment strategies <u>A. Idbaih</u> , Hopital Pitié Salpêtrière AP-HP, Paris, FR	
10:50 - 11:05	Tailoring treatment according to biology <u>P. Mischel</u> , Stanford, US	
11:05 - 11:20	Targeting IDH mutation <u>A.S. Berghoff</u> , Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT	
11:20 - 11:25	Conclusions and perspectives <u>S. Chang</u> , University of California San Francisco, San Francisco, US	
11:25 - 11:45	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

10:15 - 11:45	Type: Special session Title: In collaboration with EONS: The oncology workforce on the frontline of cancer prevention across Europe Chair(s): Rosa Giuliani, GB; Lena Sharp, SE	7.3.H - Honfleur Auditorium
10:15 - 10:20	Introduction and scientific background <u>R. Giuliani</u> ¹ , <u>L. Sharp</u> ² , ¹ The Clatterbridge Cancer Centre - Aintree, Liverpool, GB, ² RCC Stockholm-Gotland, HSF, Stockholm, SE	
10:20 - 10:35	Cancer prevention at the forefront of the political agenda: The European Union vision <u>J.F. Ryan</u> , European Commission - Directorate General Health and Food Safety, Luxembourg City, LU	
10:35 - 10:50	Why cancer prevention? The medical oncologist's perspective <u>R. Giuliani</u> , The Clatterbridge Cancer Centre - Aintree, Liverpool, GB	
10:50 - 11:05	Implementing cancer prevention: The oncology nurse's perspective <u>L. Sharp</u> , RCC Stockholm-Gotland, HSF, Stockholm, SE	
11:05 - 11:20	Promoting health for all individuals: The patient's perspective <u>F. De Lorenzo</u> , ECPC - European Cancer Patient Coalition, Brussels, BE	
11:20 - 11:40	Discussion and Q&A	
11:40 - 11:45	Conclusion and closing remarks <u>R. Giuliani</u> ¹ , <u>L. Sharp</u> ² , ¹ The Clatterbridge Cancer Centre - Aintree, Liverpool, GB, ² RCC Stockholm-Gotland, HSF, Stockholm, SE	

10:15 - 11:45 **Type: Special symposium** **7.3.O - Orléans Auditorium**
Title: What's old is new again
 Chair(s): Shivaani Kummar, US; Chia-Chi Lin, TW

10:15 - 10:20 **Introduction and scientific background**
S. Kummar, OHSU Knight Cancer Institute - Center for Health and Healing Building 1 - South Waterfront, Portland, US

10:20 - 10:35 **Drugging the undruggable: Next generation KRAS inhibitors**
M. Barbacid, Madrid, ES

10:35 - 10:50 **Beyond the genome: Novel epigenomic and metabolomic strategies**
S. Postel-Vinay, Institut Gustave Roussy, Villejuif, FR

10:50 - 11:05 **Break it down: New frontiers in protein degradation and refolding**
G. Winter, Vienna, AT

11:05 - 11:20 **From cold to hot: Immunotherapy in the genome-driven arena**
S. Kummar, OHSU Knight Cancer Institute - Center for Health and Healing Building 1 - South Waterfront, Portland, US

11:20 - 11:25 **Conclusions and perspectives**
C.-C. Lin, NTUH - National Taiwan University Hospital, Taipei City, TW

11:25 - 11:45 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

10:15 - 11:45 **Type: Mini Oral session** **7.3.Q - Quimper Auditorium**
Title: Mini Oral session: GU tumours, prostate
 Chair(s): Boris Hadaschik, DE; Martijn Lolkema, NL; Nicolas Mottet, FR

10:15 - 10:20 **1360MO - Quality of life and patient-relevant endpoints with darolutamide in the phase III ARASENS study**
K. Fizazi¹, M. Smith², M. Hussain³, F. Saad⁴, C. Sternberg⁵, E. Crawford⁶, J. Aragon-Ching⁷, S. Thiele⁸, S. Kapur⁹, A. Mohamed¹⁰, S. Srinivasan¹⁰, R. Li¹⁰, I. Kuss⁸, H. Joensuu¹¹, B. Tombal¹², ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Massachusetts General Hospital, Boston, US, ³Northwestern University Feinberg School of Medicine, Chicago, US, ⁴University of Montreal Hospital Center, Montreal, CA, ⁵Weill Cornell Medicine, New York, US, ⁶University of Colorado, Aurora, US, ⁷Inova Fairfax Hospital, Fairfax, US, ⁸Bayer AG, Berlin, DE, ⁹Bayer (South East Asia) Pte Ltd, Singapore, SG, ¹⁰Bayer HealthCare Pharmaceuticals Inc., Whippany, US, ¹¹Orion Corporation Orion Pharma, Espoo, FI, ¹²Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE

10:20 - 10:25 **LBA64 - Duration of androgen suppression with post-operative radiotherapy (DADSPORT): A collaborative meta-analysis of aggregate data**

S. Burdett¹, D. Fisher¹, C. Parker², M. Sydes¹, P. Pommier³, P. Sargos⁴, D. Spratt⁵, A. Kishan⁶, M. Brihoum⁷, C. Catton⁸, S. Chabaud⁹, N. Clarke¹⁰, A. Cook¹, I. Latorzeff¹¹, J. Tierney¹, C. Vale¹, ¹Institute of Clinical Trials and Methodology, London, GB, ²The Royal Marsden Hospital (Sutton) - NHS Foundation Trust, Sutton, GB, ³CRCL - Centre de recherche en cancerologie de Lyon, Lyon, Cedex, FR, ⁴Institute Bergonié, Bordeaux, FR, ⁵Case Western Reserve University / University Hospitals, Cleveland, US, ⁶Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US, ⁷Unicancer, Paris, Cedex, FR, ⁸Princess Margaret Cancer Center, Toronto, CA, ⁹Centre de recherche en cancerologie de Lyon (CRCL), Lyon, FR, ¹⁰The Christie and Salford Royal NHS Foundation Trusts, Manchester, GB, ¹¹Clinique Pasteur, Toulouse, FR

10:25 - 10:40 **Invited Discussant 1360MO and LBA64**

N. Mottet, CHU Saint Etienne - Hopital Nord, Saint-Étienne, FR

10:40 - 10:45 **1359MO - Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDE**

Á. Haran¹, Y. Jain², T. Hambrock², L. Murphy³, A. Cook³, L. Brown³, A. Hoyle⁴, A. Sachdeva², S.A. Ali¹, C. Amos³, M. Sydes³, G. Attard⁵, M. Parmar³, N. James⁶, N. Clarke⁴, ¹The University of Manchester, Manchester, GB, ²The Christie NHS Foundation Trust, Manchester, GB, ³Medical Research Council Clinical Trials Unit (MRC CTU), London, GB, ⁴The Christie and Salford Royal NHS Foundation Trusts, Manchester, GB, ⁵UCL Cancer Institute - UCL, London, GB, ⁶ICR - Institute of Cancer Research, London, GB

10:45 - 10:50 **1361MO - 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial**

G. Gravis Mescam¹, X. Maldonado², G. Roubaud³, R.S. Mcdermott⁴, A. Flechon⁵, B. Tombal⁶, S. Supiot⁷, D. Berthold⁸, R. Philippe⁹, G. Kacso¹⁰, F. Calabro¹¹, J.F. Berdah¹², A. Hasbini¹³, M. Silva¹⁴, A. Thiery-Vuillemin¹⁵, A. Rodriguez-Vida¹⁶, J. Mccaffrey¹⁷, H. Ribault¹⁸, S. Foulon¹⁹, K. Fizazi²⁰, ¹Institut Paoli-Calmettes, Aix-Marseille Université, CRCM, Marseille, Cedex, FR, ²Vall d'Hebron Institute of Oncology, Barcelona, ES, ³Institute Bergonié, Bordeaux, FR, ⁴St Vincent's University Hospital and Cancer Trials Ireland, Dublin, IE, ⁵Centre Léon Bérard, Lyon, FR, ⁶Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE, ⁷ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁸CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ⁹Centre Azureen Cancerologie, Mougins, FR, ¹⁰Amethyst Radiotherapy Center, Iuliu Hatieanu of Medicine and Pharmacy, Cluj-Napoca, RO, ¹¹Azienda Ospedaliera San Camillo Forlanini, Rome, IT, ¹²Clinique Sainte-Marguerite, Hyères, FR, ¹³Clinique Pasteur Lanroze, Brest, FR, ¹⁴Centre François Baclesse, Caen, FR, ¹⁵CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, ¹⁶Hospital del Mar-IMIM Research Institute, Barcelona, ES, ¹⁷The Mater Misericordiae University Hospital, Dublin, IE, ¹⁸Unicancer, Paris, Cedex, FR, ¹⁹Gustave Roussy - University of Paris-Saclay-Oncostat U1018, Villejuif, FR, ²⁰Institut Gustave Roussy, University of Paris Saclay, Villejuif, Cedex, FR

10:50 - 11:05 **Invited Discussant 1359MO and 1361MO**

B. Hadaschik, University Hospital of Essen, Essen, DE

- 11:05 - 11:10 **LBA65 - SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial**
- C. Rothermundt¹, R. Cathomas², K. Gysel³, N. Fischer⁴, R. Pereira Mestre⁵, T. Hermanns⁶, S. Rothschild⁷, N. Mach⁸, W. Mingrone⁹, M. Ciriolo¹⁰, B. Müller¹¹, A. Erdmann¹², C. Schär³, C. Mamot¹³, P. Bohanes¹⁴, A. Omlin¹, S. Bastian², K. Ribì³, S. Gillessen¹⁵, ¹Kantonsspital St. Gallen, St. Gallen, CH, ²Kantonsspital Graubünden, Chur, CH, ³SAKK - Swiss Group for Clinical Cancer Research, Bern, CH, ⁴Kantonsspital Winterthur, Winterthur, CH, ⁵EOC - Ente Ospedaliero Cantonale, Bellinzona, CH, ⁶Universitätsspital Zürich, Zurich, CH, ⁷Universitätsspital Basel, Basel, CH, ⁸Hopitaux Universitaires de Geneve, Geneva, CH, ⁹Kantonsspital Olten, Olten, CH, ¹⁰Bürgerspital Solothurn, Solothurn, CH, ¹¹Luzerner Kantonsspital, Luzern, CH, ¹²Kantonsspital Baden, Baden, CH, ¹³Kantonsspital Aarau, Aarau, CH, ¹⁴CCAC 2- Centre de Chimiothérapie Anticancéreuse, Lausanne, CH, ¹⁵EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH
- 11:10 - 11:15 **1362MO - Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study**
- E. Yu¹, S.H. Park², J. Goh³, S.J. Shin⁴, N. Mehra⁵, R. Mcdermott⁶, M.A. Sala Gonzalez⁷, P. Fong⁸, R. Greil⁹, M. Retz¹⁰, J.P. Sade¹¹, Y.-H. Huang¹², S. Begbie¹³, F. Rey¹⁴, G. Kramer¹⁵, H. Suzuki¹⁶, J. Zhang¹⁷, J. Kim¹⁷, C. Poehlein¹⁷, E. Antonarakis¹⁸, ¹University of Washington & Fred Hutchinson Cancer Research Center, Seattle, US, ²Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ³Royal Brisbane and Women's Hospital, Herston & Queensland University of Technology, Herston, AU, ⁴Severance Hospital Yonsei University Health System, Seoul, KR, ⁵Radboud University Medical Center, Nijmegen, Nijmegen, NL, ⁶St Vincents University Hospital, Dublin, IE, ⁷Hospital Josep Trueta, Bilbao, ES, ⁸Auckland City Hospital and University of Auckland, Auckland, NZ, ⁹Paracelsus Medical University Salzburg Cancer Research Institute and Cancer Cluster, Salzburg, AT, ¹⁰Rechts der Isar Medical Center, Technical University Munich, München, DE, ¹¹Instituto Alexander Fleming, Buenos Aires, AR, ¹²Taipei Veterans General Hospital, Taipei City, TW, ¹³Port Macquarie Base Hospital, Port Macquarie, AU, ¹⁴Clinica CIDO, Temuco, CL, ¹⁵Medical University of Vienna, Vienna, AT, ¹⁶Toho University Medical Center Sakura Hospital, Sakura, JP, ¹⁷Merck & Co., Inc., Rahway, US, ¹⁸Johns Hopkins University, Baltimore, US
- 11:15 - 11:20 **1363MO - Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial**
- S. Oudard¹, P. Beuzeboc², E. Voog³, P. Barthelemy⁴, A. Thiery-Vuillemin⁵, M. Bennamoun⁶, A. Hasbini⁷, K. Aldabbagh⁸, C. Saldana⁹, E. Sevin¹⁰, Y.E. Amela¹¹, G. Von Amsberg¹², N. Houede¹³, D. Besson¹⁴, S. Feyerabend¹⁵, M. Boegemann¹⁶, D. Pfister¹⁷, M. Schostak¹⁸, O. Huillard¹⁹, C. Helissey²⁰, ¹HEGP - Hopital Europeen Georges-Pompidou - APHP - University de Paris, Paris, FR, ²Foch Hospital, Suresnes, FR, ³Jean Bernard Center, Le Mans, FR, ⁴Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ⁵CHU Jean-Minjoz, Besançon, FR, ⁶Institute Mutualiste Montsouris, Paris, FR, ⁷Clinique Pasteur Lanroze, Brest, FR, ⁸Polyclinique Saint Côme, Compiègne, FR, ⁹Henri

Mondor Hospital, Paris Est Creteil university, TRePCa, Creteil, FR, ¹⁰Centre Maurice Tubiana, Caen, FR, ¹¹Centre de Cancérologie Les Dentellières, Valenciennes, FR, ¹²University Hospital Hamburg-Eppendorf, Hamburg, DE, ¹³Institut de cancérologie du Gard, Nîmes, FR, ¹⁴Centre Armoricaïn de Radiothérapie et d'Oncologie, Plérin, FR, ¹⁵Studienpraxis Urologie, Nürtingen, DE, ¹⁶UKM - University Hospital Münster, Münster, DE, ¹⁷Universitaetsklinikum Köln, Köln, DE, ¹⁸University Hospital Magdeburg, Otto von Guericke University Magdeburg, Magdeburg, DE, ¹⁹Hopital Cochin AP-HP, Paris, FR, ²⁰Military Hospital Begin, Saint-Mandé, FR

11:20 - 11:25

1364MO - Preliminary phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients

K. Fizazi¹, A. Bernard-Tessier¹, P. Barthelemy², T. Utriainen³, G. Roubaud⁴, A. Flechon⁵, J. Van Der Voet⁶, G. Gravis Mescam⁷, R. Ratta⁸, R. Jones⁹, O. Parikh¹⁰, M. Tanner¹¹, C. Garratt¹², L. Nevalaita¹³, P. Pohjanjousi¹³, T. Ikonen¹³, E. Antonarakis¹⁴, N. Cook¹⁵, ¹Institute Gustave Roussy, Villejuif, FR, ²ICANS-Institut de Cancérologie, Strasbourg, FR, ³Helsinki University Central Hospital, Helsinki, FI, ⁴Institute Bergonié, Bordeaux, FR, ⁵Centre Léon Bérard, Lyon, FR, ⁶The James Cook University Hospital, Middlesbrough, GB, ⁷IPC - Institut Paoli-Calmettes, Marseille, FR, ⁸Hopital Foch, Suresnes, FR, ⁹Velindre Cancer Centre, Cardiff, GB, ¹⁰Royal Preston Hospital-Lancashire Teaching Hospitals NHS Foundation Trust, Preston, GB, ¹¹Tampere University Hospital (Tays), Tampere, FI, ¹²Orion Corporation Orion Pharma, Newbury, GB, ¹³Orion Corporation Orion Pharma, Espoo, FI, ¹⁴Johns Hopkins University, Baltimore, US, ¹⁵The Christie NHS Foundation Trust, Manchester, GB

11:25 - 11:40

Invited Discussant LBA65, 1362MO, 1363MO and 1364MO

M. Lolkema, Erasmus MC - University Medical Center, Rotterdam, NL

10:15 - 11:45	Type: Special session Title: Sex and gender differences in oncology: From prevention to care Chair(s): Sabine Oertelt-Prigione, NL; Anna Wagner, CH	7.3.T - Toulouse Auditorium
10:15 - 10:35	Gender differences in epidemiology and attributable risk factors of non sex-related cancers <u>I. Soerjomataram</u> , IARC - International Agency for Research on Cancer, Lyon, FR	
10:35 - 10:55	Gender differences in colorectal cancer screening <u>H. Brenner</u> , DKFZ - German Cancer Research Center, Heidelberg, DE	
10:55 - 11:15	Lung cancer biology and outcomes <u>E. Felip</u> , Vall d'Hebron University Hospital, Barcelona, ES	
11:15 - 11:35	Quality-of-life <u>S. Oertelt-Prigione</u> , Radboud University Medical Center, Nijmegen, Nijmegen, NL	
11:35 - 11:45	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
10:15 - 11:45	Type: Educational session Title: State-of-the-art: Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours Chair(s): Eva Tiensuu Janson, SE; Nicola Fazio, IT	7.3.U - Urval Auditorium
10:15 - 10:40	What oncologists need to know about GEP-NET before commencing therapy <u>E. Tiensuu Janson</u> , University Hospital Uppsala Akademiska Sjukhuset, Uppsala, SE	
10:40 - 11:05	Treatment of small intestinal NET <u>M. Pavel</u> , Universitätsklinik Erlangen, Erlangen, DE	
11:05 - 11:30	Treatment of pancreatic NET <u>N. Fazio</u> , IEO - Istituto Europeo di Oncologia, Milan, IT	
11:30 - 11:45	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

10:15 - 11:45	Type: EONS session Title: Palliative and end-of-life care Chair(s): Merel van Klinken, NL	7.3.S - Strasbourg Auditorium
10:15 - 10:30	Cultural determinants of end of life <u>G. Bagcivan</u> , Koc University - School of Nursing, Istanbul, TR	
10:30 - 10:45	Gero-oncology integrative view on palliative care <u>W. Oldenmenger</u> , Erasmus MC Cancer Institute, Rotterdam, NL	
10:45 - 11:00	Navigating parental cancer when a mum or dad is at end of life <u>C. Semple</u> , Ulster Hospital - South Eastern Health and Social Care Trust, Dundonald, GB	
11:00 - 11:10	CN24 - The perceptions of healthcare professionals on the provision of palliative and end-of-life care in prisons S. Pringle ¹ , <u>G. Kotronoulas</u> ² , ¹ MVLS - Medical, Veterinary and Life Sciences College - University of Glasgow, Glasgow, GB, ² University of Glasgow, Glasgow, GB	
11:10 - 11:20	CN25 - Bereaved parents' experience of adapting to life after the death of a parent with cancer who has dependent children <u>J. Hanna</u> ¹ , C. Semple ² , ¹ Ulster University, Jordanstown, GB, ² Ulster Hospital - South Eastern Health and Social Care Trust, Dundonald, GB	
11:20 - 11:30	CN27 - Exploring the quality of dying and death of patients with cancer undergoing palliative care (PC) M. Parara ¹ , <u>S. Katsaragakis</u> ² , M. Giannakopoulou ² , E. Patiraki ² , ¹ Galilee Palliative Care Centre, Spata, Attica, GR, ² National and Kapodistrian University of Athens, Athens, GR	
11:30 - 11:40	CN23 - The end of life &#x2013; a topic we avoid: The Croatian National Cancer Patient Experience Survey <u>A. Sajnic</u> ¹ , S. Karabatic ² , J. Miličević ¹ , I. Lukic Franolic ² , N. Dodlek ³ , F. Seiwert ⁴ , M. Jakopovic ² , ¹ KBC - University Hospital Centre Zagreb, Zagreb, HR, ² KBC Zagreb - Clinic for Lung Diseases Jordanovac, Zagreb, HR, ³ KBC Osijek - Clinical Medical Center Osijek, Osijek, HR, ⁴ KBC Zagreb--Jordanovac Clinic for Lung Diseases, Zagreb, HR	
11:40 - 11:45	Q&A and discussion	

10:30 - 11:30	Type: Controversy session Title: What is the optimal approach to managing intermediate stage HPV positive oropharyngeal carcinoma? Chair(s): Sandra Schmitz, BE	7.3.G - Grenoble Auditorium
10:30 - 10:35	Introduction by the chair <u>S. Schmitz</u> , Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE	
10:35 - 10:36	Polling 1 (led by chair) <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
10:36 - 10:46	Induction and de-escalation <u>E. Cohen</u> , Moores Cancer Center - UC San Diego Health, La Jolla, US	
10:46 - 11:01	TORS and RT <u>C. Simon</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
11:01 - 11:01	Polling 2 (led by chair) <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
11:01 - 11:21	Q&A	

10:30 - 11:30	Type: Multidisciplinary session Title: Localized extremity STS: Looking beyond surgery Chair(s): Inga-Marie Schaefer, US	7.3.M - Marseille Auditorium
10:30 - 10:35	Presentation of case/condition <u>I.-M. Schaefer</u> , Brigham and Women's Hospital, Boston, US	
10:35 - 10:50	Isolated limb perfusion <u>S. Bonvalot</u> , Paris, FR	
10:50 - 11:05	RT and radioenhancer: Chemotherapy, TKI and nanoparticles <u>R.L. Haas</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL	
11:05 - 11:20	Risk-based criterion to select for neoadjuvant chemotherapy: Dream or reality? <u>D. Callegaro</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT	
11:20 - 11:30	Discussion	
11:00 - 11:45	Type: Young Oncologist session Title: Young Oncologist Brunch 2: How to write and respond to a critical peer review Chair(s): Matteo Lambertini, IT	7.3.R - Rennes Auditorium
11:00 - 11:15	How to write and respond to a critical peer review <u>P. Garrido Lopez</u> , Hospital Universitario Ramon y Cajal, Madrid, ES	
11:15 - 11:45	Discussion led by Chair <u>M. Lambertini</u> , IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT	
12:00 - 12:40	Type: Keynote lecture Title: Antigen-focused, biotech-empowered: The promise of antibody and cell-based therapies in cancer Chair(s): Sherene Loi, AU	4.B - Brest Auditorium
12:00 - 12:05	Introduction by the chair <u>S. Loi</u> , Peter MacCallum Cancer Centre, Melbourne, AU	
12:05 - 12:30	Antigen-focused, biotech-empowered: The promise of antibody and cell-based therapies in cancer <u>J. Haanen</u> , <u>T. Schumacher</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL	

12:00 - 13:30	Type: EONS Industry Satellite Symposium Title: Mundipharma - Pain management in people with cancer Chair(s): Nikolina Dodlek, HR	7.3.S - Strasbourg Auditorium
12:00 - 12:05	Welcome <u>N. Dodlek</u> , KBC Osijek - Clinical Medical Center Osijek, Osijek, HR	
12:05 - 12:30	Nursing roles in cancer pain management <u>G. Toumbis</u> , Nicosia General Hospital, Nicosia, CY	
12:30 - 12:55	Barriers to pain management in cancer <u>L. Magee</u> , Papworth Hospital NHS Foundation Trust, Cambridge, GB	
12:55 - 13:20	Pain management in home settings <u>J. Miličević</u> , KBC - University Hospital Centre Zagreb, Zagreb, HR	
13:20 - 13:30	Conclusion remarks <u>N. Dodlek</u> , KBC Osijek - Clinical Medical Center Osijek, Osijek, HR	

13:00 - 14:30	Type: Industry Satellite Symposium Title: AstraZeneca - Immunotherapy: the evolving treatment landscape in hepatobiliary cancers Chair(s): Juan Valle, GB	7.2.F - Fécamp Auditorium
13:00 - 13:05	Welcome and introduction to hepatobiliary cancers <u>J. Valle</u> , The Christie NHS Foundation Trust, Manchester, GB	
13:05 - 13:20	The immunogenic landscape of hepatobiliary cancers: rationale for combination therapy approaches in HCC and BTC <u>L. Chan</u> , The Chinese University of Hong Kong - Sino Building, Sha Tin, HK	
13:20 - 13:35	Therapeutic approaches in unresectable / advanced HCC <u>G. Abou-Alfa</u> , Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US	
13:35 - 13:45	Case-study discussion of unresectable / advanced HCC <u>G. Abou-Alfa</u> , Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US	
13:45 - 14:00	Treatment options and prospects for patients with BTC <u>J. Valle</u> , The Christie NHS Foundation Trust, Manchester, GB	
14:00 - 14:10	Case-study discussion of advanced BTC <u>L. Chan</u> , The Chinese University of Hong Kong - Sino Building, Sha Tin, HK	
14:10 - 14:30	Audience discussion and Q&A <u>J. Valle</u> , The Christie NHS Foundation Trust, Manchester, GB	

13:00 - 14:30	Type: Industry Satellite Symposium Title: F. Hoffmann-La Roche Ltd - Redefining Lung Cancer Together: Now and Next Chair(s): Stephen Liu, US	7.1.D - Dijon Auditorium
13:00 - 13:05	Welcome and Introduction <u>S. Liu</u> , Lombardi Cancer Center Georgetown University, Washington, US	
13:05 - 13:10	Patient perspective: Where are we now? <u>S. Vallone</u> , LuCE, Bern, CH	
13:10 - 13:20	Biomarkers in lung cancer: challenges and opportunities <u>F. Penault-Llorca</u> , Jean Perrin Center, Clermont-Ferrand, FR	
13:20 - 13:40	Immunotherapy, targeted therapy and beyond: navigating options for metastatic disease <u>S. Liu</u> ¹ , <u>M. Reck</u> ² , ¹ Lombardi Cancer Center Georgetown University, Washington, US, ² Krankenhaus Grosshansdorf, Grosshansdorf, DE	
13:40 - 14:05	Treatment choice in early-stage lung cancer: new insights, new outlooks <u>M. Reck</u> ¹ , <u>P. Van Schil</u> ² , ¹ Krankenhaus Grosshansdorf, Grosshansdorf, DE, ² UZA - University Hospital Antwerp, Edegem, BE	
14:05 - 14:25	Panel discussion and Q&A <u>S. Liu</u> ¹ , <u>M. Reck</u> ² , <u>F. Penault-Llorca</u> ³ , <u>P. Van Schil</u> ⁴ , <u>S. Vallone</u> ⁵ , ¹ Lombardi Cancer Center Georgetown University, Washington, US, ² Krankenhaus Grosshansdorf, Grosshansdorf, DE, ³ Jean Perrin Center, Clermont-Ferrand, FR, ⁴ UZA - University Hospital Antwerp, Edegem, BE, ⁵ LuCE, Bern, CH	
14:25 - 14:30	Conclusion <u>S. Liu</u> ¹ , <u>S. Vallone</u> ² , ¹ Lombardi Cancer Center Georgetown University, Washington, US, ² LuCE, Bern, CH	

13:00 - 14:30	Type: Industry Satellite Symposium Title: Amgen - Advancing the lung cancer treatment landscape: novel targets for improved patient care Chair(s): Fabrice Barlesi, FR	7.3.G - Grenoble Auditorium
13:00 - 13:10	Welcome and introduction <u>F. Barlesi</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
13:10 - 13:40	Non-squamous versus squamous NSCLC: actionable and emerging targets <u>J. Wolf</u> , Universitätsklinikum Köln (AöR), Köln, DE	
13:40 - 13:55	Towards a new era of biomarker-driven therapy in SCLC <u>N. Reguart Aransay</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, ES	
13:55 - 14:10	Expanding treatment opportunities in SCLC: targeting DLL3 <u>S. Champiat</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
14:10 - 14:30	Panel discussion and Q&A <u>F. Barlesi</u> ¹ , <u>J. Wolf</u> ² , <u>N. Reguart Aransay</u> ³ , <u>S. Champiat</u> ¹ , ¹ Gustave Roussy - Cancer Campus, Villejuif, FR, ² Universitätsklinikum Köln (AöR), Köln, DE, ³ Hospital Clinic y Provincial de Barcelona, Barcelona, ES	

13:00 - 14:30	Type: Industry Satellite Symposium Title: Ipsen - Disrupting the landscape: the Plus One in RCC and NSCLC Chair(s): Laurence Albiges, FR	7.3.H - Honfleur Auditorium
13:00 - 13:05	Welcome & agenda <u>L. Albiges</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
13:05 - 13:45	Triple, double and monotherapy: what is the sequence for best outcomes? <u>J. Bedke</u> ¹ , <u>G.A. De Velasco Oria</u> ² , <u>S. Pal</u> ³ , ¹ Crona Kliniken - Universitätsklinikum Tübingen, Tübingen, DE, ² Hospital Universitario 12 de Octubre, Madrid, ES, ³ City of Hope Comprehensive Cancer Center, Duarte, US	
13:45 - 14:05	Expanding the armamentarium with IO-TKIs combinations - what can be learnt from RCC for the future of NSCLC? <u>L. Albiges</u> ¹ , <u>L. Paz-Ares</u> ² , <u>S. Pal</u> ³ , <u>J. Bedke</u> ⁴ , <u>G.A. De Velasco Oria</u> ² , ¹ Institut Gustave Roussy, Villejuif, Cedex, FR, ² Hospital Universitario 12 de Octubre, Madrid, ES, ³ City of Hope Comprehensive Cancer Center, Duarte, US, ⁴ Crona Kliniken - Universitätsklinikum Tübingen, Tübingen, DE	
14:05 - 14:25	Unmet needs in NSCLC: targeting second-line treatment with TKI-IO <u>L. Paz-Ares</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
14:25 - 14:30	Closing <u>L. Albiges</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	

13:00 - 14:30	Type: ESMO Colloquium Title: ESMO Colloquium Supported by Eisai Europe Ltd.: Optimising outcomes of patients with advanced renal cancer Chair(s): Toni Choueiri, US; Camillo Guglielmo Porta, IT	7.3.O - Orléans Auditorium
13:00 - 13:10	Welcome and introduction <u>T. Choueiri</u> , Dana Farber Cancer Institute, Boston, US	
13:10 - 13:25	Biology and prognostication in advanced clear cell renal cell carcinoma (RCC) <u>V. Gruenwald</u> , University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE	
13:25 - 13:40	State of the art first-line management of patients with advanced RCC <u>T. Choueiri</u> , Dana Farber Cancer Institute, Boston, US	
13:40 - 13:55	The emerging continuum of care in advanced RCC: Second-line and beyond <u>C.G. Porta</u> , Università degli Studi di Bari Aldo Moro, Bari, IT	
13:55 - 14:10	Presentation of two clinical vignettes: Optimising dose-intensity and tolerance <u>C. Suarez Rodriguez</u> , Vall d'Hebron University Hospital, Barcelona, ES	
14:10 - 14:25	Q&A and discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
14:25 - 14:30	Concluding remarks <u>C.G. Porta</u> , Università degli Studi di Bari Aldo Moro, Bari, IT	

13:00 - 14:30	Type: Industry Satellite Symposium Title: Astellas - The maturing treatment landscape of mHSPC Chair(s): Stephane Oudard, FR	7.3.Q - Quimper Auditorium
13:00 - 13:05	Welcome and introduction <u>S. Oudard</u> , HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR	
13:05 - 13:25	Reap what you sow: Treatments for mHSPC in use today <u>I. Davis</u> , Eastern Health Clinical School - Monash University, Box Hill, AU	
13:25 - 13:45	Forget-me-nots: Unmet needs in mHSPC <u>S.F. Shariat</u> , MedUni Wien - Medical University of Vienna, Vienna, AT	
13:45 - 14:05	The grass is greener: Deciding on the most appropriate initial treatment for patients with mHSPC <u>H. Payne</u> , UCLH Foundation Trust, London, GB	
14:05 - 14:25	Q&A <u>S. Oudard</u> ¹ , <u>I. Davis</u> ² , <u>H. Payne</u> ³ , <u>S.F. Shariat</u> ⁴ , ¹ HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, ² Eastern Health Clinical School - Monash University, Box Hill, AU, ³ UCLH Foundation Trust, London, GB, ⁴ MedUni Wien - Medical University of Vienna, Vienna, AT	
14:25 - 14:30	Closing remarks <u>S. Oudard</u> , HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR	

13:00 - 14:30	Type: Industry Satellite Symposium Title: Gilead and Kite Oncology - Redefining the Lines of TNBC, Real-world management: improving survival for patients with metastatic TNBC Chair(s): Suzette Delaloge, FR	7.3.T - Toulouse Auditorium
13:00 - 13:05	Welcome and introduction <u>S. Delaloge</u> , Institut Gustave Roussy, Villejuif, FR	
13:05 - 13:10	TNBC today: How can we increase survival for a very heterogenous and aggressive disease? <u>S. Delaloge</u> , Institut Gustave Roussy, Villejuif, FR	
13:10 - 13:30	Treatment milestones in TNBC and current treatment pathways <u>A. Gennari</u> , Università Degli Studi Del Piemonte Orientale - Scuola di Medicina, Novara, IT	
13:30 - 14:05	Real-world management of TNBC: incorporating new therapies into clinical practice <u>K. Jhaveri</u> ¹ , <u>S. Kuemmel</u> ² , ¹ Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ² Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen, DE	
14:05 - 14:25	Key considerations when managing mTNBC patients: Faculty insights and audience Q&A <u>S. Delaloge</u> ¹ , <u>A. Gennari</u> ² , <u>K. Jhaveri</u> ³ , <u>S. Kuemmel</u> ⁴ , ¹ Institut Gustave Roussy, Villejuif, FR, ² Università Degli Studi Del Piemonte Orientale - Scuola di Medicina, Novara, IT, ³ Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ⁴ Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen, DE	
14:25 - 14:30	Closing Remarks <u>S. Delaloge</u> , Institut Gustave Roussy, Villejuif, FR	

13:00 - 14:30	Type: Patient Advocacy session Title: I am FINE: Frustrated * Isolated * Neglected * Emotional Chair(s): Christopher Curtis, GB; Natacha Bolanos Fernandez, ES	7.3.M - Marseille Auditorium
13:00 - 13:15	Patient's perspective...Am I fine? <u>N. Bolanos Fernandez</u> , Lymphoma Coalition, Madrid, ES	
13:15 - 13:30	Caregiver's perspective... Am I fine? <u>K. Washington</u> , Private Address - Kate Washington, Sacramento, US	
13:30 - 13:45	Physician's perspective... Am I fine? <u>F. Cardoso</u> , Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT	
13:45 - 14:00	Nurse's perspective... Am I fine? <u>L. Sharp</u> , RCC Stockholm-Gotland, HSF, Stockholm, SE	
14:00 - 14:15	Psycho-oncologist's perspective <u>G. Pravettoni</u> , IEO - Istituto Europeo di Oncologia, Milan, IT	
14:15 - 14:25	Discussion	
14:25 - 14:30	Conclusion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

13:00 - 14:30	Type: Industry Satellite Symposium Title: Daiichi Sankyo - The Current and Emerging Role of ADCs in Cancer Therapy Chair(s): Javier Cortés, ES	7.3.U - Urval Auditorium
13:00 - 13:05	Introduction <u>J. Cortés</u> , Hospital Ruber Internacional, Madrid, ES	
13:05 - 13:20	Overview of ADC Technology <u>J. Cortés</u> , Hospital Ruber Internacional, Madrid, ES	
13:20 - 13:40	Clinical Updates on ADCs in Breast Cancer <u>S. Modi</u> , MSKCC - Memorial Sloan Kettering Cancer Center, New York, US	
13:40 - 14:00	Shifting the Treatment Landscape in Lung Cancer <u>N. Girard</u> , Institut Curie, Paris, FR	
14:00 - 14:15	The Evolving Treatment Landscape in Gastric Cancer <u>M. Di Bartolomeo</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT	
14:15 - 14:30	Q&A <u>J. Cortés</u> ¹ , <u>S. Modi</u> ² , <u>N. Girard</u> ³ , <u>M. Di Bartolomeo</u> ⁴ , ¹ Hospital Ruber Internacional, Madrid, ES, ² MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ³ Institut Curie, Paris, FR, ⁴ Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT	
13:45 - 14:45	Type: EONS session Title: Cancer accommodation and disruption in young lives Chair(s): Johan De Munter, BE	7.3.S - Strasbourg Auditorium
13:45 - 14:15	A life interrupted: Experiences of living with melanoma <u>W. Mcinally</u> , <u>J. Brodie</u> , Open University, Edinburgh, GB	
14:15 - 14:30	Approach to febrile neutropenia in children and young adolescents <u>R. Kebudi</u> , Istanbul University Institute of Oncology - Istanbul Universitesi Onkoloji Enstitusu, Istanbul, TR	
14:30 - 14:45	Q&A and discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
14:45 - 16:15	Type: Proffered Paper session Title: Proffered Paper session: NSCLC, metastatic Chair(s): Helena A. Yu, US; Rina Hui, AU	4.A - Antibes Auditorium

- 14:45 - 14:55 **LBA51 - Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial**
- J. Remon Masip¹, B. Besse¹, S. Ponce Aix², A. Callejo³, K. Al-Rabi⁴, R. Bernabe Caro⁵, L. Greillier⁶, M. Majem Tarruella⁷, N. Reguart Aransay⁸, I. Monnet⁹, S. Cousin¹⁰, P. Garrido Lopez¹¹, G. Robinet¹², M.R. Garcia Campelo¹³, A.-C. Madroszyk Flandin¹⁴, J. Mazieres¹⁵, Y. Pretzenbacher¹⁶, B. Fournier¹⁶, A.-M. Dingemans¹⁷, R. Dziadziuszko¹⁸, ¹Institut Gustave Roussy, Villejuif, FR, ²Hospital Universitario 12 de Octubre, Madrid, ES, ³Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁴KHCC - King Hussein Cancer Center, Amman, JO, ⁵Hospital Universitario Virgen del Rocio, Seville, ES, ⁶Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Marseille, FR, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁸Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁹CH Intercommunal de Créteil, Creteil, FR, ¹⁰Institut Bergonie, Bordeaux, FR, ¹¹Hospital Universitario Ramon y Cajal, Madrid, ES, ¹²CHRU Brest - Hopital Augustin Morvan, Brest, FR, ¹³Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES, ¹⁴IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ¹⁵Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR, ¹⁶EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, BE, ¹⁷Erasmus MC - University Medical Center, Rotterdam, NL, ¹⁸Medical University of Gdansk, Gdansk, PL
- 14:55 - 15:05 **LBA52 - Tepotinib & osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study**
- J. Mazieres¹, T.M. Kim², B.K. Lim³, M. Wislez⁴, C. Doods⁵, G. Finocchiaro⁶, H. Hayashi⁷, C.K. Liam³, J. Raskin⁸, L.M. Tho⁹, F. De Marinis¹⁰, E. Nadal¹¹, E. Smit¹², X. Le¹³, S. Brutlach¹⁴, A.M. O'Brate Grupp¹⁴, S. Adrian¹⁴, B. Ellers-Lenz¹⁴, N. Karachaliou¹⁴, Y.-L. Wu¹⁵, ¹Université Paul Sabatier, Toulouse, FR, ²Seoul, Republic of Korea; Department of Internal Medicine, Seoul National University Hospital, Seoul, KR, ³Faculty of Medicine, University of Malaya, Kuala Lumpur, MY, ⁴Hopital Cohin, Assistance Publique – Hôpitaux de Paris, Paris, FR, ⁵University Hospitals Leuven, Leuven, BE, ⁶Humanitas Research Hospital IRCCS, Rozzano, Milan, IT, ⁷Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, JP, ⁸Antwerp University Hospital (UZA), Edegem, BE, ⁹Pantai Hospital Kuala Lumpur, Kuala Lumpur, MY, ¹⁰European Institute of Oncology, IRCCS, Milan, IT, ¹¹Catalan Institute of Oncology, L'Hospitalet, Barcelona, ES, ¹²Netherlands Cancer Institute, Amsterdam, NL, ¹³The University of Texas MD Anderson Cancer Center, Houston, US, ¹⁴Merck Healthcare KGaA, Darmstadt, DE, ¹⁵Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN
- 15:05 - 15:15 **LBA53 - ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib**
- Z. Piotrowska¹, M.-J. Ahn², Y.K. Pang³, S.H. How⁴, S.-W. Kim⁵, P.J. Voon⁶, D. Cortinovis⁷, J. De Castro Carpeno⁸, M. Tiseo⁹, D. Rodriguez Abreu¹⁰, S. Ramalingam¹¹, J. Li¹², L. Servidio¹², S. Sadow¹³, R. Hartmaier¹⁴, B.C. Cho¹⁵, ¹Massachusetts General Hospital, Boston, US, ²Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ³Faculty of Medicine, University of Malaya, Kuala Lumpur, MY, ⁴Kulliyah of Medicine, International Islamic University Malaysia, Kuantan, MY, ⁵Asan Medical Center, Seoul, KR, ⁶Hospital Umum Sarawak, Kuching, MY, ⁷San Gerardo Hospital, Monza, IT,

⁸Hospital Universitario La Paz, IdiPAZ, Madrid, ES, ⁹University of Parma, Parma, Italy and Medical Oncology Unit, University Hospital of Parma, Parma, IT, ¹⁰Gran Canaria University Hospital, Las Palmas de Gran Canaria, ES, ¹¹The Winship Cancer Institute of Emory University, Atlanta, US, ¹²Oncology Business Unit, Global Medical Affairs, Gaithersburg, US, ¹³AstraZeneca, Gaithersburg, US, ¹⁴AstraZeneca Oncology R&D, Boston, US, ¹⁵Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, KR

- 15:15 - 15:25 **Invited Discussant LBA51, LBA52 and LBA53**
H.A. Yu, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US
- 15:25 - 15:35 **Q&A**
- 15:35 - 15:45 **LBA54 - Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial**
M. Ozguroglu¹, S. Kilickap², A. Sezer³, M. Gumus⁴, I. Bondarenko⁵, M. Gogishvili⁶, M. Nechaeva⁷, M. Schenker⁸, I. Cicin⁹, G.F. Ho¹⁰, Y. Kulyaba¹¹, M. Dvorkin¹², K. Zyuhail¹³, R.I. Scheusan¹⁴, S. Li¹⁵, J.-F. Pouliot¹⁵, F. Seebach¹⁵, I. Lowy¹⁵, G. Gullo¹⁵, P. Rietschel¹⁵, ¹Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, TR, ²Hacettepe University Cancer Institute, Ankara, TR, ³Baskent Universitesi, Adana, TR, ⁴S.B. Istanbul Medeniyet Universitesi - Goztepe Egitim Ve Arastirma Hastanesi, Istanbul, TR, ⁵Dnipropetrovsk Medical Academy, Dnipro, UA, ⁶Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic, Tbilisi, GE, ⁷Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, RU, ⁸St. Nectarie Oncology Center Craiova, Craiova, RO, ⁹Trakya University Rektörlüğü, Edirne, TR, ¹⁰Pusat Perubatan Universiti Malaya (PPUM), Kuala Lumpur, MY, ¹¹Medical Center Klinika Manufaktura, Khodosivka Village, UA, ¹²BHI of Omsk Region Clinical Oncology Dispensary, Omsk, RU, ¹³Multiprofile Hospital for Active Treatment - Burgas, Burgas, BG, ¹⁴Oncocenter - Oncologie Clinica SRL, Timisoara, RO, ¹⁵Regeneron Pharmaceuticals, Inc., Tarrytown, US
- 15:45 - 15:55 **9720 - Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial**
G. Zalcman¹, A.-C. Madroszyk Flandin², O. Molinier³, C. Dayen⁴, T. Egenod⁵, D. Debieuvre⁶, S. Beaucaire-Danel⁷, A. Dixmier⁸, E. Pichon⁹, S. Galland Girodet¹⁰, E. Giroux-Leprieur¹¹, N. Cloarec¹², J. Cadranel¹³, J. Otto¹⁴, P. Romand¹⁵, A. Langlais¹⁶, F. Morin¹⁷, M. Antoine¹³, V. Westeel¹⁸, A.C. Toffart¹⁹, ¹Université Paris Cité, Paris, FR, ²IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ³Centre Hospitalier Du Mans, Le Mans, FR, ⁴Centre Hospitalier de Saint-Quentin, Saint-Quentin, Cedex, FR, ⁵CHU Limoges - Hopital Dupuytren, Limoges, FR, ⁶GHRMSA, Mulhouse, FR, ⁷Institut Curie, Paris, FR, ⁸C.H.R. Orleans - La Source, Orleans, FR, ⁹CHRU Hopitaux de Tours - Hopital Bretonneau, Tours, cedex, FR, ¹⁰Polyclinique Bordeaux Nord Aquitaine, Bordeaux, FR, ¹¹Hopital Ambroise Pare AP-HP - Université Paris Saclay, Boulogne-Billancourt, FR, ¹²CH Henri Duffaut, Avignon, FR, ¹³Hopital Tenon AP-HP, Paris, Cedex, FR, ¹⁴Centre Antoine Lacassagne, Nice, FR, ¹⁵Centre Hospitalier Alpes Leeman, Contamine-sur-Arve, FR, ¹⁶IFCT (Intergroupe Francophone de Cancérologie Thoracique), Paris, FR, ¹⁷French

Cooperative Thoracic Intergroup, Paris, FR, ¹⁸CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, ¹⁹CHU Grenoble-Alpes, La Tronche, FR

15:55 - 16:05 **Invited Discussant LBA54 and 9720**

M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE

16:05 - 16:15 **Q&A**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

14:45 - 16:15 Type: Proffered Paper session 4.B - Brest Auditorium
Title: Proffered Paper session 2: GI, upper digestive
 Chair(s): Ian Chau, GB; Hanneke van Laarhoven, NL

14:45 - 14:55 **12030 - FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO**

S. Lorenzen¹, P. Thuss-Patience², G. Folprecht³, J. Riera Knorrenschild⁴, V. Heinemann⁵, E. Goekkurt⁶, T. Dechow⁷, T. Ettrich⁸, K. Luley⁹, J.-C. Moulin¹⁰, U. Lindig¹¹, S. Angermeier¹², O. Waidmann¹³, D. Pink¹⁴, C. Bolling¹⁵, S. Junge¹⁶, C. Pauligk¹⁶, T. Gaiser¹⁷, T. Götze¹⁸, S.-E. Al-Batran¹⁸, ¹Klinikum Rechts der Isar, Technische Universität, Munich, DE, ²Charité-Universitätsmedizin Berlin/Campus Virchow Klinikum (CVK), Berlin, DE, ³Universitätsklinikum Carl Gustav Carus, Dresden, DE, ⁴Universitätsklinikum Giessen und Marburg, Marburg, DE, ⁵LMU Klinikum der Universität München, Munich, DE, ⁶Hämatologisch-Onkologische Praxis Eppendorf (HOPE), Hamburg, DE, ⁷Onkologie Ravensburg, Ravensburg, DE, ⁸University Hospital Ulm, Ulm, DE, ⁹University Hospital Schleswig-Holstein, Campus Luebeck, Lübeck, DE, ¹⁰Ortenau Klinikum Lahr, Lahr/Schwarzwald, DE, ¹¹Jena University Hospital, Jena, DE, ¹²Klinikum Ludwigsburg, Ludwigsburg, DE, ¹³Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, DE, ¹⁴Klinik und Poliklinik für Innere Medizin C, Hämatologie und Onkologie, Transplantationszentrum, Palliativmedizin, Universität Greifswald, Bad Saarow, DE, ¹⁵Agaplesion Markus Krankenhaus, Frankfurt am Main, DE, ¹⁶Institut für Klinische Krebsforschung IKF, Frankfurt am Main, DE, ¹⁷University Medical Center Mannheim, Mannheim, DE, ¹⁸Krankenhaus Nordwest, University Cancer Center Frankfurt, Frankfurt am Main, DE

14:55 - 15:05 **Invited Discussant 12030**

I. Chau, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

15:05 - 15:15 **Q&A**

15:15 - 15:25 **LBA60 - Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma: Results of the randomized phase III PRODIGE 65 - UCGI 36 - GEMPAX UNICANCER study**

C. De La Fouchardiere¹, D. Malka², S. Chabaud³, J. Raimbourg⁴, D. Botsen⁵, S. Launay⁶,

L. Evesque⁷, A. Vienot⁸, H. Perrier⁹, M. Jary¹⁰, Y. Rinaldi¹¹, C. Coutzac Bergouignan¹, J.-B. Bachet¹², C. Neuzillet¹³, N. Williet¹⁴, R. Desgrippes¹⁵, G. Brard¹⁶, N. Lachaux¹⁶, O. Bouche¹⁷, F. Ghiringhelli¹⁸, ¹Centre Léon Bérard, Lyon, FR, ²Institut Gustave Roussy, Villejuif, Cedex, FR, ³Centre de recherche en cancerologie de Lyon (CRCL), Lyon, FR, ⁴ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁵Institut Jean Godinot, Reims, FR, ⁶IPC - Institut Paoli-Calmettes, Marseille, FR, ⁷Centre Anticancer Antoine Lacassagne, Nice, FR, ⁸CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, ⁹Fondation Hôpital Saint Joseph, Marseille, FR, ¹⁰CHU de Clermont-Ferrand - Site Estaing, Clermont-Ferrand, Cedex, FR, ¹¹Hopital Européen Marseille, Marseille, FR, ¹²Groupe Hospitalier Pitié Salpetriere, Paris, FR, ¹³Institut Curie, Paris, FR, ¹⁴Hopital Nord, St Priest En Jarez, FR, ¹⁵C.H. Broussais, Saint-Malo, FR, ¹⁶UNICANCER, Paris, FR, ¹⁷CHU de Reims - Hôpital Robert Debré, Reims, Cedex, FR, ¹⁸University of Burgundy, Genetic and Immunotherapy Medical Institute, Dijon, FR

15:25 - 15:35 **Invited Discussant LAB60**

H. Wilmink, Amsterdam University Medical Center (UMC) - locatie Academic Medical Center (AMC), Amsterdam, NL

15:35 - 15:45 **Q&A**

15:45 - 15:55 **LBA12 - Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial**

A. Hollebecque¹, M. Borad², L. Goyal³, A. Schram⁴, J.O. Park⁵, P. Cassier⁶, S. Kamath⁷, D.T. Wai Meng⁸, E. Dotan⁹, R. Kim¹⁰, V. Sahai¹¹, D.-Y. Oh¹², C.-Y. Liao¹³, M. Millward¹⁴, D. Roda Perez¹⁵, C. Ferte¹⁶, R. Blakesley¹⁶, B. Wolf¹⁶, V. Subbiah¹⁷, R.K. Kelley¹⁸, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Mayo Clinic Cancer Center, Scottsdale, US, ³Massachusetts General Hospital, Boston, US, ⁴MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ⁵Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ⁶Centre Léon Bérard, Lyon, FR, ⁷Taussig Cancer Center-Cleveland Clinic, Cleveland, US, ⁸National Cancer Centre Singapore, Singapore, SG, ⁹Fox Chase Cancer Center - Main Campus, Philadelphia, US, ¹⁰H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, US, ¹¹Michigan Medicine, University of Michigan, Ann Arbor, US, ¹²Seoul National University Hospital, Seoul, KR, ¹³University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, ¹⁴Linear Clinical Research & University of Western Australia, Perth, AU, ¹⁵Hospital Clinico Universitario de Valencia, Valencia, ES, ¹⁶Relay Therapeutics, Inc., Cambridge, US, ¹⁷The University of Texas M. D. Anderson Cancer Center, Houston, US, ¹⁸UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

15:55 - 16:05 **Invited Discussant LBA12**

C. Braconi, BWSCC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB

16:05 - 16:15 **Q&A**

14:45 - 16:15	Type: Special session Title: ESMO Clinical Practice Guidelines session 2 Chair(s): Giuseppe Curigliano, IT; Emanuela Romano, FR	7.1.C - Cannes Auditorium
14:45 - 14:55	Bladder cancer: Clinical case <u>C. Oing</u> , Newcastle University, Newcastle upon Tyne, GB	
14:55 - 15:05	Bladder cancer: Discussant <u>T. Powles</u> , St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB	
15:05 - 15:15	Bladder cancer: Discussion / Q&A	
15:15 - 15:25	Primary CNS lymphoma: Clinical case <u>D. Alves</u> , Hospital Pedro Hispano - Unidade Local de Saude de Matosinhos EPE - SNS, Senhora da Hora, PT	
15:25 - 15:35	Primary CNS lymphoma: Discussant <u>A. Ferreri</u> , IRCCS Ospedale San Raffaele, Milan, IT	
15:35 - 15:45	Primary CNS lymphoma: Discussion / Q&A	
15:45 - 15:55	Metastatic non-small-cell lung cancer: Clinical case <u>L. Mezquita</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, ES	
15:55 - 16:05	Metastatic non-small-cell lung cancer: Discussant <u>L. Hendriks</u> , Maastricht, NL	
16:05 - 16:15	Metastatic non-small-cell lung cancer: Discussion / Q&A <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

14:45 - 16:15 **Type: Special symposium** **7.2.E - Évry Auditorium**
Title: Targeting DNA repair and beyond in ovarian cancer
 Chair(s): Stephanie Lheureux, CA; Clare Scott, AU

14:45 - 14:50 **Introduction and scientific background**
C. Scott, Walter and Eliza Hall Institute WEHI, Parkville, AU

14:50 - 15:05 **Can we identify the patients who will most likely benefit through HRD tests?**
I. Mcneish, London, GB

15:05 - 15:20 **PARPi resistance: What do we know now?**
S. Lheureux, University Health Network - Princess Margaret Cancer Center, Toronto, CA

15:20 - 15:35 **DNA damage repair: What targeting strategies show promise over and above PARP inhibition?**
C. Gourley, Cancer Research UK Edinburgh Centre, Edinburgh, GB

15:35 - 15:50 **Other targets beyond DDR in ovarian cancer**
I. Ray-Coquard, Centre Léon Bérard, Lyon, FR

15:50 - 15:55 **Conclusions and perspectives**
S. Lheureux, University Health Network - Princess Margaret Cancer Center, Toronto, CA

15:55 - 16:15 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

14:45 - 16:15 **Type: Educational session** **7.2.F - Fécamp Auditorium**
Title: Non-melanoma skin cancers
 Chair(s): Reinhard Dummer, CH; Ulrike Leiter-Stoppke, DE

14:45 - 15:10 **Merkel cell carcinoma, angiosarcoma & Kaposi**
U. Leiter-Stoppke, Universitaets-Hautklinik Tuebingen, Tuebingen, DE

15:10 - 15:35 **Basal cell carcinoma**
R. Dummer, Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH

15:35 - 16:00 **Cutaneous squamous cell carcinoma**
P. Ascierto, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT

16:00 - 16:15 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

14:45 - 16:15	Type: Mini Oral session Title: Mini Oral session: Basic science & translational research Chair(s): Sarah-Jane Dawson, AU; Marleen Kok, NL; John Stagg, CA	7.1.D - Dijon Auditorium
----------------------	---	---------------------------------

14:45 - 14:50	LBA72 - Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial <u>M.F. Mosele</u> ¹ , A. Lusque ² , V. Dieras ³ , E. Deluche ⁴ , A. Ducoulombier ⁵ , B. Pistilli ⁶ , T. Bachelot ⁷ , F. Viret ⁸ , C. Levy ⁹ , Y. Pradat ¹ , D. Tran ¹⁰ , N. Droin ⁶ , M. Kobayashi ¹¹ , T. Kakewaga ¹¹ , M. Deloger ¹ , B. Job ⁶ , M. Jimenez ¹² , M. Lacroix-Triki ¹³ , F. André ¹ , ¹ Gustave Roussy - Cancer Campus, Villejuif, FR, ² Institut Claudius Regaud IUCT-O, Toulouse, FR, ³ Centre Eugene - Marquis, Rennes, FR, ⁴ CHU Limoges - Hopital Dupuytren, Limoges, FR, ⁵ Centre Anticancer Antoine Lacassagne, Nice, FR, ⁶ Institut Gustave Roussy, Villejuif, Cedex, FR, ⁷ Centre Léon Bérard, Lyon, FR, ⁸ IPC - Institut Paoli-Calmettes, Marseille, FR, ⁹ Centre Francois Baclesse, Caen, FR, ¹⁰ Institut Gustave Roussy - INSERM UMR 981, Villejuif, FR, ¹¹ Daiichi Sankyo Co., Ltd., Tokyo, JP, ¹² Unicancer, Paris, FR, ¹³ Institut Gustave Roussy, Villejuif, FR	
14:50 - 14:55	904MO - Anthracycline-related cardiotoxicity in breast cancer patients carrying mutational signature of homologous recombination deficiency (HRD) <u>L. Incorvaia</u> ¹ , A. Fiorino ¹ , S. Gori ² , S. Cinieri ³ , G. Curigliano ⁴ , A. Toss ⁵ , L. Cortesi ⁵ , G.R.R. Ricciardi ⁶ , R. Chiari ⁷ , M. Peri ¹ , C. Brando ¹ , T.D. Bazan Russo ¹ , V. Gristina ¹ , A. Galvano ¹ , G. Damerino ¹ , I. Carreca ¹ , G. Novo ¹ , G. Badalamenti ¹ , V. Bazan ¹ , A. Russo ¹ , ¹ University of Palermo, Palermo, IT, ² IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, IT, ³ Ospedale A. Perrino, Brindisi, IT, ⁴ IEO - Istituto Europeo di Oncologia, Milan, IT, ⁵ Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ⁶ Centro Oncologico Ospedale Papardo, Messina, IT, ⁷ Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, IT	
14:55 - 15:00	68MO - Generalization of a deep learning model for HER2 status predictions on H&#x26;E-stained whole slide images derived from 3 neoadjuvant clinical studies <u>M. Hägele</u> ¹ , K.-R. Müller ² , C. Denkert ³ , A. Schneeweiss ⁴ , B. Sinn ⁵ , M. Untch ⁶ , M.T. Van Mackelenbergh ⁷ , C. Jackisch ⁸ , V. Nekljudova ⁹ , T. Karn ¹⁰ , M. Alber ¹¹ , F. Marmé ¹² , C. Schem ¹³ , E. Stickeler ¹⁴ , P.A. Fasching ¹⁵ , V. Mueller ¹⁶ , K. Weber ⁹ , B. Lederer ⁹ , S. Loibl ⁹ , F. Klauschen ¹⁷ , ¹ TU Berlin, BIFOLD - Berlin Institute for the Foundations of Learning and Data, Berlin, DE, ² Max-Planck-Institut für Informatik, Saarbrücken, BIFOLD - Berlin Institute for the Foundations of Learning and Data, Berlin, DE, ³ Philipps Universität Marburg und Universitätsklinikum Marburg (UKGM), Marburg, DE, ⁴ Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg, Heidelberg, DE, ⁵ Charité Berlin, Berlin, DE, ⁶ Helios Klinikum Berlin-Buch, Berlin, DE, ⁷ Universitätsklinikum Schleswig-Holstein, Kiel, DE, ⁸ Sana Klinikum Offenbach, Offenbach am Main, DE, ⁹ German Breast Group, Neu-Isenburg, DE, ¹⁰ Goethe University Hospital, Frankfurt am Main, DE, ¹¹ Charité Berlin, Aignostics GmbH, Berlin, DE, ¹² Universität Heidelberg, Universitätsfrauenklinik Mannheim, Mannheim, DE, ¹³ Mammazentrum Hamburg, Hamburg, DE, ¹⁴ Universitaetsklinikum Aachen (UKA), Aachen, DE, ¹⁵ Erlangen, Erlangen, DE, ¹⁶ Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE, ¹⁷ German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Berlin Institute of Health, Berlin, DE	

- 15:00 - 15:05 **1661MO - Genomic somatic copy number alterations drive adaptive tumor immune suppression and primary resistance to anti-PD1 + anti-angiogenics in pleural mesothelioma**
F.-X. Danlos¹, C. Baldini¹, M. Texier², A. Varga¹, S. Mouraud³, B. Job¹, D. Letourneur³, L. Cassard¹, D. Bredel³, S. Laghouati¹, J. Adam¹, N. Droin¹, A. Parpaleix¹, N. Chaput-Gras¹, A. Rabeau⁴, C. Massard¹, J.-C. Soria⁵, G. Zalcman⁶, D. Planchard¹, A. Marabelle¹,
¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Institut Gustave Roussy, Villejuif, FR, ³Institut Gustave Roussy - INSERM, Villejuif, Cedex, FR, ⁴Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR, ⁵AMGEN - USA, Thousand Oaks, US, ⁶Hopital Bichat - Claude-Bernard AP-HP, Paris, FR
- 15:05 - 15:20 **Invited Discussant LBA72, 904MO, 68MO and 1661MO**
M. Kok, Netherlands Cancer Institute, Amsterdam, NL
- 15:20 - 15:25 **1662MO - Longitudinal analysis of circulating immune cell subsets in melanoma patients (pts) treated with neo-adjuvant ipilimumab (ipi) & nivolumab (nivo)**
R. Simpson¹, M. Batten², E. Shanahan², I. Pires Da Silva³, J. Versluis⁴, I. Reijers⁴, A. Menzies³, R. Saw³, M. Gonzalez³, K. Shannon³, A. Spillane³, C. Blank⁴, R. Scolyer³, G. Long³, ¹Melanoma Institute Australia, Sydney, AU, ²University of Sydney, Sydney, AU, ³Melanoma Institute Australia, Wollstonecraft, AU, ⁴NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 15:25 - 15:30 **1663MO - DAV132 prevents antibiotic-induced intestinal microbiota dysbiosis and maintains anti-PD-1 efficacy: A proof-of-concept in tumor-bearing mice transplanted with human feces**
M. Messaoudene¹, N. Saint-Lu², F. Sablier-Gallis², S. Ferreira², C. Le Bescop², M. Ponce¹, C. Féger³, A. Andreumont², J. De Gunzburg², B. Routy¹, ¹CRCHUM - Centre de recherche du CHUM, Montreal, CA, ²Da Volterra, Paris, FR, ³EMI Biotech, Grenoble, FR
- 15:30 - 15:40 **Invited Discussant 1662MO and 1663MO**
J. Stagg, University of Montreal Health Center, Montreal, CA
- 15:40 - 15:45 **905MO - Synergistic combination of clinical, imaging and DNA methylation biomarkers improves the classification of pulmonary nodules**
J. He¹, B. Wang², J. Tao², Q. Liu¹, M. Peng², X. Qiu², Y. Yang², Z. Ye², D. Liu³, W. Li³, Z. Chen², Q. Zeng¹, J. Fan², W. Liang¹, ¹The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ²Anchordx Medical Co., Ltd, Guangzhou, CN, ³SCU - Sichuan University - Huaxi Campus, Chengdu, CN
- 15:45 - 15:50 **1664MO - Tumor-naïve methylomes and fragmentomes during pembrolizumab (P) in metastatic cancer patients**
E. Zhao¹, E. Sanz Garcia¹, Z.(. Liu¹, K. Marsh², A. Abdul Razak¹, A. Spreafico¹, P. Bedard¹, A. Hansen¹, S. Lheureux¹, D. Torti², B. Lam³, T. Pugh¹, L. Siu¹, ¹UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ²Ontario Institute for Cancer Research, Toronto, CA, ³Princess Margaret Cancer Centre, Toronto,

CA

15:50 - 15:55 **69MO - 5-Hydroxymethycytosine analysis reveals stable epigenetic changes in tumor tissue that enable cfDNA cancer predictions**
F. Feng¹, Y. Ning², Y. Xue², V. Friedl², D. Hann², B. Gibb², A. Bergamaschi², G. Guler², K. Hazen², A. Scott², T. Phillips², E. McCarthy², C. Ellison², R. Malta², A. Nguyen², V. Lopez², R. Cavet², S. Chowdhury², W. Volkmuth², S. Levy², ¹UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ²Bluestar Genomics, Inc., San Diego, US

15:55 - 16:10 **Invited Discussant 905MO, 1664MO and 69MO**
S.-J. Dawson, Peter MacCallum Cancer Centre, Melbourne, AU

14:45 - 16:15 Type: Mini Oral session **7.3.G - Grenoble Auditorium**
Title: Mini Oral session 1: GU tumours, non-prostate
 Chair(s): Aly-Khan Lalani, CA; Kate Young, GB; Joaquim Bellmunt, US

14:45 - 14:50 **1449MO - Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study**
C.G. Porta¹, M. Eto², R. Motzer³, U. De Giorgi⁴, T. Buchler⁵, N. Basappa⁶, M.J. Mendez Vidal⁷, S. Tjulandin⁸, S.H. Park⁹, B. Melichar¹⁰, T. Hutson¹¹, C. Alemany¹², B. Mcgregor¹³, C.S. He¹⁴, R. Perini¹⁵, K. Mody¹⁴, J. Mckenzie¹⁴, T. Choueiri¹³, ¹University of Bari 'A. Moro', Bari, IT, ²Kyushu University, Fukuoka, JP, ³Memorial Sloan Kettering Cancer Center, New York, US, ⁴IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, IT, ⁵Thomayer University Hospital, Prague, CZ, ⁶Cross Cancer Institute, University of Alberta, Edmonton, CA, ⁷Hospital Universitario Reina Sofía, Maimonides Institute for Biomedical Research of Córdoba, Córdoba, ES, ⁸N.N. Blokhin National Medical Research Center for Oncology, Ministry of Health of the Russian Federation, Moscow, RU, ⁹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ¹⁰Palacký University Medical School and Teaching Hospital, Olomouc, CZ, ¹¹Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, US, ¹²AdventHealth Cancer Institute, Orlando, US, ¹³Dana-Farber Cancer Institute, Boston, US, ¹⁴Eisai Inc., Nutley, US, ¹⁵Merck & Co., Inc., Rahway, US

14:50 - 14:55 **1450MO - Efficacy of a tailored approach with nivolumab and nivolumab/ipilimumab as immunotherapeutic boost in metastatic renal cell carcinoma: Final results of TITAN-RCC**
M.-O. Grimm¹, E. Esteban Gonzalez², P. Barthelemy³, M. Schmidinger⁴, J. Busch⁵, B. Perez Valderrama⁶, N. Charnley⁷, M. Schmitz⁸, U. Schumacher¹, G. Baretton⁹, I. Duran Martinez¹⁰, G.A. De Velasco Oria¹¹, F. Priou¹², J.P. Maroto Rey¹³, L. Albiges¹⁴, ¹Jena University Hospital, Friedrich-Schiller University Jena, Jena, DE, ²Hospital Universitario Central de Asturias, Oviedo, ES, ³Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ⁴Medical University of Vienna, Vienna, AT, ⁵University Hospital Charité Berlin, Berlin, DE, ⁶Hospital Universitario Virgen del Rocío, Seville, ES, ⁷Royal Preston Hospital, Preston, GB, ⁸Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, DE, ⁹University Hospital Carl Gustav Carus, TU Dresden, Dresden, DE, ¹⁰Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, ES, ¹¹Hospital 12 de Octubre,

Madrid, ES, ¹²CHD Vendee-Hopital Les Oudairies, La Roche-sur-Yon, FR, ¹³Hospital de la Santa Creu I Sant Pau, Barcelona, ES, ¹⁴Gustave Roussy Cancer Campus, University of Paris Sud, Villejuif, FR

- 14:55 - 15:10 **Invited Discussant 1449MO and 1450MO**
K. Young, The Royal Marsden Hospital - Chelsea, London, GB
- 15:10 - 15:15 **LBA75 - RACE IT: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18) – first results**
S. Schmid¹, K. Schiller², J. Lewerich¹, A.K. Seitz³, A. Sauter¹, F. Koll¹, F. Beckert¹, P. Korn¹, P. Maisch⁴, C. Rödel⁵, M. Flentje³, T. Wiegel⁴, S. Combs², F. Zengerling⁴, C. Bolenz⁴, H. Kuebler³, J. Gschwend¹, M. Retz¹, ¹TUM - Technical University of Munich, München, DE, ²TUM - Technical University of Munich, Munich, DE, ³UKW - University Hospital Würzburg, Würzburg, DE, ⁴Ulm Medical University, Ulm, DE, ⁵Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE
- 15:15 - 15:20 **1733MO - First results from BladderPath: A randomised trial of MRI versus cystoscopic staging for newly diagnosed bladder cancer**
N. James¹, S. Pirrie², W. Liu³, K. Jefferson⁴, J. Gallagher², A. Hughes², A. Knight⁵, V. Nanton⁶, H. Mintz², A. Pope², H. Doyle², J. Singh², S. Hafeez¹, P. Patel², J. Catto⁷, R. Bryan², ¹ICR - Institute of Cancer Research, London, GB, ²Institute of Cancer and Genomic Sciences - University of Birmingham, Birmingham, GB, ³The Institute of Cancer and Genomic Sciences - University of Birmingham, Birmingham, GB, ⁴University Hospital Coventry - University Hospitals Coventry and Warwickshire NHS Trust, Coventry, GB, ⁵Action on Bladder Cancer, Tetbury, GB, ⁶University of Warwick, Coventry, GB, ⁷University of Sheffield Medical School, Sheffield, GB
- 15:20 - 15:25 **1734MO - Hypoxic bladder cancers have a poorer outcome following hypofractionated vs conventionally fractionated radiotherapy in the BC2001 and BCON randomised trials**
T. Smith¹, C. West¹, B. Lane¹, J. Irlam-Jones¹, E. More¹, H. Mistry¹, P. Hoskin², S. Hussain³, E. Hall⁴, N. Porta⁴, R. Huddart⁵, N. James⁶, A. Choudhury², ¹The University of Manchester, MANCHESTER, GB, ²University of Manchester and The Christie NHS Foundation Trust, Manchester, GB, ³University of Sheffield Medical School, Sheffield, GB, ⁴ICR - Institute of Cancer Research, Sutton Surrey, GB, ⁵Royal Marsden Hospital Institute of Cancer Research, Sutton, GB, ⁶ICR - Institute of Cancer Research, London, GB
- 15:25 - 15:40 **Invited Discussant LBA75, 1733MO and 1734MO**
J. Bellmunt, Boston, US
- 15:40 - 15:45 **1310MO - Neoadjuvant platinum-based chemotherapy (NAPC) for metastatic penile squamous cell carcinoma (PSCC): An international, multicenter, real-world study**

J. Chahoud¹, A. Mustasam¹, K. Rose¹, P. Spiess¹, K. Moses², V. Master³, B. Nazha⁴, T. Zhuang⁴, A. Schneider¹, K. Marchetti⁵, E. Roussel⁶, R. Pham⁷, N. Zacharias⁷, L. Pagliaro⁸, C. Hernandez², J. Montrose⁵, C. Alifrangis⁹, M. Albersen⁶, C. Protzel¹⁰, C. Pettaway⁷, ¹H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ²Vanderbilt University Medical Center, Nashville, US, ³Emory University - Rollins School of Public Health, Atlanta, US, ⁴Winship Cancer Institute of Emory University, Atlanta, US, ⁵University of Michigan Health System, Ann Arbor, US, ⁶University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁷MD Anderson Cancer Center, Houston, US, ⁸Mayo Clinic Cancer Center, Phoenix, US, ⁹St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, ¹⁰Universitätsklinikum Rostock, Rostock, DE

15:45 - 15:50

512MO - Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: An analysis of the IGCCCG Update database

S. Gillessen¹, J. Lauritsen², N. Sauv  ³, A. Tryakin⁴, D.M. Jiang⁵, R. Huddart⁶, D. Heng⁷, A. Terbuch⁸, E. Winquist⁹, M. Chovanec¹⁰, M. Hentrich¹¹, C. Fankhauser¹², J. Shamash¹³, X. Garcia Del Muro¹⁴, D. Vaughn¹⁵, A. Heidenreich¹⁶, A. Jandari³, L. Collette¹⁷, J. Beyer¹⁸, K.G. Daugaard², ¹Universit   della Svizzera Italiana (USI) and Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH, ²Rigshospitalet, Copenhagen, DK, ³EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, BE, ⁴National Medical Research Center of Oncology named after N.N. Blokhin, Moscow, RU, ⁵University Health Network - Princess Margaret Cancer Center, Toronto, CA, ⁶Institute of Cancer Research and Royal Marsden Hospital, Surrey, GB, ⁷Tom Baker Cancer Centre - University of Calgary, Calgary, CA, ⁸LKH-Universitaetsklinikum Graz - Universitaetsklinik f  r Innere Medizin (UKIM), Graz, AT, ⁹London Regional Cancer Program (LRCP) - London Health Science Center (LHSC), London, CA, ¹⁰National Cancer Institute (N  rodny Onkologicky Ustav), Bratislava, SK, ¹¹Rotkreuzklinikum M  nchen, Munich, DE, ¹²Luzerner Kantonsspital, Sursee, CH, ¹³St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, ¹⁴ICO - Institut Catal   d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ¹⁵Abramson Cancer Center - University of Pennsylvania, Philadelphia, US, ¹⁶Universit  tsklinikum K  ln (A  R), K  ln, DE, ¹⁷International Drug Development Institute, Louvain-la-Neuve, BE, ¹⁸University Hospital Inselspital Bern, Bern, CH

15:50 - 15:55

513MO - Risk and mortality of testicular cancer in patients with psychiatric or neurodevelopmental disorders

A. Jansson¹, J. S  derling², J. Reutfors², A. Thor³, C. Sk  ld¹, G. Cohn-Cedermark², O. St  hl⁴, K. Ekstr  m Smedby², A. Pettersson², I. Glimelius¹, ¹University Hospital Uppsala/Akademiska Sjukhuset, Uppsala, SE, ²Karolinska Institutet, Stockholm, SE, ³Karolinska Institutet, Huddinge, SE, ⁴Sk  ne University Hospital, Lund, SE

15:55 - 16:10

Invited Discussant 1310MO, 512MO and 513MO

A.-K. Lalani, JCC - Juravinski Cancer Centre - Hamilton Health Sciences, Hamilton, CA

14:45 - 16:15	Type: Special session Title: ESMO In collaboration with ASCO: The use of real-world data in guiding clinical practice Chair(s): Solange Peters, CH; Eric Winer, US	7.3.H - Honfleur Auditorium
14:45 - 14:50	Introduction <u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
14:50 - 15:05	How to use real-world data <u>J. Warner</u> , Brown University, Providence, US	
15:05 - 15:20	The perspective of the regulator <u>F. Pignatti</u> , European Medicines Agency - Amsterdam, Amsterdam, NL	
15:20 - 15:35	Statistical limitations and the perspective of the statistician <u>J. Bliss</u> , ICR - Institute of Cancer Research, London, GB	
15:35 - 15:50	Limitations of clinical trials, alternative trial designs and the perspective of the clinician or patient <u>A. Partridge</u> , Dana Farber Cancer Institute, Boston, US	
15:50 - 16:15	Panel discussion and Q&A <u>M. Koopman</u> ¹ , <u>P. Jänne</u> ² , ¹ UMC - University Medical Center Utrecht, Utrecht, NL, ² Dana Farber Cancer Institute, Boston, US	
14:45 - 16:15	Type: Educational session Title: Rare head & neck cancer Chair(s): Keith Hunter, GB; Lisa Licitra, IT	7.3.O - Orléans Auditorium
14:45 - 15:10	Pathology of salivary gland cancers and sino-nasal cancers <u>K. Hunter</u> , University of Liverpool - School of Medicine, Liverpool, GB	
15:10 - 15:35	Treatment algorithm for recurrent/metastatic salivary gland cancers <u>C. Van Herpen</u> , Nijmegen, NL	
15:35 - 16:00	Contemporary approach to the multidisciplinary management of sino-nasal cancer <u>P. Bossi</u> , Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT	
16:00 - 16:15	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

14:45 - 16:15	Type: Special session Title: Insights in clinical pharmacology to optimise systemic anti-cancer treatment in daily practice Chair(s): Ron Mathijssen, NL; Emiliano Calvo, ES	7.3.M - Marseille Auditorium
----------------------	--	-------------------------------------

14:45 - 14:50	Introduction <u>E. Calvo</u> , Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES	
14:50 - 15:05	Dosing anti-cancer therapy in patients with moderate and severe kidney and liver dysfunction <u>N. Van Erp</u> , Radboud University Medical Center, Nijmegen, Nijmegen, NL	
15:05 - 15:20	Dose individualisation of TKIs <u>J. Ciccolini</u> , Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR	
15:20 - 15:35	The relevance of geno- and phenotyping cytochrome P450 prior to anticancer treatment <u>C. Samer</u> , Université de Genève (UNIGE) - Centre Médical Universitaire (CMU), Geneva, CH	
15:35 - 15:50	The relevance of endoxifen measurements in the adjuvant tamoxifen treatment of breast cancer <u>S. Koolen</u> , Erasmus MC - University Medical Center, Rotterdam, NL	
15:50 - 16:10	The rationale behind selecting recommended dose and schedule in immunotherapy <u>E. Calvo</u> , Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES	
16:10 - 16:15	Conclusions <u>R. Mathijssen</u> , Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL	

14:45 - 16:15	Type: Special session Title: ESMO Women for Oncology (W4O) Forum - Gender equity in oncology 2022: Challenges & opportunities Chair(s): Cathy Smith, BE; Pilar Garrido Lopez, ES	7.3.U - Urval Auditorium
14:45 - 14:50	Welcome <u>C. Smith</u> , Speak-Easy Communications, Brussels, BE	
14:50 - 14:55	Video contribution <u>S. Kyriakides</u> , European Commission, Brussels, BE	
14:55 - 15:02	Introduction <u>P. Garrido Lopez</u> , Hospital Universitario Ramon y Cajal, Madrid, ES	
15:02 - 16:15	Live discussion, Q&A, wrap-up <u>H. Linardou</u> ¹ , <u>P. Garrido Lopez</u> ² , <u>A. Cervantes</u> ³ , <u>C. Smith</u> ⁴ , <u>E. Mariamidze</u> ⁵ , ¹ Metropolitan Hospital, Athens, GR, ² Hospital Universitario Ramon y Cajal, Madrid, ES, ³ Hospital Clinico Universitario de Valencia, Valencia, ES, ⁴ Speak-Easy Communications, Brussels, BE, ⁵ Todua Clinic, Tbilisi, GE	

14:45 - 17:45	Type: Young Oncologist session Title: Young Oncologist Masterclass: Clinical Trials Design and Development in the 21st Century Chair(s): Teresa Amaral, DE; Anna Sophie Berghoff, AT	7.3.R - Rennes Auditorium
14:45 - 15:10	What is a well-designed clinical trial? <u>N. Harbeck</u> , Ludwig Maximilians University - Grosshadern, Munich, DE	
15:10 - 15:25	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
15:25 - 15:50	Addressing inequality in under-served populations in clinical trials <u>E. Garralda</u> , Vall d'Hebron University Hospital, Barcelona, ES	
15:50 - 16:05	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
16:05 - 16:25	Coffee break	
16:25 - 16:50	Infrastructure and policies for global clinical trials: Opportunities and threats <u>C. Gomez-Roca</u> , Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR	
16:50 - 17:05	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
17:05 - 17:30	How does the marketing authorization process work? <u>F. Pignatti</u> , European Medicines Agency - Amsterdam, Amsterdam, NL	
17:30 - 17:45	Discussion	
15:00 - 16:00	Type: Challenge your Expert Title: Management of different glioma subtypes: Should all lower-grade gliomas be treated equally? Chair(s): Lakshmi Nayak, US	7.3.Q - Quimper Auditorium
15:00 - 15:15	Presentation by Expert <u>M. Van Den Bent</u> , Rotterdam, NL	
15:15 - 16:00	Discussion led by Chair <u>L. Nayak</u> , Dana Farber Cancer Institute, Boston, US	

15:00 - 16:00 **Type: Challenge your Expert** **7.3.T - Toulouse Auditorium**
Title: CNS metastases in metastatic breast cancer
 Chair(s): Martine Piccart, BE; Priscilla Brastianos, US

15:00 - 15:15 **Presentation by Expert**
N. Lin, Dana Farber Cancer Institute, Boston, US

15:15 - 16:00 **Discussion led by Chair**
M. Piccart, Institute Jules Bordet, Brussels, BE

15:00 - 16:30 **Type: EONS Industry Satellite Symposium** **7.3.S - Strasbourg Auditorium**
Title: Janssen-Cilag International NV - Nursing Considerations with EGFR Inhibitors in NSCLC
 Chair(s): Silvija Piskorjanac, HR

15:00 - 15:05 **Introduction**
S. Piskorjanac, University Hospital Osijek, Osijek, HR

15:05 - 15:20 **Targeted therapies for EGFR NSCLC - what's new?**
S. Karabatic, KBC Zagreb - Clinic for Lung Diseases Jordanovac, Zagreb, HR

15:20 - 15:35 **Understanding Targeted Therapy for NSCLC - cancer nurses knowledge, attitude and practice**
S. Piskorjanac, University Hospital Osijek, Osijek, HR

15:35 - 15:50 **Diagnosing a person with a mutation positive lung cancer**
K. Clayton, East Cheshire NHS Trust, Macclesfield, GB

15:50 - 16:05 **What does a diagnosis mean**
J. Vick, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

16:05 - 16:30 **Discussion and Conclusion remarks**
S. Piskorjanac, University Hospital Osijek, Osijek, HR

16:30 - 18:15 **Type: Proffered Paper session** **6.P - Paris Auditorium**
Title: Presidential Symposium II
 Chair(s): Karin Jordan, DE; Florian Lordick, DE

16:30 - 16:45 **LBA4 - Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial**
R. Motzer¹, P. Russo¹, V. Gruenwald², Y. Tomita³, B. Zurawski⁴, O. Parikh⁵, S. Buti⁶, P. Barthelemy⁷, J. Goh⁸, D. Ye⁹, A. Lingua¹⁰, J.-B. Lattouf¹¹, B. Escudier¹², S. George¹³, B. Shuch¹⁴, B. Simsek¹⁵, J. Spiridigliozzi¹⁶, A. Chudnovsky¹⁶, A. Bex¹⁷, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²West-German Cancer Center Essen, University

Hospital Essen, Essen, DE, ³Niigata University Graduate School of Medical and Dental Sciences, Niigata, JP, ⁴Prof. Franciszek Łukaszczyk Oncology Centre, Bydgoszcz, PL, ⁵Lancashire Teaching Hospitals NHS Trust, Preston, GB, ⁶University Hospital of Parma, University of Parma, Parma, IT, ⁷Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ⁸Royal Brisbane and Women's Hospital, Herston, AU, ⁹Fudan University Shanghai Cancer Center, Shanghai, CN, ¹⁰Instituto Médico Río Cuarto, Río Cuarto, AR, ¹¹CHUM - Centre Hospitalier de l'Université de Montréal, Montreal, CA, ¹²Gustave Roussy - Cancer Campus, Villejuif, FR, ¹³Roswell Park Comprehensive Cancer Center, Buffalo, US, ¹⁴University of California, Los Angeles, US, ¹⁵Bristol Myers Squibb, Princeton, US, ¹⁶Bristol Myers Squibb, Princeton, US, ¹⁷Netherlands Cancer Institute, Amsterdam, NL

16:45 - 17:00

LBA5 - Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)

J.-P. Machiels¹, Y. Tao², B. Burtneess³, M. Tahara⁴, D. Rischin⁵, G. Alves⁶, I. Lima⁷, B. Hughes⁸, Y. Pointreau⁹, S. Aksoy¹⁰, S. Laban¹¹, R. Greil¹², M. Burian¹³, M. Hetnal¹⁴, L. Licitra¹⁵, R. Swaby¹⁶, Y. Zhang¹⁶, B. Gumuscu¹⁶, B. Bidadi¹⁶, L. Siu¹⁷, ¹Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc) and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Woluwe-Saint-Lambert, BE, ²Institut Gustave Roussy, Villejuif, Cedex, FR, ³Yale University School of Medicine - Yale Cancer Center, New Haven, US, ⁴National Cancer Center Hospital East, Kashiwa, JP, ⁵Peter MacCallum Cancer Centre, Melbourne, AU, ⁶Hospital Nossa Senhora da Conceicao, Porto Alegre, BR, ⁷CRIO Centro Regional Integrado de Oncologia, Fortaleza-CE, BR, ⁸Royal Brisbane and Women's Hospital, Herston, AU, ⁹Centre Jean Bernard, Le Mans, FR, ¹⁰Hacettepe University - Faculty of Medicine, Ankara, TR, ¹¹University Hospital of Ulm - Ear, Nose and Throat Medicine, Ulm, DE, ¹²Paracelsus Medizinische Privatuniversität, Salzburg, AT, ¹³Ordensklinikum Linz Barmherzige Schwestern, Linz, AT, ¹⁴Andrzej Frycz Modrzewski Krakow University, Amethyst Radiotherapy Centre, Rydygier Hospital, Krakow, PL, ¹⁵Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ¹⁶Merck & Co., Inc., Rahway, US, ¹⁷Princess Margaret Cancer Centre, Toronto, CA

17:00 - 17:15

LBA6 - Neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)

S. Patel¹, M. Othus², V. Prieto¹, M. Lowe³, E. Buchbinder⁴, Y. Chen⁵, J. Hyngstrom⁶, C. Lao⁷, T.-G. Truong⁸, S. Chandra⁹, K. Kendra¹⁰, C. Devoe¹¹, A. Hedge¹², A. Mangla¹³, E. Sharon¹⁴, L. Korde¹⁴, J. Moon², V. Sondak¹⁵, A. Ribas¹⁶, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²Fred Hutchinson Cancer Research Center, Seattle, US, ³Emory University, Atlanta, US, ⁴Dana Farber Cancer Institute, Boston, US, ⁵Cancer and Hematology Centers of Western Michigan / CRC West MI NCORP, Grand Rapids, US, ⁶University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US, ⁷University of Michigan, Ann Arbor, US, ⁸Kaiser Permanente NCAL, Vallejo, US, ⁹Northwestern University, Chicago, US, ¹⁰Ohio State University Wexner Medical Center, Columbus, US, ¹¹Northwell Health Cancer Institute, Lake Success, US, ¹²The University of Alabama at Birmingham, Birmingham, US, ¹³University Hospitals Seidman Cancer Center, Cleveland, US, ¹⁴Cancer Therapy Evaluation Program, Bethesda, US, ¹⁵Moffitt Cancer Center, Tampa, US, ¹⁶UCLA/Jonsson Comprehensive Cancer Center, Los Angeles, US

17:15 - 17:30

LBA7 - Neoadjuvant immune checkpoint inhibition in locally advanced MMR-

deficient colon cancer: The NICHE-2 study

M. Chalabi¹, Y. Verschoor², J. Van Den Berg², K. Sikorska¹, G. Beets², A. Lent³, M.C. Grootscholten², A. Aalbers², N. Buller⁴, H. Marsman³, E. Hendriks⁵, P. Burger⁶, T. Aukema⁷, S. Oosterling⁸, R. Beets-Tan¹, T. Schumacher², M. Van Leerdam², E. Voest², J. Haanen¹, ¹Netherlands Cancer Institute, Amsterdam, NL, ²NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ³OLVG Hospital, Amsterdam, NL, ⁴Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ⁵Tergooiziekenhuizen, Blaricum, NL, ⁶Catharina Hospital Eindhoven, Eindhoven, NL, ⁷Hagaziekenhuis, Den Haag, NL, ⁸Spaarne Hospital Hoofddorp, Hoofddorp, NL

17:30 - 17:45 **Invited Discussant LBA4, LBA5, LBA6, LBA7 - The immunologist point of view**
S. Loi, Peter MacCallum Cancer Centre, Melbourne, AU

17:45 - 18:00 **Invited Discussant LBA4, LBA5, LBA6, LBA7 - The medical oncologist point of view**
J. Larkin, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

18:00 - 18:15 **Q&A and discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

16:30 - 18:00 **Type: Educational session** **7.1.D - Dijon Auditorium**
Title: Minimizing some of the most distressing cancer and cancer treatment related symptoms
Chair(s): Karen Steindorf, DE; Florian Scotté, FR

16:30 - 16:55 **Fatigue, cognitive dysfunction and emotional distress**
K. Steindorf, German Cancer Research Center - National Center for Tumor Diseases (NCT), Heidelberg, DE

16:55 - 17:20 **Cachexia**
J. Arends, Universitätsklinikum Freiburg - Klinik für Innere Medizin I/Klinik für Tumorbiologie, Freiburg im Breisgau, DE

17:20 - 17:45 **Dyspnea and cough**
D. Hui, Houston, TX, US

17:45 - 18:00 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

16:30 - 17:30 **Type: Mini Oral session** **7.3.G - Grenoble Auditorium**
Title: Mini Oral session 2: Gynaecological cancers
Chair(s): Philipp Harter, DE; Antonio Jose Gonzalez Martin, ES

16:30 - 16:35 **525MO - Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with**

advanced endometrial cancer (aEC): Study 309/KEYNOTE-775

V. Makker¹, N. Colombo², A. Casado Herraiz³, B. Monk⁴, H. Mackay⁵, A.D. Santin⁶, D. Miller⁷, R. Moore⁸, S. Baron-Hay⁹, I. Ray-Coquard¹⁰, R. Shapira-Frommer¹¹, K. Ushijima¹², K. Yonemori¹³, Y.M. Kim¹⁴, E.M. Guerra Alia¹⁵, U. Sanli¹⁶, J. Huang¹⁷, J. Mckenzie¹⁷, G. Barresi¹⁸, D. Lorusso¹⁹, ¹Memorial Sloan-Kettering Cancer Center, New York City, US, ²University of Milan-Bicocca, European Institute of Oncology IRCCS, Milan, IT, ³Hospital Clinico Universitario San Carlos, Madrid, ES, ⁴University of Arizona, Creighton University, Phoenix, US, ⁵Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, CA, ⁶Yale University School of Medicine, New Haven, US, ⁷University of Texas Southwestern Medical Center, Dallas, US, ⁸University of Rochester Medical Center, Rochester, US, ⁹Royal North Shore Hospital, St Leonards, AU, ¹⁰Centre Léon Bérard, University Claude Bernard, GINECO Group, Lyon, FR, ¹¹Sheba Medical Center, Ramat, IL, ¹²Kurume University School of Medicine, Kurume, JP, ¹³National Cancer Center Hospital, Chuo-ku, JP, ¹⁴Asan Medical Center, University of Ulsan, Seoul, KR, ¹⁵Hospital Universitario Ramon y Cajal, Madrid, ES, ¹⁶Ege University, Izmir, TR, ¹⁷Eisai Inc., Nutley, US, ¹⁸MSD - Austria, Vienna, AT, ¹⁹Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Catholic University of Sacred Heart, Rome, IT

16:35 - 16:40

526MO - Pathological assessment of sentinel lymph node in early-stage cervical cancer: Results from the prospective SENTIX trial (CEEGOG-CX01; ENGOT-CX2)

D. Cibula¹, C. Köhler², S. Bajsova³, S. Sebestova⁴, I. Zapardiel⁵, G. Di Martino⁶, L. Van Lonkhuijzen⁷, B. Sehnal⁸, O. Arencibia Sánchez⁹, B. Gil Ibañez¹⁰, F. Martinelli¹¹, J. Presl¹², L. Minář¹³, R. Marek¹⁴, P. Kascak¹⁵, P. Havelka¹⁶, M. Michal¹⁷, T. Van Gorp¹⁸, K. Nemejcova¹⁹, R. Kocian¹, ¹General Teaching Hospital and The First Faculty of Medicine of Charles University in Prague, CEEGOG (Central and Eastern European Gynecologic Oncology Group), Prague, CZ, ²Asklepios Klinik Harburg, Hamburg, DE, ³University Hospital Ostrava, CEEGOG, Ostrava, CZ, ⁴Masaryk University Faculty of Medicine, Brno, CZ, ⁵IdiPAZ - Instituto de Investigacion Sanitaria del Hospital Universitario La Paz, Madrid, ES, ⁶San Gerardo Hospital, Monza, IT, ⁷Academic Medical Center, University of Amsterdam, Amsterdam, NL, ⁸University Hospital Bulovka, First Faculty of Medicine, Charles University, CEEGOG, Prague, CZ, ⁹University Hospital of the Canary Islands, Las Palmas de Gran Canaria, ES, ¹⁰Hospital Clinic of Barcelona, Barcelona, ES, ¹¹National Cancer Institute in Milan, Rome, IT, ¹²University Hospital Pilsen, Charles University, CEEGOG, Plzen, CZ, ¹³Masaryk University, CEEGOG, Brno, CZ, ¹⁴Palacky University, University Hospital Olomouc, CEEGOG, Olomouc, CZ, ¹⁵University Hospital Trencin, CEEGOG, Trencin, SK, ¹⁶Krajska Nemocnice T. Bati, a.s. (T. Batas Regional Hospital), CEEGOG, Zlin, CZ, ¹⁷Hospital Ceske Budejovice, CEEGOG, Ceske Budejovice, CZ, ¹⁸University Hospitals Leuven, BGOG (Belgium and Luxembourg Gynaecological Oncology Group), Leuven, BE, ¹⁹Charles University and General University Hospital, Prague, CZ

16:40 - 16:50

Invited Discussant 525MO and 526MO

P. Harter, Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen, DE

16:50 - 16:55

527MO - Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase 3 ATHENA–MONO study

R. Kristeleit¹, S. Ghamande², M.-C. Lim³, C. Parkinson⁴, M. Morgan⁵, M. Wilson⁶, A.

Oaknin⁷, J. Buscema⁸, P. Bessette⁹, D. Lorusso¹⁰, F. Ueland¹¹, T. Safra¹², J. Barlin¹³, F. Marmé¹⁴, T. Herzog¹⁵, I. Mcneish¹⁶, S. Goble¹⁷, S. Hume¹⁷, K. Fujiwara¹⁸, B. Monk¹⁹,
¹Guy's and St Thomas' NHS Foundation Trust, London, GB, ²Augusta University, Augusta, US, ³National Cancer Center Korea, Goyang-si, Gyeonggi-do, KR, ⁴Addenbrooke's Hospital, Cambridge, GB, ⁵University of Pennsylvania Health System, Philadelphia, US, ⁶Auckland City Hospital, Auckland, NZ, ⁷Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, ⁸Arizona Oncology, Tucson, US, ⁹University of Sherbrooke, Sherbrooke, CA, ¹⁰Fondazione Policlinico Universitario Gemelli IRCCS and Catholic University of Sacred Heart, Rome, IT, ¹¹Division of Gynecologic Oncology, College of Medicine, University of Kentucky, Lexington, US, ¹²Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IL, ¹³Division of Gynecologic Oncology, Albany Medical College, Albany, US, ¹⁴University Hospital Mannheim, Mannheim, DE, ¹⁵University of Cincinnati Cancer Center, Cincinnati, US, ¹⁶Imperial College London, London, GB, ¹⁷Clovis Oncology, Inc., Boulder, US, ¹⁸Saitama Medical University International Medical Center, Hidaka, Saitama, JP, ¹⁹HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, US

16:55 - 17:00 **528MO - Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant?**

G. Thibault¹, M. Kfoury², D. Lorusso³, A. Floquet⁴, J. Ventriglia⁵, H. Salaun⁶, M. Moubarak⁷, R. Rivoirard⁸, L. Polastro⁹, L. Favier¹⁰, B. You¹¹, D. Berton-Rigaud¹², T. De La Motte Rouge¹³, L. Mansi¹⁴, C. Abdeddaim¹⁵, K. Prulhiere¹⁶, L. Lancry Lecomte¹⁷, M. Provansal Gross¹⁸, C. Dalban¹⁹, I. Ray-Coquard¹⁹, ¹Léon-Bérard Cancer Center, Lyon, FR, ²Institut Gustave Roussy, Villejuif, Cedex, FR, ³Division of Gynecologic Oncology, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, IT, ⁴Institute Bergonié, Bordeaux, FR, ⁵Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ⁶Institut Curie, Paris, FR, ⁷KEM | Evang. Kliniken Essen-Mitte gGmbH, Essen, DE, ⁸ICLN - Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, Cedex, FR, ⁹Institute Jules Bordet, Brussels, BE, ¹⁰Centre Georges Francois Leclerc, Dijon, FR, ¹¹Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, GINECO, Univ Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, FR, ¹²ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ¹³Centre Eugene - Marquis, Rennes, FR, ¹⁴CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, ¹⁵Centre Oscar Lambret, Lille, FR, ¹⁶Polyclinique de Courlancy, Reims, FR, ¹⁷GHM - Groupe Hospitalier Mutualiste de Grenoble, Grenoble, cedex, FR, ¹⁸Institute Paoli Calmettes, Marseille, FR, ¹⁹Centre Léon Bérard, Lyon, FR

17:00 - 17:05 **529MO - Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer**

S. Banerjee¹, M. Imbimbo², P. Roxburgh³, J.-W. Kim⁴, M.H. Kim⁵, R. Plummer⁶, S. Stemmer⁷, B. You⁸, M. Ferguson⁹, R. Penson¹⁰, D. O'Malley¹¹, K. Meyer¹², H. Gao¹³, H. Angell¹³, A. Tablante Nunes¹², S. Domchek¹⁴, Y. Drew¹⁵, ¹The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, GB, ²Lausanne University Hospital, University of Lausanne, Lausanne, CH, ³Beatson West of Scotland Cancer Centre, and Institute of Cancer Sciences, University of Glasgow, Glasgow, GB, ⁴Seoul National University Hospital, Seoul, KR, ⁵Yonsei Cancer Centre, Yonsei University

College of Medicine, Seoul, KR, ⁶Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, and Newcastle University, Newcastle upon Tyne, GB, ⁷Rabin Medical Center-Beilinson Campus, Petach Tikva, IL, ⁸Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, GINECO, Univ Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, FR, ⁹Ninewells Hospital, NHS Tayside, Dundee, GB, ¹⁰Massachusetts General Hospital, Boston, US, ¹¹The Ohio State University James Comprehensive Cancer Center, Columbus, US, ¹²AstraZeneca, Gaithersburg, US, ¹³AstraZeneca, Cambridge, GB, ¹⁴University of Pennsylvania, Philadelphia, US, ¹⁵Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, GB

17:05 - 17:20

Invited Discussant 527MO, 528MO and 529MO

A.J. Gonzalez Martin, Clinica Universidad de Navarra, Madrid, ES

16:30 - 18:00

Type: Proffered Paper session

Title: Proffered Paper session: Basic science & translational research

7.3.O - Orléans Auditorium

Chair(s): Federica Di Nicolantonio, IT; Sandra Demaria, US

16:30 - 16:40

9030 - A prospective study of a multi-cancer early detection blood test

D. Schrag¹, C. McDonnell Iii², L. Nadauld³, C. Dilaveri⁴, E. Klein⁵, R. Reid⁶, C. Marinac⁷, K. Chung⁸, M. Lopatin⁸, E. Fung⁸, T. Beer⁹, ¹MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ²Sutter Institute for Medical Research, Sacramento, US, ³Intermountain Healthcare - Intermountain Cancer Center of St George, St. George, US, ⁴Mayo Clinic, Rochester, US, ⁵Stanford Comprehensive Cancer Institute, Stanford, US, ⁶US Oncology, Inc., Thornton, US, ⁷Dana Farber Cancer Institute, Boston, US, ⁸GRAIL LLC a subsidiary of Illumina Inc. currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission dated 29 October 2021, Menlo Park, US, ⁹OHSU - Center for Health & Healing Building 2, Portland, US

16:40 - 16:50

16960 - Genomic profiling and molecular targeting of lung cancer brain metastases

H. Cheng¹, M. Feng², N. Fan², E. Sokol³, F. Wang², Y. Zou², B. Farran², J. Ross³, G. Frampton³, T. Bhagat², A. Verma¹, R. Perez-Soler¹, B. Halmos¹, ¹Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, US, ²Albert Einstein College of Medicine, Bronx, US, ³Foundation Medicine, Inc, Cambridge, US

16:50 - 17:00

660 - MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors

C. Friedman¹, C. Swanton², D. Spigel³, R. Bose⁴, H. Burris⁵, W. Yu⁶, Y. Wang⁷, J. Malato⁷, R. Price⁷, W. Darbonne⁷, T. Szado⁷, K. Schulze⁷, C. Sweeney⁸, J. Hainsworth⁹, F. Meric-Bernstam¹⁰, R. Kurzrock¹¹, ¹Memorial Sloan Kettering Cancer Center, and Weill Medical College at Cornell University, New York, US, ²Francis Crick Institute, and UCL Hospitals, London, GB, ³Sarah Cannon Research Institute, Cancer Centre, and Tennessee Oncology, Nashville, US, ⁴Washington University School of Medicine, St. Louis, US, ⁵Sarah Cannon Research Institute, and Tennessee Oncology, Nashville, US, ⁶Genentech, South San Francisco, US, ⁷Genentech, Inc., South San Francisco, US, ⁸Dana Farber Cancer Institute, Boston, US, ⁹TriStaCentennial Medical Center, Nashville, US, ¹⁰The University

of Texas MD. Anderson Cancer Center, Houston, US, ¹¹Medical College of Wisconsin, Milwaukee, US

- 17:00 - 17:10 **Invited Discussant 9030, 16960 and 660**
F. Di Nicolantonio, University of Turin, Torino, IT
- 17:10 - 17:20 **Q&A**
- 17:20 - 17:30 **16600 - Dual immune checkpoint blockade induces analogous alterations in the intratumoral CD8⁺ T cell and Treg compartments**
J. Traets¹, A. Van Der Leun¹, J. Vos¹, J. Elbers², S. Patiwaal¹, X. Qiao¹, M. Machuca-Ostos¹, D. Thommen¹, J. Haanen¹, T. Schumacher¹, C. Zuur³, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²Erasmus University Medical Center, Rotterdam, NL, ³Netherlands Cancer Institute, Amsterdam, NL
- 17:30 - 17:40 **670 - Quantifying poly(ADP-Ribose) polymerase (PARP1) in vivo using a non-invasive PARP1 PET tracer**
L. Lin, T. Daoud, T. Yap, F. Wong, The University of Texas M. D. Anderson Cancer Center, Houston, US
- 17:40 - 17:50 **Invited Discussant 16600 and 670**
S. Demaria, Weill Cornell Medical College, New York, US
- 17:50 - 18:00 **Q&A**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

16:30 - 18:00	Type: Educational session Title: The enigma of public policy in oncology: ESMO at the forefront Chair(s): Ravindran Kanesvaran, SG; Rosa Giuliani, GB	7.3.M - Marseille Auditorium
16:30 - 16:35	Introduction and scientific background <u>R. Kanesvaran</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
16:35 - 16:50	MCBS: The future of cost-effective care <u>F. Roitberg</u> , ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR	
16:50 - 17:05	GDPR in oncology: The EU experience <u>P.G. Casali</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT	
17:05 - 17:20	ESMO and Covid 19: The trials and tribulations <u>M. Garassino</u> , University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US	
17:20 - 17:35	Onco-policy in Asia: ESMO to the fore <u>R. Kanesvaran</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
17:35 - 17:40	Conclusions and perspectives <u>R. Giuliani</u> , The Clatterbridge Cancer Centre - Aintree, Liverpool, GB	
17:40 - 18:00	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

16:45 - 17:45	Type: Controversy session Title: Stage III NSCLC: What defines resectability in the era of neoadjuvant chemo-IO v. PACIFIC? Chair(s): Masahiro Tsuboi, JP	7.2.F - Fécamp Auditorium
----------------------	---	----------------------------------

16:45 - 16:50	Introduction by the chair <u>M. Tsuboi</u> , National Cancer Center Hospital East, Kashiwa, JP	
16:50 - 16:51	Polling 1 (led by chair) <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
16:51 - 17:06	Pro: Stage III NSCLC: What defines resectability in the era of neoadjuvant chemo-IO v. PACIFIC? <u>J. Spicer</u> , McGill University, Montreal, CA	
17:06 - 17:21	Contra: Stage III NSCLC: What defines resectability in the era of neoadjuvant chemo-IO v. PACIFIC? <u>S. Senan</u> , Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL	
17:21 - 17:22	Polling 2 (led by chair) <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
17:22 - 17:42	Q&A	

16:45 - 17:45	Type: Multidisciplinary session Title: Young patients with newly-diagnosed multiple myeloma and severe complications Chair(s): Evangelos Terpos, GR	7.3.Q - Quimper Auditorium
----------------------	---	-----------------------------------

16:45 - 16:52	Presentation of case/condition <u>E. Terpos</u> , Athens, GR	
16:52 - 17:09	Management of renal impairment <u>K. Weisel</u> , Universitätsklinikum Tübingen, Tübingen, DE	
17:09 - 17:26	Management of bone disease <u>E. Terpos</u> , Athens, GR	
17:26 - 17:41	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

16:45 - 18:15	Type: EONS session Title: Supportive care and symptom management Chair(s): Remziye Semerci, TR	7.3.S - Strasbourg Auditorium
16:45 - 17:00	Sexual wellbeing in cancer care <u>L. Grover</u> , The London Clinic, London, GB	
17:00 - 17:15	Malta: How cancer carers live with their own chronic conditions <u>D. Chircop</u> , University of Malta - Msida Campus, Msida, MT	
17:15 - 17:30	What really matters to you? A Delphi study on priority patient-reported outcomes to evaluate when caring for people with advanced liver or advanced renal cancer <u>C. Díez De Los Ríos De La Serna</u> , Vall d'Hebron University Hospital, Barcelona, ES	
17:30 - 17:40	CN60 - OptiBra study: An RCT, optimal postoperative bra support after breast cancer surgery <u>M. Backman</u> ¹ , K. Fridblom ² , M. Hassan- Nur ³ , H. Fredholm ³ , I. Fredriksson ¹ , ¹ Karolinska Institute, Stockholm, SE, ² Tema Cancer, Karolinska University Hospital, Solna, SE, ³ Department of molecular medicine and surgery, stockholm, SE	
17:40 - 17:50	CN59 - A scoping review to establish the utility of patient reported outcome measures in blood cancer <u>S. Kirkpatrick</u> ¹ , K. Campbell ² , ¹ North Bristol NHS Trust Clinical Research Centre,, Bristol, GB, ² Edinburgh Napier University, Edinburgh, GB	
17:50 - 18:00	CN62 - Patient and public involvement in cancer research: The needs and perceptions of older adults living with and after cancer <u>A. Drury</u> ¹ , L. O'Connell ² , A. O'Brien ¹ , M. Harkin ³ , L. Rogers ¹ , ¹ University College Dublin, Dublin, IE, ² Tallaght University Hospital, Dublin, IE, ³ Age and Opportunity, Dublin, IE	
18:00 - 18:10	CN63 - Intervention pathways for low anterior resection syndrome after sphincter-saving rectal cancer surgery: A systematic scoping review. <u>E. Pape</u> ¹ , J. Burch ² , G. Van Ramshorst ¹ , Y. Van Nieuwenhove ¹ , C. Taylor ² , ¹ UZ Gent - Universitair Ziekenhuis Gent, Gent, BE, ² St Mark's Hospital, Harrow, GB	
18:10 - 18:15	Q&A and discussion	

18:15 - 19:50	Type: Patient Advocacy session Title: Join us, learn, and share: Best practices across Europe Chair(s): Petra Adamkova, CZ; Joanna Fratzczak Kazana, PL	7.3.M - Marseille Auditorium
18:15 - 18:30	Setting the scene <u>J. Fratzczak Kazana</u> , Alivia - Fundacja Onkologiczna Osób Młodych (Alivia - Young People Cancer Foundation), Warsaw, PL	
18:30 - 18:45	The Gynecological Oncology Day: The world GO day <u>P. Adamkova</u> , ESGO - European Society of Gynaecological Oncology, Prague, CZ	
18:45 - 19:00	The impact of prostate cancer treatment on quality of life: EUPROMS study <u>A. Deschamps</u> , Europa Uomo - The European Prostate Cancer Coalition, Antwerpen, BE	
19:00 - 19:15	iPoRaku (AfterCancer) <u>A. Kuna</u> , Foundation Rak'n'Roll - Win a Life!, Warsaw, PL	
19:15 - 19:30	Onko Ukraine <u>J. Fratzczak Kazana</u> , Alivia - Fundacja Onkologiczna Osób Młodych (Alivia - Young People Cancer Foundation), Warsaw, PL	
19:30 - 19:45	International Covid Blood Cancer Coalition <u>J. Pelouchova</u> , Diagnoza leukemie, z.s, Prague, CZ	
19:45 - 19:50	Conclusion	

18:30 - 20:00	Type: Industry Satellite Symposium Title: Astellas - From landmark data to clinical excellence: Improving outcomes in LA/mUC Chair(s): Ignacio Duran Martinez, ES	7.2.F - Fécamp Auditorium
18:30 - 18:40	Making milestones: The evolving treatment landscape in LA/mUC <u>A. Merseburger</u> , UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE	
18:40 - 18:55	Discovering the data: MoA and core clinical evidence <u>I. Duran Martinez</u> , HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES	
18:55 - 19:15	Defining the direction: Enfortumab vedotin eligibility and treatment initiation <u>R. Jones</u> ¹ , <u>Y. Loriot</u> ² , ¹ MVLS - Medical, Veterinary and Life Sciences College - University of Glasgow, Glasgow, GB, ² Institut Gustave Roussy, Villejuif, Cedex, FR	
19:15 - 19:35	Practical tips for treatment: Optimising outcomes and managing adverse events <u>M.J. Juan Fita</u> ¹ , <u>R. Jones</u> ² , ¹ IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, ² MVLS - Medical, Veterinary and Life Sciences College - University of Glasgow, Glasgow, GB	
19:35 - 19:45	Prioritising patients in practice: Evidence-driven care in the clinic <u>Y. Loriot</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
19:45 - 20:00	Pinpoints of interest: Panel discussion and Q&A <u>I. Duran Martinez</u> ¹ , <u>R. Jones</u> ² , <u>A. Merseburger</u> ³ , <u>Y. Loriot</u> ⁴ , <u>M.J. Juan Fita</u> ⁵ , ¹ HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES, ² MVLS - Medical, Veterinary and Life Sciences College - University of Glasgow, Glasgow, GB, ³ UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE, ⁴ Institut Gustave Roussy, Villejuif, Cedex, FR, ⁵ IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES	

18:30 - 20:00	Type: Industry Satellite Symposium Title: AstraZeneca - Cutting through complexity in NSCLC: How to navigate the patient journey Chair(s): Michael Thomas, DE	7.1.D - Dijon Auditorium
18:30 - 18:34	Welcome and Intro <u>M. Thomas</u> , Thoraxklinik Heidelberg gGmbH, Heidelberg, DE	
18:34 - 18:47	Advances in systemic therapy for resectable NSCLC <u>J. Rotow</u> , The Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, Boston, US	
18:47 - 19:00	Evolving role of the surgeon in new treatment algorithms in resectable NSCLC <u>J. Spicer</u> , McGill University, Montreal, CA	
19:00 - 19:15	Discussion and Q&A <u>M. Thomas</u> ¹ , <u>J. Rotow</u> ² , <u>L. Payen</u> ³ , <u>J. Spicer</u> ⁴ , ¹ Thoraxklinik Heidelberg gGmbH, Heidelberg, DE, ² The Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, Boston, US, ³ Hospices Civiles de Lyon, Lyon, FR, ⁴ McGill University, Montreal, CA	
19:15 - 19:28	Future of metastatic NSCLC: Considerations for Optimizing Treatment <u>M. Thomas</u> , Thoraxklinik Heidelberg gGmbH, Heidelberg, DE	
19:28 - 19:41	Comprehensive reflex biomarker testing for appropriate patient identification <u>L. Payen</u> , Hospices Civiles de Lyon, Lyon, FR	
19:41 - 19:56	Discussion and Q&A <u>M. Thomas</u> ¹ , <u>J. Rotow</u> ² , <u>L. Payen</u> ³ , <u>J. Spicer</u> ⁴ , ¹ Thoraxklinik Heidelberg gGmbH, Heidelberg, DE, ² The Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, Boston, US, ³ Hospices Civiles de Lyon, Lyon, FR, ⁴ McGill University, Montreal, CA	
19:56 - 20:00	Summary and Close <u>M. Thomas</u> , Thoraxklinik Heidelberg gGmbH, Heidelberg, DE	

18:30 - 20:00	Type: Industry Satellite Symposium Title: GSK - Immune Checkpoint Inhibitors in Mismatch Repair Deficient Solid Tumors: Expert Interviews Chair(s): Isabelle Ray-Coquard, FR	7.3.G - Grenoble Auditorium
18:30 - 18:45	Clinical considerations for ICI treatment of dMMR endometrial cancer and other dMMR solid tumors <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
18:45 - 19:10	Chair interview of Dr. Leary: Perspective on identifying patients with dMMR endometrial cancer for ICI treatment <u>A. Leary</u> , Institut Gustave Roussy, Villejuif, FR	
19:10 - 19:35	Chair interview of Dr. Cercek: Perspective on single-agent PD-1 blockade in dMMR CRC/solid tumors <u>A. Cercek</u> , Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US	
19:35 - 19:55	Panel discussion: Considerations for ICI treatment of dMMR endometrial cancer and CRC/solid tumors, expert perspectives <u>I. Ray-Coquard</u> ¹ , <u>A. Leary</u> ² , <u>A. Cercek</u> ³ , ¹ Centre Léon Bérard, Lyon, FR, ² Institut Gustave Roussy, Villejuif, FR, ³ Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US	
19:55 - 20:00	Q&A <u>I. Ray-Coquard</u> ¹ , <u>A. Leary</u> ² , <u>A. Cercek</u> ³ , ¹ Centre Léon Bérard, Lyon, FR, ² Institut Gustave Roussy, Villejuif, FR, ³ Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US	

18:30 - 20:00	Type: Industry Satellite Symposium Title: Servier - Understanding the treatment strategy in metastatic pancreatic cancer to improve patient outcomes Chair(s): Teresa Macarulla Mercade, ES; Thomas Seufferlein, DE	7.3.H - Honfleur Auditorium
18:30 - 18:40	Introduction <u>T. Seufferlein</u> , University of Ulm, Ulm, DE	
18:40 - 18:55	Treatment planning strategy in mPAC <u>C.B. Westphalen</u> , LMU Klinikum der Universität München, Munich, DE	
18:55 - 19:10	Real-world data in mPAC <u>M. Peeters</u> , UZA - University Hospital Antwerp, Edegem, BE	
19:10 - 19:25	Insights from Japan in mPAC <u>M. Ikeda</u> , National Cancer Center Hospital East, Kashiwa, JP	
19:25 - 19:35	Long-term survivors <u>T. Macarulla Mercade</u> , Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES	
19:35 - 19:55	Panel discussion <u>T. Macarulla Mercade</u> ¹ , <u>T. Seufferlein</u> ² , ¹ Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ² University of Ulm, Ulm, DE	
19:55 - 20:00	Conclusion <u>T. Seufferlein</u> , University of Ulm, Ulm, DE	

18:30 - 20:00	Type: Industry Satellite Symposium Title: Merck - Evolution of SCCHN treatment Chair(s): Ezra Cohen, US	7.3.O - Orléans Auditorium
18:30 - 18:35	Welcome and introduction <u>E. Cohen</u> , Moores Cancer Center - UC San Diego Health, La Jolla, US	
18:35 - 18:47	Treatment options for cisplatin ineligible patients with LA SCCHN <u>S. Oosting</u> , Groningen, NL	
18:47 - 18:59	Opportunities for novel combinations with radiation in LA SCCHN <u>K. Harrington</u> , ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB	
18:59 - 19:11	Evolution of treatment sequencing in SCCHN <u>P. Szturcz</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
19:11 - 19:23	New combinations in R/M SCCHN <u>A. Martins Ferreira Vargues Gomes</u> , Centro Hospitalar Universitário do Algarve - Hospital de Faro EPE-SNS, Faro, PT	
19:23 - 19:33	Summary of the data <u>E. Cohen</u> , Moores Cancer Center - UC San Diego Health, La Jolla, US	
19:33 - 19:55	Live discussion <u>E. Cohen</u> ¹ , <u>S. Oosting</u> ² , <u>K. Harrington</u> ³ , <u>A. Martins Ferreira Vargues Gomes</u> ⁴ , <u>P. Szturcz</u> ⁵ , ¹ Moores Cancer Center - UC San Diego Health, La Jolla, US, ² Groningen, NL, ³ ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB, ⁴ Centro Hospitalar Universitário do Algarve - Hospital de Faro EPE-SNS, Faro, PT, ⁵ CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
19:55 - 20:00	Closing remarks <u>E. Cohen</u> , Moores Cancer Center - UC San Diego Health, La Jolla, US	

18:30 - 20:00	Type: Industry Satellite Symposium Title: MSD - Triple Negative Breast Cancer: An Evolving Treatment Landscape Chair(s): Hope Rugo, US	7.3.Q - Quimper Auditorium
18:30 - 18:35	Introduction and Objectives <u>H. Rugo</u> , UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US	
18:35 - 18:55	Review of the Evolving Treatment Landscape in Early TNBC <u>P. Schmid</u> , Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB	
18:55 - 19:15	Review of the Evolving Treatment Landscape in metastatic TNBC <u>R. Bartsch</u> , Medizinische Universitaet Wien, Vienna, AT	
19:15 - 19:35	PD-L1 testing for metastatic TNBC <u>G. Viale</u> , IEO - Istituto Europeo di Oncologia, Milan, IT	
19:35 - 19:45	Breast Cancer Patient Case Study <u>H. Rugo</u> , UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US	
19:45 - 19:55	Q&A from Audience <u>H. Rugo</u> ¹ , <u>R. Bartsch</u> ² , <u>P. Schmid</u> ³ , <u>G. Viale</u> ⁴ , ¹ UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ² Medizinische Universitaet Wien, Vienna, AT, ³ Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB, ⁴ IEO - Istituto Europeo di Oncologia, Milan, IT	
19:55 - 20:00	Closing <u>H. Rugo</u> , UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US	

18:30 - 20:00	Type: Industry Satellite Symposium Title: Novartis - From clinical trial to real-world evidence: METex14 inhibitors in everyday practice Chair(s): Alexis Cortot, FR	7.3.T - Toulouse Auditorium
18:30 - 18:33	Welcome and introduction <u>A. Cortot</u> , CHU Lille - Centre Hospitalier Régional Universitaire de Lille, Lille, FR	
18:33 - 18:48	Identifying MET-dysregulated NSCLC: the path to diagnosis <u>K. Kerr</u> , Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB	
18:48 - 19:03	Expanding treatment options for patients with MET exon 14 skipping mutation in NSCLC <u>A. Cortot</u> , CHU Lille - Centre Hospitalier Régional Universitaire de Lille, Lille, FR	
19:03 - 19:28	MET inhibition for patients with METex14 NSCLC in the real world <u>A. Cortot</u> ¹ , <u>K. Kerr</u> ² , <u>M. Hochmair</u> ³ , ¹ CHU Lille - Centre Hospitalier Régional Universitaire de Lille, Lille, FR, ² Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB, ³ Ludwig Boltzmann Institut Applied Diagnostics - Ludwig Boltzmann Gesellschaft GmbH, Vienna, AT	
19:28 - 19:48	MET inhibition: experience from clinical trials and beyond <u>M. Hochmair</u> , Ludwig Boltzmann Institut Applied Diagnostics - Ludwig Boltzmann Gesellschaft GmbH, Vienna, AT	
19:48 - 19:58	Q&A with the audience <u>A. Cortot</u> ¹ , <u>K. Kerr</u> ² , <u>M. Hochmair</u> ³ , ¹ CHU Lille - Centre Hospitalier Régional Universitaire de Lille, Lille, FR, ² Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB, ³ Ludwig Boltzmann Institut Applied Diagnostics - Ludwig Boltzmann Gesellschaft GmbH, Vienna, AT	
19:58 - 20:00	Meeting closure <u>A. Cortot</u> , CHU Lille - Centre Hospitalier Régional Universitaire de Lille, Lille, FR	

18:30 - 20:00	Type: Industry Satellite Symposium Title: AstraZeneca - The Highs and Lows of Breast Cancer Treatment: An interactive case-based discussion Chair(s): Judy King, GB	7.3.U - Urval Auditorium
18:30 - 18:35	Welcome and introductions <u>J. King</u> , UCLH - University College London Hospitals NHS Foundation Trust, London, GB	
18:35 - 19:00	Rethinking TNBC: Treatment strategies and sequencing <u>R. Dent</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
19:00 - 19:30	Therapeutic strategies to maximise ET sensitivity and confront resistance <u>E. Hamilton</u> , Sarah Cannon Research Institute-Cancer Centre, Nashville, US	
19:30 - 19:55	The evolution of HER2-targeted treatments <u>V. Dieras</u> , Centre Eugene - Marquis, Rennes, FR	
19:55 - 20:00	Meeting Close <u>J. King</u> , UCLH - University College London Hospitals NHS Foundation Trust, London, GB	

12.09.2022

08:30 - 10:00 **Type: Special symposium** **4.A - Antibes Auditorium**
Title: Prostate-specific membrane antigen (PSMA) biology, diagnostics and treatment
Chair(s): Shahneen Sandhu, AU; Boris Hadaschik, DE

08:30 - 08:35 **Introduction and scientific background**
B. Hadaschik, University Hospital of Essen, Essen, DE

08:35 - 08:50 **PSMA biology**
N. Bander, New York, NY, US

08:50 - 09:05 **PSMA for diagnosis and staging**
D. Oprea-Lager, Amsterdam, NL

09:05 - 09:20 **LU-PSMA for prostate cancer treatment**
S. Sandhu, Peter MacCallum Cancer Centre, Melbourne, AU

09:20 - 09:35 **T cell engagers**
K. Fizazi, Institut Gustave Roussy, Villejuif, Cedex, FR

09:35 - 09:40 **Conclusions and perspectives**
B. Hadaschik, University Hospital of Essen, Essen, DE

09:40 - 10:00 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

08:30 - 10:00 **Type: Educational session** **4.B - Brest Auditorium**
Title: Personalizing treatment for mCRC in 2022
Chair(s): Chiara Cremolini, IT; Pieter Tanis, NL

08:30 - 08:55 **State-of-the art first-line therapy for mCRC**
C. Cremolini, AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT

08:55 - 09:20 **Impact of locoregional treatments in the metastatic setting**
P. Tanis, Erasmus MC Cancer Institute, Rotterdam, NL

09:20 - 09:45 **Beyond first-line: Best practices and practical nuances**
T. Price, The Queen Elizabeth Hospital - Emergency Department, Woodville, AU

09:45 - 10:00 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

08:30 - 10:00 **Type: Mini Oral session** **7.1.C - Cannes Auditorium**
Title: Mini Oral session: Breast cancer, early stage
Chair(s): Prudence Francis, AU; Luca Malorni, IT; Aleix Prat, ES

- 08:30 - 08:35** **135MO - HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522**
- R. Dent¹, J. Cortés², L. Pusztai³, H. Mcarthur⁴, S. Kuemmel⁵, J. Bergh⁶, C. Denkert⁷, Y.H. Park⁸, R. Hui⁹, N. Harbeck¹⁰, M. Takahashi¹¹, M. Untch¹², P.A. Fasching¹³, F. Cardoso¹⁴, A. Haiderali¹⁵, L. Jia¹⁵, A. Nguyen¹⁵, W. Pan¹⁵, J. O'Shaughnessy¹⁶, P. Schmid¹⁷, ¹Duke-NUS Medical School, Singapore, SG, ²Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ³Yale University School of Medicine, New Haven, US, ⁴UT Southwestern Medical Center, Dallas, US, ⁵Charité – Universitätsmedizin Berlin, Department of Gynecology with Breast Center, Berlin, DE, ⁶Karolinska University Hospital, Karolinska CCC, Solna, SE, ⁷Philipps University Marburg, Marburg, DE, ⁸Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, ⁹Westmead Hospital and the University of Sydney, Sydney, AU, ¹⁰Dept. OB&GYN, LMU University Hospital, Munich, DE, ¹¹NKO Hokkaido Cancer Center, Sapporo, JP, ¹²Helios Klinikum Berlin-Buch, Berlin, DE, ¹³Comprehensive Cancer Center Erlangen-EMN, Erlangen, DE, ¹⁴Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, PT, ¹⁵Merck & Co., Inc., Rahway, US, ¹⁶Texas Oncology, US Oncology, Dallas, US, ¹⁷Barts Cancer Institute, Queen Mary University of London, London, GB
- 08:35 - 08:40** **136MO - Differential benefit of low-dose cyclophosphamide and methotrexate maintenance chemotherapy among TNBC subtypes in the context of the IBCSG 22-00 study**
- A. Joaquin Garcia¹, M. Rediti¹, D. Venet¹, S. Majjaj¹, R. Kammler², M. Colleoni³, S. Loi⁴, G. Viale³, M. Regan⁵, F. Rothé¹, C. Sotiriou¹, ¹Institute Jules Bordet, Brussels, BE, ²ETOP - European Thoracic Oncology Platform, Bern, CH, ³IEO - Istituto Europeo di Oncologia, Milan, IT, ⁴Peter MacCallum Cancer Centre, Melbourne, AU, ⁵Dana Farber Cancer Institute, Boston, US
- 08:40 - 08:45** **137MO - Effect of peri-tumoral infiltration of local anaesthetic prior to surgery on survival in early breast cancer**
- R. Badwe¹, V. Parmar², N. Nair², R. Hawaldar³, S. Joshi⁴, S. Pawar⁵, G. Kadayaprath⁶, B. Borthakur⁷, S. Rao⁸, S. Pandya⁹, S. B¹⁰, P. Chitale¹¹, R. Neve¹², C. Harris¹³, A. Srivastava¹⁴, S. Siddique³, V. Vanmali², A. Dewade⁴, V. Gaikwad⁴, S. Gupta³, ¹Tata Memorial Centre, Mumbai, IN, ²Tata Memorial Hospital - Tata Memorial Centre, mumbai, IN, ³Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, ⁴Tata Memorial Hospital - Parel, Mumbai, IN, ⁵Kolhapur Cancer Centre, Kolhapur, IN, ⁶Max Hospital Delhi, Delhi, IN, ⁷B. Borooah Cancer Institute, Guwahati, Guwahati, IN, ⁸American Cancer Hospital and Research Centre, Hyderabad, IN, ⁹GCRI - The Gujarat Cancer and Research Institute, Ahmedabad, IN, ¹⁰Malabar Cancer Centre, Thalassery, IN, ¹¹Shree Siddhivinayak Ganapati Cancer Hospital, Miraj, IN, ¹²Sterling Multi-Speciality Hospital, Pune, IN, ¹³NEIGRIHMS - North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Shillong, IN, ¹⁴AIIMS - All India Institute of Medical Sciences, New Delhi, IN

08:45 - 09:00 **Invited Discussant 135MO, 136MO and 137MO**

P. Francis, Peter MacCallum Cancer Center, Melbourne, AU

09:00 - 09:05

139MO - Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial

M. Rediti¹, D. Venet¹, A. Joaquin Garcia¹, D. Agbor-Tarh², M. Maetens³, D. Vincent¹, S. Majjaj¹, S. El-Abed⁴, M. Liu⁵, S. Di Cosimo⁶, M. Piccart¹, L. Pusztai⁷, S. Loi⁸, R. Salgado⁹, G. Viale¹⁰, F. Rothé¹, C. Sotiriou¹, ¹Institute Jules Bordet, Université Libre de Bruxelles, Brussels, BE, ²Frontier Science, Kincaig, GB, ³KU Leuven, Leuven, BE, ⁴Breast International Group - AISBL, Brussels, BE, ⁵Mayo Clinic, Rochester, US, ⁶Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁷Yale University School of Medicine, New Haven, US, ⁸Peter MacCallum Cancer Centre, Melbourne, AU, ⁹GZA-ZNA Ziekenhuizen, Antwerp, BE, ¹⁰IEO - Istituto Europeo di Oncologia, Milan, IT

09:05 - 09:10

140MO - HER2DX genomic test in HER2-positive/hormone receptor-positive (HER2⁺/HR⁺) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analysis from the PerELISA trial

V. Guarneri¹, M.V. Dieci¹, G. Griguolo², L. Pare Brunet³, M. Marin³, F. Miglietta², M. Bottosso², C.A. Giorgi², P. Blasco⁴, O. Castillo⁴, P. Galván⁴, P. Jares⁵, J. Puig-Butille⁶, A. Vivancos⁷, P. Villagrasa Gonzalez³, J. Parker⁸, C. Perou⁹, P.F. Conte², A. Prat⁵, ¹University of Padua, Padova, IT, ²IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ³Reveal Genomics, S.L., Barcelona, ES, ⁴IDIBAPS - August Pi i Sunyer Biomedical Research Institute, Barcelona, ES, ⁵Hospital Clinic of Barcelona, Barcelona, ES, ⁶Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁷Vall d'Hebron University Hospital, Barcelona, ES, ⁸UNC - Lineberger Cancer Center, Chapel Hill, US, ⁹UNC - Lineberger Comprehensive Cancer Center, Chapel Hill, US

09:10 - 09:25

Invited Discussant 139MO and 140MO

L. Malorni, Nuovo Ospedale di Prato Santo Stefano - Azienda Usl Toscana Centro, Prato, IT

09:25 - 09:30

138MO - Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR⁺ breast cancer in the TEAM trial

J. Bartlett¹, K. Xu¹, J. Wong², G. Pond³, Y. Zhang², M. Spears¹, R. Salunga², E. Mallon⁴, K. Taylor⁵, A. Hasenburger⁶, C. Markopoulos⁷, L. Dirix⁸, C. Seynaeve⁹, C. Van De Velde¹⁰, D. Rea¹¹, C. Schnabel², K. Treuner², J. Bayani¹, ¹Ontario Institute for Cancer Research, Toronto, CA, ²Biotheranostics, A Hologic Company, San Diego, US, ³McMaster University Medical Centre - Hamilton Health Sciences, Hamilton, CA, ⁴University of Glasgow, Glasgow, GB, ⁵Cancer Research UK Edinburgh Centre, Edinburgh, GB, ⁶University Center Mainz, Mainz, DE, ⁷National and Kapodistrian University of Athens, Athens, GR, ⁸Sint-Augustinus Cancer Center, Wilrijk-Antwerp, BE, ⁹Erasmus MC Cancer Institute, Rotterdam, NL, ¹⁰Leiden University Medical Center, Amsterdam, NL, ¹¹University of Birmingham, Birmingham, GB

09:30 - 09:35

141MO - Pathological response and early survival data according to TNBCtype4 classifier in operable triple-negative breast cancer (TNBC) treated with neoadjuvant carboplatin and docetaxel

I. Echavarria Diaz-Guardamino¹, S. Lopez-Tarruella Cobo², M. Del Monte-Millan², E. Alvarez¹, Y. Jerez¹, F. Moreno Anton³, J.Á. García Saenz³, T. Massarrah², I. Ocaña¹, M. Cebollero⁴, A.I. Ballesteros Garcia⁵, U. Bohn Sarmiento⁶, H. Gomez⁷, H. Fuentes⁸, B. Herrero Lopez¹, S. Gamez Casado¹, O. Bueno⁴, M.J. Jiménez-Santos⁹, M. Roche-Molina¹, M. Martin Jimenez², ¹Hospital General Universitario Gregorio Marañón - Fundación Investigación Biomedica, Madrid, ES, ²Hospital General Universitario Gregorio Marañón - Fundación Investigación Biomedica, CIBERONC, Madrid, ES, ³Hospital Clinico Universitario San Carlos, CIBERONC, Madrid, ES, ⁴Hospital General Universitario Gregorio Marañón, Madrid, ES, ⁵Hospital Universitario de la Princesa, Madrid, ES, ⁶Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, ES, ⁷Oncosalud SAC, Lima, PE, ⁸INEN - Instituto Nacional de Enfermedades Neoplasicas, Lima, PE, ⁹CNIO - Centro Nacional de Investigaciones Oncologicas, Madrid, ES

09:35 - 09:50 **Invited Discussant 138MO and 141MO**

A. Prat, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

08:30 - 10:00	Type: Special symposium Title: Leveraging biology and technology to improve symptoms and quality of life of cancer survivors Chair(s): Ines Vaz Luis, FR; Justin Jeon, KR	7.2.E - Évry Auditorium
----------------------	---	--------------------------------

08:30 - 08:35 **Introduction and scientific background**

I. Vaz Luis, Institut Gustave Roussy, Villejuif, Cedex, FR

08:35 - 08:50 **The need for discovery science and biological basis in cancer cachexia**

M. Jamal-Hanjani, UCL Cancer Institute - Paul O'Gorman Building, London, GB

08:50 - 09:05 **Biological basis of exercise and physical activity on quality of life in cancer survivors**

J. Jeon, Yonsei University, Seoul, KR

09:05 - 09:20 **Biological basis of behavioral interventions for cancer survivors: Focus on mindfulness**

J. Bower, Los Angeles, US

09:20 - 09:35 **How do you use supportive technology to improve personalised care?**

E. Minvielle, Institut Gustave Roussy, Villejuif, FR

09:35 - 09:40 **Conclusions and perspectives**

J. Jeon, Yonsei University, Seoul, KR

09:40 - 10:00 **Discussion**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

08:30 - 09:40	Type: Mini Oral session Title: Mini Oral session: Melanoma and other skin	7.2.F - Fécamp Auditorium
----------------------	--	----------------------------------

tumours

Chair(s): Teresa Amaral, DE; Omid Hamid, US

- 08:30 - 08:35 **LBA41 - Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation**
P. Ascierto¹, M. Mandala², P.F. Ferrucci³, M. Guidoboni⁴, P. Rutkowski⁵, V. Ferraresi⁶, A.M. Arance Fernandez⁷, M. Guida⁸, E. Maiello⁹, H. Gogas¹⁰, E. Richtig¹¹, M.T. Fierro¹², C. Lebbe¹³, H. Helgadottir¹⁴, I. Melero¹⁵, G. Palmieri¹⁶, D. Giannarelli¹⁷, A. Grimaldi¹⁸, R. Dummer¹⁹, V. Chiarion Sileni²⁰, ¹Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ²University of Perugia and Papa Giovanni XXIII Cancer Center Hospital, Perugia, IT, ³IEO - Istituto Europeo di Oncologia, Milan, IT, ⁴Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS S.r.l., Meldola, IT, ⁵Maria Sklodowska Curie National Research Institute of Oncology, Warsaw, PL, ⁶IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT, ⁷Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁸IRCCS Istituto Tumori Giovanni Paolo II, Bari, IT, ⁹IRCCS Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, IT, ¹⁰Laiko General Hospital of Athens, Athens, GR, ¹¹Universitätsklinik für Dermatologie und Venerologie, Graz, AT, ¹²Oncologia Medica, Torino, IT, ¹³Hopital Saint Louis AP-HP, Paris, FR, ¹⁴Karolinska University Hospital, Stockholm, SE, ¹⁵Clinica Universitaria de Navarra, Pamplona, ES, ¹⁶University of Sassari, Sassari, IT, ¹⁷Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ¹⁸A.O.R.N. San Pio, Benevento, IT, ¹⁹Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, ²⁰IOV - Istituto Oncologico Veneto IRCCS, Padova, IT
- 08:35 - 08:40 **LBA42 - Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma**
S. Kim¹, E. Wuthrick², D. Blakaj³, Z. Eroglu², C. Verschraegen³, R. Thapa², M. Mills², K. Dibs³, C. Liveringhouse², J. Russell⁴, J. Caudell¹, A. Tarhini², J. Markowitz², D.-T. Chen², T. Rose², J. Messina², V. Sondak², K. Tsai², N. Khushalani², A. Brohl², ¹H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, ²H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ³OSUCCC - The Ohio State University Comprehensive Cancer Center - James, Columbus, US, ⁴University of Utah Health - Cancer Hospital, Salt Lake City, US
- 08:40 - 08:45 **790MO - Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)**
O. Hamid¹, A. Weise², T.M. Kim³, M. Mckean⁴, N. Lakhani⁵, J. Kaczmar⁶, K. Papadopoulos⁷, S. Chen⁸, J. Mani⁸, V. Jankovic⁸, G. Kroog⁸, T. Sims⁸, I. Lowy⁸, G. Gullo⁸, ¹The Angeles Clinical and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, US, ²Henry Ford Hospital, Detroit, US, ³Seoul National University Hospital, Seoul, KR, ⁴Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, US, ⁵START Midwest, Grand Rapids, US, ⁶MUSC Hollings Cancer Center, North Charleston, US, ⁷START San Antonio, San Antonio, US, ⁸Regeneron Pharmaceuticals, Inc., Tarrytown, US
- 08:45 - 09:00 **Invited Discussant LBA41, LBA42 and 790MO**
T. Amaral, Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE

- 09:00 - 09:05 **791MO - Clinical and tumor characteristics of patients (pts) with recurrence after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma**
- J. Versluis¹, R. Elens¹, I. Reijers¹, A. Menzies², A. Van Der Veldt³, E. Kapiteijn⁴, E. Rozeman¹, M. Klop¹, W. Van Houdt⁵, R. Saw², C. Zuur¹, T. Pennington², B. Van De Wiel⁵, R. Scolyer², A. Broeks¹, A. Van Akkooi², G. Long², C. Blank¹, ¹Netherlands Cancer Institute, Amsterdam, NL, ²Melanoma Institute Australia, Wollstonecraft, AU, ³Erasmus MC - University Medical Center, Rotterdam, NL, ⁴Leiden University Medical Center (LUMC), Leiden, NL, ⁵Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 09:05 - 09:10 **LBA43 - Intradermal IMO-2125 versus placebo as adjuvant treatment in patients with stage II pT3-4/cN0 melanoma: Interim efficacy and safety results of the randomized phase II INTRIM study**
- J. Notohardjo¹, S. Veenstra¹, B. Koster¹, V. Kandiah¹, S. Van Der Velde¹, A. Francken², G. Gooiker³, M.P. Van Den Tol¹, M. Bekkenk⁴, K. In 'T Hof⁵, M. Straver⁶, B. Molenkamp⁷, R. Vuylsteke⁸, B. Lissenberg-Witte¹, M. Labots¹, S. Chunduru⁹, A. Van Akkooi¹⁰, F. Van Den Eertwegh¹, T. De Gruijl¹, ¹Amsterdam UMC - Location Vrije Universiteit, Amsterdam, NL, ²Isala Hospital, Zwolle, NL, ³Noordwest Ziekenhuisgroep - Alkmaar, Alkmaar, NL, ⁴Amsterdam UMC - Location University of Amsterdam, Amsterdam, NL, ⁵Flevo-Ziekenhuis, Almere, NL, ⁶HMC - Haaglanden Medisch Centrum - Antoniusshove, Leidschendam, NL, ⁷Diakonessenhuis Utrecht, Utrecht, NL, ⁸Spaarne Gasthuis Haarlem Zuid, Haarlem, NL, ⁹Idera pharmaceuticals, Exton, US, ¹⁰Netherlands Cancer Institute, Amsterdam, NL
- 09:10 - 09:15 **LBA44 - Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial**
- A. Bottomley¹, M. Kicinski¹, G. Long², M. Mandala³, V. Atkinson⁴, C. Blank⁵, A. Haydon⁶, S. Dalle⁷, A. Khatkhat⁸, M. Carlini⁹, A. Meshcheryakov¹⁰, S. Sandhu¹¹, S. Puig Sarda¹², C. Coens¹, S. Suciu¹, D. Grebennik¹³, C. Krepler¹³, P. Lorigan¹⁴, C. Robert¹⁵, A. Eggermont¹⁶, ¹European Organisation for Research and Treatment of Cancer, Brussels, BE, ²The University of Sydney, and Royal North Shore and Mater Hospitals, Wollstonecraft, AU, ³University of Perugia and Papa Giovanni XXIII Cancer Center Hospital, Perugia, IT, ⁴Princess Alexandra Hospital, University of Queensland, Brisbane, AU, ⁵NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁶Alfred Hospital, Melbourne, AU, ⁷HCL Cancer Institute, Cancer Research Center of Lyon, Lyon University, Pierre Benite, FR, ⁸Fiona Stanley Hospital/Edith Cowan University, Murdoch, AU, ⁹Westmead and Blacktown Hospitals, Melanoma Institute Australia and the University of Sydney, Westmead, AU, ¹⁰N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ¹¹Peter MacCallum Cancer Centre, Melbourne, AU, ¹²Hospital Clinic de Barcelona, University of Barcelona & CIBERER, Instituto de Salud Carlos III, Barcelona, ES, ¹³Merck & Co., Inc., Rahway, US, ¹⁴Division of Cancer Sciences, University of Manchester and Christie NHS Foundation Trust, Manchester, GB, ¹⁵Gustave Roussy Cancer Campus Grand Paris & University Paris-Saclay, Villejuif, FR, ¹⁶Comprehensive Cancer Center Munich (CCCM), Munich, Germany, and University Medical Center Utrecht, Utrecht, NL
- 09:15 - 09:20 **792MO - Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable stage III melanoma**

M. Lowe¹, M. Yushak², B. Olson², A. Mokhtari¹, A. Harutyunyan², K. Delman¹, D. Parker¹, E. Evans³, T. Fisher³, G. Lesinski², R. Kudchadkar², ¹Emory University, Atlanta, US, ²Winship Cancer Institute of Emory University, Atlanta, US, ³Vaccinex Inc., Rochester, US

09:20 - 09:35 **Invited Discussant 791MO, LBA43, LBA44 and 792MO**

O. Hamid, The Angeles Clinic and Research Institute - West Los Angeles, Los Angeles, US

08:30 - 10:00 Type: Mini Oral session 7.3.G - Grenoble Auditorium
Title: Mini Oral session 2: GU tumours, non-prostate

Chair(s): Guillermo Antonio De Velasco Oria, ES; Michiel van der Heijden, NL

08:30 - 08:35 **1451MO - In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial**

M. Meylan¹, C.-M. Sun¹, R.-T. Elaidi², M. Moreira¹, A. Bougouin¹, V. Verkarre³, M. Bennamoun⁴, C. Chevreau⁵, D. Borchiellini⁶, P. Barthelemy⁷, D. Pannier⁸, D. Maillet⁹, M. Gross Goupil¹⁰, C. Tournigand¹¹, E. Braychenko², L. Phan², S. Oudard¹², W.-H. Fridman¹³, C. Sautes-Fridman¹, Y.-A. Vano¹², ¹Centre de Recherche des Cordeliers, INSERM, Université Paris Cité, Sorbonne Université, Paris, FR, ²ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie; Hôpital Européen Georges Pompidou, APHP.Centre - Université Paris Cité, Paris, FR, ³Hôpital Européen Georges Pompidou, APHP.Centre - Université Paris Cité, Paris, France, Paris, France, Paris, FR, ⁴Institut Mutualiste Montsouris, Paris, FR, ⁵Institut Universitaire du Cancer - Toulouse- Oncopole, Toulouse, FR, ⁶Centre Antoine Lacassagne, Université Côte d'Azur, Nice, FR, ⁷Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ⁸Centre Oscar Lambret, Lille, FR, ⁹IMMUCARE, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices de Lyon (IC-HCL), Pierre-Bénite, Pierre Benite, FR, ¹⁰Centre Hospitalier Universitaire de Bordeaux - Hôpital Saint-André, Bordeaux, FR, ¹¹Hôpital Henri-Mondor, AP-HP - Université de Paris Est, Créteil France; INSERM, IMRB, F-94010 Creteil, Creteil, FR, ¹²Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre - Université Paris Cité, Paris, FR, ¹³Centre de Recherche des Cordeliers, INSERM, Université Paris Cité, Sorbonne Université, Paris, France,, Paris, FR

08:35 - 08:40 **1452MO - Longitudinal analysis reveals gut microbiota shift during standard therapies in metastatic renal cell carcinoma (mRCC)**

C. Alves Costa Silva¹, G. Piccinno², L. Cerbone¹, V. Iebba³, E. Colomba¹, R. Flippot¹, C. Sow¹, I. Darik¹, A. Maltez Thomas², N. Naoun¹, A. Bernard-Tessier¹, A. Reni¹, N. Segata², B. Escudier¹, L. Zitvogel¹, L. Albiges¹, L. Derosa¹, ¹Gustave Roussy - Cancer Campus, Villejuif, Cedex, FR, ²Università degli Studi di Trento, Trento, IT, ³University of Trieste, Trieste, IT

08:40 - 08:45 **LBA69 - Belzutifan, a HIF-2α Inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: 36 months of follow-up of the phase II LITESPARK-004 study**

R. Srinivasan¹, O. Iliopoulos², W.K. Rathmell³, V. Narayan⁴, B. Maughan⁵, S. Oudard⁶, T. Else⁷, J. Maranchie⁸, S. Welsh⁹, A.B. Bøndergaard Iversen¹⁰, K. Chen¹¹, R. Perini¹¹, Y. Liu¹¹, W.M. Linehan¹, E. Jonasch¹², ¹Center for Cancer Research, National Cancer

Institute, Bethesda, US, ²Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, US, ³Vanderbilt University Medical Center, Nashville, US, ⁴University of Pennsylvania, Philadelphia, US, ⁵University of Utah, Salt Lake City, US, ⁶Georges-Pompidou Hospital, University of Paris, Paris, FR, ⁷University of Michigan, Ann Arbor, US, ⁸University of Pittsburgh, Pittsburgh, US, ⁹Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB, ¹⁰Aarhus University Hospital, Aarhus, DK, ¹¹Merck & Co., Inc., Rahway, US, ¹²The University of Texas MD Anderson Cancer Center, Houston, US

08:45 - 09:00 **Invited Discussant 1451MO, 1452MO and LBA69**

G.A. De Velasco Oria, Hospital Universitario 12 de Octubre, Madrid, ES

09:00 - 09:05 **1736MO - Pure or mixed basal/squamous tumours present decreased outcomes after neoadjuvant chemotherapy in the GETUG-AFU V05 VESPER trial**

C. Groeneveld¹, V. Harter², S. Culine³, C. Krucker¹, V. Dixon¹, A. De Reynies⁴, C. Pfister⁵, F. Radvanyi¹, Y. Allory¹, ¹Institut Curie, Paris, FR, ²François Baclesse Comprehensive Cancer Center, Caen, FR, ³Hopital Saint Louis AP-HP, Paris, FR, ⁴Université de Paris, Paris, FR, ⁵Hopital Charles-Nicolle - CHU de Rouen, Rouen, FR

09:05 - 09:10 **1737MO - Tumor and immune features associated with disease-free survival with adjuvant nivolumab in the phase III CheckMate 274 trial**

A. Necchi¹, D. Bajorin², Y. Tomita³, D. Ye⁴, M. Agerbæk⁵, D. Enting⁶, A. Peer⁷, M. Milowsky⁸, K. Kobayashi⁹, M.-O. Grimm¹⁰, F. Stenner-Liewen¹¹, J. David¹², J. Li¹², S. Chasalow¹², F. Nasroulah¹², A. Apfel¹², K. Unsal-Kacmaz¹², M. Galsky¹³, ¹Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, IT, ²Memorial Sloan Kettering Cancer Center, New York, US, ³Niigata University Graduate School of Medical and Dental Sciences, Niigata, JP, ⁴Fudan University Shanghai Cancer Center, Shanghai, CN, ⁵Aarhus University Hospital, Aarhus, DK, ⁶Guy's and St. Thomas' NHS Foundation Trust, London, GB, ⁷Rambam Health Care Center, Haifa, IL, ⁸University of North Carolina School of Medicine, Chapel Hill, US, ⁹Sapporo Medical University, Sapporo, JP, ¹⁰Jena University Hospital, Jena, DE, ¹¹University Hospital Basel, Basel, CH, ¹²Bristol Myers Squibb, Princeton, US, ¹³Icahn School of Medicine at Mount Sinai, New York, US

09:10 - 09:25 **Invited Discussant 1736MO and 1737MO**

M. Van Der Heijden, Netherlands Cancer Institute, Amsterdam, NL

08:30 - 10:00 **Type: Educational session** **7.3.O - Orléans Auditorium**
Title: Early relapses in lymphoma: How to treat?
 Chair(s): Catherine Thieblemont, FR; Marco Ladetto, IT

08:30 - 08:55 **Follicular lymphoma**
C. Thieblemont, Hopital Saint Louis AP-HP, Paris, FR

08:55 - 09:20 **Mantle cell lymphoma**
M. Ladetto, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, IT

09:20 - 09:45 **Diffuse large B-cell lymphoma**
M. Hutchings, Copenhagen, DK

09:45 - 10:00 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

08:30 - 10:00 **Type: Mini Oral session** **7.3.Q - Quimper Auditorium**
Title: Mini Oral session: NETs and endocrine tumours
 Chair(s): Mauro Cives, IT; Hans Gelderblom, NL; Maria Cabanillas, US

08:30 - 08:35 **1646MO - Phase II ATLEP trial: Final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma**
C. Dierks¹, J. Ruf², J. Seufert², M. Kreissl³, C. Klein², C. Spitzweg⁴, M. Kroiss⁵, O. Thomusch², K. Lorenz⁶, A. Zielke⁷, C. Miething², ¹Martin Luther University Halle-Wittenberg, Halle (Saale), DE, ²University Medical Center Freiburg, Freiburg im Breisgau, DE, ³Klinikum Magdeburg GmbH, Magdeburg, DE, ⁴LMU Klinikum der Universität München, Munich, DE, ⁵LMU - Ludwig Maximilians University of Munich, Munich, DE, ⁶Department of Visceral, Vascular, and Endocrine Surgery, halle, DE, ⁷Diakoniekrankenhaus Stuttgart, Stuttgart, DE

08:35 - 08:40 **1647MO - BRAF mutated anaplastic thyroid carcinoma: Clinical characteristics and outcome under BRAF inhibitors and chemotherapy in real-life practice, a multicentric retrospective study of the French ENDOCAN TUTHYREF network**
C. De La Fouchardiere¹, A. Jannin², F. Giudici³, J. Wassermann⁴, C. Chougnet⁵, D. Dru⁶, Y. Godbert⁷, F. Illouz⁸, S. Bardet⁹, N. Roudaut¹⁰, M. Batisse Lignier¹¹, L. Groussin¹², M. Klein¹³, S. Zerdoud¹⁴, L. Lamartina¹⁵, E. Baudin¹⁵, F. Borson-Chazot¹⁶, C. Do Cao², I. Borget¹⁵, J. Hadoux¹⁵, ¹Centre Léon Bérard, Lyon, FR, ²Centre Hospitalier Régional Universitaire de Lille, Lille, FR, ³Institut Gustave Roussy, Villejuif, Cedex, FR, ⁴Hôpital Pitié-Salpêtrière AP-HP, Paris, FR, ⁵Hopital Saint Louis AP-HP, Paris, FR, ⁶CHU de Nantes, Hôtel Dieu, Nantes, FR, ⁷Bergonié Institute Cancer Center, Bordeaux, FR, ⁸CHU Angers, Angers, Cedex, FR, ⁹Centre Francois Baclesse, Caen, Cedex, FR, ¹⁰Hôpital Cavale Blanche (Brest), Brest, FR, ¹¹Centre Jean Perrin, Clermont-Ferrand, FR, ¹²Hopital Cochin - Site Port-Royal AP-HP, Paris, FR, ¹³CHRU Nancy, Nancy, FR, ¹⁴IUCT - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, FR, ¹⁵Institut Gustave Roussy, Villejuif, FR, ¹⁶Hospices Civils de Lyon, Bron, FR

- 08:40 - 08:55 **Invited Discussant 1646MO and 1647MO**
M. Cabanillas, Houston, US
- 08:55 - 09:00 **888MO - Emergence of clonal hematopoiesis after peptide receptor radionuclide therapy for neuroendocrine tumors**
R. El Ferkh¹, J. Hadoux², L. Lamartina³, T. Kamoun³, L. Cysique-Foinlan¹, G. Jépiral³, M. Ducreux³, E. Baudin³, C. Marzac¹, J. Baptiste Micol¹, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Institut Gustave Roussy, Villejuif, FR, ³Gustave Roussy - Cancer Campus, Villejuif, FR
- 09:00 - 09:05 **889MO - Comparative expression of driver transcription factors in extra-pulmonary small cell carcinoma**
S. Puri¹, A. Elliott², H. Soares³, E. Lou⁴, B. Halmos⁵, C. Langer⁶, D. Uprety⁷, S. Darabi⁸, P. Walker², W. El-Deiry⁹, A. Vanderwalde¹⁰, T. Owonikoko¹¹, S. Liu¹², ¹Huntsman Cancer Institute, Salt Lake City, US, ²Caris Life Sciences - Headquarters, Irving, US, ³Huntsman Cancer Institute at the University of Utah, Salt Lake City, US, ⁴Masonic Cancer Center - University of Minnesota, Minneapolis, US, ⁵Montefiore Medical Center, New York City, US, ⁶University of Pennsylvania-Perelman Center for Advanced Medicine, Philadelphia, US, ⁷Karmanos Cancer Institute, Detroit, US, ⁸Hoag Cancer Center, Newport Beach, US, ⁹Brown University, Providence, US, ¹⁰Caris Life Sciences, Phoenix, US, ¹¹University of Pittsburgh and Hillman Cancer Center, Pittsburgh, US, ¹²Lombardi Cancer Center Georgetown University, Washington, US
- 09:05 - 09:10 **890MO - Mutation spectrum in liquid versus solid biopsies from advanced digestive neuroendocrine carcinoma patients**
H. Sorbye¹, S. Knappskog², T. Grob³, A. Venizelos², U. Amstutz³, G.O. Hjortland⁴, I.M. Lothe⁵, C. Kersten⁶, E. Hofslí⁷, A. Sundlov⁸, H. Elvebakken⁹, H. Garresori¹⁰, A. Couvelard¹¹, J. Svensson¹², A. Perren¹³, ¹Haukeland Universitetssykehus, Bergen, NO, ²University of Bergen, Bergen, NO, ³Inselspital - University Hospital Bern - Universitätsklinik für Thoraxchirurgie, Bern, CH, ⁴Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, ⁵Oslo University Hospital - Ullevål Hospital, Oslo, NO, ⁶Sorlandet Hospital, Kristiansand, NO, ⁷St. Olavs Hospital HF, Trondheim, NO, ⁸Skane University Hospital - Oncology Clinic, Lund, SE, ⁹Alesund Hospital, Alesund, NO, ¹⁰Helse Stavanger HF, Stavanger, NO, ¹¹Beaujon Hospital APHP, Clichy, FR, ¹²Sahlgrenska University Hospital - Jubileumskliniken, Göteborg, SE, ¹³University of Bern - Institute of Pathology, Bern, CH
- 09:10 - 09:15 **496MO - Final overall survival results from the NICE-NEC trial (GETNE-T1913): A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated advanced G3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin**
M.C. Riesco Martinez¹, J. Capdevila Castillon², V. Alonso³, P. Jimenez-Fonseca⁴, A. Teule⁵, E. Grande⁶, I. Sevilla⁷, M. Benavent⁸, T. Alonso-Gordoa⁹, A. Custodio¹⁰, B. Antón Pascual¹, J. Hernando², E. Polo³, O.A. Castillo Trujillo⁴, R. Garcia-Carbonero¹, ¹Hospital Universitario 12 de Octubre, IMA12, UCM, Madrid, ES, ²Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, ES, ³Instituto Aragonés de Investigación Sanitaria, Hospital Universitario Miguel Servet, Zaragoza, ES, ⁴Hospital Universitario Central de Asturias, ISPA, Oviedo, ES, ⁵Institut Català d'Oncologia (ICO) -

IDIBELL, L'Hospitalet del Llobregat, ES, ⁶MD Anderson Cancer Center Madrid, Madrid, ES, ⁷Investigación Clínica y Traslacional en Cáncer / Instituto de Investigaciones Biomédicas de Málaga (IBIMA) / Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Málaga, ES, ⁸University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Seville, ES, ⁹Hospital Universitario Ramón y Cajal, Madrid, ES, ¹⁰Hospital Universitario La Paz, Madrid, ES

09:15 - 09:20

LBA46 - Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study

T. Walter¹, A. Lievre², R. Coriat³, D. Malka⁴, F. El Hajbi⁵, F. Di Fiore⁶, O. Hentic Dhome⁷, D. Smith⁸, V. Hautefeuille⁹, G. Roquin¹⁰, M. Perrier¹¹, L. Dahan¹², V. Granger¹³, I. Sobhani¹⁴, L. Mineur¹⁵, P. Niccoli¹⁶, E. Assenat¹⁷, K. Le Malicot¹⁸, C. Lepage¹⁹, C. Lombard Bohas²⁰, ¹Hospices Civiles de Lyon - HCL - Lyon University Hospital Center, Lyon, FR, ²CHU de Rennes - Hopital Pontchaillou, Rennes, Cedex, FR, ³Hopital Cochin AP-HP, Paris, FR, ⁴Institut Gustave Roussy, Villejuif, Cedex, FR, ⁵Centre Oscar Lambret, Lille, FR, ⁶CHU de Rouen Normandie, Rouen, FR, ⁷Beaujon Hospital APHP, Clichy, FR, ⁸Hopital Haut Leveque, Pessac, FR, ⁹CHU Amiens-Picardie - Site Nord, Amiens, FR, ¹⁰CHU Angers, Angers, FR, ¹¹Reims University Hospital, Reims, FR, ¹²AP-HM - CHU La Timone Enfants, Marseille, FR, ¹³CHU Grenoble Alpes - Site Nord (La Tronche), La Tronche, FR, ¹⁴CHU Henri Mondor, creteil, FR, ¹⁵Institut Ste Catherine, Avignon, FR, ¹⁶IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ¹⁷ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, ¹⁸Fédération Francophone de Cancérologie Digestive, Dijon, FR, ¹⁹CHU Dijon, Dijon, FR, ²⁰Hopital Edouard Herriot Pav. E bis, Lyon, FR

09:20 - 09:35

Invited Discussant 888MO, 889MO, 890MO, 496MO and LBA46

M. Cives, Università degli Studi di Bari Aldo Moro, Bari, IT

09:35 - 09:40

1MO - An open-label, phase II trial of cabozantinib for advanced adrenocortical carcinoma

M. Campbell¹, C. Jimenez², J. Long³, J. Varghese³, A. Shah³, M. Zhang⁴, G. Tamsen³, M. Habra³, ¹The M. D. Anderson Cancer Center, Houston, US, ²Banner MD Anderson Cancer Center, Gilbert, US, ³The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁴MD Anderson Cancer Center, Houston, US

09:40 - 09:45

2MO - EO2401 (EO) therapeutic vaccine for patients (pts) with adrenocortical carcinoma (ACC) and malignant pheochromocytoma/paraganglioma (MPP): Phase I/II SPENCER study

E. Baudin¹, S. Grisanti², M. Fassnacht³, C. Menke-Van Der Houven Van Oordt⁴, H. Haak⁵, C. De La Fouchardiere⁶, V. Subbiah⁷, C. Jimenez⁷, J. Capdevila Castillon⁸, D. Granberg⁹, K.G. Daugaard¹⁰, M. Kroiss¹¹, D. Cosentini², O. Kimpel³, L. Lamartina¹, J. Hadoux¹, J.-M. Paillarse¹², L. Chêne¹², J. Fagerberg¹², A. Berruti², ¹Institut Gustave Roussy, Villejuif, FR, ²Università degli Studi di Brescia, Azienda Ospedaliera Spedali Civili, Brescia, IT, ³University Hospital, Würzburg, DE, ⁴Amsterdam UMC, Amsterdam, NL, ⁵Máxima Medisch Centrum, Eindhoven, NL, ⁶Centre Léon Bérard, Lyon, FR, ⁷The University of Texas MD Anderson Cancer Center (MDACC), Houston, US, ⁸Hospital Universitari Vall d'Hebron, Barcelona, ES, ⁹Karolinska Institutet, Karolinska University Hospital, Stockholm, SE, ¹⁰Rigshospitalet, Copenhagen, DK, ¹¹LMU University Hospital, Ludwig-

Maximilians-Universität, Munich, DE, ¹²Enterome, Paris, FR

09:45 - 10:00 **Invited Discussant 1MO and 2MO**

H. Gelderblom, LUMC - Leids Universitair Medisch Centrum, Leiden, NL

08:30 - 10:00	Type: Special session Title: ESMO meets pharma: Next frontiers in drug discoveries Chair(s): Charles Swanton, GB; Fabrice André, FR	7.3.U - Urval Auditorium
----------------------	---	---------------------------------

08:30 - 08:35 **Introduction**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

08:35 - 08:50 **AI-driven drug discovery**

J.-P. Rameau, Institut Gustave Roussy - INSERM UMR 981, Villejuif, FR

08:50 - 09:05 **Innovation drug discovery**

S. Malek, NIBR - Novartis Institutes for BioMedical Research, Cambridge, US

09:05 - 09:20 **Designing multispecific antibodies: ANKET for antigen-specific activation of NK cells**

E. Vivier, Aix-Marseille University - Faculté de Médecine - Timone, Marseille, FR

09:20 - 09:35 **Cell therapy: Targeting clonal antigen**

S. Quezada, London, GB

09:35 - 10:00 **Discussion**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

08:30 - 10:00 **Type: Young Oncologist session** **7.3.R - Rennes Auditorium**
Title: Young Oncologist Forum: Going on a Research Journey: From grant writing, over PhD to team management
 Chair(s): Alexios Matikas, SE; Kevin Punie, BE

08:30 - 08:50 **How to write a grant/writing your grant application**
J. Mateo, Vall d'Hebron University Hospital, Barcelona, ES

08:50 - 09:10 **Effective time management**
R. Pihlak, The Christie NHS Foundation Trust, Manchester, GB

09:10 - 09:30 **How to move between PhD and medical oncology**
A.S. Berghoff, Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT

09:30 - 09:50 **How to build and manage a research team in a competitive environment**
T. Amaral, Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE

09:50 - 10:00 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

08:30 - 10:00 **Type: EONS session** **7.3.S - Strasbourg Auditorium**
Title: Professional and educational issues in cancer nursing
 Chair(s): Grigorios Kotronoulas, GB

08:30 - 08:45 **RN4CAST data about workforce issues**
A.M. Rafferty, King's College London, London, GB

08:45 - 09:00 **Professional and educational issues in cancer nursing in Eastern European countries**
Z. Vlasisavljevic, The University Clinical Center is in Belgrade, Belgrade, RS

09:00 - 09:15 **ABC4Nurses: Education programme based on Delphi study outcomes**
A. Drury, Trinity College Dublin, Dublin, IE

09:15 - 09:25 **CN37 - Patient and public involvement in research: Reflections and experiences of doctoral cancer nurse researchers in Europe**
 M. Tanay¹, C. Díez De Los Ríos De La Serna², V. Boland³, A. Lopes⁴, M. Dornan⁵, K. Wingfield⁶, G. Yildiz⁷, D. Chircop⁸, G. Suchodolska⁹, B. Kurt¹⁰, S. Colomer-Lahiguera⁴,
¹King's College London, London, GB, ²Barcelona University, Barcelona, ES, ³Trinity College Dublin, Dublin, IE, ⁴Institute of Higher Education and Research in Healthcare - IUFRS, CHUV, Lausanne, CH, ⁵Ulster University, Newtonabbey, GB, ⁶Cardiff University, Cardiff, GB, ⁷Hacettepe University Faculty of Nursing, Ankara, TR, ⁸University of Southampton, Southampton, GB, ⁹Medical University of Gdansk, Gdańsk, PL, ¹⁰Hacettepe University, Ankara, TR

09:25 - 09:35	<p>CN39 - Development of a reference model for patient and public involvement in oncology research in French-speaking Switzerland</p> <p><u>S. Colomer-Lahiguera</u>¹, T. Corbière¹, K. Soukup¹, F. Reeb-Landry¹, A. Addeo², M. Eicher³, ¹Institute of Higher Education and Research in Healthcare - IUFRS, CHUV, Lausanne, CH, ²HUG - Hopitaux Universitaires de Geneve, Geneva, CH, ³CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH</p>	
09:35 - 09:45	<p>CN43 - Addressing the professional and educational issues for the cancer nursing and allied health professions workforce: A collaborative, strategic, UK-wide approach</p> <p>J. Armoogum (On Behalf Of Accend Steering Committee)¹, D. Bell², K. Bowles², K. Campbell³, J. Davis², M. Fores⁴, <u>M. Foulkes</u>⁵, R. Hammond⁶, V. Lavender⁷, S. Lilley⁸, L. Potter⁴, V. Taylor⁹, ¹University of the West of England, Bristol, GB, ²Macmillan Cancer Support, London, GB, ³Edinburgh Napier University, Edinburgh, GB, ⁴Health Education England, x, GB, ⁵Royal Berkshire Hospital - NHS Foundation Trust, Reading, GB, ⁶Circle Health Group, London, GB, ⁷Guy's Cancer Academy - Guy's Hospital, London, GB, ⁸Greater Manchester Cancer, Manchester, GB, ⁹University of Central Lancashire, Preston, GB</p>	
09:45 - 09:55	<p>CN38 - The effect of a mindfulness-based stress reduction program on the pediatric hematology: Oncology nurses' professional quality of life and perceived stress level</p> <p><u>T. Pehlivan</u>¹, R. Semerci², B.B. Çalışkan³, G. Yıldız⁴, N. Altınel⁴, M. Kapancı⁴, ¹Istinye University, Istanbul, TR, ²Trakya University Rektörlüğü, Edirne, TR, ³Beykent University - Beylikduzu Campus, Istanbul, TR, ⁴Medipol Mega Hospitals Complex (University Hospital), Istanbul, TR</p>	
09:55 - 10:00	<p>Q&A and discussion</p> <p><u>A. Speakers</u>, ESMO - European Society for Medical Oncology, Lugano, CH</p>	
09:00 - 10:00	<p>Type: Challenge your Expert Title: Manipulating the microbiome for clinical response Chair(s): Jennifer Wargo, US</p>	7.1.D - Dijon Auditorium
09:00 - 09:15	<p>Presentation by Expert</p> <p><u>E. Elinav</u>, Rehovot, IL</p>	
09:15 - 10:00	<p>Discussion led by Chair</p> <p><u>J. Wargo</u>, Houston, TX, US</p>	

09:00 - 10:00	Type: Challenge your Expert Title: Challenges in the treatment of mesothelioma Chair(s): Anne Tsao, US	7.3.H - Honfleur Auditorium
09:00 - 09:15	Presentation by Expert <u>S. Popat</u> , The Royal Marsden Hospital - NHS Foundation Trust, London, GB	
09:15 - 10:00	Discussion led by Chair <u>A. Tsao</u> , Houston, TX, US	
09:00 - 10:00	Type: Challenge your Expert Title: How to select patients for immunotherapy-based therapy in the first-line treatment for recurrent/metastatic head and neck squamous cell cancer Chair(s): Amanda Psyrri, GR	7.3.T - Toulouse Auditorium
09:00 - 09:15	Presentation by Expert <u>S. Oosting</u> , Groningen, NL	
09:15 - 10:00	Discussion led by Chair <u>A. Psyrri</u> , Attikon University Hospital, Haidari, GR	
10:15 - 11:45	Type: Educational session Title: The current and future of immunotherapy for metastatic NSCLC Chair(s): Natasha Leighl, CA; Pasi Jänne, US	4.A - Antibes Auditorium
10:15 - 10:40	Personalizing first-line immunotherapy: Beyond one size fits all <u>L. Paz-Ares</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
10:40 - 11:05	What's next? Emerging next-generation immunotherapy in lung cancer <u>N. Leighl</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
11:05 - 11:30	Threading the needle: Considerations for immunotherapy in special populations <u>M. Reck</u> , Krankenhaus Grosshansdorf, Grosshansdorf, DE	
11:30 - 11:45	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

10:15 - 11:45	Type: Special symposium Title: Evolving targets and treatment options in oesophagogastric cancer Chair(s): Florian Lordick, DE	4.B - Brest Auditorium
10:15 - 10:20	Introduction and scientific background <u>F. Lordick</u> , Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, DE	
10:20 - 10:35	Challenge of heterogeneity in gastric cancer <u>N. Van Grieken</u> , Amsterdam, NL	
10:35 - 10:50	Advances in HER2-targeted therapy or novel targeted therapies for HER2 <u>K. Shitara</u> , National Cancer Center Hospital East, Kashiwa, JP	
10:50 - 11:05	Emerging molecular targeted therapies <u>V. Gambardella</u> , Hospital Clinico Universitario de Valencia, Valencia, ES	
11:05 - 11:20	Immunotherapy: Present and future <u>F. Lordick</u> , Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, DE	
11:20 - 11:25	Conclusions and perspectives <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
11:25 - 11:45	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
10:15 - 11:45	Type: Proffered Paper session Title: Proffered Paper session 2: Melanoma and other skin tumours Chair(s): Reinhard Dummer, CH; Teresa Petrella, CA	7.1.C - Cannes Auditorium
10:15 - 10:25	7860 - Tumor biomarker analysis from COLUMBUS part 1: Encorafenib & binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma <u>R. Dummer</u> ¹ , N. Pathan ² , S. Deng ³ , C. Robert ⁴ , A.M. Arance Fernandez ⁵ , J.W. De Groot ⁶ , C. Garbe ⁷ , H. Gogas ⁸ , R. Gutzmer ⁹ , I. Krajsova ¹⁰ , G. Liszkay ¹¹ , C. Loquai ¹² , M. Mandala ¹³ , D. Schadendorf ¹⁴ , N. Yamazaki ¹⁵ , A. Di Pietro ¹⁶ , T. Xie ³ , P. Ascierto ¹⁷ , K. Flaherty ¹⁸ , ¹ Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, ² Pfizer, La Jolla, US, ³ Pfizer, San Diego, US, ⁴ Gustave Roussy and Paris-Saclay University, Villejuif, FR, ⁵ Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁶ Isala Oncology Center, Zwolle, NL, ⁷ Universitaets-Hautklinik Tuebingen, Tuebingen, DE, ⁸ National and Kapodistrian University of Athens, Athens, GR, ⁹ Johannes Wesling Medical Center, Ruhr University Bochum Campus Minden, Minden, DE, ¹⁰ University Hospital Prague, Prague, CZ, ¹¹ National Institute of Oncology Hungary, Budapest, HU, ¹² University Medical	

Center of the Johannes Gutenberg University Mainz, Mainz, DE, ¹³University of Perugia, Perugia, IT, ¹⁴University Hospital Essen, West German Cancer Center and German Cancer Consortium, Partner Site Essen, Essen, DE, ¹⁵National Cancer Center - Tsukiji Campus, Chuo-ku, JP, ¹⁶Pfizer, Milan, IT, ¹⁷Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ¹⁸MGH - Massachusetts General Hospital, Boston, US

- 10:25 - 10:35 **7880 - Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy (CheckMate 915)**
G. Long¹, K. Desai², T. Tang³, J. Weber⁴, S. Dolfi², C. Ritchings³, S.-P. Huang², M. Bolisetty³, M. Sausen⁵, M. Del Vecchio⁶, J. Larkin⁷, J. Baden³, D. Balli², H. Chang³, J. Loffredo⁸, N. Zhang⁹, M. Wind-Rotolo¹⁰, D. Tenney², ¹• The University of Sydney, and Royal North Shore and Mater Hospitals, Wollstonecraft, AU, ²Bristol Myers Squibb, Lawrenceville, US, ³Bristol Myers Squibb, Princeton, US, ⁴NYU Grossman School of Medicine, New York City, US, ⁵PGDx - Personal Genome Diagnostics, Baltimore, US, ⁶Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁷The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ⁸Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, US, ⁹Janssen Pharmaceutical Companies of Johnson & Johnson, San Diego, US, ¹⁰Agiros Pharmaceuticals, Inc., Cambridge, US
- 10:35 - 10:45 **Invited Discussant 7860 and 7880**
S. Patel, MD Anderson Cancer Center, Houston, US
- 10:45 - 11:00 **Q&A**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH
- 11:00 - 11:10 **7870 - Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC): Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial**
J.C. Becker¹, S. Ugurel², U. Leiter-Stoppke³, F. Meier⁴, R. Gutzmer⁵, S. Haferkamp⁶, L. Zimmer², E. Livingstone², T. Eigentler⁷, A. Hauschild⁸, F. Kiecker⁹, J. Hassel¹⁰, P. Mohr¹¹, M. Fluck¹², I. Thomas³, M. Garzarolli⁴, I. Grimmelmann¹³, K. Drexler⁶, S. Eckhardt¹⁴, D. Schadendorf², ¹DKFZ - German Cancer Research Center and University Hospital Essen, Essen and Heidelberg, DE, ²University Hospital Essen, Essen, DE, ³Universitäts-Hautklinik Tuebingen, Tuebingen, DE, ⁴Universitätsklinikum Carl Gustav Carus Dresden, Dresden, DE, ⁵Johannes Wesling Medical Center Minden and Ruhr-University Bochum, Minden, DE, ⁶UKR - University Hospital Regensburg, Regensburg, DE, ⁷Charité - Universitätsmedizin Berlin, Berlin, DE, ⁸UK-SH Campus Kiel, Kiel, DE, ⁹Vivantes Klinikum Neukoelln, Berlin, DE, ¹⁰NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE, ¹¹Elbe-Klinikum Buxtehude, Buxtehude, DE, ¹²Fachklinik Hornheide, Münster, DE, ¹³MHH - Medizinische Hochschule Hannover, Hannover, DE, ¹⁴Alcedis GmbH, Giessen, DE
- 11:10 - 11:20 **7890 - Neoadjuvant cemiplimab in patients (pts) with stage II–IV (M0) cutaneous squamous cell carcinoma (CSCC): Primary analysis of a phase II study**
N. Gross¹, D.M. Miller², N. Khushanlani³, V. Divi⁴, E. Ruiz⁵, E. Lipson⁶, F. Meier⁷, Y.B. Su⁸, P.L. Swiecicki⁹, J.L. Atlas¹⁰, J.L. Geiger¹¹, A. Hauschild¹², J.H. Choe¹³, B. Hughes¹⁴,

S.-Y. Yoo¹⁵, K. Fenech¹⁵, M. Mathias¹⁵, H. Han¹⁵, M. Fury¹⁵, D. Rischin¹⁶, ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²Beth Israel Deaconess Medical Center, Boston, US, ³H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ⁴Stanford Cancer Institute, Palo Alto, US, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, US, ⁶Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, ⁷University Hospital Carl Gustav Carus, Dresden, DE, ⁸Nebraska Cancer Specialists, Omaha, US, ⁹University of Michigan, Ann Arbor, US, ¹⁰Carolinas HealthCare System/Atrium Health, Charlotte, US, ¹¹Cleveland Clinic, Sandusky, US, ¹²UK-SH, Campus Kiel, Kiel, DE, ¹³Duke Cancer Institute, Durham, US, ¹⁴Royal Brisbane and Women's Hospital, Herston, AU, ¹⁵Regeneron Pharmaceuticals, Inc., Tarrytown, US, ¹⁶Peter MacCallum Cancer Centre, Melbourne, AU

11:20 - 11:30 **Invited Discussant 7870 and 7890**

C. Blank, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

11:30 - 11:45 **Q&A**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

10:15 - 11:45 Type: Proffered Paper session 7.2.F - Fécamp Auditorium
Title: Proffered Paper session 2: GI, lower digestive
 Chair(s): Myriam Chalabi, NL; Filippo Pietrantonio, IT

10:15 - 10:25 **LBA24 - KRYSTAL-1: Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation**

S. Klempner¹, J. Weiss², M. Pelster³, A. Spira⁴, M. Barve⁵, S.-H. Ou⁶, T. Leal⁷, T. Bekaii-Saab⁸, J. Christensen⁹, T. Kheoh⁹, K. Velastegui⁹, H. Der Torossian⁹, R. Yaeger¹⁰, ¹Massachusetts General Cancer Center, Boston, US, ²University of North Carolina-Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, US, ³Sarah Cannon Research Institute, Nashville, US, ⁴Virginia Cancer Specialists, Fairfax, US, ⁵Mary Crowley Cancer Research Center, Dallas, US, ⁶University of California Irvine, Chao Family Comprehensive Cancer Center, Orange, US, ⁷Winship Cancer Institute, Emory University, Atlanta, US, ⁸Mayo Clinic Cancer Center, Phoenix, US, ⁹Mirati Therapeutics, Inc., San Diego, US, ¹⁰Memorial Sloan Kettering Cancer Center, New York, US

10:25 - 10:35 **3150 - Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort**

Y. Kuboki¹, R. Yaeger², M. Fakih³, J. Strickler⁴, T. Masuishi⁵, E. Kim⁶, C. Bestvina⁷, C. Langer⁸, J. Krauss⁹, S. Puri¹⁰, P. Cardona¹¹, E. Chan¹¹, Q. Tran¹¹, D.S. Hong¹², ¹National Cancer Center Hospital East, Kashiwa, JP, ²Memorial Sloan Kettering Cancer Center, New York, US, ³City of Hope Comprehensive Cancer Center, Duarte, US, ⁴Duke University Medical Center, Durham, US, ⁵Aichi Cancer Center Hospital, Nagoya, JP, ⁶UC Davis Comprehensive Cancer Center, Sacramento, US, ⁷University of Chicago, Chicago, US, ⁸University of Pennsylvania, Philadelphia, US, ⁹University of Michigan, Ann Arbor, US, ¹⁰Huntsman Cancer Institute, Salt Lake City, US, ¹¹Amgen Inc., Thousand Oaks, US, ¹²University of Texas MD Anderson Cancer Center, Houston, US

- 10:35 - 10:45 **Invited Discussant LBA24 and 3150**
M.E. Elez Fernandez, Vall d'Hebron University Hospital, Barcelona, ES
- 10:45 - 11:00 **Q&A**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH
- 11:00 - 11:10 **LBA25 - FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer**
N.A. Dasari¹, S. Lonardi², R. Garcia-Carbonero³, M.E. Elez Fernandez⁴, T. Yoshino⁵, A. Sobrero⁶, J. Yao¹, P. García-Alfonso⁷, J. Kocsis⁸, A. Cubillo Gracian⁹, A. Sartore Bianchi¹⁰, T. Satoh¹¹, V. Randrian¹², J. Tomasek¹³, G. Chong¹⁴, Z. Yang¹⁵, W. Schelman¹⁵, M. Kania¹⁵, J. Tabernero⁴, C. Eng¹⁶, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²Veneto Institute of Oncology IOV-IRCCS Padua, Padova, IT, ³Hospital Universitario 12 de Octubre, Ima 12, UCM, Madrid, ES, ⁴Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁵National Cancer Center Hospital East, Kashiwa, JP, ⁶Azienda Ospedaliera San Martino, Genova, IT, ⁷Hospital Universitario Gregorio Marañón, Madrid, ES, ⁸Bács -Kiskun Megyei Oktatókórház, Kecskemét, HU, ⁹Hospital Universitario Madrid Sanchinarro Centro Integral Oncológico Clara Campal, Madrid, ES, ¹⁰Università degli Studi di Milano, Milan, IT, ¹¹Graduate School of Medicine, Osaka University, Suita, JP, ¹²Poitiers University Hospital, Poitiers, FR, ¹³Masaryk Memorial Cancer Institute, Brno, CZ, ¹⁴Austin Hospital, Heidelberg, AU, ¹⁵HUTCHMED International Inc., Florham Park, US, ¹⁶Vanderbilt Ingram Cancer Center, Nashville, US
- 11:10 - 11:20 **3160 - Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study**
S. Kopetz¹, D. Murphy², J. Pu², R. Yaeger³, F. Ciardiello⁴, J. Desai⁵, E. Van Cutsem⁶, H. Wasan⁷, T. Yoshino⁸, B. Alkuzweny⁹, T. Xie², X. Zhang¹⁰, J. Tabernero¹¹, ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²Pfizer, La Jolla, US, ³Memorial Sloan Kettering Cancer Center, New York, US, ⁴University of Campania Luigi Vanvitelli, Naples, IT, ⁵Peter MacCallum Cancer Centre, Melbourne, AU, ⁶University Hospital Gasthuisberg and University of Leuven, Leuven, BE, ⁷Hammersmith Hospital, Imperial College London, London, GB, ⁸National Cancer Center Hospital East, Kashiwa, JP, ⁹Pfizer, San Diego, US, ¹⁰Pfizer Inc., New York, US, ¹¹Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), UVic-UCC, Barcelona, ES
- 11:20 - 11:30 **Invited Discussant LBA25 and 3160**
F. Pietrantonio, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT
- 11:30 - 11:45 **Q&A**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

10:15 - 11:45	Type: Special symposium Title: Multidisciplinary updates in biomarkers in urinary cancers Chair(s): Andres Acosta, US; Debbie Robbrecht, NL	7.1.D - Dijon Auditorium
10:15 - 10:20	Introduction and scientific background <u>D. Robbrecht</u> , Erasmus MC Cancer Institute, Rotterdam, NL	
10:20 - 10:35	What is new for the pathologist? <u>A. Acosta</u> , Brigham and Women's Hospital, Boston, US	
10:35 - 10:50	ctDNA in bladder and kidney cancers <u>L. Dyrskjot</u> , Aarhus, DK	
10:50 - 11:05	Latest imaging advances in PET and beyond translated to bladder and kidney cancers <u>E.G.E. De Vries</u> , Groningen, NL	
11:05 - 11:20	Microbiome <u>L. Derosa</u> , , FR	
11:20 - 11:25	Conclusions and perspectives <u>A. Acosta</u> , Brigham and Women's Hospital, Boston, US	
11:25 - 11:45	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

10:15 - 11:45	Type: Special symposium Title: Personalized oncology in thyroid cancers: Moving from multi-targeted agents to tumor agnostic indications? Chair(s): Jaume Capdevila Castillon, ES; Marianne Pavel, DE	7.3.H - Honfleur Auditorium
10:15 - 10:20	Introduction and scientific background <u>M. Pavel</u> , Universitätsklinik Erlangen, Erlangen, DE	
10:20 - 10:35	Current management of advanced thyroid cancer in the era of targeted agents <u>D. Führer</u> , Essen, DE	
10:35 - 10:50	Tumor agnostics in thyroid cancer: RET <u>J. Capdevila Castillon</u> , Vall d'Hebron University Hospital, Barcelona, ES	
10:50 - 11:05	Tumor agnostics in thyroid cancer: NTRK, mTOR and immunotherapy <u>L. Locati</u> , ICS Maugeri: Pazienti e Famiglie Istituti Clinici Scientifici - IRCCS Milano, Milan, IT	
11:05 - 11:20	Tumor agnostics in thyroid cancer: BRAF <u>M. Cabanillas</u> , Houston, US	
11:20 - 11:25	Conclusions and perspectives <u>J. Capdevila Castillon</u> , Vall d'Hebron University Hospital, Barcelona, ES	
11:25 - 11:45	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

10:15 - 11:45	Type: Special symposium Title: Detection, characterisation and targeting of minimal residual disease Chair(s): Katerina Politi, US; Sarah-Jane Dawson, AU	7.3.O - Orléans Auditorium
10:15 - 10:20	Introduction and scientific background <u>S.-J. Dawson</u> , Peter MacCallum Cancer Centre, Melbourne, AU	
10:20 - 10:35	Persister cells: What are they, biology and heterogeneity <u>K. Politi</u> , Yale University School of Medicine - Yale Cancer Center, New Haven, US	
10:35 - 10:50	Modelling and targeting MRD in melanoma <u>R. Lee</u> , The University of Manchester, Manchester, GB	
10:50 - 11:05	Updates in circulating tumor cells for cancer monitoring, screening, metastasis and resistance <u>N. Aceto</u> , Zurich, CH	
11:05 - 11:20	MRD and adjuvant clinical trial design <u>S.-J. Dawson</u> , Peter MacCallum Cancer Centre, Melbourne, AU	
11:20 - 11:25	Conclusions and perspectives <u>K. Politi</u> , Yale University School of Medicine - Yale Cancer Center, New Haven, US	
11:25 - 11:45	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

10:15 - 11:45	Type: Special symposium Title: New developments in the management of recurrent/metastatic nasopharyngeal cancer Chair(s): Brigitte Ma, HK; Pierre Blanchard, FR	7.3.T - Toulouse Auditorium
10:15 - 10:20	Introduction and scientific background <u>B. Ma</u> , The Chinese University of Hong Kong, Sha Tin, HK	
10:20 - 10:35	Recent advances in the development of 'liquid biopsy' in early detection and therapeutic monitoring of nasopharyngeal cancer <u>W.K.J. Lam</u> , Prince of Wales Hospital, Sha Tin, HK	
10:35 - 10:50	Pivotal new phase III trials in the first-line setting: Incorporating IO into management <u>D.W.-T. Lim</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
10:50 - 11:05	Second-line and beyond: New targets, new approaches <u>B. Ma</u> , The Chinese University of Hong Kong, Sha Tin, HK	
11:05 - 11:20	Impact of locoregional therapy in the management of recurrent/metastatic NPC <u>P. Blanchard</u> , Institut Gustave Roussy, Villejuif, FR	
11:20 - 11:25	Conclusions and perspectives <u>P. Blanchard</u> , Institut Gustave Roussy, Villejuif, FR	
11:25 - 11:45	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

10:15 - 11:45	Type: Special session Title: In collaboration with the WHO: The impact of COVID-19 on cancer services globally: Challenges and lessons learned Chair(s): Rosa Giuliani, GB; André Ilbawi, CH	7.3.M - Marseille Auditorium
10:15 - 10:20	Introduction and scientific background <u>R. Giuliani</u> , The Clatterbridge Cancer Centre - Aintree, Liverpool, GB	
10:20 - 10:40	Research and innovation in cancer: Understanding the landscape and impact of pandemic <u>I. Soerjomataram</u> , IARC - International Agency for Research on Cancer, Lyon, FR	
10:40 - 11:00	Nearly three years into COVID: Projecting the impact and what we can do better <u>F. Roitberg</u> , ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR	
11:00 - 11:20	Cancer centres and networks: New ways of delivery care during and after the pandemic <u>R. Giuliani</u> , The Clatterbridge Cancer Centre - Aintree, Liverpool, GB	
11:20 - 11:25	Conclusions and perspectives <u>A. Ilbawi</u> , WHO - World Health Organization, Geneva, CH	
11:25 - 11:45	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

10:15 - 11:45	Type: Special session Title: Hard-to-treat cancers: What makes them special? Chair(s): Nicholas McGranahan, GB; Fabrice André, FR	7.3.U - Urval Auditorium
10:15 - 10:35	What defines “born to be bad” cancers? <u>N. Mcgranahan</u> , UCL Cancer Institute - Paul O'Gorman Building, London, GB	
10:35 - 10:55	Small cell lung cancer: How molecular insights have shed light on aggressive clinical behaviour <u>C. Rudin</u> , Memorial Sloan-Kettering Cancer Center, New York, US	
10:55 - 11:15	Dissecting response to treatment in adult patients with a glioma <u>R. Verhaak</u> , Jackson Laboratory for Genomic Medicine, Farmington, US	
11:15 - 11:35	How can we accelerate drug discovery and development for patients with hard-to-treat cancers? <u>E. Garralda</u> , Vall d'Hebron University Hospital, Barcelona, ES	
11:35 - 11:45	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

10:15 - 11:45	Type: EONS session Title: Empowering young cancer nurses academically, clinically and in career progression Chair(s): Bethany Maynard, GB	7.3.S - Strasbourg Auditorium
10:15 - 10:30	Building resilience among young cancer nurses <u>N. Dodlek</u> , KBC Osijek - Clinical Medical Center Osijek, Osijek, HR	
10:30 - 10:45	Supporting young cancer nurses academically <u>R. Semerci</u> , Trakya University Rektorlugu, Edirne, TR	
10:45 - 11:00	Career progression among young cancer nurses <u>B. Maynard</u> , The Royal South Hants Hospital - University Hospital Southampton NHS Foundation Trust, Southampton, GB	
11:00 - 11:10	CN41 - Comparison of professional quality of life, empathy and emotional intelligence in cancer health care professionals: A study of cancer nurses, radiation therapists and oncologists <u>P. Hunt</u> ¹ , M. Gooney ¹ , A. Hennessy ¹ , M. Keenleyside ² , S. Denieffe ¹ , ¹ South East Technological University, Waterford, IE, ² St Patrick's Hospital, Waterford, IE	
11:10 - 11:20	CN42 - The impact of an education WhatsApp group to support nurses working in an acute oncology/haematology setting during the COVID-19 pandemic <u>R.G. Lawless</u> , C. O'Shea, R. Fox, A. Elliott, A. Smullen, N. Anderson, Beaumont Hospital, Dublin, IE	
11:20 - 11:30	CN40 - Nurses' experiences during the COVID-19 pandemic: Multicenter mixed-methods study of coping and resilience strategies <u>L. Cadorin</u> , S. Cedrone, J. Polesel, C. Mazzega Fabbro, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, IT	
11:30 - 11:40	CN26 - Nurses caring for patients at the end of life report affected psychosocial work environment when relocated during the COVID-19 pandemic: A cross-sectional study <u>C. Olsson</u> ¹ , M. Dahlen Granrud ² , M. Tillfors ¹ , C. Bååth ¹ , V. Abrahamsen Grøndahl ³ , A.K. Helgesen ³ , I. Henoch ⁴ , C. Melin-Johansson ⁵ , J. Österlind ⁶ , M. Larsson ¹ , ¹ Karlstad University, Karlstad, SE, ² Inland Norway University of Applied Science, Elverum, NO, ³ Østfold University College, Fredriksta, NO, ⁴ University of Gothenburg - The Sahlgrenska Academy, Göteborg, SE, ⁵ Mid Sweden University, Östersund, SE, ⁶ Marie Cederschiöld University, Stockholm, SE	
11:40 - 11:45	Q&A and discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

10:30 - 11:30 **Type: Multidisciplinary session** **7.2.E - Évry Auditorium**
Title: Who should I test for genetics outside BRCA?
 Chair(s): Matteo Lambertini, IT

- 10:30 - 10:35 **Presentation of case/condition**
M. Lambertini, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT
- 10:35 - 10:50 **What and who to test**
K. Punie, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE
- 10:50 - 11:05 **Systemic treatment implications**
S. Paluch-Shimon, Hadassah University Hospital - Ein Kerem, Jerusalem, IL
- 11:05 - 11:20 **Surgical implications**
P. Dubsy, Onkozentrum Luzern Hirslanden-Klinik St. Anna, Luzern, CH
- 11:20 - 11:30 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

10:30 - 11:45 **Type: Multidisciplinary session** **7.3.G - Grenoble Auditorium**
Title: What is the optimal therapeutic approach in high-risk endometrial cancer?
 Chair(s): Alexandra Leary, FR

- 10:30 - 10:35 **Presentation of case/condition**
A. Leary, Institut Gustave Roussy, Villejuif, FR
- 10:35 - 10:50 **The role of surgery**
C. Marth, Innsbruck Medical University, Innsbruck, AT
- 10:50 - 11:05 **Can the molecular classification inform treatment?**
J. Mcalpine, Vancouver, CA
- 11:05 - 11:20 **What is the optimal adjuvant radiation for high-risk EC?**
S. De Boer, LUMC - Universitair Medisch Centrum, Leiden, NL
- 11:20 - 11:35 **Can the molecular classification guide adjuvant medical treatment?**
A. Leary, Institut Gustave Roussy, Villejuif, FR
- 11:35 - 11:45 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

10:30 - 11:30	Type: Multidisciplinary session Title: Management of brain metastases: Systemic treatment, radiosurgery or both? Chair(s): Giuseppe Minniti, IT	7.3.Q - Quimper Auditorium
10:30 - 10:35	Presentation of case/condition <u>G. Minniti</u> , University of Siena, Siena, IT	
10:35 - 10:50	Systemic treatment as first option <u>R. Bartsch</u> , Medizinische Universitaet Wien, Vienna, AT	
10:50 - 11:05	Do we need combined treatments? <u>S. Formenti</u> , New York, US	
11:05 - 11:20	Management of treatment-related neurological complications <u>E. Le Rhun</u> , University Hospital Zürich, Zurich, CH	
11:20 - 11:30	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
11:00 - 11:45	Type: Young Oncologist session Title: Young Oncologist Brunch 3: Molecular Tumor Board: A luxury or a necessity? Chair(s): Christoph Oing, GB	7.3.R - Rennes Auditorium
11:00 - 11:15	Molecular Tumor Board: A luxury or a necessity? <u>P. Aftimos</u> , Institute Jules Bordet, Brussels, BE	
11:15 - 11:45	Discussion led by Chair <u>C. Oing</u> , Newcastle University, Newcastle upon Tyne, GB	
12:00 - 12:30	Type: Keynote lecture Title: Breast cancer genetics: Where to now? Chair(s): Charles Swanton, GB	4.B - Brest Auditorium
12:00 - 12:05	Introduction by the chair <u>C. Swanton</u> , Francis Crick Institute, London, GB	
12:05 - 12:30	Breast cancer genetics: Where to now? <u>J. Garber</u> , Dana Farber Cancer Institute, Boston, US	

12:00 - 13:30	Type: EONS Industry Satellite Symposium Title: Baxter, Nutricia - Person-centred interprofessional practice in nutrition: Reality or a dream Chair(s): Virpi Sulosaari, FI	7.3.S - Strasbourg Auditorium
12:00 - 12:05	Welcome <u>V. Sulosaari</u> , Turku University of Applied Sciences, Turku, FI	
12:05 - 12:15	Cancer nurses' role and use of clinical guidelines in the nutritional care of people with cancer (EONS) <u>S. Parreira</u> , Hospital CUF Infante Santo, Lisbon, PT	
12:15 - 12:25	Medical oncologists' role and use of clinical guidelines in the nutritional care of people with cancer (ESMO) <u>J. Arends</u> , Universitätsklinikum Freiburg - Klinik für Innere Medizin I/Klinik für Tumorbiologie, Freiburg im Breisgau, DE	
12:25 - 12:35	Oncology dietitians' role and use of clinical guidelines in the nutritional care of people with cancer (EFAD) <u>N. Erickson</u> , LMU - Ludwig Maximilians University of Munich, Munich, DE	
12:35 - 12:45	The use of clinical guidelines in multidisciplinary nutritional care of people with cancer (ESPEN) <u>A. Laviano</u> , Sapienza - Università di Roma, Rome, IT	
12:45 - 12:55	Patient perspective: how can we provide a personalised response to address the individual nutritional needs of people with cancer <u>R. Greene</u> , HungerNdThirst Foundation, Amsterdam, NL	
12:55 - 13:25	Panel discussion <u>V. Sulosaari</u> ¹ , <u>J. Arends</u> ² , <u>R. Greene</u> ³ , <u>S. Parreira</u> ⁴ , <u>A. Laviano</u> ⁵ , <u>N. Erickson</u> ⁶ , ¹ Turku University of Applied Sciences, Turku, FI, ² Universitätsklinikum Freiburg - Klinik für Innere Medizin I/Klinik für Tumorbiologie, Freiburg im Breisgau, DE, ³ HungerNdThirst Foundation, Amsterdam, NL, ⁴ Hospital CUF Infante Santo, Lisbon, PT, ⁵ Sapienza - Università di Roma, Rome, IT, ⁶ LMU - Ludwig Maximilians University of Munich, Munich, DE	
13:25 - 13:30	Conclusion remarks <u>V. Sulosaari</u> , Turku University of Applied Sciences, Turku, FI	

13:00 - 14:30	Type: Industry Satellite Symposium Title: Gilead and Kite Oncology - Break Expectations: Novel approaches in triple-negative and HR+/HER2- metastatic breast cancer Chair(s): Martine Piccart, BE	7.2.F - Fécamp Auditorium
13:00 - 13:05	Welcome and introduction <u>M. Piccart</u> , Institute Jules Bordet, Brussels, BE	
13:05 - 13:20	Stepping into the emerging needs in metastatic breast cancer <u>M. Kok</u> , Netherlands Cancer Institute, Amsterdam, NL	
13:20 - 13:40	Exploring current treatment approaches for triple-negative and HR+/HER2- metastatic breast cancer <u>V. Dieras</u> , Centre Eugene - Marquis, Rennes, FR	
13:40 - 14:05	Expanding possibilities in triple-negative and HR+/HER2- metastatic breast cancer <u>P. Schmid</u> , Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB	
14:05 - 14:25	Audience Q&A <u>M. Piccart</u> ¹ , M. Kok ² , V. Dieras ³ , P. Schmid ⁴ , ¹ Institute Jules Bordet, Brussels, BE, ² Netherlands Cancer Institute, Amsterdam, NL, ³ Centre Eugene - Marquis, Rennes, FR, ⁴ Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB	
14:25 - 14:30	Closing Remarks <u>M. Piccart</u> , Institute Jules Bordet, Brussels, BE	

13:00 - 14:15	Type: Industry Satellite Symposium Title: Seagen - Expert Opinion: Considerations for Managing HER2+ Breast Cancer and Brain Metastases Chair(s): Diana Lüftner, DE	7.1.D - Dijon Auditorium
13:00 - 13:05	Welcome and Introduction <u>D. Lüftner</u> , MHB - Brandenburg Medical School Theodor Fontane - Institute of Social Medicine and Epidemiology, Brandenburg an der Havel, DE	
13:05 - 13:35	The HER2+ breast cancer pathway <u>O. Tredan</u> ¹ , <u>D. Lüftner</u> ² , <u>P.F. Conte</u> ³ , <u>I. Meattini</u> ⁴ , ¹ Centre Léon Bérard, Lyon, FR, ² MHB - Brandenburg Medical School Theodor Fontane - Institute of Social Medicine and Epidemiology, Brandenburg an der Havel, DE, ³ IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁴ AOUC - Azienda Ospedaliero-Universitaria Careggi, Firenze, IT	
13:35 - 13:55	Managing brain metastases <u>P.F. Conte</u> ¹ , <u>D. Lüftner</u> ² , <u>I. Meattini</u> ³ , <u>O. Tredan</u> ⁴ , ¹ IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ² MHB - Brandenburg Medical School Theodor Fontane - Institute of Social Medicine and Epidemiology, Brandenburg an der Havel, DE, ³ AOUC - Azienda Ospedaliero-Universitaria Careggi, Firenze, IT, ⁴ Centre Léon Bérard, Lyon, FR	
13:55 - 14:10	Brain metastases: challenging current perceptions <u>I. Meattini</u> ¹ , <u>D. Lüftner</u> ² , <u>O. Tredan</u> ³ , <u>P.F. Conte</u> ⁴ , ¹ AOUC - Azienda Ospedaliero-Universitaria Careggi, Firenze, IT, ² MHB - Brandenburg Medical School Theodor Fontane - Institute of Social Medicine and Epidemiology, Brandenburg an der Havel, DE, ³ Centre Léon Bérard, Lyon, FR, ⁴ IOV - Istituto Oncologico Veneto IRCCS, Padova, IT	
14:10 - 14:15	Conclusions <u>D. Lüftner</u> , MHB - Brandenburg Medical School Theodor Fontane - Institute of Social Medicine and Epidemiology, Brandenburg an der Havel, DE	

13:00 - 14:30	Type: Industry Satellite Symposium Title: Myriad Genetics - Controversies in breast and ovarian cancer genetics Chair(s): Peter Dubsy, CH	7.3.G - Grenoble Auditorium
13:00 - 13:05	Controversies in breast and ovarian cancer genetics <u>P. Dubsy</u> , Onkozentrum Luzern Hirslanden-Klinik St. Anna, Luzern, CH	
13:05 - 13:20	Should we use genetic signatures for chemotherapy decisions in ER+/HER2-premenopausal patients? <u>A. Constantinidou</u> , Bank of Cyprus Oncology Centre, Nicosia, CY	
13:20 - 13:50	Roundtable discussion <u>P. Dubsy</u> ¹ , <u>L. Teixeira</u> ² , <u>A. Constantinidou</u> ³ , <u>M. Untch</u> ⁴ , ¹ Onkozentrum Luzern Hirslanden-Klinik St. Anna, Luzern, CH, ² Hopital Saint Louis AP-HP, Paris, FR, ³ Bank of Cyprus Oncology Centre, Nicosia, CY, ⁴ Helios Klinikum Berlin-Buch, Berlin, DE	
13:50 - 14:20	Are HRD tests interchangeable? <u>K. Timms</u> , Myriad Genetics Inc, Salt Lake City, US	
14:20 - 14:25	Q&A <u>P. Dubsy</u> ¹ , <u>L. Teixeira</u> ² , <u>M. Untch</u> ³ , <u>A. Constantinidou</u> ⁴ , <u>K. Timms</u> ⁵ , ¹ Onkozentrum Luzern Hirslanden-Klinik St. Anna, Luzern, CH, ² Hopital Saint Louis AP-HP, Paris, FR, ³ Helios Klinikum Berlin-Buch, Berlin, DE, ⁴ Bank of Cyprus Oncology Centre, Nicosia, CY, ⁵ Myriad Genetics Inc, Salt Lake City, US	
14:25 - 14:30	Wrap-up <u>P. Dubsy</u> , Onkozentrum Luzern Hirslanden-Klinik St. Anna, Luzern, CH	

13:00 - 14:30	Type: Industry Satellite Symposium Title: Advanced Accelerator Application, a Novartis Company - From imaging to targeted treatments: Patient journey through the evolving landscape in mCRPC Chair(s): Karim Fizazi, FR	7.3.H - Honfleur Auditorium
13:00 - 13:05	Welcome and introduction <u>K. Fizazi</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
13:05 - 13:25	Navigating the evolving treatment landscape: Therapy sequencing in progressing mCRPC <u>B. Tombal</u> , Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE	
13:25 - 13:40	Patient journey in advanced prostate cancer: Unmet needs and quality of life <u>A. Morgans</u> , Dana Farber Cancer Institute, Boston, US	
13:40 - 13:55	The importance of imaging in managing patients with advanced prostate cancer <u>K. Herrmann</u> , University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE	
13:55 - 14:05	Multidisciplinary team: Addressing patients' needs throughout the treatment journey <u>K. Fizazi</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
14:05 - 14:15	Panel discussion: Treatment decisions in complex cases <u>K. Fizazi</u> ¹ , <u>B. Tombal</u> ² , <u>A. Morgans</u> ³ , <u>K. Herrmann</u> ⁴ , ¹ Institut Gustave Roussy, Villejuif, Cedex, FR, ² Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE, ³ Dana Farber Cancer Institute, Boston, US, ⁴ University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE	
14:15 - 14:30	Live and online Q&A <u>K. Fizazi</u> ¹ , <u>B. Tombal</u> ² , <u>A. Morgans</u> ³ , <u>K. Herrmann</u> ⁴ , ¹ Institut Gustave Roussy, Villejuif, Cedex, FR, ² Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE, ³ Dana Farber Cancer Institute, Boston, US, ⁴ University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE	

13:00 - 14:30	Type: ESMO Colloquium Title: ESMO Colloquium Supported by Daiichi-Sankyo and AstraZeneca: Targeting HER2 in advanced breast cancer: Successes and perspectives Chair(s): Giuseppe Curigliano, IT; Javier Cortés, ES	7.3.O - Orléans Auditorium
13:00 - 13:10	Welcome and introduction <u>G. Curigliano</u> , IEO - Istituto Europeo di Oncologia, Milan, IT	
13:10 - 13:30	Developments in the treatment algorithm of patients with metastatic HER2-amplified/overexpressing breast cancer <u>J. Cortés</u> , Hospital Ruber Internacional, Madrid, ES	
13:30 - 13:50	The promise of novel ADC technologies for the management of patients with HER2-low metastatic breast cancer <u>R. Greil</u> , Paracelsus Medizinische Privatuniversität, Salzburg, AT	
13:50 - 14:10	Novel ADC-based combinations with targeted agents for the continuum of HER2-expressing advanced breast cancer <u>E. Hamilton</u> , Sarah Cannon Research Institute-Cancer Centre, Nashville, US	
14:10 - 14:25	Q&A and discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
14:25 - 14:30	Concluding remarks <u>J. Cortés</u> , Hospital Ruber Internacional, Madrid, ES	

13:00 - 14:30	Type: Industry Satellite Symposium Title: F. Hoffman-La Roche LTD - What, why and how: Expert review and opinions on the potential of oral SERDs for our patients with HR+ BC Chair(s): Nick Turner, GB	7.3.Q - Quimper Auditorium
13:00 - 13:05	Welcome and Introduction <u>N. Turner</u> , London, GB	
13:05 - 13:25	What are oral SERDs and why do our patients need them? <u>K. Jhaveri</u> , Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US	
13:25 - 13:45	What have we seen from oral SERDs and what could they mean for our patients in future? <u>A. Bardia</u> , Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US	
13:45 - 14:05	What's next for oral SERDs and beyond for our patients with HR+ disease? <u>N. Turner</u> , London, GB	
14:05 - 14:25	Q&A <u>N. Turner</u> ¹ , <u>K. Jhaveri</u> ² , <u>A. Bardia</u> ³ , ¹ London, GB, ² Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ³ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US	
14:25 - 14:30	Close <u>N. Turner</u> , London, GB	

13:00 - 14:30	Type: Industry Satellite Symposium Title: Bristol Myers Squibb - The Evolving Treatment Landscape for Metastatic Melanoma: A Clinical Lens on Current Decision Making Chair(s): Paolo Ascierto, IT	7.3.T - Toulouse Auditorium
13:00 - 13:10	Welcome and introduction <u>P. Ascierto</u> , Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT	
13:10 - 13:35	Emerging Data for the First-line Treatment of Metastatic Melanoma <u>N. Meyer</u> , Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR	
13:35 - 14:00	Considerations for Treatment Selection: A Case-Based Panel Discussion <u>H. Tawbi</u> , The University of Texas MD Anderson Cancer Center, Houston, US	
14:00 - 14:25	The Melanoma Continuum of Care: Remaining Challenges and Unmet Needs <u>P. Ascierto</u> , Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT	
14:25 - 14:30	Summary and close <u>P. Ascierto</u> , Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT	

13:00 - 14:30	Type: Patient Advocacy session Title: Supporting Ukraine: The European cancer advocacy community responds Chair(s): Kathy Oliver, GB	7.3.M - Marseille Auditorium
----------------------	--	-------------------------------------

13:00 - 13:15	Welcome and introduction <u>K. Oliver</u> , IBTA - International Brain Tumour Alliance, Tadworth, GB	
13:15 - 13:30	The conflict in Ukraine and its effect on healthcare inequalities in Europe <u>R. Sullivan</u> , Institute of cancer policy, London, GB	
13:30 - 13:45	My story <u>N. Hrad</u> , Kyiv National Linguistic University, Kyiv, UA	
13:45 - 14:00	Serving the adult cancer community of Ukrainian refugees <u>K. Rizvi</u> , YCE - Youth Cancer Europe, Cluj-Napoca, RO	
14:00 - 14:15	The Safer Ukraine Collaborative: Supporting Ukrainian children with cancer affected by war <u>W. Mlynarski</u> , Medical University of Lodz, Lodz, PL	
14:15 - 14:30	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

13:00 - 14:30	Type: Industry Satellite Symposium Title: Sanofi and Regeneron - Decision-Making Discussions: IO in aNSCLC Chair(s): Roy S. Herbst, US	7.3.U - Urval Auditorium
13:00 - 13:10	Welcome and introduction <u>R.S. Herbst</u> , Yale University School of Medicine, New heaven, US	
13:10 - 13:25	The role of biomarkers in selecting first-line therapy in aNSCLC <u>R.S. Herbst</u> , Yale University School of Medicine, New heaven, US	
13:25 - 13:45	First-line therapy in aNSCLC - Clinical cases forum: A case with squamous histology <u>W. Nassib William Junior</u> , Beneficencia Portuguesa de Sao Paulo - BP Mirante, Sao Paulo, BR	
13:45 - 14:05	First-line therapy in aNSCLC - Clinical cases forum: A case of unresectable locally advanced NSCLC, ineligible for surgical resection or definitive chemoradiation <u>B. Besse</u> , Institut Gustave Roussy, Villejuif, FR	
14:05 - 14:25	First-line therapy in aNSCLC - Clinical cases forum: A case with brain metastases at presentation <u>F. Fuchs</u> , Universitätsklinik Erlangen, Erlangen, DE	
14:25 - 14:30	Closing remarks <u>R.S. Herbst</u> , Yale University School of Medicine, New heaven, US	

14:00 - 15:30	Type: EONS Industry Satellite Symposium Title: Roche - Cancer care: there is no place like home? Chair(s): Mary Tanay, GB	7.3.S - Strasbourg Auditorium
14:00 - 14:05	Introduction <u>M. Tanay</u> , King's College London, London, GB	
14:05 - 14:30	Unique national experimentation: Home care and monitoring of cancer patients treated with immunotherapy <u>C. Galvez</u> , Centre Léon Bérard, Lyon, FR	
14:30 - 14:55	Roles and responsibilities of nurses in the delivery of cancer care and treatments at home <u>G. Jones</u> , The Christie NHS Foundation Trust, Manchester, GB	
14:55 - 15:20	An oncology digital placement: preparing the nursing workforce in community care <u>A. Sanneh</u> , The Christie NHS Foundation Trust, Manchester, GB	
15:20 - 15:30	Q&A and Conclusion remarks <u>M. Tanay</u> , King's College London, London, GB	

14:45 - 16:15	Type: Special session Title: Creating a new stage between early and metastatic cancers: Illustration with lung cancers Chair(s): Pasi Jänne, US	4.A - Antibes Auditorium
14:45 - 14:50	Introduction and scientific background <u>P. Jänne</u> , Dana Farber Cancer Institute, Boston, US	
14:50 - 15:10	Novel technologies embracing blood-based biomarkers for early detection <u>A. Frankell</u> , Francis Crick Institute, London, GB	
15:10 - 15:30	Pushing the limit of detection for minimal residual disease <u>M. Diehn</u> , Stanford, US	
15:30 - 15:50	Tools and clinical application of ctDNA in the adjuvant setting <u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
15:50 - 15:55	Conclusions and perspectives <u>P. Jänne</u> , Dana Farber Cancer Institute, Boston, US	
15:55 - 16:15	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
14:45 - 16:15	Type: Educational session Title: Cellular therapies for solid tumours Chair(s): Inge-Marie Svane, DK; John Haanen, NL	4.B - Brest Auditorium
14:45 - 15:10	TILs <u>I.-M. Svane</u> , Herlev and Gentofte Hospital, Herlev, DK	
15:10 - 15:35	Gene-engineered T cells <u>C. Quintarelli</u> , Ospedale Pediatrico Bambino Gesù, Rome, IT	
15:35 - 16:00	Alternative cell therapies <u>U. Kohl</u> , Leipzig, DE	
16:00 - 16:15	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
14:45 - 16:15	Type: Proffered Paper session Title: Proffered Paper session 2: GU tumours, non-prostate Chair(s): Andre Fay, BR; Laurence Albiges, FR	7.1.C - Cannes Auditorium

- 14:45 - 14:55 **LBA68 - Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator's choice of sunitinib or cabozantinib in previously untreated advanced renal cell carcinoma (RCC): Results from a phase III randomized study (PIVOT-09)**
N. Tannir¹, M. Formiga², N. Agarwal³, S. Pal⁴, D. Cho⁵, D. George⁶, W. Hong⁷, L. Tang⁷, A. Qureshi⁸, M. Tagliaferri⁷, J. Zalevsky⁷, K. Penkov⁹, ¹The M.D. Anderson Cancer Center, Houston, US, ²A.C.Camargo Cancer Center - Centro Internacional de Pesquisa (CIPE), Sao Paulo, BR, ³University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US, ⁴City of Hope Comprehensive Cancer Center, Duarte, US, ⁵WMC Cancer Center, Weirton, US, ⁶Duke University Medical Center, Durham, US, ⁷Nektar Therapeutics, San Francisco, US, ⁸Bristol-Myers Squibb, Princeton, US, ⁹Private Medical Institution "Euromedservice", Saint-Petersburg, RU
- 14:55 - 15:05 **LBA73 - Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)**
J. Rosenberg¹, M. Milowsky², C. Ramamurthy³, N. Mar⁴, R.R. McKay⁵, T. Friedlander⁶, C. Ferrario⁷, S. Bracarda⁸, S. George⁹, H. Moon¹⁰, D. Geynisman¹¹, D. Petrylak¹², D. Borchiellini¹³, E. Burgess¹⁴, J.P. Maroto Rey¹⁵, A.-S. Carret¹⁶, Y. Yu¹⁶, M. Guseva¹⁷, B. Homet Moreno¹⁸, P. O'Donnell¹⁹, ¹MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ²University of North Carolina - Chapel Hill, Chapel Hill, US, ³University of Texas Health Science Center San Antonio, San Antonio, US, ⁴UCI Health - University of California Irvine, Orange, US, ⁵UC San Diego, La Jolla, US, ⁶UCSF - University of California San Francisco, San Francisco, US, ⁷Jewish General Hospital, Montreal, CA, ⁸Azienda Ospedaliera Santa Maria, Terni, IT, ⁹Roswell Park Comprehensive Cancer Center, Buffalo, US, ¹⁰Kaiser Permanente - Riverside Medical Center, Riverside, US, ¹¹Fox Chase Cancer Center - Main Campus, Philadelphia, US, ¹²Yale University School of Medicine, New Haven, US, ¹³CENTRE ANTOINE LACASSAGNE, NICE CEDEX, FR, ¹⁴Levine Cancer Institute, Charlotte, US, ¹⁵Hospital de la Santa Creu I Sant Pau, Barcelona, ES, ¹⁶Seagen Inc., Bothell, US, ¹⁷Astellas Pharma USA, Northbrook, US, ¹⁸Merck & Co., Inc., Rahway, US, ¹⁹The University of Chicago, Chicago, US
- 15:05 - 15:15 **Invited Discussant LBA68 and LBA73**
L. Albiges, Institut Gustave Roussy, Villejuif, Cedex, FR
- 15:15 - 15:30 **Q&A**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH
- 15:30 - 15:40 **14470 - Phase II study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC): Cohort 1 of LITESPARK-003**
T. Choueiri¹, T. Bauer², J. Merchan³, R. Figlin⁴, A. Roy⁵, R. Perini⁵, D. Vickery⁵, E. Arrowsmith⁶, ¹Dana-Farber Cancer Institute and Harvard Medical School, Boston, US, ²Sarah Cannon Research Institute and Tennessee Oncology, Nashville, US, ³University of Miami Health System, Miami, US, ⁴Cedars Sinai Medical Center, Los Angeles, US, ⁵Merck & Co., Inc., Rahway, US, ⁶Tennessee Oncology, Chattanooga, US

- 15:40 - 15:50 **14480 - Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)**
L. Albiges¹, H. Gurney², V. Atduev³, C. Suárez⁴, M.A. Climent Duran⁵, D. Pook⁶, P. Tomczak⁷, P. Barthelemy⁸, J.-L. Lee⁹, T. Nalbandian¹⁰, V. Stus¹¹, T. Ferguson¹², P. Wiechno¹³, E. Gokmen¹⁴, L. Lacombe¹⁵, C. Gedye¹⁶, R. Perini¹⁷, M. Sharma¹⁷, C. Li¹⁷, C.-H. Lee¹⁸, ¹Gustave Roussy, Villejuif, FR, ²Macquarie University, Sydney, AU, ³Volga District Medical Center, Federal Medical-Biological Agency, Nizhny Novgorod, RU, ⁴Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, ⁵Instituto Valenciano de Oncología, València, ES, ⁶Monash University, Melbourne, AU, ⁷Poznan University of Medical Sciences, Poznan, PL, ⁸Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ⁹Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ¹⁰Regional Cancer Center, Kharkiv, UA, ¹¹Dnipro State Medical University, Dnipro, UA, ¹²Fiona Stanley Hospital, Perth, AU, ¹³Oncology Center-Institute Marii Sklodowskiej-Curie, Warsaw, PL, ¹⁴Ege University Medical Faculty, Izmir, TR, ¹⁵Centre de Recherche du CHU de Québec, Quebec, CA, ¹⁶University of Newcastle, Callaghan, AU, ¹⁷Merck & Co., Inc., Rahway, US, ¹⁸Memorial Sloan Kettering Cancer Center, New York, US
- 15:50 - 16:00 **Invited Discussant 14470 and 14480**
A. Fay, PUCRS - Escola de Medicina, Porto Alegre, BR
- 16:00 - 16:15 **Q&A**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH
- 14:45 - 16:15 Type: Proffered Paper session 7.2.E - Évry Auditorium**
Title: Proffered Paper session: Head & neck cancer
 Chair(s): Brigitte Ma, HK; Paolo Bossi, IT
- 14:45 - 14:55 **6500 - A phase II study of nivolumab for high-risk oral leukoplakia**
G. Hanna¹, A. Villa², R. Shi¹, A. Oneill¹, M. Liu¹, C. Quinn¹, R. Curtin³, M. Flynn³, N. Treister¹, H. Sroussi¹, P. Vacharotayangul¹, L. Goguen⁴, D. Annino⁴, E. Rettig¹, V. Jo⁴, K. Wong⁴, R. Uppaluri⁴, R. Haddad¹, S.-B. Woo⁴, ¹Dana Farber Cancer Institute, Boston, US, ²UCSF - University of California San Francisco, San Francisco, US, ³Dana Farber Cancer Institute, BOSTON, US, ⁴Brigham and Women's Hospital, Boston, US
- 14:55 - 15:05 **6510 - Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study**
M. Dzienis¹, J. Cundom², C. Fuentes³, A. Hansen⁴, M. Nordlinger⁵, A. Pastor⁶, P. Oppelt⁷, A. Neki⁸, R. Gregg⁹, I. Lima¹⁰, F. Franke¹¹, G. Da Cunha Junior¹², J. Tseng¹³, T. Loree¹⁴, A. Joshi¹⁵, J. Mccarthy¹⁶, N. Naicker¹⁷, Y. Sidi¹⁸, B. Gumuscu¹⁸, G. De Castro Jr.¹⁹, ¹Gold Coast University Hospital (GCUH), Southport, AU, ²IDIM Instituto de Diagnostico e Investigaciones Metabolicas, Buenos Aires, AR, ³Fundacion Respirar, Buenos Aires, AR, ⁴Princess Margaret Cancer Centre, Toronto, CA, ⁵Thomas Jefferson University Hospital, Philadelphia, US, ⁶Hospital Provincial del Centenario, Rosario, AR, ⁷Washington

University School of Medicine, St. Louis, US, ⁸Baptist MD Anderson Cancer Center, Jacksonville, US, ⁹Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, CA, ¹⁰Centro Regional Integrado de Oncologia, Fortaleza, Ceara, BR, ¹¹Oncosite Centro de Pesquisa Clínica em Oncologia, Ijuí, BR, ¹²CETUS Oncologia, Belo Horizonte, Minas Gerais, BR, ¹³Orlando Health Cancer Institute, Orlando, US, ¹⁴Erie County Medical Center, Buffalo, US, ¹⁵The Townsville University Hospital, Douglas, AU, ¹⁶Dr. H. Bliss Murphy Cancer Centre, St. John's, CA, ¹⁷MSD (UK) Limited, London, GB, ¹⁸Merck & Co., Inc., Rahway, US, ¹⁹Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, BR

- 15:05 - 15:15 **Invited Discussant 6500 and 6510**
A. Psyrri, Attikon University Hospital, Haidari, GR
- 15:15 - 15:25 **Q&A**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH
- 15:25 - 15:35 **6520 - Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC)**
H.C. Toh¹, M.-H. Yang², H.-M. Wang³, C.-Y. Hsieh⁴, I. Chitapanarux⁵, K.F. Ho⁶, R.-L. Hong⁷, M.-K. Ang¹, D. Colevas⁸, E. Sirachainan⁹, C. Lertbutsayanukul¹⁰, G.F. Ho¹¹, J. Samol¹², Z. Huang¹³, C. Tan¹³, C. Ding¹³, A. Myo¹⁴, ¹National Cancer Centre Singapore, Singapore, SG, ²Taipei Veterans General Hospital, Taipei City, TW, ³Chang Gung Memorial Hospital-Linkou, Taoyuan City, TW, ⁴China Medical University Hospital, Taichung City, TW, ⁵Chiang Mai University, Chiang Mai, TH, ⁶Mount Miriam Cancer Hospital, Tanjung Bungah, MY, ⁷National Taiwan University Hospital, Taipei, TW, ⁸Stanford University School of Medicine, Stanford, US, ⁹Ramathibodi Hospital, Mahidol University, Bangkok, TH, ¹⁰King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University, Bangkok, TH, ¹¹Universiti Malaya Medical Centre, Kuala Lumpur, MY, ¹²Tan Tock Seng Hospital Singapore, Singapore, SG, ¹³Tessa Therapeutics Ltd, Singapore, SG, ¹⁴Tessa Therapeutics Ltd., Singapore, SG
- 15:35 - 15:45 **6530 - Neoadjuvant nivolumab (N) before chemoradiation (CRT) in high-risk HPV driven oropharynx cancer (OPC) - IMMUNEBOOST-HPV: A multicenter randomized phase II trial**
H. Mirghani¹, C. Even², A. Larive³, H. Pere⁴, J. Fayette⁵, L. Geoffrois⁶, F. Clatot⁷, B. Calderon⁸, Y. Tao², T.V.F. Nguyen³, E. Fabiano⁴, S. Kreps⁴, D. Veyer⁴, J. Puech⁴, C. Badoual¹, F. Garic⁹, A. Auperin³, P. Blanchard³, ¹European George Pompidou Hospital - APHP, Paris, FR, ²Institut Gustave Roussy, Villejuif, Cedex, FR, ³Gustave Roussy - Cancer Campus, Villejuif, FR, ⁴HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, ⁵Centre Léon Bérard, Lyon, FR, ⁶Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, ⁷Centre Henri Becquerel, Rouen, FR, ⁸Institut Sainte-Catherine, Avignon, FR, ⁹Unicancer, Paris, Cedex, FR
- 15:45 - 15:55 **Invited Discussant 6520 and 6530**
L. Licitra, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

15:55 - 16:05 **Q&A**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

14:45 - 15:55 Type: Mini Oral session 7.3.G - Grenoble Auditorium
Title: Mini Oral session: GI, lower digestive
 Chair(s): Per Pfeiffer, DK; Pia Osterlund, FI; Clara Montagut Viladot, ES

14:45 - 14:50 LBA26 - BREAKWATER safety lead-in (SLI): Encorafenib (E) & cetuximab (C) & chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC)

J. Tabernero¹, T. Yoshino², T.W. Kim³, R. Yaeger⁴, J. Desai⁵, H. Wasan⁶, E. Van Cutsem⁷, F. Ciardiello⁸, T. Maughan⁹, C. Eng¹⁰, J. Tie⁵, M.E. Elez Fernandez¹, S. Lonardi¹¹, X. Zhang¹², R. Chavira¹³, T. Usari¹⁴, E. Hahn¹⁵, S. Kopetz¹⁶, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²National Cancer Center Hospital East, Kashiwa, JP, ³Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ⁴Memorial Sloan Kettering Cancer Center, New York, US, ⁵Peter MacCallum Cancer Centre, Melbourne, AU, ⁶Hammersmith Hospital - Imperial College Healthcare NHS Trust, London, GB, ⁷University Hospital Gasthuisberg and University of Leuven, Leuven, BE, ⁸University of Campania Luigi Vanvitelli, Napoli, IT, ⁹Oxford Institute for Radiation Oncology, Oxford, GB, ¹⁰Vanderbilt Ingram Cancer Center, Nashville, US, ¹¹Veneto Institute of Oncology (IOV)-IRCCS, Padova, IT, ¹²Pfizer Inc., Groton, US, ¹³Pfizer Inc, New York, US, ¹⁴Pfizer Inc, Milan, IT, ¹⁵Pfizer, Boulder, US, ¹⁶The University of Texas M. D. Anderson Cancer Center, Houston, US

14:50 - 14:55 LBA27 - Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC

J. Strickler¹, A. Cercek², S. Siena³, T. André⁴, K. Ng⁵, E. Van Cutsem⁶, C. Wu⁷, A. Paulson⁸, J. Hubbard⁹, A. Coveler¹⁰, C. Fountzilas¹¹, A. Kardosh¹², P. Kasi¹³, H.J. Lenz¹⁴, K. Ciombor¹⁵, M.E. Elez Fernandez¹⁶, D. Bajor¹⁷, M. Stecher¹⁸, W. Feng¹⁹, T. Bekaii-Saab²⁰, ¹Duke Cancer Center, Durham, US, ²Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ³ASST Grande Ospedale Metropolitano Niguarda, Milan, IT, ⁴Sorbonne University and Saint-Antoine Hospital, Paris, FR, ⁵Dana Farber Cancer Institute, Boston, US, ⁶University Hospitals Gasthuisberg, Leuven & University of Leuven, Leuven, BE, ⁷Mayo Clinic Cancer Center, Phoenix, US, ⁸Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, US, ⁹Mayo Clinic, Rochester, US, ¹⁰Fred Hutchinson Cancer Center/University of Washington, Seattle, US, ¹¹Roswell Park Comprehensive Cancer Center, Buffalo, US, ¹²OHSU - Oregon Health Science University, Portland, US, ¹³Weill Cornell Medicine, New York, US, ¹⁴USC Norris Comprehensive Cancer Center, Los Angeles, US, ¹⁵Vanderbilt Ingram Cancer Center, Nashville, US, ¹⁶Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, ES, ¹⁷Case Western Reserve University / University Hospitals, Cleveland, US, ¹⁸Seagen Inc., Seattle, US, ¹⁹Seagen Inc., Bothell, US, ²⁰Mayo Clinic, Scottsdale, US

14:55 - 15:05 Invited Discussant LBA26 and LBA27

P. Pfeiffer, OUH - Odense University Hospital, Odense, DK

- 15:05 - 15:10 **317MO - Efficacy of oxaliplatin-based adjuvant chemotherapy in older patients with stage III colon cancer: An ACCENT/IDEA pooled analysis of 12 trials**
C. Gallois¹, Q. Shi², J. Meyers², T. André³, T. Iveson⁴, A. Sobrero⁵, S. Alberts², A. De Gramont⁶, J. Meyerhardt⁷, A. Shields⁸, T. Georges⁹, H.J. Schmoll¹⁰, I. Souglakos¹¹, R. Kerr¹², S. Lonardi¹³, G. Yothers¹⁴, T. Yoshino¹⁵, R. Goldberg¹⁶, J. Taieb¹⁷, D. Papamichael¹⁸, ¹HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, ²Mayo Clinic, Rochester, US, ³Hopital Saint-Antoine, Paris, FR, ⁴Southampton General Hospital, Southampton, GB, ⁵IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ⁶Franco-britannique hospital, paris, FR, ⁷Dana Farber Cancer Institute, Boston, US, ⁸Karmanos Cancer Institute, Detroit, US, ⁹UF - University of Florida Health, Gainesville, US, ¹⁰UKH - Universitätsklinikum Halle (Saale), Halle (Saale), DE, ¹¹University General Hospital of Heraklion, Heraklion, GR, ¹²Churchill Hospital, Oxford, GB, ¹³IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ¹⁴University of Pittsburgh, Pittsburgh, US, ¹⁵National Cancer Center Hospital East, Kashiwa, JP, ¹⁶West Virginia University, Morgantown, US, ¹⁷Hopital European George Pompidou, Paris, FR, ¹⁸Bank of Cyprus Oncology Centre, Nicosia, CY
- 15:10 - 15:15 **318MO - Circulating tumour DNA (ctDNA) dynamics, CEA and sites of recurrence for the randomised DYNAMIC study: Adjuvant chemotherapy (ACT) guided by ctDNA analysis in stage II colon cancer (CC)**
J. Tie¹, J. Cohen², K. Lahouel², S. Lo³, Y. Wang², R. Wong⁴, J. Shapiro⁵, S. Harris⁶, A. Khattak⁷, M. Burge⁸, L. Horvath⁹, C. Karapetis¹⁰, J. Shannon¹¹, M. Singh¹², D. Yip¹³, N. Papadopoulos², C. Tomasetti², K. Kinzler², B. Vogelstein², P. Gibbs¹⁴, ¹Peter MacCallum Cancer Centre, Melbourne, AU, ²Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, ³The University of Sydney School of Public Health, Sydney, AU, ⁴Eastern Health - Box Hill Hospital - Main Entrance, Box Hill, AU, ⁵Cabrini Health - Malvern, Malvern, AU, ⁶Bendigo Health, Bendigo, AU, ⁷Fiona Stanley Hospital, Murdoch, AU, ⁸Royal Brisbane and Women's Hospital, Herston, AU, ⁹Chris O'Brien Lifehouse, Camperdown, AU, ¹⁰Flinders Centre for Innovation in Cancer, Bedford Park, AU, ¹¹Nepean Cancer Care Centre, Kingswood, AU, ¹²Barwon Health Andrew Love Cancer Centre, Geelong, AU, ¹³The Canberra Hospital, Garran, AU, ¹⁴Walter and Eliza Hall Institute of Medical Research, Parkville, AU
- 15:15 - 15:20 **319MO - Real-world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer**
S. Cohen¹, P. Kasi², V. Aushev³, D. Hanna⁴, G. Botta⁵, S. Sharif⁶, G. Laliotis³, S. Sharma³, V. Sharma⁷, A. Alqahtani⁸, S. Chandana⁹, S. Kang¹⁰, S. Chakrabarti¹¹, B. Somer¹², A. Kasi¹³, F. Dayyani¹⁴, M. Malla¹⁵, A. Jurdi³, A. Aleshin³, S. Kopetz¹⁶, ¹University of Washington and Fred Hutchinson Cancer Center, Seattle, US, ²Weill Cornell Medicine, Engländer Institute of Precision Medicine, New York Presbyterian Hospital, New York City, US, ³Natera, Inc., Austin, US, ⁴USC - University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, US, ⁵UCSD Moores Cancer Center, La Jolla, US, ⁶University of Iowa Holden Comprehensive Cancer Center, Iowa City, US, ⁷James Graham Brown Cancer Center, Louisville, US, ⁸Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center - Georgetown University Medical Center, Washington DC, US, ⁹Cancer and Hematology Centers of Western Michigan, Grand Rapids, US, ¹⁰Winship Cancer Institute of Emory University, Atlanta, US, ¹¹Medical College of Wisconsin, Milwaukee, US, ¹²West Cancer Center, Germantown, US, ¹³KUMC - University of Kansas Medical Center, Kansas City, US,

¹⁴University of California Irvine Chao Family Comprehensive Cancer Center, Orange, US, ¹⁵West Virginia University Cancer Institute, Morgantown, US, ¹⁶The University of Texas M. D. Anderson Cancer Center, Houston, US

- 15:20 - 15:35 **Invited Discussant 317MO, 318MO and 319MO**
C. Montagut Viladot, Hospital del Mar - Parc de Salut Mar, Barcelona, ES
- 15:35 - 15:40 **320MO - A phase I clinical trial of regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy resistant MSS metastatic colorectal cancer (mCRC)**
M. Fakihi, J. Sandhu, D. Lim, S. Li, C. Wang, City of Hope Comprehensive Cancer Center, Duarte, US
- 15:40 - 15:45 **LBA28 - Prognostic effect of imaging and CEA follow-up in resected colorectal cancer (CRC): Final results and relapse free survival (RFS) - PRODIGE 13 a FFCD phase III trial**
C. Lepage¹, J.M. Phelip², L. Cany³, E. Barbier⁴, S. Manfredi⁵, P. Deguiral⁶, R. Faroux⁷, M. Baconnier⁸, D. Pezet⁹, E. Terrebbonne¹⁰, A. Adenis¹¹, M. Ben Abdelghani¹², J.F. Ain¹³, G. Breysacher¹⁴, I. Boillot Benedetto¹⁵, A. Pelaquier¹⁶, A. Lievre⁵, P. Laurent Puig¹⁷, F. Bibeau¹⁸, O. Bouche¹⁹, ¹CHU Dijon, Dijon, FR, ²CHU Saint Etienne - Hopital Nord, Saint-Étienne, FR, ³Clinique Francheville, Périgueux, FR, ⁴Fédération Francophone de Cancérologie Digestive, Dijon, FR, ⁵CHU de Rennes - Hopital Pontchaillou, Rennes, Cedex, FR, ⁶Clinique Mutualiste de l'Estuaire, Saint-Nazaire, FR, ⁷CHD Vendee - Hopital Les Oudairies, La Roche-sur-Yon, FR, ⁸CH Annecy Genevois, Annecy, FR, ⁹CHU Estaing, Clermont-Ferrand, FR, ¹⁰CHU Bordeaux - Hopital St. André, Bordeaux, FR, ¹¹ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, ¹²ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ¹³polyclinique val de saone, Macon, FR, ¹⁴Hopital Louis Pasteur, Colmar, FR, ¹⁵Saint joseph-Saint Luc, Lyon, FR, ¹⁶Centre Hospitalier Montelimar Service de Oncologie, Montelimar, FR, ¹⁷Paris Descartes University, Paris, FR, ¹⁸CHU de Caen - Hopital Cote de Nacre, Caen, FR, ¹⁹CHU de Reims - Hôpital Robert Debré, Reims, Cedex, FR
- 15:45 - 15:55 **Invited Discussant 320MO and LBA28**
P. Osterlund, Tampere University Hospital (Tays), Tampere, FI
- 14:45 - 16:15 Type: Mini Oral session 7.3.0 - Orléans Auditorium**
Title: Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies
Chair(s): Luis Paz-Ares, ES; Kersti Oselin, EE; Mariam Jamal-Hanjani, GB
- 14:45 - 14:50 **1529MO - The genomic landscape of small cell lung cancer in never smoking patients**
M. Oh¹, A. Barrett², A. Ashok², E. Mauer², E. Garon¹, A. Lisberg¹, A. Cummings¹, J. Goldman¹, ¹UCLA - David Geffen School of Medicine, Los Angeles, US, ²Tempus Labs, Inc., Chicago, US
- 14:50 - 14:55 **930MO - PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091**

S. Peters¹, B. Besse², S. Marreaud³, U. Dafni⁴, K. Oselin⁵, L. Havel⁶, E. Esteban Gonzalez⁷, D. Isla⁸, A. Martinez-Marti⁹, M. Faehling¹⁰, M. Tsuboi¹¹, J.-S. Lee¹², K. Nakagawa¹³, J. Yang¹⁴, S. Keller¹⁴, M. Mauer³, N. Jha³, R.A. Stahel¹⁵, L. Paz-Ares¹⁶, M. O'Brien¹⁷, ¹Lausanne University Hospital, Lausanne, CH, ²Institut Gustave Roussy, Villejuif, FR, ³European Organisation for Research and Treatment of Cancer, Headquarters, Brussels, BE, ⁴National and Kapodistrian University of Athens and Frontier Science Foundation Hellas, Athens, GR, ⁵North Estonia Medical Centre, Tallinn, EE, ⁶Charles University and Thomayer Hospital, Prague, CZ, ⁷Hospital Universitario Central de Asturias, Oviedo, ES, ⁸University Hospital Lozano Blesa, IIS Aragon, Zaragoza, ES, ⁹Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, ES, ¹⁰Klinikum Esslingen, Esslingen, DE, ¹¹National Cancer Center Hospital East, Kashiwa, JP, ¹²Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, KR, ¹³Kindai University Faculty of Medicine, Osaka, JP, ¹⁴Merck & Co., Inc., Rahway, US, ¹⁵European Thoracic Oncology Platform, Bern, CH, ¹⁶Hospital Universitario 12 de Octubre, CNIO & Universidad Complutense, Madrid, ES, ¹⁷The Royal Marsden Hospital - Chelsea, London, GB

14:55 - 15:00

933MO - Longitudinal monitoring of circulating tumor DNA from plasma in patients with curative resected stage IA-IIIA EGFR mutant non-small cell lung cancer

M.-J. Ahn¹, H.A. Jung¹, B.M. Ku², Y.J. Kim², S. Park¹, J.-M. Sun¹, S.-H. Lee¹, J.S. Ahn¹, J.H. Cho², H.K. Kim², Y.S. Choi², J. Kim², ¹Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ²Samsung Medical Center (SMC), Seoul, KR

15:00 - 15:15

Invited Discussant 1529MO, 930MO and 933MO

A. Passaro, IEO - Istituto Europeo di Oncologia, Milan, IT

15:15 - 15:20

LBA71 - First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743

G. Zalcman¹, Y. Oulkhair², R. Cornelissen³, L. Greillier⁴, J. Rodriguez Cid⁵, J. Mazieres⁶, P. Briggs⁷, A. Nowak⁸, A. Tsao⁹, N. Fujimoto¹⁰, S. Peters¹¹, A. Mansfield¹², S. Popat¹³, A. Nassar¹⁴, J. Bushong¹⁴, N. Hu¹⁴, T. Spires¹⁴, D. Balli¹⁴, L. Eccles¹⁴, P. Baas¹⁵, ¹Bichat-Claude Bernard University Hospital, AP-HP, Université de Paris, Paris, FR, ²Hôpital Côte de Nacre C H U Caen, Caen, FR, ³Erasmus MC Cancer Institute, Rotterdam, NL, ⁴Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Marseille, FR, ⁵Instituto Nacional de Enfermedades Respiratorias, Mexico City, MX, ⁶Service de Pneumologie, Centre Hospitalier Universitaire de Toulouse - Hôpital Larrey, Université Paul Sabatier, Toulouse, FR, ⁷Monash Medical Centre, Clayton, AU, ⁸University of Western Australia and Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, AU, ⁹MD Anderson Cancer Center, Houston, US, ¹⁰Okayama Rosai Hospital, Okayama, JP, ¹¹Lausanne University Hospital, Lausanne, CH, ¹²Mayo Clinic, Rochester, US, ¹³Royal Marsden Hospital, London, GB, ¹⁴Bristol Myers Squibb, Princeton, US, ¹⁵Netherlands Cancer Institute and Leiden University Medical Center, Amsterdam, NL

15:20 - 15:25

931MO - Final overall survival analysis of phase III study of pemetrexed/cisplatin versus vinorelbine/cisplatin for completely resected non-squamous non-small cell lung cancer: The JIPANG Study

K. Yoh¹, H. Kenmotsu², N. Yamamoto³, T. Misumi⁴, T. Takahashi², H. Saito⁵, S.

Sugawara⁶, K. Yamazaki⁷, K. Nakagawa⁸, K. Sugio⁹, T. Seto¹⁰, S. Toyooka¹¹, H. Date¹², T. Mitsudomi¹³, I. Okamoto¹⁴, K. Yokoi¹⁵, H. Saka¹⁶, H. Okamoto¹⁷, Y. Takiguchi¹⁸, M. Tsuboi¹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Shizuoka Cancer Center, Shizuoka, JP, ³Wakayama Medical University, Wakayama, JP, ⁴National Cancer Center Hospital East, Kashiwa, Japan, Kashiwa, JP, ⁵Kanagawa Cancer Center, Yokohama, JP, ⁶Sendai Kousei Hospital, Sendai, JP, ⁷National Hospital Organization Kyushu Medical Center, Fukuoka, JP, ⁸Kindai University School of Medicine - Main Campus, Osaka, JP, ⁹Oita University, Yufu, JP, ¹⁰National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, ¹¹Okayama University Graduate School of Medicine, Okayama, JP, ¹²Kyoto University Graduate School of Medicine, Kyoto, JP, ¹³Kindai University - Faculty of Medicine, Osaka, JP, ¹⁴Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, ¹⁵Nagoya University, Graduate School of Medicine, Nagoya, JP, ¹⁶Matsunami General Hospital, Gifu, JP, ¹⁷Yokohama Municipal Citizen's Hospital, Yokohama, JP, ¹⁸Chiba University, School of Medicine, Chiba, JP

15:25 - 15:40 **Invited Discussant LBA71 and 931MO**

L. Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, ES

15:40 - 15:45 **929MO - Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small cell lung cancer (NSCLC): Pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study**

J. Spicer¹, T. Cascone², G. Kar³, Y. Zheng⁴, J. Blando⁴, T.H. Tan⁵, M. Cheng⁴, R. Mager⁴, O. Hamid⁴, Y. Soo-Hoo⁴, P. Forde⁶, W. Weder⁷, M.R. Garcia Campelo⁸, I. Grenga⁴, R. Kumar⁴, L. Mcgrath³, ¹McGill University, Montreal, CA, ²The University of Texas M. D. Anderson Cancer Center, Houston, US, ³AstraZeneca, Waltham, US, ⁴AstraZeneca, Gaithersburg, US, ⁵AstraZeneca, Munich, DE, ⁶Johns Hopkins University, Baltimore, US, ⁷Privatklinik Bethanien, Zurich, CH, ⁸Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES

15:45 - 15:50 **932MO - Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816**

E. Felip¹, C. Wang², T.-E. Ciuleanu³, G. Saylor⁴, F. Tanaka⁵, K.-N. Chen⁶, H. Ito⁷, N. Girard⁸, S. Lu⁹, M. Provencio Pulla¹⁰, T. Mitsudomi¹¹, M. Awad¹², P. Forde¹³, R. Lawrance¹⁴, F. Taylor¹⁵, G. Worthy¹⁶, S. Blum¹⁷, L. Vo¹⁷, J.L. Cai¹⁷, J. Spicer¹⁸, ¹Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, ES, ²Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ³Institutul Oncologic Prof Dr Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, RO, ⁴Charleston Oncology, Charleston, US, ⁵University of Occupational and Environmental Health, Kitakyushu, JP, ⁶Peking University School of Oncology, Beijing Cancer Hospital, Beijing, CN, ⁷Kanagawa Cancer Center, Yokohama, JP, ⁸Institut du Thorax Curie-Montsouris, Institut Curie, Paris, FR, ⁹Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, CN, ¹⁰Hospital Universitario Puerta de Hierro, Madrid, ES, ¹¹Kindai University Hospital, Osaka, JP, ¹²Dana-Farber Cancer Institute, Boston, US, ¹³Johns Hopkins Kimmel Cancer Center, Baltimore, US, ¹⁴Adelphi Values, Macclesfield, GB, ¹⁵Adelphi Values, Boston, US, ¹⁶Adelphi Values, Bollington, GB, ¹⁷Bristol Myers Squibb, Princeton, US, ¹⁸McGill University Health Center, Montreal, CA

- 15:50 - 15:55 **LBA50 - Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816**
J. Deutsch¹, A. Cimino-Mathews¹, E.D. Thompson¹, D. Wang¹, R.A. Anders¹, E. Gabrielson¹, P. Illei¹, J. Jedrych¹, L. Danilova¹, J. Spicer², M. Provencio Pulla³, P. Forde⁴, D. Pandya⁵, M. Tran⁵, J. Fiore⁵, V. Devas⁵, T.R. Cottrell¹, A.S. Baras¹, J. Taube¹, ¹Johns Hopkins University SOM, Baltimore, US, ²McGill University Health Centre, Montreal, CA, ³Hospital Universitario Puerta de Hierro, Madrid, ES, ⁴Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, US, ⁵Bristol Myers Squibb, Princeton, US
- 15:55 - 16:10 **Invited Discussant 929MO, 932MO and LBA50**
K. Oselin, North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla), Tallinn, EE
- 14:45 - 16:15** **Type: Mini Oral session** **7.3.T - Toulouse Auditorium**
Title: Mini Oral session: Haematological malignancies
Chair(s): Maria Gomes da Silva, PT; Irit Avivi, IL
- 14:45 - 14:50 **623MO - Machine learning-based prediction of germinal center, MYC/BCL2 double protein expressor status, and MYC rearrangement from whole slide images in DLBCL patients**
C. Syrykh¹, J.-B. Schiratti², E. Brion², C. Joubert³, M. Baia³, L. Marlot⁴, C. Maussion², L.-W. Danneaux², S. Bologna⁵, J. Briere⁶, P. Dartigues⁷, P. Gaulard⁸, C. Haioun⁸, F. Jardin⁹, T. Molina¹⁰, H. Tilly⁹, E. Gomez⁴, D. Sondaz⁴, C. Copie-Bergman¹¹, C. Laurent¹, ¹IUCT Oncopole, LYSA, Toulouse, FR, ²OWKIN, Paris, FR, ³LYSARC (The Lymphoma Academic Research Organisation), Pierre-Bénite, FR, ⁴Institut CARNOT CALYM, Pierre-Bénite, FR, ⁵CHU Brabois, Vandoeuvre-lès-Nancy, FR, ⁶Hôpital St Louis, Paris, FR, ⁷INSTITUT GUSTAVE ROUSSY, Villejuif, FR, ⁸Centre Hospitalier Universitaire Henri-Mondor AP-HP, Créteil, FR, ⁹Centre Henri Becquerel, Rouen, FR, ¹⁰Institut Necker Enfants Malades, Paris, FR, ¹¹LYSA (The Lymphoma Study Association), Pierre-Bénite, FR
- 14:50 - 14:55 **624MO - Retrospective analysis of clinical value of ctDNA in newly diagnosed diffuse large B cell lymphoma**
T. Guan, M. Zhang, L. Su, Shanxi Provincial Cancer Hospital, Taiyuan, CN
- 14:55 - 15:05 **Invited Discussant 623MO and 624MO**
I. Avivi, Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL
- 15:05 - 15:10 **625MO - Combination of mitoxantrone hydrochloride liposome with pegaspargase in patients with extranodal NK/T-cell lymphoma: A phase I/II clinical trial**
Y. Huang¹, T. Wu¹, Y. Hu¹, Y. Li², J. Ma³, Y. Guo⁴, H. Zhou⁵, R. Yang⁶, Y. Gong⁷, Q.Y. Zhang⁸, L.E. Lin⁹, R. Zhou¹⁰, Y. Liu¹⁰, Z. Pan¹⁰, J. Xue¹¹, D. Wang¹¹, ¹Affiliated Hospital of Guizhou Medical University, Guiyang, CN, ²Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ³The First Affiliated Hospital of Guangxi Medical University, Nanning, CN, ⁴The First Affiliated Hospital of Henan

University of Science and Technology, Luoyang, CN, ⁵Hunan Cancer Hospital, Changsha, CN, ⁶Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, CN, ⁷Chongqing University Cancer Hospital, Chongqing, CN, ⁸3rd Affiliated Hospital of Harbin Medical University, Harbin, CN, ⁹Hainan General Hospital, Haikou, CN, ¹⁰CSPC Pharmaceutical Group Ltd., Shijiazhuang, CN, ¹¹CSPC Zhongqi Pharmaceutical Technology Co., Ltd, Shijiazhuang, CN

- 15:10 - 15:15 **626MO - Incidence of cardiovascular disease in Swedish healthy blood stem cell donors**
S. Pahnke, H. Hägglund, G. Larfors, Unit of haematology, UPPSALA, SE
- 15:15 - 15:20 **627MO - Orelabrutinib plus RCHOP for previously untreated non-germinal center b cell-like (GCB) diffuse large b cell lymphoma (DLBCL) patients with extranodal disease**
M. Wang, Q. Ke, Z. Li, D. Zhou, C. Liao, J. Sun, B. Guo, H. Cen, Guangxi Medical University Affiliated Tumor Hospital and Oncology Medical Center, Nanning, CN
- 15:20 - 15:35 **Invited Discussant 625MO, 626MO and 627MO**
M. Gomes Da Silva, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, PT
- 15:35 - 15:40 **621MO - Preclinical study of DASH CAR-T cells manufactured in 48 hours**
H. Wang, S.-T. Tsao, Q. Xiong, M. Gu, C. Fu, X. Li, M. Zhang, N. Li, H.-M. Hu, Hrain Biotechnology Co., Ltd., Shanghai, CN
- 15:40 - 15:45 **622MO - An asymmetrical CLL1/CD3 bispecific antibody, ABL602, exhibits CLL1 binding-dependent CD3 binding/activation and antitumor activity in acute myeloid leukemia (AML) mouse model and leukemia blasts from AML patients**
E. Lee¹, Y. Lim¹, S. Lee¹, S. Park¹, H. Park¹, Y. Koh², D. Shin², J. Won¹, ¹ABL Bio, Inc., Seongnam, KR, ²SNUH - Seoul National University Hospital, Seoul, KR
- 15:45 - 15:55 **Invited Discussant 621MO and 622MO**
I. Avivi, Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL

14:45 - 16:15 Type: Mini Oral session 7.3.U - Urval Auditorium
Title: Mini Oral session: Sarcoma
Chair(s): Sebastian Bauer, DE; Herbert Ho Fung Loong, HK; Javier Martin-Broto, ES

- 14:45 - 14:50 **1488MO - Initial results of phase II/III trial of AL102 for treatment of desmoid tumors (DT)**
M. Gounder¹, R. Jones², R. Chugh³, M. Agulnik⁴, A. Singh⁵, B. Van Tine⁶, V. Andelkovic⁷, E. Choy⁸, J. Lewin⁹, R. Ratan¹⁰, J. Kaplan¹¹, J. Yovell¹², G. Gordon¹¹, B. Kasper¹³, ¹Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ²The Royal Marsden NHS Foundation Trust + Institute of Cancer Research, London, GB, ³University of Michigan, Ann Arbor, US, ⁴City of Hope Comprehensive Cancer Center, Duarte, US,

⁵UCLA, Los Angeles, US, ⁶Washington University School of Medicine in St. Louis, St. Louis, US, ⁷Gold Coast University Hospital (GCUH), Southport, AU, ⁸Massachusetts General Hospital Cancer Center, Boston, US, ⁹Peter MacCallum Cancer Centre, Melbourne, AU, ¹⁰MD Anderson Cancer Center, Houston, US, ¹¹Ayala Pharmaceuticals, Northbrook, US, ¹²Ayala Pharmaceuticals, Rehovot, IL, ¹³UMM - Universitaetsklinikum Mannheim, Mannheim, DE

- 14:50 - 14:55 **1489MO - A phase Ib/II study of selinexor as single agent and in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST/GEIS-41 trial**
C. Serrano¹, C.M. Valverde Morales², J. Cruz Jurado³, J. Martinez Trufero⁴, J. Martinez-Garcia⁵, S. Roche⁶, A. Redondo Sanchez⁷, M. Giuppi⁸, B. Suarez⁸, C. Romagosa⁶, V. Martinez⁷, ¹Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Hospital Universitario de Canarias, San Cristobal de la Laguna, ES, ⁴Hospital Universitario Miguel Servet, Zaragoza, ES, ⁵Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, ES, ⁶Hospital Universitario Vall d'Hebron, Barcelona, ES, ⁷Hospital Universitario La Paz, Madrid, ES, ⁸GEIS - Grupo Español de Investigación de Sarcomas, Madrid, ES
- 14:55 - 15:00 **1486MO - The synovial and systemic pharmacokinetics and pharmacodynamics of intra-articular administration of the CSF1 receptor antibody AMB-05X in a phase II proof-of-concept trial in tenosynovial giant cell tumor**
H. Gelderblom¹, M. Huang², M. Van De Sande³, T. Scharschmidt⁴, O. Kostogryz⁵, L. Alani², T. Huang², L. Hsu², K. Johnson², ¹LUMC - Leids Universitair Medisch Centrum, Leiden, NL, ²AmMax Bio, Redwood City, US, ³Leiden University Medical Center, Leiden, NL, ⁴Ohio State University Medical Center, Columbus, US, ⁵Institute of Traumatology and Orthopedics of NAMS, Kiev, UA
- 15:00 - 15:15 **Invited Discussant 1488MO, 1489MO and 1486MO**
S. Bauer, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE
- 15:15 - 15:20 **1490MO - CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT PMO-1601)**
M.-V. Teleanu¹, C. Heilig¹, R. Hamacher², S. Bauer², R. Mayer-Steinacker³, V.I. Gaidzik³, P. Horak¹, L.-M. Lanz¹, T. Muskatewitz¹, H. Süsse¹, A. Freitag¹, M. Von Hornung¹, L. Wacker¹, C. Von Kalle⁴, T. Barth³, S. Fröhling¹, R. Schlenk¹, ¹German Cancer Research Center - National Center for Tumor Diseases (NCT), Heidelberg, DE, ²West German Cancer Center, University Hospital Essen, Essen, DE, ³Ulm University Hospital, Ulm, DE, ⁴Berlin Institute of Health, Berlin, DE
- 15:20 - 15:25 **1491MO - New benchmarks for designing clinical trials in advanced or metastatic liposarcoma (LPS) or synovial sarcoma (SS): An EORTC soft tissue and bone sarcoma group meta-analysis**
G. Kantidakis¹, S. Litiere¹, A. Neven², M. Vinches³, I. Judson⁴, J.-Y. Blay⁵, E. Wardelmann⁶, S. Stacchiotti⁷, L. D'Ambrosio⁸, S. Marreaud¹, W. Van Der Graaf⁹, B. Kasper¹⁰, M. Fiocco¹¹, H. Gelderblom¹¹, ¹EORTC Headquarters, Brussels, BE, ²Luxembourg Institute of Health, Strassen, LU, ³Institut du Cancer de Montpellier (ICM), Montpellier, Cedex, FR, ⁴Institute of Cancer Research, London, GB, ⁵Centre Léon Bérard,

Lyon, FR, ⁶University Hospital Muenster-Gerhard Domagk Institute of Pathology, Muenster, DE, ⁷Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT, ⁸IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, ⁹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ¹⁰UMM - Universitaetsklinikum Mannheim, Mannheim, DE, ¹¹Leiden University Medical Center (LUMC), Leiden, NL

- 15:25 - 15:35 **Invited Discussant 1490MO and 1491MO**
H.H.F. Loong, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK
- 15:35 - 15:40 **1487MO - A pan-sarcoma investigation of genetic alterations associated with high telomeric content**
R. Sharaf¹, D. Jin¹, J. Grady², G. Frampton¹, L. Albacker¹, D. Thomas², M. Montesion¹,
¹Foundation Medicine, Inc, Cambridge, US, ²Garvan Institute of Medical Research, Darlinghurst, AU
- 15:40 - 15:45 **1492MO - Immune and vascular biomarkers associated with efficacy and mechanism of actions of the combination of lenvatinib (L) and eribulin (E) in leiomyosarcoma (LMS) and liposarcoma (LPS)**
T.W.-W. Chen¹, C.-L. Hsu², J.-C. Lee², C.-C. Yen³, R.-L. Hong², S.-C. Chen³, C.-W. Yu², M.-L. Chen², M.-C. Hsu², T.-F. Kung³, A.-L. Cheng⁴, ¹National Taiwan University Hospital-College of Medicine, Taipei City, TW, ²National Taiwan University Hospital, Taipei City, TW, ³Taipei Veterans General Hospital, Taipei City, TW, ⁴NTUH - National Taiwan University Hospital, Taipei City, TW
- 15:45 - 15:50 **1493MO - Peripheral immune biomarkers of survival in patients with resectable dedifferentiated liposarcomas (DDLPS) and undifferentiated pleomorphic sarcomas (UPS) treated with neoadjuvant nivolumab +/- ipilimumab (neoICB)**
E. Nassif¹, E. Keung¹, P. Jiang¹, A. Reuben¹, S. Crosby¹, G. Mathew¹, A. Lazar², K. Torres¹, W.-L. Wang¹, A. Guadagnolo¹, A. Bishop¹, K. Hunt¹, J. Bird¹, V. Lewis¹, A. Conley², J. Wargo¹, N. Somaiah², C. Roland¹, ¹MD Anderson Cancer Center, Houston, US, ²The University of Texas M. D. Anderson Cancer Center, Houston, US
- 15:50 - 16:05 **Invited Discussant 1487MO, 1492MO and 1493MO**
J. Martin-Broto, Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES

15:00 - 16:00	Type: Controversy session Title: PD-L1 is a good predictive biomarker for anti-PD-1 therapy in oesophagogastric cancer Chair(s): Elizabeth Smyth, GB	7.2.F - Fécamp Auditorium
15:00 - 15:05	Introduction by the chair <u>E. Smyth</u> , Addenbrooke's Hospital, Cambridge, GB	
15:05 - 15:06	Polling 1 (led by chair) <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
15:06 - 15:21	Pro: PD-L1 is a good predictive biomarker for anti-PD-1 therapy in oesophagogastric cancer <u>Y. Janjigian</u> , MSKCC - Memorial Sloan Kettering Cancer Center, New York, US	
15:21 - 15:36	Contra: PD-L1 is a good predictive biomarker for anti-PD-1 therapy in oesophagogastric cancer <u>R. Sundar</u> , NUHS - National University Health System, Singapore, SG	
15:36 - 15:37	Polling 2 (led by chair) <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
15:37 - 15:57	Q&A <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	

15:00 - 16:15 **Type: Multidisciplinary session** **7.1.D - Dijon Auditorium**
Title: Management of oligometastatic prostate cancer
 Chair(s): Nicholas James, GB

15:00 - 15:15 **Definition and classification, plus presentation of case**
N. James, ICR - Institute of Cancer Research, London, GB

15:15 - 15:30 **Surgical treatment**
B. Hadaschik, University Hospital of Essen, Essen, DE

15:30 - 15:45 **Radiation**
P. Ost, Ghent, BE

15:45 - 16:00 **Systemic therapy**
S. Gillessen, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

16:00 - 16:15 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

15:00 - 16:00 **Type: Multidisciplinary session** **7.3.H - Honfleur Auditorium**
Title: Molecular tumor boards: Challenges in identifying personalised treatments for melanoma patients
 Chair(s): Ryan Sullivan, US

15:00 - 15:05 **Presentation of case/condition**
O. Hamid, The Angeles Clinic and Research Institute - West Los Angeles, Los Angeles, US

15:05 - 15:20 **The basic scientist's perspective**
R. Marais, Cancer Research UK Manchester Institute, Manchester, GB

15:20 - 15:35 **The phase I perspective**
R. Sullivan, MGH - Massachusetts General Hospital, Boston, US

15:35 - 15:50 **The oncologist's perspective**
O. Hamid, The Angeles Clinic and Research Institute - West Los Angeles, Los Angeles, US

15:50 - 16:00 **Discussion**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

15:00 - 16:00	Type: Multidisciplinary session Title: Oligometastatic disease and oligoprogression in breast cancer Chair(s): Carlos Barrios, BR	7.3.Q - Quimper Auditorium
15:00 - 15:05	Presentation of case/condition <u>C. Barrios</u> , Centro de Hematologia Oncologia E Transplante, Porto Alegre, BR	
15:05 - 15:20	Systemic therapeutic options <u>J. Cortés</u> , Hospital Ruber Internacional, Madrid, ES	
15:20 - 15:35	Radiotherapy <u>S. Rivera</u> , Villejuif, FR	
15:35 - 15:50	Surgery <u>E. Mittendorf</u> , Boston, MA, US	
15:50 - 16:00	Discussion <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
15:00 - 16:00	Type: Challenge your Expert Title: How can we use ctDNA for early detection of cancer? Chair(s): David Crosby, GB	7.3.M - Marseille Auditorium
15:00 - 15:15	Presentation by Expert <u>N. Turner</u> , London, GB	
15:15 - 16:00	Discussion led by Chair <u>D. Crosby</u> , Cancer Research UK, London, GB	

15:45 - 16:30	Type: EONS session Title: EONS closing session Chair(s): Virpi Sulosaari, FI	7.3.S - Strasbourg Auditorium
15:45 - 16:00	EONS Cancer Nursing Framework update <u>V. Sulosaari</u> , Turku University of Applied Sciences, Turku, FI	
16:00 - 16:15	Introducing the European College of Cancer Nursing <u>W. Mcinally</u> , Open University, Edinburgh, GB	
16:15 - 16:20	CN36 - Informal caregivers' contributions to self-care for patients treated with oral anticancer agents: A qualitative study <u>S. Ucciero</u> ¹ , F. Sollazzo ² , M. Di Nitto ³ , A. Durante ⁴ , F. Lacarbonara ⁵ , V. Biagioli ⁶ , F. Torino ⁷ , R. Alvaro ⁸ , E. Vellone ¹ , ¹ University of Rome Tor Vergata - School of Medicine and Surgery, Rome, IT, ² Università degli Studi di Roma la Sapienza - Facoltà di Medicina, Latina, IT, ³ Istituto Superiore di Sanità, Rome, IT, ⁴ Universidad de la Rioja, Logroño (La Rioja), ES, ⁵ University of Rome Tor Vergata, Rome, IT, ⁶ Bambino Gesù Children's Hospital IRCCS Rome, Firenze, IT, ⁷ University of Rome Tor Vergata - School of Medicine and Surgery, ROMA, IT, ⁸ Università degli Studi di Roma Tor Vergata, Roma, IT	
16:20 - 16:23	European Cancer Nursing Day 2022 Award <u>J. Barros Alfonso</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
16:23 - 16:24	European Cancer Nursing Day 2022 Winning Video <u>A. Speakers</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
16:24 - 16:25	People's Choice Poster Award <u>V. Sulosaari</u> , Turku University of Applied Sciences, Turku, FI	
16:25 - 16:30	Discussion & farewell <u>V. Sulosaari</u> , Turku University of Applied Sciences, Turku, FI	

16:00 - 17:00	Type: Young Oncologist session Title: ON-SITE ONLY: Young Oncologist Clinical Case Discussion sessions Chair(s): Christoph Oing, GB; Kevin Punie, BE; Claudia Cardone, IT; Alexios Matikas, SE	7.3.L - Lyon
16:00 - 16:00	Clinical case discussion in melanoma <u>C. Oing</u> ¹ , <u>T. Amaral</u> ² , ¹ Newcastle University, Newcastle upon Tyne, GB, ² Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE	
16:00 - 16:00	Breast cancer in pregnancy <u>L. Del Mastro</u> ¹ , <u>K. Punie</u> ² , ¹ IRCCS Ospedale Policlinico San Martino, Genova, IT, ² University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE	
16:00 - 16:00	Genetic counselling (eg. Lynch family) <u>G. Evans</u> ¹ , <u>C. Cardone</u> ² , ¹ The University of Manchester, Manchester, GB, ² Istituto Nazionale Tumori—IRCCS Fondazione Pascale, Napoli, IT	
16:00 - 16:00	Breast cancer <u>M. Oliveira</u> ¹ , <u>A. Matikas</u> ² , ¹ Vall d'Hebron University Hospital, Barcelona, ES, ² Karolinska Institutet, Huddinge, SE	
16:30 - 18:15	Type: Proffered Paper session Title: Presidential Symposium III Chair(s): Andres Cervantes, ES; Charles Swanton, GB	6.P - Paris Auditorium
16:30 - 16:45	LBA8 - Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313) <u>T. Choueiri</u> ¹ , T. Powles ² , L. Albiges ³ , M. Burotto ⁴ , C. Szczylik ⁵ , B. Zurawski ⁶ , E. Yanez Riuz ⁷ , M. Maruzzo ⁸ , A. Suarez Zaizar ⁹ , L. Fein ¹⁰ , F.A. Barros Schutz ¹¹ , D. Heng ¹² , F. Wang ¹³ , F. Mataveli ¹³ , Y.-L. Chang ¹³ , M. Van Kooten Losio ¹⁴ , C. Suarez Rodriguez ¹⁵ , R. Motzer ¹⁶ , ¹ Dana-Farber Cancer Institute, Harvard Medical School, Boston, US, ² Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London, GB, ³ Institut Gustave Roussy, Université Paris Saclay, Villejuif, FR, ⁴ Bradford Hill Clinical Research Center, Santiago, CL, ⁵ European Health Centre, Otwock, PL, ⁶ Professor Franciszek Lukaszczyk Oncology Center, Bydgoszcz, PL, ⁷ James Lind Centro de Investigacion del Cancer, Temuco, CL, ⁸ Istituto Oncologico Veneto, IOV - IRCCS, Padova, IT, ⁹ Consultorio de Medicina Especializada, Ciudad de Mexico, MX, ¹⁰ Instituto de Oncología de Rosario, Rosario, AR, ¹¹ Beneficencia Portuguesa de Sao Paulo, Sao Paulo, BR, ¹² Tom Baker Cancer Center, University of Calgary, Calgary, CA, ¹³ Exelixis, Inc., Alameda, US, ¹⁴ Bristol Myers Squibb, Boudry, CH, ¹⁵ Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, ¹⁶ Memorial Sloan Kettering Cancer Center, New York, US	
16:45 - 16:55	Invited Discussant LBA8 <u>S. Pal</u> , City of Hope Comprehensive Cancer Center, Duarte, US	

- 16:55 - 17:10 **LBA9 - Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031)**
- C. Parker¹, N. Clarke², A. Cook³, C. Catton⁴, W. Cross⁵, H. Kynaston⁶, J. Logue⁷, P.M. Petersen⁸, P. Neville⁹, R. Persad¹⁰, H. Payne¹¹, F. Saad¹², A. Stirling¹³, W. Parulekar¹⁴, M. Parmar³, M. Sydes¹⁵, ¹The Royal Marsden Hospital (Sutton) - NHS Foundation Trust, Sutton, GB, ²The University of Manchester, Manchester, GB, ³Institute of Clinical Trials and Methodology-UCL, London, GB, ⁴Princess Margaret Cancer Center, Toronto, CA, ⁵University of Leeds - Leeds Institute of Molecular Medicine (LIMM), Leeds, GB, ⁶Cardiff & Vale UHB, Cardiff, GB, ⁷The Christie NHS Foundation Trust, Manchester, GB, ⁸Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK, ⁹Medical Research Council - MRC Clinical Trials Unit, London, GB, ¹⁰University Hospitals Bristol NHS Foundation Trust, Bristol, GB, ¹¹UCLH Foundation Trust, London, GB, ¹²Hospital St. Luc du CHUM, Montreal, CA, ¹³MRC - Medical Research Council Clinical Trials Unit - University College London (UCL), London, GB, ¹⁴Canadian Cancer Trials Group, Kingston, CA, ¹⁵Medical Research Council Clinical Trials Unit, London, GB
- 17:10 - 17:20 **Invited Discussant LBA9**
- S. Gillessen, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH
- 17:20 - 17:35 **LBA10 - Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreak 200 phase III study**
- M. Johnson¹, J. De Langen², D.M. Waterhouse³, J. Mazieres⁴, A.-M. Dingemans⁵, G. Mountzios⁶, M. Pless⁷, J. Wolf⁸, M. Schuler⁹, H. Lena¹⁰, F. Skoulidis¹¹, I. Okamoto¹², S.-W. Kim¹³, H. Linardou¹⁴, S. Novello¹⁵, Y. Chen¹⁶, B. Solomon¹⁷, C. Obiozor¹⁸, Y. Wang¹⁹, L. Paz-Ares²⁰, ¹Sarah Cannon Research Institute at Tennessee Oncology, Nashville, US, ²Netherlands Cancer Institute, Amsterdam, NL, ³US Oncology Research, Cincinnati, US, ⁴Centre Hospitalier Universitaire de Toulouse, Toulouse, FR, ⁵Erasmus MC Cancer Institute, Rotterdam, NL, ⁶Henry Dunant Hospital Centre, Athens, GR, ⁷Kantonsspital Winterthur, Winterthur, CH, ⁸University Hospital Cologne, Cologne, DE, ⁹University Hospital Essen, Essen, DE, ¹⁰Centre Hospitalier Universitaire de Rennes, Hopital Pontchaillou, Rennes, FR, ¹¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ¹²Kyushu University Hospital, Fukuoka, JP, ¹³Asan Medical Center, Seoul, KR, ¹⁴Metropolitan Hospital, Athens, GR, ¹⁵Università Degli Studi Di Torino - San Luigi Hospital, Orbassano, IT, ¹⁶Cancer & Hematology Centers of Western Michigan, Grand Rapids, US, ¹⁷Peter MacCallum Cancer Centre, Melbourne, AU, ¹⁸Amgen Inc., Thousand Oaks, US, ¹⁹Amgen, Inc., Thousand Oaks, US, ²⁰Hospital Universitario 12 de Octubre, Madrid, ES
- 17:35 - 17:50 **LBA11 - IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen**
- S.M. Lee¹, C. Schulz², K. Prabhash³, B. Han⁴, A. Szczesna⁵, D. Cortinovis⁶, A. Rittmeyer⁷, D. Vicente Baz⁸, R. Califano⁹, L. Tuan Anh¹⁰, G. Liu¹¹, F. Cappuzzo¹², J. Reyes Contreras¹³, M. Reck¹⁴, Y. Hu¹⁵, S. Morris¹⁵, E. Hoeglander¹⁵, M. Connors¹⁶, H.K. Vollen¹⁵, S. Peters¹⁷, ¹University College London Hospitals NHS Foundation Trust, UCL

Cancer Institute and CRUK Lung Cancer Centre of Excellence, London, GB, ²University Hospital Regensburg, Regensburg, DE, ³Tata Memorial Hospital, Mumbai, IN, ⁴Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, ⁵Mazowieckie Centrum Leczenia Chorób Płuc i Gruzlicy, Warsaw, PL, ⁶AAST Monza San Gerardo Hospital, Monza, IT, ⁷Lungenfachklinik Immenhausen, Immenhausen, DE, ⁸Hospital Universitario Virgen de la Macarena, Seville, ES, ⁹The Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester, Manchester, GB, ¹⁰Cho Ray Hospital, Ho Chi Minh, VN, ¹¹Princess Margaret Cancer Centre, Toronto, CA, ¹²National Cancer Institute IRCCS Regina Elena, Rome, IT, ¹³Oncologico Potosino, San Luis Potosí, MX, ¹⁴Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, DE, ¹⁵F. Hoffmann-La Roche Ltd, Basel, CH, ¹⁶Genentech, Inc, South San Francisco, US, ¹⁷CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

17:50 - 18:00 **Invited Discussant LBA10 and LBA11**

N. Leighl, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

18:00 - 18:15 **Q&A and discussion**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

16:30 - 18:00 **Type: Special session** **4.B - Brest Auditorium**
Title: Emerging toxicities of new anticancer therapies
 Chair(s): Jarushka Naidoo, IE; Erica Mayer, US

16:30 - 16:40 **Introduction and scientific background**

E. Mayer, Dana Farber Cancer Institute, Boston, US

16:40 - 16:55 **Critical organ damage and late toxicities from anti-PD1**

J. Naidoo, Beaumont Hospital, Dublin, IE

16:55 - 17:10 **Late haematological malignancies of systemic anticancer therapies**

J. Baptiste Micol, Institut Gustave Roussy, Villejuif, Cedex, FR

17:10 - 17:25 **Chronic toxicities of targeted therapies and their implication on compliance: Illustration with new endocrine therapies and CDK4 inhibitors**

E. Mayer, Dana Farber Cancer Institute, Boston, US

17:25 - 17:40 **Toxicities of CAR T cell and bispecific**

C. Roddie, London, GB

17:40 - 18:00 **Discussion: How to design better trial taking into account toxicities**

A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

16:30 - 18:00 **Type: Proffered Paper session** **7.3.O - Orléans Auditorium**
Title: Proffered Paper session: NETs and endocrine tumours

Chair(s): Halfdan Sorbye, NO; Marcia Brose, US

- 16:30 - 16:40 **LBA45 - Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)**
- R. Salazar¹, S. Tafuto², M. Krogh³, A. Teule¹, R. Garcia-Carbonero⁴, H.J. Klumpen⁵, B. Cremer⁶, I. Sevilla⁷, B. Eriksson⁸, E. Tabaksblat⁹, J.-P. Metges¹⁰, N.S. Reed¹¹, J. Schrader¹², V. Navarro¹, V. Valenti¹, J. Hernando¹³, A.M. Colao², L. Vestermarck³, C. Carnaghi¹⁴, J. Capdevila¹³, ¹Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, ES, ²Maria delle Grazie Hospital, Pozzuoli, IT, ³Odense University Hospital, Odense, DK, ⁴Hospital 12 de Octubre, Imas12, UCM, Madrid, ES, ⁵Amsterdam UMC, University of Amsterdam, Amsterdam, NL, ⁶Köln Universitätsklinikum Köln (AöR), Köln, DE, ⁷Investigación Clínica y Traslacional en Cáncer / Instituto de Investigaciones Biomédicas de Málaga (IBIMA) / Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Malaga, ES, ⁸University Hospital, Uppsala, SE, ⁹Aarhus University Hospital NET Centre, Aarhus, DK, ¹⁰Brest Hôpital Augustin Morvan, Institut de Cancero-Hemato, Brest, FR, ¹¹Beatson Oncology Centre, Glasgow, GB, ¹²Hamburg Medizinische Klinik und Poliklinik, Hamburg-Eppendorf, DE, ¹³Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, ES, ¹⁴Humanitas Cancer Center, Milano, IT
- 16:40 - 16:50 **8870 - First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionuclide therapy with ¹⁷⁷Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial**
- E. Baudin¹, T. Walter², A. Beron³, D. Smith⁴, J. Hadoux⁵, C. Lachachi⁶, D. Taieb⁷, C. Ansquer⁸, L. Dierickx⁹, L. De Mestier Du Bourg¹⁰, E. Deshayes¹¹, E. Quak¹², L. Dahan¹³, R. Guimbaud¹⁴, Y. Toucheffeu¹⁵, M. Haissaguerre¹⁶, C. Do Cao¹⁷, C. Lombard Bohas¹⁸, M. Attard¹, S. Foulon¹, ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Hospices Civiles de Lyon - HCL - Lyon University Hospital Center, Lyon, FR, ³CHU Lille - Hopital Claude Huriez, Lille, FR, ⁴Hopital Haut Leveque, Pessac, FR, ⁵Institut Gustave Roussy, Villejuif, Cedex, FR, ⁶Hospices Civils de Lyon, Bron, FR, ⁷CHU de Marseille - Hôpital de la Timone, Marseille, FR, ⁸Chu Nantes Hotel Dieu, Nantes, FR, ⁹Institut Claudius Regaud, Toulouse, FR, ¹⁰Beaujon Hospital APHP, Clichy, FR, ¹¹ICM - Institut régional du Cancer de Montpellier, Val d'Aurelle, Montpellier, Cedex, FR, ¹²Centre François Baclesse, Caen, FR, ¹³AP-HM - CHU La Timone Enfants, Marseille, FR, ¹⁴Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil, Toulouse, FR, ¹⁵CHU du Nantes - Hôtel-Dieu, Nantes, Cedex, FR, ¹⁶CHU de Bordeaux-Hôpital Haut-Lévêque, Pessac, FR, ¹⁷Centre Hospitalier Régional Universitaire de Lille, Lille, FR, ¹⁸Hopital Edouard Herriot Pav. E bis, Lyon, FR
- 16:50 - 17:00 **Invited Discussant LBA45 and 8870**
- J. Strosberg, H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US
- 17:00 - 17:15 **Q&A**
- A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

- 17:15 - 17:25 **16440 - Donafenib in locally advanced/metastatic, radioactive iodine-refractory, differentiated thyroid cancer: A randomized, double-blind, placebo-controlled, multi-center phase III clinical trial (DIRECTION)**
Y. Lin¹, H. Yang², F. Shi³, A. Yang⁴, X. Han⁵, B. Liu⁶, Z. Li⁷, Q. Ji⁸, L. Tang⁹, Z. Deng¹⁰, Y. Ding¹¹, W. Fu¹², X. Xie¹³, L. Li¹⁴, X. He¹⁵, Z. Lv¹⁶, L. Wu¹⁷, L. Liu¹⁷, ¹Peking Union Medical College Hospital, Beijing, CN, ²The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ³Hunan Cancer Hospital, Changsha, CN, ⁴The First Affiliated Hospital of Xi'an Jiaotong University, Xi' An, CN, ⁵The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ⁶West China Hospital of Sichuan University, Chengdu, CN, ⁷The Affiliated Hospital of Xuzhou Medical University, Xuzhou, CN, ⁸Fudan University Shanghai Cancer Center, Shanghai, CN, ⁹The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN, ¹⁰Yunnan Cancer Hospital, Kunming, CN, ¹¹The Fifth Medical Center of Chinese PLA General Hospital, Beijing, CN, ¹²Affiliated Hospital of Guilin Medical University, Guilin, CN, ¹³The First Affiliated Hospital of Fujian Medical University, Fuzhou, CN, ¹⁴Zhejiang Cancer Hospital, Hangzhou, CN, ¹⁵Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, ¹⁶Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, CN, ¹⁷Suzhou Zelgen Biopharmaceuticals Co., Ltd, Suzhou, CN
- 17:25 - 17:35 **16450 - Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial**
J. Capdevila Castillon¹, M. Plana², B. Castelo³, L. Iglesias⁴, J. Hernando¹, R. Yaya Tur⁵, N. Baste⁶, A. Carmona-Bayonas⁷, S. Ruiz⁸, J. Trigo⁸, I. Lorenzo-Lorenzo⁹, E. Grande¹⁰, D. Lorente¹¹, L. Ugidos¹², G. Marquina¹³, A. García-Alvarez¹, M. Taberna², J. Villamayor¹⁴, J. Molina-Cerrillo¹⁵, T. Alonso-Gordoa¹⁵, ¹Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, ES, ²Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat, Barcelona, ES, ³University Hospital La Paz, Madrid, ES, ⁴Hospital 12 de Octubre, Madrid, ES, ⁵IVO - Fundacion Instituto Valenciano de Oncologia, Valencia, ES, ⁶Hospital Clínic de Barcelona, IDIBAPS, Barcelona, ES, ⁷UMU, IMIB, Hospital Universitario Morales Meseguer, Murcia, ES, ⁸Hospitales Regional y Universitario Virgen de la Victoria, IBIMA, UMA, Málaga, ES, ⁹Complejo Universitario Hospitalario de Vigo (CHUVI) Álvaro Cunqueiro, Vigo, ES, ¹⁰MD Anderson Cancer Center Madrid, Madrid, ES, ¹¹Hospital Provincial de Castellón, Castellón de La Plana, ES, ¹²Centro Integral Oncológico "Clara Campal", Hospital Universitario HM Sanchinarro, Madrid, ES, ¹³Hospital Clinico Universitario San Carlos. Department of Medicine, School of Medicine, Universidad Complutense de Madrid (UCM), IdISSC, Madrid, ES, ¹⁴Clínica Universidad de Navarra, Madrid, ES, ¹⁵Hospital Universitario Ramón y Cajal, Madrid, ES
- 17:35 - 17:45 **Invited Discussant 16440 and 16450**
M. Brose, Sidney Kimmel Cancer Center - Thomas Jefferson University, Philadelphia, US
- 17:45 - 18:00 **Q&A**
A. Speakers, ESMO - European Society for Medical Oncology, Lugano, CH

16:30 - 18:00	Type: Mini Oral session Title: Mini Oral session: Developmental therapeutics	7.3.T - Toulouse Auditorium
----------------------	---	------------------------------------

Chair(s): Myung-Ju Ahn, KR; Ulrik Lassen, DK

- 16:30 - 16:35 **455MO - NUC-7738 in patients with advanced solid tumours: Phase I results from the NuTide:701 phase I/II study**
S. Symeonides¹, A. Skolariki², N. Haris³, Z. Boh¹, M. Myers⁴, E. Oelmann⁴, J. Bloss⁴, R. Plummer³, S. Blagden², ¹Western General Hospital, Edinburgh, GB, ²Churchill Hospital, Oxford, GB, ³Freeman Hospital, Newcastle-upon-Tyne, GB, ⁴NuCana plc, Edinburgh, GB
- 16:35 - 16:40 **456MO - METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors**
S. Postel-Vinay¹, A. Italiano², P. Martin Romano³, P. Cassier⁴, L. Siu⁵, I. Lossos⁶, J. Hilton⁷, M. Mckean⁸, J. Strauss⁹, G. Falchook¹⁰, M. De Jonge¹¹, F. Opdam¹², D. Rasco¹³, J. Vermaat¹⁴, T. Crossman¹⁵, M. Zajac¹⁵, A. Hainline¹⁶, B. Kremer¹⁶, O. Barbash¹⁷, M. Gounder¹⁸, ¹Institut Gustave Roussy, Villejuif, FR, ²Institute Bergonié, Bordeaux, FR, ³Institut Gustave Roussy, Villejuif, Cedex, FR, ⁴Centre Léon Bérard, Lyon, FR, ⁵Princess Margaret Cancer Centre, Toronto, CA, ⁶University of Miami Sylvester Comprehensive Cancer Center, Miami, US, ⁷The Ottawa Hospital Regional Cancer Centre, Ottawa, CA, ⁸Sarah Cannon Research Institute, Nashville, US, ⁹Mary Crowley Cancer Research Center, Dallas, US, ¹⁰Sarah Cannon Research Institute at HealthONE, Denver, US, ¹¹Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, NL, ¹²NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ¹³South Texas Accelerated Research Therapeutics (START), San Antonio, US, ¹⁴Leiden University Medical Center, Leiden, NL, ¹⁵GlaxoSmithKline UK - Stevenage, Stevenage, GB, ¹⁶GlaxoSmithKline USA, Collegeville, US, ¹⁷GlaxoSmithKline, Philadelphia, US, ¹⁸Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US
- 16:40 - 16:55 **Invited Discussant 455MO and 466MO**
U. Lassen, Rigshospitalet, Copenhagen, DK
- 16:55 - 17:00 **457MO - A phase I study of ATR inhibitor M1774 in patients with solid tumours (DDRiver Solid Tumours 301): Part A1 results**
T. Yap¹, A. Tolcher², R. Plummer³, J. Mukker⁴, M. Enderlin⁵, C. Hicking⁵, G. Locatelli⁵, Z. Szucs⁶, I. Gounaris⁶, J. De Bono⁷, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²New Experimental Therapeutics (NEXT), San Antonio, US, ³Newcastle Hospitals Trust, Newcastle-upon-Tyne, GB, ⁴EMD Serono Research & Development Institute Inc., (an affiliate of Merck KGaA), Billerica, US, ⁵Merck Healthcare KGaA, Darmstadt, DE, ⁶Merck Serono Ltd., (an affiliate of Merck KGaA), Feltham, GB, ⁷Royal Marsden Hospital, Sutton, GB
- 17:00 - 17:05 **458MO - Efficacy of durvalumab (Durva) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic (met) cancers (Ca) (MEDIPAC)**
J. Lim¹, R. Sundar¹, A. Wong¹, W.P. Yong¹, R. Soo¹, C.E. Chee¹, S.C. Lee¹, B.-C. Goh¹, R. Dent², J. Chan², K.Y. Wong³, S. D/o Nathan Jeraj¹, L. Kwok¹, G. Schiavon⁴, A. Foxley⁵, D.S. Tan¹, ¹National University Cancer Institute, Singapore, Singapore, SG, ²NCCS - National Cancer Centre Singapore, Singapore, SG, ³Icon Cancer Center SOC Singapore - Gleneagles, Singapore, SG, ⁴AstraZeneca, Macclesfield, GB, ⁵AstraZeneca Academy

House, Cambridge, GB

17:05 - 17:20 **Invited Discussant 457MO and 458MO**

I. Brana, Vall d'Hebron University Hospital, Barcelona, ES

17:20 - 17:25 **459MO - Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation**

M. Patel¹, J.-S. Lee², M.J. De Miguel³, T. Burns⁴, A. Falcon Gonzalez⁵, T.W. Kim⁶, M. Krebs⁷, H. Prenen⁸, E. Shacham Shmueli⁹, J. Desai¹⁰, P. Lorusso¹¹, A. Sacher¹², Y. Choi¹³, N. Dharia¹³, M. Lin¹³, S. Mandlekar¹³, S. Royer-Joo¹³, J. Schutzman¹³, E. Garralda¹⁴, ¹Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, US, ²Seoul National University Bundang Hospital, Seongnam, KR, ³START MADRID, Hospital Universitario HM Sanchinarro - CIOCC, Madrid, ES, ⁴UPMC Hillman Cancer Center, Pittsburgh, US, ⁵Hospital Universitario Virgen del Rocio, Seville, ES, ⁶Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ⁷The Christie NHS Foundation Trust and The University of Manchester, Manchester, GB, ⁸UZA - University Hospital Antwerp, Edegem, BE, ⁹Chaim Sheba Medical Center, Ramat Gan, IL, ¹⁰Peter MacCallum Cancer Centre, Melbourne, AU, ¹¹Yale Smilow Cancer Center, New Haven, US, ¹²Princess Margaret Cancer Centre, University Health Network, Toronto, CA, ¹³Genentech, Inc., South San Francisco, US, ¹⁴Vall d'Hebron University Hospital, Barcelona, ES

17:25 - 17:30 **460MO - Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers**

K. Jhaveri¹, H. Han², E. Dotan³, D.-Y. Oh⁴, C. Ferrario⁵, A. Tolcher⁶, K.-W. Lee⁷, C.-Y. Liao⁸, Y.-K. Kang⁹, Y.H. Kim¹⁰, E. Hamilton¹¹, A. Spira¹², N. Patel¹³, C. Karapetis¹⁴, S.Y. Rha¹⁵, L. Boyken¹⁶, J. Woolery¹⁶, P. Bedard¹⁷, ¹Memorial Sloan Kettering Cancer Center, New York, NY, US, ²Moffitt Cancer Center, Tampa, US, ³Fox Chase Cancer Center, Philadelphia, US, ⁴Seoul National University Hospital, Seoul, KR, ⁵Jewish General Hospital, Montreal, CA, ⁶NEXT Oncology, San Antonio, US, ⁷Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, KR, ⁸University of Chicago Medicine, Chicago, US, ⁹Asan Medical Center, Seoul, KR, ¹⁰Korea University Anam Hospital, Seoul, KR, ¹¹Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US, ¹²Virginia Cancer Specialists, Fairfax, US, ¹³City of Hope, Duarte, US, ¹⁴Flinders Medical Centre and Flinders University, Bedford Park, AU, ¹⁵Yonsei Cancer Center, Yonsei University Health System, Seoul, KR, ¹⁶Zymeworks Inc., Vancouver, CA, ¹⁷Princess Margaret Cancer Centre, Toronto, CA

17:30 - 17:45 **Invited Discussant 459MO and 460MO**

M.-J. Ahn, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR

16:30 - 18:00	Type: Mini Oral session Title: Mini Oral session: Policy and preventive strategies Chair(s): Felipe Roitberg, BR; Daniel Goldstein, IL	7.3.M - Marseille Auditorium
16:30 - 16:35	1317MO - Non-OS endpoints in oncology: Strategies to bridge the gap in value attribution by regulators, payors, oncologists, and patients <u>A. Fameli</u> ¹ , M. Glover ² , B. Gutierrez ² , A. Cimen ³ , L. Nelson ² , S. Altimari ³ , T. Paulsson ¹ , ¹ GSK, London, GB, ² GSK, Upper Providence, US, ³ GSK, Zug, CH	
16:35 - 16:40	1319MO - Actual patient access to innovative medicines in six European countries <u>J. Vancoppenolle</u> , N. Franzen, S. Koole, V. Retel, W. Van Harten, The Netherlands Cancer Institute, Amsterdam, NL	
16:40 - 16:45	1320MO - New oncologic drugs since 2010: Differences in approval and access between the United States, Europe and Brazil <u>R. Barreto</u> , A. Izidoro, A.B. Visentainer, R. Mireski, CEPON - Centro de Pesquisas Oncológicas, Florianopolis, BR	
16:45 - 17:00	Invited Discussant 1317MO, 1319MO and 1320MO <u>D. Goldstein</u> , Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL	
17:00 - 17:05	1321MO - Relevance index by cancer type: Trends and regional variation analysis, 2016-2020, Republic of Korea M. Ock ¹ , <u>J. Pyo</u> ² , H. Lee ³ , H. Jeong ⁴ , M.N. Lee ⁵ , ¹ Ulsan University Hospital, Ulsan, KR, ² Asan Medical Center - University of Ulsan, Seoul, KR, ³ Korea Counseling Graduate University, Seoul, KR, ⁴ University of Ulsan College of Medicine, Seoul, KR, ⁵ Korea national open university, Seoul, KR	
17:05 - 17:10	1322MO - Selection of a set of quality indicators (QIs) on the care pathway in onco-hematology using a panel of experts <u>M. Di Palma</u> ¹ , M. Ferrua ² , E. Minvielle ³ , ¹ Gustave Roussy - Cancer Campus, Villejuif, FR, ² CH d'Argenteuil, Villejuif, Cedex, FR, ³ Institut Gustave Roussy, Villejuif, FR	
17:10 - 17:15	1318MO - Time to diagnosis among patients with cancer in the US <u>M. Gitlin</u> ¹ , N. Mcgarvey ¹ , N. Shivaprakash ¹ , Z. Cong ² , ¹ BluePath Solutions, Los Angeles, US, ² *GRAIL LLC, a subsidiary of Illumina, Inc., *Currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission dated 29 October 2021, Menlo Park, US	
17:15 - 17:30	Invited Discussant 1321MO, 1322MO and 1318MO <u>F. Roitberg</u> , ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR	

18:30 - 20:00	Type: Industry Satellite Symposium Title: MSD - Advancements in Immuno-Oncology for Endometrial and Cervical Cancers Chair(s): Robert Coleman, US	7.2.F - Fécamp Auditorium
18:30 - 18:35	Introductions and Objectives <u>R. Coleman</u> , US Oncology Research, The Woodlands, US	
18:35 - 18:50	HPV Vaccination and Cervical Cancer: What Should an Oncologist Know <u>A. Giuliano</u> , H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US	
18:50 - 19:08	The role of immunotherapy in the management of cervical cancer <u>I. Ray-Coquard</u> , Centre Léon Bérard, Lyon, FR	
19:08 - 19:23	Panel Discussion - the role of oncologists in vaccination and the role of immunotherapy in Gynecologic Cancer <u>A. Rodrigues</u> ¹ , <u>R. Coleman</u> ² , <u>I. Ray-Coquard</u> ³ , <u>A. Giuliano</u> ⁴ , ¹ Faculdade de Medicina da UFMG, Belo Horizonte, BR, ² US Oncology Research, The Woodlands, US, ³ Centre Léon Bérard, Lyon, FR, ⁴ H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US	
19:23 - 19:40	Treatment and management of advanced or recurrent endometrial cancer <u>A. Rodrigues</u> , Faculdade de Medicina da UFMG, Belo Horizonte, BR	
19:40 - 19:55	Q&A from audience <u>R. Coleman</u> ¹ , <u>I. Ray-Coquard</u> ² , <u>A. Rodrigues</u> ³ , <u>A. Giuliano</u> ⁴ , ¹ US Oncology Research, The Woodlands, US, ² Centre Léon Bérard, Lyon, FR, ³ Faculdade de Medicina da UFMG, Belo Horizonte, BR, ⁴ H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US	
19:55 - 20:00	Closing <u>R. Coleman</u> , US Oncology Research, The Woodlands, US	

18:30 - 20:00	Type: Industry Satellite Symposium Title: Novartis - Evidence-Based Practice in HR+/HER2– Advanced Breast Cancer: Illuminating the Treatment Path for Patients Chair(s): Joseph Gligorov, FR	7.1.D - Dijon Auditorium
18:30 - 18:35	Welcome and Introduction <u>J. Gligorov</u> , Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR	
18:35 - 19:00	First-Line Treatment of a Patient with HR+/HER2- ABC <u>S.X. Franco Millan</u> , CTIC Centro de Tratamiento e Investigacion Sobre Cancer, Bogota, CO	
19:00 - 19:15	Round Table Discussion <u>J. Gligorov</u> ¹ , <u>S. Chia</u> ² , <u>S.X. Franco Millan</u> ³ , ¹ Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR, ² BC Cancer Agency - Vancouver, Vancouver, CA, ³ CTIC Centro de Tratamiento e Investigacion Sobre Cancer, Bogota, CO	
19:15 - 19:40	Second-Line Treatment of a Patient with HR+/HER2- ABC <u>S. Chia</u> , BC Cancer Agency - Vancouver, Vancouver, CA	
19:40 - 19:50	Round Table Discussion <u>J. Gligorov</u> ¹ , <u>S. Chia</u> ² , <u>S.X. Franco Millan</u> ³ , ¹ Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR, ² BC Cancer Agency - Vancouver, Vancouver, CA, ³ CTIC Centro de Tratamiento e Investigacion Sobre Cancer, Bogota, CO	
19:50 - 20:00	Key Takeaways, Future Directions, and Live Q&A Session or Panel Discussion <u>J. Gligorov</u> ¹ , <u>S. Chia</u> ² , <u>S.X. Franco Millan</u> ³ , ¹ Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR, ² BC Cancer Agency - Vancouver, Vancouver, CA, ³ CTIC Centro de Tratamiento e Investigacion Sobre Cancer, Bogota, CO	

18:30 - 20:00	Type: Industry Satellite Symposium Title: MSD - A Quantum Leap in Management of HNSCC with IO Chair(s): Christophe Le Tourneau, FR	7.3.G - Grenoble Auditorium
18:30 - 18:35	Welcome and Introduction <u>C. Le Tourneau</u> , Paris, FR	
18:35 - 18:45	Current Management of HNSCC <u>C. Le Tourneau</u> , Paris, FR	
18:45 - 19:05	Evolving Landscape in LA HNSCC <u>J.-P. Machiels</u> , Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Brussels, BE	
19:05 - 19:25	Latest Updates in R/M HNSCC <u>D. Soulieres</u> , CHUM - Centre Hospitalier de l'Université de Montréal, Montreal, CA	
19:25 - 19:45	Case Discussions <u>C. Le Tourneau</u> ¹ , <u>J.-P. Machiels</u> ² , <u>D. Soulieres</u> ³ , ¹ Paris, FR, ² Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Brussels, BE, ³ CHUM - Centre Hospitalier de l'Université de Montréal, Montreal, CA	
19:45 - 20:00	Q&A and Closing Remarks <u>C. Le Tourneau</u> ¹ , <u>J.-P. Machiels</u> ² , <u>D. Soulieres</u> ³ , ¹ Paris, FR, ² Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Brussels, BE, ³ CHUM - Centre Hospitalier de l'Université de Montréal, Montreal, CA	

18:30 - 20:00	Type: Industry Satellite Symposium Title: Medscape Oncology Global - Targets of Antibody-Drug Conjugates in NSCLC: Diagnostics, Emerging Therapies, and Future Prospects Chair(s): Enriqueta Felip, ES	7.3.H - Honfleur Auditorium
18:30 - 18:35	Personalizing Treatment in NSCLC: Recent Developments <u>E. Felip</u> , Vall d'Hebron University Hospital, Barcelona, ES	
18:35 - 18:55	Novel ADC Targets in NSCLC: Rationale and Diagnostic Considerations <u>M. Thomas</u> , Thoraxklinik Heidelberg gGmbH, Heidelberg, DE	
18:55 - 19:20	Which Patients May Benefit From Emerging ADCs in NSCLC: Explaining the Clinical Trial Data <u>E. Smit</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL	
19:20 - 19:40	Preparing the Clinics and Future Prospects <u>E. Felip</u> , Vall d'Hebron University Hospital, Barcelona, ES	
19:40 - 19:58	Q&A Session <u>E. Felip</u> ¹ , <u>M. Thomas</u> ² , <u>E. Smit</u> ³ , ¹ Vall d'Hebron University Hospital, Barcelona, ES, ² Thoraxklinik Heidelberg gGmbH, Heidelberg, DE, ³ NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL	
19:58 - 20:00	Concluding Remarks <u>E. Felip</u> , Vall d'Hebron University Hospital, Barcelona, ES	

18:30 - 20:00	Type: Industry Satellite Symposium Title: Sanofi - ER+ / HER2- Breast Cancer: What's next for patients & providers? Chair(s): François Clément Bidard, FR	7.3.O - Orléans Auditorium
18:30 - 18:35	Welcome and Introduction <u>F.C. Bidard</u> , Institut Curie, Paris, FR	
18:35 - 19:00	Opportunity to Improve on the Standard of Care in Adjuvant ER+/HER2- Breast Cancer (BC) <u>N. Harbeck</u> , Ludwig Maximilians University - Grosshadern, Munich, DE	
19:00 - 19:20	Current Management Considerations in ER+/HER2- Metastatic BC <u>F.C. Bidard</u> , Institut Curie, Paris, FR	
19:20 - 19:45	Oral SERDs & Novel ETs in ER+/HER2- Metastatic BC <u>A. Chan</u> , Breast Cancer Research Centre BCRC - WA, Nedlands, AU	
19:45 - 20:00	Live Q&A with the Panel <u>F.C. Bidard</u> ¹ , <u>N. Harbeck</u> ² , <u>A. Chan</u> ³ , ¹ Institut Curie, Paris, FR, ² Ludwig Maximilians University - Grosshadern, Munich, DE, ³ Breast Cancer Research Centre BCRC - WA, Nedlands, AU	

18:30 - 20:00	Type: Industry Satellite Symposium Title: Astellas Pharma Europe Ltd - Navigating the evolving landscape of locally advanced unresectable or metastatic G/GEJ adenocarcinoma Chair(s): Hanneke van Laarhoven, NL	7.3.Q - Quimper Auditorium
18:30 - 18:35	Welcome and introductions <u>H. Van Laarhoven</u> , Academic Medical Center, University of Amsterdam, Amsterdam, NL	
18:35 - 18:55	The current landscape for locally advanced unresectable or metastatic G/GEJ adenocarcinoma <u>H. Van Laarhoven</u> , Academic Medical Center, University of Amsterdam, Amsterdam, NL	
18:55 - 19:20	Emerging treatments for locally advanced unresectable or metastatic G/GEJ adenocarcinoma <u>E. Van Cutsem</u> , UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE	
19:20 - 19:40	Working together in an evolving therapeutic landscape <u>H. Van Laarhoven</u> ¹ , <u>M. Iglesias</u> ² , <u>E. Van Cutsem</u> ³ , ¹ Academic Medical Center, University of Amsterdam, Amsterdam, NL, ² IMIM - Institut Hospital del Mar d'Investigacions Mediques, Barcelona, ES, ³ UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE	
19:40 - 19:55	Q&A session <u>H. Van Laarhoven</u> ¹ , <u>M. Iglesias</u> ² , <u>E. Van Cutsem</u> ³ , ¹ Academic Medical Center, University of Amsterdam, Amsterdam, NL, ² IMIM - Institut Hospital del Mar d'Investigacions Mediques, Barcelona, ES, ³ UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE	
19:55 - 20:00	Meeting summary and close <u>H. Van Laarhoven</u> , Academic Medical Center, University of Amsterdam, Amsterdam, NL	

18:30 - 20:00	Type: Industry Satellite Symposium Title: AstraZeneca - Navigating the real-world use of PARP inhibitors in BRCAm mCRPC: a practical discussion Chair(s): Neal Shore, US	7.3.T - Toulouse Auditorium
18:30 - 18:32	Chair's welcome and introduction <u>N. Shore</u> , Atlantic Urology Clinics, LLC, Myrtle Beach, US	
18:32 - 18:42	Why are PARP inhibitors relevant in the treatment of prostate cancer? <u>N. Shore</u> , Atlantic Urology Clinics, LLC, Myrtle Beach, US	
18:42 - 18:52	What data support the clinical activity of PARP inhibitors in mCRPC? <u>N. Mehra</u> , Radboud University Medical Center, Nijmegen, Nijmegen, NL	
18:52 - 19:12	Case-based discussion 1: personalising patient care in BRCAm prostate cancer <u>N. Shore</u> ¹ , <u>N. Mehra</u> ² , <u>A. Armstrong</u> ³ , ¹ Atlantic Urology Clinics, LLC, Myrtle Beach, US, ² Radboud University Medical Center, Nijmegen, Nijmegen, NL, ³ Duke Cancer Center, Durham, US	
19:12 - 19:32	Case-based discussion 2: practical considerations for the real-world use of PARP inhibitors in mCRPC <u>N. Shore</u> ¹ , <u>N. Mehra</u> ² , <u>A. Armstrong</u> ³ , ¹ Atlantic Urology Clinics, LLC, Myrtle Beach, US, ² Radboud University Medical Center, Nijmegen, Nijmegen, NL, ³ Duke Cancer Center, Durham, US	
19:32 - 19:47	Evolving landscape of PARP inhibitors in mCRPC <u>A. Armstrong</u> , Duke Cancer Center, Durham, US	
19:47 - 20:00	Summary and Q&A <u>N. Shore</u> ¹ , <u>N. Mehra</u> ² , <u>A. Armstrong</u> ³ , ¹ Atlantic Urology Clinics, LLC, Myrtle Beach, US, ² Radboud University Medical Center, Nijmegen, Nijmegen, NL, ³ Duke Cancer Center, Durham, US	

18:30 - 20:00	Type: Industry Satellite Symposium Title: Bristol Myers Squibb - Navigating the Integration of Immuno-Oncology Into the Perioperative Muscle-Invasive Urothelial Carcinoma Treatment Landscape Chair(s): Andrea Necchi, IT	7.3.U - Urval Auditorium
18:30 - 18:35	Welcome and Introduction <u>A. Necchi</u> , IRCCS Ospedale San Raffaele, Milan, IT	
18:35 - 18:50	The MIUC Treatment Landscape in 2022 <u>M. Roupret</u> , Sorbonne Université - Site Saint-Antoine, Paris, Cedex 12, FR	
18:50 - 19:05	Opportunities for I-O Use in the Perioperative Setting <u>M. Retz</u> , Bristol-Myers Squibb GmbH&Co. KGaA, Munich, DE	
19:05 - 19:20	Optimising Patient Treatment: Perspectives on the Future Treatment Landscape <u>A. Necchi</u> , IRCCS Ospedale San Raffaele, Milan, IT	
19:20 - 19:40	Interactive Multidisciplinary Team Meeting <u>A. Necchi</u> ¹ , <u>M. Roupret</u> ² , <u>M. Retz</u> ³ , ¹ IRCCS Ospedale San Raffaele, Milan, IT, ² Sorbonne Université - Site Saint-Antoine, Paris, Cedex 12, FR, ³ Bristol-Myers Squibb GmbH&Co. KGaA, Munich, DE	
19:40 - 19:55	Q&A <u>A. Necchi</u> ¹ , <u>M. Roupret</u> ² , <u>M. Retz</u> ³ , ¹ IRCCS Ospedale San Raffaele, Milan, IT, ² Sorbonne Université - Site Saint-Antoine, Paris, Cedex 12, FR, ³ Bristol-Myers Squibb GmbH&Co. KGaA, Munich, DE	
19:55 - 20:00	Summary and Close <u>A. Necchi</u> , IRCCS Ospedale San Raffaele, Milan, IT	

13.09.2022

09:00 - 12:40 **Type: Congress highlights** **4.A - Antibes Auditorium**
Title: Congress Highlights 1
Chair(s): Giuseppe Curigliano, IT; John Haanen, NL

- 09:00 - 09:20 **Breast cancer, early stage**
A. Bosch, Lund University - Faculty of Medicine, Malmo, SE
- 09:20 - 09:40 **Breast cancer, metastatic**
G. Curigliano, IEO - Istituto Europeo di Oncologia, Milan, IT
- 09:40 - 10:00 **Gynaecological cancers**
C. Scott, Walter and Eliza Hall Institute WEHI, Parkville, AU
- 10:00 - 10:20 **CNS tumours**
D. Brandsma, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 10:20 - 10:40 **Policy and preventive strategies**
R. Giuliani, The Clatterbridge Cancer Centre - Aintree, Liverpool, GB
- 10:40 - 11:00 **Break**
- 11:00 - 11:20 **Basic science & translational research**
C. Ottensmeier, University of Liverpool - School of Medicine, Liverpool, GB
- 11:20 - 11:40 **Developmental therapeutics**
R. Baird, Addenbrooke's Hospital, Cambridge, GB
- 11:40 - 12:00 **Genitourinary tumours, prostate**
A. Omlin, OnkoZentrum Zürich, Zurich, CH
- 12:00 - 12:20 **Genitourinary tumours, non-prostate**
M. De Santis, Charité - Universitätsmedizin Berlin, Berlin, DE
- 12:20 - 12:40 **Investigational immunotherapy**
I. Pires Da Silva, Melanoma Institute Australia, Wollstonecraft, AU

09:00 - 12:40	Type: Congress highlights Title: Congress Highlights 2 Chair(s): Amanda Psyrrri, GR; Florian Lordick, DE	4.B - Brest Auditorium
09:00 - 09:20	Melanoma and other skin tumours <u>T. Petrella</u> , Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA	
09:20 - 09:40	Sarcoma <u>T.W.-W. Chen</u> , NTU - National Taiwan University - College of Medicine, Taipei City, TW	
09:40 - 10:00	Head and neck cancer <u>J.-P. Machiels</u> , Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Brussels, BE	
10:00 - 10:20	Supportive and palliative care <u>C. Ruhlmann</u> , OUH - Odense University Hospital, Odense, DK	
10:20 - 10:40	Haematological malignancies <u>I. Glimelius</u> , Akademiska Sjukhuset Uppsala, Uppsala, SE	
10:40 - 11:00	Break	
11:00 - 11:20	Gastrointestinal tumours, lower digestive <u>M. Gerlinger</u> , ICR - Institute of Cancer Research, London, GB	
11:20 - 11:40	Gastrointestinal tumours, upper digestive <u>H. Van Laarhoven</u> , Academic Medical Center, University of Amsterdam, Amsterdam, NL	
11:40 - 12:00	NETs and endocrine tumours <u>J. Valle</u> , The Christie NHS Foundation Trust, Manchester, GB	
12:00 - 12:20	Non-metastatic NSCLC and other thoracic malignancies <u>M. Tsuboi</u> , National Cancer Center Hospital East, Kashiwa, JP	
12:20 - 12:40	NSCLC, metastatic <u>J. Lin</u> , MGH - Massachusetts General Hospital, Boston, US	